konkuk
univers
medic
center
konkuk
univers
school
medicin
seoul
korea
republ
background
induct
complet
remiss
cr
imper
longterm
surviv
adult
acut
lymphoblast
leukemia
patient
elig
transplant
hypercvad
chemotherapi
one
widelyus
frontlin
remiss
induct
regimen
patient
combin
regimen
show
cr
rate
mortal
one
cours
therapi
cycl
indic
room
improv
prior
studi
suggest
daunorubicin
lower
frequenc
cardiomyopathi
sever
complic
leukemia
patient
doxorubicin
high
induct
dose
daunorubicin
could
contribut
favor
treatment
outcom
adult
patient
base
observ
pilot
trial
conduct
adult
patient
use
daunorubicinaug
hypercvad
hypercvdd
regimen
doxorubicin
standard
hypercvad
regimen
replac
increas
dose
daunorubicin
improv
efficaci
regimen
method
conduct
pilot
trial
frontlin
remiss
induct
use
daunorubicinaug
hypercvad
regimen
hypercvdd
adult
patient
standard
hypercvad
regimen
doxorubicin
replac
daunorubicin
daunorubicin
administr
day
dose
studi
patient
less
year
age
achiev
cr
proceed
allohct
one
cours
consolid
chemotherapi
total
patient
enrol
trial
median
age
rang
six
patient
posit
bcrabl
transcript
receiv
tyrosin
kinas
inhibitor
transplant
four
patient
mix
phenotyp
acut
leukemia
b
myeloid
myeloid
b
nine
patient
b
cell
two
cell
result
patient
complet
hypercvdd
treatment
per
protocol
patient
achiev
cr
median
time
neutrophil
recoveri
platelet
recoveri
day
rang
day
rang
treatment
respect
two
patient
die
infect
first
consolid
respect
death
relat
noninfecti
toxic
includ
cardiotox
two
patient
relaps
first
consolid
one
receiv
salvag
chemotherapi
allohct
proceed
transplant
without
salvag
chemotherapi
percentag
blast
bone
marrow
thu
twelv
patient
among
transplantelig
patient
abl
proceed
allohct
overal
surviv
os
eventfre
surviv
ef
studi
patient
three
year
os
relapsefre
surviv
transplant
patient
three
year
conclus
pilot
trial
suggest
favor
efficaci
hypercvdd
chemotherapi
frontlin
remiss
induct
regimen
transplant
clinic
trial
use
regimen
warrant
conflict
interest
conflict
interest
declar
aou
careggi
cellular
therapi
transfusion
medicin
unit
florenc
itali
background
patient
acut
leukemia
al
fail
achiev
complet
remiss
cr
dismal
prognosi
rescu
allogen
hematopoiet
cell
transplant
hct
retrospect
appli
gitmo
score
pif
al
patient
divid
patient
differ
categori
low
intermedi
high
risk
todisco
e
bmt
method
studi
popul
includ
patient
al
present
primari
induct
failur
pif
receiv
allogen
hct
march
septemb
institut
median
age
yo
diseas
characterist
prior
histori
hematolog
diseas
gender
summar
tabl
patient
receiv
myeloabl
reducedintens
condit
ric
regimen
median
time
diagnosi
transplant
month
rang
month
result
among
pif
al
popul
belong
low
risk
group
intermedi
group
high
risk
group
respect
evalu
day
transplant
patient
achiev
complet
hematolog
remiss
chr
patient
shown
refractori
diseas
patient
die
within
month
rang
month
transplant
due
multiorgan
failur
pt
sepsi
pt
engraft
failur
die
due
trm
mean
os
day
median
os
day
patient
still
aliv
without
activ
diseas
mean
follow
day
day
among
three
gitmo
categori
mean
median
os
day
day
day
low
intermedi
high
risk
group
respect
patient
experienc
agvhd
patient
cgvhd
patient
receiv
corticosteroid
frontlin
treatment
unrespons
treat
secondlin
immunosuppressor
mean
time
develop
gvhd
month
agvhd
cgvhd
respect
gvhd
characterist
shown
tabl
trend
better
os
shown
patient
develop
agvhd
cgvhd
impact
shown
cmv
sierolog
statu
impact
shown
myeloabl
versu
ric
regimen
conclus
clinic
outcom
pif
al
patient
poor
minor
proport
patient
rescu
hsct
gitmo
score
use
creat
risk
score
help
identifi
patient
like
benefit
procedur
avail
reliabl
prognost
factor
particularli
import
era
altern
donor
haploident
sourc
small
sampl
size
may
prevent
assess
signific
differ
across
popul
conflict
interest
noth
disclos
tabl
tabl
institut
hematolog
blood
transfus
pragu
czech
republ
background
patient
chemorefractori
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
poor
prognosi
result
standard
hct
set
unsatisfactori
sever
sequenti
treatment
regimen
publish
consist
cytoreduct
chemotherapi
follow
hct
aplasia
without
await
recoveri
normal
hematopoiesi
rational
approach
reduc
tumor
burden
immedi
prior
transplant
method
perform
retrospect
analysi
outcom
treatment
patient
refractori
relaps
aml
md
receiv
allogen
hct
aplasia
cladribinecytarabin
salvag
chemotherapi
institut
hematolog
blood
transfus
pragu
patient
characterist
outcom
retriev
databas
contain
prospect
collect
inform
patient
receiv
hct
institut
patient
sign
inform
consent
data
collect
analysi
studi
review
institut
ethic
committe
cladribin
iv
cytarabin
iv
administ
day
hct
condit
regimen
start
day
unmanipul
pbsc
graft
infus
day
gvhd
prophylaxi
consist
posttranspl
high
dose
cyclophosphamid
day
cyclosporin
mycophenol
mofetil
result
patient
aml
md
treat
includ
patient
relaps
previou
hct
primari
induct
failur
relaps
refractori
salvag
chemotherapi
earli
molecular
relaps
poor
risk
aml
median
followup
time
day
median
age
year
hctci
score
condit
regimen
flucymel
flubu
iv
patient
donor
haploident
match
sibl
mismatch
unrel
patient
neutrophil
engraft
prompt
patient
engraft
achiev
cr
patient
die
engraft
median
time
engraft
day
patient
engraft
platelet
median
time
platelet
engraft
day
estim
os
two
year
ci
rf
ci
cumul
incid
nrm
relaps
respect
subgroup
patient
hctci
score
incid
nrm
incid
acut
gvhd
grade
incid
grade
agvhd
respect
incid
chronic
gvhd
patient
fever
first
day
follow
haploident
graft
infus
oral
mucos
usual
mild
one
patient
grade
oral
mucos
flubu
condit
mild
moder
so
syndrom
seen
patient
two
patient
die
earli
engraft
due
multiorgan
failur
conclus
allogen
hct
aplasia
cladribinecytarabin
salvag
chemotherapi
aml
md
feasibl
activ
treatment
regimen
need
studi
prospect
trial
conflict
interest
none
author
anyth
disclos
san
raffael
scientif
institut
ircc
milano
itali
hematolog
bone
marrow
transplant
unit
milano
itali
background
allogen
hematopoiet
stem
cell
transplant
allohsct
effect
cur
option
treat
adult
patient
highrisk
acut
lymphoblast
leukemia
sourc
hsct
type
condit
continu
debat
object
studi
perform
retrospect
survey
allohsct
adult
patient
institut
past
year
method
total
allohsct
patient
affect
perform
institut
analysi
restrict
patient
first
allohsct
data
present
refer
cohort
result
patient
hsct
characterist
shown
tabl
condit
regim
perform
use
high
dose
total
dose
irradi
gy
plu
alkyl
agent
treosulfanbas
plu
low
dose
tbi
treosulfanbas
without
tbi
gvhd
prophylaxi
cyclosporin
base
patient
rapamycin
base
cyclophosphamid
plu
rapamycin
median
follow
month
estim
probabl
overal
surviv
os
respect
year
estim
probabl
leukemia
free
surviv
lf
respect
year
nonrelaps
mortal
nrm
probabl
day
year
cumul
incid
agvhd
grade
iiiiv
day
cumul
incid
cgvhd
moderatesever
year
univari
analysi
factor
significantli
associ
better
overal
surviv
complet
remiss
hsct
low
dose
tbi
result
confirm
multivari
analysi
low
dose
tbi
cr
hsct
differ
os
lf
observ
mmrd
mud
os
os
mrd
better
os
compar
mmrdmud
conclus
small
retrospect
seri
hsct
could
confirm
state
diseas
transplant
signific
prognost
factor
cohort
tbi
associ
better
os
lf
low
dose
fact
high
dose
tbi
increas
nrm
agvhd
statist
signific
final
impact
os
low
dose
tbi
appear
better
outcom
high
dose
tbi
non
tbi
condit
patient
first
transplant
signific
differ
os
lf
emerg
mud
mmrd
transplant
confirm
haplohsct
effect
option
patient
lack
match
donor
conflict
interest
noth
disclos
tabl
tab
patient
hsct
characterist
cliniqu
universitair
stluc
hematolog
brussel
belgium
saint
antoin
inserm
umr
pari
franc
huch
comprehens
cancer
center
stem
cell
transplant
unit
helsinki
finland
univers
freiburg
freiburg
germani
hannov
medic
school
depart
haematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
institut
paoli
calmett
depart
hematolog
centr
de
recherch
en
de
marseil
crcm
marseil
franc
huriez
uam
allocsh
chru
lill
franc
univeristi
hospit
essen
essen
germani
chu
bordeaux
hautlevequ
pessac
franc
nouvel
hopit
civil
strasbourg
franc
saint
loui
pari
deni
diderot
pari
franc
univers
hospit
leipzig
divis
haematolog
oncolog
leipzig
germani
lyon
sud
lyon
franc
univers
hospit
gasthuisberg
depart
hematolog
leuven
belgium
erasmu
mc
cancer
institut
univers
medic
center
rotterdam
netherland
queen
elizabeth
hospit
birmingham
unit
kingdom
hospit
clinic
barcelona
spain
chaim
sheba
medic
center
tel
hashom
israel
background
monosomi
delet
frequent
cytogenet
featur
report
acut
myeloid
leukemia
aml
associ
dismal
outcom
allogen
stem
cell
transplant
sct
allow
significantli
improv
surviv
nevertheless
occur
frequent
highrisk
cytogenet
abnorm
may
influenc
outcom
sct
aim
evalu
role
sct
aml
context
addit
cytogenet
abnorm
method
select
adult
aml
report
ebmt
registri
complet
cytogenet
report
includ
first
sct
sibl
unrel
donor
ud
perform
result
total
patient
alloc
median
age
rang
median
followup
month
rang
time
sct
patient
first
remiss
subsequ
remiss
activ
diseas
ud
use
patient
myeloabl
condit
regimen
administ
leukemiafre
surviv
lf
overal
surviv
os
respect
nonrelaps
mortal
nrm
cumul
incid
relaps
ri
graftversushost
diseas
gvhd
relapsefre
surviv
grf
multivari
analysi
activ
diseas
significantli
associ
increas
nrm
ri
translat
wors
lf
os
grf
evalu
impact
addit
cytogenet
abnorm
abl
sort
differ
group
first
group
includ
patient
without
complex
karyotyp
ck
monosom
karyotyp
mk
monosomi
delet
abnorm
abn
invers
chromosom
inv
group
includ
patient
within
mk
without
abn
inv
group
includ
patient
associ
abn
inv
group
includ
patient
abn
without
inv
final
patient
combin
inv
assign
fifth
group
nrm
similar
across
group
lf
group
group
respect
p
os
group
respect
p
grf
group
group
p
multivari
analysi
confirm
signific
differ
across
group
even
analysi
focus
patient
conclus
sct
aml
provid
durabl
respons
one
third
patient
diseas
statu
time
transplant
remain
strongest
prognost
factor
wors
outcom
presenc
without
ck
absenc
mk
abn
inv
associ
better
surviv
sct
contrari
addit
abn
inv
identifi
subgroup
limit
benefit
sct
may
candid
postsct
intervent
conflict
interest
noth
disclos
abstract
previous
publish
hospit
san
pedro
de
hematologia
cacer
spain
hospit
la
fe
hematologia
valencia
spain
hospit
de
octubr
hematologia
madrid
spain
hospit
clinic
de
barcelona
hematologia
barcelona
spain
hospit
tria
pujol
badalona
badalona
spain
hospit
reina
hematolog
cordoba
spain
hospit
clinico
de
salamanca
hematologia
salamanca
spain
hospit
vall
hebron
hematolog
barcelona
spain
hospit
de
octubr
hematolog
madrid
spain
hospit
de
benito
hematologia
benito
spain
hospit
sant
pau
hematologia
barcelona
spain
hospit
clinico
san
carlo
hematologia
madrid
spain
hospit
virgen
del
rocio
hematologia
sevilla
spain
hospit
la
fe
hematologia
valenica
spain
background
retropect
compar
three
salvag
therapi
base
flagida
scheme
flagida
fludarabin
idarubicin
cytarabin
gcsf
prime
agent
flagoida
gemtuzumab
plu
flagida
pleriflag
plerixafor
prime
factor
use
compar
two
riskcriteria
classif
hovon
de
breem
salflag
bergua
method
statist
analysi
differ
group
test
use
fisher
exact
test
compar
differ
oncrcri
treatment
adjust
prognost
surviv
score
group
use
mantelhaenszel
test
use
hovon
criteria
de
breem
et
al
salflag
criteria
homogen
variabl
test
use
woolftest
surviv
analysi
kaplanmai
stratifi
analysi
compar
pleriflag
two
type
salvag
treatment
perform
matchpair
analysi
adjust
variabl
age
previou
allogen
transplant
time
relaps
refractori
month
month
karyotyp
use
mrc
statu
kariotyp
risk
consid
hovon
criteria
other
kariotyp
salflag
inv
unfavour
risk
mrc
risk
plu
intermedi
risk
patient
analys
patient
relaps
resist
induct
therapi
treat
flagida
patienta
flagoida
patient
treat
pleriflag
analysi
conduct
differ
time
flagida
regiment
treatment
relapsedresit
patient
pethema
studi
flago
use
short
period
withdraw
gemtuzumab
use
emea
agenc
pleriflag
phase
trial
relapsedrefractori
patient
treatment
similar
term
age
sex
previou
myelodisplasia
three
type
treatment
differ
characterist
unfavour
characterist
pleriflag
vs
flagida
flagoida
treatment
high
risk
karyotyp
pleriflag
vs
flagida
vs
flagoida
pleriflag
flagida
flagoida
time
relaps
less
month
previou
allogen
stemcel
transplant
patient
classifi
high
risk
use
salflag
criteria
pleriflag
vs
flagida
vs
flagoida
result
complet
remiss
cr
achiev
treat
pleriflag
treat
flagida
patient
treat
treat
flagoida
adjust
hovon
score
andsalflag
salflag
score
show
statatisit
differ
crcri
rate
odd
ratio
pleriflag
flagida
flagoida
ci
number
patient
receiv
allogen
stem
cell
transplant
case
pleriflag
sequenti
vs
flagida
vs
flgoida
differ
overal
surviv
os
pleriflag
median
mont
ci
flagida
medina
month
ci
flagoida
median
month
ci
ef
treatment
differ
adjust
salflag
risk
categori
conclus
differ
group
could
detect
result
may
influenc
high
rate
allegen
stem
cell
transplant
pleriflag
group
also
support
need
allogen
stem
trasplant
sequenti
time
schedul
even
cr
achiev
clinic
trial
registri
eudrat
conflict
interest
conflict
interest
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
immunohematolog
kirov
russian
feder
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
transfusiolog
kirov
russian
feder
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
hematolog
kirov
russian
feder
background
screen
red
blood
cell
rbc
alloantibodi
mandatori
everi
hospit
hematolog
patient
case
antibodi
detect
specif
establish
necessari
individu
select
rbc
contain
blood
compon
carri
aim
studi
frequenc
detect
rbc
alloantibodi
hematolog
patient
method
analysi
result
immunohematolog
examin
patient
hematolog
clinic
carri
screen
identif
antibodi
perform
equip
reagent
biorad
usa
result
specif
rbc
alloantibodi
detect
hematolog
patient
men
women
children
frequent
detect
antibodi
antid
e
k
antibodi
antigen
c
c
lea
dc
fya
also
detect
uncommon
anticw
jka
jkb
leb
lua
lub
antibodi
frequenc
vari
maximum
level
alloimmun
observ
group
patient
hemophilia
patient
rel
frequent
antibodi
detect
patient
acut
leukemia
myelodysplast
syndrom
von
willebrand
diseas
remain
group
patient
alloantibodi
detect
frequenc
conclus
given
patient
blood
diseas
receiv
intens
transfus
therapi
extrem
necessari
select
donor
compat
recipi
rbc
antigen
abo
rhesu
c
c
e
kell
k
system
result
indirect
antiglobulin
test
conflict
interest
none
author
anyth
disclos
chaim
sheba
medic
center
hematolog
divis
ramat
gan
israel
ebmt
pari
studi
offic
pari
franc
peke
univers
peopl
hospit
peke
china
tor
vergata
univers
rome
itali
san
raffael
scientif
institut
hematolog
divis
milano
itali
institut
paoli
calmett
marseil
franc
azienda
ospedaliera
centro
unico
regional
trapianti
alberto
neri
reggio
calabria
itali
hospit
clinic
de
salamanca
salamanca
spain
citta
della
salut
e
della
scienza
di
torino
torino
itali
ospedal
civil
pescara
itali
ospedal
san
martino
genova
itali
institut
hematolog
blood
transfus
pragu
czech
republ
hospit
de
barcelona
barcelona
spain
chaim
sheba
medic
center
ramat
gan
israel
background
fmslike
tyrosin
kinas
intern
tandem
duplic
mutat
design
patient
acut
myeloid
leukemia
particularli
high
risk
diseas
relaps
current
unclear
whether
retain
signific
prognost
role
haploident
stem
cell
transplant
haplosct
method
assess
whether
prognost
meaning
tcell
replet
haplosct
transplant
aml
patient
perform
compar
analysi
use
multicent
registri
acut
leukemia
work
parti
european
societi
blood
marrow
transplant
patient
includ
studi
aml
patient
age
underw
first
tcell
replet
haplosct
first
remiss
result
cohort
consist
denovo
aml
patient
transplant
first
remiss
tcell
replet
haplosct
analyz
group
differ
signific
degre
term
patient
age
donor
age
perform
statu
cytomegaloviru
donorrecipi
match
condit
intens
patient
like
mutat
well
medic
research
council
mrc
intermedi
risk
cytogenet
risk
categori
multivari
analysi
patient
compar
rate
relaps
incid
hazard
ratio
hr
confid
interv
ci
leukemiafre
surviv
ci
patient
surviv
significantli
impact
statu
ci
incid
nonrelaps
mortal
ci
graft
versu
host
diseasefreerelapsefre
surviv
ci
analysi
patient
treat
either
antithymocyt
globulin
atg
protocol
posttranspl
cyclophosphamid
ptci
significantli
correl
statu
clinic
outcom
either
group
final
focus
subset
analysi
patient
mrc
intermedi
risk
cytogenet
confirm
absenc
prognost
impact
also
group
patient
conclus
mutat
possibl
retain
prognost
signific
aml
patient
undergo
haplohct
suggest
haplosct
may
conceiv
overcom
neg
prognost
impact
aml
clinic
trial
registri
na
conflict
interest
author
declar
noth
disclos
heart
england
nh
trust
haematolog
birmingham
unit
kingdom
evaggelismo
gener
hospit
athen
greec
heart
england
nh
trust
birmingham
unit
kingdom
heart
england
nh
foundat
trust
birmingham
unit
kingdom
background
patient
aml
signific
risk
relaps
even
undergo
haematopoet
stem
cell
transplantationin
patient
outlook
poor
major
patient
surviv
less
yeardonor
lymphocyt
infus
unabl
tackl
kinet
haematolog
relaps
intens
chemotherapi
could
result
mortal
post
allogen
transplant
leav
signific
treatment
gap
group
patient
method
total
patient
male
femal
median
age
receiv
myeloabl
ric
allograft
fulli
match
unrel
donor
ident
sibl
standard
high
risk
aml
centr
subsequ
patient
relaps
within
first
year
patient
relaps
year
post
allogen
stem
cell
transplantth
condit
regim
includ
fludarabin
togeth
melphalan
campath
atg
patient
fludarabin
busulphan
campath
patient
tbici
buci
patient
graft
versu
host
diseas
prophylaxi
ciclosporin
patient
receiv
alemtuzumab
atg
patient
treplet
allograft
ciclosporin
low
dose
methotrex
prefer
prophylaxisal
four
patient
transplant
relaps
receiv
cours
azacitidin
follow
dli
repeat
cycl
escal
dose
dliprogress
free
surviv
pf
overal
surviv
os
assess
use
spss
softwar
result
median
follo
rang
patient
remain
aliv
caus
death
case
includ
relaps
progress
origin
diseas
case
infect
case
patient
achiev
cr
achiev
pr
ongo
diseas
post
treatment
aza
dli
median
pf
month
patient
relaps
within
year
post
transplant
receiv
azacitidin
dli
relaps
one
year
median
pf
nt
reachedth
influenc
time
relaps
pf
os
analys
show
trend
toward
better
pf
patient
relaps
month
post
allogen
stem
cell
transplant
significantli
better
os
patient
develop
gvhd
azacitidin
dli
administrationdiseas
risk
signific
pf
os
post
relaps
might
due
low
number
patient
risk
group
patient
ongo
complet
remiss
manag
achiev
full
donor
chimer
whole
blood
cell
conclus
result
indic
combin
azacitidin
escal
dose
dli
could
potenti
restor
remiss
patient
relaps
post
allogen
stem
cell
transplant
reason
amount
time
difficult
cohort
patient
especi
patient
relaps
year
post
transplantour
find
evalu
prospect
clinic
trial
result
indic
combin
azacitidin
escal
dose
dli
could
potenti
restor
remiss
patient
relaps
post
allogen
stem
cell
transplant
reason
amount
time
difficult
cohort
patient
especi
patient
relaps
year
post
transplantour
find
evalu
prospect
clinic
trial
clinic
trial
registri
na
conflict
interest
conflict
interest
disclos
univers
hospit
nanci
pediatr
oncohematolog
vandoeuvrelesn
franc
univers
hospit
nanci
hematolog
vandoeuvrelesn
franc
univers
hospit
nanci
plateform
daid
la
recherch
cliniqu
parc
vandoeuvrelesn
franc
univers
hospit
robert
hematoimmunolog
pari
franc
paolicalmett
univers
institut
hematolog
marseil
franc
univers
hospit
la
timon
pediatr
oncohematolog
marseil
franc
univers
hospit
lill
claud
huriez
hospit
hematolog
lill
franc
clermontferrand
univers
hospit
esta
hospit
hematolog
clermont
ferrand
franc
nant
univers
hospit
hematolog
nant
franc
saint
antoin
univers
hospit
hematolog
pari
franc
bordeaux
univers
hospit
hospit
hematolog
pessac
franc
centr
de
lutt
contr
le
cancer
lyon
franc
ihop
univers
hospit
pediatr
hematolog
lyon
franc
american
univers
beirut
medic
center
beirut
lebanon
geneva
univers
hospit
hematolog
stem
cell
transplant
unit
geneva
switzerland
univers
hospit
hematolog
lieg
belgium
la
univers
hospit
aphp
hematolog
pari
franc
saint
loui
univers
hospit
hematolog
pari
franc
background
first
author
contribut
equal
data
outcom
aml
adolesc
young
adult
aya
allogen
hsct
scarc
retrospect
studi
sfgmtc
analyz
outcom
aml
patient
classifi
group
accord
age
transplant
children
year
aya
year
adult
year
method
patient
age
year
receiv
first
allogen
hsct
aml
report
sfgmtc
registri
includ
result
studi
includ
patient
center
children
aya
adult
accord
classif
children
highest
rate
advers
risk
diseas
follow
aya
adult
extramedullari
diseas
observ
children
aya
adult
among
patient
complet
remiss
cr
younger
age
associ
frequent
advanc
diseas
children
aya
adult
donor
match
sibl
children
aya
adult
match
unrel
respect
children
mismatch
unrel
donor
compar
aya
adult
haploident
hsct
count
less
transplant
group
stem
cell
sourc
diverg
group
bone
marrow
bm
main
sourc
children
graft
follow
cord
blood
cb
wherea
peripher
blood
stem
cell
pbsc
main
sourc
adult
follow
bm
cb
aya
transplant
bm
case
pbsc
cb
intens
condit
myeloabl
mac
children
aya
adult
reducedintens
regimen
use
children
aya
adult
median
time
day
respect
diagnosi
median
followup
year
surviv
os
higher
children
compar
aya
adult
oneyear
cumul
incid
ci
relaps
compar
group
children
aya
adult
differ
ci
grade
iiiv
acut
gvhd
day
group
respect
contrast
oneyear
ci
chronic
gvhd
higher
adult
aya
compar
children
multivari
analysi
independ
factor
associ
better
os
younger
age
hr
bm
hr
mac
hr
lowrisk
cytogenet
hr
p
conclus
children
better
os
aya
adult
factor
associ
better
outcom
mac
regimen
absenc
poor
cytogenet
bm
stem
cell
sourc
conflict
interest
declar
conflict
interest
abstract
previous
publish
danafarb
cancer
institut
boston
unit
state
center
intern
blood
marrow
transplant
research
milwauke
wi
unit
state
pfizer
inc
new
york
ny
unit
state
background
hepat
vod
report
aml
patient
expos
antibodydrug
conjug
go
sct
method
determin
vod
risk
outcom
go
exposur
subsequ
sct
analyz
data
subset
patient
randomli
select
research
level
report
center
intern
blood
marrow
transplant
research
cibmtr
adult
aml
go
exposur
time
first
myeloabl
allogen
sct
match
age
sct
diseas
statu
sct
patient
without
go
exposur
margin
cox
regress
margin
logist
regress
model
use
determin
overal
surviv
incid
vod
respect
stepwis
model
build
approach
use
identifi
risk
factor
associ
vod
death
result
patient
patient
without
go
exposur
underw
sct
median
rang
age
patient
without
go
exposur
sct
year
year
respect
myeloabl
condit
mac
chemotherapi
go
without
go
util
frequent
mac
total
bodi
irradi
without
incid
vod
patient
withwithout
go
exposur
similar
incid
sever
vod
surviv
probabl
similar
patient
withwithout
go
exposur
day
month
year
sct
onset
vod
multivari
analysi
mva
go
exposur
associ
increas
risk
vod
ci
death
hr
ci
conclus
incid
vod
similar
aml
patient
without
go
exposur
sct
moreov
go
exposur
associ
increas
risk
vod
death
limit
studi
includ
select
bia
associ
retrospect
design
futur
analys
evalu
impact
dose
vod
risk
surviv
outcom
cohort
encor
bmt
tandem
fund
pfizer
data
coordin
center
cibmtr
preliminari
conflict
interest
v
ho
advisori
board
consult
jazz
pharmaceut
chirnoma
c
hoang
f
loberiza
employe
stock
pfizer
inc
martin
w
perez
p
steinert
zhang
w
saber
noth
disclos
hannov
medic
school
dept
hematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
background
relaps
rate
acut
myeloid
leukemia
aml
allogen
stem
cell
transplant
sct
remain
high
limit
treatment
option
low
surviv
rate
perform
retrospect
singl
center
analysi
adult
aml
patient
post
allograft
relaps
treat
chemotherapi
without
cellular
therapi
chx
donor
lymphocyt
infus
dli
second
sct
method
one
hundr
seventi
five
aml
patient
transplant
system
system
extramedullari
em
em
postallograft
relaps
includ
analysi
patient
treat
chemotherapi
irradi
without
cellular
therapi
chx
dli
alon
chemoradiotherapi
receiv
second
sct
without
previou
dli
altern
donor
chemotherapi
includ
convent
cytarabinebas
regimen
target
therapi
hypomethyl
agent
treatment
group
compar
age
de
novo
secondari
aml
em
manifest
cr
rate
sct
donor
type
myeloabl
mac
reduc
intens
condit
ric
initi
sct
kind
chemotherapi
postallograft
relaps
median
followup
year
rang
analyz
overal
surviv
os
non
relaps
mortal
nrm
first
postallograft
relaps
well
acut
chronic
gvhd
incid
start
cellular
therapi
dli
group
use
kaplanmei
statist
variabl
impact
os
identifi
cox
regress
analysi
result
five
year
os
significantli
lower
chx
group
compar
dli
group
respect
chx
dli
group
differ
age
mean
year
rate
cr
rate
match
relat
donor
rate
mac
initi
sct
well
use
hypomethyl
agent
therapi
relaps
contrast
em
manifest
de
novo
aml
p
equal
distribut
os
highest
group
p
wherea
nrm
differ
group
figur
incid
agvhd
extens
cgvhd
dli
group
respect
multivari
analysi
mac
compar
ric
first
sct
age
cr
rate
initi
sct
donortyp
em
manifest
de
novo
aml
kind
chemotherapi
sct
relev
os
postallograft
relaps
conclus
data
show
improv
surviv
adult
patient
postallograft
relaps
aml
treat
second
sct
obvious
candid
second
sct
highli
select
group
favor
characterist
contrast
patient
treat
chemotherapi
poor
outcom
limit
singlecent
retrospect
analysi
data
suggest
second
sct
may
consid
highli
select
adult
aml
patient
postallograft
relaps
conflict
interest
author
conflict
interest
disclos
first
affili
hospit
soochow
univers
hematolog
suzhou
china
jiangsu
institut
hematolog
suzou
china
soochow
univers
institut
blood
marrow
transplant
suzhou
china
first
affili
hospit
soochow
univers
respiratori
suzhou
china
background
stem
cell
transplant
sct
attract
postremiss
treatment
option
patient
intermediaterisk
acut
myeloid
leukemia
aml
favorablerisk
aml
patient
addit
nongenet
risk
factor
autolog
sct
autosct
haploident
donor
sct
haplosct
wide
use
altern
case
lack
human
leukocyt
antigen
hla
match
donor
howev
limit
data
publish
direct
comparison
two
transplant
type
method
base
transplant
databas
center
conduct
retrospect
studi
involv
patient
favor
intermediaterisk
aml
first
complet
remiss
accord
nccn
guidelin
patient
apl
extramedullari
diseas
achiev
cr
two
cycl
exclud
result
total
patient
includ
studi
underw
autosct
underw
haplosct
patient
autosct
group
older
haplosct
group
signific
differ
p
accord
nccn
guidelin
version
patient
autosct
group
classifi
patient
favorablerisk
aml
patient
haplosct
group
classifi
patient
favorablerisk
aml
p
core
bind
factor
cbf
aml
present
frequent
autosct
group
p
interv
diagnosi
transplant
remiss
transplant
longer
patient
autosct
group
p
whole
cohort
analys
impact
high
relaps
incid
autosct
group
compens
low
nonrelaps
mortal
nrm
result
compar
overal
surviv
os
versu
p
relapsefre
surviv
rf
versu
p
compar
observ
haplosct
group
howev
patient
intermediaterisk
aml
nrm
similar
group
haplosct
exhibit
superior
surviv
case
postsct
relaps
patient
intermediaterisk
aml
show
markedli
inferior
os
compar
shown
patient
favorablerisk
aml
versu
p
multivari
analys
minim
residu
diseas
mrd
measur
flow
cytometri
gene
mutat
statu
transplant
independ
predictor
os
rf
conclus
conclud
autosct
haplosct
accept
option
postremiss
treatment
patient
favor
intermediaterisk
aml
haplosct
yield
better
outcom
patient
intermediaterisk
aml
relaps
sct
still
led
poor
outcom
clearanc
mrd
sct
could
improv
prognosi
transplant
conflict
interest
none
author
anyth
disclos
tabl
comparison
transplant
outcom
pediatr
oncohematolog
stem
cell
transplant
divis
torino
itali
depart
pediatr
hematologyoncolog
istituto
di
ricovero
e
cura
caratter
scientifico
ircc
bambino
children
hospit
roma
itali
depart
pediatr
oncolog
hematolog
transplant
anna
meyer
children
hospit
firenz
itali
depart
pediatr
hematolog
oncolog
g
gaslini
institut
genova
itali
depart
pediatr
hematolog
oncolog
univers
padova
padova
itali
paediatr
oncolog
haematolog
unit
lalla
seragnoli
depart
paediatr
univers
bologna
santorsolamalpighi
hospit
bologna
itali
bmt
unit
depart
pediatr
hematooncolog
santobonopausilipon
hospit
napoli
itali
depart
pediatr
hematolog
san
gerardo
hospit
monza
itali
depart
pediatr
oncohematolog
ircc
policlinico
san
matteo
foundat
pavia
itali
background
outcom
hematopoiet
stem
cell
transplant
hsct
treatment
pediatr
patient
highrisk
acut
leukemia
increas
last
decad
howev
group
patient
requir
long
term
followup
due
late
complic
second
malign
increas
morbid
often
attribut
late
toxic
myeloabl
condit
regimen
includ
either
total
bodi
irradi
tbi
busulfan
bu
major
pediatr
patient
cohen
bmt
faraci
bmt
recent
bernard
et
al
show
late
event
seem
less
frequent
bu
compar
tbi
bernard
bmt
purpos
retrospect
multicent
studi
compar
longterm
impact
bu
tbi
occurr
late
complic
second
malign
childhood
acut
leukemia
treat
hsct
method
retrospect
evalu
incid
late
effect
pediatr
patient
median
age
year
undergo
hsct
aieop
transplant
centr
acut
lymphoid
myeloid
leukemia
aml
patient
receiv
tbi
bubas
condit
regimen
underw
hsct
complet
morpholog
remiss
late
effect
incid
calcul
cumul
incid
adjust
analysi
compet
risk
associ
categor
variabl
assess
fisher
exact
test
p
valu
consid
statist
signific
statist
analysi
perform
use
ncss
hintz
ncss
pass
number
crunch
statist
system
kaysvil
ut
usa
result
total
patient
receiv
tbi
aml
bubas
condit
regimen
aml
median
follow
hsct
year
patient
develop
least
one
longterm
late
effect
patient
show
two
complic
incid
least
one
late
complic
higher
tbi
patient
bu
patient
vs
similarli
occurr
two
late
effect
higher
tbi
group
vs
specif
univari
analys
reveal
advers
effect
height
cataract
significantli
frequent
tbibas
condit
regimen
vs
vs
p
signific
differ
observ
occurr
gonad
dysfunct
vs
hypothyroid
vs
pulmonari
function
impair
vs
tbi
bu
group
signific
higher
incid
second
tumor
observ
tbi
group
vs
conclus
retrospect
analysi
larg
cohort
patient
suggest
late
complic
seem
frequent
tbibas
condit
regimen
comparison
bubas
regimen
pattern
late
side
effect
differ
two
group
data
import
choic
hsct
condit
regimen
develop
follow
measur
thu
prospect
random
studi
aim
better
understand
role
condit
regimen
occurr
differ
late
effect
warrant
clinic
trial
registri
na
conflict
interest
author
commerci
proprietari
financi
interest
product
compani
describ
articl
japanes
red
cross
nagoya
daiichi
hospit
hematolog
nagoya
japan
background
cytomegaloviru
cmv
infect
dasatinib
therapi
report
correl
better
prognosi
patient
chronic
myeloid
leukemia
howev
observ
patient
philadelphia
chromosomeposit
acut
lymphoblast
leukemia
ph
need
hematopoiet
stem
cell
transplant
yet
clarifi
method
retrospect
assess
patient
newli
diagnos
ph
hospit
patient
receiv
tki
combin
chemotherapi
jalsg
imatinibbas
therapi
jalsg
dasatinibbas
therapi
respect
depend
period
protocol
compos
induct
phase
consolid
phase
defin
earli
molecular
complet
remiss
ecmr
one
enter
cmr
first
consolid
accord
cmv
infect
statu
seroposit
diagnosi
reactivationinfect
therapi
divid
patient
group
cmv
seroposit
reactiv
group
reactiv
seroposit
group
cmv
seroneg
infect
group
cmv
statu
test
unknown
group
result
median
age
diagnosi
year
eighteen
patient
treat
dasatinibbas
therapi
patient
treat
imatinibbas
therapi
neither
seroneg
patient
develop
cmv
infect
group
five
seroposit
patient
receiv
dasatinibbas
therapi
develop
cmv
reactiv
cmv
antigenemia
coliti
hand
none
patient
seroposit
imatinib
treatment
vs
analyz
time
achiev
cmr
among
patient
treat
dasatinibbas
therapi
patient
cmv
reactiv
group
achiev
ecmr
seven
patient
infect
cmv
without
reactiv
group
dasatinibbas
therapi
achiev
ecmr
neither
patient
never
infect
cmv
group
achiev
ecmr
group
tend
advanc
cmr
comparison
group
fisher
exact
test
among
patient
receiv
dasatinibbas
therapi
patient
receiv
allogen
hematopoiet
stem
cell
transplant
overal
surviv
year
differ
patient
ecmr
patient
without
ecmr
vs
df
nrm
year
vs
vs
respect
differ
dasatinib
patient
imatinib
patient
cmv
reactiv
transplant
vs
patient
group
die
cmv
coliti
allogen
hematopoiet
stem
cell
transplant
conclus
demonstr
cmv
reactiv
achiev
cmr
rapidli
exclus
among
dasatinibbas
therapi
patient
studi
report
earlier
cmr
induc
better
os
allogen
hematopoiet
stem
cell
transplant
studi
found
ecmr
yield
favor
prognosi
cmv
reactiv
group
develop
cmv
infect
hsct
may
reduc
overal
surviv
conflict
interest
k
miyamura
novarti
bristolmy
squibb
univers
hospit
hamburg
eppendorf
clinic
stem
cell
transplant
hamburg
germani
background
patient
aml
md
harbour
mutat
risk
relaps
allogen
stem
cell
transplant
allohsct
relaps
allohsct
poor
outcom
result
overal
surviv
remiss
appear
reli
therapi
maximis
graft
versu
leukemia
effect
unclear
whether
chemotherapi
prerequisit
donor
cell
therapi
patient
myeloid
neoplasm
tp
mutat
poor
remiss
rate
intens
chemotherapi
recent
data
suggest
efficaci
decitabin
mutat
amlmd
patient
describ
amlmd
pt
mutat
relaps
allohsct
receiv
decitabin
dac
combin
donor
lymphocyt
transfus
dli
salvag
therapi
method
retrospect
analyz
data
mutat
pt
acut
myeloid
leukemia
md
relaps
allohsct
treat
median
cycl
dac
rang
pt
receiv
dose
day
everi
day
pt
day
everi
day
dac
first
salvag
therapi
pt
allogen
stem
cell
transplant
pt
fail
therapi
azacytidin
pt
donor
lymphocyt
transfus
administr
addit
dac
median
dli
per
patient
rang
median
cell
dosag
x
x
cellskg
pt
pat
also
receiv
lenalidomid
combin
result
result
overal
respons
rate
includ
complet
cytogenet
remiss
ccr
partial
remiss
pr
patient
within
first
line
group
achiev
cr
patient
receiv
dac
second
line
treatment
previou
aza
failur
reach
cr
median
durat
cr
month
rang
patient
relaps
far
incid
acut
chronic
graftversushost
diseas
low
conclus
dac
combin
exert
clinic
efficaci
patient
aml
md
tp
mutat
abl
induc
complet
remiss
nearli
half
patient
data
suggest
altern
relaps
regim
combin
dli
allogen
stem
cell
transplant
patient
tp
mutat
role
decitabin
pretranspl
mainten
strategi
post
transplant
patient
high
risk
aml
md
mutat
evalu
prospect
clinic
trial
conflict
interest
c
wolschk
noth
disclos
abstract
previous
publish
memori
sloan
ketter
cancer
center
dept
medicin
adult
bone
marrow
transplant
servic
new
york
ny
unit
state
memori
sloan
ketter
cancer
center
dept
pediatr
bone
marrow
transplant
servic
new
york
ny
unit
state
weill
cornel
medic
colleg
dept
medicin
new
york
ny
unit
state
memori
sloan
ketter
cancer
center
dept
medicin
leukemia
servic
new
york
ny
unit
state
background
multipl
studi
demonstr
cur
effect
hct
patient
acut
leukemia
al
estim
elig
patient
undergo
procedur
histor
lack
avail
donor
among
common
reason
proceed
allogen
hct
longer
major
limit
transplant
widespread
use
cord
blood
haploident
hct
aim
prospect
determin
rate
al
patient
proceed
hct
base
diseas
risk
use
nation
comprehens
cancer
network
guidelin
identifi
reason
proceed
hct
era
altern
donor
sourc
method
patient
newli
diagnos
relaps
al
admit
center
adult
leukemia
servic
induct
reinduct
therapi
approach
enrol
prospect
observ
studi
result
april
decemb
patient
enrol
suffici
follow
day
initi
induct
reinduct
patient
identifi
white
european
substanti
represent
group
high
risk
find
hlamatch
donor
intern
registri
twentytwo
patient
hlaident
sibl
donor
fiftythre
patient
least
one
potenti
hlamatch
unrel
donor
identifi
preliminari
donor
search
case
suitabl
umbil
cord
unit
hlahaploident
donor
identifi
remain
pt
search
due
earli
death
known
match
relat
donor
allogen
hct
recommend
case
base
diseaserel
risk
via
consensu
decis
leukemia
bone
marrow
transplant
servic
patient
underw
hct
median
time
start
induct
reinduct
chemotherapi
transplant
rang
day
donor
hlaident
sibl
hlamatch
unrel
donor
mismatch
unrel
donor
umbil
cord
patient
hct
recommend
perform
progress
diseas
sinc
die
patient
die
inductionrel
complic
sever
comorbid
patient
declin
hct
patient
lost
follow
nt
case
donor
avail
barrier
transplant
conclus
base
interim
result
prospect
observ
trial
patient
underw
allogen
hct
recommend
base
diseaserel
risk
factor
suitabl
donor
identifi
patient
allogen
hct
recommend
main
barrier
transplant
earli
diseas
progress
death
conflict
interest
none
author
anyth
disclos
tabl
patient
characterist
ankara
univers
school
medicin
depart
hematolog
stem
cell
transplant
unit
ankara
turkey
background
although
allogen
hsct
ahsct
offer
cure
acut
myeloblast
leukemia
aml
patient
relaps
still
remain
limit
factor
optim
treatment
improv
outcom
poor
prognost
group
controversi
aim
search
impact
donor
lymphocyt
infus
dli
salvag
treatment
relaps
aml
patient
allogen
hsct
method
retrospect
includ
twenti
aml
patient
hematolog
relaps
ahsct
ankara
univers
faculti
medicin
bone
marrow
transplant
unit
donor
lymphocyt
infus
schedul
end
salvag
treatment
statist
analyz
relationship
respons
dli
overal
remiss
durat
patient
dli
characterist
result
demograph
featur
patient
summar
tabl
two
patient
treat
salvag
chemotherapi
donor
lymphocyt
infus
perform
end
chemotherapi
two
patient
treat
azacytidin
dli
given
end
cycl
dli
featur
patient
shown
tabl
eight
patient
reciev
dli
complet
remiss
wherea
patient
achiev
remiss
dli
respons
durat
found
relat
gender
cmv
statu
cytogenet
risk
factor
blood
percent
relaps
remiss
durat
relaps
pretranspl
acut
chronic
gvhd
relaps
also
donor
age
gender
sex
mismatch
blood
group
mismatch
recipi
statist
signific
effect
respons
durat
dli
statist
signific
factor
remiss
statu
donor
lymphocyt
infus
acut
gvhd
observ
patient
median
surviv
patient
achiev
remiss
refractori
diseas
dli
treatment
year
month
respect
estim
overal
surviv
year
achiev
remiss
respect
conclus
aml
patient
relaps
ahsct
donor
lymphocyt
infus
salvag
chemotherapi
feasibl
treatment
choic
remiss
achiev
infus
conflict
interest
author
noth
disclos
tabl
tabl
dli
featur
patient
pavlov
first
st
petersburg
state
medic
univers
rm
gorbacheva
memori
institut
children
oncolog
hematolog
transpant
st
petersburg
russian
feder
background
allogen
hematopoiet
stem
cell
transplant
allohsct
consid
best
treatment
aml
poor
prognosi
howev
often
follow
posttranspl
relaps
ptr
among
ptr
molecular
cytolog
variant
mptr
cptr
respect
recogn
gene
import
independ
prognost
indic
acut
leukemia
follow
allohsct
method
ninti
aml
patient
age
year
median
underw
allohsct
univers
enrol
studi
gene
express
level
realtim
pcr
well
bone
marrow
blast
count
measur
transplant
well
day
hsct
threshold
valu
determin
copi
bcr
gene
overal
surviv
os
relapsefre
surviv
rf
cumul
incid
relaps
cir
determin
patient
group
besid
alloc
time
interv
mptr
cptr
onethird
patient
result
level
gene
express
allohsct
rang
abl
copi
median
signific
differ
os
rf
cir
group
vs
p
p
respect
day
threshold
recogn
differ
cir
vs
respect
meanwhil
differ
paramet
group
maxim
time
point
vs
respect
vs
p
respect
gener
data
show
prognost
signific
level
normal
measur
well
day
allohsct
case
mptr
cptr
regist
patient
respect
patient
mptr
cptr
note
simultan
wherea
case
cptr
occur
delay
mptr
period
rang
day
median
day
mention
patient
upon
detect
overexpress
obtain
differ
prevent
treatment
kept
mind
explain
increas
interv
mptr
cptr
howev
prolong
interv
also
may
due
molecular
cytogenet
featur
leukemia
new
investig
topic
need
test
hypothesi
conclus
thu
aml
patient
level
bone
marrow
cell
time
point
predict
os
ef
cir
agre
well
recent
publish
data
unusu
phenomenon
cptr
delay
mptr
detect
may
use
clinic
practic
control
molecular
studi
new
medic
drug
therapeut
approach
conflict
interest
author
state
conflict
interest
hospit
universitario
central
de
asturia
oviedo
spain
universidad
de
oviedo
oviedo
spain
background
multidrug
resist
infect
mrd
special
caus
gram
neg
bacteria
gnb
associ
poor
outcom
acut
myeloblast
leukemia
aml
could
make
hinder
patient
complet
optim
treatment
stem
cell
transplant
activ
surveil
patient
screen
colon
mdrgnb
may
serv
tool
decreas
bacteri
transmiss
guid
choic
empir
antibiot
treatment
aim
studi
analyz
impact
activ
surveil
incid
mdr
gnb
infect
infect
relat
mortal
aml
patient
method
prospect
observ
studi
includ
consecut
adult
patient
aml
diagnosi
treat
intens
chemotherapi
hospit
universitario
central
de
asturia
huca
januari
octob
cohort
patient
activ
surveil
perform
cohort
compar
cohort
aml
patient
done
cohort
empir
antibiot
therapi
consid
appropri
least
one
empir
antibiot
effect
bacteria
detect
surveil
cultur
patient
receiv
fluoroquinolon
prophylaxi
data
present
mean
standard
deviat
median
rang
univari
comparison
done
use
chisquar
test
categor
variabl
exact
test
conting
tabl
frequenc
result
januari
octob
seventythre
aml
patient
receiv
intens
chemotherapi
cycl
cohort
activ
surveil
perform
along
cycl
gener
characterist
similar
cohort
median
age
year
femal
europeanleukemianet
genet
risk
favor
intermedi
high
patient
gram
neg
multidrug
resist
bacteria
colon
detect
cycl
without
differ
differ
phase
treatment
induct
regard
epidemiolog
bacteri
infect
frequent
isol
cohort
gram
neg
follow
gram
posit
polimicrobi
infect
infect
due
multidrug
resist
bacteria
detect
cycl
empir
antibiot
treatment
consid
appropri
accord
previou
surveil
cultur
infecti
episod
gram
neg
infect
statist
associ
higher
mortal
compar
infect
vs
p
main
caus
death
complet
remiss
prior
stem
cell
transplant
nonsignific
reduct
thirtyday
mortal
observ
cohort
cohort
vs
conclus
popul
acut
leukem
patient
colon
due
gn
resist
bacteria
occur
high
proport
patient
earli
event
treatment
gram
neg
bacteri
infect
remain
frequent
caus
morbid
mortal
although
activ
surveil
may
help
choic
appropri
empir
antibiot
treatment
era
multidrug
resist
larger
studi
need
demonstr
efficaci
reduc
mortal
conflict
interest
none
author
anyth
disclos
univers
hospit
pilsen
haematolog
oncolog
pilsen
czech
republ
background
older
patient
high
risk
myeloid
malign
amlmd
dismal
prognosi
cur
option
allohct
decis
offer
hct
older
pt
challeng
given
high
rate
transplant
relat
morbiditymort
recent
composit
endpoint
grf
propos
incorpor
signific
complic
allogen
transplant
use
meaning
paramet
defin
transplant
success
howev
main
variabl
affect
endpoint
particular
popul
poorli
defin
address
question
perform
singl
centr
retrospect
analysi
longterm
followup
method
consecut
year
aml
md
receiv
ric
allohct
institut
analys
grf
event
defin
acut
gvhd
gr
iii
chronic
gvhd
requir
system
therapi
extens
stage
relaps
death
whichev
come
followup
donor
match
sibl
msd
match
unrel
donor
mud
n
mismatch
mud
haploident
donor
median
age
cohort
year
rang
male
pt
advanc
diseas
hct
diseas
risk
index
dri
hct
lowintermedi
high
pt
gvhd
prophylaxi
uniformli
base
calcineurin
inhibitor
short
mtx
result
median
followup
survivor
month
rang
total
die
relaps
nrm
estim
os
rf
grf
year
wherea
correspond
probabl
respect
figur
cox
regress
hazard
model
identifi
high
dri
strongest
factor
predict
extrem
poor
osrf
hr
wherea
recipientdonor
sex
mismatch
protect
outcom
os
hr
hr
donor
year
associ
advers
os
hr
p
well
yet
borderlin
cmv
match
hr
recipi
age
year
cellskg
transplant
increas
nrm
hr
multivari
analysi
grf
endpoint
high
dri
retain
signific
impact
hr
ci
follow
donor
age
hr
ci
conclus
data
limit
retrospect
natur
inher
select
bia
despit
found
longterm
follow
signific
portion
older
patient
myeloid
malign
surviv
allohct
without
experienc
least
gfr
event
addit
observ
clear
trend
plateau
sinc
time
point
neg
impact
dri
high
donor
age
suggest
hct
perform
earli
cours
diseas
prefer
young
donor
regardless
whether
relat
unrel
conflict
interest
noth
disclos
univers
hospit
hradec
kralov
faculti
medicin
hradec
kralov
charl
univers
depart
intern
medicin
haematolog
hradec
kralov
czech
republ
background
prognosi
patient
relaps
acut
myeloid
aml
lymphoblast
leukemia
allosct
remain
dismal
treatment
option
short
overal
surviv
analyz
outcom
patient
aml
receiv
flagida
regimen
relaps
allosct
method
patient
relaps
aml
receiv
least
one
cycl
flagida
idarubicin
cytosinarabinosid
fludarabin
elig
analysi
outcom
term
progress
free
overal
surviv
analyz
impact
dli
administ
flagida
analyz
result
overal
patient
receiv
cycl
flagida
femal
male
mean
age
year
year
patient
aml
patient
receiv
flagida
relaps
relaps
cr
reach
cycl
pr
cycl
progress
diseas
cycl
evalu
due
earli
death
patient
receiv
allogen
transplant
differ
donor
patient
receiv
dli
flagida
median
followup
administr
treatment
month
month
differ
pf
os
patient
aml
month
month
os
month
month
pf
patient
receiv
post
treatment
dli
flagida
show
significantli
better
os
versu
month
conclus
flagida
plu
dli
remain
valid
clinic
option
treatment
relaps
allosct
patient
reach
long
term
remiss
post
treatment
dli
administr
conflict
interest
author
noth
disclos
medanta
medic
hospit
pediatr
hematolog
oncolog
bone
marrow
transplant
gurgaon
india
background
tcell
replet
haploident
stem
cell
transplant
sct
posttransplant
cyclophosphamid
ptci
shown
encourag
result
treatment
hematolog
malign
adult
howev
data
regard
applic
cure
pediatr
acut
lymphoblast
leukemia
meagr
present
experi
use
children
suffer
method
condit
nonmyeloabl
fludarabin
cyclophosphamid
mgkg
total
bodi
irradi
tbi
myeloabl
mgkg
fludarabin
cyclophosphamid
mgkg
tbi
fludarabin
busulfan
mgkg
receiv
ptci
mgkg
day
graft
vs
host
diseas
gvhd
prophylaxi
along
tacrolimu
mycophenol
mofetil
inform
consent
children
allograft
median
age
year
rang
male
complet
remiss
cr
prior
sct
donor
mobil
granulocyt
coloni
stimul
factor
microgramkg
daili
four
day
pbsc
collect
one
larg
volum
apheresi
procedur
donor
share
allel
recipi
donor
parent
except
one
younger
sibl
one
sexmismatch
sct
median
million
infus
rang
millionkg
result
engraft
rate
median
time
neutrophil
engraft
day
rang
platelet
engraft
day
rang
chimer
day
fulli
donor
children
one
child
relaps
bone
marrow
respond
inotuzumab
die
progress
diseas
remain
patient
aliv
median
followup
month
rang
three
children
relaps
month
post
sct
one
isol
central
nervou
system
cn
relaps
achiev
chemotherapi
follow
donor
lymphocyt
infus
dli
aliv
diseas
free
follow
month
escal
dose
dli
given
dose
cell
millionkg
induc
acut
gvhd
grade
ii
patient
second
child
isol
cn
relaps
fail
respond
dli
achiev
cisplatin
bevacizumab
month
therapi
aliv
diseas
free
month
third
child
isol
bone
marrow
relaps
blast
express
achiev
treatment
singl
dose
rituximab
cr
month
mainten
rituximab
therapi
cumul
incid
graft
versu
host
diseas
gvhd
acut
chronic
extens
respect
gradei
acut
gvhd
seen
patient
three
children
chronic
graft
vs
host
diseas
aliv
diseas
free
three
children
receiv
nonmyeloabl
condit
relaps
overal
surviv
event
free
surviv
median
follow
month
conclus
haploident
sct
ptci
safe
children
myeloabl
condit
post
transplant
dli
andor
target
therapi
help
improv
surviv
conflict
interest
none
author
anyth
disclos
makass
middl
east
institut
health
univers
hospitalslebanes
univers
hematolog
oncologybmt
beirut
lebanon
makass
middl
east
institut
health
univers
hospitalslebanes
univers
intern
medicin
beirut
lebanon
middl
east
institut
health
univers
hospitalsaint
joseph
universitylebanes
univers
cellular
therapi
beirut
lebanon
makass
univers
hospit
hematolog
oncologybmt
beirut
lebanon
makass
univers
hospit
bmt
beirut
lebanon
middl
east
institut
health
univers
hospit
bmt
beirut
lebanon
makass
univers
hospit
laboratori
medicin
beirut
lebanon
background
philadelphia
ph
chromosom
acut
lymphoblast
leukemia
repres
approxim
adult
patient
pt
ph
histor
consid
poor
prognosi
allogen
hematopoiet
stem
cell
transplant
ahsct
gold
standard
therapi
mainten
complet
remiss
cr
ph
pt
pre
post
ahsct
administr
first
gener
thyrosin
kinas
inhibitor
tki
imatinib
dramat
improv
outcom
ph
reduc
diseas
recurr
long
term
leukemiafreesurviv
reach
approxim
evid
imatinib
advers
effect
transplantrel
morbid
mortal
usag
second
gener
tki
set
improv
result
lower
number
pt
role
ponatinib
third
gener
tki
given
bridg
ahsct
ahsct
investig
achiev
molecular
remiss
ahsct
adult
pt
phall
posit
impact
relaps
long
term
outcom
ahsct
present
result
experi
adult
pt
phall
underw
ahsct
complet
molecular
respons
induct
therapi
includ
dasatinib
second
gener
tki
receiv
mainten
therapi
ahsct
dasatinib
method
pt
receiv
induct
therapi
accord
rhypercvad
regimen
associ
dasatinib
ahsct
perform
relat
donor
dasatinib
given
pre
posttranspl
dose
evalu
molecular
respons
done
qpcr
particular
everi
month
ahsct
result
pt
includ
studi
median
age
male
femal
four
pt
underw
allogen
peripher
stem
cell
transplant
ident
donor
condit
associ
total
bodi
irradi
cyclophosmamid
tbf
thiotepa
bisulfex
fludarabin
pt
two
pt
underw
haploident
allogen
bone
marrow
transplant
mother
condit
tbf
pt
start
dasatinib
mainten
therapi
approxim
month
ahsct
except
one
die
month
ahsct
cmv
pneumonia
median
durat
dasatinib
administr
mainten
therapi
month
modif
dose
dasatinib
done
major
toxic
five
pt
aliv
complet
molecular
respons
median
conclus
ahsct
r
hypercvad
dasatinib
follow
dasatinib
mainten
highli
effici
well
toler
pt
ph
conflict
interest
noth
disclos
children
hospit
soochow
univers
suzhou
china
background
explor
clinic
characterist
prognosi
pediatr
tcell
acut
lymphoblasti
leukemia
tall
enrol
protocol
present
studi
also
design
investig
clinic
signific
noncod
mutat
express
childhood
tall
method
juli
novemb
consecut
patient
year
treat
children
hospit
soochow
univers
depart
pediatr
institut
hematolog
blood
diseas
hospit
predict
valu
clinic
characterist
earli
treatment
respons
includ
prednison
respons
bone
marrow
morpholog
day
induct
chemotherapi
week
consolid
therapi
analyz
incid
noncod
mutat
analyz
polymeras
chain
reaction
pcr
sanger
sequenc
children
express
anlayz
realtim
quantit
pcr
patient
result
overal
surviv
os
event
free
surviv
ef
rate
patient
se
respect
prednison
poor
respond
strongli
associ
decreas
surviv
rate
ef
rate
patient
blast
cell
bone
marrow
morpholog
tend
lower
ef
patient
receiv
bone
marrow
transplant
high
risk
group
show
signific
differ
overal
surviv
rate
other
nt
eight
patient
present
heterozyg
somat
mutat
noncod
element
eight
patient
show
resist
prednison
treatment
express
analysi
mutat
patient
high
express
group
cox
analysi
os
identifi
high
expess
prednison
respons
independ
prognost
factor
tabl
surviv
analysi
show
patient
high
express
lower
os
ef
figur
conclus
conclud
noncod
mutat
rare
pediatr
tall
patient
patient
high
express
tend
poor
clinic
outcom
conflict
interest
author
declar
conflict
interest
workw
declar
commerci
associ
interest
repres
conflict
interest
connect
work
submit
osaka
women
children
hospit
depart
hematologyoncolog
izumi
osaka
japan
background
prognosi
refractoryrelaps
pediatr
acut
leukemia
dismal
enhanc
graftversusleukemia
effect
hlahaploident
peripher
blood
stem
cell
transplant
perform
institut
set
difficult
determin
optim
gvhd
prophylaxi
method
retrospect
review
pediatr
patient
refractoryrelaps
acut
leukemia
underw
hlahaploident
peripher
blood
stem
cell
transplant
follow
reducedintens
condit
haplo
ricpbsct
lowdos
atg
result
six
patient
acut
lymphoblast
leukemia
acut
myeloid
leukemia
four
patient
relaps
allogen
stem
cell
transplant
allosct
complet
remiss
diseas
haplo
ricpbsct
median
age
haplo
ricpbsct
year
rang
year
median
followup
durat
month
rang
month
patient
receiv
hlahaploident
graft
relat
donor
receiv
reducedintens
condit
consist
fludarabineclofarabin
melphalan
etoposid
gvhd
prophylaxi
consist
cyclosporinetacrolimu
shortterm
methotrex
methylprednisolon
atg
day
median
followup
survivor
month
rang
month
overal
surviv
os
rate
event
free
surviv
ef
rate
respect
cumul
transplantrel
mortal
trm
rate
relaps
rate
respect
among
patient
develop
acut
gvhd
develop
mild
chronic
gvhd
develop
moder
chronic
gvhd
conclus
although
sampl
size
small
followup
durat
short
osef
patient
analysi
includ
relaps
allosct
encourag
incid
sever
acut
gvhd
high
could
manag
sever
gvhd
ad
therapeut
dose
immunosuppress
improv
outcom
consid
use
combin
therapi
enhanc
antileukem
effect
molecular
target
therapeut
agent
andor
transplant
conflict
interest
noth
disclos
univers
clinic
hematolog
skopj
macedonia
former
yugoslav
republ
background
allogen
hematopoiet
stem
cell
transplant
sct
treatment
highest
cur
potenti
treatment
patient
hematolog
malign
precis
patient
acut
myeloid
leukemia
aml
known
probabl
complic
biolog
procedur
medicin
risk
complic
worst
outcom
transplant
relat
mortal
trm
higher
patient
depend
variou
factor
european
group
blood
marrow
transplant
ebmt
provid
simpl
usabl
risk
score
effici
use
evalu
risk
patient
aml
undergo
allogen
sct
method
use
ebmt
score
evalu
pretransplant
risk
patient
diagnos
aml
undergo
allogen
sct
analyz
five
factor
age
patient
year
point
year
point
point
stage
diseas
earli
point
intermedi
point
late
point
time
diagnosi
month
point
month
point
donor
type
sibl
point
unrel
point
donor
recipi
gender
combin
femal
donor
male
recipi
point
combin
point
result
could
augment
risk
individu
patient
increas
score
best
worst
made
retrospect
analysi
patient
aml
last
year
treat
allogen
sct
group
male
femal
patient
averag
age
patient
result
patient
perform
sibl
allogen
sct
match
unrel
donor
mud
allogen
sct
mostli
use
condit
regimen
buci
bucyatg
bucymel
use
unmanipul
allograft
median
number
use
stem
cell
tt
mononuclear
cell
averag
day
engraft
major
patient
period
allogen
sct
month
patient
use
ebmt
score
divid
patient
two
group
score
lower
risk
favour
higher
risk
unfavour
low
risk
group
transplant
relat
mortal
trm
patient
higher
risk
group
patient
non
relaps
mortal
nrm
patient
over
surviv
os
year
group
score
group
score
must
note
latter
group
two
patient
transplant
activ
diseas
one
haploident
donor
two
die
acut
steroid
refractori
gvhd
conclus
ebmt
score
valuabl
tool
make
adequ
identif
patient
aml
favour
risk
score
could
benefit
allogen
sct
treatment
option
conflict
interest
disclosur
stem
cell
therapi
center
nation
taiwan
univers
taipei
taiwan
republ
china
nation
taiwan
univers
hopsit
taipei
taiwan
republ
china
background
acut
myeloid
leukemia
aml
patient
european
leukemia
net
eln
favorablerisk
group
gener
requir
allogen
stem
cell
transplant
allosct
first
complet
remiss
howev
substanti
portion
patient
still
relaps
die
diseas
progress
studi
aim
refin
risk
assess
eln
favorablerisk
patient
identifi
subgroup
patient
might
benefit
allosct
method
studi
popul
compris
eln
favorablerisk
aml
patient
hyperleukocytosi
hl
defin
initi
white
blood
cell
count
observ
patient
compar
postremiss
treatment
chemotherapi
allosct
patient
hl
achiev
induct
chemotherapi
minim
time
transplant
select
bia
surviv
analysi
limit
patient
remain
least
month
median
time
allosct
achiev
result
among
hl
nonhl
group
signific
differ
gender
age
hemoglobin
level
platelet
count
initi
diagnosi
hl
patient
higher
incid
inv
cebpa
doubl
mutat
lower
incid
nonhl
patient
hl
patient
lower
cr
rate
vs
higher
relaps
rate
vs
median
followup
date
initi
diagnosi
month
hl
patient
inferior
overal
surviv
os
median
month
vs
reach
nr
relapsefre
surviv
rf
median
month
vs
nr
p
nonhl
patient
figur
among
hl
patient
attain
least
month
patient
receiv
allosct
patient
postremiss
chemotherapi
relaps
rate
higher
chemotherapi
group
allosct
group
vs
allosct
associ
significantli
better
rf
median
nr
vs
month
figur
trend
toward
better
os
median
nr
vs
month
contrari
nonhl
group
patient
receiv
postremiss
chemotherapi
alon
similar
os
rf
compar
allosct
conclus
hl
predict
higher
relaps
rate
poorer
surviv
eln
favorablerisk
aml
patient
hyperleukocytot
aml
patient
eln
favorablerisk
group
benefit
allosct
respect
rf
result
provid
evid
new
transplant
strategi
hyperleukocytot
eln
favorablerisk
patient
conflict
interest
author
declar
relev
conflict
interest
princess
margaret
cancer
centr
medic
oncolog
haematolog
toronto
canada
king
hussein
cancer
center
amman
jordan
background
patient
cytogenet
normal
cn
aml
prognost
inform
base
molecular
statu
gene
use
guid
treatment
individu
mutat
without
intern
tandem
duplic
favour
risk
diseas
offer
allogen
hct
follow
relaps
consid
higher
risk
relaps
offer
transplant
howev
data
regard
impact
statu
postallogen
hct
limit
examin
effect
statu
outcom
post
allogen
hct
patient
cn
aml
method
retrospect
singlecent
studi
includ
cn
aml
patient
underw
allogen
hct
princess
margaret
cancer
centr
overal
surviv
os
calcul
use
kaplanmei
analysi
multivari
cox
proport
hazard
regress
perform
cumul
incid
relaps
cir
nonrelaps
mortal
nrm
calcul
use
compet
risk
regress
fine
gray
method
studi
approv
univers
health
network
research
ethic
board
result
total
patient
includ
irrespect
mutat
statu
transplant
relaps
follow
convent
chemotherapi
transplant
seventytwo
patient
femal
median
age
hct
rang
median
followup
survivor
month
rang
aml
diagnosi
de
novo
secondari
anoth
hematolog
disord
condit
patient
sixtytwo
patient
relat
donor
match
unrel
haploident
donor
peripher
blood
stem
cell
use
patient
cmv
serostatu
neg
donor
recipi
transplant
myeloabl
condit
use
patient
patient
receiv
reduc
intens
regimen
univari
analysi
demonstr
os
entir
cohort
stratifi
molecular
statu
patient
demonstr
os
respect
patient
transplant
demonstr
os
figur
cir
patient
respect
relaps
occur
group
nrm
patient
respect
patient
nrm
multivari
analysi
os
nrm
confirm
signific
differ
molecular
subgroup
conclus
patient
cn
aml
undergo
allogen
hct
subgroup
similar
posttranspl
outcom
favour
risk
patient
undergo
transplant
similar
outcom
subgroup
transplant
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
univers
munich
depart
medicin
iii
univers
hospit
munich
germani
univers
munich
translat
cancer
immunolog
gene
center
munich
germani
background
allogen
stem
cell
transplant
allosct
far
cur
approach
relapsedrefractori
bprecursor
outcom
allosct
improv
deep
remiss
prior
condit
past
year
treatment
option
rr
ball
widen
significantli
approv
blinatumomab
blina
inotuzumabozogamicin
ino
immunotherapeut
agent
impress
activ
chemotherapyrefractori
diseas
howev
signific
proport
patient
still
show
refractori
diseas
earli
relaps
effect
sequenc
treatment
yet
unknown
assess
activ
ino
patient
blinarefractori
rr
bridgetotranspl
salvag
concept
method
patient
year
elig
allosct
rr
bprecursor
blina
treatment
failur
treat
ino
includ
retrospect
analysi
respons
treatment
toxic
special
attent
venoocclus
diseas
frequenc
subsequ
allosct
relapsefre
overal
surviv
evalu
result
eight
patient
male
femal
median
age
year
rang
year
bcrabl
neg
bprecursor
treat
ino
median
four
rang
prior
antineoplast
treatment
line
two
patient
undergon
previou
allosct
patient
treat
blina
prior
ino
seven
patient
blinarefractori
diseas
respons
treatment
wherea
one
patient
achiev
mrdneg
cr
two
cycl
blina
earli
relaps
day
median
time
blina
initi
start
ino
treatment
day
rang
day
shortterm
toxic
ino
mainli
hematolog
manag
thrombocytopenia
grade
one
grade
one
grade
six
patient
neutropenia
grade
one
grade
seven
patient
promin
advers
event
apart
atyp
pneumonia
one
patient
infecti
complic
record
vod
suspect
two
patient
undergo
subsequ
allosct
success
treat
defibrotid
liverassoci
consecut
morbid
mortal
observ
five
eight
patient
respond
ino
treatment
median
cycl
rang
cycl
cr
achiev
one
mrd
cri
three
mrd
mrd
pr
one
patient
respond
patient
proceed
allosct
three
five
patient
respond
ino
relaps
two
relaps
occur
day
ino
initi
respect
one
relaps
subsequ
allosct
day
ino
initi
median
relapsefre
surviv
day
rang
day
two
patient
ongo
remiss
ino
one
remain
relapsefre
day
one
patient
die
relapsefre
due
sepsi
day
ino
initi
time
analys
three
patient
aliv
median
overal
surviv
day
rang
day
conclus
induc
remiss
signific
proport
patient
blinarefractori
bprecursor
ino
repres
valuabl
therapi
option
patient
otherwis
fatal
prognosi
subsequ
allosct
enabl
heavili
pretreat
patient
limit
hematolog
toxic
observ
vod
manag
ino
induc
longlast
remiss
without
subsequ
allosct
remain
evalu
conflict
interest
none
author
anyth
disclos
uti
ospedal
civil
dipartimento
di
ematologia
medicina
trasfusional
e
biotecnologi
pescara
itali
background
isol
extramedullari
iem
relaps
rare
event
allogen
hct
characterist
prognosi
poorli
defin
aim
studi
evalu
incid
risk
factor
outcom
iem
relaps
acut
leukemia
al
patient
hct
method
retrospect
analyz
consecut
al
patient
aml
underw
allogen
hct
center
march
june
result
median
followup
month
rang
patient
live
overal
surviv
os
patient
show
al
relaps
median
followup
day
rang
among
die
diseas
progress
cumul
incid
ci
relaps
aml
p
iem
relaps
histolog
document
patient
iem
relaps
involv
testi
cn
bone
breast
skin
lymphonod
aml
patient
cn
skin
lymphnod
eye
patient
ci
iem
bone
marrow
bm
relaps
respect
median
age
patient
iem
relaps
bm
relaps
year
respect
tabl
show
characterist
patient
popul
analyz
impact
age
gender
al
type
aml
vs
presenc
em
diseas
diagnosi
cibmtr
risk
factor
diseas
statu
condit
chemotherapi
vs
tbi
mac
vs
ric
graft
sourc
bm
vs
pbsc
donor
sibl
mud
haploident
acut
chronic
gvhd
occur
iem
relaps
em
diseas
diagnosi
factor
associ
increas
risk
iem
relaps
univari
multivari
analysi
hr
ys
os
rate
iem
relaps
bm
relaps
among
patient
iem
relaps
die
diseas
progress
acut
gvhd
dli
patient
live
receiv
second
allogen
hct
chemotherapi
sorafenib
conclus
iem
relaps
rare
event
compar
bm
relaps
al
patient
seem
occur
younger
patient
associ
poor
prognosi
patient
em
diseas
diagnosi
higher
risk
develop
iem
relaps
need
close
followup
hct
detect
earli
evid
em
diseas
conflict
interest
conflict
interest
tabl
tabl
univers
prishtina
prishtina
kosovo
republ
background
kosovo
conflict
march
june
nato
airforc
fire
around
round
deplet
uranium
du
locat
increas
incid
lymphoblast
leukaemia
iraqi
children
war
period
attribut
use
du
round
rise
concern
posibl
link
use
du
round
postwar
incid
leukemia
kosovo
aim
studi
compar
incid
rate
acut
leukemia
seven
region
kosovo
prishtina
prizren
peja
gjakova
mitrovica
ferizaj
gjilan
prewar
period
period
explor
possibl
link
number
site
hit
du
round
incid
acut
leukemia
kosovo
region
method
acut
leukemia
case
diagnos
period
extract
patient
record
univers
clinic
centr
kosovo
number
site
hit
du
round
region
determin
accur
nato
record
contain
geograph
coordin
incid
rate
per
person
calcul
region
three
period
base
popul
censu
data
result
incid
rate
acut
leukemia
kosovo
increas
also
signific
differ
region
biggest
differ
incid
rate
period
found
gjakova
region
incid
increas
prizren
region
peja
region
mitrovica
region
signific
chang
observ
prishtina
gjilan
ferizaj
differ
incid
rate
period
analys
biggest
differ
found
gjakova
follow
peja
mitrovica
prizren
gjilan
ferizaj
prishtina
region
largest
number
site
hit
du
round
gjakova
region
prizren
region
peja
region
wherea
smaller
number
site
hit
region
mitrovica
prishtina
gjilan
ferizaj
conclus
biggest
differ
incid
acut
leukemia
period
observ
region
biggest
number
site
hit
du
round
one
except
mitrovica
region
known
high
concentr
lead
air
topsoil
conflict
interest
hatixh
latifipupovci
noth
disclos
cathol
bmt
center
cathol
univers
korea
hematolog
seoul
korea
republ
background
adult
patient
highrisk
acut
lymphoblast
leukemia
poor
outcom
standard
chemotherapi
usual
undergo
hematopoiet
cell
transplant
hct
match
sibl
donor
msd
match
unrel
donor
mud
match
donor
avail
hct
partiallymismatch
unrel
donor
mmud
cord
blood
cb
famili
haploident
donor
consid
tri
analyz
longterm
hct
outcom
accord
donor
type
includ
msd
mud
mmud
cb
autolog
auto
sourc
method
enrol
consecut
adult
patient
underw
transplant
first
remiss
median
age
year
rang
year
myeloabl
condit
regimen
consist
cyclophosphamid
mgkg
total
bodi
irradi
tbi
gy
doubl
cb
transplant
dcbt
tbi
gy
cytarabin
fludarabin
patient
age
year
comorbid
condit
given
ident
reducedintens
condit
regimen
consist
fludarabin
melphalan
condit
regimen
auto
tbi
gy
cytarabin
melphalan
graftversushost
diseas
gvhd
prophylaxi
attempt
administ
calcineurin
inhibitor
cyclosporin
msd
transplant
tacrolimu
unrel
donor
transplant
plu
methotrex
mycophenol
mofetil
dcbt
antithymocyt
globulin
atg
administ
patient
receiv
mmud
graft
result
median
followup
month
rang
month
overal
surviv
os
entir
patient
detail
os
msd
mud
mmud
dcbt
auto
respect
msd
mud
mmud
show
similar
relaps
rate
nonrelaps
mortal
nrm
rate
dcbt
show
higher
nrm
rate
lower
relaps
rate
auto
show
higher
relaps
rate
interestingli
calcul
gvhd
relapsefre
surviv
grf
year
msd
mud
mmud
dcbt
respect
relat
higher
incid
sever
chronic
gvhd
mud
msd
compar
dcbt
p
highrisk
subgroup
patient
includ
philadelphia
chromosomeposit
os
msd
mud
mmud
dcbt
auto
respect
grf
msd
mud
mmud
dcbt
respect
reveal
lower
relaps
sever
chronic
gvhd
rate
dcbt
conclus
longterm
data
show
outcom
similar
transplant
use
msd
mud
mmud
cb
sourc
adult
patient
howev
grf
rather
superior
patient
treat
dcbt
receiv
donor
sourc
studi
sizabl
popul
need
clarifi
role
altern
donor
transplant
adult
context
grf
conflict
interest
author
declar
conflict
interest
univers
hospit
brno
dpt
intern
medicin
hematolog
oncolog
brno
czech
republ
background
allogen
stem
cell
transplant
sct
consid
treatment
choic
mani
hematolog
disord
mainli
hematolog
malign
role
allogen
sct
wide
discuss
era
novel
drug
present
longterm
experi
allogen
sct
cohort
pt
variou
hematolog
malign
method
analyz
pt
undergo
allogen
sct
centr
novemb
june
diagnos
pt
follow
aml
pt
pt
lymphoma
pt
mdsmpn
pt
cml
pt
cll
pt
diagnos
pt
median
age
pt
year
rang
type
donor
use
graft
follow
hla
ident
sibl
unrel
donor
pbsc
bm
median
followup
sct
month
rang
median
followup
sct
surviv
pt
month
rang
myeloabl
condit
mac
use
pt
reduc
intens
condit
ric
use
pt
diseas
statu
sct
remiss
pt
activ
diseas
pt
median
time
diagnosi
sct
month
result
overal
respons
rate
allogen
sct
includ
cr
pt
pr
pt
incid
acut
gvhd
grade
iii
grade
iiiiv
incid
chronic
gvhd
limit
extens
nonrelaps
mortal
nrm
year
year
year
sct
respect
relaps
incid
year
year
year
sct
respect
median
pf
month
median
os
month
pt
gender
age
sct
type
donor
type
graft
time
diagnosi
sct
type
condit
significantli
influenc
pf
os
cohort
pt
patient
aml
got
significantli
shorter
pf
pt
diagnos
median
pf
month
versu
month
p
hr
pt
activ
diseas
sct
got
significantli
shorter
pf
pt
remiss
sct
median
pf
month
versu
month
p
hr
multivari
analysi
diagnosi
aml
versu
diagnos
median
os
month
versu
month
p
hr
activ
diseas
sct
versu
remiss
sct
median
os
month
versu
month
p
hr
signific
predictor
poor
os
conclus
allogen
transplant
still
remain
standard
treatment
option
predominantli
variou
hematolog
malign
accord
result
type
diagnosi
diseas
statu
allogen
sct
simpl
import
prognost
factor
pf
os
patient
remiss
diseas
allogen
sct
got
significantli
longer
pf
os
conflict
interest
noth
disclos
author
di
firenz
sod
ematologia
aou
careggi
firenz
itali
sod
laboratorio
general
settor
citometria
clinica
aou
careggi
firenz
itali
sod
diagnostica
genetica
aou
careggi
firenz
itali
background
earli
detect
neoplast
cell
allogen
hematopoiet
stem
cell
transplant
hsct
adult
patient
affect
acut
leukemia
provid
opportun
manag
control
potenti
reemerg
malign
clone
sever
group
report
rapidli
increas
mix
chimer
correl
higher
risk
relaps
predictor
impend
relaps
minim
residu
diseas
mrd
monitor
flow
cytometri
fc
pcrbase
chimer
bone
marrow
bm
peripher
blood
pb
sampl
specif
timepoint
hsct
restrict
chimer
analysi
sort
cell
could
earli
predictor
relaps
hsct
method
diagnosi
acut
leukemia
use
leukemiaassoci
aberr
immunophenotyp
laip
establish
patient
investig
specif
timepoint
treatment
plan
detect
laipposit
cell
dna
extract
pb
donor
recipi
hsct
chimer
assess
perform
whole
pb
sort
cell
recipi
hsct
specif
time
point
day
month
hsct
result
januari
august
patient
affect
acut
leukemia
receiv
allogen
transplant
patient
enrol
project
patient
evalu
due
toxic
transplant
hitherto
data
patient
least
evalu
carri
avail
case
result
concord
mrdneg
statu
full
donor
chimer
whole
pb
sort
fraction
occur
found
discord
patient
show
transitori
loss
chimer
immedi
convert
donor
next
detect
alway
mrd
neg
patient
show
alway
full
chimer
fraction
wherea
mrd
posit
timepoint
without
relaps
patient
chimer
analysi
sort
cell
allow
earli
diagnosi
diseas
recurr
highlight
presenc
patholog
cell
concomit
neg
signal
fcmrd
whole
pb
chimer
conclus
last
patient
clearli
repres
basic
rational
studi
chimer
assess
may
provid
opportun
earli
detect
neoplast
cell
transplant
regard
discord
result
slightli
loss
chimer
immedi
convert
mandat
confirm
detect
soon
possibl
sinc
one
singl
assess
turn
inadequ
predict
actual
diseas
relaps
would
interest
address
signific
fluctuat
chimer
whole
pb
sort
cell
larger
patient
cohort
chimer
assess
sort
fraction
earli
predictor
relaps
might
use
drive
therapeut
strategi
post
transplant
set
conflict
interest
project
fund
ministero
della
salut
region
toscana
cup
fondazion
biagioniborgogni
legato
zottola
donat
author
declar
compet
financi
interest
mazumdar
shaw
cancer
center
narayana
health
citi
pediatr
hematolog
oncolog
bone
marrow
transplant
bangalor
india
mazumdar
shaw
cancer
center
narayana
health
citi
bangalor
india
background
haematopoiet
stem
cell
transplant
hsct
remain
potenti
cur
treatment
modal
patient
acut
leukemia
first
complet
remiss
beyond
howev
fulli
hla
match
donor
unavail
major
haploident
transplant
emerg
feasibl
option
scenario
method
retrospect
analysi
pediatr
patient
acut
leukemia
undergo
haploident
stem
cell
transplant
center
august
june
result
thirti
two
patient
median
age
month
rang
form
studi
group
case
acut
lymphoblast
leukemia
b
cell
cell
case
acut
myeloid
leukemia
aml
includ
studi
among
patient
remain
wherea
among
aml
patient
patient
respect
myeloabl
condit
use
case
tbi
base
condit
use
patient
fludarabinebusulphan
base
condit
use
aml
patient
gvhd
prophylaxi
provid
form
tcr
deplet
patient
remain
receiv
post
transplant
cyclophosphamid
ptci
along
calcineurin
inhibitor
mycophenol
mofetil
peripher
blood
sourc
stem
cell
major
patient
median
infus
cell
dose
x
kg
tcr
deplet
group
x
kg
ptci
group
thirti
one
patient
achiev
haematolog
recoveri
neutrophil
engraft
median
day
vs
day
p
platelet
engraft
median
day
vs
day
p
tcr
deplet
ptci
group
respect
transplant
outcom
describ
tabl
given
tabl
cumul
incid
grade
gvhd
grade
gvhd
relaps
non
relaps
mortal
vs
vs
vs
vs
tcr
deplet
group
vs
ptci
group
respect
p
overal
surviv
vs
tcr
deplet
ptci
group
diseas
free
surviv
graph
vs
two
group
figur
conclus
haploident
hsct
feasibl
approach
paediatr
acut
leukemia
patient
lack
fulli
match
donor
conflict
interest
none
tabl
tabl
yokohama
citi
univers
medic
center
yokohama
japan
toyohashi
medic
center
toyohashi
japan
japanes
red
cross
nagoya
first
hospit
nagoya
japan
tokyo
metropolitan
cancer
infecti
diseas
center
komagom
hospit
tokyo
japan
sapporo
hokuyu
hospit
sapporo
japan
hyogo
colleg
medicin
nishinomiya
japan
nation
cancer
center
hospit
tokyo
japan
tokyo
women
medic
univers
tokyo
japan
japanes
data
center
hematopoiet
cell
transplant
nagoya
japan
nagoya
univers
graduat
school
medicin
nagoya
japan
saitama
medic
center
jichi
medic
univers
omiya
japan
background
acut
lymphoblast
leukemia
account
approxim
adult
bcell
character
poor
outcom
therefor
presenc
chromosom
abnorm
indic
allogen
hematopoiet
stem
cell
transplant
allohsct
howev
transplant
outcom
remain
unclear
retrospect
examin
impact
outcom
allohsct
patient
bcell
method
clinic
data
collect
registri
databas
japan
societi
hematopoiet
cell
transplant
select
bcell
patient
age
year
underw
first
transplant
januari
decemb
compar
clinic
featur
transplant
outcom
patient
patient
normal
karyotyp
overal
surviv
os
estim
use
kaplanmei
method
compar
use
log
lank
test
multivari
analysi
cox
proport
hazard
model
use
analyz
os
use
follow
covari
age
sex
diseas
statu
donor
sourc
condit
regimen
transplant
year
time
taken
allohsct
diagnosi
extramedullari
diseas
result
number
case
normal
karyotyp
respect
median
age
group
lower
normal
karyotyp
group
year
vs
year
p
higher
proport
group
receiv
allohsct
within
day
diagnosi
vs
p
probabl
os
group
wors
normal
karyotyp
group
subgroup
analysi
stratifi
diseas
statu
reveal
probabl
os
compar
group
normal
karyotyp
group
cr
patient
vs
contrast
group
exhibit
poorer
os
noncr
patient
vs
adjust
covari
signific
impact
os
hr
subgroup
analysi
show
affect
os
cr
patient
multivari
analysi
group
reveal
noncr
transplant
p
signific
risk
factor
poor
os
conclus
find
suggest
allohsct
cr
may
overcom
poor
prognosi
patient
conflict
interest
author
noth
disclos
tata
medic
center
clinic
haematolog
bone
marrow
transplant
kolkata
india
background
hematopoiet
cell
transplant
hct
remain
cornerston
treatment
high
risk
myeloid
malign
real
world
evid
middl
incom
countri
method
undertook
retrospect
chart
review
hct
undertaken
patient
high
risk
myeloid
malign
dec
oct
median
age
yr
rang
yr
includ
acut
myeloid
leukaemia
acut
promyelocyt
leukemia
apl
md
cml
chronic
lymphoid
blast
myeloid
blast
myelofibrosi
chronic
myelomonocyt
leukemia
blastic
plasmacytoid
dendrit
cell
neoplasm
high
risk
diseas
account
morpholog
criteria
eg
myelodysplasia
high
risk
cytogenet
molecular
profil
clinic
indic
induct
failur
relaps
diseas
etc
patient
patient
activ
diseas
primari
refractori
relaps
refractori
time
transplant
referr
amongst
patient
underw
transplant
relaps
diseas
relaps
month
within
month
relaps
month
patient
underw
allogen
hct
except
relaps
apl
autolog
hct
allogen
hct
donor
sourc
includ
match
sibl
donor
haploident
relat
donor
match
unrel
donor
condit
therapi
myeloabl
allogen
autolog
hct
reduc
intens
condit
undertaken
allogen
hct
patient
receiv
peripher
blood
stem
cell
transplant
pbsct
throat
faecal
surveil
cultur
multidrug
resist
organ
mdro
done
patient
gvhd
prophylaxi
vari
depend
type
allogen
transplant
includ
either
ptcytacmmf
approach
patient
result
median
cell
dose
cellskg
primari
graft
failur
mortal
acut
gvhd
gr
iiiiv
agvhd
cgvhd
rate
patient
respect
median
follow
day
entir
cohort
year
overal
surviv
os
relaps
free
surviv
rf
respect
median
overal
surviv
month
mdro
colon
observ
stool
surveil
patient
throat
surveil
cultur
patient
among
speci
mdro
identifi
stool
sampl
esbl
produc
gram
neg
bacilli
gnb
carbapenem
resist
gnb
vancomycin
resist
enterococci
singl
center
retrospect
seri
type
transplant
statu
diseas
time
transplant
durat
remiss
case
relaps
diseas
blood
group
sex
mismatch
donor
recipi
impact
os
rf
factor
found
significantli
affect
outcom
gender
femal
better
outcom
compar
male
conclus
middl
incom
countri
high
preval
mdro
colon
hematopoiet
cell
transplant
high
risk
myeloid
malign
tertiari
care
center
yield
modest
outcom
conflict
interest
relev
conflict
interest
oregon
health
scienc
knight
cancer
institut
center
hematolog
malign
portland
unit
state
univers
chicago
hematopoiet
stem
cell
transplant
program
chicago
il
unit
state
st
vincent
hospit
univers
melbourn
peter
maccallum
cancer
centr
melbourn
australia
univers
hospit
cologn
depart
haematolog
oncolog
cologn
germani
medic
univers
vienna
depart
medicin
vienna
austria
univers
kansa
medic
center
depart
blood
bone
marrow
transplant
kansa
citi
ks
unit
state
winship
cancer
institut
emori
univers
bone
marrow
stem
cell
transplant
center
atlanta
ga
unit
state
jame
cancer
hospit
solov
research
institut
ohio
state
univers
comprehens
cancer
center
columbu
oh
unit
state
univers
california
san
francisco
helen
diller
famili
comprehens
cancer
center
depart
hematolog
blood
marrow
transplant
san
francisco
ca
unit
state
mcmaster
univers
juravinski
hospit
cancer
centr
hamilton
canada
univers
montreal
maisonneuverosemont
hospit
montreal
canada
univers
medic
center
center
allogen
stem
cell
transplant
germani
univers
texa
md
anderson
cancer
center
depart
lymphoma
myeloma
divis
cancer
medicin
houston
tx
unit
state
univers
sydney
depart
medicin
sydney
australia
univers
minnesota
depart
medicin
divis
hematolog
oncolog
transplant
minneapoli
mn
unit
state
oslo
univers
hospit
depart
oncolog
oslo
norway
univers
michigan
comprehens
cancer
center
ann
arbor
mi
unit
state
novarti
pharma
ag
basel
switzerland
novarti
pharmaceut
corpor
east
hanov
nj
unit
state
rti
health
solut
barcelona
spain
chu
lyonsud
hospit
hospic
civil
de
lyon
depart
hematolog
lyon
franc
univers
pennsylvania
lymphoma
program
abramson
cancer
center
philadelphia
pa
unit
state
background
juliet
evalu
singl
infus
tisagenlecleucel
adult
patient
rr
dlbcl
primari
analys
show
best
overal
respons
rate
complet
respons
cr
method
patient
age
year
chemorefractori
dlbcl
line
therapi
either
fail
otherwis
inelig
autolog
hematopoiet
stem
cell
transplant
sct
baselin
patient
complet
short
health
survey
function
assess
cancer
therapylymphoma
factlym
higher
score
indic
better
qol
result
patient
infus
data
cutoff
previous
receiv
chemotherapi
treatment
relaps
sct
pt
best
respons
cr
partial
respons
pr
follow
month
prior
data
cutoff
discontinu
earlier
elig
analysi
qol
instrument
complet
patient
baselin
patient
cr
pr
patient
cr
pr
complet
assess
respect
score
patient
cr
pr
mean
baselin
mean
chang
mean
chang
indic
sustain
improv
baselin
categori
tabl
similar
trend
observ
conclus
improv
qol
observ
score
suggest
sustain
improv
result
suggest
tisagenlecleucel
therapi
may
improv
qol
among
respond
despit
patient
experienc
earli
toxic
clinic
trial
registri
clinicaltrialsgov
conflict
interest
r
maziarz
novarti
research
fund
honoraria
membership
entiti
board
directorsadvisori
committe
incyt
consult
honoraria
juno
kite
honoraria
athersi
patent
royalti
bishop
novarti
consult
includ
expert
testimoni
steer
committe
kite
battersea
consult
includ
expert
testimoni
celgen
honoraria
speaker
bureau
c
tam
novarti
honoraria
p
borchmann
novarti
honoraria
u
jaeger
roch
janssen
novarti
honoraria
membership
entiti
bodac
novarti
rf
j
mcguirk
novarti
payment
pi
cart
studi
e
waller
novarti
consult
includ
et
rf
cambium
medic
patent
royalti
membership
entiti
bodac
celldex
pra
amgen
consult
includ
et
jaglowski
novarti
kite
consult
rf
unum
pharmacycl
rf
c
andreadi
novarti
rf
honoraria
celler
incyt
pharmacycl
amgen
rf
genentech
honoraria
equiti
ownershipspous
seattl
genet
gilead
astella
honoraria
foley
novarti
consult
fleuri
merck
janssen
roch
seattl
genet
gilead
amgen
lundbeck
novarti
consult
mielk
kiadi
travel
grant
jazz
pharma
speaker
bureau
novarti
consult
celgen
cellex
gmbh
speaker
bureau
travel
grant
msd
consult
travel
grant
gilead
travel
grant
dgho
travel
support
isct
travel
support
j
westin
novarti
apotex
kite
celgen
membership
entiti
bodac
p
ho
novarti
amgen
bm
celgen
janssen
takeda
honoraria
membership
entiti
bodac
janssen
takeda
consult
v
bachanova
novarti
rf
seattl
genet
juno
zymogen
membership
entiti
bodac
oxi
rf
h
holt
novarti
membership
entiti
bodac
j
magenau
noth
disclos
anak
guenther
novarti
pharma
ag
employ
l
pacaud
j
zhang
f
tai
novarti
pharmaceut
employ
l
rasouliyan
rti
health
solut
employ
g
sall
amgen
bm
celgen
gilead
janssen
kite
merck
morphosi
novarti
servier
roch
consult
particip
symposiaab
roch
consult
research
grant
schuster
novarti
celgen
genentech
merck
janssen
r
hoffmanlaroch
bm
rf
novarti
celgen
genentech
seattl
genet
nordic
nanovector
consult
includ
et
tehran
univers
medic
scienc
hematolog
oncolog
stem
cell
transplant
research
center
tehran
iran
islam
republ
tehran
univers
medic
scienc
hematolog
oncolog
stem
cell
transplant
research
center
tehran
iran
islam
republ
background
sever
studi
reveal
signific
pretreat
cytogenet
find
tumor
cell
strong
clinic
predictor
aim
evalu
effect
pretreat
cytogenet
abnorm
treatment
outcom
iranian
adult
acut
myeloid
leukemia
aml
allogen
hematopoiet
stem
cell
transplant
hsct
method
total
adult
patient
aml
underw
allogen
hsct
march
march
shariati
gener
hospit
patient
pretreat
cytogenet
data
includ
studi
median
followup
time
month
overal
surviv
os
diseasefreesurviv
df
rate
differ
cytogenet
abnorm
compar
normal
karyotyp
result
fiveyear
os
rate
patient
os
df
rate
significantli
lower
abn
inv
del
add
abn
abn
exclud
abn
complex
karyotyp
unrel
abnorm
monosom
karyotyp
none
cytogenet
abnorm
associ
favor
outcom
conclus
studi
suggest
age
pretreat
cytogenet
abnorm
independ
predictor
treatment
outcom
hsct
aml
patient
unlik
previou
studi
studi
invers
associ
favor
outcom
classifi
intermedi
risk
group
conflict
interest
noth
disclos
institut
haematolog
blood
transfus
bmt
pragu
czech
republ
institut
haematolog
blood
transfus
dpt
genom
pragu
czech
republ
background
increas
evid
aml
minim
residu
diseas
mrd
persist
standard
induct
therapi
associ
increas
risk
relaps
poor
surviv
allogen
hematopoiet
stem
cell
transplant
allohsct
consid
effect
strategi
treatment
high
risk
aml
aim
evalu
prognost
impact
pretranspl
mrd
measur
realtim
quantit
pcr
patient
aml
receiv
allohsct
method
evalu
patient
pt
median
age
year
rang
year
women
median
followup
surviv
time
allohsct
month
twentysix
pt
posit
allohsct
pt
first
second
complet
remiss
cr
refractori
diseas
rd
fortytwo
pt
underw
myeloabl
reducedintens
allohsct
donor
ident
sibl
pt
haploident
relat
pt
match
unrel
donor
pt
mismatch
ud
pt
pt
use
pbpc
pt
bone
marrow
one
pt
intermedi
risk
prognost
score
pretranspl
mrd
level
measur
peripher
blood
pt
pt
pretranspl
mrd
level
mutant
copi
per
abl
copi
consid
mrd
neg
time
allohsct
pt
mrd
neg
posit
refractori
patient
exclud
analysi
result
estim
probabl
relaps
incid
ri
nonrelaps
mortal
nrm
eventfre
surviv
ef
overal
surviv
os
chronic
gvhd
whole
cohort
respect
thirtyon
pt
develop
acut
gvhd
significantli
better
result
observ
mrd
neg
pt
respect
ri
ef
ri
ef
mrd
neg
mrd
posit
pt
resp
p
similar
prognost
signific
observ
itd
posit
ri
ef
neg
posit
pt
resp
p
differ
signific
term
os
howev
differ
os
even
pt
rd
cr
multivari
analysi
increas
age
statist
signific
predictor
poor
os
hr
everi
year
age
ci
p
term
ef
observ
inferior
outcom
posit
pt
hr
ci
posit
hr
p
neg
hr
p
associ
higher
relaps
risk
conclus
aml
patient
mutat
mrd
posit
allohsct
clearli
associ
higher
incid
relaps
nrm
cohort
rel
high
like
due
gvhd
howev
data
suggest
allohsct
associ
develop
gvl
effect
mostli
link
gvhd
may
overcom
neg
prognost
impact
mrd
posit
conflict
interest
none
feder
almazov
northwest
medic
research
centr
st
petersburg
russian
feder
background
haplosct
appropri
altern
match
donor
unavail
although
gvhd
relaps
could
potenti
decreas
surviv
prophylact
administr
azacitidin
perform
antileukem
immunomodul
activ
help
overcom
obstacl
method
patient
aml
haplosct
includ
studi
patient
achiev
mrdneg
remiss
day
sct
mrd
assess
measur
express
administr
azacitidin
began
earlier
month
sct
case
full
engraft
absenc
activ
gvhd
dose
azacitidin
mg
everi
day
year
sct
dli
ad
case
molecular
relaps
result
patient
receiv
prophylact
administr
azacitidin
control
group
median
time
begin
azacitidin
month
median
number
cours
frequent
toxic
hematolog
anemia
thrombocytopenia
neutropenia
case
secondari
graft
failur
occur
patient
acut
gvhd
treatment
azacitidin
azatreat
four
patient
relaps
agvhd
skin
gut
one
case
gutgvhd
occur
de
novo
treatment
two
patient
requir
system
immunosuppress
methylprednisolon
control
group
agvhd
occur
patient
requir
system
immunosuppress
differ
statist
signific
due
small
number
patient
rate
chronic
gvhd
azagroup
control
group
compar
case
skinchgvhd
accompani
hepaticgvhd
one
patient
molecular
relaps
observ
azagroup
control
group
two
patient
molecular
relaps
treat
azacitidin
dli
first
patient
die
sever
agvhd
anoth
one
achiev
mrdneg
remiss
still
aliv
see
case
bone
marrow
relaps
probabl
intens
gvl
haplosct
short
period
observ
current
patient
azagroup
patient
control
group
aliv
median
observ
period
month
respect
azagroup
one
patient
die
agvhd
control
group
infect
agvhd
saw
significantli
better
overal
surviv
azagroup
conclus
prophylact
administr
aza
haplosct
patient
aml
safe
well
toler
aza
prophylaxi
significantli
improv
overal
surviv
improv
could
due
decreas
agvhd
relaps
although
differ
appear
statist
nonsignific
cohort
patient
conflict
interest
none
tabl
characterist
patient
ospedal
papa
giovanni
xxiii
hematolog
bone
marrow
transplant
unit
bergamo
itali
degli
studi
di
milano
depart
oncolog
hematolog
milan
itali
background
nucleophosmin
one
commonli
mutat
gene
acut
myeloid
leukemia
aml
present
case
mutat
repres
distinct
entiti
world
health
organ
classif
commonli
prognosi
patient
mutat
consid
favor
nevertheless
recent
studi
show
correl
persist
mrd
level
patient
advers
outcom
associ
gener
substanti
interest
use
result
mrdtest
decis
transplant
stratifi
patient
benefit
associ
allogen
stem
cell
transplant
allohsct
first
remiss
remain
investig
method
year
aml
patient
bear
mutat
median
age
rang
consecut
treat
accord
northern
itali
leukaemia
group
nilg
protocol
clinicaltrialsgov
identifi
patient
consid
elig
allogen
transplant
first
remiss
diagnosi
itd
posit
high
white
blood
cell
wbc
count
show
persist
minim
residu
diseas
mrd
molecularli
detect
consolid
high
dose
cytarabin
result
main
clinic
find
patient
analyz
summar
tabl
patient
receiv
allohsct
younger
higher
wbc
count
fltitd
mutat
diagnosi
show
frequent
persist
mrd
postiv
consolid
compar
patient
undergo
tranplant
tabl
induct
cours
patient
achiev
complet
hematolog
remiss
cr
underw
allohsct
first
complet
remiss
mrd
statu
consolid
chemotherapi
avail
patient
fortyon
patient
receiv
allohsct
donor
sibl
unrel
haploident
cord
blood
unit
diseas
free
surviv
df
significantli
better
patient
receiv
allohsct
vs
ci
figur
howev
year
os
significantli
differ
ci
patient
receiv
allohsct
compar
patient
undergo
allohsct
first
remiss
whole
patient
cohort
year
overal
surviv
os
ci
multivari
analysi
presens
mutat
persist
mrd
consolid
chemotherapi
associ
shorter
surviv
indipend
transplant
consolid
conclus
result
show
allohsct
improv
df
compar
standard
chemotherapi
also
patient
acut
myeloid
leukemia
higher
risk
leukemia
relaps
presenc
fltitd
mutat
persist
mrd
postiv
transplant
conflict
interest
none
author
anyth
disclos
tabl
patient
characterist
charl
univers
hospit
pilsen
hematooncolog
dpt
pilsen
czech
republ
background
reducedintens
transplant
rit
acut
myeloid
leukemia
aml
beyond
complet
remiss
cr
associ
higher
relaps
incid
lower
progressionfre
surviv
pf
overal
surviv
os
elderli
patient
pt
pt
comorbid
rare
benefit
myeloabl
condit
intens
chemotherapi
cht
aml
due
high
risk
treatmentrel
mortal
trm
evalu
role
rit
potenti
effect
pretransplant
characterist
treatment
pt
aml
beyond
cr
retrospect
analys
outcom
pt
undergo
rit
centr
method
sinc
pt
median
age
year
year
aml
beyond
cr
underw
rit
hctci
pt
pt
untreat
relaps
aml
pt
chemotherapyresist
diseas
pt
underw
upfront
rit
without
previou
aml
therapi
pt
blast
bone
marrow
bm
donor
hla
ident
relat
hla
haploident
relat
hla
match
unrel
hla
mismatch
unrel
sourc
stem
cell
peripher
blood
median
infus
cd
cell
condit
regimen
consist
fludarabin
melphalan
pt
pt
underw
rit
sequenti
regimen
cht
ric
result
pt
engraft
achiev
complet
remiss
cr
full
donor
chimer
fdc
day
rit
pt
develop
acut
gvhd
grade
iiiiv
among
evalu
pt
develop
chronic
gvhd
mild
moder
sever
median
followup
month
month
pt
aliv
pt
continu
cr
fdc
pt
relaps
median
time
rit
relaps
month
month
die
pt
die
due
trm
till
day
rit
estim
probabl
pf
os
presenc
blast
pb
p
bm
blast
p
hctci
p
statist
significantli
neg
affect
outcom
rit
conclus
spite
rel
small
number
evalu
pt
retrospect
type
analysi
data
suggest
rit
achiev
continu
longterm
cr
third
pt
aml
beyond
cr
elig
myeloabl
condit
intens
cht
aml
import
pretransplant
factor
significantli
influenc
rit
outcom
find
circul
blast
pb
percentag
bm
blast
hctci
statu
diseas
diagnost
cytogenet
find
age
type
donor
type
condit
regimen
significantli
affect
outcom
rit
conflict
interest
author
declar
conflict
interest
medic
park
hospit
pediatr
hematolog
oncolog
bmt
unit
istanbul
turkey
medic
park
hospit
istanbul
turkey
univers
faculti
medicin
atak
hospit
istanbul
turkey
akdeniz
univers
faculti
medicin
antalya
turkey
ege
univers
faculti
medicin
izmir
turkey
ankara
child
health
diseas
hematolog
oncolog
train
research
hospit
ankara
turkey
medic
park
antalya
hospit
antalya
turkey
ankara
univers
faculti
medicin
ankara
turkey
hacettep
univers
faculti
medicin
ankara
turkey
gazi
univers
faculti
medicin
ankara
turkey
erciy
univers
faculti
medicin
kayseri
turkey
univers
faculti
medicin
adana
turkey
univers
faculti
medicin
adana
hospit
adana
turkey
dokuz
univers
faculti
medicin
izmir
turkey
medic
park
samsun
hospit
samsun
turkey
health
scienc
univers
medic
faculti
ankara
turkey
istanbul
medipol
univers
faculti
medicin
istanbul
turkey
medic
park
hospit
istanbul
turkey
yeni
univers
faculti
medicin
hospit
istanbul
turkey
chief
turkish
pediatr
bmt
group
istanbul
turkey
background
relaps
import
caus
death
hematopoiet
stem
cell
transplant
hsct
acut
leukemia
repres
challeng
manag
problem
method
questionnair
sent
turkish
pediatr
transplant
center
report
leukem
relaps
patient
cohort
hsct
acut
leukemia
regist
turkish
pediatr
bone
marrow
registri
januari
decemb
evalu
data
obtain
patient
aml
bilineag
leukemia
indifferenti
leukemia
underw
allogen
hsct
relaps
result
median
interv
transplant
relaps
day
rang
two
hundr
twentyeight
patient
aml
bilineag
leukemia
indifferenti
leukemia
receiv
treatment
relaps
patient
achiev
complet
remiss
higher
cumul
overal
surviv
month
compar
patient
achiev
complet
remiss
ci
vs
ci
p
factor
predict
success
remiss
induct
relaps
age
year
first
transplant
ci
isol
extramedullari
relaps
ci
interv
month
first
hsct
relaps
ci
fiftyf
patient
complet
remiss
receiv
second
hsct
patient
aliv
without
diseas
median
followup
time
day
rang
conclus
result
show
treatment
prolong
surviv
pediatr
patient
relaps
hsct
acut
leukemia
select
patient
longterm
leukemiafre
surviv
could
achiev
second
hsct
conflict
interest
author
declar
conflict
interest
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
background
blinatumomab
amgen
inc
bispecif
tcell
engag
produc
remark
respons
variou
bcell
malign
mainli
patient
refractoryrelaps
acut
lymphoblast
leukemia
also
patient
refractori
heavili
pretreat
bcell
lymphoma
though
well
establish
blinatumomab
effect
toler
treatment
option
pediatr
insuffici
evid
safeti
efficaci
patient
younger
year
method
herein
present
monthsold
femal
patient
diagnos
infantil
acut
lymphoblast
leukemia
age
month
present
white
blood
cell
count
million
platelet
hemoglobin
gdl
mild
hepatosplenomegali
underw
leukapheresi
peripher
flow
cytometri
confirm
diagnosi
cytogenet
posit
mll
cn
result
bm
immunophenotyp
result
consist
posit
ball
minim
residu
diseas
mononuclear
cell
first
cycl
bm
immunophenotyp
second
cycl
neg
conclus
conclus
patient
blinatumomab
found
effect
term
diseas
control
allosct
show
extrem
safe
profil
conflict
interest
na
oxford
univers
hospit
nh
foundat
trust
oxford
unit
kingdom
nh
blood
transplant
oxford
unit
kingdom
background
allogen
haematopoiet
stem
cell
transplant
hsct
establish
cur
treatment
myeloid
malign
nonetheless
relaps
occur
patient
outcom
postallograft
remain
poor
overal
surviv
year
report
around
bejanyan
devilli
evid
show
use
cytotox
approach
select
patient
togeth
donor
lymphocyt
infus
dli
second
allograft
achiev
meaning
respons
rate
around
lim
vrhovac
schroeder
method
analys
outcom
aml
patient
develop
morpholog
relaps
allogen
hsct
perform
april
august
centr
patient
underw
monthli
bone
marrow
assess
first
year
post
transplant
thereaft
relaps
suspect
patient
relaps
aml
offer
treatment
either
intens
aml
chemotherapi
ct
azacitidin
follow
dli
appropri
case
palli
chemotherapi
best
support
care
given
overal
surviv
os
data
analys
logrank
test
kaplanmei
estim
comput
result
median
age
transplant
year
rang
major
patient
receiv
reduc
intens
condit
stem
cell
origin
mud
mrd
ucb
sourc
haploident
famili
donor
median
followup
time
day
rang
patient
transplant
aml
relaps
time
followup
posttranspl
relaps
occur
median
day
rang
follow
relaps
abl
treat
patient
salvag
chemotherapi
patient
relaps
patient
treat
intens
aml
ct
usual
flagida
fla
patient
consid
fit
intens
therapi
treat
azacitidin
although
therapi
avail
throughout
studi
period
two
patient
receiv
palli
chemotherapi
four
best
support
care
one
patient
underw
second
allograft
follow
salvag
chemotherapi
major
patient
salvag
ctazacitidin
group
receiv
dli
follow
count
recoveri
overal
surviv
relaps
patient
year
year
postrelaps
treat
intens
chemotherapi
os
compar
anoth
treatment
approach
use
figur
patient
treat
high
dose
ct
azacitidin
achiev
complet
remiss
aliv
ongo
complet
remiss
time
last
followup
conclus
abl
offer
salvag
chemotherapi
major
patient
relaps
follow
hsct
aml
data
suggest
approach
worthwhil
lead
durabl
remiss
without
use
second
stem
cell
transplant
refer
bejanyan
n
et
al
biol
blood
marrow
transplant
march
devilli
r
et
al
leukemia
lymphoma
lim
abm
et
al
epub
aheadofprint
intern
medicin
journal
june
doi
schroeder
et
al
leukemia
vrhovac
r
et
al
bone
marrow
transplant
conflict
interest
author
noth
disclos
chu
amien
cliniqu
amien
franc
chu
amien
laboratoir
de
cellulair
amien
franc
chu
amien
laboratoir
hla
amien
franc
chu
amien
laboratoir
amien
franc
background
respons
rate
common
salvag
regimen
reach
patient
refractori
acut
myeloid
leukemia
aml
earli
relaps
without
allogen
hsct
longterm
overal
surviv
os
patient
refractori
aml
hardli
reach
sever
studi
demonstr
salvag
chemotherapi
sequenti
condit
could
reduc
leukemia
relaps
risk
accept
toxic
profil
unfavor
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
therefor
decid
assess
procedur
center
amien
univers
hospit
method
conduct
monocentr
retrospect
studi
includ
patient
age
year
undergo
hematopoiet
stem
cell
transplant
hsct
sequenti
condit
januari
decemb
refractori
high
risk
aml
md
patient
receiv
sequenti
condit
contain
clofarabin
setric
other
receiv
amsacrin
base
condit
flamsa
result
median
age
year
rang
condit
patient
activ
diseas
complet
remiss
cr
includ
posit
mrd
patient
prior
treatment
least
previou
cours
chemotherapi
patient
hlaident
sibl
donor
match
unrel
donor
mismatch
unrel
donor
haploident
donor
major
patient
receiv
peripher
blood
stem
cell
pbsc
pbsc
median
count
acut
gvhd
prophylaxi
ciclosporin
combin
mycophenol
mofetil
unrel
donor
withdraw
median
time
day
median
followup
month
overal
surviv
os
year
median
os
month
month
median
diseas
free
surviv
df
month
month
patient
experienc
relaps
hsct
median
time
hsct
relaps
month
month
patient
present
grade
iii
acut
graft
versu
host
diseas
gvhd
grade
iii
iv
agvhd
gvhd
free
relaps
free
surviv
year
oneyear
cumul
incid
diseas
relat
death
nonrelaps
mortal
respect
patient
receiv
immunomodul
azacitidin
donor
lymphocyt
infus
dli
gvhd
occur
within
day
os
patient
receiv
dli
univari
analysi
relaps
hsct
immunomodul
post
hsct
figur
significantli
associ
overal
surviv
p
respect
diseas
statu
hsct
neither
agvhd
occurr
multivari
analysi
relaps
hsct
remain
predict
outcom
conclus
accord
previou
public
studi
show
interest
result
sequenti
condit
regimen
refractori
aml
accept
toxic
profil
addit
post
hsct
immunomodul
achiev
good
os
df
whatev
cytogenet
diseas
statu
hsct
unfortun
fail
identifi
predict
factor
outcom
like
gvhd
occurr
describ
elsewher
probabl
small
size
cohort
conflict
interest
jori
noth
disclos
pavlov
first
saintpetersburg
state
medic
univers
rmgorbacheva
memori
institut
oncolog
haematolog
transplant
saintpetersburg
russian
feder
background
allogen
hematopoiet
stem
cell
transplant
allohsct
effect
therapi
mani
patient
acut
myeloid
leukemia
aml
relaps
allohsct
common
caus
treatment
failur
howev
multiparamet
flow
cytometri
cytogenet
molecular
studi
onset
diseas
make
possibl
detect
minim
residu
diseas
mrd
aml
remiss
order
determin
prognosi
therapi
strategi
method
analys
consecut
patient
aml
sinc
median
age
year
median
followup
month
diseas
statu
allohsct
patient
molecular
genet
lowrisk
group
defin
standard
risk
highrisk
patient
mrd
determin
mrd
patient
posit
result
mrd
mrd
allohsct
patient
includ
mutat
gene
overexpress
leukemia
associ
immunophenotyp
result
diseasefre
surviv
df
allohsct
ci
mrd
ci
wherea
patient
ci
ci
pn
relaps
incid
ri
ci
mrd
ci
wherea
ci
mrd
ci
myeloabl
condit
mac
df
ri
allohsct
depend
mrd
patient
mrd
ci
vs
mrd
ci
ci
vs
ci
respect
wherea
reduc
intens
condit
ric
dfc
higher
ri
lower
patient
mrd
ci
vs
ci
p
ci
vs
ci
p
cytogenet
risk
group
intermedi
high
donor
type
relat
unrel
effect
df
ri
vs
vs
vs
vs
vs
vs
vs
vs
absenc
chronic
graftversushost
diseas
cgvhd
df
ri
better
patient
mrd
ci
vs
ci
p
ci
vs
ci
p
patient
cgvhd
differ
insignific
vs
vs
multivari
analysi
impact
ri
statu
diseas
mrd
mrd
ci
presenc
cgvhd
yesno
ci
df
lower
mrd
ci
p
conclus
immunophenotyp
cytogenet
molecular
data
onset
diseas
necessari
monitor
mrd
aml
remiss
presenc
mrd
neg
effect
df
ri
allohsct
mrd
statu
front
allohsct
indic
intensif
condit
regimen
conflict
interest
author
declar
compet
financi
interest
univers
hospit
lmu
munich
germani
background
clinic
treatment
strategi
dcleu
could
gener
ex
vivo
transfer
pt
altern
blast
modul
leukemiaderiv
dc
dcleu
vivoresult
tcell
activ
combin
gmcsfpicibanil
k
kit
convert
blast
dcleuvaccin
induc
antileukem
tcell
memori
without
induct
blast
prolifer
wbcultur
model
presenc
solubl
cellular
compon
pt
simul
physiolog
condit
compar
normox
n
vs
physiolog
hypox
h
cultur
condit
method
aml
healthi
wbsampl
cultur
parallel
n
h
condit
treat
k
kit
follow
mlc
proband
tcell
blastcytotoxicityassay
amlsampl
cellular
composit
dc
blastsubtyp
immunestatu
function
result
compar
result
gener
dcdcleu
wb
normoxia
vs
hypoxia
differ
kit
n
vs
h
condit
compar
proport
dc
gener
kit
k
healthi
aml
wbsampl
dcleu
also
compar
well
dcmatur
success
dcgener
dc
dcleu
compar
n
v
h
healthi
amlwb
control
without
ad
kit
wo
fail
produc
dcdcleu
furthermor
treatment
kit
induc
blast
prolifer
n
h
condit
mix
lymphocyt
cultur
mlc
tcell
kittreat
amlwb
n
vs
h
k
compar
gener
tprolif
temeff
howev
ktreat
wb
increas
tcm
n
h
significantli
antileukem
activ
tcell
wo
previou
kittreat
wb
normoxia
vs
hypoxia
cytotoxicityassay
tcell
mlc
kittreat
vs
untreat
wb
show
case
case
treat
wb
n
vs
h
improv
blastlysi
result
obtain
parallel
analys
case
n
vs
h
compar
case
case
especi
itreat
differ
antileukem
function
n
vs
h
set
found
conclus
cultiv
pbcell
kit
n
vs
h
condit
compar
dctype
tcell
subtyp
mlc
mediat
antileukem
reactiv
mean
standard
n
cultur
condit
wb
simul
reaction
bodi
well
therefor
product
cellular
product
eg
adopt
cell
transfer
h
necessari
data
show
pt
treatment
might
improv
antileukem
reactiv
vivo
dcleumedi
mechan
conflict
interest
f
gard
noth
disclos
cathol
blood
marrow
transplant
center
st
mari
hospit
colleg
medicin
cathol
univers
korea
seoul
korea
republ
st
mari
hospit
colleg
medicin
cathol
univers
korea
depart
laboratori
medicin
seoul
korea
republ
cathol
genet
laboratori
center
colleg
medicin
cathol
univers
korea
seoul
korea
republ
background
minim
residu
diseas
mrd
monitor
one
power
tool
predict
risk
relaps
studi
valid
feasibl
mrd
monitor
strategi
blymphoblast
leukemia
ball
use
highthroughput
sequenc
ht
immunoglobulin
ig
clonal
implement
routin
clinic
test
method
select
bm
specimen
patient
diagnos
ball
follow
treatment
cathol
blood
marrow
transplant
center
seoul
st
mari
hospit
cathol
univers
korea
twelv
ball
ball
ball
otherwis
specifi
includ
quantif
leukemiaspecif
fusion
transcript
fusion
transcript
measur
via
revers
transcript
quantitativepcr
rtqpcr
use
realq
realq
quantif
kit
biosewoom
inc
seoul
korea
respect
use
igh
assay
panel
invivoscrib
technolog
assess
clonal
igh
rearrang
via
ht
clonal
igh
rearrang
neg
initi
specimen
use
primer
target
conserv
framework
region
fr
within
variabl
join
region
test
use
igk
assay
panel
invivoscrib
technolog
perform
result
diagnost
bm
specimen
studi
contain
leukem
blast
except
case
median
rang
igh
clonal
observ
includ
ball
use
primer
target
three
framework
region
sum
igh
clonal
burden
vari
median
rang
igk
clonal
identifi
patient
avail
case
low
igh
clonal
burden
total
igh
clonal
burden
significantli
correl
proport
leukem
blast
bone
marrow
quantiti
leukemiaspecif
fusion
transcript
includ
could
recogn
differ
respons
clone
emerg
clone
origin
trace
ig
rearrang
present
initi
specimen
igh
clonal
burden
induct
chemotherapi
repres
patient
outcom
well
igh
assay
also
provid
inform
repertoir
divers
igh
rearrang
low
initi
valu
increas
treatment
conclus
ig
clonal
assay
via
ht
promis
tool
mrd
monitor
ball
adequ
strategi
identifi
signific
clone
monitor
individu
clone
determin
repertoir
divers
studi
accumul
prospect
data
clinic
implic
help
refin
strategi
conflict
interest
none
univers
calgari
hematolog
oncolog
calgari
canada
background
infant
leukemia
poor
prognosi
despit
advanc
therapi
childhood
leukemia
especi
acut
lymphoblast
leukemia
associ
rearrang
gene
less
month
age
diagnosi
role
transplant
high
risk
childhood
leukemia
well
defin
infant
leukemia
impact
transplant
clearli
defin
method
review
publish
literatur
carri
cinahl
embas
medlin
pubm
cochran
databas
grey
literatur
unto
period
septemb
inclus
retrospect
prospect
studi
librarian
search
variou
databas
inform
retriev
articl
done
review
inclus
criteria
also
key
word
base
pico
popul
infant
less
year
old
diagnosi
leukemia
leukemia
includ
myeloid
lymphoid
intervent
chemotherapi
hematopoiet
stem
cell
transplant
outcom
event
free
surviv
overal
surviv
exclud
studi
english
util
prefer
report
item
systemat
review
metaanalys
prisma
studi
methodolog
high
risk
bia
articl
assess
grade
accord
newcastleottawa
scale
nonrandom
studi
result
articl
identifi
databas
search
follow
duplic
remov
titl
evalu
appropri
abstract
screen
total
articl
assess
elig
studi
includ
analysi
infant
leukemia
studi
acut
lymphoblast
leukemia
acut
myeloid
leukemia
acut
lymphoblast
leukemia
prospect
trial
fail
outlin
benefit
event
free
surviv
overal
surviv
similar
result
retrospect
studi
consid
background
differ
characterist
infant
time
transplant
choic
condit
regim
acut
myeloid
leukemia
prospect
studi
use
includ
outcom
data
beyond
year
infant
aml
good
surviv
data
though
similar
small
number
patient
studi
like
lymphoblast
leukemia
event
free
surviv
infant
follow
transplant
differ
continu
chemotherapi
meta
analysi
done
use
revman
softwar
myeloid
lymphoid
leukemia
infant
comparison
chemotherapi
transplant
group
show
statist
signif
high
rate
incontin
data
rang
conclus
high
variat
studi
lead
heterogen
data
includ
differ
time
transplant
either
complet
remiss
one
two
small
sampl
size
choic
chemotherapi
condit
regimen
make
difficult
carri
meta
analysi
draw
conclus
need
random
control
trial
done
clear
role
drawn
myeloid
lymphoblast
leukemia
infant
conflict
interest
declar
conflict
interest
conflict
interest
disclos
donga
univers
depart
intern
medicin
busan
korea
republ
kyungpook
nation
univers
school
medicin
depart
intern
medicin
daegu
korea
republ
background
adult
acut
lymphoblast
leukemia
patient
commonli
relaps
allogen
stem
cell
transplant
allosct
chemotherapi
relaps
relat
clonal
cytogenet
evolut
studi
focus
cytogenet
pattern
clinic
implic
treatment
method
two
hundr
twentyfour
diagnos
two
center
south
korea
januari
decemb
among
patient
patient
abl
proceed
treatment
among
patient
achiev
complet
remiss
cr
allosct
chemotherapi
patient
relaps
cr
final
patient
cytogenet
result
initi
diagnosi
relaps
analyz
result
eighteen
patient
relaps
allohsct
convent
chemotherapi
use
chromosom
band
analysi
combin
fluoresc
situ
hybrid
male
femal
ratio
median
age
allosct
group
convent
chemotherapi
group
year
year
year
year
respect
diagnosi
aberr
karyotyp
frequent
hsct
chemotherapi
cohort
versu
p
clonal
chang
diagnosi
relaps
frequent
allosct
group
versu
compar
convent
chemotherapi
group
signific
mostli
due
clonal
evolut
appear
new
cytogenet
alter
frequent
allosct
group
versu
signific
mean
number
cytogenet
alter
increas
standard
deviat
sd
diagnosi
sd
relaps
allosct
group
convent
chemotherapi
group
sd
sd
diagnosi
p
relaps
signific
clonal
chang
correl
overal
surviv
conclus
clonal
chang
cytogenet
complex
frequent
observ
hematopoiet
stem
cell
recipi
group
chang
karyotyp
correl
overal
surviv
adult
patient
might
affect
innat
poor
prognosi
group
patient
conflict
interest
conflict
interest
abstract
previous
publish
king
hussein
cancer
center
adult
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
adult
medic
oncolog
hematolog
amman
jordan
king
hussein
cancer
center
adult
medic
oncolog
hematolog
bone
marrow
transplant
amman
jordan
king
hussein
cancer
center
clinic
pharmaci
depart
bone
marrow
transplant
servic
amman
jordan
king
hussein
cancer
center
pediatr
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
p
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
amman
jordan
king
hussein
cancer
center
pediatr
onolcogi
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
depart
cell
therapi
appli
genom
amman
jordan
king
hussein
cancer
center
nurs
depart
amman
jordan
king
hussein
cancer
center
depart
cell
theray
appli
genom
amman
jordan
king
hussein
cancer
center
bone
marrow
transplant
amman
jordan
background
allogen
hematopoiet
cell
transplant
hct
effect
potenti
cur
treatment
advanc
highrisk
aml
myelodysplast
syndrom
md
use
differ
intens
condit
regimen
myeloabl
condit
associ
reduc
risk
relaps
translat
improv
surviv
due
increas
transplantrel
mortal
trm
reducedintens
condit
ric
allow
extens
hct
much
wider
patient
popul
reduc
toxic
without
compromis
hctefficaci
retrospect
studi
report
experi
patient
high
risk
md
aml
use
differ
condit
regimen
report
long
term
outcom
method
perform
singl
center
retrospect
analysi
adult
patient
high
risk
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
underw
allogen
hct
king
hussein
cancer
center
till
kaplanmei
method
report
outcom
patient
regard
overal
progress
free
surviv
cumul
incid
relaps
trm
gvhd
identif
predict
factor
poor
outcom
patient
md
fourtyeight
de
novo
secondari
md
respect
seventeen
male
femal
sixtyon
receiv
mach
relat
donor
one
mud
one
one
allel
mismatch
relat
donor
one
umbil
cord
blood
transplantationfourtyon
twentythre
receiv
combin
calcineurin
inhibitor
either
methotrex
mmf
respectivelyfourtythre
case
receiv
mac
twentyon
reduc
intens
condit
transplant
result
total
sixtyfour
patient
includ
median
age
time
hct
year
rang
patient
receiv
pbsc
graft
patient
engraft
time
sustain
full
donor
chimer
develop
agvhd
grade
iiiv
grade
iii
develop
cgvhdafter
median
follow
time
month
probabl
progress
free
surviv
overal
surviv
respect
probabl
cumul
incid
relaps
probabl
trm
analyz
data
signific
improv
surviv
outcom
cgvhd
trend
toward
improv
progress
free
surviv
overal
surviv
patient
transplant
de
novo
aml
intermediategood
risk
cytogenet
compar
poor
risk
group
conclus
allogen
hct
potenti
cur
approach
patient
high
risk
aml
md
improv
surviv
patient
develop
cgvhd
trend
toward
improv
surviv
outcom
patient
transplant
intermedi
risk
conflict
interest
conflict
interest
zhejiang
univers
school
medicin
bone
marrow
transplant
center
first
affili
hospit
hangzhou
china
background
diseas
relaps
one
lead
caus
death
patient
acut
lymphoblast
leukemia
allogen
hematopoiet
stem
cell
transplant
allohsct
mechan
leukemia
relaps
allohsct
involv
biolog
characterist
leukemia
cell
previou
studi
perform
exom
sequenc
analys
match
diagnosi
relaps
sampl
explor
genet
basi
relaps
found
cell
respons
relaps
allohsct
show
differ
gene
mutat
primari
leukemia
cell
diagnosi
acquir
new
gene
mutat
includ
gene
mutat
happen
c
c
p
method
design
sever
small
guid
rna
also
call
sgrna
locat
exon
near
mutat
site
synthes
plasmid
donor
templat
plasmid
molecul
clone
technolog
screen
plasmid
highest
shear
effici
method
type
phall
cell
line
use
construct
mutat
model
vitro
use
technolog
success
gain
cell
line
mutat
c
c
p
prolifer
cell
line
detect
method
cell
cycl
apoptosi
drug
resist
cell
line
mutat
detect
flow
cytometri
signal
pathway
associ
protein
detect
western
blot
immunofluoresc
result
compar
neg
control
group
prolifer
cell
line
mutat
increas
mutat
cell
line
promot
cell
cell
cycl
transit
phase
phasether
signific
effect
mutat
apoptosi
drug
resist
cellsth
mutat
gene
cell
line
enhanc
activ
level
pathway
act
directli
indirectli
downstream
pathway
therebi
regul
cell
cycl
see
graph
conclus
gene
mutat
c
c
p
significantli
affect
prolifer
progress
cell
cycl
mechan
mutat
site
may
potenti
activ
downstream
srcerk
signal
pathway
signal
pathway
may
close
associ
recurr
allohsct
conflict
interest
none
author
anyth
disclos
figur
specif
site
gene
mutat
c
c
p
bd
flow
chart
mutat
cell
line
construct
figur
comparis
prolifer
cell
cycl
apoptosi
neg
control
mutat
group
figur
signal
pathway
associ
protein
downstream
detect
western
blot
immunofluoresc
kyungpook
nation
univers
hospit
daegu
korea
republ
chonnam
nation
univers
hwasun
hospit
hwasun
jeollanamdo
korea
republ
keimyung
univers
dongsan
medic
center
daegu
korea
republ
donga
medic
center
pusan
korea
republ
background
optim
number
highdos
cytarabin
hdarac
consolid
cycl
allogen
hematopoiet
cell
transplant
allohct
acut
myeloid
leukaemia
aml
fulli
standardis
studi
evalu
therapeut
valu
number
hdarac
consolid
cycl
transplant
patient
aml
first
complet
remiss
cr
method
retrospect
review
medic
record
patient
receiv
allohct
aml
without
corebind
factor
cbf
korea
patient
receiv
induct
chemotherapi
consist
idarubicin
day
cytarabin
everi
hour
day
patient
achiev
first
cr
reclassifi
three
subgroup
cycl
hdarac
cycl
cycl
group
accord
number
hdarac
consolid
cycl
transplant
result
median
age
diagnosi
year
rang
year
thirtytwo
patient
highrisk
cytogenet
intermediaterisk
cytogenet
eln
among
patient
first
cr
patient
group
respect
cumul
hdarac
dose
rang
group
hdaracrel
toxic
includ
febril
neutropenia
vs
document
infect
vs
vs
p
ten
patient
relaps
transplant
group
median
time
cr
allohct
day
rang
day
day
rang
day
rang
day
rang
pretranspl
statu
er
relaps
ninetynin
patient
receiv
myeloabl
condit
regimen
median
dose
cell
rang
ninetynin
percent
patient
achiev
neutrophil
engraft
median
time
day
rang
day
incid
rate
acut
chronic
graftversushost
diseas
gvhd
respect
median
followup
durat
day
rang
day
relapsefre
surviv
rf
group
respect
overal
surviv
nonrelaps
mortal
significantli
differ
accord
number
hdarac
consolid
cycl
advers
cytogenet
risk
group
benefit
hdarac
consolid
hazard
ratio
hr
confid
interv
ci
multivari
analysi
follow
factor
associ
rf
enl
advers
risk
group
hr
ci
hdarac
consolid
hr
ci
chronic
gvhd
hr
ci
conclus
use
hdarac
consolid
prehct
strategi
posit
role
aml
without
cbf
one
two
cycl
hdarac
seem
maxim
follow
hct
outcom
aml
patient
conflict
interest
author
declar
conflict
interest
san
raffael
scientif
institut
milano
itali
background
consolid
complet
remiss
cr
autohsct
option
patient
pt
aml
particular
elderli
one
altern
allohsct
condit
regimen
autohsct
prove
prefer
term
toxic
improv
leukemia
free
surviv
treosulfan
alkyl
agent
demonstr
achiev
maximum
diseas
control
minim
toxic
combin
fludarabin
prior
allohsct
pt
high
risk
relapsedrefractori
aml
design
new
condit
regimen
includ
treosulfan
combin
fludarabin
cytarabin
flat
test
prior
autohsct
aml
pt
data
feasibl
outcom
report
method
period
pt
de
novo
aml
median
age
cytogenet
favour
normal
intermedi
complex
evalu
molecular
pt
evalu
cebpamut
alon
neg
prognost
risk
eln
favour
intermedi
advers
evalu
pt
median
number
chemo
cycl
autohsct
flat
regimen
treosulfan
grsqm
day
fludarabin
mgsqm
day
cytarabin
grsqm
day
peg
filgrastim
sc
vial
autohsct
graft
pbsc
median
bw
time
autohsct
median
day
result
pt
aliv
day
patient
die
pancytopenia
day
invas
fungal
infect
ifi
median
time
hematopoiet
recoveri
neutrophil
day
platelet
day
extrahematolog
toxic
ctcae
median
grade
see
also
tabl
last
follow
fu
pt
aliv
median
fu
autohsct
day
thirteen
pt
relaps
median
day
transplant
median
ef
autohsct
day
median
os
diagnosi
day
fourteen
pt
yr
old
older
yr
aliv
median
fu
autosct
day
overal
nonrelaps
mortal
conclus
consolid
aml
pt
autohsct
condit
new
myeloabl
flat
regimen
feasibil
well
toler
prolong
os
diagnosi
ef
transplant
obtain
also
elderli
pt
phase
ii
studi
pt
older
ongo
center
confirm
preliminari
data
conflict
interest
none
author
anyth
disclos
tabl
tabl
univers
lieg
lieg
belgium
ebmt
pari
offic
ceresttc
pari
franc
eurocord
hopit
saint
loui
pari
franc
hopit
saint
antoin
universit
pierr
mari
curi
inserm
umr
pari
franc
institut
paoli
calmett
marseil
franc
chu
nant
nant
franc
hospit
universitario
la
fe
valencia
spain
chu
lapeyroni
montpelli
franc
erasmu
medic
center
rotterdam
rotterdam
netherland
azienda
ospedaliera
papa
giovanni
xxiii
bergamo
itali
bipinsavani
vanderbiltedu
nashvil
tn
unit
state
chaim
sheba
medic
center
telhashom
israel
background
allogen
hematopoiet
stem
cell
transplant
cur
option
patient
secondari
acut
myeloid
leukemia
saml
umbil
cord
blood
transplant
ucbt
treatment
option
patient
pt
primari
aml
lack
hlamatch
donor
systemat
larg
analysi
evalu
risk
factor
transplant
outcom
ucbt
saml
therefor
acut
leukemia
work
parti
ebmt
eurocord
perform
retrospect
registri
studi
saml
pt
given
ucbt
method
inclus
criteria
includ
age
year
secondari
aml
first
ucbt
first
complet
remiss
activ
diseas
transplant
ex
vivo
manipul
ucb
result
pt
femal
met
studi
inclus
criteria
previou
diagnos
includ
myelodysplast
syndromemyeloprolif
disord
solid
tumor
includ
breast
cancer
pt
lymphoma
acut
leukemia
chronic
lymphocyt
leukemia
multipl
myeloma
statu
transplant
pt
primari
refractori
pt
relaps
saml
remain
pt
proport
pt
good
intermedi
highrisk
cytogenet
respect
miss
fiftyeight
pt
given
singl
cbt
scbt
remain
pt
doubl
cbt
dcbt
condit
myeloabl
mac
pt
reducedintens
ric
remain
pt
forti
percent
pt
receiv
atg
one
hundr
eighteen
pt
achiev
neutrophil
engraft
pt
fail
engraft
includ
patient
transplant
versu
patient
transplant
activ
diseas
cumul
incid
grade
iiiv
grade
iiiiv
acut
gvhd
respect
two
year
cumul
incid
chronic
extens
chronic
gvhd
respect
twoyear
incid
relaps
nonrelaps
mortal
respect
pt
versu
pt
activ
diseas
transplant
twoyear
os
lf
gvhdfree
relaps
free
surviv
grf
respect
pt
versu
p
p
respect
pt
activ
diseas
transplant
factor
associ
os
multivari
analys
includ
better
surviv
femal
recipi
wors
surviv
pt
activ
diseas
transplant
p
conclus
first
analysi
cbt
rather
larg
group
pt
saml
result
suggest
cbt
may
rescu
patient
secondari
aml
absenc
hlaident
sibl
donor
futur
attempt
focu
reduc
nrm
improv
engraft
posttranspl
strategi
aim
reduc
relaps
rate
high
risk
group
patient
also
warrant
clinic
trial
registri
na
conflict
interest
conflict
interest
danafarb
cancer
institut
boston
unit
state
center
intern
blood
marrow
transplant
research
milwauke
wi
unit
state
pfizer
inc
new
york
ny
unit
state
background
vod
report
aml
patient
receiv
go
antibodydrug
conjug
analysi
character
vod
risk
pediatr
patient
receiv
go
sct
method
data
subset
patient
randomli
select
research
level
report
center
intern
blood
marrow
transplant
research
cibmtr
comparison
incid
vod
day
overal
surviv
assess
use
logist
regress
cox
regress
model
respect
stepwis
model
build
approach
use
variabl
attain
retain
final
model
result
analysi
includ
pediatr
patient
previous
receiv
go
control
patient
without
go
exposur
underw
first
allogen
sct
median
rang
age
year
patient
without
go
exposur
patient
withwithout
go
exposur
achiev
first
complet
remiss
without
complet
remiss
without
donor
sourc
balanc
patient
withwithout
go
exposur
overal
incid
vod
sever
vod
day
higher
patient
respect
without
go
exposur
overal
surviv
probabl
gener
compar
patient
without
go
exposur
day
vs
month
vs
year
vs
sct
day
vs
month
vs
year
vs
vod
onset
base
multivari
analys
go
exposur
associ
signific
risk
vod
ci
death
hr
ci
conclus
pediatr
aml
patient
go
exposur
sct
associ
higher
incid
vod
howev
go
exposur
associ
increas
risk
death
limit
studi
includ
select
bia
associ
retrospect
design
futur
analys
evalu
impact
dose
vod
risk
surviv
outcom
cohort
encor
bmt
tandem
fund
pfizer
data
coordin
center
cibmtr
preliminari
conflict
interest
c
duncan
st
martin
w
perez
p
steinert
zhang
w
saber
noth
disclos
chirnoma
c
hoang
f
loberiza
employe
stock
pfizer
inc
ludaopei
hospit
langfang
china
background
salvag
allohsct
appear
possibl
cure
way
refractori
relaps
amlin
nr
statu
howev
leukemia
relaps
remain
major
caus
transplant
failur
outcom
still
disappoint
order
improv
outcom
optim
transplant
protocol
report
result
method
retrospect
analyz
patient
refractori
relaps
aml
underw
allohsct
april
april
median
percent
blast
case
case
case
case
male
femal
median
age
year
primari
refractori
failur
remiss
relaps
patient
receiv
msdhsct
receiv
mudhsct
receiv
haplohsctth
condit
regimen
base
busulfan
mgkg
per
day
day
cy
per
day
day
combin
hdarac
per
day
day
combin
ida
per
day
arac
per
day
day
respect
case
combin
decitabin
per
day
arac
per
day
day
recpect
ida
per
day
day
case
combin
fludarabin
per
day
arac
per
day
day
recpect
per
day
day
case
combin
amsacrin
per
day
arac
per
day
patient
receiv
preemptiv
patient
receiv
mrddirect
intervent
patient
receiv
chemotherapi
immunotherapi
patient
without
intervent
therapi
intervent
therapi
includ
donor
lymphocyt
infus
donor
lymphocyt
natur
kill
cell
cytotox
lymphocyt
cell
infus
result
median
follow
time
month
df
relaps
relat
mortal
trm
respectivelyunivari
analysi
factor
surviv
show
lower
percent
blast
prehsct
better
os
vs
condit
regimen
includ
ida
better
os
compar
hdarac
vs
idaarac
vs
vs
vs
amsaarac
posthsct
without
intervent
therapi
best
os
preemptiv
intervent
vs
mrddirect
intervent
vs
intervent
relaps
vs
without
intervent
iiiv
agvhd
lower
os
compar
vs
cgvhd
better
os
vs
signific
differ
age
vs
sex
male
vs
femal
hctci
vs
type
diseas
primari
vs
secondari
extramedullari
lesion
ye
vs
donorpati
sex
match
male
male
vs
male
femal
vs
femal
femal
vs
femal
male
mnc
vs
cell
count
vs
cell
count
vs
donor
type
msd
vs
mud
vs
haplod
multivari
analysi
factor
show
posthsct
without
intervent
higher
os
df
cgvhd
higher
os
df
also
lower
incid
relaps
mortalityto
analys
impact
cgvhd
patient
posthsct
without
intervent
show
patient
cgvhd
higher
os
vs
patient
iiivagvhd
higher
trm
lower
os
conclus
patient
cgvhd
without
intervent
therapi
better
surviv
salvag
allohsct
aml
nr
statu
conflict
interest
noth
disclos
dmitri
rogachev
nation
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
moscow
institut
physic
technolog
moscow
russian
feder
background
antigen
promis
target
cancer
immunotherapi
high
immunogen
hyperexpress
variou
type
leukemia
solid
tumor
complex
determin
tlymphocyt
associ
low
frequenc
cell
peripher
blood
regard
studi
possibl
improv
detect
immun
respons
antigen
may
assist
develop
immunotherapeut
approach
cancer
method
frequenc
cell
peripher
blood
healthi
donor
n
leukemia
patient
aml
allogen
stem
cell
transplant
monitor
dextram
stain
enzymelink
immunospot
elispot
assay
peptid
pool
sampl
specif
lymphocyt
per
mononuclear
cell
consid
posit
monocytederiv
dendrit
cell
dc
gener
mononuclear
mnc
adher
cell
healthi
donor
presenc
granulocytemacrophag
colonystimul
factor
day
immatur
dc
matur
cytokin
cocktail
consist
granulocytemacrophag
colonystimul
factor
tumor
necrosi
factor
tnf
harvest
h
puls
peptid
pool
wash
peptid
control
dc
gener
use
method
without
incub
matur
phenotyp
gener
dc
determin
flow
cytometri
hladr
hlaabc
antibodi
donor
mnc
cultiv
alon
autolog
dc
specif
control
analyz
number
specif
tlymphocyt
elispotassay
result
specif
tlymphocyt
mononuclear
cell
detect
donor
frequenc
lymphocyt
healthi
donor
rang
per
mnc
median
donor
specif
lymphocyt
detect
mnc
specif
tcell
also
detect
perifer
blood
patient
specif
lymphocyt
per
mnc
aml
specif
lymphocyt
per
mnc
patient
allo
hsct
incub
mnc
dendrit
cell
number
tlymphocyt
detect
ifn
gamma
elispot
increas
time
control
cultur
dc
puls
puls
neg
elispotassay
larg
rang
valu
reflect
heterogen
popul
donor
relat
immun
respons
antigen
emphas
import
person
approach
plan
immunotherapi
tumor
use
cultur
insert
carrier
plate
system
nunc
plate
demonstr
dc
influenc
tlymphocyt
reactiv
antigen
direct
contact
conclus
incub
mnc
dc
lead
signific
increas
tcell
immun
respons
antigen
result
use
develop
new
approach
dendrit
cell
vaccin
antigen
conflict
interest
noth
disclos
aplast
anaemia
preto
medic
school
univers
paulo
preto
brazil
hospit
amar
de
carvalho
jahu
brazil
universidad
feder
curitiba
brazil
real
hospit
de
recif
brazil
hospit
samaritano
de
paulo
paulo
brazil
graacc
paulo
brazil
hospit
da
de
porto
alegr
porto
alegr
brazil
inca
rio
de
janeiro
brazil
universidad
feder
de
mina
gerai
belo
horizont
brazil
hospit
pequeno
curitiba
brazil
hospit
nossa
senhora
da
curitiba
brazil
itaci
paulo
brazil
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
background
idiopath
sever
aplast
anemia
saa
rare
lifethreaten
diseas
bone
marrow
transplant
bmt
match
sibl
donor
treatment
choic
pediatr
patient
aim
studi
determin
major
transplant
outcom
bmt
children
saa
transplant
brazil
method
retrospect
studi
analyz
consecut
patient
age
year
underw
first
allogen
bmt
saa
brazilian
bmt
center
median
age
year
male
graft
unmanipul
marrow
match
relat
mrd
sibl
rel
unrel
urd
hlamatch
mismatch
donor
condit
regimen
wide
vari
among
institut
mrd
transplant
receiv
cyclophosphamid
ratg
busulfanbas
fludarabinebas
regimen
urd
bmt
fludarabinebas
busulfanbas
vivo
tcell
deplet
includ
ratg
campath
transplantswith
mrd
one
urd
calcineurin
inhibitor
methotrex
use
bmt
acut
chronic
graftversushost
diseas
gvhd
grade
use
glucksberg
nih
scale
respect
result
median
followup
year
patient
aliv
overal
surviv
os
ci
significantli
differ
mrd
urd
seven
patient
die
evalu
engraft
mrd
primari
graft
failur
gf
contrast
urd
cumul
incid
ci
patient
engraft
graft
reject
median
day
cumul
incid
ci
significantli
differ
donor
type
thirteen
patient
bmt
aliv
last
followup
cumul
incid
grade
iiiiv
acut
gvhd
chronic
gvhd
year
signific
differ
donor
type
twentyseven
patient
die
median
month
bmt
major
caus
death
includ
infect
bleed
secondari
neoplasia
gvhd
transplant
relat
mortal
higher
urd
mrd
ci
although
reach
signific
conclus
os
pediatr
patient
transplant
saa
brazil
ci
similar
among
mrd
urd
lower
expect
intern
report
group
work
standard
nation
pediatr
bmt
protocol
improv
result
allogen
bmt
pediatr
saa
brazil
conflict
interest
conflict
interest
report
hematolog
bone
marrow
transplant
depart
algier
algeria
background
fanconi
anemia
fa
common
constitut
aplasia
haematolog
extrahaematolog
abnorm
high
risk
transform
myelodysplasia
md
acut
leukemia
al
cur
treatment
hsct
report
result
allogen
hsct
patient
pt
fa
perform
period
year
method
januari
decemb
pt
fa
underw
allogen
hsct
includ
sibl
hla
ident
phenoident
one
unrel
cord
blood
median
age
year
less
year
sex
ratio
f
averag
diagnosistranspl
time
month
fourtyeight
pt
transfus
histori
red
blood
unit
transfus
thirteen
pt
receiv
previou
treatment
androgen
corticosteroid
combin
two
type
condit
regimen
use
success
time
fludarabinecyclophosphamideantithymocyt
globulin
flucyatg
pt
fludarabinecyclophosphamid
fluci
pt
gvhd
prophylaxi
includ
associ
ciclosporin
methotrex
graft
use
peripher
blood
stem
cell
pt
averag
cell
count
bone
marrow
transplant
pt
averag
level
nucleat
cell
kg
cord
blood
cell
kg
nc
kg
juli
minim
follow
month
maxim
month
result
median
time
graft
pnc
x
day
one
patient
sever
veinoocclus
diseas
vod
acut
gvhd
observ
pt
grade
iiiiv
chronic
gvhd
pt
includ
extens
form
cmv
reactiv
note
pt
six
case
reject
observ
aliv
one
boost
second
allograft
median
followup
month
pt
aliv
strictli
normal
blood
count
pt
die
due
trm
infect
gvha
capillari
leak
syndrom
hemorrhag
vod
trm
accord
type
condit
estim
respect
one
pt
show
malign
transform
acut
leukemia
month
reject
year
overal
surviv
os
eventfre
surviv
ef
respect
os
accord
type
condit
time
month
flucyatg
fluci
without
signific
differ
differ
conclus
allogen
hsct
remain
therapeut
altern
fa
permit
restor
hematopoiet
prevent
progress
md
al
fluci
condit
adopt
year
center
well
toler
given
better
result
term
ef
trm
conflict
interest
noth
disclos
gachon
univers
gil
medic
center
gachon
univers
colleg
medicin
divis
hematolog
incheon
korea
republ
asan
medic
center
univers
ulsan
colleg
medicin
seoul
korea
republ
kyungpook
nation
univers
hospit
daegu
korea
republ
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
republ
seoul
nation
univers
hospit
seoul
korea
republ
donga
univers
medic
center
busan
korea
republ
korea
univers
anam
hospit
seoul
korea
republ
yeungnam
univers
medic
center
daegu
korea
republ
daegu
cathol
univers
hospit
daegu
korea
republ
pusan
nation
univers
hospit
busan
kosovo
republ
soon
chun
hyang
univers
hospit
seoul
korea
republ
inj
univers
busan
paik
hospit
busan
korea
republ
ulsan
univers
hospit
univers
ulsan
colleg
medicin
divis
hematolog
cellular
therapi
ulsan
korea
republ
background
mani
saa
patient
receiv
hematopoiet
stem
cell
pbsc
even
though
receiv
stem
cell
msd
need
know
addit
factor
affect
transplant
outcom
bm
pbsc
infus
method
retrospect
investig
effect
stem
cell
allogen
hematopoiet
cell
transplant
allohct
idiopath
adult
aplast
anemia
aa
mismatch
donor
mmd
includ
haploident
famili
donor
mismatch
unrel
donor
partial
match
famili
donor
altern
donor
ad
refer
either
mud
mmd
result
total
patient
includ
analysi
bm
associ
low
incid
acut
graft
versu
host
diseas
gvhd
p
acut
gvhd
bm
howev
impact
transplant
outcom
includ
chronic
gvhd
primarysecondari
graft
failur
higher
stem
cell
dose
impact
transplant
outcom
except
low
incid
extens
chronic
gvhd
msd
multivari
analysi
overal
surviv
msd
reveal
age
allohsct
year
old
prior
platelet
transfus
less
favor
prognost
factor
hand
multivari
analysi
ad
reveal
higher
stem
cell
dose
ci
signific
favor
factor
overal
conclus
pbsc
prefer
ad
higher
stem
cell
dose
easili
achiev
longer
overal
surviv
expens
acut
gvhd
howev
bm
stem
cell
prefer
msd
conflict
interest
conflict
interest
disclos
hospit
universitario
la
paz
hematolog
madrid
spain
hospit
universitario
sant
pau
hematolog
barcelona
spain
hospit
universitario
la
paz
pediatr
hematooncolog
madrid
spain
hospit
universitario
sant
pau
pediatr
oncohematolog
barcelona
spain
hospit
universitario
sant
pau
pediatr
hematooncolog
barcelona
spain
hospit
universitario
la
paz
pediatr
oncohematolog
madrid
spain
hospit
universitario
la
paz
idipaz
madrid
spain
background
haploident
stem
cell
transplant
hsct
occasion
carri
set
aplast
anaemia
aa
patient
lack
propermatch
donor
haplohsct
paediatr
set
requir
tcell
deplet
carri
profound
immunosuppress
high
risk
graft
failur
tcell
identifi
express
believ
caus
graftversushostdiseas
gvhd
tcell
memori
cell
provid
antiinfect
antitumor
effect
deplet
cell
retain
memori
tcell
graft
novel
approach
haploident
hsct
children
sever
aa
method
three
children
sever
aa
receiv
haplohsct
follow
nonmyeloabl
condit
cellselect
perform
gcsfmobil
peripher
blood
two
cellular
product
obtain
use
clinimac
devic
patient
detail
tabl
receiv
haploident
cellular
product
first
product
result
select
second
product
result
deplet
result
three
patient
receiv
haplohsct
februari
juli
two
patient
male
median
age
transplant
year
rang
graft
composit
detail
tabl
neutrophil
platelet
engraft
achiev
median
day
rang
day
rang
posttranspl
respect
graft
failur
seen
two
patient
develop
agvhd
grade
ii
gastrointestin
tract
skin
involv
steroid
respons
one
patient
present
clinic
featur
probabl
cgvhd
patient
remain
aliv
mean
followup
rang
day
posttranspl
chimer
day
full
donor
patient
present
cytomegaloviru
reactiv
none
progress
cmv
diseas
sever
infecti
complic
seen
conclus
haplohct
show
rapid
sustain
neutrophil
platelet
engraft
well
full
donor
chimer
acut
gvhd
esteroidrespons
sever
infect
seen
haplohct
novel
approach
transplant
patient
saa
lack
propermatch
famili
unrel
donor
conflict
interest
none
tabl
tabl
patient
detail
graft
composit
hospit
universitario
de
valdecilla
santand
spain
hospit
universitario
la
fe
valencia
spain
hospit
santa
creu
sant
pau
barcelona
spain
hospit
universitario
de
salamanca
salamanca
spain
hospit
universitario
virgen
del
sevilla
spain
ico
hospit
duran
reynal
barcelona
spain
hospit
gregorio
madrid
spain
hospit
clinico
de
valencia
hematolog
valencia
spain
background
although
surviv
hla
ident
bone
marrow
transplant
immunosuppress
therapi
ist
similar
patient
older
year
vs
current
guidelin
recommend
latter
group
patient
bacigalupo
blood
aim
retrospect
studi
evalu
role
hematopoiet
stem
cell
transplant
sct
older
patient
aplast
anemia
know
previou
ist
affect
neg
sct
ouctom
method
seven
spanish
center
report
total
patient
underw
sct
patient
transplant
exclud
median
age
diagnosi
year
male
seventeen
patient
inform
diagnosi
etiolog
idiopath
secondari
toxic
drug
secondari
diseas
sever
moder
sever
sever
chromosom
analysi
normal
abnorm
done
fail
clinic
featur
hemorrhag
system
infect
two
patient
pnh
clone
result
previou
ist
least
one
cours
cyclosporin
atg
given
patient
time
ist
sct
month
transplant
characterist
median
age
sct
year
despit
statist
signific
time
diagnosi
sct
delay
month
patient
receiv
ist
vs
condit
regimen
mainli
consist
cyclophosphamid
alon
combin
fludarabin
three
patient
receiv
atg
gvhd
prophylaxi
quit
differ
center
frequent
combin
cyclosporin
methotrex
mycophenol
corticosteroid
stem
cell
sourc
bone
marrow
case
donor
ident
sibl
one
patient
underw
haploident
transplant
transplant
complic
two
patient
engraft
patient
present
earli
graft
loss
nine
patient
develop
acut
gvhd
grade
grade
ii
grade
iii
six
develop
chronic
gvhd
limit
extens
outcom
five
patient
die
day
due
infect
median
follow
moth
patient
aliv
complet
remiss
partial
remiss
probabl
surviv
higher
receiv
previou
ist
figur
conclus
line
prior
report
studi
recogn
sct
suitabl
option
older
patient
diagnos
aplast
anemia
better
outcom
observ
patient
receiv
upfront
sct
ident
sibl
need
confirm
larger
seri
conflict
interest
author
noth
disclos
abstract
previous
publish
kokilaben
dhirubhai
ambani
hospit
depart
paediatr
oncolog
stem
cell
transplant
mumbai
india
kokilaben
dhirubhai
ambani
hospit
depart
stem
cell
transplant
mumbai
india
background
primari
graft
failur
remain
one
import
caus
mortal
morbid
case
stem
cell
transplant
report
case
aplast
anaemia
immedi
rescu
haploident
stem
cell
transplant
differ
donor
result
success
engraft
suggest
immedi
transplant
repeat
condit
chemoradi
therapi
result
success
engraft
case
primari
graft
failur
method
old
male
child
diagnos
sever
aplast
anemia
unfortun
match
sibl
donor
match
unrel
donor
search
yield
accept
match
elect
undertak
haploident
transplant
use
father
stem
cell
father
hla
match
high
resolut
type
dsa
neg
blood
group
condit
atg
x
day
fludarabin
mgkg
x
day
cyclophosphamid
mgkg
x
day
low
dose
tbi
gvhd
prophylaxi
post
transplant
cyclophosphamid
dose
use
unfortun
fail
engraft
count
remain
low
day
marrow
examin
sever
hypocellular
henc
day
undertook
second
rescu
haploident
transplant
primari
graft
failur
reject
father
stem
cell
decid
use
father
second
time
around
surmis
patient
might
develop
effect
antibodi
henc
time
decid
retranspl
second
time
use
mother
stem
cell
though
profoundli
cytopen
neutropen
decid
give
full
repeat
condit
protocol
surmis
still
activ
immun
system
reject
primari
graft
repeat
condit
use
protocol
start
day
mother
stem
cell
infus
day
result
engraft
success
day
second
transplant
though
transplant
complic
cutan
fungal
infect
cmv
reactiv
child
discharg
home
donor
engraft
current
child
day
though
mild
gut
gvhd
easili
manag
oral
budesonid
conclus
suggest
urgent
second
haploident
transplant
use
repeat
condit
use
success
case
primari
graft
failur
even
face
sever
cytopenia
conflict
interest
sen
noth
disclos
azienda
ospedaliera
universitaria
integrata
verona
itali
hannov
medic
univers
hannov
germani
clinica
di
oncoematologia
pediatrica
padova
itali
leiden
univers
medic
hospit
leiden
netherland
istituto
g
gaslini
genova
itali
hopit
st
loui
pari
franc
hospit
vall
dhebron
barcelona
spain
central
manchest
nh
trust
manchest
manchest
unit
kingdom
univers
heidelberg
heidelberg
germani
irrc
ospedal
pediatrico
bambino
gesu
rome
itali
great
ormond
street
hospit
london
unit
kingdom
univers
hospit
leuven
leuven
belgium
karolinska
univers
hospit
stockholm
sweden
chu
nant
nant
franc
hopitaux
universitair
de
genev
geneva
switzerland
hospit
de
la
santa
creu
sant
pau
barcelona
spain
univers
children
hospit
zurich
switzerland
royal
liverpool
univers
hospit
liverpool
unit
kingdom
klinikum
grosshadem
munich
germani
univers
hematolog
verona
itali
nottingham
univers
hospit
nh
trust
nottingham
unit
kingdom
wroclaw
medic
univers
wroclaw
poland
unit
st
istvan
st
laszlo
hospit
budapest
hungari
ladi
children
hospit
dubllin
ireland
pavlov
medic
univers
st
petersburg
st
petersburg
russian
feder
schneider
children
medic
center
petachtikva
israel
univers
hospit
collegium
medicum
umk
bydgoszcz
poland
ebmt
data
offic
leiden
itali
background
shwachmandiamond
syndrom
sd
rare
multisystem
diseas
affect
children
sd
third
caus
congenit
bone
marrow
dysfunct
fanconi
anemia
blackfandiamond
anemia
second
caus
pancreat
insuffici
cystic
fibrosi
transmiss
sd
autosom
recess
longterm
surviv
sd
patient
threaten
occurr
bone
marrow
failur
evolv
sever
aplast
anemia
myelodysplast
syndrom
acut
leukemia
case
allogen
haematopoiet
stem
cell
transplant
hsct
valuabl
therapeut
option
studi
analyz
outcom
sd
patient
given
hsct
regist
ebmt
registri
method
data
hsct
sd
patient
retriev
retrospect
ebmtpromis
databas
data
collect
complet
specif
case
report
form
sent
center
result
sd
patient
fm
transplant
ebmt
center
period
saa
mdsaml
median
time
diagnosi
yr
median
age
hsct
yr
donor
sibl
famili
donor
case
sibl
match
famili
donor
haploident
parent
unrel
donor
remain
match
mismatch
match
known
donor
sourc
bm
case
pb
cb
dr
gender
pair
fm
combin
cmv
rd
serostatu
negneg
negpo
posneg
pospo
condit
regimen
myeloabl
reduc
intens
patient
respect
tbi
tli
use
patient
respect
gvhd
prophylaxi
base
exvivo
tdeplet
patient
invivo
tdeplet
patient
atg
alemtuzumab
moreov
patient
receiv
pharmacolog
prophylaxi
gvhd
base
mainli
csa
short
methotrex
csa
plu
drug
ci
pmn
engraft
median
time
day
rate
graft
failur
grade
iii
iiiv
acut
gvhd
occur
patient
respect
chronic
gvhd
diagnos
median
fup
year
os
ci
os
saa
msdaml
p
mortal
rate
relaps
mdsaml
graft
failur
toxic
caus
specifi
conclus
largest
seri
report
far
sd
patient
given
hsct
hsct
show
valuabl
therapeut
option
sd
patient
especi
transplant
saa
safeti
toler
hsct
improv
compar
previou
histor
seri
although
type
donor
select
intens
condit
regimen
type
gvhd
prophylaxi
still
matter
investig
conflict
interest
noth
disclos
author
anadolu
medic
center
hospit
bone
marrow
transplant
koca
turkey
background
new
transplant
approach
necessari
patient
refractori
sever
aplast
anemia
saa
lack
match
sibl
unrel
donor
ud
fail
ud
report
result
haploident
hematopoiet
stem
cell
transplant
haplohsct
use
posttranspl
highdos
cyclophosphamid
method
retrospect
summar
fail
respond
previou
therapi
antithymocyt
immunoglobulin
csa
underw
haplohsct
condit
regimen
hsct
includ
cyclophosphamid
fludarabin
rabbit
atg
recipi
graft
versu
host
diseas
gvhd
prophylaxi
receiv
posttranspl
highdos
cyclophosphamid
subsequ
success
allohsct
hematopoiet
reconstitut
observ
median
interv
diagnosi
transplant
year
male
patient
femal
patient
median
age
rang
result
found
hematopoiet
reconstruct
achiev
patient
graft
failur
occur
patient
patient
underw
second
transplant
famili
haplo
donor
engraft
two
patient
die
day
due
sepsi
observ
sever
grade
acut
chronic
graft
versu
host
diseas
patient
conclus
find
show
haplohsct
success
rescu
refractori
saa
patient
lack
donor
delay
haploident
transplant
increas
sepsi
relat
death
rate
conflict
interest
conflict
interest
univers
medic
center
utrecht
pediatr
hematolog
stem
cell
transplant
utrecht
netherland
leiden
univers
medic
center
pediatr
hematologyoncolog
leiden
netherland
background
telomeropathi
compromis
complex
spectrum
diseas
caus
unprotect
shorten
telomer
result
bone
marrow
failur
organ
diseas
includ
lung
fibrosi
liver
cirrhosi
patient
telomeropathi
dyskeratosi
congenita
dc
bestknown
exampl
increas
risk
hematolog
stem
cell
transplant
hsct
associ
complic
predominantli
signific
organ
damag
follow
myeloabl
condit
regimen
patient
suffer
sever
aplast
anemia
saa
preexist
underli
congenit
bone
marrow
failur
bmf
disord
includ
fanconi
anemia
fa
dc
consid
howev
telomeropathi
encompass
wide
spectrum
clinic
present
therefor
subtl
determin
telomer
length
patient
saa
use
predict
likelihood
underli
telomeropathi
character
telomer
adjust
treatment
regimen
need
object
studi
investig
clinic
characterist
patient
suffer
saa
sever
bmf
respect
proven
suspect
telomeropathi
outcom
allogen
hsct
method
investig
patient
year
undergo
allogen
hsct
two
dutch
pediatr
hsct
depart
septemb
patient
suffer
saa
refractori
cytopenia
childhood
rcc
bmf
proven
telomeropathi
includ
two
patient
suffer
telomeropathyassoci
bmf
yet
schedul
sct
includ
analysi
characterist
presct
telomeropathi
diagnos
base
telomer
length
lymphocyt
granulocyt
determin
flow
fish
wwwrepeatdiagnosticscom
retrospect
analysi
gener
clinic
characterist
radiolog
laboratori
paramet
associ
bmf
liver
dysfunct
pulmonari
disord
complic
toxic
perform
patient
mannwhitney
fisher
exact
test
use
analyz
differ
group
result
telomeropathi
group
congenit
malform
report
frequent
versu
also
observ
elev
level
asat
alat
uln
uln
telomeropathi
group
p
abnorm
radiolog
appear
liver
frequent
report
prehsct
telomeropathi
group
compar
control
group
data
suggest
trend
macrocyt
anemia
telomeropathi
group
compar
nontest
group
differ
report
radiolog
abnorm
lung
hsct
four
patient
telomeropathi
die
follow
hsct
complic
compar
nontest
group
interestingli
base
find
telomeropathi
group
identifi
patient
nontest
group
suggest
underli
telomeropathi
die
sever
hsctassoci
complic
conclus
saasever
bmf
result
underli
telomeropathi
classic
dc
patient
undergo
allogen
hsct
determin
telomer
length
help
identifi
patient
increas
risk
hsctassoci
complic
contribut
better
outcom
hsct
patient
saa
sever
bmf
better
understand
telomer
diseas
gener
conflict
interest
none
author
anyth
disclos
univers
univers
hospit
basel
hematolog
basel
switzerland
background
aplast
anemia
aa
histor
fatal
condit
sinc
patient
benefit
treatment
consist
mainli
immunosuppress
ist
origin
hors
atg
hematopoiet
stem
cell
transplant
hsct
although
respons
rate
surviv
treatment
improv
problem
remain
includ
incomplet
respons
relaps
diseas
treatmentrel
complic
late
effect
clonal
evolut
order
assess
longterm
outcom
aplast
anemia
analys
patient
singl
center
studi
year
method
analys
long
term
outcom
patient
treat
univers
hospit
basel
result
median
age
diagnosi
year
rang
eight
patient
diagnos
moder
aa
sever
aa
sever
aa
hors
atg
firstlin
treatment
patient
patient
receiv
allogen
hsct
first
line
therapi
median
follow
year
overal
surviv
year
initi
treatment
transplant
patient
patient
initi
atg
treatment
earli
death
hsct
group
late
death
atg
group
death
rate
particular
high
first
year
posttranspl
wherea
transplant
patient
afterward
mostli
surviv
stabl
hematopoiesi
see
figur
patient
immunosuppress
treatment
show
less
earli
death
lower
overal
surviv
year
last
follow
longterm
survivor
complet
partial
remiss
detail
present
confer
conclus
aplast
anemia
survivor
show
longterm
hematopoesi
wherea
death
occur
mostli
earli
hsct
group
late
atg
group
conflict
interest
none
author
anyth
disclos
autoimmun
diseas
northwestern
univers
divis
immunotherapi
chicago
il
unit
state
northwestern
univers
divis
immunotherapi
autoimmun
diseas
chicago
il
unit
state
background
intraven
immunoglobulin
ivig
pool
prepar
igg
thousand
donor
possibl
caus
fals
posit
antibodi
patient
receiv
ivig
potenti
lead
improp
diagnos
method
record
patient
immun
mediat
neuropathi
underw
evalu
northwestern
medicin
chicago
il
review
data
collect
includ
whether
patient
receiv
ivig
time
evalu
antibodi
hepat
b
core
antihbc
human
tlymphotrop
viru
htlv
human
immunodefici
viru
hiv
syphili
antiglutam
acid
decarboxylas
antigad
result
graph
depict
percentag
patient
fals
posit
antibodi
divid
patient
receiv
ivig
versu
receiv
ivig
time
evalu
twentyseven
patient
receiv
ivig
group
receiv
ivig
two
fals
posit
identifi
one
antihbc
one
syphili
eightyeight
patient
receiv
ivig
one
hundr
fortyseven
fals
posit
identifi
group
fals
posit
antihbc
hiv
htlv
syphili
antigad
conclus
ivig
increas
incid
fals
posit
antibodi
infect
specif
antihbc
htlv
syphili
confirmatori
test
complet
antibodi
posit
patient
receiv
ivig
antigad
also
fals
elev
due
ivig
diagnos
support
high
antigad
blood
type
diabet
stiff
person
syndrom
use
caution
patient
receiv
ivig
due
likelihood
fals
posit
conflict
interest
none
author
anyth
disclos
st
vincent
centr
appli
medic
research
sydney
australia
kirbi
institut
sydney
australia
st
vincent
hospit
darlinghurst
australia
background
autolog
haematopoiet
stem
cell
transplant
asct
promis
strategi
multipl
sclerosi
ms
patient
respond
convent
treatment
mechan
abl
achiev
clinic
improv
ms
transplant
recipi
fulli
understood
method
hypothesis
asct
elimin
proinflammatori
diseasecaus
cell
halt
diseas
progress
promot
toler
via
multipl
mechan
includ
reconstitut
immuneregulatori
suppress
cell
subset
achiev
sustain
diseas
control
design
polychromat
flow
cytometri
panel
colour
characteris
subpopul
peripher
blood
cell
pbmc
ms
patient
undergo
asct
phase
ii
studi
institut
variou
differenti
marker
chemokin
receptor
traffick
marker
use
identifi
popul
uniqu
autoimmun
diseas
compar
find
obtain
nonautoimmun
lymphoma
patient
treat
asct
analysi
includ
ttest
wilcoxon
sign
rank
test
tsne
result
immun
reconstitut
assess
multicolour
flow
cytometri
eighteen
ms
patient
preasct
month
postasct
time
point
proinflammatori
diseasecaus
cell
mucosalassoci
invari
mait
cell
subset
brainhom
abil
cnshome
cell
significantli
decreas
follow
treatment
ms
p
nhl
patient
p
interestingli
ms
patient
regulatori
cell
increas
significantli
month
p
post
asct
lymphoma
patient
regulatori
cell
decreas
month
post
asct
p
express
cytotox
cell
tripl
month
post
asct
p
ms
patient
signific
chang
occur
lymphoma
patient
natur
killer
express
doubl
p
month
post
asct
ms
patient
lymphoma
patient
signific
chang
post
transplant
conclus
asct
deplet
proinflammatori
cell
ms
lymphoma
patient
howev
found
pattern
express
immuneregulatori
cell
subset
differ
patient
cohort
post
transplant
distinct
pattern
immun
reconstitut
ms
lymphoma
postasct
provid
tantalis
indic
chang
may
relat
differ
underli
pathogen
process
aid
pinpoint
chang
specif
immun
deregul
ms
find
potenti
allow
us
track
diseas
progress
treatment
outcom
monitor
presenc
specif
cell
type
may
help
improv
manag
patient
live
ms
conflict
interest
noth
disclos
sheffield
teach
hospit
nh
foundat
trust
sheffield
unit
kingdom
charit
univers
medicin
berlin
depart
rheumatolog
clinic
immunolog
berlin
germani
univers
hospit
basel
depart
rheumatolog
basel
switzerland
saint
antoin
hospit
ebmt
studi
offic
pari
franc
medizinisch
klinik
ii
germani
univers
hospit
umea
depart
hematolog
umea
sweden
medizinisch
klinik
und
poliklinik
der
technischen
dresden
dresden
germani
univers
hospit
kuopio
depart
intern
medicin
kuopio
finland
st
loui
hospit
intern
medicin
pari
franc
background
ancaassoci
vasculitid
aav
chronic
autoimmun
diseas
present
lifethreaten
multisystem
involv
current
treatment
option
still
suboptim
risk
diseas
progress
treatmentrel
toxic
autolog
haematopoiet
stem
cell
transplant
ahsct
use
number
case
patient
outcom
follow
manag
unclear
method
adult
receiv
ahsct
aav
whose
data
regist
ebmt
identifi
retrospect
ebmt
databas
treat
physician
survey
produc
retrospect
evalu
outcom
result
patient
underw
ahsct
primarili
aav
centr
across
europ
femal
male
transplant
diagnosi
granulomatosi
polyangi
eosoniphil
granulomatosi
polyangi
median
age
year
rang
year
patient
receiv
prior
line
therapi
includ
cyclophosphamid
cyc
median
cumul
dose
steroid
everi
case
rituximab
case
stem
cell
sourc
peripher
blood
everi
case
perform
case
mean
cell
dose
x
rang
condit
regimen
cycatg
patient
cyc
patient
median
followup
month
rang
month
transplantrel
mortal
trm
occur
caus
one
patient
went
remiss
later
relaps
month
respect
requir
treatment
diseas
control
time
last
clinic
followup
patient
drugdepend
partial
respons
drugdepend
complet
remiss
drugfre
complet
remiss
conclus
outcom
ahsct
heavili
pretreat
aav
patient
variabl
patient
achiev
drugfre
complet
remiss
trm
observ
quarter
nevertheless
ahsct
potenti
stabil
aav
patient
initi
fail
respond
convent
therapi
data
support
ahsct
advanc
stage
ancaposit
vascul
although
may
place
salvag
treatment
otherwis
refractori
patient
autoimmun
diseas
ahsct
may
provid
better
outcom
perform
earli
stage
diseas
overal
ahsct
perform
clinic
trial
set
experienc
center
conflict
interest
j
snowden
declar
honoraria
speak
sanofi
jazz
alexand
declar
honoria
andor
traval
support
abbvi
amgen
neovii
pfizer
author
declar
conflict
interest
sheffield
teach
hospit
nh
foundat
trust
sheffield
unit
kingdom
background
stiff
person
syndrom
sp
rare
immunemedi
neurolog
disord
characteris
muscl
rigid
spasm
high
glutam
acid
decarboxylas
gad
antibodi
autohsct
success
use
treat
limit
number
sp
patient
sander
et
al
jama
neurolog
describ
singl
centr
experi
assess
referr
sp
potenti
autohsct
method
review
six
patient
sp
across
uk
summaris
tabl
one
patient
patient
declin
autohsct
found
stabl
mycophenol
five
deem
suitabl
autograft
patient
two
patient
treat
patient
progress
encephalomyel
rigid
myoclonu
perm
variant
sp
ataxia
patient
classic
sp
patient
significantli
disabl
fail
multipl
immunotherapi
includ
intraven
immunoglobulin
ivig
plasmapheresi
patient
mobilis
cyclophosphamid
cy
gcsf
condit
cy
atg
follow
autohsct
per
ebmt
guidelin
snowden
ja
et
al
bone
marrow
transplant
third
patient
schedul
autohsct
pend
fund
authoris
two
patient
declin
fund
result
despit
significantli
reduc
perform
statu
patient
toler
procedur
routin
toxic
patient
engraft
day
hospitalis
day
develop
ebv
reactiv
requir
treatment
subsequ
neurolog
assess
show
diseas
stabilis
normalis
antigad
titr
fortnightli
ivig
discontinu
month
posttranspl
mr
spectroscopi
cerebellum
show
signific
increas
naacr
ratio
reflect
improv
metabol
activ
patient
engraft
day
discharg
day
discontinu
fortnightli
ivig
assess
show
resolut
neurolog
symptom
normalis
clinic
examin
antigad
titr
remain
high
conclus
autohsct
may
viabl
treatment
option
patient
sever
sp
support
previou
work
sander
et
al
jama
neurolog
may
also
prove
cost
effect
treatment
patient
requir
regular
treatment
expens
modal
ivig
work
warrant
establish
longterm
safeti
efficaci
costeffect
autohsct
sp
along
optimis
patient
select
transplant
techniqu
conflict
interest
j
snowden
declar
honoraria
speak
sanofi
jazz
tabl
tabl
artemi
hospit
pediatr
hematolog
oncolog
immunolog
bone
marrow
transplant
gurugram
india
artemi
hospit
depart
transfus
medicin
gurugram
india
artemi
hospit
depart
lab
hematolog
gurugram
india
artemi
hospit
agrim
institut
neurosci
gurugram
india
background
multipl
sclerosi
debilit
autoimmun
diseas
lead
progress
neurolog
deterior
categor
relaps
remit
rrm
secondari
progress
spm
primari
progress
ppm
extend
disabl
statu
scale
edss
decid
extent
disabl
rang
diseas
modifi
agent
dma
use
treat
symptom
variabl
result
limit
cost
advers
effect
new
found
interest
high
dose
chemotherapi
autolog
stem
cell
rescu
hdcascr
treatment
ms
report
initi
experi
india
method
retrospect
data
patient
suffer
ms
underw
hdcascr
januari
till
date
analyz
initi
patient
receiv
cyclophosphamid
gcsf
base
mobil
subsequ
patient
underw
gcsf
prime
peripher
blood
stem
cell
collect
day
target
pre
count
one
patient
requir
plerixifor
gcsf
mobil
suboptim
stem
cell
product
cryopreserv
dmso
patient
receiv
condit
chemotherapi
condit
use
cyclophosphamid
x
day
day
ratg
thymoglobulin
x
day
day
median
count
infus
rang
result
median
age
transplant
year
rang
yr
wherea
yr
age
patient
edss
wherea
edss
rrm
spm
ppm
drug
wherea
receiv
least
dma
enter
transplant
median
follow
day
rang
overal
surviv
patient
die
due
transplant
relat
complic
sepsi
drug
toxic
two
patient
develop
dmso
induc
kidney
damag
wherea
one
develop
neurotox
last
follow
none
patient
dma
progress
symptom
small
subset
patient
report
symptom
revers
need
substanti
neurologist
conclus
high
dose
chemotherapi
autolog
stem
cell
rescu
hdcascr
use
modal
treat
multipl
sclerosi
drug
drug
refractori
case
larger
studi
longer
follow
requir
consolid
claim
clinic
trial
registri
none
conflict
interest
none
medic
univers
warsaw
hematolog
oncolog
intern
diseas
warszawa
poland
medic
univers
warsaw
depart
neurolog
warszawa
poland
medic
univers
silesia
depart
hematolog
bone
marrow
transplant
school
medicin
katowic
katowic
poland
central
offic
nation
health
fund
warszawa
poland
background
autolog
haematopoiet
stem
cell
transplant
ahsct
extrem
effect
therapeut
option
patient
sever
multipl
sclerosi
ms
ahsct
expens
limit
data
impact
real
cost
treatment
ms
patient
outsid
clinic
trial
collabor
nation
health
fund
nhf
collect
data
cost
associ
treatment
assess
nationwid
impact
ahsct
cost
ms
treatment
among
ms
patient
method
retrospect
observ
studi
base
healthcar
administr
data
nation
health
fund
nhf
cover
entir
polish
popul
million
inhabit
treatment
cost
within
system
statist
analysi
perform
use
pair
ttest
medcalc
cost
calcul
public
payer
perspect
polish
present
euro
eur
pln
result
accord
data
nhf
preval
ms
poland
per
popul
respect
year
patient
suffer
ms
underw
ahsct
poland
treatment
cover
nhf
analys
patient
comprehens
take
consider
avail
data
ahsct
accord
nhf
data
averag
treatmentrel
cost
eur
per
year
transplant
reduc
averag
eur
per
year
transplant
p
cost
ahsct
nhf
perspect
eur
studi
period
patient
requir
treatment
diseas
modifi
drug
ahsct
two
patient
treat
dimethyl
fumar
approxim
year
procedur
one
dose
two
dose
within
month
respect
one
patient
treat
interferon
within
month
procedur
moreov
ahsct
relat
death
among
patient
studi
group
conclus
limit
data
impact
ahsct
cost
treatment
ms
real
world
analysi
nationwid
medic
data
present
ahsct
significantli
reduc
use
diseas
modifi
drug
among
ms
patient
ahsct
lead
rapid
reduct
treatment
cost
patient
public
payer
amount
treatment
cost
remain
stabl
year
ahsct
expens
transplant
may
compens
within
time
nhf
data
allow
assess
clinic
progress
diseas
clinic
trial
registri
applic
conflict
interest
noth
disclos
preto
medic
school
univers
paulo
depart
biochemistri
immunolog
preto
brazil
center
cellbas
therapi
region
hemotherapi
center
preto
medic
school
univers
paulo
preto
brazil
pari
diderot
sorbonn
pari
pari
franc
inserm
institut
universitair
saintloui
aphp
pari
franc
school
pharmaceut
scienc
preto
univers
paulo
depart
clinic
toxicolog
bromatolog
analysi
preto
brazil
plateform
technologiqu
institut
universitair
pari
franc
divis
clinic
immunolog
preto
medic
school
univers
paulo
depart
intern
medicin
preto
brazil
background
autolog
hematopoiet
stem
cell
transplant
ahsct
use
treat
sever
progress
system
sclerosi
ssc
patient
howev
exactli
ahsct
reshap
immun
system
still
need
complet
clarifi
assess
role
replic
senesc
exhaust
cell
reconstitut
tcr
characterist
clinic
outcom
postahsct
ssc
patient
method
twentyf
ssc
patient
clinic
monitor
skin
thick
modifi
rodnan
skin
score
mrss
lung
function
forc
vital
capac
fvc
semiannu
postahsct
patient
retrospect
classifi
respond
nonrespond
accord
clinic
outcom
follow
ebmt
guidelin
blood
sampl
collect
quantif
telomer
length
rtqpcr
evalu
tcr
characterist
new
gener
sequenc
reconstitut
senesc
exhaust
cell
fac
serum
cytokin
level
measur
cbaflex
vdjtool
use
assess
tcr
divers
shannon
index
rel
tcr
usag
frequenc
famili
chang
segment
pair
junction
vdjviz
vdjdb
databas
screen
annot
frequenc
cmvspecif
tcr
sequenc
motif
result
month
postahsct
end
followup
mrss
decreas
pulmonari
function
stabil
compar
preahsct
parallel
inflammatori
cytokin
level
decreas
transient
month
p
rel
ts
telomer
length
ratio
decreas
month
compar
baselin
correl
increas
cell
express
consequ
increas
percentag
express
cell
correl
neg
telomer
length
express
tcell
increas
month
ahsct
respond
patient
present
lower
gcsf
p
level
nonrespond
well
higher
express
p
b
cell
strong
shift
usag
observ
famili
exclus
respond
patient
segment
usag
increas
postahsct
compar
baselin
signific
decreas
p
famili
percentag
usag
chang
present
nonrespond
patient
signific
shift
neither
observ
follow
ahsct
vj
pair
chang
respond
patient
result
increas
tcr
divers
postahsct
compar
baselin
decreas
nonrespond
patient
among
respond
one
patient
present
cmvspecif
sequenc
remain
stabl
postahsct
nonrespond
patient
experienc
increas
cmvspecif
sequenc
parallel
patient
present
decreas
tcr
divers
conclus
homeostat
prolifer
postahsct
result
transient
telomer
attrit
increas
number
senesc
exhaust
cell
lead
high
express
patient
better
clinic
outcom
ahsct
addit
result
indic
possibl
relationship
cmv
infect
reduc
tcr
divers
diseas
relaps
ahsct
ssc
patient
conflict
interest
author
noth
disclos
imperi
colleg
london
haematolog
london
unit
kingdom
background
autolog
hematopoiet
stem
cell
transplant
hsct
utilis
treatment
sever
multipl
sclerosi
ms
result
signific
improv
neurolog
function
although
patient
could
experi
exacerb
msrelat
symptom
procedur
howev
lack
precis
inform
regard
complic
stem
cell
mobilis
collect
procedur
patient
popul
method
analys
patient
diagnos
ms
underw
stem
cell
mobil
collect
march
novemb
median
age
year
patient
male
interv
diagnosi
hsct
month
rang
patient
relapsingremit
rrm
patient
secondaryprogress
spm
patient
primaryprogress
ppm
multipl
sclerosi
median
number
previou
therapi
rang
patient
receiv
prior
treatment
median
expand
disabl
statu
scale
edss
score
rang
peripher
blood
stem
cell
mobil
cyclophosphamid
cy
day
daili
gcsf
subcutan
start
day
cy
complet
harvest
result
total
cohort
patient
underw
mobil
cygcsf
unev
patient
exacerb
ms
one
fatigu
increas
spastic
worsen
weak
mobilis
period
five
patient
requir
hospit
admiss
mobil
procedur
four
patient
develop
neutropen
fever
includ
one
septic
episod
one
patient
develop
intract
gcsf
associ
back
pain
two
addit
patient
hospitalis
nonneutropen
fever
flareup
ms
symptom
stem
cell
collect
median
cell
dose
rang
median
number
apheresi
rang
patient
need
second
day
collect
one
patient
mobilis
predict
suffici
stem
cell
day
cyclophosphamid
allow
schedul
cyclophosphamid
friday
stem
cell
collect
monday
peripher
blood
cell
concentr
day
correl
final
cell
yield
collect
figur
sinc
februari
cyclophosphamid
infus
given
outpati
procedur
differ
post
mobilis
complic
stem
cell
collect
effici
inpati
outpati
mobilis
conclus
hand
cy
gcsf
mobil
low
rate
exacerb
ms
symptom
accept
rate
post
mobilis
complic
exacerb
ms
symptom
could
occur
stem
cell
collect
procedur
complet
rais
need
prolong
follow
conflict
interest
noth
disclos
univers
florenc
depart
neurofarba
section
child
health
firenz
itali
anna
meyer
children
hospit
depart
haematologyoncolog
florenc
itali
anna
meyer
children
hospit
depart
haematologyoncolog
bmt
unit
florenc
itali
background
cytopenia
defin
reduct
one
matur
blood
cell
type
eg
neutropenia
anemia
thrombocytopenia
peripher
blood
may
typic
first
symptom
primari
immunodefici
disord
pidd
possibl
caus
cytopenia
pidd
compris
mainli
immun
dysregul
bone
marrow
failur
bmf
myelodysplasia
goal
investig
possibl
immun
mediat
mechan
underli
chronic
cytopenia
children
order
achiev
earli
diagnosi
consequ
offer
time
appropri
therapi
method
among
patient
refer
paediatr
haematologyoncolog
unit
select
thirtyf
patient
affect
chronic
cytopenia
patient
character
throughout
clinic
immunolog
haematolog
genet
investig
nineteen
patient
evalu
immunophenotyp
flow
cytometri
next
gener
sequenc
ng
analysi
gene
panel
includ
gene
frequent
implic
immunodefici
immunodysregul
result
among
thirtyf
patient
seven
patient
show
distinct
earli
onset
clinic
haematolog
phenotyp
promptli
diagnos
fanconi
anemia
shwachmandiamond
syndrom
sever
congenit
neutropenia
four
patient
defin
affect
uncharacter
bmf
twentyfour
affect
immunemedi
cytopenia
fourteen
case
isol
autoimmun
neutropenia
one
case
neutropenia
associ
thrombocytopenia
two
case
autoimmun
pancytopenia
seven
patient
differ
combin
cytopenia
multiorgan
autoimmun
immun
phenotyp
analysi
perform
nineteen
patient
immun
mediat
cytopenia
specif
pattern
found
abnorm
affect
b
subtyp
observ
decreas
effector
memori
em
termin
differenti
temra
cell
popul
increas
naiv
central
memori
cm
cell
level
b
lymphocyt
popul
show
decreas
total
b
cell
b
switch
cell
b
memori
cell
increas
cell
absenc
plasmacytoid
monocytoid
dendrit
cell
observ
one
case
preliminari
result
ng
studi
patient
reveal
mutat
follow
gene
gainoffunct
mutat
ikaro
novel
gene
previous
associ
autoimmun
immun
dysregul
valid
studi
ongo
base
immunolog
genet
studi
four
patient
success
treat
haematopoiet
stem
cell
transplant
hsct
haploident
matchedrel
unrel
set
use
reduc
intens
condit
conclus
find
show
presenc
specif
lymphocyt
subpopul
pattern
import
indic
immunemedi
pathogenesi
cytopenia
help
warn
sign
pidd
promptli
investig
genet
analysi
base
experi
earli
diagnosi
offer
time
appropri
therapi
hsct
revers
inherit
condit
good
longterm
outcom
conflict
interest
none
author
anyth
disclos
affili
drum
tower
hospit
nanj
univers
medic
school
depart
rheumatolog
immunolog
nanj
china
iebmt
data
offic
sant
antoin
hospit
depart
haematolog
inserm
umr
pierr
et
mari
curi
pari
franc
saintantoin
ebmt
data
offic
inserm
umr
pari
franc
stloui
aphp
assist
publiqu
de
de
pari
crmr
centr
de
de
maladi
autoimmun
rare
dilesdefr
pari
deni
diderot
univers
cliniqu
de
intern
maladi
autoimmun
et
pathologi
vasculair
uf
pari
franc
background
use
singlecent
cohort
chines
adult
patient
system
lupu
erythematosu
sle
defin
acr
criteria
analyz
predictor
clinic
respons
observ
year
bone
marrowderiv
bm
andor
umbil
cordderiv
uc
allogen
mesenchym
stem
cell
msc
treatment
method
inclus
criteria
adult
activ
sle
patient
age
sle
diseas
activ
index
sledai
score
despit
prior
treatment
oral
cyclophosphamid
cyc
month
mycophenol
mofetil
mmf
mgd
leflunomid
lef
mgd
month
prednison
mgd
without
hydroxychloroquin
hcq
receiv
least
one
intraven
inject
allogen
bm
andor
ucmsc
millionkilo
bodyweight
sle
clinic
biolog
symptom
sledai
score
assess
baselin
month
followup
clinic
remiss
cr
defin
sledai
without
major
organ
activ
mgday
prednison
without
mainten
oral
cyc
mmf
lef
low
diseas
activ
lda
defin
sledai
score
without
major
organ
activ
prednison
mgday
without
mainten
oral
cyc
mmf
lef
prognost
factor
cr
lda
identifi
univari
multivari
logist
regress
variabl
associ
respons
univari
analysi
p
includ
model
stepwis
select
use
result
among
femal
patient
median
age
rang
baselin
sledai
antidsdna
posit
low
serum
complement
level
sle
durat
msc
inject
month
rang
prior
treatment
consist
cyc
mmf
lef
prednison
hcq
cyc
induct
patient
receiv
least
one
uc
msc
inject
two
within
month
use
msc
dose
sourc
patient
uc
median
rang
sledai
month
msc
inject
respect
figur
cr
achiev
patient
lda
use
multivari
analysi
older
age
p
arthralgiaarthr
p
prior
oral
cyc
p
hcq
p
associ
higher
cr
rate
associ
found
cr
antidsdna
cardiorespiratori
disord
prior
prednison
cyc
induct
second
msc
inject
univari
analysi
older
age
arthralgiaarthr
associ
higher
rate
lda
patient
neurolog
disord
baselin
achiev
lda
conclus
activ
sle
patient
one
intraven
inject
allogen
msc
allow
cr
lda
within
year
studi
use
uniqu
immunosuppress
regimen
msc
sourc
collabor
ebmt
allow
refin
analysi
determin
clinic
respons
allogen
msc
promis
therapeut
option
multisystem
sle
conflict
interest
author
declar
conflict
interest
careggi
univers
hospit
florenc
cell
therapi
blood
bank
florenc
itali
careggi
univers
hospit
florenc
neurolog
florenc
itali
careggi
univers
hospit
florenc
microbiolog
virolog
unit
florenc
itali
careggi
univers
hospit
florenc
depart
experiment
clinic
medicin
florenc
itali
background
last
year
high
dose
chemotherapi
autolog
hematopoiet
stem
cell
transplant
ahsct
emerg
effect
safe
treatment
aggress
form
multipl
sclerosi
ms
nevertheless
data
publish
reconstitut
natur
vaccinationdriven
immun
ahsct
indic
revaccin
patient
report
analysi
antigenspecif
immun
recoveri
seri
ms
patient
ahsct
method
blood
sampl
ms
patient
underw
ahsct
center
analyz
patient
underw
mobil
cyclophosphamid
ctx
gc
f
condit
beamatg
regimen
antibodi
titr
varicellazost
measl
rubella
polio
hepat
b
virus
tetanu
diphtheria
toxin
analys
mobil
baselin
year
ahsct
chemiluminesc
microparticl
immunoassay
cmia
perform
determin
rubella
hepat
b
surfac
antigen
antibodi
antihbsag
enzym
immunoassay
perform
assess
varicella
zoster
measl
diphtheria
tetanu
igg
antibodi
igg
poliovirus
patient
receiv
prophylaxi
acyclovir
thrimethoprimsulphametoxazol
six
month
ahsct
patient
receiv
revaccin
followup
period
result
patient
show
complet
sustain
engraft
median
rang
time
day
respect
patient
show
complet
return
normal
lymphocyt
subset
count
within
two
year
transplant
case
measl
rubella
chickenpox
occur
transplant
median
followup
month
tabl
report
antibodi
titr
baselin
year
ahsct
loss
serum
protect
immun
observ
variabl
rate
patient
test
agent
rang
measl
diphtheria
conclus
revaccin
patient
underw
autolog
hsct
sever
autoimmun
diseas
common
practic
mani
center
also
recommend
ebmt
guidelin
howev
concern
practic
rais
put
role
vaccin
autoimmun
trigger
inde
evid
loss
protect
antibodi
titer
either
natur
vaccinationdriven
immun
report
patient
transplant
autoimmun
diseasea
seri
high
variabl
antibodi
titer
baselin
shown
howev
patient
show
protect
titr
test
agent
show
trend
maintain
possibl
approach
might
revaccin
patient
unprotect
titr
year
hsct
larger
seri
data
necessari
provid
conclus
evid
topic
conflict
interest
none
author
anyth
disclos
tabl
antibodi
titr
baselin
year
children
hospit
fudan
univers
depart
hematologyoncolog
bone
marrow
transplant
unit
shanghai
china
background
inflammatori
bowel
diseas
ibd
chronic
disord
gastrointestin
tract
earli
onset
ibd
veoibd
repres
sever
children
diseas
onset
occur
year
old
receptor
mutat
consid
one
import
gene
veoibd
current
variant
treatment
steroid
medic
immunosuppress
agent
biolog
agent
could
get
complet
remiss
allogen
hematopoiet
stem
cell
transplant
allohsct
report
induc
remiss
veoibd
method
perform
unrel
umbil
cord
blood
transplant
ucbt
consecut
children
veoibd
due
receptor
mutat
median
age
children
month
rang
month
median
bodi
weight
kg
rang
kg
patient
receiv
reduc
intens
condit
ric
regimen
consist
busulfan
fludarabin
cytarabin
prophylaxi
graftversushost
diseas
gvhd
tacrolimu
patient
receiv
hla
allelesmismatch
cord
unit
hla
fulli
match
match
match
median
nucleat
cell
cord
blood
rang
median
cell
rang
result
patient
engraft
median
time
neutrophil
engraft
day
median
time
platelet
engraft
day
median
followup
time
month
rang
month
patient
aliv
continu
donor
engraft
achiev
complet
clinic
remiss
colonoscopi
month
transplant
children
reveal
mucosa
heal
patient
grade
iiiiv
acut
graftversushost
diseas
gvhd
patient
die
caus
death
patient
infect
lead
multiorgan
failur
graft
failur
occur
month
transplant
patient
die
viru
infect
lung
bronchiol
obliteran
conclus
first
clinic
trial
unrel
ucbt
perform
veoibd
children
china
data
unrel
ucbt
ric
consid
potenti
cur
therapeut
option
children
veoibd
conflict
interest
author
declar
conflict
interest
cell
therapi
cellular
therapi
hospit
universitario
materno
infantil
vall
pediatr
hematolog
oncolog
depart
barcelona
spain
hospit
infantil
universitario
la
paz
servicio
de
madrid
spain
santa
creu
sant
pau
hospitaluniversitat
pediatr
hematolog
oncolog
hsct
unit
barcelona
spain
hospit
universitario
la
paz
clinic
immunolog
depart
madrid
spain
la
paz
biomed
research
instituteidipaz
madrid
spain
hospit
universitario
vall
dhebron
hematolog
barcelona
spain
hospit
universitario
materno
infantil
vall
unitat
de
patologia
infecciosa
de
pediatria
barcelona
spain
hospit
universitario
la
paz
servicio
de
madrid
spain
banc
de
sang
teixit
barcelona
spain
background
viral
infect
lead
fatal
complic
immunosuppress
patient
patient
hematopoiet
stem
cell
transplant
hsct
patient
primari
immunodefici
pid
use
virusspecif
lymphocyt
vst
success
treatment
prevent
viral
infect
set
describ
experi
clinic
use
vst
method
retrospect
review
lymphoapheresi
procedur
select
yield
clinic
result
vst
produc
banc
de
sang
teixit
hospit
la
paz
result
assess
outcom
patient
experienc
differ
viral
infect
treat
viru
specif
cell
total
vst
infus
analys
median
age
year
eleven
patient
receiv
infus
context
posthaematopoiet
stem
cell
transplant
viral
infect
indic
rest
patient
immunodefici
associ
cmv
infect
patient
ebv
chronic
activ
diseas
donor
donor
deem
fit
donat
chosen
depend
secret
capac
hla
match
transplant
patient
thirdparti
donor
use
multipl
infus
requir
episod
infect
relaps
lack
respons
donor
use
patient
differ
donor
toxic
complic
associ
apheresi
procedur
one
donor
requir
placement
central
venou
cathet
two
patient
experienc
infus
reaction
one
develop
aplasia
one
patient
experienc
grade
acut
gvhd
secondari
treatment
die
sepsi
respons
hsct
patient
ebv
vst
one
patient
ebv
ptld
csf
clear
infect
csf
symptom
improv
significantli
subsequ
relaps
two
patient
show
respons
receiv
treatment
brentuximab
cmv
vst
four
patient
cmv
infect
clear
viru
patient
die
progress
adenoviru
vst
one
patient
viremia
respond
clear
viremia
within
week
patient
adenoviru
diseas
progress
die
diseas
ebv
cmv
vst
patient
show
respons
nonhsct
patient
none
nontranspl
patient
cmv
infect
respond
die
diseas
patient
ebv
chronic
activ
diseas
progress
die
diseas
donor
cell
detect
chimer
patient
overal
outcom
patient
die
progress
patient
die
sepsi
conclus
product
vst
deriv
either
stem
cell
donor
thirdparti
donor
feasibl
treatment
like
safe
effect
especi
treatment
viral
infect
hsct
clinic
trial
registri
conflict
interest
none
tabl
product
characterist
pbkm
warsaw
poland
lublin
medic
univers
depart
pediatr
neurolog
lublin
poland
univers
medic
scienc
poznan
poland
background
autolog
umbil
cord
blood
ucb
repres
potenti
revolutionari
therapi
neurolog
disord
autism
spectrum
disord
asd
cerebr
palsi
cp
patient
asd
reveal
hyperact
immun
system
irregular
neuron
growth
increas
size
number
microglia
cerebr
palsi
common
caus
physic
disabl
children
may
occur
due
perinat
hypox
insult
development
brain
abnorm
genet
diseas
traumat
infecti
caus
polish
stem
cell
bank
pbkm
provid
autolog
ucb
neuroprotect
neuroregen
treatment
children
asd
cp
method
eleven
patient
age
year
month
year
month
medium
age
year
month
enrol
medic
treatment
among
patient
romanian
children
diagnos
asd
receiv
ucb
collect
year
ucb
unit
transfer
biogeni
pbkm
remain
patient
polish
patient
asd
cp
given
ucb
collect
year
romanian
patient
polish
patient
ucb
inject
remain
children
receiv
ucb
inject
characterist
autolog
cord
blood
unit
median
rang
tabl
parent
provid
sign
consent
start
ucb
administr
result
polish
patient
examin
psychologist
pedicat
test
month
ucb
administr
patient
still
wait
final
test
month
therefor
comprehens
result
avail
advers
event
record
conclus
administr
collect
reinfus
umbil
cord
blood
usb
proven
safe
welltoler
treatment
possibl
asd
cp
patient
conflict
interest
mucha
k
poteralska
j
j
orczykowska
j
k
grudniak
gladysz
marszalek
oldak
boruczkowski
pbkm
employe
tabl
tabl
miltenyi
biotec
gmbh
bergisch
gladbach
germani
background
manufactur
genemodifi
cell
requir
robust
reproduc
process
depend
materi
reagent
fulfil
specif
safeti
requir
gener
process
requir
use
human
ab
serum
reagent
commerci
limit
cultur
system
mandatori
ensur
potent
cell
expans
yield
high
number
viabl
cell
remov
need
human
ab
serum
especi
fulli
autom
manufactur
system
geneengin
cell
prepar
reduc
cost
depend
reagent
limit
avail
reduc
potenti
risk
viral
contamin
increas
commerci
scalabl
wide
demand
method
clinimac
prodigi
cell
transduct
process
enabl
robust
gener
genemodifi
cell
without
need
serum
supplement
use
mac
gmp
cell
transact
combin
texmac
gmp
medium
miltenyi
biotec
furthermor
implement
potent
solubl
polyclon
cell
stimul
reagent
allow
process
simplif
wherebi
manipul
step
bead
remov
render
unnecessari
result
develop
process
requir
human
ab
serum
demonstr
robust
serum
free
process
capabl
yield
compar
high
expans
viabl
function
chimericantigenreceptor
car
modifi
cell
furthermor
cell
phenotyp
analysi
indic
differenti
select
activ
cell
differ
serum
free
process
use
serum
supplement
interestingli
signific
higher
transduct
effici
final
car
cell
number
observ
use
serum
free
condit
addit
differ
car
cell
specif
function
analyz
vitro
vivo
observ
conclus
fullyautom
clinimac
prodigi
cell
transduct
process
minim
user
interact
enabl
prepar
high
number
function
car
cell
serum
free
process
therebi
classic
process
risk
viral
contamin
due
human
ab
serum
use
differ
devic
unnecessari
manipul
nonautom
system
reduc
minim
accordingli
improv
next
step
toward
commerci
fullyautom
manufactur
car
cell
treatment
larg
number
patient
conflict
interest
project
receiv
fund
european
union
horizon
research
innov
programm
grant
agreement
carat
la
fe
pediatr
sct
unit
valencia
spain
la
fe
hematolog
valencia
spain
la
fe
pharmaci
valencia
spain
la
fe
sct
unit
valencia
spain
background
infect
remain
major
sourc
morbid
mortal
allogen
stem
cell
transplant
arena
cord
blood
transplant
recipi
account
higher
rate
viral
infect
pharmacolog
treatment
alway
success
method
present
case
first
patient
success
treat
third
parti
cellular
therapi
refractori
cmv
infect
male
high
risk
ball
candid
allogen
sct
second
complet
remiss
cr
msd
neither
mud
avail
cord
blood
unit
chosen
donor
recipi
cmv
neg
donor
receptor
femalemal
cell
dosag
tnc
x
cd
receiv
prophylact
acyclovir
sinc
admiss
pcr
cmv
detect
perform
week
sinc
condit
posit
test
center
defin
threshold
copiesml
myeloabl
condit
regimen
thiotepa
busulfanfludarabin
atg
total
dose
mgkg
gvhd
prophylaxi
tacrolimu
shortcours
steroid
import
complic
earli
posttranspl
period
engraft
day
discharg
day
per
local
polici
blood
product
irradi
filter
transfus
primari
cmv
infect
day
treat
ganciclovir
cmv
viremia
increas
week
adequ
therapi
chang
foscarnet
time
present
diarrhea
adenoviru
found
faec
plu
mild
haematuria
jcbk
viruria
weekli
cidofovir
start
combin
foscarnet
simultan
tacrolimu
taper
day
discontinu
evid
cmv
endorgan
diseas
blood
count
biochemistri
normal
leukemia
remain
complet
remiss
patient
stabl
full
donor
chimer
studi
cmv
resist
show
cmv
mutat
cmv
antivir
resist
foscarnet
sensibl
ganciclovir
resist
cidofovir
resist
face
cmv
infect
resist
first
second
line
treatment
decid
test
benefit
third
parti
cell
therapi
per
local
regul
inform
consent
obtain
contact
memori
sloan
ketter
cancer
center
ny
ny
usa
suitabl
cell
line
cmv
specif
cytotox
lymphocyt
ctl
identifi
result
five
month
posttranspl
patient
receiv
cell
therapi
dose
anti
cmv
specif
ctl
administ
per
day
three
dose
day
immedi
side
effect
regist
quick
decrement
cmv
viral
load
observ
second
ctl
infus
control
remain
neg
gvhd
detect
far
nine
month
posttranspl
four
month
specif
anti
cmv
ctl
infus
regard
immun
reconstitut
immunoglobulin
level
normal
remain
complet
remiss
full
donor
chimer
back
school
perform
statu
excel
lanski
conclus
specif
third
parti
ctl
play
key
role
treatment
futur
earli
inclus
manag
difficult
cmv
infect
consid
clinic
trial
registri
na
conflict
interest
na
medizinisch
klinik
und
poliklinik
ii
germani
scripp
research
institut
depart
immunolog
microbiolog
jupit
fl
unit
state
background
integrin
heterodimer
transmembran
receptor
act
cellcel
cellmatrix
interact
express
integrin
vitronectin
receptor
itgav
document
sever
entiti
includ
melanoma
breast
colorect
cancer
glioblastoma
enhanc
tumor
cell
surviv
metastasi
evalu
antitumor
function
cart
cell
vitro
murin
xenograft
model
vivo
method
express
integrin
analyz
flow
cytometri
car
target
domain
deriv
human
mab
higher
vs
lower
affin
clone
equip
either
long
short
iggfc
spacer
vs
hingeonli
signal
modul
construct
express
lentivir
vector
genetransf
cell
donor
car
cell
enrich
puriti
prior
function
test
result
confirm
highlevel
express
integrin
melanoma
breast
cancer
lower
extent
jurkat
tcell
lymphoma
cell
line
observ
specif
potent
lysi
mediat
cart
cell
eg
specif
lysi
within
cocultur
cart
cell
e
ratio
observ
highlevel
product
cart
cell
product
cart
cell
stimul
tumor
cell
translat
sustain
viabil
product
prolifer
cart
cell
vitro
overal
observ
maximum
antitumor
reactiv
car
short
spacer
highaffin
target
domain
engraft
firefli
luciferas
posit
nsg
mice
led
metastat
tumor
growth
anim
mice
treat
singl
dose
cart
cell
ratio
led
complet
resolut
tumor
lesion
complet
surviv
cart
mous
cohort
end
observ
period
mice
treat
control
cell
show
rapid
tumor
progress
inferior
surviv
mice
per
group
p
cart
cell
engraft
vivo
persist
day
adopt
transfer
document
flow
cytometri
cytokin
product
document
multiplex
cytokin
analysi
mous
serum
strongest
antitumor
effect
vivo
mediat
car
short
spacer
lowaffin
target
domain
conclus
data
demonstr
cart
cell
target
integrin
confer
potent
antitumor
function
vitro
vivo
line
previou
work
found
extracellular
spacer
design
receptor
affin
affect
tumor
recognit
optim
order
deriv
car
construct
maximum
reactiv
intriguingli
also
express
tumor
vasculatur
cancerassoci
fibroblast
suggest
cart
cell
may
capabl
effici
migrat
endotheli
connect
tissu
barrier
tumor
microenviron
exert
antitumor
effect
conflict
interest
none
zhejiang
univers
school
medicin
bone
marrow
transplant
center
first
affili
hospit
hangzhou
china
univers
chicago
depart
surgeri
chicago
il
unit
state
univers
chicago
institut
molecular
engin
chicago
il
unit
state
immuquad
biotechnolog
hangzhou
china
background
chimer
antigen
receptor
car
cell
target
bcell
antigen
display
potent
antileukemia
activ
refractoryrelaps
acut
lymphocyt
leukemia
howev
influenc
autolog
immun
system
caus
cart
cell
well
examin
elucid
appli
highthroughput
tcr
sequenc
technolog
assess
system
dynam
chang
cell
repertoir
induc
cart
cell
therapi
chins
ball
patient
method
femal
patient
clinic
trial
observ
cart
administr
achiev
complet
remiss
cr
clinic
termin
cart
treatment
experienc
grade
cytokin
releas
syndrom
cr
averag
age
patient
year
old
peripher
blood
sampl
bone
marrow
sampl
cart
sampl
infus
obtain
test
tcr
full
length
mrna
deepli
sequenc
use
immunhubtm
tcr
profil
system
immunquad
biotech
briefli
race
unbias
amplif
protocol
use
algorithm
appli
raw
sequenc
data
pcr
sequenc
error
correct
v
j
c
gene
segment
map
result
observ
decreas
divers
increas
clonal
cell
repertoir
peripher
blood
bone
marrow
compar
pretreat
control
measur
invsimpson
tcr
sequenc
enrich
cell
clone
blood
bone
marrow
cart
therapi
found
cart
cell
pool
meanwhil
found
treatmentassoci
top
tcr
sequenc
lower
frequenc
pretreat
sampl
tcr
sequenc
enrich
cell
clone
could
maintain
cart
therapi
addit
cart
therapi
increas
similar
calcul
use
bub
index
cell
repertoir
bone
marrow
blood
substanti
influenc
divers
clonal
cell
repertoir
conclus
investig
show
big
chang
tcell
divers
clonal
patient
immun
system
posttreat
homogen
cell
repertoir
clonal
expans
bone
marrow
blood
compani
cart
cell
administr
impli
lysi
tumor
cart
cell
therapi
might
facilit
prime
clonal
expans
patient
tumor
antigenspecif
cell
systemat
enrich
autolog
cell
may
enlarg
therapeut
effect
synergi
conflict
interest
none
author
anyth
disclos
zhejiang
univers
hangzhou
china
bone
marrow
transplant
center
first
affili
hospit
school
medicin
zhejiang
univers
hangzhou
china
background
chimer
antigen
receptormodifi
cell
cart
therapi
one
promis
target
immunotherapi
drawn
extens
attent
result
multipl
applic
accord
publish
studi
cart
cell
cart
reach
complet
remiss
cr
rate
refractoryrelaps
lymphoma
respect
tumor
cell
immun
cell
play
central
regulatori
role
cell
divid
sever
major
subclass
accord
differ
cell
surfac
molecul
maintain
immun
balanc
method
collect
peripher
blood
sampl
patient
refractori
relaps
acut
lymphoblast
leukemia
lymphoma
differ
stage
cart
treatment
flow
cytometri
use
detect
lymphocyt
subset
peripher
blood
order
investig
impact
cart
treatment
tumor
cell
immun
possibl
mechan
result
figur
show
chang
lymphocyt
subset
cart
therapi
figur
lymphocyt
increas
significantli
activ
lymphocyt
increas
obviou
elev
subset
figur
b
helper
lymphocyt
subset
cr
explain
becam
domin
cytokin
conclus
activ
lymphocyt
significantli
increas
cr
well
subset
three
cell
subset
bear
task
kill
tumor
cell
releas
cytokin
conflict
interest
none
author
anyth
disclos
cancer
research
institut
clinic
cell
biolog
fac
core
unit
vienna
austria
medic
univers
vienna
vienna
austria
hannov
medic
school
institut
transfus
medicin
hannov
germani
hannov
medic
school
integr
research
treatment
center
ifbtx
hannov
germani
hannov
medic
school
depart
pediatr
hematolog
oncolog
hannov
germani
background
aspergillusfumigatu
asp
infect
constitut
major
caus
morbid
mortal
patient
haematopoiet
stem
cell
transplant
obtain
manufact
liscenc
gener
clinicalgrad
aspspecif
cell
via
interferongamma
ifng
cytokin
captur
system
cc
use
gmpcompliant
aspspecif
lysat
due
unexpect
discontinu
product
lysat
end
start
find
altern
test
use
aspspecif
peptidepool
cytokin
secret
assay
csa
well
alreadi
establish
gmpcoform
short
term
expans
ste
method
method
healthi
volunt
allocel
registri
screen
presenc
asptcel
via
ifng
elispot
assay
stimul
pbmc
either
lysat
differ
aspspecif
overlap
peptidepool
cat
shmt
sod
pbmc
leukapheresi
n
prepar
hannov
ifngcsa
remain
cell
sent
vienna
perform
ste
ifngcsa
cell
stimul
gmpconform
lysat
peptidepool
follow
magnet
select
ifngproduc
tcell
cell
character
phenotyp
function
flow
cytometri
ste
cell
stimul
day
either
lysat
peptidepool
final
cell
product
character
via
flow
cytometri
ifngelispot
ifnggranzymeb
flurospot
assay
result
asptcel
detect
detect
limit
pbmc
volunt
lysat
stimul
undetect
healthi
donor
peptidepool
use
puriti
lysatestimul
ifng
asptcel
magnet
enrich
use
ifng
csa
rang
stimul
overlap
peptid
pool
result
non
sastisfactori
enrich
contrast
ste
reveal
highli
specif
asptcel
spot
form
coloni
sfc
cell
lysat
cell
combin
peptidepool
cell
respect
independ
stimuli
use
predominantli
tcell
expand
vs
compar
tcell
vs
among
wherea
tcell
mainli
centralmemori
type
tcell
compris
mainli
effectormemori
tcell
target
cell
highli
function
cytotox
determin
secret
granzymeb
ifng
conclus
despit
discontinu
lysat
product
consequ
enrich
asptcel
via
ifng
cc
clinicalscal
product
peptid
poolexpand
asptcel
use
ste
method
might
enabl
effici
adopt
tcell
immunotherapi
conflict
interest
conflict
interest
st
istvan
stlaszlo
hospit
hematolog
stem
cell
transplant
budapest
hungari
st
istvan
stlaszlo
hospit
pediatr
hematolog
stem
cell
transplant
budapest
hungari
semmelwei
univers
clinic
intern
medicin
budapest
hungari
background
hematopoiet
stem
cell
transplat
increasingli
use
techniqu
treatment
sever
hematolog
diseas
cell
harvest
peripheri
blood
pbsc
bone
marrow
bm
contain
cell
caus
lifethreaten
graft
versu
host
diseas
gvhd
donor
immun
cell
respons
gvhd
select
remov
graft
use
immunomagnet
cell
separ
clinic
grade
cell
deplet
plu
miltenyi
biotec
bergischgladbach
germani
gold
standard
method
far
howev
disadvantag
time
consum
extens
manual
manipul
necessari
start
plu
separ
recent
fulli
autom
function
close
system
techniqu
clinimac
develop
avoid
manual
manipul
requir
aim
studi
anal
compar
result
cell
deplet
obtain
clinimac
plu
cm
clinimac
prodigi
system
pd
method
last
year
jul
dec
cell
deplet
perform
patient
pt
pediatr
result
result
median
valu
rang
shown
compar
nucleat
cell
viabil
cell
recoveri
nk
cell
recoveri
pd
cell
deplet
pd
cell
deplet
pd
respect
howev
obtain
significantli
higher
cell
recoveri
use
pd
system
cell
composit
final
product
compar
without
statist
differ
median
graft
cell
count
follow
bodi
weight
kg
cell
content
cell
content
cell
content
cell
content
graft
transfus
pt
die
finish
graft
manipul
pt
need
graft
select
due
suboptim
stem
cell
content
nontak
death
pt
aliv
median
follow
day
conclus
deplet
increasingli
use
separ
techniqu
clinic
practic
could
shown
cm
recent
develop
fulli
autom
pd
system
highli
effici
techniqu
graft
manipul
pd
prove
least
good
slightli
better
old
cm
system
due
simplic
compar
cost
pd
system
seem
first
choic
techniqu
futur
conflict
interest
congress
support
reti
szederjesi
tasnadi
hungarian
distributor
miltenyi
biotec
campu
virchow
berlin
berlin
germani
background
hematopoiet
stem
progenitor
cell
hspc
increasingli
use
raw
materi
advanc
therapi
medic
product
atmp
ie
genet
engin
hspc
treatment
hemoglobinopathi
howev
yet
comprehens
clearli
defin
standard
extend
qualiti
control
moreov
success
atmp
develop
process
control
depend
optim
subset
definit
method
standard
multicolor
flow
cytometri
panel
gate
strategi
develop
base
work
fritsch
transfus
valid
method
character
subset
distribut
hspc
differ
compart
bone
marrow
bm
median
autolog
stem
cell
graft
mobil
gcsf
alon
autog
median
gcsf
plu
plerixafor
autogp
median
gcsf
mobil
healthi
allogen
stem
cell
donor
allog
median
result
importantli
data
confirm
feasibl
robust
reproduc
approach
particular
found
signific
differ
distribut
subset
percentag
blymphoid
precursor
high
bm
neglig
mobil
peripher
blood
stem
cell
bm
vs
autog
autogp
allog
p
frequenc
primit
multipot
progenitor
mpp
significantli
higher
autog
allog
compar
bm
vs
p
interestingli
frequenc
mpp
also
differ
autog
allog
p
frequenc
longterm
repopul
cell
compar
autog
autogp
allog
appear
lower
bm
express
significantli
higher
bm
cell
compar
peripher
blood
stem
cell
autog
autogp
allog
p
significantli
higher
autogp
compar
autog
p
conclus
approach
allow
access
differ
subset
distribut
hspc
ie
hsc
qualiti
control
product
character
context
atmp
product
far
data
indic
import
differ
subset
composit
regard
sourc
mobil
agent
furthermor
data
reveal
differ
healthi
donor
pretreat
patient
might
critic
impact
processinggenet
engin
vivo
function
conflict
interest
none
author
anyth
disclos
research
report
abstract
support
beckman
coulter
may
support
develop
commerci
product
beckman
coulter
neither
influenc
take
respons
content
abstract
term
collabor
review
approv
charit
berlin
accord
polici
object
research
hospit
maternoinfantil
vall
dhebron
barcelona
spain
hospit
del
mar
imim
hospit
del
mar
medic
research
institut
immunologia
barcelona
spain
hospit
de
la
santa
creu
sant
pau
pediatr
servic
barcelona
spain
hospit
vall
hebron
hematolog
servic
barcelona
spain
hospit
de
la
santa
creu
sant
pau
hematolog
servic
barcelona
spain
institut
oncologia
tria
pujol
badalona
spain
institut
oncologia
duran
reynal
lhospitalet
de
llobregat
spain
banc
de
sang
teixit
cell
therapi
servic
barcelona
spain
background
donor
lymphocyt
infus
dli
commonli
use
treat
incipi
relaps
transplant
possibl
use
cord
blood
sourc
cell
develop
phase
iii
clinic
trial
assess
abil
cord
blood
donor
lymphocyt
infus
cbdli
boost
immun
vigil
use
fraction
cryobag
avail
clinic
trial
evalu
present
case
report
show
potenti
effect
cb
lymphocyt
set
method
clinic
case
three
monthold
girl
diagnos
infant
mll
rearrang
made
proceed
allogen
hematopoiet
stem
cell
transplant
first
cr
month
old
poor
respons
chemotherapi
sourc
match
unrel
cord
blood
unit
patient
fulfil
inclus
criteria
clinic
trial
condit
regimen
consist
atg
thiotepa
busulfan
fludarabin
cell
infus
use
fraction
cb
unit
tnc
result
earli
engraft
posttranspl
cours
complic
grade
acut
skin
gut
gvhd
respond
methylprednisolon
diseas
assess
month
posttranspl
demonstr
full
donor
chimer
flow
cytometri
neg
mll
pcr
immunosuppress
success
wean
month
hsct
free
gvhd
immunosuppress
persist
full
donor
chimer
flow
cytometri
bone
marrow
aspir
neg
leukem
cell
howev
mll
pcr
still
detect
level
count
low
given
poor
immun
reconstitut
risk
relaps
decis
made
infus
fraction
cord
blood
unit
day
cellskg
infus
adjust
result
rapid
expans
lymphocyt
compart
observ
earli
day
infus
threeweek
infus
patient
develop
gut
gvhd
requir
treatment
corticosteroid
cyclosporin
month
infus
lymphocyt
expans
transient
number
went
back
previou
level
second
wave
expans
note
two
month
later
equal
short
length
case
popul
observ
expans
domin
subset
lymphocyt
mostli
bear
memori
marker
interestingli
mll
pcr
level
fluctuat
becam
neg
cord
blood
dli
leukaemiafre
almost
year
posthsct
elispot
assay
routin
perform
assess
reactiv
front
panel
defin
antigen
interestingli
reactiv
tumor
peptid
collect
detect
along
followup
conclus
cord
blood
dli
seem
feasibl
cbu
store
bag
suffici
cell
dose
fraction
spite
risk
gvhd
may
need
adjust
dose
strategi
could
easi
way
boost
immun
control
minim
residu
diseas
engraft
clinic
trial
registri
clinicaltrialsgov
identifi
http
conflict
interest
author
declar
conflict
interest
acibadem
univers
istanbul
turkey
acibadem
altunizad
hospitallabcel
istanbul
turkey
background
hematopoiet
stem
cell
transplant
hsct
sever
aplast
anemia
saa
mainli
limit
high
incid
graft
failur
gvhd
mesenchym
stem
cell
msc
shown
support
hematopoiesi
vivo
display
potent
immunosuppress
effect
prevent
treat
gvhd
hsct
studi
aim
determin
potenti
benefit
msc
cotransplant
patient
saa
undergo
hsct
regard
outcom
engraft
gvhd
method
total
patient
median
age
month
rang
carri
allogen
match
siblingfamili
match
unrel
haploident
condit
regimen
includ
fludarabin
cyclophosphamid
patient
thymoglobulin
atg
use
patient
recipi
receiv
cyclosporin
csa
shortterm
methotrex
gvhd
prophylaxi
patient
drug
patient
msc
administ
venou
infus
h
hematopoiet
graft
bone
marrow
pt
peripher
blood
pt
cell
infus
intraven
median
count
result
patient
experienc
infusion
toxic
infus
msc
patient
achiev
hematopoiet
reconstitut
sustain
full
donor
chimer
pt
mix
chimer
pt
median
time
myeloid
engraft
day
rang
day
platelet
engraft
day
rang
day
incid
grade
ii
iiiiv
acut
gvhd
chronic
limit
gvhd
nine
patient
aliv
patient
die
infect
patient
followedup
median
rang
conclus
despit
limit
case
enrol
studi
find
support
previou
studi
show
hsct
combin
msc
infus
could
effect
approach
reduc
risk
graft
failur
gvhd
hsct
saa
msc
occupi
hematopoiesissupport
capac
conflict
interest
none
author
anyth
disclos
hannov
medic
school
pediatr
hematolog
oncolog
hannov
germani
integr
research
treatment
center
transplant
ifbtx
hannov
germani
hannov
medic
school
institut
transfus
medicin
hannov
germani
hannov
medic
school
institut
immunolog
hannov
germani
universitaetsmedizin
berlin
pediatr
hematolog
oncolog
berlin
germani
berlin
institut
health
berlin
germani
universitaetsmedizin
berlin
neuropatholog
berlin
germani
hannov
medic
school
hematolog
oncolog
hemostaseolog
stem
cell
transplant
hannov
germani
hannov
medic
school
cell
therapi
center
hannov
germani
background
ebvassoci
posttranspl
lymphoprolif
diseas
ptld
cn
involv
sever
complic
solid
organ
transplant
standard
treatment
reduct
immunosuppress
antibodi
applic
andor
chemotherapi
often
fail
lead
poor
outcom
transfer
ebvdirect
tcell
shown
promis
howev
contribut
transfer
endogen
tcell
larg
unknown
method
manufactur
clinicalgrad
ebvspecif
tcell
hlamatch
third
parti
donor
conduct
use
ppselect
cytokin
captur
system
miltenyi
biotech
clinimac
devic
monitor
ebv
load
perform
routin
qpcr
ebvspecif
tcell
frequenc
prepost
transfer
quantifi
elispot
use
peptid
pool
ppselect
miltenyi
biotec
enhanc
sensit
analysi
repeat
presenc
ppconsenu
peprotec
tcr
chain
repertoir
analysi
expand
pbmc
stain
antibodi
dapi
htcr
cell
sort
tcell
fac
aria
fusion
flow
cytomet
rna
extract
rneasi
plu
micro
kit
qiagen
revers
transcript
smarter
race
pcr
kit
clontech
carri
accord
manufactur
recommend
combin
amplif
tcr
illumina
adaptor
sequenc
pcr
kit
clontech
use
index
sampl
perform
nextera
primer
kit
illumina
product
purifi
agencourt
ampur
xp
kit
denatur
dilut
pool
done
describ
illumina
miseq
dilut
denatur
guid
next
gener
sequenc
perform
illumina
miseq
system
analysi
fastq
file
annot
imgthighvquest
databas
process
tcrpackag
vdjtool
result
boy
develop
multilocular
ebvposit
cn
ptld
ten
year
liver
transplant
complet
remiss
achiev
repeat
intraven
intrathec
antibodi
rituximab
administr
combin
intrathec
chemotherapi
methotrex
cytarabin
prednison
time
period
three
month
due
poor
prognosi
cn
ptld
lack
ebvspecif
tcell
patient
blood
decid
perform
ebvdirect
tcell
immunotherapi
consolid
treatment
patient
receiv
five
infus
allogen
ebvspecif
tcell
kg
bw
manufactur
cytokin
captur
system
hlamatch
unrel
third
parti
donor
relev
acut
toxic
observ
ebvspecif
tcell
becam
detect
first
inject
increas
treatment
cours
ng
tcrprofil
verifi
persist
expans
donorderiv
ebvspecif
clone
two
transfer
epitop
spread
unrel
ebv
antigen
occur
suggest
onset
endogen
tcell
product
support
detect
recipientderiv
clone
ng
tcrprofil
continu
complet
remiss
confirm
month
initi
diagnosi
conclus
repetit
transfer
partial
hlamatch
ebvspecif
tcell
third
parti
donor
evok
robust
ebvspecif
tcell
respons
high
risk
ptld
patient
tcell
specif
broaden
treatment
cours
individu
tcr
sequenc
could
attribut
donor
recipi
progeni
molecular
track
individu
tcell
help
understand
contribut
transfer
vs
endogen
virusspecif
tcell
patient
receiv
adopt
tcell
transfer
conflict
interest
author
declar
conflict
interest
work
support
german
children
cancer
fund
dk
german
feder
ministri
educ
research
ph
particip
clinic
fellow
program
fund
berlin
berlin
institut
health
abstract
previous
publish
hannov
medic
school
ped
hematolog
oncolog
hannov
germani
hannov
medic
school
transfus
medecin
hannov
germani
hannov
medic
school
institut
human
genet
hannov
germani
background
chimer
analysi
hlamismatch
stem
cell
transplant
import
diagnost
tool
clinic
decis
regard
modif
immunosuppress
particular
flowcytometri
base
detect
hla
dispar
offer
attract
option
detect
chimer
lymphocyt
subset
follow
hlamismatch
cell
transfer
present
broaden
techniqu
detect
rare
virusspecif
cell
peripher
blood
adopt
cell
transfer
flow
cytometri
method
pbmc
residu
blood
sampl
platelet
plt
apheresi
cmv
donor
cmv
donor
individu
allocel
donor
registri
isol
ficol
densiti
centrifug
pbmc
donor
stimul
separ
incub
overnight
plate
stimul
total
cell
donor
mix
ratio
donor
donor
posit
cell
isol
via
cytokin
secret
assay
csa
miltenyi
biotech
analyz
via
flow
cytometri
mab
simultan
sampl
enrich
ifn
cmv
specif
cell
analyz
molecular
chimer
str
pcr
result
magnet
enrich
mix
posit
cell
display
donor
phenotyp
donor
phenotyp
magnet
enrich
distribut
cell
similar
respect
cell
analyz
donor
donor
mix
posit
cell
suspens
show
enrich
distribut
enrich
comparison
str
analysi
enrich
cell
cell
analyz
reveal
mixtur
donor
cell
donor
cell
mixtur
cell
donor
donor
similar
result
obtain
second
mismatch
donor
pair
result
fac
chimer
avail
within
hour
molecular
chimer
magnet
enrich
took
day
conclus
increas
usag
hlamismatch
transplant
requir
fast
reliabl
determin
cell
chimer
fac
analysi
mismatch
hla
allel
provid
rapid
techniqu
detect
chimer
subpopul
avoid
need
cell
purif
sensit
compar
str
chimer
analysi
fac
chimer
combin
techniqu
function
singl
cell
identif
cytokin
secret
provid
valuabl
tool
monitor
antigenspecif
cell
partial
hlamatch
transplant
adopt
cell
transfer
prospect
studi
need
determin
fate
partial
hlamatch
antigenspecif
cell
adopt
transfer
situat
conflict
interest
author
declar
conflict
interest
chu
amien
picardi
amien
cedex
franc
background
agreement
good
practic
therapeut
use
human
cell
qualiti
control
perform
valid
process
extracorpor
photopheresi
ecp
current
refer
method
highlight
inhibit
cell
divis
ecp
remain
use
tritiat
thymidin
incorpor
requir
suitabl
environ
radioact
assay
last
year
altern
method
cfse
stain
flow
cytometri
luminesc
cell
viabil
assay
develop
report
result
advantag
drawback
assay
design
laboratori
method
perform
cfse
stain
flow
cytometri
opt
cfse
kit
invitrogen
bind
coval
intracellular
amin
use
assess
cell
prolifer
luminesc
cell
viabil
test
use
assay
promega
allow
determin
number
viabl
cell
cultur
base
quantit
luminomet
atp
present
report
presenc
metabol
activ
cell
method
perform
use
patient
cell
collect
cytapheresi
begin
preecp
metoxsalen
salf
macopharma
irradi
cell
postecp
reinject
patient
cell
obtain
type
initi
flow
cytometri
appreci
viabil
distribut
mononuclear
cell
mnc
subpopul
plate
incub
divid
two
group
non
stimul
cell
stimul
cell
solut
pha
phytohemagglutininp
sigmaaldrich
ngml
human
miltenyi
biotec
demonstr
ecp
efficaci
specif
cell
prolifer
differ
stimul
nonstimul
prepc
cell
prolif
must
greater
time
inhibit
cell
divis
prepc
postpc
cell
inh
greater
result
cfse
assay
perform
specif
preecp
postecp
viabl
cell
read
day
verifi
cfse
label
day
ecp
patient
alreadi
analyz
median
prolif
median
inh
contrast
luminesc
test
analyz
type
viabl
mnc
collect
read
day
patient
studi
median
cell
prolif
median
inh
note
cfse
test
one
patient
inh
specif
inh
hematocrit
rang
across
assay
conclus
show
low
prolif
luminesc
assay
stay
specif
caus
entir
mnc
analyz
without
target
wherea
stimul
focus
lymphocyt
whose
rate
highli
heterogen
cohort
patient
inh
specif
observ
probabl
due
hematocrit
greater
known
reduc
irradi
efficaci
howev
turn
method
answer
laboratori
specif
criteria
choic
assay
depend
laboratori
object
ecp
patholog
treat
progress
understand
postecp
cell
mechan
action
vivo
conflict
interest
conflict
interest
disclos
medizinisch
klinik
ii
germani
institut
immunologi
medizinisch
wien
austria
institut
hygien
und
angewandt
immunologi
medizinisch
wien
austria
background
immunotherapi
chimer
antigen
receptor
car
modifi
tcell
intens
preclin
clinic
investig
involv
rapidli
increas
spectrum
new
car
design
target
antigen
present
novel
dual
paramet
report
dpr
cell
line
enabl
rapid
highthroughput
test
function
character
car
method
dpr
deriv
jurkat
tcell
lymphoma
line
modifi
nfatinduc
cfp
gfp
report
gene
car
express
lentivir
genetransf
car
posit
dpr
enrich
puriti
use
egfrt
select
marker
car
dpr
cocultur
antigen
posit
stimul
cell
report
geneactiv
analyz
flow
cytometri
stimul
use
tcell
stimul
tc
cell
membranebound
scfv
trigger
dpr
use
refer
result
transduc
dpr
prototyp
car
costimul
detect
highest
nfat
report
geneinduct
hour
cocultur
posit
stimul
cell
activ
nfat
car
engag
also
confirm
primari
tcell
use
western
blot
next
express
panel
variabl
spacer
length
deriv
dpr
base
previou
work
primari
tcell
show
import
particular
spacer
design
optim
antitumor
function
dpr
rapidli
identifi
optim
construct
panel
shorten
time
requir
analysi
week
day
also
interest
determin
nfat
activ
signatur
dpr
modifi
costimul
gener
plu
detect
similar
level
nfat
induct
receptor
figur
howev
construct
compris
rather
costimulatori
moieti
show
significantli
stronger
induct
p
notabl
gener
induc
higher
level
gener
construct
gener
construct
induc
higher
level
gener
indic
costimulatori
domain
car
format
contribut
signal
corrobor
data
confirm
stimul
dpr
tcr
endogen
independ
car
readili
induc
signal
conclus
data
demonstr
potenti
use
dpr
rapidli
evalu
panel
car
construct
base
nfat
signal
data
suggest
convent
posit
costimulatori
moieti
car
construct
locat
transmembran
domain
zeta
suboptim
fulli
exploit
costimulatori
capac
find
trigger
design
novel
car
format
current
evalu
laboratori
current
integr
dpr
analysi
car
librari
differ
specif
affin
receptor
design
confid
novel
dpr
platform
acceler
preclin
develop
select
car
optim
antitumor
function
clinic
translat
conflict
interest
none
copenhagen
univers
hospit
rigshospitalet
depart
clinic
immunolog
copenhagen
denmark
copenhagen
univers
hospit
rigshospitalet
depart
hematolog
copenhagen
denmark
background
immun
reconstitut
cell
nk
cell
recogn
import
clinic
outcom
hematopoiet
stem
cell
transplant
hsct
could
depend
content
subset
distribut
cell
stem
cell
graft
method
consecut
patient
hematolog
malign
transplant
stem
cell
transplant
unit
rigshospitalet
denmark
condit
myeloabl
patient
nonmyeloabl
patient
donor
hlaident
sibl
haploident
match
unrel
cell
replet
graft
deriv
bone
marrow
peripher
blood
fresh
graft
sampl
patient
blood
sampl
day
hsct
analyz
absolut
concentr
nk
cell
bd
trucounttm
bead
subset
phenotyp
multicolor
flow
cytometri
panel
perform
bd
ii
subset
marker
includ
tcr
hladr
result
median
concentr
cell
reach
normal
rang
day
transplant
nk
cell
remain
within
normal
rang
time
point
fraction
cell
cell
stabl
distribut
show
increas
fraction
day
toward
day
within
nk
cell
compart
fraction
remain
stabl
fraction
decreas
along
parallel
increas
fraction
toward
day
immun
reconstitut
cell
fraction
correl
highli
significantli
graft
content
correspond
cell
subset
p
analyz
time
point
correl
graft
content
within
nk
cell
compart
show
greater
variat
cell
correl
day
cell
day
p
day
cell
significantli
day
conclus
immun
reconstitut
show
compel
correl
graft
content
correl
stronger
cell
nk
cell
result
relev
increas
focu
innat
effector
cell
graft
manipul
hsct
conflict
interest
author
noth
disclos
tabl
tabl
ghent
univers
hospit
hematolog
gent
belgium
holofarm
gent
belgium
telma
gent
belgium
ghent
univers
hospit
cancer
centr
gent
belgium
ghent
univers
biomark
iof
consortium
crig
gent
belgium
wahwah
vzw
gent
belgium
background
introduct
immunotherapi
major
breakthrough
treatment
cancer
gener
public
averag
patient
popul
overal
knowledg
immun
system
role
cancer
limit
moreov
explain
immun
system
immunotherapi
work
patient
caregiv
challeng
extrem
complex
seriou
game
virtual
aid
scarc
use
cancer
patient
patient
gener
howev
limit
amount
literatur
evinc
benefit
patient
caregiv
experi
servic
employ
develop
immunot
motion
comic
explain
genesi
cancer
work
mechan
three
type
immunotherapi
motion
comic
combin
digit
comic
anim
sound
effect
voiceov
andor
music
score
method
scenario
stori
board
basic
charact
design
develop
hematologist
execut
game
develop
refin
small
focu
group
consist
hematologistsoncologist
psychologist
studi
coordin
medic
student
nurs
commun
manag
result
first
usabl
version
one
hundr
tester
ask
give
opinion
anonim
questionnair
first
version
eventu
evalu
peopl
differ
background
hematologistsoncologist
pediatr
adult
psychologist
studi
coordin
medic
student
nurs
commun
manag
game
develop
laymen
small
number
patient
take
remark
observ
account
immunot
adapt
improv
final
version
result
immunot
explain
three
type
immunotherapi
engag
interact
easytounderstand
way
complex
theori
checkpoint
inhibitor
car
tcell
bite
illustr
major
evalu
consid
motion
comic
good
tool
explain
immunotherapi
patient
addit
physician
consult
first
version
level
understand
differ
depend
type
immunotherapi
explain
bite
least
clear
evalu
prompt
us
adapt
part
motion
comic
almost
evalu
felt
hope
watch
motion
comic
experienc
posit
emot
happi
wellinform
strengthen
conclus
although
motion
comic
carri
import
advantag
clear
graphic
present
complex
inform
engag
way
deliv
inform
rare
use
healthcar
set
immunot
readi
roll
first
real
hospit
set
current
prepar
clinic
trial
evalu
effect
inform
transmiss
use
immunot
motion
book
lead
better
understand
given
treatment
increas
patient
knowledg
diseas
treatment
proven
impact
hope
strength
empower
adher
treatment
meanwhil
immunot
also
keep
evolv
motion
book
enrich
augment
realiti
function
improv
understand
deepen
user
experi
furthermor
multipl
translat
forthcom
facilit
intern
career
motion
comic
lastli
immunot
also
evalu
context
educ
differ
level
clinic
trial
registri
non
applic
conflict
interest
develop
motion
comic
support
partli
number
pharmaceut
compani
form
immunotherapi
protfolio
celgen
celyad
amgen
bm
roch
novarti
msd
major
part
support
innov
fund
ghent
univers
hospit
support
compani
influenc
develop
motion
comic
individu
author
noth
disclos
improv
efficaci
granulocyt
collect
obviat
need
addit
hydroxyethyl
starch
use
terumo
bct
spectra
optia
devic
dimitra
oikonomopoul
ioanni
tsoni
vassili
anyfanti
chara
giatra
maria
vardaka
zoi
poulopoul
eirini
bika
zoi
mellio
ioanni
konstantello
tatiana
tzenou
stavro
gigant
ioanni
baltadaki
nichola
harhalaki
dimitrio
karakasi
evaggelismo
gener
hospit
depart
haematolog
bone
marrow
transplant
unit
athen
greec
ronti
hella
sa
athen
greec
background
granulocyt
transfus
gt
repres
potenti
lifesav
intervent
patient
sever
neutropen
infect
anticip
bone
marrow
recoveri
appli
set
hematopoiet
stem
cell
transplant
hsct
howev
use
limit
lack
urgent
donor
avail
well
aspect
pertain
collect
administr
adequ
granulocyt
dose
safe
manner
explor
feasibl
safeti
gt
intens
chemotherapi
andor
allogen
hsct
recipi
use
spectra
optia
devic
aim
optim
collect
efficaci
avoid
addit
hydroxyethyl
starch
he
sediment
red
blood
cell
prevent
anaphylactoid
reaction
recipi
method
total
granulocyt
collect
gc
obtain
patient
grade
iv
neutropenia
lifethreaten
infect
context
induct
chemotherapi
acut
leukemia
allogen
hsct
granulocyt
donor
male
either
volunt
donor
friend
rel
patient
select
basi
abo
compat
granulocyt
mobil
granulocytecoloni
stimul
factor
gcsf
subcutan
plu
dexamethason
mg
intramuscularli
administ
hour
prior
collect
collect
perform
spectra
optia
devic
pmn
collect
protocol
without
use
he
peripher
vein
use
vascular
access
procedur
calcium
supplement
given
oral
donor
target
dose
granulocyt
per
transfus
granulocyt
collect
product
irradi
prior
infus
patient
result
median
granulocyt
yield
per
collect
procedur
rang
median
volum
rang
ml
median
hematocrit
rang
median
blood
volum
process
rang
ml
rang
total
blood
volum
tbv
median
platelet
count
reduct
donor
rang
baselin
valu
mainli
depend
blood
volum
process
remark
side
effect
record
donor
relat
granulocyt
mobil
collect
gt
well
toler
recipi
without
febril
anaphylactoid
reaction
clinic
benefit
defin
control
neutropen
infect
hematopoiet
recoveri
engraft
achiev
granulocyt
transfus
patient
conclus
granulocyt
collect
fulli
autom
spectra
optia
devic
safe
procedur
donor
result
transfus
adequ
high
dose
granulocyt
compar
yield
granulocyt
achiev
without
addit
he
suggest
enhanc
safeti
recipi
base
data
broader
applic
gt
may
warrant
especi
context
hsct
conflict
interest
none
author
anyth
disclos
newcastl
univers
institut
cellular
medicin
newcastl
upon
tyne
unit
kingdom
background
extracorpor
photopheresi
ecp
second
line
immunemodul
therapi
use
treatment
acut
gvhd
previou
studi
suggest
role
dendrit
cell
dc
underli
toleranceinduc
mechan
action
monocyt
differenti
dc
ecp
process
although
littl
known
true
vivo
effect
dc
monocyt
popul
method
six
paediatr
patient
receiv
ecp
treatment
corticosteroidrefractorydepend
acut
gvhd
four
patient
complet
therapi
one
withdrawn
cycl
ecp
one
remain
ecp
week
whole
blood
sampl
analys
ecp
cycl
regular
interv
absolut
number
myeloid
dc
mdc
cell
plasmacytoid
dc
pdc
cell
monocyt
popul
includ
classic
monocyt
cell
enumer
bd
bioscienc
tube
use
flow
cytometri
result
compar
two
control
group
month
post
hsct
paediatr
patient
post
hsct
develop
acut
gvhd
group
paediatr
patient
acut
gvhd
receiv
ecp
group
result
among
patient
complet
ecp
therapi
overal
increas
pdc
number
observ
reduct
mdcpdc
ratio
contrast
patient
remain
ecp
exhibit
consist
low
pdc
increas
mdcpdc
ratio
overal
downward
trend
classic
monocyt
popul
seen
ecp
patient
median
mdcpdc
ratio
higher
ecp
group
month
higher
acut
gvhd
control
group
month
figur
steadi
rise
seen
mdc
pdc
number
acut
gvhd
control
group
ecp
group
static
acut
gvhd
control
group
figur
conclus
increas
pdc
popul
decreas
mdcpdc
ratio
overal
promot
favour
pdc
environ
may
underli
mechan
action
behind
ecp
plasmacytoid
dc
report
toleranceinduc
effect
includ
stimul
regulatori
tlymphocyt
caus
tlymphocyt
anergi
decreas
classic
monocyt
popul
may
due
dc
differenti
andor
deviat
inflammatori
environ
research
examin
phenotyp
dc
popul
concurr
impact
regulatori
tlymphocyt
need
conflict
interest
none
nation
research
center
hematolog
moscow
russian
feder
background
multipot
mesenchym
stromal
cell
msc
use
treatment
prevent
acut
graft
versu
host
diseas
gvhd
msc
sampl
effect
studi
msc
interact
lymphocyt
vitro
reveal
type
chang
subpopul
lymphocyt
express
hladr
lymphocyt
significantli
increas
cocultiv
part
msc
sampl
group
wherea
cocultiv
lymphocyt
msc
sampl
group
b
aim
studi
investig
differ
two
identifi
group
msc
method
msc
deriv
bone
marrow
bm
donor
male
femal
age
year
median
year
passag
cocultur
nonactiv
activ
mgml
pha
phalymphocyt
allogen
lymphocyt
ratio
day
subpopul
lymphocyt
msc
surfac
marker
analyz
time
flow
cytometri
determin
gene
express
level
rel
perform
real
time
pcr
result
differ
bm
donor
group
b
sex
age
concentr
cfu
bm
signific
differ
characterist
msc
found
total
cell
product
passag
group
time
lower
group
b
vs
day
cocultiv
lymphocyt
rel
group
time
higher
group
b
vs
rel
pparg
time
lower
vs
day
cocultiv
group
rel
time
higher
vs
thu
immunomodulatori
abil
msc
group
significantli
higher
group
b
also
indic
differ
subpopul
lymphocyt
cocultiv
msc
group
follow
signific
differ
subpopul
lymphocyt
reveal
day
cocultiv
msc
group
fraction
higher
time
vs
time
vs
effector
memori
cell
time
vs
transit
memori
cell
time
vs
nonactiv
lymphocyt
activ
lymphocyt
proport
higher
time
vs
time
vs
central
memori
cell
time
vs
time
vs
time
vs
time
vs
time
vs
time
vs
termin
effector
cell
time
lower
vs
compar
lymphocyt
cocultur
msc
group
b
conclus
reveal
individu
differ
msc
explain
msc
sampl
effect
treatment
autoimmun
diseas
acut
gvhd
other
conflict
interest
studi
financi
support
grant
russian
scienc
foundat
project
individu
author
noth
disclos
univers
clinic
heidelberg
divis
nephrolog
heidelberg
germani
univers
clinic
heidelberg
depart
intern
medicin
v
heidelberg
germani
univers
clinic
heidelberg
depart
nuclear
medicin
heidelberg
germani
univers
heidelberg
institut
immunolog
heidelberg
germani
univers
clinic
heidelberg
allgemein
viszer
und
transplantationschirurgi
heidelberg
germani
univers
clinic
heidelberg
depart
intern
medicin
iv
heidelberg
germani
background
major
limit
longterm
allograft
surviv
lifethreaten
sideeffect
immunosuppress
medic
chronic
allograft
injuri
therefor
fervent
need
induct
donorspecif
toler
without
broad
unspecif
immunosuppress
aim
clinic
phase
studi
call
mic
cell
perform
ie
donorderiv
monocyt
gain
immunosuppress
properti
incub
prolifer
inhibitor
mitomycin
c
method
kidney
transplant
recipi
mic
cell
manufactur
good
manufactur
practic
gmp
condit
leukapheresi
product
live
donor
amount
mic
cell
administ
patient
escal
mic
cell
per
kg
bodi
weight
day
group
mic
cell
per
kg
bodi
weight
day
group
b
day
group
c
live
donor
kidney
transplant
kidney
transplant
patient
receiv
standard
tripl
drug
immunosuppress
therapi
frequenc
advers
event
ae
measur
primari
outcom
day
result
clinic
kidney
transplant
recipi
median
serum
creatinin
mgdl
day
remain
stabl
median
creatinin
mgdl
day
without
signific
proteinuria
median
gmol
creatinin
day
without
reject
episod
patient
experienc
total
ae
includ
four
sever
ae
relat
mic
cell
infus
besid
two
infecti
complic
ae
like
posit
cross
match
result
de
novo
donorspecif
antibodi
reject
episod
record
patient
group
c
reduct
immunosuppress
therapi
effect
observ
phase
lowdos
cyclosporin
lowdos
entericco
mycophenol
sodium
major
immunolog
chang
observ
patient
group
c
increas
b
cell
median
day
decreas
thereaft
median
day
furthermor
transit
breg
increas
median
day
median
total
b
cell
pool
day
plasma
ratio
increas
median
cell
therapi
median
day
vitro
mix
lymphocyt
cultur
assay
lymphocyt
patient
show
minim
reactiv
irradi
donor
lymphocyt
reactiv
parti
lymphocyt
preserv
furthermor
analysi
mic
cell
product
vitro
assay
demonstr
capabl
mic
cell
induc
tolerogen
dendrit
cell
downregul
costimulatori
molecul
matur
molecul
upregul
immunosuppress
molecul
conclus
kidney
transplant
recipi
receiv
mic
cell
product
show
stabl
renal
function
without
allograft
injuri
reject
episod
even
reduct
convent
therapi
immunosuppress
drug
therefor
mic
cell
repres
innov
extrem
promis
option
donorspecif
immunosuppress
live
donor
kidney
transplant
beyond
clinic
trial
registri
eudract
number
conflict
interest
c
morath
schmitt
c
kleist
g
opelz
zeier
schaier
schmitt
p
ter
founder
tolerogenixx
gmbh
l
wang
employe
compani
hospit
universitario
la
paz
pediatr
hematooncolog
stem
cell
transplant
unit
madrid
spain
hospit
universitario
la
paz
hematolog
depart
madrid
spain
background
use
tcell
deplet
graft
haploident
stem
cell
transplant
hsct
proven
effici
prevent
graft
versu
host
diseas
gvhd
although
associ
delay
earli
tcell
recoveri
increas
risk
viral
infect
leukemia
relaps
graft
reject
convent
donor
lymphocyt
infus
dli
hsct
transplant
proven
effect
strategi
nevertheless
condit
high
preval
gvhd
even
low
dose
tcell
infus
select
lymphocyt
subpopul
low
aloreact
emerg
effect
strategi
rectifi
issu
deplet
lymphocyt
preserv
memori
tcell
could
provid
safe
sourc
function
lymphocyt
antiinfect
antileukem
antireject
properti
lower
rate
advers
effect
method
present
data
memori
tcell
dli
mdli
perform
hsct
case
mix
chimer
persist
lymphopenia
presenc
viralopportunist
infect
strategi
acceler
immun
reconstitut
result
fifteen
patient
diagnosi
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
myelodisplast
syndrom
sever
aplast
anemia
sideroblast
anemia
chronic
granulomat
diseas
receiv
one
mdli
hsct
fifteen
patient
twelv
receiv
hsct
graft
consist
cell
three
tcrab
cell
deplet
graft
total
fortythre
mdli
infus
median
dose
memori
tcell
infus
median
dose
tcell
mdli
infus
median
seventyseven
day
hsct
day
median
interv
mdli
thirtyfour
day
day
patient
receiv
mdli
four
patient
infus
occas
two
patient
infus
twentyon
mdli
administ
lymphopenia
fourteen
patient
concomit
viralopportunist
infect
cmv
ebv
bkv
adenoviru
vzv
toxoplasmosi
mix
chimerismgraft
failur
motiv
mdli
six
administ
attempt
acceler
immun
reconstitut
infus
well
toler
without
side
effect
infus
appearanceworsen
gvhd
progress
increas
tcell
count
observ
follow
six
mdli
although
transitori
respons
week
five
case
viralopportunist
infect
control
five
case
requir
median
mdli
achiev
respons
mdli
administ
case
mix
chimerismgraft
failur
none
effect
revert
situat
conclus
preliminari
data
suggest
mdli
safe
adopt
immunotherapi
strategi
even
high
dose
tcell
without
infus
side
effect
gvhd
complic
efficaci
observ
patient
lymphopenia
opportunist
infect
posit
result
patient
mix
chimerismgraft
failur
date
howev
determin
real
efficaci
strategi
prospect
studi
requir
conflict
interest
none
author
anyth
disclos
fondazion
ircc
policlinico
san
matteo
oncolog
unit
pavia
itali
fondazion
ircc
policlinico
san
matteo
pediatr
hematologyoncolog
cell
factori
pavia
itali
fondazion
ircc
policlinico
san
matteo
pediatr
hematologyoncolog
pavia
itali
background
nasopharyng
carcinoma
npc
epsteinbarr
viru
ebv
relat
highli
chemoradiosensit
malign
howev
onethird
patient
consid
incur
metastat
recurr
diseas
publish
experi
report
metastat
npc
patient
surviv
year
express
antigen
viral
protein
malign
cell
constitut
good
target
immunotherapeut
strategi
previous
show
diseas
control
autolog
ebvtarget
cell
therapi
refractoryrelaps
patient
fail
convent
treatment
method
describ
result
tcell
therapi
program
patient
oligometastat
relaps
npc
patient
treat
complet
secondlin
chemotherapi
patient
receiv
administr
ebvspecif
cytotox
lymphocyt
ctl
total
cell
doseinfus
x
repeat
case
object
respons
result
start
treat
patient
refractorymetastat
diseas
six
patient
organ
involv
metastat
lesion
patient
oligometastat
diseas
less
lesion
best
respons
secondlin
treatment
progress
diseas
pd
patient
stabl
diseas
sd
patient
partial
pr
complet
cr
respons
patient
respect
ctl
therapi
sever
advers
event
observ
patient
treat
progress
stabl
diseas
metastat
lesion
show
npc
progress
die
diseas
patient
matastas
reach
pr
secondlin
chemotherapi
stabil
diseas
year
tcell
therapi
upon
diseas
progress
treat
thirdlin
capecitabinebas
chemotherapi
reach
longlast
cr
aliv
without
evid
diseas
month
diagnosi
patient
reach
cr
secondlin
chemotherapi
receiv
adjuv
ctl
treatment
persist
cr
followup
one
patient
diseas
relaps
reach
longlast
cr
treatment
gemcitabinebas
chemotherapi
patient
oligometastat
diseas
treat
ebvctl
pr
secondlin
chemotherapi
one
reach
longlast
cr
diseas
progress
initi
stabil
pr
receiv
convent
treatment
one
patient
radiotherapi
site
diseas
line
chemotherapi
follow
cell
therapi
achiev
cr
median
followup
month
patient
aliv
evid
diseas
conclus
ebvspecif
ctl
therapi
safe
associ
clinic
benefit
patient
refractori
metastat
npc
combin
secondlin
chemotherapi
ctl
therapi
seem
yield
best
result
compar
favour
outcom
describ
literatur
clinic
trial
registri
na
conflict
interest
none
declar
hospit
de
la
santa
creu
sant
pau
hematolog
servic
barcelona
spain
hospit
del
mar
imim
hospit
del
mar
medic
research
institut
immunologia
barcelona
spain
hospit
vall
dhebron
hematolog
servic
barcelona
spain
institut
doncologia
tria
pujol
badalona
spain
institut
doncologia
duran
reynal
lhospitalet
de
llobregat
spain
hospit
maternoinfantil
vall
dhebron
barcelona
spain
hospit
de
la
santa
creu
sant
pau
pediatr
servic
barcelona
spain
banc
de
sang
teixit
cell
therapi
servic
barcelona
spain
background
donor
lymphocyt
infus
dli
test
cb
transplant
develop
phase
iii
clinic
trial
assess
abil
dli
spare
fraction
engraft
origin
product
clinic
trial
evalu
present
case
report
show
potenti
effect
cb
lymphocyt
revert
mix
chimera
method
clinic
case
year
old
male
diagnos
chemotherapi
treatment
start
use
high
risk
scheme
pethema
group
critic
complic
treatment
central
vein
thrombosi
consequ
lasparaginas
coagulopathi
evalu
end
chemotherapi
first
cr
neg
minim
residu
diseas
mrd
receiv
umbil
cb
transplant
due
lack
relat
unrel
suitabl
donor
patient
fulfil
criteria
enter
clinic
trial
condit
regiment
consist
thiotepa
mgkg
fludarabin
busulphan
mgkg
oral
administr
gvhd
prophylaxi
late
administr
atg
mgkg
cyclosporin
short
puls
prednison
thereaft
first
part
umbil
cb
contain
tnc
infus
neutrophil
platelet
recoveri
day
respect
main
complic
cytomegaloviru
reactiv
day
requir
valganciclovirganciclovir
treatment
associ
corticoid
due
differenti
diagnosi
gvhd
corticotherapi
fastli
decreas
stop
second
part
infus
cb
result
bone
marrow
aspir
show
cr
neg
mrd
howev
donor
lymphocyt
popul
chimer
decreas
see
figur
dli
schedul
day
second
part
umbil
cord
blood
infus
contain
alreadi
one
month
infus
increas
number
cell
appar
number
amplifi
next
month
cellsmicrolit
moment
infus
cellsmicrolit
day
later
cellsmicrolit
month
postdli
concomitantli
intens
prolif
activ
note
detect
cell
certain
delay
also
cell
period
revers
ratio
observ
even
although
circul
cell
infus
ratio
equal
normal
ratio
achiev
month
time
point
analyz
cell
memori
phenotyp
predomin
conclus
summari
observ
vigor
increas
presenc
circul
lymphocyt
dli
consequ
second
cb
infus
chimer
improv
achiev
total
donor
lymphocyt
chimer
maintain
also
new
cutan
digest
grade
ii
gvhd
respond
medium
dose
corticosteroid
shown
last
follow
patient
aliv
cr
full
donor
chimer
therefor
potenti
role
cell
therapi
intervent
propos
clinic
trial
registri
http
searchsearch
conflict
interest
author
declar
conflict
interest
univers
frankfurt
main
divis
stem
cell
transplant
immunolog
depart
children
adolesc
frankfurt
germani
univers
frankfurt
main
depart
hematolog
oncolog
frankfurt
germani
hospit
erlangen
depart
medicin
erlangen
germani
background
natur
killer
nk
cell
innat
lymphocyt
strong
antitumor
abil
tumor
patient
multipl
myeloma
mm
patient
elev
number
nk
cell
stem
cell
transplant
sct
report
benefit
patient
recent
show
earli
time
point
autosct
nk
cell
repres
main
nk
cell
subset
remark
nk
cell
popul
consid
immatur
express
matur
marker
exert
import
cytotox
function
challeng
tumor
cell
indic
potenti
impact
antitumor
immun
method
preclin
immun
monitor
scientif
research
studi
nk
cell
isol
kit
peripher
blood
bone
marrow
healthi
donor
mm
patient
defin
time
point
use
nk
cell
neg
isol
also
patientderiv
tumor
cell
sort
mm
patient
bone
marrow
sampl
first
diagnosi
phenotyp
function
character
perform
vitro
multicolor
flow
cytometri
assay
result
aim
nk
cell
use
adopt
cell
therapi
also
address
cytotox
patientderiv
cytokinestimul
nk
cell
mm
cell
diagnosi
autosct
detect
chang
nk
cell
phenotyp
well
cytotox
function
expans
remark
cytokin
stimul
patient
nk
cell
significantli
differ
healthi
donor
nk
cell
show
highli
activ
phenotyp
abl
significantli
enhanc
lysi
mm
cell
smaller
cohort
mm
patient
abl
isol
autolog
tumor
cell
well
bone
marrow
nk
cell
could
show
cytokinebas
ex
vivo
activ
protocol
abl
significantli
improv
even
lysi
autolog
tumor
cell
suggest
potenti
use
nk
cell
adopt
therapi
mm
patient
moreov
effort
enhanc
lysi
mm
cell
also
use
nk
check
point
inhibitor
antibodi
target
inhibitori
receptor
block
pathway
induc
signific
increas
nk
cell
mediat
cytotox
multipl
myeloma
conclus
addit
autolog
stem
cell
transplant
adopt
nk
cell
therapeut
protocol
impli
cytokinebas
ex
vivo
nk
cell
expans
procedur
might
high
interest
treatment
multipl
myeloma
patient
furthermor
function
assay
reveal
block
antibodi
promis
nk
check
point
inhibitor
conflict
interest
author
noth
disclos
abstract
previous
publish
abstract
previous
publish
cellular
therapeut
co
ltd
shanghai
china
provinc
peopl
hospit
guangzhou
china
hematolog
blood
diseas
hospit
chines
academi
medic
scienc
peke
union
medic
colleg
tianjin
china
background
although
highlight
breakthrough
target
chimer
antigen
receptor
car
cell
blood
malign
high
relaps
rate
big
challeng
cart
cell
singl
chain
variabl
fragment
scfv
domain
murin
origin
previous
murin
cart
cell
achiev
high
complet
remiss
cr
patient
relapsedrefractori
hematolog
malign
complet
remiss
rate
acut
lymphoblast
leukemia
complet
remiss
rate
nonhodgkin
lymphoma
nct
howev
unsatisfactori
relaps
rate
encount
car
singl
chain
variabl
fragment
scfv
domain
murin
origin
human
antimous
antibodi
hama
may
import
culprit
therefor
construct
car
cell
human
scfv
domain
overcom
potenti
antimurin
immunemedi
reject
method
construct
human
car
lentivir
vector
encod
car
compos
murin
human
scfv
domain
estim
antitumor
activ
safeti
vitro
cocultur
tumor
cell
line
without
express
evalu
safeti
effici
vivo
human
tumor
cell
transplant
immun
defici
mice
divid
four
group
includ
human
cart
cell
murin
deriv
cart
cell
normal
cell
buffer
preliminari
clinic
trial
four
patient
refractori
relaps
acut
lymphoblast
leukemia
conduct
afterward
four
subject
rr
ball
treat
human
cart
cell
decemb
decemb
murin
human
cart
cell
infus
dose
rang
cart
cellskg
cart
cellskg
subject
monitor
close
trial
result
posit
tumor
cell
cocultur
cart
cell
show
tumor
cell
kill
cart
cell
negtiv
tumor
cell
remain
aliv
tumor
cell
transplant
experi
group
human
car
achiev
longer
surviv
preclin
experi
show
antimalign
abil
safeti
car
cell
human
scfv
domain
preliminari
clinic
trial
four
subject
ball
treat
human
cart
cell
achiev
cr
well
mrd
neg
day
cart
cell
infus
none
suffer
irrevers
neurotox
conclus
first
multicentr
report
knowledg
success
treatment
rr
ball
human
car
cell
china
even
rr
ball
highburden
leukemia
patient
also
effect
associ
high
remiss
rate
autolog
cart
infus
though
followup
short
human
cart
cell
demonstr
antimalign
activ
subject
clinic
trial
registri
nct
conflict
interest
q
zhang
x
zhu
noth
disclos
z
wu
l
xiao
stockhold
innov
cellular
therapeut
co
ltd
hamad
medic
corpor
gmp
cellular
therapi
lab
depart
laboratori
medecin
patholog
doha
qatar
nation
center
cancer
care
research
ncccr
doha
qatar
hamad
medic
corpor
depart
laboratori
medecin
patholog
doha
qatar
background
autolog
hematopoiet
progenitor
cell
collect
apheresi
hpca
must
cryopreserv
store
transplant
cell
process
hpca
cryopreserv
includ
volum
reduct
reduc
amount
dimethyl
sulfoxid
use
cryoprotect
decreas
need
storag
space
liquid
nitrogen
tank
method
retrospect
compar
pericel
protocol
perform
autom
gmp
close
system
sepax
devic
biosaf
sa
ge
healthcar
common
manual
techniqu
use
refriger
centrifug
g
prior
plasma
remov
volum
adjust
compar
evalu
total
nucleat
cell
tnc
cell
recoveri
viabil
well
technologist
time
need
complet
procedur
total
procedur
carri
process
apheresi
product
obtain
adult
patient
eleven
hpca
unit
process
histor
techniqu
eight
hpca
unit
process
pericel
protocol
attempt
valid
techniqu
result
autom
process
requir
minut
per
procedur
wherea
manual
process
requir
minut
percentag
volum
reduct
use
sepax
technolog
rang
sd
sd
start
ml
rang
ml
sd
ml
reach
final
valu
ml
rang
ml
sd
ml
compar
perform
manual
method
mean
rang
sd
downsiz
volum
cell
suspens
ml
rang
ml
sd
ml
ml
rang
ml
sd
ml
p
valu
signific
differ
recoveri
nucleat
cell
tnc
cell
product
process
sepax
mean
rang
sd
cell
mean
rang
sd
cell
viabil
mean
rang
sd
compar
centrifug
rang
sd
mean
rang
sd
mean
rang
sd
p
valu
moreov
autom
process
demonstr
time
effect
result
compar
semiautom
centrifug
process
method
although
signific
increas
volum
reduct
percentag
use
sepax
technolog
conclus
data
demonstr
effect
suitabl
autom
procedur
volum
reduct
hpca
collect
apheresi
prior
addit
cryoprotect
controlledr
freez
pericel
protocol
perform
sepax
technolog
shorten
process
time
includ
featur
facilit
complianc
factjaci
standard
oper
gmp
environ
provid
similar
cell
recoveri
viabil
refer
techniqu
conflict
interest
studi
done
without
conflict
interest
author
acknowledg
support
member
cell
process
facil
centr
de
cellulair
institut
paolicalmett
inserm
marseil
franc
personnel
train
support
dmitri
rogachev
nation
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
viral
infect
remain
one
lead
caus
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
although
pharmacotherapi
may
help
prevent
treat
viral
diseas
drug
expens
toxic
often
ineffect
due
primari
secondari
resist
defici
convent
therapeut
increas
interest
adopt
cell
therapi
adopt
transfer
virusspecif
cytotox
lymphocyt
vst
rapidli
reconstitut
antivir
immun
without
caus
graftversushost
diseas
regard
evalu
number
vst
memori
tcell
infus
import
control
viral
infect
recoveri
broad
repertoir
tcell
tdeplet
haploident
unrel
transplant
method
tcell
deriv
gcsf
stimul
unstimul
apheresi
healthi
donor
apheresi
product
process
singlestep
deplet
procedur
clinimac
plu
prodigi
instrument
fraction
aliquot
cryopreserv
use
frequenc
cmv
ebv
adv
specif
cell
donor
peripher
blood
tcell
product
cryopreserv
monitor
gammainterferon
enzymelink
immunospot
elispot
assay
hexon
ebv
consensu
respect
excess
monocyt
cell
suspens
deplet
adhes
plastic
dish
hour
proport
monocyt
ratio
cell
suspens
determin
flow
cytometri
result
tcell
product
median
effici
vst
detect
dramat
lower
comparison
vst
detect
peripher
blood
median
median
frequenc
per
mnc
cmv
ebv
advspecif
cell
peripher
blood
tcell
product
respect
monocyt
contain
tcell
product
mediat
suppress
interferongamma
product
cell
gcsf
stimul
donor
deplet
monocyt
median
ratio
cell
suspens
p
detect
vst
significantli
increas
respect
p
among
dli
product
cryopreserv
median
frequenc
cmv
ebv
advspecif
cell
per
lymphocyt
respect
median
adhes
plastic
number
monocyt
decreas
time
frequenc
vst
detect
increas
approxim
time
p
median
frequenc
cmv
ebv
advspecif
cell
monocyt
deplet
per
lymphocyt
respect
p
conclus
excess
monocyt
cell
suspens
lead
ineffici
detect
vst
elispot
assay
prior
adhes
monocyt
recommend
correct
vst
detect
tcell
product
analysi
dli
aliquot
cryopreserv
allow
accur
quantif
specif
antivir
tlymphocyt
administ
patient
optim
antivir
therapi
conflict
interest
noth
disclos
newcastl
univers
institut
cellular
medicin
newcastl
upon
tyne
unit
kingdom
background
thymic
damag
inflict
acut
gvhd
corticosteroid
nonselect
immunosuppress
agent
neg
impact
tlymphocyt
reconstitut
follow
hsct
essenti
success
clinic
outcom
extracorpor
photopheresi
ecp
altern
immunemodul
therapi
could
promot
immun
toler
reduc
acut
gvhd
allow
wean
concurr
immunosuppress
facilit
thymic
recoveri
restor
normal
thymopoiesi
method
whole
blood
sampl
taken
paediatr
patient
corticosteroidrefractorydepend
acut
gvhd
ecp
cycl
regular
interv
thymopoiesi
prospect
assess
quantit
sequenti
monitor
tlymphocyt
use
flow
cytometri
tcell
receptor
excis
circl
trec
use
pcr
qualit
use
tcell
receptor
tcr
dna
spectratyp
analysi
serum
measur
use
elisa
indirect
reflect
thymic
output
thymic
recoveri
compar
two
control
group
month
post
hsct
paediatr
patient
post
hsct
develop
acut
gvhd
group
paediatr
patient
acut
gvhd
receiv
ecp
group
statist
analysi
perform
use
kruskalw
test
p
signific
result
ecp
patient
median
age
hsct
year
grade
iiiv
acut
gvhd
demonstr
low
thymic
output
begin
ecp
treatment
regardless
time
post
hsct
median
absolut
count
tlymphocyt
median
number
trec
blood
highli
abnorm
tcr
repertoir
four
patient
complet
ecp
therapi
median
number
ecp
cycl
treatment
ongo
one
patient
withdrawn
treatment
qualit
quantit
improv
thymic
output
seen
complet
therapi
invers
relationship
evid
patient
exampl
figur
faster
thymic
recoveri
evid
start
ecp
earlier
among
continu
ecp
one
patient
show
evid
improv
thymic
output
date
one
patient
demonstr
ongo
neglig
thymic
output
month
post
hsct
despit
week
ecp
therapi
suggest
irrevers
thymic
damag
median
age
hsct
control
group
year
group
year
compar
thymic
recoveri
three
group
show
signific
differ
tlymphocyt
absolut
count
month
respect
conclus
demonstr
first
time
ecp
facilit
thymopoiesi
paediatr
patient
agvhd
potenti
rate
patient
without
acut
gvhd
although
prospect
data
need
promot
immun
toler
environ
post
hsct
may
conduc
faster
tlymphocyt
reconstitut
approach
achiev
need
rather
current
armamentarium
immunosuppress
agent
improv
seen
patient
suggest
point
thymic
return
excess
damag
sustain
thymu
result
loss
intrins
regen
capac
persist
inadequ
tlymphocyt
reconstitut
biomark
diagnos
monitor
thymic
damag
would
valuabl
conflict
interest
none
montpelli
univers
hospit
clinic
hematolog
montpelli
franc
univers
montpelli
montpelli
franc
cliniqu
du
parc
montpelli
franc
montpelli
univers
hospit
unit
cell
therapi
montpelli
franc
montpelli
univers
hospit
institut
regen
medicin
biotherapi
montpelli
franc
background
donor
lymphocyt
infus
dli
use
prevent
cure
hematolog
malign
relaps
allogen
stem
cell
transplant
use
antitumor
effect
donor
nk
cell
dli
efficaci
correl
low
tumour
burden
henc
prophylact
preemptiv
use
mix
chimer
detect
minim
residu
diseas
develop
procedur
effect
alon
associ
antitumor
chemotherapi
target
therapi
recombin
human
granulocyt
coloni
stimul
factor
gcsf
prime
dli
gdli
deriv
frozen
aliquot
initi
peripher
hematolog
stem
cell
phsc
bag
collect
phsc
often
exce
requir
amount
transplant
cryoconserv
pernici
lymphocyt
base
antitumour
outcom
lymphocyt
infus
phsc
team
describ
efficaci
safeti
gdli
differ
situat
biolog
effect
gcsf
peripher
blood
stem
cell
suggest
decreas
antitumor
activ
prime
dli
polar
promot
regulatori
cell
tolerogen
dendrit
cell
differenti
two
retrospect
studi
compar
clinic
equival
activ
toxic
gdli
classic
dli
includ
patient
mainli
suffer
amlmd
differ
shown
clinic
outcom
monocentr
retrospect
studi
aim
compar
respons
rate
overal
surviv
os
gvhd
rate
toxic
patient
receiv
gdli
classic
dli
intend
compar
clinic
outcom
differ
malign
myeloid
malign
lymphoid
malign
myeloma
differ
situat
clinic
relaps
molecular
relaps
mix
chimer
method
perform
systemat
review
medic
chart
patient
underw
hematolog
stem
cell
transplant
donor
lymphocyt
infus
hematolog
malign
montpelli
univers
hospit
result
retrospect
evalu
data
patient
initi
diseas
myeloid
malign
lymphoid
malign
acut
lymphoid
leukemia
myeloma
indic
dli
relaps
preemptiv
detect
minim
residu
diseas
mix
chimer
prophylaxi
sixti
patient
classic
dli
gdli
success
gdli
classic
dli
respons
rate
median
overal
surviv
os
month
os
graft
versu
host
diseas
occur
treatmentrequir
gvhd
die
toxic
differ
classic
gdli
term
respons
os
gvhd
treat
gvhd
caus
mortal
factor
associ
poor
respons
mix
chimer
relaps
indic
dli
myeloid
malign
relaps
indic
associ
shorter
os
subgroup
analysi
show
differ
classic
gdli
outcom
lymphoid
myeloid
malign
myeloma
neither
cur
preemptiv
indic
conclus
taken
togeth
result
previous
publish
strongli
suggest
similar
effici
toxic
gdli
classic
dli
myeloid
malign
well
multipl
myeloma
lymphoma
treat
prevent
clinic
molecular
relaps
gdli
may
substitut
classic
dli
conflict
interest
conflict
interest
declar
zhejiang
univers
hangzhou
china
shanghai
innov
cellular
therapi
co
lmd
shanghai
china
tongji
univers
school
medicin
shanghai
china
background
chimer
antigen
receptor
cell
highli
effect
novel
immunotherapi
relapsedrefractori
bcell
malign
cytokin
releas
syndrom
cr
signific
lifethreaten
complic
understand
cr
continu
evolv
identif
risk
factor
novel
laboratori
biomark
need
evalu
strategi
mitig
toxic
method
patient
clinic
characterist
analyz
patient
receiv
therapi
multiplex
cytokin
array
perform
detect
cytokin
level
sera
stage
infus
peak
cr
cr
restor
patient
grade
cr
base
data
select
cytokin
patient
undergo
therapi
evalu
elisa
result
cr
develop
patient
grade
grade
grade
multivari
analysi
patient
clinic
characterist
identifi
high
tumor
burden
thrombocytopenia
lymphodeplet
number
previou
relaps
independ
risk
factor
cr
cytokin
teck
fcar
agrp
baffr
bdnf
brck
identifi
possibl
novel
biomark
cytokin
array
figur
confirm
novel
biomark
cr
elisa
stage
preinfus
peak
cr
cr
restor
mean
serum
level
respect
mean
serum
level
respect
mean
serum
level
respect
mean
cytokin
level
stage
peak
cr
significantli
higher
stage
preinfus
cr
restor
respect
p
figur
one
classic
cytokin
signatur
cr
thu
pair
peak
serum
level
show
strong
correl
vs
spearman
vs
spearman
vs
spearman
impli
novel
biomark
cr
similar
conclus
data
provid
novel
clue
prevent
treatment
cr
therapi
also
studi
lay
foundat
clarif
cr
pathophysiolog
conflict
interest
none
author
anyth
disclos
campu
virchowklinikum
stem
cell
facil
berlin
germani
campu
virchowklinikum
berlin
germani
background
patient
sever
acut
gvhd
respond
firstlin
therapi
system
steroid
treatment
adult
patient
ecp
establish
promis
secondlin
therapi
immunomodulatori
gener
immunosuppress
effect
far
limit
experi
pediatr
patient
evalu
safeti
outcom
retrospect
studi
method
treat
children
least
cycl
ecp
median
cycl
agvhd
median
weight
kg
rang
kg
median
age
rang
yr
children
weigh
less
kg
leukapheresi
circuit
prime
rbc
total
cycl
analyz
result
saw
advers
event
ctc
grade
ecp
treatment
particular
regard
hypotens
anaphylact
reaction
sever
sepsi
unrel
ecp
result
fatal
outcom
one
patient
cycl
ecp
rbc
transfus
plt
transfus
given
anemia
thrombocytopenia
end
ecp
treatment
children
improv
complet
remiss
gvhd
partial
respons
least
improv
also
reduct
steroid
dose
end
ecp
treatment
possibl
patient
median
time
onset
ecp
treatment
end
immunosuppress
medic
month
steroid
month
immunosuppress
medic
respect
conclus
ecp
feasibl
suffici
safe
treatment
pediatr
patient
acut
refractori
gvhd
howev
treatment
younger
children
requir
special
oper
standard
well
train
staff
technic
logist
demand
compar
ecp
adult
preliminari
clinic
data
confirm
previou
studi
suggest
effort
justifi
children
clearli
improv
ecp
conflict
interest
none
author
anyth
disclos
vilniu
univers
hospit
santaro
kliniko
hematolog
oncolog
transfus
medicin
center
vilniu
lithuania
vilniu
univers
depart
intern
famili
medicin
oncolog
faculti
medicin
vilniu
lithuania
background
classic
cell
cultur
flask
method
effect
way
expand
mesenchym
stromal
cell
msc
demand
dedic
facil
personnel
timetoproduct
signific
hurdl
small
transplant
center
commerci
avail
selfcontain
bioreactor
increas
cell
yield
decreas
manual
work
yet
increas
cost
dispos
cultur
medium
herein
report
success
integr
method
clinic
scale
msc
expans
follow
bone
marrow
aspir
process
filterbas
devic
method
human
bone
marrow
collect
healthi
donor
inform
consent
obtain
retriev
msc
fraction
filterbas
bone
marrow
msc
separ
devic
kaneka
corpor
osaka
japan
use
cell
grown
high
glucos
dmem
medium
supplement
human
platelet
lysat
uml
heparin
cell
medium
exchang
everi
day
initi
cultur
flask
passag
cell
harvest
load
quantum
cell
expans
system
terumo
bct
inc
lakewood
co
usa
passag
follow
expans
bioreactor
msc
harvest
cryopreserv
therapeut
use
sampl
taken
qualiti
control
steril
mycoplasma
dna
endotoxin
genom
integr
immunophenotyp
result
donor
rang
year
age
median
aspir
bone
marrow
fluid
volum
ml
rang
bone
marrow
mononuclear
cell
bm
mnc
cultur
flask
passag
took
median
day
rang
note
bm
mnsc
cultur
expand
median
yield
msc
expand
tflask
rang
msc
expans
bioreactor
took
median
day
rang
doubl
time
rang
h
median
h
day
final
yield
rang
cell
median
cell
per
cultur
median
time
bone
marrow
aspir
final
yield
day
rang
harvest
cell
viabil
cell
compliant
flow
cytometr
isct
criteria
neg
mycoplasma
endotoxin
one
batch
contamin
staphylococcu
warneri
releas
clinic
use
batch
releas
clinic
use
conclus
filter
base
devic
allow
initi
reduct
flask
surfac
area
requir
cultur
msc
simplifi
dramat
passag
process
withdraw
small
amount
bone
marrow
fluid
may
decreas
pain
associ
aspir
procedur
bone
marrow
dilut
peripher
blood
approach
could
success
adapt
smallscal
hospit
laboratori
clinic
expans
msc
conflict
interest
none
banc
de
sang
teixit
barcelona
spain
hospit
joan
xxiii
tarragona
spain
background
thaw
immedi
infus
common
method
use
autolog
stem
cell
transplant
advers
reaction
associ
infus
well
describ
mainli
associ
dmso
despit
origin
also
report
granulocyt
contain
red
blood
cell
osmot
lysi
develop
infus
polici
includ
postthaw
cell
wash
import
allow
administr
cell
graft
special
risk
method
present
two
case
sever
advers
reaction
occur
infus
autolog
stem
cell
graft
two
patient
nonhodgkin
lymphoma
case
kg
bw
patient
experienc
itchi
sore
throat
infus
half
first
bag
reaction
partial
solv
reduc
rate
infus
thereaft
facial
flash
erythema
suddenli
occur
accompani
low
blood
pressur
mmhg
tachycardia
dizzi
nausea
vomit
infus
interrupt
immedi
trendelemburg
posit
adopt
salin
solut
hydrocortison
oxygen
administr
one
hour
requir
recov
normal
vital
sign
one
third
bag
could
infus
case
bw
patient
ten
minut
infus
first
bag
develop
low
blood
pressur
mmhg
profus
sweat
dizzi
salin
solut
hydrocortison
administ
success
resolut
clinic
pictur
result
case
ward
physician
immedi
contact
cell
process
facil
report
sever
advers
effect
emerg
strategi
consid
team
agre
return
remain
cryopreserv
bag
core
cell
therapi
lab
graft
wash
procedur
perform
use
devic
use
autom
protocol
smartwash
result
satisfactori
cell
yield
viabil
afterward
patient
develop
complic
meanwhil
patient
exhibit
mild
cutan
reaction
disappear
hydrocortison
allow
infus
whole
volum
bag
patient
success
engraft
case
quantiti
dmso
compliant
infus
polici
less
gr
per
kg
patient
bw
qualiti
variabl
includ
viabil
coloni
growth
correct
howev
amount
granulocyt
per
kg
collect
product
high
respect
revis
consid
probabl
caus
sar
observ
conclus
postthaw
wash
allow
almost
cryopreserv
cell
final
infus
consequ
review
scientif
literatur
experi
establish
polici
prevent
sever
reaction
cell
product
granulocyteskg
recommend
postthaw
wash
multiday
infus
accord
cell
number
conflict
interest
noth
disclos
tabl
product
characterist
banc
de
sang
teixit
cell
therapi
servic
barcelona
spain
hospit
vall
dhebron
hematolog
servic
barcelona
spain
hospit
maternoinfantil
vall
dhebron
barcelona
spain
hospit
de
la
santa
creu
sant
pau
pediatr
servic
barcelona
spain
hospit
sant
joan
de
deu
barcelona
spain
hospit
de
la
santa
creu
sant
pau
hematolog
servic
barcelona
spain
institut
doncologia
duran
reynal
lhospitalet
de
llobregat
spain
institut
doncologia
tria
pujol
badalona
spain
background
select
remain
attract
method
differ
intervent
hematopit
stem
cell
transplant
current
use
methodolog
method
gvhd
prevent
boost
haematopoiesi
treatment
poor
graft
function
pgf
transplant
order
standard
highthroughput
methodolog
core
cell
therapi
lab
develop
valid
autom
cell
process
procedur
combin
system
method
includ
consecut
procedur
new
automat
procedur
appli
peripher
blood
apheresi
product
recept
first
step
consist
platelet
deplet
volum
adjust
use
smartredux
program
sepax
devic
cell
product
incub
monoclon
antibodi
wash
use
sepax
wash
system
adjust
volum
requir
clinimac
final
clinimac
tube
set
instal
cell
introduc
select
procedur
use
select
program
indic
select
enrich
first
step
deplet
context
gvhd
prophylaxi
cell
boost
relat
pgf
result
median
time
start
end
hour
tabl
show
postsepax
cell
recov
wit
puriti
yield
select
platelet
deplet
monoclon
antibodi
wash
use
sepax
devic
achiev
extens
platelet
deplet
median
almost
complet
recoveri
tnc
cell
cell
adjust
requir
volum
immunomagnet
select
achiev
consist
final
product
high
puriti
low
contain
log
deplet
importantli
potenc
maintain
cfugm
recov
select
median
clonogen
effici
seed
result
optim
engraft
conclus
present
standard
procedur
result
robust
fast
largescal
select
use
combin
two
autom
devic
approach
allow
improv
previou
result
reproduc
output
puriti
yield
maintain
optim
level
cell
viabil
potenc
result
effici
myeloid
engraft
new
automat
procedur
allow
high
throughput
central
core
cell
therapi
lab
conflict
interest
author
declar
conflict
interest
tabl
cell
puriti
yield
posit
select
abstract
previous
publish
pbkm
warszawa
poland
univers
medic
scienc
poland
background
jellyderiv
mesenchym
stem
cell
wjmsc
type
cell
popul
signific
selfrenew
multilineag
differenti
properti
high
prolifer
rate
immun
privileg
statu
nontumorigen
properti
make
ideal
autolog
allogen
use
regen
medicin
applic
wjmsc
therapi
base
cell
prepar
polish
bank
stem
cell
pbkm
shown
promis
effect
treatment
mani
diseas
injuri
method
pbkm
deliv
wjmsc
product
adult
patient
age
year
month
year
month
median
age
year
month
patient
bioethic
committe
approv
receiv
intraven
intrathec
inject
wjmsc
obtain
third
parti
donor
tpd
cell
collect
healthi
newborn
process
screen
bacteri
contamin
endotoxin
content
final
frozen
liquid
nitrogen
vapour
wjmsc
immunophenotyp
confirm
use
flow
cytometri
assay
patient
receiv
inject
one
medic
cours
averag
cell
dose
per
infus
x
bodi
weight
patient
monitor
procedur
relat
advers
event
result
wjmsc
use
adult
patient
diseas
often
use
neurolog
patient
ophthalmolog
well
orthoped
stem
cell
also
given
patient
hematolog
patient
gynecolog
patient
common
indic
amyotroph
later
sclerosi
patient
retin
pigmentosa
patient
spinal
cord
injuri
patient
wjmsc
administr
took
place
poland
immedi
stem
cell
infus
advers
event
ae
occur
anoth
ae
least
hour
wjmsc
administr
observ
ae
mild
moder
eg
common
headach
nausea
easili
manag
medic
conclus
wjmsc
wide
implement
medic
experiment
procedur
show
promis
preliminari
result
high
therapeut
valu
adult
patient
howev
research
need
longterm
result
collect
conflict
interest
author
employ
pbkm
pbkm
warsaw
poland
lublin
medic
univers
depart
pediatr
neurolog
lublin
poland
univers
medic
scienc
poznan
poland
pbkm
warszawa
poland
background
mani
neurolog
diseas
effici
treat
unknown
pathogenesi
lack
appropri
medic
concept
repair
nervou
system
stem
cell
recent
evolv
hypothesi
tissu
regener
could
achiev
stem
cell
differenti
neural
cell
act
mainli
mean
paracrin
mechan
transplant
stem
cell
capabl
produc
neurotroph
factor
may
effici
method
improv
brain
function
jelli
mesenchym
stem
cell
wjmsc
thank
polish
bank
stem
cell
pbkm
use
neurolog
poland
sinc
method
two
hundr
forti
three
neurolog
patient
age
month
year
month
median
age
year
month
bioethic
committe
approv
receiv
intraven
intrathec
inject
wjmsc
obtain
thirdparti
donor
tpd
cell
previous
collect
healthi
newborn
process
screen
bacteri
contamin
well
endotoxin
content
frozen
liquid
nitrogen
vapour
wjmsc
immunophenotyp
confirm
use
flow
cytometri
assay
patient
receiv
inject
one
medic
cours
averag
cell
dose
per
intraven
infus
x
bodi
weight
patient
examin
neurologist
day
infus
result
neurolog
patient
constist
pediatr
patient
list
pbkm
year
common
indic
cerebr
palsi
patient
autism
patient
spina
bifida
patient
remain
patient
diagnos
neurolog
diseas
total
number
diagnosi
wjmsc
administr
took
place
poland
advers
event
ae
record
inject
easili
manag
medic
occur
time
headach
nausea
lumbar
punctur
headach
blood
pressur
increas
conclus
administr
thirdparti
donor
wjmsc
seem
safe
effici
procedur
promis
preliminari
result
neurolog
patient
howev
insight
studi
benefici
therefor
longterm
result
still
need
collect
conflict
interest
author
employ
pbkm
chronic
leukaemia
myeloprolif
disord
hospit
universitario
de
salamancaibs
salamanca
spain
hospit
universitario
de
salamanca
salamanca
spain
background
nowaday
allogen
stem
cell
transplant
asct
cur
strategi
patient
high
risk
philadelphianeg
chronic
myeloprolif
neoplasm
cmn
method
patient
underw
asct
centr
cmn
differ
chronic
myeloid
leukaemia
retrospect
analys
subgroup
patient
primari
myelofibrosi
mf
secondari
mf
post
pv
post
et
post
cmn
cmn
differ
mf
cmn
cmnmd
fibrosi
result
clinic
biolog
featur
asct
characterist
summar
tabl
patient
except
two
evalu
achiev
neutrophil
platelet
engraft
two
patient
reach
platelet
concern
complic
relat
asct
patient
suffer
mucos
grade
ii
develop
cmv
reactiv
haemorrhag
cystiti
obstruct
sinusoid
syndrom
none
develop
transplant
associ
microangiopathi
total
patient
develop
acut
graft
versu
host
diseas
gvhd
grade
iiiiv
median
present
day
patient
develop
chronic
gvhd
extens
median
day
transplant
relat
mortal
trm
day
global
trm
day
post
asct
patient
achiev
complet
remiss
cr
two
minim
residu
diseas
patient
relaps
situat
one
case
evalu
earli
dead
six
patient
relaps
median
day
asct
four
approach
relaps
modul
immunosuppress
donor
lymphocyt
infus
hypometil
agent
case
mrd
reach
cr
complet
chimer
last
followup
patient
aliv
cr
activ
diseas
dead
differ
caus
relaps
case
infect
bleed
last
one
anoth
caus
hepat
failur
median
followup
month
overal
surviv
os
event
free
surviv
ef
year
respect
conclus
result
seri
confirm
potenti
cur
asct
take
account
trm
minim
observ
half
patient
long
survivor
modul
immunosuppress
play
import
role
set
post
asct
relaps
conflict
interest
noth
disclos
tabl
tabl
medicalpark
antalya
pediatr
bone
marrow
transplant
unit
antalya
turkey
ankara
child
health
diseas
haematolog
oncolog
train
research
hospit
depart
paediatr
haematolog
oncolog
ankara
turkey
background
chronic
neutrophil
leukemia
cnl
rare
myeloprolif
disord
occur
frequent
mutat
gene
receptor
colonystimul
factor
report
case
fanconi
anemia
fa
patient
develop
cnl
followup
cure
hematopoet
stem
cell
transplant
hsct
method
patient
refer
pediatr
hematolog
depart
age
year
recurr
pulmonari
infect
accompani
leukopenia
workup
reveal
elev
debinduc
chromosom
breakag
lead
diagnosi
fa
year
age
wbc
count
increas
l
howev
next
visit
month
later
wbc
count
increas
requir
examin
infect
reactiv
caus
investig
presenc
neutrophil
repres
leukocyt
peripher
smear
caus
agent
detect
mutat
detect
gene
frequent
report
patient
cnl
hsct
plan
patient
fa
could
acceler
progress
aml
result
patient
schedul
transplant
compat
unrel
donor
prepar
regimen
fludarabin
mgkg
cyclophosphamid
mgkg
antithymocyt
globulin
atg
freseniu
use
cyclosporin
mycophenol
use
graft
versu
host
diseas
gvhd
prophylaxisgcsf
use
due
mutat
histori
neutrophil
platelet
engraft
respect
grade
ii
acut
gvhd
develop
third
week
resolv
methylprednisolon
howev
chronic
gvhd
find
appear
eye
mouth
skin
month
transplant
accept
moder
chronic
gvhd
current
month
transplant
patient
still
experienc
mild
chronic
gvhd
full
chimer
receiv
tacrolimu
methylprednisolon
mutat
leukocyt
level
conclus
associ
fa
mutat
report
thu
far
knowledg
patient
studi
youngest
cnl
patient
possibl
acquir
mutat
moreov
first
case
cnl
report
patient
fa
mutat
overlook
patient
fa
longstand
neutrophilia
mutat
predispos
factor
develop
aml
conflict
interest
noth
disclos
medic
center
univers
freiburgunivers
vienna
stem
cell
transplant
vienna
austria
st
anna
children
hospit
vienna
austria
charl
univers
motol
pragu
pediatr
hematooncolog
pragu
czech
republ
pediatr
hematooncolog
germani
univers
children
hospitalchildren
hospit
essen
germani
istituto
di
ematologia
cattolica
del
cuoreg
gaslini
genova
itali
wroclaw
medic
univers
pediatr
bmt
wroclaw
poland
children
adolesc
medicin
rigshosptilet
copenhagen
denmark
univers
medic
center
hamburgeppendorf
pediatr
stem
cell
transplant
hamburg
germani
schneider
children
medic
center
bmt
unit
petach
tikva
israel
univers
adelaid
hospit
children
adolesc
helsinki
finland
univers
children
hospit
hematolog
oncolog
innsbruck
austria
univers
children
hospit
pediatr
hematologyoncolog
bratislava
slovakia
clinica
di
oncoematologia
pediatrica
ospedal
san
gerardo
monza
itali
background
era
tki
life
expect
adultelderli
patient
cml
respond
imatinib
approach
gener
popul
select
patient
treat
sct
although
pf
os
report
patient
ebmtscor
children
adolesc
cml
treat
imatinib
pf
tkifre
surviv
giona
et
al
respons
rate
children
treat
second
line
tki
compar
observ
imatinib
besid
fact
lifelong
tki
children
cml
implic
treatment
year
nontarget
effect
imatinib
growth
defici
chronic
immunosuppress
treatment
failur
due
noncompli
adolesc
remain
major
concern
prospect
multicentr
trial
clinicaltrialsgov
sct
commette
ibfm
studi
group
evalu
safeti
efficaci
sct
follow
reduc
intens
condit
regimen
ric
children
adolesc
cml
method
order
reduc
trm
late
effect
chronic
gvhd
protocol
base
atgcontain
ric
regimen
fludarabin
x
thiotepa
x
mgkg
melphalan
protocol
includ
frequent
bcrabl
monitor
post
sct
treatment
imatinib
first
year
case
increas
bcrabl
patient
persist
bcrabl
receiv
dli
second
year
sct
result
total
patient
includ
donor
match
relat
match
unrel
median
age
sct
year
patient
receiv
imatinib
second
line
tki
bcrabl
time
sct
rang
indic
sct
insuffici
molecular
responsesecondari
respons
loss
patient
patientphysician
choic
remain
patient
patient
engraft
patient
display
mix
chimer
donor
chimer
trm
year
old
boy
bcrabl
time
sct
die
day
invas
adenoviru
infect
moderatesever
chronic
gvhd
observ
patient
resolv
case
patient
receiv
immunosuppress
beyond
year
sct
correl
mix
chimer
need
secondari
intervent
six
patient
imatinib
treatment
restart
median
month
three
patient
receiv
addit
dli
second
year
sct
tki
mr
time
analysi
dliassoci
gvhd
ocur
median
followup
month
current
surviv
bcrabl
current
tkifre
surviv
conclus
sct
follow
ric
feasibl
children
adolesc
cml
associ
diseasefre
tkifre
surviv
patient
insuffici
molecular
respons
secondari
respons
loss
treat
success
ricsct
ricsct
may
valid
altern
lifelong
treatment
tki
children
adolesc
cml
clinic
trial
registri
clinicaltrialsgov
conflict
interest
none
author
anyth
disclos
hospit
la
fe
valencia
spain
hospit
clinico
salamanca
spain
hospit
vall
dhebron
barcelona
spain
hospit
clinic
barcelona
spain
hospit
puerta
de
hierro
madrid
spain
hospit
la
princesa
madrid
spain
hospit
santa
creu
sant
pau
barcelona
spain
ico
hospit
duran
reynal
barcelona
spain
hospit
clinic
valencia
spain
background
patient
cll
whose
tumor
cell
harbor
aberr
relaps
earli
chemoimmunotherapi
consid
advers
prognosi
convent
agent
patient
tradit
offer
allohct
accord
ebmt
guidelin
addit
rituximab
typic
fludarabinebas
condit
regimen
appar
improv
outcom
patient
cll
investigatoriniti
trial
hypothes
addit
ofatumumab
novel
monoclon
antibodi
greater
anticl
activ
condit
regimen
could
also
improv
outcom
patient
method
patient
cll
elig
case
aberr
diseas
relaps
within
month
last
chemoimmunotherapi
diseas
complet
partial
respons
time
transplant
donor
sibl
unrel
volunt
hla
compat
condit
regimen
compris
ofatumumab
mg
day
mg
day
mg
day
fludarabin
melphalan
gvhd
prophylaxi
cyclosporin
mycophenol
mofetil
patient
oneallel
mismatch
also
receiv
rabbit
thymoglobulin
mgkg
primari
end
point
studi
progressionfre
surviv
pf
year
result
median
age
recruit
patient
rang
year
male
donor
hlamatch
two
case
patient
proceed
allohct
except
one
whose
donor
becam
pregnant
initi
ofatumumab
therapi
withdrawn
studi
remain
patient
complet
ofatumumab
infus
patient
underw
allohct
engraft
cumul
incid
develop
kind
gvhd
year
respect
moreov
cumul
incid
develop
sever
gvhd
defin
grade
acut
extens
chronic
gvhd
year
respect
median
followup
rang
month
survivor
relaps
studi
relaps
observ
studi
pf
overal
surviv
ident
ci
ci
year
transplant
respect
figur
caus
death
septicemia
pneumonia
gvhd
cerebr
hemorrhag
pml
hemoptysi
conclus
addit
ofatumumab
condit
regimen
cll
patient
undergo
allohct
reduc
relaps
rate
complet
abl
reduc
gvhd
rate
thu
lead
high
nonrelaps
mortal
howev
longterm
followup
trial
show
clear
plateau
surviv
curv
therefor
allohct
may
still
recommend
restrict
group
patient
howev
clear
need
identifi
patient
low
risk
nonrelaps
mortal
aim
recent
ebmt
initi
clinic
trial
registri
studi
regist
clinicaltrialsgov
perform
accord
declar
helsinki
intern
confer
harmon
guidelin
good
clinic
practic
conflict
interest
purpos
trial
ofatumumab
provid
free
charg
togeth
unrestrict
grant
gsknovarti
none
author
anyth
disclos
first
pavlov
state
medic
univers
saint
petersburg
raisa
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
saint
petersburg
russian
feder
background
postpolycythemia
vera
postpvmf
postessenti
thrombocythemia
postetmf
primari
myelofibrosi
pmf
myelodysplasticmyeloprolif
neoplasm
mdsmpn
bcrablneg
hematopoiet
stem
cell
disord
gener
poor
outcom
aim
studi
compar
result
allogen
hematopoiet
stem
cell
transplant
allohsct
patient
myelofibrosi
mf
mdsmpn
evalu
target
therapi
ruxolitinib
improv
outcom
mf
method
compar
group
patient
mdsmpn
mf
without
histori
ruxolitinib
mf
pre
posttranspl
ruxolitininb
patient
age
year
includ
analysi
patient
diagnos
mf
postetmf
postpvmf
pmf
mdsmpn
acml
mdsmpn
unclassifi
patient
receiv
condit
regimen
fludarabin
plu
busulfan
mgkg
mfand
mdsmpnpatient
without
ruxolitinib
graft
versu
host
diseas
prophylaxi
gvhd
consist
antithymocyt
globulin
atgam
mgkg
thymoglobulin
mgkg
tacrolimusmophethylmycophenol
mfpatient
receiv
ruxolitinib
mg
daili
least
month
mg
gvhd
prophylaxi
cyclophosphamid
mgkg
among
diseas
stabil
allohsct
occur
patient
diseas
progress
clinic
improv
accord
eln
criteria
mdsmpnpatient
activ
diseas
moment
allohsct
allohsct
perform
unrel
relat
haploident
donor
stem
cell
sourc
granulocyt
colonystimul
factor
mobil
peripher
blood
progenitor
cell
pbsc
bone
marrow
median
number
x
pbsc
group
x
bone
marrow
group
result
median
follow
month
primari
engraft
document
patient
rate
primari
graft
failur
significantli
higher
mdsmpn
compar
mfpatient
versu
subsequ
die
due
infect
diseas
progress
acut
gvhd
grade
chronic
gvhd
document
mf
mdsmpnpatient
without
histori
ruxolitinib
therapi
mfpatient
receiv
ruxolitinib
pn
highest
incid
sever
sepsi
observ
mdsmpnpatient
compar
mfpatient
without
histori
target
therapi
rate
toxic
hepat
grade
venoocclus
liver
diseas
similar
group
patient
histori
ruxolitinib
patient
treat
ruxolitinib
found
signific
differ
os
mdsmpn
mfpatient
treat
convent
therapi
vs
os
mfpatient
treat
ruxolitinib
pre
posttranspl
significantli
superior
vs
figur
conclus
small
patient
cohort
differ
mpn
mf
convent
therapi
howev
introduct
jak
inhibitor
pre
posttranspl
period
might
improv
result
allohsct
unfavor
diseas
mf
larger
multicent
studi
requir
confirm
assumpt
conflict
interest
none
author
anyth
disclos
abstract
previous
publish
abstract
previous
publish
guy
stthoma
nh
foundat
trust
haematolog
london
unit
kingdom
king
colleg
london
london
unit
kingdom
imperi
colleg
healthcar
nh
trust
depart
clinic
scienc
london
unit
kingdom
saintloui
servic
pari
franc
ebmt
data
offic
leiden
netherland
deutsch
klinik
diagnostik
wiesbad
germani
universitaetsmedizin
berlin
berlin
germani
univers
hospit
leipzig
divis
haematolog
oncolog
leipzig
germani
king
colleg
hospit
king
colleg
london
london
unit
kingdom
univeristi
hospit
essen
haematolog
essen
germani
univers
hannov
hannov
germani
univers
heidelberg
medizinisch
klinik
u
poliklinik
v
heidelberg
germani
ulm
ulm
germani
rigshospitalet
copenhagen
denmark
chu
de
lill
liric
inserm
u
universit
de
lill
lill
franc
queen
elizabeth
hospit
haematolog
birmingham
unit
kingdom
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
medizinisch
universitaet
wien
vienna
austria
skane
univers
hospit
lund
sweden
inst
de
oncologia
porto
porto
portug
universitaetsklinikum
goettingen
goettingen
germani
klinkum
recht
der
isar
munich
germani
univers
munster
germani
univers
lieg
lieg
belgium
universitair
de
geneva
switzerland
univers
hospit
eppendorf
hamburg
germani
background
myeloprolif
neoplasm
mpn
unclassifi
mpnu
rare
inher
heterogen
diseas
entiti
present
mpntype
clinic
histolog
phenotyp
yet
fail
meet
diagnost
criteria
mpn
variant
clinic
cours
highli
vari
welldefin
treatment
algorithm
exist
outcom
allogen
haematopoiet
stem
cell
transplant
allohsct
never
document
detail
herebi
report
multicentr
ebmtregistri
base
studi
adult
mpnu
patient
method
patient
underw
allohsct
mpnu
reduc
intens
condit
ric
myeloabl
condit
mac
utilis
either
bone
marrow
peripher
blood
stem
cell
select
statist
analys
perform
spss
spss
incibm
armonk
ny
patient
provid
inform
consent
accord
declar
helsinki
result
total
patient
analys
mac
regimen
defin
ebmt
criteria
utilis
patient
receiv
ric
median
age
allohsct
year
rang
r
mac
ric
cohort
median
time
diagnosi
allohsct
mac
ric
cohort
month
r
month
respect
donor
type
follow
mac
match
sibl
donor
msd
unrel
donor
urd
n
mismatch
relat
mmr
ric
cohort
msd
urd
mmr
n
median
time
neutrophil
engraft
mac
ric
platform
ident
day
acut
chronic
c
graft
versu
host
diseas
gvhd
statu
document
entir
cohort
rate
grade
iiiv
agvhd
higher
mac
cohort
compar
ric
cohort
wherea
cgvhd
rate
limit
extens
similar
mac
cohort
versu
ric
cohort
median
follow
period
surviv
patient
month
rang
nonrelaps
mortal
nrm
probabl
consider
group
mac
ric
cumul
incid
relaps
cir
mac
ric
moreov
year
overal
surviv
os
rate
mac
ric
respect
regard
best
time
transplant
diseas
cours
near
signific
trend
improv
outcom
mac
set
recipi
underw
allohsct
within
first
year
diagnosi
compar
transplant
later
conclus
largest
studi
date
report
outcom
allohsct
mpnu
given
heterogen
diseas
cours
os
rate
appear
accept
note
nrm
cir
rate
set
consider
mac
set
transplant
earlier
diseas
cours
appear
associ
improv
surviv
note
signific
differ
relaps
rate
ric
mac
multivari
subgroup
analys
present
clinic
trial
registri
relev
conflict
interest
noth
relev
disclos
conflict
interest
author
institut
haematolog
blood
transfus
praha
czech
republ
background
introduct
tyrosinkinas
inhibitor
tki
cml
treatment
destini
chang
event
major
patient
allogen
transplant
remain
therapeut
option
patient
use
tki
suitabl
reason
method
patient
diagnosi
cml
transplant
year
mean
period
least
imatinib
avail
front
line
therapi
evalu
patient
transplant
full
effect
tki
wait
era
transit
front
transplant
tki
treatment
patient
diagnos
advanc
phase
diseas
patient
show
sever
otherwis
resolv
tki
toxic
patient
progress
tki
treatment
except
patient
transplant
ric
other
prepar
full
condit
either
busulfan
tbi
gy
use
atg
unrel
donor
overal
surviv
incid
relaps
evalu
consid
reason
transplant
indic
diseas
statu
gvhd
occurr
result
overal
surviv
year
natur
signific
differ
overal
surviv
upfront
transplant
patient
would
transplant
present
patient
advanc
phase
suffici
tki
respons
year
resp
year
resp
surviv
patient
diagnos
advanc
phase
ap
receiv
induct
chemotherapi
togeth
tki
enter
transplant
comparison
patient
diagnos
chronic
phase
cp
fail
tki
respons
year
resp
year
resp
year
resp
statist
small
number
signific
compar
patient
diagnos
cp
stay
still
cp
transplant
exclud
upfront
transplant
diagnos
cp
progress
ap
tki
treatment
diagnos
late
ap
ap
statist
worst
surviv
group
prior
transplant
acceler
one
ap
year
occurr
agvhd
gr
treatment
surviv
one
year
vs
without
complic
p
contrari
occurr
cgvhd
improv
surviv
year
vs
signific
cohort
conclus
introduct
tki
cml
treatment
select
patient
biolog
poor
charact
diseas
allogen
transplant
cur
approach
seem
patient
diagnos
advanc
phase
transplant
chemotherapi
tki
induc
remiss
better
result
primari
resist
lost
treatment
respons
tki
look
like
graft
versu
leukaemia
effect
connect
occurr
cgvhd
known
effect
cml
pretki
era
role
also
patient
although
statist
prove
small
cohort
conflict
interest
noth
disclos
nation
cancer
institut
cairo
univers
pediatr
oncolog
bmt
cairo
egypt
children
cancer
hospit
egypt
cche
pediatr
oncolog
bmt
cairo
egypt
nation
cancer
institut
cairo
univers
clinic
patholog
cairo
egypt
children
cancer
hospit
egypt
cche
clinic
patholog
cairo
egypt
children
cancer
hospit
egypt
cche
research
depart
cairo
egypt
background
despit
appar
efficaci
favor
toxic
profil
tki
allogen
sct
remain
cur
treatment
cml
especi
younger
patient
transplant
relat
morbid
mortal
consid
evalu
clinic
characterist
outcom
pediatr
cml
patient
sct
center
method
retrospect
studi
includ
pediatr
patient
year
confirm
cml
receiv
allogen
sct
stem
cell
transplant
unit
children
cancer
hospit
egypt
cche
august
june
follow
till
decemb
patient
receiv
myeloabl
condit
chemotherapi
contain
busulfancyclophosphamid
follow
stem
cell
infus
match
relat
donor
result
whole
patient
diagnos
cml
avail
match
relat
donor
subject
hsct
studi
period
patient
continu
tki
therapi
median
age
diagnosi
year
mf
ratio
thirtyseven
patient
diagnos
chronic
phase
one
case
acceler
diseas
patient
blastic
crise
averag
durat
transplant
month
bone
marrow
stem
cell
sourc
patient
peripher
blood
use
case
averag
stem
cell
dose
overal
surviv
event
free
surviv
respect
transplant
relat
mortal
one
year
incid
chronic
graft
versu
host
diseas
cgvhd
case
peripher
blood
sourc
compar
case
receiv
bone
marrow
stem
cell
p
valu
also
cgvhd
higher
fm
donorrecipi
transplant
compar
mf
mm
ff
statist
signific
conclus
consid
good
surviv
rate
low
trm
associ
hsct
pediatr
cml
patient
data
suggest
offer
transplant
patient
avail
match
relat
donor
without
need
prolong
exposur
tki
bone
marrow
stem
cell
sourc
prefer
young
patient
avoid
signific
risk
cgvhd
relat
complic
conflict
interest
author
declar
noth
disclos
rm
gorbacheva
institut
pediatr
oncolog
hematolog
transplant
ippavlov
first
st
petersburg
state
medic
univers
hematolog
st
petersburg
russian
feder
background
resist
tyrosin
kinas
inhibitor
tki
patient
chronic
myeloid
leukemia
cml
frequent
caus
point
mutat
bcrabl
kinas
domain
includ
gatekeep
mutant
confer
high
degre
resist
current
approv
tyrosin
kinas
inhibitor
except
ponatinib
method
retrospect
analysi
posit
cml
patient
pt
done
allogen
bone
marrow
transplant
allohsct
made
pt
pt
receiv
pharmacolog
therapi
pt
receiv
tki
monotherapi
combin
drug
pt
receiv
hydroxyurea
interferon
chemotherapi
time
detect
pt
cp
pt
ap
pt
bc
median
age
time
mutat
detect
year
year
hsctgroup
allohsct
group
pt
unrel
donor
pt
receiv
line
tki
hsct
pt
bc
time
hsct
pt
ap
pt
pt
number
point
ebmt
scale
point
pt
point
pt
condit
regimen
pt
reduc
intens
time
hsct
detect
month
mutat
analysi
perform
sanger
sequenc
overal
surviv
os
estim
kaplanmei
method
logrank
test
comparison
group
cox
regress
use
multivari
surviv
analysi
includ
next
covari
age
phase
time
mutat
detect
perform
allohsct
time
detect
tki
start
result
followup
time
detect
month
os
whole
group
accord
multivari
analysi
cml
phase
time
mutat
detect
significantli
affect
surviv
whole
group
pt
bc
hsct
group
nonhsct
group
die
within
first
year
indic
wherein
surviv
time
month
os
nonhsct
group
surviv
time
year
os
allohsct
surviv
time
month
live
patient
allohsct
deep
molecular
respons
signific
differ
os
tki
nontki
pharmacolog
therapi
nonhsct
group
respect
conclus
detect
mutat
tkiresist
patient
extrem
unfavor
factor
surviv
especi
advanc
phase
cml
great
reason
switch
ponatinib
new
potenti
investig
drug
possibl
allohsct
potenti
option
group
patient
case
good
select
take
consider
transplant
risk
especi
patient
cp
conflict
interest
noth
disclos
abstract
previous
publish
univers
hospit
basel
hematolog
basel
switzerland
univers
hospit
basel
patholog
basel
switzerland
background
chronic
neutrophil
leukemia
cnl
aplast
anemia
aa
rare
diseas
report
case
year
old
male
patient
medic
histori
year
saa
develop
secondari
cnl
subsequ
receiv
allogen
hematopoiet
stem
cell
transplant
hsct
best
knowledg
secondari
cnl
saa
yet
describ
method
case
report
result
diagnosi
sever
aplast
anemia
age
subsequ
treatment
encompass
three
cycl
hors
atg
cyclosporin
result
diseas
control
nine
three
seven
year
respect
third
cycl
intens
immunosuppress
therapi
cyclosporin
maintain
longterm
therapi
nineteen
year
initi
diagnosi
neutrophilia
observ
without
sign
infect
inflamm
solid
tumor
bone
marrow
examin
reveal
hypercellular
neutrophil
prolifer
discret
dysplasia
myeloid
cell
lineag
molecular
genet
detect
mutat
integr
diagnosi
made
accord
classif
confirm
diagnosi
cnl
subsequ
patient
first
treat
ruxolitinib
show
normal
neutrophil
count
within
month
treatment
stop
due
thrombocytopenia
month
allogen
hematopoiet
stem
cell
transplant
hla
ident
unrel
donor
condit
cyclophosphamid
two
day
busulphan
x
four
day
could
perform
without
relev
toxic
complic
graft
versu
host
diseas
gvhd
posttranspl
follow
month
show
complet
remiss
without
sign
gvhd
complic
conclus
describ
first
case
cnl
evolv
secondari
saa
nineteen
year
initi
diagnosi
possibl
pathophysiolog
mechan
could
includ
damag
hematopoet
stem
cell
previou
cytotox
therapi
select
myeloid
clone
occur
aplast
anemia
conflict
interest
author
conflict
interest
declar
univers
medic
center
hamburg
eppendorf
hamburg
germani
ebmt
data
offic
leiden
netherland
universitaetsmedizin
berlin
berlin
germani
univers
hospit
germani
gartnav
gener
hospit
glasgow
unit
kingdom
hospit
chu
de
lill
liric
inserm
u
de
lill
lill
franc
univers
hospit
renn
franc
hopit
st
loui
pari
franc
gustav
roussi
institut
de
villejuif
franc
hospit
saint
antoin
pari
franc
erasmu
mc
cancer
institut
rotterdam
netherland
chu
nant
nant
franc
fondazion
ircc
policlinico
san
matteo
pavia
itali
univers
germani
chu
nice
de
l
archet
nice
germani
azienda
ospedaliero
universitaria
di
udin
udin
itali
univers
freiburg
freiburg
germani
uz
leuven
leuven
belgium
institut
paoli
calmett
marseil
franc
huch
comprehens
cancer
center
helsinki
finland
centr
hospitali
lyon
sud
lyon
franc
universitair
de
geneva
switzerland
background
recent
model
use
clinicalmolecular
featur
patient
secondari
myelofibrosi
smf
develop
mysec
predict
outcom
diagnosi
howev
unclear
whether
score
mysec
dipss
prognost
transplant
set
smf
aim
valid
compar
model
smf
patient
underw
allogen
hematopoiet
stemcel
transplant
method
identifi
smf
patient
receiv
stemcel
transplant
relat
n
unrel
donor
n
avail
data
blood
level
transplant
presenc
mutat
diagnosi
mysec
model
calcul
follow
one
point
assign
presenc
constitut
symptom
platelet
two
point
assign
hemoglobin
gdl
circul
blast
calrunmut
genotyp
wherea
point
assign
year
age
risk
group
number
patient
accord
mysec
dipss
low
n
n
n
n
n
n
high
n
n
score
valid
use
kaplanmei
estim
cstatist
appli
evalu
discriminatori
power
result
median
followup
month
rang
median
time
diagnosi
transplant
month
rang
median
age
smf
patient
year
rang
overal
surviv
three
year
confid
interv
ci
stratifi
smf
accord
evolut
either
polycythemia
vera
postpv
essenti
thrombocytopenia
postet
differ
found
surviv
three
year
ci
postpv
ci
p
postet
overal
surviv
rate
three
year
accord
risk
group
dipss
follow
ci
lowrisk
ci
ci
ci
highrisk
group
overal
dipss
predict
outcom
p
regard
mysec
probabl
surviv
three
year
ci
lowrisk
ci
ci
ci
highrisk
group
mysec
model
predict
surviv
overal
p
use
assign
patient
four
discret
risk
categori
test
retain
moder
predictivit
cindex
howev
prognost
abil
improv
comparison
dipss
cindex
mysec
significantli
reclassifi
patient
accord
risk
p
conclus
comparison
dipss
valid
primari
myelofibrosi
current
also
use
risk
stratif
smf
patient
receiv
transplant
clinicalmolecular
system
mysec
provid
signific
reclassif
patient
lead
improv
prognost
capabl
conflict
interest
conflict
interest
relat
abstract
condit
regimen
heart
england
nh
foundat
trust
haematolog
birmingham
unit
kingdom
background
upfront
reduc
intens
condit
ric
allogen
stem
cell
transplant
allosct
may
confer
surviv
advantag
select
patient
heavili
pretreat
low
grade
lymphoma
although
data
alemtuzumab
use
graft
versu
host
diseas
prophylaxi
set
limit
conduct
retrospect
studi
patient
heavili
pretreat
lowgrad
lymphoma
undergo
ricalemtuzumab
allosct
heart
england
nh
trust
method
analyz
consecut
patient
median
age
year
femal
male
diagnosi
follicular
lymphoma
margin
zone
lymphoma
waldenstrom
macroglobulinaemia
underw
alemtuzumabbas
ric
allosct
siblingdonor
remain
volunteerunrel
donor
vud
heart
england
nh
trust
januari
octob
patient
condit
fmc
wherea
patient
beamcampath
total
alemtuzumab
dose
sibl
unrel
donor
transplant
patient
complet
remiss
pretranspl
remain
patient
partial
remiss
patient
receiv
median
line
treatment
prior
transplant
patient
previous
receiv
autolog
transplant
result
median
follow
month
choic
condit
seem
affect
progressionfre
pf
overal
surviv
os
p
albeit
statist
signific
improv
os
dli
donor
lymphocyt
infus
treat
patient
observ
figur
overal
patient
underw
dli
major
mix
chimer
median
day
post
transplant
term
immun
reconstitut
tcell
count
month
associ
better
os
mean
os
patient
month
month
vs
month
patient
month
besid
median
os
patient
tcell
count
month
month
acut
gvhd
affect
patient
patient
total
grade
remain
total
patient
grade
diseas
individu
exhibit
chronic
gvhd
extens
diseas
interestingli
tcell
count
month
associ
either
acut
chronic
gvhd
respect
month
whole
blood
chimer
predict
either
pf
p
os
although
trend
toward
better
outcom
patient
mix
tcell
chimer
month
final
transplant
relat
mortal
conclus
seri
alemtuzumab
base
ric
allosct
low
grade
lymphoma
threemonth
mix
tcell
chimer
necessit
dli
correl
favor
outcom
tcell
immun
reconstitut
month
seem
affect
overal
surviv
tcell
count
month
associ
acut
chronic
gvhd
summari
upfront
ric
allosct
alemtuzumab
valid
cur
treatment
high
risk
low
grade
lymphoid
malign
prospect
studi
need
identifi
key
determin
success
clinic
trial
registri
na
conflict
interest
none
list
author
anyth
disclos
ospedal
san
gerardo
monza
itali
ospedal
san
gerardo
clinica
ematologica
dell
universita
milanobicocca
monza
itali
background
recent
year
haploident
bone
marrow
transplant
haplobmt
wide
use
patient
high
risk
hematolog
malign
lack
match
relat
donor
mrd
obtain
match
unrel
donor
mud
reason
time
describ
singular
case
patient
submit
haplobmt
acut
myeloid
leukemia
aml
develop
year
mielodysplast
syndrom
submit
second
haplobmt
differ
donor
whose
hla
complet
differ
respect
first
donor
method
male
patient
undifferenti
aml
submit
haplobmt
brother
first
complet
remiss
outcom
favor
major
complic
occur
mild
selflimit
chronic
gvhd
observ
year
well
patient
present
worsen
anaemia
platelet
decreas
bone
marrow
aspir
diagnost
threelineag
myelodisplast
syndrom
blast
infiltr
monosom
karyotyp
chimer
statu
evalu
bone
marrow
peripher
mononuclear
cell
remain
full
donor
multipl
control
conclud
second
haematolog
neoplasm
deriv
transplant
marrow
worth
note
donor
actual
fine
base
good
condit
patient
submit
second
bmt
differ
donor
son
hlahaploident
respect
complet
mismatch
respect
first
donor
consid
chimaer
statu
transplant
follow
situat
haplo
gvhd
direct
complet
mismatch
reject
direct
also
graft
versu
leukemia
direct
order
reduc
risk
reject
perform
atg
mgkg
prime
day
bmt
anti
hlaantibodi
research
reveal
low
titl
antihla
classii
condit
regimen
reducedintens
tiotepabusulfanfludarabin
regimen
gvhd
prophylaxi
perform
cyclosporina
micofenolatemofetil
post
transplant
cyclophosphamid
result
signific
complic
observ
procedur
platelet
neutrophil
engraft
occur
day
respect
bmt
actual
year
patient
good
condit
infect
viral
reactiv
gvhd
complic
appear
followup
show
complet
stabl
cytogenet
remiss
chimaer
analysi
reveal
donor
engraft
either
marrow
peripher
mononucl
cell
sinc
day
conclus
report
singular
experi
doubl
haplobmt
two
complet
hla
differ
donor
perform
secondari
neoplasm
occur
transplant
cell
knowledg
similar
case
report
literatur
conflict
interest
c
giambacortipasserini
consult
honoraria
research
found
pfizer
consult
bm
author
noth
declar
ravenna
hospit
ravenna
itali
ebmt
pari
studi
offic
ceresttc
saint
antoin
hospit
depart
haematolog
pari
franc
deutsch
klinik
fuer
diagnostik
kmt
zentrum
wiesbaden
germani
univers
hospit
eppendorf
bone
marrow
transplant
centr
hamburg
germani
hannov
medic
school
depart
haematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
klinikum
grosshadern
med
klinik
iii
munich
germani
centr
hospitali
lyon
sud
pavillon
marcel
bat
servic
hematologi
lyon
franc
universitaetsklinikum
wuerzburg
med
klinik
und
poliklinik
ii
wuerzburg
germani
univers
hospit
depart
bone
marrow
transplant
essen
germani
klinik
fuer
inner
medzin
iii
ulm
ulm
germani
univers
hospit
leipzig
divis
haematolog
oncolog
leipzig
germani
univers
heidelberg
medizinisch
klinik
u
poliklinik
v
heidelberg
germani
vanderbilt
univers
medic
center
nashvil
tn
unit
state
saint
antoin
hospit
depart
haematolog
pari
franc
chaim
sheba
medic
center
depart
bone
marrow
transplant
tel
hashom
israel
background
choic
condit
regimen
particularli
crucial
set
activ
acut
myeloid
leukemia
aml
need
power
antileukem
activ
negat
good
toxic
profil
protocolth
sequenti
flamsa
regimen
fludarabinecytosin
arabinosideamsacrin
combin
tbi
busulfan
cyclophosphamid
tbf
thiotepabusulfanfludarabin
ft
fludarabinetreosulfan
three
possibl
option
method
analys
transplant
outcom
adult
pt
aml
activ
diseas
phase
primari
refractori
first
second
relaps
underw
first
sct
match
sibl
msd
unrel
donor
ud
report
alwp
ebmtsix
hundr
thirtyon
pt
receiv
receiv
tbf
pt
transplant
follow
ft
protocolaccord
institut
polici
flamsa
busulfan
tbi
base
case
respectivelypt
receiv
oral
busulfan
manipul
graft
transplant
hlamatch
donor
exclud
result
median
followup
month
flamsa
ft
group
month
tbf
groupmedian
age
transplant
year
flamsa
tbf
year
ft
group
respect
day
cumul
incid
grade
iiiv
agvhd
incid
grade
iiiiv
agvhd
flamsa
tbf
ft
respect
cumul
incid
cgvhd
sever
cgvhd
flamsa
tbf
ft
respect
complet
remiss
cumul
incid
pt
reach
day
flamsa
tbf
ft
respect
signific
differ
observ
three
condit
regimen
year
nonrelaps
mortal
nrm
flamsa
tbf
ft
respect
figur
similarli
relaps
incid
ri
rate
respect
signific
differ
observ
year
leukemiafre
surviv
lf
rate
flamsa
tbf
ft
respect
os
follow
tbf
condit
compar
flamsa
ft
final
composit
endpoint
graftvshost
diseasefre
relapsefre
surviv
grf
year
flamsa
tbf
ft
respect
multivari
analysi
signific
differ
observ
three
prepar
regimen
term
transplant
outcomekarnofski
perform
score
kp
independ
associ
better
os
hr
grf
hr
importantli
invivo
tcell
deplet
tcd
associ
lower
incid
grade
iiiiv
agvhd
hr
chronic
hr
sever
cgvhd
hr
conclus
result
suggest
three
prepar
regimen
name
flamsa
tbf
ft
provid
similar
antileukem
effect
aml
pt
activ
diseasetranspl
relat
complic
trm
outcom
differ
well
karnofski
perform
score
emerg
strong
predictor
grf
overal
surviv
invivo
tcd
associ
lower
incid
acut
chronic
gvhdin
conclus
three
condit
protocol
valid
option
transplant
pt
relapsedrefractori
aml
compar
futur
prospect
studi
conflict
interest
author
noth
declar
abstract
previous
publish
divis
stem
cell
transplant
immunotherapi
medic
depart
kiel
germani
helio
kliniken
schwerin
hematolog
oncolog
stem
cell
transplant
schwerin
germani
background
recent
year
condit
regimen
reduc
intermedi
intens
develop
extend
cur
approach
allogen
stem
cell
transplant
elderli
unfit
patient
combin
fludarabin
bcnu
melphalan
fbm
shown
activ
acut
myeloblast
leukemia
aml
myelodysplast
syndrom
md
multipl
myeloma
mm
howev
condit
regimen
combin
differ
method
vivo
cell
deplet
immunosuppress
center
two
differ
approach
cell
deplet
use
accord
physician
discret
monoclon
antibodi
alemtuzumab
rabbit
anti
tlymphocyt
globulin
neovii
retrospect
singl
center
studi
analyz
impact
use
vivo
cell
deplet
acut
toxic
condit
regimen
well
long
term
outcom
mark
et
al
blood
method
consecut
patient
transplant
center
fbm
use
condit
regimen
includ
studi
patient
treat
atg
receiv
alemtuzumab
accord
institut
standard
patient
transplant
nonrel
hla
match
donor
nrmd
treat
atg
dose
gkg
case
hla
match
relat
donor
mrd
dose
reduc
gkg
contrast
equival
dose
alemtuzumab
call
mg
absolut
transplant
nrmd
mg
mrd
transplant
address
acut
toxic
condit
regimen
clinic
symptom
record
accord
common
terminolog
criteria
advers
event
endpoint
long
term
outcom
overal
surviv
rate
relaps
acut
gvhd
result
median
age
patient
group
compar
alemtuzumab
year
atg
year
patient
treat
alemtuzumab
significantli
higher
comorbid
score
compar
atg
cohort
median
hctci
versu
patient
alemtuzumab
group
diagnos
aml
md
wherea
atg
also
use
mm
case
interestingli
toler
alemtuzumab
regard
hypotens
tachycardia
rash
fever
chill
better
atg
notabl
median
follow
month
observ
signific
differ
overal
surviv
group
alemtuzumab
atg
rate
acut
gvhd
significantli
lower
alemtuzumab
group
vs
aml
md
patient
rate
relaps
tend
higher
alemtuzumab
treat
patient
atg
cohort
versu
although
statist
signific
achiev
conclus
condit
regimen
fbm
show
impress
activ
singl
center
studi
drug
atg
alemtuzumab
toler
drug
alemtuzumab
although
achiev
level
immunosuppress
seem
deeper
chosen
dose
level
drug
sinc
outcom
cohort
compar
alemtuzumab
found
feasibl
substitut
atg
patient
acut
toxic
condit
regimen
avoid
conflict
interest
turku
univers
hospit
dept
clinic
haematolog
stem
cell
transplant
unit
turku
finland
background
due
poor
result
chemotherapi
elderli
patient
improv
control
complic
allogen
stem
cell
transplant
asct
use
asct
extend
patient
year
age
upper
age
limit
increas
year
age
assess
transplant
outcom
critic
test
feasibl
treatment
modal
older
age
group
method
institut
transplant
registri
data
retrospect
analys
patient
age
year
transplant
analysi
minimum
followup
one
year
fulfil
primari
end
point
overal
surviv
os
kaplanmei
curv
produc
cox
regress
model
use
identifi
factor
affect
os
result
median
age
rang
year
age
group
year
patient
amlmd
lymphaticplasma
cell
malign
myeloid
malign
aplast
anemia
diseas
statu
transplant
cr
half
patient
gratwohl
score
identifi
earli
diseas
intermedi
advanc
patient
donor
unrel
sourc
stem
cell
blood
marrow
ric
condit
use
patient
hlamatch
full
hlaa
c
mm
sever
acut
gvhd
occur
extens
chronic
gvhd
patient
signific
differ
os
patient
age
vs
year
even
surviv
curv
seem
better
year
fig
univari
analysi
signific
factor
os
condit
ric
occurr
chronic
gvhd
ye
best
respons
asct
cr
less
cr
conclus
asct
feasibl
treatment
modal
patient
age
year
rel
good
os
patient
year
may
wors
outcom
small
number
exclud
meaning
statist
howev
univari
analysi
age
seem
signific
factor
os
opposit
intens
condit
chronic
gvhd
best
respons
asct
conflict
interest
author
noth
disclos
istanbul
bilim
univers
hematolog
depart
istanbul
turkey
sisli
florenc
nightingal
hospit
hematopoiet
stem
cell
transplant
unit
istanbul
turkey
ankara
univers
school
medicin
ankara
turkey
medicana
ankara
intern
hospit
ankara
turkey
background
autolog
hematopoiet
stem
cell
transplant
hsct
potenti
cur
therapeut
approach
relapsedrefractori
lymphoma
although
carmustin
etoposid
cytarabin
melphalan
beam
commonli
use
condit
regimen
highdos
therapi
hdt
autohsct
date
publish
prospect
random
studi
compar
differ
type
condit
regimen
cost
avail
bcnu
forc
mani
centr
search
altern
therefor
gold
standard
regimen
establish
clinic
rehears
differ
substanti
among
institut
aim
compar
beam
altern
alkyl
eam
backbon
base
regimen
potenti
toxic
surviv
lymphoma
patient
method
patient
relaps
refractori
lymphoma
underw
autolog
hsct
evalu
three
differ
highli
activ
transplant
institut
turkey
one
hundr
eighti
adult
lymphoma
patient
age
year
follow
time
least
month
includ
patient
beam
high
dose
chemotherapi
compar
patient
receiv
nonbeam
regimen
thiotepa
eam
n
bendamustin
eam
lomustin
l
eam
use
follow
match
factor
age
gender
lymphoma
subtyp
diseas
statu
transplant
toxic
overal
surviv
caus
death
result
total
patient
male
femal
identifi
patient
patient
treat
beam
nonbeam
regimen
respect
patient
baselin
characterist
detail
tabl
statist
signific
differ
mean
age
gender
group
regard
toxic
among
group
beam
group
significantli
lower
rate
mucos
gastrointestin
toxic
nonbeam
group
respect
renal
toxic
show
differ
among
group
although
beam
group
show
lower
rate
transplant
relat
mortal
day
vs
differ
reach
statist
signific
estim
mean
surviv
time
beam
nonbeam
month
month
respect
logrank
test
figur
signific
differ
median
followup
time
taken
account
conclus
studi
show
eam
backbon
nonbeam
condit
regimen
altern
alkyl
agent
similar
result
compar
beam
regimen
term
efficaci
toxic
still
need
optim
condit
regimen
lower
toxic
better
efficaci
less
cost
beam
prospect
random
control
studi
larg
number
patient
warrant
find
optim
backbon
combin
may
establish
standard
regimen
hsct
lymphoma
patient
conflict
interest
noth
disclos
tabl
tabl
azienda
ospedaliera
universitaria
pisana
uo
ematologia
pisa
itali
aou
santa
maria
della
misericordia
di
udin
ematologia
udin
itali
ospedal
regional
maurizio
ematologia
e
centro
trapianto
di
midollo
osseo
bolzano
itali
ircc
ematologia
asmn
reggio
emilia
itali
aou
della
salut
e
della
scienza
di
torino
ematologia
dipartimento
di
biotecnologi
molecolari
e
scienz
per
la
salut
di
torino
torino
itali
ospedal
san
bortolo
ematologia
vicenza
itali
asl
po
vito
fazzi
ematologia
lecc
itali
ircc
ospedal
casa
sollievo
sofferenza
ematologia
san
giovanni
rotondo
itali
fondazion
ircc
policlinico
san
matteo
ematologia
pavia
itali
iov
ircc
uoc
di
oncologia
medica
padova
itali
ircc
ospedal
oncologico
ematologia
bari
itali
ospedal
giusepp
moscati
ematologia
taranto
itali
ircc
ospedal
san
raffael
division
di
ematologia
milano
itali
cattolica
del
sacro
cuor
istituto
di
ematologia
roma
itali
ospedal
di
ivreaasl
ematologia
ivrea
itali
azienda
ospedaliera
universitaria
pisana
uo
ematologia
universitaria
pisa
itali
asmn
ircc
ematologia
reggio
emilia
itali
azienda
ulss
ematologia
treviso
itali
aou
della
salut
e
della
scienza
di
torino
ematologia
dipartimento
di
biotecnologi
molecolari
e
scienz
per
la
salut
di
torino
torino
itali
azienda
ospedali
riuniti
di
ancona
ematologia
ancona
itali
asur
uoc
medicina
interna
ed
ematologia
civitanova
march
itali
iov
ircc
uoc
di
oncologia
medica
padova
itali
background
high
dose
chemotherapi
stem
cell
rescu
standard
care
relaps
refractori
hodgkin
diseas
hd
patient
even
newer
treatment
nowaday
avail
use
condit
regimen
beam
scheme
last
year
carmustin
shortag
issu
worldwid
itali
well
fotoemustin
emerg
possibl
altern
feam
scheme
method
retrospect
analyz
data
consecut
patient
transplant
differ
italian
center
beam
feam
regimen
report
data
hd
patient
n
result
median
age
group
femal
patient
beam
feam
patient
characterist
diagnosi
compar
stage
ii
beam
vs
feam
stage
iii
beam
vs
feam
stage
iv
beam
vs
feam
b
symptom
present
respect
beam
feam
first
line
treatment
abvd
group
radiotherapi
transplant
consolid
line
use
case
beam
cohort
vs
feam
diseas
assess
sct
show
beam
cr
pr
resist
diseas
rd
metabol
cr
pet
neg
transplant
patient
feam
group
cr
pr
rd
metabol
cr
beam
patient
higher
sorror
score
transplant
sorror
vs
neutrophil
engraft
similar
group
day
grade
iiiiv
mucos
occur
beam
feam
febril
neutropenia
grade
iiiiv
observ
respect
beam
feam
respons
statu
differ
day
post
asct
cr
beam
vs
feam
neither
last
followup
continu
cr
beam
vs
feam
nonrelaps
mortal
year
beam
vs
feam
compar
overal
surviv
os
year
differ
beam
vs
feam
death
occur
respect
beam
feam
due
diseas
progress
major
patient
howev
feam
group
trend
inferior
progressionfre
surviv
year
beam
vs
feam
higher
relaps
incid
beam
vs
feam
conclus
substitut
fotemustin
increas
gener
toxic
infecti
episod
howev
observ
sligher
higher
rate
gastrointestin
infecti
toxic
feam
patient
lead
higher
nrm
neither
significantli
worsen
os
although
retrospect
design
studi
caution
definit
conclus
observ
trend
better
pf
relaps
incid
beam
patient
could
relat
better
diseas
control
statu
time
transplant
conflict
interest
none
sheffield
teach
hospit
nh
foundat
trust
sheffield
unit
kingdom
british
societi
blood
marrow
transplant
london
unit
kingdom
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
univers
hospit
birmingham
nh
foundat
trust
birmingham
unit
kingdom
oxford
univers
hospit
nh
foundat
trust
oxford
unit
kingdom
background
sinc
linch
et
al
publish
result
bnli
trial
compar
beam
autolog
rescu
minibeam
lancet
beam
consid
gold
standard
condit
regimen
patient
relaps
hodgkin
lymphoma
uk
long
afterward
parma
studi
also
report
signific
benefit
carmustin
contain
high
dose
chemotherapi
beac
regimen
patient
nonhodgkin
lymphoma
recent
year
intermitt
shortag
drug
carmustin
lead
increas
use
drug
lomustin
substitut
method
order
compar
safeti
efficaci
beam
leam
condit
chemotherapi
conduct
retrospect
registri
survey
patient
hodgkin
nonhodgkin
lymphoma
first
autolog
transplant
uk
day
januari
decemb
least
day
follow
avail
data
sourc
med
ab
form
overal
outcom
assess
overal
surviv
os
efficaci
progress
free
surviv
pf
relaps
rate
rr
safeti
nonrelaps
mortal
nrm
result
overal
patient
identifi
centr
median
follow
nearli
year
patient
receiv
beam
leam
condit
group
well
match
year
transplant
gender
age
diagnosi
presenc
comorbid
line
prior
therapi
diseas
statu
transplant
perform
statu
median
time
neutrophil
median
day
platelet
median
day
engraft
equival
diseas
respons
transplant
cr
assess
efficaci
pf
equival
year
v
year
v
rr
year
v
year
v
term
safeti
nrm
equival
day
v
year
v
os
also
equival
year
v
year
v
conclus
comparison
beam
leam
condit
chemotherapi
first
autolog
transplant
patient
hodgkin
nonhodgkin
lymphoma
show
equival
safeti
efficaci
overal
surviv
lomustin
safe
substitut
place
carmustin
chemotherapi
clinic
trial
registri
bsbmt
ctcr
conflict
interest
j
snowden
honoraria
speakingchair
sanofi
jazz
n
morley
confer
support
advisori
board
fee
roch
king
faisal
hospit
research
center
oncolog
center
riyadh
saudi
arabia
king
fahad
specialist
hospit
adult
hematolog
stem
cell
transplant
depart
dammam
saudi
arabia
background
ideal
condit
regimen
still
remain
challeng
patient
undergo
autolog
stem
cell
transplant
asct
relapsedrefractori
hodgkin
lymphoma
rrhl
commonli
use
regimen
beam
singl
agent
highdos
melphalan
hdm
also
use
howev
far
limit
experi
data
compar
beam
vs
hdm
method
medic
record
rrhl
patient
two
differ
institut
evalu
chemosensit
diseas
salvag
chemotherapi
underw
asct
onward
review
retrospect
institut
review
board
approv
rel
smaller
cohort
patient
condit
hdm
compar
matchedpair
analysi
larger
cohort
patient
receiv
beam
patient
group
beam
vs
hdm
similar
median
age
sex
f
vs
match
diseas
statu
salvag
late
relaps
vs
earli
relapseprimari
refractori
diseas
statu
preasct
complet
remiss
cr
vs
partial
remiss
pr
beamregimen
given
standard
infus
instruct
dose
day
hdm
given
singl
day
infus
patient
receiv
prophylaxi
microbi
fungal
viral
infect
gcsf
routin
administ
dose
day
beamgroup
day
hdmgroup
kaplanmei
method
use
calcul
overal
surviv
os
progress
free
surviv
pf
result
engraft
success
median
day
neutrophil
group
whilst
platelet
faster
recoveri
notic
hdmgroup
vs
day
p
previous
report
leuk
platelet
recoveri
day
beam
day
logist
reason
extra
platelet
transfus
inpati
permacathet
median
followup
approxim
year
patient
aliv
diseasefre
beamgroup
diseasefre
hdmgroup
whole
cohort
patient
vs
vs
beam
hdmgroup
respect
transplant
relat
mortal
similar
accept
group
beamgroup
hdmgroup
merscov
outbreak
patient
receiv
beam
kfshrc
die
trm
conclus
studi
though
retrospect
demonstr
rrhl
patient
condit
regimen
consist
singledos
hdm
may
similar
efficaci
compar
beamregimen
importantli
differ
durat
chemotherapi
administr
day
beam
vs
day
hdm
result
shorter
hospit
period
shorter
period
gcsf
administr
postasct
may
contribut
bettercost
effect
hdmregimen
howev
addit
studi
larger
cohort
longer
followup
need
long
term
diseas
outcom
toxic
meticul
compar
cost
analysi
need
conflict
interest
noth
disclos
regina
elena
nation
cancer
institut
hematolog
stem
cell
transplant
unit
rome
itali
univers
la
sapienza
depart
cellular
biotechnolog
hematolog
rome
itali
regina
elena
nation
cancer
institut
biostatist
unit
rome
itali
tor
vergata
univers
hematolog
rome
itali
regina
elena
nation
cancer
institut
scientif
direct
rome
itali
background
beam
standard
condit
lymphoma
patient
undergo
asct
howev
itali
bcnu
often
substitut
fotemustin
feam
due
difficult
suppli
comparison
studi
lack
method
consecut
lymphoma
patient
undergo
asct
two
jaci
accredit
institut
review
select
beam
feam
base
bcnu
avail
median
age
year
asct
perform
aggress
nhl
case
indol
nhl
hl
first
line
case
first
salvag
treatment
advanc
phase
remain
preasct
respons
statu
cr
first
cr
second
cr
pr
refractori
diseas
case
two
group
patient
wellbalanc
analyz
paramet
expect
median
followup
beam
month
feam
month
p
result
feam
signific
higher
incid
grade
oral
mucos
vs
p
document
infect
vs
observ
nonrelaps
mortal
pulmonari
toxic
similar
two
group
respons
statu
postasct
significantli
better
beam
group
cr
vs
differ
evid
dlbcl
cr
vs
hl
patient
cr
vs
multivari
analysi
condit
independ
factor
abl
affect
posttranspl
cr
beam
vs
feam
or
ci
togeth
pretranspl
diseas
statu
cr
vs
cr
or
ci
p
pf
os
significantli
differ
beam
vs
feam
beam
vs
feam
conclus
despit
limit
due
nonrandom
natur
studi
beam
condit
regimen
seem
better
toler
although
pf
os
similar
time
consid
higher
proport
cr
postasct
longer
median
followup
beam
remain
regimen
choic
patient
longer
followup
feam
patient
allow
evalu
whether
surviv
curv
differ
next
futur
conflict
interest
none
author
conflict
interest
report
state
budgetari
healthcar
institut
nation
medic
surgic
center
na
ni
pirogov
ministri
health
russia
moscow
russian
feder
background
nowaday
random
trial
comparison
effect
toler
differ
condit
regimen
malign
lymphoma
ml
patient
aim
studi
assess
safeti
toxic
profil
overal
os
progressivefre
surviv
pf
patient
receiv
beeac
novel
condit
regimen
autohsct
primaryrefractori
relaps
ml
patient
clinicaltrialsgov
method
januari
august
patient
receiv
autohsct
hodgkin
lymphoma
hl
nonhodgkin
lymphoma
patient
women
men
median
followup
month
median
age
year
autohsct
patient
cr
pr
patient
stabl
diseas
sd
median
number
chemotherapi
line
condit
regimen
beeac
increas
dose
bendamustin
mgm
mgm
mgm
combin
fixeddos
cytarabin
etoposid
cyclophosphamid
total
divid
day
phase
studi
patient
divid
cohort
patient
bendamustin
dose
increas
mgm
result
phase
studi
show
dose
limit
toxic
describ
follow
patient
receiv
bendamustin
mgm
hematolog
toxic
present
tabl
cardiotox
effect
detect
patient
follow
hydropericardium
dri
pericard
postcytostat
cardiomyopathi
acut
biventricular
heart
failur
paroxysm
atrial
fibril
patient
sign
oral
mucos
om
classif
grade
om
grade
grade
patient
grade
intestin
mucos
ncictc
determin
patient
grade
patient
grade
grade
patient
develop
liver
toxic
ctcae
major
case
grade
patient
develop
renal
toxic
ctcae
patient
grade
cr
rate
increas
day
hsct
patient
remain
pr
sd
patient
relaps
progress
hsct
frequenc
relaps
depend
number
chemotherapi
line
cl
patient
cl
line
line
patient
cl
even
patient
nhl
bcell
lymphoma
relaps
cn
overal
mortal
patient
die
progress
diseas
cardiotox
sepsi
bleed
pulmonari
edema
radiat
therapi
postop
complic
notrel
ml
patient
die
earli
posttranspl
period
sepsi
acut
cardiotox
median
pf
os
year
respect
conclus
data
analysi
show
beeac
safeti
condit
regimen
investig
need
assess
longterm
surviv
clinic
trial
registri
clinicaltrialsgov
conflict
interest
disclosur
hospit
universitario
de
salamancaibs
hematolog
salamanca
spain
hospit
vall
dhebron
hematolog
barcelona
spain
hospit
central
de
asturia
hematolog
oviedo
spain
hospit
clinic
hematolog
barcelona
spain
complejo
hospitalario
universitario
de
santiago
de
compostela
hematolog
santiago
de
compostela
spain
hospit
universitario
la
paz
hematolog
madrid
spain
hospit
gener
universitario
gregorio
maranon
hematolog
madrid
spain
hospit
universitario
de
valdecilla
hematolog
santand
spain
hospit
universitario
la
fe
hematolog
valencia
spain
hospit
son
hematolog
palma
spain
hospit
la
princesa
hematolog
madrid
spain
hospit
universitario
de
valencia
hematolog
valencia
spain
universidad
de
navarra
hematolog
pamplona
spain
hospit
universitario
de
canaria
hematolog
san
de
la
laguna
spain
hospit
de
hematolog
jerez
de
la
frontera
spain
hospit
de
octubr
hematolog
madrid
spain
hospit
virgen
de
la
arreixaca
hematolog
murcia
spain
hospit
cajal
hematolog
madrid
spain
hospit
santa
creu
sant
pau
hematolog
barcelona
spain
hospit
arnau
de
villanoba
hematolog
valencia
spain
hospit
de
zaragoza
hematolog
zaragoza
spain
background
beam
employ
condit
regimen
lymphoma
patient
europ
howev
bcnu
hardli
avail
relat
pulmonari
complic
conduct
phase
trial
evalu
safeti
efficaci
bendamustin
instead
bcnu
beam
regimen
condit
autolog
stemcel
transplant
asct
patient
aggress
lymphoma
method
inclus
criteria
histolog
diagnosi
relaps
refractori
diffus
larg
bcell
lymphoma
dlbcl
grade
follicular
lymphoma
fl
partial
respons
pr
complet
remiss
cr
salvag
therapi
ii
transform
dlbcl
peripher
tcell
lymphoma
ptcl
first
subsequ
pr
cr
condit
regimen
consist
bendamustin
day
etoposid
day
cytarabin
day
melphalan
day
bendaeam
regimen
primari
endpoint
progressionfre
surviv
pf
year
secondari
endpoint
toxic
respons
transplant
overal
surviv
os
result
sixti
patient
median
age
year
male
spanish
hospit
includ
may
novemb
histolog
follow
dlbcl
grade
fl
transform
dlbcl
ptcl
patient
receiv
two
line
treatment
prior
asct
thirtyseven
patient
metabol
cr
assess
petct
time
transplant
pr
patient
except
one
die
earli
engraft
median
day
respect
achiev
x
neutrophil
x
platelet
total
seriou
advers
event
report
day
includ
infecti
episod
result
respiratori
failur
death
patient
transplantrel
mortal
episod
renal
failur
bendamustin
administr
revers
case
nonrelaps
mortal
day
patient
encephalopathi
infecti
complic
regard
respons
transplant
patient
achiev
cr
pr
median
followup
month
patient
relaps
diseas
secondari
neoplasm
myelodysplast
syndrom
cholangiocarcinoma
patient
die
estim
pf
os
global
seri
respect
patient
pet
diseas
studi
entri
significantli
wors
pf
vs
year
os
vs
year
patient
underw
asct
metabol
cr
prognost
factor
affect
pf
rr
os
rr
multivari
analysi
conclus
bendaeam
condit
safe
feasibl
activ
regimen
patient
aggress
lymphoma
infecti
renal
toxic
care
monitor
longterm
result
indic
efficaci
similar
previous
report
regimen
commonli
use
like
beam
pet
statu
time
transplant
key
prognost
factor
surviv
clinic
trial
registri
clinicaltrialsgov
identifi
conflict
interest
conflict
interest
relat
present
abstract
last
month
chonnam
nation
univers
hwasun
hospit
hwasun
korea
republ
sever
hospit
yonsei
univers
colleg
medicin
seoul
korea
republ
seoul
st
mari
hospit
cathol
univers
korea
seoul
korea
republ
samsung
medic
center
seoul
korea
republ
ulsan
univers
hospit
ulsan
korea
republ
nation
cancer
center
goyangsi
korea
republ
inj
univers
busan
paik
hospit
busan
korea
republ
donga
medic
center
busan
korea
republ
chonbuk
nation
univers
medic
school
jeonju
korea
republ
korea
cancer
center
hospit
korea
institut
radiolog
medic
scienc
seoul
korea
republ
gachon
univers
gil
hospit
incheon
korea
republ
kosin
univers
gospel
hospit
busan
korea
republ
ewha
woman
univers
school
medicin
seoul
korea
republ
kyungpook
nation
univers
hospit
daegu
korea
republ
soonchunhyang
univers
bucheon
hospit
bucheon
korea
republ
korea
univers
colleg
medicin
seoul
korea
republ
pusan
nation
univers
hospit
busan
korea
republ
seoul
nation
univers
hospit
seoul
korea
republ
background
recent
studi
suggest
intraven
busulfan
melphalan
bumel
might
effect
toler
condit
regimen
autolog
stem
cell
transplant
asct
patient
multipl
myeloma
mm
studi
compar
efficaci
toxic
bumel
highdos
melphalan
hdmel
condit
regimen
transplant
elig
patient
mm
method
retrospect
analyz
record
patient
newli
diagnos
mm
receiv
bumel
hdmel
condit
regimen
follow
earli
asct
less
month
initi
diagnosi
reduc
select
bia
effect
treatment
result
perform
propens
scorematch
analysi
accord
age
sex
intern
stage
system
diseas
stage
lactat
dehydrogenas
level
inclus
cyclophosphamid
induct
regimen
result
seventysix
patient
receiv
bumel
consist
intraven
busulfan
administ
mgkg
day
day
follow
melphalan
administ
day
number
patient
receiv
hdmel
consist
melphalan
day
patient
treat
thalidomidebas
regimen
induct
therapi
statist
signific
differ
complet
respons
cr
overal
respons
rate
orr
asct
observ
bumel
hdmel
cr
vs
p
orr
vs
p
median
followup
month
bumel
group
month
hdmel
group
progressionfre
surviv
month
month
respect
p
respect
nonhematolog
toxic
infect
frequent
report
bumel
group
p
statist
signific
differ
incid
grade
infect
observ
bumel
vs
hdmel
venousocclus
diseas
occur
three
patient
receiv
bumel
recov
support
therapi
conclus
conclus
bumel
effect
altern
condit
regimen
accept
toxic
earli
asct
patient
treat
thalidomidebas
induct
therapi
conflict
interest
author
declar
conflict
interest
abstract
previous
publish
univers
medic
center
hamburgeppendorf
depart
stem
cell
transplant
hamburg
germani
univers
medic
center
hamburg
eppendorf
hospit
pharmaci
hamburg
germani
univers
medic
center
hamburg
eppendorf
depart
legal
medicin
hamburg
germani
background
well
known
high
interindividu
varieti
dose
exposit
busulfan
bu
one
hand
correl
exposit
clinic
outcom
hand
therapeut
drug
monitor
tdm
consid
optimis
patient
outcom
howev
due
technic
logist
reason
pharmacokinet
pk
guid
doseadjust
establish
major
haematopoiet
stem
cell
hsct
centr
europ
yet
method
singlecentr
retrospect
analysi
adult
patient
undergo
allogen
hsct
initi
bu
dose
mgkg
bu
intraven
daili
base
adjust
ideal
bodi
weight
aibw
obes
patient
busulfan
concentr
measur
ga
chromatographymass
spectrometri
gcm
auc
calcul
use
bayesian
curv
fit
calcul
auc
outsid
predefin
target
auc
dose
adjust
undertaken
subsequ
dose
result
month
period
total
patient
malefemal
receiv
bu
tdm
vari
condit
regimen
eg
bufludarabin
bucyclophosphamid
either
antithymocyt
globulin
atg
posttransplant
cyclophosphamid
median
age
year
rang
median
bodi
mass
index
rang
aibw
initi
dose
calcul
use
patient
mean
auc
first
day
quantif
h
mgl
rang
h
mgl
calcul
busulfan
auc
dose
adjust
median
mean
target
auc
result
dose
adjust
patient
increas
busulfan
dose
subsequ
day
dose
decreas
patient
respect
dose
adjust
median
deviat
receiv
auc
target
auc
mean
patient
within
predefin
cumul
auc
target
rang
conclus
data
confirm
import
patient
individu
dose
adjust
bu
condit
adult
allo
sct
patient
implement
butdm
within
clinic
routin
care
feasibl
result
better
target
attain
cumul
bu
exposit
conflict
interest
conflict
interest
ebmt
paediatr
diseas
work
parti
divis
stem
cell
transplant
immunolog
depart
children
adolesc
univers
hospit
goeth
univers
frankfurt
main
germani
st
anna
children
hospit
vienna
austria
univers
hospit
motol
depart
pediatr
hematolog
oncolog
pragu
czech
republ
robert
parisdiderot
univers
depart
pediatr
hematoimmunolog
pari
franc
stem
cell
transplant
unit
aghia
sophia
children
hospit
thivon
papadiamantopoul
athen
greec
school
medicin
bahcesehir
univers
depart
pediatr
hematologyoncolog
istanbul
turkey
univers
medic
scienc
depart
clinic
pediatr
oncolog
hematolog
transplantolog
poznan
poland
leiden
univers
medic
center
depart
pediatr
leiden
netherland
hematologyoncolog
unit
lalla
depart
pediatr
univers
bologna
bologna
itali
hematologyoncolog
stem
cell
transplant
research
center
tehran
univers
medic
scienc
tehran
iran
islam
republ
copenhagen
univers
hospit
rigshospitalet
depart
pediatr
copenhagen
denmark
oslo
univers
hospit
rikshospitalet
depart
pediatr
medicin
oslo
norway
unit
st
istvan
st
hospit
depart
paediatr
haematolog
stem
cell
transplant
budapest
hungari
centr
pierr
et
mari
curi
servic
greff
de
moell
alger
algeria
servicio
de
hematologia
oncologia
hospit
universitario
vall
dhebron
barcelona
spain
russian
children
hospit
bmt
depart
moscow
russian
feder
timon
enfant
hospit
aphm
aixmarseil
univers
depart
pediatr
hematolog
oncolog
research
unit
ea
marseil
franc
ircc
ospedal
pediatrico
bambino
di
pavia
dipartimento
di
oncoematologia
pediatrica
e
medicina
trasfusional
rome
itali
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
cliniqu
universitair
saintluc
depart
pediatr
hematolog
oncolog
brussel
belgium
hadassahhebrew
univers
medic
center
depart
bone
marrow
transplant
jerusalem
israel
divis
stem
cell
transplant
children
research
center
crc
univers
children
hospit
zurich
switzerland
republ
clinic
research
centr
pediatr
oncolog
hematolog
minsk
belaru
bmt
unit
depart
pediatr
hematolog
oncolog
comeniu
univers
medic
school
bratislava
slovakia
pediatr
blood
disord
immunodefici
stem
cell
transplant
astrid
lindgren
children
hospit
karolinska
univers
hospit
stockholm
sweden
center
pediatr
oncolog
hematolog
bone
marrow
transplant
unit
children
hospit
affili
vilniu
univers
hospit
santariskiu
kliniko
vilniu
lithuania
tartu
univers
hospit
tartu
estonia
intern
clinic
univers
hospit
centr
depart
haematolog
zagreb
croatia
paediatr
oncohaematolog
citi
scienc
health
turin
regina
margherita
children
hospit
turino
itali
nicolau
copernicu
univers
torun
depart
pediatr
hematolog
oncolog
collegium
medicum
bydgoszcz
poland
bmtunit
univers
medic
centr
utrecht
pediatr
utrecht
netherland
child
welfar
center
borsod
counti
teach
hospit
depart
hematolog
miskolc
hungari
bone
marrow
transplant
program
instituto
portugu
oncologia
lisbon
portug
raisa
gorbacheva
memori
research
institut
pediatr
oncolog
haematolog
transplant
saint
petersburg
state
medic
ip
pavlov
univers
saint
petersburg
russian
feder
geneva
univers
hospit
geneva
univers
depart
pediatr
oncohematolog
unit
geneva
switzerland
ebmt
paediatr
diseas
work
parti
pari
franc
ebmt
pari
studi
offic
pari
franc
background
paediatr
patient
pt
two
year
age
acut
leukemia
commonli
receiv
chemotherapi
myeloabl
condit
mac
allogen
haematopoiet
stem
cell
transplant
allohsct
unknown
combin
chemotherapeut
offer
best
outcom
method
investig
outcom
differ
chemotherapybas
conditioningregimen
perform
retrospect
paediatr
diseas
work
parti
pdwp
ebmtregistri
base
studi
children
two
age
mac
first
allohsct
bone
marrow
bm
peripher
blood
sc
pbsc
cord
blood
cb
match
sibl
msd
unrel
donor
ud
first
remiss
includ
propens
score
weight
use
consid
bia
due
confound
variabl
eg
differ
size
composit
subgroup
univari
analysi
multivari
cox
model
weight
diagnosi
age
hsct
hsct
interv
diagnosi
hsct
donor
type
sc
sourc
cox
model
cluster
ebmt
center
result
total
pt
aml
includ
pt
receiv
bm
pt
cb
pbsc
ud
msd
thirtysix
differ
conditioningregimen
use
busulfancyclophosphamidemelphalanatg
bucymelatg
frequent
appli
regimen
remain
condit
summar
other
patient
treat
two
condit
group
median
age
interquartil
rang
ir
ir
median
followup
signific
differ
two
condit
cohort
bucymelatg
other
detect
lf
vs
relaps
incid
vs
os
vs
nonrelaps
mortal
vs
agvhd
grade
iiiiv
day
vs
cgvhd
vs
gvhdfreerelapsefre
surviv
vs
multivari
cox
model
signific
differ
two
condit
cohort
found
well
conclus
allohsct
children
two
year
age
high
relapserisk
acut
leukemia
offer
impress
chanc
cure
frequent
appli
regimen
bucymelatg
demonstr
superior
compar
condit
retrospect
data
current
reevalu
prospect
random
intern
trial
sctped
forum
conflict
interest
author
declar
relationship
disclos
nant
hospit
hematolog
nant
franc
saint
antoin
hospit
hematolog
pari
franc
necker
hospit
hematolog
pari
franc
saint
loui
hospit
hematolog
pari
franc
institut
paoli
calmett
hematolog
marseil
franc
caen
hospit
hematolog
caen
franc
hospit
hematolog
pari
franc
poitier
hospit
hematolog
poitier
franc
bordeaux
hospit
hematolog
bordeaux
franc
lill
hospit
hematolog
lill
franc
toulous
hospit
hematolog
toulous
franc
renn
hospit
hematolog
renn
franc
strasbourg
hospit
hematolog
strasbourg
franc
montpelli
hospit
hematolog
montpelli
franc
amien
hospit
hematolog
amien
franc
limog
hospit
hematolog
limog
franc
nanci
hospit
hematolog
nanci
franc
background
recent
publish
prospect
result
sequenti
regimen
use
clofarabin
clo
cytosin
arabinosid
reducedintens
condit
ric
regimen
case
primari
refractori
acut
myeloid
leukemia
aml
show
encourag
result
low
non
relaps
mortal
mohti
report
outcom
sequenti
regimen
larger
cohort
patient
method
retrospect
studi
includ
patient
report
within
sfgmtc
registri
receiv
clobas
sequenti
condit
regimen
allotranspl
activ
myeloid
diseas
data
obtain
promis
internetbas
system
share
european
transplant
center
patient
gave
inform
consent
allow
collect
person
data
data
base
sequenti
regimen
consist
clo
cytosin
arabinosid
day
follow
rest
ric
combin
cyclophosphamid
mgkg
iv
busulfan
mgkgday
day
antithymocyt
globulin
mgkgday
day
primari
object
studi
report
main
outcom
year
overal
surviv
os
diseas
free
surviv
df
relaps
incid
ri
nrm
gvhd
relaps
free
surviv
grf
secondari
object
identifi
prognost
factor
patient
surviv
result
januari
decemb
patient
male
median
age
year
rang
met
inclus
criteria
aml
patient
includ
secondari
aml
case
myelodysplast
myeloprolif
syndrom
statu
transplant
follow
primari
refractori
relaps
miss
major
patient
receiv
peripher
blood
stem
cell
sourc
graft
bone
marrow
patient
receiv
graft
match
donor
sibl
unrel
donor
recipi
r
cmv
statu
follow
dr
dr
dr
dr
engraft
observ
assess
case
patient
achiev
complet
remiss
cr
transplant
evalu
case
median
followup
month
rang
aliv
patient
os
df
ri
nrm
grf
respect
multivari
analysi
dr
cmv
neg
statu
associ
lower
os
hr
ci
df
hr
ci
grf
hr
ci
higher
ri
hr
ci
dr
cmv
statu
associ
nrm
conclus
despit
high
cr
achiev
larg
cohort
patient
confirm
rel
poor
outcom
patient
activ
myeloid
diseas
transplant
receiv
clofarabinebas
sequenti
regimen
favor
impact
surviv
posit
r
cmv
statu
may
relat
potenti
graftvsleukemia
effect
cmv
reactiv
thank
nk
cell
stimul
transplant
valid
hypothesi
ongo
conflict
interest
conflict
interest
institut
pediatr
oncolog
hematolog
pediatr
bmt
moscow
russian
feder
background
attempt
improv
treatment
result
patient
highrisk
ewe
sarcoma
es
neuroblastoma
nb
initi
studi
hdct
autolog
sct
includ
epigenet
therapi
order
increas
tumor
cell
chemosensit
split
condit
regimen
base
near
maximum
toler
dose
treosulfan
treo
method
two
patient
solid
tumor
multipl
bone
involv
includ
one
stage
es
cours
one
stage
nb
cours
induct
therapi
patient
age
vgpr
split
condit
regimen
consist
treosulfan
melphalan
given
inject
patient
transplant
autolog
pbsc
cellskg
gcsf
given
result
regimen
relat
toxic
moder
manag
pt
develop
grade
gi
stomat
pain
erythema
requir
parenter
nutrit
narcot
drug
diarrhea
stoolday
moder
dyspepsia
andor
dysphagia
febril
neutropenia
requir
iv
antibiot
case
transient
liver
toxic
grade
astalt
elev
hemorrhag
grade
observ
patient
receiv
rbc
plt
transfus
respect
patient
engraft
wbc
plt
respect
patient
nb
aliv
without
diseas
mo
hdct
patient
es
relaps
mo
hdct
state
research
protocol
conclus
specul
treo
base
split
regimen
addit
feasibl
accept
toxic
profil
regimen
seem
reason
solid
tumor
low
cell
growth
fraction
pt
longer
followup
period
need
make
conclus
conflict
interest
conflict
interest
univers
medic
scienc
poznan
poland
institut
hematolog
transfus
medicin
warsaw
poland
jagiellonian
univers
medic
collag
krakow
poland
medic
univers
gdansk
gdansk
poland
wroclaw
medic
univers
wroclaw
poland
background
busulfan
bu
base
myeloabl
condit
regimen
wide
use
patient
acut
myeloid
leukemia
aml
treat
allogen
hematopoiet
stem
cell
transplant
allohct
busulfan
frequent
use
combin
either
cyclophosphamid
cy
fludarabin
flu
aim
multicent
retrospect
analysi
compar
outcom
allohct
adult
patient
aml
first
complet
remiss
beyond
condit
myeloabl
buci
reduc
toxic
buflu
regimen
method
adult
patient
aml
treat
allohct
either
hlaident
sibl
unrel
donor
beyond
condit
iv
busulfan
given
myeloabl
dose
mgkg
combin
flu
cy
year
includ
analysi
patient
treat
buflu
older
median
vs
p
receiv
frequent
stem
cell
collect
peripher
blood
vs
p
result
engraft
observ
patient
median
time
neutrophil
count
gl
platelet
count
gl
recoveri
shorter
buflu
comparison
buci
day
vs
day
p
day
vs
day
p
febril
neutropenia
occur
patient
buflu
group
buci
group
noninfecti
complic
grade
observ
patient
respect
acut
gvhd
grade
iiiv
present
patient
buflu
group
patient
buci
group
p
respect
frequenc
extens
moderatesever
chronic
gvhd
p
median
follow
time
among
survivor
month
rang
os
patient
condit
buflu
condit
buci
logrank
p
respect
lf
p
addit
os
lf
patient
transplant
beyond
differ
significantli
buflu
buci
group
similarli
cumul
incid
ci
nonrelaps
mortal
ci
relaps
compar
two
group
vs
vs
respect
p
ns
multivari
analysi
faster
lymphocyt
recoveri
favor
influenc
os
hr
conclus
myeloabl
reduc
toxic
condit
regimen
base
iv
busulfan
combin
fludarabin
appear
effect
buci
combin
adult
patient
aml
first
subsequ
cr
result
studi
indic
cy
may
replac
fludarabin
busulfanbas
myeloabl
condit
regimen
without
neg
impact
diseas
control
conflict
interest
none
author
anyth
declar
mazumdar
shaw
cancer
center
narayana
health
citi
pediatr
hematolog
oncolog
bone
marrow
transplant
bangalor
india
mazumdar
shaw
cancer
center
narayana
health
citi
bangalor
india
background
hsct
relat
complic
diseas
relaps
major
obstacl
success
transplant
addit
antithymocyt
globulin
atg
reduc
reject
gvhd
incid
significantli
studi
conduct
look
rel
efficaci
rabbit
equin
atg
pediatr
hsct
condit
method
singl
centr
retrospect
analysi
thalassemia
major
sever
aplast
anemia
saa
patient
underw
hsct
januari
receiv
atg
condit
regimen
result
rabbit
equin
atg
use
part
condit
regimen
thalassemia
pesaro
class
iclass
iiclass
iii
patient
saa
frontlin
transplantaft
failur
immunosuppress
equin
atg
group
label
rabbit
atg
median
dose
use
thalassemia
saa
respect
csamtx
use
gvhd
prophylaxi
median
total
dose
equin
atg
rabbit
atg
flubucyatg
condit
regimen
class
ii
thalassemia
treosulphan
base
condit
use
class
iii
group
analyz
transplant
relat
complic
outcom
outcom
shown
compar
except
case
proven
bacteri
infect
venoocclus
diseas
acut
gvhd
seen
patient
group
chronic
gvhd
case
median
chimer
p
valu
overal
surviv
os
median
period
follow
shown
event
free
surviv
ef
respect
pvalu
saa
flubuatg
use
condit
csamtx
gvhd
prophylaxi
bone
marrow
use
stem
cell
sourc
patient
pbsc
earli
neutrophil
platelet
engraft
less
number
proven
bacteri
infect
median
chimer
day
time
interv
acut
gvhd
seen
case
os
group
conclus
effect
rabbit
hors
atg
similar
thalassemia
patient
saa
equin
atg
use
associ
earli
neutrophil
engraft
less
incid
bacteri
infect
os
group
compar
conflict
interest
none
tabl
tabl
leipzig
hematolog
int
oncolog
leipzig
germani
background
myelodysplast
syndrom
md
clinic
heterogen
diseas
allogen
stem
cell
transplant
hsct
remain
cur
treatment
appropri
condit
intens
remain
determin
younger
md
patient
lower
non
relaps
mortal
nrm
higher
cumul
incid
relaps
cir
shown
reducedintens
ric
compar
myeloabl
condit
hsct
dose
reduc
regimen
includ
ric
nonmyeloabl
nma
regimen
allow
hsct
older
individu
repres
major
md
patient
data
compar
ric
nma
condit
hsct
older
md
patient
lack
method
retrospect
analyz
md
patient
older
median
rang
year
receiv
nma
fludarabin
total
bodi
irradi
tbi
ric
fludarabin
oral
intraven
busulfan
includ
thymoglobulin
unrel
hsct
hsct
patient
year
receiv
nma
ric
condit
patient
predominantli
receiv
nma
thu
outcom
patient
younger
older
hsct
analyz
separ
karyotyp
analys
perform
central
institut
ipssr
low
low
intermedi
high
high
result
overal
nma
patient
older
age
differ
ric
nma
condit
patient
patient
younger
older
year
compar
separ
percentag
patient
receiv
therapi
demethyl
agent
andor
chemotherapi
prior
hsct
differ
ric
nma
condit
vs
howev
due
predomin
applic
nma
condit
nma
patient
less
often
receiv
demethyl
agent
alon
vs
proport
patient
blast
excess
complex
karyotyp
vs
well
score
ipssr
risk
ipssr
genet
risk
hctci
differ
nma
riccondit
patient
nmacondit
patient
graft
reject
vs
chronic
graftversushost
diseas
trend
cgvhd
vs
patient
younger
nma
associ
higher
nrm
figur
shorter
overal
surviv
os
figur
contrast
differ
cir
secondari
acut
myeloid
leukemia
cisaml
nma
ric
condit
patient
older
hsct
differ
nrm
os
cir
cisaml
regard
condit
regim
conclus
patient
age
receiv
nmahsct
graft
reject
cgvhd
trend
higher
nrm
shorter
os
studi
limit
retrospect
natur
possibl
select
bia
toward
nma
older
less
fit
patient
age
comorbid
index
hctci
differ
nma
ric
comorbid
might
appropri
reflect
hsctci
score
patient
younger
might
benefit
intens
ric
intensif
nma
eg
gy
tbi
condit
howev
nma
condit
older
patient
allow
cur
treatment
longterm
surviv
conflict
interest
g
frank
takeda
consult
pfizer
honoraria
novarti
honoraria
research
fund
schwind
novarti
consult
research
fund
author
noth
disclos
aga
khan
univers
karachi
pakistan
background
bendamustin
carmustin
shown
use
part
condit
regimen
autolog
stem
cell
transplant
sct
relaps
refractori
lymphoma
howev
bendamustin
higher
toxic
profil
compar
carmustin
studi
carmustin
avail
sporad
mani
countri
therefor
bendamustin
use
frequent
report
experi
bendamustin
part
condit
regimen
beeam
non
avail
carmustin
pakistan
method
retrospect
studi
compar
safeti
efficaci
bendamustin
day
coupl
etoposid
day
cytarabin
day
melphalan
day
beeam
versu
carmustin
day
coupl
agent
beam
condit
regimen
autolog
sct
result
total
patient
includ
studi
patient
beeam
group
patient
beam
group
median
age
year
group
hodgkin
lymphoma
n
diagnos
non
hodgkin
lymphoma
n
predominantli
diffus
larg
b
cell
mantl
cell
lymphoma
vs
patient
cr
time
transplant
beeam
beam
group
respect
median
number
cd
cell
infus
x
cd
cell
kg
similar
group
median
time
absolut
neutrophil
count
engraft
day
beeam
vs
day
beam
median
time
platelet
engraft
day
beeam
versu
day
beam
day
transplant
mortal
patient
vs
patient
patient
vs
patient
gii
iii
acut
kidney
injuri
patient
vs
patient
grade
iiiii
hyperbilirubinemia
patient
vs
patient
gii
diarrhea
end
month
patient
vs
patient
complet
respons
median
diseas
free
surviv
month
vs
month
overal
surviv
month
vs
month
beeam
beam
cohort
respect
conclus
studi
show
bendamustin
potenti
toxic
agent
condit
regimen
compar
bcnu
autolog
sct
signific
liver
kidney
gi
toxic
addit
overal
surviv
diseas
free
surviv
inferior
beam
condit
regimen
prospect
trial
need
done
determin
efficaci
safeti
bendamustin
condit
regimen
asct
conflict
interest
none
author
anyth
disclos
favaloro
univers
hospit
sanatorio
anchorena
bmt
bueno
air
argentina
sanatorio
anchorena
bmt
bueno
air
argentina
favaloro
univers
hospit
bmt
bueno
air
argentina
cemic
bmt
bueno
air
argentina
fleme
institut
bmt
bueno
air
argentina
clinica
hospit
bueno
air
bmt
bueno
air
argentina
background
cbv
cyclophosphamid
carmustin
bcnu
etoposid
commonli
use
pretranspl
condit
lymphoma
autotranspl
howev
carmustin
associ
lung
toxic
high
cost
variabl
avail
method
develop
new
cbv
regimen
cbev
swap
bendamustin
carmustin
conduct
multicent
studi
evalu
safeti
efficaci
cbev
cyclophosphamid
bendamustin
etoposid
consecut
subject
receiv
autotranspl
lymphoma
median
age
year
rang
year
male
hodgkin
lymphoma
diffus
larg
bcell
lymphoma
dlbcl
mantl
cell
lymphoma
mcl
lymphoma
diagnos
subject
fail
treatment
line
pretranspl
transplant
complet
remiss
cr
cr
partial
remiss
pr
subject
receiv
median
x
cellskg
rang
median
followup
month
rang
month
result
evalu
subject
bone
marrow
recoveri
median
day
rang
day
neutrophil
x
day
rang
day
day
platelet
x
grade
toxic
fever
gastrointestin
heart
renal
pulmonari
n
contrast
lung
toxic
carmustin
toxic
cbev
revers
subject
die
renal
multiorgan
failur
subject
aliv
die
includ
lymphoma
progress
overal
surviv
year
confid
interv
ci
includ
ci
subject
transplant
cr
ci
transplant
pr
cumul
incid
relaps
year
ci
subject
transplant
cr
ci
transplant
pr
conclus
safeti
efficaci
profil
cbev
similar
cbv
cbev
advantag
lower
cost
consist
avail
preliminari
efficaci
result
encourag
longer
followup
need
assess
safeti
efficaci
regimen
random
trial
compar
cbev
cbv
would
need
definit
address
question
conflict
interest
none
author
anyth
disclos
bmt
unit
feder
univers
parana
curitiba
brazil
hospit
infantil
pequeno
princip
curitiba
brazil
hospit
nossa
senhora
da
curitiba
brazil
background
fanconi
anemia
fa
rare
inherit
disord
character
congenit
abnorm
progress
bone
marrow
failur
cancer
predisposit
surviv
hematopoiet
cell
transplant
hct
improv
dramat
past
decad
due
use
better
preparatori
regimen
support
care
method
retrospect
studi
analyz
data
clinic
present
outcom
patient
pt
fa
transplant
median
age
transplant
rang
male
cmv
posit
receiv
median
blood
transfus
rang
transplant
pt
transplant
marrow
failur
receiv
bone
marrow
match
sibl
msd
match
relat
donor
mrd
pt
receiv
preparatori
regimen
cyclophosphamid
without
rabbitatg
gvhd
prophylaxi
cyclosporin
methotrex
result
one
patient
die
evalu
engraft
primari
graft
failur
occur
one
patient
msd
group
patient
success
rescu
transplant
use
haploident
donor
posttransplant
cy
nineti
pt
engraft
secondari
graft
failur
occur
day
transplant
four
pt
aliv
well
full
donor
chimer
hct
mucos
grade
iiiii
occur
pt
acut
gvhd
occur
evalu
pt
grade
ii
grade
iii
grade
iv
chronic
gvhd
occur
evalu
pt
nih
global
sever
score
mild
moder
sever
seven
pt
die
median
day
transplant
rang
caus
death
includ
oral
squamou
cell
carcinoma
gvhd
central
nervou
system
bleed
sepsi
transplant
relat
mortal
one
year
low
eightyfour
pt
aliv
median
followup
ys
rang
month
year
overal
surviv
differ
surviv
accord
type
donor
msd
vs
mrd
univari
analysi
surviv
much
better
pt
without
acutegvhd
compar
pt
complic
vs
p
pt
receiv
transfus
transplant
aliv
well
none
develop
acutegvhd
mild
chronic
gvhd
conclus
studi
use
without
atg
associ
excel
surviv
good
engraft
low
mortal
rate
highli
success
lowcost
preparatori
regimen
use
world
treat
patient
fa
aplast
phase
conflict
interest
author
declar
conflict
interest
maria
sklodowskacuri
memori
cancer
center
institut
oncolog
gliwic
branch
depart
bone
marrow
transplant
oncohematolog
gliwic
poland
wroclaw
medic
univers
wroclaw
poland
maria
sklodowskacuri
cancer
centr
institut
oncolog
warsaw
poland
silesian
medic
univers
katowic
poland
medic
univers
gdansk
gdansk
poland
jagiellonian
univers
medic
colleg
cracow
poland
oncolog
center
brzozow
poland
institut
hematolog
blood
transfus
warsaw
poland
poznan
univers
medic
scienc
poznan
poland
maria
sklodowskacuri
memori
cancer
center
institut
oncolog
gliwic
branch
radiotherapi
depart
gliwic
poland
background
highdos
consolid
therapi
autolog
stem
cell
support
autosct
consid
benefici
transplantelig
patient
newli
diagnos
relaps
peripher
tcell
lymphoma
ptcl
evid
base
retrospect
analys
includ
heterogen
mainli
chemotherapybas
condit
regimen
achiev
complet
remiss
cr
autosct
one
strongest
predictor
outcom
data
regard
comparison
total
bodi
irradi
tbi
nontbi
base
approach
goal
studi
method
current
analysi
includ
patient
ptcl
autograft
cr
retrospect
analyz
outcom
patient
condit
gy
tbi
given
fraction
gy
consecut
day
combin
cyclophosphamid
patient
receiv
highdos
chemotherapi
regimen
beam
bcnu
etoposid
cytarabin
melphalan
cbv
bcnu
etoposid
cyclophosphamid
patient
receiv
tbibas
regimen
transplant
singl
institut
depart
bmt
gliwic
wherea
remain
autosct
perform
polish
lymphoma
research
group
regist
center
group
characterist
follow
tbi
nontbi
respect
median
age
transplant
year
ptcl
subtyp
ptcl
alcl
alk
alk
ptcl
alcl
alk
alk
alk
statu
stage
diagnosi
median
number
pretranspl
chemotherapi
line
year
transplant
median
observ
time
month
patient
nontbi
group
receiv
pretranspl
line
therapi
transplant
earlier
year
remain
factor
compar
studi
group
result
patient
tbi
group
engraft
wherea
one
patient
chemotherapi
group
engraft
earli
late
nonrelaps
mortal
case
note
tbi
group
chemotherapi
group
four
patient
die
due
nonrelaps
caus
neoplasm
failur
probabl
overal
surviv
year
year
autosct
significantli
higher
condit
tbibas
regimen
compar
chemotherapybas
approach
vs
respect
probabl
progressionfreesurviv
year
year
vs
vs
respect
conclus
tbi
seem
effect
part
condit
autosct
ptcl
allow
potenti
obtain
better
outcom
compar
highdos
chemotherapi
regimen
patient
transplant
cr
conflict
interest
author
declar
potenti
conflict
interest
seoul
nation
univers
hospit
seoul
nation
univers
colleg
medicin
pediatr
seoul
korea
republ
seoul
nation
univers
hospit
seoul
nation
univers
colleg
medicin
laboratori
medicin
seoul
korea
republ
seoul
nation
univers
hospit
seoul
nation
univers
colleg
medicin
pharmacolog
clinic
pharmacolog
seoul
korea
republ
background
use
haploident
donor
hematopoiet
stem
cell
transplant
shown
promisss
result
hematolog
malign
nonmalign
diseas
particularli
case
without
hlamatch
donor
unfortun
data
haploident
hematopoiet
stem
cell
transplant
haplohsct
posttransplant
cyclophosphamid
ptci
children
rare
conflict
wer
use
intens
daili
pharmacokinet
pk
monitor
method
busulfan
dose
optim
intens
condit
regimen
calcul
total
exposur
busulfan
appli
targetedbusulfan
method
use
daili
pk
monitor
haplohsct
use
ptci
pediatr
patient
safeti
outcom
evalu
method
retrospect
studi
patient
underw
haplohsct
malign
diseas
nonmalign
diseas
seoul
nation
univers
children
hospit
februari
april
condit
regimen
haplohsct
compos
busulfan
fludarabin
daili
via
iv
day
cyclophosphamid
mgkg
daili
via
iv
day
busulfan
patient
age
year
patient
age
year
administ
starter
dose
day
administ
daili
thereaft
subsequ
target
dose
busulfan
analyz
accord
daili
intens
therapeut
drug
monitor
result
day
ptci
mgkg
given
day
result
median
followup
period
month
rang
month
median
valu
total
infus
busulfan
auc
x
hl
rang
median
day
neutrophil
platelet
engraft
day
day
respect
cumul
incid
ci
rate
engraft
respect
ci
rate
grade
iiiv
grade
iiiiv
acut
extens
chronic
graft
versu
host
diseas
respect
overal
surviv
rate
eventfre
surviv
rate
treatmentrel
mortal
rate
time
median
followup
respect
base
subgroup
analysi
patient
malign
relaps
incid
rate
time
median
followup
conclus
haplohsct
use
ptci
along
target
busulfanbas
myeloabl
condit
regimen
peripher
blood
stem
cell
sourc
safe
promis
therapeut
option
children
hematolog
malign
nonmalign
diseas
conflict
interest
author
declar
compet
financi
interest
ankara
univers
school
medicin
depart
hematolog
stem
cell
transplant
unit
ankara
turkey
background
highdos
chemotherapi
follow
autolog
hematopoiet
cell
transplant
auto
hsct
may
provid
surviv
benefit
patient
nonhodgkin
lymphoma
nhl
retrospect
analys
suggest
benefit
hdt
extend
elderli
patient
nhl
import
find
consid
median
age
diagnosi
year
rang
nhl
unit
state
use
us
seer
data
aim
defin
efficaci
toxic
auto
hsct
patient
year
nhl
method
januari
august
data
patient
aggress
nhl
year
age
elig
auto
hsct
accord
geriatr
assess
ga
evalu
data
obtain
ankara
univers
faculti
medicin
depart
hematolog
bone
marrow
transplant
unit
diagnosi
follow
diffus
larg
b
cell
lymphoma
primari
refractori
relaps
diseas
mantl
cell
lymphoma
first
complet
remiss
follicular
lymphoma
anaplast
larg
cell
lymphoma
compar
toxic
profil
outcom
research
group
patient
age
year
control
group
patient
year
result
patient
stage
iii
iv
diagnosi
ten
elderli
patient
activ
diseas
time
auto
hsct
median
followup
month
rang
mo
prior
transplant
major
elderli
patient
receiv
beam
protocol
condit
treatment
bone
marrow
stem
cell
use
patient
none
patient
mobil
failur
median
peripher
level
fortyeight
percent
patient
experienc
grade
mucos
patient
microbiologydocu
infect
sixtytwo
percent
patient
diarrhea
median
durat
day
rang
day
renal
toxic
occur
patient
hepat
toxic
patient
median
time
neutrophil
recoveri
day
rang
day
platelet
recoveri
day
rang
day
overal
respons
obtain
patient
cr
time
data
collect
patient
patient
year
deceas
relaps
main
cours
death
probabl
progress
free
surviv
pf
estim
overal
surviv
os
elderli
patient
respect
conclus
base
singl
center
studi
autohsct
safe
efficaci
treatment
elderli
lymphoma
patient
emphas
need
research
order
determin
riskbenefit
threshold
hsct
base
age
coupl
comorbid
fragil
conflict
interest
none
author
anyth
disclos
oxford
univers
hospit
nh
foundat
trust
clinic
haematolog
oxford
unit
kingdom
nh
blood
transplant
oxford
unit
kingdom
universidad
de
paulo
depart
haematolog
sao
paulo
brazil
background
tbibas
myeloabl
condit
mac
wellestablish
treatment
haematolog
malign
howev
radiotherapi
caus
logist
problem
transplant
schedul
associ
signific
long
shortterm
toxic
nontbi
base
mac
protocol
avail
limit
outcom
data
report
use
fludarabinbusulfanthiotepaatg
regimen
origin
develop
umbil
cord
transplant
adult
unrel
donor
haematopoiet
stem
cell
transplant
hsct
method
perform
analysi
fourteen
consecut
patient
undergo
thiotepabas
allogen
hsct
two
institut
primari
diagnos
aml
n
md
extranod
nkt
cell
lymphoma
alcl
condit
eleven
patient
complet
remiss
one
primari
refractori
aml
one
aml
partial
remiss
one
md
recipi
age
rang
year
median
eight
male
patient
receiv
myeloabl
combin
thiotepa
mgkg
busulfan
mgkg
fludarabin
rabbit
atg
mgkg
adapt
sanz
et
al
thirteen
allograft
match
unrel
donor
mud
one
mismatch
relat
donor
ten
allograft
hla
allel
match
four
twelv
recipi
seroposit
ebv
prior
transplant
result
median
followup
live
patient
month
rang
neutrophil
engraft
occur
thirteen
patient
median
nineteen
day
two
patient
experienc
delay
engraft
day
patient
primari
refractori
aml
die
prior
engraft
overal
surviv
progressionfre
surviv
three
year
respect
transplantrel
mortal
day
one
year
five
patient
die
followup
three
sepsi
day
transplant
one
diseas
relaps
day
one
ebvrel
ptld
day
acut
gvhd
occur
six
patient
five
episod
grade
one
grade
iii
chronic
gvhd
report
two
patient
twelv
ebvposit
recipi
six
experienc
asymptomat
ebv
reactiv
least
whose
titr
reach
success
treat
rituximab
n
addit
three
patient
ebv
reactiv
posttranspl
lymphoprolif
disord
ptld
two
achiev
cr
radio
immunochemotherapi
wherea
one
diagnos
four
day
prior
death
fit
treatment
patient
underli
ebv
posit
nkt
cell
lymphoma
seven
recipi
seroposit
cmv
prior
transplant
five
experienc
cmv
reactiv
cmv
seroneg
recipi
receiv
cell
seroneg
donor
conclus
thiotepabas
mac
regimen
effect
altern
tbibas
condit
allogen
hsct
associ
success
engraft
low
rate
gvhd
describ
high
incid
ebv
reactiv
advis
care
monitor
ebv
titr
patient
treat
regimen
overal
outcom
suggest
promis
protocol
use
patient
requir
myeloabl
condit
conflict
interest
none
author
anyth
disclos
maria
sklodowskacuri
institut
cancer
center
gliwic
branch
depart
bone
marrow
transplant
oncohematolog
gliwic
poland
maria
sklodowskacuri
institut
cancer
center
gliwic
branch
radiotherapi
depart
gliwic
poland
background
although
acut
myeloid
leukemia
aml
frequent
indic
allogen
hematopoiet
cell
transplant
allohct
optim
condit
establish
far
among
regimen
base
total
bodi
irradi
tbi
combin
tbi
fludarabin
flu
prospect
compar
tbi
gy
cyclophosphamid
show
similar
efficaci
reduc
toxic
center
patient
comorbid
older
age
treat
tbi
younger
fit
patient
dose
tbi
combin
flu
escal
gy
letter
regimen
report
aim
stydi
evalu
toxic
efficaci
method
analysi
includ
patient
women
men
treat
tbi
treat
tbi
year
median
age
respect
diseas
stage
procedur
follow
patient
treat
hsct
either
hlamatch
sibl
unrel
donor
tbi
administ
daili
fraction
day
immunosuppress
therapi
consist
cyclosporin
methotrex
atg
peripher
blood
use
sourc
stem
cell
result
median
neutrophil
recoveri
time
anc
l
day
group
day
group
incid
grade
acut
gvhd
extens
chronic
gvhd
respect
rate
grade
nonhematolog
toxic
respect
grade
advers
event
report
probabl
os
year
group
group
pf
probabl
respect
rate
relaps
nonrelaps
mortal
pn
respect
conclus
combin
fludarabin
tbi
character
good
toler
enhanc
efficaci
unless
contraind
tbi
seem
prefer
dose
howev
efficaci
safeti
tbi
condit
regimen
fludarabin
requir
verif
prospect
clinic
trial
conflict
interest
noth
disclos
medicalpark
antalya
pediatr
bone
marrow
transplant
unit
antalya
turkey
medicalpark
pediatr
bone
marrow
transplant
unit
turkey
background
graftversushost
diseas
gvhd
remain
major
impedi
widespread
applic
allogen
blood
marrow
transplant
haploident
hematopoet
stem
cell
transplant
increas
steadili
due
immedi
avail
donor
better
result
studi
present
result
transplant
children
receiv
haploident
hsct
center
unmanipul
bone
marrow
peripher
blood
stem
cell
gvhd
prophylaxi
posttranspl
cyclophosphamid
method
patient
receiv
busulfanbas
myeloabl
condit
regimen
weight
adjust
dose
gcsfprime
unmanipul
bm
addit
nextday
collect
pbsc
common
stem
cell
sourc
posttranspl
cy
mgkg
iv
given
day
three
five
posthsct
case
transplant
perform
day
howev
cy
given
fourth
fifth
day
stem
cell
infus
perform
day
csa
tacrolimu
mmf
mp
also
use
gvhd
prophylaxi
result
major
patient
transplant
malign
median
age
eight
yr
rang
yr
seventi
patient
engraft
evalu
subject
achiev
full
donor
chimer
one
patient
experienc
grade
iv
gvhd
grade
iiiii
acut
gvhd
develop
thirtyfour
patient
chronic
gvhd
found
fourteen
patient
fourteen
patient
die
within
first
day
mostli
due
infect
trm
forti
patient
current
aliv
median
followup
month
rang
month
os
df
ci
ci
respect
conclus
result
highrisk
patient
encourag
haploident
hsct
pediatr
patient
given
grow
data
similar
outcom
hlamatch
haploident
hsct
studi
requir
determin
whether
other
factor
may
import
donor
select
hlamatch
pediatr
popul
conflict
interest
noth
disclos
abstract
previous
publish
freeman
hospit
haematolog
newcastl
upon
tyne
unit
kingdom
background
impact
cellular
composit
transplant
outcom
remain
controversi
other
assess
role
cell
dose
outcom
mix
popul
myeloabl
reduc
intens
tcell
deplet
nondeplet
transplant
studi
assess
impact
dose
welldefin
cohort
mdsaml
patient
commonest
transplant
indic
patient
transplant
use
alemtuzumabbas
reduc
intens
condit
ric
protocol
knowledg
first
time
exclus
alemtuzumab
tcell
deplet
transplant
popul
outcom
relat
cellular
composit
evalu
method
outcom
pertain
consecut
mdsaml
patient
transplant
alemtuzumabbas
ric
protocol
period
singl
centr
retrospect
analys
includ
demograph
cell
dose
engraft
chimer
donor
lymphocyt
infus
dli
graftversushost
diseas
result
may
may
patient
underw
ric
hsct
mdsaml
twentytwo
male
averag
age
transplant
year
condit
consist
fludarabin
melphalan
patient
remaind
receiv
busulfan
instead
latter
patient
receiv
tcell
deplet
alemtuzumab
sibl
sib
transplant
match
unrel
donor
mud
transplant
mismatch
unrel
donor
transplant
receiv
ciclosporin
gvhd
prophylaxi
thirtytwo
patient
receiv
mud
receiv
sibl
donor
cell
averag
infus
cell
dose
cell
respect
averag
time
engraft
day
twentytwo
patient
receiv
dli
averag
cell
dose
rang
patient
receiv
averag
fraction
either
prophylact
therapeut
fourteen
patient
develop
acut
gvhd
grade
iiiv
chronic
gvhd
includ
progress
de
novo
acut
group
incid
grade
ii
iii
respect
patient
develop
grade
iv
chronic
group
incid
nih
sever
grade
mild
moder
sever
respect
overal
mortal
relaps
mortal
nonrelaps
mortal
signific
associ
cell
dose
outcom
includ
engraft
number
dli
infus
surviv
develop
acut
chronic
gvhd
trend
toward
higher
gvhd
rate
mud
compar
sib
acut
gvhd
chronic
gvhd
conclus
uniformli
treat
mdsaml
cohort
demonstr
impact
cell
dose
transplant
outcom
first
time
exclus
ric
alemtuzumabbas
transplant
group
conflict
interest
none
author
anyth
disclos
hospit
universitario
de
valdecilla
santand
hematolog
santand
spain
banco
de
sangr
tejido
de
cantrabria
liencr
spain
background
current
evid
reduc
intens
condit
ric
regimen
abomismatch
allogen
transplant
limit
hypothes
kind
condit
provok
longer
surviv
plasma
cell
thu
produc
isohemagglutinin
donor
erythrocyt
may
caus
delay
erythrocyt
recoveri
higher
transfus
need
pure
red
cell
aplasia
prca
although
studi
support
associ
still
controversi
surround
carri
studi
therefor
describ
experi
major
abomismatch
bone
marrow
bm
allogen
transplant
set
myeloabl
ric
condit
method
retrospect
studi
major
bidirect
aboincompat
allogen
bm
transplant
perform
center
analyz
neutrophil
platelet
engraft
red
blood
cell
rbc
recoveri
rbc
unit
transfus
day
platelet
unit
transfus
day
prca
data
analyz
ibm
spss
version
descript
static
report
median
rang
shapiro
wilk
test
use
test
normal
mean
comparison
perform
mann
whitney
u
test
result
total
transplant
includ
ric
latter
mostli
fludarabinemelphalan
condit
remain
busulphanfludarabin
scheme
base
cyclophosphamid
diagnos
mainli
amlmd
nhl
hla
ident
unrel
n
haploident
n
averag
mlkg
recipi
bodi
weight
abomismatch
erythrocyt
infus
without
differ
group
median
rbc
recoveri
day
ric
ns
identifi
case
apsr
group
recipi
group
donor
contrari
expect
mainli
myeloabl
group
median
reach
neutrophil
platelet
engraft
day
respect
platelet
unit
transfus
day
rbc
unit
transfus
day
nt
differ
group
conclus
seri
observ
tendenc
delay
rbc
recoveri
ric
group
although
statist
signific
nt
found
differ
term
transfus
requir
prca
unlik
previou
report
could
due
fact
reduc
intens
condit
group
predomin
regimen
base
alkyl
agent
may
present
higher
activ
host
plasma
cell
agent
cyclophosphamid
previous
hypothes
conclus
studi
homogen
group
patient
requir
identifi
ric
condit
like
caus
immunohematolog
complic
abo
incompat
transplant
refer
hefazi
et
al
transfus
feb
kanda
et
al
br
j
heamatol
conflict
interest
none
author
disclos
conflict
interest
cansearch
research
laboratori
univers
geneva
faculti
medicin
geneva
switzerland
univers
hospit
genevaunivers
geneva
depart
pediatr
genev
switzerland
certara
strateg
consult
montreal
canada
centr
hospitali
universitair
saintejustin
de
montreal
canada
univers
hospit
genevaunivers
geneva
pediatr
genev
switzerland
hospit
de
de
porto
alegr
porto
alegr
brazil
background
busulfan
bu
alkyl
agent
use
hematopoiet
stem
cell
transplant
hsct
children
associ
high
pharmacokinet
pk
variabl
spite
use
intraven
iv
formul
popul
pk
poppk
model
use
anthropometr
data
weight
andor
age
need
bu
dose
children
adolesc
genet
function
variant
gene
code
main
metabol
enzym
bu
consist
associ
bu
pk
recent
success
introduc
adult
poppk
model
henc
investig
aim
develop
paediatr
poppk
model
iv
bu
investig
effect
genotyp
pk
paramet
method
bu
concentrationtim
data
collect
patient
year
age
median
year
receiv
iv
bu
condit
regimen
prior
hsct
singl
center
administr
schedul
includ
weight
sex
baselin
diseas
malign
vs
nonmalign
age
condit
regimen
alkyl
agent
vs
other
haplotyp
group
diplotyp
evalu
covari
pk
paramet
use
nonlinear
mix
effect
analysi
abil
achiev
target
equival
infus
first
dose
assess
estim
first
dose
base
present
poppk
model
result
compar
avail
model
children
includ
current
dose
recommend
regulatori
agenc
result
total
transplant
includ
raw
bu
concentr
six
eighttimepoint
pk
profil
avail
analysi
first
dose
fourth
day
drug
administr
onecompart
model
firstord
elimin
best
describ
data
allometr
scale
weight
agebas
factor
bu
metabol
matur
fmat
includ
base
model
diplotyp
found
signific
covari
bu
clearanc
cl
explain
betweensubject
variabl
bu
cl
faster
slower
rapid
poor
metabol
respect
comparison
normal
metabol
bu
dose
calcul
use
paramet
propos
poppk
model
estim
achiev
target
auc
case
current
avail
perform
model
dose
calcul
accord
current
recommend
european
ema
american
fda
respect
conclus
present
studi
provid
first
poppk
model
iv
bu
children
adolesc
incorpor
genet
background
genet
variant
explain
variabl
pk
paramet
present
model
adapt
treatment
individu
metabol
potenti
intend
minim
fluctuat
drug
exposur
may
decreas
occurr
treatmentrel
toxic
suscept
individu
prospect
studi
requir
valid
current
find
conflict
interest
author
declar
conflict
interest
univers
hospit
frankfurt
goeth
univers
frankfurt
germani
background
acut
myeloid
leukemia
aml
outcom
allogen
hematopoiet
stem
cell
transplant
hsct
patient
activ
minim
residu
diseas
mrd
transplant
remain
poor
may
improv
provid
highli
effici
antileukem
drug
shortli
reduc
intens
condit
regimen
method
retrospect
analyz
impact
melphalan
follow
fludarabin
total
bodi
irradi
tbi
gy
flumeltbi
compar
fludarabin
cytarabin
amsacrin
addit
fludarabin
intraven
busulfan
flamsar
outcom
consecut
transplant
aml
patient
mrd
flumeltbi
activ
diseas
flumeltbi
flamsar
diseas
statu
prior
transplant
primari
refractori
relaps
aml
mrd
determin
quantit
polymeras
chain
reaction
qpcr
use
mutat
activ
diseas
defin
bone
marrow
bm
blast
extramedullari
diseas
patient
receiv
cellreplet
hlamatch
donor
graft
mostli
peripher
blood
stem
cell
graftversushostdiseas
gvhd
prophylaxi
consist
cyclosporin
mycophenol
mofetil
addit
antithymocyt
globulin
appli
unrel
donor
set
result
flumeltbi
group
patient
significantli
younger
vs
year
significantli
lower
median
hematopoiet
cell
transplantationcomorbid
index
vs
patient
flumeltbi
group
like
adverserisk
karyotyp
vs
wherea
patient
flamsar
group
present
secondari
aml
vs
median
bm
blast
count
vs
time
diagnosisrelaps
transplant
vs
month
differ
group
six
patient
graft
match
relat
donor
patient
match
unrel
donor
mud
patient
mud
patient
engraft
median
followup
month
rang
overal
surviv
os
significantli
superior
flumeltbi
vs
flamsar
group
vs
figur
relapsefre
surviv
vs
relaps
flumeltbi
occur
patient
highrisk
genet
complex
aberr
karyotyp
loss
mutat
patient
extramedullari
diseas
relaps
seen
patient
mrd
posit
diseas
transplant
nonrelaps
mortal
year
group
cumul
incid
acut
gvhd
grade
day
chronic
sever
gvhd
year
differ
group
vs
vs
conclus
data
suggest
addit
tbi
flumel
well
toler
associ
favor
os
patient
activ
mrd
posit
aml
face
similarli
high
risk
relaps
thu
intensifi
condit
regimen
flumeltbi
may
also
consid
mrd
posit
aml
conflict
interest
f
lang
receiv
support
frankfurt
nachwuchswissenschaftl
euto
fund
program
advisori
role
novarti
ariad
sanofi
aventi
bristolmy
squibb
receiv
fund
novarti
berg
receiv
fund
alexion
abbvi
astella
celgen
advisori
role
riemser
g
bug
receiv
honoraria
eurocept
fund
alfr
und
angelika
gutermuthstiftung
verein
knochenmarktransplantationgentherapi
frankfurt
kgf
author
noth
disclos
univers
bristol
haemoncbmt
bristol
unit
kingdom
univers
bristol
bristol
unit
kingdom
background
children
age
weight
base
busulfan
bu
dose
use
drug
monitor
achiev
therapeut
area
curv
auc
achiev
specif
target
import
success
allogen
hsct
also
reduc
hepat
toxic
object
studi
look
accuraci
achiev
target
auc
standard
weight
base
intraven
iv
bu
dose
accuraci
achiev
target
auc
dose
adjust
toxic
particular
venoocclus
diseas
vod
relat
bu
auc
method
weight
base
dose
busulfan
use
follow
kg
bu
administ
everi
hour
hour
infus
maximum
dose
auc
level
measur
first
dose
bu
dose
adjust
necessari
dose
adjust
made
repeat
level
dose
measur
patient
maximum
allow
increment
first
dose
differ
auc
target
rang
myeloabl
condit
mac
reduc
intens
condit
ric
children
haemophagocyt
lymphohistiocytosi
hlh
studi
design
retrospect
analysi
result
octob
novemb
identifi
children
median
age
yr
rang
yr
yr
receiv
bubas
condit
allogen
hsct
fourteen
patient
achiev
target
auc
without
requir
dose
modif
children
vod
dose
modif
done
remain
children
children
need
dose
modif
requir
dose
increment
receiv
mac
repeat
auc
confirm
achiev
final
auc
nine
achiev
target
auc
base
repeat
level
dose
four
patient
develop
vod
requir
treatment
defibrotid
patient
die
vod
remain
patient
nt
achiev
target
spite
maximum
dose
increment
none
develop
vod
patient
engraft
except
one
child
earli
death
due
sever
progress
vod
conclus
patient
achiev
target
auc
base
standard
weight
dose
requir
dose
increas
achiev
auc
target
dose
high
incid
vod
differ
model
bu
dose
adjust
also
includ
genet
factor
glutathion
stransferas
gst
gene
variat
may
requir
accur
bu
dose
without
increas
toxic
conflict
interest
noth
declar
nation
univers
cancer
institut
depart
haematologyoncolog
singapor
singapor
nation
univers
hospit
depart
medicin
singapor
singapor
singapor
gener
hospit
depart
haematolog
singapor
singapor
nation
univers
singapor
saw
swee
hock
school
public
health
singapor
singapor
background
nonmyeloabl
nm
hematopoiet
cell
transplant
hct
extend
potenti
cur
treatment
option
allograft
patient
previous
contraind
due
advanc
age
comorbid
method
patient
age
year
median
age
year
haematolog
malign
poor
candid
convent
hct
receiv
nm
condit
fludarabin
total
bodi
irradi
tbi
follow
filgrastimmobil
peripher
blood
stem
cell
transplant
hla
ident
match
unrel
mismatch
sibl
donor
calcineurin
inhibitor
mycophenol
mofetil
withwithout
methotrex
use
postgraft
immunosuppress
diagnos
includ
acut
leukemia
myelodysplast
syndrom
myelofibrosi
lymphoma
cml
myeloma
result
median
follow
year
rang
year
surviv
patient
overal
surviv
os
base
diseas
risk
index
dri
os
patient
low
risk
intermedi
risk
highveri
high
risk
group
respect
day
cumul
incid
acut
graft
versu
host
diseas
gvhd
grade
grade
respect
day
cumul
incid
chronic
gvhd
year
non
relaps
mortal
nrm
rate
relaps
mortal
rate
rrm
nrm
due
gvhd
patient
high
high
risk
dri
highest
risk
rrm
hr
ci
multivari
analysi
improv
os
seen
patient
low
risk
group
accord
dri
hr
ci
conclus
allogen
nm
condit
use
fludarabin
low
dose
tbi
reli
almost
exclus
graftvstumour
effect
result
long
term
remiss
still
limit
high
incid
relaps
especi
highrisk
diseas
novel
approach
explor
reduc
earli
diseas
progress
hct
without
increas
regimenrel
toxic
conflict
interest
ying
tang
noth
disclos
citi
hope
nation
medic
center
hematologyhct
duart
ca
unit
state
citi
hope
nation
medic
center
radiat
oncolog
duart
ca
unit
state
citi
hope
nation
medic
center
biostatist
popul
scienc
duart
ca
unit
state
background
fraction
total
bodi
irradi
ftbi
combin
cyclophosphamideetoposid
intraven
iv
busulfan
combin
fludarabin
cyclophosphamid
current
use
myeloabl
condit
regimen
allogen
hematopoiet
cell
transplant
allohct
patient
acut
myeloid
leukemia
aml
recent
data
suggest
iv
busulfan
may
prefer
myeloabl
regimen
patient
myeloid
malign
given
improv
overal
surviv
ci
howev
iv
busulfan
base
regimen
associ
higher
rate
sinusoid
obstruct
syndrom
report
longterm
surviv
outcom
aml
patient
undergo
allohct
receiv
ftbi
combin
cyclophosphamid
etoposid
citi
hope
medic
center
method
analyz
clinic
outcom
consecut
aml
patient
underw
allohct
center
enter
prospect
maintain
institut
registri
patient
receiv
myeloabl
condit
use
ftbi
cyclophosphamid
cy
mgkg
unrel
donor
mud
transplant
etoposid
vp
mgkg
relat
donor
transplant
patient
receiv
tacrolimu
sirolimu
graftversushost
diseas
gvhd
prophylaxi
result
patient
clinic
characterist
summar
tabl
year
overal
surviv
os
diseasefre
surviv
df
whole
cohort
ci
ci
respect
figur
six
year
nrm
relaps
rate
respect
incid
acut
gvhd
grade
iiiiv
day
extens
chronic
gvhd
incid
year
patient
divid
two
cohort
base
transplant
era
vs
show
differ
outcom
two
group
os
ci
vs
ci
df
ci
vs
ci
respect
statist
signific
differ
observ
outcom
patient
undergo
hct
year
os
p
year
df
respect
statist
signific
differ
outcom
detect
patient
receiv
graft
unrel
mud
sibl
donor
os
ci
vs
ci
df
ci
vs
ci
respect
incid
chronic
gvhd
reach
statist
signific
mud
ci
sibl
donor
ci
conclus
data
suggest
use
ftbibas
condit
aml
patient
result
excel
longterm
os
df
compar
favor
iv
busulfanbas
myeloabl
regimen
remain
clinic
import
myeloabl
condit
regimen
major
event
occur
first
year
post
allohct
therebi
result
achiev
os
plateau
indic
potenti
cure
major
patient
relaps
remain
major
caus
treatment
failur
seen
patient
refin
radiat
techniqu
use
target
dose
deliveri
method
may
improv
outcom
allow
radiat
doseescal
high
risk
aml
patient
clinic
trial
registri
refer
bredeson
c
lerademach
j
kato
k
et
al
prospect
cohort
studi
compar
intraven
busulfan
total
bodi
irradi
hematopoiet
cell
transplant
blood
copelan
ea
hamilton
bk
avalo
b
et
al
better
leukemiafre
overal
surviv
aml
first
remiss
follow
cyclophosphamid
combin
busulfan
compar
tbi
blood
rosenth
j
wong
j
stein
et
al
phase
trial
total
marrow
lymph
node
irradi
augment
reducedintens
transplant
advanc
hematolog
malign
blood
stein
palmer
j
tsai
nc
et
al
phase
trial
total
marrow
lymphoid
irradi
transplant
condit
patient
relapsedrefractori
acut
leukemia
biol
blood
marrow
transplant
conflict
interest
none
tabl
tabl
keio
univers
school
medicin
divis
hematolog
tokyo
japan
background
although
option
treatment
follicular
lymphoma
increas
allogen
hematopoiet
stem
cell
transplant
allohsct
consid
cur
treatment
analyz
longterm
outcom
patient
relapsedrefractori
follicular
lymphoma
underw
allohsct
use
reducedintens
condit
method
singleinstitut
studi
use
databas
medic
record
patient
underw
allohsct
relaps
refractori
follicular
lymphoma
use
fludarabin
plu
melphalanbas
reducedintens
condit
keio
univers
hospit
tokyo
japan
select
analyz
twentyf
patient
analyz
median
age
transplant
year
rang
condit
regimen
consist
fludarabin
melphalan
type
donor
graft
bone
marrow
peripher
blood
stem
cell
hlaident
sibl
bone
marrow
unrel
donor
cord
blood
unrel
donor
statist
analys
perform
ezr
softwar
result
case
earli
death
engraft
patient
achiev
neutrophil
engraft
median
day
rang
transplant
median
followup
period
month
rang
overal
surviv
progressionfre
surviv
rate
ci
ci
respect
three
case
trm
whose
caus
gvhd
patient
month
posttranspl
bacteri
infect
month
posttranspl
twoyear
cumul
incid
trm
ci
diseas
progressionrelaps
observ
three
patient
month
transplant
howev
patient
reachiev
complet
respons
sole
discontinu
immunosuppress
aliv
without
diseas
month
transplant
conclus
find
suggest
allohsct
use
reducedintens
condit
relaps
refractori
follicular
lymphoma
could
provid
favor
longterm
surviv
rate
low
incid
trm
diseas
progress
addit
allohsct
potenti
induc
clinic
signific
graftversuslymphoma
effect
lead
durabl
diseasefre
surviv
even
patient
diseas
progress
transplant
conflict
interest
none
author
anyth
disclos
royal
marsden
hospit
radiotherapi
london
unit
kingdom
royal
marsden
hospit
haematolog
london
unit
kingdom
royal
marsden
hospit
raidolog
london
unit
kingdom
institut
cancer
research
royal
marsden
hospit
physic
london
unit
kingdom
background
total
bodi
irradi
tbi
integr
compon
varieti
myeloabl
condit
regimen
prior
allogen
haematopoet
stem
cell
transplant
hsct
tbi
associ
signific
potenti
life
threaten
toxic
post
transplant
report
rate
radiat
induc
interstiti
pneumon
ip
post
tbi
associ
mortal
rate
nearli
chronic
kidney
diseas
report
approxim
long
term
survivor
undertook
retrospect
servic
evalu
patient
follow
introduct
forward
plan
organ
spare
intens
modul
radiotherapi
techniqu
fp
imrt
assess
incid
ip
ckd
post
full
intens
hsct
method
retrospect
analys
adult
patient
receiv
tbi
juli
februari
indic
hsct
alllbl
amlmd
cmlbc
nhl
patient
condit
cyclophosphamidetbi
etoposidetbi
fludarabinecyclophosphamidetbi
receiv
stem
cell
match
sibl
donor
match
unrel
donor
mismatch
unrel
donor
c
mismatch
mismatch
cord
donor
patient
receiv
cell
deplet
alemtuzumab
gvhd
prophylaxi
ciclosporin
ciclosporinmethotrex
tbi
dose
fraction
day
prescrib
lung
kidney
receiv
reduc
mean
dose
maxim
ip
defin
multilobar
infiltr
ct
symptom
dyspnoea
renal
dysfunct
defin
egfr
month
result
median
age
transplant
year
rang
yr
estim
year
overal
surviv
progress
free
surviv
rate
ci
ci
respect
median
follow
time
survivor
year
rang
yr
cumul
incid
ci
relaps
year
ci
ci
grade
iiiiv
agvhd
ci
chronic
gvhd
ci
non
relaps
mortal
day
ci
year
ci
rate
ip
due
caus
patient
posit
proven
evid
bacteri
viral
infect
time
seven
patient
die
chest
sepsi
median
day
tbi
rang
day
rate
idiopath
ip
ctcae
grade
patient
suffer
ip
ctcae
grade
ip
develop
median
day
rang
day
post
tbi
long
term
survivor
two
develop
ckd
one
biopsi
confirm
thrombot
microangiopathi
patient
die
ckd
conclus
novel
fp
imrt
base
tbi
techniqu
reduc
lung
kidney
dose
result
significantli
lower
rate
radiationinduc
ip
ckd
compar
publish
literatur
idiopath
ip
ctcae
grade
observ
patient
risk
long
term
renal
dysfunct
low
secondari
thrombot
microangiopathi
associ
either
gvhd
tbi
relat
seri
confirm
fp
imrtbas
tbi
safer
condit
myeloabl
hsct
publish
radiat
techniqu
clinic
trial
registri
na
conflict
interest
na
royal
manchest
children
hospit
depart
bone
marrow
transplant
manchest
unit
kingdom
faculti
medicin
benha
univers
depart
paediatr
benha
egypt
background
diamond
blackfan
anaemia
dba
rare
constitut
red
cell
aplasia
mani
patient
requir
regular
red
cell
transfus
natur
histori
includ
bone
marrow
failur
bmf
myeloid
malign
bmf
iron
overload
constitut
indic
bone
marrow
transplant
bmt
regimenrel
toxic
increas
patient
signific
iron
overload
haemoglobinopathi
reduct
intens
condit
associ
increas
risk
graft
failur
fear
transplantrel
toxic
dba
larg
restrict
transplant
sibl
donor
retrospect
survey
report
success
transplant
heavili
ironload
dba
patient
includ
unrel
donor
follow
fludarabinetreosulfanthiotepa
alemtuzumab
condit
therapi
achiev
twin
goal
high
engraft
low
procedurerel
morbid
method
five
dba
patient
one
boy
four
girl
receiv
allogen
bmt
royal
manchest
hospit
standard
pretranspl
investig
carri
includ
ferriscan
liver
biopsi
fludarabin
treosulfan
thiotepa
alemtuzumab
famili
donor
unrel
donor
condit
regimen
given
three
patient
ident
relat
donor
two
match
unrel
donor
donor
hla
allelematch
graft
versu
host
gvh
direct
least
bonemarrow
harvest
stem
cell
collect
transplant
done
accord
standard
protocol
outcom
complic
follow
transplant
record
result
median
age
transplant
six
year
one
month
old
rang
three
year
seven
month
old
seven
year
six
month
old
ferriscan
show
sever
hepat
iron
overload
patient
median
mggramdri
weight
rang
mggdw
liver
biopsi
show
fibrosi
iron
overload
fibrosi
ishak
stage
record
prophylact
defibrotid
given
hepat
fibrosi
patient
engraft
success
transplant
median
day
rang
day
remain
donorcel
engraft
red
cell
transfus
independ
donor
chimer
establish
sustain
patient
surviv
median
follow
one
year
two
month
rang
six
month
one
year
ten
month
venoocclus
diseas
acut
graft
versu
host
diseas
gvhd
grade
chronic
gvhd
conclus
condit
regimen
found
safe
effect
patient
sever
iron
overload
includ
unrel
donor
hsct
commend
protocol
red
cell
disord
sever
transfusionrel
ironoverload
find
liver
biopsi
result
influenc
outcom
abandon
conflict
interest
author
noth
disclos
abstract
previous
publish
univers
milanobicocca
dept
hematolog
bone
marrow
transplant
monza
itali
background
treatment
choic
relapsedrefractori
lymphoma
consist
high
dose
chemotherapi
hdc
follow
autolog
stem
cell
transplant
asct
institut
classic
beam
condit
regimen
modifi
use
lomustin
ccnu
place
carmustin
bcnu
method
lymphoma
nonhodgkin
lymphoma
hodgkin
lymphoma
patient
pt
treat
ceam
regimen
follow
asct
ceam
regimen
consist
ccnu
day
etoposid
total
dose
day
cytarabin
total
dose
day
melphalan
day
peripher
blood
stem
cell
pbsc
infus
day
result
median
durat
hospit
day
rang
pt
die
hospit
median
number
cell
infus
rang
median
time
hematopoiet
engraft
neutrophil
one
occur
day
rang
fever
unknown
origin
neutropenia
occur
patient
wherea
etiolog
defin
pt
bacteri
pneumonia
gastrointestin
mucos
observ
pt
whose
grade
iii
grade
iii
pt
grade
iv
median
followup
year
yr
rang
median
overal
surviv
os
reach
yr
besid
median
eventfre
surviv
ef
reach
yr
figur
transplantrel
mortal
final
pt
die
due
diseas
progress
conclus
seri
found
ceam
schedul
well
toler
without
signific
regimenrel
complic
pt
sensit
diseas
pt
die
trm
compar
wide
use
beam
regimen
result
ceam
seem
neither
add
signific
toxic
inferior
term
clinic
outcom
therefor
conclud
lomustin
valid
altern
carmustin
condit
regimen
asct
lymphoma
pt
without
lose
clinic
effect
anyway
strategi
investig
pt
refractori
lymphoma
conflict
interest
c
gambacortipasserini
consult
honoraria
research
fund
pfizer
consult
bm
author
noth
declar
king
hussein
cancer
center
adult
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
adult
medic
oncolog
hematolog
amman
jordan
king
hussein
cancer
center
adult
medic
oncolog
amman
jordan
king
hussein
cancer
center
depart
cell
therapi
appli
genom
amman
jordan
king
hussein
cancer
center
clinic
pharmaci
depart
bone
marrow
transplant
amman
jordan
king
hussein
cancer
center
pediatr
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
bone
marrow
transplnat
amman
jordan
king
hussain
cancer
center
pediatr
oncolog
hematolog
bone
marrow
transplnat
program
amman
jordan
king
hussein
cancer
center
amman
jordan
king
hussein
cancer
center
pediatr
medic
oncolog
hematolog
depart
bone
marrow
transplant
amman
jordan
king
hussain
cancer
center
adult
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
depart
cell
therapi
appliedallel
genom
amman
jordan
king
hussein
cancer
center
bone
marrow
transplant
amman
jordan
background
allogen
hematopoiet
cell
transplant
hct
effect
potenti
cur
treatment
advanc
highrisk
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
use
differ
intens
condit
regimen
optim
regimen
intens
hct
unknownmyeloabl
condit
mac
associ
reduc
risk
relaps
translat
improv
surviv
due
increas
transplantrel
mortal
trm
reducedintens
condit
ric
allow
extens
hct
much
wider
patient
popul
reduc
toxic
without
compromis
hct
efficaci
retrospect
studi
compar
result
myeloabl
reduc
intens
condit
patient
aml
high
risk
md
king
hussein
cancer
center
method
perform
singl
center
retrospect
analysi
adult
patient
high
risk
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
underw
hct
king
hussein
cancer
center
till
compar
outcom
patient
underw
mac
versu
ric
regard
overal
progress
free
surviv
cumul
incid
relaps
trm
use
kaplanmei
method
fortyfour
case
receiv
mac
receiv
ric
fortysix
patient
hct
mac
given
patient
ric
given
patient
patient
result
median
age
time
hct
year
rang
patient
receiv
pbsc
graft
sourc
median
follow
month
probabl
progress
free
surviv
pf
overal
surviv
os
whole
group
pf
os
year
receiv
hct
mac
ric
respect
patient
receiv
mac
experienc
acut
gvhd
compar
receiv
ric
versu
trm
differ
versu
p
relaps
incid
year
patient
mac
statist
differ
ric
patient
conclus
statist
signific
differ
overal
progress
free
surviv
patient
receiv
mac
vs
ric
ric
result
higher
relaps
rate
compar
mac
lower
transplantrel
mortal
statist
signific
data
support
use
mac
standard
care
fit
patient
aml
high
risk
md
conflict
interest
conflict
interest
medicana
ankara
intern
hospit
hemaolog
bone
marrow
transplant
unit
ankara
turkey
ankara
univers
faculti
medicin
hematolog
ankara
turkey
background
allogen
hematopoiet
stem
cell
tran
plantat
potenti
cur
strategi
mani
hematolog
malign
greft
versu
host
diseas
gvhd
remain
one
major
caus
morbid
mortal
antithymocyt
globulin
atg
reduc
incid
gvhd
match
unrel
mismatch
unrel
haploidenticaldonor
transplantationth
optim
dose
atg
current
unclear
aim
studi
evalu
differ
atg
dose
outcom
patient
hematolog
malign
hct
method
allogen
hematopoiet
stem
cell
tran
plantat
potenti
cur
strategi
mani
hematolog
malign
greft
versu
host
diseas
gvhd
remain
one
major
caus
morbid
mortal
antithymocyt
globulin
atg
reduc
incid
gvhd
match
unrel
mismatch
unrel
haploidenticaldonor
transplantationth
optim
dose
atg
current
unclear
aim
studi
evalu
differ
atg
dose
outcom
patient
hematolog
malign
hct
result
neutrophil
thrombocyt
engraft
period
day
atlg
group
vs
day
day
group
respect
acut
gvhd
grade
iiiv
seen
n
group
vs
group
chronic
gvhd
grade
iiiv
group
groupcontroversli
classic
knowledg
cmv
reactiv
common
group
vs
hospit
day
group
day
group
relap
rate
group
vs
group
overal
group
patient
atlg
group
n
patient
aliv
df
day
median
group
vs
day
atlg
group
os
day
median
group
day
atlg
conclus
atg
part
allogen
condit
regimen
associ
lower
acut
chronic
gvhd
incid
increas
viral
infect
especi
cmv
higher
relap
rate
atg
toxic
dose
depend
compar
atlg
mgkg
mgkg
dose
group
df
os
lower
group
paramet
statist
differ
safe
given
mismatch
mathc
unrel
allogen
transplant
conflict
interest
noth
disclos
weill
cornel
medic
centernew
york
presbyterian
hospit
depart
medicin
divis
hematologyoncolog
new
york
ny
unit
state
weill
cornel
medic
centernew
york
presbyterian
hospit
depart
patholog
new
york
ny
unit
state
background
reduc
intens
condit
regimen
improv
hla
match
better
support
care
allow
allogen
stem
cell
transplant
allosct
offer
elderli
patient
popul
cibmtr
data
show
small
percentag
elig
aml
patient
year
actual
underw
allogen
comprehens
allosct
outcom
data
age
popul
still
larg
lack
studi
examin
practic
outcom
older
patient
underw
allogen
stem
cell
transplant
hematolog
malign
weill
cornel
medic
center
method
patient
year
old
underw
allosct
jan
nov
hematolog
malign
hlaident
relat
unrel
donor
combin
haplocord
donor
includ
probabl
overal
surviv
os
progressionfre
surviv
pf
calcul
use
kaplanmei
estim
probabl
nonrelaps
relat
mortal
nrm
relaps
relat
mortal
acut
chronic
gvhd
calcul
use
r
statist
use
cumul
incid
estim
accommod
compet
risk
result
identifi
patient
older
year
underw
allogen
stem
cell
transplant
hematolog
malign
median
age
cohort
year
rang
thirti
underw
mrd
sct
mud
sct
combin
halpoidenticalumbil
cord
allosct
two
patient
age
underw
doubl
cord
allosct
aml
common
indic
transplant
follow
mdsmpn
nhl
fortyseven
low
intermedi
high
asbmt
diseas
risk
index
prior
transplant
one
hundr
eight
patient
receiv
fludarabinemelphalanbas
condit
regimen
either
atg
alemtuzumab
twelv
patient
receiv
fludarabinebusulfanbas
patient
beam
regimen
median
time
neutrophil
engraft
day
platelet
engraft
day
cumul
incid
nrm
day
year
respect
cumul
incid
relaps
year
cumul
incid
grade
iiiv
agvhd
month
cgvhd
month
respect
median
follow
survivor
month
year
pf
ci
ci
one
year
os
ci
ci
respect
figur
either
age
vs
asbmt
risk
score
donor
type
mud
vs
mrd
vs
haplocord
predict
outcom
patient
cohort
conclus
signific
proport
elderli
patient
highrisk
diseas
risk
index
older
patient
benefit
ric
allosct
hla
match
altern
donor
sourc
without
discern
impact
donor
sourc
outcom
better
predictor
outcom
patient
popul
need
identifi
use
alemtuzumab
base
vivo
cell
deplet
mrd
mud
haplocord
transplant
incid
chronic
gvhd
extrem
low
contribut
qualiti
life
among
survivor
conflict
interest
none
souraski
tel
aviv
medic
center
depart
pediatr
hematooncolog
tel
aviv
israel
rambam
health
care
campu
laboratori
toxicolog
pharmacolog
pharmacogenet
haifa
israel
technionisrael
institut
technolog
rappaport
faculti
medicin
haifa
israel
tel
aviv
univers
sackler
faculti
medicin
tel
aviv
israel
background
busulfan
bu
base
condit
regimen
wide
use
pediatr
popul
set
hematopoiet
stem
cell
transplant
oral
bu
narrow
therapeut
window
previou
studi
shown
wide
intrapati
interpati
variat
pharmacokinet
pk
behavior
drug
especi
children
intraven
iv
bu
consist
pk
profil
dose
reliabl
studi
children
evalu
pk
iv
bu
patient
undergo
allogen
bone
marrow
transplant
nevertheless
studi
analyz
safeti
efficaci
pk
iv
bu
children
solid
tumor
undergo
autolog
stem
cell
transplant
use
bu
melphalan
condit
regimen
method
novemb
novemb
consecut
pediatr
patient
undergo
autolog
stem
cell
transplant
use
condit
regimen
iv
bu
melphalan
retrospect
analyz
male
femal
median
age
year
rang
year
fourteen
patient
high
risk
neuroblastoma
patient
metastat
relaps
ewe
sarcoma
iv
bu
administr
everi
hour
total
dose
initi
bu
dose
determin
accord
patient
weight
dose
given
hour
sampl
blood
drawn
nine
separ
point
hour
follow
second
bu
dose
desir
area
curv
auc
dose
modif
done
requir
result
patient
target
auc
achiev
use
weightadjust
dose
approach
without
need
dose
modif
patient
bu
dose
modifi
increas
patient
decreas
patient
bu
well
toler
without
associ
neurotox
hepat
venoocclus
diseas
develop
one
patient
high
auc
follow
second
bu
dose
although
dose
reduct
appli
patient
engraft
aliv
day
post
transplant
conclus
although
iv
bu
consid
consist
pk
profil
result
demonstr
need
iv
bu
routin
auc
monitor
almost
half
patient
weightadjust
dose
result
desir
auc
dose
adjust
need
result
optim
system
drug
exposur
reduc
toxic
prospect
studi
analyz
larger
cohort
patient
need
consolid
result
conflict
interest
noth
disclos
keio
univers
school
medicin
divis
hematolog
tokyo
japan
background
highrisk
patient
leukemia
relaps
import
factor
interf
success
allogen
hematopoiet
stem
cell
transplant
hsct
plerixafor
inhibitor
approv
stem
cell
mobil
autolog
hsct
set
interact
plerixafor
also
potenti
mobil
leukem
cell
could
contribut
chemosensit
phase
studi
evalu
safeti
myeloabl
condit
combin
plerixafor
allogen
hsct
highrisk
leukemia
myelodysplast
syndrom
md
patient
method
patient
elig
highrisk
leukemia
defin
follow
acut
leukemia
aml
complet
remiss
complet
remiss
cr
risk
factor
eg
cytogenet
chronic
myeloid
leukemia
cml
acceler
phase
blast
crisi
second
chronic
phase
advanc
md
patient
prospect
enrol
studi
perform
use
design
escal
total
dose
plerixafor
mgkg
maximum
plerixafor
given
subcutan
hour
deliv
totalbodi
irradi
tbi
chemotherapeut
agent
divid
day
condit
tbi
gy
base
myeloabl
combin
chemotherapeut
agent
cyclophosphamid
cytarabin
etoposid
sourc
stem
cell
except
haploident
donor
elig
tacrolimu
cyclosporin
shortterm
methotrex
given
gvhd
prophylaxi
studi
approv
ethic
committe
keio
univers
school
medicin
result
dose
plerixafor
success
escal
maximum
dose
without
doselimit
toxic
total
patient
dose
plerixafor
enrol
underw
allogen
hsct
median
age
year
rang
underli
diseas
aml
cml
md
evalu
patient
leukem
cell
posit
express
stem
cell
sourc
relat
peripher
blood
stem
cell
pbsc
unrel
bone
marrow
pbsc
cord
blood
advers
event
plerixafor
administr
associ
grade
diarrhea
abdomin
pain
observ
shortli
administr
toxic
within
day
transplant
gener
consist
myeloabl
condit
allogen
hsct
patient
achiev
neutrophil
engraft
within
day
without
earli
death
patient
leukem
cell
mobil
peripher
blood
plerixafor
administr
confirm
morpholog
molecular
method
time
analysi
patient
aliv
remiss
median
followup
period
month
rang
month
conclus
plerixaforcombin
myeloabl
condit
well
toler
adult
patient
undergo
allogen
hsct
leukem
cell
mobil
peripher
observ
half
patient
futur
studi
requir
evalu
efficaci
safeti
regimen
clinic
trial
registri
thi
studi
regist
http
wwwuminacjpctrindexhtm
conflict
interest
okamoto
research
fund
sanofi
kk
author
noth
disclos
princess
margaret
cancer
centr
allogen
blood
marrow
transplant
program
depart
medic
oncolog
hematolog
toronto
canada
background
haploident
hematopoiet
cell
transplant
haplohct
potenti
cur
patient
highrisk
hematolog
malign
exist
condit
regimen
use
posttranspl
cyclophosphamid
ptci
peripher
blood
stem
cell
pbsc
graft
limit
higher
rate
chronic
graftversushost
diseas
gvhd
may
amelior
addit
antithymocyt
globulin
atg
studi
evalu
result
haplohct
reduc
intens
condit
ric
atg
ptci
cyclosporin
prevent
graft
reject
gvhd
august
adult
underw
haplohct
center
ric
consist
fludarabin
day
busulfan
day
total
bodi
irradi
gy
day
tcell
replet
pbsc
infus
day
gvhd
prophylaxi
includ
escal
dose
atg
total
mgkg
day
ptci
day
cyclosporin
day
clinic
featur
posttranspl
outcom
advers
event
collect
retrospect
chart
review
surviv
rate
timetoev
calcul
date
transplant
date
event
last
followup
inform
updat
decemb
surviv
rate
calcul
month
year
result
median
age
year
year
patient
first
remiss
second
remiss
activ
diseas
median
time
neutrophil
engraft
day
rang
day
fifteen
patient
develop
acut
gvhd
grade
howev
incid
grade
iiiiv
acut
gvhd
mild
chronic
gvhd
seen
case
patient
develop
moderatesever
chronic
gvhd
cmv
reactiv
occur
case
cmv
diseas
ebv
reactiv
occur
patient
biopsi
proven
ptld
four
patient
receiv
rituximab
symptomat
ebv
reactiv
ptld
cmv
ebv
ptldrelat
death
six
month
overal
surviv
os
relapsefre
surviv
rf
nonrelaps
mortal
nrm
respect
one
year
os
rf
nrm
respect
infect
common
caus
death
conclus
preliminari
data
suggest
unmanipul
haploident
pbsc
transplant
follow
ric
atg
ptci
csa
gvhd
prevent
strategi
result
low
rate
acut
chronicgvhd
conflict
interest
noth
disclos
method
tabl
tabl
clinic
characterist
donor
st
vincent
hospit
colleg
medicin
cathol
univers
korea
suwon
korea
republ
chonbuk
nation
univers
medic
school
hospit
jeonju
korea
republ
background
lowdos
total
bodi
irradi
tbi
reduc
intens
condit
ric
may
reduc
hostimmun
respons
diseas
relaps
howev
uncertain
whether
addit
lowdos
tbi
ric
benefit
treatment
therefor
conduct
prospect
studi
evalu
clinic
impact
lowdos
tbi
outcom
alloperipher
blood
stem
cell
transplant
pbsct
set
fludarabinebas
ric
method
tbi
ad
regimen
incorpor
busulfan
bu
mgkg
day
fludarabin
fu
day
antithymocyt
globulin
atg
mgkg
gvhd
prophylaxi
csamycophenol
mofetil
mmf
result
ten
patient
hematolog
malign
acut
leukemia
one
md
one
lymphoma
one
multipl
myeloma
underw
allopbsct
hlamatch
relat
unrel
donor
two
patient
histori
one
prior
autopbsct
median
number
cell
rang
neutrophil
engraft
achiev
patient
median
day
overal
surviv
os
relaps
free
surviv
rf
respect
year
cumul
incid
acut
graftversushost
diseas
gvhd
iii
iv
acut
gvhd
sever
chronic
gvhd
year
respect
nonrelaps
mortal
rate
year
conclus
combin
cgi
tbi
fludarabinebas
ric
allopbsct
may
stabil
donor
engraft
anticanc
activ
howev
high
incid
acut
chronic
gvhd
still
remain
problemat
current
transplant
set
optim
gvhd
prophylaxi
could
identifi
set
hope
outcom
allopbsct
would
improv
clinic
trial
registri
conflict
interest
relev
conflict
interest
disclos
univers
hematolog
oncolog
magdeburg
germani
saint
antoin
pari
franc
depart
hematolog
cell
therapi
alwp
ebmt
offic
pari
franc
augsburg
augsburg
germani
de
recherch
en
de
marseil
crcm
institut
paoli
calmett
depart
hematolog
marseil
franc
heliosklinikum
kmt
abteilung
wiesbaden
germani
univers
hospit
clinic
hematolog
grenobl
franc
hospit
montpelli
franc
toulous
toulous
franc
hopit
civil
strasbourg
franc
bordeaux
hautlevequ
bordeaux
franc
colleg
london
haematolog
depart
london
unit
kingdom
cologn
depart
intern
medicin
center
integr
oncolog
cologn
bonn
cologn
germani
saintloui
pari
franc
univers
medic
center
depart
medicin
divis
hematologyoncolog
brentwood
tn
unit
state
sheba
medic
center
telhashom
telaviv
hematolog
divis
bone
marrow
transplant
tel
aviv
israel
aviv
univers
tel
aviv
israel
leukemia
work
parti
ebmt
pari
franc
background
buflu
wide
use
nonmyeloabl
nma
condit
regimen
patient
pt
myeloid
malign
sequenti
reduc
intens
regimen
flamsa
fludarabinearacamsacrin
schmid
et
al
j
clin
oncol
chemotherapi
follow
reduc
intens
condit
riccyclophosphamid
tbi
cgi
shown
remark
activ
relapsedrefractori
rr
aml
high
risk
aml
first
second
complet
remiss
cr
modif
flamsa
develop
tbi
replac
busulfan
bu
mgkg
flamsabu
compar
outcom
aml
pt
transplant
condit
either
buflu
flamsatbi
flamsabu
method
retrospect
registri
studi
pt
elig
first
allosct
aml
de
novo
secondari
donor
match
relat
unrel
one
mismatch
antigen
allel
level
condit
consist
either
buflu
busulfan
mgkg
bw
iv
fludarabin
flamsatbi
fludarabin
cytarabin
x
amsacrin
tbi
cyclophosphamid
mgkg
bw
flamsabu
tbi
replac
busulfan
mgkg
bw
pt
avail
inform
cytogenet
risk
three
group
compar
use
kruskalw
test
quantit
variabl
chisquar
test
exact
test
categor
variabl
propens
score
match
appli
factor
includ
model
age
per
decil
statu
transplant
donor
type
cytogenet
risk
group
sex
match
pt
donor
cmv
serolog
use
vivo
cell
deplet
comparison
perform
use
weight
cox
regress
result
buflu
condit
use
pt
wherea
flamsatbi
flamsabu
use
pt
respect
median
followup
survivor
month
univari
analysi
nrm
higher
flamsabu
group
compar
flamsatbi
flubu
respect
p
ri
lower
flamsa
group
flamsatbi
flamsabu
compar
flubu
p
lf
two
year
significantli
higher
flamsatbi
group
compar
flamsabu
buflu
group
respect
trend
better
os
seen
flamsatbi
group
compar
flamsabu
group
buflu
group
respect
weight
cox
regress
reveal
two
year
transplant
flamsatbi
compar
buflu
associ
lower
ri
hr
also
trend
better
lf
flamsatbi
compar
buflu
detect
hr
os
grf
agvhd
iiiv
agvhd
iiiiv
cgvhd
ext
cgvhd
differ
compar
flamsabu
buflu
statist
signific
differ
endpoint
detect
conclus
result
retrospect
studi
show
compar
buflu
condit
flamsatbi
lead
reduc
relaps
incid
two
year
trend
better
leukemiafre
surviv
aml
patient
transplant
differ
seen
compar
buflu
flamsabu
result
need
confirm
prospect
trial
conflict
interest
heinick
jazz
pharmaceut
travel
grant
c
schmid
moilm
membership
entiti
board
director
advisori
committe
incyt
research
fund
speaker
bureau
novarti
research
fund
speaker
bureau
celgen
research
fund
speaker
bureau
jazz
membership
entiti
board
director
advisori
committe
c
scheid
amgen
consult
honoraria
takeda
consult
honoraria
bm
consult
honoraria
novarti
consult
honoraria
sanofi
consult
honoraria
janssen
consult
honoraria
celgen
consult
honoraria
g
alexion
pharmaceut
inc
consult
b
savani
jazz
pharmaceut
speaker
bureau
author
noth
disclos
turku
univers
hospit
turku
finland
background
sequenti
condit
regimen
combin
short
cours
intens
chemotherapi
reduc
intens
condit
ric
allogen
stem
cell
transplant
allosct
shown
promis
result
high
risk
relaps
refractori
myeloid
malign
report
outcom
patient
advanc
lymphoma
receiv
allosct
sequenti
condit
approach
method
retrospect
analysi
includ
lymphoma
patient
treat
turku
univers
hospit
receiv
sequenti
condit
regimen
transplant
perform
dec
aug
induct
chemotherapi
contain
fludarabin
x
cytarabin
x
without
idarubicin
x
day
rest
follow
ric
cyclophosphamid
x
mgkg
total
bodi
irradi
tbi
gy
two
patient
tbi
substitut
busulfan
treosulfan
thirteen
patient
receiv
transplant
unrel
donor
match
sibl
donor
haploident
famili
donor
stem
cell
sourc
bone
marrow
one
case
gcsfmobil
peripher
blood
remain
patient
result
eighteen
patient
median
age
year
rang
includ
lymphoma
subtyp
hl
fl
dlbcl
pmbl
aitl
mf
alcl
patient
receiv
sever
line
chemotherapi
patient
receiv
previou
autolog
sct
diseas
statu
transplant
cr
pr
progressiverefractori
diseas
untreat
relaps
fl
trmd
ebmt
risk
score
predict
trm
ric
approach
median
followup
time
surviv
patient
mo
mo
incid
grade
ii
acut
gvhd
gr
ii
gr
iv
among
evalu
patient
moder
chronic
gvhd
gvhd
relat
death
thirteen
patient
aliv
time
data
analysi
among
cr
trm
death
infectionrel
three
patient
relaps
one
patient
die
relaps
estim
median
surviv
reach
conclus
result
suggest
sequenti
chemotherapi
ric
allosct
provid
good
diseas
control
accept
toxic
lymphoma
patient
high
risk
trm
relaps
conflict
interest
author
declar
conflict
interest
king
colleg
hospit
depart
hematolog
stem
cell
transplant
london
unit
kingdom
ebmt
pari
offic
ceresttc
saint
antoin
hospit
depart
haematolog
pari
franc
huch
comprehens
cancer
center
stem
cell
transplant
unit
helsinki
finland
deutsch
klinik
fuer
diagnostik
kmt
zentrum
weisbaden
germani
hannov
medic
school
depart
haematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
univers
hospit
brno
depart
intern
med
hematooncolog
brno
czech
republ
centr
hospitali
lyon
sud
pavillon
marcel
bat
servic
hematologi
lyon
franc
univers
saarland
univers
hospit
depart
intern
med
bmt
unit
homburg
germani
vanderbilt
univers
nashvil
depart
hematolog
stem
cell
transplant
vanderbilt
tn
unit
state
saint
antoin
hospit
depart
haematolog
pari
franc
institut
hematolog
stem
cell
transplant
chaim
sheba
medic
centr
tel
hashom
tel
aviv
israel
background
allogen
stemcel
transplant
hsct
effect
way
control
treat
intermedi
high
risk
acut
myeloid
leukaemia
aml
flamsa
schmid
et
al
j
clin
oncol
chemotherapi
follow
reduc
intens
condit
riccyclophosphamid
tbi
effect
regimen
highrisk
aml
yet
extens
studi
amongst
patient
remiss
treosulfan
combin
fludarabin
shown
treoflu
effect
condit
regimen
aml
includ
higher
risk
set
especi
patient
year
age
thu
want
compar
two
regimen
flamsar
vs
treoflu
patient
age
year
method
inclus
criteria
includ
age
denovosecondari
aml
transplant
condit
treoflu
flamsar
flamsatbi
flamsabu
bu
tbi
either
hlamatch
sibl
donor
msd
hlamatch
unrel
donor
mud
result
total
patient
includ
flamsabu
treoflu
median
followup
month
flamsatbi
flamsabu
treoflu
group
respect
compar
group
flamsatbi
group
includ
younger
patient
like
receiv
msd
transplant
de
novo
posit
aml
earlier
period
treoflu
group
includ
patient
transplant
cmv
seroposit
like
receiv
bm
stem
cell
sourc
without
vivo
tcd
compar
flamsa
group
cytogenet
perform
statu
compar
among
group
three
regimen
similar
rate
engraft
respect
flamsatbi
flamsabu
treoflu
group
two
year
non
relaps
mortal
nrm
incid
grade
iiiv
acut
gvhd
year
incid
extens
chronic
gvhd
respect
compar
treoflu
relaps
incid
year
lower
flamsatbi
treo
flu
vs
flamsatbi
flamsabu
respect
median
time
month
respect
two
year
lf
os
treoflu
flamsatbi
flamsabu
group
multivari
analysi
adjust
baselin
covari
signific
differ
flamsabu
treoflu
group
outcom
paramet
flamsatbi
associ
higher
incid
acut
gvhd
hr
lower
relaps
rate
hr
better
lf
hr
compar
treoflu
conclus
patient
age
year
aml
cr
undergo
allogen
transplant
sibl
unrel
donor
flamsatbi
associ
significantli
better
lf
trend
toward
better
os
compar
treoflu
mainli
due
reduct
relaps
rate
flamsabu
similar
overal
efficaci
compar
treoflu
data
may
serv
scientif
background
well
design
random
studi
compar
flamsar
treo
flu
condit
regimen
aml
conflict
interest
conflict
interest
declar
abstract
previous
publish
tor
vergata
univers
rome
stem
cell
transplant
unit
policlinico
universitario
tor
vergata
biomedicina
e
prevenzion
rome
itali
tor
vergata
univers
rome
stem
cell
transplant
unit
policlinico
universitario
tor
vergata
rome
itali
tor
vergata
univers
hospit
rome
itali
santeugenio
hospit
rome
itali
ifo
regina
elena
nation
cancer
institut
rome
itali
azienda
ospedaliera
san
giovanni
addolorata
rome
itali
azienda
ospedaliera
santandrea
rome
itali
campu
biomedico
univers
hospit
rome
itali
tor
vergata
univers
rome
itali
laboratorio
di
immunologia
e
biologia
dei
trapianti
fondazion
ime
rome
itali
background
allogen
stem
cell
transplant
asct
repres
import
cur
therapi
adult
patient
high
risk
acut
lymphoblast
leukaemia
nowaday
data
asct
outcom
altern
donor
match
unrel
cord
blood
haploident
sourc
avail
wherea
analysi
report
concern
use
nontbi
condit
regimen
subset
patient
method
octob
octob
patient
highrisk
consid
elig
allogen
transplant
asct
refer
rome
transplant
network
rtn
jaci
accredit
metropolitan
transplant
program
base
predefin
rtn
polici
search
donor
follow
hierarch
select
hla
ident
sibl
idsib
match
unrel
donor
mud
umbil
cord
blood
ucb
haploident
donor
haplo
patient
receiv
myeloabl
reduc
intens
condit
regimen
consist
thiotepa
singl
daili
dose
iv
busulphan
fludarabin
tbf
includ
atg
mud
haplo
ucb
transplant
gvhd
prophylaxi
csamtx
combin
given
patient
ucb
patient
receiv
csapdn
wherea
haplo
recipi
mmf
anti
moab
ad
patient
transplant
diseas
progress
death
donor
unavail
loss
elig
patient
ongo
final
patient
underw
asct
mud
idsib
haplo
ucb
exclud
ucb
due
small
patient
number
patient
median
age
year
includ
preliminari
analysi
accord
diseas
statu
time
asct
patient
first
cr
cr
activ
diseas
result
patient
engraft
full
donor
chimer
either
pmn
plt
median
rang
day
rang
respect
median
number
infus
kg
rang
signific
correl
cell
dose
median
time
pmn
plt
recoveri
overal
trm
day
respect
relaps
rate
os
lf
respect
os
mud
idsib
haplo
signific
advantag
mud
compar
haploasct
agvhd
cgvhd
occur
respect
patient
experienc
grade
agvhd
regardless
donor
type
mud
idsib
haplo
final
patient
transplant
first
cr
experienc
significantli
longer
os
compar
other
vs
conclus
although
diseas
progress
occur
donor
search
main
obstacl
get
access
asct
rtn
polici
allow
high
proport
elig
patient
highrisk
transplant
specif
categori
significantli
benefit
favour
outcom
conflict
interest
none
univers
hospit
munichgrosshadern
ludwigmaximilian
univers
intern
medicin
iii
hematopoiet
stem
cell
transplant
munich
germani
background
sequenti
condit
regimen
success
use
highrisk
hr
amlmd
match
relat
mrd
unrel
donor
urd
hematopoiet
stem
cell
transplant
hsct
howev
data
avail
sequenti
condit
context
hlahaploident
transplant
haplohsct
even
fewer
known
regard
sequenti
therapi
elderli
investig
rel
merit
sequenti
mrd
urd
haplohsct
matchedpair
analysi
compar
outcom
recipi
age
year
perform
method
thirtysix
patient
highrisk
hr
amlmd
underw
haplohsct
consid
potenti
match
recipi
mrd
urd
hsct
patient
year
old
receiv
sequenti
condit
either
flamsa
clofarabin
shortli
prior
reducedintens
condit
ric
transplant
januari
june
institut
hlamatch
set
vivo
tcell
deplet
antithymocyteglobulin
atg
perform
haplohsct
ptci
use
match
criteria
compris
diseas
activ
blast
ye
diseas
statu
relaps
refractori
highrisk
age
seventeen
pt
undergo
haplohsct
success
pairmatch
seventeen
recipi
msd
usd
hsct
respect
mrd
urd
hsct
uniformli
perform
use
flamsar
peripher
blood
stem
cell
pbsc
stem
cell
sourc
wherea
haplo
hsct
patient
receiv
clofarabiner
patient
bone
marrow
graft
result
median
age
entir
cohort
year
group
consist
md
patient
hr
profil
aml
patient
relaps
refractori
unfavor
cytogenet
median
followup
year
mrd
urd
haplo
recipi
respect
graft
reject
occur
neutrophil
engraft
achiev
median
day
msd
urd
haplo
hsct
respect
cumul
incid
ci
acut
gvhd
day
group
yet
consid
higher
grade
agvhd
ci
mrd
urd
haplohsct
ci
nrm
msd
urd
haplo
recipi
respect
wherea
ci
relaps
within
first
year
compar
mrd
haplo
hsct
trend
toward
better
diseas
control
seen
haplo
signific
differ
observ
os
msd
urd
haplo
recipi
respect
lf
mrd
urd
haplorecipi
significantli
differ
group
conclus
tcellreplet
sequenti
haplo
allograft
use
ptci
base
gvhd
prophylaxi
older
age
hr
mdsaml
patient
feasibl
result
outcom
compar
mrd
urd
hsct
henc
repres
valuabl
altern
hr
amlmd
elderli
conflict
interest
noth
disclos
erciy
univers
faculti
medicin
hematolog
depart
kayseri
turkey
background
high
dose
chemotherapi
follow
autolog
stem
cell
import
step
multipl
myeloma
treatment
melphalan
alkyl
agent
prefer
drug
condit
regimen
dosag
time
import
regard
side
effect
engraft
time
engraft
time
determin
enfect
durat
hospitalis
method
compar
neutrophil
thrombocyt
engraft
retrospect
patient
multipl
myeloma
reciv
melphalan
singl
dose
day
day
condit
regimen
result
patient
reciv
melphalan
day
patient
day
mean
neutrophil
engraftmet
time
day
group
day
group
day
day
respect
p
mean
thrombocyt
engraftmet
time
day
group
day
group
day
day
respect
p
conclus
conclus
administir
melphalan
day
beter
day
term
neutrophil
engraft
henc
term
durat
hospitalis
conflict
interest
author
declar
conflict
interest
feder
state
institut
scienc
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
bone
marrow
transplant
kirov
russian
feder
feder
state
institut
scienc
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
head
kirov
russian
feder
background
current
tendenc
primari
multipl
myeloma
mm
patient
younger
year
includ
induct
subsequ
high
dose
chemotherapi
autolog
hematopoiet
stem
cell
transplant
autohsct
gold
standard
condit
regimen
consid
melphalan
high
dose
hdmel
effort
optim
condit
protocol
combin
melphalan
bortezomib
made
manag
drug
resist
enhanc
plasmat
cell
sensit
melphalan
method
period
autohsct
mm
patient
perform
clinic
tradit
condit
regimen
use
autohsct
singl
doubl
hdmel
group
combin
high
dose
melphalan
bortezomib
use
autohsct
singl
doubl
borhdmel
group
autohsct
complet
remiss
cr
good
partial
remiss
vgpr
achiev
patient
patient
hdmel
group
patient
borhdmel
group
partial
remiss
pr
achiev
patient
hdmel
group
patient
borhdmel
group
toxic
profil
hdmel
borhdmel
condit
regimen
assess
result
number
patient
optim
respons
treatment
autohsct
increas
p
monitor
period
month
median
month
median
os
achiev
year
os
respect
year
rf
median
os
achiev
vgpr
cr
achiev
hdmel
borhdmel
group
respect
p
use
bortezomib
condit
regimen
influenc
os
mm
patient
ci
relaps
rate
patient
receiv
borhdmel
time
lower
receiv
hdmel
ci
period
myelotox
hematopoiesi
aplasia
frequent
complic
mucos
grade
iii
proport
patient
peripher
polyneuropathi
increas
borhdmel
group
nt
observ
mortal
associ
autohsct
hematopoiet
recoveri
rate
similar
addit
bortezomib
standard
condit
regimen
increas
hematolog
nonhematolog
toxic
conclus
use
condit
regimen
high
dose
melphalan
bortezomib
increas
rf
without
toxic
increas
combin
melphalan
bortezomib
could
perspect
measur
autohsct
effici
enhanc
mm
patient
conflict
interest
author
declar
conflict
interest
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
depart
patholog
laboratori
medicin
beirut
lebanon
background
allogen
hematopoiet
stem
cell
transplant
allosct
offer
chanc
longterm
remiss
possibl
cure
mani
hematolog
malign
condit
regimen
play
import
role
choic
influenc
variou
factor
age
patient
perform
statu
diseas
risk
remiss
statu
time
transplant
studi
compar
outcom
thiotepabas
condit
regimen
allogen
stem
cell
transplant
adult
hematolog
malign
method
retrospect
studi
identifi
consecut
patient
differ
hematolog
malign
thirteen
patient
receiv
remain
patient
receiv
thirti
eight
percent
patient
group
receiv
stem
cell
match
relat
sibl
haploident
donor
haplo
diseas
statu
transplant
first
complet
remiss
group
respect
respect
none
patient
group
transplant
group
three
patient
partial
respons
pr
receiv
patient
progress
diseas
receiv
one
time
transplant
result
incid
acut
graftversushost
diseas
agvhd
grade
ii
chronic
cgvhd
occur
patient
year
median
followup
month
transplant
relat
mortal
trm
day
year
respect
trm
observ
group
relaps
incid
year
none
time
transplant
oneyear
progressionfre
surviv
pf
overal
surviv
os
respect
one
year
pf
os
vs
vs
group
respect
univari
multivari
analysi
age
transplant
total
dose
thiotepa
signific
impact
trm
pf
os
conclus
acknowledg
retrospect
natur
small
heterogen
popul
studi
result
suggest
thiotepabas
condit
allogen
transplant
high
risk
hematolog
malign
feasibl
effect
includ
haplo
set
effect
total
dose
thiotepa
transplant
outcom
need
confirm
larger
studi
conflict
interest
author
noth
disclos
tabl
patient
transplant
characterist
heart
england
nh
foundat
trust
birmingham
unit
kingdom
univers
birmingham
birmingham
unit
kingdom
south
warwickshir
nh
foundat
trust
warwick
unit
kingdom
background
chimer
kinet
donor
lymphocyt
infus
dli
import
tool
success
reduc
intens
condit
ric
alemtuzumabbas
allogen
stem
cell
transplant
sct
although
impact
patient
outcom
scarc
studi
method
retrospect
analysi
consecut
patient
myeloid
lymphoid
malign
receiv
alemtuzumabbas
ric
allogen
sct
match
sibl
alemtuzumab
dose
match
unrel
alemtuzumab
dose
donor
median
recipi
age
year
rang
femal
myeloid
diseas
condit
consist
fludarabin
melphalan
fludarabin
busulphan
fludarabin
cyclophosphamid
whilst
lymphoma
treat
fludarabin
melphalan
beam
fludarabin
beam
fludarabin
melphalan
gemcitabin
result
median
followup
month
median
overal
surviv
os
relaps
free
surviv
rf
month
month
respect
statist
differ
outcom
two
diseas
categori
time
transplant
significantli
longer
lymphoid
myeloid
transplant
median
vs
month
p
associ
os
os
wors
patient
highrisk
lymphoid
diseas
highgrad
tcell
lymphoma
partial
remiss
transplant
hr
adjust
age
sex
diseas
lineag
full
chimer
donor
whole
marrow
month
correl
superior
os
hr
rf
hr
donor
tcell
compart
confer
inferior
transplantrel
mortal
trm
wherea
trm
seen
mix
tcell
chimera
acut
gvhd
common
patient
lymphoid
malign
correl
full
donor
tcell
chimer
whole
blood
chimer
month
mix
tcell
chimer
predict
patient
would
go
receiv
dli
p
month
mix
whole
blood
tcell
chimer
predict
use
dli
respect
patient
mix
tcell
chimer
month
went
dli
first
dli
dose
given
median
day
posttranspl
patient
receiv
median
infus
dli
associ
improv
surviv
outcom
mix
tcell
patient
treat
dli
aliv
year
compar
mix
tcell
cohort
receiv
dli
conclus
patient
seri
ric
alemtuzumabbas
allogen
transplant
threemonth
full
donor
statu
whole
blood
threemonth
mix
tcell
chimer
follow
dli
associ
favour
rf
os
alexandro
kanellopoulo
graham
mcilroy
contribut
equal
work
conflict
interest
author
noth
disclos
tata
memori
centr
bone
marrow
transplant
unit
actrec
mumbai
india
background
myeloabl
condit
regimen
allogen
transplant
signific
toxic
warrant
explor
reduc
intens
regimen
treosulfan
alkyl
agent
shown
low
organ
toxic
retrospect
analyz
toxic
outcom
treosulfan
base
condit
regimen
patient
hematolymphoid
malign
method
twentyf
patient
md
underw
allogen
transplant
januari
juli
includ
studi
hematopoiet
cell
transplantcomorbid
index
hctci
score
ebmt
score
diseas
risk
index
dri
transplant
calcul
patient
patient
receiv
fludarabin
day
treosulfan
day
ten
patient
also
receiv
gy
tbi
patient
receiv
arac
day
idarubicin
day
gvhd
prophylaxi
cyclosporin
csa
methotrex
mycophenol
mmf
match
sibl
post
transplant
cyclophosphamid
csa
mmf
use
haploident
rabbit
atg
use
unrel
donor
transplant
chimer
done
monthli
year
neutrophil
engraft
ne
defin
absolut
neutrophil
count
anc
consecut
day
without
gcsf
support
platelet
engraft
pe
defin
platelet
count
x
consecut
day
unsupport
acut
toxic
record
accord
ctcae
version
overal
surviv
os
calcul
date
transplant
date
death
last
followup
lfu
relaps
free
surviv
rf
calcul
date
transplant
date
progress
relaps
death
lfu
remiss
result
median
age
year
rang
male
median
ebmt
hct
ci
score
rang
respect
fourteen
patient
high
intermedi
low
dri
grade
iiiiv
mucos
diarrhea
seen
patient
respect
complet
donor
chimer
seen
patient
respect
median
time
ne
pe
day
respect
five
patient
relaps
die
due
transplant
complic
incid
grade
iiiv
acut
gvhd
chronic
gvhd
respect
os
rf
year
respect
entir
cohort
accord
high
intermedi
low
dri
os
rf
respect
conclus
treosulfan
base
condit
regimen
excel
toxic
profil
reason
relaps
free
surviv
even
patient
high
dri
prospect
comparison
condit
regimen
warrant
conflict
interest
conflict
interest
author
declar
conflict
interest
fund
fund
studi
st
istvan
st
laszlo
hospit
hematolog
stem
cell
transplant
budapest
hungari
semmelwei
univers
hematolog
budapest
hungari
background
sever
grade
iiiiv
acut
extens
chronic
graft
versu
host
diseas
gvhd
main
caus
nonrelaps
transplant
relat
mortal
trm
allogen
haematopoiet
stem
cell
transplant
hsct
nonhla
ident
donor
use
posttranspl
cyclophosphamid
cy
improv
result
hsct
case
report
analys
outcom
patient
pt
malign
haematolog
diseas
receiv
postgraft
cy
allohsct
hla
ident
unrel
donor
method
year
patient
transplant
unrel
donor
posttransplant
cy
unit
median
follow
month
median
age
year
sex
male
diagnosi
aml
mm
mf
md
condit
regimen
myeloabl
total
bodi
irradi
tbi
fludarabin
flu
tbietoposid
vep
tbimelphalan
bu
fluantithymocyta
globulion
atg
bu
fluatg
tiotepa
tt
buflu
nonmyeloabl
tbi
low
dose
bu
flu
gvhd
prophylaxi
postgraft
cy
day
mgkgdtacrolimu
mycophenolat
mofetil
pt
tacrolimu
sirolimu
pt
stem
cell
sourc
gcsf
stimul
unmanipul
periferi
stem
cell
result
acut
gvhd
observ
grade
pt
grade
pt
grade
chronic
extens
gvhd
pt
relaps
pt
live
die
noninfect
complic
op
mucos
grade
pt
sever
haemorrhag
cystiti
pt
maha
pt
infecti
complic
bacteri
septicaemia
pt
fungal
infect
pt
viral
infect
pt
cmv
ebv
adeno
rsv
parainfluenza
live
pt
relaps
die
pt
caus
death
pt
relapsebacterialvir
infect
cmv
adeno
parainfluenza
pt
gvhdbacteri
sepsi
pt
gvhdviral
infect
rsv
ebv
pt
gvhdbacteri
sepsisvir
infect
cmv
pt
cmv
pneumon
without
gvhd
pt
candida
sepsi
without
gvhd
overal
surviv
os
progressionfre
surviv
pf
trm
relaps
acut
gvhd
incid
grade
acut
gvhd
conclus
use
postgraft
cy
allogen
hsct
hla
mismatch
unrel
donor
result
better
outcom
previous
use
protocol
grade
acut
gvhd
almost
complet
disappear
viral
infect
must
close
monitor
result
show
twenti
percentag
os
benefit
compar
histor
patient
cohort
conflict
interest
e
torbagyi
noth
disclos
earli
complic
late
effect
qualiti
life
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
physic
therapi
associ
graft
versu
host
diseas
swindon
unit
kingdom
univers
hospit
leuven
leuven
belgium
univers
zagreb
school
medicin
salata
croatia
myo
clinic
rochest
mn
unit
state
background
qualiti
life
qol
return
normal
social
work
activ
one
major
concern
patient
healthcar
profession
follow
hematopoiet
stem
cell
transplant
evid
behind
exercis
effect
intervent
improv
qualiti
life
hsct
patient
well
establish
contradict
report
mani
studi
lean
toward
littl
statist
signific
benefit
rehabilit
exercis
exercis
prescript
scienc
demand
individualis
achiev
meaning
outcom
systemat
review
attempt
analys
exercis
hsct
patient
prescrib
reflect
patient
need
method
set
perform
systemat
review
literatur
evalu
current
hsct
exercis
prescript
impact
function
qualiti
life
includ
auto
allo
hsct
patient
undergo
rehabilit
hsct
without
gvhd
search
undertaken
use
sage
journal
wileyblackwel
clinic
key
ovid
sciencedirect
pubm
central
proquest
medic
librari
springerlink
proquest
nurs
alli
health
sourc
directori
op
use
boolean
logic
follow
term
hsct
rehabilit
exercis
physiotherapi
physic
therapi
bone
marrow
transplant
qualiti
life
identifi
articl
search
addit
refer
result
articl
identifi
duplic
left
articl
base
inclusionexclus
criteria
fulltext
articl
includ
review
articl
report
use
scientif
base
exercis
prescript
individualis
patient
studi
involv
exercis
intervent
hsct
scenario
found
poorli
design
lack
detail
type
exercis
eccentr
vs
concentr
load
fail
acknowledg
scienc
exercis
prescript
hsct
patient
individu
strength
failur
demand
custom
design
exercis
prescript
includ
appropri
frequenc
durat
intens
type
exercis
match
patient
divers
variabl
like
age
cancer
type
drug
radiat
transplant
presenc
specif
symptom
cardiopulmonari
function
individu
lifestyl
obes
age
prior
treatment
associ
comorbid
impact
drug
musculoskelet
system
conclus
although
scienc
behind
exercis
prescript
evolv
perfect
applic
patient
athlet
popul
last
decad
applic
hsct
rehabilit
arena
appear
underutilis
current
review
found
two
studi
thirteen
util
element
scientif
basi
exercis
prescript
custom
design
exercis
regim
per
individu
patient
physic
capac
final
progress
patient
per
physiolog
paramet
articl
provid
justif
chosen
exercis
prescript
provid
detail
scientif
rational
baselin
exercis
design
calcul
progress
futur
studi
includ
element
design
reliabl
reproduc
trial
conflict
interest
none
hospit
hematolog
hemotherapi
madrid
spain
hospit
gener
de
villalba
hematolog
hemotherapi
madrid
spain
hospit
rey
juan
carlo
madrid
spain
hospit
infanta
elena
hamatolog
hemotherapi
madrid
spain
background
sinusoid
obstruct
syndrom
so
also
known
hepat
venoocclus
diseas
vod
potenti
devast
complic
hematopoiet
stem
cell
transplant
hsct
sosvod
incid
vari
risk
factor
mortal
rate
higher
case
evolv
multiorgan
failur
diagnosi
base
achiev
baltimor
modifi
seattl
criteria
establish
respect
grade
sever
also
base
clinic
criteria
could
assign
retrospect
advanc
hsct
develop
defibrotid
effect
treatment
compel
definit
new
clinic
criteria
well
new
sever
grade
system
new
classif
propos
european
societi
bone
marrow
transplant
esbmt
aim
describ
experi
center
compar
new
classic
classif
criteria
sosvod
method
retrospect
analyz
case
sosvod
secondari
allogen
hsct
center
classifi
retrospect
follow
old
new
classif
criteria
propos
ebmt
result
relat
allogen
hsct
perform
center
develop
sosvod
male
femal
mean
age
year
diagnosi
prolymphocyt
cell
leukemia
complex
karyotyp
line
treatment
acut
lymphoblast
cell
leukemia
line
treatment
peripher
cell
lymphoma
no
line
treatment
prot
lymphoblast
leukemia
line
treatment
three
haploident
cyclophosphamid
day
well
cyammf
one
hla
ident
sibl
standard
cyamtx
receiv
myeloabl
condit
high
dose
tbi
ric
intraven
busulfan
regard
risk
factor
sosvod
karnofski
receiv
hepatotox
drug
hsct
advanc
diseas
hsct
risk
factor
weight
gain
moment
diagnosi
pain
hepatomegali
bilirubin
level
transaminas
level
time
unl
moment
diagnosi
doubl
bilirubin
level
less
hour
develop
multiorgan
failur
requir
intens
care
ultrasound
doppler
perform
hepatomegali
decreas
speed
venou
flow
baltimor
criteria
fulfil
modifi
seattl
criteria
fulfil
new
sosvod
ebmt
criteria
met
treat
defibrotid
diuret
fluid
restrict
also
acetylcystein
high
dose
methylprednisolon
use
vodso
resolv
none
die
vodso
conclus
patient
develop
sosvod
risk
factor
impli
high
risk
develop
sosvod
hsctone
patient
achiev
new
ebmt
criteria
sosvod
sinc
reach
de
bilirubin
level
requir
modifi
seattl
criteria
still
necessari
caseshaploident
transplant
myeloabl
tbi
review
seem
associ
sosvod
conflict
interest
none
author
anyth
disclos
tabl
tabl
abstract
previous
publish
hospit
clinico
san
carlo
madrid
spain
hospit
la
princsa
madrid
spain
background
thrombot
microangiopathi
tma
rel
common
often
misdiagnos
complic
hsct
show
main
featur
relat
possibl
aetiolog
case
post
hscttma
receiv
hospit
test
method
clinician
nearli
spanish
territori
send
us
sampl
activ
test
normal
rang
due
tma
find
patient
search
inhibitor
andor
igg
autoantibodi
perform
activ
data
tma
debut
platelet
haemoglobin
creatinin
schistocyt
relev
clinic
condit
etc
record
analysi
next
gener
sequenc
ng
case
altern
pathway
complement
regul
case
perform
request
result
tma
case
hscttma
percentag
hscttma
grow
year
total
tma
case
hscttma
shown
drastic
reduct
activ
characterist
thrombot
thrombocitopen
purpura
ttp
howev
mechan
respons
defici
seem
differ
case
tabl
mild
activ
reduct
found
patient
without
inhibitor
andor
igg
autoantibodi
remain
case
normal
activ
statist
signific
differ
haematologicalbiochem
paramet
found
group
mild
reduct
versu
normal
activ
pathogen
mutat
complement
regul
found
patient
studi
ng
carrier
risk
haplotyp
atyp
haemolyt
urem
syndrom
ahu
mani
case
tma
caus
drug
toxic
withdraw
drug
resolv
tma
associ
cyclosporin
tacrolimu
sirolimu
infect
caus
dissemin
intravascular
coagul
dic
could
respons
case
hscttma
final
sever
gvhd
common
find
kind
patient
conclus
increment
percentag
hscttma
respect
tma
everi
year
suggest
global
crescent
awar
condit
seriou
complic
hsct
differ
caus
produc
tma
endotheli
drug
toxic
dic
ttp
probabl
other
unclear
sever
gvhd
act
caus
tma
altern
trigger
process
predispos
patient
presenc
risk
haplotyp
ahu
two
patient
analyz
suggest
condit
relat
hcst
act
trigger
ahu
ttp
extrem
uncommon
thu
plasma
exchang
therapi
controversi
first
line
treatment
unknown
frequent
potenti
aetiolog
due
incomplet
avail
clinic
data
cohort
treatment
depend
aetiolog
tma
presenc
complic
tri
distinguish
possibl
caus
tma
mandatori
everi
patient
hscttma
conflict
interest
none
author
anyth
disclos
tabl
hscttma
patient
activ
turku
univers
hospit
dept
clinic
haematolog
stem
cell
transplant
unit
turku
finland
background
compar
old
antiemet
prophylaxi
simpl
new
one
old
protocol
includ
one
aprepit
capsul
emend
substanc
pneurokinin
receptor
antagonist
day
chemotherapi
one
ivinject
palonosetron
aloxi
receptor
antagonist
day
new
oral
combin
product
akynzeo
contain
netupit
palonosetron
given
day
iv
dexamethason
given
similarli
protocol
method
collect
inform
patient
receiv
cytostat
high
risk
nausea
vomit
part
autolog
allogen
hematopoiet
stem
cell
transplant
hsct
patient
receiv
new
oral
product
fill
questionnair
first
day
take
capsul
group
data
concern
nausea
patient
receiv
old
antiemet
protocol
analys
medic
record
group
result
group
patient
autohsct
allohsct
group
autohsct
allohsct
respect
group
suffer
nausea
first
day
chemotherapi
comparison
group
half
patient
suffer
nausea
even
day
start
antiemet
treatment
compar
result
old
treatment
main
result
shown
tabl
conclus
data
support
assumpt
new
oral
combin
product
may
slightli
longerlast
effect
prevent
nausea
chang
treatment
protocol
given
good
result
long
time
first
price
akynzeo
almost
half
old
treatment
second
singl
dose
netupit
longer
effect
hour
new
protocol
seem
effici
conveni
patient
easier
nausea
prophylaxi
pleasant
patient
nurs
staff
conflict
interest
none
istanbul
univers
istanbul
medic
faculti
pediatr
hematologyoncolog
istanbul
turkey
istiny
univers
bahcelievl
medic
park
bone
marrow
transplant
unit
istanbul
turkey
bahcesehir
univers
bahcelievl
medic
park
bone
marrow
transplant
unit
istanbul
turkey
background
recent
evalu
serum
vitamin
level
pediatr
hematopoiet
stem
cell
transplant
hsct
patient
gain
popular
close
relat
develop
gvhd
complic
aim
assess
serum
vitamin
level
relat
gvhd
complic
graft
failur
hsct
patient
method
serum
vitamin
level
children
mean
age
year
male
femal
hsct
baselin
first
third
month
transplant
evalu
medic
park
hospit
istanbul
turkey
year
patient
divid
group
accord
diagnosi
leukemia
anemia
immunodefici
solid
tumor
serum
vitamin
level
regard
defici
ngml
insuffici
ngml
suffici
ngml
children
vitamin
defici
given
u
stoss
therapi
dropday
mainten
therapi
patient
insuffici
given
mainten
therapi
result
baselin
serum
vitamin
level
children
ngml
one
month
transplant
ngml
children
three
month
measur
ngml
children
forti
percent
patient
vitamin
defici
patient
insuffici
transplant
baselin
level
ngml
leukemia
group
ngml
anemia
group
six
patient
die
studi
patient
gvhd
graft
failur
low
level
vitamin
compar
noncompl
patient
ngml
ngml
respect
signific
differ
first
third
month
vitamin
level
noncompl
patient
ngml
ngml
respect
although
serum
level
vitamin
lower
patient
given
mainten
therapi
significantli
increas
stoss
therapi
group
first
month
vs
conclus
effect
serum
vitamin
defici
pediatr
hematopoiet
stem
cell
transplant
gain
import
term
gvhd
develop
graft
failur
cure
studi
high
preval
vitamin
defici
transplant
found
moreov
patient
gvhd
graft
failur
lower
vitamin
level
baselin
respons
mainten
oral
therapi
weekli
stoss
therapi
success
screen
vitamin
level
transplant
suppli
requir
support
seem
import
cure
complic
conflict
interest
none
author
anyth
disclos
cruce
hospit
hematolog
barakaldo
spain
background
light
chain
amyloidosi
al
plasma
cell
disord
character
small
plasma
cell
clone
produc
misfold
light
chain
kappa
lambda
deposit
tissu
select
patient
highdos
melphalan
treatment
follow
autolog
blood
stem
cell
transplant
asct
effect
therapi
revers
diseas
howev
procedur
associ
higher
treatment
relat
morbid
mortal
especi
patient
cardiac
invol
method
retrospect
analyz
record
patient
median
age
year
rang
al
underw
asct
patient
characterist
list
tabl
analyz
overal
surviv
os
well
transplant
relat
morbid
mortal
grade
respons
measur
month
asct
patient
os
estim
method
measur
diagnosi
death
caus
death
unrel
relaps
diseas
progress
first
day
consid
trm
procedurerel
death
result
median
major
viscera
organ
invol
time
asct
rang
nine
patient
receiv
induct
therapi
asct
one
patient
receiv
kind
induct
underw
upfront
asct
nine
patient
mobiliz
use
stimul
factor
one
receiv
plerixafor
condit
regimen
consist
highdos
melphalan
either
toxic
frequent
sever
unusu
morbid
found
stem
cell
mobil
stem
cell
compon
infus
includ
cardiac
hemodynam
complic
common
complic
posttranspl
neutropen
fever
requir
broadspectrum
antibiot
mucos
patient
moder
patient
sever
two
patient
develop
renal
failur
two
develop
hemodynam
complic
two
cardiac
complic
one
patient
die
consequ
transplantrel
complic
median
os
whole
group
month
hematolog
overal
respons
rate
complet
remiss
good
partial
respons
partial
respons
respect
wherea
organ
respons
median
follow
month
patient
die
progress
month
asct
respect
conclus
experi
asct
effect
therapi
patient
al
durabl
respons
rate
despit
improv
patient
select
approach
stem
cell
mobil
perisct
manag
morbid
mortal
higher
hematolog
malign
undergo
asct
suggest
strict
patient
select
base
age
organ
invol
risk
adapt
approach
treatment
patient
al
conflict
interest
none
tabl
tabl
patient
characterist
univers
clinic
hematolog
skopj
skopj
macedonia
former
yugoslav
republ
background
autolog
stem
cell
transplant
asct
improv
surviv
patient
myeloma
lymphoma
associ
morbid
non
relaps
mortal
nrm
hematopoiet
cell
transplant
comorbid
index
hctci
shown
predict
risk
nrm
surviv
allogen
transplant
test
util
hctci
predictor
nrm
overal
surviv
os
patient
undergo
asct
method
analyz
outcom
patient
highdos
melphalan
high
dose
anti
lymphoma
chemotherapi
year
individu
comorbid
prospect
collect
time
asct
impact
hctci
potenti
prognost
factor
includ
karnofski
perform
score
kp
nrm
surviv
studi
multivari
regress
model
result
hctci
score
studi
cohort
respect
subject
stratifi
risk
group
hctci
score
versu
hctci
score
versu
hctci
score
higher
hctci
associ
lower
kp
subject
score
versu
hctci
score
hctci
score
associ
melphalan
dose
reduct
versu
score
cohort
oneyear
nrm
low
confid
interv
multivari
analysi
overal
surviv
inferior
group
hctci
score
rel
risk
confid
interv
p
hctci
score
rel
risk
confid
interv
p
factor
affect
os
autolog
recipi
among
lymphoma
myeloma
patient
hctci
karnofski
score
number
cellskg
time
diagnosi
transplant
p
factor
affect
trmnrm
hctci
ecog
karnofski
score
number
hospit
day
bodi
weight
p
conclus
asct
mm
lymphoma
associ
low
nrm
death
predominantli
relat
diseas
progress
comorbid
evalu
autolog
transplant
lymphoprolif
diseas
use
tool
predict
transplant
outcom
conflict
interest
conflict
interest
hospit
clinic
barcelona
stem
cell
trasplant
unit
hematolog
depart
barcelona
spain
hospit
clinic
barcelona
gynecolog
oncolog
unit
institut
clinic
gynecolog
obstetr
neonatolog
barcelona
spain
background
femal
longterm
survivor
allogen
hematopoiet
stem
cell
transplant
allohsct
incur
signific
burden
late
effect
genit
chronic
graftversushost
diseas
cgvhd
common
frequent
underestim
complic
dramat
affect
qualiti
life
ovarian
failur
sexual
dysfunct
osteoporosi
human
papillomaviru
hpv
persist
import
concern
order
improv
diagnosi
manag
complic
start
program
systemat
surveil
hematologist
gynecologist
earli
late
complic
femal
allohsct
recipi
report
one
year
experi
method
thirti
patient
year
includ
retrospect
analysi
seventeen
patient
start
surveil
hematologist
focus
specif
femal
health
issu
everi
month
immedi
allohsct
patient
present
genit
symptom
andor
develop
cgvhd
refer
special
gynecolog
consult
anoth
patient
previous
diagnos
cgvhd
also
refer
gynecologist
tabl
collect
data
cgvhd
vulvovagin
symptom
gynecolog
examin
cervic
cytolog
hpv
test
menopaus
statu
gonad
function
vitamin
level
bone
densitometri
scan
result
genit
symptom
dyspareunia
vagin
dryness
discharg
tight
vulvar
pain
present
patient
eight
patient
develop
cgvhd
mild
moder
sever
median
month
rang
transplant
genit
involv
organ
score
score
diagnos
month
diagnosi
cgvhd
group
patient
previous
diagnos
cgvhd
mild
moder
sever
show
genit
gvhd
score
score
diagnos
median
month
cgvhd
diagnosi
patient
mild
cgvhd
genit
gvhd
signific
correl
oral
mucosa
cgvhd
vagin
cgvhd
observ
patient
oral
vagin
cgvhd
patient
receiv
topic
corticosteroid
clinic
improv
thirtyperc
includ
patient
show
posit
hpv
test
serotyp
vaccin
recommend
patient
precancer
lesion
identifi
lead
cervic
coniz
patient
nineteen
patient
menopaus
prior
allohsct
women
normal
ovarian
function
develop
ovarian
failur
procedur
menopaus
hormon
replac
therapi
recommend
accept
patient
lead
resum
menstruat
improv
menopaus
symptom
almost
patient
low
level
vitamin
osteopenia
osteoporosi
conclus
seri
almost
femal
allohsct
recipi
refer
genit
symptom
show
genit
cgvhd
hpv
posit
gynecolog
precancer
lesion
ovarian
failur
almost
abnorm
miner
metabol
bone
diseas
recognit
oral
mucosa
cgvhd
prompt
gynecolog
examin
owe
high
cooccurr
genit
cgvhd
systemat
gynecolog
evalu
within
first
year
allow
earli
diagnosi
genit
cgvhd
earli
diagnosi
complic
essenti
optim
treatment
outcom
avoid
sever
sequela
improv
qualiti
life
conflict
interest
receiv
scholarship
dkm
foundat
dedic
clinic
assist
lateeffect
followup
unit
new
program
hospit
barcelona
start
one
year
ago
none
author
anyth
disclos
fundacion
jimenez
diaz
hematolog
madrid
spain
fundacion
jimenez
diaz
madrid
spain
background
autolog
transplant
seen
best
treatment
option
patient
patient
need
red
cell
platelet
transfus
part
support
care
aplasia
phase
condit
patient
refus
blood
interestingli
peopl
agre
stem
cell
transplant
even
progenitor
cell
infus
red
cell
platelet
method
centr
often
choos
jehova
wit
adher
religi
belief
allow
blood
transfus
red
cell
platelet
plasma
report
case
treat
autolog
hematopiet
transplant
without
blood
support
perform
make
chang
regular
procedur
blood
draw
weekli
clinic
need
pediatr
tube
tranexam
acid
erythropoietin
condit
least
hemoglobin
proceed
result
patient
lcg
man
mantl
cell
lymphoma
stage
ivb
diagnos
past
histori
relev
ischem
cardiomiopathi
need
revascular
hypercholesterolemia
acut
divetiicul
treat
altern
rchoprdhap
evalu
fourth
cycl
show
partial
fail
first
attempt
collect
stem
cell
second
tri
done
plerixafor
succes
cycl
patient
evalu
show
complet
remiss
will
hematopoiet
transplant
without
blood
support
condit
done
full
dose
beam
got
cellskg
engraft
neutrophil
day
platelet
day
clinic
cours
complic
emesi
mucos
angor
neutropen
fever
need
parenter
nutrit
discharg
length
stay
day
patient
fmg
woman
igg
multipl
mieloma
diagnos
anemia
extens
bone
diseas
differ
center
past
histori
relev
high
blood
pressur
treat
first
line
vcd
stop
hepatotox
zoledron
acid
treat
lenalidomid
plu
dexametason
reach
vgpr
came
us
ask
autolog
transplant
sign
inform
consent
reject
blood
support
stem
cell
movil
collect
schedul
succes
condit
high
dose
melphalan
done
got
cellskg
engraft
neutrophil
platelet
day
mayor
complic
seen
discharg
length
stay
day
follow
outpati
clinic
conclus
summari
possibl
perform
stem
cell
transplant
without
blood
support
patient
need
awar
risk
feasibl
procedur
team
procedur
patient
need
implement
chang
address
problem
avoid
conflict
interest
noth
disclos
univers
north
carolina
chapel
hill
chapel
hill
nc
unit
state
atara
biotherapeut
inc
south
san
francisco
ca
unit
state
background
posttranspl
lymphoprolif
disord
ptld
uncommon
seriou
lifethreaten
often
deadli
diseas
may
occur
post
transplant
method
assess
burden
ptldrelat
mortal
allogen
hematopoiet
stem
cell
transplant
hct
review
summar
publish
literatur
comprehens
literatur
search
identifi
studi
publish
later
report
patientlevel
data
patient
develop
ptld
follow
hct
patientlevel
data
includ
age
hct
time
hct
ptld
surviv
follow
ptld
abstract
identifi
public
aggreg
provid
summari
statist
result
identifi
articl
publish
later
suffici
patientlevel
data
age
hct
time
death
end
followup
aggreg
data
consist
patient
develop
ptld
includ
children
age
hct
adult
mean
age
hct
year
among
children
year
among
adult
mean
time
hct
ptld
day
ci
children
n
day
ci
adult
n
patient
avail
data
overal
popul
patient
die
ptld
includ
children
adult
mean
time
ptld
death
day
ci
among
children
mean
age
year
ci
day
ci
among
adult
mean
age
year
ci
median
time
ptld
death
day
iqr
children
day
iqr
among
adult
conclus
ptld
follow
hct
aggress
diseas
impact
young
popul
diseas
carri
signific
mortal
rate
rel
short
time
diagnosi
death
conflict
interest
employe
atara
biotherapeut
inc
sourc
fund
atara
biotherapeut
inc
tokai
univers
school
medicin
depart
cell
transplant
regen
medicin
isehara
japan
tokai
univers
school
medicin
depart
pediatr
isehara
japan
background
fanconi
anemia
fa
patient
high
rate
bone
marrow
failur
acut
leukemia
solid
cancer
hematopoiet
stem
cell
transplant
hsct
effect
cure
bone
marrow
failur
longterm
survivor
hsct
risk
cancer
analyz
incid
cancer
fa
patient
undergo
hsct
japan
evalu
risk
factor
secondari
cancer
method
perform
retrospect
analysi
patient
fa
underw
hsct
surviv
least
year
post
hsct
male
femal
age
year
hsct
median
year
hematolog
diagnosi
aplast
anemia
myelodysplast
syndrom
md
acut
myelogen
leukemia
aml
fifteen
patient
receiv
hlamatch
relat
bone
marrow
bm
receiv
hlamatch
relat
cord
blood
cb
hlamismatch
relat
bm
peripher
blood
hlamatch
unrel
bm
hlamismatch
unrel
bm
condit
regimen
consist
cyclophosphamid
cy
mgkg
irradi
gy
other
cy
regimen
fludarabin
flu
cy
mgkg
irradi
gy
other
result
maximum
follow
year
includ
aliv
year
hsct
two
hematolog
malign
one
tcell
lymphoma
one
donortyp
aml
thirteen
solid
cancer
cancer
esophagu
head
neck
squamou
cell
carcinoma
ehnscc
common
solid
cancer
occur
patient
median
time
onset
ehnscc
year
rang
year
hsct
median
age
diagnosi
ehnscc
year
rang
year
four
patient
ehnscc
receiv
hlamismatch
donor
receiv
flu
regimen
lower
dose
irradi
moreov
patient
histori
chronic
gvhd
extens
type
limit
type
although
small
number
patient
group
allow
multivari
analys
univari
analys
show
signific
differ
surviv
free
ehnscc
patient
receiv
hlamatch
donor
receiv
hlamismatch
donor
patient
chronic
gvhd
without
chronic
gvhd
patient
receiv
gy
irradi
receiv
gy
irradi
solid
cancer
one
skin
cancer
year
hsct
one
liver
cancer
hepat
b
c
year
hsct
solid
cancer
exclud
liver
cancer
treat
surgeri
patient
tcell
lymphoma
donortyp
aml
die
progress
diseas
four
patient
ehnscc
die
cancer
progress
patient
liver
cancer
die
bleed
esophag
varic
conclus
high
risk
solid
cancer
fa
patient
hsct
prognosi
poor
import
establish
followup
system
check
highrisk
organ
longterm
fa
survivor
hsct
howev
difficult
predict
conflict
interest
yabe
noth
disclos
ao
ss
antonio
e
biagio
alessandria
itali
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
background
donor
cellderiv
leukemia
dcl
rare
complic
allogen
hematopoiet
cell
transplant
allohct
character
emerg
leukem
clone
donor
cell
develop
overt
acut
leukemia
differ
method
use
confirm
origin
neoplast
cell
includ
cytogenet
fish
molecular
dna
marker
major
report
case
regard
patient
underw
allohct
treat
hematolog
diseas
involv
bone
marrow
present
case
dcl
develop
patient
underw
allohct
treat
metastat
clearcel
renal
cell
carcinoma
rcc
without
prior
exposur
chemoradiotherapi
method
case
report
septemb
metastat
rcc
diagnos
old
male
treatment
given
patient
enrol
fred
hutchinson
cancer
research
center
protocol
hlamatch
relat
nonmyeloabl
allohct
receiv
allohct
april
condit
fludarabin
total
bodi
irradi
tbi
reinfus
unmodifi
peripher
blood
stem
cell
graft
gvhd
prophylaxi
includ
mycophenol
mofetil
mmf
cyclosporin
unfortun
graft
reject
day
underw
gcsf
mobil
apheresi
autolog
stem
cell
august
receiv
second
allohct
donor
condit
cyclophosphamid
atg
follow
chimer
analysi
donor
evid
gvhd
result
novemb
day
second
allohct
patient
develop
leukopenia
bone
marrow
biopsi
done
diagnosi
acut
myelomonocyt
leukemia
without
molecular
abnorm
chimer
analysi
peripher
blood
marrow
cell
remain
donor
analysi
flowsort
blast
also
donor
confirm
diagnosi
donorcel
deriv
aml
induct
therapi
follow
scheme
start
complet
remiss
fulldonor
chimer
achiev
patient
receiv
autohct
februari
condit
cyclophosphamid
tbi
februari
patient
relaps
rcc
underw
surgeri
start
system
therapi
may
pazopanib
success
august
nivolumab
current
multipl
rcc
tumor
right
kidney
evid
metastat
diseas
sign
leukemia
relaps
year
autosct
patient
donor
aliv
healthi
conclus
mechan
leukemogenesi
dcl
still
unknown
report
describ
patient
develop
complic
allohct
solid
tumor
malign
subject
rel
small
amount
chemotherapi
compar
analog
patient
hematolog
malign
could
hypothes
irradi
damag
marrow
microenviron
could
contribut
develop
leukemia
donor
cell
directli
expos
tbi
administ
part
condit
first
allohct
otherwis
also
hypothes
donor
microchimer
still
present
second
condit
regimen
remain
donor
cell
expos
directli
cyclophosphamid
result
mutat
event
remark
patient
continu
surviv
metastat
rcc
year
diagnosi
possibl
cell
alloimmun
contribut
surviv
conflict
interest
author
noth
disclos
leukemia
bmt
program
bc
vancouv
canada
thammasat
univers
pathumthani
thailand
univers
british
columbia
medicin
vancouv
canada
post
graduat
institut
medic
educ
research
depart
intern
medicin
chandigarh
india
prohealth
clinic
research
vancouv
canada
background
declin
bone
miner
densiti
bmd
common
follow
allogen
stem
cell
transplant
allosct
multipl
factor
contribut
acceler
bone
loss
lead
osteoporosi
fractur
zoledron
acid
za
infus
shown
attenu
bone
loss
patient
studi
aim
character
bone
loss
year
allosct
identifi
patient
transplant
specif
factor
associ
declin
bmd
bone
qualiti
includ
effect
za
method
allosct
patient
centr
bmd
lumbar
spine
trabecular
bone
score
tb
indic
bone
architectur
dual
xray
absorptiometri
dxa
pretranspl
day
year
postallosct
za
administ
patient
high
fractur
risk
either
preallosct
day
postallosct
patient
categor
accord
world
health
organ
criteria
tscore
osteoporosi
normal
osteopenia
result
evalu
bmd
chang
oneyear
adult
patient
allosct
pair
dxa
scan
pair
scan
avail
patient
miss
baselin
bmd
return
one
year
patient
die
one
year
myeloma
patient
exclud
median
age
allosct
year
femal
patient
one
year
bmd
normal
patient
osteopenia
patient
osteoporosi
patient
compar
baselin
normal
osteopenia
osteoporosi
p
median
age
normal
year
osteopenia
year
osteoporosi
year
factor
correl
bmd
includ
take
calcium
preallosct
vs
vs
respect
pretranspl
menopaus
vs
vs
famili
histori
osteoporosiship
fractur
vs
vs
baselin
bodi
mass
index
median
vs
vs
kg
baselin
osteopeniaosteoporosi
vs
vs
p
first
year
allosct
fractur
occur
normal
patient
osteopenia
patient
osteoporosi
patient
median
followup
time
year
threeyear
fracturefre
surviv
normal
osteopenia
osteoporosi
panel
patient
classifi
za
preallosct
za
za
bmd
tb
best
maintain
patient
preallosct
za
lesser
protect
patient
given
za
day
panel
b
conclus
declin
bmd
bone
architectur
tb
common
allosct
increas
fractur
seen
oneyear
post
allosct
especi
patient
osteoporosi
bmd
clinic
risk
factor
predict
osteoporosi
oneyear
post
allosct
includ
older
age
menopaus
statu
posit
famili
histori
take
calcium
supplement
lower
bmi
za
effect
attenu
bone
loss
given
preallosct
lesser
efficaci
given
day
recogn
risk
bone
health
patient
popul
lead
aggress
prevent
therapi
risk
conflict
interest
r
broadi
receiv
advisori
board
andor
speaker
honorarium
janssen
sanofi
astella
jazz
pharmaceut
kendler
receiv
advisori
board
andor
honorarium
amgen
pfizer
alexion
eli
lilli
author
noth
declar
ircc
ospedal
pediatrico
bambino
pediatr
hematolog
oncolog
rome
itali
ircc
ospedal
pediatrico
bambino
patholog
rome
itali
background
graft
failur
gf
import
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
proven
immunemedi
gf
caus
residu
host
cell
surviv
condit
regimen
howev
popul
still
poorli
character
method
studi
bone
marrow
infiltr
patient
experienc
gf
hsct
obtain
bm
aspir
patient
gf
suspect
also
studi
cell
infiltr
flowcytometri
immunohistochemistri
immunofluoresc
express
cell
surfac
marker
assess
flow
cytometri
use
follow
monoclon
ab
mab
result
decemb
august
patient
develop
gf
underw
bone
marrow
sampl
median
day
rang
median
age
transplant
year
rang
underw
hsct
sever
aplast
anemia
patient
acut
lymphoblast
leukemia
patient
acut
myeloid
leukemia
patient
donor
partial
match
famili
donor
case
match
relat
donor
remain
one
two
patient
present
antihla
antibodi
patient
underw
hsct
period
use
control
bm
lymphocyt
infiltr
character
increas
number
enlarg
number
vacuol
macrophag
indic
activ
phagocyt
activ
signific
increas
cell
display
predomin
effector
memori
phenotyp
moreov
significantli
express
marker
prolong
activ
eg
overexpress
downregul
exhaust
final
divers
cell
repertoir
analyz
evalu
chain
popul
polyclon
distribut
spectratyp
across
tcr
gene
famili
found
compar
control
higher
expans
famili
observ
demonstr
popul
besid
activ
prolifer
cytotox
express
specif
molecul
granzym
b
perforin
conform
presenc
apoptot
cell
vicin
notabl
also
cell
popul
analyz
show
markedli
increas
activ
profil
underlin
overstimul
environ
nk
lymphocyt
p
conclus
demonstr
popul
infiltr
bm
patient
experienc
gf
activ
prolifer
express
cytotox
specif
molecul
granzym
b
perforin
interestingli
observ
expans
predominantli
polyclon
indic
immun
respons
direct
toward
sever
antigen
immunodomin
one
final
express
sever
exhaust
senesc
marker
confirm
statu
prolong
activ
lymphocyt
conflict
interest
none
author
anyth
disclos
silesian
medic
univers
hematolog
bone
marrow
transplant
katowic
poland
background
isol
extramedullari
relaps
iemr
increasingli
observ
late
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
acut
myeloid
leukemia
aml
howev
optim
therapeut
approach
mode
leukemia
relaps
remain
uncertain
method
retrospect
analyz
incid
clinic
present
treatment
option
longterm
outcom
iemr
cohort
consecut
patient
pt
aml
underw
allohsct
center
june
decemb
pt
relaps
site
result
pt
relaps
fm
median
age
year
rang
year
experienc
histolog
proven
isol
iemr
median
time
month
mt
rang
mt
follow
allohsct
pt
develop
skin
andor
subcutan
tissu
infiltr
site
relaps
includ
case
central
nervou
system
cn
paraspin
soft
tissu
small
intestin
lymph
node
paranas
sinus
breast
treatment
plan
isol
em
relaps
includ
case
system
chemotherapi
system
chemotherapi
secondari
allohsct
imatinib
dasatinib
surgeri
pt
cn
involv
receiv
intrathec
therapi
cytarabin
one
case
addit
cn
irradi
appli
pt
die
median
time
mt
rang
mt
due
resist
system
relaps
infecti
complic
extens
graft
versu
host
diseas
follow
allohsct
patient
remain
aliv
diseasefre
mt
follow
secondari
allohsct
conclus
data
indic
iemr
follow
allohsct
occur
signific
proport
pt
aml
anatom
site
relaps
vari
wide
among
pt
skin
cn
frequent
involv
accord
experi
intens
system
therapi
includ
secondari
allohsct
may
produc
favor
respons
proport
case
howev
longterm
prognosi
pt
iemr
remain
poor
effect
treatment
strategi
iemr
still
remain
challeng
conflict
interest
none
author
anyth
disclos
seoul
nation
univers
hospit
intern
medicin
seoul
korea
republ
background
autolog
stem
cell
transplant
asct
essenti
treatment
highrisk
lymphoma
multipl
myeloma
patient
one
wide
use
indic
measur
amount
collect
hematopoiet
stemprogenitor
cell
hspc
least
posit
cell
known
accept
optim
transplant
outcom
consider
patient
expos
chemotherapeut
agent
radiat
therapi
turn
reduc
bone
marrow
function
caus
difficulti
collect
suffici
amount
stem
cell
asct
studi
aim
analyz
factor
associ
bone
marrow
engraft
clinic
outcom
among
patient
underw
low
hspc
asct
method
retrospect
review
patient
receiv
asct
seoul
nation
univers
hospit
januari
januari
total
patient
collect
among
patient
patient
underw
hsct
less
hspc
clinic
inform
obtain
clinic
record
review
surviv
risk
factor
analysi
conduct
use
kaplanmei
curv
cox
proport
hazard
model
result
total
lymphoma
patient
myeloma
patient
analyz
median
followup
durat
month
rang
median
overal
surviv
os
month
confid
interv
ci
median
relapsefre
surviv
rf
month
ci
univari
analysi
neutrophil
engraft
lymphoma
patient
show
delay
engraft
compar
myeloma
patient
age
also
signific
factor
indic
patient
older
year
need
time
engraft
patient
whose
durat
stem
cell
mobil
scm
asct
one
year
show
significantli
delay
engraft
count
less
also
associ
poor
neutrophil
engraft
among
mobil
method
bone
marrow
harvest
factor
meaning
associ
poor
neutrophil
engraft
sex
initi
stage
treatment
respons
asct
show
signific
differ
neutrophil
engraft
multivari
analysi
lymphoma
hr
ci
line
previou
treatment
histori
hr
ci
one
year
elaps
scm
asct
hr
ci
less
count
hr
ci
factor
independ
associ
neutrophil
engraft
platelet
engraft
multivari
analysi
reveal
lymphoma
hr
ci
age
hr
ci
less
count
hr
hr
clinic
meaning
expect
success
platelet
engraft
conclus
studi
focus
low
count
asct
patient
popul
conclud
could
predict
neutrophil
platelet
engraft
clinic
outcom
use
clinic
inform
suggest
plan
patienttailor
strategi
asct
conflict
interest
none
author
anyth
disclos
bsthospit
universitari
german
tria
pujol
transfus
servic
badalona
spain
icohospit
universitari
german
tria
pujol
josep
carrera
leukemia
research
institut
universitat
autonoma
de
barcelona
hematolog
servic
badalona
spain
background
hyperferritinemia
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
relat
lower
overal
surviv
os
higher
nonrelaps
mortal
nrm
probabl
due
iron
overload
io
toxic
hepat
cardiac
cell
increas
risk
fungal
bacteri
infect
aim
studi
analys
number
red
blood
cell
rbc
unit
transfus
rbc
unit
chelat
therapi
ct
recommend
prior
allohsct
could
impact
os
probabl
develop
infect
bacteri
fungal
hepat
sinusoid
obstruct
syndrom
so
graftversushost
diseas
gvhd
method
retrospect
analysi
patient
undergo
first
allohsct
januari
juli
compar
patient
transfus
less
rbc
unit
allograft
demograph
imag
clinic
data
serum
ferritin
creactiv
protein
crp
erythrocyt
sediment
rate
esr
liver
function
data
previou
allograft
collect
previou
rbc
transfus
histori
month
later
allograft
liver
function
data
month
later
allograft
collect
previou
postallohsct
ct
histori
bacteri
sepsi
two
blood
posit
cultur
invas
fungal
infect
ifi
histori
so
grade
iiiiv
mucos
gvhd
acut
chronic
data
well
cardiac
respiratori
event
allograft
procedur
collect
incid
os
nrm
relaps
ri
analyz
result
two
differenti
group
divid
accord
rbc
unit
transfus
preallohsct
mean
sd
statist
signific
differ
group
order
previous
relat
biochem
paramet
preallohsct
mean
sd
ferritin
vs
p
ist
vs
esr
vs
glutamicpyruv
transaminas
vs
p
differ
os
year
ri
nrm
compar
rbc
transfus
io
toxic
elev
esr
crp
statist
signific
differ
group
so
event
vs
without
signific
differ
iiiiv
mucos
grade
graft
gvhd
type
respiratori
cardiac
event
bacteri
multiresist
bacteria
ifi
incid
rbc
unit
transfus
group
month
postallohsct
statist
signific
mean
sd
vs
p
although
differ
term
ct
histori
prior
allohsct
practic
increas
postallohsct
vs
even
though
scarc
practic
conclus
studi
patient
receiv
rbc
unit
allohsct
present
higher
serum
ferritin
valu
higher
so
incid
receiv
less
rbc
unit
import
insist
adequ
ct
submit
patient
allohsct
whenev
possibl
patient
transfus
histori
order
optim
clinic
haematolog
respons
assess
conflict
interest
author
declar
conflict
interest
hospit
universitario
de
salamanca
salamanca
spain
background
recent
year
extend
use
haploindent
donor
patient
lack
hla
match
donor
publish
studi
compar
efficaci
type
transplant
term
surviv
graft
versu
host
diseas
gvhd
analyz
earli
complic
transplant
aim
carri
compar
studi
main
complic
haploident
transplant
haplo
unrel
donor
urd
transplant
secondli
analysi
os
mrt
ef
global
seri
method
retrospect
analysi
patient
receiv
allotranspl
urd
haplo
allogen
stem
cell
transplant
centr
includ
cord
blood
sct
exclud
statist
analysi
done
spss
x
result
patient
includ
urd
vivo
deplet
atg
haplo
donor
posttranspl
cyclophosphamid
gener
characterist
differ
two
group
shown
tabl
patient
receiv
haplo
transplant
statist
signific
p
higher
incid
late
graft
lead
prolong
median
admiss
time
higher
number
cmv
reactiv
higher
hemorrhag
cystiti
incid
urd
group
higher
incid
agvhd
grade
iiiiv
trombotyc
microangiopathi
tma
observ
statist
signific
associ
patient
agvhd
tma
differ
number
readmiss
main
reason
readmiss
group
infect
urd
group
higher
percentag
readmiss
agvhd
differ
term
mrt
p
ef
p
os
p
conclus
experi
use
haplo
urd
associ
similar
day
readmiss
hospit
howev
pattern
complic
differ
analysi
import
ir
order
organ
resourc
era
patient
donor
howev
due
retrospect
natur
studi
result
confirm
studi
conflict
interest
noth
disclos
jb
medic
ltd
sudburi
unit
kingdom
liuc
cattaneo
castellanza
va
center
health
econom
social
health
care
manag
castellanza
itali
univers
witwatersrand
school
public
health
faculti
health
scienc
johannesburg
south
africa
ircc
san
raffael
scientif
institut
hematolog
bmt
unit
milan
itali
univers
vitasalut
san
raffael
milan
itali
jazz
pharmaceut
health
econom
outcom
research
palo
alto
ca
unit
state
background
current
analysi
compar
costeffect
defibrotid
df
vs
best
support
care
bsc
wale
itali
base
phase
countryspecif
data
two
countri
patient
venoocclus
diseas
multiorgan
dysfunct
vod
mod
posthematopoiet
stem
cell
transplant
hsct
method
countryspecif
markov
costutil
model
compar
df
treatment
bsc
includ
acut
phase
longterm
phase
lifetim
horizon
transit
probabl
acut
phase
base
endpoint
surviv
complet
respons
cr
model
includ
four
health
state
sever
vod
cr
surviv
death
surviv
longterm
phase
extrapol
use
kaplanmei
curv
exponenti
function
publish
literatur
welsh
italian
life
tabl
sensit
analys
use
propensityadjust
efficaci
studi
richardson
use
cox
regress
adjust
account
baselin
differ
treatment
arm
hospit
cost
calcul
take
differ
time
cr
arm
averag
hsct
length
stay
wale
itali
assum
intens
care
unit
time
wale
itali
high
depend
unit
time
wale
itali
sever
vod
util
valu
assum
acut
liver
failur
endstag
liver
diseas
score
util
cr
set
agematch
gener
popul
cost
outcom
discount
per
year
wale
itali
result
overal
cost
higher
wale
model
compar
italian
model
differ
cost
df
bsc
higher
itali
estim
wale
itali
tabl
df
group
italian
model
show
higher
increas
life
year
ly
qualityadjust
life
year
qali
compar
wale
model
consequ
wale
model
show
better
increment
costeffect
ratio
icer
compar
itali
vs
sensit
analysi
show
lower
icer
countri
wale
itali
conclus
df
treatment
vod
mod
repres
costeffect
use
health
resourc
welch
italian
context
icer
estim
compar
bsc
accept
willing
pay
threshold
limit
analysi
includ
longerterm
extrapol
clinic
trial
data
assumpt
resourc
util
pattern
countri
result
driven
estim
rapid
recoveri
reduc
length
stay
improv
surviv
dftreat
patient
sensit
analysi
confirm
robust
compar
result
countri
conflict
interest
analysi
fund
jazz
pharmaceut
inc
j
belsey
e
kemadj
receiv
consult
payment
jazz
pharmaceut
health
econom
servic
respect
health
technolog
apprais
submiss
defibrotid
u
restelli
croce
conflict
interest
f
ciceri
serv
consult
molm
incyt
k
villa
fulltim
employe
jazz
pharmaceut
inc
cours
employ
receiv
stock
option
exercis
stock
award
ordinari
share
jazz
pharmaceut
plc
cryostem
marseil
franc
institut
paolicalmett
cell
therapi
marseil
franc
robert
pediatr
hematolog
pari
franc
saintloui
transplant
hematolog
pari
franc
background
hematopoiet
stem
cell
transplant
hsct
cur
treatment
numer
blood
diseas
patient
cure
hematolog
diseas
complic
includ
notabl
graft
versu
host
diseas
gvhd
infecti
conditioningrel
could
highli
injuri
lack
knowledg
gvhd
longterm
complic
physiopatholog
along
limit
relev
studi
explain
absenc
cur
treatment
context
cryostem
project
promot
francophon
societi
stem
cell
transplant
cell
therapi
sfgmtc
set
uniqu
biobank
europ
firstli
dedic
gvhd
sinc
enlarg
hsct
complic
goal
speed
biomark
discoveri
develop
adequ
treatment
fine
improv
healthcar
provid
transplant
patient
method
cryostem
network
bring
togeth
transplant
unit
biolog
resourc
center
brc
throughout
franc
transplant
unit
respons
blood
sampl
treat
brc
deriv
three
type
sampl
cell
dmso
plasma
dri
pellet
accord
harmon
procedur
protocol
patient
suffer
blood
disord
leukemia
lymphoma
aplast
anemia
justifi
hsct
indic
elig
includ
protocol
similarli
will
relat
donor
geno
haploident
hsct
also
elig
inclus
blood
sampl
taken
pre
posthsct
line
simpl
sampl
schedul
take
account
acut
andor
chronic
appear
gvhd
cryostem
collect
biolog
sampl
associ
clinic
data
donor
patient
central
mbiolim
biobank
softwar
enabl
homogen
label
traceabl
realtim
monitor
oper
result
sinc
cryostem
oper
standard
collect
highqual
biolog
sampl
wellannot
clinic
data
almost
donor
patient
lead
nearli
aliquot
avail
research
process
systemat
blood
sampl
pre
posthsct
gvhd
occurr
moreov
iso
certif
success
obtain
februari
ensur
collect
qualiti
focu
user
expect
satisfact
along
greater
intern
profil
cryostem
goal
provid
nation
intern
scientif
commun
sampl
improv
medic
knowledg
hsct
complic
field
patient
care
date
five
french
one
german
research
project
grant
almost
cryostem
sampl
explor
gvhd
complic
identifi
marker
risk
follow
transplant
monitor
predict
respons
therapi
map
immun
system
donor
andor
recipi
better
understand
gvhd
complic
occurr
part
result
public
expect
end
year
moreov
around
ten
new
project
submit
cryostem
scientif
committe
intern
expert
review
earli
demonstr
fundament
requir
dedic
biobank
improv
research
gvhd
conclus
conclus
cryostem
uniqu
network
europ
dedic
hsct
complic
recogn
intern
highqual
sampl
current
cryostem
provid
nation
intern
scientif
commun
improv
medic
knowledg
hsctrelat
field
oncolog
hematolog
immunolog
ultim
concern
patient
qualiti
life
conflict
interest
none
author
anyth
disclos
centro
hospitalar
e
de
coimbra
clinic
haematolog
depart
coimbra
portug
faculti
medicin
univers
coimbra
coimbra
portug
background
autolog
hematopoiet
stem
cell
transplant
ahsct
highdos
melphalan
condit
multipl
myeloma
lymphoma
minut
day
associ
high
morbid
special
oral
om
gastrointestin
gim
mucos
concept
cryotherapi
came
highlight
base
premis
local
vasoconstrict
reduc
exposur
oral
mucosa
short
infus
agent
howev
guidelin
recommend
usag
mainli
due
low
evid
support
major
studi
includ
reduc
number
patient
aim
evalu
effect
cryotherapi
implement
standard
practic
outcom
patient
submit
ahsct
method
patient
submit
ahsct
center
receiv
cryotherapi
group
cri
patient
instruct
keep
oral
cryotherapi
shortli
min
melphalan
administr
prospect
analyz
group
cri
compar
group
patient
submit
ahsct
use
cryotherapi
noncri
patient
group
receiv
chlorhexidin
mouth
wash
hospit
stay
develop
om
also
receiv
lidocainenystatin
calcium
phosphat
solut
toxic
classifi
accord
result
studi
period
patient
underw
ahsct
receiv
cryotherapi
group
ident
main
clinic
biolog
featur
om
incid
found
significantli
lower
cri
group
compar
noncri
group
vs
rr
ci
howev
median
om
sever
group
pn
grade
also
similar
cri
noncri
respect
rr
ci
pn
cryotherapi
also
seem
reduc
gim
sever
incid
gim
grade
cri
vs
noncri
rr
ci
although
without
signific
impact
gim
incid
pn
number
patient
need
opioid
therapi
hospit
stay
durat
similar
group
pn
differ
observ
need
total
parenter
nutrit
infect
engraft
paramet
pn
mean
length
hospit
stay
five
day
shorter
cri
group
although
statist
signific
vs
day
pn
cryotherapi
seem
protect
measur
om
develop
even
adjust
age
diabet
mellitu
comorbid
previou
radiotherapi
number
treatment
line
condit
regimen
volum
dmso
administ
cryotherapi
procedur
welltoler
discontinu
patient
conclus
om
one
promin
toxic
highdosag
melphalan
condit
regimen
use
cryotherapi
reduc
om
incid
even
adjust
patient
diseas
ahsct
characterist
cryotherapi
readili
avail
inexpens
welltoler
adjuv
therapi
offer
ahsct
patient
larg
random
trial
necessari
obtain
signific
result
identifi
best
cryotherapi
protocol
conflict
interest
none
declar
fukushima
medic
univers
depart
pediatr
oncolog
fukushima
japan
nation
cancer
center
hospit
depart
hematopoiet
stem
cell
transplant
tokyo
japan
tokyo
metropolitan
cancer
infecti
diseas
center
komagom
hospit
hematolog
divis
tokyo
japan
toranomon
hospit
divis
hematolog
tokyo
japan
nation
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
kanagawa
children
medic
center
divis
hematooncolog
regen
medicin
yokohama
japan
osaka
citi
univers
hematolog
graduat
school
medicin
osaka
japan
hyogo
colleg
medicin
divis
hematolog
hyogo
japan
nagoya
univers
graduat
school
medicin
depart
pediatr
nagoya
japan
tokyo
women
medic
univers
hospit
depart
pharmaci
tokyo
japan
kanazawa
univers
innov
clinic
research
center
icrek
kanazawa
japan
hamamatsu
univers
school
medicin
depart
pharmacolog
hamamatsu
japan
nation
cancer
center
hospit
depart
pediatr
oncolog
tokyo
japan
background
hepat
venoocclus
diseas
also
call
sinusoid
obstruct
syndrom
vodso
potenti
lifethreaten
complic
condit
hematopoiet
stem
cell
transplant
hsct
associ
patient
transplantrel
risk
factor
overal
estim
preval
posthsct
japan
defibrotid
approv
treatment
prophylaxi
vodso
posthsct
japan
report
result
japanes
prophylact
use
program
defibrotid
prevent
protocol
method
phase
multicent
openlabel
random
control
trial
pediatr
adult
patient
undergo
myeloabl
condit
allogen
hsct
risk
factor
vodso
vodso
diagnos
accord
modifi
seattl
criteria
plu
weight
gain
patient
random
standard
care
without
defibrotid
prophylaxi
dose
mgkgday
divid
iv
infus
osteopetrosi
stratif
variabl
defibrotid
began
one
day
hsct
condit
continu
day
posthsct
control
patient
develop
vodso
receiv
defibrotid
treatment
primari
endpoint
incid
vodso
day
posthsct
result
full
analysi
set
popul
includ
patient
random
defibrotid
prophylaxi
control
group
mean
age
year
rang
age
year
demograph
clinic
characterist
includ
vodso
risk
factor
wellmatch
defibrotid
control
group
common
risk
factor
among
patient
activ
diseas
second
myeloabl
transplant
condit
busulfan
plu
melphalancyclophosphamid
vodso
occur
day
posthsct
patient
defibrotid
prophylaxi
group
vs
patient
control
group
estim
day
day
surviv
defibrotid
prophylaxi
group
control
group
ci
vs
vs
respect
estim
day
grade
iiiiv
acut
gvhd
defibrotid
prophylaxi
group
control
group
least
advers
event
report
patient
group
overal
ae
profil
gener
similar
prophylaxi
control
group
seriou
advers
event
report
patient
defibrotid
group
report
control
although
common
treatment
relat
ae
hemorrhag
cumul
hemorrhag
incid
signific
group
defibrotid
group
versu
control
conclus
incid
vodso
low
group
total
number
patient
small
studi
reach
plan
registr
number
case
defibrotid
group
patient
control
group
patient
registr
period
final
statist
analysi
abl
judg
data
go
use
safeti
inform
case
insur
adapt
therapeut
use
conflict
interest
support
jazz
pharmaceut
disclosur
studi
support
health
labour
scienc
research
grant
clinic
trial
develop
new
drug
medic
devic
ministri
health
labour
welfar
japan
label
use
defibrotid
investig
prophylaxi
hepat
venoocclus
diseasesinusoid
obstruct
syndrom
japan
saint
antoin
hospit
hematolog
cellular
therapi
servic
pari
franc
pierr
et
mari
curi
upmc
sorbonn
pari
franc
inserm
umr
pari
franc
saint
antoin
hospit
upac
c
de
de
et
pari
franc
background
sinusoid
obstruct
syndrom
so
formerli
known
hepat
venoocclus
diseas
vod
seriou
complic
hematopoiet
stem
cell
transplant
hsct
sosvod
usual
occur
within
week
hsct
ebmt
diagnosi
criteria
revis
includ
late
form
prophylact
use
defibrotid
recommend
paediatr
set
howev
data
gener
adult
popul
scarc
method
retrospect
review
file
consecut
patient
receiv
defibrotid
prophylaxi
sosvod
undergo
allogen
hsct
may
august
donor
match
relat
haploident
unrel
stem
cell
sourc
peripher
blood
stem
cell
bone
marrow
cord
blood
condit
regimen
consist
fludarabin
busulfan
thiotepa
busulfan
fludarabin
sequenti
condit
thiotepabas
clofarabinebas
amasacrinebas
total
bodi
irradiationbas
reduc
intens
condit
incid
so
accord
ebmt
diagnosi
criteria
well
hsctrelat
complic
determin
toler
evalu
hemorrhag
event
incid
result
patient
high
risk
sosvod
accord
ebmt
criteria
median
durat
defibrotid
therapi
day
patient
also
receiv
ursodeoxychol
acid
sosvod
prophylaxi
day
transplant
bleed
occur
patient
defibrotid
prophylaxi
discontinu
patient
case
due
bleed
case
need
antithrombot
therapi
overal
sosvod
occur
case
first
day
follow
hsct
day
two
case
lateonset
sosvod
day
two
case
sosvod
moder
one
case
sever
case
death
relat
sosvod
median
follow
month
rang
overal
surviv
progress
free
surviv
incid
relaps
nrm
respect
cumul
incid
grade
iiiv
grade
iiiiv
acut
graftversushost
diseas
gvhd
respect
cumul
incid
moder
sever
chronic
gvhd
final
cumul
incid
transplantassoci
microangiopathi
confid
interv
conclus
cohort
highrisk
patient
undergo
allogen
hsct
defibrotid
use
combin
ursodeoxychol
acid
prove
effect
prophylact
strategi
associ
low
incid
sosvod
accord
new
ebmt
diagnosi
criteria
accept
safeti
profil
also
defibrotid
prophylaxi
reduc
incid
hsct
complic
acut
gvhd
endothelium
cell
activ
syndrom
overal
prophylact
role
defibrotid
sosvod
adult
patient
potenti
protect
effect
endotheli
cellsrel
complic
warrant
investig
control
prospect
studi
conflict
interest
mohti
receiv
research
support
lectur
honoraria
jazz
pharmaceut
fukushima
medic
univers
depart
pediatr
oncolog
fukushima
japan
nation
cancer
center
hospit
depart
hematopoiet
stem
cell
transplant
tokyo
japan
tokyo
metropolitan
cancer
infecti
diseas
center
komagom
hospit
hematolog
divis
tokyo
japan
toranomon
hospit
divis
hematolog
tokyo
japan
nation
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
kanagawa
children
medic
center
divis
hematooncolog
regen
medicin
yokohama
japan
osaka
citi
univers
hematolog
graduat
school
medicin
osaka
japan
hyogo
colleg
medicin
divis
hematolog
hyogo
japan
nagoya
univers
graduat
school
medicin
depart
pediatr
nagoya
japan
tokyo
women
medic
univers
hospit
depart
pharmaci
tokyo
japan
kanazawa
univers
innov
clinic
research
center
icrek
kanazawa
japan
hamamatsu
univers
school
medicin
depart
pharmacolog
hamamatsu
japan
nation
cancer
center
hospit
depart
pediatr
oncolog
tokyo
japan
background
hepat
venoocclus
diseas
also
call
sinusoid
obstruct
syndrom
vodso
potenti
lifethreaten
complic
condit
hematopoiet
stem
cell
transplant
hsct
associ
patient
transplantrel
risk
factor
sever
hepat
vodso
multiorgan
failur
mof
may
associ
mortal
overal
estim
preval
posthsct
japan
defibrotid
approv
treatment
prophylaxi
vodso
posthsct
japan
report
result
japanes
therapeut
use
program
defibrotid
treatment
protocol
method
phase
multicent
openlabel
nonrandom
singlearm
trial
pediatr
adult
patient
hepat
vodso
without
mof
elig
patient
met
modifi
baltimor
vodso
criteria
total
bilirubin
mgdl
hepatomegali
ascit
weight
gain
day
posthsct
plu
mof
renal
trebl
creatinin
level
reduc
creatinin
clearanc
dialysi
andor
pulmonari
oxygen
satur
need
oxygen
supplementationventil
depend
defibrotid
dose
mgkgday
divid
iv
infus
recommend
treatment
durat
day
primari
endpoint
day
surviv
patient
secondari
endpoint
day
surviv
patient
vod
plu
mof
day
complet
respons
patient
patient
vod
plu
mof
vod
safeti
profil
pharmacokinet
analysi
result
total
patient
hepat
vodso
vodso
postallogen
hsct
patient
mof
patient
median
age
year
age
year
year
male
common
primari
diseas
acut
myelogen
leukemia
acut
lymphoblast
leukemia
lymphoma
common
prophylaxi
regimen
graftvshost
diseas
gvhd
report
tacrolimu
other
regimen
kaplanmei
estim
surviv
rate
day
surviv
patient
confid
interv
ci
mof
patient
group
kaplanmei
estim
day
surviv
ci
estim
cr
rate
day
ci
patient
ci
mof
patient
group
surviv
rate
cr
rate
day
mof
patient
approxim
equival
final
phase
analysi
us
trial
advers
event
ae
report
patient
treatmentrel
ae
trae
patient
trae
patient
pulmonari
hemorrhag
respiratori
failur
epistaxi
hematuria
post
procedur
hemorrhag
hemothorax
mediastin
hemorrhag
pharmacokinet
defibrotid
similar
report
japanes
healthi
volunt
conclus
japanes
treatment
studi
day
surviv
rate
patient
vodso
plu
mod
consist
prior
defibrotid
studi
new
safeti
signal
observ
conflict
interest
support
jazz
pharmaceut
disclosur
studi
support
health
labour
scienc
research
grant
clinic
trial
develop
new
drug
medic
devic
ministri
health
labour
welfar
japan
label
use
defibrotid
investig
treatment
hepat
venoocclus
diseasesinusoid
obstruct
syndrom
japan
oxford
univers
hospit
nh
foundat
trust
dermatolog
oxford
unit
kingdom
oxford
univers
hospit
nh
foundat
trust
haematolog
oxford
unit
kingdom
background
cutan
graftversushost
diseas
gvhd
follow
allogen
stem
cell
transplant
major
caus
morbid
signific
impact
qualiti
life
british
committe
standard
haematolog
recognis
valu
earli
input
dermatologist
date
report
model
optim
deliveri
dermatolog
servic
stem
cell
transplant
recipi
sought
address
potenti
unmet
need
develop
dedic
dermatolog
servic
bone
marrow
transplant
bmt
clinic
haematolog
outpati
depart
aim
servic
develop
project
quantifi
clinic
need
b
evalu
patient
report
outcom
experi
servic
method
demograph
clinic
detail
case
refer
specialist
opinion
record
march
decemb
establish
casemix
assess
clinic
need
base
data
model
involv
dedic
consult
dermatologist
work
collabor
multidisciplinari
bmt
team
approv
formal
oper
juli
patient
evalu
servic
measur
use
outcom
experi
questionnair
oeq
valid
tool
bring
togeth
patient
report
outcom
oeqo
score
experi
oeq
score
care
higher
oeq
score
repres
better
outcom
enhanc
experi
modifi
selfadminist
oeq
question
use
anonymis
data
collect
two
month
result
establish
clinic
need
patient
median
age
yr
rang
yr
refer
review
dermatologist
servic
develop
mean
number
patient
review
per
clinic
rang
account
total
attend
review
requir
result
addit
consult
broad
rang
skin
condit
diagnos
chronic
cutan
oral
gvhd
commonest
present
respect
servic
evalu
respons
rate
respond
use
dermatolog
servic
report
see
dermatolog
time
median
oeqo
score
rang
report
see
dermatolog
extrem
help
median
oeq
score
rang
report
involv
much
want
manag
decis
report
inform
provis
extrem
help
overal
rate
outcom
visit
dermatologist
bmt
clinic
excel
conclus
demonstr
clinic
need
dedic
dermatolog
servic
bmt
clinic
manag
cutan
diseas
dedic
parallel
dermatolog
servic
enabl
accur
earli
diagnosi
cutan
oral
gvhd
potenti
improv
morbid
appropri
time
use
localtop
treatment
patientderiv
data
oeq
increasingli
use
evalu
new
servic
overal
oeq
score
high
support
clinician
view
collabor
work
environ
bmt
clinic
optimis
manag
skin
diseas
follow
allograft
transplant
improv
patientfocus
inform
resourc
skin
diseas
could
enhanc
patient
experi
data
collect
longterm
outcom
posttranspl
patient
skin
condit
provid
object
demonstr
impact
dedic
dermatolog
servic
conflict
interest
noth
declar
fondazion
ircc
istituto
nazional
tumori
milano
itali
univers
milano
dept
oncolog
hematolog
milano
itali
background
posttranspl
cyclophosphamid
ptci
improv
outcom
haploident
hematopoiet
cell
transplant
haplohct
nevertheless
toxic
emerg
earli
posttransplant
period
report
extens
evalu
earli
complic
patient
undergo
ptci
haplohct
method
retrospect
evalu
consecut
patient
undergo
ptci
haplosct
lymphoid
myeloid
malign
april
decemb
institut
result
median
age
transplant
year
rang
median
line
previou
treatment
rang
includ
autolog
transplant
patient
affect
myeloprolif
diseas
patient
lymphoma
multipl
myeloma
diseas
risk
index
high
patient
condit
regimen
myeloabl
one
besid
ptci
gvhd
prophylaxi
cyclosporin
tacrolimu
mycophenol
mofetil
graft
sourc
bone
marrow
patient
peripher
blood
stem
cell
infecti
noninfecti
toxic
evalu
day
cumul
incid
record
confid
interv
ci
bacteri
infect
grade
ci
invas
fungal
infect
cmv
reactiv
incid
ci
one
cmv
diseas
coliti
major
event
occur
first
month
median
day
rang
requir
one
line
therapi
ebv
reactiv
rate
ci
posttranspl
lymphoprolif
disord
evid
patient
success
treat
preemptiv
rituximab
record
ci
incid
hemorrhag
cystiti
patient
symptom
associ
bk
viru
reactiv
one
patient
detect
urinari
adenoviru
dna
adenoviru
relat
diseas
incid
ci
grade
cytokin
releas
syndrom
incid
within
day
ci
mainli
relat
cyclophosphamid
administr
regard
endotheli
toxic
encount
ci
incid
thrombot
microangiopathi
venoocclus
diseas
report
pulmonari
toxic
idiopath
pneumonia
syndrom
diffus
alveolar
hemorrhag
absent
cardiac
event
incid
ci
specif
arrhythmia
pericard
median
followup
survivor
month
rang
overal
progress
free
surviv
ci
ci
relaps
incid
nonrelapsemort
nrm
year
ci
ci
gvhdfree
relapsefre
surviv
gfr
year
ci
relaps
gvhd
nrm
line
previou
report
incid
acut
gvhd
grade
day
ci
ci
respect
incid
chronic
gvhd
moder
year
ci
conclus
data
show
high
incid
infecti
complic
ptci
haplohct
particular
cmv
reactiv
frequent
often
challeng
treat
moreov
hemorrhag
cystiti
associ
bk
viru
reactiv
second
common
viral
complic
carri
sever
clinic
consequ
patient
high
readmiss
rate
candid
ptci
haplohct
consid
high
risk
cmv
bk
reactiv
treat
accordingli
conflict
interest
noth
disclos
berlin
berlin
germani
biostatist
dkfz
heidelberg
germani
univers
hospit
medicin
v
heidelberg
germani
background
standard
laboratori
paramet
current
use
predict
sinusoid
obstruct
syndromevenoocclus
diseas
sosvod
endotheli
activ
stress
index
easix
base
simpl
formula
ldh
ul
x
creatinin
mgdl
thrombocyt
proven
predict
outcom
overal
mortal
gvhd
lancet
haematol
aim
current
studi
assess
easix
might
valuabl
predict
sosvod
allosct
method
sosvod
defin
accord
revis
ebmt
criteria
capac
easix
predict
sosvod
test
retrospect
consecut
adult
patient
undergo
allosct
singl
institut
train
cohort
primari
endpoint
predict
sosvod
measur
day
allosct
easixzero
secondari
endpoint
predict
overal
mortal
om
hyperbilirubinaemia
easixzero
easix
taken
start
condit
therapi
easixpr
result
valid
independ
cohort
adult
allosct
recipi
anoth
singl
institut
transplant
result
sosvod
diagnos
patient
median
onset
day
train
cohort
patient
median
onset
valid
cohort
respect
easix
test
uni
multivari
cox
regress
analys
use
age
donor
type
mismatch
diseas
score
strength
condit
confound
train
cohort
increas
easixzero
significantli
associ
sosvod
incid
uni
hr
ci
multi
hr
ci
similarli
easixzero
predict
incid
sosvod
valid
cohort
uni
hr
ci
p
multi
hr
ci
p
contrast
sosvod
incid
predict
easixpr
uni
multi
howev
easixpr
strongli
associ
hyperbilirubinaemia
mgdl
allosct
kruskalwallistest
p
train
cohort
valid
cohort
moreov
hyperbilirubinaemia
mgdl
allosct
patient
diagnos
sosvod
predict
increas
overal
mortal
cohort
train
uni
hr
ci
multi
hr
ci
valid
uni
hr
ci
multi
hr
ci
effect
om
hyperbilirubinaemia
patient
without
sosvod
also
independ
later
develop
acut
gvhd
figur
show
kaplanmei
estim
sosvod
incid
om
allosct
accord
easixzero
quartil
train
set
cohort
separ
conclus
easixzero
reflect
patient
immedi
reaction
condit
toxic
power
predictor
sosvod
overal
mortal
adult
allosct
recipi
patient
high
easixzero
score
might
candid
clinic
evalu
intensifi
strategi
prevent
sosvod
allosct
strong
associ
earli
hyperbilirubinaemia
absenc
sosvod
increas
overal
mortal
need
explor
conflict
interest
author
noth
disclos
ebv
associ
lymphoprolifer
allogen
hematopoiet
stem
cell
transplant
anna
ivana
peter
dominika
veronika
alexandra
comeniu
univers
children
hospit
depart
paediatr
haematolog
oncolog
bratislava
slovakia
background
posttranspl
lymphoprolif
disord
ptld
lymphoid
andor
plasmacyt
prolifer
occur
result
immunosuppress
allogen
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
present
case
report
patient
ebv
associ
lymphoprolifer
allogen
hsct
period
year
ebv
infect
reactiv
patient
allogen
hsct
present
ebv
associ
lymphoprolif
disord
earli
post
transplant
complic
method
year
period
incid
posttranspl
complic
transplant
unit
patient
allogen
transplant
retrospect
compar
clinic
record
tri
find
featur
potenti
fatal
post
transplant
complic
patient
common
explor
level
immunosuppress
develop
clinic
sign
coexist
virus
result
patient
allogen
hsct
condit
regimen
contain
antithymocyt
globulin
atg
mean
tcell
immunosuppress
receiv
cyclosporin
csa
hsct
ebv
reactiv
occur
found
higher
level
csa
usual
tri
achiev
three
patient
highest
level
ngml
none
patient
present
acut
graftversushost
diseas
gvhd
cystiti
posit
bk
viremia
viruria
ebv
reactiv
day
hsct
one
patient
hsct
ebv
seroneg
ebv
seroposit
donor
consid
princip
risk
factor
ptld
along
degre
tcell
immunosuppress
median
day
hsct
first
clinic
symptom
first
higher
ebv
load
appear
day
hsct
receiv
result
significantli
elev
ebv
copi
blood
first
dose
rituximab
start
immedi
patient
start
preemptiv
therapi
rituximab
one
patient
clinic
sign
lymphoprolifer
high
ebv
load
copiesml
detect
two
ambulatori
monitor
receiv
result
high
ebv
load
copiesml
alreadi
clinic
symptom
fever
fatigu
massiv
lymphadenopathi
hepatopathi
appear
main
clinic
sign
besid
dose
rituximab
everi
day
reduc
immunosuppress
patient
receiv
hepatoprotect
support
therapi
success
treat
patient
rituximab
chemotherapi
cell
therapi
need
conclus
ptld
seriou
complic
hsct
fatal
case
monitor
ebv
copi
regular
basi
help
us
start
preemptiv
treatment
ptld
rituximab
optim
schedul
ebv
pcr
monitor
ambulatori
set
remain
unclear
detect
increas
ebv
load
clinic
sign
diseas
appear
ambulatori
set
relationship
bk
viru
reactiv
consecut
ebv
reactiv
close
describ
higher
rate
immunosuppress
could
reason
virus
reactiv
conflict
interest
none
declar
seoul
nation
univers
hospit
seoul
korea
republ
colleg
pharmaci
hanyang
univers
ansan
korea
republ
background
purpos
studi
show
efficaci
prophylact
olanzapinecontain
antiemet
regimen
consist
olanzapin
oln
palonosetron
pal
dexamethason
dex
prevent
nausea
vomit
patient
receiv
high
dose
anticanc
agent
condit
autolog
hematopoiet
stem
cell
transplant
asct
method
retrospect
studi
perform
patient
receiv
thiotepa
busulfan
cyclophosphamid
tbc
condit
regimen
asct
oln
pal
dex
opd
regimen
consist
mg
oral
oln
mg
intraven
pal
mg
intraven
dex
day
mg
oral
oln
alon
day
patient
receiv
opd
regimen
emesi
prevent
tbc
condit
seoul
nation
univers
hospit
novemb
novemb
receiv
opd
center
includ
result
analyz
patient
male
median
age
year
underli
diseas
patient
multipl
myeloma
patient
nonhodgkin
lymphoma
bcell
tcell
lymphoma
term
emesi
control
complet
respons
cr
vomit
achiev
earli
period
first
hour
condit
overal
period
day
patient
respons
pr
vomit
grade
vomit
ncictca
earli
overal
period
respect
seriou
toxic
occur
howev
mild
dizzi
hypotens
paresthesia
resolv
without
manag
hour
onset
symptom
compar
result
data
primari
central
nervou
system
lymphoma
patient
well
receiv
tbc
base
asct
differ
antiemet
regimen
asan
medic
center
korea
decemb
juli
antiemet
regimen
asan
medic
center
contain
oln
includ
lorazepam
tabl
antiemet
regimen
without
opd
result
cr
pr
patient
achiev
cr
pr
respect
overal
period
cr
achiev
frequent
patient
opd
contain
regimen
conclus
opd
regimen
remark
antiemet
potenti
tbc
condit
assum
opd
could
also
consid
effect
antiemet
therapi
variou
highlyemetogen
chemotherapi
includ
condit
asct
conflict
interest
author
noth
disclos
tabl
antiemet
regimen
center
snuh
seoul
nation
univers
hospit
amc
asan
medic
center
oln
olanzapin
pal
palonosetron
dex
dexamethason
lrz
lorazepam
sra
serotonin
receptor
antagonist
receptor
antagonist
chu
nant
nant
franc
crcina
inserm
u
nant
franc
chu
nant
biolog
nant
franc
background
cardiovascular
complic
involv
morbimort
allogen
stem
cell
transplant
allosct
howev
littl
known
regard
impact
outcom
cardiovascular
risk
factor
time
allosct
retrospect
studi
aim
examin
impact
pretranspl
cardiovascular
risk
factor
allosct
overal
os
diseasefre
df
surviv
method
adult
year
old
allotranspl
singl
univers
center
januari
decemb
elig
studi
ten
cardiovascular
risk
factor
previous
defin
consid
mahmood
lancet
point
attribut
present
allow
build
variou
score
statist
analysi
result
cohort
compris
male
femal
median
age
year
rang
initi
diseas
myeloid
lineag
lymphoid
transplant
patient
complet
remiss
cr
partial
remiss
pr
activ
diseas
ninetyon
patient
receiv
myeloabl
condit
regimen
receiv
reducedintens
sequenti
regimen
donor
sibl
haploident
match
unrel
donor
mismatch
unrel
donor
unrel
cord
blood
peripher
blood
stem
cell
main
sourc
graft
case
receiv
bone
marrow
patient
left
ventricular
eject
fraction
time
transplant
median
os
month
ci
os
df
respect
whole
group
overal
incid
grade
acut
chronic
gvhd
overal
incid
relaps
nonrelaps
mortal
nrm
respect
number
patient
involv
consid
cardiovascular
risk
factor
transplant
year
year
smoker
hypertens
diabet
firstdegre
famili
histori
coronari
diseas
totalcholesterol
triglycerid
hdlcholesterol
n
ldlcholesterol
univari
analysi
hdlcholesterol
activ
diseas
transplant
factor
associ
lower
os
vs
vs
vs
cr
vs
pr
respect
df
vs
vs
cr
vs
pr
respect
howev
multivari
analysi
diseas
statu
time
transplant
retain
signific
os
hr
ci
df
hr
ci
consid
variou
cardiovascular
risk
score
statist
analysi
none
predict
surviv
patient
transplant
incid
cardiovascular
event
within
first
year
patient
aliv
one
year
none
patient
die
cardiovascular
diseas
conclus
result
suggest
elev
cardiovascular
risk
factor
time
allosct
impact
surviv
adult
patient
therefor
presenc
lead
reconsid
procedur
may
make
patient
higher
risk
allosct
conflict
interest
noth
disclos
instituto
de
oncologia
de
lisboa
francisco
gentil
endocrinolog
lisbon
portug
background
bone
marrow
transplant
bmt
therapeut
option
sever
hematolog
diseas
either
benign
malign
nonhematolog
condit
due
reduc
mortal
bmt
survivor
therapi
increas
time
risk
develop
therapyrel
late
effect
endocrin
dysfunct
frequent
object
studi
character
endocrin
disord
found
bmt
survivor
follow
late
effect
clinic
lec
method
retrospect
studi
analysi
clinic
record
patient
submit
bmt
inclus
criteria
follow
lec
followup
least
three
year
statist
analysi
data
made
microsoft
excel
ibm
spss
statist
result
studi
collect
patient
femal
male
mean
age
bmt
treatment
year
patient
done
bmt
twenti
mean
followup
time
month
followup
patient
women
men
p
develop
least
one
endocrinopathi
endocrin
complic
significantli
frequent
patient
submit
bmt
year
age
compar
older
twenti
p
despit
time
followup
shorter
older
group
vs
gener
occurr
endocrinopathi
hypogonad
women
men
complic
signific
differ
gender
p
dyslipidemia
osteopeniaosteoporosi
hypothyroid
somatropin
defici
nodular
thyroid
diseas
diabet
prediabet
thyroid
cancer
divid
patient
age
bmt
year
found
statist
differ
occurr
hypogonad
lower
age
group
compar
older
p
dyslipidemia
first
group
vs
second
p
conclus
higher
risk
hypogonad
seen
older
women
possibl
due
higher
ovarian
toxic
plu
natur
ovarian
reserv
declin
occur
along
year
dyslipidemia
observ
older
group
probabl
relat
lifestylecardiovascular
risk
factor
survivor
bmt
frequent
endocrinopathi
earli
identif
complic
repres
improv
qualiti
life
avoid
associ
morbimort
first
portugues
studi
analys
theme
present
one
largest
sampl
found
intern
literatur
conflict
interest
author
deni
conflict
interest
matter
chu
ucl
namur
montgodinn
hematolog
yvoir
belgium
chu
ucl
namur
montgodinn
hpc
collect
center
yvoir
belgium
background
engraft
syndrom
es
clinic
condit
increasingli
report
periengraft
period
follow
autolog
hematopoiet
stem
cell
transplant
asct
diagnosi
criteria
drug
manag
remain
wide
heterogen
aim
assess
burden
condit
antimicrobi
manag
adult
patient
hospit
asct
fiveyear
period
tertiari
belgian
referr
center
method
medic
data
patient
underw
asct
januari
decemb
retrospect
review
hospit
discharg
report
screen
follow
item
engraft
syndrom
unexplain
fever
andor
diarrhea
andor
cutan
rash
shortli
day
preced
follow
neutrophil
recoveri
includ
patient
subsequ
evalu
accord
spitzer
maiolino
diagnosi
criteria
antimicrobi
data
review
electron
medic
record
result
fiveyear
period
asct
perform
chu
ucl
namur
main
indic
multipl
myeloma
lymphoid
malign
acut
myeloid
leukemia
testicular
carcinoma
diagnosi
es
retain
patient
spitzer
andor
maiolino
diagnosi
criteria
met
patient
spitzer
maiolino
spitzermaiolino
patient
nt
meet
criteria
mainli
delay
es
symptom
onset
isol
fever
resurg
postengraft
patient
howev
consid
probabl
es
case
review
medic
record
fever
present
patient
main
secondari
symptom
skin
rash
andor
diarrhea
patient
one
clinic
present
involv
pulmonari
infiltr
hypoxemia
weight
gain
thirti
patient
treat
cefepim
piperacillintazobactam
empir
antimicrobi
therapi
escal
meropenem
patient
corticosteroid
administr
patient
evolut
es
favor
patient
conclus
es
clinic
syndrom
frequent
describ
context
asct
current
es
diagnosi
criteria
heterogen
allow
earli
recognit
appropri
clinic
manag
empir
firstlin
escal
antimicrobi
therapi
remain
context
wide
prescrib
refin
diagnosi
criteria
appropri
initi
corticosteroid
therapi
could
decreas
broad
spectrum
antimicrobi
consumpt
reduc
inhospit
lengh
stay
conflict
interest
author
noth
disclos
memori
sloan
ketter
cancer
center
bone
marrow
transplant
depart
pharmaci
new
york
ny
unit
state
cornel
univers
depart
medicin
new
york
ny
unit
state
memori
sloan
ketter
depart
biostatist
new
york
ny
unit
state
memori
sloan
ketter
cancer
center
depart
bone
marrow
transplant
new
york
ny
unit
state
background
engraft
syndrom
es
increasingli
report
complic
ahct
incid
character
symptom
occur
periengraft
includ
fever
skin
rash
diarrhea
pulmonari
infiltr
neurolog
complic
criteria
diagnosi
propos
limit
data
exist
risk
factor
manag
examin
patient
underw
ahct
light
chain
al
amyloidosi
defin
characterist
associ
es
develop
method
retrospect
examin
incid
risk
factor
characterist
treatment
es
patient
al
amyloidosi
receiv
first
ahct
melphalan
condit
risk
factor
es
develop
assess
use
logist
regress
model
os
pf
estim
use
kaplanmei
method
differ
assess
logrank
test
cumul
incid
nrm
estim
use
method
compet
risk
relaps
consid
compet
risk
result
patient
pt
al
amyloidosi
median
age
rang
male
receiv
ahct
melphalan
receiv
ahct
pt
receiv
melphalan
pt
receiv
melphalan
day
pt
untreat
prior
ahct
pt
receiv
median
one
line
therapi
rang
common
induct
therapi
bortezomibdexamethason
melphalandexamethason
cyclophosphamidebortezomibdexamethason
pt
patient
mobil
filgrastim
alon
pt
receiv
plerixafor
pt
receiv
chemomobil
cyclophosphamid
vdtpace
median
infus
dose
cellskg
rang
x
cellskg
incid
es
clinic
featur
es
fever
infiltr
imag
rash
bsa
noninfecti
diarrhea
liquid
requir
antimotil
agent
univari
analysi
tabl
identifi
lack
exposur
cyclophosphamid
preahct
statist
signific
risk
factor
develop
es
pt
treat
es
corticosteroid
cs
pt
treat
support
median
cs
prednison
methylprednisolon
dose
mgkg
rang
mgkg
median
day
day
pt
receiv
cs
median
day
rang
day
pt
requir
cs
puls
follow
taper
day
day
median
length
hospit
stay
day
day
median
day
day
day
patient
without
es
cumul
incid
nrm
year
pf
os
year
respect
differ
pf
os
among
pt
es
conclus
es
occur
al
patient
undergo
ahct
potenti
prolong
hospit
stay
prompt
treatment
cs
steroid
taper
favor
approach
sinc
recrudesc
common
detail
comparison
pt
multipl
myeloma
present
conflict
interest
noth
disclos
ghent
univers
hospit
pediatr
cardiolog
ghent
belgium
ghent
univers
hospit
pediatr
endocrinolog
ghent
belgium
ghent
univers
hospit
pediatr
hematolog
oncolog
stem
cell
transplant
ghent
belgium
ghent
univers
movement
sport
scienc
ghent
belgium
background
physic
fit
import
determin
qualiti
life
hematopoiet
stem
cell
transplant
sinc
cardiac
function
influenc
exercis
perform
aim
present
studi
assess
factor
interrelationship
method
children
stabl
followup
year
post
hsct
invit
particip
studi
patient
underw
cardiopulmonari
exercis
test
cpet
echocardiographi
assess
left
right
ventricular
lv
rv
systol
lv
diastol
function
lv
wall
dimens
health
relat
qualiti
life
hrqol
evalu
use
child
adolescentreport
questionnair
exercis
hrqol
data
match
healthi
control
patient
echocardiograph
measur
compar
normal
valu
result
fortythre
hsctpatient
perform
maxim
exercis
test
boy
weight
length
bsa
time
transplant
exercis
test
year
aml
myelodysplasia
repres
indic
hsct
patient
group
equal
healthi
control
regard
age
height
weight
hsct
patient
lower
maxim
oxygen
consumpt
vs
p
shorter
exercis
durat
p
lower
maxim
load
ppeak
vs
p
reach
ventilatori
anaerob
threshold
vat
earlier
vs
echocardiographi
demonstr
decreas
interventricular
septal
wall
thick
ivsd
zvalu
p
systol
lv
function
diminish
children
measur
tissu
doppler
mitral
valv
higher
compar
normal
valu
age
gender
weight
point
toward
degre
diastol
dysfunct
high
ee
zvalu
p
children
lv
dilat
wors
oxygen
consumpt
maxim
exercis
qualiti
life
gener
good
overal
hrqolscor
emot
function
score
slightli
lower
compar
healthi
control
vs
vs
patient
anthracyclin
therapi
lowest
vs
p
taps
paramet
right
ventricular
function
lower
compar
refer
valu
popul
taps
zvalu
conclus
lv
rv
dysfunct
justifi
need
thorough
cardiac
followup
children
hsct
lower
physic
fit
level
decondit
emphas
import
cpet
fit
program
patient
anthracyclin
seem
vulner
group
qualiti
life
mildli
affect
long
time
hsct
conflict
interest
k
vandekerckhov
receiv
grant
clinic
phd
fellow
flemish
scientif
research
board
fwo
vlaanderen
grant
number
remain
author
noth
disclos
hospit
universitario
de
valdecilla
hematolog
santand
spain
background
hematopoiet
stem
cell
transplant
hsct
cur
strategi
malign
nonmalign
diseas
cumul
effect
exposur
chemo
radiotherapi
injur
tissu
lead
long
term
complic
survivor
develop
least
one
late
side
effect
impact
neg
qualiti
life
best
follow
protocol
well
defin
method
perform
retrospect
studi
pediatr
cohort
patient
least
month
surviv
hsct
perform
compil
late
effect
le
follow
previous
uniform
definit
organ
system
cardiovascular
respiratori
hepat
ocular
endocrin
osteomuscular
central
nervou
system
second
neoplasm
psychosoci
issu
cumul
incid
event
overal
surviv
estim
finegray
regress
kaplanmei
respect
result
perform
allogen
autolog
stem
cell
transplant
seven
patient
receiv
second
alohsct
median
year
procedur
male
femal
median
age
hsct
year
twentytwo
patient
nonneoplast
disord
case
donor
hla
match
sibl
syngen
unrel
donor
peripher
blood
use
stem
cell
sourc
patient
umbil
cord
blood
progenitor
patient
cell
deplet
use
patient
ict
includ
condit
regimen
patient
incid
sever
chronic
graft
versu
host
diseas
median
follow
year
transplant
patient
develop
least
one
secondari
le
median
system
affect
per
patient
iqr
frequent
observ
le
ocular
mainli
cataract
endocrin
mainli
hypogonad
hypothyroid
secondari
neoplasm
cumul
incid
endocrinolog
ocular
year
respect
cardiovascular
respiratori
osteomuscular
cumul
incid
year
respect
cumul
incid
second
neoplasm
year
figur
overal
surviv
year
respect
conclus
incid
long
term
secondari
le
stem
cell
transplant
pediatr
cohort
high
previous
report
frequent
observ
le
ocular
mainli
cataract
endocrin
mainli
hypogonad
hypothyroid
secondari
neoplasm
although
less
frequent
le
cardiovascular
respiratori
osteomuscular
must
keep
mind
cumul
incid
second
neoplasm
certain
side
effect
impli
prolong
follow
adher
educ
patient
rel
must
reinforc
conflict
interest
noth
disclos
maisonneuverosemont
de
divis
hematolog
medic
oncolog
stem
cell
transplant
program
depart
medicin
montreal
canada
background
highdos
chemotherapi
hdt
follow
autolog
hematopoiet
stem
cell
transplant
ahsct
safe
fit
elderli
patient
chemosensit
nonhodgkin
lymphoma
nhl
goal
studi
assess
qualiti
life
qol
elderli
patient
follow
ahsct
method
singlecent
research
ethic
committe
approv
studi
investig
qol
survivor
follow
ahsct
treatment
nhl
elderli
inclus
criteria
defin
patient
age
receiv
ahsct
nhl
center
januari
januari
surviv
fiftynin
patient
origin
cohort
met
inclus
criteria
particip
survey
patient
requir
sign
inform
consent
use
instrument
assess
mobil
selfcar
usual
activ
paindiscomfort
anxietydepress
also
use
function
assess
cancer
therapybon
marrow
transplant
factbmt
questionnair
assess
physic
wellb
pwb
socialfamili
wellb
swb
emot
wellb
ewb
function
wellb
fwb
bmt
specif
concern
higher
score
indic
better
qol
differ
score
correl
condit
regimen
gender
age
hematopoiet
cell
transplant
comorbid
index
score
hctci
karnofski
index
diseas
statu
transplant
relaps
result
median
time
ahsct
month
patient
relaps
time
qol
assess
result
questionnair
shown
tabl
patient
report
impair
four
five
domain
lower
karnofski
index
diagnost
associ
impair
mobil
selfcar
anxieti
signific
patient
relaps
transplant
compar
impact
outcom
factbmt
questionnair
result
demonstr
physic
social
emot
wellb
good
function
wellb
variabl
cohort
relaps
associ
impair
ewb
well
bmt
specif
concern
lower
total
factbmt
result
compar
impact
outcom
conclus
studi
demonstr
physic
social
function
wellb
preserv
elderli
patient
follow
ahsct
low
karnosfki
score
prior
transplant
predictor
disabl
follow
ahsct
relaps
follow
ahsct
remain
signific
impedi
maintain
good
qol
conflict
interest
author
noth
disclos
tabl
overal
result
maria
sklodowskacuri
institut
cancer
center
gliwic
branch
depart
bone
marrow
transplant
oncohematolog
gliwic
poland
swp
univers
social
scienc
human
depart
psycholog
warsaw
poland
background
hematopoiet
stem
cell
transplant
hsct
potenti
highli
stress
event
affect
wellb
patient
stage
procedur
pre
around
afterhsct
research
focus
mainli
function
patient
procedur
research
present
focus
essenti
element
wellb
support
relationship
method
two
hundr
patient
first
autolog
allogen
hsct
healthi
partner
spous
anoth
rel
independ
complet
measur
daili
posit
neg
affect
daili
social
support
need
receiv
provid
satisfact
daili
relationship
satisfact
consecut
even
hospit
discharg
multilevel
model
use
investig
fix
random
effect
variabl
chang
time
result
result
indic
neg
affect
systemat
decreas
patient
healthi
partner
day
patient
posit
affect
increas
relationship
satisfact
decreas
time
partner
need
social
support
increas
day
wherea
provid
support
decreas
patient
report
decreas
receiv
support
support
satisfact
healthi
partner
report
opposit
direct
chang
support
compon
time
conclus
find
suggest
deterior
support
exchang
detriment
patient
time
patient
receiv
less
less
support
partner
despit
still
high
demand
affect
wors
assess
relationship
may
relat
fact
patient
better
shape
partner
gradual
withdraw
support
feel
exhaust
paradox
expect
support
patient
stage
deterior
ought
taken
consider
practic
approach
conflict
interest
noth
disclos
st
vincent
hospit
depart
haematolog
darlinghurst
australia
alfr
hospit
lung
transplant
servic
melbourn
australia
st
vincent
hospit
lung
transplant
unit
darlinghurst
australia
background
sever
pulmonari
chronic
graftversushost
diseas
cgvhd
potenti
lifethreaten
complic
affect
allogen
stem
cell
transplant
allosct
recipi
among
treatment
option
cgvhd
influenc
outcom
pulmonari
involv
overal
surviv
os
low
patient
otherwis
fit
free
primari
diseas
lung
transplant
ltx
report
small
number
worldwid
transplant
aim
investig
outcom
ltx
perform
indic
australia
method
retrospect
review
transplant
indic
outcom
two
major
australian
lung
transplant
unit
match
control
patient
transplant
within
time
period
develop
extens
cgvhd
identifi
purpos
os
comparison
result
patient
age
median
year
receiv
bilater
cadaver
lung
transplant
pulmonari
cgvhd
two
allosct
malign
diseas
acut
leukaemia
common
indic
ltx
perform
median
year
post
allosct
rang
median
interv
month
time
transplant
unit
review
ltx
two
earli
death
month
occur
infecti
caus
three
patient
die
pulmonari
infect
one
lung
allograft
reject
two
three
case
second
malign
primari
diseas
relaps
one
patient
underw
second
ltx
month
lung
allograft
reject
median
follow
five
year
rang
os
post
ltx
compar
favour
ishlt
registri
os
ltx
perform
indic
well
publish
natur
histori
sever
pulmonari
cgvhd
os
curv
time
allosct
ltx
control
cgvhd
cohort
patient
age
year
median
follow
shown
figur
outcom
appear
similar
among
patient
develop
extens
cgvhd
irrespect
whether
ltx
perform
conclus
ltx
feasibl
option
select
patient
sever
pulmonari
gvhd
set
outcom
appear
superior
nonltx
base
therapi
pulmonari
cgvhd
like
similar
gener
ltx
popul
conflict
interest
author
noth
disclos
thoma
jefferson
univers
medic
oncolog
philadelphia
pa
unit
state
thoma
jefferson
univers
biostastist
philadelphia
pa
unit
state
background
haploident
stem
cell
transplant
haplosct
cur
therapi
patient
myeloid
disord
lack
hlamatch
donor
primarili
diseas
elderli
recent
advanc
haplosct
suggest
perform
safe
older
patient
util
peripher
blood
pb
twostep
approach
associ
low
graft
failur
rapid
engraft
crucial
older
patient
report
longterm
outcom
method
retrospect
analyz
patient
age
year
aml
n
biphenotyp
leukemia
n
md
n
mpn
n
cmml
n
receiv
twostep
haplosct
decemb
march
condit
myeloabl
tbi
reducedintens
ric
tbi
afterward
larg
fix
dose
allogen
cell
infus
x
step
follow
highdos
cyclophosphamid
cy
mgkgday
x
day
induc
bidirect
toler
select
stem
cell
product
infus
cy
step
gvhd
prophylaxi
compris
tacrolimu
mmf
result
seventyon
patient
male
femal
receiv
twostep
haplosct
ric
median
age
year
rang
median
durat
followup
year
group
rel
younger
patient
median
age
year
rang
compar
ric
group
median
age
year
rang
activ
diseas
transplant
ric
two
patient
previou
autolog
sct
two
patient
receiv
prior
allogen
sct
kp
group
ric
group
hctci
score
group
ric
group
patient
experienc
graft
failur
median
time
anc
platelet
engraft
day
day
respect
pf
ric
os
ric
cumul
incid
ci
nonrelaps
mortal
ric
complet
remiss
time
haplosct
associ
trend
toward
improv
os
vs
p
year
ci
relaps
whole
group
ric
ci
agvhd
grade
iiiv
grade
iiiiv
ci
cgvhd
multivari
analysi
age
independ
predictor
nrm
hr
p
kp
hr
p
condit
hr
p
show
strong
trend
toward
greater
nrm
conclus
matur
singleinstitut
data
suggest
haplosct
safe
effect
treat
aml
md
twostep
pb
haplosct
associ
rapid
uniform
engraft
without
graft
reject
gvhd
rate
compar
bone
marrow
graft
approach
result
suggest
age
alon
barrier
haplosct
older
fit
patient
conflict
interest
author
noth
disclos
sultan
qaboo
univers
hospit
pharmaci
muscat
oman
sultan
qaboo
univers
pharmacolog
muscat
oman
sultan
qaboo
univers
hospit
hematolog
muscat
oman
background
hepat
venoocclus
diseas
vod
one
seriou
complic
post
allogen
hematopoiet
stem
cell
transplant
hsct
busulfan
bu
metabol
occur
liver
high
exposur
defin
area
concentr
time
curv
auc
steadi
state
concentr
css
ngml
shown
correl
risk
vod
object
studi
assess
role
gst
polymorph
incid
hepat
vod
patient
undergo
hsct
method
retrospect
singl
center
cohort
studi
includ
patient
underw
hsct
indic
period
januari
octob
center
modifi
seattl
criteria
use
defin
hepat
vod
patient
genotyp
polymorph
use
capillari
electrophoresi
genotyp
use
dna
sequenc
thermal
cycler
sequenc
impact
gst
polymorph
hepat
vod
examin
use
test
standard
descript
analyt
statist
graph
creat
use
stata
version
result
patient
target
css
ngml
common
diagnosi
prior
transplant
acut
leukemia
patient
inherit
hemoglobinopathi
patient
second
common
diagnosi
overal
patient
develop
vod
incid
vod
patient
delet
compar
insert
p
incid
vod
patient
delet
compar
insert
p
ten
percent
patient
aa
ag
gg
genotyp
develop
vod
differ
statist
signific
p
incid
vod
genotyp
cc
cc
cg
respect
signific
differ
p
incid
vod
genotyp
aa
ag
signific
differ
p
similarli
incid
vod
genotyp
gg
gc
cc
cc
p
conclus
glutathion
stransferas
polymorph
associ
hepat
vod
like
due
narrow
exposur
variabl
patient
receiv
pharmacokinet
base
bu
dose
recommend
factor
known
associ
hepat
vod
model
futur
studi
ask
question
conflict
interest
conflict
interest
studi
support
intern
grant
colleg
medicin
health
scienc
sultan
qaboo
univers
sultan
qaboo
univers
hospit
hematolog
muscat
oman
sultan
qaboo
univers
hospit
pharmaci
muscat
oman
sultan
qaboo
univers
pharmacolog
muscat
oman
background
overal
surviv
os
post
bmt
associ
primari
diseas
intens
prepar
regimen
use
among
other
glutathion
stransferas
gst
polymorph
may
chang
drug
exposur
busulfan
bu
base
prepar
regimen
therefor
may
also
associ
mortal
aim
herein
assess
impact
gst
polymorph
mortal
rate
patient
undergo
hsct
method
singl
center
retrospect
cohort
studi
adult
pediatr
patient
receiv
intraven
bu
prior
hsct
sultan
qaboo
univers
hospit
januari
octob
indic
genotyp
gst
polymorph
done
pretranspl
patient
sampl
use
capillari
electrophoresi
insert
delet
dna
sequenc
impact
gst
polymorph
os
compar
use
logrank
test
kaplanmei
curv
use
estim
os
standard
descript
analyt
statist
graph
creat
use
statist
softwar
stata
version
result
total
number
patient
includ
male
femal
follow
patient
die
median
time
death
reach
os
day
one
two
year
respect
caus
death
mostli
due
combin
graft
lossrelaps
without
sepsi
follow
sever
gvhd
without
sepsi
doubl
insert
significantli
increas
risk
death
predict
os
addit
insert
increas
risk
death
also
associ
os
p
variant
signific
effect
rate
os
pvalu
conclus
doubl
insert
increas
risk
death
patient
undergo
hsct
result
need
confirm
larger
prospect
studi
conflict
interest
conflict
interest
studi
support
intern
grant
colleg
medicin
health
scienc
sultan
qaboo
univers
univers
athen
alexandra
hospit
depart
obstetr
gynecolog
athen
greec
children
hospit
endocrin
dept
athen
greec
univers
athen
aretaeion
hospit
dept
obstetr
gynecolog
athen
greec
agia
sophia
children
hospit
athen
stem
cell
transplant
unit
athen
greec
agia
sophia
children
hospit
stem
cell
transplant
unit
athen
greec
children
hospit
p
kyriak
endocrinolog
athen
greec
agia
sophia
children
hospit
athen
greec
background
chronic
graft
versu
host
diseas
cgvhd
seriou
complic
allogen
bmt
genit
cgvhd
remain
underrecognis
variant
aim
present
two
case
haematocolpo
due
vagin
synechia
form
result
gvhd
follow
bmt
late
childhood
adolesc
method
allotranspl
perform
femal
patient
year
age
two
patient
hematocolpo
recogn
result
first
patient
diagnos
fanconi
syndrom
allogen
bmt
develop
mild
chronic
gvhd
limit
skin
mucosa
treat
symptomat
without
corticosteroid
eighteen
month
posttranspl
thelarch
hormon
investig
consist
hypergonadotrop
hypogonad
fsh
age
year
start
estradiol
valer
dose
mg
daili
good
clinic
respons
year
age
pelvic
sonogram
reveal
collect
within
upper
vagina
assum
hematocolpo
pelvic
mri
confirm
obstruct
show
collect
blood
asymptomat
remain
surveil
regular
scan
show
gradual
increas
size
haematocolpo
six
month
initi
identif
obstruct
spontan
discharg
haematocolpo
examin
vagina
appear
obliter
still
howev
pinhol
open
drain
brown
discharg
identifi
stent
small
haegar
dilat
gradual
dilat
eas
vagina
fulli
patent
report
normal
period
howev
two
month
follow
vagina
appear
obliter
approxim
introitu
obviou
passag
seen
examin
anaesthesia
withdraw
bleed
pinpoint
open
seen
bluntli
open
dilat
initi
digit
plane
easili
identifi
vagina
made
fulli
patent
minim
bleed
second
girl
age
year
underw
allogen
bmt
myelodysplast
syndrom
menarch
year
develop
gvhd
limit
skin
treat
high
dose
steroid
therapi
one
year
post
transplant
amenorrhea
hormon
investig
consist
hypergonadotrop
hypogonad
fsh
start
sex
steroid
replac
therapi
estradiol
valer
start
mg
daili
subsequ
increas
mg
three
month
increas
dose
haematocolpo
measur
mm
seen
pelvic
sonogram
patient
asymptomat
kept
surveil
increas
haematocolpo
notic
eventu
spontan
drainag
collect
nevertheless
within
two
month
vagina
restenos
obliter
oestradiol
dose
increas
led
spontan
lysi
vagin
stenosi
three
year
later
remain
cyclic
combin
prepar
hrt
regular
cyclic
bleed
conclus
genit
symptom
may
readili
report
patient
post
bmt
physician
awar
possibl
late
effect
gvhd
genitalia
inquir
symptom
acquaint
address
complic
conflict
interest
conflict
interest
hospit
german
tria
pujol
institut
oncologia
institut
de
recerca
contra
la
josep
carrera
hematolog
badalona
spain
background
hematopoiet
stem
cell
transplantationassoci
thrombot
microangiopathi
tatma
potenti
lethal
complic
limit
therapeut
option
incid
tatma
transplant
variabl
due
lack
standard
diagnost
criteria
predispos
factor
includ
condit
regimen
immunosuppress
agent
gvhd
hla
missmatch
opportunist
infect
tatma
usual
occur
within
day
hsct
mortal
rate
treatment
strategi
tatma
limit
therapeut
plasma
exchang
tpe
shown
effect
initi
earli
suggest
delay
tpe
therapi
might
relat
poor
outcom
rate
method
perform
retrospect
studi
episod
tatma
regist
novemb
singl
centr
subanalysi
report
recent
patient
addit
inform
result
characterist
pacient
receiv
allogen
hsct
shown
tabl
women
median
age
year
rang
year
patient
receiv
total
bodi
irradi
gvhd
prophylaxi
includ
calcineurin
inhibitor
cyclosporin
tacrolimu
patient
neurolog
manifest
renal
involv
patient
concomit
infect
patient
activ
gvhd
acut
gvhd
treatment
withdraw
calcineurin
inhibitor
plasma
exchang
rituximab
defibrotid
patient
achiev
tatma
complet
respons
patient
longterm
survivor
caus
death
directli
relat
tatma
gvhd
infect
data
recent
patient
refractori
hipertens
requir
treatment
control
first
signal
tatma
ldh
elev
renal
failur
thrombocytopenia
interv
first
signal
tatma
onset
treatment
day
rang
day
median
time
hsct
diagnosi
tatma
month
rang
month
probabl
os
tatma
month
ci
conclus
tatma
sever
complic
hsct
associ
high
mortal
lack
standard
diagnost
criteria
delay
onset
treatment
first
sign
tatma
seri
increas
ldh
level
conflict
interest
autor
declar
conflict
interest
fund
fondo
de
inversion
sanitaria
rticc
instituto
carlo
iii
cerca
program
generalitat
de
catalunya
la
caixa
foundat
rticcinstituto
carlo
iii
proyecto
de
ayuda
pacient
de
la
dkm
tabl
pacient
characterist
pavlov
first
saint
petersburg
state
medic
univers
intens
care
unit
saint
petersburg
russian
feder
pavlov
first
saint
petersburg
state
medic
univers
saint
petersburg
russian
feder
background
hemorrag
cystiti
hc
allogen
hematopoet
stem
cell
transplant
allohsct
common
complic
incid
develop
hc
lead
increas
blood
transfus
risk
urinari
tract
obstruct
renal
failur
etiolog
hc
well
defin
probabl
reason
hc
toxic
chemotherapi
persist
viral
infect
polyomaviru
famili
addit
impact
agvhd
need
investig
aim
studi
analys
epidemiolog
risk
factor
hc
children
allohsct
differ
conditiong
regimen
method
patient
yo
median
gb
aml
malign
disias
inherit
diseas
aa
myeloabl
condit
regimen
bu
mgkgflu
cy
mgkg
use
pt
reduc
intens
condit
regimen
flu
bu
mgkg
mel
thio
mgkg
pt
sourc
allohsct
match
relat
donor
haploident
match
unrel
bone
marrow
bm
use
peripher
blood
stem
cell
pbsc
combin
bm
pbsc
prophylaxi
agvhd
basi
csa
tacro
mmf
atg
csa
tacro
sirolimusptci
mesna
administ
mgkg
iv
infus
min
prior
cy
studi
epidemiolog
hc
children
risk
factor
hc
detect
viru
bkpyv
jcpyv
pcr
transfus
depend
os
mean
kaplanmei
method
assess
result
hc
develop
patient
sever
hc
grade
iiiiv
develop
interv
allohsct
hc
onset
day
durat
hc
day
factor
increas
risk
hc
develop
age
year
cyclophosphamid
part
condit
regimen
graftversushost
diseas
grade
iiiv
bkpyv
detect
urin
patient
hc
jcpyv
detect
urin
patient
hc
patient
hc
frequenc
blood
transfus
unit
per
day
median
number
dose
rang
differ
patient
without
hc
patient
sever
hc
intens
bleed
need
blood
transfus
unit
per
day
total
number
dose
median
transplant
relat
mortal
children
hc
complex
complic
gvhd
infect
hc
direct
caus
death
pt
surviv
patient
without
hc
patient
hc
ci
conclus
hc
children
allohsct
common
complic
along
influenc
overal
surviv
risk
factor
hc
cy
condit
regimen
gvhd
allow
develop
approach
prophylaxi
effect
treatment
conflict
interest
author
noth
disclos
univers
medicin
pharmaci
v
babe
pediatr
bone
marrow
transplant
timisoara
romania
univers
medicin
pharmaci
v
babe
pediatr
timisoara
romania
emerg
children
hospit
l
turcanu
bone
marrow
transplant
timisoara
romania
emerg
children
hospit
l
turcanu
oncohematolog
timisoara
romania
background
allogen
hematopoiet
stem
cell
transplant
allohsct
remain
therapeut
approach
high
transplantrel
morbid
among
complic
hemorrhag
thrombot
disturb
common
especi
earli
posttranspl
phaseth
aim
studi
ass
transplantrel
earli
late
haemostat
impair
patient
undergo
allohsct
method
retrospect
studi
number
patient
receiv
allohsct
center
bone
marrow
transplant
timisoara
romania
januari
septemb
fourtyfour
receiv
graft
relat
donor
one
cord
blood
wherea
unrel
match
donor
among
studi
group
indic
allohsct
acut
lymphoblast
leukemia
patient
acut
myeloblast
leukemia
aml
patient
chronic
myelogen
leukemia
cml
patient
case
myelodisplast
syndrom
md
juvenil
myelomonocyt
leukemia
jmml
child
sever
sever
aplast
anemia
saa
case
chronic
granulomat
diseas
cgd
children
sever
combin
immunodefici
children
hemophagocyt
lymphohistiocytosi
child
thalassemia
major
one
child
patient
receiv
heparin
prophylaxi
venoocclus
diseas
antithrombin
iii
atiii
level
measur
twice
weekli
preemptiv
given
level
decreas
result
among
bleed
complic
degre
bleed
score
upper
gastrointestin
gi
tract
bleed
twice
frequent
lower
gi
tract
bleed
intracrani
hemorrhag
occur
case
regard
thrombot
thrombohemorrhag
disord
dic
associ
sepsi
encount
case
transplantationrel
thrombot
microangiopathi
diagnos
patient
patient
present
hepat
vod
among
four
sever
form
atiii
administr
necessari
least
conclus
hemostat
complic
still
caus
high
morbid
among
transplant
recipi
case
associ
mortal
sever
form
vod
may
requir
use
expens
drug
contribut
high
cost
often
lifesav
bone
marrow
transplant
procedur
atiii
seem
effect
prevent
progress
vod
sever
form
conflict
interest
noth
disclos
azienda
ospedaliera
universitaria
pisana
pisa
itali
degli
studi
di
pisa
pisa
itali
background
hepat
c
viru
hcv
infect
caus
macrofhag
activ
syndrom
ma
pediatr
popul
never
report
previous
method
describ
case
ma
associ
hcv
infect
girl
acut
lymphoblast
leukemia
underw
hematopoiet
stem
cell
transplant
hsct
attain
viral
suppress
ledipasvirsofosbuvir
result
ukranian
girl
prob
cell
infect
hcvrna
iuml
receiv
chemotherapi
accord
aieop
lal
protocol
myeloabl
allogen
hsct
mud
engraft
hsct
neutrophil
patient
present
epigastr
pain
icter
skin
fever
vomit
diarrhea
blood
exam
show
progress
cytopenia
wbc
hb
gdl
hypofibrinogenemia
alt
ast
hyperbilirubinemia
tot
direct
mgdl
hypertrigliceridemia
hyperferritinemia
blood
cultur
neg
cmv
ebv
adenoviruspcr
neg
serolog
hepat
hbvdna
neg
hcvrna
iuml
clinic
examin
abdomin
ultrasound
reveal
hepatosplenomegali
bom
show
cr
increas
histiocyt
macrophag
hemophagocytosi
sign
gvhd
ma
secondari
hcv
infect
suspect
treatment
highdos
corticosteroid
cyclosporinea
ledipasvirsofusbivir
initi
hsct
fever
disappear
laboratori
exam
improv
quantit
pcr
hcv
rna
decreas
iuml
week
antivir
treatment
hcvrna
neg
patient
present
fever
headach
left
facial
droop
right
converg
strabismu
aphasia
disequilibrium
gait
unsteadi
absenc
deep
tendon
reflex
clumsi
hand
drowsi
brainmri
show
multipl
supra
infratentori
area
masslik
appear
central
necrosi
surround
hyperintens
ring
broad
laboratori
workup
confirm
cerebr
reactiv
ma
thu
dose
intraven
corticosteroid
increas
intraven
mannitol
administ
reduc
intracrani
pressur
phenobarbit
carbamazepin
initi
antivir
therapi
ledipasvirsofusbivir
discontinu
total
month
follow
month
hsct
patient
alert
fulli
orient
fluent
speech
normal
languag
perman
left
facial
droop
diffus
left
lower
extrem
weak
reduc
deep
tendon
reflex
steppag
gait
left
brainmri
show
neither
new
lesion
enlarg
previous
describ
area
last
quantit
pcr
hcvrna
neg
bm
aspir
cr
ma
full
donor
chimer
conclus
term
ma
design
clinicopatholog
entiti
occur
differ
hemophagocyt
syndrom
hss
primari
hemophagocyt
lymphohistiocytosi
hlh
recogn
immunogenet
basi
secondari
hss
due
autoimmun
diseas
malign
underli
infect
secondari
hs
due
viral
infect
commonli
due
herp
group
case
ma
probabl
trigger
hcv
earli
treatment
ledipasvirsofosbuvir
reveal
highli
effect
hcv
infect
welltoler
patient
despit
viral
clearanc
hlh
persist
time
perman
neurolog
impair
conflict
interest
noth
disclos
nation
research
centr
hematolog
bone
marrow
depart
moscow
russian
feder
nation
research
centr
hematolog
flow
cytometri
laboratori
moscow
russian
feder
background
allogen
hematopoiet
stem
cell
transplant
allohsct
effect
therapi
leukemia
patient
differ
memori
cell
subset
form
main
pool
adapt
immun
leukemia
cell
howev
shown
previous
cell
go
subset
respons
acut
graft
versu
host
diseas
agvhd
onset
high
dose
posttranspl
ptci
present
safe
effect
approach
prevent
gvhd
research
overse
impact
ptci
differ
memori
cell
recoveri
allohsct
method
peripher
blood
pb
sampl
collect
patient
acut
leukemia
day
allohsct
edtatub
group
consist
patient
male
femal
median
age
year
year
old
underw
allohsct
patient
receiv
atg
within
immunosuppress
therapi
classic
immunosuppress
therapi
includ
csammfmtx
ptci
day
use
patient
monoptci
relaps
patient
allohsct
csammfptci
patient
transplant
unrel
mismatch
donor
flow
cytometri
analysi
perform
bd
fac
canto
ii
becton
dickinson
usa
use
exclud
dead
cell
analysi
antibodi
becton
dickinson
usa
use
defin
memori
subset
naiv
stem
cell
memori
tnvtscm
central
memori
tcm
transit
memori
ttm
effector
memori
tem
termin
effector
tte
mannwhitney
u
test
use
nonparametr
data
analysi
pvalu
less
consid
signific
data
analysi
conduct
util
spss
ver
ibm
chicago
ill
usa
result
accord
data
tnvtscm
cell
subset
suscept
ptci
due
lowest
number
cell
pb
within
follow
period
allohsct
day
number
tnvtscm
ptci
versu
classic
immunosuppress
regimen
day
versu
respect
day
versu
respect
find
demonstr
ptci
influenc
cell
compart
go
associ
feasibl
immunosuppress
mechan
subset
tcm
ttm
tem
tte
changeabl
regardless
immunosuppress
regimen
conclus
success
reconstitut
memori
cell
provid
effect
immun
could
help
suppli
antileukemia
respons
allohsct
found
reduc
tnvtscm
cell
pb
ptci
hypothet
could
play
key
role
prevent
gvhd
possibl
immunosuppress
mechan
ptci
associ
influenc
cell
compart
time
ptci
seem
affect
consider
memori
effector
pool
cell
go
platform
graftversusleukemia
effect
allohsct
conflict
interest
relev
conflict
interest
declar
vilniu
univers
hospit
santaro
kliniko
hematolog
oncolog
transfus
medicin
center
vilniu
lithuania
state
research
institut
centr
innov
medicin
vilniu
lithuania
background
preval
antihla
antibodi
aha
among
hsct
recipi
report
differ
studi
higher
percentag
parou
femal
signific
aha
especi
donorspecif
aha
investig
hsct
field
howev
find
appli
haploident
cord
blood
set
result
mostli
address
impact
donorspecif
aha
graft
failur
donorspecif
aha
found
associ
primari
graft
failur
higher
transplantrel
mortal
trm
rate
inferior
overal
surviv
os
haploident
bone
marrow
cord
blood
transplant
studi
unrel
donor
ud
hsct
confirm
donorspecif
aha
associ
fail
engraft
howev
quit
studi
investig
signific
aha
nondonorspecif
hsct
outcom
main
object
prospect
studi
evalu
clinic
relev
antihla
ab
ud
allohsct
method
june
septemb
adult
patient
reach
followup
first
unrel
donor
hsct
die
within
period
recruit
prospect
studi
donorpati
pair
match
hlaa
b
c
loci
addit
loci
type
patient
sera
sampl
collect
schedul
start
condit
regimen
month
hsct
antihla
antibodi
screen
specif
identifi
solidphas
immunoassay
immucor
luminex
platform
hlamatchmak
program
use
perform
structur
hla
class
class
ii
match
eplet
level
result
patient
median
age
year
rang
patient
men
seventyfour
donor
patient
pair
match
patient
achiev
neutrophil
engraft
hsct
patient
secondari
graft
failur
overal
preval
preform
antihla
antibodi
donorspecif
antibodi
found
patient
retain
antihla
antibodi
hsct
presenc
preform
antihla
antibodi
found
associ
frequest
develop
earli
grade
iii
iv
acut
graftversushost
diseas
agvhd
posttranspl
complic
p
higher
transplantrel
mortal
p
shorter
overal
surviv
p
preform
antihla
antibodi
affect
engraft
incid
relaps
graft
failur
event
free
surviv
antihla
antibodi
detect
hsct
impact
develop
earli
complic
outcom
hsct
nine
patient
develop
de
novo
antihla
antibodi
hsct
case
donorspecif
direct
mismatch
conclus
preform
antihla
antibodi
impact
develop
sever
agvhd
higher
transplant
relat
mortal
reduc
overal
surviv
unrel
donor
hsct
therefor
routin
test
antihla
antibodi
may
consid
pretranspl
workup
recipi
conflict
interest
conflict
interest
grant
research
council
lithuania
ankara
univers
school
medicin
depart
hematolog
stem
cell
transplant
unit
ankara
turkey
ankara
univers
school
medicin
depart
intern
medicin
ankara
turkey
background
hepat
b
viru
hbv
infect
global
diseas
estim
million
peopl
turkiy
chronic
hepat
b
infect
reactiv
hbv
wellrecogn
complic
patient
undergo
highdos
chemotherapi
hematopoet
stem
cell
transplant
hct
preval
hbv
infect
multipl
myeloma
mm
patient
rang
frequenc
revers
seroconvers
autohsct
unclear
perform
retrospect
studi
assess
incid
hbv
reactiv
liver
toxic
method
conduct
retrospect
studi
patient
malefemal
mm
auto
hsct
ankara
univers
school
medicin
bone
marrow
transplant
unit
januari
octob
clinic
databas
electron
medic
record
search
collect
liver
function
test
hbv
serolog
viral
load
test
result
patient
liver
function
test
start
condit
regimen
autohsct
liver
function
test
perform
threemonth
interv
followup
period
hbv
serolog
repeat
autohsct
except
abnorm
transaminas
level
result
median
age
cohort
year
rang
year
median
followup
interv
month
bortezomib
base
regimen
given
induct
therapi
major
patient
five
patient
activ
hbv
infect
time
autohsct
patient
use
antivir
treatment
follow
autohsct
serolog
obtain
neg
patient
fiftytwo
patient
ad
resolv
hbv
infect
posit
hepat
b
core
antibodi
hbcab
neg
hepat
b
surfac
antigen
hbsag
patient
resolv
hbv
infect
receiv
preemptiv
antivir
therapi
mgday
tenofovir
autohsct
none
patient
hbv
reactiv
transplant
followup
period
venoocclus
diseas
fulmin
liver
failur
observ
baselin
serum
transaminas
level
normal
patient
five
patient
higher
alt
ast
level
patient
higher
alt
normal
ast
level
mean
alt
level
conclus
period
monitor
liver
function
prolong
followup
may
need
autohsct
detect
hbv
reactiv
liver
toxic
find
need
confirm
prospect
studi
larger
number
patient
conflict
interest
author
noth
disclos
american
univers
beirut
medic
center
intern
medicin
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
intern
medicin
beirut
lebanon
background
high
dose
chemotherapi
autolog
peripher
stem
cell
transplant
apsct
becom
standard
care
multipl
hematolog
malign
limit
data
investig
effect
condit
regiment
lung
function
post
apsct
studi
aim
identifi
pulmonari
function
chang
occur
postapsct
myeloma
lymphoma
patient
receiv
melphalan
beam
condit
respect
method
retrospect
studi
approv
institut
review
board
american
univers
beirut
medic
center
includ
patient
underw
apsct
avail
pretranspl
week
pretranspl
pulmonari
function
test
result
measur
spirometri
valu
includ
forc
expiratori
volum
second
forc
vital
capac
fvc
ratio
forc
midexpiratori
flow
rate
obtain
forc
maxim
expiratori
vital
capac
maneuv
total
lung
capac
tlc
residu
volum
rv
measur
use
helium
dilut
techniqu
addit
diffus
capac
measur
use
singlebreath
carbon
monoxid
method
dlco
result
includ
total
patient
avail
pulmonari
function
test
result
fortyf
patient
transplant
multipl
myeloma
receiv
melphalan
condit
regiment
patient
transplant
lymphoma
receiv
beam
condit
median
age
transplant
year
rang
melphalan
group
year
rang
beam
group
twenti
five
patient
melphalan
group
smoker
compar
patient
beam
group
patient
observ
greater
decreas
lung
volum
patient
receiv
beam
compar
melphalan
group
decreas
percent
patient
receiv
beam
receiv
melphalan
fvc
decreas
beam
melphalan
respect
howev
statist
signific
decreas
dlco
tlc
smoke
age
diseas
statu
transplant
gender
signific
impact
lung
volum
chang
posttranspl
conclus
acknowledg
retrospect
natur
studi
limit
sampl
size
conclud
beam
condit
regiment
associ
signific
decreas
fvc
posttranspl
compar
melphalan
condit
conflict
interest
author
noth
disclos
tabl
pft
chang
post
apsct
hospit
german
tria
pujol
institut
doncologia
institut
de
recerca
contra
la
josep
carrera
clinic
hematolog
depart
badalona
spain
background
hepat
sinusoid
obstruct
syndrom
hso
gener
show
first
day
sct
remain
associ
high
morbid
mortal
clinic
symptom
includ
weight
gain
hyperbilirubinemia
pain
hepatomegali
ascitesfluid
retent
main
risk
factor
previou
sct
iron
overload
treatment
gemtuzumab
inotuzumab
ozogamizin
object
studi
evalu
incid
treatment
outcom
patient
pt
hso
sct
singl
centr
method
januari
septemb
sct
perform
pt
hso
sever
grade
follow
new
ebmt
criteria
mohti
et
al
bmt
result
thirtythre
pt
develop
hso
characterist
sct
pt
describ
tabl
twentytwo
pt
least
one
risk
factor
pt
risk
factor
prophylact
strategi
use
pt
low
weight
heparin
ursodeoxychol
acid
global
cumul
incid
sosh
day
significantli
higher
cord
sct
peripher
blood
sct
vs
p
median
time
sct
hso
day
pt
show
earli
onset
day
twentyon
pt
met
criteria
severeveri
sever
sosh
liver
biopsi
confirm
diagnosi
pt
hepat
venou
pressur
gradient
mm
hg
pt
nine
evalu
pt
develop
multiorgan
failur
twenti
pt
treat
defibrotid
dft
support
treatment
st
patient
severeveri
sever
hso
receiv
frequent
dft
st
pt
ten
pt
treat
dft
receiv
st
recov
sixteen
among
allosct
pt
develop
acut
gvhd
grade
iv
liver
gvhd
pt
pt
longterm
survivor
caus
death
hso
gvhd
relaps
infect
graftfailur
second
neoplasm
median
os
month
ci
studi
neither
number
risk
factor
sever
hso
significantli
influenc
os
conclus
hso
incid
studi
similar
refer
even
hso
recov
pt
surviv
remain
low
clinic
trial
registri
appli
conflict
interest
found
fondo
de
investigacion
sanitaria
rticc
instituto
carlo
iii
cerca
program
generalitat
de
catalunya
la
caixa
foundat
rticcinstituto
carlo
iiith
author
declar
conflict
interest
tabl
characterist
patient
rm
gorbacheva
memori
institut
hematolog
oncolog
transplant
pavlov
first
saint
petersburg
state
medic
univers
st
petersburg
russian
feder
background
sever
poor
graft
function
spgf
remain
seriou
multifactori
complic
allohsct
although
incid
variou
pre
posttranspl
risk
factor
spgf
report
still
controversi
insuffici
defin
aim
studi
investig
incid
baselin
pretranspl
risk
factor
nongvhd
associ
spgf
method
perform
retrospect
prospect
analysi
graft
function
larg
cohort
adult
patient
allohsct
criteria
spgf
peripher
blood
cytopenia
anc
plt
x
hb
gl
time
sustain
engraft
full
stabl
mix
donor
chimer
absenc
underli
diseas
relaps
graft
reject
grade
iiiiv
agvhd
factor
analyz
includ
age
gender
diagnosi
ferritin
level
donor
type
mrd
mud
haplo
sex
blood
group
match
donor
pregnanc
sourc
graft
bm
pb
number
infus
mnc
cell
condit
regimen
mac
ric
gvhd
prophylaxi
convent
ptcybas
cumul
incid
spgf
calcul
consid
death
relaps
reject
sever
agvhd
compet
event
independ
risk
factor
analyz
multivari
finegray
proport
hazard
regress
model
compet
event
result
studi
includ
adult
patient
median
age
year
rang
mf
success
engraft
allohsct
differ
indic
aml
cml
hl
nhl
cll
md
pmf
mdsmpn
saa
median
followup
hsct
day
total
patient
develop
spgf
cumul
incid
ci
ci
day
respect
median
time
hsct
onset
spgf
day
univari
analysi
diagnosi
statu
hsct
identifi
distinct
risk
group
spgf
low
saa
acut
leukemia
cr
cml
lymphoma
intermedi
acut
leukemia
noncr
statu
high
md
mdsmpn
pmf
cumul
incid
respect
anoth
potenti
risk
factor
univari
analysi
donor
type
mrd
mud
vs
haplo
pretranspl
ferritin
level
percentil
ngml
vs
multivari
finegray
proport
hazard
regress
model
confirm
signific
diagnosi
cr
statu
risk
group
hr
ci
pretranspl
ferritin
level
ngml
hr
ci
fifti
patient
restor
good
graft
function
includ
hsc
boost
median
spgf
durat
day
remain
patient
unfavor
outcom
spgf
includ
death
relaps
median
day
graft
reject
median
day
spgf
onset
conclus
data
substanti
supplement
current
understand
incid
risk
factor
outcom
spgf
allohsct
earli
detect
stratif
may
contribut
improv
spgf
outcom
conflict
interest
noth
disclos
hannov
medic
school
depart
hematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
intens
care
hematolog
oncolog
patient
ichop
germani
hannov
medic
school
depart
respiratori
diseas
german
centr
lung
research
dzl
hannov
germani
hannov
medic
school
depart
gastroenterolog
hepatolog
endocrinolog
hannov
germani
hannov
medic
school
depart
nephrolog
hypertens
hannov
germani
academ
teach
hospit
braunschweig
medic
clinic
v
nephrolog
rheumatolog
blood
purif
braunschweig
germani
background
intens
care
unit
icu
admiss
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
associ
rel
poor
outcom
analyz
reason
icu
admiss
well
short
longterm
outcom
critic
ill
hsct
recipi
method
consecut
adult
patient
transplant
hannov
medic
school
patient
least
admit
icu
includ
retrospect
studi
result
main
reason
icu
admiss
acut
respiratori
failur
arf
sever
sepsissept
shock
cardiac
problem
reason
like
acut
renal
failur
bleed
impair
conscious
occur
admiss
emerg
surgeri
encount
graftvshostdiseas
gvhd
let
icu
admiss
patient
admit
icu
monitor
exclud
analysi
median
time
hsct
icu
transfer
day
depend
reason
admiss
patient
cardiac
event
respiratori
failur
sever
sepsi
gvhd
requir
intens
care
median
day
hsct
ns
respect
contrast
patient
emerg
surgic
procedur
admit
day
p
icu
stay
arf
occur
patient
half
patient
arf
due
extrapulmonari
reason
eg
cardiogen
pulmonari
edema
extrapulmonari
sepsi
result
ard
noninvas
ventil
niv
use
primari
approach
patient
niv
failur
requir
secondari
intub
invas
mechan
ventil
use
patient
arf
median
ventil
time
day
cardiac
event
occur
patient
treatment
vasopressor
necessari
patient
mainli
due
septic
shock
occur
patient
suffer
acut
kidney
injuri
half
requir
renal
replac
therapi
icu
hospit
icu
admiss
respect
icu
mortal
rate
depend
main
reason
admiss
shown
figur
cox
proport
hazard
ratio
model
use
predict
chang
likelihood
icu
mortal
timedepend
manner
icu
mortal
higher
earli
period
transplant
signific
decreas
found
patient
later
day
likelihood
mortal
higher
compar
nonicu
patient
p
remark
postdischarg
surviv
icu
patient
compar
surviv
nonicu
patient
year
vs
ns
conclus
besid
arf
septic
shock
cardiac
event
main
reason
icu
admiss
shortterm
surviv
critic
ill
hsct
patient
requir
organ
support
system
still
remain
poor
likelihood
mortal
decreas
continu
day
transplant
plateau
reach
half
year
longterm
surviv
hsct
recipi
discharg
hospit
significantli
affect
former
icu
stay
conflict
interest
none
royal
brisban
women
hospit
brisban
australia
univers
queensland
brisban
australia
background
nutrit
support
allogen
haematopoiet
stem
cell
transplant
import
compon
care
prevent
malnutrit
howev
consensu
optim
method
supplementari
feed
nonrandomis
studi
indic
enter
nutrit
en
may
improv
patient
outcom
compar
parenter
nutrit
pn
level
toler
nasogastr
feed
unclear
randomis
studi
aim
determin
toler
proactiv
earli
en
comparison
pn
standard
care
method
patient
undergo
allogen
transplant
reduc
intens
fludarabin
melphalan
myeloabl
cyclophosphamid
tbi
condit
elig
particip
patient
random
en
nasogastr
tube
insert
day
stem
cell
infus
feed
commenc
oral
intak
declin
rate
feed
increas
goal
patient
intoler
en
convert
pn
standard
care
group
commenc
pn
per
unit
protocol
primari
endpoint
toler
en
group
percentag
patient
random
en
must
discontinu
method
chang
pn
requir
topup
pn
data
also
collect
clinic
outcom
assess
use
ctcae
version
criteria
result
forti
four
patient
mean
age
male
femal
consent
particip
randomis
en
standard
care
en
group
eleven
toler
en
nine
chang
pn
two
withdrew
studi
reason
chang
pn
gastrointestin
intoler
tube
dislodg
patient
declin
reinsert
tube
dislodg
sever
mucos
prevent
reinsert
develop
ileu
patient
requir
top
pn
data
complic
rate
avail
patient
requir
pn
standard
care
group
patient
en
group
statist
signific
differ
group
clinic
outcom
grade
complic
includ
elev
liver
enzym
en
pn
p
hyperglycaemia
en
pn
hypertriglyceridaemia
en
pn
mucos
en
pn
cathet
relat
infect
en
pn
platelet
engraft
day
en
pn
time
neutrophil
engraft
en
mean
day
pn
day
length
hospit
stay
en
median
day
pn
day
gvhd
incid
day
en
group
pn
p
incid
grade
gvhd
en
group
pn
group
p
day
surviv
en
pn
conclus
half
patient
receiv
allogen
transplant
toler
en
commenc
earli
postcondit
base
rel
small
number
appar
differ
clinic
outcom
en
pn
use
earli
en
reduc
use
pn
associ
cost
risk
consid
first
line
nutrit
support
clinic
trial
registri
trial
regist
anzctr
http
wwwanzctrorgau
refer
number
conflict
interest
sarah
andersen
conflict
interest
fund
receiv
royal
brisban
hospit
post
graduat
research
scholarship
remain
author
noth
disclos
sheffield
teach
hospit
nh
foundat
trust
haematolog
sheffield
unit
kingdom
univers
sheffield
oncolog
metabol
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
physiotherapi
sheffield
unit
kingdom
sheffield
hallam
univers
nurs
midwiferi
sheffield
unit
kingdom
sheffield
hallam
univers
health
social
care
research
sheffield
unit
kingdom
univers
sheffield
school
health
relat
research
scharr
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
collabor
leadership
appli
health
research
care
clahrc
sheffield
unit
kingdom
background
ahsct
intens
procedur
use
routin
consolid
inductionreinduct
chemotherapi
first
second
line
treatment
mm
patient
year
select
older
patient
recoveri
qualiti
life
qol
postahsct
take
averag
month
mm
patient
meet
nation
physic
activ
guidelin
posttreat
declin
activ
treatment
due
perceiv
barrier
exercis
includ
pain
fear
injuri
fatigu
exercis
rehabilit
programm
safe
deliv
patient
recov
ahsct
improv
physic
perform
muscl
strength
aerob
capac
psycholog
outcom
immunolog
function
fatigu
mm
patient
reduc
exercis
capac
pretranspl
may
benefit
prehabilit
defin
process
continuum
care
occur
time
cancer
diagnosi
begin
acut
treatment
provid
target
intervent
improv
health
reduc
incid
sever
current
futur
impair
prehabilit
shown
effect
diseas
date
research
prehabilit
mm
patient
runup
ahsct
method
object
mix
method
studi
determin
whether
feasibl
conduct
randomis
control
trial
rct
pretranspl
exercis
mm
patient
await
ahsct
studi
summaris
figur
fund
uk
nihr
ethic
committe
approv
fulli
inform
consent
referr
central
hsct
servic
cover
approxim
million
identifi
patient
mm
commenc
inductionreinduct
chemotherapi
appropri
candid
ahsct
patient
invit
particip
weekli
session
individualis
supervis
exercis
whilst
await
ahsct
locat
exercis
programm
physiotherapi
depart
hospit
coloc
hsct
servic
quantit
data
obtain
determin
feasibl
target
includ
rate
recruit
adher
advers
event
outcom
measur
includ
walk
distanc
qol
qualit
interview
undertaken
purpos
sampl
patient
captur
experi
studi
intervent
result
studi
recruit
period
patient
screen
recruit
target
twentythre
averag
age
rang
recruit
exercis
programm
complet
programm
main
reason
nonparticip
distanc
travel
time
manag
commit
illhealth
main
reason
noncomplet
programm
commenc
ahsct
conclus
prehabilit
deliv
weekli
session
individualis
supervis
exercis
potenti
intervent
mm
patient
whilst
await
ahsct
howev
signific
hurdl
combin
prehabilit
ongo
inductionreinduct
treatment
minor
patient
complet
programm
main
theme
nonparticip
travel
time
commit
phase
patient
hospit
appoint
ongo
chemotherapi
time
import
complet
may
compromis
start
ahsct
rct
design
evalu
deliveri
prehabilit
mm
patient
preahsct
warrant
includ
decentralis
app
base
prehabilit
strategi
conflict
interest
author
conflict
interest
declar
ankara
univers
school
medicin
depart
hematolog
stem
cell
transplant
unit
ankara
turkey
ankara
univers
school
medicin
depart
intern
medicin
ankara
turkey
background
allogen
hematopoiet
stem
cell
transplant
increas
use
treatment
wide
rang
benign
malign
hematolog
disord
howev
prognost
biomark
allohsct
need
improv
risk
assess
help
guid
therapeut
surveil
strategi
allevi
risk
death
procedur
prognost
valu
hypoalbuminemia
high
level
c
reactiv
protein
crp
determin
posttransplant
outcom
remain
unclear
studi
aim
investig
associ
earlier
time
point
serum
albumin
crp
level
acut
gvhd
day
nonrelaps
mortal
among
patient
hematolog
malign
underw
allohsct
method
analysi
includ
consecut
patient
underw
allohct
variou
hematolog
malign
bone
marrow
failur
syndrom
ankara
univers
school
medicin
bone
marrow
transplant
unit
januari
june
use
institut
databas
evalu
detail
characterist
patient
treatment
outcom
serum
albumin
crp
level
day
infus
posttranspl
obtain
patient
file
demograph
featur
patient
donor
summar
result
total
consecut
patient
femalemal
receiv
allohsct
institut
cover
januari
june
median
age
patient
time
transplant
year
rang
year
five
common
diagnosi
acut
myeloid
leukemia
aml
acut
lymphoblast
leukemia
nonhodgkin
lymphoma
nhl
myelodisplast
syndrom
md
aplast
anemia
aa
tabl
donor
sourc
gener
match
relat
donor
patient
receiv
myeloabl
regimen
cyclosporinea
base
acut
gvhd
prophylaxi
median
serum
albumin
crp
level
gdl
rang
gdl
gdl
rang
gdl
mgl
rang
mgl
mgl
rang
mgl
stem
cell
infus
day
observ
twofold
higher
proport
occurr
acut
gvhd
day
nonrelaps
death
subgroup
patient
hypoalbuminemia
gdl
gdl
day
relationship
crp
subgroup
presenc
acut
gvhd
day
nonrelaps
mortal
conclus
measur
serum
albumin
routin
perform
cheap
standard
readili
avail
result
make
attract
biomark
data
limit
retrospect
natur
studi
therefor
need
interpret
caution
larger
prospect
studi
warrant
conflict
interest
author
noth
disclos
tabl
demograph
featur
patient
donor
divis
hematolog
cellular
therapi
allegheni
health
network
cancer
institut
pittsburgh
pa
unit
state
background
hematopoiet
stem
cell
transplant
comorbid
index
hctci
predict
outcom
allogen
hematopoiet
stem
cell
transplant
index
correl
nonrelaps
mortal
nrm
readmiss
rate
correl
hctci
variabl
complic
autolog
transplant
uncertain
method
retrospect
analyz
autolog
transplant
episod
individu
recipi
perform
institut
januari
decemb
recipi
discharg
intens
outpati
daili
followup
readmiss
hctci
karnofski
perform
score
kp
ferritin
prealbumin
level
diseas
transplant
data
element
accord
cibmtr
criteria
analyz
univari
method
test
variabl
correl
rate
readmiss
within
first
day
transplant
result
median
age
recipi
year
rang
indic
transplant
plasma
cell
disord
lymphoma
leukemia
testicular
cancer
condit
regimen
includ
melphalan
flubutbi
beam
carboplatinetoposid
other
readmiss
rate
common
indic
readmiss
sever
mucos
follow
infect
neutropen
fever
respect
hctci
prealbumin
predict
readmiss
respect
kp
greater
predict
lower
readmiss
rate
pretranspl
ferritin
level
ngml
increas
likelihood
readmiss
conclus
correl
hctci
prealbumin
serum
level
readmiss
rate
kp
less
pretranspl
ferritin
level
greater
ngml
statist
significantli
predict
higher
rate
readmiss
autolog
hct
statist
robust
model
predict
readmiss
would
clinic
util
intend
construct
multivari
model
predict
readmiss
includ
ferritin
kp
covari
conflict
interest
none
author
anyth
disclos
dmitri
rogachev
nation
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
russian
children
hospit
moscow
russian
feder
background
treosulfanbas
regimen
use
condit
allogen
hsct
allohsct
children
allow
reduc
incid
transplantrel
mortal
earli
toxic
data
longterm
effect
method
propos
retrospect
studi
late
complic
allohsct
children
hematolog
malign
got
allohsct
bmt
depart
russian
children
hospitaldmitri
rogachev
nation
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
surviv
least
year
hsct
result
thirti
patient
malign
diseas
aml
high
risk
refractori
jmml
lymphoma
cml
md
xlp
median
age
year
rang
boy
girl
receiv
treosulfanbas
condit
regimen
treosulfan
fludarabin
thiotepa
melphalan
stem
cell
sourc
bone
marrow
peripher
stem
cell
cord
blood
combin
patient
twelv
children
receiv
transplant
hlamatch
relat
donor
mrd
hlamatch
unrel
donor
mud
patient
receiv
deplet
haploident
graft
gvhd
prophylaxi
consist
cyclosporin
mofetil
mrd
haploident
transplant
tacrolimusmycophenol
mofetil
mud
transplant
median
number
transplant
nucleat
cell
rang
patient
engraft
median
time
neutrophil
recoveri
day
rang
median
followup
year
overal
surviv
eventfre
surviv
relapsefre
surviv
risk
relaps
incid
sever
earli
toxic
regist
sixteen
patient
acut
gvhd
grade
iiiv
children
grade
iiiiv
seven
patient
develop
relaps
die
seventeen
children
chronic
graftversushost
diseas
gvhd
cumul
incid
ci
chronic
gvhd
chronic
extens
gvhd
eight
patient
develop
endocrin
complic
none
hypergonadotrop
hypogonad
ci
thyroid
gland
patholog
patient
subclin
hypothyroid
ci
physic
develop
delay
six
patient
demonstr
bone
miner
densiti
patholog
ci
nobodi
except
one
patient
infecti
meningoenceph
neurotox
central
nervou
system
impair
children
demonstr
neurocognit
defect
cardiovascular
abnorm
reveal
patient
gastrointestin
urinari
peripher
neurolog
ophthalmolog
complic
associ
predominantli
chronic
gvhd
three
patient
die
due
chronic
gvhd
andor
infect
one
patient
develop
secondari
solid
tumor
glioblastoma
also
die
despit
fertil
preserv
case
childbear
report
till
conclus
treosulfanbas
condit
regimen
effect
approach
reduc
seriou
late
complic
includ
hypergonadotrop
hypogonad
thyroid
gland
patholog
central
nervou
system
impair
allogen
hsct
compar
histor
data
busulfanbas
condit
longterm
effect
conflict
interest
noth
disclos
fondazion
policlinico
universitario
gemelli
cattolica
roma
itali
background
endotheli
cell
ec
damag
play
relev
role
pathogenesi
sever
lifethr
complic
hematopoiet
stem
cell
transplant
hsct
sinusoid
obstruct
syndromevenoocclus
diseas
sosvod
thrombot
microangiopathi
graft
versu
host
diseas
chemo
radiotherapi
toxic
increas
circul
microbi
product
allogen
lymphocyt
reaction
exposur
immunosuppress
drug
activ
sever
ec
pathway
includ
inflamm
adhes
coagul
apoptosi
defibrotid
df
exhibit
sever
endotheliumprotect
activ
approv
treatment
sosvod
hsct
patient
nevertheless
exact
mechan
action
precis
recogn
therefor
use
gene
profil
approach
evalu
pathway
modul
df
ec
expos
lipopolysaccharid
lp
method
endotheli
coloni
form
cell
ecfc
obtain
umbil
cord
blood
accord
method
ingram
et
al
blood
confluent
ecfc
passag
ii
iii
subject
exposur
lp
ngml
experi
without
df
ngml
select
experi
cell
pretreat
h
df
addit
lp
total
rna
extract
revert
first
strand
cdna
kit
sabioci
qiagen
genotyp
profil
control
treat
cell
evalu
use
human
endotheli
cell
biolog
sabioci
qiagen
data
analyz
use
profil
pcr
array
data
analysi
templat
sabioci
qiagen
rel
chang
gene
express
calcul
use
cycl
threshold
method
adhes
assay
assess
evalu
percentag
carboxyfluorescein
succinimidyl
ester
cfse
label
mononuclear
cell
remain
adher
layer
ecfc
incub
result
microarray
includ
gene
involv
angiogenesi
cell
adhes
inflammatori
respons
coagul
platelet
activ
apoptosi
vasoconstrict
vasodilat
figur
show
lpstreat
cell
display
signific
upregul
sever
gene
involv
mention
pathway
cell
contemporari
expos
lp
df
df
abl
reduc
upregul
gene
express
case
tissu
factor
revert
level
compar
unstimul
cell
result
overal
decreas
adhes
capac
lpsdf
treat
cell
comparison
cell
expos
lp
figur
interestingli
df
exposur
lp
treatment
prevent
lp
modul
major
involv
gene
conclus
find
suggest
df
effect
might
highli
depend
exposur
set
moreov
observ
might
explain
favor
outcom
sosvod
df
therapi
earli
start
conflict
interest
author
noth
disclos
karolinska
institutet
depart
health
stockholm
sweden
astrid
lindgren
hospit
karolinska
univers
hospit
stockholm
sweden
rikshospitalet
univers
hospit
depart
pediatr
oslo
norway
julian
mari
centr
copenhagen
univers
hospit
pediatr
clinic
copenhagen
denmark
children
cancer
centr
queen
silvia
children
adolesc
hospit
gothenburg
gothenburg
sweden
karolinska
institutet
depart
clinic
scienc
intervent
technolog
stockholm
sweden
univers
helsinki
helsinki
univers
hospit
divis
haematologyoncolog
stem
cell
transplant
hospit
helsinki
finland
aarhu
univers
hospit
skejbi
depart
pediatr
aarhu
denmark
background
allogen
hematopoiet
stem
cell
transplant
allohsct
improv
eventfreesurviv
acut
myeloid
leukemia
aml
indic
weigh
burden
late
effect
method
order
assess
addit
toxic
associ
allohsct
treatment
childhood
aml
compar
selfreport
healthrel
outcom
childhood
aml
survivor
treat
either
without
allohsct
survivor
childhood
aml
treat
accord
nophoaml
protocol
allohsct
younger
year
aliv
august
sent
questionnair
altogeth
allohsct
survivor
elig
sibl
complet
questionnair
correspond
data
deriv
previous
aml
survivor
cure
chemotherapi
use
comparison
result
median
followup
rang
year
allohsct
allohsct
survivor
report
frequent
physic
health
limit
vs
p
medic
cardiovascular
diseas
vs
p
use
analges
vs
p
survivor
treat
chemotherapi
impair
health
problem
prevent
allohsct
survivor
attend
school
manag
job
versu
among
survivor
treat
chemotherapi
p
among
allohsct
survivor
year
older
median
age
rang
year
seven
women
report
twelv
natur
conceiv
pregnanc
three
men
report
six
natur
conceiv
pregnanc
partner
pregnanc
eight
children
born
three
femal
survivor
one
partner
male
survivor
pregnant
time
studi
conclus
childhood
aml
survivor
treat
allohsct
experi
physic
health
limit
use
medic
convent
treat
aml
survivor
sever
natur
conceiv
pregnanc
report
allohsct
childhood
aml
conflict
interest
author
declar
conflict
interest
financi
support
receiv
swedish
childhood
cancer
foundat
mari
childhood
cancer
foundat
mari
wilhelmsson
support
stockholm
counti
council
combin
clinic
resid
phd
train
program
st
anna
children
hospit
sct
outpati
clinic
vienna
austria
st
anna
children
hospit
vienna
austria
medic
univers
vienna
depart
radiotherapi
vienna
austria
st
anna
children
hospit
sct
outpati
clinic
vienna
austria
background
thyroid
dysfunct
total
bodi
irradi
tbi
preced
hematopoiet
stem
cell
transplant
hsct
well
describ
less
paediatr
data
avail
regard
influenc
graft
versu
host
diseas
gvhd
especi
includ
nonthyroid
ill
nti
syndrom
spectrum
dysfunct
therefor
studi
retrospect
thyroid
abnorm
ta
longterm
followup
fu
correl
variou
patient
transplant
characterist
particular
focu
nation
institut
health
nih
gvhdconsensusgroup
criteria
method
investig
patient
allogen
patient
autolog
hsct
malign
diseas
receiv
tbi
gy
median
fu
year
rang
year
exclus
criteria
thyroid
dysfunct
hsct
death
relaps
hsct
thyroid
function
evalu
serial
measur
basal
tsh
free
thyroid
ultrasonographi
ta
correl
variou
wellknown
patient
tbi
transplant
characterist
gvhd
score
accord
nihgvhdconsensu
criteria
reclassifi
hsct
prospect
thereaft
result
cumul
incid
ta
subclin
hypothyroid
nti
overt
hypothyroid
pituitari
hypothyroid
autoimmun
thyroid
dysfunct
signific
risk
factor
ta
allogen
hsct
match
unrel
donor
hsct
first
complet
remiss
tbi
fraction
monoclon
antibodi
condit
regard
gvhd
acut
andor
chronic
gvhd
gener
acut
gvhd
grade
iv
detail
significantli
associ
occurr
ta
correl
gvhd
subgroup
accord
nihdefinit
interestingli
addit
appli
radiotherapi
head
upper
chest
wall
result
higher
incid
ta
ultrasonographi
perform
patient
regard
reduc
volum
thyroid
gland
incid
ta
compar
contrast
could
observ
correl
nodular
chang
occurr
ta
thyroid
carcinoma
diagnos
conclus
find
fit
well
publish
data
emphas
import
longterm
aftercar
gvhd
subanalysi
suffer
problem
small
patient
number
nihdefin
subgroup
due
lower
incid
chronic
gvhd
paediatr
popul
result
may
provid
basi
multicentr
studi
evalu
impact
tbi
nihdefin
gvhd
immunosuppress
treatment
larger
data
set
conflict
interest
noth
disclos
abstract
previous
publish
hospit
de
la
santa
creu
sant
pau
hematolog
barcelona
spain
hospit
de
la
santa
creu
sant
pau
pharmaci
barcelona
spain
background
chemotherapyinduc
nausea
vomit
cinv
signific
side
effect
stem
cell
transplant
sct
despit
prophylact
therapi
nepa
netupit
plu
palonosetron
prove
highli
effect
high
emetogen
chemotherapi
howev
data
scarc
sct
recipi
method
objet
evalu
efficaci
safeti
nepa
cohort
patient
receiv
high
emetogen
condit
regimen
sct
sinc
septemb
nepa
administ
oral
fixeddos
combin
mg
netupit
palonosetron
first
day
chemotherapi
becam
standard
center
sct
recipi
treat
high
emetogen
condit
regimen
dexamethason
dxm
given
mg
daili
chemotherapi
mg
daili
subsequ
hour
result
outcom
first
patient
treat
nepa
dxm
institut
describ
baselin
characterist
detail
figur
acut
phase
day
chemotherapi
patient
achiev
complet
respons
cr
defin
emesi
rescu
antiemet
patient
emesi
present
mild
moder
nausea
period
maximum
emet
episod
singl
patient
respons
improv
delay
phase
hour
last
dose
chemotherapi
patient
achiev
cr
patient
mild
moder
nausea
five
patient
histori
signific
nausea
emesi
prior
chemotherapi
four
develop
emesi
nepa
regimen
patient
requir
palonosetron
breakthrough
emesi
sinc
success
rescu
singl
dose
olanzapin
metoclopramid
lorazepam
nonhematolog
advers
effect
attribut
studi
medic
minor
hiccup
n
headach
somnol
complic
conclus
nepabas
antiemet
regimen
seem
encourag
term
prophylaxi
cinv
sct
set
result
warrant
evalu
larger
cohort
base
promis
result
enrol
new
patient
ongo
conflict
interest
moreno
martinez
present
vifor
cinv
author
noth
disclos
univers
verona
hematolog
bone
marrow
transplant
unit
verona
itali
ospedal
san
bortolo
hematolog
bone
marrow
transplant
unit
vicenza
itali
univers
brescia
hematolog
bone
marrow
transplant
unit
brescia
itali
background
patient
undergo
allogen
hematopoiet
stem
cell
transplant
hsct
expos
number
neurolog
complic
may
relat
drug
infect
metabol
alter
cerebrovascular
event
immunemedi
disord
includ
myositi
myasthenia
gravi
demyelin
polyneuropathi
central
nervou
system
cn
manifest
graft
versu
host
diseas
gvhd
multifactori
etiolog
neurolog
complic
hsct
patient
make
diagnosi
difficult
howev
time
rigor
character
complic
obtain
attempt
avoid
fatal
outcom
longterm
effect
data
regard
neurolog
complic
hsct
patient
deriv
small
seri
vari
larg
respect
incid
sever
aim
studi
describ
incid
characterist
outcom
neurolog
complic
larg
seri
consecut
hsct
patient
method
data
retriev
medic
record
patient
transplant
januari
januari
italian
centr
complic
affect
either
central
peripher
nervou
system
classifi
base
etiolog
maffini
et
al
biol
blood
marrow
transplant
time
onset
day
post
day
result
overal
median
age
year
fm
caucasian
patient
analys
present
neurolog
complic
among
patient
receiv
reducedintens
hsct
myeloabl
hsct
donor
match
relat
case
haploident
match
mismatch
unrel
neurolog
complic
immunemedi
case
infectionrel
drugrel
relapserel
cerebrovascular
due
cn
neoplasia
median
time
hsct
neurolog
symptom
appear
month
approxim
day
fourteen
patient
present
cmv
reactiv
receiv
treatment
gvhd
onset
neurolog
symptom
three
drugrel
neurolog
toxic
occur
within
day
observ
patient
asian
african
ethnic
detail
neurolog
complic
accord
etiolog
time
onset
depict
figur
thirteen
patient
die
due
neurolog
complic
relaps
diseas
immunemedi
infectionrel
drugrel
cerebrovascular
cn
malign
median
time
symptom
onset
death
month
among
patient
surviv
current
present
longterm
effect
gvhdrelat
tetraplegia
sensit
neuropathi
respect
conclus
although
affect
limit
number
patient
seri
neurolog
complic
associ
signific
mortal
sever
longterm
disabl
multicentr
prospect
studi
use
common
classif
system
await
order
identifi
real
incid
risk
factor
neurolog
complic
hsct
patient
conflict
interest
author
abstract
noth
disclos
g
papanicola
hospit
thessaloniki
greec
aristotl
univers
thessaloniki
thessaloniki
greec
background
neurolog
manifest
underrecogn
potenti
lifethreaten
complic
post
allogen
hematopoiet
cell
transplant
allohct
despit
advanc
field
diagnosi
manag
remain
challeng
therefor
record
neurolog
complic
longterm
outcom
allohct
recipi
method
retrospect
review
chart
consecut
allogen
hct
recipi
transplant
center
neurolog
complic
record
base
clinic
data
imag
electroencephalographi
electromyographi
patholog
cerebrospin
fluid
test
neurolog
consult
hospit
patient
antithymocyt
globulin
atg
mgkg
administ
part
condit
unrel
altern
transplant
result
among
allohct
recipi
sibl
unrel
haploident
twin
donor
cord
blood
present
neurolog
complic
incid
neurolog
complic
significantli
lower
sibl
transplant
major
develop
central
nervou
systemcn
complic
late
posttranspl
median
interquartil
rangeir
patient
present
episod
median
month
ir
time
neurolog
complic
associ
acut
chronic
graftversushostdiseasegvhd
p
respect
neurolog
complic
includ
cn
relaps
thrombot
microangiopathi
cn
hemorrhag
posterior
revers
encephalopathi
drugassoci
polyneuropathi
seizur
leukoencephalopathi
thromboembol
event
neuralgia
myopathi
sinusoid
obstruct
syndrom
guillainbarr
syndrom
wernick
encephalopathi
myeliti
multipl
sclerosi
cn
infect
attribut
aspergillosi
mucormycosi
cytomegaloviru
epsteinbarr
enceph
lymphoprolif
diseas
human
herpesviru
human
herpesviru
toxoplasmosi
other
otherwis
specifi
median
followup
month
ir
incid
chronic
gvhd
relaps
mortal
treatmentrel
mortal
overal
surviv
os
patient
neurolog
complic
atg
administr
chronic
gvhd
sibl
transplant
resolut
neurolog
complic
p
signific
predictor
os
multivari
analysi
favor
os
independ
associ
resolut
neurolog
syndrom
p
absenc
chronic
gvhd
sibl
transplant
conclus
studi
highlight
wide
spectrum
manifest
etiolog
neurolog
complic
allohct
recipi
sibl
transplant
associ
lower
incid
better
os
affect
patient
irrespect
pretranspl
characterist
prompt
diagnosi
requir
adequ
manag
major
determin
surviv
complic
occur
late
posttranspl
period
particularli
immunocompromis
patient
thu
longterm
increas
awar
collabor
expert
physician
warrant
improv
patient
outcom
conflict
interest
conflict
interest
report
tabl
patient
neurolog
complic
allama
iqbal
medic
colleg
lahor
pakistan
mayo
clinic
neurolog
rochest
mn
unit
state
king
faisal
specialist
hospit
research
center
oncolog
riyadh
saudi
arabia
mayo
clinic
medicin
rochest
mn
unit
state
background
although
neurolog
complic
hematopoiet
cell
transplant
hct
common
literatur
gap
identifi
estim
exact
burden
outcom
condit
allogen
autolog
hct
set
method
herein
conduct
systemat
review
regard
noninfecti
neurolog
outcom
hct
recipi
quantifi
frequenc
complic
occur
across
collect
data
gaug
import
relev
risk
factor
outcom
abund
data
alreadi
exist
infecti
neurolog
complic
manuscript
primarili
focus
noninfecti
complic
search
medic
literatur
done
per
pico
criteria
briefli
case
report
case
seri
clinic
trial
retrospect
studi
includ
systemat
review
metaanalys
review
articl
preclin
studi
exclud
recipi
modal
hct
ie
autolog
allogen
bone
marrow
peripher
blood
umbil
cord
elig
complic
evalu
includ
cerebrovascular
accid
cva
peripher
neuropathi
pn
myasthenia
gravi
mg
seizur
autoimmun
neurolog
complic
mg
guillainbarr
syndrom
gb
posterior
revers
encephalopathi
syndrom
pre
databas
search
includ
amedo
free
medic
journal
clinic
key
directori
open
access
journal
doaj
ovid
medlin
proquest
medic
librari
pubm
central
sage
journal
scienc
direct
springerlink
wileyblackwel
addit
manual
search
done
sever
publish
articl
articl
may
retriev
data
total
elig
articl
extract
accord
predefin
variabl
paramet
quantit
analysi
result
result
reveal
follow
frequenc
compar
us
gener
popul
case
cva
sampl
size
n
compar
frequenc
per
year
popul
case
pn
n
compar
frequenc
popul
case
mg
n
compar
frequenc
popul
case
seizur
n
compar
frequenc
popul
case
pre
n
unknown
incid
gener
popul
see
tabl
conclus
seen
result
may
conclud
hct
associ
increas
risk
neurolog
complic
recognit
increas
risk
conjunct
risk
factor
given
quantit
extent
expect
hct
recipi
popul
allow
accur
vigil
monitor
patient
earli
sign
develop
complic
thu
facilit
earlier
therapeut
intervent
provid
protect
substanti
morbid
complic
may
caus
affect
popul
conflict
interest
author
noth
disclos
tabl
neurolog
complic
hct
king
faisal
specialist
hospit
research
center
oncolog
center
riyadh
saudi
arabia
background
hdc
autosct
gold
standard
treatment
patient
relaps
refractori
diffus
larg
b
cell
lymphoma
dlbcl
hodgkin
lymphoma
hl
despit
improv
care
treatment
diseas
relat
caus
continu
main
caus
death
long
run
post
transplant
treatment
relat
mortal
trm
account
death
larg
studi
report
diseas
trm
relat
death
aim
analyz
caus
death
patient
hdc
autosct
die
caus
unrel
diseas
method
hdc
autosct
data
review
death
nonrelaps
mortal
nrm
defin
time
death
without
relapserecurr
condit
incorpor
nrm
death
unrel
diseas
patient
diseas
duntodiseasewd
nrm
duntodiseasewd
captur
patient
die
local
hospit
due
unknown
caus
infect
count
trm
result
decemb
consecut
patient
biopsi
proven
dlbcl
hl
underw
hdc
autosct
median
age
hdc
autosct
year
year
year
nhl
hl
total
die
die
diseas
due
trm
due
nrm
duntodiseasewd
tabl
detail
main
caus
death
male
femal
median
age
hdc
autosct
year
year
median
time
death
month
month
caus
death
categor
four
group
infect
noninfecti
organ
failur
second
malign
other
miscellan
group
infect
siteorgan
lung
cn
maxillaryparanas
sinu
area
hemophagocytosissepsi
patient
die
noninfecti
organ
failur
lung
complic
adren
insuffici
liver
failur
multiorgan
failur
rupturedcarotid
aneurysm
second
malign
observ
tmdsleukemia
breast
nasopharyng
carcinoma
three
patient
accid
car
accid
drown
precis
detail
avail
patient
unknown
caus
conclus
larg
cohort
rel
young
patient
nrm
duntodiseasewd
almost
equal
trm
magnitud
issu
larger
expect
import
inform
care
discuss
patient
inform
decisionmak
set
peopl
rural
area
gener
less
access
healthcar
urban
counterpart
often
mean
longer
respons
time
emerg
conflict
interest
noth
disclos
author
tabl
tabl
main
caus
death
american
univers
beirut
medic
center
depart
clinic
nutrit
beirut
lebanon
aix
marseil
univers
doctor
school
life
scienc
health
marseil
franc
american
univers
beirut
medic
center
beirut
lebanon
divis
hematologyoncolog
depart
intern
medicin
beirut
lebanon
american
univers
beirut
medic
center
bone
marrow
transplant
program
depart
intern
medicin
beirut
lebanon
american
univers
beirut
medic
center
clinic
research
unit
beirut
lebanon
aix
marseil
univers
institut
paolicalmett
marseil
franc
background
condit
preced
hematopoiet
stem
cell
transplant
hsct
associ
elev
rate
malnutrit
hospit
discharg
day
post
hsct
studi
aim
assess
impact
nutrit
intervent
provid
hospit
discharg
nutrit
statu
day
post
hsct
method
studi
singl
center
random
control
trial
adult
patient
receiv
hsct
elig
particip
data
collect
initi
admiss
random
occur
hospit
discharg
around
discharg
hospit
recruit
patient
random
control
group
cg
receiv
usual
care
intervent
group
ig
receiv
nutrit
counsel
monthli
basi
optim
nutrit
function
statu
primari
outcom
patient
gener
subject
global
assess
pgsga
score
day
post
hsct
malnutrit
also
assess
though
american
societi
parenter
enter
nutrit
academi
nutrit
dietet
malnutrit
score
handgrip
strength
hg
compar
norm
data
assess
diminish
fat
mass
index
fmi
assess
via
bioimped
analysi
post
hospit
discharg
assess
done
day
post
hsct
group
percent
energi
result
particip
random
august
august
analyz
male
autolog
hsct
ig
cg
group
compar
statist
signific
chang
characterist
hospit
admiss
percent
patient
well
nourish
low
ig
vs
cg
pgsga
categori
percentag
patient
diminish
hg
high
ig
vs
cg
group
day
post
hsct
ig
wellnourish
patient
vs
pgsga
categori
cg
less
wellnourish
patient
vs
pgsga
categori
compar
admiss
valu
respect
group
oral
calor
intak
better
ig
assess
point
post
discharg
compar
cg
p
compar
admiss
percentag
patient
high
fmi
decreas
ig
vs
increas
cg
vs
day
post
hsct
post
discharg
percentag
patient
diminish
hg
improv
pronouncedli
ig
yet
similar
valu
reach
day
post
sct
graph
legend
left
panel
energi
intak
refer
percent
intak
compar
patient
individu
need
p
differ
group
right
panel
malnutrit
assess
base
aspenand
malnutrit
tool
aspenand
american
societi
parenter
enter
nutrit
academi
nutrit
dietet
differ
admiss
day
post
hsct
intervent
group
differ
admiss
day
post
hsct
control
group
conclus
rct
show
nutrit
counsel
post
hsct
improv
nutrit
statu
reduc
obes
post
hsct
patient
effect
sarcopenia
clinic
trial
registri
clinicaltrialgov
registri
conflict
interest
none
hematolog
azienda
sanitaria
universitaria
integrata
di
udin
di
udin
dame
udin
itali
hematolog
policlinico
umberto
sapienza
univers
rome
rome
itali
transfus
medicin
azienda
universitaria
integrata
di
udin
udin
itali
hematolog
azienda
sanitaria
universitaria
integrata
udin
itali
immunoematolog
transfus
medicin
sapienza
univers
rome
rome
itali
background
detect
donorspecif
antihla
antibodi
dsa
report
associ
higher
rate
graft
failur
gf
wors
overal
surviv
os
higher
transplantrel
mortal
trm
mismatch
hematopoiet
stem
cell
transplant
hsct
efficaci
desensit
treatment
remain
unclear
method
prospect
evalu
presenc
dsa
use
solid
phase
system
luminex
labscreen
mix
singl
antigen
class
ii
one
lambda
patient
undergo
unmanipul
unrel
mismatch
sct
usct
unmanipul
haploident
sct
haplosct
dsa
bind
level
express
mean
fluoresc
intens
mfi
subsequ
compar
hematopoiet
engraf
trm
os
patient
dsa
underw
desensit
treatment
patient
without
dsa
result
eightythre
consecut
patient
acut
leukemia
myelodysplast
syndrom
lymphoma
myeloma
median
age
year
underw
hsct
januari
octob
underw
hla
minor
major
mismatch
usct
haplosct
gvhd
prophylaxi
base
cyclosporin
atg
methotrex
usct
cyclosporin
mycophenol
posttranspl
cyclophosphamid
haplosct
dsa
detect
patient
median
dsa
level
rang
patient
underw
haplosct
usct
three
haplosct
usct
receiv
desensit
treatment
exclud
outcom
analysi
primari
gf
desensit
treatment
consist
median
number
plasma
exchang
pex
procedur
rang
patient
addict
rituximab
intraven
immunoglobulin
ivig
patient
observ
signific
differ
cumul
incid
neutrophil
platelet
engraft
p
fig
patient
dsa
receiv
desensit
treatment
patient
dsa
overal
trm
os
differ
two
group
p
p
conclus
dsa
detect
usct
candid
haplosct
candid
associ
failur
obtain
allogen
engraf
patient
receiv
desensit
treatment
contrari
patient
underw
desensit
treatment
show
engraft
os
trm
rate
similar
patient
dsa
neg
transplant
studi
show
search
dsa
mandatori
mismatch
transplant
moreov
underlin
potenti
benefit
desensit
treatment
set
hsct
dsa
conflict
interest
conflict
interest
disclos
medic
univers
depart
pediatr
hematolog
oncolog
bone
marrow
transplant
poland
medic
univers
depart
anesthesiolog
intens
care
poland
background
pediatr
allogen
hematopoiet
stem
cell
transplant
allohsct
lifesav
therapi
wide
rang
diseas
nevertheless
remain
high
risk
procedur
associ
mani
lifethreaten
complic
therefor
consider
number
patient
requir
transfer
pediatr
intens
care
unit
picu
transplant
aim
studi
assess
incid
outcom
picu
admiss
allohsct
well
report
detail
patient
characterist
potenti
prognost
factor
surviv
method
studi
base
retrospect
data
analysi
children
adolesc
underw
allohsct
depart
pediatr
hematolog
oncolog
bone
marrow
transplant
year
particularli
analyz
patient
requir
transfer
picu
within
year
transplant
clinic
epidemiolog
featur
transplant
procedur
laboratori
find
intens
appli
therapi
assess
primari
endpoint
death
discharg
picu
surviv
discharg
also
evalu
statist
analysi
perform
use
statistica
softwar
result
analyz
popul
patient
requir
admiss
picu
five
patient
admit
twice
picu
fortysix
patient
receiv
stem
cell
due
malign
diseas
due
nonmalign
disord
main
indic
admiss
respiratori
failur
septic
shock
neurolog
disord
acut
kidney
injuri
median
day
post
hsct
moment
transfer
length
picu
hospit
day
twentyf
case
sever
granulocytopenia
day
picu
admiss
fiftyfour
case
requir
mechan
ventil
receiv
cardiac
support
need
renal
support
thirtyfour
discharg
case
die
among
discharg
patient
day
surviv
surviv
compar
survivor
death
case
like
receiv
haploident
allohsct
vs
requir
mechan
ventil
vs
receiv
aggress
catecholamin
cardiac
support
vs
lower
granulocyt
level
day
death
compar
day
discharg
differ
age
sex
underli
diseas
stem
cell
sourc
day
reason
admiss
granulocyt
count
moment
admiss
acut
graft
versu
host
diseas
statist
irrelev
main
caus
death
picu
cardiopulmonari
failur
septic
shock
mof
acut
graft
versu
host
diseas
relaps
conclus
pediatr
recipi
allohsct
picu
care
high
rate
mortal
mainli
patient
requir
aggress
approach
includ
mechan
ventil
greater
chanc
death
curiou
prognost
factor
granulocyt
count
end
treatment
oppos
day
admiss
may
suggest
besid
support
care
hematolog
recoveri
requir
care
consider
patient
hospit
picu
allohsct
conflict
interest
none
author
anyth
declar
king
fahad
specialist
hospit
adult
hematolog
stem
cell
transplant
depart
dammam
saudi
arabia
background
given
current
improv
support
care
broadspectrum
antibiot
growth
factor
suffici
control
nauseavomit
mucos
toxic
autolog
hematopoiet
stem
cell
transplant
asct
could
perform
outpati
basi
select
patient
offer
benefit
shorter
hospit
less
exposur
hospit
pathogen
nosocomi
infect
demonstr
thu
safe
also
cost
effect
profil
method
evalu
feasibl
safeti
aforement
approach
perform
asct
outpati
basi
total
pt
diagnos
either
relapsedrefractori
hodgkin
lymphoma
n
multipl
myeloma
pt
mm
underw
tandem
asct
eight
femal
male
median
age
ys
elig
criteria
outpati
asct
standard
clinic
laboratori
test
plu
psychosoci
evalu
patient
complianc
assess
hour
caregiv
avail
time
access
hospit
sign
inform
consent
condit
regimen
consist
singl
agent
melphalan
graft
infus
support
care
given
alloc
room
antimicrobi
antifung
antivir
prophylaxi
administ
day
filgrastim
mcgkg
day
till
neutrophil
recoveri
infect
document
antimicrobi
antifung
prophylaxi
discontinu
upon
stabl
neutrophil
recoveri
antivir
prophylaxi
continu
month
patient
evalu
daili
everi
day
outpati
clinic
criteria
admiss
fever
intract
nauseavomit
diarrhea
mucos
need
total
parenter
nutrit
toxic
grade
result
median
day
neutrophil
recoveri
platelet
recoveri
pt
platelet
never
drop
lower
fourteen
admiss
requir
total
inabl
foodfluid
uptak
due
sever
mucos
febril
neutropenia
engraft
syndrom
infect
success
treat
broad
spectrum
antibiot
patient
admit
intens
care
unit
whole
asct
total
hospit
day
rang
admiss
median
hospit
day
rang
favor
compar
averag
hospit
day
singl
convent
asct
toxic
observ
pt
aliv
month
post
ahsct
conclus
data
indic
outpatientasct
feasibl
safe
approach
provid
caregiv
avail
close
patient
monitor
adequ
support
care
keep
mind
nosocomi
complic
potenti
high
cost
prolong
hospit
seem
outpati
asct
offer
lower
risk
infect
signific
cost
save
compar
convent
inpati
asct
approach
conflict
interest
none
author
anyth
declar
rm
gorbacheva
institut
pediatr
oncolog
hematolog
transplant
ip
pavlov
first
st
petersburg
state
medic
univers
anesthesiolog
depart
st
petersburg
russian
feder
valdman
institut
pharmacolog
pavlov
first
st
petersburg
medic
univers
st
petersburg
russian
feder
rm
gorbacheva
institut
pediatr
oncolog
hematolog
transplant
ip
pavlov
first
st
petersburg
state
medic
univers
st
petersburg
russian
feder
pediatr
medic
univers
depart
anesthesiolog
pediatr
intens
care
st
petersburg
russian
feder
background
gastrointestin
tract
mucos
gitm
one
common
complic
earli
posttranspl
period
develop
patient
grade
mostli
depend
condit
regimen
use
oral
caviti
involv
patient
somat
state
posttranspl
cytopenia
durat
gitm
usual
associ
nausea
vomit
pain
food
liquid
intak
impair
higher
risk
infect
bleed
thu
factor
signific
influenc
qualiti
life
gitm
patient
requir
continu
pain
manag
often
narcot
analges
use
opiat
infus
rate
depend
clinic
situat
inherit
opiat
receptor
polymorph
determin
sensit
patientcontrol
analgesia
pca
often
optim
way
achiev
ration
dose
regimen
adult
howev
pediatr
posthsct
patient
util
often
disput
method
group
consecut
pediatr
hsct
recipi
median
age
rang
year
grade
gitm
evalu
gitm
sever
evalu
accord
toxic
scale
pain
intens
assess
tool
depend
patient
age
capabl
patient
divid
two
group
base
age
year
n
year
n
accord
pain
intens
patient
receiv
iv
tramadol
morphin
fentanyl
via
pca
patient
unabl
control
equip
reason
assist
caregiv
target
pain
score
point
scale
use
younger
patient
older
patient
group
determin
individu
case
process
control
dedic
pain
manag
team
member
result
median
initi
pain
intens
rang
rang
point
median
breakthrough
pain
intens
rang
rang
point
first
younger
second
older
group
accordingli
therapi
initi
averag
baselin
breakthrough
pain
intens
decreas
first
second
group
respect
abil
fluid
intak
preserv
first
group
second
group
patient
eight
first
group
second
group
patient
also
abl
eat
solid
food
bolu
button
oper
seven
younger
group
one
older
group
patient
normal
daili
activ
preserv
patient
first
group
second
younger
patient
pca
ceas
due
drowsi
photophobia
older
group
patient
main
therapi
cessat
reason
nausea
vomit
exacerb
upright
posit
dizzi
patient
conclus
pca
allow
individu
select
analges
dose
provid
good
balanc
pain
relief
side
effect
regardless
mucos
sever
manag
pediatr
popul
significantli
improv
qualiti
life
comfort
level
pediatr
patient
clinic
trial
registri
conflict
interest
instituto
nacion
de
hematolog
ciudad
de
mexico
background
scenario
high
dose
chemotherapi
hdt
autolog
stem
cell
transplant
asct
hematooncolog
diseas
still
controversi
efficaci
safeti
granulocytestimul
cytokin
pegyl
versu
nonpegyl
form
hematolog
recoveri
infect
risk
hospit
stay
overal
surviv
eventfre
surviv
method
retrospect
compar
januari
novemb
receiv
filgrastim
neutrophil
recoveri
pegfilgrastim
mg
singl
dose
day
febril
neutropenia
neu
defin
temperatur
one
measur
one
hour
haematolog
recoveri
defin
first
consecut
day
neutrophil
platelet
consecut
day
without
transfus
requir
statist
analysi
numer
variabl
student
test
nomin
variabl
ordin
one
mann
whitney
u
result
total
patient
two
cohort
similar
baselin
characterist
analyz
gender
median
age
chemotherapi
line
prior
asct
diseas
statu
asct
mobil
scheme
myeloabl
condit
regimen
accord
diseas
median
infus
cell
median
age
year
male
sex
diagnos
multipl
myeloma
lymphoma
lymphoma
germcel
tumor
infus
cell
media
bodi
weight
filgrastim
pegfilgrastim
group
respect
fortyon
patient
receiv
filgrastim
pegfilgrastim
media
durat
neutropenia
day
day
febril
neutropenia
media
durat
day
day
clinic
microbiolog
document
infect
occur
filgrastim
pegfilgrastim
group
respect
media
dose
requir
filgrastim
group
dose
pegfilgrastim
group
p
platelet
transfus
requir
media
platelet
apheresispool
rbc
concentr
media
rbc
concentr
group
median
hospit
stay
day
asct
discharg
day
day
filgrastim
pegfilgrastim
group
respect
overal
surviv
therapyrel
mortal
transplant
signific
either
seriou
advers
event
grade
report
conclus
equival
filgrastim
pegfilgrastim
consid
term
efficaci
safeti
hematolog
recoveri
febril
neutropenia
prophylaxi
asct
cohort
shorter
durat
neutropenia
transfus
requir
rbc
concentr
clinic
signific
paramet
howev
taken
reserv
due
greater
number
patient
pegfilgrastim
regard
cost
mg
pegfilgrastim
vial
cost
usd
mcg
filgrastim
vial
usd
mexico
superior
costbenefit
issu
conflict
interest
noth
disclos
vanderbilt
univers
medic
center
medicin
nashvil
tn
unit
state
vanderbilt
univers
medic
center
pharmaci
nashvil
tn
unit
state
vanderbilt
univers
medic
center
nurs
nashvil
tn
unit
state
vanderbilt
univers
medic
center
biostatist
nashvil
tn
unit
state
background
signific
barrier
longterm
surviv
allogen
hematopoiet
cell
transplant
hct
myeloid
neoplasm
diseas
relaps
posthct
mainten
therapi
hypomethyl
agent
hma
commonli
use
prevent
relaps
hct
mani
transplant
center
howev
data
support
practic
limit
hypothes
posthct
hma
would
limit
impact
diseas
outcom
practic
pattern
physician
would
heterogen
method
singl
institut
retrospect
studi
patient
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
underw
hct
patient
frequent
treat
azacitidin
x
day
cycl
diseas
risk
index
dri
util
order
draw
comparison
treat
least
one
cycl
hma
posthct
untreat
posthct
hma
patient
compar
diseas
biolog
armand
blood
relaps
free
surviv
rf
overal
surviv
os
calcul
use
kaplanmei
method
compar
use
logrank
test
cox
proport
hazard
model
use
multivari
analys
order
assess
practic
variat
posthct
hma
use
conduct
blind
review
hct
physician
nonhct
leukemia
physician
use
pertin
patient
data
fleiss
kappa
agreement
assess
agreement
prescrib
practic
result
total
patient
treat
untreat
studi
treat
patient
like
older
vs
year
highhigh
vhh
dri
vs
receiv
reducedintens
condit
vs
addit
fewer
treat
patient
develop
acut
graft
versu
host
diseas
gvhd
vs
trend
toward
earlier
relaps
amongst
treat
patient
vhh
risk
diseas
compar
untreat
median
vs
day
similarli
hma
use
intermedi
lowrisk
il
group
associ
substanti
shorter
rf
compar
untreat
group
median
day
vs
reach
p
import
interact
hma
use
dri
identifi
rf
os
analysi
patient
treat
hma
shorter
median
os
compar
untreat
patient
vhh
day
vs
day
il
day
vs
day
peripher
blood
chimer
data
patient
receiv
treatment
posthct
hma
demonstr
higher
incid
mix
myeloid
lymphoid
chimer
final
blind
review
hct
leukemia
physician
reveal
moder
agreement
amongst
hct
physician
fair
agreement
leukemia
physician
prescrib
pattern
conclus
data
support
routin
use
posthct
hma
mainten
treat
patient
particularli
ilrisk
diseas
experienc
inferior
rf
compar
treat
patient
cohort
posthct
hma
mainten
associ
lower
incid
acut
gvhd
possibl
enhanc
effect
treg
lymphocyt
may
reduc
posthct
graft
versu
leukemia
effect
find
underli
mechan
need
studi
result
prospect
studi
posthct
hma
better
defin
role
intervent
conflict
interest
none
author
anyth
disclos
hospit
universitario
austral
derqui
argentina
hospit
italiano
bueno
air
argentina
instituto
alexand
fleme
bueno
air
argentina
fundacion
favaloro
bueno
air
argentina
hospit
aleman
bueno
air
argentina
hospit
italiano
la
plata
argentina
fundaleu
bueno
air
argentina
hospit
privado
cordoba
argentina
sanatorio
anchorena
bueno
air
argentina
hospit
britanico
bueno
air
argentina
cetramor
rosario
argentina
cemic
bueno
air
argentina
sanatorio
britanico
rosario
argentina
sanatorio
allend
cordoba
argentina
cibmtr
medic
colleg
wisconsin
medicin
milwauke
wi
unit
state
background
sever
effort
predict
mortal
autolog
stem
cell
transplant
asct
like
hctci
index
demonstr
valu
asct
sever
group
includ
us
valid
score
set
asct
combin
comorbid
patient
characterist
object
describ
comprehens
score
includ
comorbid
clinic
factor
analyz
impact
score
earli
morbid
endpoint
mechan
ventil
shock
dialysi
nrm
os
asct
method
retrospect
review
data
adult
patient
receiv
asct
argentina
multipl
myeloma
mm
lymphoma
compar
nrm
relaps
grey
test
os
kaplan
meyer
morbid
endpoint
long
term
multivari
analysi
mva
nrm
finegray
regress
factor
remain
signific
mva
nrm
includ
score
assign
valu
hazard
ratio
hr
result
mean
age
year
male
mm
nonhodgkin
lymphoma
nhl
hodgkin
lymphoma
hl
fiftythre
percent
cr
pr
sdpd
receiv
three
chemotherapi
line
transplant
heavili
pretreat
regard
comorbid
hctci
median
follow
year
rang
year
earli
nrm
day
year
os
year
mva
risk
factor
show
independ
signific
impact
nrm
male
patient
point
age
point
year
point
hctci
point
hl
point
nhl
point
hazard
ratio
nrm
increas
proport
score
patient
group
low
risk
lr
score
intermedi
risk
ir
score
high
risk
hr
score
high
risk
vhr
score
score
associ
progress
increas
earli
morbid
endpoint
tabl
moreov
score
significantli
associ
earli
nrm
day
vs
vs
vs
well
long
term
year
vs
vs
vs
respect
p
hazard
ratio
ci
ref
lr
os
year
vs
vs
vs
respect
p
hazard
ratio
ci
ref
lr
conclus
describ
novel
score
predict
nrm
os
larg
cohort
autolog
transplant
perform
argentina
tool
serv
tailor
condit
regimen
defin
risk
outpati
transplant
program
conflict
interest
relev
conflict
interest
disclos
tabl
earli
endpoint
abstract
previous
publish
haeunda
paik
hospit
inj
univers
colleg
medicin
intern
medicin
busan
korea
republ
inj
univers
colleg
medicinebusan
paik
hospit
intern
medicin
busan
korea
republ
hospit
intern
medicin
busan
korea
republ
inj
univers
colleg
medicinesangy
paik
hospit
intern
medicin
seoul
korea
republ
haeunda
paik
hospit
intern
medicin
busan
korea
republ
background
prostglandin
use
prevent
sinusoid
obstructionvenoocclus
diseas
sosvod
liver
allogen
hematopoiet
stem
cell
transplant
hsct
hematolog
malign
method
given
continu
intraven
infus
day
day
allogen
hsct
dose
microgramskghour
patient
studi
accord
risk
factor
sosvod
diagnosi
intensif
condit
previou
liver
abnorm
diagnosi
sosvod
made
revis
diagnosi
sever
criteria
sosvod
new
classif
european
societi
blood
marrow
transplant
seventi
eight
patient
underw
allogen
hsct
septemb
novemb
treat
seven
receiv
result
median
age
includ
patient
yearold
rang
yearold
male
patient
actual
incid
sosvod
one
patient
group
one
patient
non
group
p
sosvod
develop
two
patient
diagnosi
day
day
hematopoiet
stem
cell
infus
two
patient
one
modrat
sosvod
one
sever
sosvod
new
ebmt
criteria
sever
grade
two
patient
diagnos
sosvod
acut
leukemia
conclus
prophylact
treatment
may
decreas
incid
sosvod
patient
allogen
hematopoiet
stem
cell
transplant
conflict
interest
noth
disclos
fondazion
ircc
istituto
nazional
tumori
milano
itali
univers
milano
dept
oncolog
hematolog
milano
itali
ospedal
santa
croce
e
carl
cuneo
itali
background
effect
protect
diet
pd
patient
prolong
neutropenia
never
test
prospect
adult
hematolog
patient
versu
non
restrict
diet
nrd
method
start
sinc
juli
multicent
random
intervent
studi
compar
use
pd
vs
nrd
hematolog
patient
year
prolong
neutropenia
day
expect
random
alloc
two
diet
type
adher
studi
repres
ingest
least
one
dietspecif
food
day
patient
unabl
ingest
food
consider
applic
pd
food
cook
andor
thick
peel
fruit
consid
dietspecif
nrd
raw
fruit
veget
wash
per
standard
hygien
hospit
standard
consid
dietspecif
moreov
patient
receiv
allogen
hematopoiet
cell
transplant
allohct
alloc
two
studi
cohort
interim
analysi
safeti
plan
enrol
first
patient
result
evalu
independ
data
monitor
safeti
committe
result
enrol
patient
dropout
due
medic
reason
analysi
cohort
repres
patient
seventeen
patient
receiv
allohct
patient
pd
patient
nrd
group
respect
cyclosporin
plu
methotrex
use
standard
gvhd
prophylaxi
patient
antithymocyt
globulin
ad
case
matchedunrel
donor
accord
institut
guidelin
number
patient
develop
least
event
group
rel
risk
confid
interv
ci
tabl
secondari
endpoint
analyz
number
patient
develop
gastrointestin
infect
fever
unknown
origin
hospit
versu
versu
pd
nrd
respect
weight
variat
start
studi
discharg
vs
differ
hospit
length
day
vs
day
day
death
report
allohct
patient
patient
develop
acut
gvhd
grade
seattl
criteria
day
vs
respect
patient
die
day
conclus
preliminari
analysi
show
signific
differ
use
pd
versu
nrd
hematolog
patient
prolong
neutropenia
term
infect
death
result
support
continu
studi
conflict
interest
noth
disclos
tabl
tabl
studi
outcom
accordingli
diet
type
foscal
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
divis
neumolog
bucaramanga
colombia
clinica
carlo
ardila
lull
foscal
hematolog
transplant
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
bucaramanga
colombia
background
literatur
describ
patient
undergo
hematopoiet
stem
cell
transplant
may
develop
approxim
earli
late
pulmonari
complic
import
increas
morbid
mortal
relat
death
method
conduct
ambispect
studi
review
record
patient
underw
allogen
transplant
institut
one
underw
autolog
stem
cell
transplant
follow
day
day
day
result
total
patient
studi
autolog
transplant
mean
age
year
old
femal
male
beam
bcnu
etoposid
cytarabin
melphalan
condit
regimen
common
use
found
incid
earli
infect
complic
day
day
late
infect
complic
day
see
tabl
noninfect
complic
respect
also
allogen
transplant
review
mean
age
year
old
male
femal
myeloabl
condit
regimen
thiopet
busulfan
fludarabin
meanwhil
reduc
intens
cyclosporin
methotrex
usual
use
gvhd
prophylaxi
earli
infect
complic
day
day
late
infect
complic
day
noninfect
complic
respect
chang
spirometri
transplant
mild
restrict
ventilatori
defect
predominantli
defect
found
carbon
monoxid
diffus
capac
lung
usual
defect
identifi
mild
decreas
dlco
normal
alveolar
volum
conclus
comparison
report
literatur
hematopoiet
stem
cell
transplant
center
around
world
incid
complic
found
center
much
lower
keep
tendenc
predominantli
infecti
caus
conflict
interest
author
declar
conflict
interest
universidad
autonoma
de
bucaramangafosc
intern
medicin
divis
hematolog
hematopoiet
stem
cell
transplant
bucaramanga
colombia
universidad
autonoma
de
bucaramanga
school
medicin
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
epidemiolog
bucaramanga
colombia
universidad
autonoma
de
bucaramanga
school
medicin
data
manag
bucaramanga
colombia
background
import
increas
surviv
rate
patient
hematopoiet
stem
cell
transplant
hsct
subsequ
assess
healthrel
qualiti
life
hrqol
stc
recipi
gain
great
interest
medic
commun
method
retrospect
cohort
studi
conduct
hsct
adult
patient
recruit
singl
institut
colombia
south
america
novemb
march
hrql
assess
day
hsct
use
european
organ
research
treatment
cancer
qualiti
life
questionnair
core
eortc
exclus
criteria
result
fortynin
patient
includ
men
women
averag
age
age
present
studi
show
declin
global
qualiti
life
ql
regardless
type
sct
especi
function
scale
first
month
demonstr
similar
studi
wettergren
et
al
statist
signific
differ
physic
function
scale
first
sixthmonth
posttransplant
role
function
scale
first
month
social
function
scale
first
third
month
compar
mean
baselin
compar
autolog
allogen
sct
autolog
sct
group
greater
declin
qualiti
life
allogen
sct
group
statist
signific
decreas
role
function
scale
autolog
sct
patient
first
month
posttransplant
show
probabl
decreas
role
function
time
like
autolog
allogen
transplant
three
month
transplant
social
function
scale
autolog
group
show
higher
declin
rate
allogen
rr
analyz
symptom
scale
autolog
allogen
sct
pain
like
autolog
sct
patient
allogen
three
month
posttransplant
ic
statist
signific
differ
two
group
six
month
posttransplant
exclud
nonmyeloabl
sct
patient
studi
show
statist
signific
differ
compar
autolog
vs
allogen
sct
day
posttransplant
signific
declin
global
ql
rr
physic
function
rr
role
function
rr
fatigu
rr
nauseavomit
rr
autolog
vs
allogen
transplant
differ
emot
function
rr
social
function
rr
three
month
global
qf
rr
ic
six
month
differ
compar
myeloabl
vs
nonmyeloabl
sct
mortal
six
month
posttransplant
conclus
signific
declin
qualiti
life
follow
hematopoiet
stem
cell
transplant
hsct
patient
show
improv
ql
three
month
posttranplant
reach
baselin
level
six
month
autolog
sct
patient
greater
declin
ql
allogen
sct
patient
conflict
interest
author
declar
potenti
conflict
interest
univers
medicin
greifswald
greifswald
germani
westpfalz
hospit
kaiserslautern
germani
background
substanti
lack
data
men
health
hypogonad
adult
allogen
stem
cell
transplant
method
therefor
conduct
prospect
unicentr
nonintervent
clinic
studi
health
focu
male
hypogonad
adult
allogen
stem
cell
transplant
follow
time
one
year
result
abl
includ
patient
acut
myeloid
leukaemia
aml
frequent
underli
diseas
mainli
use
intermedi
intens
condit
protocol
term
graft
versu
host
diseas
gvhd
prophylaxi
homogen
popul
sinc
patient
receiv
low
dose
alemtuzumab
mg
day
respect
mg
case
mismatch
erectil
dysfunct
loss
libido
loss
effici
frequent
symptom
hypogonad
inclus
studi
hypogonad
alreadi
frequent
primari
hypogonad
found
eight
case
secondari
hypogonad
one
case
observ
hypogonad
month
inpati
treatment
anymor
might
still
impair
fertil
still
rise
fsh
level
end
observ
period
signific
associ
hypogonad
myeloabl
condit
kind
donor
interestingli
signific
associ
nicotin
abus
conclus
whole
report
first
data
male
hypogonad
allogen
stem
cell
transplant
interestingli
case
hypogonad
observ
month
inpati
treatment
hypogonad
high
impact
organ
function
qualiti
live
studi
especi
longer
follow
period
necessari
clinic
trial
registri
ethic
approv
octob
conflict
interest
author
state
conflict
interest
regard
studi
rigshospitalet
depart
paediatr
adolesc
medicin
copenhagen
denmark
rigshospitalet
institut
inflamm
research
center
rheumatolog
spine
diseas
copenhagen
denmark
univers
copenhagen
depart
nutrit
exercis
sport
copenhagen
denmark
baylor
colleg
medicin
usdaar
children
nutrit
research
center
depart
pediatr
houston
tx
unit
state
rigshospitalet
depart
haematolog
copenhagen
denmark
background
patient
undergo
allogen
haematopoiet
stem
cell
transplant
hsct
challeng
high
degre
system
inflamm
due
cytotox
effect
condit
regimen
elev
metabol
demand
amino
acid
involv
tissu
repair
regener
hematopoiet
cell
antioxid
defens
studi
address
amino
acid
level
transplant
remain
unknown
amino
acid
defici
may
aggrav
treatmentrel
morbid
aim
present
studi
measur
plasma
level
free
amino
acid
paa
transplant
investig
whether
paalevel
relat
level
inflamm
treatmentrel
complic
method
includ
patient
age
treat
allogen
hsct
copenhagen
denmark
patient
receiv
pretreat
myeloabl
condit
base
total
bodi
irradi
combin
chemotherapi
chemotherapi
alon
free
plasma
concentr
human
amino
acid
measur
use
ultraperform
liquid
chromatographi
baselin
day
posttranspl
along
creactiv
protein
crp
interleukin
level
day
posttranspl
result
signific
decreas
paa
concentr
baselin
day
found
tyrosin
aspart
glutamin
asparagin
citrullin
increas
observ
leucin
valin
tryptophan
phenylalanin
p
day
posttranspl
sever
amino
acid
invers
correl
crp
particular
serin
p
glutamin
p
p
glycin
p
p
lysin
p
p
also
glutam
acid
alanin
arginin
cystein
histidin
tryptophan
threonin
taurin
prolin
methionin
p
high
level
crp
associ
larger
decreas
plasma
level
amino
acid
baselin
day
suggest
dynam
relationship
inflammatori
respons
associ
pronounc
serin
glutamin
glycin
threonin
r
p
eleven
patient
develop
sever
agvhd
defin
grade
patient
develop
sinusoid
obstruct
syndrom
so
patient
so
significantli
lower
level
amino
acid
compar
patient
without
so
day
includ
glutam
acid
serin
arginin
glycin
lysin
valin
tryptophan
threonin
prolin
furthermor
patient
sever
agvhd
lower
level
serin
glutamin
cystein
glycin
lysin
threonin
conclus
signific
chang
occur
plasma
concentr
sever
human
amino
acid
hsct
associ
found
low
plasma
concentr
amino
acid
involv
antiinflammatori
mechan
includ
tissu
renew
increas
system
inflamm
so
sever
agvhd
studi
address
reduc
paa
caus
insuffici
intak
andor
increas
consumpt
amino
acid
due
stress
metabol
whether
substitut
amino
acid
cours
transplant
may
reduc
treatmentrel
morbid
conflict
interest
author
declar
financi
conflict
interest
campu
biomedico
univers
hospit
hematolog
stem
cell
transplant
transfus
medicin
cellular
therapi
rome
itali
tor
vergata
univers
rome
stem
cell
transplant
unit
policlinico
universitario
tor
vergata
rome
itali
tor
vergata
univers
hospit
divis
urolog
rome
itali
tor
vergata
univers
divis
blood
bank
depart
immunohematolog
rome
itali
sapienza
univers
stem
cell
transplant
unit
depart
hematolog
rome
itali
sapienza
univers
stem
cell
transplant
unit
depart
hematolog
rome
itali
santeugenio
hospit
divis
hematolog
transplant
rome
itali
tor
vergata
univers
medic
statist
depart
biolog
rome
itali
civil
hospit
stem
cell
transplant
unit
pescara
itali
tor
vergata
univers
hospit
rome
itali
european
institut
oncolog
milan
univers
hematooncolog
divis
milano
itali
tor
vergata
univers
rome
stem
cell
transplant
unit
policlinico
universitario
tor
vergata
biomedicina
e
prevenzion
rome
itali
background
haemorrhag
cystiti
hc
occur
allogen
transplant
significantli
affect
qualiti
life
case
becom
intract
increas
risk
death
date
therapi
establish
report
first
experi
rome
transplant
network
rtn
treat
patient
refractori
posttranspl
hc
use
haemostat
agent
fibringlu
fg
diffus
spray
bleed
mucosa
endoscop
applic
cumul
incid
pain
discontinu
complet
remiss
defin
regress
symptom
absenc
haematuria
day
day
fg
applic
respect
herein
report
updat
experi
patient
includ
new
patient
enter
multicentr
studi
fg
treatment
grade
posttranspl
hc
method
respect
first
patient
new
patient
slightli
older
receiv
heterogen
condit
regimen
present
frequent
grade
hc
receiv
less
cidofovir
underw
later
fg
treatment
howev
except
cidofovir
therapi
differ
statist
signific
descript
analysi
demograph
clinic
characterist
patient
perform
includ
median
standard
deviat
rang
continu
variabl
absolut
rel
frequenc
categor
variabl
take
account
correspond
compet
risk
pain
discontinu
cathet
remov
complet
respons
estim
cumul
incid
method
overal
surviv
estim
accord
kaplanmei
productlimit
method
result
patient
receiv
allogen
transplant
highrisk
hematolog
malign
cb
hla
ident
sib
mud
haplo
patient
develop
grade
acut
gvhd
occur
median
day
rang
transplant
bk
viremia
viruria
detect
time
hc
onset
posit
patient
hc
occur
median
day
rang
transplant
grade
patient
respect
time
fg
treatment
administ
median
day
rang
hc
onset
number
fg
applic
patient
overal
respons
obtain
patient
partial
complet
patient
non
respond
respond
patient
pain
discontinu
occur
median
day
rang
cathet
remov
median
day
rang
fg
univari
analysi
complet
respons
significantli
correl
type
graft
donor
grade
hc
interv
time
hc
onset
fg
applic
probabl
surviv
patient
respect
conclus
last
analysi
confirm
fg
therapi
feasibl
effect
repeat
inexpens
procedur
treat
grade
hc
allogen
transplant
furthermor
fg
appli
earli
onset
hc
conflict
interest
none
nation
cancer
center
hospit
depart
hematopoiet
stem
cell
transplant
tokyo
japan
tohoku
univers
graduat
school
medicin
sendai
japan
jyoban
hospit
tokiwa
foundat
fukushima
japan
japanes
data
center
hematopoiet
cell
transplant
nagoya
japan
kanagawa
cancer
center
yokohama
japan
keio
univers
school
medicin
tokyo
japan
institut
medic
scienc
univers
tokyo
tokyo
japan
kyoto
univers
kyoto
japan
yokohama
citi
univers
medic
center
yokohama
japan
tohoku
univers
hospit
sendai
japan
jikei
univers
school
medicin
tokyo
japan
tokai
univers
school
medicin
isehara
japan
jichi
medic
univers
tochigi
japan
hyogo
cancer
center
akashi
japan
toranomon
hospit
tokyo
japan
st
luke
intern
hospit
tokyo
japan
nagoya
univers
graduat
school
medicin
nagoya
japan
background
relationship
employ
statu
qol
allohct
remain
elucid
address
critic
issu
conduct
nationwid
crosssect
questionnair
studi
method
allohct
recipi
hematolog
diseas
age
year
transplant
year
without
relaps
survey
includ
qol
assess
factbmt
particip
ask
provid
lifestyl
inform
multivari
model
construct
examin
relationship
qol
employ
statu
adjust
background
covari
result
patient
inform
studi
consent
obtain
respond
patient
year
age
survey
includ
analysi
cohort
consist
male
median
age
survey
median
time
allohct
year
time
survey
patient
employ
fulltim
employ
parttim
unemployedhousewifestud
experienc
career
chang
jobsemployersposit
allohct
cohort
divid
group
employ
statu
patient
employ
fulltim
without
career
chang
fullsam
highest
score
physic
pc
mental
mc
rolesoci
rc
compon
summari
factbmt
total
patient
employ
fulltim
significantli
lower
score
p
domain
compar
fullsam
group
figur
patient
survey
pc
compar
gener
popul
regardless
employ
statu
signific
differ
among
group
hand
patient
employ
fulltim
significantli
lower
pc
compar
fullsam
group
mc
compar
gener
popul
signific
differ
among
group
patient
without
chronic
gvhd
survey
pc
mc
rc
fullsam
group
higher
gener
popul
patient
gvhd
pc
rc
employ
fulltim
significantli
lower
compar
fulltim
group
gener
popul
conclus
employ
statu
highli
correl
qol
allohct
impact
may
differ
accord
patient
age
gvhd
statu
clinic
trial
registri
conflict
interest
author
conflict
interest
disclos
kosin
univers
colleg
medicin
depart
intern
medicin
busan
korea
republ
kosin
univers
gospel
hospit
regist
nurs
stem
cell
transplant
clinic
nurs
specialist
busan
korea
republ
kosin
univers
colleg
medicin
depart
biochemistri
cancer
research
institut
busan
korea
republ
donga
univers
colleg
medicin
depart
intern
medicin
busan
korea
republ
pusan
nation
univers
yangsan
hospit
yangsan
korea
republ
ulsan
univers
hospit
univers
ulsan
colleg
medicin
ulsan
korea
republ
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
republ
background
transplantationrel
mortal
trm
import
factor
patient
undergo
allogen
stem
cell
transplant
allosct
trm
divid
earli
late
trm
base
day
transplant
howev
caus
trm
report
age
patient
tumor
burden
prior
transplant
comorbid
condit
intens
condit
infect
acut
gvhd
etc
howev
report
develop
transplant
techniqu
incid
trm
also
decreas
lack
report
incid
rate
trm
report
caus
trm
therefor
studi
conduct
analyz
trm
rate
korea
analyz
caus
trm
method
studi
includ
patient
acut
leukemia
md
myelodysplast
syndrom
cml
chronic
myeloid
leukemia
receiv
allosct
underw
condit
regimen
base
fludarabin
daili
cyclophosphamid
daili
intraven
busulfan
mgkg
daili
ratg
total
dose
mgkg
prior
allosct
patient
receiv
peripher
blood
stem
cell
graft
sourc
receiv
calcinurin
inhibitor
gvhd
prophylaxi
start
result
data
patient
five
univers
hospit
south
korea
sep
jun
collect
retrospect
analyz
consecut
patient
median
age
year
rang
male
patient
acut
leukemia
other
md
cml
patient
receiv
myeloabl
condit
regimen
receiv
reduc
intens
condit
patient
receiv
allosct
other
incid
rate
earli
trm
patient
predict
factor
earli
trm
age
younger
less
year
vs
vs
diseas
statu
allosct
vs
noncr
vs
p
type
allosct
sibl
vs
unrel
vs
haploident
vs
vs
howev
intens
condit
year
allosct
shown
differ
result
compar
previou
report
reduc
intens
condit
ric
shown
higher
trm
myeloabl
condit
mac
vs
ric
perform
frequent
acut
gvhd
grade
ii
count
comorbid
condit
shown
signific
differ
multivari
analysi
noncr
unrel
donor
independ
signific
risk
factor
earli
trm
rr
p
respect
conclus
studi
incid
earli
trm
defin
death
within
day
stem
cell
transplant
addit
patient
noncr
pretranspl
diseas
statu
receiv
unrel
donor
sourc
transplant
cell
identifi
signific
high
incid
rate
earli
trm
conflict
interest
author
conflict
interest
report
instituto
de
oncologia
porto
francisco
gentil
medic
oncolog
porto
portug
instituto
de
oncologia
porto
francisco
gentil
bone
marrow
transplant
depart
porto
portug
instituto
de
oncologia
porto
francisco
gentil
cellular
therapi
depart
porto
portug
background
success
hematopoiet
cell
transplant
hct
led
develop
secondari
malign
patient
would
otherwis
longterm
survivor
among
malign
solid
tumor
myelodysplast
syndrom
posttranspl
lymphoprolif
diseas
ptld
aim
describ
common
second
malign
tumor
hct
instituto
de
oncologia
porto
ipop
well
determin
differ
time
diagnosi
second
neoplasia
allogen
autolog
transplant
method
retrospect
cohort
patient
submit
hematopoiet
cell
transplant
ipop
sinc
june
june
data
second
malign
tumor
main
diagnosi
led
hematopoiet
transplant
date
diagnosi
collect
result
patient
treat
center
sinc
elig
studi
women
men
median
age
submit
autolog
transplant
common
second
malign
tumor
diagnos
oral
caviti
patient
posttranspl
lymphoprolif
diseas
patient
myelodysplast
syndrom
patient
nonmelanoma
skin
cancer
patient
median
time
diagnosi
second
tumor
sinc
transplant
month
patient
die
median
overal
surviv
year
sinc
diagnosi
first
malign
neoplasia
patient
diagnosi
third
neoplasia
median
time
diagnosi
second
tumor
patient
submit
autolog
transplant
year
allogen
transplant
year
statist
signific
conclus
success
hct
led
complic
secondari
malign
patient
would
longterm
survivor
common
second
malign
tumor
diagnos
institut
seem
concord
retrospect
studi
hct
survivor
advis
increas
risk
develop
malign
follow
hct
encourag
report
concern
symptom
physician
conflict
interest
author
report
conflict
interest
istanbul
univers
istanbul
faculti
medicin
intern
medicin
depart
istanbul
turkey
istanbul
univers
istanbul
faculti
medicin
intern
medicin
depart
divis
hematolog
istanbul
turkey
medipol
univers
intern
medicin
depart
divis
hematolog
istanbul
turkey
background
secondari
primari
malign
spm
includ
acut
leukemia
myelodysplast
syndrom
hodgkin
lymphoma
nonhodgkin
lymphoma
solid
tumor
aris
hematopoiet
stem
cell
transplant
hsct
patient
rel
rare
complic
transplant
investig
incid
posttranspl
spm
cohort
patient
undergon
autolog
peripher
hsct
method
medic
record
patient
receiv
autolog
hsct
institut
surviv
least
one
year
review
result
median
age
rang
year
sex
ratio
mf
median
followup
sinc
transplant
rang
year
patient
die
transplant
mostli
due
diseas
progress
previou
diseas
includ
multipl
myeloma
n
plasma
cell
disord
n
lymphoma
lymphoma
acut
leukemia
chronic
myeloid
leukemia
patient
develop
spm
differ
origin
median
latenc
transplant
secondari
neoplasm
year
rang
year
cml
patient
diagnos
tyrosin
kinas
inhibitor
tki
refractori
standard
treatment
interferon
cytarabin
donor
achiev
hematolog
respons
etoposid
base
chemotherapi
underw
autolog
sct
tki
era
imatinib
follow
nilotinib
provid
molecular
respons
year
transplant
diagnos
ovarian
cancer
ym
mm
patient
nearli
complet
respons
transplant
lenalidomid
give
mainten
year
hsct
routin
screen
petct
reveal
mass
lesion
histolog
document
renal
cell
carcinoma
case
mm
patient
complet
respons
receiv
lenalidomid
mainten
year
hsct
develop
epitheli
tumor
local
tongu
case
mm
patient
nearli
complet
respons
develop
year
hsct
concurr
bladder
carcinoma
pheocromocytoma
patient
aliv
cure
spm
conclus
factor
effect
secondari
cancer
occurr
hsct
declar
age
late
period
hsct
use
prior
alkyl
agent
use
topoisomeras
ii
inhibitor
high
dose
pre
transplant
radiotherapi
studi
encompass
consecut
case
transplant
institut
spm
ratio
would
chang
time
among
risk
factor
case
list
moreov
smoke
addit
risk
factor
last
patient
thu
benefit
risk
includ
spm
weigh
decis
autolog
hsct
taken
account
spm
curabl
malign
gener
conflict
interest
author
noth
disclos
hiroshima
red
cross
hospit
atom
bomb
survivor
hospit
divis
haematolog
hiroshima
japan
hiroshima
red
cross
hospit
atom
bomb
survivor
hospit
divis
transfus
hiroshima
japan
hiroshima
red
cross
hospit
atom
bomb
survivor
hospit
divis
laboratori
hiroshima
japan
background
allogen
haematopoiet
stem
cell
transplant
allohsct
effect
treatment
hematolog
malign
secondari
solid
tumor
sst
allohsct
report
import
problem
perform
retrospect
survey
sst
develop
follow
allohsct
method
retrospect
analyz
record
hematolog
malign
adult
patient
underw
allohsct
hospit
januari
novemb
sst
confirm
tissu
biopsi
surgic
specimen
result
seventeen
patient
develop
sst
allohsct
tabl
patient
acut
myeloid
leukemia
aml
acut
lymphoblast
leukemia
myelodysplast
syndrom
md
md
overt
aml
malign
lymphoma
chronic
myeloid
leukemia
median
time
sst
diagnosi
follow
allohsct
day
rang
age
rang
year
allohsct
median
eight
patient
treat
fullintens
condit
regimen
high
dose
total
bodi
irradi
tbi
contain
regimen
nine
patient
treat
reducedintens
condit
regimen
donor
sourc
sibl
bone
marrow
bm
patient
sibl
peripher
blood
stem
cell
patient
unrel
bm
patient
unrel
cord
blood
patient
fourteen
patient
develop
chronic
graft
versu
host
diseas
gvhd
patient
extens
develop
sst
five
patient
taken
methylprednisolon
mpsl
patient
taken
mpsl
tacrolimu
time
sst
diagnosi
six
patient
develop
secondari
solid
tumor
organ
chronic
gvhd
three
patient
develop
two
secondari
solid
tumor
lesion
two
patient
develop
two
solid
tumor
legion
simultan
six
patient
receiv
local
surgeri
patient
surgeri
radiat
patient
chemotherapi
radiat
patient
surgeri
chemotherapi
radiat
patient
cryoablat
one
patient
die
therapi
current
patient
aliv
patient
diseasefre
therapi
sst
median
time
surviv
follow
therapi
sst
day
rang
therapi
sst
one
patient
relaps
primari
hematolog
malign
md
overt
aml
caus
death
progress
sst
patient
progress
primari
hematolog
malign
patient
conclus
suggest
sst
develop
among
hematolog
malign
patient
allohsct
rare
need
novel
follow
strategi
manag
sst
hematolog
malign
patient
allohsct
conflict
interest
author
noth
disclos
tabl
site
secondari
solid
tumor
allohsct
uti
ospedal
civil
pescara
dipartimento
di
ematologia
medicina
trasfusional
e
biotecnologi
pescara
itali
clinica
odontoiatrica
alma
mater
studiorum
di
bologna
dipartimento
di
scienz
biomedich
e
neuromotori
bologna
itali
background
limit
inform
occurr
sst
oral
caviti
first
airway
patient
undergo
allogen
hct
aim
retrospect
studi
determin
incid
clinic
outcom
sst
oral
caviti
first
airway
assess
potenti
risk
factor
patient
allotranspl
center
method
tabl
show
characterist
patient
popul
time
transplant
result
full
engraft
donor
cell
evid
patient
acut
chronic
gvhd
affect
patient
respect
mortal
rate
due
either
transplantrel
caus
recurr
origin
diseas
patient
patient
respect
moreov
patient
die
late
nontranspl
relat
caus
time
report
patient
live
median
followup
year
followup
patient
develop
malign
oral
caviti
tongu
oral
mucosa
larynx
year
median
year
hct
case
histolog
examin
show
squamou
cell
carcinoma
cumul
incid
ci
develop
sst
patient
underw
surgic
resect
tumor
addit
receiv
radiotherapi
chemotherapi
relev
patient
affect
chronic
gvhd
buccal
caviti
involv
current
patient
live
sstfree
patient
die
tumor
progress
univari
analysi
factor
associ
increas
ci
sst
nonmalign
hematolog
diseas
reduc
intens
condit
drug
use
condit
regimen
differ
irradi
busulfan
chronic
gvhd
p
oral
chronic
gvhd
p
fine
gray
model
multivari
analysi
factor
maintain
signific
nonmalign
hematolog
diseas
hr
oral
chronic
gvhd
hr
overal
kaplan
meyer
surviv
patient
stt
conclus
studi
demonstr
oral
chronic
gvhd
diagnosi
nonmalign
hematolog
diseas
strong
risk
factor
develop
new
sst
oral
caviti
first
airway
patient
cgvhd
especi
involv
oral
caviti
must
receiv
long
care
monitor
surveil
order
prevent
develop
secondari
cancer
conflict
interest
conflict
interest
tabl
characterist
patient
popul
time
king
hussein
cancer
center
amman
jordan
background
surviv
post
hematopoiet
stem
cell
transplant
hsct
improv
number
patient
live
free
origin
diseas
increas
result
long
term
effect
hsct
increasingli
identifi
second
malign
sm
follow
hsct
sequela
surviv
qualiti
life
particular
concern
method
retrospect
chart
review
conduct
patient
underw
hsct
jan
nov
obtain
irb
approv
analysi
perform
use
kaplan
meier
curv
logrank
test
surviv
chisquar
mannwhitney
test
categor
numer
item
respect
result
studi
period
transplant
perform
median
followup
post
hsct
month
rang
sixteen
patient
develop
sm
median
month
median
age
time
hsct
patient
sm
year
rang
similar
whole
group
among
patient
develop
sm
primari
diagnos
aml
hodgkin
lymphoma
mm
fanconi
anemia
cml
chronic
phase
neuroblastoma
second
hematolog
malign
diagnos
develop
second
cancer
myeloid
leukemia
commonest
second
solid
tumor
observ
n
commonli
squamou
cell
carcinoma
os
develop
second
malign
median
surviv
month
signific
differ
os
second
hematolog
vs
solid
tumor
use
fisher
exact
test
signific
associ
develop
sm
age
transplant
allogen
transplant
myeloabl
condit
use
tbi
p
conclus
indefinit
followup
earli
detect
sm
may
improv
qualiti
life
surviv
post
hsct
surveil
report
sm
essenti
new
transplant
program
like
popul
rate
secondari
tumor
lower
report
literatur
possibl
due
short
followup
conflict
interest
author
declar
conflict
interest
hospit
gener
universitario
gregorio
hematolog
madrid
spain
instituto
de
sanitaria
gregorio
madrid
spain
hospit
gener
universitario
gregorio
genom
unit
madrid
spain
background
graft
failur
gf
unusu
threaten
complic
allogen
hsct
allohsct
chimer
monitor
shown
contribut
earli
detect
gf
object
studi
describ
chimer
dynam
patient
develop
gf
allohsct
method
characterist
outcom
patient
diagnos
gf
allohsct
sinc
singl
centr
retrospect
analyz
chimer
studi
perform
peripher
blood
pb
cell
tc
weekli
sinc
day
strpcr
patient
classifi
two
group
primari
gf
absenc
neutrophil
engraft
day
secondari
gf
develop
sever
cytopenia
progress
mix
chimer
mc
initi
achiev
neutrophil
engraft
relaps
rule
case
result
seven
patient
diagnos
primari
gf
patient
secondari
gf
tabl
evid
caus
identifi
primari
gf
case
median
percentag
recipi
cell
chimer
analysi
day
pb
tc
respect
figur
salvag
two
patient
treat
donor
lymphocyt
infus
dli
five
second
allohsct
median
time
salvag
therapi
day
rang
five
patient
achiev
engraft
six
complet
chimer
cc
fourmonth
os
salvag
seven
patient
diagnos
secondari
gf
achiev
initi
neutrophil
engraft
median
day
rang
median
time
gf
allohsct
day
rang
six
develop
cmv
reactiv
gf
median
percentag
recipi
cell
chimer
analysi
day
diagnosi
moment
gf
confirm
pb
tc
respect
figur
salvag
one
patient
treat
dli
six
second
allohsct
median
time
salvag
therapi
day
rang
gf
confirm
five
patient
achiev
engraft
cc
fourmonth
os
salvag
conclus
patient
primari
gf
present
persist
mc
earli
serial
chimer
analysi
allohsct
particullari
high
percentag
recipi
cell
tc
patient
secondari
gf
show
increas
percentag
recipi
cell
gf
establish
henc
use
serial
multilineag
chimer
especi
tc
may
predict
identifi
primari
secondari
gf
allow
earli
intervent
experi
time
individu
second
allohsct
gf
succes
salvag
signific
proport
patient
conflict
interest
author
noth
disclos
tabl
characterist
patient
transplant
medic
school
hannov
paediatr
haematolog
oncolog
hannov
germani
background
girl
thalassemia
major
pesaro
risk
class
transplant
hlamatch
unrel
femal
donor
may
graft
frozen
unmanipul
pbsc
mnckg
cmv
serostatu
donorrecipi
posit
condit
fludarabinetreosulfan
thiothepaatg
gvhd
prophylaxi
csamtx
posttranspl
complic
engraft
syndrom
treat
prednison
mgkgday
day
overlap
steroidresist
acut
skingvhd
grade
gut
liver
gvhd
therapi
csa
prednison
mgday
ruxolitinib
day
engraft
day
leucocyt
platelet
achiev
discharg
day
chimer
polyomavirusassoci
hemorrhag
cystiti
day
sever
cmvreactiv
sinc
treat
ganciclovir
cidofovir
foscarnet
patient
develop
diabet
mellitu
treat
insulin
poor
graft
function
requir
innumer
blood
transfus
erythrocyt
thrombocyt
day
posthsct
present
sever
diffus
skelet
muscular
pain
extrem
requir
high
dose
intraven
hydromorphon
nonopioid
analges
time
sign
gvhd
ruxolitinib
decreas
dose
prednison
csaneurotox
suspect
gvhd
treatment
chang
sirolimu
fluconazol
given
antifung
prophylaxi
antinuclear
ena
antibodi
well
antibodi
scleroderma
polymyositisdermatomyos
present
patient
progress
swell
knee
distal
thigh
mri
examin
show
typic
sign
extens
myositi
periost
knee
distal
femur
tibia
concomitantli
patient
fold
increas
serum
ldh
diagnosi
tatma
confirm
measur
solubl
membran
attack
complex
level
significantli
increas
basal
level
addit
proteinuria
mgdl
increas
urin
proteintocreatinin
ratio
normal
serum
creatinin
scystatin
never
schistocytosi
peripher
blood
possibl
due
high
transfus
requir
time
diagnosi
tatma
requir
two
antihypertens
drug
third
one
ad
later
method
eculizumab
start
day
mg
load
dose
follow
mg
week
mg
weekli
week
receiv
one
cycl
rituximab
day
sirolimu
stop
day
slow
decreas
signific
reduct
etanercept
initi
patient
receiv
dose
etanercept
sc
mg
day
result
one
week
later
discharg
myositi
periost
kidney
abnorm
complet
resolv
day
dose
eculizumab
becam
transfusionfre
first
time
achiev
platelet
current
sign
tatma
acut
chronic
gvhd
discuss
far
periost
myositi
never
describ
tatma
system
vasculopathi
etanercept
improv
endotheli
function
inhibit
major
trigger
develop
tatma
conclus
treatment
sever
tatma
remain
challeng
inhibitor
etanercept
combin
eculizumab
could
potenti
contribut
resolv
often
treatmentrefractori
condit
conflict
interest
conflict
interest
rigshospitalet
univers
copenhagen
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
helsinki
helsinki
univers
central
hospit
divis
haematologyoncolog
stem
cell
transplant
children
hospit
helsinki
finland
univers
copenhagen
depart
nutrit
exercis
sport
copenhagen
denmark
rigshospitalet
univers
copenhagen
pediatr
nutrit
unit
copenhagen
denmark
rigshospitalet
univers
copenhagen
depart
growth
reproduct
copenhagen
denmark
karolinska
institutet
univers
hospit
pediatr
endocrinolog
unit
depart
women
children
health
stockholm
sweden
background
chang
bodi
composit
associ
increas
risk
metabol
syndrom
cardiovascular
diseas
function
impair
therefor
investig
bodi
composit
male
longterm
survivor
pediatr
allohsct
method
conduct
crosssect
followup
studi
male
danish
finnish
age
year
median
rang
followup
year
dualenergi
xray
absorptiometri
scan
measur
bodi
fat
lean
mass
calcul
lean
bodi
mass
index
skelet
muscl
mass
index
fat
mass
index
relat
lean
bodi
mass
fat
mass
height
zscore
calcul
american
healthi
refer
popul
result
mean
sd
bodi
mass
index
bmi
normal
patient
obes
bmi
wherea
underweight
bmi
accord
definit
soft
lean
mass
percentag
lean
bodi
mass
index
skelet
muscl
mass
index
significantli
reduc
indic
gener
loss
skelet
muscl
tissu
fat
mass
index
similar
refer
popul
androidgynoid
fat
mass
ag
ratio
increas
reflect
alter
fat
mass
distribut
toward
abdomin
obes
tabl
figur
lean
bodi
mass
significantli
reduc
ag
ratio
significantli
increas
patient
tbi
base
condit
compar
nontbi
tabl
importantli
howev
patient
nontbi
group
still
significantli
reduc
lean
bodi
mass
index
skelet
muscl
mass
index
compar
refer
popul
tabl
accord
patient
malign
diseas
pronounc
reduct
lean
bodi
mass
index
skelet
muscl
mass
index
benign
diseas
mean
sd
zscore
vs
vs
respect
chang
bodi
fat
percentag
lean
bodi
mass
index
skelet
muscl
mass
index
tend
improv
increas
followup
time
hsct
chang
ag
ratio
becam
deterior
longer
followup
tabl
conclus
major
male
longterm
survivor
markedli
decreas
skelet
muscl
mass
bmi
fat
mass
appear
normal
ag
ratio
increas
chang
bodi
composit
indic
increas
risk
function
impair
well
metabol
cardiovascular
diseas
among
survivor
pediatr
allohsct
conflict
interest
author
noth
disclos
tabl
zscore
analyz
signific
one
sampl
ttest
two
sampl
ttest
mannwhitney
u
test
univari
linear
regress
rambam
health
care
campu
divis
pulmonolog
haifa
israel
technion
israel
institut
technolog
ruth
bruce
rappaport
faculti
medicin
haifa
israel
rambam
health
care
campu
intern
medicin
c
haifa
israel
rambam
health
care
campu
hematolog
bmt
haifa
israel
background
postallogen
stem
cell
transplant
asct
lung
injuri
occur
patient
may
secondari
multipl
factor
includ
highdos
therapi
incorpor
condit
regimen
administ
treat
primari
diseas
infect
immunolog
reaction
immun
suppress
graftversushost
diseas
gvhd
sign
symptom
pulmonari
complic
often
nonspecif
insidi
prompt
diagnosi
crucial
treatment
delay
associ
rapid
deterior
advers
outcom
aim
present
studi
identifi
risk
factor
predictor
postasct
pulmonari
function
test
pft
abnorm
use
regular
lung
function
monitor
method
adult
patient
underw
asct
sign
inform
consent
follow
month
postasct
design
pulmonologist
underw
detail
respiratori
evalu
pft
accord
american
thorac
societi
at
european
respiratori
societi
er
guidelin
includ
diffus
capac
carbon
monoxid
dlco
vital
capac
vc
total
lung
capac
tlc
forc
volum
vital
capac
fvc
forc
expiratori
volum
second
find
compar
presct
pft
result
consecut
adult
patient
enrol
studi
median
age
rang
year
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
past
smoker
hlamatch
relat
unrel
donor
use
patient
patient
receiv
tbibas
condit
regimen
transplant
recipi
develop
acut
gvhd
grade
sixti
six
percent
patient
chronic
gvhd
cgvhd
mostli
mildmoder
follow
asct
patient
die
common
caus
death
relat
relaps
primari
hematolog
condit
occur
patient
first
month
posttranspl
patient
develop
pulmonari
complic
infecti
noninfecti
infecti
noninfecti
patient
respect
six
patient
diagnos
bronchiol
obliteran
mean
declin
presct
month
mean
rvtlc
ratio
increas
month
p
although
dlco
declin
month
postsct
statist
signific
correl
observ
declin
rise
rvtlc
ratio
p
declin
declin
dlco
p
declin
associ
femal
gender
cgvhd
viral
infect
conclus
rvtlc
ratio
shown
statist
signific
chang
baselin
year
postasct
correl
drop
alter
dlco
rvtlc
simpl
spirometri
test
adequ
suggest
pulmonari
impair
follow
sct
particularli
import
lowresourc
center
spirometri
access
complet
pft
moreov
reproduc
easier
perform
patient
clinic
trial
registri
na
conflict
interest
noth
disclos
faculti
medicin
univers
hospit
motol
pragu
czech
republ
background
preval
allogen
hematopoiet
stem
cell
transplant
hsct
survivor
continu
increas
gonad
insuffici
infertil
frequent
late
complic
method
analys
data
success
pregnanc
patient
pt
follow
hsct
childhood
centr
total
patient
older
year
check
outpati
depart
result
patient
becam
parent
forti
children
born
overal
group
term
healthi
first
pregnanc
document
year
hsct
age
year
median
age
patient
time
hsct
year
patient
treat
due
saa
patient
underw
hsct
due
malign
diagnosi
detect
spontan
gravid
pt
cyclophosphamid
regimen
male
full
myeloabl
busulphan
base
condit
pt
male
follow
tbi
gy
full
busulphan
use
biolog
father
cryopreserv
sperm
use
testicular
sperm
retriev
pt
tese
testicular
sperm
extract
patient
util
assist
reproduct
techniqu
ivf
donor
donor
femal
underw
repeat
unsuccess
ivf
hyperstimul
becam
later
pregnant
spontan
even
one
tbi
gy
base
regimen
conclus
gonadotox
hsct
well
known
posttranspl
complic
affect
qualiti
life
fertil
issu
must
routin
discuss
peritranspl
care
field
reproduct
medicin
impress
advanc
achiev
offer
best
option
fertil
preserv
pregnanc
outcom
better
knowledg
pregnanc
rate
especi
paediatr
popul
follow
hsct
requir
data
analysi
intern
cooper
support
mhcz
conceptu
develop
univers
hospit
motol
conflict
interest
author
noth
disclos
hospit
clinic
barcelona
stem
cell
trasplant
unit
hematolog
depart
barcelona
spain
hospit
clinic
barcelona
endocrinolog
nutrit
depart
barcelona
spain
background
advanc
allohsct
procedur
support
care
use
reduc
intens
condit
regimen
older
patient
led
signific
improv
longterm
surviv
transplant
survivor
elev
probabl
late
morbid
mortal
hematolog
diseas
relaps
predomin
caus
mortal
first
year
studi
analyz
longterm
complic
patient
aliv
diseasefre
year
allohsct
present
studi
prospect
investig
within
first
year
transplant
preval
risk
factor
develop
call
late
effect
method
accord
recommend
screen
prevent
practic
longterm
survivor
majhail
n
et
al
prospect
evalu
allohsct
recipi
month
postsct
patient
also
evalu
chronic
gvhd
accord
nih
consensu
criteria
gvhd
diagnosi
analyz
data
physic
examin
blood
pressur
heart
rate
respiratori
rate
bodi
mass
index
bmi
laboratori
test
blood
cell
count
liver
renal
function
test
fast
lipid
profil
glucos
thyroid
function
cortisol
test
calcium
pth
vitamin
tcell
count
immunoglobulin
level
iron
overload
respiratori
function
bone
densiti
scan
perform
patient
present
risk
factor
osteoporosi
patient
also
evalu
ophthalmologist
pneumologist
dermatologist
gynecologist
result
thirtynin
patient
evalu
femal
median
age
year
chronic
gvhd
diagnos
patient
almost
patient
present
cardiovascular
risk
factor
de
novo
transplant
dyslipidemia
hypertens
diabet
four
patient
cardiovascular
diseas
organ
damag
allohsct
twelv
patient
cortisol
level
lower
receiv
glucocorticoid
twelv
patient
requir
nutrit
intervent
due
low
high
bmi
dietari
supplement
reach
normal
bmi
eightyseven
percent
patient
vitamin
level
lower
osteopenia
male
femal
osteoporosi
male
femal
menopaus
women
glucocorticoid
treatment
women
men
identifi
risk
factor
bone
loss
receiv
treatment
calcifediol
achiev
normal
level
vitamin
bone
mass
increas
one
patient
conclus
adult
group
allohsct
recipi
identifi
high
preval
cardiovascular
risk
factor
signific
number
patient
abnorm
miner
metabol
bone
diseas
hypocortisol
nutrit
defici
earli
identif
treatment
condit
could
use
prevent
sever
frequenc
common
late
effect
allohsct
conflict
interest
receiv
scolarship
dkm
foundat
dedic
clinic
assit
lateeffect
followup
unit
new
program
hospit
barcelona
start
one
year
ago
author
noth
disclos
apollo
special
cancer
hospit
paediatr
blood
marrow
transplant
chennai
india
background
cytokin
releas
syndrom
well
document
phenomenon
patient
undergo
novel
monoclon
antibodi
therapi
haematopoiet
stem
cell
transplant
hsct
increas
use
haploident
hsct
benign
haematolog
condit
urgent
need
earli
recognit
treatment
entiti
reduc
morbid
mortal
method
retrospect
analysi
data
centr
last
year
children
underw
replet
haploident
haematopoiet
stem
cell
transplant
post
transplant
cyclophosphamid
ptci
perform
replet
graft
haploident
hsct
known
releas
cytokin
result
allo
effect
serial
serum
ferritin
perform
surrog
marker
cytokin
releas
twice
week
children
undergo
haploident
hsct
day
infus
engraft
normal
rang
serum
ferritin
centr
ng
ml
fold
increas
serum
ferritin
level
herald
symptom
cytokin
releas
storm
cr
grade
cr
perform
per
revis
cr
grade
system
rang
mild
fever
fluid
retent
myalgia
hypoxaemia
hypotens
need
vasopressor
death
result
total
haploident
hsct
patient
data
replet
graft
post
transplant
cyclophosphamid
perform
analys
retrospect
children
age
month
year
age
forti
children
transplant
benign
haematolog
condit
like
primari
immun
defici
aplast
anaemia
adrenoleucodystrophi
haemoglobinopathi
twelv
patient
relaps
refractori
leukaemia
amongst
children
transplant
benign
haematolog
condit
grade
cr
seen
children
grade
children
grade
result
death
document
children
ferritin
level
increas
exponenti
normal
baselin
level
patient
ferritin
level
seen
children
die
intervent
etarnacept
use
children
two
children
salvag
use
earli
inhibitor
tociluzimab
mg
kg
none
children
malign
demonstr
sign
cr
seen
children
benign
condit
p
valu
less
conclus
haploident
hsct
increasingli
offer
infant
children
benign
haematolog
disord
repres
cost
effect
option
cure
life
threaten
disord
estim
serum
level
marker
cytokin
releas
avail
centr
c
reactiv
protein
serum
ferritin
use
surrog
marker
earli
recognit
clinic
entiti
use
easili
access
low
cost
investig
like
serial
serum
ferritin
crp
result
appropri
intervent
reduc
mortal
clinic
trial
registri
na
conflict
interest
none
haukeland
univers
hospit
depart
medicin
bergen
norway
univers
bergen
institut
clinic
scienc
section
hematolog
bergen
norway
oslo
univers
hospit
rikshospitalet
depart
hematolog
oslo
norway
univers
oslo
institut
basic
medic
scienc
depart
nutrit
oslo
norway
univers
oslo
institut
clinic
medicin
oslo
norway
background
recent
perform
random
control
trial
evalu
effect
individu
nutrit
support
qualiti
life
graftversushost
diseas
gvdh
infecti
complic
nutrit
statu
allogen
stem
cell
transplant
nasq
trial
studi
particip
random
either
intervent
group
receiv
earli
posttranspl
nutrit
support
mainli
base
enter
nutrit
oral
intak
tube
feed
control
group
receiv
parenter
nutrit
initi
dose
attend
physician
want
evalu
effect
enter
parenter
nutrit
metabolom
plasma
profil
allotranspl
recipi
three
week
posttranspl
method
select
patient
intervent
group
control
group
minim
differ
two
group
ensur
patient
treat
busulphan
plu
cyclophosphamid
totalbodi
irradi
plu
cyclophosphamid
receiv
gvhd
prophylaxi
ciclosporin
methotrex
patient
aliv
without
relaps
day
posttranspl
includ
analysi
plasma
sampl
collect
one
week
prior
three
week
graft
infus
metabolit
profil
metabolit
assess
use
mass
spectrometri
result
signific
differ
two
patient
group
respect
gvhd
report
sever
mucos
posttranspl
goal
secur
adequ
total
energi
intak
met
intervent
group
control
group
receiv
substanti
higher
dose
parenter
nutrit
averag
total
dose
kcal
rang
intervent
group
kcal
rang
kcal
pvalu
promin
posttranspl
metabol
chang
common
group
signific
increas
level
secondari
bile
acid
endocannabinoid
togeth
reduc
level
food
preserv
plasmalogen
retinol
metabolit
main
posttranspl
differ
two
group
higher
acylcarnitin
intervent
enter
group
significantli
higher
level
mitochondri
activ
marker
nformylmethionin
control
parenter
group
two
last
observ
suggest
insuffici
calori
intak
control
group
higher
degre
fat
mobil
catabol
metabol
posttranspl
amino
acid
carbohydr
metabolit
significantli
alter
observ
signific
increas
system
level
sever
primari
secondari
bile
acid
see
potenti
liverprotect
secondari
bile
acid
isoursodeoxychol
ursodeoxychol
corticosteron
show
significantli
higher
concentr
control
group
final
also
abl
detect
signific
higher
level
bilirubin
metabolit
control
group
posttranspl
conclus
allotranspl
recipi
show
alter
metabol
profil
earli
transplant
mainli
due
conditioningtransplantationreconstitut
wherea
type
nutrit
support
minor
effect
observ
also
suggest
enter
nutrit
support
reduc
need
parenter
nutrit
secur
adequ
energi
intak
cohort
patient
clinic
trial
registri
wwwclinicaltrialsgov
conflict
interest
studi
receiv
financi
support
blix
famili
foundat
eivind
pedersen
foundat
helsevest
norwegian
cancer
societi
oslo
univers
hospit
univers
bergen
throne
holst
foundat
enter
feed
support
nutricia
children
hospit
endocrin
dept
athen
greec
agia
sophia
children
hospit
stem
cell
transplant
unit
athen
greec
children
hospit
p
kyriak
endocrinolog
athen
greec
children
hospit
p
kyriak
dept
biochemistri
athen
greec
background
allogen
bone
marrow
transplant
bmt
treatment
choic
number
childhood
malign
well
thalassemia
major
aplast
anemia
immunodefici
number
endocrin
long
term
sequela
recogn
aim
report
incid
thyroid
dysfunct
patient
underw
allogen
bmt
childhood
adolesc
method
patient
boy
transplant
hla
match
donor
mean
age
year
rang
year
follow
prospect
measur
tsh
twice
yearli
use
chemiluminesc
patient
elev
tsh
higher
repeat
evalu
month
time
thyroid
sonogram
perform
yearli
patient
receiv
radiat
therapi
rt
least
patient
histori
rt
initi
diagnosi
includ
acut
lymphocyt
leukemia
acut
myelocyt
leukemia
thalassemia
fanconi
anemia
aplast
anemia
sever
combin
immunodefici
condit
regimen
consist
busulfan
cyclophosphamid
fludarabin
antithymocyt
globulin
four
patient
receiv
total
bodi
irradi
tbi
seven
patient
receiv
cn
prophylaxi
gy
result
age
last
evalu
yr
year
post
bmt
fifti
patient
patient
normal
thyroid
function
twenti
five
patient
primari
hypothyroid
evidenc
tsh
level
higher
low
low
normal
level
verifi
second
measur
start
replac
therapi
lthyroxin
one
patient
tsh
higher
return
normal
normal
thyroid
function
among
patient
hypothyroid
receiv
tbi
receiv
prophylaxi
rt
four
patient
compens
hypothyroid
evidenc
tsh
level
rang
greater
less
none
progress
far
overt
hypothyroid
one
patient
histori
tbi
borderlin
elev
tsh
low
consid
central
hypothyroid
start
replac
therapi
one
hypothyroid
patient
receiv
tbi
thyroid
nodul
fna
consist
dysplast
nodul
bethesda
one
normothyroid
patient
also
receiv
tbi
papillari
ca
underw
thyroidectomi
conclus
thyroid
dysfunct
quit
common
complic
bmt
pediatr
popul
exact
mechan
clear
patient
receiv
radiat
prior
bmt
increas
risk
patient
underw
bmt
evalu
thyroid
function
routin
order
prevent
overt
hypothyroid
conflict
interest
conflict
interest
abstract
previous
publish
hospit
aleman
stem
cell
transplant
bueno
air
argentina
background
poor
graft
function
pgf
complic
allogen
stem
cell
transplant
sct
increas
morbl
mortal
due
infect
bleed
stasia
et
al
defin
presenc
cytopenia
least
hemopoiet
cell
line
neutroplhil
count
platelet
count
x
hemoglobin
least
consecut
week
beyond
day
achiev
engraft
presenc
full
donor
chimer
absenc
sever
gvhd
cmv
reactiv
relaps
drug
relat
myelosuppress
hypocellular
bone
marrow
mechan
report
relat
presenc
high
proport
ifn
produc
alloreact
cell
inflammatori
stimul
gvhd
viral
infect
lead
decreas
prolifer
hsc
appropri
treatment
well
establish
second
transplant
select
stem
cell
boost
infus
growth
factor
use
differ
rate
success
eltrombopag
trombopoietin
mimet
oral
molecul
bind
cmpl
receptor
hsc
stimul
prolifer
differenti
approv
second
line
treatment
aplast
anemia
object
report
improv
hematopoiesi
patient
pt
present
pgf
defin
stasia
treat
eltrombopag
method
report
aml
pt
pt
receiv
haploident
sct
juli
april
condit
regimen
use
tbiflu
pt
pt
buflu
hematopoiet
recoveri
neutrophil
l
plt
recoveri
respect
pt
present
cmv
reactiv
day
pt
present
gii
skin
gvhd
respons
steroid
tratment
etrombopag
initi
day
due
fall
platelet
neutrophil
count
associ
pgf
defin
stasia
mg
day
increas
mg
week
result
pt
becam
platelet
transfus
independ
stop
gcsf
administr
day
pt
stop
eltrombopag
day
plt
count
one
becam
eltrombopag
depend
sinc
plt
drop
everi
time
stop
medic
die
day
due
cn
haemorragh
third
pt
improv
plt
count
l
without
evid
increas
month
treatment
fourth
pt
stop
eltrombopag
administr
day
due
sever
skin
toxic
incipi
respons
pt
cr
day
postranspl
conclus
although
respons
heterogen
eltrombopag
well
toler
improv
cell
count
allow
transfus
independ
short
time
period
eltrombopag
consid
part
treatment
strategi
pgf
case
second
transplant
cell
boost
requir
may
improv
clinic
statu
wait
procedur
conflict
interest
v
milov
receiv
honoraria
novarti
abstract
previous
publish
children
hospit
endocrin
dept
athen
greec
agia
sophia
children
hospit
stem
cell
transplant
unit
athen
greec
background
homozyg
bthalassemia
bthal
diseas
encount
increas
frequenc
mediterranean
countri
tradit
clinic
manag
involv
regular
blood
transfus
regular
chelat
therapi
howev
cur
treatment
modal
remain
allogen
hematopoiet
stem
cell
transplant
allohsct
increas
number
long
term
survivor
transplant
homozyg
beta
thalassemia
posttransplant
infertil
major
concern
method
perform
retrospect
analysi
data
regard
pregnanc
childbirth
patient
underw
allohsct
bthal
total
children
bthal
receiv
allohsct
match
sibl
donor
msd
voluntari
unrel
donor
vud
median
age
transplant
year
rang
year
patient
male
femal
older
year
time
transplant
patient
condit
busulfan
cyclophosphamid
fludarabin
antithymocyt
globulin
without
total
bodi
irradi
graft
versu
host
diseas
prophylaxi
consist
cyclosporin
methotrex
sperm
cryopreserv
result
patient
develop
hypergonadotrop
hypogonad
femal
patient
receiv
substitut
therapi
estrogen
progesteron
two
male
femal
long
term
survivor
two
document
recoveri
ovarian
function
normal
gonadotropin
mens
resumpt
report
childbirth
two
femal
long
term
survivor
achiev
childbirth
vitro
fertil
wherea
remain
report
spontan
concept
one
male
long
term
survivor
need
assist
reproduct
techniqu
order
achiev
childbirth
conclus
secondari
amenorrhea
hypergonadotrop
hypogonad
occur
almost
univers
postpubert
femal
undergo
none
marrow
transplant
homozyg
betathalassemia
hormon
substitut
mandatori
order
maintain
secondari
sex
characterist
bone
densiti
spontan
recoveri
occur
prognost
factor
fulli
elucid
includ
age
amh
level
hemosiderosi
longterm
followup
special
team
necessari
document
unev
pregnanc
patient
promis
patient
well
inform
possibl
transplant
followup
whenev
possibl
prevent
measur
preserv
fertil
undertaken
conflict
interest
comflict
interest
hospit
universitario
puerta
de
hierro
majadahonda
hematolog
majadahonda
spain
hospit
universitario
puerta
de
hierro
majadahonda
pharmaci
majadahonda
spain
background
calcineurininhibitor
cni
backbon
graftversushost
diseas
gvhd
prophylaxi
manag
allogen
hematopoiet
cell
transplant
allohct
associ
earli
complic
includ
transplantassoci
thrombot
microangiopathi
tatma
acut
renal
failur
arf
remov
cni
wide
recommend
set
question
remain
replac
cni
particular
earli
allohct
method
review
case
allohct
monoclon
antibodi
basiliximab
use
replac
cni
result
cniassoci
tatma
arf
case
tatma
nonimmun
hemolyt
anemia
high
ldh
low
haptoglobin
neg
coomb
test
schistocyt
per
highpow
field
thrombocytopenia
baselin
uderzo
c
result
identifi
allohct
recipi
basiliximab
use
replac
cyclosporin
tacrolimu
result
cniassoci
tatma
arf
men
women
median
age
year
allohct
includ
cordblood
plu
thirdparti
donor
cell
match
sibl
match
unrel
donor
follow
myeloabl
nonmyeloabl
condit
regimen
basiliximab
use
replac
cni
use
gvhd
prophylaxi
gvhd
treatment
start
earlier
patient
receiv
cni
gvhd
prophylaxi
treatment
median
day
allohct
iqr
versu
iqr
basiliximab
iv
administ
twice
weekli
day
repeat
sever
week
requir
median
treatment
dose
prophylaxi
group
treatment
group
note
case
risk
prophylaxi
group
develop
gvhd
follow
cnireplac
basiliximab
ci
patient
risk
cmv
infect
reactiv
cmv
prior
start
basiliximab
develop
cmv
infect
thereaft
ci
overal
patient
die
context
cnitox
basiliximab
replac
sever
infect
invas
fungal
infect
cmv
pneumon
multiorgan
failur
unknown
origin
tatma
venoocclus
diseas
probabl
overal
surviv
relat
episod
day
start
basiliximab
ci
beyond
cnireplac
basiliximab
patient
receiv
addit
treatment
tatma
gvhd
includ
corticosteroid
eculizumab
etanercept
defibrotid
plasmapheresi
rituximab
combin
drug
conclus
need
withdraw
cni
result
tatma
arf
allohct
therapeut
challeng
current
guidanc
choic
altern
drug
set
data
suggest
basiliximab
may
option
patient
good
toler
low
rate
subsequ
gvhd
viral
reactiv
accept
surviv
rate
challeng
clinic
situat
prospect
studi
better
explor
role
basiliximab
context
warrant
conflict
interest
author
noth
disclos
hospit
universitario
puerta
de
hierro
majadahonda
madrid
spain
instituto
de
sanitaria
puerta
de
hierro
segovia
arana
madrid
spain
background
transplantassoci
thrombot
microangiopathi
tatma
sever
earli
transplant
complic
result
endotheli
injuri
beyond
remov
treatment
precipit
factor
recent
treatment
eculizumab
tatma
remain
therapeut
challeng
defibrotid
may
consid
therapeut
option
condit
method
review
case
tatma
treat
defibrotid
allogen
transplant
recipi
case
noninmun
hemolyt
anemia
high
ldh
low
haptoglobin
neg
coomb
test
schistocyt
per
highpow
field
thrombocytopenia
case
without
sign
renal
neurolog
dysfunct
classifi
probabl
tatma
cho
b
et
al
result
identifi
tatma
episod
treat
defibrotid
allogen
transplant
recipi
men
median
age
year
old
singlecord
blood
plu
thirdparti
donor
cell
hlaident
sibl
unrel
donor
myeloabl
condit
regimen
tbi
tabl
concomit
risk
factor
time
ta
tma
onset
calcineurin
inhibitor
cni
treatment
case
cyclosporin
tacrolimu
acut
gvhd
grade
case
cmv
reactiv
sever
fungal
pulmonari
aspergillosi
scedosporium
prolifican
septicemia
bacteri
e
coli
sepsi
infect
median
onset
tatam
day
transplant
case
earli
onset
week
late
onset
nine
episod
probabl
tatma
without
organ
dysfunct
renal
failur
resist
hypertens
present
concomit
diffus
alveolar
hemorrhag
first
line
replac
cni
basiliximab
drug
gvhd
perform
case
defibrotid
subsequ
administ
monotherapi
case
combin
rituximab
andor
plasma
exchang
agent
other
vincristin
mesenchym
stromal
cell
eculizumab
bevacizumab
median
time
start
defibrotid
treatment
day
tatma
diagnosi
qd
episod
qd
median
durat
day
complet
resolut
tatma
cr
achiev
episod
median
time
day
defibrotid
initi
cr
associ
reduc
allcaus
mortal
cr
case
multilobar
pneumonia
toxic
encephalopathi
versu
case
without
cr
tatam
relat
diffus
alveolar
hemorrhag
lymphocyt
enceph
sever
infect
tatma
case
trigger
sever
infect
earli
day
onset
higher
mortal
rate
vs
rate
cr
higher
case
probabl
tatma
without
renal
failur
vs
conclus
provid
encourag
evid
suggest
defibrotid
proven
safe
effect
sinusoid
obstruct
syndrom
may
also
role
endotheli
dysfunct
syndrom
monotherapi
combin
agent
data
show
complet
resolut
tatma
two
third
case
even
higher
earli
treatment
valid
singlecent
experi
prospect
control
studi
warrant
conflict
interest
author
noth
disclos
sheffield
teach
hospit
nh
foundat
trust
specialis
cancer
servic
sheffield
unit
kingdom
univers
sheffield
depart
oncolog
metabol
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
depart
haematolog
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
depart
microbiolog
sheffield
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
depart
infecti
diseas
sheffield
unit
kingdom
background
revaccin
programm
follow
hct
import
yet
often
complet
antibodi
titr
vaccin
prevent
diseas
vpd
may
reconstitut
readili
postauto
postallo
hct
use
platform
late
effect
clinic
check
whether
longterm
survivor
undergo
revaccin
programm
postauto
sct
adequ
antibodi
titr
rang
vpd
method
consecut
patient
year
postauto
sct
attend
late
effect
clinic
evalu
month
period
may
novemb
patient
miss
patient
includ
interim
analysi
blood
drawn
day
clinic
measur
antibodi
titr
follow
diphtheria
tetanu
haemophilu
influenza
type
b
hib
danish
pneumococc
subtyp
measl
mump
rubella
varicella
vzv
cutoff
predefin
laboratori
refer
interv
patient
median
age
patient
year
rang
median
age
auto
sct
year
rang
primari
diagnost
categori
haematooncolog
solid
tumour
autoimmun
diseas
previous
receiv
document
chemotherapi
prior
auto
sct
patient
receiv
previou
radiotherapi
tbi
mantl
whole
brain
neck
mediastin
neck
chest
pelvic
patient
receiv
beam
condit
remaind
receiv
varieti
condit
regimen
cem
atgcyclo
carboetoposid
tbimelph
tbicyclo
tice
result
patient
mean
year
auto
sct
rang
interim
analysi
avail
result
date
reveal
low
level
antidiptheria
antibodi
found
patient
immun
along
inadequ
antipneumococc
immun
patient
robust
titr
serotyp
test
protect
antimeasl
antibodi
titr
also
absent
patient
contrast
good
antihib
titr
vzv
igg
threshold
consid
protect
conclus
signific
defici
protect
vpd
observ
defici
antipneumococc
immun
particular
concern
whilst
recommend
adher
routin
vaccin
programm
earli
hct
strategi
involv
screen
subsequ
select
vaccin
consid
long
term
survivor
postauto
sct
undergo
routin
revaccin
programm
late
effect
clinic
provid
good
opportun
facilit
pragmat
approach
conflict
interest
conflict
interest
studi
clinic
evalu
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
republ
seoul
nation
univers
hospit
seoul
nation
univers
colleg
medicin
seoul
korea
republ
sever
hospit
yonsei
univers
colleg
medicin
seoul
korea
republ
seoul
st
mari
hospit
colleg
medicin
cathol
univers
korea
seoul
korea
republ
asan
medic
center
univers
ulsan
colleg
medicin
seoul
korea
republ
chonnam
nation
univers
hwasun
hopspit
chonnam
nation
univers
medic
school
hwasun
korea
republ
background
sinusoid
obstruct
syndrom
venoocclus
diseas
sosvod
potenti
lethal
complic
follow
hematopoiet
stem
cell
transplant
hsct
convent
sever
criteria
sosvod
retrospect
classifi
appropri
determin
therapeut
option
studi
aim
valid
revis
ebmt
sever
criteria
sosvod
korean
patient
diagnos
sosvod
accord
convent
criteria
regard
day
surviv
mortal
although
recent
revis
ebmt
criteria
propos
adult
popul
tri
see
could
also
applic
pediatr
transplant
recipi
method
six
institut
particip
studi
among
patient
undergon
hsct
data
patient
met
clinic
definit
sosvod
obtain
assess
verifi
patient
met
either
convent
modifi
seattl
baltimor
ebmt
diagnost
criteria
result
total
patient
children
adult
identifi
definit
sosvod
patient
studi
subject
met
modifi
seattl
criteria
b
group
patient
e
group
satisfi
baltimor
ebmt
criteria
respect
children
adult
among
studi
subject
fulfil
ebmt
diagnost
criteria
sosvod
use
convent
sever
criteria
moder
form
predomin
sever
one
without
mild
one
contrast
major
studi
subject
belong
sever
sever
form
ebmt
sever
criteria
appli
day
surviv
rate
mild
moder
sever
sever
sosvod
respect
day
surviv
patient
sever
sosvod
significantli
lower
other
vs
p
result
mainli
influenc
pediatr
recipi
vs
rather
adult
vs
trend
also
true
compar
day
surviv
sever
sosvod
mildmoderatesever
one
b
group
children
adult
total
e
group
children
adult
total
day
mortal
caus
sosvod
whole
studi
subject
b
group
e
group
respect
sosvodrel
mortal
occur
exclus
patient
sever
sosvod
conclus
sever
form
account
major
sosvod
accord
revis
ebmt
sever
criteria
presenc
highli
predict
earli
posttranspl
mortal
although
new
sever
criteria
could
also
applic
pediatr
patient
signific
proport
children
sosvod
might
miss
obviat
need
valid
new
ebmt
diagnosi
sever
criteria
sosvod
pediatr
patient
conflict
interest
studi
financi
support
handok
cardiff
vale
univers
health
board
south
wale
blood
marrow
transplant
programm
cardiff
unit
kingdom
abertaw
bro
morgannwg
univers
health
board
south
wale
blood
marrow
transplant
programm
swansea
unit
kingdom
background
although
hsct
potenti
cur
mani
transplantelig
patient
fail
procedur
even
identifi
earli
therefor
review
reason
patient
remov
transplant
wait
list
south
wale
blood
marrow
transplant
swbmt
programm
serv
welsh
popul
method
new
cancer
patient
wale
discuss
multidisciplinari
team
mdt
meet
cancer
type
code
enter
electron
welsh
cancer
databas
canisc
potenti
hsct
recipi
identifi
meet
enter
swbmt
wait
list
patient
progress
monitor
bmt
team
ensur
time
assess
bmt
minimis
wait
end
treatment
transplantdata
present
patient
plasma
cell
disord
pcd
lymphoma
acut
leukaemia
main
indic
bmt
assess
bmt
clinic
determin
rate
reason
deferr
bmt
result
result
summaris
figur
autolog
transplant
rate
pcd
lymphoma
respect
pcd
patient
main
reason
progress
bmt
patient
choic
patient
fit
diseas
progress
lymphoma
main
reason
diseas
progress
patient
choic
patient
fit
patient
relaps
apl
subsequ
attain
molecular
cr
went
transplant
allogen
transplant
aml
patient
achiev
bmt
relaps
main
reason
transplant
result
similar
patient
transplant
relaps
account
transplant
lymphoma
transplant
relaps
main
reason
attain
bmt
entir
cohort
transplant
achiev
bmt
due
relapseprogress
conclus
data
repres
realworld
experi
nation
transplant
programm
show
despit
close
monitor
patient
fail
achiev
transplant
due
diseas
progressionrelaps
repres
precari
posit
patient
malign
conflict
interest
conflict
interest
experiment
stem
cell
transplant
taipei
veteran
gener
hospit
divis
transfus
medicin
depart
medicin
taipei
taiwan
republ
china
nation
yangm
univers
school
medicin
depart
medicin
taipei
taiwan
republ
china
nation
taiwan
univers
institut
biochem
scienc
taipei
taiwan
republ
china
fujen
univers
depart
life
scienc
new
taipei
citi
taiwan
republ
china
background
investig
whether
use
induc
regulatori
cell
itreg
instead
natur
regulatori
cell
ntreg
reduc
incid
acut
graftversushost
diseas
agvhd
within
short
time
method
splenocyt
mice
use
sourc
cell
cell
isol
kit
induc
regulatori
cell
itreg
cell
incub
coat
plate
presenc
day
itreg
harvest
identifi
express
via
flow
cytometri
function
itreg
confirm
via
qpcr
marker
gene
express
experi
recipi
balbc
irradi
infus
donor
bone
marrow
cell
without
donor
cell
intraven
inject
express
ratio
express
peripher
blood
cell
gvhd
identif
marker
itreg
inject
agvhd
mous
immunosuppress
assay
result
function
itreg
cell
harvest
induct
cell
known
ntreg
collect
need
day
itreg
collect
time
less
ntreg
cell
memori
cell
report
abl
induc
agvhd
effector
cell
neg
cell
surfac
therefor
agvhd
mice
identifi
increas
cell
ratio
posit
express
neg
express
cell
cell
depletedbon
marrow
cell
transfus
balbc
mice
tcdbm
ratio
howev
ratio
agvhd
mice
increas
meanwhil
cell
decreas
compar
tcdbm
mice
agvhd
mice
itreg
treatedagvhd
mice
ratio
decreas
cell
increas
indic
agvhd
mice
recov
itreg
treatment
mice
phenotyp
similar
bone
marrow
infus
mice
indic
supplement
itreg
could
suppress
incid
agvhd
conclus
collect
enough
itreg
cell
agvhd
therapi
collect
time
itreg
cell
shorten
significantli
compar
harvest
time
ntreg
cell
conclud
increas
peripher
blood
cell
could
sensit
marker
agvhd
itreg
treatment
reduc
cell
infiltr
peripher
blood
decreas
cell
ratio
use
itreg
therapi
prevent
agvhd
possibl
conflict
interest
chiou
noth
disclos
hebei
yanda
lu
daopei
hospit
langfang
china
shenzhen
genoimmun
medic
institut
shenzhen
china
immunochina
pharmaceut
co
ltd
beij
china
background
although
chimer
antigen
receptormodifi
treatment
approv
treat
refractoryrelaps
b
cell
acut
lymphocyt
leukemia
ball
still
mainli
use
autolog
therapi
allogen
hematopoiet
stem
cell
transplant
allohsct
report
two
patient
relaps
ball
treat
cell
bridg
allohsct
donor
cart
great
success
method
first
case
girl
relaps
ball
could
achiev
cr
cours
reinduct
chemotherapi
could
gener
cart
cell
lymphocyt
persist
low
peripher
blood
wbc
blast
bone
marrow
receiv
cell
total
mother
match
achiev
morpholog
complet
remiss
cr
still
minim
residu
diseas
mrd
therefor
given
autolog
cart
therapi
second
case
boy
relaps
ball
receiv
cell
hla
match
brother
cr
achiev
cart
treatment
patient
bridg
allohsct
donor
result
first
case
achiev
morpholog
cr
mrd
still
posit
patient
donor
chimer
therefor
therapi
subsequ
achiev
mrd
neg
cr
per
flow
cytometri
studi
receiv
allohsct
day
allocart
day
autocart
donor
allocart
post
allohsct
chimer
donor
type
grade
skin
acut
graft
versu
host
diseas
agvhd
current
diseas
free
month
post
allohsct
second
case
achiev
mrd
neg
cr
receiv
cell
sibl
brother
chimer
peripher
blood
went
day
post
cart
cell
infus
rapidli
drop
day
patient
bridg
allohsct
day
cart
therapi
donor
leukocyt
success
engraft
chimer
donor
type
grade
ii
skin
agvhd
current
diseas
free
month
post
allohsct
conclus
allocart
treatment
feasibl
patient
prior
allohsct
patient
cart
cell
abl
manufactur
lymphocyt
therapi
consid
option
cr
achiev
cart
therapi
bridg
allohsct
use
donor
may
result
longterm
diseasefre
surviv
conflict
interest
none
declar
aou
citta
della
salut
e
della
scienza
di
torino
oncoematologia
pediatrica
torino
itali
background
haploident
hematopoiet
stem
cell
transplant
vivo
tcell
deplet
high
dose
cyclophosphamid
haplohsctctx
current
one
larg
adopt
strategi
patient
need
transplant
lack
hlamatch
donor
longterm
result
procedur
still
limit
main
aim
studi
evalu
longterm
overal
surviv
os
pediatr
popul
undergo
haplohsctctx
advanc
stage
hematolog
malign
secondari
endpoint
studi
assess
potenti
pitfal
strategi
regard
transplant
relat
mortal
trm
relaps
incid
ri
acut
chronic
gvhd
incid
method
retrospect
evalu
pediatr
patient
median
age
year
undergo
haplohsctctx
center
hematolog
malign
patient
beyond
second
diseas
remiss
refractori
least
one
previou
line
chemo
radiat
therapi
transplant
condit
regimen
includ
cyclophosphamid
total
dose
mgkg
fludarabin
total
dose
mgmq
tbi
gy
singl
fraction
gvhd
prophylaxi
base
highdos
cyclophosphamid
mgkgday
day
tacrolimu
mofetil
micofenol
patient
underw
clinic
hematolog
posttransplant
assess
accord
center
polici
os
calcul
accord
kaplanmei
method
trm
ri
calcul
cumul
incid
ci
adjust
analysi
compet
risk
relaps
transplantrel
death
consid
compet
risk
respect
agvhd
cgvhd
incid
calcul
ci
well
case
death
reason
consid
compet
risk
analys
perform
use
ncss
softwar
hintz
ncss
pass
number
crunch
statist
system
kaysvil
ut
usa
result
median
follow
studi
popul
day
rang
year
hsct
os
ci
trm
ci
ri
ci
incid
grade
iiiv
acut
gvhd
ci
case
gvhd
involv
skin
easili
manag
system
steroid
treatment
case
chronic
gvhd
observ
studi
popul
caus
death
diseas
progress
patient
adenoviru
infect
patient
cerebr
hemorrhag
patient
conclus
retrospect
data
confirm
safeti
haplohsctctx
also
set
patient
previous
heavili
treat
high
risk
develop
transplantrel
toxic
especi
occurr
immunolog
complic
acut
chronic
gvhd
low
conflict
interest
author
commerci
proprietari
financi
interest
product
compani
describ
articl
g
papanicola
hospit
bone
marrow
transplant
unit
dept
hematolog
thessaloniki
greec
g
papanicola
hospit
public
cord
blood
bank
dept
hematolog
thessaloniki
greec
background
allogen
hematopoiet
cell
transplant
hct
main
sourc
peripher
blood
mobil
umbil
cord
blood
ucb
hematopoiet
stem
cell
home
connect
differ
factor
affect
hematopoiet
reconstitut
hct
cell
commun
cytokin
growth
factor
adhes
molecul
microparticl
mp
studi
analys
mp
peripher
graft
patient
post
hct
ucb
method
sampl
collect
graft
peripher
blood
patient
underw
hct
depart
four
patient
diagnos
acut
myeloid
leukemia
acut
lymphoblast
leukemia
inform
consent
obtain
patient
patient
receiv
peripher
blood
stem
cell
pbsc
transplant
sibl
donor
patient
complet
remiss
hct
regard
condit
patient
receiv
myeloabl
regimen
patient
receiv
reduc
intens
condit
ric
number
stem
cell
derivedmp
estim
plasma
graft
well
peripher
blood
patient
day
transplant
cord
blood
unit
cbu
process
use
sepax
autom
method
biosaf
adjust
variabl
cbu
includ
number
per
graft
viabil
number
determin
flow
cytometri
mononuclear
cell
seed
semisolid
cultur
presenc
cocktail
growth
factor
coloni
form
unit
granulocytemacrophag
cfugm
burst
form
unit
erythroid
bfue
colonyform
unitgranulocyt
erythrocyt
monocytemacrophag
megakaryocyt
cfugemm
coloni
growth
electron
microscop
photograph
obtain
proceed
tem
statist
analysi
perform
use
ttest
depend
normal
distribut
variabl
result
detect
graft
peripher
blood
patient
post
hct
per
unit
significantli
associ
p
rho
wherea
statist
signific
correl
ucb
detect
pre
postprocess
sepax
univari
analysi
found
number
preprocess
vs
postprocess
statist
signific
mean
posit
correl
p
rho
addit
preprocess
vspostprocess
statist
signific
neg
correl
viabil
p
rho
p
rho
clonal
assay
hemopoiet
progenitor
show
number
statist
signific
mean
posit
correl
number
cfugm
p
rho
bfue
p
rho
conclus
result
present
studi
indic
presenc
hematopoiet
stem
cell
derivedmp
pbsc
transplant
ucb
peripher
blood
patient
undergo
hct
furthermor
peripher
blood
hct
patient
number
day
associ
absolut
number
ucb
number
preand
postprocess
statist
correl
cfugm
bfue
role
engraft
transplant
determin
conflict
interest
author
declar
conflict
interest
sourc
fund
greek
ministri
health
fujian
institut
hematolog
fujian
provinci
key
laboratori
hematolog
fujian
medic
univers
union
hospit
l
depart
hematolog
fuzhou
china
background
clinic
data
suggest
pretranspl
iron
overload
due
high
transfus
requir
may
affect
graft
function
allogen
hematopoiet
stem
cell
transplant
allohsct
method
set
allohsct
balbc
mice
use
recipi
donor
respect
recipi
mice
inject
intraperiton
iron
sucros
cumul
dose
mg
mg
mg
three
experiment
group
control
phosphatebuff
salin
mice
receiv
total
bodi
irradi
hsct
plasma
iron
level
iron
store
liver
spleen
bone
marrow
bm
measur
hematolog
paramet
cell
hematopoiet
colonyform
capac
monitor
evalu
hematopoiet
recoveri
bone
marrow
deriv
mesenchym
stem
cell
bmmsc
isol
assess
prolifer
immunohistochem
analysi
assess
bm
microenviron
express
haematopoiet
chemokin
immunolog
paramet
result
iron
overload
aggrav
pgf
observ
result
peripher
blood
cell
significantli
lower
number
recov
less
rapidli
dosedependend
manner
compar
control
p
experiment
group
bm
hypocellular
cell
count
colonyform
unit
significantli
decreas
p
bmmsc
show
longer
doubl
time
control
p
furthermor
immunohistochem
analysi
demonstr
immunolog
impair
low
express
stem
cell
factor
vascular
endotheli
growth
conclus
current
evid
show
iron
overload
import
risk
factor
pgf
damag
hematopoiet
stem
cell
microenviron
highlight
need
optim
iron
manag
improv
transplant
outcom
conflict
interest
without
conflict
interest
abstract
previous
publish
imperi
colleg
london
haematolog
london
unit
kingdom
background
patient
undergo
allogen
stem
cell
transplant
allosct
suscept
viral
infect
due
prolong
period
immunosuppress
signific
number
patient
respond
optim
pharmacolog
therapi
method
select
viralspecif
tlymphocyt
healthi
donor
use
close
system
clinimac
prodigi
grade
gmp
room
cell
collect
leukapheresi
stimul
hour
pool
viral
peptiv
induc
express
viralspecif
memori
cell
cell
label
antibodi
coupl
iron
bead
pass
magnet
column
enrich
lymphocyt
popul
elut
fraction
process
fulli
autom
take
hour
result
median
age
patient
year
rang
patient
male
diagnosi
acut
myeloid
leukaemia
patient
acut
lymphoblast
leukaemia
patient
one
patient
myelodysplast
syndrom
chronic
myeloid
leukaemia
follicular
lymphoma
cutan
tcell
lymphoma
sever
aplast
anaemia
betathalassemia
major
sickl
cell
diseas
diamondblackfan
anaemia
transplant
donor
haploident
hlaident
sibl
match
unrel
donor
condit
myeloabl
reduc
intens
transplant
viralspecif
tlymphocyt
select
cytomegaloviru
cmv
donor
bkviru
bkv
ebsteinbarrviru
ebv
adenoviru
adv
one
donor
respect
median
viral
load
time
infus
copiesul
cmv
x
copiesul
bkv
copiesul
ebv
copiesul
adv
patient
fail
respond
anticmv
median
ganciclovir
foscarnet
cidofovir
antiebv
rituximab
antibkv
cidofovir
brincidofovir
antiadv
cidofovir
therapi
total
patient
develop
acut
gvhd
receiv
system
corticosteroid
time
tcell
infus
median
viralspecif
cell
dose
obtain
x
cmv
x
bkv
x
ebv
x
adv
characterist
select
process
describ
tabl
patient
receiv
viralspecif
tcell
median
day
bkv
day
cmv
day
ebv
day
adv
patient
receiv
singl
infus
infusion
reaction
record
evid
new
onset
acut
gvhd
detect
patient
cmv
infect
achiev
cr
neg
pcr
none
develop
cmv
diseas
patient
bkv
haemorrhag
cystiti
respond
cr
one
pr
although
remain
persist
posit
urin
pcr
patient
ebv
viraemia
becam
pcr
neg
although
achiev
cr
one
pr
petct
scan
patient
adv
infect
die
week
advspecif
tcell
infus
multiorgan
failur
without
respond
conclus
viralspecif
tlymphocyt
manufactur
healthi
stem
cell
donor
infus
safe
allogen
sct
patient
refractori
convent
antivir
viral
load
respons
could
seen
patient
popul
without
signific
sideeffect
conflict
interest
conflict
interest
drvhauner
children
hospit
ludwigsmaximiliansunivers
depart
pediatr
hematolog
oncolog
stem
cell
transplant
munich
germani
drvhauner
children
hospit
ludwigsmaximiliansunivers
immunodefici
unit
immunolog
diagnost
laboratori
munich
germani
drvhauner
children
hospit
ludwigsmaximiliansunivers
munich
germani
background
autosom
domin
hyperigesyndrom
adhi
rare
primari
immunodefici
multisystem
disord
result
heterozyg
mutat
gene
adhi
character
skelet
dysplasia
recurr
pulmonari
skin
infect
eg
staphylococc
abscess
eczematoid
dermat
due
increas
suscept
bacteria
fungi
immunolog
workup
patient
usual
reveal
impair
cell
differenti
markedli
elev
igelevel
sinc
mani
patient
rather
well
antiinfect
prophylaxi
support
care
earli
case
report
suggest
benefit
allogen
hematopoet
stem
cell
transplant
hsct
adhi
patient
rare
refer
hsct
literatur
still
contain
hand
patient
underw
hsct
variabl
condit
regimen
match
mismatch
donor
patient
experienc
sever
diseas
relat
complic
hsct
consequ
benefit
hsct
report
variabl
current
gener
consensu
consid
patient
sever
pulmonari
diseas
hsct
could
howev
postul
transplant
patient
earlier
diseas
caus
correct
immunodefici
perman
organ
damag
due
infecti
complic
occur
may
extend
lifeexpect
improv
qualiti
life
adhi
patient
method
report
year
old
femal
adhiespati
present
one
pneumatocel
bronchiectas
modestli
impair
pulmonari
function
follow
recurr
pneumonia
past
medic
histori
also
includ
recurr
skin
infect
seriou
haemoptysi
patholog
fractur
atop
eczema
consid
lung
infect
major
lifelimit
complic
adhi
potenti
posit
influenc
hsct
patient
request
transplant
extens
discuss
pro
con
obtain
full
inform
consent
famili
underw
elect
hsct
receiv
bone
marrow
hlamatch
sibl
donor
reducedintens
condit
consist
alemtuzumab
treosulfan
fludarabin
thiotepa
graftversushost
diseas
gvhd
prophylaxi
cyclosporin
csa
mycophenol
mofetil
mmf
result
peritranspl
cours
complic
acut
gastrointestin
bleed
renal
failur
unknown
origin
continu
kidney
function
impair
led
earli
taper
discontinu
cyclosporin
day
hsct
absenc
acut
gvhd
neutrophil
platelet
engraft
day
respect
current
day
free
gvhd
infect
exhibit
full
donor
chimer
recov
kidney
function
view
preexist
pulmonari
diseas
remain
antibiot
prophylaxi
conclus
adhi
patient
underw
hsct
prehsct
diseas
complic
rel
littl
perman
organ
damag
may
add
understand
whether
earli
hsct
lead
improv
qualiti
life
increas
lifeexpect
adhi
patient
conflict
interest
noth
disclos
gene
therapi
bone
marrow
transplant
center
first
affili
hospit
zhejiang
univers
school
medicin
hangzhou
china
school
medicin
hangzhou
normal
univers
depart
patholog
hangzhou
china
beckman
research
institut
citi
hope
nation
medic
center
depart
diabet
metabol
diseas
research
duart
ca
unit
state
background
wiskottaldrich
syndrom
xlink
immunodefici
diseas
caus
mutat
gene
encod
scaffold
protein
call
protein
wasp
wasp
function
import
actin
regul
hematopoiet
cell
combin
rna
guid
cluster
regularli
interspac
short
palindrom
repeat
crispr
togeth
piggybac
technolog
use
direct
seamless
gene
correct
use
strategi
correct
integrationfre
induc
pluripot
stem
cell
ipsc
gener
male
patient
first
gene
manipul
creat
correct
wasipsc
select
marker
piggybac
excis
achiev
seamless
correct
detect
exogen
sequenc
found
genom
dna
correct
wasipsc
cwasipsc
monocytesmacrophag
success
gener
failur
podosom
format
restor
cwasipscsderiv
macrophag
method
nonintegr
wasipsc
creat
reprogram
male
patient
fibroblast
episom
plasmid
express
lmyc
shrna
result
wasipsc
character
express
pluripot
marker
residu
vector
dna
detect
pcr
gene
mutat
confirm
sequenc
correct
mutat
meanwhil
introduc
select
marker
gfppuro
posit
select
homolog
recombin
first
examin
sequenc
gene
region
mutat
found
ttaa
site
serv
insert
site
piggybac
cassett
target
mutat
site
locu
two
sgrna
express
vector
cotransfect
target
vector
contain
piggybac
cassett
one
wasipsc
cell
line
correct
gene
detect
pcr
final
achiev
footprintless
correct
excisioncompetentintegrationdefect
transposas
express
vector
cotransfect
gfp
vector
cwasipsc
threestep
differenti
method
contain
cocultur
use
direct
differenti
toward
monocytesmacrophag
result
wasip
cell
gener
episom
plasmid
carri
mutat
gene
parent
patient
fibroblast
contain
exogen
vector
integr
genom
combin
piggybac
achiev
gene
correct
without
footprint
cwasip
cell
creat
restor
mutat
gene
cwasip
clone
carri
residu
piggybac
segment
transposon
excis
wasipsc
cwasipsc
differenti
monocytesmacrophag
macrophag
deriv
wasipsc
restor
format
podosom
prove
impair
wasipscderiv
macrophag
conclus
combin
piggybac
system
achiev
footprintless
sitespecif
correct
wasipsc
podosom
format
failur
caus
mutat
restor
gene
correct
integrationfre
reprogram
effici
gene
correct
without
leav
exogen
segment
genom
dna
patientspecif
induc
pluripot
stem
cell
wasipsc
could
offer
safe
approach
cure
diseas
conflict
interest
yan
long
noth
disclos
abstract
previous
publish
king
colleg
london
london
unit
kingdom
univers
hospit
carl
gustav
caru
dresden
germani
imperi
colleg
healthcar
nh
trust
london
unit
kingdom
plymouth
hospit
nh
trust
plymouth
unit
kingdom
royal
hallamshir
hospit
sheffield
unit
kingdom
central
manchest
univers
hospit
manchest
unit
kingdom
univers
hospit
southampton
southampton
unit
kingdom
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
background
mesenchym
stromal
cell
msc
therapi
dramat
improv
overal
surviv
patient
steroidresist
acut
graft
versu
host
diseas
agvhd
howev
proport
patient
respond
criteria
patient
stratif
avail
recent
discov
msc
undergo
apoptosi
soon
infus
crucial
immunosuppress
effect
msc
apoptosi
effect
cytotox
cell
harbour
gvhd
recipi
studi
test
feasibl
use
vitro
cytotox
activ
patient
peripher
blood
mononuclear
cell
pbmc
msc
predict
clinic
respons
msc
cohort
patient
method
pbmc
steroidresist
agvhd
patient
collect
within
one
week
msc
treatment
one
patient
receiv
two
dose
msc
cytotox
assay
perform
dose
independ
third
parti
msc
cocultur
patient
pbmc
hour
level
msc
apoptosi
assess
flowcytometri
use
annexin
v
cytotox
express
proport
annexin
msc
perform
assay
oper
blind
patient
clinic
detail
inform
consent
obtain
patient
accord
local
ethic
committe
requir
respons
treatment
assess
one
week
msc
infus
patient
defin
respond
improv
least
least
one
organ
affect
agvhd
observ
b
nonrespond
stabl
progress
diseas
result
median
age
patient
year
rang
transplant
perform
part
treatment
follow
malign
aml
cml
mdsmpn
nhlhlmm
median
time
transplant
msc
treatment
day
rang
median
time
gvhd
diagnosi
msc
msc
infus
patient
receiv
methylprednisolon
alon
combin
two
drug
case
patient
receiv
mycophenol
mofetil
cyclosporin
respons
msc
treatment
achiev
infus
pbmc
respond
exhibit
significantli
higher
cytotox
msc
comparison
nonrespond
mean
ci
versu
ci
respect
p
fig
importantli
studi
receiveroper
characterist
curv
reveal
cutoff
predict
clinic
respons
sensit
specif
conclus
data
show
vitro
cytotox
assay
use
predictor
clinic
respons
msc
gvhd
patient
conflict
interest
noth
disclos
newcastl
univers
icm
newcastl
upon
tyne
unit
kingdom
rotherham
nh
foundat
trust
rotherham
unit
kingdom
royal
hospit
sick
children
glasgow
unit
kingdom
birmingham
children
hospit
birmingham
unit
kingdom
great
ormond
street
hospit
london
unit
kingdom
nh
blood
transplant
london
unit
kingdom
leed
children
hospit
leed
unit
kingdom
queen
elizabeth
hospit
birmingham
unit
kingdom
background
extracorpor
photopheresi
ecp
immunomodulatori
apheresi
therapi
use
treat
varieti
disord
children
particularli
acut
chronic
c
graftversushost
diseas
gvhd
solid
organ
transplant
reject
advantag
includ
diseas
control
reduct
system
immunosuppress
dose
lack
toxic
side
effect
seen
convent
immunosuppress
potenti
disadvantag
relat
line
infect
bleed
well
lack
access
low
bodi
weight
patient
perform
review
ecp
uk
paediatr
patient
method
retrospect
data
collect
paediatr
patient
treat
ecp
across
uk
perform
data
collect
includ
demograph
detail
underli
diagnosi
reason
ecp
previou
therapi
use
prior
ecp
responseoutcom
result
data
receiv
six
centr
patient
receiv
ecp
male
patient
agvhd
cgvhd
solid
organ
transplant
reject
median
age
commenc
ecp
year
year
median
weight
commenc
treament
kilogram
children
weigh
patient
bloodprim
heparin
patient
blood
prime
acda
central
apheresi
line
insert
patient
patient
central
splitcath
line
central
hickman
line
ecp
treatment
venou
access
type
inform
avail
patient
children
start
ecp
corticosteroiddepend
diseas
corticosteroidrefractori
diseas
concurr
system
infect
reason
unavail
patient
treat
immunosuppress
therapi
prior
commenc
ecp
patient
complic
associ
central
venou
access
line
infect
patient
thrombocytopaenia
otherwis
ecp
safe
well
toler
patient
median
time
commenc
ecp
onset
diseas
day
day
median
number
ecp
cycl
overal
children
complet
respons
treatment
partial
respons
respons
patient
respons
ecp
treatment
unknown
treatment
ongo
patient
patient
complet
treatment
acut
gvhd
complet
respons
chronic
gvhd
children
solid
organ
transplant
complet
respons
ecp
treatment
patient
die
infect
diseas
progress
partial
respons
ecp
treatment
complet
respons
conclus
ecp
safe
welltoler
paediatr
patient
includ
median
time
commenc
ecp
long
suggest
ecp
use
late
manag
diseas
complic
like
due
histor
issu
access
treatment
patient
acgvhd
like
complet
respons
treatment
comparison
chronic
gvhd
solid
organ
transplant
reject
easier
access
ecp
may
result
less
delay
start
treatment
may
lead
better
outcom
clinic
trial
registri
na
conflict
interest
none
author
anyth
disclos
hungarian
nation
blood
transfus
servic
budapest
hungari
st
istvan
st
laszlo
hospit
budapest
depart
hematolog
hsct
budapest
hungari
semmelwei
univers
budapest
depart
intern
medicin
budapest
hungari
univers
hospit
frankfurtmain
divis
stem
cell
transplant
immunolog
frankfurt
germani
background
steroid
refractori
graftversushost
diseas
gvhd
seriou
complic
allogen
hematopoiet
stem
cell
transplant
hsct
experi
accumul
immunomodulatori
effect
mesenchym
stem
cell
msc
infus
numer
immunopatholog
disord
gvhd
signal
method
evalu
efficaci
novel
msc
product
exclus
use
licens
mscffm
deriv
bone
marrow
mscffm
kuci
et
al
haematologica
submit
namedpati
basi
case
gvhd
refractori
convent
immunosuppress
treatment
patient
steroidresist
gvhd
treat
mscffm
time
per
case
weekli
dose
million
cellskg
clinic
respons
assess
day
administ
first
dose
complet
remiss
defin
complet
disappear
symptom
partial
remiss
assess
signific
relief
symptom
gener
improv
condit
evalu
red
blood
cell
platelet
concentr
need
patient
treatment
result
patient
receiv
total
cycl
mscffmtreatment
dose
per
cycl
median
age
year
malefemal
ratio
distribut
underli
malign
n
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelofibrosi
myelodysplast
syndrom
multipl
myeloma
tcell
lymphoma
nine
patient
undergon
allogen
hsct
match
unrel
donor
three
stem
cell
deriv
hlaident
rel
first
episod
gvhd
hsct
observ
median
day
involv
organ
skin
gut
skin
gut
combin
lung
case
appli
averag
line
treatment
vari
line
start
mscffm
treatment
median
time
mscffm
first
infus
day
stem
cell
transplant
hsct
day
first
episod
gvhd
four
cycl
mscffmtreatment
led
complet
remiss
result
partial
remiss
patient
gvhd
nih
stage
score
mscffm
infus
decreas
median
treatment
overal
surviv
day
first
gvhd
mscffm
treatment
need
red
blood
cell
concentr
reduc
averag
reduct
platelet
concentr
need
averag
reduct
conclus
accord
observ
mscffmtherapi
effect
treatment
gvhd
major
observ
case
overal
cumul
respons
rate
reduct
transfusion
need
mscffm
treatment
also
show
promis
result
applic
thirdparti
mscffm
offer
promis
altern
therapi
gvhd
gvhdassoci
complic
hsct
research
requir
warrant
optim
start
dosag
mscffm
treatment
along
issu
longterm
safeti
clinic
trial
registri
na
conflict
interest
noth
disclos
abstract
previous
publish
manchest
univers
hospit
nh
foundat
trust
manchest
unit
kingdom
synergu
ab
health
econom
evid
synthesi
stockholm
sweden
background
allogen
hematopoiet
stem
cell
transplant
allohsct
associ
increas
risk
gvhd
strong
prognost
predictor
earli
mortal
within
first
two
year
follow
allohsct
object
studi
review
harm
outcom
report
among
patient
receiv
treatment
acut
gvhd
method
systemat
literatur
search
perform
medlin
embas
cochran
central
databas
studi
includ
clinic
trial
cohort
studi
report
ae
patient
diagnos
agvhd
allohsct
receiv
follow
treatment
combin
corticosteroid
extracorpor
photopheresi
ecp
basiliximab
inolimomab
etanercept
infliximab
sirolimu
mmf
everolimu
imatinib
pentostatin
rituximab
methotrex
alemtuzumab
ruxolitinib
mesenchym
stromal
cell
msc
paper
report
prophylact
use
abovement
treatment
exclud
review
review
conduct
inlin
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
prisma
harm
checklist
figur
result
seventeen
studi
report
advers
effect
ae
ten
differ
therapi
use
treatment
agvhd
identifi
month
followup
infecti
ae
per
patient
report
etanercept
compar
per
patient
mmf
case
msc
grade
ae
per
patient
report
across
three
month
follow
across
month
followup
infecti
ae
per
patient
report
ecp
etanercept
infliximab
comparison
grade
infect
cumul
incid
ae
etanercept
mmf
pentostatin
respect
month
followup
one
studi
report
cumul
incid
grade
infect
annual
patient
treat
mmf
infecti
ae
per
patient
year
followup
report
basiliximab
inolimomab
laboratori
abnorm
sever
grade
report
case
etanercept
mmf
pentostatin
cumul
incid
respect
event
report
absent
ecp
infliximab
basiliximab
seriou
ae
lead
death
report
per
patient
month
followup
etanercept
per
patient
year
followup
basiliximab
inolimomab
respect
msc
infus
use
seriou
ae
per
patient
annual
report
month
followup
seriou
ae
per
patient
report
ecp
one
retrospect
cohort
studi
report
central
line
infect
per
patient
month
followup
cumul
incid
mild
hypotens
event
ecp
treatment
conclus
result
suggest
ecp
may
lead
lower
incid
infecti
ae
compar
pharmaceut
treatment
howev
due
lack
standard
report
sever
grade
inconsist
definit
seriou
ae
definit
conclus
drawn
conduct
clinic
trial
headtohead
comparison
conflict
interest
studi
sponsor
mallinckrodt
pharmaceut
author
receiv
research
grant
conduct
analysi
fld
receiv
speaker
fee
research
fund
travel
expens
confer
attend
mallinckrodt
pharmaceut
manchest
univers
hospit
nh
foundat
trust
manchest
uk
depart
haematolog
manchest
unit
kingdom
synergu
ab
health
econom
evid
synthesi
stockholm
sweden
background
cgvhd
occur
allogen
hematopoiet
stem
cell
transplant
allohsct
recipi
affect
nearli
everi
organ
tissu
bodi
recommend
treatment
option
cgvhd
initi
immunosuppress
corticosteroid
includ
extracorpor
photopheresi
ecp
tyrosin
kinas
inhibitor
mtor
inhibitor
nucleosid
analogu
monoclon
antibodi
immunosuppress
method
systemat
literatur
review
conduct
use
medlin
embas
cochran
central
databas
follow
inclus
criteria
use
patient
cgvhd
allohsct
treat
ecp
basiliximab
inolimomab
etanercept
infliximab
sirolimu
mycophenol
mofetil
mmf
everolimu
imatinib
pentostatin
rituximab
methotrex
alemtuzumab
ruxolitinib
mesenchym
stromal
cell
msc
report
treatment
relat
advers
effect
articl
exclud
review
case
report
seri
literatur
reviewsmetaanalysi
report
prophylact
use
treatment
identifi
articl
meet
inclus
criteria
assess
accord
recommend
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
prisma
harm
checklist
result
abstract
identifi
databas
search
figur
studi
met
inclus
criteria
report
advers
effect
ae
seven
differ
treatment
analysi
show
patient
receiv
ecp
treatment
averag
grade
ae
per
patient
followup
period
month
compar
imatinib
low
dosag
mg
averag
grade
ae
per
patient
reduct
dose
imatinib
reduc
grade
ae
per
patient
within
month
followup
imatinib
show
dose
relat
toxic
higher
dose
mg
result
averag
grade
ae
per
patient
month
followup
increas
ae
per
patient
dosag
increas
mg
month
followup
studi
pediatr
cgvhd
popul
report
pentostatin
higher
ae
rate
per
patient
month
compar
month
followup
vs
respect
one
studi
cgvhd
patient
treat
sirolimu
number
ae
per
patient
followup
period
two
studi
rituximab
treatment
asian
popul
cgvhd
report
small
rate
ae
per
patient
annual
howev
us
popul
ae
per
patient
month
month
followup
report
two
independ
studi
sever
ae
relat
msc
report
phase
iii
trial
averag
per
patient
per
annum
conclus
result
systemat
review
suggest
fewer
ae
per
patient
ecp
use
treatment
patient
cgvhd
compar
immunosupress
agent
howev
current
level
evid
permit
determin
whether
specif
drug
class
drug
significantli
lower
incid
ae
conflict
interest
studi
sponsor
mallinckrodt
pharmaceut
author
receiv
research
grant
conduct
analysi
fld
receiv
speaker
fee
research
fund
travel
expens
confer
attend
mallinckrodt
pharmaceut
umc
ljubljana
hematolog
depart
ljubljana
slovenia
background
graft
versu
host
diseas
gvhd
major
complic
allogen
stem
cell
transplant
sct
contribut
reduc
qualiti
life
increas
mortal
antihuman
tlymphocyt
immun
globulin
atg
gvhd
prophylaxi
shown
reduc
incid
chronic
gvhd
match
unrel
recent
match
sibl
allogen
sct
without
affect
relaps
free
surviv
overal
surviv
adopt
atg
grafalon
neovii
sibl
allogen
sct
initi
public
januari
analys
result
patient
treat
center
method
retrospect
collect
data
institut
databas
patient
sibl
donor
receiv
atg
includ
use
cumul
incid
analysi
assess
gvhd
free
surviv
kaplanmei
analysi
overal
surviv
result
transplant
patient
one
rest
men
median
age
year
common
indic
aml
ten
patient
md
cml
one
pmf
cll
nine
patien
high
risk
diseas
present
eleven
first
cr
rest
second
cr
time
sct
common
condit
protocol
use
cybu
patient
follow
tbf
flumel
cytbi
ttflubu
sibl
donor
fulli
hla
match
stem
cell
collect
peripher
blood
gvhd
prophylaxi
csamtx
myeloabl
csammf
nonmyeloabl
set
patient
receiv
atg
cumul
dose
mgkg
seriou
side
effect
two
patient
present
acut
gvhd
involv
skin
gut
grade
two
patient
present
chronic
gvhd
involv
gut
lung
grade
six
patient
relaps
median
day
rang
followup
seven
patient
die
caus
death
relaps
gvhd
infect
graph
conclus
atg
use
sibl
allogen
sct
gvhd
prophylaxi
safe
acut
chronic
gvhd
rate
surprisingli
low
patient
group
observ
rel
high
relaps
rate
compar
initi
report
patient
group
older
heterogen
regard
diagnosi
condit
larger
proport
high
risk
diseas
case
diagnosi
accord
result
intens
post
sct
relaps
detect
andor
prevent
employ
atg
use
research
warrant
elucid
role
atg
sibl
allogen
sct
conflict
interest
neovii
honoraria
lectur
mcmaster
univers
medicin
hamilton
canada
univers
toronto
dalla
lana
school
public
health
toronto
canada
dalhousi
univers
halifax
canada
hospitali
universitair
de
pavillon
de
quebec
citi
canada
univers
toronto
princess
margaret
cancer
centr
toronto
canada
univers
saskatchewan
saskatoon
cancer
centr
saskatoon
canada
laval
cha
quebec
citi
canada
univers
washington
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
univers
new
south
wale
st
vincent
hospit
sydney
australia
vancouv
gener
hospit
univers
british
columbia
vancouv
canada
univers
mcgill
mcgill
univers
health
centr
montreal
canada
univers
montreal
hopit
maisonneuverosemont
montreal
canada
british
columbia
children
hospit
child
famili
research
institut
michael
cuccion
childhood
cancer
research
program
vancouv
canada
cancercar
manitoba
winnipeg
canada
juravinski
hospit
cancer
centr
hamilton
canada
background
previous
report
decreas
incid
steroid
use
primari
endpoint
chronic
graft
versu
host
diseas
cgvhd
symptom
burden
lee
scale
exactli
follow
pretreat
atg
patient
receiv
unrel
donor
transplant
lancet
oncol
report
result
follow
patient
rang
month
atg
group
rang
month
atg
group
method
elig
patient
age
year
haematolog
malign
receiv
either
myeloabl
nonmyeloablativereduc
intens
nmaric
condit
hct
unrel
donor
atg
administr
consist
mgkg
mgkg
day
day
day
result
recruit
assign
elig
patient
treatment
analyz
modifi
intent
treat
atg
atg
followup
patient
patient
atg
group
atg
group
free
steroid
use
adjust
odd
ratio
ci
primari
endpoint
cumul
incid
cgvhd
significantli
lower
atg
group
compar
atg
group
adjust
odd
ratio
ci
differ
incid
relaps
vs
atg
atg
group
respect
nonrelaps
mortal
vs
atg
atg
group
respect
overal
surviv
greater
atg
group
vs
atg
atg
respect
adjust
hr
ci
crf
chronic
graft
versu
host
diseas
relaps
free
surviv
higher
atg
group
versu
atg
group
crf
grf
present
cgvhd
symptom
burden
lee
scale
clinic
significantli
lower
atg
group
compar
atg
group
adjust
mean
se
vs
n
p
conclus
follow
studi
demonstr
benefit
atg
previous
report
sustain
month
patient
receiv
atg
lower
incid
cgvhd
lower
use
steroid
fewer
symptom
cgvhd
atg
standard
care
canada
hct
perform
myeloabl
condit
unrel
donor
blood
stem
cell
graft
independ
survey
result
avail
clinic
trial
registri
isrctn
conflict
interest
author
receiv
grant
support
sanofi
corpor
combinationfund
cihrindustri
investigatoriniti
studi
travel
honorarium
support
sanofi
sponsor
corpor
symposium
ebmt
west
china
hospit
sichuan
univers
chengdu
china
background
relaps
diseas
graftversushost
diseas
gvhd
two
major
event
allogen
stemcel
transplant
lead
signific
mobil
mortal
preclin
research
clinic
trial
histon
deacetylas
hdac
inhibitor
increas
cytotox
alkyl
contain
condit
therapi
reduc
acut
gvhd
therefor
conduct
phase
ii
clinic
trial
select
hdac
inhibitor
chidamid
also
name
combin
posttransplant
cyclophosphamid
base
gvhd
prophylaxi
patient
undergo
myeloabl
condit
match
allogen
pbsct
method
elig
patient
age
year
diagnos
hematolog
malign
karnofski
perform
score
candid
myeloabl
hct
hla
allel
match
donor
recipi
hlaa
hlab
hlac
highresolut
type
requir
graft
sourc
pbsc
patient
receiv
myeloabl
condit
regimen
consist
oral
chidamid
given
twice
weekli
dose
mg
day
week
post
transplant
intraven
busulfan
mgkg
day
intraven
fludarabin
cytarabin
respect
day
pbsc
infus
day
gvhd
prophylaxi
posttransplant
cyclophosphamid
mgkg
day
cyclosporin
start
day
absenc
gvhd
cyclosporin
taper
start
day
discontinu
day
minim
residu
diseas
mrd
determin
multiparamet
flow
cytometri
result
juli
sep
patient
enrol
singlecent
prospect
phase
clinic
trial
median
age
studi
particip
year
year
thirti
patient
diagnosi
acut
myeloid
leukemia
acut
lymphocyt
leukemia
myelodysplast
syndrom
twelv
patient
mrd
activ
diseas
median
x
cellskg
cell
sibl
donor
n
unrel
donor
infus
recipi
neutrophil
platelet
engraft
median
day
day
day
day
transplant
respect
case
primari
secondari
graft
failur
day
grade
agvhd
median
time
onset
day
patient
develop
grade
agvhd
figur
median
followup
time
whole
cohort
month
cumul
incid
relaps
year
figur
median
time
relaps
day
day
posttranspl
nrm
incid
year
median
followup
time
whole
cohort
month
estim
progress
free
surviv
overal
surviv
year
respect
chronic
extens
gvhd
year
result
gvhdfree
relapsefre
surviv
conclus
ntroduc
chidamid
condit
gvhd
prophylaxi
posttransplant
cyclophosphamid
cyclosporin
patient
undergo
match
myeloabl
condit
hct
safe
feasibl
chidamid
decreas
gvhd
preserv
suffici
graftversusleukemia
respons
conflict
interest
jie
ji
noth
disclos
massachusett
gener
hospit
blood
marrow
transplant
program
boston
unit
state
danafarb
cancer
institut
depart
biostatist
comput
biolog
boston
unit
state
univers
virginia
school
medicin
divis
hematologyoncolog
charlottesvil
va
unit
state
background
chronic
graftversushost
diseas
cgvhd
import
caus
morbid
mortal
recipi
allogen
hematopoiet
cell
transplant
system
corticosteroid
remain
mainstay
cgvhd
therapi
recent
cell
surfac
marker
activ
lymphocyt
identifi
potenti
novel
target
gvhd
therapi
brentuximab
vedotin
bv
antibodydrug
conjug
target
shown
activ
steroidrefractori
acut
gvhd
phase
studi
chen
et
al
blood
given
overlap
pathophysiolog
acut
chronic
gvhd
conduct
phase
studi
bv
treatment
steroidrefractori
cgvhd
method
patient
least
year
age
diagnosi
steroidrefractori
chronic
gvhd
defin
persist
diseas
despit
mgkgday
prednison
equival
least
week
diseas
respond
therapi
beyond
steroid
clinic
scenario
steroid
contraind
modifi
studi
design
use
primari
endpoint
determin
maximum
toler
dose
mtd
bv
popul
six
escal
dose
bv
plan
mgkg
dose
level
mgkg
dose
level
mgkg
dose
level
mgkg
dose
level
mgkg
dose
level
mgkg
dose
level
bv
administ
iv
day
cycl
cycl
therapi
period
doselimit
toxic
dlt
evalu
first
cycl
grade
peripher
neuropathi
includ
definit
dlt
result
nineteen
patient
enrol
studi
withdraw
consent
prior
dose
amongst
patient
receiv
bv
nih
cgvhd
sever
includ
mild
moder
sever
median
number
cycl
therapi
rang
reason
stop
therapi
includ
toxic
patient
decis
complet
plan
therapi
lack
respons
death
dlt
observ
peripher
neuropathi
cohort
grade
pre
cohort
grade
sepsi
cohort
grade
mtd
reach
trial
prematur
close
due
toxic
seven
patient
develop
grade
advers
event
attribut
therapi
four
patient
develop
moder
sever
peripher
neuropathi
lead
cessat
treatment
case
overal
patient
partial
respons
assess
treat
physician
complet
respons
observ
one
patient
progress
cgvhd
respons
patient
unevalu
eleven
patient
abl
decreas
system
corticosteroid
dose
month
initi
bv
includ
patient
abl
stop
corticosteroid
complet
conclus
bv
activ
treatment
steroidrefractori
cgvhd
yet
use
limit
treatmentrel
toxic
includ
peripher
neuropathi
continu
effort
investig
target
approach
cgvhd
caus
broad
immunosuppress
need
tabl
tabl
clinic
trial
registri
clinicaltrialsgov
identifi
conflict
interest
seattl
genet
inc
provid
brentuximab
vendotin
clinic
trial
fund
dr
chen
receiv
research
fund
adienn
otsuka
work
perform
outsid
current
studi
author
declar
conflict
interest
aou
careggi
cellular
therapi
transfusion
medicin
unit
florenc
itali
aou
careggi
cardiomyopathi
unit
florenc
itali
background
despit
prophylaxi
immunosuppress
therapi
agent
nearli
patient
experi
acut
graftversushost
diseas
agvhd
allogen
hematopoiet
cell
transplant
hsct
cardiac
gvhd
rare
event
diagnosi
usual
carri
exclus
method
femal
aml
fab
xx
itd
mutat
eln
int
diagnos
novemb
admit
hospit
induct
treatment
includ
two
cycl
ice
high
dosag
arac
without
achiev
complet
hematolog
remiss
chr
receiv
cours
inhibitor
achiev
chr
posit
flow
cytometri
minim
residu
diseas
fcmrd
molecular
residu
diseas
may
cellreplet
pbsc
hsct
hlaident
sibl
donor
perform
echocardiographi
pretranspl
show
eject
fraction
ef
normal
cardiac
paramet
condit
consist
tbf
regimen
ciclosporin
methotrex
given
gvhd
prophylaxi
day
skin
agvhd
grade
occur
treat
topic
steroid
bone
marrow
evalu
show
chr
neg
fcmrd
molecular
analysi
neg
full
donor
bone
marrow
chimer
day
agvhd
grade
global
skin
liver
intestin
ecog
occur
stool
studi
neg
infect
endoscopi
perform
due
patient
condit
treatment
mgkg
daili
iv
metilprednison
start
respons
day
day
treatment
infliximab
start
without
improv
anoth
gvhd
therapi
line
ad
extracorpor
photopheresi
ecp
small
improv
detect
agvhd
global
grade
bone
marrow
evalu
reveal
chr
neg
fcmrd
molecular
analysi
neg
donor
bone
marrow
chimer
day
chronic
overlap
gvhd
diagnosi
perform
moder
global
score
pulmonari
ct
scan
reveal
plueral
pericardi
effus
hepat
splenic
seros
treatment
mgkg
daili
iv
metilprednison
start
patient
condit
got
wors
ecog
progress
fatigu
dyspnea
hypotens
detect
therefor
day
complet
cardiolog
evalu
shown
reveal
global
dysfunct
ef
mild
pericardi
effus
compromis
heart
function
ecg
demonstr
sinu
tachycardia
sign
cardiac
ischemia
cardio
enzym
neg
nt
probnp
pgml
cmv
ebv
hsv
adenoviru
toxoplasma
bk
viral
load
neg
cardiac
failur
therefor
interpret
autoimmun
myocard
level
bilirubin
quickli
increas
mgdl
due
myocard
ecp
stop
rituximab
start
cardio
evalu
repeat
day
reveal
mild
improv
ef
stabl
pericardi
effus
level
worsen
nt
probnp
pgml
patient
condit
got
wors
hemorrhag
shock
day
occur
transfus
therapi
ineffect
patient
die
permiss
autopsi
deni
result
result
conclus
possibl
cardiac
gvhd
latest
event
sever
cgvhd
scenario
seros
cardiac
involv
rare
manifest
cgvhd
attribut
diagnosi
exclus
cardio
mri
myocardi
biopsi
perform
whenev
cardiac
gvhd
suspect
conflict
interest
noth
disclos
abstract
previous
publish
peke
univers
peopl
hospit
beij
china
background
acut
graftversushost
diseas
agvhd
major
complic
allogen
stem
cell
transplant
effect
immun
cell
risk
agvhd
studi
extens
lymphocyt
express
ctype
lectin
prove
share
transcript
profil
innat
function
across
previous
defin
subset
among
three
main
cell
subset
divid
two
popul
express
either
intermedi
high
level
previou
studi
show
cell
peripher
blood
day
around
neutrophil
engraft
could
predict
marker
agvhd
set
ident
allohsct
howev
impact
cell
gcsfprime
graft
includ
gcsfprime
bone
marrow
gbm
gcsfprime
peripher
blood
gpb
cell
reconstitut
agvhd
haplohsct
set
remain
unknown
studi
aim
investig
whether
differ
cell
subset
affect
agvhd
haplohsct
method
patient
enrol
adult
hematolog
malign
underw
allohsct
march
juli
center
gbm
gpb
haploident
donor
examin
posthsct
peripher
immun
reconstitut
analyz
recipi
underw
haplohsct
underw
identicalhsct
transplant
briefli
fresh
cell
stain
follow
antibodi
detect
via
multicolor
flow
cytometeri
result
cohort
patient
whose
graft
analyz
suffer
agvhd
median
grade
iiiv
agvhd
median
among
patient
grade
iiiv
agvhd
experienc
acut
gastrointestin
gvhd
median
patient
divid
low
highdos
group
base
median
dose
cell
subset
result
show
lowdos
group
cell
gpb
higher
cumul
incid
gastrointestin
agvhd
compar
highdos
group
therefor
studi
relationship
cell
subset
reconstitut
agvhd
cohort
patient
whose
peripher
reconstitut
analyz
patient
undergo
haplohsct
suffer
agvhd
patient
undergo
identicalhsct
agvhd
median
number
cell
haplogroup
cellsul
cellsul
cellsul
respect
median
number
cell
identicalgroup
cellsul
cellsul
cellsul
respect
cell
reconstitut
haplogroup
slower
identicalgroup
p
moreov
patient
haplogroup
gastrointestin
agvhd
lower
frequenc
cell
also
lower
absolut
number
posthsct
compar
without
gastrointestin
agvhd
conclus
cell
gpb
might
predict
occurr
gastrointestin
agvhd
haplohsct
cell
reconstitut
associ
gastrointestin
agvhd
conflict
interest
noth
disclos
vanderbilt
univers
medic
center
medicin
nashvil
tn
unit
state
vanderbilt
univers
cell
development
biolog
nashvil
tn
unit
state
vanderbiltingram
cancer
center
nashvil
tn
unit
state
vanderbilt
univers
medic
center
neurolog
surgeri
nashvil
tn
unit
state
cytobank
inc
mountain
view
ca
unit
state
vanderbilt
univers
medic
center
biostatist
nashvil
tn
unit
state
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
univers
minnesota
medicin
minneapoli
mn
unit
state
dana
farber
cancer
institut
boston
unit
state
h
lee
moffitt
cancer
center
research
institut
tampa
fl
unit
state
background
classif
chronic
graftversushost
diseas
cgvhd
chang
nih
consensu
criteria
score
mild
moder
sever
calcul
multipl
organ
domain
import
inform
organ
score
may
lost
use
overal
sever
score
har
machin
learn
identifi
clinic
phenotyp
determin
cluster
stratifi
outcom
could
translat
clinic
prognost
tool
method
adult
patient
cgvhd
enrol
prospect
multicent
studi
assess
clinic
phenotyp
identifi
use
incid
patient
cgvhd
consortium
male
median
age
rang
test
addit
case
two
studi
extracorpor
photopheresi
ecp
research
conduct
inform
consent
irb
approv
accord
declar
helsinki
train
enrol
score
involv
involv
calcul
eye
liver
joint
mouth
gi
bodi
surfac
area
erythema
sclerosi
fascia
measur
hopkin
score
analysi
includ
visn
dimension
reduct
amir
et
al
natur
biotechnolog
flowsom
patient
cluster
van
gassen
et
al
cytometri
marker
enrich
model
mem
featur
enrich
score
diggin
et
al
natur
method
cox
proport
hazard
overal
surviv
chisquar
cluster
comparison
respons
measur
use
nih
criteria
test
clinic
applic
decis
tree
base
seri
question
develop
classifi
patient
cluster
mem
use
compar
phenotyp
defin
initi
machin
learn
decis
tree
analysi
mem
label
report
enrich
organ
deenrich
organ
organx
superscript
scale
deenrich
enrich
result
machin
learn
analysi
reveal
patient
cluster
figur
includ
sclerot
phenotyp
cluster
enrich
joint
fascia
sclerosi
lack
liver
mouth
involv
liver
phenotyp
cluster
mix
phenotyp
cluster
enrich
mouth
eye
liver
gi
involv
decis
tree
classifi
patient
phenotyp
compar
cluster
identifi
cluster
differ
surviv
ecp
respons
significantli
wors
overal
surviv
observ
sever
liver
phenotyp
patient
cluster
hr
ci
mix
phenotyp
cluster
hr
compar
cluster
patient
classifi
sclerot
phenotyp
lower
respons
ecp
compar
mix
phenotyp
patient
cluster
vs
cluster
cluster
nt
explain
nih
sever
alon
nih
sever
nt
significantli
stratifi
surviv
conclus
machin
learn
tool
reveal
pattern
cgvhd
organ
score
character
phenotyp
group
differ
surviv
treatment
respons
clinic
applic
tool
identifi
patient
group
creat
identifi
cluster
evalu
associ
biomark
immun
cell
type
addit
clinic
respons
figur
tsne
analysi
show
patient
cluster
identifi
flowsom
left
organ
score
heat
patient
b
patient
cluster
label
mem
clinic
trial
registri
conflict
interest
j
gandelman
byrn
mistri
k
diggin
h
chen
lee
j
pidala
j
song
noth
disclos
h
polikowski
employe
cytobank
inc
mountain
view
ca
arora
consult
takeda
receiv
research
fund
pharmacycl
llc
c
cutler
consult
pfizer
pharmacycl
kite
bristolmy
squibb
incyt
astella
flower
consult
pharmacycl
llc
j
irish
cofound
board
member
cytobank
inc
receiv
research
support
incyt
corp
janssen
pharmacycl
jagasia
consult
receiv
research
fund
mallinckrodt
formerli
therako
inc
janssen
fukushima
medic
univers
fukushima
japan
background
genom
loss
mismatch
hla
recent
describ
mechan
leukemia
immun
escap
relaps
allogen
hsct
l
crucitti
et
al
report
incid
risk
factor
clinic
outcom
myeloid
malign
relaps
loss
mismatch
hla
incompat
hsct
howev
featur
lymphoid
malign
relaps
loss
mismatch
hla
poorli
understood
aim
studi
investig
risk
factor
outcom
patient
underw
tcellreplet
haploident
transplant
use
gvhd
prophylact
regimen
consist
lowdos
atg
mgkg
bodi
weight
tacrolimu
methotrex
prednisolon
method
inclus
criteria
studi
patient
achiev
neutrophil
engraft
thu
exclud
earli
death
case
immun
reject
whose
genom
hla
loss
relaps
abl
assess
nonhla
loss
relaps
defin
reappear
leukem
cell
relaps
site
concomit
detect
patientspecif
hla
molecular
type
result
total
pediatr
patient
underw
consecut
haploident
transplant
includ
analys
indic
hsct
case
diagnosi
highrisk
malign
underli
diagnos
transplant
follow
n
aml
n
myeloidnk
acut
precursor
leukemia
mnkal
n
mix
phenotyp
acut
leukemia
mpal
n
juvenil
myelomonocyt
leukemia
n
age
distribut
year
median
year
median
followup
survivor
day
rang
document
relaps
assess
genom
hla
eight
case
relaps
molecular
type
reveal
select
genom
loss
patientspecif
hla
haplotyp
leukem
cell
eight
case
hla
loss
four
occur
patient
underw
transplant
two
aml
patient
one
mnkal
patient
one
mpal
patient
time
sinc
hsct
significantli
differ
hla
loss
relaps
nonhla
loss
relaps
median
vs
day
p
seven
eight
hla
loss
relaps
patient
six
nine
nonhla
loss
relaps
patient
underw
transplant
presenc
activ
diseas
occurr
relaps
hla
loss
relaps
patient
eight
nonhla
loss
relaps
patient
experienc
acut
gvhd
evalu
patient
four
hla
loss
relaps
patient
five
nonhla
loss
relaps
patient
experienc
chronic
gvhd
univari
analysi
tcell
dose
infus
transplant
weakli
associ
increas
risk
hla
loss
outcom
hla
loss
nonhla
loss
relaps
similarli
poor
patient
whose
genom
hla
assess
two
nonhla
loss
relaps
patient
undergon
transplant
complet
remiss
surviv
sustain
remiss
conclus
conclus
hla
loss
frequent
mechan
evas
tcell
alloreact
relaps
patient
lymphoid
myeloid
malign
transplant
haploident
donor
warrant
routin
screen
transplant
set
conflict
interest
author
declar
conflict
interest
ege
univers
faculti
medicin
hematolog
izmir
turkey
background
allogen
hematopoiet
stem
cell
transplant
hsct
potenti
cur
varieti
hematolog
malign
despit
high
respons
rate
acut
promyelocyt
leukemia
subset
patient
still
relaps
graftvsleukemia
gvl
effect
allogen
transplant
offer
best
antileukemia
activ
patient
advanc
diseas
success
notori
hamper
graftvshost
diseas
gvhd
remain
lifethreaten
complic
standard
treatment
gvhd
highdos
corticosteroid
steroidrefractori
gvhd
associ
poor
prognosi
secondlin
treatment
includ
number
agent
mesenchym
stromal
cell
alemtuzumab
azacitidin
sirolimu
cyclophosphamid
antitnf
agent
ruxolitinib
howev
clinic
experi
agent
remain
limit
report
interest
case
underw
allogen
hsct
third
time
follow
acut
steroidrefractori
gvhd
treat
multipl
agent
method
male
refractori
promyelocyt
leukemia
pml
underw
allogen
hsct
full
hlamatch
sibl
donor
two
time
end
relaps
pml
patient
relaps
second
allogen
hsct
central
nervou
system
cn
involv
underw
myeloabl
allogen
hsct
hlamatch
relat
donor
condit
busulfan
cyclophosphamid
gvhd
prophylaxi
consist
cyclosporin
methotrex
day
patient
develop
overal
grade
iv
acut
gvhd
biopsi
proven
stage
iv
gastrointestin
gvhd
refractori
high
dose
corticosteroid
patient
condit
rapidli
deterior
becam
critic
despit
addit
mycophenol
mofetil
cyclophosphamid
day
etanercept
administ
twice
week
due
insuffici
respons
previou
therapi
day
mesenchym
stromal
cell
cellskg
bodyweight
given
intraven
ruxolitinib
start
concomitantli
mesenchym
stromal
cell
dose
mg
twice
day
day
patient
clinic
condit
gradual
improv
complet
resolut
agvhd
also
confirm
histolog
day
suffici
respons
achiev
bone
marrow
aspir
remiss
without
evid
cn
involv
examin
recoveri
progressiveacut
gvhd
extracorpor
photopheresi
everi
week
mycophenol
mofetil
given
sinc
gvhd
complet
control
patient
still
clinic
follow
remiss
result
report
male
patient
complic
sever
acut
gvhd
third
allohsct
due
relaps
pml
combin
therapi
overcam
sever
acut
gvhd
remiss
pml
achiev
sever
gvhd
may
accompani
intens
gvl
effect
presum
provid
remiss
leukemia
conclus
gvhd
remain
seriou
barrier
success
allohct
clear
major
improv
occur
prevent
treat
patient
multipl
drug
treatment
demonstr
clinic
improv
steroid
refractori
gvhd
clinic
evid
still
need
highlight
nevertheless
increas
understand
biolog
clinic
manifest
transplantationrel
factor
gvhd
get
better
organ
conflict
interest
none
declar
aou
citta
della
salut
e
della
scienza
di
torino
oncoematologia
pediatrica
torino
itali
background
addit
rabbit
antithymocyt
globulin
gvhd
prophylaxi
shown
highli
effect
reduc
transplant
relat
mortal
morbid
avail
data
best
antithymocyt
globulin
prepar
use
pediatr
popul
limit
far
primari
aim
studi
investig
differ
term
overal
surviv
os
pediatr
patient
treat
genzymesanofi
cambridg
atgthymo
patient
treat
neovii
biotech
lexington
atggrafalon
secondari
endpoint
studi
evalu
differ
regard
transplant
relat
mortal
trm
relaps
incid
ri
acut
chronic
gvhd
incid
method
retrospect
evalu
pediatr
patient
median
age
year
undergo
hsct
center
hematolog
malign
receiv
part
gvhd
prophylaxi
schedul
either
atgthymo
n
total
dose
mgkg
atggrafalon
total
dose
mgkg
patient
underw
clinic
hematolog
posttransplant
assess
accord
center
polici
os
calcul
accord
kaplanmei
method
signific
observ
differ
establish
logrank
test
trm
ri
calcul
cumul
incid
ci
adjust
analysi
compet
risk
relaps
transplantrel
death
consid
compet
risk
respect
agvhd
cgvhd
incid
calcul
ci
well
case
death
reason
consid
compet
risk
differ
term
ci
compar
use
grey
test
statist
analys
perform
use
ncss
softwar
hintz
ncss
pass
number
crunch
statist
system
kaysvil
ut
usa
result
median
follow
day
rang
atgthymo
group
day
rang
atggrafalon
group
year
hsct
patient
treat
atgthymo
os
ci
patient
treat
atggrafalon
os
ci
differ
statist
signific
patient
receiv
atgthymo
show
trm
ci
patient
receiv
atggrafalon
ci
differ
statist
signific
ri
similar
group
ci
atgthymo
ci
atggrafalon
similarli
patient
show
occurr
rate
grade
iiiv
agvhd
cgvhd
respect
ci
ci
atgthymo
group
ci
ci
atggrafalon
group
p
conclus
retrospect
data
suggest
patient
treat
atggrafalon
improv
surviv
compar
patient
treat
atgthymoglobulin
advantag
seem
relat
reduc
trm
obvious
result
preliminari
need
confirm
larger
prospect
random
control
trial
aim
also
establish
use
drug
extend
situat
ie
hsct
sibl
donor
describ
adult
conflict
interest
author
commerci
proprietari
financi
interest
product
compani
describ
articl
ege
univers
faculti
medicin
hematolog
izmir
turkey
ege
univers
faculti
medicin
dermatolog
izmir
turkey
background
graftversushost
diseas
gvhd
major
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
associ
signific
morbid
mortal
gvhd
major
caus
morbid
mortal
affect
allohsct
recipi
account
death
follow
procedur
one
earliest
common
manifest
gvhd
cutan
gvhd
consist
essenti
maculopapular
rash
begin
anywher
bodi
often
start
palm
sole
involv
method
conduct
retrospect
analysi
adult
patient
allogen
hematopoiet
stem
cell
transplant
allohsct
develop
cutan
gvhd
novemb
novemb
clinic
detail
record
includ
demograph
underli
diagnosi
detail
hsct
condit
regim
immunosuppress
agent
use
grade
cutan
gvhd
overal
outcom
grade
cutan
gvhd
respond
immunosuppress
treatment
includ
studi
result
among
patient
cutan
gvhd
found
patient
accompani
viscer
hepaticgastrointestin
cgvhd
n
mucou
involv
n
lung
involv
n
follow
allogen
hct
match
relat
unrel
haploident
variou
indic
amlmd
hodgkin
lymphoma
nonhodgkin
lymphoma
myeloma
cml
cll
aplast
anemia
among
patient
cutan
gvhd
median
age
year
gender
malefemal
peripher
blood
sourc
patient
reducedintens
condit
use
acut
cutan
gvhd
grade
ii
occur
grade
iii
occur
grade
iv
occur
among
patient
cutan
gvhd
fail
convent
immunosuppress
therapi
could
adequ
control
corticosteroid
treatment
patient
altern
second
line
treatment
includ
cyclophosphamid
ruxolitinib
mesenchym
stromal
cell
extracorpor
photopheresi
ecp
uval
phototherapi
use
thirtyf
patient
ecp
administ
twice
week
start
median
day
diagnosi
acut
gvhd
uval
phototherapi
median
durat
ecp
month
median
number
ecp
procedur
patient
overal
respons
rate
n
complet
respons
rate
n
partial
respons
rate
n
ten
patient
respons
conclus
due
increas
incid
hematolog
diseas
hsct
common
therapi
worldwid
parallel
gvhd
highli
preval
patient
receiv
allohsct
cutan
gvhd
common
manifest
follow
hsct
appear
acut
chronic
comorbid
affect
greatli
qualiti
life
ecp
effect
treatment
steroidrefractori
gvhd
especi
cutan
mucou
involv
cutan
gvhd
conflict
interest
none
declar
hospit
virgen
de
la
niev
depart
hematolog
granada
spain
hospit
virgen
de
la
niev
depart
dermatolog
granada
spain
background
toxic
epiderm
necrolysi
ten
lifethreaten
blister
skin
diseas
typic
induc
drug
poorli
understood
pathogenesi
incid
main
featur
ten
hematopoiet
stem
cell
transplant
hsct
patient
evalu
document
case
literatur
extens
blister
desquam
present
cutan
acut
graftversushost
diseas
gvhd
sever
variant
condit
mimick
ten
skin
diseas
exhibit
clinic
histolog
similar
make
virtual
imposs
differenti
context
hsct
method
present
two
recent
case
diagnos
cutan
sever
gvhdnet
hsct
centr
hospit
virgen
de
la
niev
granada
spain
result
patient
man
myelodysplast
syndrom
subject
allogen
hsct
match
relat
donor
nonmyeloabl
condit
regimen
day
observ
maculopapular
rash
improv
steroid
administr
day
patient
develop
rapidli
progress
gener
erythema
mucos
involv
fever
sirolimu
extracorpor
photopheresi
ad
current
treatment
follow
day
clinic
deterior
observ
blister
present
posit
nikolski
sign
bodi
surfac
area
high
dose
steroid
ruxolitinib
initi
point
numer
complic
day
patient
releas
hospit
cutan
hepat
ocular
chronic
gvhd
treat
immunosuppress
therapi
day
patient
die
respiratori
infect
patient
allogen
matchedrel
donor
hsct
perform
nonmyeloabl
condit
regimen
woman
chronic
lymphat
leukemia
day
develop
gastrointestin
symptom
treat
steroid
biopsi
confirm
acut
grade
gvhd
day
observ
worsen
gastrointestin
condit
progress
mucos
involv
dissemin
rash
fever
sirolimu
ad
current
treatment
follow
day
multipl
blister
format
larg
area
epiderm
denud
appear
bodi
surfac
area
figur
intens
plasmapheresi
photopheresi
ruxolitinib
initi
day
patient
releas
hospit
still
aliv
day
case
biopsi
show
morpholog
find
compat
grade
gvhd
net
make
imposs
differenti
second
case
immunohistochem
studi
show
lymphocyt
ratio
conclus
hsct
patient
exhibit
progress
sever
skin
diseas
mucos
involv
fever
sever
cutan
gvhdnet
suspect
discrimin
entiti
challeng
gastrointestin
liver
involv
andor
lymphocyt
ratio
tilt
diagnost
balanc
toward
gvhd
side
probabl
best
approach
treatment
patient
dual
involv
intens
treatment
gvhd
usual
manag
net
avoid
drug
may
trigger
diseas
conflict
interest
none
author
anyth
disclos
king
faisal
specialist
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
background
optim
gvhd
prophylaxi
cb
transplant
establish
mmf
wide
use
gvhd
prophylaxi
sct
experi
follow
cb
transplant
still
limit
retrospect
compar
csasteroid
csammf
gvhd
prophylaxi
cb
transplant
method
pediatr
transplant
recipi
underw
cb
transplant
jan
decemb
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
data
diagnosi
transplantrel
paramet
incid
gvhd
vod
viral
bacteri
fungal
infect
first
posttranspl
abstract
femal
median
age
transplant
year
year
patient
indic
sct
group
csammf
remain
group
b
csasteroid
patient
fulli
hlamatch
unit
remain
antigen
mismatch
result
acut
gvhd
occur
group
compar
group
b
pvalu
sever
agvhd
grade
seen
group
group
b
pvalu
post
infus
chimer
studi
group
group
b
median
time
neutrophil
engraft
day
group
day
group
b
respect
incid
vod
higher
group
compar
group
b
bacteri
viral
fungal
three
infect
rate
also
higher
group
vs
group
b
pvalu
respect
cumul
incid
chronic
gvhd
cgvhd
group
comparison
group
b
conclus
despit
trend
lower
gvhd
incid
csammf
group
differ
statist
significantli
differ
compar
csasteroid
group
rate
vod
bacteri
viral
fungal
infect
post
sct
cgvhd
higher
csammf
group
engraft
faster
higher
chimer
studi
csasteroid
group
studi
need
higher
number
patient
evalu
effect
csammf
conflict
interest
none
declar
univers
zagreb
school
medicin
zagreb
croatia
univers
hospit
centr
zagreb
zagreb
croatia
geno
ltd
zagreb
croatia
faculti
scienc
univers
split
split
croatia
andrija
stampar
school
public
health
zagreb
croatia
nation
institut
health
nation
cancer
institut
bethesda
wa
unit
state
background
chronic
graftversushost
diseas
cgvhd
immun
disord
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
character
alter
homeostasi
humor
immun
respons
product
antibodi
chang
glycosyl
immunoglobulin
g
igg
abund
class
antibodi
associ
autoimmun
diseas
resembl
cgvhd
studi
evalu
potenti
igg
nglycosyl
discriminatori
analysi
patient
allohsct
without
cgvhd
method
plasma
sampl
collect
cgvhd
patient
control
particip
allohsct
without
cgvhd
match
age
gender
includ
natur
histori
cgvhd
studi
univers
hospit
center
zagreb
croatia
chronic
gvhd
diagnos
accord
establish
nih
criteria
laboratori
test
done
complet
blood
count
coagul
biochemistri
immunolog
igg
isol
blood
plasma
analyz
liquid
chromatographymass
spectrometri
discriminatori
model
obtain
condit
logist
regress
igg
glycopeptid
measur
laboratori
result
literatur
base
clinic
signific
laboratori
marker
associ
cgvhd
leukemia
p
valu
consid
signific
result
cgvhd
patient
control
similar
regard
gender
male
age
median
vs
year
main
diseas
leukemia
myeloabl
condit
vs
relat
donor
hsct
sourc
peripher
blood
vs
cgvhd
patient
frequent
previou
acut
gvhd
control
group
vs
median
time
cgvhd
diagnosi
studi
enrol
day
major
patient
sever
moder
global
nih
cgvhd
score
activ
diseas
clinic
impress
patient
receiv
system
immunosuppress
patient
lower
b
cell
albumin
vitamin
higher
ggt
crp
beta
microglobulin
control
logist
regress
individu
glycopeptid
identifi
sever
potenti
signific
candid
figur
next
model
built
use
glycopeptid
measur
princip
compon
glycanpc
figur
reduc
effect
multicolinear
third
model
use
literatur
base
clinic
signific
laboratori
marker
associ
cgvhd
laboratori
paramet
reduc
princip
compon
labpc
figur
final
model
combin
statist
signific
paramet
previou
model
identifi
follow
paramet
signific
discrimin
cgvhd
patient
control
figur
higher
platelet
count
hemoglobin
erythrocyt
main
contributor
figur
origin
glycopeptid
candid
select
correct
use
platelet
identifi
cgvhd
patient
lower
lower
figur
conclus
studi
indic
increas
discriminatori
power
model
combin
laboratori
paramet
iggglycopeptid
measur
distinguish
cgvhd
patient
control
method
also
identifi
glycan
structur
significantli
lower
cgvhd
patient
indic
disturb
antibodydepend
cellmedi
cytotox
reduc
antiinflammatori
igg
featur
suggest
glycan
great
research
potenti
clarifi
event
cgvhd
conflict
interest
none
author
anyth
disclos
instituto
nacion
de
ciencia
medica
nutricion
salvador
zubiran
hematolog
oncolog
tlalpan
mexico
background
hypercholesterolemia
lead
cholesterol
accumul
macrophag
immun
cell
promot
inflammatori
respons
although
link
cholesterol
inflamm
best
exemplifi
atherosclerosi
similar
mechan
may
also
contribut
metabol
disord
obes
autoimmun
diseas
context
acut
graftversushost
diseas
agvhd
immunolog
syndrom
involv
tissu
damag
mediat
donor
lymphocyt
result
imbal
effector
regulatori
arm
immun
system
affect
outcom
allogen
hematopoiet
stem
cell
transplant
allohsct
aim
studi
investig
associ
hypercholesterolemia
donor
recipi
incid
agvhd
method
retrospect
analysi
perform
identifi
patient
receiv
allogen
hsct
nation
institut
medic
scienc
nutrit
may
august
exclus
criteria
includ
incomplet
laboratori
inform
engraft
failur
day
mortal
final
cohort
includ
patient
undergo
allohsct
data
obtain
electron
paper
medic
record
document
donor
recipi
cholesterol
includ
level
perform
hsct
high
cholesterol
consid
total
cholesterol
accord
intern
guidelin
analysi
donor
cholesterol
level
donor
complet
data
includ
agvhd
death
relaps
without
agvhd
consid
compet
risk
pvalu
consid
signific
spss
use
result
patient
male
median
age
year
rang
underli
diseas
follow
acut
lymphoblast
leukemia
aplast
anemia
myelodysplast
syndrom
acut
myeloblast
leukemia
lymphoma
chronic
lymphocyt
leukemia
other
acut
graftversushost
diseas
present
patient
figur
show
statist
signific
increas
agvhd
associ
hypercholesterolemia
recipi
vs
also
shown
figur
hypercholesterolemia
donor
associ
increas
agvhd
vs
hypercholesterolemia
donor
receptor
also
associ
increas
agvhd
vs
variabl
type
donor
relat
unrel
haploident
gender
dispar
hsc
sourc
age
cmv
infect
lab
result
ldl
hdl
cbc
liver
function
glucos
iron
test
multivari
analysi
statist
signific
observ
result
shown
conclus
date
first
studi
associ
hypercholesterolemia
aghvd
studi
report
medic
statin
particular
may
role
modul
graftversushost
diseas
hand
studi
exclus
report
hypercholesterolemia
consequ
hepat
gvhd
accord
result
test
variabl
conclud
hypercholesterolemia
recipi
donor
independ
factor
develop
agvhd
nonetheless
prospect
studi
larger
cohort
necessari
conflict
interest
none
author
conflict
interest
disclos
abstract
previous
publish
brigham
women
hospit
danafarb
cancer
institut
oral
medicin
dentistri
boston
unit
state
harvard
school
dental
medicin
boson
unit
state
dana
farber
cancer
institut
boston
unit
state
harvard
medic
school
boston
unit
state
background
open
label
phase
studi
oral
chronic
graftversushost
diseas
cgvhd
topic
dexamethason
versu
tacrolimu
solut
reveal
superior
efficaci
dexamethason
object
studi
report
longterm
manag
outcom
studi
cohort
complet
trial
method
retrospect
record
review
perform
date
studi
complet
januari
topic
therapi
system
immunosuppress
therapi
nih
oral
cgvhd
score
advers
effect
record
cgvhdrelat
outpati
visit
patient
follow
fu
character
follow
time
interv
month
result
forti
patient
male
median
age
complet
clinic
trial
persist
oral
cgvhd
patient
remain
topic
therapi
dexamethason
dex
patient
clobetasol
clo
andor
tacrolimu
tac
reduc
n
n
n
respect
mean
nih
sensit
score
fluctuat
nih
sever
mean
maximum
ulcer
score
decreas
month
month
nine
patient
develop
oral
candidiasi
treat
antifung
therapi
conclus
patient
de
novo
symptomat
oral
cgvhd
like
requir
longterm
care
topic
immunomodulatori
therapi
possibl
year
topic
steroid
tacrolimu
therapi
safe
effect
manag
condit
secondlin
topic
therapi
refractori
oral
cgvhd
requir
investig
clinic
trial
registri
na
conflict
interest
conflict
interest
declar
author
univers
hospit
basel
diagnost
hematolog
basel
switzerland
background
one
diagnost
criteria
transplantassoci
thrombot
microangiopathi
tatma
quantif
schistocyt
peripher
blood
detect
schistocyt
helmet
cell
valu
method
debat
sinc
evalu
schistocyt
technic
variabl
semiautom
digit
microscopi
system
develop
order
differenti
peripher
blood
cell
erythrocyt
morpholog
variabl
way
test
diagnost
accuraci
precis
digit
microscopi
compar
convent
microscopi
respect
recognit
schistocyt
set
acut
graftversushostdiseas
agvhd
method
peripher
blood
smear
allogen
autolog
hsct
patient
januari
retrospect
examin
one
month
three
month
transplant
quantif
schistocyt
digit
microscopi
vision
hema
westmedica
austria
done
erythrocyt
correl
clinic
sign
agvhdtatma
peripher
blood
smear
healthi
blood
donor
also
analyz
control
result
tabl
schistocyt
count
percent
erythrocyt
deviat
given
allogen
hsct
patient
without
agvhd
autolog
hsct
group
allogen
hsct
without
hla
mismatch
hlamm
control
group
valu
month
group
compar
pair
wilcoxon
test
valu
month
group
mannwhitney
test
patient
month
establish
agvhd
alreadi
respect
treatment
schistocyt
significantli
increas
month
allogen
p
autolog
hsct
p
compar
control
statist
significantli
higher
schistocyt
count
found
month
patient
agvhd
patient
hla
mismatch
compar
baselin
start
condit
furthermor
allogen
hsct
patient
high
schistocyt
count
upper
quartil
significantli
frequent
agvhd
chisquar
test
high
lactat
dehydrogenas
ldh
level
chisquar
test
hla
mismatch
chisquar
test
conclus
schistocyt
reliabl
precis
count
mean
digit
microscopi
system
increas
acut
phase
allogen
hsct
within
context
agvhd
probabl
indirect
sign
microangiopathi
might
use
addit
indic
endotheli
gvhd
long
possibl
tatma
syndrom
evolv
patient
agvhd
andor
hla
mismatch
frequent
endotheli
damag
appropri
cutoff
schistocyt
defin
valid
prospect
conflict
interest
author
declar
conflict
interest
tabl
tabl
rotherham
nh
foundat
trust
depart
haematolog
rotherham
unit
kingdom
background
extracorpor
photopheresi
ecp
use
second
line
therapi
steroid
refractori
depend
intoler
chronic
gvhd
cgvhd
cgvhd
activ
tissu
macrophag
produc
factor
contribut
format
fibrot
lesion
scaveng
receptor
express
monocyt
macrophag
proteolyt
cleav
solubl
follow
activ
increas
serum
patient
system
scleroderma
pulmonari
fibrosi
recent
data
show
plasma
rais
activ
cgvhd
de
novo
cgvhd
patient
compar
hsct
patient
without
cgvhd
healthi
control
sinc
ecp
involv
period
infus
preapoptot
leukocyt
engulf
apoptot
cell
macrophag
induc
antiinflammatori
phenotyp
conduct
pilot
studi
investig
whether
ecp
affect
product
put
biomark
vivo
macrophag
activ
method
serum
sampl
collect
moder
sever
cgvhd
patient
male
femal
age
rang
agematch
healthi
control
male
femal
ecp
month
interv
year
patient
cgvhd
affect
skin
mucos
membran
liver
joint
gut
eye
genit
none
respiratori
involv
serum
level
assess
elisa
data
analys
use
graphpad
prism
statist
test
perform
includ
mannwhitney
anova
repeat
measur
appropri
result
cgvhd
patient
significantli
elev
serum
level
median
iqr
compar
healthi
control
median
iqr
subanalysi
perform
group
patient
accord
whether
level
median
level
preecp
baselin
retrospect
analysi
reveal
cgvhd
patient
signific
reduct
serum
level
month
p
mean
sd
ngml
vs
respect
sustain
month
ecp
p
mean
sd
ngml
contrast
patient
mean
sd
show
signific
chang
serum
level
period
although
glucocorticoid
strongli
regul
express
signific
differ
prednisolon
dosag
patient
group
preecp
baselin
mean
sd
vs
respect
reduct
patient
month
independ
signific
reduct
immunosuppress
prednisolon
mean
sd
mgd
conclus
consist
recent
data
found
significantli
elev
cgvhd
patient
compar
healthi
control
data
suggest
ecp
therapi
reduc
vivo
macrophag
activ
measur
level
subset
cgvhd
patient
independ
reduct
glucocorticoid
immunosuppress
preliminari
result
may
provid
insight
possibl
macrophagemedi
mechan
ecp
requir
investig
clinic
trial
registri
na
conflict
interest
c
burton
n
matthew
noth
disclos
alfr
speaker
fee
mallinckrodt
pediatr
oncohaematolog
bmt
unit
children
hospit
chair
paediatr
univers
brescia
brescia
itali
pediatr
oncohaematolog
bmt
unit
children
hospit
univers
brescia
brescia
itali
pediatr
children
hospit
univers
brescia
brescia
itali
children
hospit
brescia
brescia
itali
children
hospit
univers
brescia
brescia
itali
stem
cell
laboratori
section
hematolog
blood
coagul
children
hospit
spedali
civili
brescia
brescia
itali
background
heterozyg
familiar
sporad
gata
mutat
consist
wide
spectrum
phenotyp
includ
cytopenia
myelodysplasia
myeloid
leukemia
viral
bacteri
infect
pulmonari
alveolar
proteinosi
lymphedema
describ
case
year
old
child
kosovar
origin
diagnos
gata
mutat
c
p
manifest
symptom
like
persist
anemia
leukopenia
fever
method
urgent
underw
haploident
peripher
blood
stem
cell
father
use
busulfanmelphalancyclophosfamid
condit
regimen
patient
subsequ
graft
failur
persist
aplasia
condit
fludarabinthiotepaatgcyclophosfamid
tbi
rad
underw
second
haploident
transplant
matern
bone
marrow
stem
cell
engraft
reach
patient
start
diffus
bleed
petechia
hematoma
mane
hemat
vomit
clinic
manifest
thrombot
microangiopathi
tma
start
octreotid
eculizumab
monoclon
antibodi
onceweek
daili
transfus
platelet
erythrocyt
plasma
good
respons
sinc
day
increas
level
bilirubina
liver
enzym
investig
demonstr
hepat
gvh
grade
iii
reason
subject
session
extracorpor
photopheresi
high
dose
corticosteroid
without
signific
resultsdur
hematolog
reconstitut
patient
also
cmv
reactiv
treat
gancyclovir
cmv
immunoglobulin
hemorrag
cystiti
polyomavirusth
patient
juli
also
develop
relat
steroid
side
effect
osteopenia
patholog
fractur
tibia
osteonecrosi
stop
treatment
eculizumab
month
later
ruxolitinib
month
later
result
actual
patient
good
health
one
year
second
blood
marrow
transplant
conclus
case
illustr
benefit
eculizumab
therapi
sever
tma
blood
marrow
transplant
resist
classic
therapi
furthermor
use
ruxolitinib
salvag
therapeut
agent
patient
steroid
refractori
acut
gvhd
conflict
interest
author
conflict
interest
declar
st
vincent
hospit
sydney
haematolog
sydney
australia
hospit
de
la
santa
creu
sant
pau
iib
sant
pau
jose
carrera
leukemia
research
institut
universidad
de
barcelona
haematolog
barcelona
spain
hospit
universitario
vall
haematolog
barcelona
spain
background
steroid
refractori
acut
graft
versu
host
diseas
agvhd
poor
prognosi
etanercept
potenti
effect
treatment
strategi
condit
date
small
studi
avail
present
result
larg
cohort
patient
affect
grade
iiiv
steroid
refractori
agvhd
receiv
monoclon
antibodi
differ
centr
sydney
barcelona
method
allogen
stem
cell
transplant
recipi
diagnos
moder
sever
steroid
refractori
agvhd
april
june
includ
analysi
outcom
measur
includ
overal
respons
rate
day
median
surviv
infecti
complic
caus
death
statist
analys
includ
kaplanmei
surviv
curv
coxregress
analysi
univari
multivari
model
identifi
independ
predictor
respons
etanercept
surviv
result
fiftyeight
patient
median
age
year
rang
includ
studi
median
followup
survivor
month
overal
respons
rate
day
cr
pr
cr
pr
respect
median
surviv
month
month
respond
month
nonrespond
respect
p
overal
surviv
respond
nonrespond
p
factor
associ
respons
etanercept
grade
iv
acut
gvhd
hr
low
serum
albumin
level
etanercept
start
hr
factor
advers
associ
overal
surviv
grade
iv
acut
gvhd
hr
nonrespons
etanercept
hr
p
conclus
etanercept
modest
effect
moder
sever
steroid
refractori
agvhd
lead
around
short
term
respons
howev
long
term
outcom
remain
poor
one
third
long
term
survivor
result
highlight
need
identifi
effect
therapi
set
conflict
interest
j
sierra
agaur
sgr
peri
catalan
govern
instituto
de
salud
carlo
iii
ministerio
de
competitividad
spain
author
noth
disclos
vanderbiltingram
cancer
center
nashvil
tn
unit
state
medic
univers
graz
graz
austria
univers
cologn
germani
hospit
st
loui
univers
pari
pari
franc
uke
hamburgeppendorf
hamburg
germani
univers
hospit
munich
lmu
munich
germani
hackensack
univers
medic
center
john
theurer
cancer
center
hackensack
nj
unit
state
unifi
st
istvan
st
laszlo
hospit
budapest
hungari
vanderbilt
univers
medic
center
nashvil
tn
unit
state
mallinckrodt
pharmaceut
bedminst
nj
unit
state
formerli
mallinckrodt
pharmaceut
bedminst
nj
unit
state
background
moder
sever
cgvhd
defin
nih
criteria
requir
system
therapi
associ
impair
qol
phase
ipilot
prospect
random
multicent
intern
studi
confirm
addit
ecp
standard
care
soc
calcineurin
inhibitor
corticosteroid
safe
well
toler
patient
pt
hypothes
soc
would
associ
worsen
qol
compar
ecp
soc
method
sixti
adult
pt
newonset
moder
sever
cgvhd
requir
system
therapi
receiv
week
soc
vs
soc
ecp
baselin
sever
gvhd
assess
overal
statu
cgvhd
similar
two
group
soc
soc
ecp
moder
sever
assess
qol
use
function
assess
cancer
therapybon
marrow
transplant
summat
factg
wellb
wb
domain
includ
physic
pwb
social
swb
emot
ewb
function
fwb
plu
bmt
specif
bmt
tool
secondari
endpoint
bmt
trial
outcom
index
toi
calcul
sum
pwb
ewb
bmt
pt
complet
qol
survey
baselin
week
respect
qol
variou
time
point
measur
use
time
trend
analys
ordin
logist
regress
use
studi
associ
organ
specif
score
qol
result
pt
soc
ecp
soc
elig
qol
assess
time
trend
analysi
reveal
signific
worsen
qol
pwb
ewb
factg
score
soc
arm
signific
chang
qol
domain
observ
soc
ecp
pt
factbmt
total
score
approach
signific
favor
soc
ecp
qol
score
bodili
pain
domain
significantli
worsen
soc
pt
signific
chang
observ
soc
ecp
pt
primari
assessor
blind
assessor
increas
nih
cgvhd
score
associ
worsen
score
sever
qol
domain
indic
crossvalid
factbmt
qol
tool
cgvhd
studi
organ
domain
associ
qol
worsen
includ
skin
ewb
bmt
bmt
total
bmt
toi
gastrointestin
pwb
bmt
fact
bmt
total
bmt
toi
eye
swb
ewb
fwb
factg
bmt
fact
bmt
total
bmt
toi
jointsfascia
pwb
swb
ewb
fwb
factg
fact
bmt
total
bmt
toi
lung
pwb
swb
ewb
fwb
factg
fact
bmt
total
bmt
toi
limit
cohort
chang
steroid
dose
associ
chang
qol
measur
instrument
use
conclus
first
prospect
random
therapeut
clinic
trial
assess
impact
ecp
soc
variou
qol
domain
use
establish
tool
like
factbmt
worsen
organ
specif
nih
score
across
multipl
organ
domain
significantli
associ
worsen
qol
score
pt
moder
sever
cgvhd
qol
maintain
ecp
current
soc
associ
worsen
qol
notabl
domain
mention
clinic
trial
registri
clinic
trial
registri
http
conflict
interest
jagasia
speaker
bureau
honoraria
research
support
mallinckrodt
pharmaceut
speaker
bureau
honoraria
pharmacycl
inc
research
support
janssen
h
greinix
speaker
bureau
honoraria
mallinckrodt
pharmaceut
novarti
amgen
celgen
sanofi
bristolmy
squibb
c
scheid
honoraria
amgen
bristolmy
squibb
celgen
janssen
novarti
sanofi
g
speaker
bureau
honoraria
therako
inc
mallinckrodt
pharmaceut
compani
f
ayuk
speaker
bureau
honoraria
therako
inc
mallinckrodt
pharmaceut
compani
j
tischer
donato
h
chen
chen
noth
disclos
chin
h
employe
mallinckrodt
pharmaceut
g
mitri
former
employe
mallinckrodt
pharmaceut
hacettep
univers
faculti
medicin
pediatr
ankara
turkey
background
graft
versu
host
diseas
gvhd
remain
clinic
challeng
despit
aggress
firstlin
treatment
limit
success
allogen
hemotopoiet
stem
cell
transplant
sinc
children
vulner
longterm
effect
gvhd
prolong
treatment
steroid
immunosuppress
agent
extracorpor
photopheresi
ecp
could
attract
steroidspar
secondlin
therapi
ecp
cellbas
therapi
induc
toler
donor
lymphocyt
host
antigen
howev
apheresi
children
associ
uniqu
challeng
restrict
use
method
retrospect
analyz
nine
patient
treat
ecp
steroiddepend
refractori
acut
chronic
gvhd
offlin
approach
perform
use
continu
flow
cell
separ
spectra
optia
terumo
bct
ultraviolet
irradi
uvapit
system
system
offer
advantag
children
smaller
extracorpor
volum
reduct
final
collect
volum
citrat
anticoagul
blood
anticoagul
ratio
use
hematocrit
platelet
count
desir
start
leukapheresi
red
blood
cell
prime
circuit
perform
lowbodi
weight
children
kg
doublelumen
central
cathet
place
prior
procedur
schedul
durat
ecp
treatment
patient
characterist
given
tabl
result
among
three
acut
gvhd
patient
complet
respons
observ
two
patient
one
partial
respons
die
due
infect
treatment
one
patient
overlap
syndrom
show
minim
respons
stabl
diseas
die
infect
chronic
gvhd
group
three
patient
achiev
partial
respons
one
complet
respons
one
patient
could
evalu
sinc
die
earli
phase
treatment
live
patient
concomit
immunosuppress
therapi
consider
reduc
common
advers
effect
catheterrel
infect
lead
treatment
interrupt
conclus
ecp
might
safe
effect
welltoler
treatment
children
refractori
acut
chronic
gvhd
largescal
prospect
studi
need
establish
optim
schedul
durat
ecp
standard
treatment
protocol
pediatr
patient
gvhd
help
reduc
therapyrel
advers
effect
clinic
trial
registri
na
conflict
interest
noth
disclos
tabl
characterist
children
treat
ecp
complejo
asistenci
universitario
de
salamancaibs
hematolog
salamanca
spain
background
gvhd
common
complic
allosct
extracorpor
photopheresi
ecp
base
inmunemodulatori
therapi
emerg
one
use
salvag
treatment
due
high
rate
respons
excel
safeti
profil
method
report
singl
center
retrospect
studi
patient
steroidrefractori
depend
acut
chronic
gvhd
treat
ecp
cellex
system
patient
agvhd
receiv
consecut
sessionsweek
week
sessionsfortnight
protocol
cghvd
sessionsfortnight
week
sessionsmonth
ecp
final
steroid
stop
progress
gvhd
result
baselin
transplant
characterist
gvhd
data
shown
tabl
aghvd
median
time
agvhd
ecp
day
grade
iv
agvhd
skin
frequent
organ
involv
multiorgan
diseas
median
prior
line
orr
one
patient
grade
iiiii
agvhd
respond
patient
grade
iv
respond
best
respons
achiv
skin
damag
organ
respons
skin
orr
cr
follow
gut
liver
median
followup
ecp
month
os
ecp
year
respect
cr
ecp
favour
predict
factor
os
median
os
reach
vs
month
grade
iv
agvhd
patient
advers
outcom
median
os
reach
vs
month
cgvhd
median
time
cgvhd
ecp
patient
moder
sever
cgvhd
princip
organ
involv
skin
mucosa
median
prior
line
orr
respons
moder
cgvhd
superior
best
organ
respons
observ
oral
mucosa
skin
median
followup
month
os
ecp
year
major
patient
could
stop
steroid
patient
reactiv
agvhd
cgvhd
ecp
major
respond
intensif
conclus
ecp
effect
safe
salvag
therapi
gvhd
especi
grade
iv
agvhd
moder
cgvhd
allow
stop
steroid
best
organ
respons
skin
agvhd
skin
mucosa
cgvhd
conflict
interest
noth
disclos
tabl
tabl
first
affili
hospit
zhejiang
univers
school
medicin
hangzhou
china
ningbo
hospit
ningbo
china
background
previou
studi
combin
anticytokin
therapi
basiliximab
etanercept
achiev
promis
respons
patient
steroidrefractori
acut
graftversushost
diseas
sragvhd
howev
vivo
immun
chang
follow
treatment
elucid
method
boy
relaps
acut
lymphocyt
leukemia
underw
hlahaploident
peripher
blood
stem
cell
transplant
mother
phase
day
develop
grade
agvhd
skin
gastrointestin
involv
refractori
steroid
treatment
thereaft
second
line
treatment
basiliximab
etanercept
prescrib
achiev
complet
respons
perform
immunophenotyp
interferon
gamma
ifn
product
cytotox
assay
peripher
blood
lymphocyt
flow
cytometri
combin
anticytokin
treatment
serum
cytokin
ifn
detect
elisa
result
detect
gradual
rise
nkt
cell
control
gvhd
str
test
show
expand
nkt
cell
donor
origin
cytokin
increas
time
agvhd
decreas
baselin
increas
week
reach
second
peak
week
treatment
simultan
found
nk
nktlike
cell
patient
produc
high
level
ifngamma
furthermor
nktlike
cell
show
prefer
prolifer
respons
analysi
show
expand
nkt
like
cell
predomin
posit
express
kir
neg
show
potent
cytotox
leukemia
cell
expans
nkt
cell
last
year
patient
leukemia
free
surviv
month
hsct
time
report
conclus
case
increas
serum
caus
cytokin
storm
gvhd
prioriti
nkt
cell
prolifer
respons
may
led
unus
expans
nkt
cell
immunecontract
caus
basiliximab
etanercept
clinic
cours
suggest
combin
anticytokin
treatment
may
reset
immun
system
innat
immun
cell
got
superior
rapid
expans
may
contribut
control
gvhd
leukemia
well
conflict
interest
author
conflict
financi
interest
massachusett
gener
hospit
center
transplant
scienc
boston
unit
state
harvard
medic
school
boston
unit
state
massachusett
gener
hospit
blood
marrow
transplant
program
boston
unit
state
danafarb
cancer
institut
hematolog
malign
boston
unit
state
massachusett
gener
hospit
hematologyoncolog
boston
unit
state
background
chronic
graftversushost
diseas
cgvhd
frequent
complic
allogen
hematopoiet
cell
transplant
hct
lead
caus
late
morbid
mortal
previous
believ
cell
mediat
diseas
recent
shown
involv
activ
b
cell
well
sever
inflammatori
mediat
cytokin
known
modul
tcell
prolifer
b
cell
fate
shown
play
role
system
inflamm
fibrosi
measur
plasma
concentr
year
posthct
correl
result
presenc
cgvhd
method
retrospect
studi
patient
underw
hct
initi
analysi
determin
level
healthi
control
vs
patient
underw
hct
subsequ
analyz
level
accord
develop
cgvhd
correl
plasma
level
sever
organ
involv
cgvhd
result
level
significantli
higher
hct
patient
compar
healthi
control
median
ngml
respect
figur
among
hct
patient
level
also
significantli
higher
patient
develop
cgvhd
n
compar
cgvhd
year
posthct
median
ngml
figur
use
cutoff
valu
ngml
use
clinic
predict
advers
event
chronic
heart
failur
patient
hct
patient
level
rang
patient
cutoff
rang
ngml
patient
cgvhd
year
posthct
experienc
moderatetosever
cgvhd
time
patient
cgvhd
year
experienc
moderateto
sever
cgvhd
analyz
organ
involv
clear
differ
observ
among
patient
diagnos
cgvhd
present
multipl
organ
involv
individu
organ
breakdown
includ
skin
oral
ocular
liver
gi
among
patient
cgvhd
experienc
multipl
organ
involv
individu
organ
involv
includ
skin
oral
ocular
liver
gi
conclus
result
demonstr
signific
differ
incid
sever
cgvhd
base
level
year
posthct
suggest
potenti
role
pathobiolog
cgvhd
investig
requir
determin
whether
serv
predict
biomark
cgvhd
patient
undergo
allogen
hct
conflict
interest
c
huang
noth
disclos
directli
relev
current
studi
relat
studi
involv
compani
support
econugen
inc
suppli
dietari
supplement
match
placebo
clinic
trial
examin
blockad
patient
osteoarthr
eliaz
therapeut
inc
provid
research
gift
examin
approach
remov
circul
anim
model
author
noth
disclos
univers
hospit
faculti
medicin
dentistri
palacki
univers
dpt
hematooncolog
olomouc
czech
republ
univers
hospit
faculti
medicin
dentistri
palacki
univers
dpt
biochemistri
olomouc
czech
republ
univers
hospit
faculti
medicin
dentistri
palacki
univers
dpt
molecular
patholog
olomouc
czech
republ
background
agvhd
still
repres
seriou
earli
complic
allogen
stem
cell
transplant
allosct
associ
signific
mortal
nevertheless
symptom
agvhd
particularli
gi
form
specif
sometim
clinic
distinguish
infect
resist
corticosteroid
cs
observ
case
therefor
search
infect
particularli
opportunist
viral
one
includ
investig
algorithm
use
biopsi
involv
gut
mucosa
method
adult
patient
allograft
variou
hematolog
malign
develop
possibl
gi
symptom
agvhd
median
rang
posttranspl
day
underw
biopsi
rectalcol
mucosa
follow
histolog
virolog
evalu
morpholog
histopatholog
grade
gut
agvhd
evalu
two
independ
pathologist
pcr
analysi
cmv
ebv
adv
dna
includ
complex
assess
overal
clinic
grade
agvhd
resist
immunosuppress
patient
treat
agvhd
includ
associ
number
virus
detect
gut
analyz
nonrelaps
nrm
posttranspl
overal
surviv
os
regard
immunosuppress
resist
viral
detect
gut
assess
well
result
histopatholog
sign
grade
ii
iii
iv
gut
agvhd
found
case
respect
skin
liver
system
agvhd
symptom
concomitantli
observ
recipi
gi
involv
respect
patient
develop
overal
clinic
manifest
agvhd
grade
iiiiv
recipi
also
suffer
fever
onset
suspect
agvhd
found
viral
dna
gut
mucosa
two
case
hand
cmv
ebv
dna
found
host
respect
seven
patient
gi
stage
iii
overal
grade
iiiiv
receiv
treatment
agvhd
symptom
complet
resolv
antivir
therapi
support
care
recipi
surviv
even
without
chronic
gvhd
cgvhd
median
rang
posttranspl
day
treat
patient
refractori
immunosuppress
administ
agvhd
observ
trend
higher
number
virus
gut
among
recipi
surprisingli
higher
nrm
refractori
patient
vs
result
wors
os
vs
howev
detect
differ
viral
dna
mucosa
associ
increas
risk
nrm
vs
well
lower
os
vs
conclus
virolog
evalu
viral
dna
detect
use
pcr
techniqu
biopsi
gi
mucosa
may
use
diagnost
manag
agvhd
particularli
refractori
one
conflict
interest
author
declar
conflict
interest
peke
univers
peopl
hospit
peke
univers
institut
hematolog
beij
key
laboratori
hematopoiet
stem
cell
transplant
collabor
innov
center
hematolog
beij
china
nanfang
hospit
southern
medic
univers
guangzhou
china
background
macrophag
import
popul
immun
cell
classifi
classic
produc
proinflammatori
cytokin
altern
produc
antiinflammatori
cytokin
unbalanc
polar
shown
play
critic
role
occurr
develop
diseas
cancer
diabet
therefor
repolar
may
novel
therapeut
option
treat
diseas
allogen
hematopoiet
stem
cell
transplant
allohsct
effect
treatment
malign
hematopoiet
diseas
granulocyt
colonystimul
factor
gcsf
induc
immun
toler
shown
play
critic
role
allohsct
gcsf
applic
healthi
donor
modul
balanc
cell
promot
regulatori
cell
differenti
well
affect
myeloidderiv
suppressor
cell
induct
cell
mention
import
factor
associ
occurr
acut
graftversushost
diseas
agvhd
haematologica
haematologica
eur
j
immunol
eur
j
immunol
j
hematol
impact
endogen
gcsf
induct
describ
mous
model
human
howev
littl
known
associ
subgroup
allograft
occurr
agvhd
patient
underw
allohsct
method
investig
effect
gcsf
percentag
bone
marrow
bm
peripher
blood
pb
healthi
donor
flow
cytometri
moreov
effect
gcsf
function
includ
diiacldl
uptak
dapi
bind
assay
migrat
assay
investig
vitro
subsequ
evalu
associ
ratio
occurr
agvhd
patient
underw
allohsct
result
found
gcsf
mobil
polar
pb
bm
found
decreas
gcsf
mobilizedbm
gbm
day
gcsf
gcsf
mobilizedpb
gpb
day
gcsf
compar
stablebm
sbm
stablepb
spb
pregcsf
administr
moreov
found
decreas
gpb
wherea
reciproc
increas
gbm
result
ratio
markedli
decreas
gpb
gbm
gcsf
mobil
bm
show
reduc
migrat
increas
phagocyt
activ
patient
receiv
higher
ratio
infus
exhibit
higher
incid
grade
iiiv
agvhd
conclus
find
suggest
unbalanc
polar
gcsf
mobil
character
decreas
ratio
proinflammatori
antiinflammatori
gpb
gbm
moreov
studi
demonstr
dysfunct
bm
gcsf
mobil
character
decreas
capac
migrat
increas
phagocyt
activ
meanwhil
cumul
incid
analys
suggest
patient
receiv
lower
ratio
infus
exhibit
lower
incid
grade
iiiv
agvhd
thu
specul
ratio
may
predict
occurr
grade
iiiv
agvhd
therefor
data
indic
gcsfinduc
immun
toler
may
mediat
polar
allohsct
therebi
gcsfmobil
potenti
novel
immunotherapeut
strategi
agvhd
futur
conflict
interest
noth
disclos
sultan
qaboo
univers
hospit
pharmaci
muscat
oman
sultan
qaboo
univers
hospit
hematolog
muscat
oman
sultan
qaboo
univers
pharmacolog
muscat
oman
sultan
qaboo
univers
hospit
child
health
muscat
oman
background
acut
graft
versu
host
diseas
agvhd
import
complic
post
hematopoiet
stem
cell
transplant
hsct
lead
morbid
mortal
intens
prepar
regimen
associ
risk
agvhd
albeit
mark
variabl
hypothes
glutathion
stransferas
gst
polymorph
affect
metabol
busulfan
bu
henc
may
impact
risk
agvhd
therefor
plan
assess
role
gst
polymorph
risk
agvhd
method
singl
center
retrospect
cohort
studi
adult
pediatr
patient
receiv
bu
prior
hsct
sultan
qaboo
univers
hospit
januari
octob
indic
includ
genotyp
gst
polymorph
done
pretranspl
patient
sampl
use
capillari
electrophoresi
insert
delet
dna
sequenc
thermal
cycl
sequenc
impact
gst
polymorph
agvhd
assess
use
test
multivari
regress
perform
agvhd
includ
predictor
variabl
p
valu
univari
test
standard
descript
analyt
statist
graph
creat
use
statist
softwar
stata
version
result
incid
rate
agvhd
among
studi
popul
skin
liver
gut
agvhd
grade
ii
iii
iv
agvhd
seen
patient
respect
combin
doubl
delet
increas
risk
agvhd
statist
signific
differ
incid
compar
singl
doubl
insert
p
multivari
regress
model
includ
condit
medic
use
combin
impact
remain
statist
signific
p
model
prepar
regimen
also
predictor
agvhd
patient
receiv
cyclobuflu
risk
agvhd
compar
patient
receiv
combin
buci
atg
bumel
atg
flubu
atg
p
incid
agvhd
differ
allel
significantli
differ
aa
ag
gg
p
incid
significantli
differ
test
polymorph
loci
p
respect
differ
incid
agvhd
differ
polymorph
group
also
statist
signific
p
respect
conclus
combin
doubl
delet
increas
risk
agvhd
patient
undergo
hsct
use
bubas
prepar
regimen
best
knowledg
first
report
associ
result
confirm
true
may
use
predict
agvhd
stratifi
patient
agvhd
prophylaxi
conflict
interest
conflict
interest
studi
support
intern
grant
colleg
medicin
health
scienc
sultan
qaboo
univers
abstract
previous
publish
kyungpook
nation
univers
hospit
hematologyoncolog
daegu
korea
republ
univers
toronto
comput
scienc
toronto
canada
chonnam
nation
univers
hwasun
hospit
hematologyoncolog
hwasun
korea
republ
chonnam
nation
univers
hwasun
hospit
genom
research
center
hematopoiet
diseas
hwasun
korea
republ
soon
chun
hyang
univers
bucheon
hospit
hematologyoncolog
bucheon
korea
republ
univers
toronto
molecular
genet
toronto
canada
princess
margaret
cancer
centr
medic
oncolog
hematolog
toronto
canada
background
integr
next
gener
sequenc
ng
treatment
decis
algorithm
patient
receiv
allogen
hematopoiet
cell
transplant
hct
demand
previou
work
demonstr
higher
mutat
allel
burden
variant
allel
frequenc
vaf
day
hct
correl
increas
risk
relaps
hr
p
poor
overal
surviv
os
hr
hct
patient
acut
myeloid
leukemia
aml
present
studi
evalu
whether
develop
chronic
gvhd
cgvhd
could
overcom
advers
prognost
impact
higher
mutat
burden
vaf
posthct
reduc
risk
relaps
improv
os
addit
also
incorpor
eln
risk
stratif
aml
analyz
whether
vaf
posthct
also
independ
prognost
eln
risk
group
method
current
studi
includ
aml
patient
receiv
hct
perform
ng
target
myeloid
gene
panel
agil
custom
probe
set
sampl
use
illumina
hiseq
sequenc
sampl
includ
bone
marrowperipher
blood
sampl
taken
diagnosi
prehct
posthct
day
well
sampl
longer
followup
tcell
fraction
donor
os
cumul
incid
relaps
cir
compar
accord
multipl
variabl
includ
age
acut
gvhd
cgvhd
well
eln
genet
risk
group
statist
analys
perform
use
r
statist
softwar
result
total
mutat
detect
sampl
taken
diagnosi
patient
median
mutat
per
patient
target
coverag
group
posthct
vafhigh
develop
cgvhd
lead
improv
outcom
respect
os
os
rate
group
without
cgvhd
respect
well
relaps
risk
cir
group
without
cgvhd
respect
similarli
group
vaf
posthct
vaflow
cir
lower
group
cgvhd
group
without
cgvhd
cir
vs
p
although
statist
differ
os
group
multivari
analysi
presenc
cgvhd
independ
prognost
factor
cir
vafhigh
hr
vaflow
group
hr
find
impli
therapeut
intervent
increas
chanc
cgvhd
develop
would
bring
therapeut
benefit
vafhigh
group
addit
somat
mutat
vaf
posthct
independ
eln
risk
group
excel
stratif
vaf
posthct
regard
os
relaps
well
replic
intermedi
advers
subgroup
eln
respect
conclus
day
monitor
mutat
burden
use
ng
consid
incorpor
futur
practic
posttranspl
manag
aml
patient
could
identifi
high
risk
relaps
patient
requir
preemptiv
intervent
includ
rapid
taper
immunosuppress
gvhd
prophylaxi
well
preemptiv
donor
lymphocyt
infus
attempt
case
high
vaf
group
conflict
interest
conflict
interest
disclos
hospit
hematopoiet
stem
cell
transplant
unit
hematolog
depart
institut
oncolog
hematolog
barcelona
spain
institut
josep
carrera
barcelona
spain
institut
pi
sunyer
idibap
barcelona
spain
background
safeti
efficaci
highdos
ptci
combin
tacrolimu
mycophenol
mofetil
previous
demonstr
nonmyeloabl
condit
transplant
cellreplet
bone
marrow
haploident
relat
donor
also
found
effect
sole
prophylaxi
gvhd
hlamatch
bone
marrow
transplant
howev
littl
inform
regard
efficaci
safeti
ptci
use
context
match
unrel
donor
mud
andor
peripher
blood
stem
cell
sourc
report
experi
use
ptci
plu
tacrolimu
gvhd
prophylaxi
mud
hlaident
allogen
hematopoiet
stem
cell
transplant
mud
allohsct
method
nineteen
consecut
mud
allohsct
recipi
includ
median
age
rang
unrel
donor
select
perform
accord
standard
criteria
includ
high
resolut
type
allel
hlaa
b
cw
result
patient
hctci
acut
leukemia
complet
remiss
time
transplant
diseas
risk
index
dri
intermedi
high
veryhigh
fifteen
patient
receiv
reduc
intens
condit
regimen
fludarabinebusulfan
patient
peripher
blood
stem
cell
one
primari
graftfailur
observ
median
time
neutrophil
platelet
recoveri
day
rang
day
respect
sixtyf
percent
patient
full
donor
chimer
month
allohsct
case
hemorrhag
cystiti
observ
mild
three
patient
develop
proven
probabl
invas
pulmonari
aspergillosi
sever
bacteri
infect
three
patient
risk
develop
acut
grade
iiiv
gvhd
grade
ii
achiev
complet
remiss
system
corticosteroid
treatment
one
patient
develop
chronic
gvhd
three
patient
die
without
diseas
relapseprogress
infect
pulmonari
complic
two
patient
relaps
high
high
dri
one
median
followup
surviv
patient
month
rang
overal
surviv
progressionfre
surviv
respect
conclus
result
suggest
mud
allohsct
highrisk
popul
patient
advanc
age
high
hctci
use
ptci
plu
tacrolimu
gvhd
prophylaxi
peripher
blood
graft
safe
associ
low
incid
gvhd
relaps
encourag
surviv
outcom
prospect
studi
includ
higher
number
patient
longer
followup
need
valid
find
conflict
interest
noth
disclos
medic
univers
vienna
depart
dermatolog
vienna
austria
medic
univers
vienna
depart
intern
medicin
bone
marrow
transplant
unit
vienna
austria
background
skin
reaction
remain
one
common
manifest
acut
chronic
graft
versu
host
diseas
gvhd
allogen
hsct
recipi
donor
cell
shown
respons
graftversusleukemia
effect
thu
regard
major
player
graftversushost
reaction
littl
known
potenti
role
host
immun
cell
subset
gvhd
tissueresid
memori
cell
trm
recent
describ
mice
uniqu
subset
nonrecircul
radioresist
cell
variou
organ
method
determin
presenc
resili
trm
human
tissu
track
peripher
blood
skinderiv
cell
patient
process
hsct
one
year
transfer
donor
stem
cell
serial
sampl
taken
nonlesion
skin
time
point
hsct
day
analyz
presenc
cell
subtyp
use
lymphocyt
home
molecul
resid
marker
isol
cell
evalu
prolif
capac
upon
cell
receptor
tcr
stimul
skin
section
patient
transplant
sex
hlaa
mismatch
donor
cell
assess
chimer
fluoresc
situ
hybrid
xy
chromosom
hla
phenotyp
respect
section
process
use
autom
imag
acquisit
analysi
softwar
result
upon
myeloabl
treatment
recircul
cell
declin
skin
peripher
blood
subset
dermal
cell
express
tissu
resid
marker
remain
stabl
even
hsct
moreov
skinresid
cell
surviv
condit
treatment
display
high
prolif
potenti
tcr
stimul
compar
cell
isol
skin
nontranspl
donor
strikingli
chimer
analysi
reveal
unlik
peripher
blood
dermal
cell
recipi
coexist
donor
cell
constitut
dermal
cell
month
engraft
subdivid
patient
accord
develop
acut
gvhd
later
time
point
trm
enrich
skin
earli
time
point
hsct
patient
later
develop
acut
gvhd
compar
sign
gvhd
conclus
identifi
longliv
remark
larg
popul
hostderiv
dermal
cell
may
play
far
unappreci
role
gvhd
best
knowledg
first
definit
proof
trm
human
tissu
implic
infecti
chronicinflammatori
diseas
conflict
interest
j
strobl
recipi
doc
fellowship
austrian
academi
scienc
g
stari
support
austrian
feder
reserv
bank
arbeitsgemeinschaft
dermatologisch
forschung
author
noth
disclos
hospit
german
tria
pujol
institut
doncologia
institut
de
recerca
contra
la
josep
carrera
clinic
hematolog
badalona
spain
clinic
hematolog
badalona
spain
background
combin
calcineurin
inhibitor
cai
short
cours
methotrex
mtx
common
regimen
gvhd
prophylaxi
studi
directli
compar
administr
versu
dose
mtx
object
studi
evalu
impact
dose
mtx
omiss
outcom
method
januari
decemb
first
allogen
sct
perform
institut
patient
pt
plan
receiv
cai
short
cours
mtx
gvhd
prophylaxi
pt
avail
final
analysi
result
patient
characterist
tabl
seventyseven
pt
receiv
plan
mtx
dose
receiv
dose
per
protocol
complet
plan
dose
due
sever
mucos
mucos
plu
hyperbilirubinemia
hso
hyperbilirubinemia
atg
administ
gvhd
prophylaxi
pt
complet
mtx
dose
receiv
mtx
dose
four
mtx
dose
frequent
administ
previou
period
p
two
pt
receiv
mtx
dose
show
primari
graft
failur
ys
os
probabl
pt
receiv
mtx
dose
ci
ci
median
followup
ys
ys
respect
nrm
similar
patient
complet
plan
dose
receiv
differ
engraft
relaps
incid
nrm
acut
gvhd
develop
sever
chronic
gvhd
ci
ci
pt
receiv
mtx
dose
subgroup
pt
receiv
atg
pt
dose
mtx
also
associ
lower
probabl
develop
sever
chronic
gvhd
ci
vs
ci
moreov
probabl
composit
endpoint
gvhdfreerelapsefre
surviv
ci
ci
pt
receiv
versu
dose
mtx
conclus
administr
dose
mtx
associ
cai
gvhd
prophylaxi
convent
allogen
sct
associ
wors
os
nrm
relat
better
grf
surviv
clinic
trial
registri
appli
conflict
interest
author
declar
conflict
interest
fund
fondo
de
investigacion
sanitaria
rticc
instituto
carlo
iii
cerca
program
generalitat
de
catalunya
la
caixa
foundat
rticcinstituto
carlo
iii
tabl
demograph
diseas
sct
characterist
abstract
previous
publish
nation
research
center
hematolog
bmt
depart
moscow
russian
feder
background
report
impact
methotrex
acut
gvhd
rate
allohsct
match
unrel
donor
due
differ
graft
sourc
method
studi
analysi
includ
engraft
patient
male
femal
median
age
year
rang
underw
allohsct
match
unrel
donor
patient
hematolog
malign
aml
lpd
md
cll
cml
cmml
patient
underw
mac
condit
regimen
patient
ric
patient
receiv
standard
gvhd
prophylaxi
hors
atg
day
total
dose
mgkg
cyclosporin
csa
day
daili
dose
mgkg
mycophenol
mofetil
mmf
day
total
daili
dose
mg
without
methotrex
mtx
day
studi
group
form
base
type
graft
sourc
bone
marrow
pbsc
group
without
mtx
match
age
diseas
phase
number
infus
cell
exact
test
use
tabl
kaplanmei
analysi
wilcoxon
test
use
surviv
analysi
group
comparison
pvalu
less
consid
signific
result
accord
data
cumul
incid
agvhd
grade
iiiv
bone
marrow
recipi
vs
without
mtx
respect
signific
varianc
case
pbsc
graft
sourc
use
mtx
reduc
agvhd
cumul
incid
conclus
show
use
methotrex
allohsct
match
unrel
donor
combin
atg
csa
mmf
relev
pbsc
recipi
lead
signific
decreas
agvhd
incid
conflict
interest
noth
disclos
geneva
univers
hospit
oncolog
depart
divis
hematolog
geneva
switzerland
background
chronic
graftversushost
diseas
cgvhd
seriou
complic
allogen
hematopoiet
stem
cell
transplant
hsct
associ
signific
morbid
mortal
surviv
complet
partial
respons
previou
secondari
system
treatment
recurr
malign
year
initi
system
therapi
cgvhd
recent
report
composit
endpoint
associ
clinic
benefit
martin
pj
et
al
blood
present
studi
investig
effect
partial
tcell
deplet
ptcd
strategi
gvhd
prophylaxi
endpoint
order
evalu
impact
clinic
evolut
cgvhd
method
perform
retrospect
analysi
consecut
patient
diagnos
system
therapyrequir
cgvhd
center
undergo
allogen
hsct
hematolog
diseas
patient
receiv
ptcd
graft
consist
vitro
alemtuzumab
incub
infus
follow
day
addback
donor
cell
patient
receiv
nontcd
graft
donor
lymphocyt
infus
dli
provid
absenc
gvhd
three
month
patient
receiv
ptcd
graft
reduc
intens
condit
need
patient
transplant
either
ptcd
nontcd
graft
failur
free
surviv
ff
defin
event
death
diseas
relaps
secondari
system
treatment
respons
year
assign
complet
respons
cr
partial
respons
pr
stabl
diseas
sd
progress
diseas
pd
success
defin
ff
cr
pr
year
instaur
initi
treatment
cgvhd
diagnosi
respons
treatment
retrospect
determin
accord
nih
consensu
criteria
respons
rate
compar
use
chisquar
test
kaplanmei
estim
employ
determin
probabl
overal
surviv
os
ff
sinc
cgvhd
diagnosi
cumul
incid
system
treatment
cessat
calcul
relaps
death
defin
competit
event
compar
use
gray
test
result
median
age
year
rang
year
patient
hlamatch
relat
unrel
donor
male
femal
donor
median
time
hsct
system
therapyrequir
cgvhd
month
rang
patient
present
postdli
cgvhd
sever
cgvhd
endpoint
success
observ
patient
patient
achiev
ff
ptcd
associ
significantli
higher
endpoint
success
achiev
compar
nontcd
transplant
figur
accordingli
patient
receiv
ptcd
higher
cumul
incid
system
treatment
interrupt
ci
compar
patient
receiv
nontcd
graft
ci
figur
convers
effect
ptcd
observ
os
ptcd
ci
nontcd
ci
ff
ptcd
ci
nontcd
ci
conclus
ptcd
appear
improv
endpoint
success
achiev
system
therapyrequir
cgvhd
result
earlier
cessat
treatment
without
affect
os
result
suggest
ptcd
could
amelior
clinic
evolut
cgvhd
improv
patient
qualiti
life
conflict
interest
author
noth
disclos
dana
farber
institut
divis
hematolog
malign
boston
unit
state
instituto
de
medicina
molecular
jlacerda
lab
lisboa
portug
hospit
de
santa
maria
de
hematologia
e
de
medula
lisboa
portug
harvard
medic
school
boston
unit
state
faculdad
de
medicina
da
universidad
de
lisboa
lisboa
portug
background
role
naiv
tcell
set
chronic
graftversushost
diseas
cgvhd
allogen
hematopoiet
stem
cell
transplant
controversi
within
tcell
recent
studi
identifi
small
subset
cell
repres
memori
stem
cell
scm
despit
express
marker
scm
less
differenti
memori
cell
antigenspecif
distinguish
selfrenew
capac
superior
tcell
engraft
allogen
transplant
model
studi
examin
posttranspl
reconstitut
tcell
express
marker
lineag
relationship
tcell
subset
like
involv
cgvhd
method
period
prospect
monitor
patient
underw
allogen
hematopoiet
stem
cell
transplant
myeloabl
condit
without
tcell
deplet
posttranspl
period
recoveri
scm
true
tn
cell
studi
within
regulatori
cell
treg
convent
tcell
tcon
tcell
correl
develop
cgvhd
understand
immunechang
occur
cgvhd
compar
three
group
sampl
sampl
collect
cgvhd
diagnos
sampl
collect
cgvhd
sampl
nogvhdcontrol
group
collect
median
time
previou
group
figur
result
median
followup
day
patient
develop
cgvhd
median
time
onset
cgvhd
day
absolut
count
n
percentag
tn
scm
regulatori
tcell
treg
cgvhd
cohort
significantli
lower
earli
time
point
tn
tn
n
scm
n
signific
differ
observ
tcon
compart
within
tcell
n
scm
significantli
lower
posttranspl
cgvhd
patient
contrast
n
effector
memori
em
significantli
higher
n
conclus
cohort
immun
compart
patient
develop
cgvhd
distinguish
earli
timepoint
onset
diseas
reduc
recoveri
regulatori
tn
scm
subset
predomin
em
scm
tcell
although
lineag
relationship
within
tcell
subset
difficult
assign
recent
studi
suggest
differenti
pathway
scm
em
cell
may
explain
observ
increas
em
scm
tcell
cohort
increas
differenti
scm
em
cell
like
reflect
uncontrol
effector
respons
alloantigen
overal
data
suggest
earli
imbal
regulatori
effector
subset
influenc
subsequ
develop
cgvhd
conflict
interest
author
declar
compet
financi
interest
abstract
previous
publish
depart
hematolog
stem
cell
transplant
king
colleg
hospit
london
unit
kingdom
depart
medicin
stanford
univers
hospit
stanford
ca
unit
state
depart
hematolog
stem
cell
transplant
vanderbilt
univers
nashvil
tn
unit
state
background
antithymocyt
globulin
atg
antibodi
alemtuzumab
use
prophylaxi
graftversushost
diseas
gvhd
unrel
donor
allograft
urd
leukaemia
dose
regimen
empir
weightbas
furthermor
target
agent
recipi
cell
postcytotox
chemotherapi
function
recipi
weight
recent
shown
recipi
peripher
blood
absolut
lymphocyt
count
alc
day
atg
administr
interact
dose
atg
administ
predict
transplant
outcom
kennedi
et
al
soiffer
et
al
hypothes
similar
phenomenon
may
occur
use
alemtuzumab
compar
outcom
atg
vs
alemtuzumab
base
regimen
method
retrospect
analyz
patient
patient
alemtuzumab
gvhd
prophylaxi
undergo
unrel
allogen
hematopoiet
cell
transplant
leukaemia
myelodysplast
syndrom
md
compar
similar
patient
receiv
atg
anoth
centr
result
patient
receiv
alemtuzumab
patient
receiv
wherea
atg
group
patient
receiv
patient
receiv
mgkg
patient
receiv
dose
respect
median
followup
month
alemtuzumab
month
atg
group
compar
atg
group
alemtuzumab
group
significantli
number
patient
receiv
mismatch
donor
graft
vs
patient
intermedi
diseas
risk
index
higher
exposur
myeloabl
regimen
vs
overal
surviv
os
progress
free
surviv
pf
relaps
year
nrm
nonrelaps
mortal
alemtuzumab
group
respect
compar
atg
group
respect
except
earli
relaps
year
vs
atg
alemtuzumab
signific
atg
group
adjust
baselin
covari
dispar
incid
sever
grade
acut
chronic
graft
vs
host
diseas
agvhdcgvhd
alemtuzumab
atg
mildmoder
agvhd
cgvhd
alemtuzumab
atg
respect
sever
chronic
gvhd
lower
alemtuzumab
arm
within
alemtuzumab
group
chronic
mildmoderatgvhd
significantli
lower
lower
dose
multivari
analysi
peripher
blood
alc
day
atg
administr
total
amount
atg
interact
predict
os
hazard
ratio
p
howev
alemtuzumab
group
absolut
lymphocyt
count
first
dose
irrespect
dose
day
alemtuzumab
interact
significantli
os
pf
respect
univari
well
multivari
analysi
conclus
conclud
similar
atg
peripher
blood
alc
interact
interact
alemtuzumab
peripher
blood
alc
find
prospect
valid
allow
optim
alemtuzumab
atg
dose
base
patient
specif
alc
studi
explain
mechanist
detail
clinic
find
need
undertaken
refin
strategi
acut
gvhd
prophylaxi
use
atg
alemtuzumab
overal
transplant
outcom
similar
atg
alemtuzumab
base
urd
transplant
clinic
trial
registri
conflict
interest
author
contribut
equal
jagasia
k
raj
correspond
author
hospit
universitario
de
salamancaibs
hematolog
salamanca
spain
hospit
de
octubr
hematolog
madrid
spain
hospit
marqu
de
valdecilla
hematolog
santand
spain
hospit
carlo
haya
hematolog
malaga
spain
background
use
hlahaploident
transplant
haplosct
posttransplant
cyclophosphamid
ptci
becom
frequent
therapeut
approach
patient
without
avail
hlamatch
relat
unrel
donor
accord
sever
report
incid
acut
gvhd
similar
even
inferior
observ
hlamatch
allogen
hematopoiet
stem
cell
transplant
current
limit
data
regard
chronic
gvhd
set
addit
impact
haploident
donor
graft
sourc
along
condit
regimen
remain
unknown
object
purpos
studi
analyz
incid
risk
factor
treatment
respons
chronic
gvhd
patient
undergo
haplosct
ptci
method
conduct
multicent
retrospect
studi
patient
four
spanish
center
receiv
haplosct
decemb
septemb
result
patient
transplant
characterist
detail
tabl
median
followup
time
month
median
time
neutrophil
engraft
day
platelet
engraft
day
primari
graft
failur
complet
bone
marrow
chimer
achiev
median
day
transplant
relat
mortal
trm
day
one
year
respect
cumul
incid
ci
grade
iiiv
acut
gvhd
grade
iiiiv
case
incid
chronic
gvhd
two
year
mild
moder
sever
univari
analysi
observ
mieloabl
condit
associ
chronic
gvhd
p
howev
multivari
analysi
statist
signific
characterist
relat
chronic
gvhd
shown
tabl
median
time
chronic
gvhd
onset
day
progress
overlap
patient
onset
chronic
gvhd
patient
immunosuppress
therapi
henc
develop
chronic
gvhd
mayb
relat
either
reduc
stop
patient
median
treatment
line
chronic
gvhd
thu
overal
respons
rate
orr
ci
relaps
one
year
overal
composit
end
point
one
two
year
respect
overal
surviv
os
one
two
year
respect
conclus
haplosct
promis
therapeut
approach
low
rate
gvhd
chronic
gvhd
predominantli
mild
show
good
respons
first
line
treatment
data
show
risk
factor
may
predispos
develop
chronic
gvhd
conflict
interest
author
relev
conflict
interest
disclos
tabl
tabl
patient
transplant
characterist
rigshospitalet
depart
hematolog
copenhagen
denmark
background
recent
research
discov
gut
microbiota
play
major
role
develop
acut
graftversushost
diseas
agvhd
yet
studi
impact
gut
decontamin
prior
allogen
hematopoiet
stem
cell
transplant
allohsct
risk
agvhd
limit
conflict
method
septemb
rigshospitalet
chang
prophylact
measur
infect
patient
undergo
allohsct
includ
discontinu
use
oral
gut
decontamin
cefuroxim
tobramycin
nystatin
prior
transplant
includ
retrospect
cohort
consecut
patient
underw
first
allohsct
rigshospitalet
transplant
chang
jan
aug
transplant
chang
sep
apr
studi
within
first
day
transplant
develop
agvhd
grade
iiiv
gastrointestin
agvhd
stage
iiiv
nonrelaps
mortal
nrm
respect
patient
receiv
myeloabl
condit
gvhd
prophylaxi
consist
ciclosporin
methotrex
multivari
cox
proport
hazard
model
censor
subject
death
relaps
employ
estim
hazard
ratio
hr
priori
defin
covari
age
stem
cell
sourc
femaledonortomalerecipi
donor
relat
plu
match
use
total
bodi
irradi
use
antithymocyt
globulin
result
gut
decontamin
nondecontamin
patient
compar
regard
age
median
year
respect
sex
femal
respect
differ
regard
diagnosi
stem
cell
sourc
peripher
blood
respect
donor
relat
match
relat
donor
respect
agvhd
grade
iiiv
occur
confid
interv
ci
gut
decontamin
patient
ci
nondecontamin
patient
figur
gastrointestin
agvhd
stage
iiiv
occur
ci
gut
decontamin
patient
ci
nondecontamin
patient
nonrelaps
mortal
day
transplant
ci
gut
decontamin
patient
ci
nondecontamin
patient
adjust
multivari
analysi
receipt
gut
decontamin
prior
transplant
significantli
associ
increas
hazard
agvhd
grade
iiiv
hr
ci
howev
statist
signific
increas
hazard
gastrointestin
agvhd
stage
iiiv
hr
ci
nonrelaps
mortal
hr
ci
conclus
patient
receiv
oral
gut
decontamin
prior
allohsct
adjust
potenti
confound
increas
risk
develop
agvhd
within
first
day
transplant
also
trend
adjust
analysi
toward
patient
also
increas
risk
gastrointestin
agvhd
nonrelaps
mortal
associ
reach
statist
signific
result
support
idea
disrupt
gut
microbiota
prior
transplant
worsen
risk
develop
agvhd
conflict
interest
none
author
anyth
disclos
king
hussein
cancer
center
cell
therapi
appli
genom
amman
jordan
univers
regensburg
depart
hematolog
oncolog
regensburg
germani
background
laboratori
test
predict
risk
graftversushost
diseas
gvhd
monitor
activ
allogen
hematopoiet
cellular
transplant
hsct
describ
immunolog
assay
may
help
detect
gvhd
use
interferongamma
ifng
product
use
realtim
pcr
rtpcr
assay
method
obtain
peripher
blood
mononuclear
cell
pbmnc
blood
sampl
patient
undergo
allogen
hcst
sampl
assess
ifng
product
use
rtpcr
assay
differ
time
point
hsct
measur
ifng
product
gvhd
biomark
use
mix
lymphocyt
reaction
mlr
protocol
pbmnc
patient
challeng
vitro
recipi
cell
obtain
hsct
bt
autolog
control
repres
donor
cell
onesid
mlr
hour
mlr
ifng
product
measur
use
rtpcr
ifng
fold
chang
use
unit
express
product
two
fold
ifng
product
consid
signific
increas
patient
group
accord
time
point
depend
presenc
gvhd
immunosuppress
statu
time
blood
collect
never
gvhd
cyclosporin
csa
never
gvhd
immunosuppress
csa
corticosteroid
onset
gvhd
csa
corticosteroid
gvhd
treatment
corticosteroid
gvhd
high
dose
corticosteroid
result
patient
neither
gvhd
immunosuppress
show
basal
ifng
product
patient
pbmnc
challeng
bt
respect
ifng
product
increas
bt
set
gvhd
low
immunosuppress
respect
onset
gvhd
without
addit
immunosuppress
intervent
ifng
product
significantli
higher
bt
vs
compar
gvhd
immunosuppress
p
well
gvhd
treatment
corticosteroid
p
even
gvhd
high
dose
corticosteroid
p
overal
ifng
product
recipi
bt
sampl
found
higher
control
sampl
confirm
specif
detect
assay
conclus
find
suggest
recipi
pbmnc
produc
signific
amount
infg
indic
activ
gvhd
challeng
recipi
hlamatch
cell
mimick
vivo
sensit
stimulu
immunosuppress
corticosteroid
suppress
ifng
respons
must
consid
surrog
assay
gvhd
respons
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
hannov
medic
school
hematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
helmholtz
centr
infect
research
braunschweig
germani
hannov
medic
school
core
facil
qualiti
manag
health
technolog
assess
transplant
hannov
germani
background
gastrointestin
tract
popul
highli
divers
microbi
ecosystem
microbiota
potent
modul
local
inflamm
system
immun
respons
howev
medic
treatment
broadspectrum
antibiot
treatment
often
given
cours
allogen
hematopoiet
stem
cell
transplant
allohsct
influenc
divers
microbiota
therebi
impair
host
immun
relationship
chang
divers
gut
microbiota
occurr
major
inflammatori
well
immun
relat
complic
especi
acut
gvhd
allohsct
larg
unknown
method
examin
longitudin
chang
intestin
microbi
divers
patient
undergo
allohsct
relationship
subsequ
complic
especi
acut
gvhd
prospect
clinic
trial
collect
fecal
specimen
patient
admit
allohsct
weekli
hsct
rrna
gene
sequenc
use
character
microbiota
microbi
divers
quantifi
use
shannon
index
moreov
collect
approxim
differ
clinic
variabl
includ
condit
regimen
antibiot
use
nutrit
investig
impact
gut
microbiota
final
comparison
differ
group
median
rang
mean
standard
deviat
calcul
statist
analysi
perform
use
wilcoxon
ttest
result
allohsct
accompani
treatment
antibiot
treatment
condit
therapi
lead
mark
decreas
intestin
microbi
divers
pronounc
two
week
hsct
reduct
sampl
hsct
sampl
two
week
hsct
contrari
expect
found
differ
divers
microbiota
acut
gvhd
patient
nonacut
gvhd
patient
onset
clinic
symptom
vs
two
week
hsct
howev
patient
develop
acut
gvhd
show
delay
recoveri
microbiota
comparison
patient
without
acut
gvhd
especi
week
hsct
signific
differ
divers
group
vs
among
patient
acut
gvhd
differ
patient
receiv
treatment
corticosteroid
mean
sd
vs
furthermor
detail
analys
show
around
time
clinic
manifest
gvhd
median
week
hsct
lower
divers
patient
suffer
high
grade
gvhd
compar
suffer
low
grade
gvhd
mean
sd
vs
sd
week
hsct
p
conclus
allohsct
observ
drastic
decreas
intestin
microbi
divers
patient
abl
distinguish
patient
subsequ
develop
acut
gvhd
howev
high
grade
gvhd
reflect
lower
divers
therefor
microbiom
divers
cours
gvhd
might
serv
potenti
biomark
gvhd
outcom
treatment
respons
analys
larger
number
case
need
confirm
result
addit
studi
specif
bacteri
speci
might
deliv
inform
conflict
interest
author
conflict
interest
disclos
russian
children
research
hospit
moscow
russian
feder
dmitri
rogachev
nation
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
sever
gvhd
treatment
alway
face
seri
clinic
challeng
sever
infect
organ
toxic
graft
hypofunct
hypofunct
lead
poor
prognosi
thu
graft
function
recoveri
crucial
success
outcom
treatment
mesenchym
stem
cell
msc
intraven
applic
togeth
combin
immunosuppress
therapi
wide
use
method
treatment
sever
gvhd
experi
intraoss
inject
msc
limit
aim
investig
effect
safeti
intraoss
inject
msc
method
seven
patient
refractori
cytopenia
result
sever
gvhd
iiiv
gr
includ
age
median
yo
f
rate
two
patient
acut
lymphoblast
leukemia
aplast
anemia
hsct
type
mud
mismatch
mud
mrd
graft
type
bm
pbsc
msc
inject
help
intraoss
needl
directli
iliac
crest
msc
dose
median
millionskg
median
day
first
inject
result
patient
includ
studi
restor
graft
function
month
graft
function
improv
correl
gvhd
symptom
reduct
median
number
inject
recov
graft
function
complic
found
median
followup
month
patient
aliv
diseas
free
conclus
thu
intraoss
inject
msc
safe
welltoler
method
restor
graft
function
reduc
gvhd
method
could
feasibl
option
patient
complic
cours
gvhd
due
absenc
toxic
complic
futur
studi
could
organ
conflict
interest
conflict
interest
tata
memori
centr
actrec
bone
marrow
transplant
unit
navi
mumbai
india
background
musculoskelet
gvhd
chronic
diseas
vari
manifest
fasciiti
scleroderma
myositi
joint
stiff
arthriti
similar
autoimmun
disord
crosstalk
tcell
b
cell
macrophag
fibroblast
releas
variou
cytokin
system
steroid
cyclosporin
tacrolimu
sirolimu
mycophenolatemofetil
etanarcept
imatinib
use
far
respons
signific
treatment
relat
toxic
cost
leflunomid
antit
cell
prolif
action
inexpens
minim
advers
effect
steroid
spare
agent
use
diseas
modifi
drug
rheumatoid
arthriti
leflunomid
shown
effect
gvhd
anim
model
use
clinic
unknown
method
leflunomid
use
singl
agent
patient
chronic
musculoskelet
gvhd
march
octob
dose
use
mg
daili
day
follow
mg
daili
sever
assess
nation
institut
health
nih
joint
score
photograph
rang
motion
prom
score
baselin
month
monthli
thereaft
respons
defin
improv
joint
symptom
rang
motion
prom
score
rang
best
score
nih
score
rang
best
score
baselin
mri
specif
site
involv
done
patient
time
diagnosi
gvhd
result
five
patient
set
receiv
leflunomid
median
age
year
rang
male
femal
one
patient
mix
phenotyp
acut
leukemia
mpal
primari
myelofibrosi
pmf
ph
cml
blast
crisi
mdsaml
three
patient
fulli
match
sibl
unrel
donor
haploident
donor
graft
respect
gcsf
mobilis
pbsc
graft
condit
regimen
use
fludarabin
melphalan
treosulphan
gy
tbi
cytbi
rabbit
atg
gvhd
prophylax
includ
cyclosporin
tacrolimu
methotrex
mycophenol
mofetil
posttranspl
cyclophosphamid
musculoskelet
gvhd
cours
patient
shown
tabl
median
durat
onset
musculoskelet
gvhd
median
baselin
prom
score
nih
score
respect
median
time
achiev
best
respons
day
median
prom
nih
score
best
respons
none
patient
receiv
adjuv
therapi
toxic
due
leflunomid
conclus
first
case
seri
show
efficaci
leflunomid
set
musculoskelet
gvhd
knowledg
larg
prospect
studi
set
warrant
conflict
interest
none
author
anyth
disclos
tabl
cours
musculoskelet
gvhd
leflunomid
univers
gothenburg
section
hematolog
gothenburg
sweden
sahlgrenska
univers
hospit
section
hematolog
gothenburg
sweden
univers
gothenburg
depart
hematolog
gothenburg
sweden
lund
univers
depart
cancer
epidemiolog
lund
sweden
background
tcell
deplet
tcd
antithymocyt
globulin
atg
alemtuzumab
decreas
risk
chronic
gvhd
cgvhd
allosct
unrel
donor
urd
retrospect
studi
compar
outcom
urdtcd
match
sibl
donor
msdnotcd
method
patient
allograft
sahlgrenska
univers
hospit
patient
aplast
anemia
unconvent
transplant
procedur
exclud
remain
patient
median
age
male
msd
urd
hla
condit
ric
mac
bm
pbsc
diagnos
amlal
mdsmpncml
cllhdnhlmm
immunosuppress
includ
ciclosporina
csa
methotrex
tcd
urd
thymoglobulin
mgkg
antilymphocyt
globulin
mgkg
alemtuzumab
chronic
gvhd
grade
nih
month
allosct
result
analysi
followup
live
patient
median
month
urd
patient
older
vs
year
younger
donor
vs
year
p
wherea
risk
categori
bmpbsc
ricmac
similar
standard
methotrex
dose
mgsqm
use
urd
patient
wherea
msd
patient
receiv
mgkg
median
csa
trough
level
day
higher
urd
patient
vs
p
os
yr
km
estim
msd
urd
group
respect
followup
cumul
incid
caus
death
msd
urd
group
relaps
vs
gvhd
vs
infect
vs
vs
os
lf
superior
msd
group
log
rank
test
nrm
relaps
incid
higher
mud
vs
p
vs
respect
urd
patient
ebv
infect
vs
incid
fungal
cmv
infect
similar
grade
iiiv
acut
gvhd
msd
vs
moderatesever
cgvhd
month
p
msd
urd
patient
respect
glucocorticoid
treatment
month
ongo
msd
vs
p
similar
signific
pattern
month
larg
differ
earli
month
mortal
found
msd
urd
caus
death
urd
relaps
infect
gvhdrelat
infect
multivari
cox
analysi
adjust
risk
ricmac
diagnosi
acut
leukemia
vs
csa
higher
mortal
rate
urd
patient
first
year
remain
ci
conclus
studi
preval
cgvhd
higher
msd
patient
howev
urd
patient
significantli
wors
term
os
lf
nrm
seemingli
due
mortal
first
year
transplant
specul
combin
tcd
methotrex
higher
csa
level
urd
patient
may
increas
risk
relaps
lethal
infect
albeit
influenc
confound
factor
comorbid
previou
treatment
clear
result
merit
studi
optim
tcd
dose
conflict
interest
conflict
interest
abstract
previous
publish
univers
pediatr
hematologyoncolog
pediatr
bmt
unit
istanbul
turkey
background
graft
versu
host
diseas
gvhd
major
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
unrel
donor
antithymocyt
globulin
atg
commonli
use
prophylaxi
gvhd
studi
accord
optimum
dose
atg
especi
pediatr
patient
limit
method
therefor
analyz
retrospect
studi
patient
receiv
atgfreseniu
atgf
gvhd
prophylaxi
match
unrel
donor
mud
hsct
total
patient
identifi
median
age
year
rang
median
durat
followup
month
rang
month
seventi
seven
patient
receiv
myeloabl
regimen
patient
receiv
reduc
intens
condit
regimen
atgfreseniu
given
patient
group
total
dose
mgkg
mgkg
day
patient
group
total
dose
mgkg
mgkg
day
gvhd
prophylaxi
consist
cyclosporin
csa
patient
csamethotrex
mtx
patient
csamycophenol
mofetil
mmf
patient
csammfmtx
patient
result
acut
grade
iii
grade
iiiiv
gvhd
observ
patient
group
patient
group
patient
sever
acut
gvhd
iii
incid
mildmoder
chronic
gvhd
sever
chronic
gvhd
group
group
group
group
respect
incid
acut
chronic
gvhd
statist
differ
two
group
sixti
four
patient
one
viral
infect
patient
one
viral
infect
cumul
incid
transplant
relat
mortal
trm
whole
patient
day
probabl
overal
surviv
os
day
trm
os
differ
two
group
conclus
addit
lowdos
atg
mgkg
mgkg
gvhd
prophylaxi
pediatr
patient
receiv
mud
hsct
result
increas
incid
acut
grade
iii
grade
iiiiv
gvhd
comparison
pediatr
studi
higher
dose
atg
mgkg
incid
chronic
gvhd
similar
studi
atg
pharmacokinet
pharmacodynam
ongo
effect
lowdos
patientspecif
dose
atg
assess
prospect
clinic
trial
conflict
interest
none
tohoku
univers
hospit
depart
hematolog
rheumatolog
sendai
japan
background
although
combin
tacrolimu
tac
shortterm
methotrex
mtx
one
standard
gvhd
prophylaxi
unclear
whether
use
cord
blood
transplant
cbt
appropri
method
retrospect
analyz
outcom
patient
hematolog
malign
age
year
underw
singleunit
cbt
tacmtx
prevent
gvhd
tac
administ
day
mgkg
continu
intraven
target
concentr
ngml
mtx
intraven
day
follow
day
result
total
first
cbt
aml
cmlbc
md
mpd
lymphoid
malign
includ
fortyeight
patient
receiv
cbt
first
second
cr
standard
risk
sr
patient
third
cr
nonremiss
highrisk
hr
median
age
patient
year
rang
myeloabl
condit
mac
cyclophosphamid
cy
plu
tbi
cytarabin
reducedintens
condit
ric
fludarabin
plu
cy
melphalan
tbi
given
cbt
median
nucleat
cell
dose
rang
kg
rang
respect
cumul
incid
neutrophil
engraft
day
confidenti
interv
ci
platelet
recoveri
day
ci
median
time
neutrophil
engraft
platelet
engraft
day
rang
day
rang
respect
rate
acut
gvhd
grade
ci
rate
acut
gvhd
grade
ci
median
followup
month
cumul
incid
chronic
gvhd
ci
use
system
steroid
gvhd
treatment
need
patient
acut
gvhd
grade
cgvhd
signific
differ
rate
engraft
gvhd
mac
ric
group
rate
overal
surviv
ci
sr
group
ci
hr
group
cumul
incid
relaps
year
ci
sd
group
ci
hd
group
cumul
incid
nonrelaps
mortal
nrm
year
ci
conclus
gvhd
prophylaxi
fkmtx
result
low
rate
sever
acut
gvhd
contribut
low
incid
nrm
cbt
howev
result
engraft
rate
relaps
rate
satisfactori
prospect
studi
need
find
optim
dosag
mtx
gvhd
prevent
cbt
conflict
interest
author
conflict
interest
disclos
princess
margaret
hospit
dmoh
toronto
canada
princess
margaret
hospit
toronto
canada
background
nonmyeloabl
condit
regimen
use
intraven
fludarabin
busulphan
atg
post
transplant
cyclophosphamid
ptci
gvhd
prophylaxi
demonstr
good
efficacysafeti
sever
studi
hla
match
mismatch
transplant
ptci
atg
shown
decreas
risk
acut
chronic
gvhd
respect
adopt
combin
regimen
gvhd
prophylaxi
match
unrel
donor
mud
pbsct
princess
margaret
hospit
toronto
order
decreas
rate
acut
chronic
gvhd
patient
popul
method
adult
patient
median
age
rang
hematolog
malign
treat
protocol
princess
margaret
hospit
octob
decemb
patient
receiv
stem
cell
transplant
hla
match
unrel
donor
remaind
receiv
stem
cell
fulli
match
unrel
donor
pretranspl
condit
consist
iv
fludarabin
day
iv
busulphan
mgkgday
day
low
dose
tbi
gvhd
prophylaxi
rabbit
atg
day
ptci
mgkgday
cyclosporin
mgkgday
result
median
follow
day
rang
day
cumul
os
pf
patient
respect
day
mortal
overal
mortal
nonrelaps
mortal
nrm
primari
graft
failur
secondari
graft
failur
subgroup
analysi
versu
hla
match
transplant
latter
group
significantli
inferior
os
df
os
vs
os
pf
vs
pf
p
overal
incid
acut
gvhd
grade
acut
gvhd
steroid
refractori
acut
gvhd
seen
patient
overal
incid
chronic
gvhd
extens
chronic
gvhd
seen
patient
overal
relaps
rate
relaps
occur
within
first
one
year
conclus
experi
confirm
ptci
atg
combin
safe
effect
gvhd
prophylaxi
match
unrel
donor
peripher
blood
stem
cell
transplant
accept
non
relaps
mortal
relaps
rate
low
rate
acut
gvhd
chronic
gvhd
conflict
interest
author
conflict
interest
disclos
abstract
previous
publish
leiden
univers
medic
center
leiden
netherland
background
tcell
deplet
reduc
risk
acut
graftversushostdiseas
gvhd
allogen
stem
cell
transplant
allosct
increas
relaps
risk
therefor
prophylact
donor
lymphocyt
infus
dli
may
necessari
provok
graftversusleukemiaeffect
howev
postpon
dli
gvhd
still
occur
depend
time
dli
dose
evalu
outcom
combin
allosct
prophylact
dli
standard
statist
model
suffici
novel
method
like
multist
model
need
report
outcom
lowtox
condit
regimen
combin
invivo
invitro
tcell
deplet
follow
schedul
prophylact
dli
frail
elderli
year
patient
high
risk
acut
leukemia
method
patient
aml
receiv
fludarabin
day
busulphan
mgkg
day
alemtuzumab
day
infus
peripher
blood
bone
marrow
stem
cell
graft
hlamatch
alemtuzumab
ad
patient
unrel
donor
receiv
thymoglobulin
standard
post
transplant
immun
suppress
therapi
ist
gvhd
prophylaxi
given
gvhd
requir
system
ist
develop
transplant
freshli
harvest
dli
given
month
allosct
patient
veryhigh
risk
diseas
dose
tcellskg
subsequ
month
dose
tcellskg
patient
multist
model
design
evalu
event
relat
allosct
dli
first
year
transplant
result
median
age
year
rang
patient
engraft
median
time
day
neutrophil
year
overal
surviv
os
confid
relaps
rate
nonrelaps
mortal
nrm
respect
one
patient
receiv
second
allosct
second
donor
origin
unrel
donor
refus
collect
dli
thirteen
patient
receiv
experiment
tcell
product
part
studi
protocol
figur
show
outcom
multist
model
year
allosct
dli
need
therapeut
ist
gvhd
relaps
die
die
due
nrm
receiv
standard
dli
dli
need
therapeut
ist
die
due
nrm
relaps
year
patient
aliv
without
relaps
treat
ist
time
conclus
tcell
deplet
allosct
reducedintens
condit
regimen
follow
schedul
prophylact
dli
feasibl
elderli
patient
high
risk
acut
leukemia
three
year
os
low
relaps
rate
nrm
one
year
surviv
patient
istfre
multist
model
show
prior
dli
nrm
low
increas
follow
dli
illustr
necess
optim
dose
time
manipul
tcell
therapi
conflict
interest
none
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
oxford
univers
hospit
nh
foundat
trust
oxford
unit
kingdom
background
oral
mucos
involv
graft
versu
host
diseas
gvhd
common
significantli
impact
qualiti
life
howev
oral
mucos
sign
symptom
due
gvhd
correct
diagnosi
essenti
order
manag
correctli
avoid
unnecessari
immunosuppress
aim
studi
review
oral
mucos
diagnos
present
patient
review
dedic
oral
medicin
specialist
servic
bone
marrow
transplant
outpati
clinic
method
data
collect
may
octob
patient
review
oral
medicin
specialist
bone
marrow
transplant
bmt
outpati
clinic
demograph
clinic
data
collect
includ
haematolog
diagnosi
transplant
type
time
sinc
transplant
oral
medicin
diagnosi
treatment
gvhd
manifest
treatment
oral
medicin
diagnos
categoris
activesymptomat
manifest
gvhd
inact
manifest
gvhd
late
effect
relat
transplant
unrel
diagnosi
data
analys
descript
use
microsoft
excel
result
month
period
patient
encount
record
consist
individu
patient
mean
age
year
rang
year
mean
time
posttranspl
month
rang
month
mean
number
clinic
review
oral
medicin
specialist
rang
commonest
haematolog
diagnos
acut
myeloid
leukaemia
follicular
lymphoma
acut
lymphoblast
leukaemia
myelodysplasia
common
transplant
type
sampl
reduc
intens
condit
ric
sibl
allograft
follow
ric
match
unrel
donor
allograft
patient
encount
relat
activesymptomat
oral
gvhd
mean
time
posttranspl
relat
inact
oral
gvhd
manifest
late
effect
bmt
due
unrel
diagnosi
patient
encount
patient
take
system
immunosuppress
patient
encount
led
increas
system
immunosuppress
activesymptomat
oral
gvhd
patient
encount
activesymptomat
oral
gvhd
result
prescript
topic
therapi
unrel
oral
mucos
diagnos
includ
viral
papillomata
plaqueinduc
gingiv
recurr
aphthou
stomat
chronic
hyperplast
candidiasi
benign
hyperkeratosi
pseudomembran
candidiasi
drugrel
pigment
smallfibr
neuropathi
oral
dysaesthesia
dysgeusia
subject
xerostomia
postinflammatori
hyperalgesia
dental
infect
white
hairi
tongu
late
effect
diagnos
includ
squamou
cell
carcinoma
verruciform
xanthoma
see
figur
overal
patient
two
site
affect
gvhd
least
one
encount
activesymptomat
oral
gvhd
conclus
cohort
demonstr
oral
mucosa
commonli
involv
patient
multisit
gvhd
major
patient
activesymptomat
oral
gvhd
manag
use
topic
therapi
rather
increas
immunosuppress
moreov
third
patient
oral
mucos
symptom
sign
attend
bmt
clinic
nongvhd
diagnos
presenc
dedic
oral
medicin
specialist
bmt
clinic
ensur
correct
diagnosi
optim
manag
conflict
interest
none
author
anyth
disclos
russian
children
research
hospit
moscow
russian
feder
dmitri
rogachev
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
usag
peripher
blood
stem
cell
pbsc
hematopoiet
stem
cell
transplant
hsct
limit
due
increas
risk
gvhd
hand
less
traumat
donor
aim
compar
gvhd
incid
hsct
pbsc
vs
bone
marrow
bm
method
sixti
two
patient
transplant
pbsc
match
relat
donor
period
novemb
may
bm
diagnosi
follow
aml
pbsc
bm
accordingli
saa
accordingli
jmml
accordingli
accordingli
gender
male
pbsc
bm
femal
accordingli
age
median
pbsc
yo
month
year
bm
yo
month
year
condit
regimen
mac
pbsc
bm
ric
accordingli
rituximab
pbsc
bm
atg
pbsc
bm
graft
pbsc
group
sibl
children
hla
father
hla
cell
dose
kg
kg
graft
bm
group
sibl
parent
hla
hla
kg
kg
result
compar
histor
data
equal
group
patient
receiv
bm
match
relat
donor
result
donor
without
complic
patient
receiv
adequ
immunosuppress
therapi
pbsc
median
time
engraft
day
day
rejectionrelaps
regist
case
one
patient
pbsc
group
experienc
primari
reject
graft
patient
sever
agvhd
iiiiv
st
seven
patient
transform
cgvhd
patient
limit
patient
extens
form
gvhd
one
patient
extens
cgvhd
three
patient
limit
cgvhd
without
previou
histori
agvhd
chronic
gvhd
led
sever
disabl
four
patient
five
patient
fulli
recov
chronic
gvhd
two
patient
extens
chronic
gvhd
die
infecti
complic
median
followup
month
os
bm
median
time
engraft
day
day
rejectionrelaps
n
two
patient
bm
group
experienc
primari
reject
agvhd
iiiiv
st
diagnos
extens
cgvhd
limit
cgvhd
caus
death
relaps
infecti
complic
median
followup
month
os
conclus
thu
pbsc
match
relat
donor
transplant
increas
risk
gvhd
comparison
bm
pbsc
transplant
could
feasibl
option
hsct
less
traumat
donor
adequ
prevent
gvhd
requir
success
outcom
conflict
interest
none
declar
institut
oncolog
hematolog
hospit
hematopoiet
stem
cell
transplant
unit
hematolog
depart
barcelona
spain
biomed
diagnost
center
pharmacolog
toxicolog
depart
ciberehd
barcelona
spain
biomed
diagnost
center
pharmacolog
toxicolog
depart
barcelona
spain
hospit
pharmacolog
depart
barcelona
spain
institut
hematolog
oncolog
hospit
idibap
institut
josep
carrera
hematopoiet
stem
cell
transplant
unit
hematolog
depart
barcelona
spain
background
tacrolimu
tac
pivot
immunosuppress
agent
use
allohsct
besid
intraven
iv
twicedaili
oral
tac
oncedaili
prolongedreleas
formul
becom
avail
tac
narrow
therapeut
index
small
variat
drug
exposur
due
formul
differ
signific
impact
patient
outcom
scarc
data
use
oncedaili
tac
set
allohsct
analyz
pharmacokinet
advagraf
first
month
allohsct
method
total
patient
hematolog
malign
receiv
allohsct
tacbas
regimen
prophylaxi
gvhd
seventeen
patient
receiv
mgkg
iv
continu
infus
follow
convers
advagraf
ratio
patient
recov
regimenrel
gastrointestin
toxic
group
ivpo
nine
addit
patient
start
immunosuppress
directli
dose
group
po
patient
receiv
prophylaxi
fluconazol
acyclovir
level
tac
cmin
measur
three
time
week
patient
also
measur
area
concentrationtim
curv
advagraf
initi
tac
dose
adjust
maintain
cmin
ngml
dose
reduct
recommend
serum
creatinin
increas
upper
limit
normal
seriou
toxic
appear
acut
kidney
injuri
aki
defin
accord
common
terminolog
criteria
advers
event
ctcae
result
ivpo
group
patient
iv
tac
median
cmin
within
therapeut
rang
oral
convers
cmin
within
therapeut
rang
patient
level
po
group
patient
median
cmin
within
therapeut
rang
differ
found
group
mean
peak
tac
concentr
cmax
vs
attain
median
time
howev
patient
group
po
signific
higher
exposit
tac
mean
vs
signific
correl
observ
tac
cmin
whole
popul
patient
lower
level
cmin
present
tac
exposur
therapeut
rang
first
month
transplant
figur
graft
failur
observ
eight
patient
develop
acut
gvhd
grade
grade
ii
grade
iii
one
infratherapeut
level
tac
patient
develop
aki
grade
grade
grade
without
addit
nephrotox
drug
seventeen
patient
requir
dose
adjust
due
renal
toxic
initi
posaconazol
andor
thrombot
microangiopathi
conclus
oncedaili
oral
tac
advagraf
suitabl
altern
twicedaili
tac
allohsct
convers
iv
tac
advagraf
basi
patient
receiv
fluconazol
result
adequ
exposur
tac
patient
howev
signific
proport
high
tac
exposur
risk
aki
lower
convers
ratio
consid
conflict
interest
conflict
interest
hospit
gener
universitario
gregorio
maranon
hematholog
hemotherapi
madrid
spain
instituto
de
sanitaria
gregorio
maranon
madrid
spain
hospit
region
universitario
de
hematholog
hemotherapi
spain
universidad
complutens
de
madrid
madrid
spain
background
posttranspl
high
dose
cyclophosphamid
ptci
effect
prevent
graftversushost
diseas
gvhd
hlahaploident
hematopoiet
stem
cell
transplant
hsct
use
ptci
hlaident
hsct
less
explor
studi
analyz
result
ptci
gvhd
prophylaxi
hlaident
sibl
hsct
compar
obtain
prophylaxi
methotrex
mtx
cyclosporin
csa
method
hlaident
sibl
hsct
spanish
hospit
analyz
perform
use
mtxcsa
gvhd
prophylaxi
perform
use
ptci
result
baselin
characterist
posttranspl
complic
shown
tabl
gvhd
prophylaxi
consist
mtx
day
csa
day
mtxcsa
group
ptci
group
reciev
cyclophosphamid
mgkgd
day
patient
combin
csa
day
cyclophosphamid
day
patient
follow
csa
mycophenol
mofetil
day
median
followup
month
mtxcsa
group
month
ptci
group
overal
surviv
os
eventfre
surviv
ef
respect
differ
observ
cumul
incid
relaps
vs
nonrelaps
mortal
nrm
show
higher
trend
csamtx
group
vs
cumul
incid
day
grade
iiiv
vs
iiiiv
vs
acut
gvhd
significantili
higher
mtxcsa
group
figur
cumul
incid
chronic
moder
sever
gvhd
show
higher
trend
mtx
cohort
vs
conclus
experi
spite
limit
number
patient
gvhd
prophylaxi
use
ptci
combin
addit
immunosupres
hlaident
sibl
hsct
use
mostli
peripher
blood
graft
sourc
reduc
cumul
incid
acut
gvhd
compar
standard
prophylaxi
mtxcsa
studi
longer
followup
need
confirm
observ
conflict
interest
author
noth
disclos
tabl
baselin
characterist
hsct
complic
candiolo
cancer
institutefpo
ircc
medic
oncolog
hematopoiet
stem
cell
unit
candiolo
itali
turin
metropolitan
transplant
center
torino
itali
aou
citta
della
salut
e
della
scienza
di
torino
ospedal
infantil
regina
margherita
pediatr
oncohematolog
stem
cell
transplant
cellular
therapi
divis
torino
itali
candiolo
cancer
institutefpo
ircc
collect
process
laboratori
candiolo
itali
univers
torino
depart
oncolog
torino
itali
background
hematopoiet
cell
transplant
hct
cur
approach
acut
myeloid
leukemia
aml
still
lifethreaten
toxic
graftversushost
diseas
gvhd
infect
limit
fullpotenti
impact
diseas
posttranspl
cyclophosphamid
ptci
proven
effect
reduc
acut
gvhd
agvhd
chronic
gvhd
cgvhd
incid
bonemarrow
hct
ident
haploident
donor
increasingli
adopt
set
use
ptci
peripher
blood
stem
cell
allopbsct
transplant
hlamatch
unrelatedrel
donor
still
investig
report
outcom
cohort
patient
highintermedi
risk
aml
treat
approach
method
analyz
patient
highintermedi
risk
lam
pbsc
transplant
hlamatch
unrelatedrel
donor
august
juli
complet
respons
cr
transplant
induct
salvag
regimen
gvhd
prophylaxi
ptci
mgkg
day
tacrolimu
day
mycophenol
mofetil
mmf
day
day
condit
regimen
reduc
patient
myeloabl
primari
object
cumul
incid
agvhd
cgvhd
secondari
object
event
free
surviv
ef
cgvhdef
overal
surviv
os
transplant
relat
mortal
trm
result
patient
median
age
rang
year
patient
first
cr
patient
second
third
cr
median
dose
rang
x
infus
one
patient
engraft
mmf
stop
day
patient
median
day
tacrolimu
discontinu
rang
cmv
reactiv
occur
patient
regard
gvhd
patient
develop
agvhd
grade
iiiii
gi
skin
median
day
onset
day
rang
grade
iv
observ
treat
steroid
steroid
plu
calcineurin
inhibitor
two
patient
develop
cgvhd
day
respect
system
treatment
requir
steroid
tacrolimu
abl
discontinu
immunosuppress
day
day
respect
median
followup
rang
month
ef
cgvhdef
os
trm
incid
patient
develop
multiresist
pseudomona
aeruginosa
septicemia
die
transplant
nowaday
patient
aliv
evid
diseas
complet
complet
reintegr
normal
daili
life
activ
conclus
highintermedi
risk
aml
set
report
result
appear
compar
literaturedata
moreov
thee
result
suggest
ptci
also
pbschct
maintain
favor
profil
limit
acut
cgvhd
incid
sharp
reduct
trm
relev
decreas
transplant
toxic
mortal
confirm
might
expand
indic
hct
aml
leukemia
relaps
still
repres
limit
low
gvhd
incid
earli
discontinu
might
contribut
futur
transform
hct
safe
immunolog
platform
cellular
therapi
potenti
increas
graft
versu
leukemia
effect
clinic
trial
registri
wwwclinicaltrialsgov
conflict
interest
none
author
anyth
disclos
academ
medic
center
oral
maxillofaci
surgeri
amsterdam
netherland
academ
centr
dentistri
amsterdam
oral
medicin
amsterdam
netherland
cedarssinai
health
center
lo
angel
ca
unit
state
citi
hope
duart
ca
unit
state
weill
cornel
medic
colleg
new
york
ny
unit
state
univers
california
blood
marrow
transplant
san
diego
ca
unit
state
univers
buffalo
oral
biolog
buffalo
ny
unit
state
centr
de
haut
energi
nice
franc
background
cancer
patient
treat
allogen
hematopoiet
stem
cell
transplant
hsct
may
develop
oral
complic
associ
chronic
graft
versu
host
diseas
cgvhd
salivari
gland
may
affect
result
hyposaliv
xerostomia
feel
dri
mouth
may
present
signific
burden
patient
patient
may
troubl
sleep
speak
swallow
decreas
salivari
defens
mechan
predispos
mucos
dental
hypersensit
well
opportunist
oral
infect
includ
rampant
dental
cari
current
treatment
option
cgvhdassoci
salivari
gland
dysfunct
limit
addit
intervent
would
thu
welcom
addit
current
avail
manag
strategi
studi
suggest
photobiomodul
pbm
therapi
use
low
dose
light
therapi
previous
call
low
level
laser
therapi
reduc
inflamm
fibrosi
promot
tissu
repair
hypothes
pbm
therapi
may
amelior
salivari
gland
dysfunct
aim
explor
whether
pbm
may
play
role
manag
hyposaliv
xerostomia
associ
oral
cgvhd
method
eight
patient
cgvhdassoci
hyposalivationxerostomia
treat
pbm
use
nm
intraor
laser
probe
mw
puls
hz
illumin
area
mw
per
point
jpoint
j
orific
major
salivari
gland
extraor
cluster
led
nm
mw
total
puls
hz
illumin
area
mw
j
j
appli
major
salivari
gland
cervic
lymph
node
chain
bilater
patient
underw
least
one
pbm
treatment
per
week
follow
data
present
week
treatment
unstimul
stimul
whole
salivari
flow
measur
minut
pbm
therapi
patient
complet
visual
analogu
scale
va
score
order
assess
xerostomia
result
pbm
therapi
significantli
attenu
hyposaliv
xerostomia
patient
wherea
one
patient
experienc
less
xerostomia
whole
salivari
product
improv
margin
patient
longstand
gvhdassoci
dri
mouth
pbm
therapi
follow
protocol
describ
effect
conclus
result
suggest
control
studi
conduct
confirm
efficaci
safeti
pbm
therapi
cgvhd
relat
salivari
gland
dysfunct
determin
optim
pbm
therapi
protocol
conflict
interest
pbm
devic
provid
thor
photomedicin
ltd
chesham
buckinghamshir
uk
ospedali
riuniti
umberto
clinic
hematolog
ancona
itali
bimind
softwar
hous
jesi
itali
ospedal
mazzoni
uoc
ematologia
e
terapia
cellular
ascoli
piceno
itali
ospedal
della
misericordia
dept
hematol
udin
itali
politecnica
dell
march
dipartimento
di
scienz
clinich
e
molecolari
clinic
hematolog
ancona
itali
ospedali
riuniti
umberto
sistema
informatico
aziendal
ancona
itali
background
chronic
gvhd
cgvhd
repres
first
caus
transplantrel
mortal
reduc
qualiti
life
transplant
epidemiolog
cgvhd
larg
unknown
moreov
diagnosi
cgvhd
easili
miss
onset
often
late
posttranspl
period
requir
specif
follow
gener
practition
usual
familiar
entiti
standard
cgvhd
manag
nih
consortium
propos
consensu
definit
diagnosi
score
respons
criteria
howev
criteria
use
minor
trial
updat
consensu
nih
criteria
offer
share
framework
better
studi
rare
diseas
criteria
valid
prospect
clinic
trial
moreov
learn
period
need
critic
point
could
emerg
applic
new
criteria
includ
possibl
discrep
organ
specif
measur
global
rate
scale
accord
physician
patientreport
symptom
method
develop
electron
medic
record
base
integr
system
call
dossier
allow
complet
traceabl
transplant
clinic
laboratori
data
start
background
develop
algorithm
calcul
cgvhd
score
overal
respons
combin
core
specif
measur
global
rate
scale
includ
lee
scale
system
also
keep
track
criteria
led
diagnosi
also
photograph
support
includ
chang
immunosuppress
therapi
perform
advers
event
includ
infecti
complic
result
retrospect
test
algorithm
perform
patient
enrol
clinic
intervent
studi
nilotinib
cgvhd
mean
doubl
check
softwarepap
support
show
perfect
overlap
result
similar
outcom
accord
respons
evalu
convent
softwarebas
assess
start
preliminari
data
tool
extend
italian
center
particip
prospect
multicent
observ
studi
newli
diagnos
cgvhd
crosi
gitmo
studi
aim
prospect
evalu
overal
incid
cgvhd
longterm
efficaci
whichev
treatment
larg
popul
adult
pediatr
patient
accord
nih
criteria
valid
respons
assess
hard
outcom
event
free
surviv
ef
overal
surviv
os
nonrelaps
mortal
nrm
figur
show
data
flow
respons
calcul
accord
algorithm
data
central
store
italian
center
particip
studi
italian
center
success
use
tool
real
time
fashion
remain
start
conclus
softwar
repres
ideal
tool
evalu
standard
fashion
cgvhd
patient
allow
increas
physician
expertis
improv
qualiti
data
captur
patient
evalu
final
tool
could
substanti
increas
qualiti
futur
intervent
studi
field
thu
help
select
effect
compound
difficult
treat
diseas
conflict
interest
author
noth
disclos
chungnam
nation
univers
hospit
depart
intern
medicin
daejeon
korea
republ
background
alter
fecal
microbiota
affect
incid
extent
graftversu
host
diseas
gvhd
allogen
hematopoiet
stem
cell
transplant
allohsct
patient
hematolog
malign
receiv
antibiot
treatment
febril
neutropenia
prior
allohsct
pretranspl
use
antibiot
may
influenc
fecal
microbiota
thu
investig
whether
pretranspl
use
antibiot
influenc
incid
extent
gvhd
method
retrospect
analyz
consecut
adult
patient
hematolog
malign
receiv
allohsct
chungnam
nation
univers
hospit
patient
receiv
haploident
donor
cord
blood
transplant
exclud
pretranspl
use
antibiot
defin
usag
antibiot
condit
chemotherapi
result
studi
includ
patient
median
age
rang
year
patient
aml
md
cml
seventytwo
patient
receiv
transplant
sibl
patient
receiv
calcineurin
inhibitor
shortcours
methotrex
gvhd
prophylaxi
thirtyon
patient
receiv
antithymocyt
globulin
patient
receiv
antibiot
prior
hsct
patient
receiv
glycopeptid
cefepim
piperacillintazobactam
carbapenem
patient
receiv
glycopeptid
frequent
extens
chronic
gvhd
cgvhd
vs
year
frequent
cgvhd
lung
vs
year
multivari
analysi
howev
reveal
nonus
atg
hlamismatch
donor
transplant
signific
risk
factor
extens
cgvhd
pretranspl
use
glycopeptid
influenc
overal
surviv
os
gvhdrelat
mortal
median
os
month
glycopeptid
vs
reach
nonglycopeptid
gvhdrelat
mortal
year
glycopeptid
vs
nonglycopeptid
conclus
pretranspl
use
glycopeptid
tend
increas
incid
extens
cgvhd
especi
lung
conflict
interest
conflict
interest
aou
della
salut
e
della
scienza
di
torino
dipartimento
di
oncologia
e
ematologia
ssd
trapianto
allogenico
di
cellul
staminali
torino
itali
degli
studi
di
torino
dipartimento
di
biotecnologi
molecolari
e
scienz
per
la
salut
torino
itali
degli
studi
di
torino
centro
di
biotecnologi
molecolari
dipartimento
di
scienz
medich
torino
itali
aou
della
salut
e
della
scienza
di
torino
dipartimento
di
oncologia
e
ematologia
torino
itali
aou
della
salut
e
della
scienza
di
torino
clinic
epidemiolog
torino
itali
background
reliabl
biomark
could
crucial
defin
patient
highrisk
develop
acut
graftvshost
diseas
agvhd
extracellular
vesicl
ev
membraneenclos
structur
secret
cell
bodi
fluid
may
repres
attract
biomark
recent
carri
preliminari
studi
investig
potenti
role
biomark
agvhd
lia
g
et
al
leukemia
three
ev
membran
antigen
associ
onset
agvhd
confirm
preliminari
find
design
prospect
studi
enrol
patient
variou
hematolog
malign
undergo
allograft
moreov
ev
character
content
method
thirtyf
patient
far
enrol
serum
sampl
collect
follow
timepoint
pretranspl
day
monthli
year
ev
extract
use
protaminebas
precipit
method
analyz
express
membran
protein
flowcytometri
guava
easycyt
flow
cytomet
total
ev
concentr
fluoresc
distribut
percentag
posit
ev
evalu
biomark
mirna
extract
ev
use
combin
trizol
commerci
kit
mirneasi
mini
kit
qiagen
mirna
quantifi
real
time
pcr
defin
rel
express
level
compar
healthi
donor
logist
regress
analysi
odd
ratio
calcul
proport
chang
pretranspl
level
marker
result
overal
patient
develop
grade
iiiv
agvhd
preliminari
result
patient
studi
show
express
correl
develop
agvhd
fig
level
cell
adhes
molecul
famili
associ
increas
risk
agvhd
platelet
endotheli
cell
adhes
molecul
associ
decreas
risk
biomark
show
proport
signal
chang
baselin
gvhd
onset
gradual
increas
decreas
preliminari
result
patient
studi
mirna
express
level
show
upregul
fig
associ
increas
risk
agvhd
absolut
level
proport
signal
chang
conclus
confirm
signific
associ
onset
gvhd
underli
role
endothelium
immun
cell
interact
involv
sever
pathway
includ
notch
signal
system
investig
role
may
provid
insight
pathogenesi
acut
gvhd
conflict
interest
boccadoro
honoraria
research
fund
sanofi
celgen
bristolmy
squibb
novarti
amgen
janssen
honoraria
abbvi
research
fund
mundipharma
b
bruno
honoraria
gilead
pfizer
hospira
honoraria
research
fund
celgen
research
fund
pierr
fabr
adienn
hospira
italia
msd
italia
abstract
previous
publish
oregon
health
scienc
univers
portland
unit
state
indiana
blood
marrow
transplant
indianapoli
unit
state
jewish
hospit
merci
health
cincinnati
oh
unit
state
texa
transplant
physician
group
san
antonio
tx
unit
state
citi
hope
nation
medic
center
depart
hematolog
hematopoiet
cell
transplant
duart
ca
unit
state
univers
alabama
birmingham
birmingham
al
unit
state
univers
california
san
diego
san
diego
ca
unit
state
fate
therapeut
inc
san
diego
ca
unit
state
karmano
cancer
institutewayn
state
univers
depart
oncolog
blood
marrow
stem
cell
transplant
program
detroit
mi
unit
state
background
protmun
next
gener
graft
fda
fast
track
design
reduct
incid
sever
acut
graftversushost
diseas
gvhd
patient
undergo
allogen
hematopoiet
cell
transplant
hct
method
protect
ongo
phase
openlabel
phase
doubleblind
random
control
trial
protmun
adult
subject
hematolog
malign
undergo
mobil
peripher
blood
hct
follow
myeloabl
condit
mac
use
hla
b
c
dr
match
unrel
donor
murd
receiv
standard
gvhd
prophylaxi
methotrex
tacrolimu
protmun
manufactur
onsit
day
hct
pharmacolog
modul
donor
peripher
blood
stem
cell
pbsc
allograft
exvivo
two
small
molecul
enhanc
biolog
properti
therapeut
function
graft
result
phase
stage
protect
includ
seven
adult
subject
median
age
rang
hematolog
malign
aml
md
undergo
murd
hct
follow
mac
protmun
manufactur
success
case
pharmacolog
modul
confirm
mark
increas
potenc
marker
cell
mean
dose
cell
administ
cell
rang
cell
rang
cell
overal
median
time
studi
day
rang
first
day
follow
hct
seven
subject
remain
aliv
relapsefre
event
graft
failur
median
time
neutrophil
engraft
day
rang
protmunerel
seriou
advers
event
report
investig
three
seven
subject
experienc
acut
gvhd
first
day
follow
hct
respond
standardofcar
steroid
treatment
median
time
resolut
maximum
gvhd
grade
day
rang
day
conclus
protmun
reproduc
manufactur
deliv
part
standardofcar
hct
protmun
well
toler
case
graftfailur
diseaserelaps
random
doubleblind
phase
portion
commenc
enrol
clinic
trial
registri
conflict
interest
r
maziarz
receiv
honoraria
novarti
pharmaceut
corpor
incyt
juno
therapeut
kite
therapeut
athersi
saad
consult
actinium
receiv
honoraria
spectrum
diaz
medcalf
fremgen
c
storgard
employe
fate
therapeut
j
edward
j
essel
c
freyt
c
karan
tzachani
deol
noth
disclos
depart
hematolog
oncolog
stem
cell
transplant
univers
hospit
freiburg
freiburg
germani
bmt
unit
tel
aviv
medic
center
tel
aviv
israel
sackler
faculti
medicin
tel
aviv
univers
tel
aviv
israel
depart
patholog
molecular
medicin
mcmaster
univers
hamilton
canada
institut
hematolog
davidoff
cancer
center
rabin
medic
center
petah
tikva
israel
depart
pediatr
hematologyoncolog
bambino
children
hospit
rome
itali
depart
pediatr
scienc
univers
pavia
pavia
itali
novarti
pharmaceut
corpor
east
hanov
nj
unit
state
novarti
pharma
ag
basel
switzerland
depart
hematolog
hokkaido
univers
faculti
medicin
graduat
school
medicin
sapporo
japan
background
steroidrefractori
chronic
graftversushost
diseas
srcgvhd
associ
high
morbid
longterm
mortal
well
reduc
qualiti
life
repres
unmet
medic
need
retrospect
studi
zeiser
et
al
ruxolitinib
demonstr
promis
outcom
well
toler
patient
srcgvhd
cmv
reactiv
rate
thrombocytopenia
rate
underli
malign
relaps
favor
compar
publish
literatur
use
best
avail
therapi
bat
patient
srcgvhd
present
phase
studi
investig
efficaci
ruxolitinib
addon
therapi
corticosteroid
therapi
patient
srcgvhd
method
random
openlabel
multicent
studi
patient
age
year
underw
allogeneichematopoiet
stem
cell
transplant
allohsct
evid
myeloid
platelet
engraft
absolut
neutrophil
count
platelet
diagnos
moder
sever
cgvhd
accord
nation
institut
health
nih
consensu
criteria
jagasia
et
al
elig
inclus
exclus
criteria
compris
patient
receiv
prior
jak
inhibitor
acut
gvhd
except
patient
achiev
complet
respons
cr
partial
respons
pr
jak
inhibitor
week
prior
cycl
day
fail
prior
sct
month
overlap
syndrom
elig
patient
random
ruxolitinib
mg
oral
twice
daili
arm
investigatordetermin
bat
arm
patient
random
bat
arm
allow
cross
ruxolitinib
arm
figur
durat
treatment
andor
followup
year
week
primari
object
compar
efficaci
ruxolitinib
vs
bat
overal
respons
rate
orr
month
orr
defin
proport
patient
cr
pr
accord
nih
respons
guidelin
lee
et
al
overal
patient
plan
enrol
achiev
power
orr
comparison
assum
odd
secondari
endpoint
includ
failurefre
surviv
modifi
lee
symptom
score
result
first
patient
enrol
june
conclus
enrol
ongo
trial
regist
clinicaltrialsgov
clinic
trial
registri
clinicaltrialsgov
conflict
interest
robert
zeiser
honoraria
speaker
symposium
jazz
pharmaceut
honoraria
speaker
novarti
stephen
ronan
foley
consult
novarti
advisori
board
celgen
b
gadbaw
e
atienza
employe
novarti
n
hollaend
employe
novarti
pharma
ag
teshima
consult
research
fund
advisori
board
novarti
r
ram
yeshurun
f
locatelli
conflict
interest
disclos
abstract
previous
publish
abstract
previous
publish
regensburg
inner
medizin
iii
regensburg
germani
background
rituximab
recent
describ
also
first
line
therapi
chronic
graftversushostdiseas
cgvhd
retrospect
analyz
efficaci
safeti
patient
receiv
rituximab
treatment
cgvhd
regensburg
univers
method
respons
allogen
stem
cell
transplant
patient
median
age
rang
year
evalu
within
one
year
rituximab
treatment
cgvhd
diagnos
grade
appli
nih
criteria
median
time
stem
cell
transplant
cgvhd
onset
rituximab
applic
day
rang
day
rang
respect
overal
sever
cgvhd
start
treatment
rituximab
moder
sever
main
organ
manifest
skin
patient
oral
patient
lung
patient
patient
platelet
lower
onset
cgvhd
patient
fail
sustain
respons
prior
steroid
treatment
patient
one
prior
line
therapi
patient
two
line
three
line
patient
receiv
dose
rituximab
appli
weekli
patient
receiv
dose
cycl
patient
receiv
addit
immunosuppress
agent
patient
new
immunosuppress
agent
start
parallel
rituximab
result
best
respons
observ
follow
patient
achiev
complet
respons
patient
partial
respons
patient
mix
respons
patient
nondur
respons
patient
respond
patient
includ
lethal
infecti
complic
develop
seriou
infect
requir
hospit
within
month
rituximab
therapi
infecti
caus
fungal
viral
bacteri
conclus
rituximab
show
moder
activ
treatment
cgvhd
patient
fail
primari
treatment
signific
incid
sever
infecti
complic
warrant
evalu
conflict
interest
none
author
anyth
disclos
american
univers
beirut
faculti
medicin
beirut
lebanon
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
intern
medicin
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
depart
patholog
laboratori
medicin
beirut
lebanon
background
aim
pilot
nonintervent
observ
studi
examin
genet
polymorph
drug
metabol
enzym
dme
transport
involv
voriconazol
andor
cyclosporin
disposit
among
patient
undergo
allogen
stem
cell
transplant
sct
assess
relationship
polymorph
clinic
laboratori
paramet
relat
cyclosporin
kinet
toxic
within
patient
popul
method
clinic
data
dna
collect
subject
underw
sct
receiv
cyclosporin
base
immunosuppress
voriconazol
prophylaxi
fungal
infect
sampl
genotyp
use
dmet
plu
array
affymetrix
known
candid
gene
involv
disposit
metabol
transport
cyclosporin
voriconazol
analyz
averag
concentrationdos
cd
ratio
cyclosporin
ngml
mgkg
calcul
use
avail
level
daili
dose
per
particip
weight
result
expect
definit
interact
voriconazol
cyclosporin
wherebi
cd
ratio
cyclosporin
lower
administ
alon
compar
administ
voriconazol
statist
signific
median
rang
cd
cyclosporin
ngml
mgkg
vs
without
voriconazol
respect
p
statist
signific
associ
genet
polymorph
cd
ratio
cyclosporin
combin
voriconazol
figur
parallel
allel
carrier
statist
significantli
higher
creatinin
valu
therapi
median
rang
creatinin
mgdl
vs
allel
carrier
vs
refer
figur
interestingli
trend
associ
though
statist
signific
phenotyp
candid
gene
expect
direct
cd
ratio
cyclosporin
combin
voriconazol
conclus
one
pharmacogenet
studi
patient
undergo
sct
first
show
genet
polymorph
drug
transport
play
role
interact
voriconazol
cyclosporin
cyclosporin
relat
nephrotox
patient
undergo
sct
move
forward
increas
sampl
size
potenti
show
signific
associ
addit
candid
gene
clinic
trial
registri
author
conflict
interest
declar
conflict
interest
author
declar
conflict
interest
medic
center
univers
hamburg
dept
stem
cell
transplant
hamburg
germani
medic
center
univers
hamburg
dept
hematolog
oncolog
hamburg
germani
background
steroidrefractori
gvhd
srgvhd
allogen
stem
cell
transplant
allohsct
treatment
option
limit
ruxolitinib
jak
inhibitor
caus
blockad
jakstat
pathway
reduc
inflammatori
effect
shown
activ
srgvhd
extracorpor
photopheresi
ecp
immunomodulatori
leukapheresisbas
procedur
show
singl
center
experi
toler
efficaci
combin
therapeut
strategi
sracut
gvhd
method
patient
male
femal
sragvhd
liver
skin
mainli
upper
lower
gitract
combin
allohsct
treat
ruxolitinib
median
age
year
r
donor
sourc
mmud
mud
mrd
steroid
refractori
defin
improv
day
aggrav
day
steroid
treatment
start
ruxolitinib
overal
grade
ii
grade
iii
grade
iv
acut
gvhd
median
day
gvhd
onset
transplant
day
r
median
start
ruxolitinib
day
r
median
durat
ruxolitinib
therapi
day
r
median
dosag
mg
per
day
x
mg
addit
treatment
ruxolitinib
follow
patient
receiv
ruxolitinib
calcineurin
inhibitor
patient
calcineurin
inhibitor
alon
patient
addit
mycophenol
mofetil
mmf
case
patient
ecp
extracorpor
photopheresi
ad
steroid
rapidli
taper
start
ruxolitinib
median
time
stop
steroid
onset
ruxolitinib
day
r
result
overal
respons
treatment
ruxolitinib
combin
immunosuppress
therapi
receiv
ecp
patient
includ
complet
remiss
partial
remiss
patient
benefit
therapi
main
reason
stop
therapi
receiv
complet
remiss
statu
follow
sever
cytopenia
sever
infect
benefit
ruxolitinib
therapi
reason
patient
ruxolitinib
associ
side
effect
main
side
effect
cytopenia
patient
develop
worsen
anemia
one
two
ctc
grade
patient
worsen
platelet
count
leukocyt
count
one
three
ctc
grade
infecti
complic
observ
patient
cmv
reactiv
ruxolitinib
therapi
observ
case
oneyear
estim
surviv
patient
start
ruxolitinib
patient
die
sever
refractori
agvhd
sever
infect
combin
refractori
gvhd
associ
therapi
one
patient
die
due
sepsi
gvhd
cr
two
due
relaps
conclus
treatment
sragvhd
ruxolitinib
combin
ecp
rapid
taper
steroid
could
show
high
rate
complet
remiss
overal
encourag
one
year
overal
surviv
cytopenia
common
side
effect
clinic
trial
registri
na
conflict
interest
n
receiv
research
grant
honorarium
novarti
author
conflict
interest
ankara
univers
school
medicin
depart
hematolog
stem
cell
transplant
unit
ankara
turkey
background
despit
major
improv
allogen
hematopoet
stem
cell
transplant
ahsct
last
decad
corticosteroidrefractori
acut
chronic
graftversushost
diseas
gvhd
still
remain
lifethreaten
complic
novel
insight
pathophysiolog
gvhd
highlight
relev
role
host
inflamatori
respons
govern
janu
kinas
famili
ruxolitinib
potent
inhibitor
janu
kinas
proven
efficaci
myelofibrosi
recent
employ
corticosteroidrefractori
gvhd
encourag
overal
respons
rate
method
case
present
present
singl
center
experi
steroid
refractori
gvhd
patient
treat
ruxolitinib
patient
demograph
summar
tabl
patient
treat
initi
mg
bid
reduc
mg
bid
patient
grade
advers
event
median
follow
patient
month
three
four
acut
gvhd
patient
achiev
respons
partial
respons
one
patient
die
week
ruxolitinib
therapi
due
sepsi
one
chronic
gvhd
patient
treat
ruxolitinib
improv
observ
measur
patient
despit
short
treatment
durat
grade
thrombocytopenia
grade
neutropenia
observ
acut
gvhd
patient
grade
thrombocytopenia
observ
chronic
gvhd
patient
cytomegaloviru
reactiv
observ
acut
gvhd
patient
treat
prophylact
gancyclovir
result
see
tabl
conclus
seri
ruxolitinib
effect
salvag
therapi
patient
gvhd
refractori
standard
treatment
conflict
interest
author
noth
disclos
tabl
patient
demograph
georg
papanicola
hospit
hematolog
bmt
unit
thessaloniki
greec
background
steroidrefractori
sr
cgvhd
remain
major
complic
allohsct
associ
high
rate
morbid
mortal
treatment
altern
urgent
need
novel
agent
ruxolitinib
current
investig
howev
limit
clinic
data
exist
literatur
especi
regard
toxic
profil
challeng
group
sever
immunocompromis
patient
method
retrospect
studi
patient
receiv
ruxolitinib
salvag
therapi
srgvhd
analyz
respons
rate
major
toxic
result
fifteen
patient
receiv
ruxolitinib
sr
cgvhd
institut
patient
median
age
year
rang
undergon
allohsct
acut
leukemia
ii
md
iii
hodgkin
lymphoma
iv
cml
myelofibrosi
condit
regimen
myeloabl
reduc
intens
ten
patient
transplant
wellmatch
unrel
donor
sibl
donor
gvhd
prophylaxi
consist
cyclosporin
combin
shortterm
methotrex
mycophenol
mofetil
mmf
plu
rabbit
atg
case
mud
allohsct
twelv
patient
develop
acut
gvhd
grade
ii
grade
iiiiv
steroid
sensit
patient
grade
ii
grade
iiiiv
refractori
agvhd
progress
overlap
syndrom
multipl
treatment
line
present
sr
extens
cgvhd
involv
skin
lung
liver
intestin
tract
heavili
pretreat
median
prior
treatment
line
includ
corticosteroid
mmf
thalidomid
extracorpor
photopheresi
ruxolitinib
initi
addon
immunosuppress
median
month
post
cgvhd
diagnosi
rang
month
start
total
daili
dose
mg
four
patient
show
partial
respons
enabl
reduct
immunosuppress
respons
rate
notabl
receiv
less
treatment
line
median
rang
two
progress
remain
stabl
particularli
import
patient
overlap
syndrom
respond
ruxolitinib
regard
toxic
develop
sever
cytopenia
grade
iiiiv
requir
dose
modif
eventu
discontinu
three
case
infect
anoth
import
complic
ruxolitinib
administr
particular
cmv
reactiv
occur
patient
one
present
sever
recurr
cmv
retin
partial
visual
loss
except
case
cmv
reactiv
respond
antivir
therapi
addit
almost
case
complic
infect
resist
bacteria
especi
respiratori
system
one
case
possibl
aspergillosi
diagnos
six
patient
eventu
die
infect
without
respond
ruxolitinib
therapi
respiratori
infect
four
septic
shock
grade
iv
neutropenia
followup
median
month
rang
recurr
origin
diseas
conclus
studi
show
ruxolitinib
may
benefit
patient
srcgvhd
possibl
even
earli
administr
drug
associ
major
toxic
high
rate
discontinu
make
proper
administr
challeng
necessit
close
monitor
especi
regard
viral
bacteri
infect
prospect
studi
larg
cohort
need
confirm
result
conflict
interest
noth
disclos
degli
studi
di
brescia
unit
blood
diseas
stem
cell
transplant
depart
clinic
experiment
scienc
asst
spedali
civili
brescia
brescia
itali
degli
studi
di
brescia
laboratorio
crea
centro
di
ricerca
ematooncologica
ail
asst
spedali
civili
brescia
brescia
itali
background
relaps
occurr
allogen
stem
cell
transplant
allosct
repres
one
main
concern
atg
use
gvhdprophylaxi
method
clinic
laboratori
data
atgexpos
unexpos
patient
submit
allosct
acut
leukemia
myelodysplast
syndrom
januari
decemb
retrospect
collect
standard
gvhdprophylaxi
mostli
repres
cyclosporin
methotrex
median
followup
month
rang
result
clinic
characterist
cohort
detail
tabl
patient
characterist
mac
myeloabl
condit
regimen
acut
gvhd
agvhd
occur
patient
cumul
incid
vs
month
atg
control
group
respect
overal
patient
surviv
day
transplant
evalu
cgvhd
occurr
atgexpos
patient
show
signific
lower
rate
global
moderatesever
chronic
gvhd
cgvhd
vs
vs
cumul
incid
year
vs
vs
atg
versu
standard
prophylaxi
respect
trend
increas
incid
cmv
reactiv
record
atg
group
vs
graft
failur
record
differ
observ
two
group
term
transplantrel
mortal
vs
relapsefre
surviv
vs
relapseincid
vs
overal
surviv
vs
year
atg
control
group
respect
univari
analysi
previou
agvhd
gvhdprophylaxi
without
atg
donor
age
sibl
femal
donor
correl
higher
risk
cgvhd
occurr
multivari
analysi
previou
agvhd
hr
femal
donor
hr
confirm
detriment
role
contrari
atg
util
associ
signific
reduct
cgvhd
hr
conclus
atg
seem
prevent
cgvhd
without
affect
relaps
transplantrel
mortal
conflict
interest
none
author
anyth
disclos
tabl
tabl
ipofg
porto
de
de
medula
porto
portug
background
graftversushost
diseas
gvhd
immunolog
disord
affect
mani
organ
system
includ
gastrointestin
tract
liver
skin
lung
chronic
gvhd
cgvhd
still
major
complic
longterm
survivor
allohsct
occur
patient
surviv
month
transplant
pulmonari
involv
common
pulmonari
complic
significantli
contribut
late
mortal
allohsct
furthermor
lateonset
noninfecti
pulmonari
complic
present
restrict
lung
function
impair
restrict
pulmonari
function
test
pft
pattern
late
interstiti
pneumon
ip
cryptogen
organ
pneumonia
cop
airway
obstruct
obstruct
pft
pattern
bronchiol
obliteratan
bo
howev
bo
pulmonari
complic
current
consid
diagnost
cgvhd
late
ip
well
cop
may
occur
associ
cgvhd
regard
associ
manifest
cgvhd
rare
case
occur
isol
method
descript
clinic
case
result
femal
diagnos
acut
myeloid
leukemia
rc
hovon
arm
protocol
follow
consolid
high
dose
cytarabin
describ
allograft
bone
marrow
relat
donor
sister
hla
isogrup
cmv
igg
perform
januari
prophylaxi
gvhd
made
methotrex
cyclosporin
april
patient
irrit
cough
dyspnea
moder
effort
deterior
dyspnea
minim
effort
motiv
hospit
juli
patient
deni
dri
eye
dri
skin
weight
lost
diagnost
studi
carri
exclud
infect
cardiac
thromboembol
possibl
manifest
gvhd
ct
scan
evid
depolyz
glass
densif
upper
lobe
right
lung
sever
other
peribronchi
distribut
suggest
cop
spirometri
mix
ventilatori
alter
cpt
posit
respons
bronchodil
decreas
co
diffus
capac
pulmonari
biopsi
show
aspect
suggest
organiz
pneumonia
may
correspond
manifest
graft
diseas
treatment
kg
day
prednisolon
nebul
fluticazon
aclidinium
bromid
formoterol
initi
clinic
imag
improv
conclus
cop
rare
present
cgvhd
sometim
lead
complex
diagnosi
lead
delay
initi
therapi
major
patient
cop
persist
bothersom
progress
symptom
initi
therapi
oral
glucocorticoid
dose
prednison
mgkg
per
day
recoveri
usual
complet
resolut
symptom
normal
chest
film
occur
twothird
patient
symptomat
improv
occasion
quit
dramat
occur
one
two
week
although
patient
improv
gradual
sever
week
month
conflict
interest
noth
disclos
kyoto
univers
depart
hematolog
oncolog
kyoto
japan
kyoto
univers
hospit
depart
clinic
pharmacolog
therapeut
kyoto
japan
background
signific
drug
monitor
mycophenol
acid
mpa
activ
constitu
mycophenol
mofetil
mmf
unclear
gvhd
prophylaxi
cord
blood
transplant
cbt
method
retrospect
analyz
data
patient
receiv
first
cbt
gvhd
prophylaxi
calcineurin
inhibitor
plu
mmf
institut
receiv
mgkg
oral
mmf
everi
hour
day
measur
blood
concentr
mpa
immedi
hour
take
mmf
estim
area
curv
analyz
impact
mpa
day
transplant
outcom
result
median
observ
time
survivor
rang
day
median
age
rang
year
percentag
patient
diagnos
aml
md
ml
respect
percentag
patient
complet
remiss
partial
remiss
respect
fifti
two
percent
patient
receiv
myeloabl
condit
receiv
tbi
cumul
incid
neutrophil
engraft
median
day
neutrophil
engraft
rang
day
cumul
incid
preengraft
syndrom
pe
grade
iiiv
acut
gvhd
agvhd
grade
iiiiv
agvhd
limit
chronic
gvhd
cgvhd
extens
cgvhd
respect
twoyear
overal
surviv
cumul
incid
relaps
nonrelaps
mortal
respect
mpa
day
hml
mean
standard
deviat
associ
incid
pe
rate
sepsi
engraft
patient
hml
higher
patient
vs
p
mpa
day
hml
exclud
case
engraft
failur
divid
patient
two
group
incid
grade
iiiv
agvhd
tend
higher
group
hml
group
b
hml
vs
p
rate
reactiv
group
higher
group
b
vs
p
reason
result
might
frequent
use
corticosteroid
agvhd
group
level
serum
albumin
lower
p
incid
diarrhea
tend
higher
vs
p
group
signific
differ
two
group
overal
surviv
cumul
incid
relaps
cgvhd
conclus
cbt
blood
concentr
mpa
may
impact
incid
agvhd
infect
case
poor
nutrit
diarrhea
frequent
monitor
dose
adjust
mpa
may
necessari
sinc
blood
concentr
mpa
tend
low
clinic
trial
registri
registri
conflict
interest
author
noth
disclos
american
univers
beirut
medic
center
depart
intern
medicin
divis
gastroenterolog
beirut
lebanon
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
background
gastrointestin
gi
graft
versu
host
diseas
gvhd
occur
patient
undergo
allogen
hematopoiet
stem
cell
transplat
hsct
diagnosi
reli
combin
clinic
symptom
exclus
caus
diarrhea
histolog
evalu
gi
biopsi
howev
optim
endoscop
approach
still
unclear
area
gi
tract
highest
diagnost
yield
still
topic
debat
method
aim
compar
diagnost
yield
differ
anatom
site
biopsi
diagnosi
gi
gvhd
assess
correl
endosocop
find
histolopatholog
seri
patient
american
univers
beirut
medic
center
aubmc
tertiari
care
center
case
biopsi
proven
gi
gvhd
obtain
patholog
databas
aubmc
retrospect
analyz
demograph
clinic
endoscop
data
result
total
patient
diagnos
gi
gvhd
year
averag
age
diagnosi
year
patient
male
common
indic
hsct
acut
myeloid
leukemia
patient
common
present
symptom
sever
diarrhea
patient
diagnosi
gi
gvhd
occur
day
median
interv
day
patient
patient
histori
skin
gvhd
combin
upper
endoscopi
sigmoidoscopi
biopsi
highest
diagnost
yield
diagnos
gi
gvhd
compar
upper
endoscopi
sigmoidoscopi
colonoscopi
respect
macroscop
normal
mucosa
rectosigmoid
duoden
biopsi
highest
diagnost
yield
macroscop
abnorm
mucosa
highest
yield
rectosigmoid
biopsi
lower
endoscopi
duoden
biopsi
upper
endoscopi
conclus
patient
suspect
gi
gvhd
best
endoscop
approach
combin
upper
endoscopi
flexibl
sigmoidoscopi
biopsi
normal
well
abnorm
mucosa
emphas
normal
mucosa
biopsi
especi
duodenum
rectosigmoid
better
diagnost
yield
conflict
interest
author
noth
disclos
tabl
politecnica
dell
march
dipartimento
di
scienz
clinich
e
molecolari
ancona
itali
azienda
ospedaliero
universitaria
ospedali
riuniti
servizio
di
immunologia
clinica
ancona
itali
azienda
ospedaliero
universitaria
ospedali
riuniti
clinica
di
ematologia
ancona
itali
background
clinic
manifest
chronic
graftversushost
diseas
cgvhd
often
resembl
system
autoimmun
diseas
associ
autoantibodi
includ
antinuclear
antibodi
ana
report
clinic
prognost
relev
associ
still
unclear
tyrosin
kinas
inhibitor
nilotinib
current
investig
treatment
cgvhd
sought
investig
relationship
presenc
ana
outcom
cgvhd
follow
administr
nilotinib
method
fifteen
patient
sever
cgvhd
follow
hematopoiet
stem
cell
transplant
hsct
nine
transplant
patient
without
cgvhd
control
evalu
clinic
data
collect
file
panel
specif
ana
assess
quantit
immunoblot
assay
alifax
padova
itali
proport
cell
subpopul
includ
helper
cytotox
regulatori
b
lymphocyt
nk
nkt
cell
assess
flow
cytometri
bekton
dickinson
san
ca
data
compar
test
differ
consid
statist
signific
p
result
patient
develop
cgvhd
organ
commonli
involv
skin
eyesmouth
sicca
syndrom
lung
ana
detect
seven
patient
figur
panel
frequent
specif
antissaro
case
specif
antissb
anticenp
ab
antinucleosom
antipmscl
case
sicca
syndrom
clinic
manifest
associ
presenc
ana
case
follow
skin
diseas
case
one
control
test
anaposit
figur
panel
note
patient
suffer
isol
xerostomia
differ
time
cgvhd
onset
follow
hsct
observ
anaposit
ananeg
patient
vs
day
compar
control
figur
panel
cgvhd
patient
significantli
higher
proport
nkt
cell
p
lower
proport
b
nk
cell
p
ratio
shown
well
regulatori
cell
figur
panel
f
compar
two
group
howev
latter
subset
show
trend
toward
higher
valu
among
anaposit
compar
ananeg
cgvhd
patient
vs
differ
cgvhd
progress
respons
nilotinib
observ
anaposit
ananeg
patient
six
month
treatment
eight
anaposit
remain
stabl
seven
anaposit
improv
conclus
agreement
publish
data
presenc
ana
frequent
among
patient
develop
cgvhd
uncommon
among
transplant
patient
without
condit
common
cgvhd
clinic
featur
skin
diseas
sicca
syndrom
latter
also
frequent
manifest
among
anaposit
cgvhd
individu
although
frequenc
b
cell
increas
among
patient
develop
cgvhd
data
suggest
b
cell
may
play
pathogen
role
onset
condit
presenc
ana
may
predict
develop
particular
clinic
manifest
sicca
syndrom
sixmonth
cours
nilotinib
stabil
improv
cgvhd
studi
patient
independ
presenc
ana
evalu
autoantibodi
immun
popul
nilotinib
treatment
ongo
conflict
interest
author
noth
disclos
king
fahd
specialist
hospit
adult
hematolog
stem
cell
transplant
depart
dammam
saudi
arabia
background
despit
improv
chronic
graft
vs
host
diseas
cgvhd
manag
still
remain
lead
caus
late
nonrelaps
mortal
also
contribut
high
morbid
rate
poor
qualiti
life
post
allogen
stem
cell
transplant
allosct
even
modernera
gvhd
treatment
kinas
inhibitor
consider
number
patient
cgvhd
control
new
approach
highli
demand
overcom
refractori
method
herein
present
clinic
cours
outcom
patient
refractori
cgvhd
multipl
line
treatment
includ
inhibitor
ruxolitinib
inhibitor
bortezomib
given
singl
agent
howev
combin
bortezomib
ruxolitinib
proven
extrem
efficaci
suggest
addit
effect
two
agent
result
year
old
male
allograft
hepatosplen
tcell
lymphoma
myeloabl
regimen
consist
total
bodi
irradi
cyclophosphamid
graft
sourc
blood
stem
cell
fullmatch
sister
gvhd
prophylaxi
cyclosporin
plu
shortterm
methotrex
administ
earli
cours
post
transplant
unev
howev
second
month
post
allosct
immunosuppress
taper
rigor
molecularli
detect
diseas
two
month
later
achiev
complet
molecular
remiss
donororigin
hematopoiet
cell
presenc
inducedgvhd
extens
skin
involv
scleroderma
lichenoid
lesion
highest
modifiedrodnan
skin
score
mrss
sever
buccal
mucos
liver
involv
highest
level
sgot
iul
sgpt
uil
alp
uil
total
billirubin
umol
first
treat
calcineurin
inhibitor
plu
steroid
improv
notic
mycophenol
mofetil
mmf
ad
howev
signific
respons
achiev
sinc
extracorpor
photopheresi
avail
patient
put
ruxolitinib
bid
month
treatment
discontinu
gvhd
progress
skinliv
next
put
bortezomib
day
everi
day
plu
mmf
steroid
cycl
patient
stabl
find
still
steroid
depend
differ
mechan
action
decid
add
treatment
ruxolitinib
bid
month
combin
patient
experienc
markedli
skin
improv
sclerodermatosi
improv
mrss
lichenoid
lesion
disappear
liver
test
becam
normal
notic
month
treatment
patient
mmf
steroid
dose
feasibl
reduc
still
bortezomib
ruxolitinib
aforement
dose
treatment
period
experienc
major
toxic
includ
neuropathi
myelotox
last
evalu
complet
metabol
remiss
statu
along
donor
chimera
confirm
conclus
heavili
retreat
patient
refractori
cgvhd
combin
bortezobib
ruxolitinib
prove
highli
effect
demonstr
also
toxic
inhibitori
effect
lymphocyt
addit
antiinflammatori
properti
bortezomib
ruxolitinib
seem
result
possibl
synergist
complementari
effect
undoubtedli
futur
clinic
trial
clarifi
role
combin
treatment
cgvhd
conflict
interest
author
noth
disclos
st
luke
intern
hospit
depart
hematolog
tokyo
japan
background
tacrolimu
tac
commonli
adopt
allogen
hematopoiet
stem
cell
transplant
allosct
prevent
graftversushost
diseas
gvhd
tac
plu
shortterm
methotrex
use
one
standard
regimen
gvhd
prophylaxi
usual
continu
infus
intraven
tac
tac
civ
convert
oral
twicedaili
formul
tac
bid
patient
recov
regimenrel
gastrointestin
toxic
oncedaili
modifi
releas
formul
oral
tac
tac
qd
recent
develop
report
almost
equival
tac
bid
kidney
liver
transplant
tac
qd
expect
contribut
improv
conveni
adher
allsct
recipi
method
retrospect
review
clinic
outcom
patient
underw
allosct
decemb
april
use
tac
qd
convert
tac
civ
gvhd
prophylaxi
result
twentyfour
patient
includ
studi
median
age
patient
time
sct
year
one
patient
receiv
relat
bone
marrow
relat
peripher
blood
stem
cell
unrel
bone
marrow
thirteen
patient
receiv
myeloabl
condit
median
time
convers
civ
qd
day
sct
major
convers
rate
civ
qd
studi
cumul
incid
grade
iiiv
acut
gvhd
day
probabl
overal
surviv
cumul
incid
nonrelaps
mortal
year
respect
ten
patient
experienc
ctcae
grade
increas
creatinin
convers
tac
qd
requir
transient
suspens
drug
patient
grade
increas
aspar
aminotransferas
ast
andor
alanin
aminotransferas
alt
occur
patient
cumul
incid
termin
immunosuppress
agent
includ
tac
gvhd
prophylaxi
andor
treatment
year
respect
conclus
studi
show
tac
qd
well
toler
similar
efficaci
safeti
profil
tac
bid
allosct
oncedaili
medic
regimen
tac
qd
improv
conveni
drug
adher
gvhd
prophylaxi
allosct
conflict
interest
author
noth
disclos
newcastl
univers
newcastl
upon
tyne
unit
kingdom
newcastl
univers
icm
newcastl
upon
tyne
unit
kingdom
background
evid
suggest
imbal
cytokin
set
acut
graftversushost
diseas
agvhd
restor
balanc
may
benefici
manag
agvhd
report
one
mechan
behind
extracorpor
photopheresi
ecp
howev
chang
cytokin
set
agvhd
previous
studi
use
ratio
interferon
gamma
interleukin
use
previou
studi
repres
balanc
cytokin
method
measur
cytokin
paediatr
patient
receiv
ecp
treatment
agvhd
follow
allogen
haematopoiet
cell
transplant
malign
primari
immun
defici
serum
sampl
taken
ecp
treatment
cytokin
measur
use
enhanc
cytokin
bead
assay
bd
bioscienc
cba
human
enhanc
sensit
master
buffer
kit
use
marker
repres
balanc
ratio
calcul
use
mean
absolut
valu
time
point
patient
result
analysi
data
show
reduct
ifni
ratio
therapi
figur
calcul
use
median
ratio
patient
timepoint
consist
resolut
symptom
agvhd
conclus
although
prospect
data
need
preliminari
evid
suggest
ecp
may
modul
cytokin
profil
agvhd
possibl
mediat
effect
dc
polaris
thelper
holtick
u
et
al
transplant
clinic
trial
registri
na
conflict
interest
author
noth
disclos
univers
kansa
medic
center
depart
hematolog
malign
cellular
therapi
westwood
ks
unit
state
univers
kansa
medic
center
patholog
laboratori
medicin
westwood
ks
unit
state
univers
kansa
medic
center
hematolog
malign
cellular
therapi
westwood
ks
unit
state
univers
kansa
medic
center
depart
biostatist
school
medicin
westwood
ks
unit
state
background
graftversushost
diseas
major
contributor
morbid
mortal
allogen
hct
patient
incid
acut
gvhd
high
transplant
hla
ident
sibl
mud
greinix
chronic
gvhd
occur
allogen
hct
patient
fatal
case
corticosteroid
standard
treatment
gvhd
steroidrefractori
surviv
poor
standard
secondlin
therapi
although
option
includ
mycophenyl
mofetil
sirolimu
rituximab
monoclon
antibodi
recent
fdaapprov
ibrutinib
ecp
involv
remov
cell
patient
treat
psoralen
expos
ultraviolet
light
induc
apoptosi
lymphocyt
reinfus
apoptot
lymphocyt
tolerogen
effect
antigenpres
cell
respons
rate
chronic
gvhd
bredeson
howev
respons
may
take
week
manifest
flower
beaton
effect
ecp
treat
chronic
gvhd
along
limit
data
suggest
efficaci
gvhd
prevent
shaughnessi
miller
creat
interest
studi
ecp
prophylaxi
method
singlecent
seventeenpati
prospect
cohort
conduct
kansa
univers
cancer
center
includ
patient
underw
myeloabl
allogen
hct
hematolog
malign
patient
exclud
felt
unabl
toler
ecp
receiv
rituximab
within
month
patient
treat
aml
cml
lymphoma
also
includ
particip
provid
inform
consent
approv
institut
review
board
kumc
patient
receiv
myeloabl
condit
either
busulphan
cyclophosphamid
cyclophosphamid
total
bodi
irradi
tbi
patient
receiv
gvhd
prophylaxi
tacrolimu
cyclosporin
plu
methotrex
atg
allow
unrel
donor
particip
receiv
two
ecp
treatment
prior
condit
regimen
well
addit
treatment
day
patient
assess
weekli
day
least
everi
three
month
day
per
nih
protocol
result
patient
consent
one
patient
withdrew
consent
prior
receiv
ecp
treatment
patient
receiv
ecp
treatment
complet
entir
protocol
six
patient
receiv
partial
protocol
subsequ
remov
protocol
withdrew
consent
due
medic
complic
malign
patient
receiv
ecp
includ
analysi
ten
total
agvhd
event
occur
grade
two
one
grade
two
grade
actuari
rate
agvhd
one
death
attribut
agvhd
six
total
cgvhd
event
occur
mildmoder
sever
actuari
rate
cgvhd
overal
surviv
aml
patient
two
year
advers
event
attribut
ecp
addit
transfus
need
safe
undergo
ecp
minim
four
sixteen
patient
requir
addit
blood
product
unit
prbc
unit
platelet
conclus
studi
small
draw
conclus
efficaci
howev
highrisk
cohort
major
mud
mismatch
donor
acut
chronic
gvhd
rate
within
accept
rang
occur
mildmoder
sever
aml
patient
outcom
excel
twoyear
overal
surviv
random
control
trial
use
prophylact
ecp
warrant
conflict
interest
fund
therako
medic
univers
gdansk
depart
hematolog
transplantolog
gdansk
poland
medic
univers
gdansk
depart
monitor
therapi
pharmacogenet
gdansk
poland
background
allogen
hematopoiet
cell
transplant
hct
cur
option
patient
haematolog
malign
howev
nonrelaps
mortal
relat
infecti
complic
acut
graft
versu
host
diseas
gvhd
still
import
subpopul
proinflammatori
lymphocyt
may
impact
hct
outcom
correl
amount
lymphocyt
occurr
earli
posthct
complic
aim
studi
method
prospect
analys
data
patient
undergo
hct
last
month
due
haematolog
malign
studi
includ
femal
male
patient
median
age
year
ten
patient
transplant
unrel
donor
mudmmud
sibl
haploident
donor
analys
count
tregulatori
lymphocyt
treg
peripher
blood
concentr
serum
sampl
collect
prior
condit
hct
day
use
flow
cytometri
lymphocyt
defin
cell
treg
result
patient
acut
gvhd
grade
iii
diagnos
case
skin
involv
patient
skin
intestin
manifest
median
time
hct
agvhd
develop
day
rang
median
time
engraft
day
rang
one
patient
achiev
neutrophil
engraft
seriou
infecti
complic
defin
bacteraemia
septic
shock
typhliti
observ
case
fever
unknown
origin
patient
correl
lymphocyt
count
procedur
infecti
event
hct
median
valu
x
find
connect
amount
sct
day
hct
gvhd
develop
howev
strong
correl
lower
absolut
count
day
agvhd
develop
median
valu
x
gvhd
group
vs
x
p
one
week
median
time
gvhd
occurr
addit
observ
chang
median
fluoresc
intens
mfi
shift
bright
fluoresc
time
agvhd
develop
gvhd
onset
mfi
vs
mfi
onset
patient
gvhd
also
present
lower
ratio
day
p
observ
differ
treg
amount
group
serum
level
correl
amount
cell
except
day
sct
p
detect
examin
sampl
median
valu
fgml
conclus
higher
lymphocyt
count
hct
protect
valu
infecti
complic
lower
amount
time
regener
may
prognost
factor
gvhd
develop
chang
mfi
valu
need
investig
conflict
interest
sadowskaklasa
noth
disclos
ege
univers
medic
faculti
depart
hematolog
izmir
turkey
ege
univers
medic
faculti
depart
ophthalmolog
izmir
turkey
background
ocular
complic
develop
substanti
percentag
patient
allogen
stem
cell
transplant
asct
one
import
complic
ocular
graft
versu
host
diseas
gvhd
develop
patient
asct
typic
present
dri
eye
keratoconjunct
sicca
kc
ocular
gvhd
potenti
lead
blind
impair
qualiti
life
method
one
hundr
seventi
three
patient
underw
asct
januari
june
includ
studi
ocular
complic
treatment
retrospect
record
ocular
gvhd
evalu
short
tear
breakup
time
decreas
schirmer
test
ocular
surfac
stain
score
accord
oxford
scheme
rang
result
patient
femal
male
underw
asct
male
femal
develop
ocular
gvhd
underli
diseas
acut
myeloid
leukemia
n
acut
lymphoblast
leukemia
n
myelodysplast
syndrom
n
myelofibrosi
n
lymphoma
n
aplast
anemia
patient
receiv
peripher
blood
stem
cell
sourc
match
sibl
donor
msd
transplant
match
unrel
donor
mud
transplant
haploident
transplant
median
age
first
symptom
year
median
time
first
symptom
month
common
ocular
manifest
ocular
gvhd
kc
sever
score
ocular
gvhd
shown
tabl
oxford
stain
score
grade
grade
grade
grade
grade
grade
patient
manifest
cataract
requir
surgeri
corneal
perfor
due
grade
kc
patient
treat
bandag
contact
len
patient
diagnos
kc
treat
artifici
tear
twenti
requir
addit
topic
cyclosporin
requir
addit
topic
steroid
fluorometholon
loteprednol
conclus
ocular
gvhd
present
kc
common
ocular
complic
asct
sever
kc
even
corneal
perfor
might
end
loss
eye
may
develop
order
prevent
undesir
complic
patient
underw
asct
care
monitor
possibl
ocular
gvhd
appropri
treatment
promptli
start
need
conflict
interest
author
noth
disclos
tabl
sever
score
ocular
gvhd
univers
toronto
allogen
blood
marrow
transplant
program
princess
margaret
cancer
centr
toronto
canada
background
chronic
graft
versu
host
diseas
cgvhd
major
complic
follow
allogen
hematopoiet
stem
cell
transplant
hct
mani
studi
shown
elev
pretranspl
ferritin
level
associ
increas
risk
morbid
mortal
follow
hct
given
ferritin
associ
system
inflamm
plausibl
potenti
prognost
marker
onset
cgvhd
present
studi
attempt
determin
prognost
impact
serum
ferritin
level
time
cgvhd
diagnosi
method
sixtytwo
patient
ferritin
level
data
avail
cgvhd
diagnosi
enrol
studi
patient
underw
hct
diagnos
cgvhd
princess
margaret
cancer
centr
toronto
canada
patient
characterist
median
age
refin
diseas
risk
index
low
intermedi
high
donor
type
hlamatch
relat
donor
hlamatch
partiallymatch
unrel
donor
condit
regimen
myeloabl
n
reduc
intens
cgvhd
classifi
use
nih
consensu
criteria
primari
outcom
overal
surviv
os
cgvhdrelat
mortal
crm
relaps
kaplanmei
method
use
os
cumul
incid
use
crm
relaps
consid
compet
risk
multivari
analysi
employ
cox
proport
hazard
regress
model
os
finegray
method
incid
crm
relaps
factor
evalu
includ
recipi
age
donorrecipi
sex
cmv
match
comorbid
score
perform
index
gvhd
prophylaxi
ferritin
level
cgvhd
diagnosi
ferritin
level
prior
hct
recurs
partit
use
stratifi
patient
low
high
risk
group
base
serum
ferritin
level
cgvhd
diagnosi
vs
ngml
prior
hct
vs
ngml
factor
p
univari
analysi
includ
multivari
analysi
result
signific
differ
patient
characterist
low
high
ferritin
level
cgvhd
group
median
followup
durat
among
survivor
month
diagnosi
cgvhd
median
onset
cgvhd
day
median
ferritin
level
cgvhd
ngml
fig
correl
ferritin
level
cgvhd
diagnosi
prior
hct
univari
analysi
reveal
compar
lowferritin
cgvhd
group
highferritin
group
decreas
os
rate
vs
p
fig
b
increas
crm
rate
vs
p
fig
c
differ
relaps
incid
vs
fig
multivari
analysi
ferritin
level
cgvhd
diagnosi
found
independ
prognost
factor
os
p
hr
ci
crm
p
hr
ci
high
ferritin
level
cgvhd
diagnosi
also
show
good
correl
increas
cgvhd
grade
conclus
cohort
elev
ferritin
level
time
cgvhd
diagnosi
significantli
associ
decreas
os
increas
crm
independ
prognost
factor
includ
prehct
ferritin
level
find
suggest
ferritin
level
cgvhd
could
use
stratifi
patient
accord
prognosi
time
diagnosi
cgvhd
addit
studi
includ
larger
sampl
size
prospect
investig
warrant
conflict
interest
author
report
conflict
interest
leiden
univers
medic
center
hematolog
leiden
netherland
leiden
univers
medic
center
patholog
leiden
netherland
leiden
univers
medic
center
molecular
cell
biolog
leiden
netherland
vu
univers
medic
center
center
gynaecolog
oncolog
amsterdam
netherland
background
condit
regimen
preced
allogen
stem
cell
transplant
allosct
caus
tissu
damag
acceler
develop
graftversushost
diseas
gvhd
tcell
deplet
allosct
postpon
applic
donor
lymphocyt
infus
dli
may
reduc
gvhd
tissu
injuri
restor
time
dli
studi
investig
presenc
tissu
injuri
inflammatori
condit
skin
period
hematolog
recoveri
immun
reconstitut
allosct
method
skin
biopsi
immunohistochem
stain
hla
class
ii
use
marker
hla
class
ii
express
cell
character
activ
tcell
activ
profession
antigen
present
cell
apc
tissu
repair
macrophag
sex
mismatch
patient
donor
coupl
origin
cell
skin
biopsi
determin
multiplex
analysi
combin
xyfish
fluoresc
immunohistochemistri
result
inflammatori
environ
due
pretranspl
condit
detect
time
infus
stem
cell
graft
irrespect
type
condit
regimen
appli
signific
increas
hla
class
ii
posit
macrophag
increas
tcell
observ
immun
reconstitut
period
week
total
bodi
irradi
contain
myeloabl
allosct
macrophag
show
sign
interact
coloc
patient
donor
tcell
contrast
skin
biopsi
taken
gvhd
increas
hla
class
ii
express
cell
coincid
tcell
interact
observ
result
overt
inflammatori
reaction
presenc
activ
apc
activ
donor
tcell
local
upregul
hla
class
ii
express
epiderm
cell
absenc
gvhd
hla
class
ii
posit
macrophag
patient
origin
gradual
replac
time
donor
deriv
macrophag
although
patient
deriv
macrophag
detect
even
week
allosct
conclus
condit
regimen
appli
prior
allosct
caus
tissu
damag
skin
tissu
damag
result
local
increas
activ
apc
contrast
inflam
situat
gvhd
interact
take
place
activ
apc
activ
donor
tcell
tissu
damag
caus
allosct
result
dermal
recruit
hla
class
ii
posit
tissu
repair
macrophag
coexist
increas
number
patient
donor
deriv
tcell
without
sign
specif
interact
initi
immun
respons
thu
local
skin
damag
caus
condit
regimen
appear
insuffici
singl
factor
provok
gvhd
induct
conflict
interest
author
conflict
interest
disclos
children
hospit
soochow
univers
suzhou
china
background
umbil
cord
blood
transplant
ucbt
wide
use
effect
treatment
children
hematolog
malign
good
immun
reconstitut
fewer
viral
reactiv
thymoglobulin
omit
ucbt
children
hematolog
malign
howev
graftversushost
diseas
gvhd
common
complic
transplant
affect
outcom
ucbt
total
nucleat
cell
tnc
dose
human
leukocyt
antigen
hla
match
affect
probabl
gvhd
outcom
ucbt
howev
priorit
characterist
unit
select
well
establish
method
review
outcom
ucbt
children
transplant
hematolog
malign
myeloabl
condit
calcineurininhibitor
mycophenol
mofetil
immunosuppress
median
age
ucbt
month
rang
month
median
weight
kg
rang
kg
patient
surviv
day
myeloid
engraft
result
median
dose
tnc
rang
patient
infus
tnc
patient
infus
tnc
notabl
higher
probabl
iiiiv
acut
gvhd
agvhd
found
patient
infus
higher
dose
tnc
versu
howev
differ
rate
chronic
gvhd
cgvhd
proport
surviv
versu
versu
respect
hlaa
b
c
allel
match
mismatch
mm
allel
mm
allel
compar
recipi
mm
unit
recipi
mm
unit
higher
rate
cgvhd
versu
lower
rate
surviv
versu
differ
rate
agvhd
versu
conclus
find
support
consider
hla
b
allel
donorrecipi
hlamatch
unit
select
control
infus
dose
tnc
practic
chang
field
conflict
interest
author
declar
conflict
interest
workw
declar
commerci
associ
interest
repres
conflict
interest
connect
work
submit
complejo
asistenci
universitario
de
salamancaibs
hematolog
salamanca
spain
background
chronic
gvhd
remain
therapeut
challeng
steroid
standard
treatment
outcom
satisfactori
imatinib
test
steroidsrefractori
gvhd
srgvhd
inhibit
autoantibodi
againt
pdgfr
identifi
patient
sclerot
chronic
gvhd
retrospect
studi
shown
variabl
respons
result
random
phase
ii
salli
arai
et
al
month
lower
probabl
longterm
followup
beyond
month
neccesari
due
sclerot
process
gvhd
revers
slowli
method
report
retrospect
analysi
patient
srcgvhd
treat
imatinib
cgvhd
diagnosi
respons
evalu
stablish
nih
criteria
respons
evalu
month
imatinib
start
mgday
increas
mg
accord
respons
toler
result
baselin
transplant
characterist
chronic
gvhd
data
start
imatinib
shown
tabl
median
time
cgvhd
imatinib
treatment
month
patient
receiv
line
treatment
prior
imatinib
sever
moder
cgvhd
median
durat
treatment
month
median
dosi
mgday
patient
evalu
month
exitu
discontinu
treatment
month
intoler
potenci
toxic
non
respons
evalu
show
orr
partial
respons
patient
respons
stabl
diseas
progress
diseas
evalu
orr
complet
respons
partial
respons
n
patient
stabl
diseas
could
stop
lower
steroid
patient
treat
steroid
time
start
imatinib
regard
safeti
data
grade
side
effect
observ
patient
discontinu
imatinib
due
gastrointestin
intoler
edema
median
followup
start
treatment
month
patient
still
treatment
still
aliv
exitu
due
cgvhd
conclus
imatinib
success
rate
low
assess
longer
durat
treatment
show
higher
orr
prospect
trial
longterm
followup
necessari
verifi
efficaci
conflict
interest
noth
disclos
tabl
tabl
pavlov
first
saint
petersburg
state
medic
univers
rm
gorbacheva
memori
institut
hematolog
oncolog
transplant
saintpetersburg
russian
feder
background
steroidrefractori
graftversushost
diseas
srgvhd
lifethreaten
complic
allogen
stem
cell
transplant
current
standard
care
complic
exist
modal
surviv
remain
rel
low
pilot
studi
conduct
children
adult
develop
steroidrefractori
steroiddepend
acut
chronic
gvhd
method
patient
age
year
children
adult
includ
prospect
studi
ebmteln
criteria
use
steroid
refractori
diseas
ruutu
et
al
acut
srgvhd
moder
sever
chronic
srgvhd
acut
myeloid
leukemia
acut
lymphoblast
leukemia
nonmalign
diseas
malign
diseas
graft
relat
donor
unrel
haploident
patient
acut
gvhd
median
prior
line
therapi
rang
patient
chronic
gvhd
median
prior
line
rang
acut
gvhd
patient
grade
iiiiv
diseas
chronic
gvhd
patient
sever
nih
diseas
ruxolinib
administ
start
dose
mg
bid
adult
mgkgday
bid
tid
children
dose
modif
perform
patient
grade
hematolog
toxic
ruxolinib
continu
complet
respons
absenc
respons
day
acut
gvhd
six
month
chronic
gvhd
result
median
followup
aliv
patient
month
rang
overal
respons
acut
gvhd
complet
respons
cr
observ
patient
median
time
cr
day
rang
one
patient
continu
partial
respons
pr
one
progress
diseas
overal
respons
chronic
gvhd
patient
achiev
cr
median
month
treatment
rang
month
achiev
pr
median
month
treatment
rang
five
patient
relaps
therapi
four
die
due
progress
underli
malign
nonrelaps
mortal
occur
patient
multidrugresist
sepsi
caus
death
case
overal
surviv
higher
chronic
acut
srgvhd
patient
vs
differ
respons
rate
mortal
adult
children
p
stratif
type
gvhd
three
sever
advers
event
document
chronic
gvhd
group
sepsi
myasthenia
gravi
rsviru
pneumonia
eight
acut
gvhd
patient
sepsi
one
bkviru
enceph
one
viral
gastriti
recurr
sever
bleed
one
mixedpathogen
pneumonia
requir
mechan
ventil
dose
reductiondrug
interrupt
due
cytopenia
requir
acut
gvhd
chronic
gvhd
patient
conclus
despit
small
group
size
preliminari
result
indic
ruxolitinib
promis
agent
srgvhd
random
prospect
studi
requir
confirm
ruxolitinib
superior
approach
clinic
trial
registri
clinicaltrialsgov
conflict
interest
moiseev
novarti
honoraria
consult
fee
travel
grant
author
noth
disclos
aphp
st
loui
deni
diderot
inserm
umr
pari
franc
univers
leipzig
depart
hematolog
oncolog
leipzig
germani
royal
melbourn
hospit
melbourn
australia
hopit
saintantoin
pari
franc
univers
hospit
freiburg
depart
hematolog
oncolog
stem
cell
transplant
freiburg
germani
novarti
pharmaceut
corpor
east
hanov
nj
unit
state
novarti
pharma
ag
basel
switzerland
background
success
allogen
hematopoiet
stem
cell
transplant
allohsct
hamper
graftversushost
diseas
gvhd
increas
mortal
risk
patient
steroid
refractori
sr
acut
gvhd
agvhd
treatment
popul
remain
unmet
need
use
ruxolitinib
treatment
patient
sragvhd
support
retrospect
analysi
zeiser
et
al
present
global
studi
develop
evalu
ruxolitinib
phase
trial
method
random
openlabel
multicent
studi
ruxolitinib
mg
twice
daili
vs
investigatordetermin
best
avail
therapi
bat
patient
sragvhd
post
allohsct
figur
patient
age
year
clinic
diagnos
grade
sragvhd
evid
myeloid
platelet
engraft
absolut
neutrophil
count
platelet
elig
inclus
exclus
criteria
compris
patient
receiv
system
treatment
sragvhd
clinic
present
resembl
de
novo
chronic
gvhd
gvhd
overlap
syndrom
acut
chronic
gvhd
featur
fail
prior
sct
month
activ
uncontrol
infect
primari
object
compar
efficaci
ruxolitinib
vs
bat
overal
respons
rate
orr
day
treatment
orr
defin
proport
patient
arm
exhibit
complet
respons
cr
partial
respons
pr
without
receiv
addit
system
therapi
earlier
progress
mix
respons
nonrespons
key
secondari
object
compar
rate
durabl
orr
day
ruxolitinib
bat
defin
proport
patient
arm
achiev
crpr
day
maintain
crpr
day
secondari
object
includ
orr
day
durat
respons
cumul
steroid
dose
day
overal
surviv
eventfre
surviv
failurefre
surviv
nonrelaps
mortal
malign
relapseprogress
incid
cgvhd
pharmacokinet
paramet
exposureefficaci
relationship
patientreport
outcom
safeti
target
enrol
random
patient
result
first
patient
first
visit
occur
march
conclus
enrol
ongo
decemb
patient
random
clinic
trial
registri
clinicaltrialsgov
conflict
interest
g
honoraria
speaker
symposium
novarti
niederwies
consult
novarti
j
szer
advisori
board
consult
honoraria
alexion
advisori
board
consult
honoraria
consult
speaker
shire
pharmaceut
advisori
board
honoraria
consult
speaker
sanofigenzym
advisori
board
honoraria
consult
consult
speaker
pfizer
advisori
board
amgen
advisori
board
novarti
mohti
consult
novarti
consult
honoraria
research
fund
consult
speak
sanofi
r
zeiser
honoraria
invit
speaker
symposium
jazz
pharmaceut
honoraria
invit
speaker
novarti
b
gadbaw
b
molloy
employe
novarti
l
osullivandjentuh
conflict
interest
disclos
n
von
bubnoff
consult
role
trial
steer
committe
novarti
research
fund
novarti
honoraria
bm
trial
regist
clinicaltrialsgov
memori
sloan
ketter
cancer
center
new
york
ny
unit
state
washington
univers
school
medicin
st
loui
mo
unit
state
hospit
universitario
puerta
de
hierro
majadahonda
madrid
spain
incyt
corpor
wilmington
de
unit
state
univers
milan
azienda
socio
sanitaria
territorial
papa
giovanni
xxiii
bergamo
itali
background
gvhd
signific
sourc
patient
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
allohsct
current
standard
care
gvhd
prophylaxi
calcineurin
inhibitor
cni
combin
methotrex
mtx
mycophenol
mofetil
mmf
antithymocyt
globulin
atg
commonli
use
regimen
itacitinib
potent
select
janu
kinas
jak
inhibitor
demonstr
accept
safeti
profil
combin
steroid
phase
studi
patient
acut
gvhd
report
describ
studi
design
ongo
trial
assess
efficaci
safeti
itacitinib
ad
cnibas
gvhd
prophylaxi
regimen
method
singlearm
openlabel
phase
studi
evalu
itacitinib
combin
cnibas
regimen
gvhd
prophylaxi
studi
enrol
patient
age
year
undergo
allohsct
use
peripher
blood
stem
cell
pbsc
match
relat
unrel
donor
hematolog
malign
candid
reducedintens
condit
regimen
karnofski
perform
statu
ps
score
ecog
ps
patient
exclud
receiv
prior
allohsct
jak
inhibitor
therapi
activ
uncontrol
infect
sever
organ
dysfunct
patient
initi
oral
itacitinib
mg
qd
day
allohsct
dose
reductioninterrupt
permit
toxic
manag
treatment
taper
day
discontinu
day
unless
patient
diagnos
gvhd
experi
malign
relaps
unaccept
toxic
withdraw
consent
cnibas
gvhd
therapi
tacrolimusmtx
cyclosporin
ammf
without
atg
administ
per
institut
practic
result
approxim
patient
enrol
primari
endpoint
hematolog
recoveri
defin
proport
patient
neutrophil
platelet
recoveri
day
secondari
endpoint
includ
gvhd
relapsefre
surviv
grf
relapsefre
surviv
rf
transplantrel
mortal
trm
safeti
assess
addit
secondari
endpoint
describ
figur
conclus
import
evalu
efficaci
safeti
itacitinib
combin
cnibas
regimen
gvhd
prophylaxi
expect
provid
key
insight
inform
futur
gvhd
prophylaxi
studi
clinic
trial
registri
conflict
interest
peral
schroeder
receiv
honoraria
research
fund
incyt
corpor
r
duart
receiv
honoraria
particip
advisori
board
incyt
corpor
arbushit
p
langmuir
yan
employ
stock
incyt
corpor
rambaldi
declar
potenti
conflict
interest
studi
fund
incyt
corpor
univers
hospit
freiburg
freiburg
im
breisgau
germani
incyt
corpor
wilmington
de
unit
state
massachusett
gener
hospit
boston
unit
state
background
approxim
patient
receiv
allogen
hematopoiet
stem
cell
transplant
ahsct
hematolog
disord
develop
acut
graftversushost
diseas
agvhd
lead
caus
nonrelaps
mortal
nrm
fdaapprov
treatment
agvhd
minor
patient
experi
sustain
respons
corticosteroid
cs
standardofcar
treatment
janu
activ
kinas
jak
implic
gvhd
pathogenesi
jak
inhibitor
demonstr
improv
agvhd
outcom
preserv
graftversusleukemia
effect
preclin
model
shown
preliminari
clinic
efficaci
patient
csrefractori
agvhd
itacitinib
potent
select
inhibitor
demonstr
accept
safeti
profil
phase
studi
patient
csnaiv
csrefractori
agvhd
report
summar
studi
design
ongo
phase
trial
firstlin
treatment
itacitinib
patient
agvhd
method
random
doubleblind
placebocontrol
multicent
phase
studi
compar
efficaci
itacitinib
placebo
combin
cs
firstlin
treatment
agvhd
elig
patient
year
age
receiv
ahsct
hematolog
malignancydisord
grade
iiiv
agvhd
magic
criteria
patient
exclud
receiv
ahsct
day
cs
agvhd
cs
indic
gvhd
within
day
random
prior
jak
inhibitor
therapi
sinc
ahsct
gvhd
overlap
syndrom
activ
infect
evid
relaps
primari
diseas
sever
organ
dysfunct
estim
patient
random
itacitinib
mg
oral
qd
placebo
methylprednisolon
prednison
equival
mgkgd
dose
appropri
diseas
sever
per
local
treatment
guidelin
patient
receiv
studi
treatment
treatment
failur
unaccept
toxic
complet
treatment
taper
death
result
primari
endpoint
overal
respons
rate
orr
day
key
secondari
endpoint
nrm
month
addit
secondari
endpoint
describ
figur
conclus
trial
expect
provid
comprehens
efficaci
safeti
data
itacitinib
initi
therapi
combin
cs
patient
agvhd
may
inform
futur
treatment
strategi
clinic
trial
registri
http
conflict
interest
r
zeiser
serv
steer
committe
member
novarti
incyt
corpor
arbushit
p
langmuir
yan
employ
stock
incyt
corpor
bin
chen
serv
consult
takeda
pharmaceut
magenta
therapeut
jazz
pharmaceut
engen
incyt
corpor
studi
fund
incyt
corpor
abstract
encor
abstract
submit
present
bmt
tandem
hopit
stloui
lariboisier
hematolog
pari
franc
hopit
hautlevequ
hematolog
pessac
franc
chu
de
lill
hematolog
lill
franc
chu
clermont
ferrand
hematolog
clermont
ferrand
franc
institut
paoli
calmett
hematolog
marseil
franc
chu
hautepierr
hematolog
strasbourg
franc
hopit
necker
hematolog
pari
franc
centr
leon
berard
hematolog
lyon
franc
institut
jule
bordet
hematolog
bruxel
belgium
univers
melbourn
faculti
medicin
melbourn
australia
elsalysbiotech
lyon
franc
biossec
pari
franc
hopit
piti
salpetrier
hematolog
pari
franc
background
despit
improv
allogen
hematopoiet
stem
cell
transplant
acut
graftversushost
diseas
agvhd
remain
signific
issu
transplant
major
caus
nonrelaps
mortal
especi
case
steroidresist
sr
recent
publish
result
phase
random
studi
compar
inolimomab
monoclon
antibodi
versu
antithymocyt
globulin
atg
sra
gvhd
et
al
blood
composit
primari
object
evalu
overal
surviv
os
year
without
chang
baselin
alloc
therapi
studi
conclud
statist
signific
differ
two
arm
regard
primari
endpoint
favor
inolimomab
one
side
extens
safeti
analysi
could
complet
time
show
although
differ
two
group
regard
number
patient
experienc
least
one
advers
event
ae
grade
vs
inolimomab
atg
group
respect
report
complet
safeti
result
studi
method
fortynin
patient
random
inolimomab
atg
group
respect
median
time
onset
agvhd
day
rang
secondlin
treatment
start
day
initi
steroid
treatment
rang
without
signific
differ
two
arm
inolimomabtr
patient
receiv
mgkgday
induct
last
week
mgkg
time
per
week
mainten
total
treatment
durat
day
patient
control
arm
receiv
rabbit
atg
genzym
dose
mgkg
consecut
day
result
absolut
number
ae
grade
ae
significantli
increas
atg
group
compar
inolimomab
group
vs
vs
respect
p
number
patient
relat
ae
grade
relat
ae
grade
significantli
increas
atg
group
compar
inolimomab
group
vs
vs
respect
furthermor
statist
signific
differ
overal
incid
infecti
episod
appar
favor
inolimomab
p
reduct
potenti
lifethreaten
ae
like
sepsi
septic
shock
vs
vs
inolimomab
atg
group
respect
addit
exploratori
analysi
paramet
primari
composit
endpoint
show
trend
favor
inolimomab
mostli
driven
differ
os
year
one
side
differ
chang
initi
alloc
treatment
one
side
conclus
result
point
improv
toler
profil
inolimomab
especi
regard
lifethreaten
infect
compar
atg
period
avail
agent
indic
agvhd
given
efficaci
surviv
appear
least
equival
atg
significantli
better
safeti
profil
inolimomab
may
repres
suitabl
altern
patient
sragvhd
especi
candid
clinic
trial
evalu
new
drug
clinic
trial
registri
http
wwwclinicaltrialsregistereuctrsearchsearch
eudract
conflict
interest
noth
disclos
graftversushost
diseas
preclin
anim
model
univers
duisburgessen
univers
hospit
essen
depart
bone
marrow
transplant
westgerman
cancer
center
essen
germani
fraunhof
institut
biomed
engin
st
ingbert
germani
saarland
univers
institut
formal
ontolog
medic
inform
scienc
germani
saarland
univers
depart
clinic
pharmaci
germani
saarland
univers
depart
pediatr
oncolog
hematolog
homburg
saar
germani
univers
depart
comput
scienc
germani
saarland
univers
institut
virolog
homburg
saar
germani
averbi
gmbh
freiburg
germani
saarland
univers
depart
intern
medicin
homburg
saar
germani
background
allogen
stem
cell
transplant
model
score
risk
assess
sororscor
frequentlyus
order
evalu
patient
fit
transplant
ideal
would
translat
individu
risk
assess
incid
viral
infect
transplantationassoci
disord
graftversushost
diseas
gvhd
could
reduc
new
gener
model
develop
high
amount
heterogen
medic
data
need
harmon
integr
store
analyz
provid
highest
level
data
protect
secur
european
union
gener
data
protect
regul
eugdpr
impact
develop
model
present
ontologybas
platform
support
data
owner
model
develop
share
harmon
data
machinelearn
system
biolog
driven
model
stem
cell
transplant
method
differ
hospit
upload
pseudonym
data
deidentif
pseudonymisationservic
run
local
semiautomat
process
structur
eg
laboratori
data
unstructur
data
eg
medic
report
unlik
current
medic
data
integr
approach
use
mere
concept
ontolog
annot
chosen
ontologybas
data
integr
approach
allow
complex
descript
realiz
deep
express
hospit
research
perform
data
integr
task
ie
extend
ontolog
creat
data
annot
sinc
familiar
kind
data
instead
creat
annot
manual
semiautomat
tool
viral
diseas
ontolog
trunk
vdot
aggreg
tool
provid
formal
semant
descript
concept
use
framework
establish
ontolog
descript
biomed
data
predict
model
vdot
extens
semiautomat
gener
search
semant
repositori
standard
ontolog
relat
need
concept
other
vdot
semant
data
annot
servic
support
data
owner
easili
annot
similar
data
ontolog
use
stringmatch
algorithm
match
concept
potenti
ontolog
path
creat
iter
search
vdot
util
semant
constraint
path
select
perform
likelihood
rank
annot
inform
extract
framework
store
harmon
data
tripl
data
warehous
platform
central
databas
search
analyz
model
develop
secur
servic
ensur
data
protect
data
integr
via
data
access
audit
trail
model
workbench
enabl
model
develop
search
analyz
integr
data
check
data
qualiti
possibl
correl
gener
hypothes
result
develop
webbas
platform
xploit
integr
process
pseudonym
semant
annot
data
aggreg
inform
extract
model
develop
order
develop
machinelearn
system
biolog
driven
model
stem
cell
transplant
platform
facilit
interact
modeldevelop
clinician
acceler
dataintegr
accord
eugdpr
integr
structur
unstructur
data
sourc
may
impact
model
develop
conclus
develop
semant
data
integr
platform
enhanc
develop
predict
model
data
integr
tool
allow
clinician
model
develop
work
togeth
effici
machin
learn
model
develop
may
reveal
new
insight
enhanc
predict
model
stem
cell
transplant
platform
open
partner
hospit
enlarg
data
basi
model
develop
conflict
interest
none
author
anyth
disclos
fund
xploit
project
fund
german
feder
ministri
educ
research
bmbf
grant
id
medic
univers
warsaw
hematolog
oncolog
intern
diseas
warszawa
poland
medic
univers
warsaw
depart
experiment
clinic
physiolog
laboratori
centr
preclin
research
warszawa
poland
medic
univers
warsaw
central
laboratori
anim
experi
warszawa
poland
medic
univers
warsaw
depart
patholog
warszawa
poland
background
major
obstacl
organ
transplant
reject
transplant
organ
need
life
long
immunosuppress
hypothes
immunoabl
connect
autolog
hematopoiet
transplant
simpl
cyclophosphamideinduc
posttranspl
clonal
delet
lymphocyt
clone
crossreact
transplant
allograft
would
lead
reset
immun
system
recipi
block
acut
reject
immun
toler
allograft
without
need
lifelong
immunosuppress
clinic
rational
hypothesi
toler
recipi
haploident
hematopoiet
cell
transplant
human
posttranspl
cyclophosphamid
delet
autoreact
lymphocyt
clone
allow
long
term
toler
recipi
despit
differ
hla
antigen
hypothes
autograft
bone
marrow
could
modul
similar
way
posttranspl
cyclophosphamid
toler
transplant
allogen
tissu
haploident
fulli
incompat
method
two
differ
rat
strain
use
experi
spragu
dawley
sprd
rat
use
recipi
skin
graft
spontan
hypertens
rat
shr
rat
model
show
high
immunogen
rapid
reject
graft
expand
model
also
use
spdrshr
rat
skin
donor
model
haploident
organ
transplant
model
famili
graft
result
skin
graft
shr
rat
transplant
sprd
rat
graft
acut
reject
day
control
rat
includ
rat
underw
autolog
bone
marrow
transplant
without
posttranspl
cyclophosphamid
rat
posttranspl
cyclophosphamid
without
previou
autolog
hematopoiet
stem
cell
transplant
sprd
rat
receiv
autolog
hsct
shr
skin
graft
posttranspl
cyclophosphamid
acut
reject
block
rat
abl
toler
graft
day
without
immunosuppress
also
haploident
spdrshr
skin
graft
reject
treatment
well
toler
day
autolog
hsct
without
addit
immunosuppress
conclus
reset
immun
system
donor
autolog
hematopoiet
transplant
posttransplant
cyclophosphamid
lead
delet
highli
activ
lymphocyt
clone
prevent
acut
reject
allograft
rat
reject
graft
slow
similar
fashion
fulli
incompat
haploident
transplant
result
give
intrigu
question
type
simpl
straightforward
treatment
support
short
term
immunosuppress
therapi
could
stop
acut
organ
reject
b
lead
lifelong
immunotler
less
immunogen
tissu
liver
kidney
c
could
use
novel
condit
approach
autoimmun
diseas
especi
patient
requir
organ
transplant
due
termin
organ
failur
caus
autoimmun
clinic
trial
registri
protocol
studi
approv
regist
local
bioethic
committe
anim
experi
medic
univers
warsaw
conflict
interest
noth
disclos
inj
univers
busan
paik
hospit
intern
medicin
hematooncolog
busan
korea
republ
inj
univers
microbiolog
immunolog
busan
korea
republ
busan
gener
hospit
hematooncolog
busan
korea
republ
background
although
mesenchym
stem
cell
msc
appli
cellular
therapeut
control
graftversushost
diseas
gvhd
clinic
still
need
improv
immunomodulatori
activ
recent
indoleamin
dioxygena
ido
mediat
tryptophan
metabol
recogn
one
critic
mechan
immunomodulatori
activ
msc
investig
full
tryptophan
metabol
mous
msc
effect
gvh
respons
method
msc
isol
bone
marrow
ido
mice
expand
vitro
mesencult
medium
mrna
express
tryptophan
metabol
enzym
includ
ido
well
downstream
enzym
kynurenin
kmo
kynureninas
kynu
cell
determin
use
rtpcr
presenc
absenc
ifngamma
kmo
kynu
express
msc
gener
transfect
plasmid
vector
suppress
activ
msc
measur
allogen
mix
lymphocyt
reaction
result
meek
suppress
activ
ido
allogen
cell
respons
observ
comparison
wtmsc
ido
komsc
found
ido
induc
ifngamma
downstream
enzym
kmo
kynu
cell
regardless
ifngamma
stimul
gener
msc
express
kmo
kynu
gene
transfect
observ
inhibitori
activ
alloreact
cell
respons
significantli
increas
conclus
result
demonstr
mous
msc
induc
ido
express
ifngamma
downstream
enzym
indic
cell
partial
induc
tryptophan
metabol
stimul
ifngamma
studi
suggest
msc
may
abl
improv
immunoregulatori
activ
produc
activ
regulatori
metabolit
transduct
downstream
tryptophan
enzym
clinic
trial
registri
na
conflict
interest
none
author
anyth
disclos
nation
research
center
hematolog
laboratori
transplant
immunolog
moscow
russian
feder
background
allogen
hematopoet
stem
cell
transplant
allohsct
commonli
use
treat
hematopoet
malign
shown
allohsct
donor
cell
facilit
erad
residu
diseas
target
alloantigen
larg
extent
henc
alloantigen
also
call
minor
histocompat
antigen
miha
context
hlamatch
allohsct
recogn
promis
target
cell
immunotherapi
relaps
leukemia
date
around
miha
known
restrict
common
well
studi
hla
allel
miha
describ
hla
allel
report
second
miha
restrict
allel
hlab
method
hlab
donor
genotyp
code
polymorph
use
real
time
allel
specif
pcr
select
individu
dendrit
cell
differenti
peripher
blood
monocyt
cocultur
autolog
pbmc
presenc
peptid
cultur
restimul
fresh
peptidepuls
dc
weekli
ad
everi
day
first
restimul
second
restimul
cell
stain
antibodi
ifngamma
intracellular
stain
perform
detect
function
responselymphoblastoid
cell
line
differ
hla
genotyp
use
target
cell
cytotox
assay
cytotox
effect
measur
caspas
assay
result
report
peptid
rqpdlvlrl
previous
suggest
potenti
miha
present
hlaa
granado
et
al
inde
immunogen
miha
restrict
allel
hlab
origin
suggest
hlaa
restrict
predict
netmhc
algorithm
howev
mhcbind
algorithm
make
contradict
predict
affin
peptid
hlaa
predict
wrong
hla
restrict
made
basi
analysi
immunopeptidom
dataset
show
strong
correl
peptid
occurr
hlab
genotyp
test
hypothesi
attempt
cell
expans
hlab
donor
succeed
obtain
cell
clone
specif
recogn
hlab
cell
show
strong
cytotox
effect
conclus
recent
studi
suggest
tutor
cell
effici
escap
immun
respons
dowregul
express
particular
hla
allel
cell
surfac
suggest
target
miha
restrict
differ
allel
simultan
suffici
effect
accordingli
discoveri
new
miha
restrict
less
frequent
hla
allel
import
well
anoth
interest
side
work
hla
restrict
sometim
refin
use
data
analysi
fund
provid
rfbr
grant
number
conflict
interest
none
author
anyth
disclos
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
republ
dongsan
medic
center
keimyung
univers
school
medicin
daegu
korea
republ
background
although
human
mesenchym
stem
cell
msc
particular
interest
owe
immunosuppress
effect
clinic
benefit
often
limit
therefor
strategi
promot
msc
immunosuppress
properti
need
sought
studi
investig
effect
ex
vivo
cultur
condit
presenc
inflammatori
stimuli
includ
poli
c
immunosuppress
properti
msc
method
gene
express
profil
poli
c
treatment
compar
use
rtpcr
analysi
microarray
addit
impact
treatment
regul
ido
pge
express
msc
vitro
vivo
function
analyz
result
express
chemokin
gene
immunomodulationassoci
gene
anticanc
effectassoci
gene
baff
adhesionassoci
gene
significantli
upregul
msc
wherea
express
gene
poli
c
treat
msc
slightli
increas
chang
furthermor
msc
significantli
increas
surviv
rate
graftversushost
diseas
gvhd
mice
compar
msc
without
stimul
downregul
ido
msc
shrna
result
restor
tcell
prolifer
vitro
decreas
surviv
rate
gvhd
mice
overexpress
ido
significantli
increas
msc
tcell
inhibitori
function
surviv
rate
gvhd
mice
also
investig
impact
inflammatori
stimuli
express
pathway
member
product
bone
marrow
bm
msc
increas
express
cyclooxygenas
cox
impact
express
prostaglandin
e
synthas
pge
product
hand
toll
like
receptor
stimul
poli
c
increas
express
pge
result
signific
increas
level
effect
revers
upon
inhibit
indomethacin
pge
downregul
sirna
reduc
level
decreas
msc
capac
inhibit
hpbmc
prolifer
administr
msc
inhibit
pge
express
reduc
mortal
gvhd
mice
result
indic
upregul
pge
via
critic
bmmscsmediat
immunosuppress
secret
via
pathway
conclus
given
ex
vivo
cultur
expans
essenti
clinic
applic
msc
result
suggest
poli
c
prime
cultur
expans
could
effect
strategi
enhanc
msc
immunosuppress
properti
conflict
interest
noth
disclos
samsung
medic
center
sungkyunkwan
univers
school
medicin
pediatr
seoul
korea
republ
pusan
nation
univers
chidren
hospit
pediatr
pusan
korea
republ
background
mesenchym
stem
cell
msc
capabl
act
modul
immun
respons
may
applic
treatment
allogen
diseas
graftversu
host
diseas
gvhd
clinic
use
msc
limit
heterogen
aris
due
differ
msc
sourc
methodolog
use
isol
studi
aim
character
effect
mechan
interferon
ifn
prime
msc
subsequ
immunomodulatori
activ
method
msc
isol
four
differ
human
tissu
name
bone
marrow
adipos
tissu
cord
blood
wharton
jelli
umbil
cord
stimul
induc
immunomodulatori
capac
tcell
prolifer
measur
phytohemagglutinin
stimul
cocultur
human
peripher
bloodderiv
mononuclear
cell
hpbmc
mitomycin
ctreat
msc
use
brdu
assay
anim
model
gvhd
establish
irradi
nodscid
mice
inject
hpbmc
effect
immunomodulatori
msc
assess
gene
express
profil
conduct
msc
treat
result
five
hundr
twelv
gene
upregul
msc
one
gene
indoleamin
ido
found
highli
express
msc
stimul
upregul
ido
occur
pathway
wherea
margin
upregul
either
poli
c
stimul
tolllik
receptor
moreov
prolifer
tcell
suppress
cocultur
msc
prolifer
suppress
cocultur
msc
addit
infus
msc
prime
significantli
reduc
symptom
gvhd
nodscid
mice
result
increas
surviv
rate
compar
mscinfus
mice
furthermor
infus
idooverexpress
msc
increas
surviv
rate
gvhd
mice
similar
extent
observ
msc
moreov
infus
msc
ido
downregul
elicit
effect
conclus
data
indic
stimul
induc
ido
express
msc
pathway
key
modul
immunosuppress
properti
data
suggest
cell
therapi
use
msc
prime
could
highli
effect
treat
allogen
diseas
includ
gvhd
conflict
interest
research
support
grant
korea
health
technolog
r
project
korea
health
industri
develop
institut
khidi
fund
ministri
health
welfar
republ
korea
grant
number
author
noth
disclos
newcastl
univers
institut
cellular
medicin
newcastl
upon
tyne
unit
kingdom
northern
centr
bone
marrow
transplant
newcastl
upon
tyne
hospit
newcastl
upon
tyne
unit
kingdom
background
although
mani
agent
avail
prophylaxi
treatment
option
establish
graft
versu
host
diseas
gvhd
especi
steroid
resist
remain
limit
offer
excit
therapeut
opportun
absenc
receptor
leucocyt
give
potenti
separ
gvhd
graft
versu
tumour
effect
role
gvhd
howev
remain
controversi
method
use
adapt
previous
describ
human
skin
explant
model
explor
potenti
use
recombin
treat
gvhd
vitro
model
briefli
pbmc
two
healthi
donor
isol
combin
suspend
cultur
medium
cultur
five
seven
day
mix
lymphocyt
reaction
mlr
supernat
remov
store
skin
punch
biopsi
normal
donor
excess
skin
plastic
surgeri
cut
four
piec
equal
size
trim
excess
dermi
fragment
incub
hour
cultur
medium
alon
mlr
supernat
alon
mlr
supernat
plu
mlr
supernat
plu
hour
sampl
formalin
fix
paraffin
embed
haemotoxylin
eosin
stain
accord
local
gvhd
protocol
gvhd
grade
assess
use
lerner
grade
system
perform
blind
independ
assessor
result
sampl
cultur
medium
alon
show
consist
grade
damag
mlr
supernat
show
grade
damag
addit
alway
effect
alway
increas
grade
gvhd
addit
howev
result
resolut
grade
experi
perform
figur
almost
ident
respons
rate
previous
observ
methylprednisolon
xn
wang
unpublish
produc
mlr
reaction
measur
elisa
total
concentr
baselin
recombin
could
calcul
concentr
mlrmlr
plu
rang
total
mlr
plu
rang
conclus
total
concentr
mlr
supernat
without
rang
measur
serum
patient
gvhd
addit
result
supraphysiolog
concentr
respons
seen
higher
dose
rais
possibl
biphas
respons
therapeut
effect
seen
physiolog
rang
presenc
receptor
target
organ
gvhd
leucocyt
give
potenti
treatment
without
loss
graft
versu
tumour
effect
rna
sequenc
use
establish
signatur
separ
respond
nonrespond
conflict
interest
ami
clinic
research
train
fellowship
fund
bloodwis
none
author
conflict
interest
disclos
relat
work
new
york
univers
langon
health
blood
marrow
transplant
new
york
ny
unit
state
spectrum
health
pediatr
blood
marrow
transplant
grand
rapid
mi
unit
state
michigan
state
univers
depart
chemistri
east
lans
mi
unit
state
background
substrat
competit
proteasom
inhibitor
bortezomib
shown
prevent
gvhd
murin
model
earli
phase
clinic
trial
howev
sustain
administr
bortezomib
aggrav
gvhdrelat
intestin
injuri
part
due
paradox
increas
interleukin
il
imidazolin
scaffold
compound
prevent
proteasom
cap
bind
ring
thu
modul
proteasom
activ
aim
studi
effect
dendrit
cell
dc
matur
cytokin
product
cell
prolifer
differenti
vitro
also
examin
abil
protect
mice
mhcmismatch
gvhd
model
method
dc
isol
peripher
blood
healthi
volunt
treat
differ
concentr
hr
stimul
lipopolysaccharid
lp
hr
dc
stain
antibodi
matur
marker
analyz
flow
cytometri
dc
viabil
assess
stain
proinflammatori
cytokin
measur
supernat
dc
cultur
treat
stimul
lp
similarli
effect
cell
differenti
studi
healthi
volunt
mononuclear
cell
stimul
cell
activ
antibodi
without
addit
regulatori
cell
treg
enumer
stain
antibodi
ifni
minimum
experi
done
triplic
anova
tukey
post
hoc
test
use
statist
analysi
p
valu
consid
signific
balbc
preclin
gvhd
model
adopt
evalu
effect
gvhd
develop
mice
transplant
group
intraperiton
inject
either
vehicl
mgkg
day
mgkg
day
result
inhibit
express
dc
matur
marker
includ
dc
viabil
remain
unchang
compar
control
significantli
decreas
dc
product
decreas
higher
concentr
importantli
caus
paradox
prestimul
dc
mononuclear
cell
cultur
decreas
percentag
cell
increas
treg
treg
ratio
vivo
improv
gvhd
score
surviv
compar
control
notic
caus
gvhd
exacerb
mice
treat
day
conclus
cell
differenti
reduc
increas
treg
ratio
amelior
gvhd
aggress
murin
model
contrari
effect
bortezomib
caus
paradox
surg
prestimul
dc
exacerb
gvhd
mice
treat
sustain
fashion
conflict
interest
samer
alhomsi
noth
disclos
incyt
corpor
wilmington
de
unit
state
biomodel
llc
watertown
unit
state
background
graftversushostdiseas
gvhd
sever
complic
aris
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
potent
select
modul
signal
attract
therapeut
strategi
manag
acut
gvhd
method
acut
gvhd
induc
balbc
mice
use
establish
mhcmismatch
mous
model
balbc
recipi
given
intraven
inject
combin
splenocyt
tcell
deplet
bone
marrow
cell
receiv
allogen
cell
transfer
donor
mice
anim
dose
oral
vehicl
potent
select
inhibitor
itacitinib
bid
gvhd
clinic
score
assess
standard
method
cytokin
profil
quantifi
luminex
analys
efficaci
itacitinib
evalu
target
therapeut
agent
filgotinib
ibrutinib
could
use
manag
gvhd
result
itacitinib
administr
highli
effect
prophylact
therapeut
dose
regimen
amelior
bodi
weight
loss
improv
gvhd
score
detriment
effect
engraft
similar
efficaci
observ
versu
bid
dose
regimen
filgotinib
select
inhibitor
bid
efficaci
model
ibrutinib
potent
btk
itk
inhibitor
bid
show
modest
effect
recoveri
bodi
weight
loss
effect
gvhd
score
combin
ibrutinib
itacitinib
addit
therapeut
benefit
rel
singl
agent
oral
itacitinib
administr
balbc
mice
achiev
coverag
bid
bid
respect
maxim
upregul
relev
cytokin
observ
peripher
blood
colon
signific
differ
cytokin
profil
diseas
stage
observ
treatment
itacitinib
differ
observ
absolut
number
tcell
tcell
blood
spleen
conclus
itacitinib
select
inhibitor
administ
prophylact
therapeut
signific
effect
amelior
diseas
sever
mhcmismatch
model
acut
gvhd
modul
level
relev
cytokin
import
pathophysiolog
acut
gvhd
conflict
interest
juvekar
b
ruggeri
condon
p
smith
p
scherl
montgomeri
p
delait
incyt
corpor
employe
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
wuhan
china
background
report
farnesyltransferas
geranylgeranyltransferas
inhibitor
could
help
reduc
graftversushost
gvhd
diseas
significantli
without
neg
impact
immun
reconstitut
previous
report
level
lymphocyt
peripher
blood
acut
gvhd
agvhd
patient
mice
significantli
elev
inhibit
reliev
sever
murin
agvhd
work
present
regulatori
mechan
agvhd
method
particip
initi
event
culmin
agvhd
well
amplifi
diseas
process
establish
therefor
induc
cell
injuri
use
simul
cours
agvhd
vitro
assess
contribut
prenyl
human
lymphocyt
lymphocyt
human
peripher
blood
mononuclear
cell
pbmc
select
neg
select
use
magnet
bead
effect
antagomirnc
concentr
stimul
assess
contribut
prenyl
vivo
wellestablish
mhc
mismatch
bone
marrow
transplant
bmt
model
balbc
use
investig
effect
defici
prenyl
vivo
cgi
xray
irradi
balbc
mice
transplant
bm
cell
spleen
cell
mice
treat
antagomirnc
load
dose
mgkg
mgkg
intraven
twice
weekli
posttranspl
mice
lymphocyt
magnet
isol
pbmc
examin
express
prenyltransferas
human
lymphocyt
mice
lymphocyt
realtim
quantitativepcr
western
blot
evalu
sever
agvhd
use
histopatholog
score
system
farnesyltransferas
activ
immunohistochemistri
result
result
indic
stimul
cell
imit
agvhd
vitro
induc
higher
express
p
coincident
stimul
cell
result
higher
express
farnesyltransferas
ft
subunit
fnta
common
fntb
mrna
protein
level
similarli
increas
geranylgeranyltransferaseii
ggtii
subunit
rabggta
rabggtb
mrna
express
intriguingli
suppress
could
revers
phenomenon
restrain
fnta
fntb
mrna
protein
express
p
also
decreas
rabggta
rabggtb
p
mrna
level
simultan
agvhd
mice
model
compar
control
group
agvhd
group
caus
higher
express
fnta
fntb
rebggta
rabggtb
howev
exacerb
revers
inhibit
b
p
suggest
initi
develop
agvhd
prenyltransferas
level
increas
suppress
decreas
express
prenyltransferas
vivo
vitro
next
consist
discov
defici
agvhd
mice
lower
histopatholog
score
live
small
intestin
possess
decreas
farnesyl
protein
farnesyltransferas
activ
spleen
result
confirm
simul
role
farnesyltransferas
geranylgeranyltransferas
inhibitor
reliev
effect
agvhd
conclus
work
suggest
origin
notion
inhibit
lymphocyt
prenyl
protect
agvhd
conflict
interest
author
declar
conflict
interest
nation
research
center
hematolog
laboratori
transplant
immunolog
moscow
russian
feder
background
minor
histocompat
antigen
miha
polymorph
peptid
encod
nonsynonym
singl
nucleotid
polymorph
snp
could
immunogen
allohsct
hlamatch
set
miha
sole
mediat
antitumor
gvl
effect
detriment
graftversu
host
effect
gvhd
date
miha
present
differ
hla
allel
describ
mihaspecif
cell
receptor
tcr
sequenc
known
accordingli
divers
mihaspecif
repertoir
remain
larg
undescrib
present
studi
miha
specif
immun
respons
allohsc
analysi
tcr
sequenc
specif
sever
miha
approach
base
vitro
mihaspecif
expans
cell
ng
sequenc
tcr
repertoir
method
hlamatch
donor
patient
undergo
allohst
genotyp
panel
known
miha
peripher
blood
sampl
taken
patient
mismatch
miha
variou
time
point
allohsct
cell
cultiv
presenc
miha
peptid
feeder
cell
percentag
mihaspecif
cell
expans
peripher
blood
sampl
measur
mhctetram
stain
restimul
expand
cell
magnet
separ
fraction
subject
tcr
repertoir
sequenc
illumina
platform
separ
panel
healthi
hlagenotyp
volunt
genotyp
snp
code
miha
miha
dendrit
cell
differenti
peripher
blood
monocyt
cocultur
autolog
cell
presenc
miha
peptid
restimul
cell
separ
fraction
tcr
repertoir
analyz
result
demonstr
miha
specif
cell
mihamismatch
hlamatch
allohsct
could
rare
detect
direct
mhctetram
stain
peripher
blood
nevertheless
patient
gvhd
known
miha
mismatch
mihaspecif
cell
could
detect
vitro
cultiv
sequenc
tcr
repertoir
cell
specif
miha
patient
healthi
miha
neg
volunt
analysi
tcr
sequenc
demonstr
tcr
specif
particular
miha
substanti
level
similar
conclus
recent
demonstr
sequenc
tcr
specif
common
antigen
similar
larg
extent
suggest
tcr
specif
could
deduc
sequenc
given
substanti
number
previous
describ
sequenc
specif
antigen
thu
mihaspecif
tcr
cluster
suffici
well
describ
miha
specif
cell
might
detect
analysi
bulk
repertoir
sequenc
succeed
altern
mhctetram
approach
allow
detect
mihaspecif
cell
expand
moment
fund
provid
russian
scienc
foundat
grant
conflict
interest
author
noth
disclos
hannov
medic
univers
institut
immunolog
hannov
germani
hannov
medic
univers
depart
hematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
background
graftversushostdiseas
gvhd
account
frequent
complic
follow
bone
marrow
transplant
bmt
current
therapi
corticosteroid
often
ineffici
usual
accompani
varieti
advers
effect
famili
protein
crucial
regul
cell
surviv
normal
malign
cell
control
mitochondri
apoptot
pathway
competit
bind
proapoptot
protein
groov
either
pro
antiapoptot
protein
control
induct
apoptosi
target
domain
prosurviv
molecul
cell
use
aim
evalu
possibl
effici
prevent
gvhd
method
primari
cell
segreg
fraction
magnet
separ
activ
vitro
either
antibodi
cocultur
allogen
balbc
bmderiv
dendrit
cell
bmdc
apoptosi
mitochondri
outer
membran
permeabil
momp
rate
assess
flow
cytometri
surviv
experi
mice
treat
either
intraperiton
controlvehicl
consecut
day
start
bmt
mice
score
daili
sign
clinic
gvhd
result
compar
level
protein
involv
momp
induct
depend
cell
activ
stage
show
distinct
kinet
express
protein
follow
incub
rest
activ
cell
report
greater
induct
apoptosi
activ
compar
rest
cell
figur
differenti
effect
abrog
presenc
high
level
use
immunoblot
flow
cytometri
demonstr
upregul
prosurviv
protein
bclxl
parallel
downregul
proapoptot
protein
puma
direct
proport
concentr
ad
hint
toward
antagonist
effect
induct
apoptosi
via
mimet
furthermor
could
show
greater
resist
regulatori
cell
treg
compar
convent
cell
suggest
differ
regulatori
element
regul
mitochondri
apoptosi
pathway
treg
use
murin
acut
gvhd
model
demonstr
treatment
led
significantli
delay
onset
gvhd
prolong
surviv
bmt
conclus
report
differenti
effect
cell
differ
express
profil
protein
depend
activ
state
furthermor
could
show
prolong
surviv
bmt
delay
onset
acut
gvhd
howev
observ
function
antagon
signal
toward
induct
mitochondri
apoptosi
cell
might
reason
incomplet
gvhdprevent
conflict
interest
none
author
anyth
disclos
johann
gutenbergunivers
medic
centr
mainz
germani
johann
gutenbergunivers
medic
centr
haematolog
oncolog
pneumolog
uct
mainz
germani
institut
immunolog
univers
medic
center
johann
gutenbergunivers
mainz
germani
mainz
germani
background
differ
type
cell
deplet
tcd
use
prevent
graft
versu
host
diseas
gvhd
allogen
stem
cell
transplant
like
antithymocyt
globulin
atg
monoclon
antibodi
alemtuzumab
despit
tcd
nearli
half
patient
develop
acut
chronic
gvhd
regulatori
cell
treg
requir
control
gvhd
therefor
focu
treg
function
differ
tcd
regimen
investig
role
develop
gvhd
method
analys
peripher
blood
sampl
patient
acut
chronic
gvhd
well
without
gvhd
altemtuzumab
atg
healthi
individu
treg
stain
activ
marker
garp
tgfbeta
hladr
well
function
marker
granzym
gitr
supress
treg
function
evalu
csfe
suppress
assay
rule
influenc
immunosuppress
prednisolon
tacrolimu
use
patient
gvhd
analys
treg
function
express
activ
marker
vitro
use
healthi
treg
addit
analys
effect
patient
serum
treg
function
result
treg
number
show
signific
differ
patient
acut
chronic
gvhd
treg
marker
differ
patient
alemtuzumab
atg
despit
express
alemtuzumab
treatment
patient
agvhd
show
signific
elev
level
treg
mean
comparison
patient
without
gvhd
patient
chronic
gvhd
treg
dervi
patient
gvhd
show
reduc
supress
capac
ex
vivo
compar
healthi
treg
especi
patient
acut
gvhd
alemtuzumab
treatment
treg
less
function
compar
treg
patient
garptgfbeta
well
upregul
treg
compra
treg
treg
deriv
patient
without
gvhd
compar
acut
gvhd
healthi
treg
compar
gvhd
patient
signific
differ
treg
marker
gvhdgroup
comparison
healthi
individu
cyclosporin
corticosteroid
ex
vivo
vitro
influenc
treg
marker
express
supress
capac
serum
patient
acut
chronic
gvhd
without
immunosuppress
drug
show
antiprolif
effect
effector
cell
enhanc
supress
capac
healthi
treg
conclus
treg
patient
gvhd
show
reduc
supress
functionhigh
garp
tgfbeta
express
seem
associ
less
develop
acut
gvhd
especi
alemtuzumab
lead
increas
treg
reduc
supress
capac
differ
activ
marker
patient
agvhd
patient
treg
post
allogen
stem
cell
transplant
never
develop
acut
gvhd
serum
patient
gvhd
enhanc
supress
treg
function
clinic
trial
registri
conflict
interest
none
granulocyt
osteoclast
disord
depart
bone
marrow
transplant
hadassah
univers
medic
center
jerusalem
israel
hadassah
hebrew
univers
medic
center
ein
kerem
depart
bone
marrow
transplant
cancer
immunotherapi
jerusalem
israel
background
infantil
malign
osteopetrosi
imo
autosom
recess
condit
character
defect
osteoclast
activ
hematopoiet
bone
marrow
transplant
avail
cure
past
sever
year
new
condit
regim
donor
option
emerg
thu
extend
possibl
cure
greater
number
patient
improv
outcom
bone
marrow
transplant
detail
outcom
bone
marrow
transplant
cohort
patient
treat
combin
fludarabin
treosulphan
thiotepa
antithymocyt
globulin
method
patient
imo
underw
hsct
fludarabin
treosulphan
thiotepa
antithymocyt
globulin
center
retrospect
review
studi
result
overal
surviv
case
gvhd
case
vod
eight
case
hypercalcemia
almost
patient
suffer
viral
reactiv
success
treat
case
conclus
conclud
transplant
children
imo
use
fludarabin
treosulphan
thiotepa
antithymocyt
globulin
safe
effect
perform
earli
possibl
follow
diagnosi
prior
develop
sever
diseas
sequela
clinic
trial
registri
applic
conflict
interest
conflict
interest
author
haemoglobinopathi
inborn
error
metabol
r
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
first
state
pavlov
medic
univers
st
petersburg
st
petersburg
russian
feder
background
hurler
syndrom
mp
ih
sever
form
mucopolysaccharidosi
rare
genet
disord
caus
defici
alphaliduronidas
enzym
intraven
enzym
replac
therapi
ert
revers
aspect
mp
ih
hepatomegali
splenomegali
glycosaminoglycanuria
amelior
other
pulmonari
function
cardiac
diseas
arthropathi
exercis
toler
neurolog
benefit
thought
inconsider
blood
brain
barrier
block
enzym
reach
cn
hematopoiet
stem
cell
transplant
hsct
cur
treatment
option
hurler
syndrom
myeloabl
condit
regimen
mac
allow
achiev
good
engraft
higher
probabl
toxic
complic
reduc
intens
condit
regimen
ric
associ
less
transplant
relat
mortal
higher
risk
graft
failur
normal
fals
fals
fals
ru
xnone
xnone
style
definit
tablemsonormalt
msostylenam
msostylenoshow
ye
msostylepar
msoparamarginbottom
msopagin
widoworphan
fontfamili
cambria
aim
assess
effect
allohsct
children
hurler
syndrom
defin
prognost
factor
compar
ric
mac
clinic
set
evalu
efficaci
safeti
ptci
prophylaxi
gvhd
method
studi
includ
pt
mp
ih
allogen
unrel
hsct
median
age
diagnosi
month
rang
median
time
start
ert
month
rang
median
time
allohsct
month
rang
condit
regimen
mac
pt
ric
pt
gvhd
prophylaxi
pt
receiv
classic
regimen
pt
receiv
combin
posttranspl
cyclophosphamid
ptci
pt
receiv
antithymocyt
globulin
atg
case
rabbit
atg
administ
day
case
combin
ptci
hors
atg
atg
use
dose
day
graft
sourc
bone
marrow
bm
pt
median
number
peripher
blood
stem
cell
pbsc
pt
median
number
cd
result
engraft
achiev
pt
fiveyear
os
age
diagnosi
time
start
ert
time
allohsct
import
prognost
factor
mp
ih
establish
prior
month
os
result
hurler
syndrom
diagnos
later
os
case
ert
start
prior
month
os
later
children
allohsct
prior
month
os
later
statist
signific
differ
os
children
mac
ric
vs
cumul
incid
ci
acut
gvhd
chronic
gvhd
ptci
decreas
ci
acut
gvhd
significantli
vs
conclus
allohsct
standard
care
mp
ih
ric
mac
regimen
demonstr
equal
effici
children
hurler
syndrom
ptci
decreas
ci
acut
gvhd
promis
option
need
investig
clinic
set
conflict
interest
noth
disclos
instituto
da
hospit
da
da
universidad
de
paulo
sao
paulo
brazil
blood
system
research
institut
san
francisco
ca
unit
state
univers
california
san
francisco
benioff
children
hospit
oakland
oakland
ca
unit
state
research
triangl
institut
rockvil
md
unit
state
hemomina
belo
horizont
brazil
hemop
recif
brazil
hemop
recif
brazil
hemorio
rio
de
janeiro
brazil
hemomina
juiz
de
fora
brazil
hemomina
mont
claro
brazil
universidad
de
paulo
instituto
de
medicina
tropic
paulo
brazil
hospit
da
da
faculdad
de
medicina
da
universidad
de
paulo
paulo
brazil
hospit
da
da
faculdad
de
medicina
da
universidad
de
paulo
de
hematologia
hemoterapia
e
terapia
celular
paulo
brazil
univers
oxford
churchil
hospit
depart
haematolog
nhsbt
oxford
unit
kingdom
background
sickl
cell
diseas
scd
worldwid
public
health
problem
brazil
estim
affect
patient
despit
advanc
qualiti
life
reduc
mortal
cur
treatment
hematopoiet
stem
cell
transplant
hsct
recent
brazilian
ministri
health
moh
establish
regul
base
intern
recommend
requir
public
health
system
pay
hsct
scd
patient
defin
indic
howev
brazilian
center
perform
hsct
scd
number
elig
hsct
candid
accord
regul
unknown
method
redsiii
scd
cohort
establish
investig
outcom
larg
sampl
scd
patient
brazil
patient
six
brazilian
citi
belo
horizont
juiz
de
fora
mont
claro
rio
de
janeiro
recif
sao
paulo
select
recruit
routin
visit
cross
section
analysi
enrol
data
conduct
identifi
number
hsct
candid
cohort
accord
brazilian
moh
criteria
patient
sickl
cell
anemia
sca
year
old
stroke
cerebrovascular
diseas
antibodi
chronic
transfus
therapi
ctt
follow
despit
treatment
hydroxyurea
vasocclus
crise
voc
acut
chest
syndrom
ac
episod
last
year
priapism
avascular
necrosi
avn
result
patient
enrol
redsiii
cohort
sca
patient
children
year
least
hsct
indic
indic
common
indic
transplant
stroke
follow
voc
cerebrovascular
diseas
priapism
ac
ctt
alloantibodi
avn
comparison
patient
without
hsct
indic
summar
tabl
children
would
elig
hsct
least
nonscd
full
sibl
elig
criteria
expand
includ
patient
year
would
addit
hsct
candid
conclus
studi
provid
use
real
world
data
regard
recent
enact
hsct
regul
would
impact
brazilian
scd
patient
estim
sca
patient
depend
age
could
benefit
hsct
estim
could
appli
countri
high
preval
scd
studi
provid
critic
data
estim
financi
cost
infrastructur
would
requir
implement
new
regul
clinic
trial
registri
applic
conflict
interest
author
declar
conflict
interest
relat
manuscript
tabl
comparison
patient
royal
manchest
children
hospit
manchest
unit
kingdom
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
manchest
center
genom
medicin
manchest
unit
kingdom
background
cord
blood
cb
prefer
cell
sourc
haematopoiet
cell
transplant
hct
children
hurler
syndrom
hs
lack
noncarri
hlamatch
famili
donor
cb
previous
shown
associ
greater
donor
chimer
better
idua
enzym
level
recent
report
demonstr
graft
failur
occur
exclus
cb
transplant
cbt
implement
pharmacokinet
guid
myeloablativebusulfan
bupk
compar
outcom
children
undergo
cbt
match
unrel
donor
mud
transplant
modern
era
hct
method
examin
outcom
children
hs
receiv
first
unrel
hct
royal
manchest
children
hospit
great
ormond
street
hospit
busulfan
pk
monitor
cyclophosphamid
use
condit
regimen
switch
busulfan
fludarabin
atg
use
cb
alemtuzumab
use
mud
outcom
interest
includ
overal
surviv
os
transplantrel
mortal
trm
engraft
surviv
es
donor
chimer
leucocyt
idua
comparison
surviv
outcom
cbt
mud
analys
use
logrank
analysi
result
median
age
transplant
month
mud
month
cbt
interv
diagnosi
hct
significantli
shorter
cbt
median
month
compar
mud
month
os
mud
cbt
oneyear
trm
cbt
trm
mud
es
mud
cbt
six
graft
failur
occur
cbt
aplast
type
differ
incid
agvhd
cgvhd
viral
reactiv
cmv
ebv
adenoviru
cb
mud
recipi
donor
chimer
idua
level
avail
patient
cbt
mud
engraft
one
year
first
hct
signific
differ
full
donor
chimer
mud
n
cbt
patient
donor
chimer
greater
proport
cb
recipi
supraphysiolog
idua
enzym
institut
refer
rang
compar
mud
recipi
conclus
find
reiter
surviv
rate
unrel
donor
transplant
good
hs
children
engraft
cb
provid
superior
idua
level
remain
import
cell
sourc
affect
children
reason
underpin
graft
loss
address
immin
prevent
untoward
consequ
delay
engraft
cb
recipi
clinic
trial
registri
none
conflict
interest
none
tabl
latest
graft
function
chimer
enzym
level
medic
school
hannov
paediatr
haematolog
oncolog
hannov
germani
medic
school
hannov
cellular
therapi
centr
hannov
germani
medic
school
hannov
institut
transfus
medicin
hannov
germani
background
boy
thalassemia
major
consanguin
parent
receiv
first
transfus
age
four
turkey
receiv
blood
transfus
almost
everi
second
day
innumer
episod
hemoglobinuria
treat
corticosteroid
immunoglobulin
continu
hemolysi
six
month
first
transfus
present
hospit
sever
anemia
gdl
hb
congest
heart
failur
identifi
jk
b
kp
antibodi
phenotypematch
compat
rbc
unit
use
hemolysi
persist
diagnosi
hyperhemolysi
syndrom
made
two
methylprednisolonepuls
day
everi
week
stabil
transfus
everi
week
six
month
later
present
hemolysi
howev
irregular
antibodi
detect
hemolysi
resolv
two
puls
methylprednisolon
immunoglobulin
mycophenol
mofetil
mmf
mmf
given
condit
hsct
deferasirox
use
chelat
therapi
septemb
age
year
receiv
transplant
hla
ident
mother
blood
type
donor
ccdee
jk
b
kp
neg
recipi
ccdee
patient
hlaantibodi
graft
bone
marrow
mnckg
x
condit
fludarabinetreosulfan
thiothepaatg
gvhd
prophylaxi
csamtx
earli
posttransplantat
cours
unev
engraft
platelet
leucocyt
day
initi
mix
chimer
neutrophil
lymphocyt
donor
observ
csa
rapidli
reduc
withdrawn
day
gvhd
occur
full
donor
erythropoiesi
blood
type
hb
fell
leucocyt
platelet
still
normal
rang
blood
type
show
mix
donor
recipi
popul
new
antibodi
red
blood
cell
identifi
molecular
genet
analysi
show
major
statu
confirm
complet
erythropoiet
loss
graft
method
three
week
later
receiv
pbsc
boost
purifi
cell
gvhd
prophylaxi
use
result
patient
hematopoiesi
revert
complet
donor
blood
type
molecular
genet
show
minor
statu
gvhd
occur
nine
month
later
transfusionfre
full
donor
erythropoiesi
stabl
mix
myeloid
chimer
donor
lanski
score
conclus
use
stem
cell
boost
lowdos
tcell
addback
effect
treatment
earli
complet
graft
reject
without
gvhd
approach
show
promis
potenti
treatment
earli
transplant
reject
hemoglobinopathi
avoid
controversi
use
donor
lymphocyt
infus
nonmalign
diseas
conflict
interest
none
declar
abstract
previous
publish
tokai
univers
school
medicin
depart
cell
transplant
regen
medicin
isehara
japan
tokai
univers
school
medicin
depart
pediatr
isehara
japan
background
graft
reject
major
obstacl
hematopoiet
stem
cell
transplant
hsct
treatment
inherit
metabol
disord
primari
immunodefici
wiskottaldrich
syndrom
retrospect
investig
feasibl
fulldos
intraven
busulfan
ivbu
base
condit
regimen
pediatr
nonmalign
diseas
method
sixteen
patient
includ
male
femal
inherit
metabol
disord
primari
immunodefici
underw
hsct
fulldos
ivbubas
condit
regimen
enrol
median
rang
age
hsct
year
month
year
underli
diseas
mucopolysaccharidosi
n
wiskottaldrich
syndrom
n
icel
diseas
n
metachromat
leukodystrophi
n
reticular
dysgenesi
n
condit
regimen
rang
mgkgdose
accord
bodi
weight
ivbu
time
per
day
consecut
day
follow
cyclophosphamid
cy
mgkgday
antithymocyt
globulin
mgkg
consecut
day
patient
receiv
ivbu
cyatg
order
patient
receiv
revers
order
ie
cy
ivbuatg
graftversushost
diseas
prophylaxi
select
accord
donor
statu
result
two
infantil
patient
develop
hepat
sinusoid
obstruct
syndrom
respond
well
treatment
defibrotid
recombin
thrombomodulin
patient
achiev
neutrophil
count
erythrocyt
median
day
respect
donor
element
week
hsct
measur
shorttandem
repeat
method
use
whole
bone
marrow
specimen
reach
patient
eight
week
hsct
patient
achiev
donor
type
chimer
analys
use
peripher
blood
specimen
also
perform
shorttandem
repeat
method
whole
blood
separ
granulocyt
tcell
other
week
among
patient
show
donor
type
whole
peripher
blood
patient
exhibit
tcell
mix
chimer
recipi
type
eventu
decreas
three
patient
develop
recipientderiv
chimer
granulocyt
fraction
week
two
improv
administr
granulocyt
colonystimul
factor
donor
lymphocyt
infus
patient
lost
followup
late
graft
reject
observ
patient
icel
diseas
mucopolysaccharidosi
patient
icel
diseas
deterior
rapidli
graft
reject
die
diseas
month
hsct
patient
mucopolysaccharidosi
lost
bone
marrow
graft
owe
posttransplantemerg
donorspecif
antihla
antibodi
underw
success
rehsct
unrel
cord
blood
fifteen
patient
aliv
well
month
year
hsct
conclus
fulldos
ivbubas
condit
regimen
provid
excel
shortterm
toxic
myeloid
engraft
inherit
metabol
disord
primari
immunodefici
howev
serial
chimer
analysi
confirm
lineagespecif
engraft
import
detect
mix
chimer
administ
earli
intervent
donor
lymphocyt
infus
conflict
interest
author
declar
conflict
interest
royal
manchest
children
hospit
manchest
unit
kingdom
manchest
royal
infirmari
manchest
unit
kingdom
manchest
center
genom
medicin
manchest
unit
kingdom
background
haemopoiet
cell
transplant
hct
confer
longterm
diseasemodifi
therapi
transplantpermiss
inherit
metabol
diseas
imd
donorderiv
leucocyt
engraft
serv
stabl
sourc
defici
enzym
insitu
crosscorrect
neighbour
tissu
includ
neuron
well
immunomodulatori
effect
signific
inflammatori
compon
diseas
method
examin
outcom
children
imd
receiv
first
hct
royal
manchest
children
hospit
outcom
interest
includ
overal
surviv
os
transplantrel
mortal
trm
engraft
surviv
es
predictor
os
es
trm
analys
use
cox
proportionalhazard
model
finegray
compet
risk
model
result
children
imd
includ
analysi
histor
cohort
current
cohort
primari
diagnos
mucopolysaccharidos
mp
xlink
adrenoleukodystrophi
xald
metachromat
leukodystrophi
alphamannosidosi
wolman
diseas
n
other
n
aspartylglucosaminuria
fucosidosi
glycogen
storag
diseas
ib
niemannpick
taysach
diseas
os
improv
ci
histor
cohort
ci
current
cohort
p
oneyear
trm
reduc
ci
histor
cohort
ci
current
cohort
cox
model
year
transplant
age
transplant
male
grade
iiiiv
gvhd
predictor
overal
surviv
current
cohort
none
pretranspl
factor
transplant
factor
transplant
relat
complic
associ
os
os
children
transplant
current
cohort
xald
ci
mp
ci
imd
engraft
surviv
es
doubl
ci
histor
cohort
ci
current
cohort
p
proport
patient
graft
failur
decreas
histor
cohort
current
cohort
p
thirteen
patient
histor
cohort
four
patient
current
cohort
receiv
second
transplant
aliveandengraft
histor
cohort
incid
gvhd
grade
iiiiv
agvhd
cgvhd
current
cohort
incid
gvhd
grade
iiiiv
agvhd
cgvhd
survivor
followedup
manchest
full
chimer
mix
chimer
conclus
find
confirm
hct
perform
experienc
metabol
transplant
centr
increasingli
safe
provid
lifelong
therapi
children
imd
result
lead
reapprais
role
transplant
centr
includ
diseas
current
practis
risk
percept
risk
base
surviv
data
previou
era
like
includ
diseas
ert
current
standard
treatment
attenu
mpsi
mpsii
conflict
interest
none
author
anyth
declar
artemi
hospit
pediatr
hematolog
oncolog
immunolog
bone
marrow
transplant
gurugram
india
background
sickl
cell
diseas
scd
remain
associ
high
risk
morbid
earli
death
even
best
support
care
fail
improv
qualiti
life
end
stage
renal
diseas
esrd
one
rare
complic
scd
warrant
hematopoiet
stem
cell
transplant
hsct
kidney
transplant
one
hsct
patient
esrd
challeng
task
report
case
sickl
cell
nephropathi
scn
esrd
transplant
use
reduc
intens
condit
ric
along
cell
deplet
tcr
alphabeta
deplet
method
year
old
boy
ro
nigeria
known
case
scd
diagnos
year
age
multipl
episod
venoocclus
crisi
manag
symptomat
start
hydroxyurea
yr
age
benefit
much
present
us
worsen
renal
function
oligourea
odema
evalu
diagnos
esrd
renal
biopsi
suggest
scn
put
renal
replac
therapi
rrt
sibl
screen
potenti
donor
younger
sibl
found
hla
match
convent
bucyatg
right
choic
consid
esrd
condit
fludarabin
till
dose
adjust
base
crcl
busulfan
till
atg
pfizeratgam
till
subsequ
receiv
gcsf
prime
peripher
harvest
cell
deplet
graft
brother
absolut
cell
million
cellskg
log
reduct
alpha
beta
cell
log
reduct
cell
addit
immun
suppress
given
continu
rrt
cours
hsct
result
neutrophil
platelet
engraft
day
success
discharg
day
post
bmt
cours
complic
febril
neutropenia
mild
cmv
reactiv
manag
iv
antibiot
ganciclovir
day
donor
chimer
continu
rrt
plan
consid
renal
transplant
due
cours
prefer
donor
conclus
hsct
follow
renal
transplant
possibl
long
term
cur
option
scn
esrd
ric
flubuatg
cell
deplet
safest
way
hsct
case
clinic
trial
registri
none
conflict
interest
none
abstract
previous
publish
abstract
previous
publish
artemi
hospit
pediatr
hematolog
oncolog
immunolog
bone
marrow
transplant
gurugram
india
children
clinic
kampala
uganda
kampala
medic
chamber
kampala
uganda
case
clinic
kampala
uganda
mulago
teach
hospit
depart
haematolog
kampala
uganda
mulago
teach
hospit
depart
pediatr
kampala
uganda
sickl
cell
foundat
lago
nigeria
univers
teach
hospit
lago
nigeria
background
sickl
cell
diseas
scd
remain
associ
high
risk
morbid
earli
death
hematopoiet
stem
cell
transplant
hsct
cur
option
hla
match
relat
donor
mrd
consid
better
donor
tradit
myeloabl
mab
condit
regimen
use
mrd
hsct
reduc
intens
condit
ric
use
less
often
present
compar
outcom
mab
vs
ric
mrd
hsct
scd
method
consecut
patient
underw
hsct
scd
mrd
jan
till
date
median
age
hsct
yr
rang
five
patient
yr
consid
adult
receiv
ric
bu
mgkgday
x
day
cy
x
day
hatg
atgam
x
day
receiv
gcsf
prime
peripher
harvest
stem
cell
median
dose
rang
twenti
patient
yr
receiv
mab
bu
mgkgday
x
day
cy
x
day
hatg
atgam
x
day
two
receiv
gcsf
prime
peripher
harvest
stem
cell
wherea
seventeen
receiv
bone
marrow
one
patient
receiv
cord
blood
product
median
dose
rang
pbbm
mnc
cord
blood
unit
graft
versu
host
diseas
gvh
prophylaxi
bmpbsc
patient
cyclosporin
divid
dose
start
methotrex
follow
day
post
bmt
cyclosporin
methylprednisolon
cbt
result
patient
aliv
median
follow
day
rang
till
overal
surviv
diseas
free
surviv
donor
chimer
wherea
mix
stabl
chimer
last
follow
experienc
grade
iii
gvh
skingut
ric
group
mab
group
success
manag
either
topic
steroid
short
cours
parenter
steroid
experienc
chronic
musculoskelet
gvh
cmv
reactiv
seen
patient
ric
patient
mab
group
conclus
ric
reduc
dose
cyclophosphamid
consid
scd
patient
undergo
mrd
hsct
help
prevent
exposur
higher
dose
cyclophosphamid
turn
decreas
immedi
long
term
complic
prospect
studi
larger
cohort
requir
prove
clinic
trial
registri
none
conflict
interest
none
king
abdulaziz
medic
citi
oncolog
riyadh
saudi
arabia
background
patient
sever
sickl
cell
diseas
scd
phenotyp
manifest
stroke
complic
may
benefit
allogen
hematopoiet
stem
cell
transplant
sct
recent
report
pediatr
patient
use
myeloabl
regimen
show
excel
outcom
similar
progress
adult
hamper
higher
rate
transplant
relat
mortal
trm
infertil
method
conduct
retrospect
studi
adult
patient
institut
scd
underw
match
relat
sct
period
patient
receiv
hydroxyurea
hu
maxim
toler
dose
hypertransfus
month
prior
sct
preper
regimen
nma
consist
alemtuzumab
mgkg
divid
day
day
follow
tbi
cgi
day
stem
cell
collect
pbsc
apheresi
day
gcsf
target
cell
gvhd
prophylaxi
sirolimu
day
continu
one
year
post
sct
dose
modif
base
chimer
ef
defin
time
sct
graft
failur
develop
gvhd
death
caus
ef
os
via
time
end
point
analysi
comput
use
kaplanmeir
test
result
total
adult
patient
enrol
median
age
year
indic
transplant
recurrentrefractori
voc
stroke
recurr
avn
recurr
ac
donor
relat
sibl
fulli
match
median
age
year
total
donor
sc
carrier
averag
hgb
stem
cell
mobil
ugkg
gcsf
donor
averag
stem
cell
collect
x
signific
complic
result
gcsf
use
donor
sc
trait
patient
condit
alemtuzumab
tbi
regimen
gvhd
prophylaxi
sirolmu
one
patient
fail
prior
transplant
receiv
flubu
atg
gvhd
prophylaxi
csa
mtx
median
durat
anc
platelet
engraft
day
respect
averag
hb
pre
postsct
gl
gl
respect
averag
hb
pre
postsct
respect
none
patient
develop
acut
chronic
gvhd
scd
crise
develop
post
sct
one
patient
develop
aplast
anemia
retain
donor
cell
chimer
underw
second
success
sct
donor
flucyclo
atg
patient
stabl
mix
chimer
result
full
donor
myeloid
engraft
normal
blood
count
median
follow
day
patient
aliv
free
sc
crise
last
follow
os
ef
respect
shown
figur
conclus
herein
report
sct
adult
sever
scd
use
nma
regimen
safe
feasibl
result
amelior
diseas
sever
excel
result
encourag
given
high
preval
debilit
natur
scd
region
clinic
trial
registri
applic
conflict
interest
conflict
interest
american
univers
beirut
beirut
lebanon
chronic
care
center
beirut
lebanon
lebanes
american
univers
beirut
lebanon
background
allogen
hematopoiet
stem
cell
transplant
allohsct
cur
therapi
transfusiondepend
thalassemia
multipl
barrier
prevent
implement
allo
hsct
thalassemia
patient
low
middleincom
countri
includ
statu
patient
pretranspl
financi
barrier
need
extend
follow
posttranspl
method
overcom
major
barrier
set
lebanon
collabor
develop
academ
transplant
servic
philanthrop
center
thalassemia
care
includ
chelat
monitor
complic
provid
mani
year
chronic
care
center
ccc
financi
support
provid
govern
insur
ccc
al
walid
ben
talal
foundat
gnk
foundat
transplant
posttranspl
care
provid
pediatr
bmt
program
american
univers
beirut
abstract
retrospect
review
outcom
allohsct
consecut
transfusiondepend
thalassemia
patient
underw
transplant
support
partnership
result
twelv
patient
male
femal
median
age
rang
year
underw
allohsct
previouslyment
period
donor
matchedrel
median
serum
ferrtin
time
transplant
rang
mgdl
median
liver
cardiac
iron
content
mri
mgg
rang
rang
mgg
respect
condit
regimen
consist
busulfan
fix
weightdepend
dose
cyclophosphamid
mg
kgday
x
day
atg
genzym
rabbit
mgkgday
x
day
gvhd
prophylaxi
consist
cyclosporin
methotrex
stem
cell
sourc
bm
patient
g
csf
mobil
pbsc
two
patient
median
cell
dose
rang
x
per
kg
patient
achiev
sustain
neutrophil
platelet
engraft
median
rang
rang
day
eight
patient
complet
chimer
four
patient
partial
chimer
rang
howev
patient
becam
transfusionindepend
complet
recoveri
acut
grade
ii
skin
gvhd
occur
one
patient
none
patient
develop
chronic
gvhd
one
patient
develop
sever
vod
requir
intensivecar
admiss
recov
fulli
major
toxic
observ
median
followup
rang
month
gvhdfree
surviv
rate
conclus
barrier
allobmt
thalassemia
could
overcom
partnership
academ
transplant
servic
govern
insur
communitybas
philanthrop
institut
middleincom
countri
plan
introduc
busalfan
pharmacokinet
near
futur
conflict
interest
relev
conflict
interest
tehran
univers
medic
scienc
hematolog
oncolog
stem
cell
transplant
research
center
tehran
iran
islam
republ
background
allogen
hematopoiet
stem
cell
transplant
hsct
avail
cur
option
thalassemia
major
tm
patient
current
wide
use
worldwid
high
probabl
eventfre
surviv
recent
shown
msc
transdifferenti
hepatocytelik
cell
vitro
abil
perform
normal
metabol
function
liver
cell
howev
vivo
abil
hepatocyt
differenti
donor
msc
replac
damag
hepatocyt
tm
patient
yet
thoroughli
demonstr
method
extract
data
hematologyoncolog
stem
cell
transplant
research
center
horcsct
registri
databas
illustr
characterist
tm
patient
longterm
followup
februari
decemb
total
tm
patient
underw
hsct
follow
myeloabl
condit
regimen
consecut
cotransplant
msc
conduct
patient
prospect
random
intervent
studi
assay
liver
fibrosi
improv
result
peripher
blood
pb
use
common
sourc
allogen
hematopoiet
stem
cell
patient
although
reject
rate
chronic
gvhd
significantli
higher
patient
whose
graft
sourc
bone
marrow
bm
signific
differ
year
os
found
vs
compar
pb
graft
p
signific
differ
os
among
follow
age
group
year
old
year
old
year
old
p
os
significantli
lower
patient
older
year
p
random
trial
patient
age
classifi
lrc
iii
receiv
cotransplant
msc
compar
nonmsc
patient
differ
reject
rate
two
group
vs
p
interestingli
incid
acut
gvhd
higher
msc
compar
nonmsc
patient
vs
incid
chronic
gvhd
significantli
differ
two
group
msc
vs
nonmsc
p
fibroscan
mri
perform
msc
nonmsc
patient
transplant
one
year
mri
mean
score
increas
significantli
within
group
p
without
signific
differ
p
fibroscan
score
also
increas
one
year
hsct
chang
significantli
differ
msc
nonmsc
patient
p
conclus
hsct
offer
promis
outcom
tm
patient
world
result
superior
perform
earlier
age
strongli
suggest
age
would
incorpor
risk
classif
import
influenc
factor
moreov
observ
consider
improv
liver
fibrosi
evalu
fibroscan
follow
cotransplant
msc
howev
larger
studi
requir
clearli
defin
effect
msc
improv
hepat
fibrosi
conflict
interest
conflict
interest
report
hematopoiet
stem
cell
children
hospit
soochow
univers
suzhou
china
background
compar
clinic
outcom
human
leucocyt
antigen
match
hlam
hla
mismatch
hlami
umbili
cord
blood
stem
cell
transplant
ucbt
treatment
children
hematolog
diseas
method
patient
low
resolut
receiv
hlami
patient
receiv
hlami
patient
receiv
hlam
ucbt
patient
high
resolut
receiv
hlami
less
patient
receiv
hlami
patient
receiv
hlam
ucbt
children
hospit
soochow
univers
april
septemb
result
low
resolut
engraft
neutrophil
platelet
respect
high
resolut
implant
neutrophil
platelet
respect
acut
graft
versu
host
diseas
agvhd
rate
low
resolut
high
resolut
tabl
overal
surviv
os
rate
low
resolut
respect
high
resolut
figur
conclus
children
hematolog
diseas
ucbt
differ
hlam
hlami
engraft
agvhd
decreas
mismatch
loci
high
resolut
transplantrel
mortal
trm
increas
children
lack
match
donor
hlami
cord
blood
stem
cell
altern
stem
cell
sourc
high
resolut
would
help
us
choos
better
donor
conflict
interest
author
declar
conflict
interest
workw
declar
commerci
associ
interest
repres
conflict
interest
connect
work
submit
ege
univers
hospit
depart
intern
medicin
divis
hematolog
izmir
turkey
background
allogen
hematopoiet
stem
cell
transplant
hsct
survivor
risk
develop
therapyrel
complic
may
mortal
data
outcom
elderli
patient
limit
recent
year
develop
reducedintens
condit
ric
nonmyeloabl
nma
regimen
extend
perform
hsct
elderli
popul
goal
retrospect
studi
identifi
factor
impact
safeti
efficaci
allogen
hsct
elderli
patient
method
singlecent
retrospect
studi
examin
outcom
allogen
hsct
elderli
patient
year
old
januari
decemb
patient
met
inclus
criteria
includ
studi
diagnosi
age
regimen
toxic
overal
surviv
os
progress
free
surviv
pf
analyz
accord
age
time
transplant
result
among
patient
male
femal
median
age
transplant
time
year
rang
approxim
onethird
cohort
year
old
accord
diagnosi
aml
md
mm
kll
kml
pmf
incid
febril
neutropenia
admiss
intens
care
unit
among
patient
hla
match
sibl
hla
match
unrel
haploident
donor
ricnma
regimen
administ
condit
regimen
transplant
median
followup
month
rang
diseas
relaps
observ
patient
os
month
grade
acut
chronic
gvhd
observ
patient
os
month
year
post
hsct
year
post
hsct
os
pf
nrm
respect
year
post
hsct
os
hla
match
sibl
donor
associ
best
outcom
median
os
month
year
post
hsct
os
wherea
median
os
hla
match
unrel
haploident
month
month
respect
haploident
donor
grade
gvhd
associ
higher
nrm
p
p
respect
also
abl
condit
regimen
associ
inferior
outcom
ricnma
regimen
os
month
regimen
os
month
conclus
consequ
elderli
age
advers
effect
nrm
relaps
os
allogen
hsct
well
toler
allogen
hematopoiet
stem
cell
transplant
ricnma
regimen
may
feasibl
treatment
option
elderli
patient
low
comorbid
index
reason
advanc
age
alon
consid
contraind
allogen
hsct
conflict
interest
none
declar
gustav
roussi
cancer
campu
hematolog
villejuif
franc
gustav
roussi
cancer
campu
inserm
villejuif
franc
faculti
medicin
pari
sud
le
kremlin
franc
background
allogen
stem
cell
transplant
sct
remain
cornerston
treatment
strategi
hematolog
malign
previous
age
comorbid
consid
limit
factor
introduct
reduc
intens
condit
regimen
ric
understand
donor
immun
function
allogen
sct
adult
age
year
gain
place
object
determin
overal
surviv
os
defin
time
death
irrespect
caus
relapsefre
surviv
rf
defin
surviv
without
death
relaps
nonrelaps
mortal
nrm
defin
time
death
without
evid
diseas
relaps
cumul
incid
relaps
ri
defin
time
relaps
method
retrospect
studi
total
patient
age
year
older
undergo
ric
allogen
hematopoiet
sct
hematolog
malign
diseas
combin
institut
result
median
followup
year
os
rf
year
ci
ci
respect
cumul
incid
nrm
relaps
ci
ci
respect
differ
os
term
hctci
comorbid
risk
score
donor
type
ric
condit
regimen
type
statist
signific
respect
grade
iiiv
acut
gvhd
occur
patient
cumul
incid
grade
ii
iv
acut
gvhd
day
eighteen
patient
develop
chronic
gvhd
ege
univers
faculti
medicin
depart
hematolog
izmir
turkey
ege
univers
faculti
medicin
depart
patholog
izmir
turkey
background
blastic
plasmacytoid
dendrit
cell
neoplasm
bpdcn
clinic
aggress
tumor
deriv
precursor
plasmacytoid
dendrit
cell
rare
aggress
hematolog
neoplasm
includ
among
acut
myeloid
leukemia
relat
precursor
disord
classif
hematolog
diseas
classifi
distinct
entiti
among
myeloid
neoplasm
revis
bpdcn
typic
occur
elderli
patient
mean
age
year
preval
male
patient
present
cutan
lesion
without
bone
marrow
involv
leukem
dissemin
minor
case
present
leukemia
without
skin
involv
cytopenia
lymphadenopathi
andor
splenomegali
present
signific
major
patientsw
report
experi
allogen
transplant
bpcdn
method
three
patient
blastic
plazmositoid
dentrit
cell
neoplazm
treat
hypercvad
regimen
period
septemb
june
clinic
data
patient
collect
retrospect
result
patient
male
age
admit
hospit
fever
weight
loss
weak
lymphadenopathi
gener
examin
reveal
lymphadenopathi
two
multipl
lymphadenopathi
one
hepatosplenomegali
two
skin
lesion
skin
lesion
bruiselik
brown
violac
infiltr
plaqu
back
bodi
extrem
one
patient
brownpurpl
tumor
mass
also
brownpurpl
nodular
lesion
head
region
laboratori
test
reveal
patient
pancytopenia
two
sever
thrombocytopenia
patient
bone
marrow
lymph
node
biopsi
show
diffus
infiltr
medium
size
blast
irregular
nuclear
contour
slightli
larg
cytoplasm
high
mitot
index
ihc
express
skin
biopsi
two
patient
reveal
diffus
infiltr
analog
cellsthey
diagnos
blastic
plasmacytoid
dentrit
cell
neoplasm
one
develop
confus
lumbar
punctur
perform
neurolog
symptom
cranial
mr
imag
found
clivu
involv
also
cn
involv
patholog
proven
cerebrospin
fluid
cytolog
patient
start
hypercvad
chemotherapi
one
cours
chemotherapi
two
achiev
complet
remiss
one
two
patient
achiev
cr
patient
could
nt
achiev
cr
present
persist
fever
hypotens
tachycardia
organ
dysfunct
develop
die
sepsi
one
achiev
complet
remiss
one
cours
chemoterapi
treat
three
cours
chemoterapi
mainten
afterward
underw
transplant
peripher
blood
progenitor
cell
relat
one
missmatch
donorbuci
administ
condit
regimen
transplant
present
one
year
diagnosi
still
cr
conclus
two
three
patient
achiev
cr
hypercvad
chemotherapi
optim
treatment
unknown
cn
prophylaxi
must
routin
incorpor
treatment
protocol
bpdcn
highli
malign
prognosi
poor
overal
surviv
report
month
adult
patient
relaps
within
two
year
reason
hematopoiet
stem
cell
transplant
either
autolog
allogen
requir
attain
sustain
remiss
conflict
interest
declar
tor
vergata
univers
clinic
infecti
diseas
rome
itali
tor
vergata
univers
depart
hematolog
rome
itali
background
surviv
hivposit
patient
hematolog
diseas
activ
antiretrovir
therapi
haart
era
continu
improv
hodgkin
hl
nonhodgkin
lymphoma
nhl
remain
common
malign
popul
allogen
hematopoiet
cell
transplant
allohsct
recommend
therapi
relapsedrefractori
hl
diseas
autolog
stem
cell
mobil
case
report
patient
hiv
report
case
refractori
classic
hl
patient
dissemin
tuberculosi
time
hiv
diagnosi
method
patient
old
man
admit
hospit
fever
lymphopenia
asthenia
physic
examin
gener
lymphadenopathi
detect
laboratori
test
show
anemia
lymphopenia
quantiferontb
gold
test
mantoux
skin
test
result
neg
total
bodi
pet
ct
scan
show
paraaort
aortocav
iliac
lymphadenopathi
splenomegali
bone
involv
hiv
test
result
posit
lymph
node
biopsi
reveal
posit
mycobacterium
tuberculosi
pcr
classic
hodgkin
lymphoma
ebvrel
diagnosi
iv
b
stage
diseas
accord
ann
arbor
stage
system
count
cell
hiv
viremia
cpml
ebv
viremia
cpml
prophylaxi
opportunist
infect
standard
anti
tubercular
drug
start
consid
clinic
condit
need
start
chemotherapi
cart
tdfftc
raltegravir
start
two
week
later
patient
start
abvd
regimen
doxorubicin
bleomycin
vinblastin
dacarbazin
petct
scan
cycl
result
neg
petct
scan
cycl
howev
reveal
diseas
progress
resist
firstlin
chemotherapi
secondlin
treatment
start
igev
ifosfamid
gemcitabin
vinorelbin
prednisolon
combin
regimen
cycl
therapi
patient
declar
resist
first
stem
cell
mobil
gcsf
fail
consider
clinic
condit
comorbid
thirdlin
therapi
brentuximab
vedotin
mgkg
administ
four
cycl
conclud
petct
scan
revalu
document
resist
diseas
case
discuss
label
treatment
brentuximabbendamustin
decid
revalu
petct
scan
cycl
show
complet
remiss
patient
fail
second
attempt
pbsc
mobil
plerixafor
gcsf
admit
blood
marrow
transplant
unit
month
diagnosi
complet
remiss
hematolog
diseas
time
cell
count
hiv
viremia
result
undetect
result
patient
underw
allohsct
hla
compat
myeloabl
condit
engraft
obtain
day
acut
gvhd
detect
antitubercular
therapi
prolong
day
stem
cell
transplant
petct
scan
result
neg
month
posttranspl
immunolog
paramet
improv
cell
count
hiv
ebv
viremia
undetect
conclus
despit
sever
immunosuppress
induc
hiv
infect
allohsct
valid
option
patient
refractoryrelaps
hodgkin
lymphoma
fail
autohsct
clinic
follow
close
monitor
essenti
conflict
interest
none
author
anyth
disclos
forti
memori
research
institut
gurugram
india
background
allogen
stem
cell
transplant
allosct
servic
children
still
far
behind
india
compar
develop
countri
resourc
constraint
pauciti
literatur
develop
world
present
experi
allosct
variou
benign
malign
paediatr
diseas
method
retrospect
analysi
total
children
male
femal
underw
allosct
januari
may
tertiari
care
hospit
north
india
done
mean
age
patient
year
rang
year
indic
benign
diseas
hemoglobinopathi
thalassemia
major
tm
sickl
cell
diseas
scd
aplast
fanconi
diamondblackfan
immunodefici
one
wiskottaldrich
syndrom
chediakhigashi
syndrom
malign
acut
myeloid
leukaemia
aml
acut
lymphoblast
leukaemia
juvenil
myelomocyt
leukaemia
jmml
myelodysplast
relaps
chronic
myeloid
leukaemia
cml
donor
hlamatch
singl
antigen
match
unrel
sourc
stem
cell
peripher
blood
patient
bone
marrow
patient
chose
posttranspl
cyclophosphamid
base
approach
major
haploident
transplant
except
patient
cell
receptor
alpha
beta
cd
deplet
done
result
total
patient
patient
aliv
diseas
free
median
followup
day
rang
day
median
time
neutrophil
engraft
day
rang
day
patient
includ
patient
underw
second
allosct
five
patient
reject
one
tm
scd
aml
cml
jmml
patient
aliv
diseas
free
acut
graft
versu
host
diseas
gvhd
report
patient
grade
chronic
gvhd
patient
day
mortal
caus
non
relaps
mortal
venoocclus
seven
patient
die
due
relaps
andor
progress
diseas
none
patient
succumb
cytomegaloviru
bk
viru
epsteinbarr
viru
adenoviru
diseas
conclus
result
compar
mani
nation
intern
publish
report
term
complic
outcom
treatment
give
hope
mani
children
need
allogen
stem
cell
transplant
develop
world
clinic
trial
registri
applic
conflict
interest
none
hanov
medic
school
ped
liver
kidney
metabol
diseas
hanov
germani
hanov
medic
school
ped
haematolog
hanov
germani
hanov
medic
school
nephrolog
hanov
germani
essen
univers
hospit
ped
haematolog
essen
germani
background
advanc
allogen
hematopoiet
stem
cell
transplant
hsct
malign
nonmalign
diseas
result
longterm
survivor
cardiovascular
cv
diseas
one
lead
noncanc
caus
mortal
studi
aim
evalu
risk
factor
rf
subclin
cv
organ
damag
survivor
hsct
paediatr
age
method
enrol
children
year
hsct
crosssect
approach
anthropometr
data
laboratori
valu
offic
ambulatori
blood
pressur
monitor
abpm
evaluatedcv
organ
damag
determin
noninvas
measur
aortic
puls
wave
veloc
pwv
carotid
intima
media
thick
imt
left
ventricular
mass
index
lvmi
sd
score
everi
measur
calcul
age
appropri
result
mean
age
children
enrol
year
male
high
preval
obes
dyslipidemia
respect
hypertens
present
children
mask
hypertens
detec
abpm
increas
imt
elev
pwv
detect
imt
pwv
imt
physic
activ
posit
impact
worsen
time
hsct
elev
pwv
sd
associ
multivari
analysi
higher
waist
circumfer
hsct
carri
age
year
anthracyclin
therapi
histori
venoocclus
diseas
associ
lower
lvmi
conclus
result
show
surprisingli
high
rate
subclin
cv
organ
damag
classic
rf
children
hsct
therefor
diagnosi
manag
wellknown
cv
risk
factor
belong
clinic
care
hsct
conflict
interest
author
declar
conflict
interest
exist
british
societi
blood
marrow
transplant
london
unit
kingdom
nottingham
univers
hospit
trust
clinic
haematolog
nottingham
unit
kingdom
addenbrook
hospit
haematolog
cambridg
unit
kingdom
univers
hospit
southampton
haematolog
southampton
unit
kingdom
background
mark
anniversari
hsct
sinc
pioneer
work
donal
thoma
year
sinc
bsbmt
found
john
goldman
toni
goldston
sinc
time
transplant
evolv
chang
sourc
stem
cell
condit
regimen
diseas
treat
patient
demograph
gvhd
strategi
support
care
method
method
activ
overal
surviv
data
uk
hsc
transplant
perform
analys
determin
transplant
evolv
uk
time
period
result
time
period
patient
underw
transplant
procedur
allograft
autolog
total
number
transplant
procedur
per
year
continu
rise
although
increas
activ
mainli
autolog
set
whilst
allograft
number
appear
plateau
autolog
procedur
children
done
use
pbsc
wherea
adult
case
year
allograft
set
paediatr
adult
transplant
done
pbsc
number
cord
transplant
appear
also
plateau
use
tbi
declin
adult
paediatr
set
reduc
intens
condit
account
adult
approx
paediatr
procedur
adult
autograft
allograft
set
mark
increas
number
patient
age
year
undergo
hsct
number
patient
age
year
transplant
rapidli
rise
surprisingli
number
allograft
cml
steepli
declin
sinc
similar
recent
reduct
number
allograft
cll
due
introduct
effect
new
drug
diseas
contrast
allograft
aml
continu
rise
due
lack
new
drug
disord
autograft
set
increas
number
transplant
perform
autoimmun
diseas
number
myeloma
autograft
steadili
rise
overal
surviv
post
autograft
increas
steadili
across
decad
nhl
hd
myeloma
possibl
due
partli
reduc
trm
also
improv
salvag
therapi
relaps
follow
allograft
continu
improv
os
also
seen
saa
md
whilst
cml
mark
improv
os
era
like
due
introduct
tki
improv
sinc
contrast
aml
outcom
improv
across
last
decad
conclus
bsbmt
registri
data
demonstr
transplant
evolv
past
decad
new
techniqu
allow
patient
benefit
transplant
done
safe
new
drug
treatment
influenc
surviv
reduc
transplant
activ
diseas
new
indic
replac
result
overal
continu
expans
conflict
interest
j
byrn
c
crawley
honoraria
jazz
pharmaceut
j
perri
k
orchard
r
pearc
noth
declar
hospit
gener
universitario
gregorio
hematologybmt
unit
madrid
spain
hospit
gener
universitario
gregorio
madrid
spain
background
cmv
reactiv
frequent
complic
allogen
hematopoiet
stem
cell
transplant
hsct
group
report
associ
improv
relaps
free
surviv
overal
surviv
hsct
hlaident
donor
natur
killer
cell
nk
import
effector
innat
immun
respons
viral
infect
cell
therefor
critic
limit
cmv
replic
aim
studi
evalu
impact
cmv
reactiv
hsct
associ
nk
matur
profil
transplant
outcom
patient
underw
peripher
blood
unmanipul
haploident
hsct
haplohsct
postranspl
cyclophosphamid
ptci
institut
method
juli
june
consecut
patient
underw
haplohsct
three
die
day
haplosct
patient
retrospect
analyz
tabl
cmv
reactiv
monitor
perform
twice
weekli
admiss
hsct
later
weekli
use
plasmar
time
pcr
assay
nk
cell
assess
day
nk
absolut
count
percentag
nk
cell
result
median
followup
month
cumul
incid
cmv
reactiv
observ
day
day
day
none
develop
cmv
infect
analysi
nk
cell
show
median
absolut
count
absolut
count
absolut
count
patient
develop
cmv
reactiv
day
show
higher
percentag
p
relationship
detect
among
patient
cmv
reactiv
day
overal
cumul
incid
df
year
patient
cmv
reactiv
day
show
trend
toward
better
df
rate
compar
cmv
reactiv
p
figur
cumul
incid
relaps
patient
cmv
reactiv
day
patient
without
reactiv
figur
conclus
studi
show
signific
correl
nk
matur
cmv
reactiv
haplohsct
ptci
trend
toward
better
df
cmv
reactiv
day
studi
need
confirm
observ
conflict
interest
noth
disclos
tabl
tabl
institut
hematolog
blood
transfus
depart
apheresi
pragu
czech
republ
institut
hematolog
blood
transfus
clinic
depart
pragu
czech
republ
background
peripher
hematopoiet
stem
cell
pbpc
usual
obtain
donor
use
growth
factor
mobil
gcsf
use
origin
product
neupogen
past
today
biosimilar
prepar
introduc
econom
aspect
start
use
biosimilar
gcsf
zarzio
sinc
januari
depart
goal
show
whether
mobil
effect
origin
whether
differ
donorbas
mobil
age
point
view
method
famili
donor
mobil
origin
gcsf
period
donor
mobil
biosimilar
gcsf
period
group
donor
indic
n
neupogen
z
zarzio
gcsf
sc
one
dose
administ
eveninggroup
n
receiv
kg
per
day
group
z
per
day
separ
start
dose
gcsf
separ
perform
spectra
optia
terumo
cmnc
mode
first
separ
evalu
consid
mobil
failur
valu
peripher
blood
less
optimum
transplant
dose
kg
recipi
minimum
dose
result
signific
differ
group
age
gender
side
effect
stimul
group
n
z
rate
failur
mobil
group
n
z
collect
pbpc
perform
similar
group
n
tbv
z
tbv
median
cell
one
collect
cd
kg
recipi
n
kg
group
z
minimum
transplant
dose
collect
case
reach
optimum
transplant
dose
n
z
group
median
number
collect
one
howev
donor
complet
case
two
separ
n
z
also
divid
group
two
subgroup
age
less
yr
better
mobil
detect
group
n
age
yr
howev
fact
impact
result
collect
conclus
find
signific
differ
mobil
famili
donor
use
differ
type
gcsf
util
differ
type
gcsf
age
seem
import
issu
routin
follow
donor
mobil
period
longer
year
use
origin
product
current
begin
use
biosimilar
gcsf
believ
outcom
type
gcsf
expect
conflict
interest
noth
disclos
nation
special
hospit
activ
treatment
haematolog
diseas
sofia
bulgaria
background
hematopoiet
stem
cell
hsc
transplant
establish
method
treatment
malign
benign
hematolog
diseas
hsc
intens
metabol
therefor
durat
storag
short
day
long
term
storag
possibl
frozen
main
reason
cellular
damag
slow
freez
cell
dehydr
due
extracellular
ice
format
lead
irrevers
deform
loss
cell
membran
presenc
cellular
suspens
cryoprotect
agent
reduc
damag
use
dimethyl
sulfoxid
intracellular
cryoprotect
hydroxyethyl
starch
plasma
albumin
extracellular
one
establish
appropri
content
cryoprotect
solut
investig
combin
dmso
differ
extracellular
cryoprotect
method
apheresisderiv
hematopoiet
stem
cell
mix
cryoprotect
solut
frozen
cryoprotect
solut
contain
dmso
final
concentr
human
albumin
without
isoton
solut
hydroxyethyl
starch
he
differ
rel
molecular
weight
autolog
plasma
cell
vital
test
mix
cryoprotect
solut
first
day
third
sixth
twelfth
month
storag
trypan
blue
exclus
result
viabil
cell
follow
storag
differ
cryoprotect
solut
exceed
presenc
absenc
he
cryoprotect
solut
affect
viabil
howev
sampl
he
better
viabil
human
albumin
concentr
higher
conclus
dmso
toxic
cell
might
lead
seriou
advers
reaction
heart
rhythm
disord
hemodynam
disturb
bronchial
spasm
etc
infus
addit
extracellular
cryoprotect
give
opportun
use
smaller
concentr
dmso
final
suspens
thu
reduc
incid
sever
advers
event
infus
thaw
cell
human
albumin
may
use
substitut
high
molecular
weight
hydroxyethyl
starch
extracellular
cryoprotect
conflict
interest
none
hebei
yanda
lu
daopei
hospit
divis
bone
marrow
transplant
beij
china
hebei
yanda
lu
daopei
hospit
beij
china
background
aim
studi
determin
safeti
efficaci
condit
regimen
consist
total
bodi
irradi
tbi
cyclophosphamid
cy
prior
allogen
hematopoiet
stem
cell
transplant
allohsct
forpati
nktcell
lymphoma
leukemia
method
retrospect
analyz
patient
nktcell
lymphoma
leukemia
receiv
condit
regimen
myeloablativeallohsct
hospit
juli
april
five
nine
patient
aggress
natur
killer
cell
leukemia
ankl
three
refractori
extranod
nktcell
lymphoma
one
ebvassoci
tnkcell
lymphoprolif
diseas
tnklpd
median
age
year
male
femal
ratio
median
diseas
cours
diagnosi
transplant
month
eight
patient
persist
ebvposit
allohsct
eight
patient
five
hemophagocyt
lymphohistiocytosi
hlh
six
patient
diseas
control
prior
allohsct
one
patient
underw
match
unrel
donor
hsct
four
receiv
haploid
hsct
crd
four
receiv
hlamatch
sibl
transplant
condit
regimen
use
consist
tbi
day
cyclophosphamid
day
mgkg
day
total
dose
antithymocyt
globulin
atg
given
case
mgkg
atgfresenniu
case
atg
given
hlamatch
sibl
transplant
gvhd
prophylaxi
cyclosporin
tacrolimu
mycophenol
mofetil
methotrex
given
result
patient
underw
treatment
success
median
time
neutrophil
engraft
day
median
time
platelet
engraft
day
grade
iiivagvhd
occur
case
cumul
incid
grade
iiiv
agvhd
five
case
limit
cgvhd
ebv
infect
patient
undetect
transplant
median
followup
month
seven
patient
remain
diseasefre
two
patient
die
pulmonari
infect
thrombot
microangiopathi
respect
overal
surviv
rate
conclus
result
indic
condit
regimen
allohsct
improv
diseasefre
surviv
patient
nktcell
lymphoma
leukemia
conflict
interest
noth
disclos
northwestern
univers
feinberg
school
medicin
divis
immunotherapi
autoimmun
diseas
chicago
il
unit
state
northwestern
univers
feinberg
school
medicin
depart
neurolog
chicago
il
unit
state
background
patient
multipl
sclerosi
ms
undergo
autolog
hematopoiet
stem
cell
transplant
hsct
experi
delay
fever
associ
rabbit
antithymocyt
globulin
ratg
induc
temporari
neurolog
pseudoflar
method
inpati
record
review
ms
patient
underw
hsct
northwestern
medicin
chicago
illinoi
month
period
juli
juli
data
collect
includ
record
temperatur
neurolog
symptom
day
transplant
fever
occur
blood
cultur
result
steroid
protocol
given
recurr
fever
neurolog
symptom
report
patient
provid
relat
fever
result
patient
review
patient
fever
patient
fever
mean
temperatur
rang
sixtyseven
percent
patient
develop
fever
day
post
hsct
fever
also
report
day
sixtyf
percent
patient
develop
neurolog
symptom
predomin
weak
fatigu
febril
episod
first
temperatur
spike
blood
cultur
drawn
chest
xray
obtain
methylprednisolon
iv
given
vancomycin
ad
addit
prophylact
cefepim
broaden
antibiot
coverag
methylprednisolon
iv
order
two
consecut
day
spike
twentytwo
patient
recurr
fever
receiv
second
cours
methylprednisolon
iv
three
consecut
day
two
patient
posit
escherichia
coli
urin
cultur
associ
febril
episod
one
patient
posit
clostridium
difficil
day
fever
treat
oral
vancomycin
day
blood
cultur
neg
growth
fever
resolv
within
three
hour
steroid
administr
along
resolut
neurolog
symptom
conclus
fever
neutropenia
ratg
cyclophosphamid
condit
ms
usual
secondari
ratg
fever
associ
pseudoflar
resolv
rapidli
administr
methylprednisolon
expand
antibiot
coverag
vigil
import
rule
infect
conflict
interest
author
noth
disclos
manip
hospit
pediatr
hematooncolog
bmt
jaipur
india
manip
hospit
hematopatholog
molecular
diagnost
jaipur
india
manip
hospit
pediatr
critic
care
jaipur
india
manip
hospit
infceti
diseas
jaipur
india
manip
hospit
immunohematolog
jaipur
india
background
hematopoiet
stem
cell
transplant
hsct
cure
patient
thalassemia
major
probabl
find
suitabl
match
includ
match
unrel
donor
india
move
publish
result
treplet
haploident
hsct
haplosct
posttranspl
cyclophosphamid
ptci
investig
haplosct
indian
pt
method
august
septemb
pt
thalassemia
major
underw
haplosct
ptci
strategi
centr
sixteen
subject
male
femal
median
age
yr
rang
pretranspl
pesaro
risk
group
classi
classii
classiii
donor
sourc
peripher
stem
cell
pbsc
pbsccord
cell
pt
donor
mother
pt
father
brother
pt
pt
given
two
cycl
dexamethasonefludarabin
everi
day
two
condit
regimen
use
regimena
atg
rabbit
flu
bu
pt
regimenb
regimen
athiotepa
use
pt
donor
specif
anti
hla
antibodi
dsa
present
pt
none
classi
classii
classiii
pt
treatment
dsa
given
patient
mfi
gvhd
prophylaxi
ptci
tacrolimu
mycophenol
mofetil
mmf
start
tacrolimu
given
till
month
mmf
taper
replet
pbsc
pbsccord
cell
given
target
dose
result
regimen
toler
vod
liver
seen
two
case
regimenb
none
reject
graft
median
time
neutrophil
engraft
rang
platelet
day
rang
acut
gvhd
seen
liver
skin
gvhd
grade
iii
gut
gvhd
grade
iii
iv
observ
pt
one
die
chronic
gvhd
observ
limit
skin
pt
viral
reactiv
observ
pt
bkv
pt
cmv
adenoviru
pt
transplant
relat
mortal
trm
total
death
trm
two
pt
classii
four
classiii
six
pt
multidrug
resist
sepsi
four
six
patient
classii
classiii
refractori
macrophag
activ
syndrom
along
sepsi
two
late
death
attribut
macrophag
activ
syndrom
ma
gut
gvhd
ma
respect
pt
classiii
patient
die
pretranspl
dsa
titr
mfi
hla
classi
ii
studi
report
thalassemia
free
overal
surviv
classi
ii
iii
respect
median
followup
month
rang
month
conclus
replet
haplosct
ptci
produc
excel
result
class
ii
pt
combin
dsa
classiii
pt
predict
poor
surviv
probabl
ma
warrant
novel
intervent
overcom
hurdl
conflict
interest
none
stem
cell
laboratori
section
hematolog
blood
coagul
children
hospit
spedali
civili
brescia
brescia
itali
pediatr
oncohematolog
bmt
unit
children
hospit
spedali
civili
brescia
brescia
itali
pediatr
oncohematolog
bmt
unit
children
hospit
chair
paediatr
univers
brescia
brescia
itali
background
analysi
short
tandem
repeat
str
predomin
method
post
hematopoiet
stem
cell
transplant
hsct
monitor
donor
engraft
enabl
earli
detect
diseas
relaps
level
engraft
provid
use
inform
graftversushost
diseas
gvhd
graftversustumor
gvt
effect
facilit
therapeut
intervent
good
standard
method
center
allow
analysi
donor
chimer
also
patient
low
white
cell
count
due
high
sensibl
test
method
analyz
earli
donor
chimer
paediatr
patient
lla
talassemia
scid
cid
hyper
ige
syndrom
aplast
anemia
md
lad
hsct
str
analysi
perform
peripher
blood
pb
presenc
low
number
white
blood
cell
wbc
count
blood
popul
analyz
pbl
peripher
blood
lymphocyt
pmn
polimorphonucl
cell
result
total
paediatr
patient
evalu
donor
chimer
hsct
averag
wbc
count
moment
analysi
rang
first
timepoint
patient
total
donor
chimer
pbl
pmn
donor
cell
mix
chimer
pbl
donor
cell
rang
total
pmn
mix
chimer
pbl
donor
cell
rang
pmn
donor
cell
rang
patient
autolog
donor
cell
method
help
predict
tool
monitor
hsct
outcom
particular
patient
autolog
reconstitut
analysi
perform
day
post
hsct
wbc
allow
go
second
transplant
day
patient
affect
sever
aplast
anemia
slow
hematolog
reconstitut
str
analysi
perform
wbc
day
post
hsct
result
condit
would
allow
standard
analysi
chimer
confirm
donor
engraft
donor
cell
pbl
donor
cell
pmn
conclus
str
method
best
appropri
tool
hand
predict
event
diseas
relaps
graft
reject
experi
assay
allow
prompt
salvag
therapeut
approach
case
unsuccess
procedur
sinc
chimer
analysi
perform
soon
possibl
give
opportun
rapidli
find
anoth
donor
modifi
condit
regimen
conflict
interest
author
conflict
interest
declar
univers
hospit
patra
bone
marrow
transplant
unit
patra
greec
background
clinic
outcom
patient
transplant
activ
myeloid
leukemia
aml
extrem
poor
recent
retrospect
studi
report
overal
surviv
encourag
result
report
sequenti
administr
precondit
along
condit
regimen
neutropenia
flamsalik
protocol
schmidt
et
al
aim
studi
effect
allogen
transplant
flamsalik
sequenti
condit
regimen
patient
activ
myeloid
diseas
sequenti
chemoallo
method
analys
patient
underw
allohct
activ
myeloid
leukemia
patient
receiv
chemotherapi
precondit
one
week
begin
condit
regimen
accord
approv
protocol
ethic
comite
overal
surviv
os
relaps
free
surviv
rf
obtain
method
kaplanmei
patient
censor
last
follow
still
aliv
relaps
rel
non
relaps
mortal
nrm
consid
compet
risk
result
overal
patient
male
femal
median
age
year
rang
transplant
activ
myeloid
diseas
de
novo
aml
secaml
omf
thirteen
patient
refractori
diseas
patient
mdsaml
nt
receiv
chemotherapi
median
cycl
chemotherapi
rang
median
number
blast
begin
precondit
rang
precondit
given
day
includ
administr
aracytin
variabl
dosag
grmq
one
patient
receiv
etoposid
mgmq
one
patient
receiv
gclac
condit
regimen
given
bcnuflumel
busilvexflutt
donor
relat
sibl
match
unrel
donor
unrel
donor
haploident
donor
patient
engraft
median
time
recov
leukocyt
count
achiev
untransfus
platelet
day
day
respect
cyclosporin
interrupt
patient
day
median
follow
day
rang
patient
aliv
complet
remiss
seven
patient
die
due
nrm
median
day
rang
due
relaps
estim
os
df
year
respect
year
respect
cumul
incid
nrm
year
respect
rel
respect
caus
nrm
predominantli
viral
infect
jc
conclus
carri
allogen
transplant
combin
intens
chemotherapi
administ
condit
regimen
neutropenia
therapeut
option
patient
activ
myeloid
diseas
compar
publish
result
present
sequenti
chemoallo
strategi
show
surviv
superior
classic
allohct
ferguson
et
al
comparison
necessari
prospect
studi
larger
number
patient
conflict
interest
noth
disclos
cattolica
del
sacro
cuor
haematolog
rome
itali
cattolica
del
sacro
cuor
haematolog
rome
itali
azienda
ospedaliera
bmm
centro
trapianti
di
midollo
osseo
reggio
calabria
itali
aou
della
salut
e
della
scienza
di
torino
presidio
molinett
haematolog
torino
itali
background
occurr
cytopenia
follow
allogen
haemopoiet
stem
cell
transplant
hsct
report
occur
patient
within
day
brit
j
haematol
infect
andor
graftvshost
diseas
report
predict
factor
gvhd
annal
treatment
select
cell
donor
report
effect
form
therapi
biol
blood
marrow
transplant
sep
howev
impli
avail
second
donat
donor
addit
median
interv
boost
infus
trilineag
recoveri
month
eltrombopag
epag
recent
shown
effect
manag
patient
acquir
aplast
anemia
n
engl
j
med
apr
method
ten
patient
retrospect
collect
among
center
rome
reggio
calabria
torino
receiv
epag
uni
bi
trilineag
cytopenia
diagnos
aml
md
femal
median
age
year
rang
median
cell
dose
infus
rang
engraft
achiev
patient
median
interv
hsct
reach
neutrophil
day
reach
platelet
day
epag
start
median
interv
hsct
day
rang
given
median
number
day
rang
dose
mgday
two
patient
also
receiv
epo
gcsf
togeth
epag
trilinear
cytopenia
hypothesi
epag
would
effect
treat
late
cytopenia
develop
engraft
allogen
hsct
result
nine
patient
complet
respons
patient
partial
respons
shown
tabl
three
patient
thrombocytopenia
increas
teir
median
plt
count
two
patient
prca
associ
major
abo
mismatch
increas
median
hb
level
one
patient
neutropenia
recov
complet
four
patient
pancytopenia
show
respons
complet
patient
one
patient
remain
anem
conclus
epag
effect
patient
unilinear
bilinear
trilinear
cytopenia
followjg
allogen
hsct
believ
data
may
warrant
prospect
trial
conflict
interest
conflict
interest
declar
tabl
tabl
gaziantep
univers
faculti
medicin
intern
medicin
gaziantep
turkey
gaziantep
univers
faculti
medicin
hematolog
gaziantep
turkey
gaziantep
univers
faculti
medicin
cardiolog
gaziantep
turkey
gaziantep
univers
faculti
medicin
hematolog
bone
marrow
tranplant
unit
gaziantep
turkey
background
hematopoiet
stem
cell
transplant
hsct
process
deliv
progenitor
stem
cell
patient
choic
treatment
variou
malign
nonmalign
diseas
patient
treat
mobil
regimen
hsct
mobil
regimen
includ
myeloabl
nonmyeloabl
reduceddos
regimen
complic
develop
hsct
among
common
complic
cardiac
origin
seen
stage
treatment
acut
subacut
chronic
includ
heart
failur
hf
cardiovascular
side
effect
mobil
regimen
cytoreduct
therapi
cumul
anthracyclin
chemotherapeut
particular
may
sever
cardiac
side
effect
cardiac
side
effect
among
import
determin
surviv
pab
investig
group
diseas
method
studi
patient
underw
hsct
bone
marrow
transplant
unit
gaziantep
univers
medic
faculti
hematolog
depart
investig
retrospect
analysi
patient
underw
transplant
evalu
offici
medulla
system
file
scan
archiv
normal
fals
fals
fals
tr
xnone
xnone
style
definit
tablemsonormalt
msostylenam
normal
tablo
msostylenoshow
ye
msostylepar
msoparamarginbottom
msopagin
widoworphan
fontfamili
calibri
ef
pap
valu
analyz
symptomori
echo
examin
perform
pretranspl
postranspl
period
cut
ef
valu
accord
esc
european
societi
cardiolog
pap
mmhg
accord
esc
result
studi
hsct
patient
allogen
autolog
analyz
ef
pap
valu
investig
patient
use
symptomori
echocardiographi
echo
examin
pretranspl
postranspl
period
group
pretranspl
ef
valu
similar
median
increas
posttranspl
ef
observ
allohsct
autolog
hsct
patient
patient
underw
ahsct
fiveyear
mortal
rate
patient
pap
level
mmhg
patient
normal
pap
valu
p
overal
fiveyear
surviv
rate
found
median
month
patient
pretranspl
pap
mmhg
patient
pap
mmhg
p
conclus
conclus
pretranspl
pap
mmhg
import
risk
factor
affect
mortal
overal
surviv
patient
ahsct
conflict
interest
submit
paper
entitl
evalu
cardiac
paramet
bone
marrow
transplant
patient
effect
pulmonari
arteri
pressur
surviv
congress
paper
publish
author
read
approv
manuscript
none
author
potenti
conflict
interest
regard
paper
king
faisal
specialist
hospit
research
center
adult
hematologybmt
riyadh
saudi
arabia
background
acut
myeloid
leukemia
aml
relaps
allogen
hematopoiet
cell
transplant
allohct
associ
high
risk
death
report
surviv
rate
month
bone
marrow
relaps
bmr
frequent
present
extramedullari
relaps
emr
isol
along
bmr
less
common
method
studi
patient
aml
underw
allohct
institut
januari
decemb
limit
retrospect
analysi
patient
receiv
myeloabl
condit
complet
remiss
cr
time
transplant
receiv
match
relat
transplant
patient
exclud
avoid
heterogen
result
seventi
seven
studi
patient
experienc
diseas
relaps
bmr
emr
univari
analysi
reveal
femal
patient
relaps
month
post
allohct
signific
associ
postrelaps
death
tabl
gender
time
relaps
remain
signific
multivari
analysi
forc
relaps
type
variabl
final
model
pvalu
respect
howev
relaps
type
either
bmr
emr
show
signific
associ
risk
death
logist
regress
chronic
gvhd
timedepend
covari
prove
significantli
associ
emr
conclus
studi
conclud
regardless
relaps
type
bmr
emr
patient
gender
time
transplant
relaps
signific
factor
predict
risk
death
late
relaps
known
risk
factor
influenc
surviv
research
gender
dispar
affect
prognosi
must
sought
conflict
interest
conflict
interest
tabl
univari
analysi
use
cox
regress
king
faisal
specialist
hospit
research
center
jeddah
saudi
arabia
ibn
sina
nation
colleg
jeddah
saudi
arabia
background
hematopoiet
stem
cell
transplant
hsct
becom
accept
therapeut
modal
wide
varieti
diseas
increasingli
util
treatment
nonmalign
disord
frequent
consid
cur
treatment
children
seriou
hematolog
disord
includ
thalassemia
major
tm
sickl
cell
diseas
scd
method
retrospect
analyz
clinic
laboratori
outcom
data
pediatr
patient
hemoglobinopathi
consecut
underw
bmt
result
total
number
transplant
hemoglobinopathi
patient
studi
period
tm
remain
scd
mean
age
time
transplant
year
male
femal
patient
receiv
allogen
full
match
relat
donor
transplant
brother
sister
mother
father
condit
regimen
bucyatg
flubucyatg
italian
protocol
sourc
stem
cell
patient
bone
marrow
mean
stem
cell
dose
cd
x
patient
receiv
csamtx
gvhd
prophylaxi
acut
gvhd
observ
skin
involv
gut
liver
skin
gut
grade
ii
iii
iv
gvhd
observ
patient
respect
chronic
gvhd
notic
patient
skin
involv
patient
median
durat
anc
engraft
rang
one
patient
delay
anc
engraft
day
anoth
patient
expir
day
post
transplant
median
platelet
engraft
rang
day
patient
remain
patient
delay
platelet
engraft
day
cmv
reactiv
observ
case
within
day
post
bmt
major
asymptomat
remain
clinic
manifestationorgan
involv
pneumonia
skin
manifest
cmv
case
resolv
case
level
antigenemia
declin
within
week
result
continu
gcv
therapi
overal
surviv
os
rate
event
free
surviv
ef
rate
median
durat
follow
month
two
beta
thalassemia
major
patient
lost
engraft
month
month
transplant
patient
expir
tm
one
day
post
bmt
pulmonari
hemorrhag
massiv
ich
anoth
day
ard
conclus
result
pediatr
bmt
program
institut
nearli
compar
report
literatur
far
transplantrel
morbid
mortal
concern
howev
durat
followup
short
longterm
outcom
yet
determin
conflict
interest
none
leiden
univers
medic
center
depart
immunohematolog
blood
transfus
leiden
netherland
leiden
univers
medic
center
pediatr
divis
stem
cell
transplant
leiden
netherland
leiden
univers
medic
center
depart
hematolog
leiden
netherland
background
umbil
cord
blood
ucb
unit
unrel
donor
use
stem
cell
transplant
sct
differ
type
bag
volum
size
erythrocyt
content
although
modern
ucb
unit
small
volum
contain
littl
red
blood
cell
rbc
older
unit
still
use
sct
center
use
criteria
wash
product
base
nmdp
bbind
safeti
report
number
rbc
case
major
blood
group
incompat
product
wash
remov
erythrocyt
dimethylsulfoxid
dmso
analyz
larg
cohort
patient
transplant
ucb
studi
impact
ucb
volum
erythrocyt
content
wash
qualiti
control
engraft
method
retrospect
data
collect
ucb
transplant
perform
center
adult
pediatr
patient
variou
indic
follow
data
collect
provid
ucb
bank
product
releas
volum
number
rbc
whether
rbc
deplet
volum
reduct
perform
prior
freez
product
data
collect
viabil
ishag
thaw
wash
perform
furthermor
patient
engraft
studi
result
data
ucb
unit
analyz
ucb
unit
volum
ml
sixteen
ucb
unit
wash
thaw
eleven
ucb
contain
rbc
unit
larg
volum
median
ml
rang
ml
unit
unknown
whether
rbc
reduct
perform
ucb
bank
unit
could
retriev
collect
date
group
older
product
collect
rel
unit
volum
ml
n
high
unknown
number
rbc
n
wash
ucb
unit
six
show
viabil
wash
howev
viabil
thaw
wash
reason
compar
viabil
wash
invers
correl
found
volum
unit
viabil
thaw
patient
transplant
singl
cb
doubl
cb
patient
fail
show
engraft
eight
patient
receiv
wash
cb
unit
conclus
data
show
clear
correl
wash
ucb
unit
risk
nonengraft
versu
necessarili
due
wash
procedur
like
due
preexist
high
amount
rbc
unit
high
volum
ucb
unit
ml
therefor
need
avoid
due
higher
risk
nonengraft
causal
mechan
clear
rbc
might
influenc
post
thaw
qualiti
ucb
unit
hemolysi
conflict
interest
j
overdevest
noth
disclos
geneva
univers
hospit
dpt
nephrolog
uitlnrh
switzerland
basel
univers
hospit
dpt
haematolog
basel
switzerland
geneva
univers
hospit
dpt
oncohaematolog
switzerland
univers
hospit
zurich
dpt
haematolog
zurich
switzerland
children
hospit
zurich
switzerland
swiss
blood
stem
cell
registri
bern
switzerland
background
crucial
criterion
success
allogen
hematopoiet
stem
cell
transplant
hsct
hla
match
recipi
donor
practic
hla
match
perform
phenotyp
level
recent
studi
propos
match
haplotyp
level
could
benefici
eg
reduc
graft
versu
host
diseas
sever
mud
match
unrel
donor
avail
method
aim
studi
twofold
first
use
high
resolut
type
patient
live
switzerland
potenti
candid
unrel
donor
search
determin
hla
haplotyp
descent
use
famili
member
segreg
analysi
sum
rank
two
haplotyp
patient
compar
frequenc
estim
volunt
donor
swiss
registri
use
surrog
predictor
success
search
ie
find
mud
bmdw
databas
second
put
impact
phase
hla
haplotyp
ie
consid
frequent
rare
indirect
paramet
haplotyp
match
clinic
outcom
hsct
analys
cohort
patient
transplant
mud
patient
mainli
affect
malign
diseas
larg
major
repres
acut
leukaemia
myelodysplast
myeloprolif
syndrom
patient
age
quarter
rest
evenli
distribut
greater
year
old
result
logist
regress
analysi
show
highli
signific
effect
haplotyp
rank
outcom
search
bmdw
furthermor
roc
curv
analysi
show
best
tradeoff
true
fals
posit
rate
choos
cut
correspond
sum
rank
ie
equival
patient
carri
least
one
rare
haplotyp
howev
could
find
signific
effect
overal
surviv
figur
acut
chronic
graft
versu
host
diseas
relaps
follow
hsct
despit
consid
differ
frequenc
cut
off
genotyp
subgroup
categor
hla
haplotyp
conclus
studi
provid
use
data
optim
unrel
bone
marrow
donor
search
switzerland
beyond
could
confirm
previou
find
match
haplotyp
level
clinic
impact
follow
hsct
due
extrem
polymorph
hla
gene
studi
warrant
better
comprehend
mani
factor
play
clinic
trial
registri
na
conflict
interest
none
maria
sklodowskacuri
institut
oncolog
center
gliwic
branch
depart
bone
marrow
transplant
oncohematolog
gliwic
poland
maria
sklodowskacuri
institut
oncolog
center
gliwic
branch
analyt
clinic
biochemistri
depart
gliwic
poland
background
hematopoiet
stem
andor
progenitor
cell
name
hsc
hpc
tradit
identifi
flow
cytometri
posit
cell
flow
cytometri
gold
standard
unfortun
methodolog
timeconsum
operatordepend
current
mani
produc
diagnost
equip
offer
autom
hematolog
analyz
possibl
hpc
enumer
techniqu
fast
easi
perform
requir
use
expens
antibodi
first
aim
studi
examin
correl
enumer
hpc
perform
sysmex
cell
peripher
blood
mobil
patient
second
aim
determin
optim
cutoff
point
hpc
predict
cell
count
suffici
number
perform
affect
apheresi
method
hpc
cell
count
fresh
sampl
peripher
blood
sampl
collect
patient
men
women
median
age
year
rang
year
mobil
intermediatedos
cytosin
arabinosid
follow
gcsf
case
patient
singl
inject
plerixafor
use
increas
number
circul
hsc
patient
carri
diagnosi
mm
nhl
hl
other
flow
cytometri
analysi
perform
accord
ishag
guidelin
cell
doublelabel
phycoerythrin
pe
conjug
fluorescein
isothiocyan
fitc
conjug
monoclon
antibodi
bd
bioscienc
analyz
use
fluorocytomet
fac
canto
ii
hpc
enumer
perform
use
sysmex
sysmex
kobe
japan
result
median
number
blood
rang
median
number
rang
strong
correl
number
hpc
cell
p
next
roc
curv
creat
marker
test
qualiti
hpc
cutoff
valu
distinguish
cell
count
determin
auc
youden
index
conclus
strong
correl
number
hpc
count
sysmex
cell
sampl
peripher
blood
predictor
may
use
make
decis
start
apheresi
conflict
interest
noth
disclos
policlinico
umberto
sapienza
univers
rome
hematolog
rome
itali
sapienza
univers
rome
immunoematolog
transfus
medicin
rome
itali
background
impact
abo
incompat
recipi
donor
outcom
hematopoiet
stem
cell
transplant
hsct
immunehematolog
ih
complic
role
ih
monitor
hsct
still
debat
aim
studi
evalu
impact
abo
mismatch
develop
immedi
late
ih
complic
df
os
gvhd
trm
moreov
analyz
efficaci
protocol
use
sapienza
univers
rome
manag
abo
incompat
patient
undergo
hsct
method
januari
decemb
prospect
analyz
consecut
patient
femal
receiv
match
relat
donor
match
unrel
cord
haploident
donor
within
day
prior
hsct
everi
week
day
posthsct
everi
day
rbc
engraft
patient
underw
complet
ih
assess
includ
abo
rh
blood
phenotyp
indirect
antiglobulin
test
direct
antiglobulin
test
antia
antib
igm
igg
titrat
aboincompat
case
graft
manipul
desensit
strategi
defin
accord
abo
incompat
donor
sex
femal
donor
graft
plasma
deplet
donor
transfus
histori
rbc
plt
transfus
support
establish
accord
ih
featur
data
prospect
collect
databas
includ
age
sex
diagnosi
donor
hematopoiet
stem
cell
sourc
condit
regimen
posthsct
complic
cmvebv
infect
venousocclus
diseas
hemorrhag
cystiti
hemolyticurem
syndrom
gvhd
result
fourtynin
patient
aboident
aboincompat
major
minor
bidirect
seven
patient
receiv
nonmyeloabl
condit
regimen
reduc
intens
patient
myeloabl
regimen
stem
cell
sourc
bone
marrow
patient
peripher
blood
patient
cord
blood
case
plasma
deplet
graft
carri
case
graft
subject
erythrosediment
case
plasma
rbc
deplet
perform
two
patient
treat
plasmapheresi
abo
bidirect
incompat
abo
major
high
titer
antik
alloantibodi
hemolysi
infus
observ
patient
abo
major
bidirect
incompat
donor
engraft
pmn
plt
rbc
graft
failur
complic
differ
patient
without
abo
incompat
patient
major
abo
incompat
suffer
pure
red
cell
aplasia
two
patient
experienc
autoimmun
hemolyt
anemia
factor
associ
prolong
blood
support
rbc
abo
incompat
hemorrhag
cystiti
haploident
transplant
abo
incompat
show
signific
impact
gvhd
os
df
conclus
prospect
studi
confirm
abo
incompat
repres
barrier
allohsct
howev
associ
prolong
transfusion
requir
experi
abo
incompat
influenc
risk
gvhd
strict
ih
monitor
share
standard
procedur
allow
perform
appropri
transfus
support
treat
patient
effici
limit
posthsct
ih
complic
conflict
interest
author
declar
conflict
interest
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
american
univers
beirut
medic
center
faculti
medicin
beirut
lebanon
background
report
proxim
transplant
center
affect
outcom
allogen
stem
cell
transplant
allosct
conduct
studi
american
univers
beirut
medicalcent
aubmc
referr
center
middleeast
locat
lebanon
determin
differ
surviv
patient
resid
lebanon
refer
abroad
method
identifi
consecut
adult
patient
underw
allosct
hematolog
malign
one
hundr
three
patient
resid
lebanon
male
femal
patient
refer
abroad
male
femal
follow
patient
resid
lebanon
done
via
clinic
visit
resid
abroad
either
clinic
appoint
andor
phonecal
case
could
travel
lebanon
patient
transplant
characterist
list
result
median
age
transplant
rang
localgroup
versu
rang
foreigngroup
patient
engraft
median
time
neutrophil
engraft
day
group
rang
day
local
foreign
group
respect
localgroup
patient
receiv
atg
patient
foreign
group
incid
acutegraftversushostdiseas
higher
localgroup
case
case
foreign
group
similarli
incid
chronicgraftversushost
diseas
localgroup
superior
foreigngroup
patient
vs
patient
respect
median
follow
month
rang
patient
aliv
local
foreign
group
respect
median
os
month
local
group
reach
foreign
group
median
progressionfreesurviv
pf
reach
group
caus
death
classifi
two
categori
diseas
relat
trm
local
group
patient
die
diseas
relat
due
trm
wherea
patient
die
foreign
group
death
diseas
relat
death
trm
conclus
result
impli
geograph
distanc
impact
os
howev
might
impact
pf
take
consider
patient
local
group
underw
haploident
transplant
find
need
verifi
larger
scale
studi
conflict
interest
author
noth
declar
tabl
patient
transplant
characterist
institut
clinic
transfus
medicin
immunogenet
ulm
german
red
cross
blood
transfus
servic
baden
wuerttemberg
hessen
univers
hospit
ulm
transplant
immunolog
ulm
germani
institut
transfus
medicin
univers
ulm
ulm
germani
univers
leipzig
hematologyoncolog
leipzig
germani
univers
ulm
depart
intern
medicin
iii
ulm
germani
univers
kiel
divis
stem
cell
transplant
immunotherapi
depart
intern
medicin
kiel
germani
campu
virchow
berlin
hematologyoncolog
berlin
germani
johann
gutenbergunivers
mainz
depart
intern
medicin
iii
mainz
germani
univers
hospit
depart
intern
medicin
ii
germani
institut
clinic
transfus
medicin
immunogenet
ulm
german
red
cross
blood
transfus
servic
baden
wuerttemberg
hessen
univers
hospit
ulm
ulm
germani
drst
german
registri
stem
cell
transplant
ulm
germani
background
petersdorf
et
al
first
report
associ
patient
high
express
hlac
c
allotyp
wors
hsct
outcom
use
data
c
express
mainli
deriv
africanamerican
app
et
al
main
object
studi
examin
applic
app
et
al
model
caucasian
use
quantif
methodolog
much
larger
sampl
healthi
german
blood
donor
subsequ
gener
second
proxi
express
model
specif
investig
effect
patient
nonshar
pn
c
express
level
outcom
appli
previous
mention
express
model
hla
cmismatch
hsct
set
method
buffi
coat
healthi
german
blood
donor
test
flow
cytometri
previous
describ
app
et
al
order
determin
c
express
lymphocyt
refer
mean
fluoresc
intens
mfi
valu
measur
c
antigen
subsequ
categor
high
low
express
cohort
singl
cmismatch
transplant
pair
c
express
model
use
order
investig
impact
high
lowexpress
pnsc
allotyp
hsct
outcom
overal
surviv
os
diseas
free
surviv
df
relaps
incid
ri
nonrelaps
mortal
nrm
set
outcom
endpoint
statist
signific
set
p
result
except
hlac
two
express
model
found
fulli
concord
definit
low
highexpress
c
antigen
analysi
pnsc
express
effect
hsct
outcom
reveal
unexpect
correl
high
express
better
os
due
lower
nrm
although
similar
trend
observ
statist
signific
met
app
et
al
model
death
caus
analysi
reveal
tendenc
lower
infectionrel
mortal
high
express
pnsc
vs
differ
observ
gvhdassoci
death
interestingli
overal
patient
c
express
influenc
outcom
endpoint
conclus
basic
conclus
studi
hlac
antigen
exhibit
similar
express
pattern
regardless
race
high
express
pnsc
may
play
role
better
infect
control
singl
hlac
mismatch
hsct
set
albeit
noteworthi
find
must
confirm
independ
significantli
larger
cohort
definit
conclus
drawn
conflict
interest
none
author
anyth
declar
tabl
univari
multivari
analys
hospit
universitario
la
princesa
hematolog
hemotherapi
madrid
spain
background
high
rate
relaps
remain
main
barrier
long
term
surviv
though
great
improv
first
complet
remiss
rate
achiev
adult
acut
lymphoblast
leukemia
hsct
could
cur
option
highrisk
patient
patient
experi
relaps
controversi
indic
time
exist
larg
patient
cohort
evalu
method
hsct
perform
patient
hospit
doubl
allohsct
median
age
year
patient
year
n
philadelphia
posit
ph
diseas
statu
transplant
divid
ph
ph
advanc
diseas
ad
mrd
activ
diseas
ph
ph
primari
endpoint
diseasefre
surviv
df
overal
surviv
os
secondari
endpoint
refin
acut
graft
vs
host
diseas
agvhd
chronic
gvhd
cgvhd
incid
relaps
incid
ri
nonrelaps
mortal
nrm
result
median
follow
year
year
whole
cohort
df
os
rate
respect
os
df
ph
ph
patient
underw
hsct
respect
os
pf
ad
similar
ph
ph
respect
incid
agvhd
cgvhd
twenti
six
case
extens
cgvhd
occur
ri
median
time
month
late
relaps
seem
unlik
year
hsct
incid
earli
nrm
day
frequent
death
caus
pneumonia
respiratori
failur
sinusoid
obstruct
syndrom
septic
shock
acut
gvhd
conclus
cohort
highlight
high
os
ph
ph
underw
hsct
indic
import
achiev
best
respons
hsct
howev
quit
accept
percentag
ph
ad
benefit
hsct
take
account
common
group
seem
princip
object
futur
improv
strategi
decreas
ri
order
achiev
higher
os
df
conflict
interest
noth
disclosur
tabl
tabl
nation
special
hospit
activ
treatment
haematolog
diseas
sofia
bulgaria
background
dimethylsulfoxid
dmso
main
intracellular
cryoprotect
agent
longterm
storag
hematopoiet
stem
cell
hsc
usual
use
final
concentr
lower
concentr
dmso
spare
side
effect
cell
toxic
heart
rhythm
disord
hemodynam
disturb
bronchial
spasm
etc
patient
transfus
use
shorter
period
storag
eighteen
month
report
stem
cell
viabil
transplant
result
sampl
frozen
dmso
store
period
month
method
peripher
hemopoet
stem
cell
process
frozen
cryoprotect
solut
contain
final
concentr
dmso
he
hsa
cell
store
mechan
freezer
eight
patient
one
nhl
seven
mm
cytapheres
cell
cryopreserv
sinc
patient
requir
second
transplant
sever
year
later
autolog
cell
collect
first
mobil
store
month
use
result
differ
cell
viabil
test
trypan
blue
exclus
test
patient
engraft
success
similar
engraft
time
wbc
platelet
first
second
transplant
conclus
dmso
toxic
cell
lead
seriou
advers
reaction
heart
rhythm
disord
hemodynam
disturb
bronchial
spasm
etc
infus
addit
extracellular
cryoprotect
give
opportun
use
smaller
concentr
dmso
final
suspens
thu
reduc
incid
sever
posttransfus
advers
event
small
group
patient
show
longterm
storag
degre
dmso
safe
reduc
advers
event
result
dmso
toxic
storag
easier
less
time
space
consum
conflict
interest
none
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
immunolog
servic
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
imib
univers
murcia
haematolog
servic
stem
cell
transplant
unit
el
palmar
murcia
spain
background
longterm
followup
data
immun
reconstitut
engraft
stabil
pediatr
patient
undergo
autolog
stem
cell
transplat
asct
remain
poorli
report
method
retrospect
observ
studi
patient
age
year
undergo
asct
tertiari
hospit
januari
decemb
time
engraft
defin
first
consecut
day
neutrophil
exceed
x
platelet
x
without
transfus
immunolog
reconstitut
assess
total
lymphocyt
lymphocyt
b
lymphocyt
natur
killer
nk
ratio
day
transplant
normal
lymphocyt
popul
valu
defin
includ
pediatr
aid
clinic
trial
group
studi
result
asct
procedur
perform
patient
median
followup
month
median
age
hsct
year
male
indic
hsct
solid
tumor
patient
malign
hemopathi
remain
bumel
account
condit
protocol
use
thiotepabas
regimen
also
use
median
number
x
infus
observ
rapid
neutrophil
platelet
engraft
kinet
median
time
engraft
day
day
respect
immun
reconstitut
assess
patient
full
recoveri
lymphocyt
along
lymphocyt
count
achiev
day
lymphocyt
show
prompt
recoveri
one
month
post
asct
figur
similarli
nk
cell
show
normal
sustain
count
day
contrast
b
lymphocyt
show
slower
recoveri
normal
count
day
evolut
result
revers
ratio
figur
first
post
sct
year
document
bacteri
viral
fungal
infect
patient
respect
one
patient
die
infect
bronchopulmonari
aspergillosi
day
post
sct
eventfre
surviv
ef
day
one
year
post
sct
respect
overal
surviv
os
day
one
year
post
sct
respect
conclus
data
show
rapid
immun
reconstitut
low
transplant
mortal
rate
patient
undergo
asct
observ
defici
transient
follow
rel
reliabl
pattern
recoveri
conflict
interest
none
stanford
univers
pediatr
stanford
ca
unit
state
stanford
univers
medicin
stanford
ca
unit
state
stanford
univers
obstetr
gynecolog
stanford
ca
unit
state
background
use
umbil
cord
blood
ucb
sourc
hematopoiet
stem
cell
hsc
allogen
hematopoiet
stem
cell
transplant
hsct
often
result
delay
engraft
immun
reconstitut
platelet
recoveri
compar
marrow
standard
character
cord
blood
product
includ
total
nucleat
cell
count
coloni
form
unit
assay
wide
adopt
measur
potenc
recogn
divers
hematopoiet
stem
progenitor
cell
hspc
popul
within
pool
proport
popul
well
understood
end
present
novel
data
set
reveal
frequenc
differ
hspc
popul
human
ucb
method
novemb
novemb
ucb
sampl
collect
labor
deliveri
unit
irbapprov
protocol
mononuclear
cell
isol
densiti
gradient
centrifug
use
ficol
paqu
plu
label
use
microbead
kit
ultrapur
miltenyi
biotec
posit
select
hspc
enrich
cell
stain
human
cocktail
target
follow
lineag
marker
prior
analysi
bd
fac
aria
ii
flow
cytomet
antibodi
obtain
bd
biolegend
ebiosci
result
cord
blood
collect
individu
immunophenotyp
primit
earli
commit
progenitor
cell
surfac
marker
tabl
high
degre
heterogen
observ
individu
frequenc
rang
span
one
log
cell
type
although
median
hsc
immunophenotyp
cell
rang
larg
phenotyp
common
lymphoid
progenitor
consist
found
less
cell
median
strike
contrast
common
myeloid
progenitor
phenotyp
express
largest
proport
earli
progenitor
median
preliminari
analysi
show
median
frequenc
phenotyp
megakaryoct
progenitor
rang
conclus
signific
variat
cellular
content
human
ucb
suggest
immunophenotyp
sampl
prior
hsct
may
provid
import
inform
regard
individu
graft
potenc
low
clp
mkp
immunophenotyp
frequenc
provid
potenti
new
explan
prolong
period
immun
reconstitut
platelet
recoveri
key
featur
ucb
hsct
taken
togeth
result
provid
rapid
method
map
cellular
content
ucb
may
pave
way
function
studi
improv
graft
select
ucb
hsct
conflict
interest
none
author
anyth
disclos
tabl
popul
frequenc
ucbderiv
pool
american
univers
beirut
medic
center
divis
hematologyoncolog
depart
intern
medicin
beirut
lebanon
american
univers
beirut
medic
center
depart
clinic
nutrit
beirut
lebanon
aix
marseil
doctor
school
life
scienc
health
marseil
franc
american
univers
beirut
medic
center
bone
marrow
transplant
program
depart
intern
medicin
beirut
lebanon
aix
marseil
cnr
inserm
crcm
institut
paolicalmett
marseil
franc
background
among
hematopoiet
stem
cell
transplant
hsct
patient
micronutri
profil
alter
due
increas
excret
decreas
intak
increas
need
nutrient
nutrit
care
hsct
focus
meet
energi
protein
need
minim
attent
micronutri
need
aim
assess
adequaci
vitamin
miner
intak
among
hsct
patient
peritranspl
phase
method
random
control
trial
approv
institut
review
board
patient
admit
undergo
hsct
american
univers
beirut
medic
center
invit
join
studi
assess
point
admiss
transplant
hospit
discharg
day
post
hsct
studi
particip
random
hospit
discharg
intervent
group
ig
control
group
cg
ig
receiv
standard
meal
plan
nutrit
counsel
assess
point
post
hospit
discharg
aim
optim
energi
protein
intak
cg
receiv
standard
hospit
care
assess
point
qualiti
life
qol
assess
use
function
assess
cancer
therapi
fact
bone
marrow
transplant
bmt
questionnair
intak
patient
monitor
recal
collect
analyz
via
nutritionist
data
analyz
age
gender
base
dietari
refer
intak
dri
valu
result
report
percentag
dri
result
ig
particip
median
age
year
vs
cg
group
male
ig
cg
hospit
discharg
qol
clinic
better
ig
ig
vs
cg
result
post
hospit
discharg
show
alarmingli
low
intak
level
vitamin
group
assess
point
median
intak
dri
ig
dri
cg
assess
point
median
vitamin
e
intak
remain
dri
ig
dri
cg
intak
mani
micronutri
show
signific
improv
discharg
day
ig
intak
statist
better
beta
caroten
vitamin
k
c
zinc
potassium
phosphor
magnesium
manganes
iron
ig
chang
cg
lower
magnitud
fiber
intak
better
ig
reach
need
assess
point
conclus
studi
fill
research
gap
provid
overview
nutrient
intak
among
hsct
patient
peritranspl
phase
result
show
nutrit
counsel
improv
intak
micronutri
remain
risk
control
intervent
group
clinic
trial
registri
clinicaltrialsgov
june
conflict
interest
author
report
conflict
interest
institut
hematolog
immunolog
la
habana
cuba
la
habana
cuba
univers
children
hospitalhospit
rigshospitalet
paediatr
adolesc
medicin
copenhagen
denmark
background
hematopoiet
progenitor
obtain
peripher
blood
pb
use
increasingli
autolog
allogen
transplant
advantag
disadvantag
report
pb
use
instead
bone
marrow
bm
graft
sourc
children
method
evalu
patient
age
year
hematolog
diseas
acut
lymphoblast
leukemia
acut
myeloid
leukemia
chronic
myeloid
leukemia
aplast
anemia
one
hodgkin
lymphoma
one
sickl
cell
diseas
receiv
allogen
hematopoiet
transplant
sibl
donor
institut
hematolog
immunolog
cuba
june
april
patient
bm
use
sourc
cell
progenitor
obtain
pb
variou
variabl
compar
two
sourc
result
number
mononuclear
cell
graft
x
bm
group
pb
group
neutrophil
platelet
recoveri
faster
transfus
requir
lower
pb
use
patient
present
febril
episod
neutrophil
engraft
pb
group
major
episod
correspond
fever
unknown
origin
bm
group
microorgan
identifi
often
two
group
acut
graftversushost
diseas
regard
frequenc
sever
chronic
graftversushost
diseas
greater
frequenc
sever
patient
receiv
pb
probabl
overal
surviv
day
bm
pb
wherea
probabl
overal
surviv
month
respect
conclus
observ
transplant
hematopoiet
progenitor
cell
mobil
pb
offer
advantag
compar
bm
transplant
howev
small
number
patient
studi
fact
random
studi
allow
definit
conclus
conflict
interest
juan
carlo
jaim
fagundo
noth
disclos
instituto
de
oncologia
porto
porto
portug
background
cryopreserv
method
use
storag
hematopoiet
progenitor
cell
hpc
transplant
set
studi
aim
evalu
impact
sever
techniqu
freez
cryopreserv
thaw
process
well
determin
qualiti
criteria
includ
stabil
program
method
april
octob
unit
compos
remain
hpc
four
allogen
donor
frozen
cryopreserv
accord
standard
procedur
facil
approv
ethic
committe
cryoprotector
solut
ad
cellular
suspens
compos
dimethyl
sulfoxid
final
volum
human
serum
albumin
ratio
product
assess
regard
steril
blood
cultur
aerobicanaerob
condit
mycolog
function
quantif
granulocytemonocyt
colonyform
unit
cfugm
cellular
viabil
total
nucleat
cell
tnc
trypan
blue
exclus
method
cell
stain
tnc
recoveri
evalu
hematolog
counter
cell
flow
cytometri
final
cell
cryofreez
eva
bag
steril
secondari
contain
control
temperatur
store
liquid
nitrogen
tank
six
unit
thaw
water
bath
continu
agit
crystal
disappear
end
prefreez
assay
repeat
addit
macroscop
assess
product
bag
integr
made
hpc
traceabl
assur
electron
paper
registri
physic
local
within
tank
data
complianc
cryogen
bag
label
concern
identif
legibl
liquid
nitrogen
tank
evalu
nitrogen
quantiti
temperatur
corros
level
integr
box
result
median
time
cryopreserv
day
uniti
compli
establish
criteria
sampl
test
none
present
haemolysi
neither
aggreg
steril
freez
thaw
prove
contamin
storag
regard
function
cfugm
growth
test
sampl
result
obtain
viabil
recoveri
shown
tabl
cryogen
secondari
bag
undamag
well
nitrogen
tank
metal
box
track
cellular
product
donor
patient
trace
patient
donor
ensur
case
conclus
preestablish
qualiti
criteria
steril
function
cellular
viabil
haematolog
recoveri
met
physic
paramet
unaffect
show
cryopreserv
short
period
time
affect
qualiti
product
oper
procedur
place
follow
intend
prolong
studi
order
evalu
stabil
long
term
cryopreserv
hpc
eventu
defin
maximum
storag
period
predefin
time
frame
donor
conflict
interest
author
noth
disclos
srtiget
milan
itali
san
raffael
scientif
institut
cytometri
laboratori
milan
itali
san
raffael
scientif
institut
pediatr
immunohematolog
bone
marrow
transplant
unit
milan
itali
mbbm
foundationasst
san
gerardo
bmt
unit
pediatr
depart
monza
itali
san
raffael
scientif
institut
hematolog
bone
marrow
transplant
unit
milan
itali
vitasalut
san
raffael
milan
itali
background
human
hematopoiesi
complex
dynam
system
morpholog
function
divers
matur
cell
type
gener
maintain
throughout
life
bone
marrow
bm
hematopoiet
stemprogenitor
cell
hspc
bone
marrow
transplant
bmt
gene
therapi
gt
base
autolog
infus
genecorrect
hspc
definit
treatment
sever
human
blood
disord
immunodefici
hematolog
tumor
gener
tool
analysi
hematopoiet
system
composit
remain
one
crucial
goal
understand
caus
hematolog
diseas
monitor
hematopoiet
reconstitut
patient
transplant
design
novel
therapeut
approach
test
efficaci
method
design
novel
multiparametr
flowcytometri
protocol
call
whole
blood
dissect
wbd
object
intern
patent
applic
wait
public
capabl
unambigu
identifi
quantifi
absolut
number
differ
blood
cell
type
includ
hspc
subtyp
major
myeloid
lymphoid
lineag
compart
differ
stage
matur
singl
testtub
either
bonemarrow
bm
peripher
blood
pb
sampl
combin
surfac
marker
viabil
cell
marker
count
bead
wbd
cover
averag
sampl
reproduc
standard
costtimeeffici
manner
result
valid
technolog
perform
morpholog
evalu
analyz
bm
pb
sampl
adult
pediatr
healthi
donor
highlight
agerel
shift
blood
cell
composit
test
efficaci
protocol
clinic
bm
sampl
unveil
known
novel
hematopoiet
unbal
immunedefici
patient
includ
adult
pediatr
wiskottaldrich
syndrom
individu
pediatr
adenosinedeaminas
defici
adascid
patient
subject
chronic
granulomat
diseas
cgd
applic
wbd
leukem
sampl
diagnosi
treatment
assess
type
matur
state
leukem
blast
current
analyz
effect
gcsf
gcsfplerixafor
administr
mobil
hspc
bm
nich
pb
aim
quantifi
character
mobil
hspc
mhspc
popul
dynam
cell
mobil
preliminari
analys
show
rel
distribut
hspc
subpopul
compos
bm
hspc
mhspc
two
type
mobil
differ
suggest
divers
capac
differ
hspc
subset
respond
distinct
mobil
agent
final
appli
wbd
protocol
comprehens
analyz
humaninmous
graft
immunodefici
mice
transplant
human
cord
blood
hspc
wbd
abl
detect
character
quantifi
hematopoiet
output
composit
engraft
human
hspc
humaninmous
transplant
set
fundament
assess
safeti
efficaci
treatment
studi
biolog
human
hematopoiet
system
conclus
overal
wbd
protocol
provid
oneshot
comprehens
evalu
human
hematopoiet
system
wide
rang
preclin
clinic
applic
go
character
hematopoiet
disord
monitor
hematopoiet
reconstitut
hspc
mainten
patient
transplant
gene
therapi
conflict
interest
wbd
object
intern
patent
applic
wait
public
bassoricci
l
aiuti
biasco
l
coinventor
wbd
first
state
pavlov
medic
univers
st
petersburg
raisa
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
st
petersburg
russian
feder
first
pavlov
state
medic
univers
st
petersburg
raisa
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
st
petersburg
russian
feder
fist
electrotechn
univers
st
petersburg
russian
feder
background
allogen
hematopoiet
stem
cell
transplant
allohsct
cur
therapi
pediatr
myelodysplast
syndrom
md
success
engraft
crucial
surviv
patient
allohsct
analyz
factor
influenc
hematopoiet
engraft
outcom
children
myelodysplast
syndrom
md
allohsct
method
studi
includ
md
patient
pt
median
age
rang
year
distribut
md
subtyp
follow
refractori
cytopenia
childhood
rcc
refractori
anemia
excess
blast
refractori
anemia
excess
blast
transform
raeb
raebtaml
n
juvenil
myelomonocyt
leukemia
jmml
thirtynin
male
femal
children
enrol
moment
allohsct
hypocellular
bone
marrow
pt
normocellular
pt
hypercellular
pt
pt
divid
two
group
accord
cytogenet
find
high
risk
monosomi
andor
complex
karyotyp
children
low
risk
other
cytogenet
abnorm
normal
karyotyp
time
diagnosi
allohsct
month
median
sourc
allohsct
match
relat
donor
pt
haploident
match
unrel
myeloabl
condit
mac
regimen
use
pt
reduc
intens
condit
ric
pt
bone
marrow
bm
use
pt
peripher
blood
stem
cell
pbsc
pt
combin
bm
pbsc
pt
statist
analysi
perform
use
spss
logist
regress
model
use
univari
multivari
analys
result
fiveyear
overal
surviv
os
children
md
allohsct
median
follow
month
rang
os
mac
ric
engraft
achiev
pt
mac
pt
ric
pt
result
univari
analysi
risk
factor
engraft
present
signific
factor
univari
analysi
includ
multivari
multivari
analysi
favor
predict
factor
engraft
type
md
type
md
vs
jmml
cytogenet
find
low
risk
vs
high
risk
hematopoiet
stem
cell
dose
vs
time
graft
failur
observ
frequent
pt
hypocellular
bone
marrow
case
donor
elder
yo
univari
anal
conclus
present
studi
defin
five
predict
factor
engraft
children
md
allohsct
howev
two
donor
age
number
cell
graft
practic
use
conflict
interest
conflict
interest
american
univers
beirut
medic
center
intern
medicin
divis
hematologyoncolog
bone
marrow
transplant
unit
beirut
lebanon
henri
ford
health
system
depart
patholog
laboratori
medicin
detroit
mi
unit
state
american
univers
beirut
medic
center
depart
patholog
laboratori
medicin
beirut
lebanon
background
autolog
peripher
blood
stem
cell
transplant
apsct
treatment
option
use
variou
hematolog
malign
apsct
prolong
diseas
free
surviv
improv
surviv
may
cur
investig
variabl
affect
engraft
among
patient
treat
high
dosechemotherapi
apsct
method
adult
patient
underw
apsct
american
univers
beirut
medic
center
male
femal
median
age
year
cohort
includ
multipl
myeloma
mm
nonhodgkin
lymphoma
hodgkin
lymphoma
patient
malign
patient
receiv
highdos
chemotherapi
regimen
without
total
bodi
irradi
median
time
diagnosi
first
transplant
month
rang
median
number
apheresi
rang
result
median
number
infus
cell
rang
contain
dmso
median
dose
gkg
bw
rang
statu
diseas
transplant
apsct
follow
patient
complet
remiss
cr
partial
remiss
pr
patient
stabl
relaps
diseas
statu
absolut
neutrophil
count
anc
recoveri
reach
median
day
rang
platelet
recoveri
occur
median
day
rang
find
univari
multivari
analys
summar
tabl
multivari
analysi
diagnosi
mm
low
dmso
dose
gkg
bw
high
infus
associ
rapid
engraft
neutrophil
within
day
apst
low
dmso
dose
high
infus
associ
engraft
platelet
within
day
conclus
conclus
result
impli
low
dmso
associ
earlier
engraft
indic
high
yield
collect
requir
smaller
volum
freez
henc
dmso
dose
predict
earli
engraft
use
biomark
richer
stem
cell
collect
addit
number
infus
import
predictor
neutrophil
platelet
engraft
howev
find
need
confirm
larger
studi
conflict
interest
none
author
anyth
declar
tabl
factor
affect
engraft
apsct
vanderbilt
univers
school
medicin
nashvil
tn
unit
state
vanderbilt
univers
medic
center
depart
patholog
microbiolog
immunolog
nashvil
tn
unit
state
vanderbilt
univers
medic
center
depart
biostatist
nashvil
tn
unit
state
vanderbilt
univers
medic
center
depart
hematologyoncolog
nashvil
tn
unit
state
vanderbilt
univers
medic
center
nashvil
tn
unit
state
background
addit
patient
histori
cytogenet
clinician
begun
use
next
gener
sequenc
ng
guid
treatment
decis
patient
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
impact
molecular
aberr
hematopoiet
cell
transplant
hct
outcom
still
studi
method
evalu
patient
aml
md
undergo
hct
singl
center
avail
ng
data
time
activ
diseas
prior
transplant
ng
done
panel
commonli
mutat
loci
diseaserel
gene
patient
group
number
mutat
vs
differ
group
includ
diseas
risk
index
dri
armand
blood
summar
use
descript
statist
progress
free
surviv
pf
overal
surviv
os
estim
perform
use
log
rank
test
assess
differ
group
multivari
analysi
done
use
cox
proport
hazard
regress
result
cohort
consist
patient
major
patient
transplant
aml
includ
secondari
aml
transplant
md
eighti
percent
patient
least
mutat
mutat
occur
total
gene
commonli
mutat
signific
differ
age
gender
high
dri
patient
mutat
versu
mutat
univari
analysi
patient
least
one
mutat
decreas
os
day
vs
reach
signific
differ
pf
mutat
associ
decreas
pf
os
day
vs
reach
day
vs
reach
respect
p
mutat
associ
decreas
pf
day
vs
reach
p
os
expect
correl
high
dri
spearman
rho
p
multivari
analysi
high
dri
hr
ci
independ
risk
factor
associ
inferior
surviv
mutat
trend
toward
signific
hr
conclus
analysi
presenc
mutat
myeloidspecif
ng
panel
associ
decreas
os
pf
high
dri
continu
independ
risk
factor
associ
poor
outcom
patient
mutat
continu
poorli
hct
conflict
interest
none
author
anyth
disclos
shinshu
univers
pediatr
matsumoto
japan
nagano
children
hospit
pediatr
azumino
japan
background
cytomegaloviru
cmv
infect
caus
signific
morbid
follow
allogen
stem
cell
transplant
sct
umbil
cord
blood
transplant
ucbt
particular
increas
risk
cmv
complic
lack
cmvspecif
immun
delay
immun
reconstitut
morbid
aris
due
either
primari
infect
cmv
reactiv
cmv
transmiss
blood
compon
transfusiontransmit
cmv
ttcmv
could
sourc
primari
infect
seroneg
sct
patient
histor
blood
compon
cmvneg
donor
provid
highrisk
patient
minim
risk
ttcmv
suppli
limit
increas
demand
leukocytereduc
blood
compon
wide
implement
altern
method
howev
unclear
whether
leukocytereduc
cellular
compon
safe
seroneg
blood
product
highrisk
patient
ucbt
patient
method
retrospect
analyz
incid
cmv
viremia
ucbt
patient
receiv
leukocytereduc
cmvunselect
blood
compon
singl
japanes
pediatr
center
sinc
januari
prestorag
leukocytereduct
implement
blood
compon
japan
less
residu
white
blood
cell
per
unit
pretranspl
cmv
serostatu
determin
onset
patient
except
patient
receiv
granulocyt
transfus
patient
could
determin
igg
infant
includ
scid
patient
matern
transmit
immunoglobulin
ig
g
absent
abil
produc
igg
patient
could
determin
serostatu
evid
cmv
infect
decid
frequent
cmv
pcr
cmv
igm
ucbt
monitor
cmv
viremia
perform
least
weakli
cmv
viremia
defin
posit
cmv
antigenemia
antigenposit
cell
singl
slide
detect
cmv
dna
whole
blood
pcr
cmv
diseas
defin
endorgan
diseas
result
among
patient
treat
ucbt
cmvseroneg
patient
identifi
patient
receiv
leukocytereduc
blood
product
red
cell
platelet
patient
includ
patient
receiv
antithymocyt
globulin
remain
neg
cmv
viremia
none
develop
cmv
diseas
hand
patient
develop
cmv
viremia
patient
cmv
viremia
detect
three
patietn
receiv
granulocyt
transfus
two
scid
patient
infect
cmv
ucbt
nineteen
cmvseroposit
patient
one
patient
develop
cmv
viremia
cmv
serostatu
unknown
conclus
use
prestorag
leukocytereduct
zero
case
cmv
viremia
detect
seroneg
ucbt
patient
find
show
safeti
leukocytereduct
altern
strategi
prevent
ttcmv
patient
group
conflict
interest
author
declar
conflict
interest
associ
work
ipofg
porto
de
de
medula
porto
portug
ipofg
porto
de
terapia
celular
porto
portug
background
allogen
hematopoiet
stem
cell
transplant
allohsct
standard
care
mani
highrisk
malign
nonmalign
diseas
engraft
primari
goal
treatment
strategi
graft
failur
spite
variabl
low
incid
still
remain
import
complic
increas
morbid
mortal
allohsct
report
describ
outcom
patient
present
primari
graft
failur
pgf
method
retrospect
studi
analys
patient
submit
allohsct
institut
incid
graft
failur
patient
failur
reach
absolut
neutrophil
count
patient
graft
failur
achiev
engraft
result
patient
describ
pgf
male
median
age
year
patient
transplant
malign
acut
leukaemia
chronic
myeloid
leukaemia
myelodysplast
myeloprolif
neoplasm
nonhodgkin
lymphoma
nonmalign
diseas
fanconi
anaemia
other
allohsct
cell
sourc
cord
blood
peripher
hematopoiet
blood
stem
cell
n
select
bone
marrow
twentytwo
patient
perform
transplant
die
infect
present
late
autolog
recoveri
transplant
condit
regimen
myelobl
nonmyeloablativereduc
intens
nmaric
atgalemtuzumab
without
chemotherapi
condit
patient
receiv
unmanipul
graft
fifteen
patient
donnor
allohsct
median
time
transplant
day
median
overal
surviv
os
allohsct
month
respect
median
os
allohsct
nmaric
vs
myeloabl
regimen
vs
month
atg
month
alemtuzumab
nr
patient
perform
nmaric
regimen
hazard
ratio
death
hr
ci
group
receiv
atg
ci
p
alemtuzumab
ci
p
transplant
median
os
vs
month
engraft
nonengraft
patient
respect
group
engraft
criteria
ci
p
os
year
pgf
ci
allohsct
patient
malign
diseas
os
ic
seventeen
patient
die
graft
failur
infect
gvhd
caus
conclus
pgf
infrequ
low
incid
rate
complic
declin
time
sinc
mani
risk
factor
discov
still
increas
use
ric
wider
applic
hlamismatch
donor
might
revers
trend
heterogen
therapeut
strategi
pgf
occur
verifi
tendenc
superior
nmaric
regimen
regimen
contain
alemtuzumab
popul
larger
random
studi
parallel
new
strategi
determin
ideal
condit
need
conflict
interest
author
conflict
interest
chu
ucl
namur
montgodinn
hematolog
montgodinn
yvoir
belgium
hospic
civil
de
lyon
centr
hospitali
lyonsud
hematolog
lyon
franc
centr
lyon
hematolog
lyon
franc
background
demonstr
schmid
et
al
sequenti
use
intens
chemotherapi
follow
reduc
intens
condit
ric
allosct
prophylact
dli
pdli
allosct
repres
effect
treatment
hr
aml
md
despit
encourag
data
efficacytox
pdli
remain
poorli
assess
report
singlecent
retrospect
studi
pdli
allosct
hr
aml
md
method
centr
hospitali
lyonsud
franc
patient
median
age
year
hr
aml
md
receiv
pdli
allosct
within
sequenti
treatment
base
cytoreduct
flamsaregimen
ricmacallosct
pdli
allosct
start
around
day
day
discontinu
immunosuppress
cr
patient
without
gvhd
infect
initi
dose
x
cellskg
follow
absenc
gvhd
escal
cell
dose
interv
three
time
hr
diseas
includ
refractori
leukemia
delay
respons
induct
relaps
second
remiss
unfavor
genet
featur
secondari
aml
progress
md
andor
raeb
hripss
endpoint
studi
includ
pdli
feasibl
achiev
durabl
cr
full
donor
chimer
treatment
relat
toxic
impact
surviv
result
repeat
gradual
administr
pdli
feasibl
patient
receiv
dli
receiv
dli
pdli
agvhd
concern
patient
almost
low
grade
resolv
gvhd
acut
chronic
major
complic
observ
dli
procedur
requir
system
treatment
half
resolut
case
total
chronic
gvhd
concern
patient
limit
extens
persist
third
remain
extens
major
cumul
incid
trm
low
although
patient
cr
time
allosct
pr
sd
relaps
primari
refractori
cr
month
transplant
hematopoiet
recoveri
full
donor
chimer
twentyseven
patient
cr
pdli
studi
popul
persist
cr
pdli
patient
remain
cr
last
followup
pdli
chimer
improv
patient
remain
stabl
deterior
seven
patient
total
full
chimer
dli
obtain
full
donor
chimer
bm
pb
dli
relaps
concern
patient
median
day
allosct
cumul
incid
relaps
median
followup
month
median
os
month
ci
os
ci
os
ci
conclus
studi
confirm
feasibl
posit
effect
chimer
longterm
diseas
control
pdli
administr
flamsa
regimenallosct
hr
aml
md
price
gvhd
mostli
resolut
low
rate
chronic
gvhd
trm
conflict
interest
conflict
interest
policlinico
umberto
sapienza
univers
rome
hematolog
rome
itali
background
patient
undergo
chemotherapi
peripher
insert
central
cathet
picc
seem
associ
lower
rate
complic
compar
convent
percutan
insert
devic
cvad
moreov
insert
remov
picc
easier
cost
lower
compar
cvad
far
limit
experi
use
picc
set
allogen
hematopoiet
stem
cell
transplant
hsct
view
advantag
picc
vs
cvad
decid
use
picc
patient
candid
receiv
hsct
report
experi
systemat
use
picc
hsct
patient
sapienza
univers
rome
method
total
silicon
polyurethan
picc
insert
octob
august
catheterrel
bloodstream
infect
crbsi
mechan
malfunct
obstruct
disloc
ruptur
catheterrel
thrombot
complic
crtc
prospect
analyz
result
one
hundr
picc
insert
patient
malefemal
median
age
year
rang
fiftyon
patient
receiv
hsct
unrel
donor
sibl
donor
haploident
transplant
fiftysix
patient
acut
leukemia
chronic
lymphoprolif
diseas
myeloabl
mac
reduc
ric
intens
condit
regimen
employ
patient
respect
polyurethan
silicon
picc
use
patient
respect
devic
singl
lumen
patient
doubl
lumen
eightyf
picc
place
basilica
brachial
vein
respect
devic
insert
without
complic
crbsi
occur
case
rate
crbi
per
picc
day
coagulaseneg
staphylococcu
common
agent
associ
clinic
signific
complic
picc
remov
case
univari
analysi
picc
materi
factor
affect
crbsi
polyurethan
vs
silicon
p
crtc
observ
case
rate
crt
per
picc
day
patient
receiv
anticoagul
therapi
lowweight
heparin
follow
resolut
univari
analysi
variabl
show
correl
crtc
mechan
complic
occur
case
correspond
mechan
complic
per
picc
day
type
condit
mac
vs
ric
p
place
insert
basil
vs
brachial
vein
p
influenc
mechan
complic
variabl
remain
signific
multivari
analysi
global
median
durat
situ
picc
placement
day
conclus
experi
complic
observ
use
picc
patient
undergo
hsct
advers
event
relat
picc
manag
affect
transplant
outcom
silicon
picc
basil
vein
access
seem
correl
lower
incid
infecti
mechan
complic
conclud
picc
safe
reliabl
longterm
venou
access
patient
undergo
allogen
hsct
conflict
interest
author
declar
conflict
interest
akdeniz
univers
pediatr
hematolog
oncolog
depart
antalya
turkey
health
ministri
antalya
educ
research
hospit
antalya
turkey
background
hematopoiet
stem
cell
transplant
hsct
cur
treatment
bone
marrow
failur
fanconi
anemia
fa
underli
dna
repair
defect
reduc
intens
condit
ric
regimen
prefer
group
patient
method
studi
plan
present
result
fludarabinebas
radiotherapi
free
prepar
regimen
patient
fa
underw
hsct
pediatr
stem
cell
transplant
unit
akdeniz
univers
hospit
data
fa
patient
transplant
ric
prepar
regimen
includ
fludarabin
day
cyclophosphamid
mgkg
day
antithymocyt
globulin
freseniu
retrospect
analyz
file
result
total
patient
underw
hsct
period
girl
boy
median
age
year
rang
transplant
constitut
characterist
associ
fa
short
statur
microcephali
skin
pigment
absent
patient
diagnos
confirm
deb
test
group
patient
moder
sever
bone
marrow
failur
transplant
patient
chromosom
abnorm
sourc
hsct
bone
marrow
bm
peripher
stem
cell
psc
cord
blood
cb
rest
patient
twelv
patient
receiv
hsct
match
sibl
donor
patient
match
famili
donor
match
unrel
donor
median
infus
cell
dose
bm
pbsc
receiv
rang
cb
receiv
graft
versu
host
diseas
gvhd
prophylaxi
includ
cyclosporin
group
mycophenol
mofetil
mud
patient
engraft
within
median
follow
year
rang
overal
surviv
total
group
sever
acut
graft
versu
host
diseas
grade
occur
patient
three
patient
complic
venoocclus
diseas
vod
patient
suffer
hemorrhag
cystiti
eleven
patient
lost
median
month
rang
hsct
patient
receiv
stem
sourc
unrel
donor
group
rel
transplant
patient
lost
msd
mfd
transplant
sever
infect
caus
gvhd
relat
immunosuppress
treatment
major
caus
death
four
patient
lost
due
sever
hemorrhag
cystiti
lead
renal
failur
patient
vod
relat
complic
due
regimen
relat
toxic
patient
aliv
full
chimer
good
clinic
statu
conclus
result
show
excel
outcom
hsct
fludarabinebas
radiotherapi
free
prepar
regimen
msd
mfd
recipi
even
though
good
engraft
rate
interv
complic
increas
mortal
mud
recipi
conclud
effort
warrant
improv
outcom
mud
group
conflict
interest
none
author
anyth
disclos
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
fondazion
ircc
policlinico
san
matteo
pediatr
hematolog
oncolog
pavia
itali
hospit
universitario
la
paz
pediatr
hematooncolog
madrid
spain
berlin
depart
pediatr
oncologyhematologystem
cell
transplant
berlin
germani
univers
hospit
nanci
allogen
hematopoiet
stem
cell
transplant
unit
depart
hematolog
franc
chimerix
durham
nc
unit
state
analyticalas
london
unit
kingdom
background
allogen
hematopoiet
cell
transplant
allohct
recipi
particularli
pediatr
patient
risk
lifethreaten
adenoviru
adv
viremia
risk
well
recogn
lack
multicent
data
common
practic
regard
adv
screen
monitor
treatment
method
advanc
retrospect
multicent
multin
studi
incid
manag
clinic
outcom
adv
infect
european
adult
pediatr
allohct
recipi
physician
particip
institut
ask
complet
survey
outlin
current
practic
manag
adv
infect
allohct
recipi
question
specif
address
screen
monitor
treatment
result
survey
data
avail
physician
treat
pediatr
patient
treat
adult
patient
see
tabl
almost
pediatr
physician
respond
center
employ
screen
protocol
minor
adult
physician
report
center
screen
protocol
pediatr
physician
indic
screen
adv
infect
weekli
biweekli
use
blood
stool
blood
stool
contrast
routin
screen
use
adult
physician
respond
though
adult
patient
high
risk
adv
infect
graftversushost
diseas
gvhd
recipi
tcell
deplet
haploident
cord
blood
mismatch
transplant
screen
frequent
posit
blood
sampl
note
treatment
trigger
pediatr
physician
half
defin
threshold
copiesml
adult
physician
treat
preemptiv
adv
viremia
major
defin
threshold
frequent
report
firstlin
treatment
pediatr
adult
patient
offlabel
iv
cidofovir
investig
medic
brincidofovir
follow
cellbas
therapi
conclus
advanc
practic
pattern
survey
confirm
pediatr
allohct
recipi
higher
risk
adv
infect
monitor
close
wherea
adult
patient
gener
monitor
less
frequent
adult
characterist
could
place
higher
risk
adv
infect
gvhd
monitor
close
pediatr
adult
patient
viremia
common
treatment
trigger
offlabel
iv
cidofovir
commonli
consid
treatment
spite
toxic
concern
treatment
practic
center
survey
gener
consist
guidelin
european
confer
infect
leukaemia
ecil
refer
matthesmartin
feuchting
shaw
p
engelhard
ljungman
p
manag
adenoviru
adv
infect
confer
infect
leukaemia
avail
http
conflict
interest
k
rao
zecca
voigt
c
pochon
investig
advanc
studi
sponsor
chimerix
e
vainoriu
brundag
e
mozaffari
g
nichol
employe
studi
sponsor
chimerix
khachatryan
employe
analyticalas
research
consult
conduct
studi
behalf
sponsor
chimerix
king
hussein
cancer
center
cell
therapi
appli
genom
amman
jordan
background
cellular
product
manufactur
complex
oper
constitut
cell
collect
cell
process
product
storag
releas
addit
mani
calcul
robust
document
qualiti
control
system
requir
databas
maintain
inventori
store
product
perform
manual
calcul
time
consum
prone
manual
error
method
captur
list
key
step
singl
password
protect
excel
spreadsheet
worksheet
well
document
qualiti
quantiti
store
product
care
orchestr
design
spreadsheet
allow
user
subtl
advantag
track
trend
ongo
oper
simpl
scroll
result
password
protect
formula
ensur
errorproof
calcul
save
time
user
identifi
posit
neg
trait
simpl
scroll
simpl
chang
design
spreadsheet
use
convent
prolif
potenti
assay
coloni
form
cell
methyl
cellulos
variou
cell
type
conclus
creativ
spreadsheet
real
asset
cord
blood
bank
oper
use
cellular
product
bank
save
time
prevent
calcul
error
track
trend
ongo
oper
institut
time
correct
action
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
universidad
autonoma
de
bucaramangafosc
intern
medicin
divis
hematolog
hematopoiet
stem
cell
transplant
bucaramanga
colombia
universidad
autonoma
de
bucaramanga
school
medicin
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
obstetr
gynecolog
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
epidemiolog
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
bucaramanga
colombia
background
past
decad
hematopoiet
stem
cell
transplant
hsct
evolv
experiment
procedur
becom
standard
treatment
sever
hematopoiet
disord
shortterm
morbid
mortal
diseas
relaps
hsctrelat
complic
well
document
aim
present
studi
assess
surviv
rate
patient
underw
hsct
method
retrospect
cohort
studi
conduct
tertiari
referr
center
colombia
south
america
patient
transplant
either
use
autolog
allogen
hsct
novemb
decemb
kaplanmei
method
use
assess
overal
surviv
relapsefre
surviv
rate
day
one
year
five
year
follow
hsct
result
patient
older
year
mean
age
year
rang
seventytwo
men
women
patient
differ
type
hematolog
diseas
common
hematolog
diseas
multipl
myeloma
follow
nonhodgkin
lymphoma
acut
leukemia
one
hundr
six
patient
receiv
autolog
hsct
allogen
hsct
multipl
myeloma
common
indic
autolog
transplant
acut
leukemia
allogen
transplant
overal
surviv
autolog
hsct
ic
one
year
ic
five
year
allogen
hsct
ic
one
year
five
year
relapsefre
surviv
allogen
transplant
ic
one
year
five
year
one
year
five
year
autolog
transplant
death
due
relaps
diseas
progress
type
transplant
mortal
rate
autolog
hsct
per
popul
per
popul
allogen
hsct
conclus
overal
relapsefre
surviv
autolog
allogen
hsct
similar
report
exist
literatur
common
caus
death
hsct
patient
primari
diseas
transplantrel
mortal
low
conflict
interest
author
declar
potenti
conflict
interest
gaziantep
univers
faculti
medicin
intern
medicin
gaziantep
turkey
gaziantep
univers
depart
hematolog
gaziantep
turkey
gaziantep
univers
faculti
medicin
gaziantep
turkey
gaziantep
univers
faculti
medicin
bone
marrow
transplant
unit
gaziantep
turkey
background
aim
studi
investig
clinic
featur
cytomegaloviru
cmv
infect
effect
hematopoiet
stem
cell
transplant
hsct
effect
antivir
treatment
protocol
method
studi
perform
gaziantep
univers
faculti
medicin
bone
marrow
transplant
center
retrospect
total
patient
allogen
autolog
stem
cell
transplant
includ
studi
cmv
viremia
perform
polymerasechainreact
pcr
routin
twice
week
first
month
case
clinic
suspicion
result
cmvpcr
posit
detect
allogen
hsct
patient
autolog
hsct
patient
statist
signific
increas
number
cmvpcr
valu
copiesml
nonmyeloabl
nma
group
compar
myeloabl
group
acutechron
gvhd
observ
allogen
hsct
patient
cmv
viremia
detect
patient
detect
patient
statist
signific
relationship
develop
acut
chronic
gvhd
cmv
viremia
p
first
mortal
higher
group
without
cmv
viremia
allogen
hsct
patient
p
p
surviv
rate
viremia
group
nonviremia
group
statist
signific
differ
two
group
term
surviv
p
patient
receiv
valganciclovir
treatment
viremia
cmv
diseas
develop
advers
effect
requir
drug
discontinu
observ
conclus
gvhd
associ
cmv
viremia
earli
late
mortal
rate
smiliar
patient
without
cmvantigenemia
surviv
similar
hsct
patient
without
cmv
viremia
preemptiv
therapi
cmv
viremia
valganciclovir
safe
effect
hsct
conflict
interest
author
read
approv
manuscript
none
author
potenti
conflict
interest
regard
paper
adnan
mender
univers
hematolog
aydin
turkey
addenbrook
hospit
hematolog
aydin
turkmenistan
adnan
mender
univers
aydin
turkey
kent
hospit
izmir
turkey
background
glucos
transport
protein
express
malign
cell
role
cell
prolifer
aim
effect
level
leucocyt
thrombocyt
engraft
myeloma
patient
autolog
stem
cell
transplant
prospect
trial
method
investig
done
stem
cell
harvest
patient
two
transplant
center
exclus
critera
diabet
mellitu
bodi
mass
index
bmi
glut
level
determin
elisa
mean
valu
accept
two
harvest
collect
adnan
mender
univers
nonintervent
ethic
comiss
approv
studi
human
elisa
kit
catalog
use
fore
test
sandwichelisa
procedur
result
evalu
spectrophotometr
analysi
absorb
micropl
reader
dar
optic
densiti
nm
wavelength
result
analys
spss
window
version
modul
result
median
age
femalemal
rate
complet
remiss
rate
partial
remiss
rate
posit
correl
level
neutrophil
engraft
correl
thrombocyt
engraft
posit
correl
mark
patient
partial
remisss
engraft
time
independ
cd
posit
cell
count
conclus
studi
show
pretranspl
level
high
myeloma
patient
partial
remiss
neutrophil
engraft
delay
patient
wherea
level
low
myeloma
patient
complet
remiss
posttransplat
neutrophil
engraft
becam
earlier
conflict
interest
none
author
anyth
declar
middl
east
institut
health
univers
hospitalsaint
joseph
universitylebanes
univers
cellular
therapi
unitregen
medicin
inflamm
laboratori
bsalim
lebanon
saint
antoin
joseph
univers
regen
medicin
inflamm
laboratori
beirut
lebanon
middl
east
institut
health
univers
hospit
bsalim
lebanon
saint
antoin
joseph
univers
cancer
metabol
lab
beirut
lebanon
middl
east
institut
health
univers
hospit
cellular
therapi
bsalim
lebanon
makass
middl
east
institut
health
univers
hospitalslebanes
univers
hematolog
oncologybmt
beirut
lebanon
saint
joseph
univers
regen
medicin
inflamm
laboratori
beirut
lebanon
background
adipos
tissu
abund
access
sourc
autolog
stem
cell
also
capabl
multilineag
cell
differenti
past
year
clinic
trial
look
develop
new
therapi
differ
kind
diseas
neurodegen
diseas
cutan
diseas
heart
problem
well
autoimmun
diseas
howev
hematopoiet
stem
cell
use
cancer
treatment
adipos
deriv
stem
cell
admsc
therapeut
properti
due
trophic
effect
cytokin
chemokin
produc
object
studi
evalu
effect
stem
cell
deriv
adipos
tissu
admsc
ovarian
cancer
especi
term
prolifer
apoptosi
immunophenotyp
tumor
marker
method
effect
measur
vitro
cell
molecular
level
incub
cancer
ovarian
cell
primari
cell
along
supernat
stem
cell
anoth
approach
would
cultiv
cell
togeth
admsc
amount
tumor
marker
protein
mark
ovarian
cancer
also
measur
elisa
prolifer
immunomodul
effect
admsc
along
apoptosi
cancer
cell
measur
cultur
count
coloni
format
evalu
variat
immunophenotyp
cocultur
perform
use
flow
cytometri
techniqu
result
third
subcultur
cell
notic
prolifer
without
modif
immunophenotyp
cfuf
test
show
prolifer
admsc
along
cell
line
multipl
healthi
cell
duplic
chang
phenotyp
supernat
admsc
increas
cell
death
apoptosi
decreas
level
ldh
hcgbeta
cocultur
cell
line
tumorigen
aggress
cancer
reduc
decreas
cocultur
supernat
admsc
howev
rate
assert
stem
state
conclus
reduct
ldh
hcgbeta
cocultur
show
therapeut
characterist
admsc
ovarian
cancer
conflict
interest
noth
disclos
first
pavlov
state
medic
univers
st
petersburg
russian
feder
raisa
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
st
petersburg
russian
feder
background
allohsct
standard
treatment
high
risk
hematolog
malignanciesrelaps
allohsct
common
reason
treatment
failur
rate
possibl
therapeut
option
includ
chemotherapi
immuadopt
therapi
dli
target
therapi
second
allohsctth
present
studi
retrospect
singleinstitut
experi
second
allohsct
pt
oncohematolog
diseas
aim
evalu
effici
factor
affect
outcom
second
allohsct
children
relaps
first
allohsct
method
analyz
outcom
children
second
allohsct
hematolog
malign
pt
pt
smd
ptfirst
allohsct
perform
mud
pt
mrd
pt
haplodonor
syngen
donor
ptcondit
regimen
mac
pt
pt
ric
ptsindic
allohsct
relaps
pt
graft
failur
includ
pt
progress
diseas
ptsmedian
age
time
first
allohsct
yo
median
age
second
hsct
yo
median
time
allohsct
month
cr
second
allohsct
mac
pt
ric
pt
gvhd
prophylaxi
includ
posttranspl
cy
day
pt
pt
allohsct
haplodonor
chosen
pt
includ
pt
haplo
donor
first
allohsct
pt
mud
donor
substitut
pt
mud
without
donor
substitut
pt
mrd
without
donor
substitut
ptmedian
number
cytoreduct
therapi
prior
hsct
perform
pt
pt
transplant
aplasiano
respons
pt
achiev
remiss
blast
cytoreduct
achiev
transplant
sourc
gcsf
prime
unmanipul
bm
pt
unmanipul
bm
pt
unmanipul
combin
pbsc
pt
underw
pttherapi
pt
hma
pt
mainten
pt
result
thirtythre
patient
achiev
engraft
median
time
neutrophil
engraft
day
clinic
remiss
achiev
pt
os
accord
kaplanmei
method
median
followup
yearsther
statist
signific
impact
condit
regimen
os
mac
vs
donor
type
nt
affect
os
without
donor
substitut
os
pt
cytoreduct
pt
remiss
better
pt
achiev
remiss
cytoreduct
frequent
transplant
complic
grade
ii
agvhd
pt
mild
moder
cgvhd
pt
caus
death
pt
trm
pt
pt
agvhd
os
better
without
agvhd
pt
cgvhd
compar
without
cgvhd
os
significantli
better
patient
post
transplant
therapi
dli
hma
target
therapi
mainten
therapi
compar
patient
without
therapi
vs
conclus
allohsct
effect
treatment
option
relaps
allohsctpati
achiev
blast
cytoreduct
remiss
prior
allohsct
improv
outcomer
allohsct
compar
macpost
transplant
therapi
requir
improv
result
hsct
conflict
interest
noth
disclos
santanna
school
advanc
studi
pisa
itali
azienda
ospedaliera
universitaria
pisana
pisa
itali
azienda
ospedaliera
universitaria
anna
meyer
firenz
itali
background
last
year
prioriti
allogen
donor
select
chang
need
stringent
hlamatch
remain
elus
especi
pediatr
hsct
method
children
age
year
underw
first
allogen
hsct
malign
institut
includ
patient
classifi
accord
donor
sourc
umbil
cord
blood
unit
ucbu
match
unrel
mud
mismatch
unrel
mmud
match
sibl
msd
haploident
haplo
donor
probabl
os
df
gvhdfree
relapsefre
surviv
grf
calcul
accord
kaplanmei
method
logrank
test
use
statist
analysi
cumul
incid
procedur
gray
test
use
assess
differ
relaps
nrm
agvhd
grade
cgvhd
neutrophil
platelet
engraft
result
patient
categor
msd
mud
mmud
haplo
ucbu
graft
group
uniform
age
sex
graft
composit
except
lower
median
cellular
ucbu
eleven
haplo
lymphocytedeplet
one
receiv
posttransplant
cyclophosphamid
haplo
receiv
mainli
chemotherapybas
ric
regimen
pbsc
graft
other
receiv
predominantli
tbibas
regimen
bm
graft
compar
posthsct
cmv
diseas
rate
observ
major
endpoint
report
tabl
togeth
standard
error
se
os
p
df
p
significantli
higher
mud
msd
haplo
compar
mmud
ucbu
although
statist
nonsignific
relaps
frequent
among
mmud
ucbu
haplo
probabl
relaps
rate
haplo
neg
affect
small
sampl
size
primari
graft
failur
occur
ucbu
mud
haplo
one
secondari
graft
failur
record
mud
group
cumul
incid
agvhd
cgvhd
neutrophil
platelet
engraft
compar
among
group
except
absenc
agvhd
delay
platelet
engraft
ucbu
group
nonrelaps
death
observ
mmud
ucbu
msd
mud
haplo
show
significantli
higher
grf
p
compar
other
figur
grf
se
number
event
e
conclus
despit
variat
hsct
procedur
inclus
small
dissimilar
cohort
msd
mud
haplo
shown
similar
outcom
yet
favor
compar
mmud
ucbu
although
hlamatch
play
paramount
role
donor
select
use
differ
haploident
hsct
platform
may
allow
expans
donor
pool
yield
compar
outcom
conflict
interest
noth
disclos
tabl
major
endpoint
sisli
florenc
nightingal
hospit
hematopoiet
stem
cell
transplant
unit
istanbul
turkey
istanbul
bilim
univers
hematolog
depart
istanbul
turkey
turkish
stem
cell
coordin
center
turkok
turkish
ministri
health
istanbul
turkey
background
turkish
stem
cell
coordin
center
turkok
establish
turkish
ministri
health
april
order
facilit
unrel
hematopoiet
stem
cell
hsc
transplant
turkey
juli
facilit
hsct
transplant
registri
istanbul
tri
transplant
registri
ankara
tran
two
univers
affili
donor
search
coordin
center
offici
respons
search
match
organ
deliveri
unrel
donor
hsc
turkey
foundat
turkok
theoret
decreas
time
spent
find
suitabl
match
donor
aim
studi
compar
time
frame
admiss
confirm
workup
infus
hsc
turkok
wmda
nmdp
facilit
intern
volunt
donor
registri
method
allogen
hsct
peform
turkey
mud
singl
center
analysi
dedic
activ
hsct
center
perform
allogen
hsct
per
year
util
altern
donor
sourc
patient
chart
review
retrospect
patient
admit
center
within
variou
high
risk
hematolog
malign
mostli
acut
leukemia
identifi
studi
patient
divid
two
group
patient
receiv
hsc
match
unrel
donor
mudt
facilit
turkok
patient
receiv
hsc
intern
registri
facilit
tri
tran
mudi
durat
applic
find
suitabl
match
tam
durat
match
confirm
tmc
time
applic
hsc
transplant
tatx
calcul
two
group
time
durat
admiss
donor
identif
admiss
hsct
distribut
normal
mean
valu
compar
two
group
mannwhitney
u
test
p
consid
statist
signific
result
hsc
recipi
overal
median
durat
tam
tmc
tatx
rang
rang
rang
respect
mudi
overal
median
durat
tam
tmc
tatx
rang
rang
rang
wherea
mudt
timelin
tam
tmc
tatx
rang
rang
rang
respect
p
valu
compar
analysi
betwen
mudi
mudt
tam
tmc
tatx
p
respect
conclus
rel
limit
size
hsc
recipi
mud
observ
acceler
kinet
tam
tmc
mean
nation
registri
posit
impact
find
avail
match
confirm
process
hand
improv
translat
rapid
hsct
tatx
mudi
mudt
signific
turkok
establish
improv
organ
confirm
donor
collect
hsc
decreas
timelin
applic
confirm
encourag
time
spent
confirm
workup
collect
still
high
turkok
recent
establish
donor
bank
room
improv
conflict
interest
noth
disclos
sydney
children
hospit
sydney
cord
blood
bank
randwick
australia
nsw
health
patholog
bmt
laboratori
randwick
australia
background
cord
blood
cb
bank
perform
haematopoiet
progenitor
cell
hpc
enumer
assay
provid
qualit
data
correl
engraft
outcom
standardis
hpc
assay
enumer
cell
content
incorpor
primit
hpc
compart
project
aim
develop
assay
calcul
content
hpc
address
hypothesi
compart
contribut
engraft
clinic
outcom
method
sampl
met
nation
therapeut
good
administr
intern
netcordfound
accredit
cellular
therapi
regulatori
requir
cord
blood
bank
mean
collect
volum
cb
ml
mean
total
nucleat
cell
tnc
count
process
rang
cell
percentag
white
blood
cell
wbc
compart
enumer
kit
use
studi
contain
antibodi
viabil
dye
annexinv
combin
antibodi
mention
detect
cell
undergo
apoptosi
differ
hpc
stage
result
nonlinear
regress
invers
correl
cell
cell
observ
test
sampl
exampl
cell
percentag
wbc
wbc
tnc
convers
cell
percentag
wbc
wbc
tnc
cell
significantli
smaller
cell
p
determin
forward
scatter
analysi
express
cell
popul
could
divid
accord
proport
differ
hpc
compart
percentag
cell
increas
percentag
cell
wbc
increas
result
demonstr
level
express
shift
hpc
develop
primit
intermedi
later
stage
use
one
way
anova
demonstr
hpc
viabil
differ
among
subset
characteris
biomark
p
viabil
cell
decreas
percentag
cell
wbc
increas
howev
viabil
cell
chang
increas
cell
percentag
wbc
addit
hpc
viabil
relationship
cell
cell
verifi
incorpor
annexinv
conclus
advanc
flow
cytometr
technolog
clinic
grade
reagent
access
high
qualiti
cbu
final
product
abl
demonstr
primit
cell
enumer
result
show
hpc
subset
classifi
three
compart
bright
primit
intermedi
bright
later
stage
conclus
incorpor
standard
hpc
enumer
methodolog
may
provid
addit
qualit
data
improv
correl
hpc
content
clinic
engraft
conflict
interest
author
noth
disclos
iran
univers
medic
scienc
tehran
iran
islam
republ
background
umbil
cord
blood
stem
cell
transplant
use
extens
allogen
set
acquir
genet
disord
hematopoiesi
less
experi
util
autolog
cord
blood
transplant
great
controversi
role
autolog
cord
blood
collect
storag
case
pediatr
sever
aplast
anemia
occur
annual
unit
state
grow
number
children
sever
aplast
anemia
may
stem
cell
harvest
cord
blood
collect
method
report
success
use
autolog
cord
blood
transplant
treatment
yearsold
boy
idiopath
sever
aplast
anemia
aliasghar
children
hospit
receiv
atgam
mgkg
eight
day
infus
stem
cell
sandimmun
mgkg
oral
per
hour
receiv
total
nucleat
cell
result
platelet
engraft
per
microlit
three
consecut
day
occur
four
week
infus
cell
sandimmun
discontinu
one
month
platelet
engraft
complet
blood
count
normal
month
infus
cell
well
complet
month
transplant
conclus
increas
number
peopl
cryopreserv
autolog
cord
blood
use
autolog
cord
blood
treatment
sever
aplstic
anemia
might
consid
initi
therapi
appear
privat
cord
blood
bank
applic
past
howev
need
extens
studi
confirm
idea
clinic
trial
registri
clinic
trial
registr
conflict
interest
studi
support
iran
univers
medic
scienc
abstract
previous
publish
gaziantep
univers
faculti
medicin
depart
hematolog
gaziantep
turkey
gaziantep
univers
faculti
medicin
depart
intern
medicin
gaziantep
turkey
gaziantep
univers
faculti
medicin
bone
marrow
transplant
center
gaziantep
turkey
background
thrombocytopenia
peripher
hematopoiet
stem
cell
transplant
phsct
associ
morbid
mortal
eltrombopag
thrombopoietin
receptor
agonist
tpa
success
use
primarili
treatment
chronic
itp
thrombocytopenia
associ
aplast
anemia
myelodysplast
syndrom
recent
use
eltrombopag
treatment
thrombocytopenia
allogen
phsct
promis
method
use
eltrombopag
patient
hematolog
malign
experienc
graft
failur
first
phsct
develop
platelet
engraft
failur
follow
second
bone
marrow
transplant
univers
gaziantep
bone
marrow
unit
present
retrospect
result
patient
male
one
femal
mean
age
year
diagnos
aml
nhl
patient
underw
allogen
phsct
myeloabl
regimen
platelet
engraft
failur
detect
followup
patient
acut
grade
skin
gvhd
develop
nhl
patient
mycophenol
mofetil
csa
steroid
immunosuppress
given
complet
respons
week
howev
thrombocytopenia
persist
none
patient
viral
infect
relaps
bone
marrow
biopsi
patient
hypocellular
number
megakaryocyt
decreas
eltrombopag
initi
patient
day
transplant
averag
respons
obtain
patient
l
plt
mean
durat
respons
day
side
effect
associ
eltrombopag
observ
conclus
eltrombopag
use
safe
effect
patient
platelet
engraft
failur
phsct
conflict
interest
author
noth
disclos
immunodefici
diseas
macrophag
gsk
valu
evid
outcom
brentford
unit
kingdom
cellohealth
insight
london
unit
kingdom
background
current
treatment
option
adenosin
deaminasesever
combin
immunodefici
adascid
includ
haematopoiet
stem
cell
transplant
hsct
enzym
replac
therapi
ert
gene
therapi
gt
littl
known
regard
caregiv
percept
treatment
emot
impact
make
treatment
decis
method
research
conduct
telephon
interview
caregiv
patient
adascid
particip
recruit
usa
franc
uk
itali
patient
associ
direct
referr
healthcar
profession
studi
inclus
criteria
caregiv
child
must
diagnosi
adascid
onset
within
first
year
life
must
involv
gsk
gt
studi
includ
sibl
research
compliant
relev
countri
market
research
regul
result
nine
caregiv
parent
usa
franc
uk
itali
recruit
close
involv
treatment
decis
though
great
relianc
expert
advic
absenc
public
inform
care
centr
excel
caregiv
confid
specialist
team
howev
journey
point
involv
primari
care
local
hospit
frustrat
major
caregiv
caregiv
report
time
spent
consid
treatment
option
highli
emot
challeng
time
hardest
contempl
hsct
gt
hsct
consid
better
establish
gt
howev
decis
proceed
influenc
donor
avail
respond
awar
gt
relat
concern
includ
perceiv
risk
leukaemia
lack
longterm
data
treatment
greatest
concern
caregiv
need
chemotherapi
consequenti
impact
child
health
experi
treatment
date
mix
vari
success
report
gt
hsct
patient
receiv
ert
caregiv
satisfi
treatment
conclus
caregiv
would
benefit
detail
comprehens
inform
packag
explain
differ
treatment
adascid
cover
side
effect
transplant
chemotherapi
steroid
well
benefitrisk
profil
possibl
sequenc
treatment
improv
emot
support
mechan
would
also
welcom
conflict
interest
r
bergemann
employe
sharehold
glaxosmithklin
gsk
e
mustchin
j
barrett
gaffuri
e
bouchard
commiss
gsk
conduct
research
acknowledg
studi
fund
gsk
editori
support
provid
clem
hindley
fishawack
indicia
ltd
fund
gsk
great
north
children
hospit
newcastl
upon
tyne
hospit
nh
foundat
trust
paediatr
bone
marrow
transplant
newcastl
upon
tyne
unit
kingdom
background
mhc
class
ii
mhc
ii
defici
bare
lymphocyt
syndrom
rare
primari
immunodefici
amen
hematopoiet
stem
cell
transplant
hsct
howev
report
outcom
still
limit
object
studi
analyz
pretranspl
comorbid
outcom
hsct
patient
mhc
ii
defici
method
perform
retrospect
studi
patient
underw
hsct
procedur
mhc
ii
defici
centr
result
averag
median
age
hsct
year
rang
day
year
eleven
patient
male
femal
two
patient
requir
second
transplant
due
graft
failur
sixteen
patient
viral
infect
pretranspl
donor
follow
match
mud
mrd
mmud
haploident
donor
stem
cell
sourc
pbsc
bm
cord
blood
condit
myeloabl
busulfancyclophosphamid
alemtuzumab
antilfa
treosulfancyclophosphamid
treosulfanfludarabinethiotepaantithymocyt
globulinrituximab
reduc
toxic
treosulfanfludarabinealemtuzumab
reduc
intens
condit
fludarabinemelphalanalemtuzumab
overal
surviv
patient
die
caus
death
sever
interstiti
pneumonia
two
patient
also
multiorgan
failur
late
death
year
posttranspl
sepsi
skin
gvhd
maximum
grade
ii
seen
patient
patient
requir
system
steroid
rest
respond
topic
treatment
one
patient
chronic
gvhd
autoimmun
observ
length
follow
year
median
rang
day
year
viral
reactiv
common
conclus
hsct
success
treatment
mhc
ii
defici
note
patient
transplant
sinc
aliv
well
includ
post
deplet
haploident
graft
conflict
interest
author
conflict
interest
disclos
abstract
previous
publish
children
hospit
pittsburgh
upmc
bmt
ct
pittsburgh
pa
unit
state
univers
pittsburgh
depart
immunolog
pittsburgh
pa
unit
state
univers
pittsburgh
school
medicin
depart
infecti
diseas
microbiolog
pittsburgh
pa
unit
state
upmc
hematopoiet
stem
cell
laboratori
pittsburgh
pa
unit
state
children
hospit
pittsburgh
upmc
divis
pulmonari
medicin
allergi
immunolog
pittsburgh
pa
unit
state
upmc
divis
pulmonari
allergi
critic
care
medicin
pittsburgh
pa
unit
state
background
primari
immunodefici
patient
may
develop
pulmonari
complic
inelig
either
lung
transplant
bmt
due
futil
report
first
subject
enrol
first
human
prospect
clinic
trial
clinicaltrialsgov
receiv
tandem
bolt
subsequ
bmt
deceas
uno
donor
hypothes
hematopoiet
stem
cell
prepar
organ
donor
vertebr
bodi
vb
would
yield
greater
cell
dose
compar
iliac
crest
aspirateswith
limit
harvest
time
due
parallel
organ
recoveri
team
cryopreserv
deplet
bone
marrow
could
gener
durabl
hematopoiesi
donor
deriv
immun
full
donor
persist
mix
chimer
could
establish
toler
bidirect
follow
withdraw
immunosuppress
drug
isd
method
case
year
old
femal
null
scid
recurr
bacteri
fungal
pneumonia
underw
bolt
hla
antigen
allel
level
match
donor
marrow
suspens
prepar
vb
log
follow
deplet
cryopreserv
along
fold
fewer
tnc
cell
iliac
crest
month
postbolt
start
bmt
condit
hydroxyurea
thiotepa
tbi
combin
serotherapi
deplet
host
b
nk
lymphocyt
month
later
marrow
thaw
infus
cellskg
cellskg
engraft
donor
cell
note
persist
cell
lymphopenia
mostli
host
origin
receiv
dli
week
later
cellskg
result
dli
result
domin
donor
b
cell
chimer
donor
myeloid
cell
granulocyt
monocyt
myeloid
dc
along
nk
lymphocyt
declin
steadili
first
month
stabil
bal
valu
exhibit
differ
kinet
b
cell
tcrbcr
repertoir
trec
exceed
prebmt
valu
month
b
bk
viru
specif
cell
clear
viremia
suggest
effect
reconstitut
pathogen
specif
immun
donorrecipi
cmv
neg
mild
skin
gvhd
postdli
clear
week
mgkg
prednison
serial
lung
biopsi
neg
reject
last
followup
report
isd
month
postbmt
month
postisd
withdraw
circul
donor
cell
unrespons
host
dc
respond
third
parti
apc
fulfil
critic
tenet
toler
toler
toward
host
apc
treg
independ
case
year
old
woman
cvid
ecmo
underw
bolt
episod
lung
reject
becom
elig
bmt
match
month
later
total
vb
cellskg
vb
cellskg
infus
engraft
day
whole
blood
chimer
cell
host
origin
convert
follow
dli
conclus
case
first
human
demonstr
durabl
engraft
immun
compet
acquisit
toler
deceas
donor
vb
marrow
match
singl
class
mhc
allel
provid
proof
principl
current
also
test
adult
clinic
trial
registri
http
conflict
interest
none
author
anyth
disclos
apollo
special
cancer
hospit
paediatr
blood
marrow
transplant
chennai
india
background
haploident
haematopoiet
stem
cell
transplant
hsct
offer
possibl
cure
children
primari
immun
defici
disord
match
donor
access
gene
therapi
describ
encourag
result
use
post
transplant
cyclophosphamid
cohort
children
method
data
present
retrospect
analysi
children
underw
replet
haploident
haematopoiet
stem
cell
transplant
post
transplant
cyclophosphamid
ptci
primari
immunedefici
disord
centr
three
year
period
children
reduc
intens
condit
use
fludarabin
melphalan
treosufan
addit
gy
total
bodi
radiotherapi
children
infant
less
month
cyclophosphamid
dose
mgkgday
day
incid
engraft
graft
reject
infect
graft
versu
host
diseas
event
free
overal
surviv
unusu
complic
document
result
total
children
underw
haploident
hsct
ptci
diagnosi
sever
combin
immun
defici
wiskott
aldrich
syndrom
haemophagocyt
lymphohistiocytosi
hyper
ig
syndrom
mendelian
suscept
mycobacteri
diseas
children
graft
failur
seen
children
surviv
autolog
reconstitut
infant
transplant
cytokin
releas
syndrom
one
babi
could
salvag
use
tociluzimab
viral
infect
result
death
seen
child
hlh
progress
result
death
child
none
children
grade
graft
versu
host
diseas
follow
period
day
day
overal
surviv
diseas
free
surviv
conclus
uniqu
studi
children
primari
immun
defici
disord
differ
aetiolog
undergo
haploident
hsct
ptci
surviv
averag
cost
hsct
usd
univers
access
care
still
issu
develop
countri
ptci
offer
cost
effect
modal
therapi
gene
therapi
unrel
hsct
ex
vivo
cell
deplet
techniqu
still
beyond
reach
mani
famili
insur
cover
unusu
complic
like
cytokin
releas
storm
document
especi
infant
children
undergo
hsct
hlh
need
prospect
evalu
clinic
trial
registri
na
conflict
interest
none
pediatr
oncohaematolog
bmt
unit
children
hospit
univeris
brescia
brescia
itali
children
hospit
univers
brescia
brescia
itali
children
hospit
paediatr
univers
brescia
brescia
itali
pediatr
immunolog
children
hospit
univers
brescia
brescia
itali
stem
cell
laboratori
section
haematolog
blood
coagul
spedali
civili
brescia
brescia
itali
pediatr
oncohaematolog
bmt
unit
children
hospit
chair
paediatr
univers
brescia
brescia
itali
background
autosom
recess
hyper
ige
syndrom
hie
caus
mutat
associ
sever
cellular
immunodefici
viral
bacteri
infect
eczema
food
allergi
malign
sinc
hematopoiet
stem
cell
transplant
propos
cur
treatment
method
report
five
case
patient
treat
bone
marrow
transplant
median
age
transplant
year
month
fifth
patient
came
low
econom
condit
countri
nt
receiv
earli
bone
marrow
transplant
transplant
patient
present
eczema
sinopulmonari
infect
food
allergi
common
featur
mucocutan
candidiasi
skin
abscess
bronchiectasi
viral
seriou
infect
skelet
anomali
retain
primari
teeth
fractur
hyperextens
joint
vascular
abnorm
lacunar
brain
infarct
malign
neuroblastoma
less
frequent
myeloabl
condit
regimen
busulfan
treosulfan
fludarabin
thiotepa
atg
use
three
patient
one
patient
treat
reducedintens
regimen
fludarabin
alemtuzumab
melphalan
three
patient
receiv
allograft
match
unrel
donor
one
haploident
relat
donor
sourc
stem
cell
peripher
blood
bone
marrow
gvhd
prophylaxi
base
cyclosporin
mycophenol
mofetil
steroid
result
complet
engraft
neutrophil
platelet
achiev
three
patient
median
day
respect
one
patient
activ
infect
time
transplant
nt
achiev
donor
engraft
boost
necessari
patient
die
due
sever
pneumonia
stabl
donor
chimer
observ
patient
advers
event
transplant
acut
gvhd
followup
month
complic
progress
multifoc
leukoencephalopathi
papillari
thyroid
carcinoma
papilledema
pneumonia
sepsi
featur
hie
except
food
allergen
sensit
nt
observ
patient
show
reduct
serum
ige
median
rang
iuml
iuml
eosinophil
count
median
rang
lymphocyt
count
increas
median
rang
lymphocyt
prolifer
becam
normal
fifth
patient
girl
congenit
immun
defici
type
associ
system
lupu
erythematosu
optic
atrophi
maculopathi
neurolupu
antiphospholipid
syndrom
nt
receiv
earli
bone
marrow
transplant
develop
wart
herp
viru
type
cutan
infect
superinfect
staphilococcu
aureu
pseudomona
aeruginosa
candida
albican
cutan
lymphoma
conclus
allogen
bone
marrow
transplant
defici
result
immunolog
reconstitut
revers
hie
featur
nt
eventfre
experi
show
import
correct
time
bone
marrow
transplant
patient
conflict
interest
author
conflict
interest
declar
hacettep
univers
faculti
medicin
pediatr
immunolog
ankara
turkey
hacettep
univers
faculti
medicin
pediatr
allergi
immunolog
ankara
turkey
hacettep
univers
faculti
medicin
ankara
turkey
marmara
univers
pendik
train
research
hospit
pediatr
allergi
immunolog
turkey
medic
univers
vienna
pediatr
hematolog
oncolog
immunolog
vienna
austria
duke
univers
school
medicin
duke
medic
center
rheumatolog
immunolog
durham
nc
unit
state
background
adenosin
deaminas
ada
defici
autosom
recess
primari
immunodefici
time
metabol
disord
lead
accumul
toxic
metabolit
purin
pathway
ada
defici
account
sever
combin
immunodefici
scid
gener
patient
present
first
month
life
manifest
recurr
opportunist
fungal
viral
bacteri
infect
lymphopenia
failur
thrive
late
onset
form
diseas
also
known
manifest
appear
milder
aim
studi
evalu
outcom
ada
defici
patient
clinic
laboratori
find
ert
hematopoiet
stem
cell
transplant
hsct
gene
therapi
method
twelv
patient
ada
defici
follow
hacettep
univers
pediatr
immunolog
nine
diagnos
scid
dignos
late
onset
ada
defici
cliinic
laboratori
find
cid
immunophenotyp
done
flow
cytometri
ada
enzym
activ
metabolit
measur
found
defect
sanger
sequenc
ada
gene
perform
result
age
onset
vari
month
year
nine
patient
put
pegyl
ada
enzym
replac
therapi
ert
two
born
ert
one
die
quickli
could
given
use
definit
period
hsct
gene
therapi
two
patient
lateonset
ada
defici
ert
still
use
suffici
control
symptom
addit
ivig
prophylact
atibacteri
therapi
one
patient
ada
defici
ert
insuffici
control
immunodefici
symptom
four
transplant
match
famili
donor
without
condit
aliv
one
transplant
match
unrel
donor
condit
therapi
die
soon
hsct
gene
therapi
perform
one
four
two
diagnos
ert
donor
one
hsct
die
one
tranplant
aliv
patient
poliposi
coli
need
ivig
albumin
therapi
also
hsct
f
ivig
therapi
stop
one
gene
therapi
perform
well
aliv
ivig
therapi
conclus
genet
diagnosi
scid
cid
utmost
import
chanc
give
ert
plan
definit
therapi
patient
ada
defici
enzym
replac
therapi
succes
patient
partial
ada
defici
present
featur
combin
immunodefici
although
ert
insuffici
control
symptom
sever
ada
defici
use
short
period
gain
time
definit
therapi
hsct
gene
therapi
associ
diseas
protein
loss
possibl
stop
ivig
therapi
hsct
perform
without
condit
therapi
clinic
trial
registri
conflict
interest
noth
disclos
king
hussein
cancer
center
amman
jordan
background
hemophagocyt
lymphohistiocytosi
hlh
hyperinflammatori
syndrom
high
mortal
even
appropri
treatment
allogen
hematopoiet
cell
transplant
hct
consid
cur
treatment
patient
primari
hlh
report
surviv
rang
method
retrospect
analyz
outcom
cohort
patient
diagnos
primari
hlh
king
hussein
cancer
center
khcc
result
identifi
patient
male
femal
median
age
diagnosi
month
rang
patient
chediakhigashi
griscelli
syndrom
six
patient
famili
histori
hlh
ident
twin
boy
develop
diseas
simultan
cn
involv
diagnosi
present
one
patient
patient
receiv
standard
immunochemotherapi
per
protocol
eleven
patient
underw
hct
median
age
hct
month
rang
median
time
diagnosi
hct
month
rang
time
hct
patient
achiev
pr
patient
cr
seven
patient
receiv
myeloabl
condit
busulfan
cyclophosphamid
rabbit
antithymocyt
globulin
atg
etoposid
four
patient
receiv
reduc
intens
condit
fludarabinemelphalanatg
thiotepa
fludarabin
cyclophosphamid
atg
donor
hlamatch
sibl
patient
unrel
cord
blood
patient
median
time
neutrophil
platelet
engraft
day
rang
day
rang
respect
acut
gvhd
develop
patient
grade
iii
patient
limit
chronic
gvhd
develop
median
follow
surviv
patient
primari
hlh
post
hct
month
rang
nine
patient
aliv
last
follow
overal
surviv
event
free
surviv
two
patient
die
one
day
post
hct
due
cmv
infect
patient
relaps
day
post
hct
die
diseas
surviv
patient
patient
mix
donor
chimer
full
donor
chimer
note
patient
nine
patient
immun
suppress
immun
reconstitut
studi
avail
seven
patient
six
patient
normal
lymphocyt
subset
one
patient
low
b
cell
count
conclus
primari
hlh
fatal
diseas
make
definit
diagnosi
essenti
allogen
hematopoiet
stem
cell
transplant
hct
cur
treatment
prospect
studi
warrant
valid
previou
find
genet
studi
help
guid
definit
therapi
earli
referr
transplant
famili
counsel
conflict
interest
mayada
abu
shanap
noth
disclos
dmitri
rogachev
nation
research
centr
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
nb
dna
repair
disord
low
dose
busulfan
base
condit
usual
use
hematopoiet
stem
transplant
nb
patient
safeti
efficaci
demonstr
patient
anoth
dna
repair
defect
fanconi
anemia
treosulfan
new
alkyl
agent
thu
far
report
use
treosulfan
contain
condit
hsct
dna
repair
disord
method
octob
novemb
hsct
deplet
graft
perform
center
nb
patient
slavic
homozyg
mutat
median
age
hsct
year
malefemal
ratio
patient
indic
hsct
malign
immunodefici
autoimmun
infecti
complic
patient
transplant
match
unrel
includ
second
hsct
relat
sibl
donor
patient
busulfan
bu
base
condit
use
bu
fludarabin
flu
cyclophosphamid
cy
new
approach
treosulfan
treo
use
patient
receiv
combin
flu
second
hsct
flu
cy
patient
receiv
thymoglobulin
rituximab
gvhd
prophylaxi
includ
tacrolimu
patient
short
cours
methotrex
result
patient
bu
contain
condit
primari
engraft
bu
contain
condit
well
toler
patient
grade
acut
gvhd
gut
patient
die
adenovir
hepat
lymphoma
relaps
unfortun
patient
reject
graft
median
time
reject
month
hsct
second
hsct
die
high
grade
lymphoma
go
receiv
second
transplant
sinc
januari
patient
receiv
treo
contain
condit
engraft
date
median
fu
month
observ
earli
complic
drug
induc
organ
damag
gvhd
sever
infect
hsct
one
patient
treoflu
condit
mix
predominantli
donor
chimer
patient
addit
cy
full
donor
chimer
last
fu
conclus
herein
report
first
experi
safeti
efficaci
low
dose
treosulfan
contain
condit
hsct
graft
deplet
patient
dna
repair
disord
also
report
good
toler
second
transplant
reduc
intens
condit
nb
patient
conflict
interest
noth
disclos
univers
health
scienc
ankara
child
health
diseas
hematolog
oncolog
train
research
hospit
pediatr
hematolog
oncolog
ankara
turkey
baskent
univers
medic
faculti
pediatr
hematolog
oncolog
ankara
turkey
baskent
univers
medic
faculti
pediatr
gastroenterolog
hepatolog
nutrit
ankara
turkey
background
famili
hemophagocyt
lymphohistiocytosi
hlh
fatal
disord
may
progress
acut
fulmin
liver
failur
report
concern
hematopoiet
stem
cell
transplant
hsct
liver
transplant
patient
acquir
aplast
anemia
experi
patient
hlh
limit
present
child
hlh
underw
success
hsct
orthotop
liver
transplant
olt
method
characterist
patient
transplant
treatment
record
result
girl
present
acut
liver
failur
underw
olt
haploident
father
afterward
liver
patholog
disclos
find
hlh
molecular
analysi
reveal
homozyg
syntaxin
mutat
olt
treat
hlh
direct
therapi
experienc
posterior
revers
encephalopathi
syndrom
pre
manag
antiepilept
treatment
underw
hsct
month
olt
hlamatch
sibl
heterozyg
mutat
receiv
reduc
intens
condit
fludarabin
busulfan
qid
target
area
curv
auc
mgl
x
h
antithmocyt
globulin
mgkgtotal
nacetylcystein
nac
appli
condit
order
prevent
liver
toxic
defibrotid
ursodeoxychol
acid
prophylact
appli
order
prevent
sinu
obstruct
syndrom
so
day
bone
marrow
harvest
yield
nucleat
cell
cell
given
patient
cyclosporin
target
ngml
methotrex
use
graft
versu
host
diseas
gvhd
prophylaxi
earli
posttranspl
period
unev
except
mild
increas
liver
transaminas
day
alt
ul
ast
ul
short
cours
methylprednisolon
given
instead
methotrex
myeloid
thrombocyt
recoveri
occur
day
respect
experienc
gvhd
organ
toxic
febril
neutropenia
fungal
viral
infect
experienc
epilept
seizur
month
hsct
without
clinic
laboratori
find
hlh
chang
immunosuppress
treatment
cyclosporin
everolimu
target
ngml
seizur
control
last
month
analysi
reveal
donor
chimer
day
month
respect
stil
well
month
hsct
conclus
limit
experi
literatur
concern
subsequ
olt
hsct
differ
donor
although
patient
three
differ
hla
group
somat
liver
bone
marrow
experienc
gvhd
liver
reject
believ
reduc
intens
condit
contain
low
busulfan
dose
prophylaxi
contain
nac
defibrotid
prevent
so
orthotop
liver
reduc
intens
condit
suffici
provid
donor
chimer
without
gvhd
organ
toxic
conflict
interest
none
author
anyth
disclos
dr
von
hauner
univers
children
hospit
munich
germani
background
allogen
hematopoiet
stem
cell
transplant
hsct
match
relat
unrel
donor
result
excel
cure
rate
around
children
inborn
nonmalign
disord
patient
lack
match
donor
use
mismatch
haploident
famili
donor
histor
associ
inferior
outcom
due
reject
gvhd
infecti
complic
invivo
tcell
deplet
posttranspl
cyclophosphamid
ptci
shown
result
outcom
compar
match
famili
unrel
donor
adult
malign
diseas
explor
use
combin
upfront
serotherapi
establish
reduc
toxic
myeloabl
condit
regimen
children
nonmalign
diseas
method
describ
institut
experi
eleven
patient
receiv
tcell
replet
haploident
parent
bone
marrow
graft
median
age
year
rang
four
patient
suffer
primari
immunodefici
ipex
syndrom
defici
xiap
pnp
defici
five
patient
sickl
cell
diseas
scd
two
thalassaemia
one
patient
undergon
previou
unsuccess
hsct
graft
contain
median
total
nucleat
cell
condit
consist
alemtuzumab
fludarabin
treosulfan
thiotepa
cyclophosphamid
patient
except
one
pnp
receiv
submyeloabl
busulfan
auc
instead
treosulfanthiotepa
five
patient
receiv
rituximab
three
pretranspl
plasmapheresi
presenc
antidonor
hla
antibodi
gvhd
prophylaxi
consist
cyclophosphamid
day
follow
mmf
tacrolimu
result
median
followup
month
patient
aliv
patient
donor
chimer
two
patient
experienc
secondari
graft
loss
autolog
reconstitut
one
retranspl
success
donor
pnp
one
aliv
diseas
scd
neutrophil
platelet
engraft
occur
day
median
respect
tcell
immun
reconstitut
time
median
cell
day
cell
day
seven
cmv
reactiv
one
vzv
reactiv
cmv
diseas
observ
one
patient
experienc
mild
vod
acut
gvhd
limit
overal
grade
skin
two
patient
chronic
gvhd
observ
conclus
experi
ptci
haplo
approach
contain
upfront
serotherapi
result
excel
engraft
absenc
sever
gvhd
relev
transplant
relat
morbid
mortal
children
nonmalign
diseas
ptci
haplo
strategi
may
compar
favour
respect
technic
financi
demand
vitro
tcell
deplet
strategi
yet
larger
prospect
prefer
compar
studi
warrant
evalu
approach
clinic
trial
registri
na
conflict
interest
author
declar
conflict
interest
ankara
univers
faculti
medicin
hematolog
ankara
turkey
hacettep
univers
faculti
medicin
pediatr
immunolog
ankara
turkey
ankara
univers
faculti
medicin
intern
medicin
ankara
turkey
ankara
univers
faculti
medicin
pediatr
immunolog
ankara
turkey
background
primari
immunodefici
pid
associ
recurr
infect
multipl
microbi
agent
thought
rare
condit
neglect
mani
year
howev
awar
among
pediatrician
help
us
notic
impor
pid
huge
heterogen
underli
convent
phenotyp
major
pid
inherit
autosom
recess
ar
form
prevel
pid
diseas
high
turkey
high
consanguin
marriag
high
fertil
lead
factor
hematopoiet
stem
cell
transplant
hsct
mostli
perform
chilhood
aim
present
first
time
report
allogen
hsct
match
unrel
donor
mud
adult
patient
diagnos
isol
deficieni
due
induc
cell
kinas
itk
gene
mutat
method
patient
year
old
male
born
mother
marri
matern
cousin
one
brother
two
sister
known
immun
defici
statu
despit
patient
signific
medic
histori
recurr
infect
confirm
immun
defici
delay
thu
transplant
rel
older
age
condit
nonmyeloabl
regimen
contatin
fludarabin
day
busulfan
mgkgday
day
busulfan
dose
calcul
consid
pharmacokinet
data
includ
area
curv
auc
assess
donor
hla
match
unrel
donor
graft
versu
host
diseas
gvhd
prophylaxi
involv
cyclosporin
mgkgday
mycophenol
mofetil
mgkgday
antithymocyt
globulin
dose
mgkgday
day
result
follow
lower
respiratori
symptom
perian
infect
imipenem
teicoplanin
given
sputum
cultur
reveal
pseudomona
aeruginosa
also
order
prophylact
intraven
immunoglobulin
ivig
gkg
weekli
viral
load
ebv
cmv
weekli
screen
pcr
due
increas
cmv
viral
load
copiesml
patient
order
parenter
ganciclovir
dose
mgkgday
ebv
viral
load
also
high
peak
copiesml
spontan
regress
observ
engraft
neutrophil
platelet
engraft
took
place
day
respect
requir
three
unit
pack
red
blood
cell
posttransplant
period
donor
chimer
day
found
distribut
lymphocyt
subtyp
flow
cytometr
analysi
demonstr
tcell
bcell
conclus
time
hsct
pid
diseas
adulthood
consid
rather
late
howev
hsct
yet
offer
cur
potenti
without
caus
seriou
toxic
due
condit
regimen
increas
rate
infect
neutropen
period
patient
strictli
followedup
risk
acutechron
gvhd
although
observ
gvhd
case
long
term
effect
immunosupress
treatment
among
patient
also
seriou
concern
clinic
trial
registri
applicapl
conflict
interest
none
author
anyth
disclos
bmt
unit
feder
univers
parana
curitiba
brazil
hospit
infantil
pequeno
princip
curitiba
brazil
hospit
nossa
senhora
da
curitiba
brazil
hospit
israelita
albert
einstein
sao
paulo
brazil
hospit
samaritano
de
sao
paulo
sao
paulo
brazil
hospit
de
da
universidad
feder
rio
grand
sul
porto
alegr
brazil
preto
medic
school
univers
paulo
ribeirao
preto
brazil
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
background
absenc
unaffect
match
sibl
altern
donor
transplant
may
cur
varieti
primari
immunodefici
pid
use
ptci
significantli
decreas
upfront
cost
haploident
hematopoiet
stem
cell
transplant
hsct
allow
use
worldwid
result
strategi
treat
pid
howev
unknown
aim
studi
analyz
outcom
children
pid
hsct
altern
donor
use
ptci
gvhd
prophylaxi
method
multicent
retrospect
studi
transplant
patient
pt
pt
transplant
brazilian
bmt
center
median
age
month
rang
month
year
male
diagnosi
scid
wiskottaldrich
syndrom
cgd
hlh
one
kostmann
syndrom
lrba
lad
ipex
chediakhigashi
altern
donor
includ
haploident
relat
donor
relat
donor
match
unrel
donor
bone
marrow
use
hsct
gvhd
prophylaxi
includ
ptci
associ
calcineurin
inhibitor
mycophenol
mofetil
pt
activ
infect
failur
thrive
sever
autoimmun
complic
transplant
four
scid
transplant
mechan
ventil
upfront
transplant
transplant
perform
rescu
pt
primari
secondari
graft
failur
alreadi
haploident
hsct
ptci
result
median
followup
year
rang
day
pt
aliv
overal
surviv
os
os
scid
pid
p
ns
eighteen
pt
receiv
ric
regimen
upfront
hsct
aliv
well
one
second
haploident
hsct
mix
chimer
frequent
evalu
pt
graft
failur
import
complic
ric
group
primari
graft
failur
pgf
progress
loss
donor
chimer
longterm
survivor
fourteen
pt
receiv
busulfanbas
regimen
upfront
transplant
achiev
full
donor
chimer
aliv
well
one
pt
cgd
develop
pgf
die
due
dissemin
fungal
infect
second
unrel
cord
blood
hsct
pt
rescu
primari
secondari
graft
failur
hsct
receiv
ric
regimen
aliv
full
donor
chimer
altogeth
pt
die
median
day
transplant
rang
progress
loss
donor
chimer
associ
sever
infect
major
caus
death
group
conclus
allohct
use
altern
donor
ptci
promis
cure
pid
best
condit
regimen
yet
defin
sinc
pt
refer
countri
dissemin
bcgit
andor
sever
bacteri
viral
fungal
infect
earli
diagnosi
delay
bcg
vaccin
could
improv
outcom
patient
conflict
interest
author
declar
conflict
interest
abstract
previous
publish
abstract
previous
publish
infecti
complic
divis
stem
cell
transplant
immunotherapi
medic
depart
kiel
germani
helio
kliniken
schwerin
hematolog
oncolog
stem
cell
transplant
schwerin
germani
background
recent
new
insight
mechan
immun
reconstitut
allogen
transplant
made
microbiom
gut
play
import
role
may
respons
mani
infecti
complic
transplant
might
also
relev
develop
gvhd
new
strategi
gut
decontamin
use
rifaximin
antibiot
select
activ
convent
drug
tri
prevent
bacteri
infect
without
disrupt
put
help
probiot
center
chang
convent
gut
decontamin
gd
ciprofloxacin
colistin
unconvent
gd
rifaximin
patient
receiv
allogen
stem
cell
transplant
present
comparison
strategi
method
studi
consecut
patient
includ
underw
allogen
stem
cell
transplant
februari
june
center
convent
gd
decontamin
use
patient
treat
rifaximin
patient
characterist
group
compar
regard
median
age
diseas
condit
regimen
stem
cell
sourc
donor
characterist
follow
endpoint
analyz
compar
strategi
gd
decontamin
fever
bacteremia
infect
interest
clostridium
difficil
multiresist
germ
septic
death
acut
chronic
gvhd
rate
relaps
surviv
result
overal
surviv
rate
cohort
nearli
similar
convent
gd
decontamin
rifaximin
treatment
signific
differ
found
endpoint
address
infecti
complic
includ
rate
septic
death
although
rate
bacteremia
slightli
higher
rifaximin
group
compar
convent
gd
decontamin
cohort
versu
interestingli
one
infect
clostridium
difficil
found
rifaximin
group
wherea
case
observ
convent
gd
decontamin
statist
signific
rate
acut
gvhd
tend
lower
group
treat
rifaximin
compar
convent
gd
decontamin
cohort
achiev
statist
signific
wherea
rate
chronic
gvhd
compar
differ
rate
relaps
note
conclus
unconvent
gut
decontamin
rifaximin
feasibl
seem
prevent
infect
clostridium
difficil
effect
convent
strategi
howev
test
potenti
benefit
approach
prospect
studi
random
treatment
group
warrant
conflict
interest
none
ghent
univers
hospit
pediatr
hematolog
oncolog
stem
cell
transplant
ghent
belgium
ghent
univers
hospit
centrum
molecular
diagnos
ghent
belgium
ghent
univers
hospit
pharmaci
pediatr
hematooncolog
stem
cell
transplant
ghent
belgium
background
human
adenoviru
hadv
dna
genom
portion
viral
dna
persist
host
cell
viral
replic
stop
either
circular
extra
chromosom
integr
host
dna
hadv
persist
epitheli
cell
lymphoid
tissu
caus
reactiv
immunosuppress
hadv
viremia
frequent
observ
hematopoiet
stem
cell
transplant
hsct
associ
morbid
mortal
children
method
data
consecut
transplant
pediatr
patient
patient
underw
allogen
allo
autolog
auto
hsct
ghent
univers
hospit
period
januari
august
present
patient
follow
quantit
pcr
start
condit
least
day
longer
case
complic
pcr
method
use
follow
instruct
manufactur
adv
viru
rgene
tm
realtim
pcr
detect
system
biorad
gener
extract
protocol
nuclisen
result
eleven
patient
underw
auto
hsct
high
risk
solid
tumor
mostli
brain
tumor
neuroblastoma
condit
regimen
accord
standard
protocol
none
autolog
transplant
pt
experienc
adenoviru
reactiv
allogen
set
pt
underw
hsct
thirtyeight
receiv
graft
match
unrel
donor
mud
sibl
haploident
parent
extens
tcell
deplet
condit
regimen
myeloabl
allohsct
allogen
group
hadv
viremia
frequent
found
hadv
viremia
level
found
allohsct
allohsct
found
viremia
copiesml
viral
load
copiesml
patient
symptom
hadv
diseas
patient
die
hadv
immunosuppress
therapi
taper
whenev
possibl
accept
respons
decreas
viremia
case
three
patient
need
cidofovir
order
control
hadv
two
patient
activ
hadv
viremia
die
invas
aspergillu
fumigatu
infect
one
case
sever
gvhd
hadv
viremia
observ
mud
transplant
vivo
tcell
deplet
atg
remarkebl
pt
underw
cell
deplet
haploident
transplant
experi
hadv
howev
might
due
low
number
patient
hadv
viremia
earli
event
hsct
whole
cohort
mean
time
detect
day
patient
hadv
detect
day
much
longer
higher
level
viremia
reactiv
day
ttest
p
conclus
hadv
infect
still
problem
pediatr
hsct
recommend
weekli
monitor
pcr
hadv
mud
pt
pt
high
viral
load
taper
immunosuppress
usual
suffici
pt
earli
onset
rapid
evolv
hadv
viremia
preemptiv
therapi
cidofovir
must
consid
clinic
trial
registri
na
conflict
interest
none
hospit
universitario
la
paz
pediatr
hematooncolog
madrid
spain
univers
hospit
nanci
allogen
hematopoiet
stem
cell
transplant
unit
depart
hematolog
franc
fondazion
ircc
policlinico
san
matteo
pediatr
hematolog
oncolog
pavia
itali
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
berlin
depart
pediatr
oncologyhematologystem
cell
transplant
berlin
germani
chimerix
durham
nc
unit
state
analyticalas
new
york
ny
unit
state
background
allogen
hematopoiet
cell
transplant
allohct
resourceintens
procedur
necessit
prolong
stay
hospit
posttranspl
adenoviru
adv
infect
posttranspl
period
potenti
prolong
transplant
hospit
may
lead
readmiss
order
assess
potenti
impact
adv
infect
healthcar
util
analyz
durat
hospit
among
pediatr
allohct
recipi
without
adv
infect
larg
multicent
studi
method
advanc
multicent
multin
studi
incid
manag
clinic
outcom
adv
infect
adult
pediatr
allohct
recipi
across
europ
studi
conduct
retrospect
includ
recipi
allohct
januari
septemb
analysi
pediatr
allohct
recipi
year
adv
infect
diagnos
first
month
transplant
identifi
hospit
categor
transplant
hospit
readmiss
hospit
discharg
transplant
hospit
hospit
categor
accord
whether
adv
note
discharg
summari
posit
adv
test
note
hospit
hospit
patient
die
analyz
separ
two
subgroup
hospit
posit
adv
test
note
also
analyz
viremia
clinic
relev
viremia
copiesml
blood
result
overal
pediatr
allohct
patient
includ
adv
infect
within
month
follow
allohct
develop
viremia
median
length
stay
transplant
hospit
day
patient
adv
viremia
day
clinic
relev
viremia
copiesml
see
tabl
contrast
patient
without
adv
infect
transplant
hospit
median
length
stay
day
p
readmiss
median
length
stay
also
longer
patient
adv
viremia
viremia
copiesml
compar
patient
adv
analysi
patient
reach
clinic
relev
viremia
copiesml
hospit
longest
durat
stay
transplant
hospit
subsequ
readmiss
conclus
adv
infect
pediatr
allohct
recipi
associ
signific
medic
resourc
util
measur
durat
hospit
stay
pediatr
allohct
recipi
clinic
relev
adv
viremia
stay
hospit
day
longer
without
adv
infect
transplant
hospit
mandat
screen
identif
monitor
treatment
adv
infect
like
signific
clinic
econom
impact
patient
popul
conflict
interest
c
pochon
zecca
k
rao
voigt
investig
advanc
studi
sponsor
chimerix
e
vainoriu
brundag
e
mozaffari
g
nichol
employe
studi
sponsor
chimerix
j
meng
employe
analyticalas
research
consult
conduct
studi
behalf
sponsor
chimerix
pediatr
oncohaematolog
bmt
unit
pediatr
chidren
hospit
brescia
brescia
itali
otorhinolaryngolog
pediatr
children
hospit
brescia
brescia
itali
stem
cell
laboratori
section
hematolog
blood
coagul
children
hospit
spedali
civili
brescia
brescia
itali
background
acut
invas
fungal
potenti
fatal
infect
immunocompromis
patient
bone
marrow
transplant
recipi
although
candida
aspergillu
common
fungal
isol
less
common
pathogen
alternaria
speci
emerg
opportunist
agent
associ
clinic
syndrom
method
describ
case
year
old
child
affect
sever
aplast
anaemia
character
sever
leukopenia
thrombocytopenia
anaemia
develop
alternaria
infect
parasan
sinus
aplasia
phase
second
match
unrel
bone
marrow
transplant
patient
underw
first
urgent
haploident
pbsc
transplant
worsen
respiratori
distress
requir
picu
admiss
noninvas
ventil
support
condit
perform
tbi
rd
fludarabin
cyclophosphamid
atg
cyclophosphamid
fluconazol
use
antifung
prophylaxi
unfortun
secondari
graft
failur
occur
recurr
sever
leukopenia
second
bone
marrow
transplant
plan
match
unrel
donor
condit
fludarabin
tbi
rd
cyclophosphamid
atg
well
toler
peripher
posit
select
cell
infus
condit
day
patient
complain
pain
upper
dental
arch
right
cheek
evid
swell
mild
gingiv
note
site
pain
day
transplant
due
appear
fever
worsen
symptom
ct
scan
paranas
sinus
brain
perform
secret
sphenoid
frontal
maxillari
sinus
ethmoid
eros
detect
find
compat
mycot
osteonecrosi
paranas
sinus
prompt
endoscop
surgeri
perform
day
procedur
includ
intranas
antrotomi
right
sphenoidotomi
frontal
senotomi
partial
ethmoidectomi
patholog
analysi
demonstr
necrot
tissu
fungal
hypha
ongo
antifung
therapi
micafungin
enhanc
oral
posaconazol
daili
liposom
amphotericin
b
cultur
examin
secret
lead
diagnosi
alternaria
alternata
infect
micafungin
stop
accord
sensit
profil
result
pain
fever
quickli
disappear
surgic
intervent
surgic
debrid
necessari
order
achiev
complet
resolut
complic
neutrophil
platelet
engraft
day
respect
antifung
combin
therapi
carri
six
month
patient
heal
aplast
anaemia
sequela
relat
infect
conclus
rapid
recoveri
neutrophil
count
extens
aggress
treatment
includ
surgic
debrid
antifung
combin
therapi
essenti
overcom
potenti
fatal
complic
refer
alternaria
altern
invas
fungal
infect
patient
fanconi
anemia
unrel
bone
marrow
transplant
clin
drug
investig
feb
vol
suppl
pediatr
invas
fungal
rhinosinus
immunocompromis
children
cancer
otolaryngol
head
neck
srg
sep
conflict
interest
author
conflict
interest
declar
depart
clinic
pediatr
oncolog
haematolog
bone
marrow
transplant
medic
univers
wroclaw
wroclaw
poland
depart
clinic
pediatr
oncolog
haematolog
collegium
medicum
bydgoszcz
bydgoszcz
poland
depart
microbiolog
medic
univers
bydgoszcz
bydgoszcz
poland
depart
immunolog
clinic
transplantolog
collegium
medicum
krakow
poland
depart
pediatr
oncolog
haematolog
bone
marrow
transplant
poznan
medic
univers
poznan
poland
depart
pediatr
oncolog
haematolog
bone
marrow
transplant
medic
univers
lublin
lublin
poland
background
fungal
infect
becom
one
main
caus
morbid
mortal
children
hematopoiet
stem
cell
transplant
hsct
main
risk
factor
prolong
neutropenia
broadspectrum
antibiot
aim
studi
analyz
incid
outcom
invas
fungal
infect
polish
pediatr
hematopoiet
stem
cell
transplant
center
period
month
year
method
total
number
patient
receiv
hsct
group
consist
children
diagnos
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
aml
hodgkin
lymphoma
hl
nonhodgkin
lymphoma
nhl
sever
aplast
anemia
saa
myelodysplast
syndrom
md
solid
tumor
st
nonhematolog
diseas
result
period
ifi
diagnos
ifi
diagnos
year
case
year
median
age
year
sever
neutropenia
present
patient
proven
ifi
found
case
probabl
ifi
diagnos
patient
cultur
proven
agent
candida
spp
aspergillu
spp
fusarium
spp
mucor
wherea
proven
ifi
identifi
histopatholog
among
proven
ifi
lung
frequent
affect
organ
involv
ifi
follow
paranas
sinus
case
gastrointestin
tract
liver
spleen
case
genitourinari
tract
two
antifung
prophylaxi
consist
posakonazol
fluconazol
caspofungin
voriconazol
liposom
amphotericin
b
micafungin
case
antifung
prophylaxi
use
death
due
ifi
main
reason
death
progress
malign
multiorgan
failur
conclus
incid
ifi
decreas
turn
year
probabl
due
effect
antifung
prophylaxi
common
site
ifi
remain
respiratori
tract
major
pediatr
patient
hsct
ppifi
surviv
prospect
studi
requir
assess
impact
antifung
prophylaxi
surviv
conflict
interest
none
ege
univers
medic
faculti
hematolog
depart
izmir
turkey
background
invas
fungal
infect
ifi
one
preval
reason
morbid
mortal
patient
hematolog
malign
either
receiv
chemotherapi
hematopoiet
stem
cell
transplant
hsct
fluconazol
one
drug
antifung
prophylaxi
hsct
order
reduc
recurr
prior
ifi
secondari
prophylaxi
requir
voriconazol
effect
also
secondari
prophylaxi
hsct
patient
method
retrospect
evalu
patient
hematolog
diseas
undergo
autolog
autohsct
allogen
hsct
ahsct
ege
univers
hematolog
depart
bone
marrow
transplant
unit
ifi
classifi
accord
eortc
criteria
possibl
probabl
proven
probabl
ifi
need
certain
microbiolog
criteria
eg
serum
galactomannan
host
factor
clinic
featur
wherea
proven
ifi
requir
histopatholog
find
posit
cultur
primari
steril
site
rather
microbiolog
criteria
possibl
ifi
defin
case
highli
like
caus
fungal
etiolog
although
mycolog
evid
lackinggalactomannan
test
perform
biweekli
hospit
complet
respons
defin
resolut
sign
ifi
partial
respons
clinic
radiolog
improv
resolut
attribut
symptom
sign
fungal
diseas
radiolog
stabil
equat
partial
respons
stabl
respons
defin
minor
improv
sign
diseas
radiolog
stabil
wherea
progress
diseas
defin
worsen
clinic
symptom
sign
diseas
new
site
diseas
radiolog
worsen
preexist
lesion
result
autohsct
ahsct
patient
evalu
three
patient
autohsct
ahsct
group
receiv
voriconazol
prophylaxi
patient
characterist
summar
tabl
patient
time
fungal
infect
induct
chemotherapi
transplant
patient
activ
fungal
infect
hsct
one
patient
patholog
microbiolog
proven
fungal
infect
mucormicosi
sinus
success
treat
eight
patient
respond
well
secondari
voriconazol
prophylaxi
breakthrough
infect
one
patient
mildli
elev
liver
enzym
voriconazol
administr
conclus
studi
group
voriconazol
success
prevent
breakthrough
infect
show
voriconazol
effect
safe
secondari
prophylaxi
hsct
need
comprehens
studi
patient
conflict
interest
author
whose
name
list
certifi
affili
involv
organ
entiti
financi
interest
nonfinanci
interest
abstract
imperi
colleg
london
haematolog
london
unit
kingdom
background
cmv
infect
diseas
manag
preemptiv
antivir
therapi
strategi
associ
signific
morbid
subsequ
econom
burden
method
analys
consecut
patient
undergo
allogen
stem
cell
transplant
allosct
risk
cmv
infect
patient
andor
donor
cmv
seroposit
focus
incid
cmv
infect
healthcar
resourc
util
estim
length
inpati
stay
recurr
hospit
rate
result
median
age
year
male
cmv
serolog
recipientdonor
distinguish
group
pospo
posneg
negpo
transplant
condit
myeloabl
reduc
intens
donor
type
hlaident
sibl
match
unrel
mismatch
unrel
haploident
donor
tcell
deplet
alemtuzumab
perform
patient
manag
preemptiv
therapi
cmv
reactiv
confirm
consecut
pcr
sampl
cmv
reactiv
occur
patient
median
day
post
sct
case
cmv
reactiv
median
day
diagnosi
gvhd
acut
gvhd
develop
patient
cmv
reactiv
median
day
post
allosct
system
steroid
start
patient
median
day
cmv
reactiv
total
patient
receiv
antivir
therapi
per
preemptiv
protocol
intraven
ganciclovir
given
first
line
antivir
therapi
patient
foscarnet
given
oral
valganciclovir
cidofovir
patient
three
patient
receiv
anticmv
therapi
median
time
cmv
reactiv
start
antivir
therapi
day
patient
start
antivir
within
hour
reactiv
median
durat
antivir
therapi
day
overal
respons
antivir
therapi
complet
remiss
neg
cmvpcr
partial
respons
reduct
cmv
pcr
copi
patient
die
respons
could
evalu
ganciclovir
foscarnet
respect
respons
rate
accord
differ
initi
treatment
ganciclovir
cr
pr
foscarnet
cr
pr
valganciclovir
cr
pr
total
patient
requir
secondlin
antivir
therapi
patient
partial
respons
patient
cr
patient
second
cmv
reactiv
cmv
relaps
addit
patient
chang
initi
antivir
differ
reason
renal
toxic
intoler
deescal
oral
valganciclovir
total
patient
requir
rehospitalis
treatment
cmv
reactiv
patient
risk
cmv
reactiv
median
number
day
hospit
conclus
cmv
infect
occur
patient
risk
respons
first
line
antivir
satisfactori
although
signific
risk
relaps
anticmv
therapi
impact
healthcar
resourc
high
rate
rehospitalis
conflict
interest
noth
disclos
bone
marrow
transplant
unit
depart
clinic
experiment
scienc
univers
brescia
brescia
itali
hematolog
bone
marrow
transplant
unit
ircc
san
raffael
scientif
institut
vitasalut
san
raffael
univers
milano
itali
sapienza
univers
depart
cellular
biotecholog
hematolog
policlinico
umberto
rome
itali
background
cmv
repres
one
seriou
lifethreaten
complic
allogen
stem
cell
transplantaion
allosct
preemptiv
treatment
anticmv
drug
highli
effect
toxic
repetit
reactiv
cmv
repres
major
challeng
clinic
practic
use
anticmv
specif
immunoglobulin
megalotect
controversi
method
retrospect
collect
data
patient
hematolog
malign
submit
allosct
italian
bone
marrow
transplant
unit
onehundr
fifteen
patient
develop
least
one
cmv
reactiv
cmv
copi
median
day
rang
transplant
case
megalotect
use
follow
schedul
patient
receiv
uikg
weekli
patient
ukg
everi
week
patient
uikg
everi
week
cmv
viremia
neg
megalotect
ad
highrisk
patient
base
haploident
allosct
steroid
therapi
agvhd
unfavor
cmv
serolog
combin
dr
case
dr
case
case
megalotect
use
preemptiv
therapi
case
prophylaxi
moreov
specif
anticmv
drug
use
firstlin
togeth
megalotect
case
foscarnet
case
valgancyclovir
case
gancyclovir
case
result
overal
treatment
well
toler
report
infus
reaction
advers
event
megalotect
administ
median
dose
rang
dose
rang
patient
treat
preemptiv
prophylact
focus
case
treat
megalotect
preemptiv
patient
except
achiev
least
one
cmv
viremia
neg
tratment
median
time
first
neg
day
rang
case
secondlin
treatment
use
median
interv
subsequ
anticmv
treatment
first
neg
day
rang
patient
mainten
treatment
megalotect
alon
abl
control
persist
lowlevel
cmv
viremia
copiesml
without
anticmv
specif
treatment
focus
case
treat
megalotect
prophylaxi
patient
develop
cmv
reactiv
treat
gancyclovir
respons
interestingli
highrisk
patient
cmv
diseas
observ
case
pneumon
case
coliti
conclus
preliminari
experi
megalotect
suggest
safe
well
toler
preemptiv
prophylaxi
set
conclus
data
regard
efficaci
treatment
reduc
cumul
dose
anticmv
specif
drug
interestingli
use
preemptiv
therapi
megalotect
abl
maintain
low
level
cmv
viremia
allow
spare
drug
toxic
case
prospect
random
trial
warrent
address
specif
issu
particulari
patient
highrisk
multipl
cmv
reactiv
cmv
diseas
conflict
interest
malagola
j
peccatori
iori
advisori
board
biotest
carol
davila
univers
medicin
pediatr
hematolog
bmt
bucharest
romania
carol
davila
univers
medicin
pediatr
bucharest
romania
carol
davila
univers
medicin
bucharest
romania
fundeni
clinic
institut
bucharest
romania
background
bk
viru
polyomavirida
famili
usual
affect
individu
mainli
childhood
remain
latent
urotheli
cell
bkv
reactiv
hsct
allotranspl
recipi
may
differ
present
rang
complet
asymptomat
sever
hemorrhag
cystiti
hc
rare
patient
develop
nephriti
pneumonia
cn
diseas
aim
studi
evalu
patient
bkv
reactiv
allogen
hsct
order
analyz
incid
sever
risk
factor
outcom
viral
reactiv
singl
center
method
retrospect
analyz
pediatr
patient
bkv
reactiv
admit
fundeni
clinic
institut
diagnosi
viral
reactiv
establish
base
bkv
pcr
urin
plasma
sampl
clinic
sign
imagist
investig
condit
regimen
use
accord
type
diseas
gvhd
prophylaxi
consist
standard
methotrex
ciclosporintacrolimu
atg
posttranspl
ciclophosphamid
mmf
tacrolimu
haplotranspl
recipi
parent
sign
inform
consent
form
result
center
perform
procedur
allogen
transplant
mud
msd
haplo
patient
diagnosi
patient
aml
patient
saa
patient
md
patient
diamond
blackfan
anemia
patient
fanconi
anemia
patient
patient
present
bkv
reactiv
follow
hsct
procedureth
incid
bkv
reactiv
haplotranspl
mud
msd
symptom
consist
hematuria
case
present
sever
hematuria
dysuria
polakyuria
cn
symptom
symptom
appear
day
day
median
day
last
day
median
day
two
haplotranspl
patient
bkv
infect
induc
sever
cytokin
releas
syndrom
cr
level
pcr
level
bkv
urin
sampl
onset
rang
copiesml
median
plasma
sampl
level
rang
copiesml
median
copiesml
patient
present
coinfect
cmv
patient
concomit
sever
intestin
gvhd
develop
mild
skin
gvhd
afterward
develop
sever
skin
intestin
gvhd
bkv
reactiv
imagist
investig
abdomin
ultrasound
perform
patient
present
thicken
bladder
mucosa
patient
clot
bladder
treatment
includ
extens
hydrat
patient
levofloxacin
patient
cidofovir
patient
rfvii
patient
support
treatment
patient
patient
requir
continu
bladder
irrig
patient
requir
emerg
bladder
electrocauter
patient
develop
acut
kidney
injuri
patient
aliv
fulli
recov
donor
chimer
conclus
bkv
reactiv
common
complic
hsct
associ
signific
morbid
could
detect
correl
bkv
reactiv
grade
iiiiv
acut
gvhd
cyclophosphamid
use
donor
type
incid
bkv
reactiv
studi
hc
appear
patient
cr
associ
patient
bkv
pcr
level
urin
billion
copiesml
studi
need
order
complet
understand
pathophysiolog
mechan
bkv
diseas
conflict
interest
colita
anca
noth
disclos
wroclaw
medic
univers
depart
intern
occup
diseas
hypertens
clinic
oncolog
wroclaw
poland
medic
univers
gdansk
depart
hematolog
transplantolog
poland
wroclaw
medic
univers
hematolog
bone
marrow
transplant
wroclaw
poland
cancer
center
institut
oncolog
depart
bone
marrow
transplant
hematologyoncolog
gliwic
poland
poznan
univers
medic
scienc
depart
hematolog
bone
marrow
transplant
poland
background
bkv
relat
haemorrhag
cystiti
bkvhc
allogen
stem
cell
transplant
hsct
still
remain
issu
mani
year
risk
factor
recogn
although
specif
prophylaxi
exist
promis
result
achiev
cidofovir
hyperbar
oxygen
therapi
ranom
trial
result
studi
tri
establish
role
preemptiv
monitor
bkvdna
copi
select
highest
risk
patient
method
analyz
cohort
patient
fm
median
age
allogen
stem
cell
transplant
mainli
due
acut
leukemia
diagnosi
acut
leukemia
vs
indic
major
patient
transplant
unrel
donor
mudmrd
haploident
case
base
myeloabl
condit
macric
patient
monitor
bkvdna
pcr
day
observ
subsequ
day
still
ongo
identifi
two
group
patient
bkv
reactiv
develop
haemorrhag
cystiti
hc
develop
complic
nhc
result
whole
cohort
patient
identifi
case
bkv
reactiv
period
monitor
consist
hc
nhc
case
find
signific
differ
group
regard
patient
age
sex
diagnosi
condit
mac
vs
ric
stem
cell
sourc
cell
number
donor
origin
mud
vs
mrd
signific
differ
concern
number
mismatch
hsct
includ
haploident
transplant
higher
rate
hc
group
vs
haploident
hsct
includ
hc
group
well
median
time
hc
onset
day
analyz
number
bkvdna
urin
copi
condit
day
differ
groupsw
find
differ
group
urin
bkvdna
day
surprisingli
median
number
copi
higher
nhc
group
measur
point
vs
vs
vs
respect
although
serum
result
revers
higher
number
copi
hc
group
day
differ
signific
mean
vs
differ
acut
gvhd
onset
signific
although
chronic
gvhd
higher
rate
observ
hc
group
vs
differ
os
group
two
patient
success
treat
cidofovir
mg
per
kg
b
week
dose
median
conclus
preliminari
result
show
essenti
role
hla
mismatch
serum
viremia
develop
hc
preemptiv
monitor
seem
use
select
bkvdna
serum
posit
patient
indroduc
proper
treatment
futur
ie
low
dose
cidofovir
randmiz
trial
result
deliv
inful
bkv
reactiv
cgvhd
onset
need
investig
clinic
trial
registri
applic
conflict
interest
noth
declar
ircc
san
raffael
scientif
institut
milan
itali
background
adenoviru
adv
infect
though
uncommon
show
high
mortal
immunocompromis
patient
especi
allogen
hematopoiet
transplant
allohsct
brincidofovir
bcv
oral
bioavail
lipid
conjug
cidofovir
vitro
activ
adv
doublestrand
dna
virus
method
treat
patient
brincidofovir
tablet
formul
dissemin
local
adv
infect
patient
adult
median
age
transplant
year
old
stem
cell
donor
unrel
famili
haploident
patient
receiv
pbsc
one
receiv
myeloabl
condit
gvhd
prophylaxi
base
sirolimu
plu
mmf
one
receiv
antithymoglobulin
atg
receiv
posttranspl
cyclophosphamid
patient
receiv
acyclovir
antivir
prophylaxi
result
pt
engraft
transplant
median
time
day
median
follow
day
median
time
adv
reactiv
day
transplant
six
pt
document
gvhd
grade
grade
gut
involv
requir
high
dose
steroid
case
second
line
treatment
case
six
pt
high
adv
load
diagnosi
rang
copiesml
peripher
blood
pb
pt
also
adv
isol
organ
specimen
gastrointestin
tract
case
plu
urin
one
case
concomitantli
four
case
document
bk
viru
infect
sever
hemorrhag
cystiti
pt
also
dna
virus
reactiv
cmv
herp
viru
six
case
five
pt
treat
endoven
cidofovir
median
administr
case
progress
renal
dysfunct
prevent
us
proceed
drug
two
patient
never
treat
cidofovir
due
concomit
renal
dysfunct
brincidofovir
treatment
given
median
time
day
twice
weekli
adv
load
decreas
pb
pt
reach
neg
case
median
time
negativ
day
treatment
start
clinic
improv
case
organ
involv
seen
pt
two
case
adv
diseas
hyperacut
without
possibl
see
treatment
benefit
sinc
patient
die
earli
diagnosi
decreas
cmv
load
pb
document
pt
suggest
potenti
activ
also
virus
adv
two
pt
despit
clinic
laboratori
improv
develop
worsen
diarrhea
grade
accord
ctcae
score
probabl
relat
concomit
intestin
gvhd
certain
advers
event
report
bcv
therapi
conclus
although
perform
small
cohort
analysi
suggest
bcv
manag
efficaci
adv
diseas
posttranspl
frail
pt
consid
treatment
option
due
low
toxic
profil
conflict
interest
noth
disclos
icohospit
universitari
german
tria
pujol
josep
carrera
leukemia
research
institut
universitat
autonoma
de
barcelona
clinic
hematolog
badalona
spain
background
bacteri
infect
frequent
complic
hsct
elev
morbid
mortal
catheterrel
bacteremia
one
frequent
method
studi
catheterrel
infect
hsct
singl
institut
identifi
type
cathet
infect
respons
microorgan
result
observ
catheterrel
infect
hsct
autolog
allogen
main
clinic
characterist
patient
summar
tabl
median
day
cathet
emplac
infect
frequent
isol
bacteria
staphylococu
epidermidi
staphylococcu
aureu
coagulaseneg
staphylococcu
staphylococcu
homini
staphylococu
haemolyticu
escherichia
coli
pseudomona
aeruginosa
rotia
mucilaginosa
serratia
marcesen
klebsiella
pneumonia
one
patient
also
note
polymicrobian
infect
acinetobact
baumaniistenotrophomona
maltophilia
staphylococcu
epidermidisenterobact
cloaca
stenotrophomona
maltophiliaenterobact
cloaca
coagulaseneg
staphylococcuscorynebacterium
one
patient
bacteria
identifi
case
cellul
area
emplac
autolog
hsct
frequent
infect
cathet
infect
follow
convent
subclavian
infect
convent
jugular
infect
observ
infect
picc
use
type
transplant
unusu
allogen
hsct
frequent
infect
cathet
infect
follow
convent
subclavian
infect
convent
jugular
infect
picc
infect
observ
infect
picc
cathet
recent
includ
clinic
practic
relat
cathet
infect
site
emplac
observ
conclus
frequent
type
infect
cathet
autolog
hsct
thicker
tunnel
allogen
hsct
frequent
involv
staphylococcu
spp
frequent
bacteria
polymicrobian
infect
concomit
cellul
frequent
observ
catheterrel
infect
relat
site
emplac
home
care
import
factor
catheterrel
infect
support
part
grant
fund
fondo
de
investigacion
sanitaria
rticc
instituto
carlo
iii
cerca
program
generalitat
de
catalunya
la
caixa
foundat
rticcinstituto
carlo
iii
conflict
interest
potenti
conflict
interest
report
author
tabl
clinic
characterist
seri
kum
imam
reza
hospit
kermanshah
iran
islam
republ
background
tuberculosi
uncommon
infecti
complic
stem
cell
transplant
report
patient
present
fuo
day
allograft
transplant
day
engraft
phase
perform
statu
deterior
time
evalu
possibl
diagnosi
fever
transplant
especi
common
like
hsv
cmv
aspergillosi
bacteri
infect
acut
gastrointestin
gvhd
grade
control
mehylprednisolon
per
kg
despit
wide
spectrum
empir
antibacteri
antifung
fever
continu
decreas
method
diagnosi
made
blood
tb
pcr
posit
cerebr
mass
detect
brain
ct
scan
antitubercul
treatment
initi
result
treat
four
drug
combin
therapi
due
ich
death
conclus
mycobacteri
infect
consid
allograft
recipi
till
without
pulmonari
tb
gvhd
therapi
fuo
special
endem
world
area
sensit
assay
like
pcr
method
detect
sooner
poor
prognosi
diseas
immunocompromis
patientswith
wide
spread
evalu
patient
rare
present
common
diseas
aould
diagnos
conflict
interest
none
universidad
autonoma
de
bucaramangafosc
intern
medicin
divis
hematolog
hematopoiet
stem
cell
transplant
bucaramanga
colombia
universidad
autonoma
de
bucaramanga
school
medicin
bucaramanga
colombia
clinica
carlo
ardila
lull
foscal
divis
hematolog
hematopoiet
stem
cell
transplant
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
bucaramanga
colombia
universidad
autonoma
de
bucaramangafosc
intern
medicin
divis
infecti
diseas
bucaramanga
colombia
background
chaga
diseas
cd
protozoan
zoonosi
caus
trypanosoma
cruzi
cruzi
patient
previous
infect
parasit
higher
risk
diseas
reactiv
druginduc
immunosuppress
transplant
cruzi
reactiv
report
occur
case
mostli
hematopoiet
stem
cell
transplant
hstc
method
case
report
old
colombian
man
diagnos
classic
hodgkin
lymphoma
hl
octob
treat
six
cycl
abvd
doxorubicin
bleomycin
vinblastin
dacarbazin
complet
remiss
relaps
diseas
januari
next
manag
strategi
hematopoiet
transplant
pretranspl
evalu
report
posit
serolog
studi
cd
evid
electrocardiographi
echocardiographi
abnorm
result
patient
receiv
salvag
chemotherapi
cycl
eshap
etoposid
methylprednisolon
cytarabin
cisplatin
follow
condit
regimen
beam
carmustin
etoposid
cytarabin
melphalan
june
day
autolog
hsct
patient
found
fever
elev
creactiv
protein
without
clinic
evid
infect
normal
blood
cultur
treatment
meropenem
initi
three
day
later
x
hematopoiet
cell
infus
day
anoth
episod
fever
vancomycin
ad
treatment
therapi
blood
urin
cultur
normal
imag
studi
show
evid
foci
infect
despit
empir
antibiot
treatment
day
patient
persist
fever
elev
creactiv
protein
level
manag
escal
meropenem
tigecyclin
amikacin
caspofungin
myeloid
engraft
occur
day
day
fever
persist
antibiot
treatment
switch
polymyxin
b
microstrout
test
perform
show
evid
trypomastigot
see
imag
reactiv
diseas
confirm
therapi
nifurtimox
mgday
day
initi
parasitolog
treatment
followup
perform
microstrout
weekli
test
becam
neg
three
week
later
addit
patient
present
graft
failur
requir
sever
transfus
octob
patient
admit
gener
weak
fatigu
intermitt
fever
facial
edema
posit
microstrout
test
treatment
initi
benznidazol
mgday
day
followup
microstrout
test
neg
three
week
begin
treatment
current
patient
present
symptom
posit
microstrout
test
suggest
diseas
reactiv
patient
relaps
six
month
transplant
treatment
brentuximab
conclus
immunosuppress
salvag
condit
chemotherapi
previou
transplant
probabl
caus
cd
reactiv
patient
hsct
candid
previou
infect
cruzi
initi
monitor
possibl
reactiv
frequent
parasitolog
studi
condit
phase
prior
transplant
case
febril
syndrom
unknown
etiolog
urgent
parasitolog
screen
requir
conflict
interest
author
declar
potenti
conflict
interest
asuiud
santa
maria
della
misericordia
hematolog
bone
marrow
transplant
udin
itali
asuiud
santa
maria
della
misericordia
microbiolog
udin
itali
asui
triest
uo
ematologia
microbiolog
udin
itali
azienda
sanitaria
universitaria
integrata
hematolog
udin
itali
background
polymicrobi
bloodstream
infect
pbsi
may
complic
cours
hematolog
diseas
although
repres
rare
event
clinic
characterist
outcom
pbsi
occur
stem
cell
transplant
sct
still
poorli
understood
method
analyz
clinic
characterist
outcom
pbsi
occur
patient
hematolog
diseas
period
compar
sct
case
nottranspl
patient
result
sct
case
pbsi
occur
autosct
allosct
mud
hlaid
haplo
pbsi
occur
first
day
sct
case
day
sct
case
day
case
common
underl
hematolog
diseas
acut
myeloid
leukemia
aml
median
age
onset
pbsi
entir
popul
yr
acut
gvhd
grade
present
patient
chronic
gvhd
report
tabl
major
case
sever
neutropenia
common
bacteri
associ
gramneg
plu
gramposit
bacteria
without
differ
two
group
common
isol
coagulaseneg
staphylococcu
spp
enterococcu
spp
e
coli
p
aeruginosa
suscept
antibiot
treatment
record
concomit
pneumonia
enter
report
case
resolut
rate
pbsi
without
differ
two
group
mortal
pbsi
relat
sct
case
septic
shock
occur
case
septic
shock
relat
mortal
sct
notsct
case
multidrug
resist
mdr
bacteria
involv
pbsi
sctcase
mortal
mdr
pbsi
relat
significantli
higher
sct
patient
vs
conclus
observ
studi
confirm
pbsi
rare
infecti
complic
sctpatient
frequent
first
day
sct
sever
neutropenia
concomit
gvhd
uncommon
mortal
pbsi
relat
lower
septic
shock
occur
mortal
shock
relat
higher
sct
case
vs
mdr
bacteria
involv
pbsi
mortal
mdr
pbsi
relat
significantli
higher
sct
case
vs
conflict
interest
maria
elen
zannier
noth
disclos
tabl
characterist
outcom
pbsi
ircc
san
raffael
hospit
hematolog
bone
marrow
transplant
unit
milano
itali
ircc
san
raffael
hospit
infecti
diseas
unit
milan
itali
background
multidrugresist
gramneg
bacteria
mdrogn
emerg
caus
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
therefor
pretranspl
mdrogn
colon
often
consid
rel
contraind
transplant
aim
studi
assess
impact
pretranspl
colon
clinic
outcom
hsct
method
threehundredfortyeight
consecut
patient
transplant
hospit
juli
januari
allogen
autolog
hsct
screen
pretranspl
mdrogn
colon
patient
undergo
second
transplant
exclud
univari
comparison
surviv
curv
made
use
logrank
test
gray
test
use
univari
comparison
ci
function
analyz
associ
transplant
endpoint
pretranspl
colon
mdrogn
pathogen
multivari
cox
proport
hazard
model
built
use
backward
select
procedur
adjust
clinic
factor
known
influenc
outcom
pretranspl
colon
main
effect
term
held
step
model
build
result
pretranspl
mdrogn
colon
found
allohsct
autohsct
recipi
auto
allohsct
carrier
pretranspl
mdrogn
show
signific
differ
overal
surviv
os
transplantrel
mortal
trm
infectionrel
mortal
irm
compar
noncarri
os
carrier
compar
noncarri
vs
autohsct
vs
allohsct
trm
vs
autohsct
vs
allohsct
irm
vs
autohsct
vs
allohsct
multivari
analysi
grade
iiiiv
acut
graftversushost
diseas
agvhd
independ
factor
detriment
os
p
trm
p
irm
p
cohort
patient
posttranspl
gramneg
bloodstream
infect
report
caus
mdrogn
autohsct
allohsct
relat
mortal
overal
notic
surviv
month
patient
develop
carbapenemresist
klebsiella
pneumonia
infect
conclus
conclud
extend
singlecent
experi
pretranspl
mdrogn
colon
significantli
impact
transplant
outcom
onset
agvhd
major
risk
factor
detriment
outcom
think
cohort
adopt
institut
protocol
activ
surveil
earli
initi
target
antimicrobi
therapi
carrier
onset
neutropen
fever
success
impact
clinic
outcom
thu
make
os
trm
irm
significantli
differ
pretranspl
mdrogn
carrier
noncarri
clinic
trial
registri
applic
conflict
interest
forcina
biotest
consult
ipo
porto
medic
oncolog
porto
portug
ipo
porto
bone
marrow
transplant
depart
porto
portug
ipo
porto
cellular
therapi
depart
porto
portug
background
nocardia
spp
genu
gramposit
saprophyt
bacteria
may
caus
diseas
human
common
diseas
site
lung
skin
central
nervou
system
dissemin
diseas
may
occur
immunocompromis
host
includ
patient
undergon
hematopoiet
stem
cell
transplant
increas
risk
infect
method
perform
singlecentr
retrospect
analysi
case
juli
laboratori
confirm
nocardiosi
defin
compat
clinic
present
either
isol
nocardia
spp
identif
pcr
result
identifi
patient
met
inclus
criteria
isol
nocardia
spp
pcrbase
diagnosi
median
age
diagnosi
year
minmax
male
common
type
transplant
allogen
matchedunrel
donor
allogen
matchedrel
donor
autolog
stem
cell
transplant
transplant
due
acut
myeloid
leukemia
patient
nonhodgkin
lymphoma
patient
myelodysplast
syndrom
patient
median
time
transplant
diagnosi
nocardiosi
day
minmax
major
patient
prophylact
cotrimoxazol
greater
prednison
administ
patient
take
least
one
immunosuppress
drug
patient
fever
median
temperatur
minmax
lung
involv
three
case
snc
involv
suspect
two
case
brain
abscess
one
case
asept
refractori
mening
nocardia
spp
identifi
pcr
agent
isol
lcr
cultur
cultur
identif
nocardia
spp
done
blood
cultur
patient
patient
sampl
taken
lung
biopsi
respiratori
sampl
skin
pleura
case
lumbar
punctur
perform
one
pcr
identif
nocardia
spp
done
mortal
rate
median
surviv
day
diagnosi
larg
due
concomit
invas
opportunist
infect
conclus
nocardiosi
rare
sampl
late
complic
hematopoiet
stem
cell
transplant
common
involv
lung
poor
prognosi
mostli
due
opportunist
infect
one
patient
diagnosi
nocardiosi
day
stem
cell
transplant
die
neutropen
sepsi
engraft
period
mean
inocul
like
occur
procedur
due
previou
immunosuppress
high
index
suspicion
requir
immunosuppress
antibiot
therapi
must
care
manag
patient
order
improv
dismal
outcom
conflict
interest
author
report
conflict
interest
azienda
ospedaliera
universitaria
senes
uoc
terapi
cellulari
e
officina
trasfusional
siena
itali
background
cytomegaloviru
cmv
infect
common
allogen
stem
cell
transplant
asct
may
caus
seriou
even
fatal
diseas
specif
prophylaxi
cmv
infect
possibl
antivir
drug
cmv
hyperimmun
globulin
prophylaxi
may
particularli
import
high
risk
patient
receiv
high
level
immunosuppress
method
sever
random
trial
effect
cmv
hyperimmun
globulin
prevent
cmv
infect
diseas
asct
given
conflict
result
carri
retrospect
singl
center
experi
evalu
safeti
effect
prophylact
regimen
high
titer
cmv
immunoglobulin
cytotectmegalotect
high
risk
asct
patient
thirti
adult
patient
underw
myeloabl
asct
unrel
haploident
donor
acut
myeloid
lymphoblast
leukemia
institut
januari
june
evalu
seventeen
patient
receiv
peripher
blood
stem
cell
transplant
unrel
donor
busulphan
base
condit
regimen
graft
versu
host
diseas
gvhd
prophylaxi
short
cours
methotrex
cyclosporin
antilymphocyt
globulin
thirteen
patient
treat
thiotepa
fludarabin
busulphan
base
regimen
follow
bone
marrow
haploident
transplant
gvhd
prophylaxi
high
dose
posttransplant
cyclophosphamid
mycophenol
acid
cyclosporin
patient
receiv
prophylact
regimen
administr
cmv
hyperimmun
globulin
biotest
germani
mlkg
everi
three
week
day
month
transplant
prepar
report
contain
titer
neutral
antibodi
result
cmv
reactiv
occur
patient
patient
show
whole
blood
cmv
dna
copi
number
fifth
twentieth
week
transplant
nine
patient
aris
cmv
dna
copi
seroconvert
spontan
without
therapi
despit
high
level
cmv
dna
copiesml
median
valu
rang
eight
remain
patient
show
clinic
sign
cmv
infect
receiv
antivir
therapi
ganciclovir
control
viral
load
conclus
experi
cmv
hyperimmun
globulin
prophylaxi
appear
welltoler
advers
reaction
record
seem
effect
control
reduc
cmv
viral
load
high
risk
asct
patient
cmv
hyperimmun
globulin
schedul
seem
effect
reduc
number
patient
need
treat
myelotox
antivir
drug
particulari
first
week
asct
hematolog
recoveri
often
achiev
final
data
indic
cmv
hyperimmun
globulin
prophylaxi
safe
use
asct
popul
find
support
trial
efficaci
prophylaxi
cmv
infect
asct
popul
conflict
interest
monica
tozzi
consult
biotest
germani
author
declar
compet
interest
pavlov
first
saint
petersburg
state
medic
univers
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
saint
petersburg
russian
feder
background
infecti
complic
main
mortal
caus
hematopoiet
stem
cell
transplant
hsct
diagnost
valu
inflamm
marker
septic
immunocompromis
patient
remain
controversi
method
raisa
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
patient
acut
myeloid
leukemia
acut
lymphoblast
leukemia
inherit
diseas
lymphoma
myelodysplast
syndrom
chronic
myelogen
leukemia
chronic
lymphoblast
leukemia
chronic
myeloprolif
diseas
medulloblastoma
enrol
prospect
studi
median
age
year
year
patient
underw
hsct
allogen
unrel
allogen
relat
n
haploident
autolog
main
inclus
criterion
time
exceed
creactiv
protein
crp
level
normal
rate
mgl
level
crp
psp
pct
cystatin
c
cysc
interleukin
interferon
routin
laboratori
test
estim
three
checkpoint
admiss
icu
depart
hour
admiss
case
time
crp
level
decreas
compar
initi
valu
patient
termin
state
result
sepsi
establish
patient
base
clinic
laboratori
criteria
patient
elev
crp
diagnosi
sepsi
confirm
median
valu
inflamm
marker
group
patient
without
sepsi
crp
mgdl
pct
ngdl
psp
ngml
pgml
pgml
pgml
respect
initi
decreas
glomerular
filtrat
rate
gfr
differ
etiolog
observ
patient
patient
without
sepsi
renal
failur
observ
case
n
respect
reveal
correl
psp
pct
increas
cysc
level
decreas
gfr
p
wherea
group
patient
without
sepsi
signific
correl
increas
psp
level
decreas
gfr
p
psp
level
reliabl
indic
presenc
sepsi
patient
normal
kidney
function
auc
ci
p
sensit
se
specif
sp
among
biomark
valuabl
pct
auc
ci
p
se
sp
crp
auc
ci
p
se
sp
conclus
pct
crp
highli
specif
sensit
sepsi
marker
patient
hsct
psp
level
patient
sepsi
suspicion
normal
renal
function
may
also
highli
specif
diagnost
marker
valuabl
renal
dysfunct
conflict
interest
conflict
interest
nation
univers
hospit
pharmaci
singapor
singapor
nation
univers
cancer
institut
depart
haematologyoncolog
singapor
singapor
background
posaconazol
oral
suspens
choic
antifung
prophylaxi
agent
institut
allogen
hematopoiet
cell
transplant
allohct
recipi
delayedreleas
tablet
formul
design
overcom
absorpt
limit
associ
suspens
recent
approv
singapor
studi
aim
compar
efficaci
safeti
posaconazol
suspens
vs
tablet
antifung
prophylaxi
within
first
day
allohct
method
twentyfour
patient
receiv
allohct
novemb
august
includ
retrospect
studi
patient
given
either
posaconazol
suspens
three
time
daili
tablet
daili
begin
day
allohct
onward
day
allohct
suspect
drugassoci
toxic
occurr
invas
fungal
diseas
ifd
addit
posaconazol
switch
fluconazol
daili
upon
neutrophil
engraft
cost
save
reason
therapeut
antifung
therapi
start
fungal
infect
indic
accord
standard
eortcmsg
criteria
result
two
studi
group
compar
demograph
except
patient
posaconazol
tablet
group
older
vs
compris
less
chines
vs
compar
suspens
group
also
larger
proport
patient
receiv
prednisolon
tablet
group
vs
one
patient
receiv
posaconazol
tablet
develop
ifd
studi
patient
develop
candida
krusei
fungemia
day
allohct
howev
unlik
due
posaconazol
prophylaxi
failur
posaconazol
switch
iv
anidulafungin
day
hyperbilirubinemia
venoocclus
diseas
vod
treatment
drug
relat
toxic
result
posaconazol
interrupt
occur
patient
receiv
tablet
vs
suspens
vs
common
reason
lead
temporari
switch
intraven
antifung
prophylaxi
agent
mucos
group
grade
liver
toxic
observ
two
tablet
recipi
thought
unrel
posaconazol
one
due
vod
patient
liver
function
improv
continu
posaconazol
tablet
conclus
retrospect
studi
suggest
posaconazol
delayedreleas
tablet
suspens
compar
effect
sampl
size
small
conclud
better
absorpt
posaconazol
tablet
confer
better
protect
ifd
earli
phase
allohct
mucos
lead
temporari
discontinu
posaconazol
prophylaxi
remain
major
concern
new
tablet
formul
suspens
liver
function
test
monitor
close
treatment
drug
toxic
allohct
patient
receiv
posaconazol
conflict
interest
noth
disclos
msd
uk
hoddesdon
unit
kingdom
merck
co
inc
north
wale
pa
unit
state
merck
co
inc
kenilworth
nj
unit
state
phmr
berkley
grove
unit
kingdom
background
data
recent
phase
iii
clinic
trial
demonstr
efficaci
letermovir
prophylaxi
cmv
reactiv
adult
cmvseroposit
recipi
allogen
haematopoiet
stemcel
transplant
hsct
object
costeffect
analysi
evalu
clinic
econom
valu
letermovir
compar
preemptiv
treatment
payer
perspect
scotland
method
decisionanalyt
model
evalu
total
cost
lifetim
qualityadjust
lifeyear
qali
perspect
nation
health
servic
nh
social
work
scotland
efficaci
data
includ
rate
preemptiv
therapi
cmv
infect
cmv
diseas
rehospit
mortal
qualiti
life
incorpor
clinic
trial
data
week
posttranspl
primari
endpoint
trial
clinic
signific
cmvinfect
week
posttranspl
cost
preemptiv
treatment
cmv
diseas
trial
outcom
obtain
publish
sourc
lifeyear
first
week
estim
mortal
observ
clinic
trial
lifeyear
post
week
estim
week
survivor
appli
rel
risk
death
hsct
gener
mortal
risk
life
tabl
scotland
util
valu
appli
base
data
collect
clinic
trial
longerterm
data
publish
sourc
annual
cost
treat
survivor
base
proport
patient
receiv
year
immunosuppress
agent
treatment
chronic
graftversushost
diseas
onset
day
transplant
sensit
analysi
explor
impact
includ
data
extend
followup
period
variou
endpoint
collect
week
posttranspl
model
use
annual
discount
rate
result
basecas
analysi
letermovir
reduc
number
cmv
infect
requir
preemptiv
treatment
vs
standard
care
soc
vs
week
posttranspl
prophylaxi
letermovir
result
lower
allcaus
mortal
week
comparison
soc
vs
mean
increas
lifeyear
qali
total
cost
week
posthsct
per
patient
result
increment
costeffect
ratio
icer
per
qali
gain
sensit
analysi
use
data
week
posttranspl
signific
effect
result
result
probabilist
sensit
analysi
indic
letermovir
cost
effect
iter
per
qali
gain
iter
per
qali
gain
conclus
result
model
would
suggest
prophylaxi
use
letermovir
costeffect
treatment
strategi
commonli
accept
icer
threshold
model
input
greatest
impact
result
reduct
rate
mortal
increas
age
patient
treat
letermovir
increas
cost
prophylaxi
letermovir
conflict
interest
c
brown
e
taymor
employe
merck
sharp
dohm
limit
uk
receiv
salari
benefit
j
schelfhout
jiang
employe
merck
co
inc
receiv
salari
benefit
glover
employe
phmr
grant
fund
msd
conduct
model
hospit
universitario
puerta
de
hierro
majadahonda
hematolog
majadahonda
spain
biomed
scienc
research
institut
puerta
de
hierrosegovia
de
arana
clinic
biostatist
unit
majadahonda
spain
hospit
universitario
puerta
de
hierro
majadahonda
microbiolog
majadahonda
spain
hospit
universitario
puerta
de
hierro
majadahonda
depart
majadahonda
spain
universidad
de
madrid
madrid
spain
background
despit
preemptiv
therapi
pet
cytomegaloviru
infect
cmvi
pose
neg
impact
outcom
allogen
hct
recipi
potenti
use
resourc
patient
manag
method
retrospect
studi
analys
impact
cmvi
clinic
outcom
resourc
use
includ
hospit
length
stay
lo
consecut
allogen
hct
recipi
particular
focu
recurr
cmvi
episod
result
allogen
hct
recipi
includ
men
median
age
year
amlmd
chronic
lymphoprolif
disord
myeloma
match
relat
cordblood
unrel
haploident
donor
myeloabl
condit
risk
cmvi
donor
andor
recipi
posit
serolog
acut
gvhd
grade
iiiv
cmv
diseas
occur
case
cmvi
occur
patient
patient
risk
median
day
posthct
impact
overal
surviv
vs
year
patient
median
age
higher
cmv
serolog
risk
vs
p
cmvi
rate
vs
compar
matchedrel
hct
cordblood
haploident
hctrecipi
higher
cmvi
rate
vs
respect
earlier
onset
vs
within
day
posthct
p
acut
gvhd
also
increas
cmvi
rate
vs
p
among
patient
first
cmvi
recurr
cmvi
episod
cmvi
recurr
also
higher
cordblood
haploident
versu
match
relat
hct
hr
ci
p
age
time
hct
per
year
hr
ci
acut
gvhd
hr
ci
p
term
clinic
burden
hospit
lo
throughout
first
year
posthct
overal
day
longer
patient
cmvi
vs
without
p
tabl
increas
lo
addit
day
patient
recurr
cmvi
significantli
higher
one
cmvi
episod
day
p
term
treatment
cmv
reactiv
respond
line
treatment
line
line
rate
advers
effect
pet
line
treatment
increas
usual
drug
line
conclus
despit
preemptiv
therapi
cmvi
remain
hurdl
success
allogen
hct
signific
impact
patient
outcom
use
resourc
recurr
cmvi
episod
frequent
particular
highrisk
hctgroup
cordblood
haploident
acut
gvhd
pose
signific
impact
outcom
strong
driver
hospit
lo
resourc
burden
hct
program
conflict
interest
none
author
anyth
declar
ege
univers
medic
faculti
hematolog
depart
izmir
turkey
background
cytomegaloviru
cmv
infect
one
seriou
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
ahsct
risk
factor
cmv
infect
divers
monitor
cmv
statu
crucial
ahsct
recipi
method
retrospect
evalu
patient
hematolog
diseas
undergo
ahsct
ege
univers
hematolog
depart
bone
marrow
transplant
unit
patient
characterist
type
donor
transplant
regimen
donor
patient
cmv
statu
cmv
monitor
cmv
antivir
treatment
result
clinic
statu
patient
cmv
infect
record
patient
donor
screen
cmv
serolog
statu
cmv
igm
igg
posttranspl
cmv
dna
monitor
perform
start
day
transplant
biweekli
day
longer
case
complic
weekli
day
monthli
year
ahsct
result
fifti
onepati
develop
cmv
infect
patient
viral
reactiv
patient
symptomat
infect
symptomat
cmv
infect
coliti
pneumonia
cystiti
retin
stem
cell
sourc
peripher
blood
patient
underli
diseas
number
patient
follow
acut
myeloid
leukemia
acut
lymphocyt
leukemia
myelodisplast
syndrom
multipl
miyeloma
lymphoma
lymphoma
aplast
anemia
myelofibrosi
chronic
myeloid
leukemia
condit
regimen
reducedintens
condit
myeloabl
patient
baselin
characterist
studi
popul
summar
tabl
cmv
infect
occur
day
ahsct
two
patient
patholog
proven
cmv
infect
colon
lung
biopsi
eight
patient
two
cmv
infect
attack
number
patient
treat
gancyclovir
valgancyclovir
gancyclovirvalgancyclovir
gancyclovirfoscarnet
thirti
eight
patient
neg
cmv
dna
level
antivir
treatment
nineteen
patient
concomit
graftversu
host
diseas
twenti
patient
aliv
reason
death
infecitonssepsi
transplant
complic
reason
progress
diseas
cmv
pneumon
conclus
studi
popul
recipi
seroposit
therefor
cmv
infect
occur
viral
reactiv
rather
transmiss
donor
cmv
monitor
made
regularli
order
reduc
cmvrelat
mortal
conflict
interest
author
whose
name
listedcertifi
affili
involv
organ
entiti
financi
interest
nonfinanci
interest
abstract
ege
uvivers
medic
faculti
hematolog
depart
izmir
turkey
background
cytomegaloviru
cmv
infect
autolog
stem
cell
transplant
autohsct
less
frequent
allogen
hematopoiet
stem
cell
transplant
howev
cmv
infect
may
preval
sever
autohsct
case
method
retrospect
evalu
patient
hematolog
diseas
undergo
autohsct
ege
univers
hematolog
depart
bone
marrow
transplant
unit
patient
characterist
transplant
regimen
cmv
monitor
cmv
antivir
treatment
result
clinic
statu
patient
cmv
infect
record
posttranspl
cmv
dna
monitor
perform
start
day
transplant
biweekli
engraft
cmv
dna
found
posit
screen
continu
monthli
three
month
discharg
result
twenti
two
patient
develop
cmv
viral
reactiv
none
symptomat
infect
underli
diseas
number
patient
follow
multipl
miyeloma
lymphoma
lymphoma
acut
myeloid
leukemia
andamiloidosi
condit
regimen
melphalan
day
multipl
miyeloma
buci
busulfan
mgkg
day
cyclophasphamid
mgkg
day
acut
myeloid
leukemia
beam
bcnu
day
etoposid
onday
arac
day
melphalan
day
tecam
etoposid
day
thiotepa
day
day
cyclophosphamid
mgkg
day
melphalan
day
mean
age
studi
popul
year
male
femal
patient
cmv
infect
occur
day
autohsct
patient
one
cmv
infect
attack
number
patient
treat
gancyclovir
valgancyclovir
gancyclovirvalgancyclovir
twenti
patient
neg
cmv
dna
level
antivir
treatment
two
nonhodgkin
lymphoma
patient
die
progress
hematolog
diseas
also
gancyclovir
treatment
ten
patient
concomit
pneumonia
fungal
patient
system
bacteri
infectionthirteen
patient
aliv
reason
death
infectionsepsi
progress
diseas
reason
conclus
cmv
one
major
infecti
problem
autohsct
associ
drug
make
sever
cellmedi
immunodefici
furthermor
highli
cmv
seroposit
popul
like
viral
reactiv
may
preval
conflict
interest
author
whose
name
list
certifi
affili
involv
organ
entiti
financi
interest
nonfinanci
interest
abstract
abstract
previous
publish
st
istvan
st
laszlo
hospit
depart
hematolog
stem
cell
transplant
budapest
hungari
semmelwei
univers
depart
intern
medicin
budapest
hungari
background
hemophagocyt
lymphohistiocytosi
syndrom
potenti
lifethreaten
condit
often
preced
ebv
infect
ebvinduc
hlh
allohsct
adult
rariti
case
report
literatur
method
report
case
posttranspl
ebvinduc
hlhsyndrom
observ
time
depart
case
share
featur
patient
underw
match
unrel
donor
mud
allohsct
myelodysplast
syndrom
md
hlhiniti
event
delay
ebv
infect
present
rapidonset
sever
cytopenia
fever
result
patient
woman
underw
mud
allohsct
due
extens
chronic
graftversushost
diseas
gvhd
receiv
combin
immunosuppress
therapi
tacrolimu
ruxolitinib
continu
year
hsct
rapidli
progress
sever
anemia
thrombocytopenia
develop
immunosuppress
stop
bone
marrow
histolog
show
dysplast
featur
patient
remain
fulldonor
chimera
becam
febril
requir
hospit
blood
test
show
significantli
elev
ldhcrpddimer
level
respect
high
serum
ebv
viral
load
suspect
posttranspl
lymphoprolif
diseas
ptld
rchop
therapi
initi
treatment
patient
becam
transfusionindepend
fever
ceas
aforement
enzym
level
drop
rapidli
ebv
copi
number
fell
zero
week
later
symptom
recur
high
serum
ferritin
level
could
detect
patient
fulfil
criteria
hlhsyndrom
etoposid
ivonc
weekli
dexamethason
po
start
immedi
fever
stop
promptli
ldhcrpddimer
level
drop
rapidli
week
later
etoposid
therapi
suspend
due
myelotox
week
start
treatment
patient
still
pancytopen
ldhcrpddimer
level
markedli
elev
respect
ferritin
level
decreas
significantli
patient
man
underw
mud
allohsct
gvhd
develop
month
hsct
mix
chimer
sever
anemia
thrombocytopenia
could
observ
bone
marrow
histolog
reveal
suppress
granulopoiesi
monocytosi
lymphocytosi
high
serum
ebv
copi
number
could
detect
suspicion
ptld
rchop
therapi
administ
ebv
copi
number
fell
zero
blood
count
improv
patient
persist
fever
second
bone
marrow
histolog
show
sign
hemophagocytosi
serum
ferritin
level
high
patient
fulfil
criteria
hlhsyndrom
tacrolimu
methylprednisolon
therapi
start
week
later
patient
afebril
anemia
thrombocytopenia
even
chimer
improv
conclus
ebvassoci
hlhsyndrom
occur
even
year
allogen
asct
rapid
recognit
rare
condit
immedi
therapi
essenti
observ
rapid
clinic
laboratori
improv
patient
initi
treatment
unfortun
requir
immunosuppress
therapi
easili
applic
highli
vulner
popul
conflict
interest
noth
disclos
collegium
medicum
umk
bydgoszcz
poland
cancer
center
institut
oncolog
gliwic
poland
medic
univers
wroclaw
poland
medic
univers
gdansk
poland
medic
univers
katowic
poland
medic
univers
poznan
poland
medic
univers
lublin
poland
medic
univers
warszawa
poland
medic
univers
lodz
poland
jagiellonian
univers
medic
collag
krakow
poland
jagiellonian
univers
medic
colleg
krakow
poland
militari
institut
medicin
warszawa
poland
institut
hematolog
transfus
medicin
warszawa
poland
background
infect
signific
caus
morbid
mortal
resourc
util
hsct
children
adult
object
comparison
incid
type
fungal
viral
bacteri
outcom
infect
pediatr
adult
transplant
center
tc
poland
crosssect
studi
period
method
consecut
patient
transplant
pediatr
adult
tc
includ
retrospect
studi
report
known
etiolog
infect
analyz
studi
differ
pediatr
adult
tc
shown
odd
ratio
result
data
followup
pediatr
adult
hsct
recipi
analyz
bacteri
infect
incid
children
adult
patient
p
similar
allohsct
vs
ns
higher
pediatr
autohsct
vs
p
comparison
adult
incid
compar
subgroup
patient
amlmd
nhlhd
saa
howev
adult
myeloma
patient
autohsct
bacteri
infect
infectionrel
mortal
irm
bacteri
infect
lower
pediatr
patient
vs
invas
fungal
diseas
ifd
incid
children
adult
patient
p
higher
allohsct
vs
p
autohsct
vs
p
children
regardless
level
diagnosi
proven
vs
p
probabl
vs
p
possibl
ifd
vs
p
incid
higher
pediatr
patient
vs
p
amlmd
vs
p
compar
adult
irm
ifd
slightli
decreas
pediatr
patient
vs
ns
howev
signific
differ
found
respect
level
ifd
diagnosi
proven
vs
probabl
vs
possibl
vs
viral
infect
incid
children
adult
p
allohsct
vs
p
autohsct
respect
incid
higher
children
follow
infect
cmv
vs
p
bkv
vs
p
ebv
vs
p
adv
vs
p
influenza
vs
viral
infect
contribut
mortal
usual
coexist
infect
irm
viral
infect
similar
children
adult
viral
infect
vs
ns
specif
infect
cmv
vs
ns
bkv
vs
ns
ebv
vs
ns
adv
vs
ns
influenza
vs
ns
conclus
comparison
adult
pediatr
patient
higher
incid
infect
pediatr
patient
better
outcom
bacteri
infect
fungal
viral
infect
irm
compar
children
adult
conflict
interest
none
author
anyth
disclos
abstract
previous
publish
univers
calgari
alberta
children
hospit
calgari
canada
univers
calgari
calgari
canada
background
epstein
barr
viru
ebv
infect
reactiv
common
occurr
allogen
hematopoiet
stem
cell
transplant
hsct
sought
determin
overal
incid
ebv
reactiv
ebvrel
posttranspl
lymphoprolif
diseas
ptld
children
method
retrospect
chart
review
children
age
year
underw
allogen
hematopoiet
stem
cell
transplant
alberta
children
hospit
calgari
alberta
canada
januari
januari
result
period
allogen
stem
cell
transplant
patient
perform
malign
nonmalign
condit
popul
male
averag
age
year
overal
incid
nonzero
ebv
level
overal
incid
ebv
greater
iuml
incid
ptld
found
studi
use
antithymocyt
globulin
atg
condit
significantli
associ
develop
increas
ebv
titr
ebv
reactiv
associ
presenc
ebv
posit
donor
ebv
statu
recipi
statist
signific
factor
mismatch
ebv
statu
donor
recipi
higher
risk
ebv
reactiv
popul
receiv
peripher
blood
stem
cell
compar
cord
blood
bone
marrow
use
cord
blood
protect
multivari
analysi
use
atg
presenc
ebv
posit
donor
remain
signific
factor
patient
receiv
treatment
ebv
level
greater
iuml
receiv
rituximab
part
therapi
associ
ebv
reactiv
develop
graft
versu
host
diseas
gvhd
graft
failur
death
popul
conclus
ebv
reactiv
common
children
undergon
allogen
hsct
overal
incid
greater
iuml
statist
associ
use
atg
ebv
posit
donor
use
peripher
blood
stem
cell
despit
high
frequenc
nonzero
level
ebv
develop
clinic
symptom
featur
ptld
uncommon
treatment
initi
onset
symptom
major
patient
conflict
interest
none
author
anyth
disclos
g
papanicola
hospit
hematolog
depart
bmt
unit
thessaloniki
greec
g
papanicola
hospit
patholog
depart
thessaloniki
greec
background
ebvrel
posttranspl
lymphoprolif
diseas
ebvptld
seriou
complic
allohct
antithymocyt
globulin
atg
administr
agvhd
prophylaxi
identifi
import
predispos
factor
method
determin
incid
ebvptld
chart
review
consecut
allohct
recipi
transplant
center
evalu
factor
potenti
influenc
ebvptld
develop
outcom
result
among
allohct
recipi
sibl
mud
haploident
twin
cord
blood
patient
develop
ebvptld
diagnosi
confirm
biopsi
case
monomorph
polymorph
hllike
ptld
one
case
develop
sole
ebv
enceph
remain
three
case
clinic
diagnos
basi
gener
lymphadenopathi
coupl
high
peripher
blood
pb
ebv
titl
patient
suffer
aml
cml
sever
aplast
anemia
plasmacyt
leukemia
notabl
leukemia
patient
relapsedrefractori
diseas
case
cml
blastic
crisi
time
transplant
ebvptld
incid
significantli
higher
haploident
versu
convent
versu
mud
versu
sibl
allohct
versu
note
haploident
allohct
complic
ebvptld
tcell
deplet
addback
infus
transduc
donor
lymphocyt
one
tcell
replet
major
ebvptld
case
receiv
rabbit
atg
part
condit
regimen
agvhd
prophylaxi
dose
rang
median
addit
case
receiv
atg
secondlin
treatment
hyperacut
gvhd
condit
intens
found
significantli
associ
ebvptld
occurr
classic
myeloabl
reducedtox
reducedintens
case
ebvptld
occur
earli
posttranspl
cours
median
rang
day
case
preced
onset
agvhd
median
interv
agvhd
diagnosi
day
one
case
coincid
agvhd
diagnosi
day
allohct
one
case
develop
soon
day
induct
gvhd
dli
ebvptld
case
present
gener
lymphadenopathi
fever
case
clear
evid
concurr
infect
exist
case
therefor
least
remain
case
fever
consid
b
symptom
ebvptld
diagnosi
median
ebv
titl
pb
copiesml
rang
nine
patient
treat
intraven
rituximab
six
patient
diseas
resolv
case
cn
involv
succumb
remain
four
patient
unsuccess
treat
combin
bleomycinvindesineifnaimmunoglobulinsdli
conclus
ebvptld
earli
complic
allohct
particularli
follow
atg
administr
agvhd
prophylaxi
treatment
highest
incid
ebvptld
mud
versu
sibl
allohct
may
explain
select
atg
administr
former
howev
identifi
trend
higher
incid
among
haploident
allohct
prompt
treatment
rituximab
effect
except
cn
involv
take
account
particularli
dismal
outcom
cn
involv
sought
confirm
intrathec
rituximab
consid
conflict
interest
conflict
interest
univers
medic
center
hamburgeppendorf
stem
cell
transplant
hamburg
germani
univers
medic
center
hamburgeppendorf
hospit
pharmaci
hamburg
germani
background
cytomegaloviru
cmv
reactiv
diseas
import
complic
allogen
hematopoiet
stem
cell
transplant
allosct
lead
increas
transplant
relat
mortal
case
treatment
failur
monotherapi
either
ganciclovir
foscarnet
standard
salvag
therapi
exist
combin
ganciclovir
foscarnet
seem
promis
strategi
evid
regard
efficaci
toxic
regimen
method
conduct
retrospect
chart
review
includ
adult
patient
cmv
reactiv
allosct
receiv
combin
therapi
ganciclovir
foscarnet
half
initi
dosag
failur
monotherapi
least
day
octob
septemb
univers
medic
center
hamburgeppendorf
germani
patient
least
consecut
day
combin
includ
microbiolog
respons
assess
quantit
polymeras
chain
reaction
pcr
monitor
viremia
twice
weekli
toxic
evalu
regard
leukocyt
count
glomerular
filtrat
rate
gfr
daili
combin
treatment
result
patient
episod
combin
treatment
elig
evalu
episod
show
median
onset
viremia
day
transplant
rang
day
median
durat
combin
therapi
day
combin
therapi
start
failur
monotherapi
either
ganciclovir
foscarnet
median
follow
complet
pcr
respons
day
episod
provid
evalu
pcr
data
show
complet
pcr
respons
median
day
combin
treatment
anoth
show
least
partial
respons
median
day
patient
receiv
differ
mainten
regimen
combin
treatment
five
episod
initi
complet
respons
develop
relaps
viremia
median
day
episod
could
evalu
toxic
evalu
toxic
perform
day
treatment
afterward
sampl
size
becam
small
n
median
baselin
leukocyt
count
x
rang
x
median
leukocyt
count
stabl
day
treatment
deviat
baselin
less
vari
deviat
day
day
median
baselin
gfr
mlmin
mlmin
median
gfr
stay
stabl
day
treatment
median
deviat
baselin
rang
decreas
day
median
deviat
day
treatment
median
deviat
conclus
combin
ganciclovir
foscarnet
half
initi
dosag
seem
effect
strategi
treat
cmv
reactiv
failur
monotherapi
allogen
stem
cell
transplant
recipi
lead
complet
respons
almost
two
third
patient
sampl
major
differ
median
leukocyt
count
combin
treatment
seem
relat
durat
combin
therapi
nephrotox
monitor
care
conflict
interest
none
author
anyth
disclos
hospit
de
barcelona
barcelona
spain
background
infect
remain
major
caus
morbid
patient
undergo
autolog
stem
cell
transplant
asct
patient
experi
fever
aplasia
earli
engraft
despit
convent
oral
antibacteri
prophylaxi
implement
strategi
reduc
incid
neutropen
fever
nf
lymphoma
patient
manag
athom
asct
method
januari
june
lymphoma
patient
manag
athom
sinc
day
asct
condit
beam
patient
receiv
prophylaxi
oral
quinolon
fluconazol
aerol
pentamidin
lowdos
oral
acyclovir
seroposit
herp
simplex
viru
sixtyon
patient
receiv
prophylact
ceftriaxon
ct
gday
iv
lyct
piperacillintazobactam
pt
iv
lypt
use
portabl
intermitt
infus
pump
firstlin
therapi
athom
nf
pt
iv
prophylact
ct
refriger
meropenem
iv
prophylact
pt
use
portabl
intermitt
infus
pump
drug
use
propens
score
ps
analysi
match
nearest
neighbor
match
method
use
calip
width
equal
standard
deviat
logit
ps
follow
factor
includ
ps
model
age
gender
type
lymphoma
number
preasct
line
diseas
stage
hctci
cell
dose
match
final
studi
popul
group
result
main
characterist
patient
outcom
ps
match
shown
tabl
differ
variabl
includ
ps
model
regard
outcom
differ
group
respect
durat
neutropenia
first
day
fever
incid
grade
mucos
ncictcscor
significantli
higher
group
lyct
vs
well
fever
vs
p
rel
risk
rr
number
need
treat
nnt
bacteri
infect
lyct
vs
lypt
document
vs
coagulaseneg
staphylococci
frequent
bacteria
isol
readmiss
requir
patient
group
lyct
lypt
multivari
binari
logist
regress
model
pt
retain
independ
protect
factor
p
mucos
risk
factor
nf
conclus
use
piperacillintazobactam
prophylaxi
athom
asct
program
lymphoma
patient
allow
us
significantli
reduc
incid
neutropen
fever
minim
readmiss
rate
conflict
interest
author
declar
disclosur
erciy
univers
faculti
medicin
depart
pediatr
divis
pediatr
hematolog
oncolog
hematopoiet
stem
cell
transplant
unit
kayseri
turkey
erciy
univers
faculti
medicin
depart
microbiolog
divis
mycolog
kayseri
turkey
background
candida
kefyr
formerli
candida
pseudotropicali
current
recogn
kluyveromyc
marxianu
topic
interest
increas
incid
especi
among
immun
compromis
patient
hematolog
disord
higher
incid
colon
patient
acut
myelogen
leukemia
receiv
induct
chemotherapi
report
also
underlin
mortal
rate
caus
c
kefyr
higher
c
albican
addit
c
kefyr
also
report
remark
agent
catheterrel
infect
fourfold
higher
adher
affin
polystyren
surfac
compar
c
albican
method
aim
report
experi
c
kefyr
infect
two
children
underw
haploident
autolog
hematopoiet
stem
cell
transplant
hsct
result
patient
old
girl
primit
neuroectoderm
tumor
lung
underw
autolog
hsct
regimen
busulfanmelphalan
accord
euroew
protocol
day
hsct
hospit
fever
physic
examin
unremark
c
kefyr
grew
cathet
cultur
treat
gcsf
dose
granulocyt
suspens
neutropenia
liposom
amphotericin
b
day
wide
spectrum
antibiot
patient
old
boy
infant
leukemia
underw
cell
receptor
alfa
beta
deplet
haploident
hsct
mother
day
hsct
hospit
bloodi
diarrhea
c
kefyr
grew
stool
cultur
treat
fluconazol
conclus
transplant
physician
vigil
increas
incid
candida
keyfr
emerg
yeast
addit
bloodi
diarrhea
relat
c
kefyr
hsct
may
mimic
gastrointestin
graft
versu
host
diseas
may
caus
diagnost
problem
familiar
yeast
conflict
interest
coauthor
declar
noth
disclos
univers
clinic
hematolog
skopj
macedonia
former
yugoslav
republ
background
multidrug
resist
mdr
bacteria
increasingli
frequent
hsct
recipi
signific
differ
etiolog
bacteri
infect
preval
resist
strain
exist
differ
transplant
center
extendedspectrum
betalactamas
produc
escherichia
coli
vancomicyn
resist
enterococci
penicillinresist
pneumococci
methicillinresist
staphylococcu
aureu
major
problem
manag
aim
evalu
frequenc
multidrug
resist
bacteria
center
clinic
part
caesar
network
multidrug
resist
bacteri
isol
europa
method
year
period
transplant
patient
differ
hematolog
malign
nonmalign
diseas
patient
treat
steril
room
condit
hepa
filter
low
bacteri
diet
antibacteri
prophylaxi
consist
ciprofloxacin
empir
antibiot
regimen
administ
combin
thirdgener
cephalosporin
amynoglicosid
second
line
therapi
imipenemvancomycin
result
everi
patient
time
week
monitor
blood
cultur
central
venou
cathet
cultur
sputum
urin
cultur
bacteri
isol
distribut
mdr
bacteria
esbl
posit
escherichia
coli
vr
enterococcu
mdr
pseudomona
aer
klebsiella
aerogen
mrsa
acinetobact
baumanii
stenotrophomona
maltophilia
fatal
outcom
due
sepsi
patient
vre
mdr
pseudomona
stenotrophomona
maltophilia
conclus
monitor
local
microflora
crucial
everi
transplant
center
empir
firstlin
therapi
must
individu
accord
ecil
escal
deescal
strategi
necesseri
better
outcom
group
immunocompromis
patient
conflict
interest
noth
declar
divis
hematolog
hsct
programm
univers
perugia
perugia
itali
divis
infecti
diseas
univers
perugia
perugia
itali
background
hematopoiet
stem
cell
transplant
hsct
hepat
b
viru
hbv
reactiv
particular
interest
infect
common
worldwid
fact
billion
peopl
infect
hbv
caus
chronic
infect
million
hbv
reactiv
hsct
report
recipi
evid
resolv
hbv
infect
neg
hbv
surfac
antigen
posit
hepat
b
core
antibodi
hbcab
posit
hepat
surfac
antibodi
hbsab
isolatedhbsag
absenc
vaccin
transplant
singlecentr
retrospect
studi
investig
incid
risk
factor
time
hbv
reactiv
patient
histori
resolv
infect
isol
hbsab
underw
allogen
hsct
method
januari
may
allogen
hsctrecipi
enrolledneoplast
diseas
present
fanconi
anemiain
patient
receiv
match
sibl
unrel
donor
transplant
cell
deplet
haplohsct
regulatori
convent
cell
adopt
immunotherapi
treghaplohsct
unmanipulatedhaplohsct
posttranspl
cyclophosphamid
condit
regimen
includ
highdos
chemotherapi
without
tbi
posttranspl
pharmacolog
immunosoppressionwa
given
recipi
transplant
donorsand
hsct
candid
routin
test
hbsag
hbcab
hbsab
recipi
also
test
serum
hbv
dna
asdetermin
polymeras
chain
reaction
versant
k
pcr
evid
hbv
reactiv
develop
posit
hbsag
transplant
chang
serum
level
hbv
dna
result
risk
hbv
reactiv
transplant
recipi
present
evid
resolv
hbv
infect
hbcab
posit
hbsab
isol
hbsab
none
hbsagposit
donor
werehbcab
posit
hbsab
hbv
reactiv
occur
transplant
recipi
risk
median
onset
year
hsct
antivir
prophylaxix
lamivudin
lmv
administ
patient
risk
none
reactiv
test
p
patient
reactiv
receiv
haplohsct
haplohsct
unmanipul
haplohsct
none
develop
acut
chronic
graftvshost
diseas
receiv
immunosoppress
therapi
hbvrelat
death
occur
patient
reactiv
none
develop
acut
hepat
treat
entecavir
conclus
hbv
infect
major
clinic
issu
immunocompromis
patient
includ
allohsct
recipi
consid
number
infect
patient
increas
present
studi
demonstr
hbvreactiv
late
frequent
complic
hsct
among
patient
serolog
evid
resolv
occult
hbv
infect
confirm
lmv
prophylaxi
protect
hbv
reactiv
conflict
interest
none
tokyo
women
medic
univers
hematolog
tokyo
japan
background
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
diseas
common
autolog
hematopoiet
stem
cell
transplant
autohsct
report
show
efficaci
prophylact
antivir
drug
routin
use
prophylaxi
remain
controversi
method
singl
center
retrospect
studi
survey
patient
receiv
autohsct
tokyo
women
medic
univers
hospit
patient
lymphoma
receiv
modifi
beam
regimen
ranimustin
etoposid
cytarabin
melphaln
plasma
cell
disord
pcd
receiv
highdos
melphalan
condit
regimen
receiv
antivir
prophylaxi
hsct
diagnosi
herp
zoster
made
base
presenc
characterist
vesicular
skin
lesion
confirm
antibodytomembran
antigen
test
case
studi
perform
accord
helsinki
declar
approv
ethic
committe
tokyo
women
medic
univers
result
total
patient
analyz
median
age
year
old
median
follow
survivor
month
consist
lymphoma
patient
patient
pcd
tenyear
overal
surviv
rate
lymphoma
patient
pcd
patient
total
patient
experienc
herp
zoster
year
autohsct
oneyear
cumul
incid
herp
zoster
five
patient
develop
dissemin
diseas
among
patient
experienc
day
autohsct
neutrophil
engraft
contrast
earli
intervent
antivir
drug
amelior
diseas
neither
fatal
case
viscer
infect
addit
four
patient
experienc
hsv
diseas
herp
zoster
number
chemotherapi
cycl
autohsct
increas
risk
herp
zoster
hazard
ratio
confidenti
interv
furthermor
four
patient
past
histori
herp
zoster
experienc
two
develop
dissemin
diseas
conclus
cumul
incid
herp
zoster
autohsct
without
antivir
prophylaxi
higher
previous
report
case
longterm
antivir
prophylaxi
prophylact
antivir
drug
earli
autohsct
recommend
dissemin
herp
zoster
case
case
engraft
excess
risk
outbreak
fatal
infect
patient
high
number
chemotherapi
cycl
past
histori
respect
signific
risk
factor
herp
zoster
autohsct
longterm
antivir
prophylaxi
may
effect
patient
risk
factor
conflict
interest
work
support
jpss
kakenhi
grant
number
ircc
san
raffael
hospit
hematolog
bone
marrow
transplant
unit
milano
itali
san
giusepp
moscati
hospit
hematolog
bone
marrow
transplant
unit
taranto
itali
background
mortal
due
sever
bacteri
sepsi
ss
occur
posttranspl
aplasia
remain
unaccept
high
rang
especi
true
case
multidrug
resist
bacteria
firstlin
antimicrobi
therapi
inadequ
suggest
opportun
immuneintervent
approach
synerg
standard
treatment
reduc
infectionrel
mortal
irm
aim
studi
explor
whether
addit
igmenrich
immunoglobulin
igmigiv
standard
antimicrobi
therapi
potenti
reduc
irm
improv
overal
surviv
os
day
infect
onset
method
total
adult
patient
develop
ss
accord
standard
criteria
retrospect
evalu
april
patient
receiv
igmigiv
consecut
day
adjunct
firstlin
therapi
antimicrobi
agent
kaplanmei
curv
use
estim
os
diseas
recurr
gvhd
death
caus
compet
risk
irm
univari
comparison
surviv
curv
made
use
logrank
test
gray
test
use
univari
comparison
ci
function
result
sixteen
patient
receiv
autolog
hsct
autohsct
allogen
hsct
allohsct
chemotherapi
alon
ct
median
followup
infect
onset
day
rang
major
patient
diagnos
acut
leukemia
activ
diseas
ss
onset
beyond
firstlin
therapi
nine
carri
carbapenemresist
klebsiella
pneumonia
kpc
patient
grade
iv
neutropenia
clinicallydocu
ss
mostli
due
kpc
follow
escherichia
coli
pseudomona
aeruginosa
pa
acinetobact
baumanii
gramposit
bacteria
isol
firstlin
antimicrobi
therapi
consid
inadequ
patient
despit
progress
septic
shock
igmigiv
use
surviv
day
ss
onset
overal
autohsct
allohsct
ct
entir
cohort
surviv
ss
onset
accord
pathogen
case
isol
gramposit
kpc
gramneg
bacteria
overal
surviv
day
transplant
similar
compar
autohsct
allohsct
vs
regardless
preval
ss
caus
kpc
pa
allohsct
group
vs
interestingli
death
regist
kpcrelat
ss
hsct
patient
igmigiv
use
adjunct
therapi
irm
auto
allohsct
respect
conclus
earli
addit
igmigiv
antimicrobi
therapi
hsct
neutropen
patient
develop
ss
could
amelior
os
reduc
infectionrel
mortal
thu
improv
overal
transplant
outcom
knowledg
largest
studi
investig
role
igmigiv
hsct
patient
certainli
warrant
confirm
prospect
wider
cohort
patient
clinic
trial
registri
applic
conflict
interest
forcina
biotest
consult
santa
maria
della
misericordia
hospit
pediatr
oncolog
hematolog
perugia
itali
santa
creu
hospit
pediatr
hematolog
sant
pau
spain
la
paz
hospit
pediatr
hematolog
madrid
spain
univers
colleg
medic
school
divis
infect
immun
london
unit
kingdom
univers
verona
pediatr
oncolog
hematolog
verona
itali
background
human
herp
viru
hhv
infect
increasingli
recogn
among
allogen
hematopiet
stem
cell
transplant
hsct
recipi
risk
reactiv
highrisk
patient
although
infect
transient
selflimit
sometim
associ
enceph
acut
graftversushost
diseas
agvhd
graft
failur
report
two
cohort
pediatr
manipul
hsct
reactiv
diseas
repres
main
earli
posttranspl
infecti
complic
method
two
cohort
recruit
pediatr
median
age
year
transplant
center
perugia
barcelona
madrid
patient
acut
leukemia
receiv
myeloabl
condit
regimen
tbi
tli
exvivo
graft
manipul
select
tregtcon
infus
patient
martelli
mf
et
alblood
tcell
deplet
patient
median
content
respect
antivir
prophylaxi
aciclovir
foscarnet
patient
dnaemia
cmv
adenoviru
check
quantit
qualit
pcr
twice
week
condit
regimen
start
recoveri
reactiv
enceph
defin
ecil
guidelin
wwwecilleukemiacom
result
patient
engraft
median
day
respect
reactiv
median
day
infus
rang
median
viral
load
blood
copiesml
rang
eight
patient
develop
limbic
enceph
cn
fluid
receiv
antivir
treatment
foscarnet
mgkg
twice
day
ganciclovir
mgkg
twice
day
foscarnet
plu
ganciclovir
day
rang
patient
respond
treatment
symptom
improv
negativ
dnaemia
blood
cn
none
die
even
three
patient
experienc
longterm
neurolog
sequela
moreov
suspect
symptomat
organ
diseas
patient
differ
local
liver
lung
stomach
multiorgan
enceph
pneumonia
gastriti
pneumonia
enter
infect
document
organ
sampl
broncoalveolar
lavag
liver
gastric
bowel
biopsi
dnaemia
higher
blood
patient
respond
antivir
treatment
foscarnet
mg
mgkg
twice
day
infect
associ
grade
agvhd
patient
gut
liver
graft
failur
differ
term
efficaci
observ
foscarnet
dosag
lowest
dose
associ
less
toxic
differ
term
immunolog
reconstitut
observ
patient
develop
diseas
patient
conclus
infect
frequent
viral
complic
pediatr
patient
undergo
haploident
hsct
despit
absenc
lethal
case
good
respons
current
antivir
drug
determin
prolong
hospit
signific
morbid
organ
diseas
agvhd
graft
failur
occurr
treatment
could
associ
toxic
moreov
central
nervou
system
involv
may
caus
neurolog
longterm
sequela
suggest
dnaemia
monitor
use
transplant
set
order
diagnos
treat
earli
preemptiv
infect
conflict
interest
k
perruccio
noth
disclos
univers
torino
depart
molecular
biotechnolog
health
scienc
torino
itali
ssd
trapianto
allogenico
di
cellul
staminali
aou
della
salut
e
della
scienza
di
torino
depart
oncolog
torino
itali
aou
della
salut
e
della
scienza
di
torino
clinic
epidemiolog
torino
itali
sc
baldi
e
riberi
aou
della
salut
e
della
scienza
di
torino
depart
clinic
chemistri
torino
itali
background
creactiv
protein
crp
procalcitonin
pct
propos
potenti
biomark
differenti
diagnosi
inflammatori
complic
bacteri
nonbacteri
infect
patient
hematolog
malign
purpos
studi
determin
potenti
role
pct
crp
test
differenti
febril
complic
recipi
allograft
first
day
transplant
method
fourhundredfortyf
patient
underw
allograft
januari
decemb
center
simultan
determin
pct
crp
perform
patient
includ
current
analysi
donor
hlaident
sibl
haploident
unrel
total
simultan
pct
crp
determin
day
day
perform
febril
episod
pct
crp
serum
valu
defin
posit
valu
ng
mgl
respect
data
retrospect
retriev
computeris
databas
depart
clinic
chemistri
standard
fever
workup
also
includ
blood
cultur
chest
x
ray
blood
chemistri
blood
count
simultan
crp
pct
level
use
defin
studi
group
level
pct
crp
posit
neg
pct
posit
crp
pct
crp
neg
correl
pct
crp
level
clinic
complic
evalu
margin
effect
predict
probabl
accord
multivari
multinomi
logist
model
result
overal
pct
valu
posit
compar
posit
crp
valu
pctcrp
determin
done
first
day
transplant
median
day
constant
increas
simultan
determin
pctcrp
throughout
studi
period
determin
group
categor
follow
neg
pctcrp
neg
pctposit
crp
posit
pctcrp
determin
show
posit
pct
neg
crp
onset
document
gramneg
infect
posit
pctcrp
valu
seen
highli
signific
compar
patient
document
infect
p
patient
document
invas
fungal
infect
probabl
discord
valu
pctnegativecrp
posit
show
posit
valu
patient
develop
cytokin
releas
syndrom
cr
day
haploident
allograft
probabl
posit
pct
level
wherea
crp
almost
invari
high
statist
signific
differ
patient
without
cr
report
probabl
posit
pctcrp
antithymocyt
globulin
atg
treatment
graftvshost
diseas
prophylaxi
high
significantli
higher
receiv
atg
conclus
despit
limit
retrospect
design
studi
simultan
pctcrp
determin
help
differenti
diagnosi
differ
complic
allograft
find
form
basi
investig
specif
diagnost
algorithm
includ
pctcrp
determin
monitor
inflammatori
infecti
complic
allograft
conflict
interest
noth
disclos
univers
medic
center
johann
gutenberg
univers
depart
hematolog
medic
oncolog
pneumolog
mainz
germani
background
invas
fungal
diseas
ifd
still
repres
major
threat
immunocompromis
patient
especi
allogen
hematopoiet
stem
cell
transplant
hsct
despit
fact
limit
data
avail
regard
incid
epidemiolog
ifd
hsct
era
antifung
prophylaxi
therefor
aim
studi
analyz
ifd
local
hsct
patient
ensur
adequaci
antifung
manag
method
patient
treat
allogen
hsct
januari
decemb
retrospect
analyz
regard
patient
characterist
like
age
gender
underli
diseas
diseas
statu
type
transplant
overal
surviv
os
addit
patient
suspect
ifd
investig
regard
diagnost
procedur
type
ifd
ifdrel
mortal
other
result
januari
decemb
patient
underw
allogen
hsct
center
patient
mainli
male
median
age
year
rang
patient
suffer
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
prior
hsct
patient
treat
mainli
use
reduc
intens
condit
ric
regiment
unrel
match
donor
mud
serv
stem
cell
sourc
patient
receiv
prophylact
prolong
therapeut
antifung
broadspectrum
medic
mainli
posaconazol
patient
found
possibl
ifd
accord
revis
european
organ
research
treatment
cancermycos
studi
group
eortcmsg
criteria
patient
present
probabl
ifd
wherea
patient
fungal
pathogen
could
isol
repres
proven
ifd
detect
isol
candida
spp
aspergillu
spp
patient
probableproven
ifd
incid
median
age
year
rang
mainli
suffer
aml
mainli
underw
ric
allogen
hsct
mud
invas
pulmonari
diseas
common
site
probableproven
fungal
infect
transplant
recipi
provenprob
ifd
treat
often
intens
care
unit
icu
indic
higher
morbid
popul
trend
ifd
vs
nonifd
univari
analysi
progress
underli
diseas
prior
transplant
ifd
vs
nonifd
associ
higher
incid
probableproven
ifd
trend
howev
patient
receiv
posaconazol
po
antifung
agent
less
frequent
diagnos
ifd
compar
nonpo
treat
transplant
recipi
po
ifd
vs
nonifd
oneyear
os
ifdpati
lower
trend
nonifd
popul
conclus
even
presenc
broadspectrum
antifung
medic
signific
percentag
patient
allogen
hsct
suspect
ifd
result
higher
morbitiy
mortal
presenc
refractori
malign
diseas
associ
ifd
shown
howev
posaconazol
medic
seem
protect
antifung
agent
posaconazol
treat
transplant
recipi
show
less
frequent
probableproven
ifd
although
rel
high
incid
possibl
ifd
indic
lack
suffici
diagnost
workup
address
futur
optim
antifung
manag
patient
cohort
conflict
interest
j
moehrk
e
wagnerdrouet
theobald
noth
disclos
radsak
honoraria
consult
travel
grant
celgen
novarti
travel
grant
daiichi
sankyo
astella
gilead
teschner
honoraria
travel
grant
gilead
msd
honoraria
pfizer
travel
grant
astella
jazz
consult
advisori
board
msd
gilead
pfizer
bc
cancer
leukemia
bone
marrow
transplant
program
british
columbia
vancouv
canada
thammasat
univers
div
hematolog
dept
intern
medicin
pathumthani
thailand
background
hypogammaglobulinemia
hgg
common
complic
allogen
stem
cell
transplant
allosct
practic
vari
across
center
respect
immunoglobulin
ig
level
monitor
replac
strategi
studi
aim
identifi
risk
factor
hgg
effect
intraven
immunoglobulin
ivig
replac
allosct
outcom
cohort
adult
acut
leukemia
myelodysplast
syndrom
md
patient
method
analyz
risk
factor
hgg
patient
underw
allosct
acut
myeloid
leukemia
aml
md
acut
lymphoblast
leukemia
patient
categor
normal
ig
level
igg
gl
mild
hgg
igg
gl
sever
hgg
igg
gl
risk
factor
develop
hgg
analyz
use
multivari
ordin
logist
regress
overal
surviv
os
eventfre
surviv
ef
incid
infect
compar
result
identifi
patient
underw
allosct
md
aml
threeyear
period
igg
level
day
avail
myeloabl
regimen
use
case
reducedintens
case
donor
sibl
case
unrelateddonor
case
cord
blood
case
haploident
case
ig
level
normal
case
mild
hgg
case
sever
hgg
case
adjust
diseas
statu
preallosct
allosct
type
receipt
methotrex
donor
type
prednison
dose
acut
graftversushost
diseas
agvhd
grade
odd
ratio
grade
p
predict
hgg
cytomegaloviru
cmv
posit
donor
mitig
risk
hgg
compar
cmv
neg
pair
dr
follow
dr
dr
purpos
surviv
analysi
patient
subclassifi
normal
ig
case
mild
hgg
ivig
case
sever
hgg
ivig
case
mild
hgg
without
ivig
case
sever
hgg
without
ivig
case
sever
hgg
without
ivig
significantli
associ
wors
ef
ahr
p
figur
adjust
diseas
statu
preallosct
comorbid
index
gvhd
prophylaxi
regimen
receipt
methotrex
dose
donor
type
histocompat
mismatch
graft
sourc
agvhd
cmv
reactiv
prednison
dose
howev
ivig
replac
hgg
statu
associ
os
multivari
analysi
cumul
incid
infect
group
shown
figur
significantli
increas
incid
year
sever
hgg
without
ig
replac
conclus
result
show
sever
hgg
occur
one
fifth
patient
acut
gvhd
increas
risk
hgg
patient
receiv
transplant
cmv
reactiv
donor
reduc
risk
hgg
hgg
ivig
replac
affect
os
sever
hgg
without
ivig
replac
associ
inferior
ef
data
suggest
replac
therapi
given
patient
sever
hgg
infect
rate
reduc
ig
replac
sever
nonsever
hgg
group
conflict
interest
gerri
honoraria
seattl
genet
lundbeck
advisori
committe
janssen
hogg
consult
novarti
roch
sanofi
h
sutherland
honoraria
janssen
c
toze
honoraria
csl
bere
author
conflict
interest
declar
candiolo
cancer
institutefpo
ircc
medic
oncolog
hematopoiet
stem
cell
unit
candiolo
itali
turin
metropolitan
transplant
center
torino
itali
aou
citta
della
salut
e
della
scienza
di
torino
ospedal
infantil
regina
margherita
pediatr
oncohematolog
stem
cell
transplant
cellular
therapi
divis
torino
itali
candiolo
cancer
institutefpo
ircc
collect
process
laboratori
candiolo
itali
univers
torino
depart
oncolog
torino
itali
background
posttranspl
cyclophosphamid
ptci
hlamatch
bone
marrow
haploident
hematopoiet
cell
transplant
increasingli
use
due
effect
graftversushost
diseas
gvhd
control
recent
report
ptci
allogen
peripher
blood
stem
cell
transplant
allopbsct
exert
control
gvhd
impact
infect
complic
still
investig
perform
retrospect
studi
infecti
complic
adult
patient
receiv
ptci
allopbsct
method
consecut
patient
underw
allopbsct
ptci
march
juli
fpoircc
candiolo
itali
includ
receiv
pbsct
ptci
day
tacrolimu
mycophenol
mofetil
gvhd
prophylaxi
reduc
intens
condit
regimen
use
patient
myeloabl
regimen
recipi
donor
cmvposit
main
transplant
outcom
incid
bacteri
fungal
viral
infect
evalu
result
patient
median
age
transplant
rang
year
patient
myeloid
malign
lymphoid
malign
median
dose
rang
x
infus
median
followup
rang
month
overal
surviv
progressionfre
surviv
nonrelaps
mortal
respect
grade
iiiv
acutegvhd
observ
patient
chronicgvhd
cumul
incid
ci
oneyear
infect
ci
episod
occur
patient
event
identifi
neutrophil
aplasia
day
median
day
occurr
rang
patient
develop
pneumonia
due
gramneg
gn
rod
due
gramposit
gp
bacteria
patient
experienc
gn
urosepsi
twentyfour
bloodstream
infect
due
gp
bacteria
gn
rod
one
patient
die
pseudomona
aeruginosa
sepsi
infect
relat
mortal
irm
hospit
requir
patient
fever
pneumonia
clostridium
difficil
infect
success
treat
discharg
one
patient
giardia
lamblia
gastrointestin
infest
cure
metronidazol
patient
cytomegaloviru
cmv
reactiv
median
time
day
rang
treat
valganciclovir
preemptiv
treatment
none
develop
cmv
associ
diseas
five
patient
bk
hemorrhag
cystiti
herp
zoster
viru
vzv
reactiv
resolv
valacyclovir
patient
hepat
b
viru
hbv
posit
hct
viral
reactiv
lamivudin
prophylaxi
requir
entecavir
one
hepat
c
viru
hcv
posit
patient
start
sofosbuvirvelpatasvir
hct
increas
viral
load
patient
probabl
fungal
pneumonia
evid
chest
ct
scan
galactomannan
posit
cure
voriconazol
conclus
conclus
data
show
allopbsct
follow
ptci
associ
low
incid
infect
complic
occur
mainli
within
first
day
allohct
possibl
explan
could
effect
control
acut
chronic
gvhd
consequ
earli
discontinu
immunosuppress
major
patient
conflict
interest
author
noth
disclos
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
imib
univers
murcia
haematolog
servic
stem
cell
transplant
unit
el
palmar
murcia
spain
background
infect
common
signific
caus
mortal
morbid
allogen
hematopoiet
stem
cell
transplant
allohsct
method
retrospect
observ
studi
patient
age
year
undergo
allohsct
tertiari
hospit
januari
decemb
studi
total
pediatr
patient
underw
allo
hsct
median
followup
month
receiv
cord
blood
cb
peripher
blood
pb
haploident
pb
bone
marrow
bm
assess
infect
incid
earli
day
intermedi
late
sinc
day
period
post
allohsct
infect
defin
isol
bacteri
viral
fungal
pathogen
associ
symptom
diseas
bacteremia
sepsi
septic
shock
defin
consensu
criteria
pediatr
intens
care
spanish
societi
pediatr
emerg
spanish
societi
secipseup
alonso
sala
mt
et
al
result
regard
viral
infect
cb
recipi
develop
viral
infect
rate
three
post
allohsct
period
frequent
viral
pathogen
detect
blood
stream
cmv
group
follow
bk
viru
intermedi
period
epstein
barr
viru
ebv
post
allohsct
period
frequent
pathogen
isol
urin
bk
viru
stool
adenoviru
period
upper
respiratori
tract
frequent
pathogen
isol
parainfluenza
viru
follow
rhinoviru
regard
bacteri
infect
earli
post
allohsct
patient
suffer
febril
syndrom
sepsi
bacteri
pathogen
isol
along
whole
followup
frequent
pathogen
isol
blood
stream
without
symptom
sepsi
staphylococcu
epidermidi
follow
staphylococcu
homini
earli
intermedi
post
allohsct
urinari
tract
infect
mainli
due
eschecherichia
coli
follow
klebsiella
pneumonia
stool
frequent
pathogen
isol
clostridium
difficil
along
followup
follow
camylobact
jejunii
intermedi
late
period
upper
respiratori
tract
found
haemophilu
influenza
late
period
regard
fungal
infect
detect
cutan
oral
candidiasi
period
post
allohsct
case
isol
aspergillu
niger
possibl
invas
fungal
infect
lower
respiratori
tract
anoth
case
isol
candida
glabrata
stool
associ
pneumonia
spleen
abscess
mortal
rate
one
patient
die
septic
shock
die
relapseprogress
gvhd
conclus
data
describ
incid
infect
pediatr
allohsct
program
find
statist
differ
incid
viral
bacteri
fungal
infect
earli
intermedi
late
period
patient
receiv
cb
haploident
pb
bm
stem
cell
stem
cell
sourc
seem
affect
incid
infect
complic
allohsct
number
patient
small
subgroup
conflict
interest
none
abstract
previous
publish
univers
colleg
london
infect
london
unit
kingdom
karolinska
univers
hospit
stockholm
sweden
ebmt
data
offic
leiden
netherland
univers
freiburg
freiburg
germani
univers
hospit
leipzig
leipzig
germani
germani
chu
lapeyroni
montpelli
franc
jesu
children
hospit
madrid
spain
hospit
universitari
la
fe
valencia
spain
centr
henri
becquerel
rouen
franc
freeman
hospit
newcastleupontyn
unit
kingdom
hospit
santa
creu
sant
pau
barcelona
spain
henri
mondor
creteil
franc
ospedal
san
martino
genova
itali
rigshospitalet
copenhagen
denmark
univers
hospit
basel
switzerland
sheffield
teach
hospit
nh
foundat
trust
sheffield
unit
kingdom
chaim
sheba
medic
center
tel
hashom
israel
first
state
pavlov
medic
univers
st
petersburg
st
petersburg
russian
feder
children
hospit
westmead
sydney
australia
univers
hospit
eppendorf
hamburg
germani
hospit
region
de
malaga
spain
beilinson
hospit
petachtivka
israel
univers
children
hospit
switzerland
gartnav
gener
hospit
glasgow
unit
kingdom
hospit
u
de
valdecilla
santand
spain
hospit
de
la
princesa
madrid
spain
madrid
spain
turku
univers
hospit
turku
finland
ospedal
donna
bambino
verona
itali
univers
hospit
collegium
medicum
umk
bydgoszcz
poland
background
import
caus
enceph
posthsct
epidemiolog
risk
factor
well
characteris
case
previous
report
children
optim
antivir
therapi
unknown
method
case
transplant
januari
decemb
collect
enceph
defin
dna
detect
csf
coincid
acuteonset
alter
mental
statu
encephalopathi
short
term
memori
loss
seizur
data
collect
ct
mri
clinic
outcom
includ
neurolog
sequela
antivir
therapi
time
start
durat
result
case
centr
fulfil
definit
enceph
fifti
two
myeloid
neoplasm
lymphoid
diseas
case
children
yr
adult
patient
male
femal
mortal
enceph
high
lower
children
versu
older
adult
respect
cb
hsct
lower
bmpb
hsct
mortal
associ
gvhd
half
case
except
cb
hsct
abbrevi
tabl
bm
bone
marrow
cb
cord
blood
myeloabl
nma
nonmyeloabl
nk
known
pb
peripher
blood
bmpb
hsct
ident
sibl
mismatch
relat
unrel
die
within
month
enceph
case
receiv
transplant
dead
within
month
nineti
one
case
receiv
antivir
therapi
foscarnet
ganciclovir
ganciclovir
foscarnet
cidofovir
mortal
within
month
enceph
foscarnet
ganciclovir
ganciclovir
foscarnet
none
cidofovir
case
median
time
hsct
detect
dna
csf
day
interv
day
median
time
children
detect
dna
day
adult
age
year
median
time
dna
detect
csf
cb
transplant
day
versu
bm
pb
hsct
conclus
mortal
enceph
high
children
adult
occur
myeloabl
nonmyeloabl
hsct
antivir
therapi
similarli
dismal
outcom
enceph
usual
expect
occur
within
week
transplant
studi
one
third
case
occur
later
conflict
interest
k
ward
noth
disclos
tabl
patient
characterist
outcom
istanbul
univers
istanbul
faculti
medicin
intern
medicin
depart
istanbul
turkey
istanbul
univers
istanbul
faculti
medicin
intern
medicin
depart
divis
hematolog
istanbul
turkey
medipol
univers
depart
intern
medicin
divis
hematolog
istanbul
turkey
background
multipl
myeloma
mm
b
cell
lymphoprolif
disord
immun
paralysi
relat
biolog
diseas
treatment
caus
infect
along
cours
diseas
aim
character
epidemiolog
infect
mm
patient
autolog
hsct
era
new
drug
induct
method
medic
record
mm
patient
receiv
autolog
hsct
may
novemb
institut
review
evalu
infect
epidemiolog
primari
analysi
includ
data
infecti
outcom
mortal
first
day
posthsct
secondari
analysi
compar
outcom
among
differ
prior
therapi
vad
regimen
obligatori
first
line
induct
regimen
transplant
elig
patient
bortezomib
base
therapi
could
use
patient
renal
failur
cardiac
comorbid
countri
patient
receiv
antimicrobi
prophylaxi
fluconazol
ciprofloxacin
acyclovir
high
dose
melphalan
sole
condit
regimen
result
nearli
patient
receiv
two
line
induct
regimen
vad
follow
bortezomib
base
induct
regimen
median
durat
neutropenia
granulocyt
count
x
l
day
overal
incid
fever
requir
antimicrobi
treatment
patient
fever
unknown
origin
fuo
wherea
primari
bacteremia
occur
pneumonia
sever
skin
infect
patient
patient
experienc
candidi
andor
herpet
stomat
despit
prophylaxi
invas
fungal
infect
occur
enterocol
one
patient
infect
relat
death
studi
period
one
patient
die
diseas
progress
frequent
isol
pathogen
gramposit
cocci
patient
experienc
cmv
infect
firstlin
antimicrobi
therapi
success
patient
fuo
surviv
patient
posit
blood
cultur
found
significantli
shorter
posit
urin
cultur
also
unfavor
effect
surviv
statist
signific
signific
associ
cell
dose
febril
neutropenia
diseas
age
influenc
antimicrobi
treatment
line
conclus
retrospect
studi
singl
center
experi
show
histor
motion
mm
treatment
turkey
epidemiolog
infect
reflect
local
flora
build
base
empir
antimicrobi
treatment
indic
also
infect
major
morbid
reason
major
caus
death
autolog
hsct
conflict
interest
author
noth
disclos
tabl
blood
urin
cultur
amar
carvalho
foundat
hsct
program
jahu
brazil
univers
paulo
institut
tropic
medicin
sao
paulo
brazil
background
influenza
inf
viral
infect
seriou
even
immunocompet
host
hsct
recipi
earli
diagnosi
treatment
necessari
avoid
complic
inf
especi
progress
pneumonia
amar
carvalho
hospit
ach
inf
control
polici
hsct
unit
includ
annual
vaccin
daili
monitor
symptom
respiratori
sampl
presenc
symptom
treatment
oseltamivir
inf
b
detect
retrospect
compar
frequenc
complic
mortal
proven
case
inf
b
diagnos
hsct
program
ach
method
tcth
candid
perform
respiratori
viru
screen
admiss
hsct
unit
transplant
nasal
wash
sampl
taken
presenc
respiratori
symptom
inf
b
diagnosi
made
dfa
rtpcr
oseltamivir
introduc
physician
discret
patient
chart
imag
retrospect
review
investig
result
identifi
case
inf
case
occur
transplant
candid
condit
median
day
vari
day
remain
case
median
age
year
rang
year
thirti
patient
inf
inf
b
median
durat
excret
evalu
patient
day
diagnosi
patient
upper
respiratori
symptom
radiolog
alter
suggest
pneumonia
frequent
symptom
cough
fever
coryza
nasal
congest
sore
throat
oseltamivir
given
patient
treatment
durat
rang
day
median
day
quinolon
use
patient
receiv
antibiot
therapi
ten
patient
develop
pneumonia
despit
use
oseltamivir
two
patient
die
despit
treatment
oseltamivir
present
resolut
process
complic
without
complic
two
death
inf
regard
morbid
differ
inf
inf
b
conclus
clinic
manifest
complic
similar
patient
inf
inf
b
infect
inf
mortal
conflict
interest
clariss
machado
noth
disclos
g
papanikola
hospit
hematolog
depart
hct
unit
thessaloniki
greec
background
cmv
infect
post
allogen
hematopoet
cell
transplant
allohct
remain
signific
factor
morbid
transplant
despit
close
monitor
cmv
viral
load
preemptiv
use
specif
antivir
treatment
posit
impact
howev
graft
versu
leukemia
gvl
effect
cytotox
lymphocyt
expans
suggest
method
retrospect
studi
incid
cmv
reactiv
patient
underw
allohct
intens
preemptiv
antivir
therapi
standard
care
clinic
possibl
clinicobiolog
correl
sought
patient
suffer
hematolog
malign
aplast
anemia
receiv
graft
match
sibl
volunt
haploident
rel
donor
myeloabl
reduc
intens
condit
ric
ninetytwo
patient
transplant
cr
cmv
reactiv
consid
viral
load
viral
genom
copi
vgc
ml
plasma
document
regular
weekli
molecular
monitor
viral
load
rqpcr
case
patient
receiv
preemptiv
therapi
valacyclovir
gancyclovir
foscarnet
two
consecut
sampl
viral
load
vgcml
consid
success
clearanc
viremia
result
overal
patient
present
cmv
reactiv
median
day
resolut
achiev
patient
median
day
among
patient
present
new
reactiv
nineteen
patient
succumb
day
reactiv
reactiv
significantli
correl
myeloabl
condit
vs
ric
haploident
donor
haplo
vs
vud
vs
sibl
ebv
viremia
patient
ebv
vs
without
p
comparison
relaps
free
surviv
rf
similar
regardless
presenc
cmv
overal
surviv
os
significantli
wors
patient
cmv
vs
month
ci
vs
ebv
reactiv
vs
month
ci
vs
os
differ
among
patient
differ
type
transplant
donor
pretranspl
statu
chronic
gvhd
patient
present
earli
day
reactiv
cmv
consid
rf
os
significantli
chang
conclus
current
studi
despit
regular
monitor
earli
use
preemptiv
therapi
reactiv
cmv
relat
wors
overal
surviv
similar
rf
without
benefit
possibl
gvl
action
use
specif
antivir
cytotox
cell
line
promis
better
outcom
immunocompromis
allograft
patient
conflict
interest
none
author
anyth
disclos
henri
mondor
hospit
hematolog
creteil
franc
lyon
sud
hospit
hematolog
lyon
franc
pasteur
institut
mycolog
pari
franc
saint
loui
hospit
pari
franc
henri
mondor
hospit
public
health
creteil
franc
background
invas
aspergillosi
ia
remain
lifethreaten
complic
allogen
hematopoiet
stem
cell
transplant
hsct
mainli
driven
gvhd
howev
hsct
procedur
indic
chang
time
could
modifi
risk
compar
histor
seri
conduct
studi
hsct
recipi
order
identifi
pre
posttranspl
factor
associ
occurr
ia
allogen
hsct
method
retrospect
multicent
casecontrol
studi
carri
two
prospect
registri
saif
surveil
de
aspergillos
invas
en
franc
institut
pasteur
pari
french
registri
ia
hsct
promis
registri
ebmt
nineteen
center
particip
repres
allogen
hsct
perform
period
time
identifi
consecut
case
proven
probabl
ia
occur
allogen
hsct
recipi
saif
four
control
individu
match
center
age
year
transplant
recruit
among
patient
develop
ia
hsct
promis
registri
analyz
pre
posttranspl
risk
factor
accord
time
ia
result
identifi
case
probabl
proven
ia
accord
eortcmsg
criteria
control
median
date
ia
day
earli
day
ia
late
ia
late
ia
consid
pretranspl
factor
earli
ia
tend
associ
unrel
donor
absenc
complet
remiss
late
ia
atg
use
condit
late
ia
associ
dr
cmv
serolog
tend
associ
underli
diseas
consid
pre
posttranspl
factor
earli
ia
significantli
associ
lack
engraft
tend
associ
absenc
complet
remiss
late
ia
grade
acut
gvhd
tend
associ
relaps
transplant
late
ia
grade
acut
gvhd
relaps
transplant
secondari
neutropenia
conclus
ia
observ
allogen
hsct
nowaday
late
event
two
third
case
occur
least
two
third
case
observ
ten
year
ago
late
case
differ
risk
factor
earlier
case
rais
differ
issu
prophylact
strategi
take
account
specif
risk
factor
ia
occur
especi
gvhd
relaps
secondari
neutropenia
clinic
trial
registri
applic
conflict
interest
noth
disclos
tabl
multivari
analysi
pre
posttranspl
univers
genoa
dissal
ospedal
policlinico
san
martino
divis
infecti
diseas
genoa
itali
policlinico
gb
rossi
verona
itali
ebmt
data
offic
leiden
netherland
poznan
univers
medic
scienc
poznan
poland
hospit
u
de
valdecilla
santand
spain
centr
hospitali
lyonsud
lyon
franc
univers
hospit
basel
switzerland
st
loui
pari
franc
ospedal
san
gerardo
monza
itali
chu
de
dijon
dijon
franc
timon
marseil
franc
leiden
univers
hospit
leiden
netherland
institut
paoli
calmett
marseil
franc
aou
citta
della
salut
e
della
scienza
di
torino
torino
itali
chu
bordeaux
bordeaux
franc
huch
comprehens
cancer
center
helsinki
finland
addenbrook
hospit
cambridg
unit
kingdom
gustav
roussi
villejuif
franc
tartu
univers
hospit
tartu
estonia
tor
vergata
univers
rome
itali
ico
hospit
duran
reynal
barcelona
spain
univers
hospit
collegium
medicum
umk
bydgoszcz
poland
background
immunocompromis
patient
particularli
transplant
recipi
increas
risk
legionella
infect
howev
data
legionellosi
hsct
come
mainli
case
singlecentr
case
seri
predictor
factor
influenc
outcom
remain
unknown
aim
studi
report
case
legionellosi
hsct
present
ebmt
registri
identifi
predictor
legionellosi
legionellaassoci
death
nonrelaps
mortal
nrm
patient
infect
method
registrybas
studi
perform
identifi
case
posthsct
legionellosi
analys
risk
factor
control
identifi
ratio
follow
match
criteria
centr
year
transplant
length
followup
least
day
diagnosi
legionellosi
case
result
year
case
centr
countri
identifi
main
countri
franc
itali
spain
median
case
per
year
report
rang
median
time
hsct
diagnosi
legionellosi
day
rang
patient
develop
legionellosi
within
month
posthsct
month
hsct
month
month
hsct
patient
mostli
male
median
age
year
rang
diagnos
mainli
acut
leukaemia
lymphoma
multipl
myeloma
chronic
myeloid
leukaemia
patient
underli
diseas
relaps
year
develop
legionellosi
patient
develop
legionellosi
first
allohsct
first
autohsct
patient
includ
analysi
predictor
legionellosi
compar
control
case
like
undergon
first
second
hsct
p
complet
remiss
free
infect
month
develop
legionellosi
also
slightli
like
receiv
allohsct
auto
hsct
overal
patient
die
due
legionellosi
among
patient
legionellosi
predictor
death
due
legionella
identifi
fewer
patient
die
decad
compar
previou
one
vs
predictor
nrm
cohort
time
hsct
legionellosi
hr
ci
femal
sex
hr
ci
particular
patient
develop
legionellosi
within
month
hsct
twice
high
nrm
compar
case
develop
later
hr
ci
conclus
legionellosi
rare
complic
hsct
occur
mainli
first
year
post
hsct
associ
mortal
rate
almost
decreas
last
decad
probabl
due
improv
rapid
diagnosi
treatment
sinc
legionellosi
frequent
affect
patient
remiss
without
infecti
complic
correct
manag
import
order
preserv
benefit
confer
transplant
conflict
interest
author
noth
disclos
ircc
san
raffael
scientif
institut
hematolog
bmt
unit
milan
itali
background
invas
fungal
diseas
ifd
lead
caus
morbid
infectionrel
mortal
among
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
consid
bedsid
reliabl
realtim
noninvas
techniqu
lung
ultrasound
us
could
signific
role
diagnost
workup
followup
lung
lesion
also
oncohematolog
area
method
prospect
nonintervent
studi
bedsid
lung
us
examin
perform
diagnosi
day
start
antifung
treatment
convex
probe
ge
healthcar
use
agreement
literatur
lichtenstein
et
al
hemithorax
divid
area
anterior
later
posterior
criterion
determin
echograph
diagnosi
pneumonia
find
subpleur
lung
consolid
evid
static
dynam
air
bronchogram
result
ten
consecut
patient
includ
studi
within
month
recruit
period
patient
establish
diagnosi
pulmonari
invas
fungal
diseas
ifd
accord
eortcmsg
definit
patient
consid
high
risk
develop
posttranspl
ifd
accord
gitmo
criteria
patient
median
age
receiv
allogen
hsct
highrisk
hematolog
malign
acut
leukemia
cml
hl
nhl
patient
complet
remiss
stem
cell
donor
famili
haploident
hla
ident
sibl
n
unrel
volunt
n
stem
cell
sourc
tcell
replet
pbsc
patient
receiv
treosulfanbas
condit
regimen
gvhd
prophylaxi
ptci
sirolimu
earli
hsct
procedur
neutrophil
engraft
major
patient
document
possibl
probabl
pulmonari
ifd
posaconazol
use
antifung
therapi
case
voriconazol
isavuconazol
patient
combin
ambisom
plu
azol
necessari
patient
lung
us
perform
case
concomitantli
gold
standard
highresolut
ct
scan
diagnosi
pneumonia
confirm
baselin
us
patient
patient
show
consolid
frequent
side
lung
rather
right
left
side
lung
one
present
air
bronchogram
contigu
focal
bline
pleural
line
attenu
correspond
affect
area
evid
case
pleural
basal
effus
detect
patient
followup
document
clinic
improv
demonstr
also
ct
scan
lung
us
patient
except
one
pneumon
lesion
appear
sonograph
smaller
volum
pleural
effus
decreas
patient
document
ifd
respons
importantli
us
find
result
compar
ct
scan
result
conclus
lung
us
shown
promis
techniqu
due
high
sensit
detect
lung
lesion
also
followup
examin
advantag
save
time
money
particular
contribut
us
techniqu
could
potenti
relev
multidisciplinari
ifd
manag
highrisk
popul
especi
compar
time
radiat
exposur
requir
obtain
result
radiolog
survey
clinic
trial
registri
na
conflict
interest
noth
disclos
kyoto
univers
depart
hematolog
graduat
school
medicin
kyoto
japan
background
viral
infect
seriou
complic
affect
surviv
allogen
hematopoiet
stem
cell
transplant
allohsct
therefor
import
identifi
highrisk
patient
viral
infect
advanc
present
studi
develop
lymphocyteauc
new
predict
valu
immun
reconstitut
evalu
impact
viral
infect
allohsct
method
total
patient
underw
first
allohsct
kyoto
univers
hospit
includ
analysi
human
whose
reactiv
mostli
detect
neutrophil
engraft
includ
patient
surviv
day
transplant
estim
lymphocyteauc
day
day
analysi
cytomegaloviru
cmv
virus
includ
adenoviru
adv
bk
viru
bkv
jc
viru
jcv
varicella
zoster
viru
vzv
epsteinbarr
viru
ebv
includ
patient
surviv
day
transplant
estim
lymphocyteauc
day
day
analyz
associ
lymphocyteauc
risk
viru
activ
landmark
day
hhv
reactiv
day
cmv
reactiv
viru
infect
result
total
patient
underw
bone
marrow
transplant
peripher
blood
stem
cell
transplant
singl
cord
blood
transplant
cbt
respect
median
age
rang
median
period
first
lymphocytecount
day
transplant
fortyeight
patient
diagnos
reactiv
patient
develop
enceph
cmv
antigenemia
detect
patient
patient
develop
cmv
infect
twenti
patient
diagnos
viral
infect
adv
bkv
jcv
vzv
ebv
increas
lymphocyteauc
margin
associ
high
frequenc
significantli
associ
low
frequenc
cmv
antigenemia
appar
associ
lymphocyteauc
virus
malign
lymphoma
primari
diseas
ahr
p
cbt
donor
sourc
ahr
p
suggest
risk
factor
reactiv
occurr
acut
gvhd
ahr
p
recipi
age
ahr
cmv
antigenemia
conclus
lymphocyteauc
could
good
predict
valu
immun
reconstitut
cmv
reactiv
regard
reactiv
lymphocyteauc
associ
growth
viral
load
might
suggest
rapid
growth
donor
lymphocyt
especi
cord
blood
cell
data
suggest
lymphocyteauc
could
inform
valu
use
clinic
strategi
viral
infect
allohsct
along
new
insight
reactiv
recipi
hsct
conflict
interest
conflict
interest
santa
maria
della
misericordia
hospit
pediatr
oncologyhematolog
perugia
itali
univers
perugia
gastroenterolog
hepatolog
unit
depart
medicin
perugia
itali
background
children
affect
hrall
hcv
infect
absenc
cytolysi
hlahaploident
stem
cell
transplant
hsct
treat
offlabel
directact
antivir
daa
consid
label
therapi
pediatr
popul
cours
could
present
transplant
liver
dysfunct
due
toxic
viral
infect
gvhd
main
problem
differenti
diagnosi
order
discrimin
viral
hepat
gvhd
liver
biopsi
need
specif
therapi
method
year
old
hispan
patient
affect
hrall
transplant
familiar
haploident
donor
genotyp
hcv
chronic
infect
transplant
hcv
rna
respect
iuml
iuml
iuml
condit
regimen
consist
fraction
tbi
total
dose
thiotepa
fludarabin
ciclophosphamid
graft
cell
deplet
rang
associ
adopt
immun
therapi
regulatori
cell
convent
cell
without
post
transplant
gvhd
prophylaxi
result
patient
engraft
yearold
yearold
patient
develop
sever
cholestasi
cytolysi
bilirubin
mgdl
mgdl
iul
iul
alt
iul
iul
ast
iul
iul
respect
day
day
transplant
liver
biopsi
made
evid
histolog
sign
agvhd
associ
hepat
signific
increas
hcv
viremia
respect
iuml
iuml
reveal
third
patient
nt
present
post
transplant
liver
dysfunct
gvhd
treat
short
cours
steroid
associ
photopheresi
mofetil
micofenol
hcv
therapi
administ
ribavirin
sofosbuvir
yearold
patient
yearold
patient
week
viremia
monitor
week
begin
therapi
start
daa
signific
improv
observ
term
liver
function
neg
viremia
week
hcv
viremia
yearold
patient
still
neg
week
end
therapi
sustain
virolog
respons
highli
predict
definit
viral
erad
yearold
patient
increas
bilirubin
mgdl
ast
iul
alt
iul
iul
observ
two
week
end
antivir
treatment
recurr
hcv
rna
viremia
iuml
analysi
viral
resist
perform
new
pediatr
offlabel
antivir
therapi
base
sofosbuvir
valpatasvir
ribavirin
administ
rapid
normal
liver
function
negativis
viremia
two
week
conclus
gvhd
viral
hepat
hcv
infect
patient
frequent
associ
post
transplant
period
offlabel
daa
therapi
pediatr
patient
safe
effect
treatment
hcv
hepat
allogen
hsct
even
associ
immunosuppress
treatement
gvhd
without
sideeffect
futur
approv
daa
pediatr
patient
could
provid
earli
cure
hcv
hepat
hrleukem
patient
beforeaft
transplant
conflict
interest
author
noth
disclos
cidara
therapeut
san
diego
ca
unit
state
evotec
manchest
unit
kingdom
background
rezafungin
novel
echinocandin
exhibit
potent
vitro
activ
fumigatu
develop
treatment
prophylaxi
invas
fungal
infect
efficaci
multipl
mous
aspergillosi
infect
model
present
support
potenti
use
treatment
prevent
aspergillosi
method
vitro
activ
rezafungin
evalu
fumigatu
clinic
isol
collect
jmi
intern
sentri
surveil
program
suscept
determin
minimum
effect
concentr
mec
valu
accord
clsi
broth
microdilut
guidelin
dissemin
aspergillosi
neutropen
icr
mice
infect
fumigatu
atcc
iv
cfumous
day
treatment
h
infect
rezafungin
given
either
singl
mgkg
iv
ip
daili
mgkg
bid
dose
surviv
monitor
day
model
use
prophylaxi
except
rezafungin
sc
mgkg
dose
day
prior
infect
pulmonari
aspergillosi
icr
mice
made
neutropen
cyclophosphamid
day
mgkg
cyclophosphamidecortison
given
day
mgkg
intranas
challeng
fumigatu
cfumous
initi
day
prophylaxi
rezafungin
singl
dose
ip
mgkg
posaconazol
po
mgkg
micafungin
ip
mgkg
start
day
prior
infect
surviv
monitor
day
result
rezafungin
show
potent
vitro
activ
clinic
fumigatu
isol
mec
rang
valu
respect
lung
epitheli
line
fluid
concentr
singl
human
auc
equival
dose
rezafungin
mous
found
consider
higher
hour
postdos
one
halflif
interv
fumigatu
treatment
dissemin
aspergillosi
rezafungin
ivip
mgkg
bid
x
show
signific
increas
surviv
compar
vehicl
surviv
compar
either
singl
mgkg
dose
mgkg
bid
x
prophylaxi
singl
mgkg
dose
given
day
prior
infect
show
improv
surviv
dose
mgkg
show
surviv
challeng
pulmonari
aspergillosi
model
dosedepend
increas
surviv
observ
singl
prophylaxi
rezafungin
dose
human
mg
auc
equival
dose
mgkg
mice
rezafungin
show
increas
surviv
rel
control
comparison
micafungin
posaconazol
suggest
advantag
rezafungin
higher
surviv
rate
compar
micafungin
posaconazol
respect
human
auc
equival
dose
figur
posaconazol
mgkg
higher
human
auc
show
statisticallysignific
increas
surviv
rate
rel
control
conclus
rezafungin
effect
treatment
prophylaxi
neutropen
mous
dissemin
pulmonari
aspergillosi
infect
model
given
long
human
h
rezafungin
could
prove
use
intermitt
outpati
inpati
echinocandin
treatment
prophylaxi
conflict
interest
v
ong
flanagan
k
bartiz
employe
ownership
interest
cidara
therapeut
g
hough
employe
cidara
therapeut
sattar
sharp
p
thomm
employe
evotec
univers
cincinnati
colleg
medicin
cincinnati
oh
unit
state
cidara
therapeut
san
diego
ca
unit
state
background
rezafungin
formerli
novel
longact
echinocandin
pharmacokinet
achiev
high
frontload
plasma
exposur
allow
onceweekli
dose
rezafungin
current
develop
prophylaxi
candida
aspergillu
pneumocysti
minim
potenti
myelosuppress
drugdrug
interact
often
complic
today
antifung
prophylaxi
patient
undergo
bone
marrow
transplant
bmt
biofilm
format
fungi
consid
surviv
mechan
biofilm
notori
difficult
treat
hypothes
morpholog
pneumocysti
mammalian
lung
akin
biofilm
present
studi
vitro
biofilm
format
p
carinii
use
explor
abil
rezafungin
prevent
biofilm
format
treat
matur
biofilm
method
biofilm
use
p
carinii
p
murina
isol
rat
mous
lung
tissu
grown
millicel
cultur
insert
multiwel
plate
supplement
rpmi
medium
matur
biofilm
grown
day
prior
treatment
nascent
biofilm
insert
receiv
test
compound
time
inocul
media
alon
use
neg
control
entir
content
insert
per
time
point
harvest
assess
atp
content
use
luciferinluciferas
base
assay
day
treatment
result
seven
day
treatment
matur
biofilm
rezafungin
efficaci
decreas
atp
compar
untreat
control
dose
effect
prevent
biofilm
format
previou
studi
use
biofilm
assay
report
decreas
atp
matur
biofilm
anidulafungin
caspofungin
micafungin
rezafungin
efficaci
prevent
biofilm
format
similar
anidulafungin
concentr
shown
decreas
atp
vs
untreat
biofilm
contrast
caspofungin
littl
micafungin
effect
biofilm
format
conclus
longact
echinocandin
rezafungin
formerli
efficaci
prevent
biofilm
format
reduc
viabil
matur
biofilm
p
jirovecii
find
conjunct
previous
publish
data
demonstr
effect
pneumocysti
candida
aspergillu
prophylaxi
immunosuppress
preclin
model
suggest
util
rezafungin
set
bmt
conflict
interest
cushion
research
fund
cidara
therapeut
nih
task
order
subcontractor
patterson
pi
vitro
screen
antifung
activ
us
veteran
affair
merit
review
collin
none
disclos
j
lock
v
ong
k
bartiz
employe
ownership
interest
cidara
therapeut
citi
hope
nation
medic
center
duart
ca
unit
state
md
anderson
cancer
center
houston
tx
unit
state
hopit
st
loui
pari
franc
karolinska
univers
hospit
stockholm
sweden
samsung
medic
center
sungkyunkwan
univers
seoul
korea
republ
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
univers
chicago
medic
center
chicago
il
unit
state
seoul
st
mari
hospit
cathol
univers
korea
seoul
korea
republ
weil
cornel
medic
center
new
york
ny
unit
state
univers
hospit
basel
basel
switzerland
chu
de
bordeaux
bordeaux
franc
mayo
clinic
phoenix
az
unit
state
gilead
scienc
inc
foster
citi
ca
unit
state
dana
farber
cancer
institut
boston
unit
state
brigham
women
hospit
boston
unit
state
background
presatovir
significantli
reduc
nasal
viral
load
sign
symptom
rsv
infect
healthi
human
challeng
studi
evalu
whether
presatovir
safe
effect
treatment
hct
patient
rsv
lrti
method
hct
patient
confirm
rsv
upper
lower
respiratori
tract
evid
new
chest
xray
abnorm
consist
lrti
random
receiv
oral
presatovir
everi
day
dose
placebo
addit
center
standard
care
enrol
stratifi
supplement
oxygen
requir
lm
lmin
treatment
ribavirin
primari
endpoint
time
weight
averag
chang
rsv
viral
load
day
measur
nasal
sampl
secondari
endpoint
includ
number
day
without
supplement
oxygen
use
develop
respiratori
failur
requir
mechan
ventil
allcaus
mortal
result
januari
april
subject
center
enrol
tabl
median
age
year
interquartil
rang
iqr
presatovir
year
iqr
placebo
arm
subject
male
presatovir
placebo
median
durat
symptom
prior
first
dose
similar
presatovir
day
iqr
placebo
day
iqr
arm
median
baselin
rsv
viral
load
presatovir
copiesml
iqr
placebo
copiesml
iqr
inhal
oral
presatovir
inhal
oral
intraven
placebo
treat
subject
given
ribavirin
despit
maintain
mean
plasma
trough
least
day
presatovir
treatment
reduc
mean
time
weight
averag
chang
viral
load
presatovir
copiesml
placebo
copiesml
mean
treatment
differ
copiesml
confid
interv
median
number
supplement
oxygenfre
day
presatovir
iqr
day
placebo
iqr
day
proport
subject
develop
respiratori
failur
presatovir
placebo
allcaus
mortal
presatovir
placebo
result
similar
exploratori
analys
evalu
whether
treatment
effect
modifi
durat
symptom
baselin
supplement
oxygen
use
ribavirin
use
lymphopenia
time
sinc
hct
graftversushost
diseas
treatmentemerg
advers
event
teae
similar
arm
presatovir
placebo
fewer
grade
teae
vs
includ
fewer
infect
respiratoryrel
grade
teae
among
presatovirtr
patient
conclus
presatovir
treatment
well
toler
hct
patient
rsv
lrti
result
improv
viral
overal
clinic
outcom
clinic
trial
registri
clinicaltrialsgov
identifi
conflict
interest
dadwal
research
fundingsit
investig
gilead
ansun
biopharma
oxford
immunotec
glaxosmithklin
aicuri
shire
merck
consultantadvisori
board
merck
r
chemali
research
fundingsit
investig
gilead
merck
chimerix
ansun
biopharma
pulmotec
novarti
shire
oxford
immunotec
advisori
board
ablynx
janssen
adama
biolog
merck
chimerix
astella
medicin
compani
workhard
consult
ansun
biopharma
xenex
oxford
immunotec
p
ljungman
site
investigatorresearch
fund
astella
gilead
oxford
immunotec
merck
advisori
board
merck
aicuri
ablynx
honoraria
shire
kim
site
investigatorresearch
fund
teachingspeak
gilead
janssen
celltrion
boeckh
investigatorconsultingresearch
fund
merck
astella
chimerix
shire
gilead
consult
abbvi
helocyt
waghmar
site
investigatorresearch
fund
gilead
aviragen
therapeut
k
mullan
site
investigatorresearch
fund
gilead
astella
chimerix
contrafect
crestovo
glaxosmithklin
leonard
merlin
biopharm
medimmun
merck
sage
shire
synexi
advisori
board
chimerix
merck
synexi
speakerhonoraria
astella
merck
nohla
dsmb
member
catherin
small
site
investigatorresearch
fund
gilead
merck
viiv
glaxo
han
h
hirsch
site
investigatorresearch
fund
gilead
advisori
board
chimerix
speakerhonoraria
novarti
bergeron
lee
e
blanchard
r
patron
site
investigatorsresearch
fund
gilead
mckevitt
port
r
jordan
guo
p
german
j
chien
employeesalari
gilead
francisco
marti
site
investigatorresearch
fund
gilead
chimerix
glaxosmithklin
merck
shire
honoraria
visterra
dsmb
member
unit
medic
speak
roch
molecular
diagnost
consult
alexion
dsmb
member
basilea
speak
fate
therapeut
endpoint
committe
glaxosmithklin
consult
merck
consult
tabl
lrti
hct
studi
klinikum
bremen
mitt
hematologyoncolog
bremen
germani
klinikum
bremen
link
der
weser
hematologyoncolog
bremen
germani
klinikum
bremen
mitt
ear
nose
throat
surgeri
bremen
germani
klinikum
bremen
mitt
opthalmolog
bremen
germani
background
tcell
larg
granular
lymphocyt
leukemia
tlglleukemia
rare
lymphoprolif
disord
exhibit
chronic
month
elev
larg
granular
lymphocyt
lgl
peripher
blood
character
clonal
expans
cytotox
cell
recogn
classif
among
matur
cell
nk
cell
neoplasm
promin
clinic
featur
tlgl
leukemia
includ
neutropenia
anemia
rheumatoid
arthriti
ra
prognosi
normal
good
os
main
cours
death
sever
infect
due
neutropenia
indic
treatment
includ
sever
neutropenia
anc
x
moder
neutropenia
anc
x
associ
recurr
infect
symptomat
transfus
depend
anemia
associ
autoimmun
condit
requir
therapi
standard
treatment
lgl
leukemia
immunosuppress
therapi
clinic
experi
report
use
lowdos
methotrex
cyclophosphamid
cyclosporin
singl
agent
case
allogen
stem
cell
transplant
describ
method
case
report
result
patient
diagnos
tlglleukemia
treatment
indic
mild
neutropenia
recur
infect
last
respons
gcsf
mtx
cyclophosphamid
fludarabin
chop
novemb
bone
marrow
biopsi
show
infiltr
tlgl
result
sever
pancytopenia
regular
transfus
daili
applic
gcsf
januari
may
administ
mabcampath
name
patient
program
bminfitr
went
sever
pancytopenia
persist
sever
episod
life
threaten
neutropen
fever
occur
search
treatment
option
hlaident
sibl
sister
identifi
juli
perform
allogen
transplant
follow
ric
condit
protocol
fluci
aplasia
patient
develop
vast
phegmon
infect
right
face
origin
maxillari
sinu
spread
right
orbita
bacteri
infect
assum
could
proven
multipl
biopsi
bloodstream
aspergillu
fumigatu
identifi
passtain
treatment
infect
consist
broad
antibacteri
antifung
agent
hematolog
regener
time
day
gcsf
could
discontinu
perman
first
time
sinc
diagnosi
due
good
oper
manag
ent
ophthalmolog
team
persist
damag
occur
bmbiopsi
day
show
donor
chimer
residu
infiltr
tlglleukemia
right
patient
immunosuppress
gave
first
dli
booster
graft
versu
lymphoma
effect
conclus
tlglleukemia
rare
lymphoprolif
disord
patient
eventu
refractori
convent
immunosuppress
chemotherapi
urgent
need
altern
treatment
allogen
transplant
suitabl
donor
mrd
mud
ric
may
provid
cure
select
patient
patient
benefit
partial
respons
freedom
transfus
gcsf
infecti
complic
transplant
occur
regular
due
long
last
immunosuppress
neutropenia
conflict
interest
main
author
u
ritter
b
hertenstein
noth
disclos
henri
mondor
hospitalassist
publiqu
hopitaux
de
pari
aphp
hematolog
franc
henri
mondor
hospit
franc
univers
pari
est
franc
henri
mondor
hospit
parasitolog
franc
henri
mondor
hospit
hematolog
franc
henri
mondor
hospit
univers
hospit
hematolog
franc
background
pneumocysti
jirovecii
pneumonia
pcp
high
mortal
rate
allogen
hsct
trimethoprimsulfamethoxazol
tmpsmx
prefer
primari
prophylaxi
altern
lower
efficaci
accord
local
procedur
base
ecil
guidelin
look
patient
transplant
depart
jan
order
evalu
whether
patient
correctli
prophylax
pcp
mani
case
receiv
tmpsmx
method
assess
consecut
patient
transplant
center
followup
month
local
jaci
procedur
mention
tmpsmx
first
option
pcp
prophylaxi
doublestrength
tablet
time
week
associ
folin
acid
start
engraft
altern
case
tmpsmx
intoler
atovaquon
ato
mg
period
risk
defin
month
myeloabl
condit
regimen
month
regimen
case
long
immunosuppress
drug
given
pcp
prophylaxi
prolong
week
stop
last
period
risk
censor
time
death
pcp
onset
collect
number
pcp
case
number
day
risk
day
cover
prophylaxi
atrisk
period
reason
withdraw
tmpsmx
result
eigthteen
case
pcp
occur
engraft
tmpsmx
ato
prophylaxi
transient
withdrawn
possibl
side
effect
month
stop
median
period
risk
pcp
day
median
number
day
cover
prophylaxi
day
ratio
day
without
prophylaxisno
day
risk
patient
develop
pcp
vs
thirteen
patient
never
receiv
prophylaxi
die
engraft
includ
develop
pcp
sever
complic
engraft
among
patient
receiv
pcp
prophylaxi
first
drug
given
transplant
tmpsmx
ato
patient
pretranspl
intoler
tmpsmx
poor
engraft
howev
patient
receiv
tmpsmx
sole
prophylact
drug
atrisk
period
inde
tmpsmx
stop
suspect
intoler
patient
cytopenia
liver
test
abnorm
rash
unknown
caus
result
patient
consecut
receiv
tmpsmx
ato
receiv
pentamidin
aerosol
option
conclus
despit
good
complianc
guidelin
mani
concern
still
remain
pcp
prophylaxi
hsct
patient
may
develop
pcp
engraft
especi
case
graft
reject
tmpsmx
often
replac
ato
keep
tmpsmx
atrisk
period
case
occur
sever
month
stop
rais
issu
find
paramet
decid
long
prophylaxi
continu
tmpsmx
often
replac
ato
probabl
given
enough
time
stop
maerten
j
et
al
clinic
trial
registri
na
conflict
interest
noth
disclos
son
espas
univers
hospit
hematolog
palma
de
mallorca
spain
son
espas
univers
hospit
microbiolog
palma
de
mallorca
spain
son
espas
univers
hospit
pharmacolog
palma
de
mallorca
spain
background
cmv
infect
one
import
complic
lead
morbimort
first
year
postallohsct
use
highdos
steroid
graft
versu
host
diseas
gvhd
tcell
deplet
mismatch
unrel
donor
constitut
main
predispos
factor
highest
risk
cmv
infect
associ
seroneg
donor
seroposit
recipi
r
graft
contain
cmvspecif
cell
insid
immunocompromis
recipi
latent
cmv
infect
although
effect
current
anticmv
drug
associ
myelosuppress
renal
toxic
thu
novel
agent
better
safeti
profil
prophylaxi
develop
maribavir
letermovir
new
drug
increas
significantli
health
cost
aim
determin
seri
patient
could
benefit
prophylaxi
method
patient
undergo
allohsct
center
retrospect
review
novemb
analyz
cmv
reactiv
pcr
cmv
serostatu
allohsct
check
well
preemptiv
treatment
rate
respons
consid
incid
cmv
reactiv
cmvrelat
diseas
addit
relat
gvhd
coinfect
bk
viru
examin
result
patient
analyz
median
follow
aliv
patient
month
characterist
patient
summar
tabl
r
patient
present
reactiv
r
patient
p
consid
donor
serostatu
r
patient
incid
cmv
reactiv
similar
dr
dr
risk
cmv
diseas
higher
dr
patient
versu
patient
gvhd
present
cmvreactiv
patient
bk
viru
hemorrhag
cystiti
present
cmv
reactiv
concomitantli
seri
patient
haploident
donor
higher
rate
cmv
reactiv
versu
around
other
haploident
nonrel
donor
present
highest
rate
cmv
diseas
versu
hlaident
sibl
donor
yearoveral
surviv
whole
seri
patient
die
due
infect
patient
also
activ
gvhd
report
cmvrelat
diseas
result
death
conclus
seri
patient
cmv
dr
togeth
dr
highest
rate
cmv
reactiv
group
patient
could
benefit
prophylaxi
new
anticmv
drug
futur
also
haploident
unrelateddonor
allohsct
could
consid
new
approach
conflict
interest
author
noth
disclos
tabl
tabl
patient
characterist
abstract
previous
publish
hospit
universitario
central
de
asturia
hematolog
stem
cell
trasplant
oviedo
spain
hospit
central
de
asturia
oviedo
spain
hospit
central
de
asturia
hematolog
stem
cell
trasplant
oviedo
spain
universidad
de
oviedo
oviedo
spain
hospit
central
de
asturia
microbiolog
oviedo
spain
hospit
central
de
asturia
hematolog
oviedo
spain
background
antimicrobi
resist
rapidli
increas
worldwid
constitut
univers
threat
health
care
limit
data
multipl
drug
resist
bacteria
mdr
haematolog
hospit
patient
without
inform
resist
gramneg
bacteria
mrgn
method
screen
programm
mdr
strain
associ
guidelin
contact
isol
implement
hospit
know
preval
mdr
colon
among
haematolog
patient
extend
spectrum
betalactamas
esbl
produc
enterobacteriacea
multiresist
acinetobact
baumannii
mrab
mulitresist
pseudomona
aeruginosa
mrpa
indentif
risk
factor
colon
infect
among
colon
collect
sampl
hospit
patient
hematolog
unit
hospit
universitario
central
de
asturia
januari
octob
main
reason
admiss
acut
leukemia
myelodysplast
syndrom
follow
stem
cell
transplant
allogen
autolog
routin
surveil
cultur
activ
screen
throat
anu
parallel
obtain
weekli
obtain
two
consecut
neg
result
result
screen
sampl
rectal
throat
posit
mrd
patient
colon
mrgn
median
durat
day
k
pneumonia
common
isol
carbapenemresist
esbl
enterobact
cloaca
carbapenem
resist
esbl
escherichia
coli
mrba
mrpa
patient
throat
posit
posit
rectal
sampl
risk
factor
colon
show
tabl
patient
develop
mrgn
infect
patient
carriag
esbl
produc
seem
consequ
infect
colon
patient
increas
risk
infect
admiss
intens
care
unit
p
conclus
rate
mrgn
colon
high
hospit
patient
associ
significantli
higher
frequenc
subsequ
infect
high
risk
hospit
patien
mandatori
develop
screen
programm
mdr
strain
associ
guidelin
contact
isol
rectal
sampl
identif
coloniz
patient
higher
perform
pharyng
grow
problem
antimicrobi
resist
among
pathogen
isol
hematolog
patient
hematopoiet
stem
cell
transplant
pauciti
new
antibacteri
drug
limit
use
drug
altern
develop
strategi
decreas
infect
conflict
interest
none
tabl
tabl
risk
factor
colon
humanita
cancer
center
bone
marrow
transplant
unit
rozzano
milan
itali
humanita
cancer
center
infecti
diseas
unit
rozzano
milan
itali
humanita
cancer
center
hematolog
rozzano
milan
itali
background
invas
fungal
infect
ifi
repres
one
common
side
effect
allogen
hematopoiet
stem
cell
transplant
allosct
donor
type
graftversushostdiseas
pretranspl
diseas
statu
durat
neutropen
phase
relev
variabl
associ
risk
develop
ifi
earli
late
late
phase
postallo
sct
particular
incid
ifi
higher
mismatch
relat
donor
haplosct
rel
matchedrel
donor
mrd
transplant
vs
recent
guidelin
recommend
antimold
prophylaxi
patient
high
risk
ifi
attempt
reduc
risk
ifi
haplosct
posttranspl
cyclophosphamid
ptci
retrospect
analyz
efficaci
caspofungin
antifung
prophylaxi
ap
institut
method
novemb
june
consecut
patient
undergo
haplosct
ptci
hemotolog
malign
receiv
antimold
prophylaxi
caspofungin
day
day
neutrophil
engraft
patient
characterist
follow
median
age
male
lymphoprolif
diseas
acut
myeloid
leukemia
complet
remiss
cr
condit
regimen
nonmyeloabl
nma
case
graft
sourc
either
repres
bone
marrow
peripher
blood
stem
cell
pbsc
median
day
neutrophil
engraft
accord
gitmo
stratif
ifi
risk
earli
late
phase
patient
respect
high
risk
ifi
result
median
followup
year
threeyear
os
progressionfre
surviv
pf
nrm
respect
cumul
incid
ci
grade
acut
graftversushostdiseas
gvhd
moderatesever
chronic
gvhd
respect
five
patient
earli
phase
late
phase
diagnos
provenprob
pp
ifi
due
ct
scan
imag
detect
galactomannan
bronchoalveolar
lavag
median
day
ppifi
day
ci
ifi
patient
die
ifi
univari
analysi
tabl
activ
diseas
time
transplant
variabl
associ
trend
increas
risk
ifi
compar
patient
cr
vs
note
increas
risk
ifi
observ
patient
within
highrisk
cohort
accord
gitmo
stratif
multivari
analysi
advers
diseas
statu
variabl
associ
higher
risk
ifi
hr
compar
ap
caspofungin
histor
cohort
patient
treat
ev
itraconazol
institut
found
ci
ifi
lower
caspofungin
rang
rel
itraconazol
differ
reach
statist
signific
conclus
summari
ap
caspofungin
effect
strategi
prevent
ppifi
haplosct
ptci
highrisk
patient
studi
warrant
reduc
incid
ifi
patient
higher
risk
especi
activ
diseas
time
transplant
conflict
interest
author
conflict
interest
disclos
policlinico
umberto
roma
itali
ircc
san
raffael
scientif
institut
milano
itali
ircc
policlinico
matteo
pavia
itali
policlinico
tor
vergata
roma
itali
ircc
h
san
martino
genova
itali
ospedal
oncologico
businco
cagliari
itali
ospedal
careggi
firenz
itali
ao
citta
della
salut
e
della
scienza
torino
itali
casa
sollievo
della
sofferenza
san
giovanni
rotondo
itali
comprensorio
sanitario
di
bolzano
bolzano
itali
centro
trapianti
metropolitano
torinio
itali
az
osp
bianchi
melacrino
morelli
reggio
calabria
itali
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
ircc
ca
granda
ospedal
maggior
policlinico
milano
itali
ospedal
niguarda
milano
itali
ao
san
camillo
forlanini
roma
itali
ospedal
ferrarotto
degli
studi
di
catania
catania
itali
ao
croce
e
carlo
cuneo
itali
ospedal
la
maddalena
palermo
itali
modena
modena
itali
azienda
ospedalierouniversitaria
santa
maria
della
misericordia
udin
itali
ao
ss
antonio
e
biagio
alessandria
itali
ospedal
san
gerardo
clinica
ematologica
dell
universita
milanobicocca
monza
itali
ospedal
san
giusepp
moscato
taranto
itali
ospedal
civil
pescara
itali
ao
ospedali
riuniti
villa
sofia
cervello
palermo
itali
policlinico
gemelli
univ
cattolica
sacro
cuor
roma
itali
policlinico
consorzial
di
bari
bari
itali
po
r
binaghi
cagliari
itali
ospedal
g
da
saliceto
di
piacenza
piacenza
itali
ospedal
papa
giovanni
xxiii
bergamo
itali
ircc
auo
ist
san
martino
genova
itali
istituto
seragnoli
bologna
itali
ao
papa
giovanni
xxiii
bergamo
itali
background
patient
acut
leukemia
al
refractori
initi
salvag
chemotherapi
undergo
allogen
hematopoiet
stemcel
transplant
allohsct
high
risk
invas
fungal
diseas
ifd
particular
invas
aspergillosi
earli
day
post
transplant
phase
risk
particularli
high
patient
receiv
transplant
unrel
mismatch
relat
donor
girmenia
et
al
mould
activ
primari
antifung
prophylaxi
recommend
set
method
across
gitmo
centr
treatment
algorithm
promot
includ
altern
donor
search
earli
treatment
plan
adult
patient
primari
induct
failur
relaps
al
patient
without
avail
unrel
donor
receiv
transplant
cbt
famili
haploident
donor
trial
gitmo
nonrespond
acut
leukemia
failur
eudract
patient
without
histori
pretranspl
ifd
receiv
primari
antifung
prophylaxi
pap
micafungin
dose
mg
day
engraft
rate
provenprob
possibl
ifd
document
micafungin
prophylaxi
within
first
day
transplant
evalu
histor
comparison
patient
characterist
among
previou
gitmo
survey
perform
result
juli
octob
patient
submit
allohsct
receiv
micafungin
pap
median
age
year
donor
unrel
cb
haplo
overal
patient
develop
provenprobal
ifd
invas
aspergillosi
case
within
day
day
transplant
respect
ifd
document
patient
receiv
antifung
prophylaxi
breakthrough
infect
possibl
breakthrough
pulmonari
ifd
document
patient
cumul
incid
provenprob
ifd
patient
studi
patient
gitmo
survey
consid
patient
activ
al
transplant
receiv
transplant
unrel
mismatch
relat
donor
receiv
mouldact
antifung
prophylaxi
show
significantli
lower
probabl
ifd
day
transplant
studi
popul
vs
figur
two
patient
discontinu
micafungin
pap
due
presum
drugrel
side
effect
conclus
prospect
multicent
studi
seem
show
micafungin
safe
effect
option
earli
pap
patient
activ
al
undergo
allohsct
unrel
mismatch
relat
donor
clinic
trial
registri
eudract
conflict
interest
noth
disclos
ao
croce
e
carl
hematolog
cuneo
itali
universita
di
bari
ao
policlinico
di
bari
intern
medicin
oncolog
bari
itali
background
gramneg
bacteremia
gnb
major
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
ahsct
particular
carbapenemresist
klebsiella
pneumonia
crkp
infect
colon
hsct
repres
predict
condit
subsequ
infect
high
morbid
mortal
rate
perturb
microbiota
composit
result
aberr
system
immun
respons
well
pathogen
colon
mucos
invas
probiot
nutrit
supplement
contain
defin
amount
viabl
microorgan
preserv
microbiota
upon
administr
confer
benefit
host
propos
mechan
probiot
great
interest
ahsct
set
block
adhes
suppress
growth
pathogen
bacteria
intestin
epithelium
product
inhibitori
agent
directli
bind
gramneg
bacteria
enhanc
modul
intestin
immun
respons
maintain
normal
level
shortchain
fatti
acid
repair
intestin
permeabl
upregul
intestin
electrolyt
absorpt
howew
safeti
administ
viabl
bacteria
sever
immunecompromis
neutropen
ahsct
adult
patient
evalu
yet
method
crkp
endem
hospit
order
minim
impact
crkp
infect
colon
ahsct
recipi
evalu
safeti
feasibl
multistrain
probiot
prepar
commerci
avail
bromatech
itali
somminist
fix
weekli
schedul
begin
day
continu
neutropen
phase
discharg
studi
cohort
compris
consecut
adult
recipi
ahsct
treat
januari
june
sixteen
patient
suffer
acut
leukemia
myelodisplast
syndrom
complet
remiss
transplantth
condit
regimen
busulfan
fludarabin
base
patient
intend
myeloabl
donor
hla
ident
transplant
stem
cell
sourc
peripher
blood
procedur
sorror
case
note
patient
experienc
crkp
infect
transplant
crkp
carrier
high
risk
develop
preengraf
infect
high
mortal
rate
result
median
time
wbc
engraf
day
sever
mucos
grade
iii
seen
patient
thirtheen
patient
develop
grade
ii
agvhd
one
grade
iii
patient
discharg
hospit
infect
advers
event
due
probiot
observ
day
except
one
aliv
patient
compliant
protocol
suspend
intak
probiot
admiss
ahsct
four
patient
stop
intak
day
mucos
among
preengraf
gnb
document
observ
crkp
ecoli
case
patient
colon
pathogen
transplant
conclus
small
experi
multistrain
probiot
appear
safe
effect
preventig
crk
p
morbid
mortal
ahsct
set
particular
somministr
neutropen
phase
seem
possibl
conflict
interest
none
author
anyth
disclos
tor
vergata
univers
clinic
infecti
diseas
depart
system
medicin
rome
itali
tor
vergata
univers
depart
hematolog
stem
cell
transplant
unit
rome
itali
background
fungal
infect
possibl
complic
patient
haematolog
neoplasia
although
known
infect
may
complic
phase
follow
chemotherapi
allogen
hematopoiet
stem
cell
transplant
hsct
data
concern
fungal
infect
affect
elig
patient
candid
hsct
method
collect
clinic
data
patient
consid
candid
allogen
hsct
juli
decemb
rome
transplant
network
rtn
jaci
accredit
metropolitan
transplant
program
establish
rome
sinc
observ
patient
continu
novemb
diagnosi
ifi
defin
possibl
probabl
proven
establish
european
organ
research
treatment
cancer
result
patient
haematolog
malign
discuss
consid
elig
hsct
patient
lost
elig
observ
period
patient
die
progress
diseas
compat
hsct
patient
chang
centr
novemb
evalu
patient
receiv
hsct
median
time
date
elig
transplant
day
rang
eleven
previou
fungal
infect
proven
probabl
possibl
pneumonia
sinus
candida
sepsi
hepato
splenic
candidia
regist
patient
consid
elig
lost
elig
worsen
health
condit
observ
remain
patient
transplant
absenc
fungal
infect
patient
elig
patient
appear
factor
favor
elig
patient
hsct
ci
p
valu
yate
test
among
elig
patient
previou
fungal
infect
wait
hsct
longer
period
time
without
previou
histori
fungal
infect
mean
day
day
vs
day
student
p
valu
conclus
fungal
infect
complic
may
preclud
access
hsct
caus
slowdown
treatment
lead
transplant
data
show
diagnosi
fungal
infect
transplant
may
factor
could
extend
time
receiv
transplant
clinic
trial
registri
applic
conflict
interest
project
award
grant
gilead
hannov
medic
school
hematolog
hemostasi
oncolog
stem
cell
transplant
hannov
germani
background
allogen
hematopoiet
stem
cell
transplant
hsct
cur
treatment
malign
hematolog
diseas
adult
due
delay
immun
reconstitut
hsct
human
cytomegaloviru
cmv
often
reactiv
lead
increas
morbid
prolong
hospit
also
contribut
higher
mortal
rate
natur
killer
nk
cell
recent
describ
undergo
persist
reconfigur
respons
cmv
reactiv
method
multicolor
flow
cytometri
panel
monitor
cmvspecif
nk
cell
reconstitut
establish
peripher
blood
patient
analyz
day
posthsct
interv
day
median
age
patient
year
rang
transplant
acut
leukaemia
receiv
reduc
intens
condit
ric
receiv
anti
tlymphocyt
immun
globulin
atg
gvhdprophylaxi
cyclosporin
csa
combin
mycophenol
motefil
mmf
patient
transplant
match
donor
twentyfour
patient
reactiv
cmv
median
age
year
rang
median
day
reactiv
day
posthsct
rang
pbmc
cmvseroposit
healthi
individu
isol
densiti
gradient
leukoreduct
system
chamber
nk
cell
neg
select
magnet
separ
purif
nk
cell
achiev
cell
sort
select
nk
cell
expand
cocultur
irradi
allogen
pbmc
feeder
cell
medium
supplement
pha
uml
result
signific
increas
absolut
cell
count
nk
cell
observ
postcmv
reactiv
compar
patient
reactiv
cmv
interestingli
slight
decreas
express
nk
cell
link
cytotox
phenotyp
cell
observ
cmvreactiv
possibl
consequ
cell
death
lytic
activ
turn
show
signific
increas
postcmv
reactiv
demonstr
regul
activ
capac
nk
cell
also
costimulatori
abil
cell
prolifer
cytokin
product
remark
compar
cmvspecif
cell
routin
monitor
quantifi
tetram
stain
nk
cell
cell
popul
show
similar
kinet
increas
absolut
cell
count
cmvreactiv
impress
high
cell
count
nk
cell
maintain
postreactiv
preliminari
studi
aim
expand
popul
perform
use
cmvseroposit
healthi
individu
fourteen
day
cultur
expans
achiev
studi
aim
assess
prolif
capac
particular
nk
cell
subpopul
function
properti
posthsct
ongo
present
consid
crosstalk
innat
adapt
immun
cell
crucial
effect
respons
cmvinfect
studi
investig
product
key
cytokin
chemokin
warrant
conclus
taken
togeth
result
indic
nk
cell
undergo
dynam
modul
respons
cmvreactiv
expans
popul
occur
respons
cmv
addit
result
also
suggest
nk
cell
may
abl
substitut
miss
cmvspecif
cell
shortli
hsct
conflict
interest
author
declar
conflict
interest
feder
state
institut
scienc
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
kirov
russian
feder
background
transplant
autolog
hematopoiet
stem
cell
autohsct
common
therapi
patient
newli
diagnos
multipl
myeloma
mm
contraind
use
method
period
myelotox
hematopoiesi
often
accompani
infecti
complic
spectrum
caus
agent
infecti
complic
sever
clinic
manifest
divers
purpos
studi
evalu
relationship
polymorph
statu
immun
respons
gene
etiolog
infecti
complic
earli
posttranspl
period
patient
mm
method
evalu
patient
mm
age
year
median
year
underw
autohsct
neutropenia
period
clinic
andor
microbiolog
confirm
infecti
complic
observ
among
examin
four
men
seven
women
genotyp
polymorph
locu
immun
respons
gene
perform
polymeras
chain
reaction
allelespecif
primer
pretranspl
period
result
group
includ
five
patient
experienc
mucos
posttranspl
period
form
stomat
esophag
enteropathi
predomin
discharg
mucou
membran
upper
respiratori
tract
urin
bacteri
pathogen
enterococcu
faecium
enterococcu
faecali
enterococcu
aeruginosa
streptococcu
viridan
two
patient
invas
pulmonari
aspergillosi
group
consist
four
patient
clinic
manifest
pneumonia
dnacmv
hepat
dnahbv
rnahcv
vesicular
rash
mucou
membran
skin
dnahsv
herp
zoster
respect
compar
detect
haplotyp
immun
respons
gene
presenc
bacterialfung
viral
complic
differ
found
affect
gene
interleukin
il
tabl
patient
mm
autohsct
complic
bacteri
fungal
etiolog
compar
patient
viral
diseas
correl
presenc
homozygot
heterozygot
wildtyp
allel
gene
locu
presenc
mutant
allel
haplotyp
gene
mutat
point
conclus
take
account
reveal
mutat
affect
promot
region
gene
consequ
influenc
level
final
protein
receptor
immunoglobulin
g
involv
implement
antimicrobi
immun
conclud
studi
polymorph
pretranspl
period
allow
individu
prognosi
develop
infecti
complic
differ
etiolog
autohsct
patient
mm
develop
person
tactic
prevent
occurr
consid
pilot
natur
studi
research
need
direct
clinic
trial
registri
none
conflict
interest
author
declar
conflict
interest
tabl
haplotyp
gene
mm
abstract
previous
publish
amar
carvalho
foundat
hsct
program
jahu
brazil
amar
carvalho
foundat
hsct
jahu
brazil
univers
paulo
institut
tropic
medicin
sao
paulo
brazil
background
haploident
stem
cell
transplant
haplosct
attract
option
patient
requir
hematopoiet
stem
cell
transplant
hsct
hlamatch
donor
may
extend
transplant
virtual
patient
use
posttranspl
cyclophosphamid
gvhd
prevent
dramat
improv
outcom
becom
new
standard
transplant
perform
similar
posttransplant
outcom
observ
includ
posttransplant
surviv
differ
engraft
kinet
pattern
dna
viru
reactiv
present
studi
aim
compar
episod
viral
reactiv
haplosct
recipi
matchedrel
donor
mrd
match
unrel
donor
mud
hsct
recipi
method
better
character
frequenc
viral
reactiv
select
mrd
mud
consecut
recipi
followup
longer
day
submit
hsct
hsct
program
amar
carvalho
foundat
haplosct
recipi
inclus
criteria
appli
includ
control
polici
viral
infect
includ
rsv
screen
admiss
weekli
viral
surveil
antigenemia
cmv
quantit
pcr
ebv
condit
surveil
perform
mrd
hsct
reconstitut
cmvimmun
evalu
quantiferoncmv
qtfcmv
qiagen
usa
hsct
patient
respiratori
symptom
hemorrhag
cystiti
taken
nasal
wash
urineblood
sampl
detect
respiratori
virus
rv
bk
virusadenoviru
respect
result
cmv
viru
highest
incid
reactiv
transplant
qtfcmv
reactiv
mrd
mud
haplosct
respect
haplosct
nonreact
mrd
mud
reactiv
day
mrd
mud
haplosct
reconstitut
cmvimmun
respect
two
patient
die
enceph
viral
infect
reactiv
accord
type
hsct
shown
tabl
conclus
observ
similar
frequenc
hemorrhag
cystiti
rv
infect
cmv
reactiv
among
haplosct
mrd
mud
hsct
recipi
ebv
reactiv
significantli
higher
mud
hsct
comparison
haplosct
opposit
reactiv
frequent
observ
haplosct
surveil
necessari
mud
hsct
well
haplohsct
conflict
interest
clariss
machado
noth
disclos
tabl
viral
infect
accord
hsct
type
fred
hutchinson
cancer
research
center
seattl
wa
unit
state
nation
cancer
research
center
east
chiba
japan
univers
washington
seattl
wa
unit
state
center
diseas
control
prevent
atlanta
ga
unit
state
seattl
children
hospit
seattl
wa
unit
state
background
respiratori
virus
frequent
detect
hematopoiet
cell
transplant
hct
infect
start
upper
respiratori
tract
infect
uri
progress
lower
respiratori
tract
diseas
lrd
literatur
indic
patient
lrd
present
without
prior
uri
parainfluenza
viru
piv
one
common
respiratori
virus
mortal
piv
lrd
approxim
aim
studi
evalu
factor
associ
piv
lrd
without
uri
first
manifest
hct
recipi
piv
infect
method
hct
recipi
piv
lrd
retrospect
analyz
lrd
defin
piv
detect
lower
respiratori
tract
use
convent
cultur
direct
fluoresc
antibodi
test
andor
polymeras
chain
reaction
pcr
cid
uri
defin
piv
detect
nasopharyng
sampl
lrd
diagnos
day
one
day
uri
diagnosi
also
consid
lrd
without
prior
uri
logist
regress
model
use
evalu
crosssect
associ
risk
factor
occurr
lrd
without
prior
uri
result
lrd
case
lrd
without
prior
uri
symptom
median
time
piv
lrd
hct
day
rang
day
rang
lrd
case
without
prior
uri
respect
median
time
progress
day
rang
among
patient
prior
uri
patient
lrd
without
prior
uri
nasopharyng
test
perform
result
neg
sampl
examin
use
pcr
multivari
logist
regress
model
factor
associ
develop
lrd
without
prior
uri
versu
lrd
progress
uri
low
total
lung
capac
tlc
piv
infect
oxygen
requir
diagnosi
copathogen
detect
lower
respiratori
tract
tabl
peripher
blood
stem
cell
transplant
cell
sourc
serotyp
significantli
associ
lrd
without
prior
uri
univari
analysi
signific
multivari
analysi
among
case
calcul
viral
load
bronchoalveolar
lavag
bal
sampl
viral
load
significantli
differ
lrd
case
without
prior
uri
mortal
rate
lrd
compar
two
group
hr
conclus
approxim
half
hct
recipi
piv
lrd
present
without
uri
scenario
like
patient
restrict
lung
function
coinfect
lung
oxygen
requir
diagnosi
result
suggest
intens
virolog
test
bal
fluid
requir
even
asymptomat
patient
conflict
interest
seo
boeckh
receiv
research
support
ansun
biopharma
inc
boeckh
also
serv
consult
ansun
biopharma
j
englund
receiv
research
support
chimerix
glaxosmithklin
author
declar
compet
financi
interest
tabl
risk
factor
lrd
without
prior
uri
memori
sloan
ketter
cancer
center
pediatr
blood
marrow
transplant
new
york
ny
unit
state
children
hospit
pittsburgh
univers
pittsburgh
medic
center
pediatr
divis
blood
marrow
transplant
cellular
therapi
pittsburgh
pa
unit
state
memori
sloan
ketter
cancer
center
biostatist
new
york
ny
unit
state
background
ebvdriven
lymphoprolif
diseas
continu
signific
contributor
transplant
relat
morbid
mortal
amongst
patient
receiv
allogen
hsct
especi
receiv
cell
deplet
graft
treatment
monoclon
antibodi
rituximab
consid
standard
upfront
therapi
remain
consider
variat
threshold
use
begin
therapi
well
time
number
dose
administ
reach
complet
remiss
rituximab
therapi
associ
infus
reaction
cytopenia
prolong
hypogammaglobulinemia
investig
clinic
featur
might
predict
respons
lead
riskadapt
approach
therapi
method
retrospect
review
adult
pediatr
patient
underw
allogen
hsct
institut
receiv
rituximab
therapi
ebv
viremia
without
ptld
complet
patient
stratifi
respons
therapi
earli
complet
respond
complet
respond
nonrespond
base
number
dose
need
resolut
viremia
clinic
evid
ptld
detail
rituximab
therapi
well
transplant
type
incid
graft
versu
host
diseas
statu
immun
reconstitut
evalu
univari
multivari
analys
investig
statist
signific
factor
amongst
respons
group
result
patient
met
elig
criteria
data
analysi
patient
earli
complet
respond
late
complet
respond
nonrespond
respect
none
earli
complet
respond
complet
respond
relaps
univari
multivari
analys
presenc
ptld
radiograph
andor
clinic
use
acceler
dose
schedul
count
remain
signific
group
number
day
diagnosi
onset
therapi
near
reach
statist
signific
conclus
data
suggest
patient
achiev
earli
complet
respons
dose
rituximab
relaps
suggest
clinician
use
presenc
ptld
count
risk
factor
indic
acceler
dose
schedul
complet
cours
rituximab
like
necessari
achiev
complet
respons
overal
data
provid
inform
treat
clinician
tri
balanc
treat
ebv
untoward
side
effect
rituximab
therapi
conflict
interest
noth
disclos
nagoya
univers
graduat
school
medicin
depart
pediatr
nagoya
japan
background
viral
infect
constitut
signific
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
establish
polymeras
chain
reaction
pcr
base
qualit
quantit
monitor
viru
reactiv
allow
optim
manag
antivir
treatment
howev
studi
pediatr
patient
analyz
risk
viral
reactiv
follow
allogen
hsct
method
retrospect
analyz
outcom
japanes
pediatr
patient
underw
allogen
hsct
institut
peripher
blood
specimen
obtain
weekli
patient
hospit
day
post
hsct
realtim
quantit
pcr
monitor
cytomegaloviru
cmv
epsteinbarr
viru
ebv
human
herpesviru
perform
result
express
viral
copi
per
ml
whole
blood
sampl
patient
diagnos
viral
reactiv
cmv
ebv
load
copiesml
respect
consecut
pcr
result
median
age
patient
year
rang
year
graft
sourc
includ
hla
match
bone
marrow
n
hla
match
haploident
bone
marrow
n
hla
match
cord
blood
n
fiftyseven
patient
administ
antithymocyt
globulin
atg
condit
regimen
sixtytwo
patient
receiv
steroid
treatment
engraft
syndrom
andor
graft
versu
host
diseas
overal
incid
viral
reactiv
patient
day
follow
allogen
hsct
n
pcrbase
blood
analysi
reveal
signific
cmv
reactiv
n
ebv
reactiv
n
reactiv
n
patient
median
time
onset
cmv
ebv
reactiv
day
rang
day
day
rang
day
day
rang
day
respect
three
patient
develop
viral
diseas
cmv
pneumon
cmv
enceph
ebv
posttransplant
lymphoprolif
disord
multivari
analysi
haploident
bone
marrow
graft
significantli
associ
cmv
reactiv
ci
p
ebv
reactiv
ci
p
cord
blood
graft
independ
factor
associ
reactiv
ci
p
ebv
reactivationassoci
risk
factor
includ
atg
treatment
ci
p
differ
os
patient
without
viral
reactiv
signific
ci
vs
ci
p
possibl
effect
preemptiv
treatment
howev
high
ebv
load
copiesml
consecut
pcr
associ
poor
prognosi
ci
vs
ci
p
conclus
demonstr
signific
correl
cord
blood
transplant
reactiv
although
diseas
includ
enceph
children
cohort
hand
earli
detect
cmv
ebv
reactiv
follow
preemptiv
antivir
treatment
effect
control
infect
without
tissu
organ
damag
clinic
trial
registri
none
conflict
interest
none
hospit
juan
huelva
spain
background
benefit
use
antibacteri
prophylaxi
patient
undergo
autolog
hematopoiet
stem
cell
transplant
asct
remain
unclear
although
scientif
data
support
practic
limit
wich
antibiot
choos
defin
guid
encourag
use
fluorquinolon
sete
hand
antibiot
resist
one
import
challeng
day
clostridium
difficil
infect
also
matter
concern
center
levofloxacin
prophylaxi
administ
oral
od
patient
undergo
asct
aim
studi
review
impact
levofloxacin
prophylaxi
term
bacterian
resist
clostridiumdifficil
infect
rate
method
retrospect
evalut
febril
episod
pathogen
isol
outcom
patient
oncohematolog
diseas
undergo
asct
one
singl
center
januari
may
result
eightythre
asct
perform
centr
period
averag
age
patient
year
rang
male
frequent
underli
diseas
lymphoprolif
syndrom
slpc
follow
monoclon
gammapathi
gm
one
case
acut
promyelocyt
leukemia
complet
respons
diseas
statu
asct
partial
respons
slpc
partial
respons
patient
gm
sixtyseven
patient
fever
episod
wich
infect
suspect
condit
regimen
day
asct
happen
neutropen
period
neutrophil
count
patient
infect
episod
mucos
grade
patient
without
suspect
infect
infect
central
venou
cathet
suspect
focu
patient
follow
respiratori
focu
patient
given
empir
antibiot
antipseudomon
activ
case
ad
teicoplanin
empir
antifung
therapi
case
due
persist
fever
seven
patient
develop
septic
shock
blood
cultur
posit
case
gramposit
pathogen
gramneg
one
case
candida
extendedspectrum
betalactamaseproduc
organ
isol
one
case
baumanii
infect
one
patient
develop
septic
shock
hospit
intens
care
unit
none
patient
present
clostridium
difficil
diarrhoea
death
relat
procedur
infect
caus
first
day
asct
conclus
seri
major
isol
pathogen
gramposit
also
publish
studi
wich
fluorquinolon
prophylaxi
given
levofloxacin
prophylaxi
patient
underw
asct
environ
consid
safe
procedur
studi
need
determin
efficaci
costeffect
conflict
interest
none
peke
univers
peopl
hospit
beij
china
background
follow
increas
use
haploident
stem
cell
transplant
haplohsct
treatment
hematopoiet
diseas
complic
attribut
viral
infect
remain
challeng
problem
improv
transplant
outcom
epsteinbarr
viru
ebv
reactiv
relat
diseas
common
threat
high
mortal
context
haplohsct
previou
studi
demonstr
impair
recoveri
cell
day
haplohsct
significantli
correl
occurr
ebv
reactiv
immunosuppress
drug
mycophenol
mofetil
mmf
commonli
use
prevent
treatment
acut
graft
versu
host
diseas
agvhd
follow
hsct
effect
inhibit
cell
prolifer
reason
lead
delay
recoveri
tcell
subset
howev
influenc
mmf
cell
whether
earli
withdraw
prophylact
mmf
administr
could
favorit
cell
recoveri
decreas
ebv
reactiv
context
haplohsct
unknown
method
studi
prospect
includ
adult
patient
receiv
haplohsct
peke
univers
peopl
hospit
inclus
criteria
follow
diagnos
hematopoiet
malign
year
old
achiev
complet
remiss
transplant
mgkg
atg
condit
regimen
patient
divid
group
base
treatment
time
mmf
gvhd
prophylaxi
defin
longerterm
treatment
usual
withdrew
day
transplant
shorterterm
treatment
withdrew
engraft
transplant
incid
ebv
cmv
reactiv
agvhd
statist
compar
group
recoveri
characterist
tcell
subset
monitor
flow
cytometri
day
follow
transplant
effect
mmf
surviv
activ
ebvassoci
cytotox
function
cell
investig
invitro
experi
result
median
administr
time
mmf
prophylaxi
day
shorterterm
group
day
longerterm
group
p
statist
differ
age
gender
ratio
type
primari
diseas
statu
ebv
serolog
two
cohort
incid
agvhd
compar
regardless
differ
time
cours
mmf
prophylaxi
p
strikingli
incid
ebv
reactiv
patient
shorterterm
mmf
markedli
decreas
compar
longerterm
group
p
meanwhil
median
count
peripher
cell
shorter
mmf
group
continu
higher
longerterm
group
day
posthaplohsct
furthermor
invitro
treatment
activ
metabolit
mycophenol
acid
mpa
significantli
induc
apoptosi
peripher
cell
secret
capac
cytotox
effect
ebvtarget
cell
also
dramat
inhibit
upon
mpa
treatment
conclus
shorterterm
prophylaxi
mmf
significantli
improv
recoveri
cell
decreas
incid
ebv
reactiv
accompani
increas
agvhd
haplohsct
find
may
help
improv
outcom
hematopoiet
transplant
clinic
trial
registri
clinic
trial
no
conflict
interest
author
declar
conflict
interest
studi
support
nation
natur
scienc
foundat
china
no
foundat
innov
research
group
nation
natur
scienc
foundat
china
azienda
ospedaliera
universitaria
integrata
verona
itali
univers
genova
ospedal
policlinico
san
martino
genua
itali
pediatr
oncohematolog
stem
cell
transplant
cellular
therapi
divis
aou
della
salut
e
della
scienza
regina
margherita
children
hospit
turin
itali
royal
free
univers
colleg
medic
school
london
unit
kingdom
karolinska
univers
hospit
stockholm
sweden
ebmt
data
offic
leiden
netherland
univers
hospit
collegium
medicum
umk
bydgoszcz
poland
background
diagnosi
monitor
preemptiv
treatment
treatment
adenoviru
adv
infect
may
vari
among
centr
idwp
undertook
survey
assess
manag
adv
infect
method
questionnair
mail
ebmt
center
juli
deadlin
respons
novemb
replay
return
centr
respons
rate
result
center
profil
adult
pediatr
mixutur
median
number
adv
infect
diagnos
year
amongst
centr
rang
adv
diagnosi
centr
test
regularli
patient
adv
infect
advpcr
method
immunofluoresc
center
test
adv
allogen
hematopoiet
stem
cell
transplant
ahsct
recipi
wherea
center
adv
test
perform
specif
subgroup
haploident
mismatch
mud
unrel
cord
blood
sampl
sourc
centr
use
whole
blood
use
plasma
centr
use
serum
advpcr
center
advpcr
test
respons
miss
centr
centr
test
adv
sitesorgan
mainli
stool
upper
lower
respiratori
tract
specimen
urin
adv
surveil
day
advpcr
perform
blood
weekli
twice
weekli
everi
week
accord
patient
symptom
immun
recoveri
centr
advpcr
performpcr
stool
sampl
weekli
everi
week
accord
patient
symptom
immun
recoveri
advpcr
perform
respiratori
sampl
weekli
accord
patient
symptom
immun
recoveri
treatment
adv
infect
routin
therapeut
strategi
administr
cidofovir
cdv
reduct
immunosuppress
adopt
immunotherapi
cdv
avail
centr
use
dosag
mgkgweek
probenecidth
threshold
start
cdv
two
consecut
pcr
posit
centr
copiesml
high
intermedi
risk
patient
copiesml
low
risk
patient
durat
cdv
treatment
level
decreas
copiesml
median
time
week
last
year
brincidofovir
use
centr
wherea
advctl
treatment
use
centr
mainli
failur
cdv
conclus
although
adv
infect
usual
frequent
almost
respond
centr
consid
seriou
enough
deserv
regular
test
usual
advpcr
blood
cdv
repres
main
therapeut
option
although
one
fourth
respond
center
use
novel
drug
andor
immunotherapi
conflict
interest
conflict
interest
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
bmt
unit
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
bm
pbsc
apheresi
depart
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
laboratori
cytogenet
molecular
biolog
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
virolog
microbiolog
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
laboratori
hemopatholog
immunolog
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
sofia
bulgaria
background
human
cytomegaloviru
cmv
infect
remain
one
major
complic
follow
hematopoiet
stem
cell
transplant
hsct
associ
consider
morbid
mortal
incid
cmv
infect
approach
allogen
bone
marrow
transplant
recipi
cmv
seroposit
r
andor
receiv
transplant
cmvseroposit
donor
present
approach
manag
cmv
consist
serial
monitor
peripher
blood
use
either
cmv
antigen
antigenemia
assay
polymeras
chain
reaction
pcr
initi
preemptiv
therapi
either
ganciclovir
foscarnet
patient
becom
posit
factor
identifi
cmv
reactiv
includ
cmv
seroposit
donor
type
condit
regimen
use
tcell
deplet
graftversushost
diseas
gvhd
method
studi
includ
adult
patient
men
women
undergo
allogen
stem
cell
transplant
hsct
divid
three
risk
group
low
risk
dr
intermedi
risk
dr
high
risk
dr
dr
serial
weekli
monitor
cmv
viremia
perform
use
quantit
polymeras
chain
reaction
pcr
major
patient
convent
myeloabl
transplant
reduc
intens
condit
ric
use
either
match
siblingfamili
unrel
donor
graft
sourc
pbsc
bone
marrow
vivo
tcell
deplet
atg
perform
recipi
result
cmv
reactiv
seen
patient
median
day
post
hsct
rang
patient
treat
antivir
therapi
respons
seen
ten
patient
develop
cmv
diseas
median
day
post
hsct
die
median
follow
month
patient
without
cmv
reactiv
significantli
higher
surviv
compar
patient
cmv
reactiv
cmv
serostatu
import
risk
factor
incid
viral
reactiv
highrisk
group
compar
intermedi
risk
lowrisk
group
p
addit
presenc
acut
graftversushost
diseas
gvhd
hla
incompat
p
associ
increas
risk
ric
transplant
multivari
analysi
cmv
serostatu
ric
transplant
acut
gvhd
hla
incompat
remain
independ
predictor
cmv
reactiv
conclus
recipi
cmv
serostatu
continu
import
variabl
overal
surviv
transplant
era
antivir
preemptiv
therapi
prophylaxi
surviv
disadvantag
appear
larg
restrict
highli
immunosuppress
patient
recipi
tcelldeplet
graft
graft
hlamismatch
unrel
donor
analysi
demonstr
import
defin
pretranspl
cmv
serostatu
outcom
transplant
cmv
reactiv
diseas
remain
major
problem
highrisk
patient
undergo
allogen
hsct
conflict
interest
conflict
interest
univers
manchest
faculti
biolog
medicin
health
manchest
unit
kingdom
royal
manchest
children
hospit
depart
virolog
manchest
unit
kingdom
royal
manchest
children
hospit
depart
blood
marrow
transplant
manchest
unit
kingdom
royal
manchest
children
hospit
depart
molecular
diagnost
manchest
unit
kingdom
background
sinc
faecal
shed
adenoviru
adv
earli
sign
loss
immun
control
adv
sought
determin
role
faecal
adenovir
kinet
predict
adenoviraemia
surviv
outcom
follow
allogen
stem
cell
transplant
children
method
total
recipi
allogen
haematopoiet
stem
cell
transplant
februari
septemb
screen
weekli
adenoviraemia
till
immunerecoveri
andor
cessat
immunosuppress
pretranspl
blood
faecal
polymeras
chain
reaction
pcr
perform
patient
patient
diarrhoea
also
test
faecal
adv
weekli
faecal
pcr
perform
symptomat
diarrhoea
adv
pcr
techniqu
sensit
copiesml
blood
copiesgm
faec
use
result
adv
detect
total
patient
faecal
adv
posit
adenoviraemia
detect
transplant
recipi
fiftyeight
patient
adenoviraemia
test
faecal
pcr
patient
posit
faecal
pcr
median
time
detect
faecal
adv
day
iqr
median
time
detect
adenoviraemia
day
iqr
interestingli
found
linear
relationship
peak
blood
pcr
valu
faecal
pcr
valu
prior
adenoviraemia
figur
relationship
linear
patient
malign
transplant
nonmalign
disord
threshold
adv
level
copiesgm
fece
predict
adenoviraemia
sensit
specif
respect
malign
patient
figur
b
twentysix
patient
high
faecal
viru
load
threshold
valu
copiesgm
transplant
nonmalign
condit
thu
prolif
kinet
viru
gastrointestin
gi
tract
determin
sever
adenoviraemia
pretranspl
immun
statu
compromis
previou
chemotherapi
like
determin
abil
host
local
adv
infect
gi
tract
p
patient
symptomat
diarrhoea
faecal
pcr
serial
monitor
prior
dissemin
patient
median
time
day
iqr
observ
threshold
faecal
pcr
level
copiesgm
onset
adenoviraemia
interest
find
similar
nonrelaps
mortal
nrm
patient
without
adv
faecal
adv
howev
significantli
higher
nrm
observ
patient
adenoviraemia
figur
c
thu
adenoviraemia
increas
likelihood
nrm
henc
prevent
adenoviraemia
control
prolifer
adv
patient
reach
threshold
faecal
pcr
level
may
reduc
likelihood
nrm
conclus
gi
tract
primari
site
adenovir
reactiv
prolif
kinet
viru
gi
tract
determin
risk
sever
adenoviraemia
sinc
nrm
significantli
higher
patient
adenoviraemia
preemptiv
intervent
reduct
immunesupress
effect
antivir
therapi
aim
prevent
adenoviraemia
patient
reach
threshold
level
faecal
adenoviru
clinic
trial
registri
na
conflict
interest
none
henri
mondor
hospit
hematolog
creteil
franc
henri
mondor
hospit
mycolog
creteil
franc
background
toxoplasmosi
rare
well
known
complic
allogen
hsct
case
due
reactiv
seroposit
recipi
r
toxoplasmosi
occur
month
transplant
pneumocysti
jirovecii
prophylaxi
trimethoprimsulfamethoxazol
tmpsmx
usual
prevent
case
toxoplasmosi
hsct
howev
weekli
screen
qpcr
r
patient
recommend
intern
guidelin
earli
identif
reactiv
especi
tmpsmx
given
order
interven
develop
toxoplasmosi
diseas
center
systemat
screen
r
patient
use
fragment
qpcr
blood
engraft
month
even
patient
tmpsmx
absorpt
complianc
tmpsmx
may
variabl
due
recent
earli
toxoplasmosi
review
case
reconsid
pertin
procedur
especi
focus
case
observ
hsct
method
assess
patient
develop
blood
bal
posit
qpcr
posit
cytolog
exam
show
characterist
among
patient
transplant
patient
screen
engraft
initi
weekli
everi
week
month
accord
visit
daycar
center
posit
qpcr
patient
diagnost
workup
includ
fundu
oculi
examin
cn
ct
scan
lung
ct
scan
addit
investig
accord
clinic
present
toxoplasmosi
infect
diseas
defin
accord
martino
et
al
result
among
consecut
patient
patient
develop
toxoplasmosi
among
earli
case
infect
document
posit
blood
qpcr
toxoplasmosi
diseas
patient
seroposit
toxoplasmosi
donor
except
one
seroneg
patient
especi
immunosuppress
transplant
cordblood
unrel
donor
one
receiv
previou
autolog
transplant
two
condit
sequenti
regimen
receiv
atg
condit
none
receiv
tmpsmx
time
first
posit
sampl
five
patient
die
day
first
posit
sampl
dissemin
toxoplasmosi
multiviscer
failur
mvf
without
document
caus
n
mvf
associ
venoocclus
diseas
n
accord
procedur
qpcr
blood
screen
start
time
diagnosi
conclus
earli
toxoplasmosi
allogen
hsct
rare
event
associ
high
mortal
rate
probabl
favor
fact
tmpsmx
usual
start
engraft
howev
case
anticip
weekli
blood
qpcr
screen
transplant
engraft
patient
seroposit
toxoplasmosi
transplant
recommend
start
screen
transplant
later
seropreval
toxoplasmosi
increas
age
decreas
last
decad
face
cmv
situat
seroneg
donor
give
older
seroposit
patient
increas
risk
reactiv
clinic
trial
registri
applic
conflict
interest
noth
disclos
oxford
univers
hospit
nh
foundat
trust
depart
haematolog
oxford
unit
kingdom
nh
blood
transplant
oxford
unit
kingdom
oxford
univers
hospit
nh
foundat
trust
depart
microbiolog
oxford
unit
kingdom
oxford
univers
hospit
nh
foundat
trust
depart
clinic
immunolog
oxford
unit
kingdom
background
respiratori
syncyti
viru
rsv
infect
account
signific
morbid
mortal
among
allogen
hsct
patient
retrospect
studi
suggest
ribavirin
treatment
prevent
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
reduc
mortal
aerosol
ribavirin
administr
clinic
challeng
rais
safeti
concern
due
teratogen
mutagen
oral
ribavirin
offer
altern
treatment
modal
remain
rel
lack
data
outcom
patient
treat
way
method
data
consecut
adult
patient
receiv
oral
ribavirin
treatment
centr
twoyear
period
novemb
novemb
analys
patient
underw
first
allogen
hsct
malign
haematolog
condit
rsv
test
pcr
throat
swab
accord
institut
protocol
patient
confirm
rsv
evid
lrti
clinic
andor
radiolog
treat
oral
ribavirin
mgkgday
divid
three
daili
dose
intraven
immunoglobulin
ivig
day
result
median
age
rsv
infect
year
rang
concomit
acut
chronic
gvhd
affect
eight
patient
seven
treat
prednisolon
time
rsv
diagnosi
median
time
transplant
present
rsv
infect
month
rang
posttranspl
one
patient
treat
inpati
median
length
stay
durat
treatment
day
respect
half
patient
suffer
coinfect
patient
underw
chest
xr
investig
compat
infect
case
ct
chest
perform
case
confirm
featur
keep
infect
case
common
radiolog
find
ground
glass
opacif
nodular
three
patient
requir
admiss
intens
care
unit
two
diagnos
rsv
preengraft
third
patient
long
term
immunosuppress
chronic
gvhd
ribavirin
gener
well
toler
major
side
effect
transfusiondepend
haemolyt
anaemia
six
patient
die
median
followup
month
rang
follow
rsv
diagnosi
one
death
attribut
rsv
death
occur
within
day
diagnosi
rsv
infect
give
mortal
rate
follow
rsv
infect
conclus
studi
one
largest
date
report
experi
oral
ribavirin
allogen
hsct
set
treatment
rsv
infect
data
suggest
oral
ribavirin
ivig
safe
approach
manag
rsv
lrti
posttranspl
although
rsvattribut
mortal
low
signific
proport
patient
clinic
unwel
time
diagnosi
requir
aggress
manag
inpati
set
conflict
interest
author
declar
conflict
interest
lymphoma
azienda
ospedaliera
universitaria
pisana
uo
ematologia
universitaria
pisa
itali
aou
santa
maria
della
misericordia
di
udin
ematologia
udin
itali
ospedal
regional
maurizio
ematologia
e
centro
trapianto
di
midollo
osseo
bolzano
itali
ircc
ospedal
san
raffael
division
di
ematologia
milano
itali
ospedal
san
bortolo
ematologia
vicenza
itali
ircc
ematologia
asmn
reggio
emilia
itali
aou
della
salut
e
della
scienza
di
torino
ematologia
dipartimento
di
biotecnologi
molecolari
e
scienz
per
la
salut
di
torino
torino
itali
asl
po
vito
fazzi
ematologia
lecc
itali
ircc
ospedal
oncologico
ematologia
bari
itali
iov
ircc
uoc
di
oncologia
medica
padova
itali
ospedal
giusepp
moscati
ematologia
taranto
itali
fondazion
ircc
policlinico
san
matteo
ematologia
pavia
itali
ircc
ospedal
casa
sollievo
sofferenza
ematologia
san
giovanni
rotondo
itali
ospedal
di
ivreaasl
ematologia
ivrea
itali
asur
uoc
medicina
interna
ed
ematologia
civitanova
march
itali
cattolica
del
sacro
cuor
istituto
di
ematologia
roma
itali
asmn
ircc
ematologia
reggio
emilia
itali
azienda
ospedali
riuniti
di
ancona
ematologia
ancona
itali
iov
ircc
uoc
di
oncologia
medica
padova
itali
azienda
ulss
ematologia
treviso
itali
aou
della
salut
e
della
scienza
di
torino
ematologia
dipartimento
di
biotecnologi
molecolari
e
scienz
per
la
salut
di
torino
torino
itali
background
due
bcnu
unavail
sever
transplant
center
europ
switch
beam
fotemustinebas
condit
feam
although
studi
support
equival
two
regimen
method
retrospect
compar
safeti
efficaci
outcom
feam
respect
beam
patient
report
subgroup
analysi
mantl
cell
lymphoma
patient
analyz
asct
perform
lymphoma
italian
center
select
beam
feam
condit
link
bcnu
avail
clinic
characterist
result
patient
characterist
similar
feam
n
beam
patient
major
patient
stage
iv
diagnosi
beam
feam
b
symptom
beam
feam
patient
femal
beam
feam
clinic
practic
patient
transplant
first
line
consolid
beam
feam
induct
treatment
compar
hypercvad
beam
feam
chop
like
regimen
beam
feam
chophd
arac
beam
feam
respons
statu
asct
cr
pr
beam
group
feam
patient
cr
pr
patient
pet
neg
scan
beam
group
vs
even
pet
data
miss
feam
group
neutrophil
engraft
similar
group
day
oral
mucos
sligher
sever
feam
group
grade
feam
vs
beam
incid
sever
toxic
ctcae
grade
differ
two
group
grade
febril
neutropenia
fn
occur
similar
rate
grade
fn
feam
vs
beam
respons
statu
differ
day
post
asct
cr
beam
vs
feam
neither
last
followup
continu
cr
vs
nonrelaps
mortal
beam
vs
feam
compar
well
death
occur
respect
beam
feam
due
diseas
progress
major
patient
overal
surviv
os
year
differ
beam
vs
feam
neither
relaps
rate
beam
vs
feam
progressionfre
surviv
year
beam
vs
feam
conclus
substitut
fotemustin
increas
gener
toxic
infecti
episod
howev
observ
sligher
gastrointestin
toxic
feam
patient
lead
higher
nrm
neither
significantli
worsen
os
pf
cumul
relaps
incid
compar
well
induct
therapi
impact
patient
outcom
even
diseas
assess
transplant
bias
pet
data
miss
feam
group
conclus
statistic
signific
differ
emerg
beam
feam
mcl
patient
conflict
interest
none
portugues
institut
oncolog
hematolog
lisbon
portug
portugues
institut
oncolog
clinic
research
unit
lisbon
portug
portugues
institut
oncolog
dermatolog
lisbon
portug
background
primari
cutan
tcell
lymphoma
pctcl
heterogen
rare
group
lymphoprolif
disord
treatment
gener
cur
allogen
cell
transplant
allohct
could
potenti
cure
patient
potenti
graftversuslymphoma
effect
role
explor
mainli
mycosi
syndrom
mfss
largest
studi
publish
includ
patient
cibmtr
patient
stage
iv
mf
lechowicz
mj
et
al
bmt
studi
suggest
allohct
provid
diseas
control
heavili
treat
advanc
mfss
method
retrospect
review
pctcl
patient
submit
allohct
centr
statist
perform
spss
surviv
analysi
kaplanmei
methodolog
result
seven
patient
pctcl
perform
allohct
five
diagnosi
mfss
two
patient
primari
cutan
cytotox
peripher
cell
lymphoma
no
patient
advanc
stage
diseas
median
age
year
transplant
median
hematopoiet
cell
transplant
comorbid
index
hcti
seri
median
previou
line
therapi
time
transplant
patient
stabl
diseas
partial
remiss
complet
remiss
progress
diseas
reduc
intens
condit
fludarabinemelphalan
chosen
acut
graft
versu
host
diseas
agvhd
occur
five
seven
patient
one
liver
three
skin
one
skin
gastrointestin
liver
involv
one
patient
mix
mfgvhd
skin
manifest
respond
well
extracorpor
photopheresi
four
patient
requir
escal
immunosuppress
two
still
calcineurin
inhibitor
four
five
patient
evolv
chronic
cutan
gvhd
two
patient
die
one
hepat
agvhd
one
pneumonia
one
patient
progress
current
stabl
skindirect
therapi
frequent
complic
observ
infect
hemorrhag
cystiti
follow
vascular
venoocclus
diseas
requir
defibrotid
haematolog
complic
thrombot
thrombocytopen
purpura
transplantrel
toxic
acut
chronic
renal
failur
metabol
syndrom
endocrinopathi
depress
requir
psychiatr
support
median
followup
month
estim
overal
surviv
os
month
progress
free
surviv
pf
month
one
patient
progress
diseas
pf
drop
month
robust
estim
like
affect
small
sampl
size
conclus
singl
center
experi
confirm
allohct
feasibl
multitr
advanc
stage
ctcl
patient
toxic
toler
accept
small
seri
notic
diseas
stabil
transplant
seem
import
better
respons
prospect
studi
would
requir
confirm
impress
still
diseas
control
achiev
one
patient
progress
diseas
nonetheless
two
patient
die
first
day
illustr
seriou
complic
expect
conclus
small
seri
add
publish
data
regard
allohct
ctcl
confirm
feasibl
procedur
highlight
potenti
regard
diseas
control
possibl
cure
patient
aggress
ctcl
conflict
interest
conflict
declar
evaggelismo
gener
hospit
depart
haematolog
bone
marrow
transplant
unit
athen
greec
attikon
univers
hospit
athen
greec
depart
intern
medicin
athen
greec
metaxa
hospit
depart
haematolog
piraeu
greec
background
allogen
hematopoiet
stem
cell
transplant
allohsct
therapeut
approach
cur
potenti
hodgkin
lymphoma
hl
failur
autolog
stem
cell
transplant
asct
current
allohsct
feasibl
increas
number
patient
mainli
due
novel
therapeut
agent
serv
bridg
allosct
avail
appropri
donor
major
patient
purpos
studi
analyz
efficaci
prognost
factor
outcom
allohsct
patient
advanc
hl
method
patient
age
median
year
underw
allohsct
hl
median
time
rang
month
initi
diagnosi
patient
previous
expos
median
rang
line
treatment
patient
undergon
asct
receiv
brentuximab
vedotin
nivolumab
prior
allohsct
time
allohsct
patient
complet
remiss
cr
partial
remiss
pr
refractori
relaps
condit
regimen
reducedintens
fludarabinemelphalan
nonmyeloabl
fludarabinelowdos
total
bodi
irradi
includ
alemtuzumab
antithymocyt
globulin
donor
hla
ident
sibl
volunt
unrel
match
hlaa
b
c
loci
graft
sourc
peripher
blood
one
patient
receiv
bone
marrow
due
previou
salvag
treatment
nivolumab
result
median
followup
rang
month
patient
aliv
cr
estim
overal
surviv
os
ci
year
ci
year
cumul
incid
ci
nonrelaps
mortal
nrm
ci
month
progressionfre
surviv
pf
ci
year
relaps
occur
patient
median
time
rang
month
allohsct
nine
patient
overt
clinic
relaps
metabol
relaps
petct
criteria
ci
relaps
progress
ci
month
multivari
analysi
chemosensit
diseas
factor
significantli
associ
better
pf
vs
year
hr
twelv
patient
receiv
donor
lymphocyt
infus
dli
due
overt
clinic
relaps
metabol
relaps
persist
mix
chimer
three
patient
receiv
dli
combin
brentuximab
vedotin
respond
dli
partial
respons
metabol
remiss
full
donor
chimer
immunotherapi
lowdos
nivolumab
mgkg
everi
week
administ
patient
exhibit
prompt
respons
take
account
respons
immun
manipul
current
pf
cpf
reach
year
conclus
conclus
allohsct
cur
modal
approxim
half
patient
relapsedrefractori
hl
relaps
remain
major
concern
follow
allotranspl
howev
diseas
control
may
becom
feasibl
mean
preemptiv
dli
checkpoint
inhibitor
conflict
interest
author
noth
disclos
samsung
medic
center
sungkyunkwan
univers
medicin
seoul
korea
republ
gyoung
sang
nation
univers
changwon
korea
republ
seoul
nation
univers
seoul
korea
republ
nation
cancer
center
hospit
goyangc
korea
republ
ajou
univers
suwon
korea
republ
chonnam
nation
univeristi
hwasoon
korea
republ
soon
chun
hyang
univers
hospit
seoul
korea
republ
samsung
medic
center
sungkyunkwan
univers
seoul
korea
republ
background
natur
killer
nk
tcell
lymphoid
malign
compris
extranod
nktcell
lymphoma
enktl
aggress
nkcell
leukaemia
ankl
cell
tumour
infect
epsteinbarr
viru
ebv
prognos
enktl
ankl
remain
poor
particular
surviv
outcom
patient
relaps
refractori
diseas
extrem
poor
allogen
stem
cell
transplant
sct
use
frontlin
consolid
treatment
prevent
relaps
advanc
diseas
salvag
treatment
chemotherapi
relapsedsensit
diseas
howev
limit
data
concern
outcom
frontlin
salvag
sct
patient
enktl
ankl
method
retrospect
analys
patient
underw
allogen
sct
februari
februari
newli
diagnos
patient
high
risk
diseas
n
underw
upfront
allogen
sct
wherea
patient
relaps
refractori
diseas
n
receiv
allogen
sct
salvag
chemotherapi
patient
receiv
myeloabl
n
reducedintens
n
condit
regimen
depend
institut
polici
recent
updat
surviv
diseas
statu
novemb
result
enktl
n
common
ankl
n
patient
stage
iv
diseas
median
age
time
allogen
sct
year
rang
year
diseas
statu
patient
prior
sct
complet
respons
n
partial
respons
n
persist
diseas
n
higher
proport
ankl
patient
enktl
patient
receiv
upfront
allogen
sct
howev
diseas
statu
prior
allogen
sct
condit
regimen
donor
sourc
differ
upfront
salvag
allogen
sct
group
febril
neutropenia
occur
half
patient
n
patient
experienc
acut
graftversushost
diseas
follow
skin
n
liver
n
gut
n
median
followup
month
allogen
sct
median
overal
surviv
os
progressionfre
surviv
pf
allogen
sct
month
confid
interv
ci
month
ci
respect
twelv
patient
die
diseas
relaps
nondiseaserel
caus
death
occur
within
day
allogen
sct
mostli
relat
diseas
relaps
n
os
allogen
sct
differ
enktl
ankl
p
upfront
salvag
sct
p
preallogen
sct
diseas
statu
elev
serum
lactat
dehydrogenas
significantli
associ
postsct
pf
complet
chimer
significantli
associ
better
pf
p
signific
differ
observ
pf
accord
condit
regimen
sourc
stem
cell
p
conclus
allogen
sct
may
benefici
patient
enktl
ankl
given
patient
could
maintain
remiss
allogen
sct
howev
upfront
allogen
sct
perform
highli
select
patient
risk
diseas
relaps
nondiseaserel
mortal
remain
high
clinic
trial
registri
applic
conflict
interest
author
noth
disclos
institut
doncologia
hospit
duran
reynal
barcelona
spain
institut
paolicalmett
marseil
franc
semmelweiss
univers
budapest
hungari
charl
univers
hospit
pragu
czech
republ
univers
cologn
cologn
germani
haphp
saintloui
servic
diderot
sorbonn
pari
pari
franc
karolinska
univers
hospit
stockholm
sweden
georg
papanicola
gener
hospit
thessaloniki
greec
nottingham
univers
hospit
nottingham
unit
kingdom
univers
hospit
brno
brno
czech
republ
maria
sklodowskacuri
instituteoncolog
center
warsaw
poland
chu
nant
nant
franc
hospit
de
la
santa
creu
sant
pau
barcelona
spain
kuopio
univers
hospit
kuopio
finland
ebmt
data
offic
leiden
netherland
ebmt
statist
unit
pari
franc
sanofi
genzym
cambridg
unit
state
st
bartholomew
hospit
bart
health
nh
trust
london
unit
kingdom
univers
heidelberg
heidelberg
germani
background
plerixafor
plu
granulocyt
coloni
stimul
factor
gcsf
administ
patient
lymphoma
poor
mobilis
haematopoiet
stem
cell
hsc
enhanc
mobilis
hsc
collect
subsequ
autolog
haematopoiet
stem
cell
transplant
hsct
method
intern
multicentr
nonintervent
registri
studi
evalu
longterm
follow
patient
lymphoma
year
receiv
plerixafor
stem
cell
mobilis
follow
hsct
compar
patient
receiv
mobilis
method
complet
hsct
patient
complet
first
autolog
hsct
balanc
main
baselin
characterist
comparison
group
propens
score
match
conduct
follow
mobilis
regimen
compar
gcsf
plerixafor
gp
vs
gcsf
alon
gp
vs
gcsf
chemotherapi
gc
gcsf
plerixafor
chemotherapi
gpc
vs
gc
primari
outcom
measur
progress
free
surviv
pf
overal
surviv
os
relaps
rate
rr
proven
poor
mobilis
defin
patient
fail
previou
attempt
mobilis
result
total
patient
lymphoma
ebmt
registri
met
elig
studi
criteria
patient
mobilis
plerixaforbas
regimen
propens
score
vs
patient
match
gp
vs
gcsf
alon
cohort
vs
gp
vs
gc
cohort
vs
gpc
vs
gc
cohort
loss
statist
power
due
propens
score
overcom
imbal
comparison
arm
comparison
group
treat
plerixafor
greater
proport
patient
proven
poor
mobilis
comparison
group
treat
plerixafor
vs
gp
vs
gcsf
vs
gp
vs
gc
vs
gp
vs
gpc
estim
median
pf
month
ci
calcul
nc
vs
ci
nc
gp
vs
gcsf
ci
nc
vs
nc
ci
nc
gp
vs
gc
ci
nc
vs
ci
nc
gpc
vs
gc
os
pf
lower
gp
versu
gpc
well
gpc
versu
gc
os
pf
higher
gp
versu
gcsf
howev
differ
group
os
pf
gener
small
rr
rate
similar
group
infect
infest
common
standard
organ
class
advers
event
plerixafor
compar
group
conclus
registri
studi
indic
plerixafor
treatment
overcom
mobilis
issu
patient
difficult
mobilis
rate
advers
event
gener
similar
plerixafor
compar
cohort
without
plerixafor
treatment
patient
may
proceed
transplant
howev
firm
conclus
made
statist
analys
underpow
within
studi
group
identifi
propens
score
match
group
also
imbalanc
higher
proport
patient
treat
plerixafor
proven
poor
mobilis
therefor
repres
patient
group
predispos
wors
outcom
clinic
trial
registri
conflict
interest
studi
fund
sanofi
genzym
anna
sureda
speaker
fee
travel
grant
sanofi
silvia
montoto
grant
travel
gilead
speaker
fee
roch
outsid
scope
submit
work
peter
dreger
receiv
speaker
honoraria
gilead
kite
consult
abbvi
gilead
janssen
roch
christian
chabannon
report
receiv
compens
data
transfer
ebmt
conduct
studi
grant
person
fee
nonfinanci
support
sanofi
sa
outsid
scope
submit
work
masszi
receiv
financi
support
advisori
board
membership
abbvi
bm
janssencilag
novarti
pfizer
takeda
outsid
scope
submit
work
christof
scheid
report
honoraria
travel
support
sanofi
catherin
thieblemont
receiv
financi
support
advisori
board
membership
roch
takeda
janssencilag
bayer
celgen
outsid
scope
submit
work
anna
dabrowskaiwanicka
receiv
person
fee
ebmt
foundat
data
transfer
conduct
studi
esa
jantunen
receiv
speaker
fee
research
grant
sanofi
qiani
liu
marina
celanov
employe
sanofi
steffi
van
der
werf
paul
bosman
arian
boumendi
david
pohlreich
e
wahlin
ioanna
sakellari
nigel
russel
andrea
janikova
cyril
touzeau
albert
esquirol
noth
disclos
gaziantep
univers
faculti
medicin
depart
hematolog
gaziantep
turkey
gaziantep
univers
faculti
medicin
bone
marrow
transplant
center
gaziantep
turkey
background
hodgkin
lymphoma
hl
potenti
cur
malign
diseas
lymphoid
tissu
although
possibl
treat
success
patient
current
treatment
method
case
mayb
refractori
earlyl
relaps
treatment
autolog
peripher
stem
cell
transplant
apsct
follow
highdos
rescu
chemotherapi
relaps
refractori
hl
becom
standard
treatment
option
guidelin
studi
present
result
refractoryrelaps
hl
patient
treat
apsct
method
file
patient
underw
apsct
juli
juli
review
retrospect
result
patient
lymphoma
present
gaziantep
univers
bone
marrow
transplant
unit
result
mean
age
diagnosi
year
old
male
femal
patient
diagnos
relap
refractor
hl
apsct
median
time
diagnosi
administr
month
distribut
histolog
subtyp
diagnosi
nodular
sclerosi
mix
cellular
lymphocyt
poor
nodular
lymphocyt
predomin
lymphocyt
rich
accord
intern
prognost
score
ip
patient
low
patient
middl
patient
high
nine
patient
stage
iii
diagnosi
patient
stage
iiiiv
bone
marrow
involv
patient
bulki
mass
patient
cisplatinbas
relaps
refractur
obtain
patient
remiss
obtain
patient
rescu
treatment
base
gemcitabin
mobil
regimen
cisplatinbas
gcsf
use
patient
gemcitabinebas
gcsf
regimen
use
patient
median
collect
apheresi
procedur
product
contain
median
x
kg
cell
infus
prepar
regimen
beam
mito
mel
buotocyc
applic
patient
second
full
remiss
patient
third
full
remiss
neutrophil
scar
day
median
platelet
engraft
day
febril
neutropen
attack
detect
patient
followup
period
month
relaps
develop
patient
six
patient
die
progress
diseas
current
patient
complet
remiss
expect
overal
surviv
rate
year
diseasefre
surviv
rate
clinic
risk
factor
affect
surviv
apsct
conclus
result
autolog
stem
cell
transplant
suggest
import
treatment
option
relaps
refractor
hl
patient
low
transplantrel
mortal
risk
longterm
surviv
advantag
conflict
interest
author
noth
disclos
hospit
de
octubr
hematologia
madrid
spain
hospit
de
octubr
madrid
spain
hospit
de
salamanca
salamanca
spain
hospit
marqu
de
valdecilla
santand
spain
hospit
santa
creu
sant
pau
barcelona
spain
hospit
universitario
de
canaria
tenerif
spain
hospit
universitario
de
jerez
jerez
spain
hospit
la
princesa
madrid
spain
hospit
universitario
de
madrid
spain
hospit
vall
dhebron
barcelona
spain
hospit
universitario
de
bellvitg
bellvitg
spain
hospit
universitario
spain
hospit
cajal
madrid
spain
hospit
universitario
virgen
de
arraxiaca
murcia
spain
hospit
central
de
asturia
oviedo
spain
hospit
universitario
de
vigo
vigo
spain
hospit
universitario
moral
de
mesegu
murcia
spain
hospit
la
candelaria
tenerif
spain
hospit
clinic
de
barcelona
barcelona
spain
hospit
clinico
lozano
blesa
zaragoza
spain
hospit
la
fe
valencia
spain
hospit
universitario
salamanca
salamanca
spain
hospit
barcelona
barcelona
spain
hospit
del
mar
imim
hospit
del
mar
medic
research
institut
barcelona
spain
background
patient
follicular
lymphoma
fl
experienc
earli
therapi
failur
etf
within
two
year
frontlin
chemotherapyimmunochemotherapi
poor
overal
surviv
os
autolog
stem
cell
transplant
asct
shown
os
benefit
relaps
fl
rituximabfre
induct
regimen
nevertheless
effect
earli
relaps
fl
uncertain
method
spanish
geltamo
registri
identifi
patient
underw
asct
primari
refractori
diseas
second
complet
respons
second
partial
respons
etf
defin
failur
achiev
least
pr
frontlin
frontlin
chemotherapyimmunochemotherapi
lymphoma
progress
within
two
year
frontlin
chemotherapyimmunochemotherapi
identifi
two
group
eft
cohort
primari
refractori
patient
transplant
noneft
cohort
fl
patient
receiv
asct
either
experi
etf
follow
firstlin
therapi
transplant
result
etf
cohort
nonetf
cohort
total
patient
expos
rituximab
ascttim
interv
first
relaps
primari
treatment
asct
month
cohort
etf
group
total
patient
receiv
asct
within
first
year
treatment
failur
median
followup
asct
year
median
time
progress
within
firstlin
therapi
month
month
patient
etf
nonetf
cohort
respect
p
patientdiseas
characterist
well
balanc
cohort
except
age
ann
arbor
stage
diagnosi
statu
diseas
moment
asct
signific
differ
pf
etf
nonetf
cohort
pf
rate
time
asct
respect
nevertheless
patient
experi
eft
interv
first
relaps
primari
treatment
asct
year
pf
similar
noneft
cohort
signific
differ
os
p
etf
nonetf
cohort
os
rate
time
asct
respect
figur
rituximab
expos
patient
differ
pf
os
eft
noneft
cohort
eftrituximab
expos
patient
pf
os
respect
plateau
pf
curv
beyond
year
followup
conclus
asct
may
potenti
abrog
neg
prognost
effect
earli
relaps
chemo
rchemotherapi
patient
experi
eft
interv
first
relaps
primari
treatment
asct
less
year
similar
outcom
undergo
asct
without
eft
longterm
fl
diseas
free
surviv
patient
relaps
rituximabcontain
regimen
sensit
new
regimen
rchemotherapi
howev
valu
asct
refractori
patient
must
elucid
conflict
interest
conflict
interest
r
gorbacheva
memori
research
institut
pediatr
oncolog
hematolog
transplant
first
state
pavlov
medic
univers
st
petersburg
st
petersburg
russian
feder
background
children
classic
hodgkin
lymphoma
chl
nonhodgkin
lymphoma
nhl
cure
first
line
therapi
rest
demonstr
relaps
refractori
rr
cours
diseas
approxim
half
patient
unfavor
risk
group
salvag
second
line
chemotherapi
autolog
hematopoiet
stem
cell
transplant
hsct
immunotherapi
promis
approach
clinic
situat
endpoint
studi
includ
respons
brentuximab
vedotin
bv
combin
bv
bendamustin
b
progress
free
surviv
pf
safeti
children
adolesc
rr
chl
nhl
method
analysi
includ
children
adolesc
rr
chl
nhl
express
patient
nhl
distribut
subtyp
follow
anaplast
larg
cell
lymphoma
primari
mediastin
bcell
lymphoma
diffus
larg
bcell
lymphoma
ann
arbor
stage
system
use
chl
murphi
stage
system
nhl
treatment
regimen
rr
chl
consist
bv
mgkg
triweekli
combin
bv
mgkg
day
b
day
cycl
rr
nhl
children
receiv
bv
monotherapi
mgkg
triweekli
median
number
bv
cycl
chl
rang
nhl
result
children
rr
chl
overal
respons
rate
orr
bv
achiev
patient
complet
respons
cr
partial
respons
pr
stabl
diseas
progress
oneyear
pf
calcul
use
kaplanmei
method
group
median
time
progress
day
rang
combin
bv
b
rr
chl
result
orr
patient
cr
pr
patient
rr
nhl
achiev
cr
bv
bv
treatment
children
proceed
hsct
autolog
allogen
sever
seriou
side
effect
regist
patient
polyneuropathi
acut
pancreat
anaphylact
shock
side
effect
success
cure
conclus
half
children
adolesc
rr
chl
respond
monotherapi
bv
pf
remain
low
bv
prove
effect
safe
option
achiev
remiss
prior
hsct
bv
rr
nhl
combin
bv
b
rr
chl
demonstr
high
respons
rate
group
small
draw
final
conclus
conflict
interest
noth
disclos
tabl
patient
characterist
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
bmt
unit
sofia
bulgaria
univers
hospit
st
georg
hematolog
depart
plovdiv
bulgaria
univers
hospit
st
marina
bmt
unit
varna
bulgaria
univers
hospit
st
marina
hematolog
depart
varna
bulgaria
univers
hospit
alexandrovska
hematolog
depart
sofia
bulgaria
universt
hospit
st
ivan
rilski
hematolog
depart
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
sofia
bulgaria
univers
hospit
st
ivan
rilski
hematolog
depart
sofia
bulgaria
background
patient
hodgkin
lymphoma
hl
relaps
autolog
stem
cell
transplant
asct
poor
long
term
outcom
therapeut
option
subgroup
patient
heterogen
includ
salvag
chemotherapi
radiotherapi
palli
care
new
drug
biolog
agent
august
fda
approv
brentuximab
vedotin
bv
two
indic
patient
hl
patient
fail
asct
patient
asct
option
failur
least
two
previou
line
therapi
introduct
bv
onto
clinic
practic
improv
prognosi
surviv
patient
hl
relaps
asct
primari
endpoint
overal
respons
rate
orr
type
respons
toxic
profil
event
free
surviv
ef
overal
surviv
os
patient
hl
relaps
asct
treat
bv
method
thirti
three
patient
hl
treat
bv
relaps
asct
hematolog
clinic
bulgaria
studi
male
femal
ratio
mean
age
common
histolog
type
nodular
sclerosi
b
symptom
patient
asct
perform
patient
two
auto
one
auto
allo
sct
median
number
prior
anti
cancer
therapi
rang
includ
asct
patient
receiv
prior
radiotherapi
bv
introduc
patient
relapseprogress
asct
consolid
therapi
asct
median
number
cycl
rang
result
orr
crpr
confirm
patient
cr
pr
sd
progress
statu
start
bv
therapi
may
relat
pf
patient
treat
bv
cycl
lower
os
receiv
cours
vs
p
patient
treat
cycl
bv
lower
pf
cycl
vs
p
patient
respond
progress
treatment
bv
less
os
respond
cr
pr
sd
vs
p
number
cours
conduct
bv
independ
factor
affect
os
pf
gener
treatment
well
toler
toxic
profil
similar
previous
report
neurolog
toxic
seen
one
patient
stop
therapi
allerg
reaction
aspergilosi
lung
hepat
b
reactiv
one
conclus
report
indic
bv
singl
agent
effect
safe
good
toler
standard
clinic
practic
result
confirm
intern
experi
conflict
interest
conflict
interest
almazov
nation
medic
research
centr
st
petersburg
russian
feder
background
relaps
hl
allosct
still
present
major
clinic
problem
treatment
option
limit
result
relaps
treatment
unsatisfactori
present
case
treatment
hodgkin
lymphoma
relaps
allosct
combin
dli
brentuximab
vedotin
method
year
old
femal
primari
refractori
hodgkin
lymphoma
ivb
nodular
sclerosi
type
involv
intrathorac
lymphnod
lung
diagnos
februari
first
line
therapi
cycl
beacopp
partial
respons
achiev
second
line
therapi
cycl
dhap
maintain
partial
respons
lace
condit
regimen
autolog
stem
cell
transplant
perform
august
earli
progress
novemb
occur
ct
scan
detect
increas
target
lymph
node
size
preced
allogen
stem
cell
transplant
donor
mother
haploident
hla
condit
regimen
nonmyeloabl
cyflumel
acut
gvhd
prophylaxi
ptcycsammf
sours
transplant
pbsc
dose
engraft
leukocyt
platelet
day
complet
donor
chimer
ct
scan
show
tumor
mass
reduct
partial
remiss
achiev
followup
maintain
partial
respons
sign
gvhd
month
stem
cell
transplant
pet
ct
detect
progress
diseas
increas
fdg
uptak
deauvil
treatment
relaps
withdraw
immunosupress
therapi
gvhd
observ
month
stem
cell
transplant
patient
still
progress
bsymptom
occur
new
metabol
activ
lymphnod
petct
treatment
brentuximab
vedotin
sinc
dli
bv
mgkg
day
donor
leucocyt
infus
cycl
treatment
receiv
donor
lymphocyt
infus
escal
schedul
per
kilo
respect
result
cycl
brentuximab
vedotin
partial
metabol
respons
archiv
cycl
brentuximab
vedotin
patient
achiev
complet
metabol
respons
total
cycl
bv
perform
activ
gvhd
detect
advers
event
feel
well
conclus
brentuximab
vedotin
combin
donor
lymphocyt
infus
seem
effect
treatment
option
hodgkin
lymphoma
relaps
haploident
stem
cell
transplant
conflict
interest
none
univers
univers
hospit
heidelberg
hematolog
heidelberg
germani
hospit
universitari
dexeu
barcelona
spain
istituto
clinico
humanita
milano
itali
hautlevequ
bordeaux
franc
centr
hospitali
lyon
sud
lyon
franc
american
univers
beirut
medic
center
beirut
lebanon
centr
hospitali
universitair
de
renn
renn
franc
klinikum
ernst
von
bergmann
potsdam
germani
domenico
russo
azienda
ospedaliera
spedali
civili
di
brescia
brescia
itali
univers
hospit
basel
basel
switzerland
alexandro
spyridonidi
univers
hospit
patra
patra
greec
hannov
medic
school
hannov
germani
uh
bristol
bristol
unit
kingdom
univers
hospit
heidelberg
heidelberg
germani
queen
mari
univers
london
london
unit
kingdom
background
patient
hodgkin
lymphoma
hl
relaps
allogen
stem
cell
transplant
allosct
poor
prognosi
limit
treatment
option
immunotherapi
check
point
inhibitor
ci
target
receptor
demonstr
strike
clinic
activ
durabl
respons
hl
thu
ci
test
patient
hl
relaps
allosct
howev
concern
reactiv
graftversushost
diseas
gvhd
set
rais
method
conduct
retrospect
survey
patient
receiv
treatment
ci
relaps
hl
allosct
collect
inform
patient
fulfil
criteria
patient
receiv
median
prior
line
treatment
allosct
rang
eight
patient
transplant
unrel
donor
three
patient
relat
donor
nine
mismatch
rel
donor
result
median
time
allosct
relaps
confid
interv
month
median
time
allosct
start
ci
treatment
confid
interv
month
patient
median
rang
ci
treatment
cycl
administ
upon
ci
treatment
patient
achiev
complet
remiss
cr
patient
partial
remiss
pr
one
patient
evalu
median
time
respons
month
confid
interv
median
followup
initi
ci
treatment
month
confid
interv
two
patient
die
due
fungal
pneumonia
steroid
refractori
acut
gvhd
respect
figur
upon
ci
treatment
episod
acut
gvhd
occur
four
patient
one
patient
experienc
steroid
refractori
grade
gvhd
wherea
acut
grade
gvhd
treatment
sensit
remain
patient
gvhd
sever
decreas
subsequ
dose
ci
treatment
episod
chronic
gvhd
ci
treatment
occur
three
patient
conclus
line
report
studi
confirm
treatment
ci
target
receptor
safe
administ
patient
hl
relaps
allosct
result
good
tumor
respons
conflict
interest
conflict
interest
king
abdulaziz
medic
citi
oncolog
riyadh
saudi
arabia
king
abdullah
intern
medic
research
center
riyadh
saudi
arabia
king
saud
bin
abdulaziz
univers
health
scienc
riyadh
saudi
arabia
background
attain
complet
metabol
respons
cmr
prior
autolog
transplant
hsct
relaps
refractori
classic
hodgkin
lymphoma
rr
chl
highli
predict
prolong
remiss
addit
brentuximab
vedotin
bv
bendamustin
shown
produc
higher
complet
respons
previous
achiev
chemotherapi
alon
lacasc
et
al
blood
ifosfamid
gemcitabin
vinorelbin
igev
activ
salvag
regimen
excel
stem
cell
mobil
potenti
aim
examin
efficaci
igev
combin
bv
igevbv
first
subsequ
salvag
rr
chl
prior
hsct
method
patient
rr
chl
candid
cur
hsct
identifi
record
retriev
retrospect
irb
approv
bv
given
intraven
infus
mgkg
day
igev
administ
previous
report
santoro
et
al
haematologica
deauvil
score
regard
neg
positron
emiss
tomographi
pet
prehsct
patient
proceed
hsct
partial
remiss
pr
better
achiev
categor
continu
variabl
compar
use
chisquar
wilcoxon
kruskalw
respect
overal
surviv
os
progress
free
surviv
pf
comput
use
kaplanmeir
method
log
rank
test
result
total
patient
receiv
igevbv
first
salvag
second
third
salvag
median
age
year
male
ten
patient
refractori
diseas
median
time
progress
month
prehsct
pet
neg
evalu
patient
total
nine
patient
requir
singl
salvag
line
requir
two
five
requir
three
line
median
number
three
salvag
cycl
twenti
two
patient
achiev
pr
better
abl
proceed
hsct
follow
igevbv
remain
requir
subsequ
line
hsct
median
follow
post
hsct
month
estim
pf
os
respect
cohort
subsequ
stratifi
whether
igevbv
given
first
subsequ
salvag
failur
least
one
regimen
correspond
baselin
characterist
shown
tabl
patient
receiv
igevbv
first
salvag
receiv
significantli
fewer
salvag
cycl
median
vs
p
well
bv
consolid
post
hsct
vs
p
trend
toward
higher
incid
prehsct
cmr
vs
p
observ
pf
os
igevbv
first
vs
subsequ
salvag
vs
p
vs
p
respect
conclus
igevbv
especi
given
first
salvag
associ
high
cmr
rate
fewer
salvag
cycl
result
impress
remiss
post
hsct
given
limit
analysi
longer
follow
prospect
valid
warrant
conflict
interest
author
declar
conflict
interest
univers
hospit
dubrava
zagreb
croatia
univers
zagreb
school
medicin
zagreb
croatia
background
dose
adjust
epoch
rituximab
daepochr
etoposid
prednison
vincristin
cyclophosphamid
doxorubicin
effici
feasibl
regimen
treatment
diffus
larg
bcell
lymphoma
dlbcl
howev
contin
need
improv
therapi
younger
poor
risk
subgroup
role
autolog
stem
cell
transplant
asct
part
od
first
line
therapi
clear
method
may
octob
total
patient
poor
risk
dlbcl
defin
andor
plan
receiv
total
six
eight
cycl
daepochr
follow
consolid
asct
part
first
line
therapi
criteria
need
transplant
elig
age
absenc
transplantlimit
comorbid
mean
age
year
patient
male
total
patient
increas
ldh
ann
arbor
iiiiv
patient
patient
proceed
asct
four
patient
die
daepochr
therapi
one
patient
withdrew
consent
transplant
procedur
three
patient
fail
collect
adequ
graft
myeloabl
perform
beam
beeam
regimen
patient
result
median
follow
whole
cohort
month
os
pf
rate
year
respect
figur
patient
complet
daepochr
chemotherapi
patient
last
cycl
daepoch
success
use
stem
cell
mobil
transplant
patient
orr
cr
pr
prior
asct
respect
median
follow
transplant
patient
month
os
nad
pf
year
respect
treatment
followup
period
unexpect
toxic
cardiovascular
complic
although
earli
secondari
malign
one
patient
die
due
transplant
relat
complic
median
time
neutrophil
recoveri
platelet
recoveri
day
one
patient
receiv
additon
radiotherapi
two
patient
relaps
asct
pr
chemotherapi
conclus
daepochr
asct
first
line
therapi
poor
risk
aggress
dlbcl
highli
effici
feasibl
therapeut
option
result
show
although
gener
recommend
asct
consolid
therapi
may
benefici
subgroup
poor
risk
patient
without
signific
addit
toxic
conflict
interest
author
noth
disclos
institut
hematolog
blood
transfus
depart
cellular
therapi
praha
czech
republ
first
faculti
medicin
charl
univers
pragu
depart
medicin
praha
czech
republ
gener
univers
hospit
pragu
depart
medicin
praha
czech
republ
first
faculti
medicin
charl
univers
pragu
depart
patholog
physiolog
praha
czech
republ
background
comparison
younger
patient
limit
data
patient
year
old
transplant
rr
lymphoma
furthermor
studi
describ
patient
actual
transplant
take
account
whole
cohort
elderli
patient
may
avail
asct
method
singlecentr
studi
consecut
patient
year
rr
lymphoma
indic
asct
patient
indic
transplant
includ
transplant
variou
reason
identifi
comprehens
record
weekli
meet
transplant
group
categor
data
compar
pearson
chisquar
test
continu
data
mannwhitney
u
test
surviv
curv
construct
accord
kaplanmei
compar
logrank
test
result
median
age
identifi
patient
year
rang
men
frequent
diagnos
diffus
larg
bcell
lymphoma
dlbcl
patient
follicular
lymphoma
fl
patient
patient
lymphoma
hl
mobil
patient
collect
cellskg
patient
indic
treatment
plerixafor
success
harvest
actual
transplant
patient
whole
cohort
reason
dropout
resist
diseas
patient
poor
mobil
patient
infect
patient
toxic
patient
refus
transplant
patient
median
pf
os
month
month
whole
group
median
followup
month
live
patient
transplant
patient
pf
os
resp
month
transplant
caus
progress
diseas
pf
os
resp
month
differ
signific
dlbcl
median
pf
os
month
respect
signific
transplant
transplant
patient
follicular
lymphoma
pf
month
transplant
month
nontranspl
patient
os
v
month
p
respect
five
patient
lymphoma
three
aliv
month
indic
asct
conclus
patient
year
rr
lymphoma
indic
transplant
one
half
actual
transplant
compar
favor
prospect
studi
recruit
younger
patient
overal
progressionfre
surviv
whole
cohort
especi
transplant
patient
encourag
autolog
transplant
offer
patient
year
good
overal
health
statu
one
major
obstacl
proceed
transplant
poor
mobil
new
mobil
strategi
urgent
need
financi
support
grant
azv
czech
ministri
public
health
clinic
trial
registri
applic
conflict
interest
robert
pytlik
receiv
honoraria
sanofi
previou
month
conflict
interest
author
instituto
nacion
de
cancerologia
mexico
ciudad
de
mexico
mexico
background
numer
studi
shown
neg
petct
prior
asct
prognost
valu
predict
overal
progressionfre
surviv
patient
aggress
lymphoma
nhl
lymphoma
hl
role
petct
posttranspl
followup
yet
establish
major
relaps
occur
first
month
diffus
b
larg
cell
lymphoma
month
lh
therefor
necessari
studi
identifi
patient
earli
accord
lugano
recommend
longterm
surveil
petct
lymphoma
discourag
howev
practic
may
valuabl
highrisk
lymphoma
popul
patient
undergo
asct
object
evalu
prognost
valu
petct
time
detect
relaps
progress
lymphoma
asct
method
retrospect
crosssect
analyt
studi
lymphoma
hl
lymphoma
nhl
patient
undergo
asct
januari
decemb
includ
first
pet
ct
perform
week
asct
followup
pet
ct
scan
perform
interv
month
result
patient
elig
studi
nhl
hl
nhl
group
median
age
year
patient
stage
iiiiv
present
extranod
involv
neg
pet
ct
prior
procedur
partial
respons
posit
petct
lh
group
median
age
year
patient
stage
iiiiv
extranod
involv
neg
petct
prior
procedur
partial
respons
posit
petct
first
posttranspl
control
nhl
patient
lh
petct
posit
prior
transplant
studi
becam
neg
procedur
fortytwo
percent
nhl
lh
patient
followup
petct
compat
relaps
patient
start
rescu
treatment
major
patient
clinic
manifest
suspici
relaps
time
patient
relaps
underw
biopsi
type
lymphoma
corrobor
studi
posit
petct
asct
probabl
relaps
hl
none
patient
obtain
neg
posttranspl
pet
ct
relaps
npv
conclus
posit
first
postasct
petct
associ
high
risk
relaps
popul
patient
kept
close
surveil
contrari
report
group
studi
allow
us
detect
earli
relaps
absenc
clinic
data
patient
neg
earli
petct
justifi
perform
neg
studi
followup
unlik
posit
studi
necessari
defin
period
detect
relaps
adopt
deauvil
score
clinic
trial
registri
rev
conflict
interest
none
tabl
valu
pet
ct
accord
time
asct
first
pavlov
state
medic
univers
saint
petersburg
raisa
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
saint
petersburg
russian
feder
background
human
immunodefici
viru
hiv
infect
associ
increas
incid
nonhodgkin
lymphoma
nhl
hodgkin
lymphoma
hl
throughout
haart
era
autolog
stem
cell
transplant
asct
report
feasibl
safe
use
approach
either
rescu
consolid
hivrel
lymphoma
patient
howev
number
publish
compar
studi
accord
hiv
statu
limit
method
sinc
jan
seven
patient
hivrel
lymphoma
undergon
asct
includ
prospect
sing
centr
studi
studi
group
hiv
group
data
nonhivinfect
patient
lymphoma
undergon
asct
period
time
control
group
collect
compar
efficaci
safeti
procedur
median
follow
time
month
primari
end
point
overal
surviv
os
relaps
rate
month
asct
secondari
end
point
time
hematopoiet
recoveri
organ
toxic
common
terminolog
criteria
advers
event
ctcae
toxic
analys
use
underli
diseas
hivgroup
hl
nhl
condit
regimen
beam
bcnu
replac
bendamustin
hiv
viral
load
undetect
median
number
cell
cellsmcl
patient
haart
assess
potenti
differ
patient
diseas
treatment
characterist
group
show
signific
differ
result
overal
surviv
os
month
patient
os
month
hivgroup
vs
control
group
relaps
rate
underli
diseas
month
hivgroup
control
group
median
time
leukocyt
neutrophil
platelet
recoveri
respect
hivgroup
control
group
rate
organ
toxic
accord
ctcae
outlin
tabl
conclus
oneyear
overal
surviv
patient
hivrel
lymphoma
relaps
rate
differ
control
group
found
signific
differ
two
group
hematopoiet
recoveri
toxic
rate
preliminari
data
provid
evid
hiv
statu
affect
outcom
asct
lymphoma
patient
hivrel
lymphoma
consid
candid
asct
meet
standard
transplant
criteria
conflict
interest
author
noth
disclos
tabl
tabl
univers
hospit
duesseldorf
clinic
haematolog
duesseldorf
germani
life
scienc
center
statist
duesseldorf
germani
univers
hospit
duesseldorf
clinic
neuropatholog
duesseldorf
germani
univers
hospit
duesseldorf
clinic
neurosurgeri
duesseldorf
germani
background
primari
central
nervou
system
nonhodgkinlymphoma
pcnslnhl
extranod
bcell
lymphoma
inferior
prognosi
convent
treatment
compar
peripher
nodal
counterpart
highdos
therapi
hdt
follow
autolog
blood
stem
cell
transplant
asct
shown
induc
high
rate
long
term
diseas
free
surviv
patient
pcnsl
definit
role
comparison
intens
convent
chemo
immunotherapi
ccit
still
clear
method
retrospect
collect
data
patient
femal
median
age
year
rang
pcnsnhl
diagnos
treat
univers
hospit
januari
decemb
convent
chemotherapi
ct
group
patient
treat
ccit
includ
hdmtx
rituximab
two
patient
receiv
consolid
radiotherapi
highdos
therapi
hdt
group
patient
receiv
induct
ccit
follow
hdt
asct
three
patient
treat
sole
radiotherapi
patient
receiv
best
support
care
result
ctgroup
treat
ccit
median
cycl
mtx
rituximab
r
without
hdt
asct
overal
respons
rate
treatmentrel
death
pf
month
os
month
median
followup
month
rang
hdtgroup
follow
ccit
induct
median
cycl
rmtx
cycl
rhdcytarabin
thiotepa
achiev
cr
pr
prior
hdt
condit
regimen
bcnuthiotepa
r
beam
r
median
followup
month
rang
overal
respons
rate
treatmentrel
death
pf
os
month
respect
hdtasct
patient
aliv
complet
partial
remiss
die
pd
trm
patient
achiev
cr
prior
hdt
achiev
durabl
cr
ctgroup
patient
aliv
complet
partial
remiss
patient
continu
crpr
salvag
hdtasct
salvag
radiotherapi
salvag
chemotherapi
twentyon
patient
die
progress
diseas
compar
ctgroup
patient
hdtgroup
significantli
better
pf
vs
month
wherea
os
significantli
differ
vs
month
howev
patient
hdtgroup
also
significantli
younger
compar
ctgroup
year
vs
year
p
signific
differ
pf
os
group
treat
without
rituximab
conclus
intens
ccit
induct
follow
hdt
asct
feasibl
low
treatment
relat
mortal
select
patient
pcnsnhl
singl
center
retrospect
analysi
respons
pf
better
convent
ccit
alon
howev
patient
receiv
hdt
asct
younger
sever
patient
ctgroup
achiev
second
respons
salvag
therapi
includ
asct
random
studi
need
defin
role
hdt
asct
primari
treatment
pcnsnhl
conflict
interest
author
conflict
interest
hematolog
bone
marrow
transplant
depart
algier
algeria
background
efficaci
high
dose
therapi
hdt
follow
autolog
stem
cell
transplant
asct
refractori
relaps
hodgkin
lymphoma
hl
report
optim
hdt
regim
determin
one
standard
beam
includ
carmustin
bcnu
etoposid
aracytin
melphalan
view
unavail
bcnu
substitut
drug
bendamustin
beam
protocol
beeam
method
retrospect
studi
august
decemb
patient
pt
hl
treat
asct
hdt
protocol
beeam
bendamustin
mainli
hl
ann
arbor
stage
iv
pt
refractori
hl
ann
arbor
stage
iii
pt
stage
ii
pt
median
age
year
sex
ratio
statu
pt
graft
partiel
respons
pr
complet
respons
cr
therapeut
line
pt
unconfirm
cr
therapeut
line
hdt
use
beeam
bendamustin
aracytin
etoposid
melphalan
peripher
hsc
collect
cytapheresi
mobil
gcsf
alon
median
rate
cell
x
kg
median
followup
month
result
averag
durat
hospit
day
pt
aplasia
averag
durat
day
transfus
support
assur
red
blood
cell
pt
platelet
transfus
pt
median
time
graft
day
twentynin
patient
hyperthermia
clinic
document
cathet
infect
pneumon
diarrhea
microbiolog
document
blood
cultur
pt
staphylococcu
coagulas
neg
staphylococcu
aureu
e
coli
klebsiella
pneomona
acinetobact
renal
toxic
note
pt
grade
grade
pt
hepat
toxic
pt
grade
grade
grade
death
observ
trm
follow
renal
toxic
set
sever
sepsisof
pt
evalu
posttransplant
pt
cr
pt
pr
relaps
observ
pt
median
durat
month
octob
pt
aliv
conclus
good
toler
bendamustinebas
hdt
observ
beeam
protocol
seem
interest
therapeut
altern
bcnu
unavail
conflict
interest
noth
disclos
abstract
previous
publish
rm
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
ip
pavlov
first
st
petersburg
state
medic
univers
st
petersburg
russian
feder
background
allohsct
cur
potenti
patient
rr
chl
recent
year
novel
ric
regimen
fludarabinebendamustin
flube
khouri
et
al
posttranspl
cyclophosphamidebas
gvhd
prophylaxi
ptci
luznik
new
compound
immunotherapi
allosct
monoclon
antibodi
brentuximab
vedotin
bv
chen
inhibitor
nivolumab
nivo
youn
potenti
improv
allohsct
outcom
purpos
analysi
evalu
outcom
patient
rr
chl
undergo
allohsct
flube
ptcybas
gvhd
prophylaxi
treat
bv
nivo
allohsct
method
retrospect
evalu
allohsct
patient
median
age
male
rr
chl
undergon
allohsct
analysi
includ
two
group
patient
group
receiv
flube
condit
ptci
gvhd
prophylaxi
bvnivo
bridg
therapi
group
b
patient
receiv
melphalan
busulfanbas
ric
condit
convent
gvhd
prophylaxi
chemotherapybas
bridg
group
bv
use
bridg
patient
nivo
patient
time
analysi
median
followup
month
group
month
group
b
differ
patient
two
group
accord
median
age
year
gender
male
previou
histori
autohsct
median
treatment
line
radiat
therapi
type
donor
vs
relat
unrel
haplo
respect
patient
group
achiev
better
remiss
statu
allohsct
cr
pr
sdpd
compar
group
b
cr
pr
sdpd
result
twoyear
os
ef
whole
popul
cumul
incid
nonrelaps
mortal
year
group
group
b
respect
relaps
incid
respect
signific
improv
os
ef
group
versu
group
b
vs
respect
six
patient
relaps
allohsct
success
treat
differ
dose
nivo
mgkg
figur
differ
grade
iiiv
grade
iiiiv
vs
agvhd
reduc
incid
moder
sever
cgvhd
group
vs
rate
composit
endpoint
extens
cgvhd
relapsefre
surviv
significantli
better
group
compar
group
b
vs
p
impact
compon
group
strategi
demonstr
figur
conclus
observ
improv
allohsct
outcom
introduct
flube
condit
ptci
gvhd
prophylaxi
bridg
therapi
bv
nivo
observ
correspond
improv
diseas
statu
prior
allohsct
consid
group
median
surviv
short
observ
need
nivo
demonstr
promis
efficaci
treatment
relaps
allohsct
impact
individu
factor
interpret
analysi
due
overlap
strategi
conflict
interest
coauthor
conflict
interest
noth
disclos
makass
middl
east
institut
health
univers
hospitalslebanes
univers
hematolog
oncologybmt
beirut
lebanon
makass
univers
hospit
hematolog
oncologybmt
beirut
lebanon
middl
east
institut
health
univers
hospit
bmt
beirut
lebanon
middl
east
institut
health
univers
hospit
hematolog
oncolog
beirut
lebanon
bahman
hospit
hematolog
oncolog
beirut
lebanon
middl
east
institut
health
univers
hospit
blood
bank
beirut
lebanon
middl
east
institut
health
univers
hospitalsaint
joseph
universitylebanes
univers
cellular
therapi
beirut
lebanon
makass
univers
hospit
laboratori
medicin
beirut
lebanon
background
highdos
chemotherapi
hdct
follow
autolog
peripher
stem
cell
transplant
apbsct
improv
surviv
reduc
risk
relaps
patient
pt
lymphoma
l
relaps
first
line
treatment
beam
frequent
hdct
use
l
bcnu
longer
avail
replac
thiotepa
approv
french
nation
agenc
secur
drug
use
part
hdct
follow
apbsct
retrospect
studi
ebmt
show
differ
team
beam
term
toxic
surviv
pt
auto
transplant
l
sellner
l
et
al
bone
marrow
french
prospect
non
intervent
multicent
studi
ongo
pt
l
evalu
efficaci
toxic
team
thiotepa
day
melphalan
asct
present
preliminari
result
experi
pt
hodgkin
lymphoma
hl
diffus
larg
b
cell
nonhodgkin
lymphoma
dlbcl
underw
team
follow
apbsct
relaps
firstlin
treatment
method
team
similar
french
studi
thiotepa
given
dose
apbsct
perform
minim
number
cell
infus
manag
febril
neutropenia
perform
accord
guidelin
evalu
toxic
done
accord
grade
scale
result
median
age
femal
male
diagnosi
hl
pt
dlbcl
pt
four
pt
hl
underw
apbsct
second
complet
remiss
cr
refractori
relaps
abvd
obtain
cr
line
salvag
therapi
includ
one
patient
pt
pt
pt
dlbcl
underw
apbsct
second
cr
median
number
cell
transfus
median
time
neutrophil
platelet
recoveri
respect
pt
develop
vomit
grade
pt
oral
mucos
occur
pt
grade
one
pt
diarrhea
occur
pt
grade
pt
develop
febril
neutropenia
two
pt
develop
pneumonia
one
bacteremia
due
ecoli
esbl
pt
coliti
due
clostridium
difficil
pt
aliv
cr
median
conclus
hdct
team
hl
dlbcl
induc
low
toxic
high
efficaci
short
follow
team
could
valuabl
altern
beam
must
investig
larger
prospect
clinic
trial
conflict
interest
noth
disclos
hospit
ampang
haematolog
ampang
malaysia
background
new
era
role
autolog
stem
transplant
asct
hodgkin
lymphoma
hl
evolv
advent
target
drug
brentuximab
checkpoint
inhibiotr
follow
better
understand
pathogenesi
molecular
biolog
diseas
howev
novel
agent
expens
wide
feasibl
includ
center
therefor
us
asct
remain
standard
approach
relapsedrefractori
hl
fail
frontlin
multiag
chemotherapi
withwithout
radiotherapi
salvag
treatment
studi
analyz
result
asct
perform
among
hl
patient
center
hospit
ampang
method
medic
record
hl
patient
underw
asct
retriev
hospit
ampang
databas
evalu
retrospect
progress
post
asct
updat
electron
clinic
follow
note
nation
registr
depart
contact
patient
lost
follow
confirm
surviv
statu
result
total
hl
patient
underw
asct
studi
june
june
male
preponder
median
age
year
rang
year
malay
remain
major
ethnic
group
nodular
scleros
subtyp
advanc
stage
stage
iv
major
receiv
chemotherapi
mobil
averag
cell
dose
collect
condit
perform
beam
flam
lace
graft
averag
day
transplant
outcom
evalu
dec
show
overal
surviv
os
year
year
respect
detail
assess
day
multivari
analysi
ascertain
predictor
transplant
outcom
among
cohort
patient
includ
diseas
statu
chemosensit
ethnic
differ
present
among
cohort
patient
relaps
post
asct
proceed
ric
allograft
match
relat
sibl
one
haploident
donor
conclus
conclus
despit
emerg
effect
potent
novel
target
therapi
highdos
chemotherapi
follow
asct
still
hold
import
role
excel
rescu
therapi
regard
toler
either
physic
financi
well
overal
surviv
conflict
interest
noth
disclos
maria
sklodowskacuri
cancer
centr
institut
depart
lymphoprolif
diseas
warszawa
poland
maria
sklodowskacuri
cancer
centr
institut
depart
patholog
laboratoti
diagnost
warszawa
poland
background
high
grade
bcell
lymphoma
myc
andor
rearrang
hgbclr
hgbcl
no
myc
doubl
express
de
diffus
larg
b
cell
lymphoma
dlbcl
highrisk
dlbcl
ipi
usual
progress
standard
immunochemotherapi
valu
myeloabl
chemotherapi
follow
autolog
hematopoiet
cell
transplant
autohct
first
remiss
highrisk
lymphoma
patient
remain
confirm
report
outcom
autohct
consolid
first
remiss
patient
aggress
bcell
lymphoma
risk
factor
method
total
consecut
patient
highrisk
aggress
bcell
lymphoma
hgbclr
hgbl
no
de
highrisk
dlbcl
plan
receiv
rchop
daepochr
follow
beam
autohct
firstlin
treatment
median
age
rang
three
ipi
risk
factor
present
patient
result
patient
achiev
complet
remiss
rchop
daepochr
induct
therapi
proceed
autohct
remain
receiv
line
therapi
autohct
one
patient
die
earli
transplant
median
followup
month
autohct
progress
free
surviv
pf
overal
surviv
os
ci
ci
hr
hazard
ratio
death
progress
patient
receiv
one
line
vs
two
line
therapi
autohct
ci
p
ci
p
respect
hr
death
increas
dedlbcl
vs
highrisk
dlbcl
dedlbcl
vs
hgbcl
subgroup
ci
pn
ci
pn
respect
hr
progress
dedlbcl
vs
highrisk
dlbcl
increas
ci
differ
statist
signific
signific
differ
hr
progress
dedlbcl
vs
hgbcl
ci
hgbcl
vs
highrisk
dlbcl
ci
hr
death
increas
patient
receiv
rchop
vs
daepochr
statist
signific
signific
differ
hr
progress
rchop
daepochr
group
conclus
less
patient
aggress
highrisk
lymphoma
achiev
complet
remiss
first
line
treatment
failur
achiev
complet
remiss
induct
therapi
associ
increas
risk
death
diagnosi
dedlbcl
increas
risk
death
risk
progress
compar
diagnosi
highrisk
dlbcl
nonsignificantli
increas
risk
death
compar
hgbcl
singleinstitut
data
suggest
rchop
follow
consolid
autohct
suboptim
treatment
highrisk
aggress
lymphoma
patient
particular
patient
doubl
express
dlbcl
conflict
interest
noth
disclos
nation
medic
reserch
institut
oncolog
na
petrov
oncologyhematolog
bone
marrow
transplant
saint
petersburg
russian
feder
nation
medic
reserch
institut
oncolog
na
petrov
patholog
saint
petersburg
russian
feder
nation
medic
reserch
institut
oncolog
na
petrov
saint
petersburg
russian
feder
background
doubl
express
cmyc
independ
risk
factor
aggress
cours
diffus
larg
bcell
lymphoma
patient
dlbcl
overcom
earli
treatment
intensif
method
analyz
data
use
chisquar
test
independ
odd
ratio
full
analisi
test
progress
free
surviv
pf
estim
kaplanmei
method
comparison
pf
experiment
group
longrank
test
multifactor
analysi
pf
multinomi
logist
regress
statist
signific
differ
p
result
analyz
pt
dlbcl
year
old
median
age
yo
underw
treatment
nation
medic
research
center
oncolog
napetrov
sixti
four
pt
perform
earli
stage
diseas
ii
pt
advanc
stage
iii
iv
extranod
involv
observ
pt
bsymptom
pt
determin
gcbsubtyp
nongcb
use
han
algorithm
estim
immunohistochem
marker
cd
mum
daepochr
hypercvadr
first
line
receiv
pt
upfront
highdos
chemotherapi
autosct
receiv
pt
pf
pt
ci
pf
significantli
lower
pt
bsymptom
vs
rr
ci
p
advanc
stage
vs
rr
ci
p
express
vs
rr
ci
p
vs
rr
ci
p
higher
vs
rr
ci
p
doubleexpressor
lymphoma
del
doubl
express
cmyc
observ
patient
among
patient
del
pf
lower
significantli
differ
compar
nondel
data
relat
earli
treatment
intensif
subgroup
daepochr
hypercvadr
upfront
highdos
chemotherapi
autosct
del
subgroup
also
associ
advanc
stage
diseas
iiiiv
vs
iii
p
bsymptom
vs
p
higher
vs
p
conclus
data
confirm
aggress
cours
diseas
patient
del
compar
standard
group
may
suggest
benefit
pt
undergo
earlytreat
intensif
rdaepoch
rhypercvad
upfront
high
dose
chemotherapi
autolog
stem
cell
transplant
clinic
trial
registri
na
conflict
interest
conflict
interest
kobe
citi
medic
center
gener
hospit
haematolog
kobe
japan
background
patient
relaps
nonhodgkin
lymphoma
nhl
undergon
autolog
stem
cell
transplant
asct
wellestablish
serum
biomark
correl
postasct
surviv
present
studi
investig
prognost
signific
serum
solubl
receptor
level
prior
asct
method
studi
retrospect
analys
patient
underw
asct
relaps
nhl
januari
septemb
primari
endpoint
overal
surviv
os
secondari
endpoint
progress
free
surviv
pf
os
pf
curv
construct
use
kaplanmei
method
compar
logrank
test
studi
compli
standard
declar
helsinki
current
ethic
guidelin
approv
institut
ethic
board
result
studi
includ
patient
time
asct
median
patient
age
year
rang
year
histolog
subtyp
nhl
patient
follow
aggress
bcell
lymphoma
patient
indol
bcell
lymphoma
patient
peripher
tcell
lymphoma
patient
extranod
nktcell
lymphoma
nasal
type
patient
diseas
statu
asct
complet
respons
cr
patient
partial
respons
patient
ranimustin
etoposid
cytarabin
methotrex
administ
patient
condit
regimen
rituximab
coadminist
patient
median
level
asct
uml
rang
uml
receiv
oper
characterist
curv
analysi
identifi
uml
satisfactori
cutoff
valu
predict
surviv
os
rate
significantli
wors
patient
higher
level
lower
level
vs
addit
progress
free
surviv
rate
significantli
wors
patient
higher
level
lower
level
vs
among
patient
cr
time
asct
os
rate
significantli
wors
higher
level
lower
level
vs
conclus
patient
relaps
nhl
show
respons
salvag
chemotherapi
undergon
asct
level
time
asct
might
prognost
conflict
interest
tanaka
noth
disclos
univers
hospit
salamanca
nuclear
medicin
depart
salamanca
spain
univers
hospit
salamanca
hematolog
depart
salamanca
spain
univers
hospit
salamancaibs
hematolog
depart
salamanca
spain
univers
hospit
salamancaibs
nuclear
medicin
depart
salamanca
spain
background
stem
cell
transplant
sct
becom
potenti
cur
treatment
patient
diagnos
hodgkin
hl
non
hodgkin
lymphoma
nhl
autolog
sct
posit
pet
associ
high
rate
relaps
andor
progress
allogen
sct
allosct
petct
lower
posit
predict
valu
ppv
due
graft
vs
lymphoma
effect
although
posit
pretranspl
petct
may
associ
poorer
outcom
howev
role
petct
allosct
still
less
well
known
aim
studi
assess
predict
prognost
valu
presct
day
month
sct
petct
patient
hl
nhl
underw
allosct
method
prospect
studi
patient
diagnos
hl
nhl
underw
allosct
center
three
petct
studi
schedul
patient
day
year
sct
perform
within
day
sct
pet
result
analyz
correl
clinic
statu
paramet
patient
metabol
respons
petct
assess
follow
lugano
criteria
result
mean
age
patient
year
old
male
averag
number
previou
treatment
line
receiv
allosct
patient
receiv
previou
autosct
patient
donorrel
dr
sct
haplosct
sourc
peripher
blood
progenitor
reduc
intens
condit
ric
patient
statu
sct
complet
metabol
respons
cr
metabol
progres
stablerefractari
diseas
patient
neg
show
abnorm
pet
clinic
evid
relaps
progress
year
allosct
remain
patient
show
relaps
later
neg
patient
aliv
diseas
free
year
follow
patient
posit
neg
patient
neg
show
relaps
also
later
progress
confirm
pet
surveil
mean
follow
year
aliv
diseas
free
conclus
studi
demonstr
posit
preallosct
petct
associ
poorer
outcom
addit
suggest
petct
studi
perform
year
allosct
better
outcom
predictor
day
sct
petct
conflict
interest
author
state
conflict
interest
tabl
prognost
valu
king
abdulaziz
medic
citi
riyadh
saudi
arabia
king
abdullah
intern
medic
research
center
riyadh
saudi
arabia
king
saud
bin
abdulaziz
univers
health
scienc
riyadh
saudi
arabia
background
patient
relaps
refractori
classic
hodgkin
lymphoma
rr
chl
achiev
less
partial
respons
pr
follow
first
line
salvag
chemotherapi
poor
outcom
villa
et
al
haematologica
antibodi
drug
conjug
adc
brentuximab
vedotin
bv
use
part
salvag
regimen
post
hct
consolid
improv
remiss
rate
aim
examin
outcom
rr
chl
patient
requir
two
line
salvag
compar
patient
requir
singl
line
salvag
contemporari
era
chemoimmunotherapi
method
due
irb
approv
pt
rr
chl
candid
cur
hct
identifi
record
retriev
retrospect
bv
given
intraven
infus
mgkg
day
salvag
chemotherapi
everi
week
start
day
post
hct
deauvil
score
regard
complet
metabol
respons
cmr
prehct
patient
proceed
hct
partial
remiss
pr
better
achiev
irrespect
petct
statu
categor
continu
variabl
compar
use
chisquar
wilcoxon
kruskalw
respect
overal
surviv
os
progress
free
surviv
pf
comput
use
kaplanmeir
method
log
rank
test
multivari
analys
perform
use
cox
regress
model
result
total
pt
rr
chl
identifi
includ
analysi
among
cohort
requir
one
line
salvag
requir
two
line
remain
requir
three
line
patient
abl
achiev
pr
better
proceed
hct
cohort
subsequ
stratifi
requir
one
two
salvag
line
prior
hct
baselin
characterist
strata
shown
tabl
signific
differ
found
regard
gender
proport
refractori
diseas
time
relaps
case
requir
two
salvag
line
prior
hct
patient
significantli
younger
p
receiv
bv
often
part
salvag
chemotherapi
post
hct
consolid
p
trend
higher
cmr
statu
prehct
requir
singl
vs
two
salvag
line
vs
p
multivari
analysi
pf
male
gender
advers
prognost
factor
wherea
neg
petct
protect
shown
tabl
ii
year
estim
pf
os
patient
requir
one
vs
two
line
salvag
vs
p
vs
p
respect
conclus
observ
patient
requir
two
line
salvag
prior
hct
achiev
compar
outcom
requir
singl
line
salvag
like
part
due
incorpor
bv
result
higher
cmr
rate
expect
prehct
result
import
implic
patient
may
refer
hct
given
histor
report
poor
outcom
given
limit
analysi
find
examin
conflict
interest
relev
conflict
interest
centro
hospitalar
e
de
coimbra
hematolog
depart
coimbra
portug
univers
coimbra
faculti
medicin
cimago
coimbra
portug
background
high
dose
chemotherapi
hdc
follow
autolog
stem
cell
transplant
asct
use
treatment
relapsedrefractori
nonhodgkin
lymphoma
nhl
firstremiss
consolid
mantlecel
lymphoma
unclear
whether
complet
respons
asct
correl
better
surviv
evalu
prognost
valu
diseas
statu
complet
remiss
cr
vs
partial
remiss
pr
cohort
patient
nhl
method
unicentr
retrospect
analysi
patient
nhl
treat
hdt
asct
patient
receiv
peripher
blood
stem
cell
support
condit
beam
regimen
carmustin
etoposid
arac
melphalan
respons
assess
accord
lugano
classif
use
kaplanmei
method
estim
progress
free
surviv
pf
overal
surviv
os
logrank
test
compar
risk
group
univari
analysi
perform
signific
predictor
use
adjust
multivari
cox
regress
model
result
includ
patient
mainli
male
median
age
year
preval
histolog
subtyp
diffus
larg
bcell
lymphoma
mantlecel
lymphoma
follicular
lymphoma
median
number
therapeut
line
patient
diffus
larg
bcell
lymphoma
follicular
lymphoma
mainli
treat
rchoprcvp
firstlin
achiev
cr
relaps
r
eshapdhapic
perform
secondlin
follow
asct
salvag
therapi
order
achiev
consolid
cr
major
patient
mantlecel
lymphoma
receiv
rchoprdhap
follow
consolid
asct
first
remiss
median
followup
time
asct
month
os
year
pf
respect
asct
patient
cr
pr
acst
patient
assess
respons
due
earli
death
toxic
remain
achiev
cr
pr
fail
respond
patient
cr
asct
present
significantli
longer
pf
compar
pr
vs
month
addit
patient
cr
asct
present
longer
os
pf
compar
pr
vs
vs
month
p
howev
patient
significantli
lower
pf
compar
patient
continu
cr
asct
vs
month
univari
analysi
indic
remiss
statu
preasct
signific
predictor
pf
asct
hr
ci
multivari
analysi
show
factor
retain
prognost
valu
adjust
age
histolog
ann
arbor
stage
number
previou
treatment
conclus
data
provid
evid
cr
previou
asct
independ
predictor
pf
patient
nhl
cr
asct
also
correl
higher
pf
os
highest
pf
patient
continu
cr
use
effect
induct
regimen
order
improv
initi
respons
may
advantag
term
clinic
benefit
postasct
conflict
interest
none
author
anyth
disclos
saint
antoin
hospit
aphp
hematolog
cellular
therapi
pari
franc
sorbonn
univers
pierr
et
mari
curi
upmc
pari
franc
inserm
umr
pari
franc
center
hematolog
lyon
franc
hospit
hematolog
pari
franc
saint
loui
hospit
pari
franc
victor
dupouy
hospit
hematolog
argenteuil
franc
french
polynesia
hospit
hematolog
papeet
french
polynesia
background
autolog
hematopoiet
stem
cell
transplant
autosct
consid
standard
approach
high
risk
relapsedrefractori
nonhodgkin
hodgkin
lymphoma
although
larg
varieti
condit
regimen
avail
includ
wide
use
beam
carmustin
etoposid
cytarabin
melphalan
consensu
regard
standard
approach
context
carmustin
shortag
chosen
replac
thiotepa
howev
clinic
data
team
thiotepa
etoposid
cytarabin
melphalan
condit
regimen
still
spars
retrospect
thu
design
multicent
prospect
studi
assess
efficaci
toxic
team
condit
regimen
method
team
regimen
consist
total
dose
thiotepa
mgkg
etoposid
cytarabin
melphalan
patient
underw
autosct
team
condit
includ
analysi
fullfil
follow
criteria
age
year
biopsyproven
hodgkin
nonhodgkin
lymphoma
hiv
seroneg
first
autosct
result
fiftyeight
male
fourteen
femal
median
age
year
rang
analyz
thu
far
karnofski
score
patient
lymphoma
diffus
larg
b
cell
mantl
cell
follicular
margin
zone
grey
zone
hodgkin
peripher
tcell
grade
lymphoid
granulomatosi
advanc
stage
diseas
ann
arbor
stage
iiiiv
note
patient
diseas
statu
time
autosct
complet
respons
cr
patient
partial
respons
includ
patient
never
reach
cr
progress
diseas
median
cell
infus
graft
rang
median
time
neutrophil
recoveri
day
rang
median
time
platelet
recoveri
gl
day
rang
signific
regimenrel
toxic
mucos
patient
median
rang
diarrhea
patient
median
rang
nonhematolog
grade
advers
event
occur
patient
central
lineassoci
bloodstream
infect
occur
patient
four
patient
requir
intens
care
unit
transfer
patient
evalu
respons
cr
death
directli
attribut
diseas
progress
relaps
occur
patient
median
followup
month
rang
nonrelaps
mortal
nrm
two
patient
die
aplasia
infect
one
patient
die
day
autosct
necrot
fasciiti
last
followup
patient
relaps
die
still
aliv
estim
overal
surviv
progressionfre
surviv
respect
conclus
team
condit
regimen
seem
safe
valid
platform
autosct
patient
highrisk
relapsedrefractori
lymphoma
although
mucos
diarrhea
frequent
nrm
similar
report
nrm
beam
condit
regimen
clinic
trial
registri
studi
regist
clinicaltrialsgov
conflict
interest
mohamad
mohti
remi
duleri
florent
malard
receiv
honoraria
lectur
keocyt
whose
drug
includ
studi
author
declar
compet
financi
interest
heidelberg
univers
hospit
medicin
v
heidelberg
germani
st
marienkrankenhau
siegen
siegen
germani
oncolog
practic
darmstadt
darmstadt
germani
heidelberg
univers
hospit
heidelberg
germani
background
ebmt
eric
propos
treatment
algorithm
patient
highrisk
chronic
lymphocyt
leukemia
cll
pathway
inhibitor
pi
era
algorithm
suggest
allogen
hematopoiet
cell
transplant
allohct
option
patient
relapsedrefractori
rr
cll
respond
pi
high
diseasespecif
risk
abnorm
andor
del
along
low
transplant
risk
wellmatch
donor
lack
comorbid
algorithm
level
allohct
also
consid
patient
rr
cll
progress
pi
even
higher
transplant
risk
algorithm
level
method
object
singl
centr
retrospect
analysi
investig
algorithm
feasibl
compar
nontranspl
care
term
safeti
efficaci
intenttotreat
elig
patient
cll
bprolymphocyt
leukemia
bpll
meet
entri
criteria
algorithm
refer
institut
allohct
evalu
jan
oct
primari
endpoint
progressionfre
surviv
pf
enter
algorithm
result
total
patient
enter
algorithm
diagnos
cll
patient
bpll
patient
median
age
entri
patient
harbour
lesion
resist
chemoimmunotherapi
median
pretreat
regimen
first
pi
ibrutinib
idelalisib
venetoclax
median
followup
month
pf
overal
surviv
os
algorithm
entri
patient
respect
patient
enter
meet
requir
proceed
allohct
level
donor
comorbid
refus
five
patient
progress
pi
thu
proceed
patient
patient
allohct
intend
translat
pf
vs
nohct
vs
intenttohct
group
p
togeth
patient
enter
directli
total
patient
progress
higher
diseasespecif
risk
justifi
mismatch
transplant
rescu
treatment
patient
venetoclax
ibrutinib
idelalisib
rituximab
direct
allohct
pf
patient
reach
compar
patient
remain
p
altogeth
patient
proceed
allohct
show
mrdneg
pf
os
year
transplant
conclus
ebmter
algorithm
seem
inferior
pionli
strategi
patient
highrisk
rr
cllbpll
promis
outlook
patient
undergo
allohct
respond
pi
patient
progress
pi
effect
rescu
subsequ
altern
pi
allohct
consolid
conflict
interest
noth
disclos
icohospit
universitari
joan
xxiii
hematolog
tarragona
spain
hospit
hematolog
barcelona
spain
background
autolog
stem
cell
transplant
asct
standard
care
patient
multipl
myeloma
lymphoma
nevertheless
associ
morbid
mortal
hematopoiet
cell
transplant
comorbid
index
hctci
score
use
evalu
comorbid
outcom
allogen
hematopoiet
cell
transplant
hct
prove
predictor
nonrelaps
mortal
nrm
allogen
hct
public
evalu
use
hctci
set
asct
heterogen
result
score
abil
predict
nrm
overal
survivor
os
group
patient
method
analyz
asct
perform
center
novemb
april
individu
comorbid
prospect
collect
time
asct
patient
assign
hctci
score
test
util
hctci
predictor
nrm
surviv
patient
undergo
asct
surviv
curv
probabl
estim
use
kaplanmei
method
logrank
analysi
multivari
analysi
perform
use
cox
proport
hazard
regress
model
variabl
analyz
includ
hctci
age
gender
type
diseas
myeloma
lymphoma
diseas
stage
karnofski
perform
score
kp
tabl
nrm
defin
mortal
transplant
absenc
diseas
relapseprogress
thu
cumul
incid
probabl
nrm
calcul
account
relaps
compet
risk
result
median
followup
month
ci
patient
hctci
score
present
median
os
month
trend
toward
inferior
os
multivari
analysi
hctci
score
retain
independ
advers
prognost
factor
ci
nrm
month
hctci
score
month
hctci
score
group
figur
conclus
higher
hctci
score
predict
nrm
associ
inferior
surviv
patient
undergo
asct
cohort
conflict
interest
noth
disclos
tabl
patient
characterist
hctci
score
chonnam
nation
univers
hwasun
hospit
hematologyoncolog
hwasungun
korea
republ
chonbuk
nation
univers
hospit
hematologyoncolog
jeonju
korea
republ
background
peripher
tcell
lymphoma
ptcl
respond
poorli
convent
chemotherapi
studi
demonstr
upfront
highdos
chemotherapi
hdt
autolog
stem
cell
transplant
asct
consolid
could
lead
long
term
progressionfre
surviv
pf
ptcl
howev
predict
factor
determin
undergo
hdtasct
primari
treatment
studi
investig
respons
assess
use
fdg
petct
could
predict
indic
determin
upfront
hdtasct
treatment
ptcl
method
evalu
role
petct
proceed
upfront
hdtasct
analyz
newli
diagnos
patient
ptcl
age
year
jan
dec
compar
clinic
outcom
accord
interim
final
respons
petct
two
group
hdtasct
group
test
cohort
nonhdtasct
valid
group
valid
cohort
respect
total
patient
enrol
test
cohort
patient
valid
cohort
patient
underw
interim
final
petct
primari
treatment
respons
interim
final
petct
assess
visual
analysi
use
deauvil
fivepoint
scale
result
patholog
frequenc
hdtasct
group
includ
nodal
type
extranod
type
treatment
regimen
mainli
consist
anthracyclinebas
choplik
nonanthracylinebas
chemotherapi
ipi
score
diagnosi
factor
respect
median
followup
month
pf
rate
accord
interim
petct
respons
deauvil
score
deauvil
score
deauvil
score
respect
figur
hand
analyz
pf
rate
base
final
petct
respons
pf
rate
well
stratifi
deauvil
score
deauvil
score
deauvil
score
respect
figur
b
p
valid
cohort
pf
rate
accord
interim
petct
respons
deauvil
score
deauvil
score
deauvil
score
respect
figur
c
p
howev
pf
rate
base
final
petct
respons
well
discrimin
well
test
cohort
figur
p
conclus
final
petct
assess
base
deauvil
show
prognost
signific
outcom
upfront
hdtasct
howev
interim
petct
respons
could
predict
outcom
patient
ptcl
conflict
interest
noth
disclos
univers
hospit
bristol
bristol
unit
kingdom
lymphoma
work
parti
ebmt
pari
franc
ebmt
lymphoma
work
parti
pari
franc
univers
heidelberg
heidelberg
germani
univers
heidelberg
haematolog
heidelberg
germani
hopit
necker
pari
franc
uclh
london
unit
kingdom
asklepio
clinic
st
georg
hamburg
germani
univers
maastrich
maastrich
netherland
hospit
duran
reynal
haematolog
barcelona
spain
fundeni
clinic
institut
bucharest
romania
st
bartholemew
hospit
london
unit
kingdom
background
autolog
autosct
allogen
stem
cell
transplant
allosct
employ
manag
patient
indol
lymphoma
indnhl
optim
sequenc
therapi
well
establish
role
sct
manag
indnhl
challeng
recent
advent
new
therapeut
option
analys
transplant
activ
indnhl
report
ebmt
registri
last
decad
determin
geograph
tempor
chang
utilis
sct
method
retrospect
analysi
ebmt
databas
inclus
criteria
autosct
allo
sct
inclus
indnhl
pre
fl
post
result
autosct
allosct
fullfil
inclus
criteria
percentag
ebmt
regist
centr
report
sct
indnhl
risen
maximum
number
autosct
occur
allosct
ratio
autosct
allosct
per
countri
show
mark
variat
rang
differ
persist
time
median
age
autosct
allosct
risen
yr
rang
yr
yr
yr
respect
regard
autosct
median
time
diagnosi
sct
increas
month
percentag
patient
transplant
primari
refractoryprogress
diseas
fallen
use
autosct
first
respons
peak
autosct
period
reduct
use
tbi
base
condit
whilst
use
peripher
blood
stem
cell
increas
respect
allosct
median
time
diagnosi
allosct
increas
month
percentag
perform
prior
autosct
increas
percentag
patient
primari
refractoryprogress
diseas
time
allosct
fallen
unrel
donor
account
allosct
cord
blood
haploident
famili
donor
use
myeloabl
condit
fallen
transplant
prior
use
tbi
base
condit
fallen
conclus
mark
nation
individu
transplant
centr
variat
use
autosct
allosct
indnhl
probabl
reflect
difficulti
defin
right
time
sct
indnhl
increas
time
diagnosi
sct
may
relat
improv
nontranspl
therapi
increas
use
altern
donor
reduc
intens
condit
allosct
allosct
perform
prior
autosct
addit
better
select
patient
less
patient
receiv
either
autosct
allosct
refractoryprogress
diseas
conflict
interest
author
noth
disclos
minim
residu
diseas
toler
chimer
immun
reconstitut
fondazion
ircc
ca
granda
ospedal
maggior
policlinico
univers
milan
bmthematolog
unit
milano
itali
fondazion
ircc
ca
granda
ospedal
maggior
policlinico
flow
cytometri
facil
servic
depart
milano
itali
unit
medic
statist
biometri
bioinformat
giulio
maccacaro
univers
milan
campu
cascina
rosa
fondazion
ircc
istituto
nazional
tumori
depart
clinic
scienc
commun
health
milano
itali
background
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
prompt
immun
reconstitut
appear
essenti
clinic
outcom
howev
complet
immunolog
recoveri
may
requir
year
prolong
immunodefici
affect
lead
potenti
sever
complic
includ
posttranspl
infect
relaps
secondari
malign
method
aim
prospect
evalu
immunolog
reconstitut
possibl
associ
clinic
outcom
blood
sampl
patient
undergo
allohsct
center
januari
june
analyz
baselin
start
condit
differ
time
point
follow
transplant
month
extens
flow
cytometri
assay
includ
doubl
posit
thymocyt
effector
central
memori
tcm
effector
memori
tem
cell
regulatori
cell
igmmemori
switchedmemori
sm
b
cell
regulatori
cytotox
natur
killer
nk
cell
result
patient
median
age
yr
rang
yr
includ
studi
indic
allohsct
acut
leukemia
myeloid
lymphoblast
myelodysplast
syndrom
nonhodgkin
lymphoma
hodgkin
diseas
primari
myelofibrosi
expect
nk
first
cell
subset
return
normal
level
transplant
earli
expans
regulatori
cell
month
subsequ
expans
cytotox
cell
month
regard
cell
observ
progress
peripher
expans
matur
subset
especi
tem
month
like
origin
donor
matur
cell
subsequ
maintain
preval
cell
reconstitut
cell
donor
hematopoiet
cell
thymic
pathway
delay
start
increas
month
lead
longlast
limit
tcell
repertoir
b
cell
tend
return
normal
count
within
month
mainli
thank
cell
memori
sm
cell
remain
low
year
allohsct
patient
treat
acutegvhd
observ
mark
reduct
nk
cell
mainli
belong
cytotox
subset
subsequ
decreas
effector
memori
cell
evid
time
point
evalu
hand
occurr
treatmentrequir
chronic
gvhd
primarili
affect
bcell
reconstitut
quantit
function
patient
experienc
earli
cmv
reactiv
time
point
observ
signific
reduct
almost
tlymphocyt
except
tcm
tem
subset
blymphocyt
worth
mention
patient
show
ebv
reactiv
appear
lower
count
tcm
cell
baselin
evalu
comparison
patient
experi
ebv
reactiv
conclus
extens
flow
cytometr
analysi
allow
studi
specif
immun
reconstitut
allohsct
suggest
possibl
correl
clinic
outcom
conflict
interest
none
author
anyth
disclos
univers
hospit
bristol
nh
trust
haematolog
bristol
unit
kingdom
epsom
st
helier
univers
hospit
nh
trust
haematolog
london
unit
kingdom
background
beamcampath
condit
allogen
stem
cell
transplant
allosct
develop
reduc
high
transplantrel
mortal
patient
lymphoma
whilst
simultan
deliv
intens
antineoplast
therapi
platform
allogen
stemcel
engraft
describ
outcom
beamcampath
allosct
lymphoma
treat
singl
centr
report
high
incid
long
term
mix
donorrecipi
chimer
mdrc
method
retrospect
analysi
patient
lymphoma
undergo
beamcampath
allosct
centr
chimer
analysi
perform
peripher
blood
utilis
short
tandem
repeat
pcr
mdrc
defin
recipi
donor
statist
analysi
perform
spss
result
patient
femal
male
median
age
transplant
year
rang
identifi
histolog
diagnos
hodgkin
lymphoma
dlbcl
lowgrad
nhl
mantl
cell
tcell
lymphoma
patient
receiv
median
prior
line
therapi
rang
includ
autosct
cr
pr
pretranspl
donor
match
sibl
match
unrel
mismatch
unrel
hlamatch
syngen
median
cell
dose
respect
median
time
platelet
neutrophil
engraft
day
patient
develop
graft
failur
receiv
stemcel
top
graft
failurepoor
function
myeloid
mdrc
develop
acut
gvhd
grade
develop
chronic
gvhd
extens
patient
die
nonrelaps
mortal
nrm
infect
gvhd
ptld
cumul
incid
nrm
year
preval
tcell
lineag
mdrc
peak
subsequ
declin
time
whilst
myeloid
lineag
mdrc
remain
rel
stabl
year
see
figur
year
patient
mdrc
whole
blood
tcell
myeloid
lineag
respect
full
recipi
myelopoiesi
develop
one
patient
develop
recipientderiv
aml
full
recipi
tcell
lymphopoiesi
one
patient
subsequ
relaps
patient
receiv
median
rang
donor
lymphocyt
infus
dli
mdrc
relaps
median
start
dose
patient
develop
acut
postdli
gvhd
grade
chronic
gvhd
limit
tcell
myeloid
mdrc
respect
convert
full
donor
chimer
dli
median
follow
year
patient
relaps
achiev
cr
pr
therapi
dli
die
lymphoma
cumul
incid
relaps
year
year
year
pf
os
respect
conclus
beamcampath
condit
allosct
cur
mani
patient
high
risk
lymphoma
mdrc
common
tcell
myeloid
lineag
persist
mdrc
half
convert
full
donor
myeloid
tcell
lineag
follow
dli
analysi
indic
identifi
pretranspl
factor
associ
mdrc
impact
relaps
rate
conflict
interest
author
noth
disclos
hospit
gener
universitario
gregorio
hematolog
depart
madrid
spain
instituto
de
sanitaria
gregorio
iisgm
madrid
spain
hospit
gener
universitario
gregorio
genom
unit
madrid
spain
background
relaps
remain
main
caus
treatment
failur
patient
hsct
identif
highrisk
patient
crucial
posttranspl
manag
includ
mainten
target
therapi
fmslike
tyrosin
kinas
mutat
associ
unfavor
prognosi
acut
myeloid
leukemia
aml
object
studi
assess
signific
prehsct
earli
posthsct
minim
residu
diseas
mrd
studi
multiparametr
flow
cytometri
mfc
molecular
analysi
patient
mutat
aml
method
consecut
adult
patient
transplant
aml
complet
remiss
cr
retrospect
analyz
tabl
patient
persist
refractori
diseas
exclud
mrd
studi
mfc
bm
aspir
quantit
rtpcr
mll
assess
bm
andor
peripher
blood
pb
sampl
obtain
within
day
hsct
day
hsct
result
condit
regimen
myeloabl
stem
cell
sourc
use
pbsc
case
tabl
patient
show
neg
prehsct
mrd
wherea
show
posit
valu
rtpcr
mfc
method
characterist
patient
group
significantli
differ
median
followup
month
overal
surviv
os
vs
prehsct
mrdneg
mrdposit
patient
respect
event
free
surviv
ef
vs
hr
cumul
incid
grade
iiiv
acut
gvhd
vs
moderatesever
chronic
gvhd
vs
respect
relaps
incid
vs
trm
vs
day
posthsct
prehsct
mrd
neg
patient
prehsct
mrd
patient
ceas
immunosuppress
therapi
group
prehsct
posit
mrd
present
posit
mrd
day
wherea
mrd
detect
group
prehsct
neg
mrd
patient
show
posit
mrd
day
present
os
vs
compar
patient
neg
day
mrd
ef
vs
respect
conclus
unicentr
experi
posttranspl
homogen
manag
patient
aml
transplant
detect
mrd
show
reduc
os
ef
differ
signific
due
limit
number
case
differ
ef
occur
spite
patient
detect
prehsct
mrd
show
negativ
earli
hsct
immunosuppress
stop
earlier
henc
patient
posit
mrd
transplant
repres
highrisk
group
studi
need
confirm
higherrisk
patient
may
benefit
program
posttranspl
intervent
includ
earli
immunosuppress
withdraw
dli
new
targetdirect
drug
conflict
interest
author
noth
disclos
kyoto
univers
kyoto
japan
background
previous
report
flowcytometri
fcm
base
detect
minim
residu
diseas
mrd
hematopoiet
stem
cell
transplant
hsct
associ
poor
overal
surviv
patient
acut
myelogen
leukemia
aml
hematolog
complet
remiss
cr
studi
compar
mrdposit
patient
noncr
patient
method
includ
adult
patient
aml
myeloabl
condit
mac
reducedintens
underw
first
allogen
hsct
april
februari
kyoto
univers
hospit
median
age
rang
mrd
bone
marrow
hsct
measur
use
fcm
search
target
antigen
detect
mrd
threecolor
fcm
analys
perform
use
differenti
panel
everi
diseas
patient
allow
us
detect
mrd
result
sixtytwo
fortythre
patient
hematolog
cr
noncr
diseas
statu
hsct
respect
hematolog
cr
patient
patient
includ
mrdposit
group
mrd
wherea
includ
mrdneg
group
mrd
mrdposit
group
patient
includ
mrdhigh
group
mrd
includ
mrdlow
group
mrd
mac
use
noncr
mrdhigh
mrdlow
mrdneg
group
respect
p
overal
surviv
rate
noncr
mrdhigh
mrdlow
mrdneg
group
respect
p
figur
multipl
regress
analysi
mrdhigh
group
show
compar
overal
mortal
noncr
group
mrdhigh
vs
noncr
hazard
ration
hr
mrdlow
vs
noncr
hr
mrdneg
vs
noncr
hr
p
relaps
rate
noncr
mrdhigh
mrdlow
mrdneg
group
respect
p
signific
differ
nonrelaps
mortal
among
four
group
conclus
analysi
fcmbase
detect
mrd
reveal
mrd
posit
significantli
associ
high
risk
relaps
death
even
patient
aml
hematolog
cr
transplant
outcom
compar
mrdhigh
noncr
group
stronger
condit
therapi
hsct
would
treatment
option
patient
highlyposit
mrd
conflict
interest
conflict
interest
peke
univers
peopl
hospit
peke
univers
institut
hematolog
beij
china
background
effect
relaps
achiev
complet
molecular
respons
cmr
bcrablabl
minim
residu
diseas
mrd
neg
multiparamet
flow
cytometri
mfc
philadelphia
chromosomeposit
phall
earli
stage
hematopoiet
stem
cell
transplant
hsct
remain
unknown
method
aim
studi
examin
valu
mrd
detect
mfc
rqpcr
earli
stage
transplant
predict
relaps
leukemiafre
surviv
lf
result
patient
maintain
cmr
statu
month
associ
lower
relaps
rate
better
lf
without
cmr
howev
cmr
statu
month
could
predict
relaps
lf
neg
mfc
month
associ
lower
relaps
rate
respect
better
lf
respect
multivari
analysi
show
mrd
statu
identifi
mfc
month
cmr
month
exhibit
better
discrimin
relaps
hr
ci
hr
ci
p
df
hr
ci
hr
ci
among
patient
patient
relaps
mrdposit
accord
mfc
rqpcr
detect
posttransplant
conclus
summari
mrd
detect
mfc
rqpcr
detect
earli
stage
import
predictor
outcom
patient
phall
test
play
complementari
role
predict
prognosi
conflict
interest
xiangyu
zhao
noth
disclos
univers
hospit
bologna
hematolog
bologna
itali
background
reconstitut
immun
cell
subset
allogen
hematopoiet
stem
cell
transplant
hsct
relev
patient
outcom
studi
impact
sever
factor
includ
stem
cell
sourc
type
diseas
condit
regimen
graft
versu
host
diseas
gvhd
immun
reconstitut
larg
monocentr
cohort
patient
method
studi
adult
patient
receiv
pbsc
bm
ucb
transplant
bologna
univers
hospit
data
collect
analys
number
immun
cell
subset
peripher
blood
specif
time
point
month
year
transplant
total
sampl
process
multicolor
flow
cytometri
employ
measur
number
circul
b
lymphocyt
nk
cell
apc
subtyp
monocyt
plasmacytoid
pdc
myeloid
mdc
dendrit
cell
result
recoveri
pdc
month
transplant
significantli
increas
patient
receiv
ucb
compar
pbsc
bm
transplant
p
time
point
moreov
confirm
increas
b
nk
cell
number
delay
recoveri
cell
subset
ucb
transplant
compar
pbsc
bm
transplant
factor
affect
immun
recoveri
chronic
gvhd
number
pdc
reduc
patient
extens
cgvhd
compar
patient
limit
gvhd
without
cgvhd
month
month
p
recoveri
cell
nk
cell
unaffect
cgvhd
wherea
b
cell
recoveri
also
reduc
cgvhd
p
month
conclus
studi
show
patient
undergo
ucb
transplant
better
reconstitut
plasmacytoid
dc
well
nk
cell
b
cell
compar
patient
receiv
pbsc
bm
graft
also
pdc
recoveri
significantli
delay
patient
cgvhd
conflict
interest
mario
arpinati
noth
disclos
peke
univers
peopl
hospit
beij
china
beij
hightrust
diagnost
co
ltd
beij
china
background
immun
reconstruct
critic
therapeut
efficaci
outcom
patient
undergon
haploident
hematopoiet
stem
cell
transplant
haplohsct
previou
studi
demonstr
recoveri
cell
invers
correl
ebv
reactiv
haplohsct
moreov
proport
cell
continu
decreas
recipi
regardless
statu
ebv
reactiv
day
day
haplohsct
reason
caus
delay
cell
recoveri
remain
elus
cell
specif
activ
expand
small
nonpeptid
phosphoantigen
hlaunrestrict
manner
aminobisphosphon
pamidron
zoledron
acid
zol
confirm
trigger
cell
expans
vitro
vivo
mani
immunotherapeut
strategi
target
cell
zol
conduct
patient
variou
hematolog
malign
solid
tumor
dendrit
cell
dc
potent
antigen
present
cell
report
promot
cell
prolifer
present
phosphoantigen
glycoprotein
howev
whether
bisphosphon
could
stimul
prolifer
cell
unmanipul
haplohsct
dc
play
role
process
still
unknown
method
recoveri
characterist
cell
dc
monitor
patient
around
day
unmanipul
haplohsct
compar
healthi
donor
immunophenotyp
perform
use
flow
cytometri
furthermor
invitro
effect
pamidron
recov
cell
haplohsct
recipi
investig
express
measur
use
flow
cytometri
realtim
quantit
pcr
statist
analys
perform
use
spss
result
concentr
recov
cell
signific
lower
recipi
day
haplohsct
compar
healthi
donor
p
invitro
function
experi
show
pamidron
stimul
strong
prolifer
cell
healthi
donor
wherea
fail
trigger
cell
haplohsct
recipi
quantit
rtpcr
analysi
show
express
level
statist
differ
donor
haplohsct
recipi
respect
differ
found
compar
proport
cell
group
percentag
dc
includ
pdc
mdc
strikingli
decreas
recipi
haplohsct
respect
correl
analysi
found
proport
mdc
dc
pdc
significantli
associ
ratio
recov
cell
haplohsct
p
conclus
current
studi
indic
reduc
proport
cell
unmanipul
haplohsct
inhibit
prolifer
respons
pamidron
stimul
vitro
correl
analysi
found
decreas
dc
content
associ
delay
cell
recoveri
haplohsct
find
provid
evid
explor
new
strategi
rescu
impair
recoveri
cell
haplohsct
recipi
use
invitro
induc
bisphosphonatepretr
autolog
allolog
dc
conflict
interest
author
declar
conflict
interest
studi
support
beij
postdoctor
research
foundat
nation
natur
scienc
foundat
china
foundat
innov
research
group
nation
natur
scienc
foundat
china
erciy
univers
faculti
medicin
pediatr
hematolog
oncolog
kayseri
turkey
background
hematopoiet
stem
cell
transplant
hsct
use
success
treatment
mani
hematolog
malign
genet
metabol
disord
stem
cell
engraft
well
stem
cell
recoveri
complex
medic
process
first
day
transplant
reinfus
allogen
autolog
stem
cell
migrat
bone
marrow
begin
process
produc
replac
blood
cell
process
call
engraft
stem
cell
start
produc
new
blood
cell
within
week
follow
infus
hsct
earli
detect
engraft
would
critic
valu
clinician
aim
studi
help
identifi
engraft
earlier
new
automat
cbc
analyz
paramet
method
sixteen
patient
underw
hsct
achiev
myeloid
platelet
engraft
march
august
includ
studi
diagnos
patient
aml
primer
immunodefici
thalassemia
major
ewe
sarcoma
neuroblastoma
hodgkin
lymphoma
patient
treat
allogen
haploident
haplo
unrel
mud
rel
mfd
sibl
msd
autolog
hsct
myeloid
platelet
engraft
time
transplant
patient
follow
new
autom
cbc
paramet
cbc
differenti
administ
sysmex
kobe
japan
day
myeloid
engraft
defin
first
consecut
day
absolut
neutrophil
count
anc
exceed
time
transplant
platelet
engraft
consid
occur
platelet
count
without
transfus
day
result
patient
achiev
absolut
neutrophil
count
anc
median
day
rang
day
figur
median
absolut
neutrophil
immatur
granulocyt
ig
count
myeloid
engraft
day
respect
iganc
ratio
percentag
neutrophil
ne
immatur
granulocyt
ig
found
respect
ig
count
ig
valu
increas
median
day
myeloid
engraft
day
respect
figur
time
absolut
monocyt
count
mo
monocyt
percentag
mo
respect
percentag
monocyt
valu
normal
valu
median
day
engraft
patient
median
day
platelet
count
without
transfus
reach
percentag
immatur
platelet
fraction
ipf
platelet
engraft
day
conclus
accord
result
studi
new
cbc
paramet
ig
ipf
may
help
engraft
follow
patient
hsct
although
number
patient
studi
increas
ig
count
ig
suggest
myeloid
engraft
earlier
new
platelet
paramet
ipf
determin
cutoff
valu
larg
group
studi
help
follow
platelet
engraft
hsct
patient
conflict
interest
noth
disclos
univers
hospit
duesseldorf
depart
hematolog
oncolog
clinic
immunolog
duesseldorf
germani
heinrich
hein
univers
institut
patholog
duesseldorf
germani
background
order
elucid
pathomechan
risk
factor
treatment
option
extramedullari
relaps
xr
allogen
blood
stem
cell
transplant
asct
retrospect
collect
patient
myeloid
malign
mym
xr
transplant
databas
method
adult
patient
receiv
first
asct
mym
center
identifi
relaps
result
relaps
molecular
mr
isol
bone
marrow
br
isol
xr
combin
br
xr
also
consid
later
relaps
total
patient
experienc
xr
median
month
asct
sixteen
patient
alreadi
treat
dli
xr
evid
cgvhd
diagnosi
xr
primari
diagnos
aml
md
mpn
saml
highrisk
cytogenecti
accord
eln
ipssr
initi
affect
site
cn
isol
meningiosi
leukaemica
skin
skin
muscl
skin
lymph
node
lymph
node
gastric
mucosa
muscl
bone
bone
soft
tissu
pleuralpericardi
effus
testi
dissemin
multipl
site
seven
patient
multipl
chloroma
follow
patient
chloroma
test
express
result
cologn
score
frequent
therapi
radiat
either
alon
combin
system
therapi
dli
st
intrathec
therapi
five
patient
receiv
st
without
radiat
st
hma
patient
escal
intens
chemotherapi
ic
total
ic
given
patient
six
patient
receiv
second
asct
one
patient
testicular
relaps
orchiectomi
patient
receiv
best
support
care
four
patient
cn
xr
receiv
intrathec
chemotherapi
nine
patient
die
earli
avail
respons
assess
complet
remiss
achiev
ic
second
asct
sorafenib
radiat
orchiectomi
partial
remiss
induc
patient
orr
local
respons
radiat
seen
anoth
patient
progress
locat
median
remiss
durat
month
rang
two
patient
aliv
cr
median
follow
month
subsequ
asct
one
two
year
surviv
median
surviv
patient
month
patient
isol
xr
better
overal
surviv
vs
month
patient
isol
cn
diseas
vs
month
pn
conclus
xr
relev
prognost
dismal
event
asct
occur
late
often
subsequ
relaps
heavili
treat
includ
dli
patient
despit
cgvhd
argu
evolutionari
immun
escap
mechan
patholog
background
still
understood
found
evid
express
consequ
convent
chemo
immunotherapi
fail
new
treatment
strategi
need
conflict
interest
author
noth
disclos
sultan
qaboo
univers
pharmacolog
muscat
oman
sultan
qaboo
univers
hospit
pharmaci
muscat
oman
sultan
qaboo
univers
hospit
hematolog
muscat
oman
sultan
qaboo
univers
hospit
child
health
muscat
oman
background
busulfan
bu
base
prepar
regimen
bu
exposur
associ
risk
graft
loss
glutathion
stransferas
gst
polymorph
affect
bu
drug
exposur
therefor
may
affect
risk
graft
loss
bu
metabol
occur
liver
initi
get
conjug
glutathion
catalyz
mainli
gst
isoenzym
isoenzym
involv
lower
extent
soon
bu
conjug
lose
alkyl
properti
herein
plan
studi
impact
gst
polymorph
risk
graft
loss
patient
undergo
hematopoiet
stem
cell
transplant
hsct
bu
base
prepar
regimen
method
singl
center
retrospect
cohort
studi
adult
pediatr
patient
receiv
intraven
bu
prior
hsct
sultan
qaboo
univers
hospit
januari
octob
indic
genotyp
gst
polymorph
done
pretranspl
patient
sampl
use
capillari
electrophoresi
insert
delet
dna
sequenc
impact
gst
polymorph
graft
loss
assess
use
logrank
test
standard
descript
analyt
statist
graph
creat
use
statist
softwar
stata
version
result
four
patient
graft
loss
follow
period
median
time
graft
loss
reach
graft
loss
free
surviv
day
day
day
incid
graft
loss
heterozyg
genotyp
ag
compar
wild
type
genotyp
aa
differ
statist
signific
p
differ
incid
statist
signific
loci
pvalu
higher
signific
differ
incid
graft
loss
delet
insert
group
p
similarli
insert
delet
signific
impact
graft
loss
conclus
patient
heterozyg
higher
risk
graft
loss
like
relat
lower
bu
clearanc
result
need
confirm
larger
differ
popul
patient
heterozyg
undergo
therapeut
drug
monitor
prepar
regimen
guid
appropri
dose
bu
lower
risk
relaps
conflict
interest
conflict
interest
studi
support
intern
grant
colleg
medicin
health
scienc
sultan
qaboo
univers
univers
medic
center
mainz
haematolog
oncolog
pneumolog
mainz
germani
goeth
univers
frankfurt
main
hospit
children
adolesc
cellular
immunolog
frankfurt
germani
background
allogen
haematopoiet
stem
cell
transplant
hsct
cur
treatment
option
mani
haematolog
malign
longterm
effect
engraft
immun
system
crucial
treatment
success
one
hand
desir
effect
leucemia
cell
gvl
wherea
hand
new
immun
system
also
act
healthi
tissu
caus
graftversushost
diseas
gvhd
context
nkcell
particular
interest
mediat
gvlenhanc
gvhdlimit
effect
examin
patient
blood
sampl
hsct
determin
relev
differ
nkcell
subpopul
develop
gvhd
relaps
gvl
method
analys
blood
sampl
patient
agvhd
cgvhd
relaps
healthi
control
nkcell
divid
differ
group
depend
express
use
flow
cytometri
fac
addit
examin
express
tigit
immunosuppress
routin
administ
set
hsct
perform
function
test
evalu
effect
express
marker
pbmc
incub
hour
either
prednisolon
tacrolimu
drug
differ
concentr
subsequ
flow
cytometri
perform
result
patient
hsct
whole
nkcell
popul
exhibit
increas
express
activ
marker
subpopul
patient
cgvhd
increas
signific
patient
cgvhd
relaps
show
highest
express
activ
marker
compar
buffycoat
express
activ
receptor
increas
nkcell
patient
compar
healthi
control
p
valu
wherea
express
inhibitori
receptor
significantli
increas
patient
agvhd
cgvhd
relaps
patient
express
increas
compar
healthi
control
reach
statist
signific
patient
agvhd
p
increas
patientderiv
nkcell
compar
healthi
control
p
relaps
whole
nkcell
popul
reduc
express
patient
cgvhd
relaps
contrast
patient
agvhd
show
increas
express
subpopul
patient
express
inhibitori
receptor
tigit
increas
signific
immunosuppress
therapi
vitro
influenc
express
activ
inhibitori
receptor
nkcell
except
high
dose
steroid
result
signific
increas
conclus
nkcell
patient
hsct
show
distinct
chang
express
certain
marker
especi
increas
express
inhibitori
marker
tigit
may
account
impair
function
cell
albeit
increas
activ
receptor
decreas
express
patient
cgvhd
relaps
may
play
decis
role
pathophysiolog
complic
better
understand
individu
composit
nkcell
patient
could
lead
futur
individu
nkcellbas
donor
lymphocyt
infus
conflict
interest
none
author
anyth
disclos
leiden
univers
medic
center
leiden
netherland
juliana
children
hospit
haga
teach
hospit
den
haag
netherland
erasmu
medic
center
sophia
children
hospit
rotterdam
netherland
background
nglycan
attach
conserv
glycosyl
site
fragment
crystalliz
fc
region
immunoglobulin
g
igg
larg
influenc
structur
function
antibodi
presenc
absenc
specif
monosaccharid
proven
crucial
modul
affin
igg
bind
activ
complement
system
follow
allogen
hematopoiet
stem
cell
transplant
hsct
presenc
almost
complet
donor
chimer
igg
expect
produc
glycosyl
b
cell
donor
origin
investig
extent
igg
glycosyl
patient
transplant
determin
factor
donor
genet
recipi
environ
method
current
studi
character
select
group
patient
steadi
state
posthsct
igg
fc
glycosyl
profil
use
igg
subclassspecif
liquid
chromatographymass
spectrometri
method
analyz
plasmaserum
igg
fc
glycosyl
profil
pediatr
patient
prehsct
six
twelv
month
posthsct
compar
profil
donor
agematch
healthi
control
data
analysi
perform
separ
patient
treat
malign
nonmalign
hematolog
diseas
result
patient
treat
hematolog
malign
promin
igg
fc
glycosyl
differ
donor
recipi
prehsct
observ
galactosyl
lower
patient
compar
donor
independ
igg
subclass
furthermor
signific
differ
present
galactosyl
compar
recipi
prehsct
healthi
agematch
control
therefor
low
galactosyl
state
like
reflect
glycosyl
chang
caus
diseas
andor
treatment
thereof
twelv
month
hsct
patient
treat
hematolog
malign
still
show
lower
igg
fc
galactosyl
compar
donor
indic
recipi
produc
igg
fc
glycosyl
pattern
partli
mimic
profil
recipi
prehsct
donor
profil
note
although
patientsubgroup
treat
nonmalign
hematolog
diseas
prehsct
galactosyl
level
differ
donor
twelv
month
posthsct
galactosyl
also
lower
donor
low
level
galactosyl
stage
hsct
studi
patient
stabl
uncompl
clinic
condit
compar
two
subgroup
furthermor
prehsct
patient
group
treat
hematolog
malign
show
distinct
featur
decreas
sialyl
hybridtyp
glycan
compar
healthi
control
normal
transplant
conclus
b
cell
children
hsct
mainli
donor
origin
patient
investig
reach
independ
igg
supplement
found
igg
fc
glycosyl
pediatr
cohort
reflect
glycosyl
pattern
donor
data
suggest
extern
local
influenc
igg
fc
glycosyl
oper
hsct
well
long
term
hsct
independ
origin
diseas
conflict
interest
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
univers
children
hospit
depart
stem
cell
transplant
switzerland
background
reduc
intens
condit
ric
significantli
contribut
improv
outcom
hsct
nonmalign
diseas
pediatr
patient
yet
earli
graft
reject
delay
develop
wane
donor
chimer
subsequ
graft
loss
remain
signific
challeng
time
diagnosi
immunotherapeut
intervent
may
prevent
graft
loss
may
entail
substanti
side
effect
gvhd
method
retrospect
assess
immun
reconstitut
lineagespecif
donor
chimer
pediatr
patient
median
age
month
rang
month
consecut
transplant
center
nonmalign
diseas
immunodefici
hlh
hemoglobinopathi
uniform
condit
regimen
reduc
intens
condit
consist
busulfan
pkadjust
target
cumul
exposur
highdos
fludarabin
serotherapi
alemtuzumab
patient
atg
patient
graft
deriv
match
unrel
mud
patient
match
relat
mrd
patient
mismatch
unrel
mmud
patient
haploident
haplodonor
patient
donor
assess
tcell
reconstitut
includ
memori
tcell
subtyp
includ
regulatori
cell
well
recent
thymic
emigr
rte
tcell
compart
lineagespecif
chimer
perform
mean
immunomagnet
bead
fac
separ
follow
subsequ
analysi
vntr
fish
xy
gendermismatch
transplant
requir
result
acut
gvhd
ii
occur
patient
patient
experienc
limit
chronic
gvhd
viral
reactiv
detect
patient
cmv
patient
ebv
patient
patient
without
manifest
diseas
myeloid
chimer
primari
engraft
donorspecif
case
three
patient
mud
haplodonor
develop
mix
myeloid
chimer
beyond
month
posttranspl
two
recipi
mud
graft
achiev
stabl
longterm
mix
chimer
without
immunotherapeut
intervent
third
patient
haplodonor
becam
aplast
month
posttranspl
cours
ebv
reactiv
partial
reconstitut
autolog
myeloid
cell
despit
increas
donor
chimer
nkcell
compart
follow
rituximabtreat
stem
cell
boost
patient
revert
full
dc
earli
tcell
chimer
day
posttranspl
assess
patient
demonstr
predominantli
recipi
tcell
chimer
high
content
regulatori
cell
none
patient
immunotherapeut
intervent
promot
dc
perform
acut
gvhd
rapidli
perman
convert
tcell
compart
toward
donortyp
wherea
context
viral
reactiv
origin
antivir
tcell
respons
transient
influenc
chimer
tcell
compart
thymic
output
measur
increas
tcell
rte
lead
slow
steadi
convers
tcell
pool
donortyp
conclus
ric
regimen
appli
studi
allow
persist
recipi
cell
signific
proport
patient
nevertheless
patient
experienc
graft
loss
indic
promot
toler
donor
host
immun
system
major
patient
clinic
trial
registri
conflict
interest
none
centro
hospitalar
e
de
coimbra
clinic
haematolog
depart
coimbra
portug
faculti
medicin
univers
coimbra
coimbra
portug
centro
hospitalar
e
de
coimbra
flow
cytometri
unit
clinic
patholog
depart
coimbra
portug
background
cell
effectorcytotox
cell
involv
immun
surveil
preclin
evid
support
anticanc
activ
success
autolog
hematopoiet
stem
cell
transplant
ahsct
depend
previou
erad
neoplast
clone
reconstitut
hematopoiet
immun
system
current
vitro
modul
immun
cell
grow
import
although
lymphocyt
recov
transplant
extens
studi
limit
data
cell
aim
evalu
number
cell
main
function
subpopul
well
popul
multipl
myeloma
mm
patient
submit
ahsct
order
understand
reconstitut
occur
ahsct
impact
postahsct
recoveri
method
analyz
mm
patient
underw
ahsct
previous
condit
melphalan
dc
day
ahsct
quantif
character
cell
peripher
blood
sampl
perform
flow
cytometri
base
express
result
median
age
cohort
year
male
result
show
subpopul
decreas
immedi
ahsct
subsequ
signific
increas
respect
return
preahsct
level
otherwis
subpopul
decreas
significantli
compar
dc
higher
number
cell
infus
correl
higher
proport
higher
volum
dimethylsulfoxid
infus
correl
lower
proport
increas
number
p
well
associ
extend
time
engraft
furthermor
increas
proport
associ
higher
need
pack
rbc
unit
increas
cell
associ
greater
necess
platelet
transfus
length
hospit
stay
lower
patient
higher
number
well
associ
subpopul
oral
gastrointestin
mucos
incid
febril
neutropenia
correl
preahsct
diseas
respons
subpopul
dc
well
respons
subpopul
conclus
result
although
preliminari
show
cell
subpopul
role
postahsct
recoveri
increas
cell
associ
delay
hematolog
recoveri
hand
lower
dimethylsulfoxid
volum
higher
number
cell
infus
associ
higher
number
respect
necessari
studi
evalu
relationship
cell
subpopul
respons
therapeuticsahsct
well
util
modul
conflict
interest
none
declar
san
raffael
scientif
institut
hematolog
bone
marrow
transplant
unit
milano
itali
vitasalut
san
raffael
univers
san
raffael
scientif
institut
milano
itali
istituto
distruzion
superior
racchettida
vinci
liceo
scientifico
crema
itali
san
raffael
scientif
institut
immunohematolog
transfus
medicin
unit
milano
itali
san
raffael
scientif
institut
unit
immunogenet
leukemia
genom
immunobiolog
divis
regen
medicin
stem
cell
gene
therapi
milano
itali
san
raffael
scientif
institut
experiment
hematolog
unit
divis
immunolog
transplant
infecti
diseas
program
immunolog
bioimmunotherapi
cancer
pibic
milano
itali
background
allogen
stem
cell
transplant
allohct
survivor
defin
relev
risk
develop
longterm
complic
consequ
life
expect
remain
lower
compar
age
sex
match
popul
recent
registri
studi
cibmtr
outlin
late
fatal
infect
lfi
allohct
remain
high
contribut
third
death
occur
year
hct
histori
gvhd
age
hlamatch
associ
increas
mortal
morbid
lfi
far
detail
regard
immunereconstitut
ir
longterm
followup
ltfu
avail
aim
studi
evalu
crosssect
analysi
statu
ir
survivor
respect
donor
type
distanc
hct
gvhd
occurr
method
standard
ltfu
allohct
survivor
appli
center
analyz
data
consecut
collect
institut
databas
start
includ
adult
pt
underw
allohct
institut
written
consent
given
pt
allow
use
medic
record
research
accord
declar
helsinki
consid
analysi
pt
overal
surviv
statu
immun
recoveri
analyz
b
cell
ratio
igg
iga
igm
collect
year
beyond
result
median
followup
r
pt
evalu
donor
match
unrel
donor
mud
case
hla
ident
sibl
mrd
haploident
rel
haplo
cord
blood
followup
avail
pt
respect
respect
followup
compar
ir
pt
followup
vs
vs
signific
differ
iga
p
igm
p
ratio
p
better
recoveri
longest
followup
period
respect
type
donor
overal
pt
receiv
hct
mrd
show
better
iga
ratio
mudhaplo
evalu
earli
time
point
show
better
ratio
mrd
vs
haplomud
differ
late
time
point
iga
recoveri
signific
variabl
compar
pt
acut
chronic
gvhd
vs
entir
cohort
p
compar
moderatesever
chronic
gvhd
entir
cohort
iga
signific
conclus
immun
statu
mrd
allohct
better
earli
phase
vs
haplomud
compar
late
phase
allohct
survivor
still
affect
ir
impair
ltfu
provid
biolog
justif
occurr
lfi
especi
presenc
gvhdhistori
studi
provid
justif
monitor
ir
individu
treatment
followup
conflict
interest
noth
disclos
abstract
previous
publish
ef
bourgogn
franch
comt
besancon
franc
chu
jean
minjoz
hematolog
besancon
franc
franch
comt
besancon
franc
chu
jean
minjoz
hematolog
besancon
franc
background
larg
granular
lymphocyt
lgl
prolifer
chronic
lymphoprolif
disord
usual
associ
along
cytopenia
immun
abnorm
howev
elev
number
lgl
follow
allogen
hematopoiet
cell
transplant
allohct
unknown
signific
method
perform
retrospect
analysi
consecut
patient
underw
allohct
univers
hospit
franc
studi
lgl
lymphocytosi
defin
persist
lgl
peripher
blood
one
month
lgl
identifi
immunophenotyp
criteria
lymphocyt
andor
morpholog
criteria
blood
smear
perform
deeper
analyz
clonal
pcr
broader
immunophenotyp
character
flow
cytometri
subset
sampl
patient
circul
lgl
result
among
patient
met
defin
criteria
lgl
lymphocytosi
post
allosct
median
onset
lgl
lymphocytosi
month
month
averag
durat
month
month
repartit
hematopoiet
diseas
patient
lgl
amlal
mdsmpn
lymphomamultipl
myeloma
hematopoiet
malign
stem
cell
sourc
peripher
blood
hematopoiet
stem
cell
umbil
cord
blood
bone
marrow
graft
compatilib
phenoident
genoident
haploident
sex
ratio
ident
two
group
without
lgl
p
signific
differ
patient
without
lgl
lymphocytosi
condit
regimen
attenu
condit
lgl
group
group
p
standard
condit
lgl
group
n
group
p
respect
develop
acut
graftversushost
gvh
p
chronic
gvh
p
two
group
differ
hand
notic
increas
cmv
infect
patient
display
lgl
lymphocytosi
compar
control
group
without
lgl
vs
p
subset
sampl
lgl
lymphocytosi
analyz
tcell
receptor
gene
rearrang
shown
clonal
rearrang
moreov
patient
benefit
expand
immunophenotyp
loss
express
found
patient
detect
alter
tcell
surfac
marker
other
patient
conclus
studi
report
variabl
incid
lgl
lymphocytosi
allohctin
retrospect
monocentr
cohort
incid
rise
identifi
statist
correl
cmv
infect
lgl
expans
although
tlgl
prolifer
clonal
persist
detect
pejor
impact
clinic
outcom
patient
lgl
suggest
clonal
lgl
expans
reactiv
potenti
benefici
immun
respons
context
allogen
graft
conflict
interest
none
author
anyth
disclos
lyon
sud
univers
hospit
laboratori
hematolog
pierr
benit
franc
lill
univers
hospit
hematolog
laboratori
lill
franc
lyon
univers
hospit
depart
pediatr
hematolog
ihop
lyon
franc
lill
univers
hospit
laboratori
hematolog
lill
franc
lyon
univers
hospit
laboratori
hematolog
lyon
franc
institut
cancer
research
lill
lill
franc
lyon
univers
hospit
depart
hematolog
lyon
sud
hospit
lyon
franc
background
clonal
heterogen
aml
blast
cell
popul
well
document
use
next
gener
sequenc
ng
strategi
heterogen
extend
presenc
lsc
fraction
among
leukem
popul
dynam
compart
evolv
overcom
cell
select
pressur
diseas
progress
treatment
includ
allogen
hematopoiet
stem
cell
transplant
hsct
propos
strategi
quantif
lsc
time
diagnosi
followup
identifi
patient
advers
outcom
method
design
mfc
panel
base
antibodi
combin
identifi
pattern
lsc
cell
compart
backbon
use
tube
complet
lineag
defin
marker
andor
lsc
identifi
marker
result
pediatr
aml
patient
treat
lyon
clinic
center
ihop
accord
clinic
trial
among
children
age
year
undergo
hsct
base
follow
criteria
highrisk
aml
pretranspl
condit
regimen
base
busulfan
combin
cyclophosphamid
fludarabin
patient
gvhd
prophylaxi
consist
csa
alon
vivo
cell
deplet
use
antithymocyt
globulin
bone
marrow
unrel
donor
prednisolon
cord
blood
cell
stem
cell
sourc
half
hsct
hlamsd
match
sibl
donor
other
murd
match
unrel
donor
mmurd
missmatch
unrel
donor
statist
analysi
perform
use
spss
window
kaplanmey
method
use
surviv
probabl
estim
logrank
test
use
comparison
group
preliminari
data
tend
show
clinic
impact
term
surviv
df
os
lsc
level
diagnosi
relev
establish
score
system
includ
level
lsc
diagnosi
mrd
chemotherapi
distinguish
patient
good
outcom
seri
see
fig
even
highrisk
patient
good
outcom
lsc
diagnosi
andor
mrd
lsc
undetect
follow
hand
patient
belong
favor
group
lsc
andor
mrd
lsc
posit
poor
outcom
conclus
summari
confirm
presenc
lsc
subpopul
repres
total
bulk
leukem
cell
diagnosi
could
help
identifi
patient
poor
outcom
despit
heterogen
complex
aml
lsc
compart
still
use
lsc
quantif
biomark
respons
hsct
therapi
studi
greater
benefit
gvl
effect
seem
observ
patient
lowlevel
lsc
patient
highlevel
lsc
therapeut
modal
chosen
erad
lsc
use
target
immunotherapi
allograft
monitor
lsc
fraction
use
clinic
trial
overcom
chemoresist
lsc
result
confirm
prospect
larger
cohort
patient
could
consid
use
complementari
prognost
paramet
riskstratif
aml
patient
futur
clinic
trial
clinic
trial
registri
conflict
interest
disclosur
academician
ippavlov
first
stpetersburg
state
medic
univers
rm
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
stpetersburg
russian
feder
background
meningioma
gene
locat
chromosom
band
overexpress
associ
poor
prognosi
patient
acut
myeloid
leukemia
baldu
et
al
heuser
et
al
therefor
check
clinic
signific
aberr
express
patient
hsc
addit
investig
possibl
use
gene
marker
minim
residu
diseas
method
materi
obtain
aml
patient
allohsct
rna
isol
revers
transcript
reaction
gene
express
analyz
use
oncoprim
system
inogen
express
result
normal
gene
threshold
level
two
valu
use
copi
gene
per
copi
gene
result
assess
possibl
use
gene
express
order
estim
minim
residu
diseas
compar
express
data
number
blast
cell
could
detect
presenc
correl
depend
similar
pictur
observ
compar
express
data
chimer
transcript
well
level
donor
chimer
addit
patient
character
resist
therapi
prior
transplant
detect
signific
increas
express
level
higher
valu
observ
patient
advers
cytogenet
risk
p
moreov
obtain
data
detect
overexpress
hsc
signific
prognost
valu
patient
overexpress
gene
copi
hsc
decreas
overal
surviv
note
time
achiev
express
level
copi
copi
gene
associ
greater
probabl
posttranspl
relaps
p
p
respect
assess
effect
condit
regim
type
reveal
signific
differ
prognost
signific
patient
regist
hyperexpress
hsct
p
conclus
result
indic
marker
therapi
effici
recommend
estim
minimum
residu
diseas
time
obtain
result
indic
aggress
characterist
posit
tumor
clone
may
caus
develop
posttransplant
relaps
lack
prognost
signific
high
express
posttranspl
period
allow
assum
presenc
respons
ongo
posttranspl
immunoadopt
therapi
infus
donor
lymphocyt
conflict
interest
author
declar
absenc
conflict
interest
manchest
royal
infirmari
clinic
haematolog
manchest
unit
kingdom
manchest
royal
infirmari
therapeut
stem
cell
laboratori
manchest
unit
kingdom
background
allogen
stem
cell
transplant
allosct
cur
option
mani
haematolog
malign
reduc
intens
condit
ric
regimen
tcell
deplet
tcd
strategi
extend
use
allosct
elderli
patient
comorbid
carri
low
rate
nonrelaps
mortal
low
incid
sever
graftversushost
diseas
gvhd
howev
tcd
allosct
slow
immun
reconstitut
high
incid
mix
donor
chimer
mdc
associ
impend
relaps
donor
lymphocyt
infus
dli
enhanc
graftversusleukaemia
effect
given
prevent
relaps
patient
mdc
method
fiftyseven
patient
underw
ric
tcd
allosct
receiv
preemptiv
dli
due
mdc
januari
juli
institut
median
age
transplant
year
rang
diagnos
acut
myeloid
leukaemia
myelodysplast
syndrom
acut
lymphoblast
leukaemia
atyp
chronic
myeloid
leukaemia
eightyfour
percent
complet
remiss
time
allosct
partial
remiss
receiv
allosct
without
previou
treatment
thirtyfour
patient
match
sibl
donor
match
unrel
donor
mismatch
unrel
donor
chimer
assess
polymeras
chain
reaction
pcr
short
tandem
repeat
str
peripher
blood
bone
marrow
sampl
fluoresc
situ
hybridis
fish
donorrecipi
sex
mismatch
everi
month
first
six
month
everi
month
mdc
defin
donor
percentag
dli
administ
use
escal
dose
patient
achiev
full
donor
chimer
fdc
develop
gvhd
relaps
result
median
donor
chimer
time
dli
rang
median
day
transplant
first
dli
day
rang
median
dli
administr
rang
median
follow
month
total
patient
develop
gvhd
postdli
patient
acut
gvhd
chronic
gvhd
acut
gvhd
grade
seen
patient
grade
grade
limit
chronic
gvhd
extens
chronic
gvhd
gvhd
treat
system
agent
case
system
agent
system
agent
receiv
topic
treatment
two
patient
die
due
gvhd
median
time
last
dli
gvhd
day
rang
fdc
achiev
patient
eleven
patient
relaps
overal
surviv
os
year
first
dli
presenc
fdc
chronic
gvhd
dli
associ
better
surviv
respect
conclus
preemptiv
dli
post
tcd
ric
allohsct
patient
mdc
reduc
risk
relaps
patient
achiev
fdc
chronic
gvhd
postdli
associ
better
outcom
conflict
interest
none
san
raffael
scientif
institut
unit
immunogenet
leukemia
genom
immunobiolog
milano
itali
san
raffael
scientif
institut
unit
senesc
stem
cell
age
differenti
cancer
srtiget
milano
itali
san
raffael
scientif
institut
hematolog
bone
marrow
transplant
unit
milano
itali
gendx
utrecht
netherland
univers
vitasalut
san
raffael
center
statist
biomed
scienc
milano
itali
background
despit
consider
progress
understand
leukemia
biolog
numer
patient
receiv
allogen
hsct
still
lack
reliabl
marker
monitor
minim
residu
diseas
mrd
issu
hematopoiet
chimer
serv
valid
surrog
recent
develop
quantitativepcr
base
assay
increas
dramat
sensit
chimer
monitor
prospect
studi
clinic
util
still
lack
method
design
prospect
nonintervent
singlecent
studi
compar
chimer
monitor
peripher
blood
pb
bone
marrow
bm
patient
undergo
myeloabl
allohsct
highrisk
leukemia
studi
group
compris
aml
patient
high
high
diseas
risk
index
dri
control
group
patient
hodgkin
nonhodgkin
lymphoma
without
bm
diseas
involv
transplant
protocol
chimer
monitor
use
commerci
qpcrbase
assay
kmrtype
kmrtrack
gendx
utrecht
bm
evalu
perform
day
allohsct
accord
practic
center
total
bm
tp
per
patient
pb
chimer
monitor
perform
timepoint
tp
least
addit
tp
inbetween
bm
evalu
total
pb
tp
per
patient
result
twenti
patient
studi
group
evalu
donor
hsc
engraft
subsequ
relaps
median
time
time
relaps
day
rang
aliv
complet
remiss
end
oneyear
followup
fu
die
remiss
end
fu
day
control
group
patient
evalu
engraft
die
end
fu
day
patient
develop
bm
involv
throughout
studi
altogeth
collect
analyz
sampl
pb
bm
pairwis
comparison
pb
bm
sampl
collect
tp
demonstr
higher
host
chimer
bm
compar
pb
mean
respect
surpris
lack
correl
two
measur
analyz
entir
dataset
found
predict
model
obtain
consid
threshold
maxim
reproduc
sensit
method
pb
sampl
bm
sampl
score
posit
case
increas
mix
chimer
imc
exceed
threshold
valu
amongst
studi
group
patient
relaps
imc
preced
relaps
pb
case
bm
case
time
imc
detect
relaps
averag
day
pb
rang
day
bm
rang
fals
posit
imc
nonrelaps
patient
studi
group
pb
bm
similar
frequenc
document
also
control
group
conclus
present
studi
first
knowledg
prospect
address
qpcrbase
chimer
monitor
highrisk
aml
patient
undergo
allohsct
pb
result
superior
bm
chimer
monitor
highsensit
techniqu
allow
also
shorter
interv
monitor
due
reduc
invas
conflict
interest
studi
support
european
commiss
eranet
transcan
lv
italian
ministri
health
fc
lv
lv
associazion
italiana
per
la
ricerca
sul
cancro
startup
grant
lv
dkm
mechtild
harf
research
grant
lv
reagent
kindli
provid
gendx
utrecht
lv
receiv
research
fund
gendx
author
declar
relev
conflict
interest
disclos
heart
england
nh
trust
haematolog
depart
birmingham
unit
kingdom
background
reduc
intens
condit
ric
allogen
stem
cell
transplant
allosct
incorpor
alemtuzumab
enabl
transplant
heavili
pretreat
patient
low
grade
well
high
grade
lymphoma
pauciti
data
regard
impact
variou
reconstitut
marker
transplant
outcom
method
retrospect
analys
data
patient
treat
haematolog
depart
heart
england
nh
trust
femal
male
median
age
year
diagnosi
lymphoma
underw
ric
alemtuzumab
base
allosct
carmustin
etoposid
cytarabin
melphalan
beam
campath
patient
fludarabinebeamcampath
patient
fludarabinemelphalancampath
fmc
patient
condit
regimen
alemtuzumab
dose
mg
daili
volunt
unrel
donor
n
mg
sibl
donor
transplant
n
result
patient
follow
median
month
patient
acut
graft
versu
host
diseas
gvhd
grade
ii
iv
patient
chronic
gvhd
median
tcell
count
month
respect
median
tcell
count
month
respect
median
absolut
lymphocyt
count
alc
day
respect
tcount
month
associ
better
overal
surviv
os
median
os
tcell
patient
month
month
vs
month
patient
tcell
month
p
valu
progress
free
surviv
pf
p
valu
immun
reconstitut
marker
correl
os
pf
cumul
incid
life
threaten
bacteri
infect
cmv
reactiv
ebv
reactiv
respiratori
viral
infect
respect
period
follow
tcell
count
month
associ
significantli
less
life
threaten
bacteri
infect
p
valu
cmv
ebv
reactiv
respiratori
viral
infect
likewis
alc
month
associ
significantli
less
life
threaten
bacteri
infect
p
valu
tcell
count
associ
significantli
less
cmv
reactiv
p
valu
ebv
reactiv
respiratori
viral
infect
life
threaten
bacteri
infect
none
immun
reconstitut
marker
associ
occurr
acut
chronic
gvhd
final
trend
reduc
overal
surviv
cmv
reactiv
although
statist
signific
p
valu
conclus
data
suggest
tcell
count
year
may
confer
surviv
advantag
lymphoma
patient
treat
ricallo
sct
immun
reconstitut
marker
month
signific
correl
bacteri
infect
cmv
reactiv
gvhd
patient
clinic
trial
registri
applic
conflict
interest
noth
disclos
royal
melbourn
hospit
melbourn
australia
univers
melbourn
melbourn
australia
austin
hospit
austin
australia
background
vitamin
vitd
normal
physiolog
role
innat
adapt
immun
addit
classic
effect
calcium
phosphat
homeostasi
recipi
allogen
haematopoiet
stem
cell
transplant
allohsct
pretranspl
vitd
defici
associ
increas
cancer
relaps
inferior
overal
surviv
retrospect
crosssect
studi
unclear
howev
whether
vitd
defici
indic
pretranspl
comorbid
modifi
risk
factor
posttranspl
outcom
aim
studi
examin
impact
vitd
replac
surviv
gvhd
posttranspl
method
perform
retrospect
match
cohort
analysi
patient
undergo
allohsct
royal
melbourn
hospit
seventyeight
patient
receiv
vitd
supplement
cholecalciferol
calcitriol
daili
start
allohsct
year
transplant
part
two
sequenti
prospect
clinic
trial
case
match
ratio
control
patient
receiv
vitd
supplement
use
propens
score
match
accord
variabl
patient
age
graft
type
donor
type
condit
intens
year
transplant
diseas
risk
index
dri
pretranspl
vitd
level
analysi
endpoint
includ
overal
surviv
os
cumul
incid
non
relaps
mortal
nrm
relaps
cir
relaps
free
surviv
rf
acut
chronic
graft
versu
host
diseas
gvhd
surviv
analysi
perform
use
kaplanmei
method
cumul
incid
calcul
compet
risk
analysi
comparison
via
gray
test
result
vitd
replac
nonreplac
group
well
match
key
baselin
characterist
tabl
median
followup
month
pre
transplant
vitd
level
influenc
patient
outcom
allohsct
moreov
vitd
replac
impact
os
year
os
replac
vs
nonreplac
nrm
replac
vs
nonreplac
cumul
incid
relaps
replac
vs
nonreplac
also
signific
differ
rate
acut
gvhd
chronic
gvhd
howev
among
patient
high
risk
cancer
relaps
high
high
dri
vitd
replac
associ
improv
os
year
replac
os
vs
nonreplac
rf
year
vs
trend
toward
reduc
cancer
relaps
vitd
replac
patient
year
cir
vs
signific
differ
rate
nrm
acut
chronic
gvhd
replac
nonreplac
patient
observ
highrisk
subcohort
vitd
replac
impact
posttranspl
surviv
gvhd
incid
patient
low
intermedi
dri
conclus
vitamin
replac
may
improv
surviv
allohsct
patient
high
high
dri
perhap
reduc
incid
relaps
work
requir
determin
immunolog
impact
vitd
replac
posttranspl
graft
versu
leukaemia
effect
conflict
interest
none
author
anyth
disclos
medic
univers
depart
hematolog
transplantolog
poland
background
impact
blood
group
incompat
transplant
effect
remain
unclear
aim
studi
assess
frequenc
occurr
incompat
main
rare
blood
group
antigen
impact
result
transplant
method
patient
aml
allogen
transplant
peripher
blood
stem
cell
myeloabl
condit
donor
extend
panel
blood
group
antigen
examin
abo
rh
kell
duffi
kidd
ss
mn
p
antigen
abo
rh
system
kell
determin
tube
method
remain
use
micropl
method
result
studi
group
abo
compat
found
patient
donor
rh
system
assess
reduc
compat
rate
full
compat
antigen
abo
rh
kell
group
found
pair
analysi
examin
system
show
compat
group
antigen
donorrecipi
pair
influenc
incompat
examin
incid
acut
chronic
graft
versu
host
diseas
transplant
relat
mortal
significantli
higher
rate
relaps
found
period
year
transplant
group
patient
full
compat
examin
system
regardless
transplant
time
conclus
full
compat
mani
blood
group
could
risk
factor
relaps
allosct
conflict
interest
none
author
anyth
disclos
univers
manchest
school
medicin
manchest
unit
kingdom
royal
manchest
children
hospit
bone
marrow
transplant
unit
manchest
unit
kingdom
manchest
royal
infirmari
transplant
laboratori
manchest
unit
kingdom
st
mari
hospit
willink
biochem
genet
unit
manchest
unit
kingdom
background
allogen
haematopoiet
stem
cell
transplant
hsct
wide
use
treat
nonmalign
condit
inborn
error
metabol
immunodefici
bone
marrow
failur
mix
chimer
mc
commonli
observ
phenomenon
case
conflict
bodi
evid
whether
consequ
addit
intervent
necessari
lineag
specif
chimer
myeloid
tcell
increasingli
explor
attempt
explain
chimer
kinet
immun
reconstitut
post
transplant
well
inform
best
manag
patient
mc
statu
studi
purpos
explor
predictor
mc
graft
failur
variat
outcom
patient
complet
chimer
cc
mc
util
whole
blood
lineag
specif
chimer
predict
graft
outcom
method
patient
sampl
includ
hsct
perform
children
nonmalign
condit
juli
march
centr
total
hsct
identifi
howev
exclud
due
insuffici
data
present
result
case
includ
studi
follow
variabl
consid
patient
gender
age
transplant
date
transplant
diseas
condit
regimen
tcell
deplet
donor
stem
cell
sourc
aliv
deceas
statu
chimer
statu
variabl
assess
use
univari
multivari
logist
regress
analysi
statist
programm
relationship
myeloid
chimer
tcell
chimer
transplant
outcom
also
investig
patient
lineag
specif
analysi
result
total
patient
exhibit
cc
patient
exhibit
mc
reduc
intens
condit
regimen
well
young
age
time
transplant
identifi
signific
predictor
mc
year
transplant
mc
statu
identifi
signific
predictor
graft
failur
patient
highlevel
mc
defin
donor
graft
failur
develop
contrast
none
patient
lowlevel
mc
defin
donor
develop
graft
failur
earli
full
donor
myeloid
chimer
identifi
use
predictor
long
term
engraft
associ
rise
donor
tcell
chimer
subsequ
algorithm
creat
guid
clinic
manag
chimer
nonmalign
diseas
take
consider
natur
diseas
tcell
non
tcell
diseas
well
lineag
specif
chimer
statu
conclus
highlevel
mc
better
predictor
graft
failur
lowlevel
mc
myeloid
chimer
could
use
reliabl
indic
transplant
outcom
addit
tcell
chimer
monitor
import
patient
tcell
immunodefici
final
algorithm
suggest
use
inform
predict
graft
outcom
well
need
specif
intervent
patient
nonmalign
diseas
whilst
utilis
lineag
specif
chimer
analysi
conflict
interest
author
declar
conflict
interest
abstract
previous
publish
multipl
myeloma
institut
hematolog
transfus
medicin
depart
hematolog
warsaw
poland
poznan
univers
medic
scienc
depart
hematolog
bone
marrow
transplant
poznan
poland
medic
univers
warsaw
depart
hematolog
oncolog
intern
medicin
warsaw
poland
institut
hematolog
transfus
medicin
depart
hematopoiet
stem
cell
transplant
warsaw
poland
militari
institut
medicin
depart
hematolog
bone
marrow
transplant
unit
warsaw
poland
maria
sklodowskacuri
memori
cancer
center
institut
oncolog
gliwic
branch
depart
bone
marrow
transplant
oncohematolog
gliwic
poland
medic
univers
silesia
depart
hematolog
bone
marrow
transplant
katowic
poland
medic
univers
depart
hematolog
blood
neoplasm
bone
marrow
transplant
poland
jagiellonian
univers
medic
colleg
depart
hematolog
poland
background
role
allogen
hematopoiet
cell
transplant
allohct
therapi
multipl
myeloma
mm
despit
cur
well
establish
mainli
due
high
transplantrel
mortal
trm
object
studi
describ
use
allohct
poland
outsid
clinic
trial
evalu
outcom
method
data
patient
pt
median
age
year
rang
receiv
allohct
timepoint
mm
cours
collect
analyz
base
questionnair
sent
transplant
center
poland
studi
cohort
pt
stage
iii
accord
salmonduri
classif
time
allohct
median
number
treatment
regimen
allohct
rang
pt
autohsct
preced
allotranspl
pt
part
tandem
autoallo
protocol
relapsedrefractori
diseas
patient
receiv
allohct
consolid
firstlin
treatment
allohct
pt
least
partial
remiss
condit
ric
protocol
base
fludarabin
use
pt
pt
treat
myeloabl
condit
mainli
base
melphalan
tbi
treosulphan
stem
cell
relat
unrel
donor
graft
median
dose
cellskg
peripher
blood
pb
stem
cell
transplant
pt
result
engraf
occur
pt
infecti
complic
day
observ
pt
fuo
bacteri
viral
fungal
sever
toxic
complic
ctcae
grade
develop
pt
acut
gvhd
occur
patient
grade
iii
iv
eight
patient
develop
limit
chronic
gvhd
extens
relaps
rate
transplant
complet
remiss
good
partial
remiss
relaps
last
follow
median
follow
rang
month
pt
die
earli
death
caus
death
includ
relapsedrefractori
diseas
infect
gvhd
other
suicid
mof
cardiac
arrest
hu
median
os
month
pf
month
figur
b
respect
absenc
agvhd
correl
longer
os
vs
month
pf
vs
month
presenc
chgvhd
associ
longer
pf
vs
month
os
vs
month
os
pf
differ
significantli
ccord
condit
regimen
diseas
stage
year
allohct
conclus
result
suggest
allohct
mm
associ
high
risk
complic
includ
trm
howev
may
give
long
term
surviv
patient
howev
identif
benefici
group
remain
elus
posit
effect
chgvhd
surviv
confirm
presenc
antimyeloma
effect
due
long
time
scale
studi
mani
patient
treat
novel
agent
era
result
must
interpret
care
conflict
interest
none
author
anyth
disclos
saitama
medic
center
jichi
medic
univers
divis
hematolog
saitama
japan
japanes
red
cross
medic
center
tokyo
japan
shizuoka
cancer
center
shizuoka
japan
toyama
prefectur
central
hospit
toyoma
japan
kurashiki
central
hospit
kurashiki
japan
gunma
univers
graduat
school
health
scienc
maebashi
japan
background
allogen
hematopoiet
stem
cell
transplant
allohct
consid
potenti
cur
therapi
patient
multipl
myeloma
graftversusmyeloma
effect
howev
rel
higher
transplantrel
mortal
relaps
rate
restrict
use
role
allohct
remain
unclear
era
novel
agent
method
conduct
retrospect
studi
patient
pretreat
multipl
myeloma
underw
allohct
institut
japan
primari
endpoint
progressionfre
surviv
pf
allohct
secondari
endpoint
overal
surviv
os
nonrelaps
mortal
nrm
overal
respons
rate
result
median
number
previou
therapi
rang
patient
receiv
least
one
novel
agent
allohct
probabl
pf
year
year
confid
interv
ci
ci
respect
probabl
os
year
year
ci
ci
respect
multivari
analysi
year
age
older
less
good
partial
respons
vgpr
allohct
independ
signific
advers
factor
pf
hazard
ratio
hr
ci
hr
ci
os
hr
ci
hr
ci
convers
probabl
pf
os
year
patient
younger
year
achiev
vgpr
better
allohct
ci
ci
respect
overal
respons
rate
ci
proport
vgpr
better
allohct
increas
allohct
incid
nrm
year
year
ci
year
age
older
associ
higher
nrm
hr
ci
incid
nrm
year
patient
younger
year
ci
although
patient
age
year
older
ci
conclus
show
allohct
feasibl
heavili
pretreat
patient
multipl
myeloma
even
novel
agent
era
especi
allohct
promis
therapi
patient
younger
year
vgpr
better
allohct
conflict
interest
none
author
anyth
disclos
univers
hospit
depart
medicin
germani
klinikum
depart
medicin
iii
germani
background
role
allogen
hematopoiet
stem
cell
transplant
hsct
multipl
myeloma
mm
therapi
well
defin
often
reserv
select
patient
later
stage
diseas
addit
patient
highrisk
diseas
might
benefit
allogen
hsct
although
evid
weak
uncertainti
best
time
sequenc
therapi
method
retrospect
analyz
outcom
mm
patient
receiv
allogen
hsct
center
respect
cytogenet
risk
factor
prior
therapi
transplant
characterist
statist
analysi
perform
use
kaplanmei
approach
cumul
incid
method
cox
proport
hazard
model
result
median
age
patient
time
transplant
year
among
total
patient
patient
receiv
stem
cell
graft
hlaident
sibl
donor
patient
either
unrel
donor
hla
match
unrel
donor
mud
mismatch
relat
donor
patient
receiv
tandem
autologousallogen
transplant
upfront
patient
receiv
allogen
hsct
relaps
set
two
seven
treatment
line
includ
one
two
autolog
hsct
condit
regimen
mainli
consist
busulfan
melphalan
tbibas
gy
regimen
median
followup
surviv
patient
year
median
overal
surviv
os
progress
free
surviv
pf
time
allogen
hsct
month
respect
pf
os
year
ci
ci
respect
cumul
incid
nonrelaps
death
three
month
one
year
three
year
cumul
incid
relaps
one
two
three
year
respect
patient
cytogenet
abnorm
report
consid
highrisk
mm
delet
transloc
transloc
andor
amplif
os
significantli
reduc
patient
receiv
two
line
therapi
prior
allogen
hsct
hr
ci
associ
still
present
subgroup
patient
receiv
allogen
hsct
relaps
set
hr
ci
os
associ
advers
cytogenet
age
type
donor
remiss
statu
prior
allogen
hsct
conclus
graftversusmyeloma
effect
follow
allogen
hsct
offer
addit
treatment
element
might
valuabl
even
combin
subsequ
novel
antibodi
base
strategi
despit
recent
improv
outcom
allogen
hsct
still
consid
select
mm
patient
poor
prognosi
whether
patient
benefit
allogen
hsct
earlier
phase
diseas
eg
reinduct
follow
first
second
relaps
rather
late
stage
diseas
deserv
investig
random
trial
includ
novel
agent
conflict
interest
author
conflict
interest
disclos
hospit
universitario
la
princesa
madrid
spain
hospit
la
princesa
madrid
spain
background
present
case
spontan
ruptur
spleen
uncommon
lifethreaten
complic
al
amyloidosi
method
woman
diagnos
al
amyloidosi
treat
cycl
bortezomib
dexamethason
refer
hospit
asct
patient
renal
infiltr
amyloid
confirm
biopsi
wtith
nephrot
syndrom
chronic
renal
failur
creatinin
mgdl
clearenc
peripher
neuropathi
anemia
cardiac
gastrointestin
infiltr
found
abdomin
ecographi
evid
visceromegali
coagul
paramet
normal
rang
includ
factor
x
assign
score
low
risk
accord
mayo
clinic
stage
system
ntprobnp
pgml
troponina
ngml
dflc
mgdl
proceed
transplant
procedur
mobil
hematopoiet
progrenitor
carri
hospit
admiss
regimen
gcsf
dose
mcg
everi
hour
day
obtain
product
suitabl
asct
condit
regimen
melphalan
transplant
took
place
initi
without
complic
leukocyt
engraft
nt
day
result
day
patient
requir
admiss
icu
due
hypotens
tachycardia
sudden
worsen
anemia
abdomin
pain
left
iliac
fossa
abdomin
ct
show
splenic
ruptur
acut
subcapsular
hematoma
secondari
hemoperitoneum
figur
patient
cardiorespiratori
arrest
secondari
hemorrhag
shock
reanim
stabil
stabl
urgent
splenectomi
perform
favor
outcom
histopatholog
report
spleen
reveal
extens
amyloid
infiltr
follow
day
patient
present
clinic
improv
discharg
icu
transfer
hematolog
transplant
unit
hour
patient
suffer
cardiorespiratori
arrest
die
conclus
splenic
involv
amyloidosi
rather
frequent
nontraumat
splenic
ruptur
fatal
case
patient
recov
favor
acut
episod
later
die
sudden
death
probabl
cardiorespiratori
arrest
consequ
sequela
splenic
ruptur
hemorrhag
shock
electromechan
dissoci
subclin
amyloid
deposit
publish
alter
coagul
splenomegali
factor
predispos
splenic
ruptur
patient
undergo
asct
howev
patient
present
condit
therefor
case
illustr
patient
al
amyloidosi
even
low
risk
sever
acut
complic
compromis
patient
life
conflict
interest
none
author
anyth
disclos
sodc
hematolog
aou
careggi
florenc
itali
bmt
unit
azienda
ospedaliera
universitaria
careggi
florenc
itali
hematolog
pisa
itali
hematolog
aou
careggi
florenc
itali
hematolog
bone
marrow
transplant
unit
pisa
itali
background
autolog
stem
cell
transplant
asct
current
approv
gold
standard
first
line
treatment
multipl
myeloma
mm
patient
pt
younger
year
furthermor
consid
feasibl
fit
elderli
pt
retrospect
studi
method
evalu
toler
efficaci
high
dose
chemotherapi
follow
asct
retrospect
analyz
consecut
mm
pt
age
older
underw
upfront
asct
hematolog
unit
florenc
pisa
januari
novemb
result
analyz
pt
male
femal
median
age
rang
among
pt
evalu
fish
pt
high
cytogenet
risk
iss
stage
avail
pt
iss
iss
iss
induct
therapi
bortezomibbas
pt
vd
pt
vtd
pt
receiv
thalidomid
plu
dexamethason
eleven
pt
receiv
type
induct
peripher
blood
stem
cell
pbsc
collect
highdos
cyclophosphamid
pt
gsqm
pt
gsqm
pt
gsqm
pt
plu
gcsf
pt
receiv
type
mobil
therapi
plerixafor
administ
pt
asct
pt
complet
responsestring
complet
respons
crscr
good
partial
respons
vgpr
partial
respons
pr
condit
regimen
consist
melphalan
mgsqm
pt
mgsqm
pt
mgsqm
pt
pt
underw
condit
therapi
median
cellskg
reinfus
rang
pt
achiev
neutrophil
recoveri
median
day
rang
platelet
recoveri
median
day
rang
asct
frequent
non
hematolog
complic
fever
grade
patient
pt
advers
event
repres
grade
gastrointestin
toxic
nausea
vomit
diarrhea
mucos
pt
cardiovascular
event
patient
atrial
fibril
tvp
case
pneumonia
case
acut
renal
impair
case
viral
reactiv
cmv
hzv
reactiv
transplantrel
mortal
record
within
day
post
transplant
pt
month
followup
period
avail
three
month
asct
among
evalu
pt
pt
crscr
pt
vgpr
pt
pr
pt
diseas
progress
three
pt
underw
tandem
asct
median
followup
transplant
month
rang
experienc
diseas
relaps
death
occur
median
pf
os
month
conclus
asct
effect
safe
firstlin
treatment
approach
also
elderli
mm
care
pt
select
reduc
toxic
procedur
conflict
interest
staderini
noth
disclosur
son
llatzer
hospit
palma
de
mallorca
spain
mutua
terrassa
hospit
barcelona
spain
background
autolog
stem
cell
transplant
asct
perform
elig
multipl
myeloma
mm
patient
even
older
year
although
clinic
trial
exclud
age
must
consid
conjunct
perform
statu
comorbid
assess
suitabl
asct
method
perform
retrospect
observ
studi
involv
mm
patient
spanish
hospit
hospit
mutua
terrassa
barcelona
hospit
son
llatzer
palma
de
mallorca
underw
asct
decemb
june
patient
separ
two
group
depend
age
moment
transplant
group
year
old
group
year
old
older
data
collect
electron
medic
record
statist
analys
ibm
softwar
use
kaplanmeir
method
use
perform
surviv
analysi
logrank
test
compar
cohort
p
consid
statist
signific
result
patient
analyz
year
old
older
median
age
transplant
year
median
followup
month
median
overal
surviv
os
month
ci
treatment
respons
evalu
accord
imwg
criteria
patient
group
achiev
least
good
partial
respons
vgpr
asct
group
year
old
patient
year
old
differ
observ
group
regard
ecog
hctci
time
transplant
hematolog
recoveri
also
similar
day
day
group
year
old
respect
signific
differ
occurr
infect
postasct
period
vs
group
year
old
respect
reevalu
show
vgpr
better
patient
age
year
patient
year
median
os
transplant
better
group
year
old
differ
signific
vs
conclus
upfront
asct
consid
elig
mm
patient
even
year
excel
function
statu
retrospect
analysi
myeloma
patient
treat
asct
period
confirm
asct
effect
strategi
even
patient
year
old
toxic
outcom
compar
younger
patient
frailti
index
consid
measur
activ
daili
live
plu
comorbid
identifi
popul
low
risk
transplantrel
complic
would
realist
approach
elig
age
alon
conflict
interest
author
declar
conflict
interest
tabl
basic
inform
ewha
woman
univers
school
medicin
depart
intern
medicin
seoul
korea
republ
ewha
woman
univers
school
medicin
depart
pediatr
seoul
korea
republ
ewha
woman
univers
graduat
school
parmaceut
scienc
seoul
korea
republ
yonsei
univers
colleg
medicin
yonsei
biomed
research
institut
seoul
korea
republ
background
though
bortezomib
btz
effect
drug
achiev
excel
respons
newli
diagnos
multipl
myeloma
mm
via
increas
oxid
stress
need
elucid
mechan
ro
increas
role
antioxid
especi
prx
also
way
potenti
antimyeloma
treatment
proteosom
inhibitor
btz
aim
studi
identifi
sourc
ro
treatment
btz
mm
cell
line
antioxid
enzym
especi
trx
role
ro
gener
btz
also
tri
find
way
potenti
effect
ro
product
apoptosi
mm
cell
lin
regul
trx
method
human
mm
cell
line
treat
btz
induc
apoptosi
medium
supplement
fb
humidifi
atmospher
apoptosi
measur
stain
flow
cytometri
mitosox
red
use
detect
cellular
mitochondri
level
ro
form
prx
prx
ii
prx
iii
detect
western
blot
assay
steadi
state
level
sulfiredoxin
srx
caspas
also
studi
western
blot
analysi
evalu
effect
srx
deplet
cell
transfect
small
interf
rna
sirna
result
apoptosi
mm
cell
btz
treatment
increas
concord
mitochondri
ro
increment
mm
cell
monom
indic
activ
form
prx
iii
decreas
dimer
indic
inact
form
prx
iii
increas
mm
cell
treatment
btz
among
prx
regul
sirna
upregul
ro
gener
apoptosi
mm
cell
togeth
decreas
increas
multim
prxiii
addit
synergist
effect
apoptosi
mm
cell
inhibit
sirna
btz
treatment
simultan
howev
increment
cystein
prxiii
observ
meanwhil
srx
reduc
enzym
prx
induc
mm
cell
btz
treatment
regul
srx
sirna
promot
ro
gener
apoptosi
btztreat
mm
cell
conclus
result
show
inactiv
prxiii
multim
format
hyperoxid
found
btzinduc
mitochondri
ro
gener
apoptosi
mm
cell
prxiii
oxid
due
regul
reduc
btztreat
mm
cell
design
rais
ro
stress
regul
antioxid
ie
trx
treatmentstrategi
may
use
potenti
btzinduc
apoptosi
mm
cell
conflict
interest
author
noth
disclos
abstract
previous
publish
abstract
previous
publish
king
hussein
cancer
center
amman
jordan
background
highdos
chemotherapi
hdc
follow
autolog
stem
cell
transplant
asct
remain
standard
care
young
patient
multipl
myeloma
mm
time
respons
evalu
asct
well
studi
retrospect
evalu
correl
respons
day
day
term
progress
free
surviv
pf
overal
surviv
os
method
chart
patient
diagnos
multipl
myeloma
receiv
hdc
asct
king
hussein
cancer
center
khcc
januari
till
decemb
retrospect
review
result
serum
protein
electrophoresi
urin
protein
electrophoresi
day
day
post
asct
collect
respons
determin
accord
criteria
intern
work
group
myeloma
pf
os
calcul
use
kaplan
meier
method
result
one
hundr
nineteen
patient
includ
median
followup
month
complet
respons
cr
achiev
patient
day
day
respect
day
patient
better
respons
day
wors
respons
patient
respons
day
patient
achiev
cr
nt
significantli
better
pf
os
compar
patient
achiev
cr
vs
month
p
vs
reach
p
respect
day
significantli
better
pf
vs
month
result
signific
os
vs
month
moreov
patient
achiev
respons
day
better
pf
os
compar
patient
respons
stabl
diseas
sd
diseas
progress
dp
vs
month
p
vs
month
p
respect
day
pf
significantli
better
respond
vs
month
signific
os
month
vs
reach
p
conclus
hdc
asct
mm
recommend
respons
evalu
day
rather
day
better
correl
pf
studi
requir
confirm
find
era
consolid
mainten
treatment
conflict
interest
noth
disclos
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
laboratori
haematopatholog
immunolog
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
transplant
unit
sofia
bulgaria
univers
nation
specialis
hospit
activ
treatment
haematolog
diseas
sofia
bulgaria
background
capillari
zone
electrophoresi
cze
total
immunoglobulin
measur
tig
standard
techniqu
quantif
monoclon
protein
mig
allow
quantit
discrimin
heavylight
chain
hlc
involveduninvolv
immunoglobulin
pair
compar
measur
mig
cze
tig
method
serial
serum
sampl
patient
iga
serial
serum
sampl
igg
intact
multipl
myeloma
patient
prospect
evalu
mig
measur
use
cze
sebia
capillari
system
tiga
hlc
concentr
spaplu
pass
bablok
fit
analysi
use
determin
correl
assay
result
total
sampl
iga
mm
patient
detect
mig
cze
hlc
analysi
perform
sampl
exhibit
abnorm
hlc
ratio
measur
involv
hlc
ihlc
median
compar
well
mig
measur
cze
median
tiga
measur
serial
sampl
tiga
normal
rang
sampl
sampl
hlc
ratio
also
abnorm
ihlc
correl
well
total
iga
l
chang
ihlc
rang
correl
chang
mig
rang
tiga
ihlc
median
rang
tiga
rang
igg
mm
patient
sampl
detect
mig
sampl
analys
hlc
abnorm
hlc
ratio
record
measur
ihlc
correl
mig
measur
cze
chang
ihlc
median
rang
baselin
also
correl
chang
mprotein
median
rang
conclus
mig
measur
compar
cze
monoclon
protein
detect
conflict
interest
noth
disclos
sheba
medic
center
ramat
gan
israel
hadassah
hebrew
univers
hospit
jerusalem
israel
background
studi
mechan
neoplast
plasma
cell
shape
bm
microenviron
may
help
develop
new
therapeut
target
treat
mm
identifi
bcell
chemoattract
novel
factor
express
tumor
microenviron
mm
associ
macrophag
polar
osteoclastogenesi
extramedullari
progress
method
util
vivo
xenograft
model
bmdissemin
myeloma
well
analysi
mm
cell
line
stromal
compon
primari
sampl
patient
mm
result
analysi
bm
mmbear
mice
inocul
human
cell
reveal
signific
increas
comparison
control
mice
p
attempt
character
mmassoci
chang
bm
milieu
reveal
murin
chemoattract
one
increas
factor
upon
mm
develop
furthermor
elev
amount
detect
blood
mmbear
anim
comparison
healthi
control
immunohistochem
stain
identifi
myeloid
cell
main
sourc
increas
murin
mmoccupi
bm
importantli
murin
mrna
express
strongli
correl
human
mrna
level
p
demonstr
interrel
tumor
burden
induct
moreov
reduct
mm
load
antimyeloma
agent
includ
bortezomib
panobinostat
result
parallel
decreas
murin
bm
blood
suggest
possibl
use
level
surrog
marker
respons
antimm
novel
therapi
express
associ
antiinflammatori
phenotyp
inde
observ
signific
upregul
addit
marker
mertk
bm
infiltr
mm
strong
correl
express
p
vitro
studi
confirm
abil
mm
cell
line
induc
product
concurr
express
marker
mertk
cocultur
furthermor
interact
reciproc
induc
express
mm
cell
line
primari
human
cell
mechanist
bruton
tyrosin
kinas
btk
signal
found
involv
mmmediat
induct
addit
stimul
lp
solubl
increas
secret
btk
inhibitor
ibrutinib
interf
induct
result
mm
cell
interact
use
osteoclastogen
assay
elucid
downstream
effect
elev
recombin
well
medium
produc
cocultur
mm
increas
rankl
express
induc
trap
osteoclast
format
vitro
neutral
block
activ
final
presenc
primari
mm
sampl
evalu
elev
level
transcript
protein
detect
bm
aspir
mm
patient
comparison
normal
bm
elev
level
correl
gene
express
signatur
associ
osteoclast
activ
phenotyp
furthermor
markedli
increas
express
observ
within
plasmacytoma
sampl
suggest
elev
level
may
associ
extramedullari
diseas
conclus
togeth
find
suggest
may
thu
serv
potenti
novel
target
diagnosi
treatment
mm
conflict
interest
conflict
interest
declar
rambam
health
care
campu
hematolog
bmt
haifa
israel
technion
israel
institut
technolog
ruth
bruce
rappaport
faculti
medicin
haifa
israel
shaar
zedek
medic
center
hematolog
jerusalem
israel
background
highdos
therapi
follow
autolog
stem
cell
transplant
asct
multipl
myeloma
mm
improv
overal
respons
increas
depth
progressionfre
surviv
pf
overal
surviv
os
studi
compar
singl
tandem
asct
provid
conclus
result
introduct
novel
mm
treatment
tandem
asct
becom
rare
use
albeit
hint
resurg
recent
year
current
retrospect
analysi
evalu
safeti
efficaci
tandem
asct
mm
patient
base
longterm
followup
method
data
newlydiagnos
mm
patient
underw
tandem
asct
rambam
depart
hematolog
evalu
approv
patient
receiv
cours
vad
vincristin
adriamycin
dexamethason
induct
cyclophosphamid
stem
cell
mobil
highdos
melphalan
use
condit
second
asct
preform
within
month
first
one
patient
underw
second
asct
relaps
exclud
analysi
novel
agent
administ
progress
patient
outcom
paramet
transplant
includ
engraft
advers
event
clinic
respons
os
pf
median
observ
period
year
rang
analyz
result
final
analysi
includ
consecut
patient
median
age
year
rang
male
femal
mm
subtyp
igg
iga
free
light
chain
patient
respect
three
patient
present
nonsecretori
myeloma
median
treatment
durat
diagnosi
first
asct
month
rang
median
time
asct
month
rang
median
cellskg
administ
first
second
transplant
respect
engraft
compar
asct
median
time
neutrophil
engraft
day
platelet
engraft
day
first
second
transplant
respect
hospit
length
similar
transplant
versu
day
signific
advers
event
observ
asct
therapyrel
death
occur
week
second
asct
respons
rate
induct
patient
achiev
good
partial
respons
vgpr
better
overal
respons
rate
increas
follow
first
asct
patient
achiev
vgpr
better
improv
second
transplant
patient
demonstr
vgpr
better
median
followup
diagnosi
deathlatest
evalu
year
rang
os
respect
pf
median
year
diagnosi
still
aliv
conclus
current
analysi
longterm
followup
consecut
mm
patient
demonstr
tandem
asct
given
part
initi
induct
safe
efficaci
provid
high
surviv
rate
outcom
least
compar
observ
novel
potenti
toxic
agent
need
continu
administ
clinic
set
henc
potent
chemotherapeut
modal
tandem
asct
need
reevalu
current
era
clinic
trial
registri
na
conflict
interest
noth
disclos
hopit
saint
antoin
pari
franc
tor
vergata
univers
rome
rome
itali
ebmt
data
offic
leiden
leiden
netherland
institut
paoli
calmett
marseil
franc
nottingham
univers
nottingham
unit
kingdom
hammersmith
hospit
london
unit
kingdom
chu
nant
nant
franc
karolinska
univers
hospit
stockholm
sweden
st
st
laszlo
hospit
budapest
hungari
chu
de
lill
lill
franc
umea
univers
hospit
umea
sweden
univers
hospit
brno
brno
czech
republ
st
jame
hospit
dublin
ireland
skane
univers
hospit
lund
sweden
hospit
universitario
central
de
asturia
asturia
spain
ico
hospit
duran
reynal
barcelona
spain
central
clinic
hospit
warsaw
poland
univers
hospit
wale
cardiff
unit
kingdom
charl
univers
hospit
pragu
czech
republ
cliniqu
universitair
st
luc
brussel
belgium
univers
hospit
basel
switzerland
kuopio
univers
hospit
kuopio
finland
univers
hospit
aachen
aachen
germani
univers
heidelberg
heidelberg
germani
univers
hospit
eppendorf
hamburg
germani
background
newli
diagnos
myeloma
induct
regimen
aim
reach
best
respons
proceed
asct
numer
regimen
test
differ
length
longer
treatment
necessarili
improv
respons
method
within
calm
databas
select
patient
progress
proceed
asct
singl
line
therapi
split
patient
accord
time
begin
induct
time
stem
cell
collect
surrog
marker
number
treatment
cycl
less
month
mo
mo
mo
analyz
three
type
regimen
velcad
plu
imid
plu
steroid
pid
vtd
vrd
velcadebas
regimen
vd
vcd
cyclophosphamid
plu
thalidomid
plu
dexamethason
ctd
result
patient
characterist
sex
myeloma
isotyp
differ
three
time
period
karnofski
score
higher
mo
p
median
age
year
median
time
initi
collect
month
month
pt
month
pt
mo
pt
pt
pid
vel
pt
ctd
vel
mostli
given
mo
ctd
mo
period
vs
vs
mo
vs
vs
mo
vs
vs
mo
pid
vs
vel
vs
ctd
respect
p
rate
respons
mrstabl
pr
vgpr
post
induct
treatment
differ
mo
vs
mo
mo
vs
vs
vs
vs
vs
vs
median
followup
month
similar
three
time
period
median
os
mo
differ
mo
mo
mo
mo
mo
mo
figur
differ
three
induct
regimen
pid
mo
vel
mo
ctd
mo
figur
median
pf
mo
similar
three
time
period
three
regimen
multivari
analysi
iss
iii
interv
diagnosi
initi
treatment
less
month
wors
os
type
induct
regimen
durat
induct
regimen
impact
os
pf
influenc
respons
induct
respons
transplant
interv
diagnosi
initi
less
month
similar
os
pf
relat
type
induct
regimen
durat
induct
high
risk
cytogenet
defin
del
p
andor
associ
wors
os
p
pf
conclus
respons
induct
regimen
respons
transplant
influenc
pf
os
three
type
induct
regimen
gave
similar
result
whatev
length
treatment
conflict
interest
support
grant
sanofi
conflict
interest
coauthor
relat
work
hospit
clinic
de
barcelona
hematolog
barcelona
spain
background
autolog
hematopoiet
stem
cell
transplant
asct
abl
achiev
hematolog
organ
respons
improv
surviv
patient
amyloidosi
howev
asct
role
controversi
due
high
transplantrel
mortal
trm
rate
tailor
patient
select
polici
perform
asct
special
center
improv
support
measur
main
strategi
decreas
trm
purpos
studi
analyz
impact
posttranspl
gcsf
administr
primari
prophylaxi
engraft
syndrom
corticosteroid
outcom
patient
amyloidosi
undergo
asct
beyond
tailor
patient
select
polici
improv
support
care
measur
method
patient
amyloidosi
underw
asct
singl
institut
includ
median
age
year
patient
receiv
melphalan
condit
amyloidosi
transplant
program
make
tailor
select
polici
sinc
use
gcsf
posttranspl
day
neutrophil
recoveri
sinc
use
corticosteroid
prophylaxi
day
neutrophil
establish
patient
risk
subgroup
accord
select
polici
use
gcsf
corticosteroid
group
nonselect
gcsf
group
b
select
gcsf
group
c
select
nongcsf
group
select
nongcsf
corticosteroid
prophylaxi
result
median
followup
year
ci
signific
differ
regard
age
gender
comorbid
index
median
dose
among
differ
subgroup
b
c
found
p
group
higher
patient
proport
receiv
melphalan
subgroup
incid
mucos
intestin
toxic
grade
respect
diagnosi
engraft
syndrom
establish
base
maiolino
criteria
infecti
fever
microbiolog
isol
respect
global
trm
os
complet
analysi
among
subgroup
detail
tabl
multivari
analysi
variabl
impact
trm
subgroup
risk
hr
comorbid
index
hr
tabl
tabl
conclus
tailor
select
polici
togeth
avoid
gcsf
use
corticosteroid
posttranspl
patient
amyloidosi
undergo
asct
seem
contribut
reduc
trm
conflict
interest
author
noth
disclos
japanes
red
cross
medic
center
divis
hematolog
tokyo
japan
background
lenalidomid
bortezomib
dexamethason
combin
rvd
one
effect
induct
treatment
regimen
transplantelig
newli
diagnos
patient
multipl
myeloma
ndmm
modif
often
requir
advers
event
eg
skin
rash
neutropenia
other
introduc
modifi
rvd
rvdlite
regimen
transplantelig
ndmm
sinc
march
report
retrospect
analysi
efficaci
safeti
rvdlite
regimen
japanes
patient
method
rvdlite
regimen
introduc
patient
march
april
japanes
red
cross
medic
center
rvdlite
regimen
consist
lenalidomid
day
bortezomib
day
dexamethason
day
respons
advers
event
progress
free
surviv
efficaci
autolog
stem
cell
collect
retrospect
analyz
result
median
age
rang
mf
iggigaigdbj
iss
iiiiii
eight
grade
neutropenia
observ
patient
grade
thrombocytopenia
observ
grade
nonhematolog
advers
event
observ
patient
skin
rash
respons
rvdlite
peripher
blood
stem
cell
success
collect
patient
preemptiv
plerixafor
use
patient
median
number
cell
x
rang
upfront
highdos
melphalan
autolog
stemcel
transplant
hdmasct
perform
patient
best
respons
hdmasct
includ
scr
conclus
rvdlite
regimen
well
toler
efficaci
compar
previou
report
rvd
regimen
weekli
administr
bortezomib
conveni
patient
lenalidomid
may
lead
high
complianc
result
suggest
rvdlite
regimen
safe
use
transplantelig
ndmm
conflict
interest
author
declar
conflict
interest
instituto
portugu
de
oncologia
de
lisboa
francisco
gentil
bmt
unit
lisboa
portug
centro
hospitalar
de
oncolog
setub
portug
instituto
portugu
de
oncologia
de
lisboa
francisco
gentil
haematolog
lisboa
portug
background
high
dose
chemotherapi
hdct
remain
essenti
treatment
modal
multipl
myeloma
patient
prolong
surviv
median
age
present
sever
comorbid
mainli
renal
failur
present
particular
challeng
choic
condit
regimen
unit
patient
creatinin
clearenc
sever
comorbid
consid
frail
assist
physician
condit
melphalan
sqm
method
preform
retrospect
compar
analysi
patient
year
old
submit
melphalan
mg
sqm
versu
patient
treat
mg
sqm
period
result
seventi
two
patient
evalu
median
age
tmo
yo
group
male
respect
iss
stage
equival
group
mel
nd
mel
nd
bortezomib
base
regimen
use
first
line
vs
thalidomid
vs
diseas
statu
transplant
compar
mel
pt
cr
vs
prvgpr
vs
pdsd
vs
cohort
age
yo
creatinin
cl
one
heart
ischem
diseas
one
pulmonari
diseas
median
time
neutrophil
recoveri
versu
day
platelet
recoveri
day
cohort
median
stay
unit
versu
day
best
respons
bmt
cr
vs
prvgpr
vs
pdsd
vs
median
followup
versu
month
median
pf
vs
month
time
new
treatment
vs
month
overal
surviv
vs
month
conclus
dosi
melphalan
frail
patient
remain
matter
discuss
studi
compar
trial
popul
cohort
quiet
similar
except
creatinin
clearenc
signific
differ
toxic
although
pf
significantli
differ
mel
associ
significantli
better
outcom
term
overal
surviv
reflet
better
trend
prolong
time
new
treatment
also
present
feasibl
mel
prefer
conflict
interest
conflict
interest
declar
tehran
univers
medic
scienc
hematolog
oncolog
stem
cell
transplant
research
center
tehran
iran
islam
republ
tehran
univers
medic
scienc
tehran
iran
islam
republ
background
despit
remark
progress
surviv
avail
novel
agent
major
patient
multipl
myeloma
mm
relaps
curabl
mm
remain
limitedautolog
stem
cell
transplant
autohct
accept
method
multipl
myeloma
mm
patient
usual
cur
issu
allogen
hematopoiet
stem
cell
transplant
allohct
challeng
yet
myeloma
investig
allohct
mm
compar
autohct
method
retrospect
studi
recruit
patient
januari
januari
patient
autolog
group
allogen
group
group
patient
underw
stem
cell
transplant
achiev
complet
respon
partial
respon
first
line
induct
therapi
salvag
perform
allogen
hct
use
peripher
blood
stem
cell
center
patient
rel
young
less
year
old
good
perform
match
sibl
donor
accept
undergo
allogen
hct
condit
regimen
autolog
group
melphalan
allogen
group
fludarabin
plu
melphalan
day
gvhd
prophylaxi
consist
methotrex
cyclosporin
outcom
compar
two
group
use
logrank
gray
test
cox
proport
hazard
result
median
followup
autolog
allogen
group
month
five
year
diseasefre
surviv
autohct
sd
sd
allohct
patient
pvalu
five
year
overal
surviv
autohct
sd
sd
allohct
patient
pvalu
show
signific
statist
differ
two
group
mortal
rate
autohct
allohct
common
caus
death
two
group
relaps
progress
diseas
primari
diseas
five
year
relaps
incid
ci
allohct
ci
autohct
gray
test
pvalu
five
year
trm
incid
ci
ci
allogen
autolog
patient
respect
gray
test
pvalu
conclus
despit
statist
signific
differ
two
group
term
os
df
relaps
incid
meaning
better
allogen
group
perhap
reason
nonsignific
os
improv
allogen
group
higher
earli
death
due
higher
trm
suggest
studi
need
longer
follow
see
whether
allohct
result
os
improv
conflict
interest
author
conflict
interest
regard
studi
heidelberg
heidelberg
germani
univers
hospit
salamanca
salamanca
spain
hackensack
univers
medic
center
john
theurer
cancer
center
hackensack
nj
unit
state
indiana
cancer
pavilion
indianapoli
unit
state
wilhelminen
cancer
research
institut
depart
medicin
vienna
australia
amgen
inc
south
san
francisco
ca
unit
state
amgen
inc
thousand
oak
ca
unit
state
medic
colleg
wisconsin
milwauke
wi
unit
state
background
phase
aspir
carfilzomiblenalidomidedexamethason
krd
vs
lenalidomidedexamethason
rd
endeavor
trial
carfilzomibdexamethason
vs
bortezomibdexamethason
vd
carfilzomibbas
regimen
demonstr
superior
overal
surviv
os
vs
standard
therapi
relapsedrefractori
multipl
myeloma
rrmm
method
subgroup
adhoc
analysi
aspir
endeavor
os
evalu
base
prior
autolog
stem
cell
transplant
asct
statu
result
patient
prior
asct
aspir
endeavor
baselin
patient
diseas
characterist
gener
balanc
treatment
group
aspir
patient
prior
asct
treat
krd
month
improv
median
os
first
relaps
asct
month
improv
median
os
month
vs
month
endeavor
consist
os
benefit
observ
vs
vd
across
asct
subgroup
benefit
evid
prior
transplant
group
updat
safeti
analysi
advers
event
compar
patient
without
prior
asct
consist
previou
report
hari
et
al
leukemia
apr
tabl
studi
result
carfilzomib
studi
adata
cutoff
bdata
cutoff
chari
et
al
leukemia
apr
dfor
pf
asct
autolog
stem
cell
transplant
krd
carfilzomiblenalidomidedexamethason
rd
lenalidomidedexamethason
carfilzomibdexamethason
vd
bortezomibdexamethason
itt
intenttotreat
os
overal
surviv
ne
estim
conclus
result
suggest
carfilzomibbas
regimen
led
clinic
meaning
improv
surviv
patient
receiv
prior
asct
patient
treat
first
relaps
differ
observ
krd
vs
rd
asct
vs
vd
transplantinelig
patient
aspir
endeavor
studi
support
onyx
pharmaceut
inc
amgen
subsidiari
clinic
trial
registri
conflict
interest
hartmut
goldschmidt
receiv
research
support
amgen
bm
celgen
chugai
janssen
sanofi
mundipharma
takeda
novarti
particip
advisori
board
adapt
biotechnolog
amgen
bm
celgen
janssen
sanofi
takeda
speaker
bureau
celgen
janssen
novarti
chugai
bm
arttempi
mariavictoria
mateo
receiv
consult
fee
celgen
janssen
amgen
takeda
david
siegel
particip
speaker
bureau
ad
board
amgen
celgen
takeda
bm
janssen
rafat
abonour
consult
celgen
takeda
jensen
heinz
ludwig
receiv
research
grant
amgen
takeda
particip
speaker
bureau
amgen
takeda
janssen
celgen
bm
mihaela
obreja
karim
iskand
employe
stock
amgen
parameswaran
hari
receiv
research
grant
amgen
centro
hospitalar
de
porto
portug
faculdad
de
medicina
da
universidad
porto
porto
portug
background
although
autolog
hematopoiet
stem
cell
transplant
asct
wide
perform
multipl
myeloma
mm
intensifi
respons
improv
overal
surviv
os
virtual
patient
experi
relaps
progress
rp
aim
describ
pattern
rp
determin
os
progress
free
surviv
pf
patient
method
raw
clinic
featur
mm
patient
refer
melphalanbas
asct
first
line
induct
chemotherapi
retrospect
analyz
avail
data
patient
obtain
analysi
diagnosi
rp
characterist
os
pf
year
calcul
multivari
logist
regress
analysi
perform
result
median
time
rp
month
mo
interv
median
followup
rp
interv
fiftyf
per
cent
patient
relaps
complet
respons
patient
first
sign
mm
rp
biochem
overal
biochem
criteria
rp
detect
patient
reappear
progress
serum
mprotein
salvag
treatment
requir
clinic
rp
experienc
patient
frequent
due
hemoglobin
decreas
attribut
mm
extramedullari
involv
rp
anemia
bone
lytic
lesion
extramedullari
involv
common
featur
also
frequent
present
diagnosi
p
rp
median
patient
requir
salvag
treatment
median
tabl
summar
analysi
determin
surviv
shorter
patient
relaps
less
upfront
asct
median
versu
patient
requir
treatment
pf
better
women
median
versu
although
statist
signific
logist
regress
analysi
patient
clinic
rp
least
biochem
rp
seem
better
os
median
versu
pf
median
versu
show
lower
ldh
serum
mprotein
level
p
similar
serum
free
light
chain
ratio
patient
retranspl
rp
superior
os
median
versu
pf
median
versu
tabl
tabl
variabl
relat
conclus
patient
common
pattern
rp
biochem
anemia
lytic
bone
lesion
extramedullari
involv
close
monitor
especi
present
diagnosi
rp
new
asct
seem
best
therapeut
approach
improv
os
pf
conflict
interest
none
author
anyth
disclos
tuni
centr
nation
de
greff
de
moell
osseus
tuni
tunisia
background
evalu
impact
diseas
statu
autolog
stem
cell
transplant
asct
overal
surviv
os
progress
free
surviv
pf
patient
newli
diagnos
multipl
myeloma
age
year
method
retrospect
studi
conduct
patient
age
less
year
receiv
asct
februari
decemb
induct
therapi
consist
dexamethason
thalidomid
condit
autolog
base
melphalan
major
patient
receiv
mainten
therapi
thalidomid
start
month
postasct
continu
month
respons
assess
use
imwg
criteria
os
pf
compar
accord
diseas
statu
use
logrank
test
result
median
age
year
sexratio
monoclon
compon
type
complet
immunoglobulin
case
light
chain
nonsecretori
myeloma
multipl
plasmacytoma
asct
patient
crvgpr
partial
respons
pr
progress
diseas
induct
failur
one
hundr
thirti
two
patient
receiv
mainten
therapi
fortyfour
patient
receiv
salvag
treatment
first
asct
thalidomid
n
bortezomib
lenalidomid
other
second
asct
perform
patient
transplant
relat
mortal
median
followup
month
rang
day
month
os
pf
significantli
differ
patient
crvgpr
achiev
less
vgpr
asct
vs
month
vs
month
respect
howev
patient
continu
crvgpr
asct
significantli
longer
pf
obtain
crvgpr
asct
reach
vs
month
patient
achiev
crvgpr
asct
higher
os
compar
less
vgpr
reach
vs
month
respect
conclus
result
provid
evid
achiev
maintain
crvgpr
asct
posit
impact
os
pf
patient
less
vgpr
induct
td
undergo
asct
conflict
interest
none
cancer
centr
london
london
unit
kingdom
st
georg
hospit
immunolog
london
unit
kingdom
background
current
treatment
pathway
mm
patient
autolog
stem
cell
transplant
asct
central
manag
imwg
inevit
previous
receiv
receiv
daratumumab
dara
cellular
inmmunolog
statu
host
alter
ash
abstract
serum
immunoglogulin
alter
may
imping
safeti
asct
method
serum
immunoglogulin
studi
patient
mm
previou
line
treatment
age
igg
iga
bj
treat
institut
dara
plusminu
velcad
revlimid
minimum
followup
month
undertook
asct
three
patient
asct
dara
induc
alter
immun
statu
may
caus
post
asct
issu
delay
engraft
infect
possibl
autolog
gvhd
dara
infus
relat
reaction
rechalleng
next
dose
dara
post
asct
result
one
patient
respond
dara
mark
sever
suppress
normal
unaffect
immunoglogulin
level
month
baselin
one
patient
even
cr
tabl
darainduc
immun
paresi
undertook
pilot
asct
studi
three
patient
stem
cell
collect
commit
transplant
prior
start
dara
asct
patient
f
iga
previou
line
year
treatment
cycl
dara
prior
asct
cycl
cycl
post
anc
engraft
day
inpati
stay
day
pre
asct
mrdve
post
asct
mrd
neg
patient
iggk
year
treatment
cycl
dara
prior
asct
post
anc
engraft
day
inpati
stay
day
mdr
statu
pre
asct
bj
p
trace
post
asct
mrdve
patient
iga
al
previou
year
treatment
cycl
dara
pre
asct
post
anc
engraft
day
inpati
stay
day
mrd
statu
pre
asct
ip
po
post
asct
mrdve
three
patient
dara
circul
time
transplant
conclus
describ
profound
immunoglogulin
suppress
patient
dara
even
dara
circul
blood
asct
patient
engraft
discharg
hospit
promptli
evid
autolog
gvhd
unexpect
infect
irr
next
infus
dara
clinic
trial
registri
none
conflict
interest
janssen
honorarium
pavlov
first
st
petersburg
state
medic
univers
rm
gorbacheva
memori
institut
hematolog
oncolog
transplant
st
petersburg
russian
feder
background
patient
pt
multipl
myeloma
mm
achiev
complet
respons
cr
primari
therapi
includ
autolog
hematopoiet
cell
transplant
autohsct
poor
outcom
preclin
clinic
evid
suggest
immun
checkpoint
program
ligand
axi
play
import
role
suppress
immun
surveil
mm
monotherapi
inhibitor
effect
pt
mm
hypothes
administr
nivolumab
inhibitor
lymphodeplet
state
postautohsct
improv
therapeut
efficaci
mm
method
conduct
phase
singlearm
studi
nivolumab
autohsct
mm
pt
achiev
pre
autohsct
complet
respons
cr
induct
therapi
nivolumab
administ
mg
iv
fix
dose
day
day
autohsct
endpoint
safeti
overal
respons
rate
orr
pt
age
year
mm
molecular
risk
group
cr
statu
induct
therapi
elig
receiv
highdos
melphalan
iv
result
current
twelv
pt
enrol
male
femal
median
age
year
rang
two
pt
light
chain
mm
four
pt
iga
six
pt
igg
mm
pt
except
receiv
tripleregimen
primari
therapi
median
cycl
rang
induct
therapi
pt
achiev
partial
respons
pr
three
pt
lost
respons
autohsct
progress
diseas
among
pt
grade
toxic
pt
patient
infus
reaction
patient
coliti
none
pt
immunemedi
advers
reaction
primari
secondari
graft
failur
median
time
neutrophil
platelet
engraft
day
rang
day
rang
respect
ten
pt
consid
evalu
respons
assess
median
followup
day
rang
none
progress
diseas
relaps
pt
complet
respons
evalu
serolog
bone
marrow
bm
studi
morpholog
flow
cytometri
orr
cr
rate
two
pt
achiev
vgpr
four
pt
stay
pr
one
pt
progress
diseas
stabil
conclus
preliminari
result
addit
nivolumab
autohsct
show
rel
safeti
therapi
efficaci
combin
requir
evalu
clinic
trial
registri
http
clinicaltrialsgov
conflict
interest
author
noth
disclos
kansai
medic
univers
first
depart
intern
medicin
osaka
japan
kansai
myeloma
forum
osaka
japan
osaka
univers
graduat
school
medicin
depart
biostatist
data
scienc
osaka
japan
japanes
red
cross
osaka
hospit
depart
hematolog
osaka
japan
osaka
univers
graduat
school
medicin
depart
hematolog
oncolog
osaka
japan
kyoto
prefectur
univers
medicin
divis
hematolog
oncolog
depart
medicin
kyoto
japan
graduat
school
medicin
kyoto
univers
depart
hematolog
oncolog
kyoto
japan
osaka
saiseikai
nakatsu
hospit
depart
hematolog
osaka
japan
toyonaka
municip
hospit
depart
intern
medicin
hematolog
osaka
japan
jcho
kyoto
kuramaguchi
medic
center
depart
hematolog
kyoto
japan
nara
hospit
kinki
univers
school
medicin
depart
hematolog
nara
japan
kindai
univers
faculti
medicin
depart
hematolog
rheumatolog
osaka
japan
matsushita
memori
hospit
depart
hematolog
osaka
japan
rinku
gener
medic
center
depart
hematolog
osaka
japan
japanes
red
cross
kyoto
daini
hospit
depart
hematolog
kyoto
japan
jcho
kobe
central
hospit
depart
intern
medicin
hyogo
japan
japanes
red
cross
kyoto
daiichi
hospit
depart
hematolog
kyoto
japan
nishiwaki
municip
hospit
depart
hematolog
hyogo
japan
pl
gener
hospit
depart
hematolog
osaka
japan
osaka
intern
cancer
center
depart
hematolog
osaka
japan
kyotokatsura
hospit
kyoto
japan
omihachiman
commun
medic
center
depart
hematolog
shiga
japan
osaka
citi
univers
graduat
school
medicin
hematolog
osaka
japan
background
clinic
signific
consolid
mainten
therapi
high
dose
chemotherapi
autolog
stem
cell
transplant
hdtasct
remain
controversi
therefor
evalu
effect
therapi
use
databas
kansai
myeloma
forum
kmf
method
symptomat
multipl
myeloma
patient
receiv
hdtasct
analyz
consolid
therapi
defin
second
hdtasct
shortterm
intens
therapi
hdtasct
mainten
therapi
longterm
continu
therapi
result
median
age
yo
consolid
therapi
includ
second
hdtasct
bortezomib
b
base
regimen
lenalidomid
l
base
thalidomid
base
median
overal
surviv
os
patient
consolid
wherea
without
consolid
median
time
next
treatment
ttnt
without
consolid
accord
regimen
second
hdtasct
significantli
prolong
ttnt
second
hdtasct
bbase
lbase
p
howev
differ
os
accord
regimen
mainten
therapi
includ
lbase
tbase
bbase
median
os
patient
mainten
wherea
patient
without
mainten
median
ttnt
without
mainten
subgroup
analys
signific
prolong
ttnt
os
accord
regimen
conclus
cohort
signific
differ
withwithout
consolid
mainten
therapi
hdtasct
howev
second
hdtasct
consolid
therapi
significantli
prolong
ttnt
valu
consolid
mainten
therapi
hdtasct
evalu
clinic
practic
clinic
trial
registri
http
kmubvitscomrinriapplyprojectaspx
conflict
interest
jk
paid
honoraria
celgen
bristolmy
squibb
ono
janssen
jk
institut
receiv
research
fund
celgen
bristolmy
squibb
hs
paid
honoraria
takeda
celgen
novarti
cs
paid
honoraria
fujimoto
ono
celgen
paid
bristolmy
squibb
janssen
celgen
jka
institut
receiv
research
fund
takeda
im
institut
receiv
research
fund
celgen
member
receiv
grant
celgen
takeda
fujimoto
ono
de
chu
de
laval
divis
hematolog
medic
oncolog
depart
medicin
vill
de
canada
background
highdos
chemotherapi
follow
autolog
stem
cell
transplant
asct
consid
standard
care
firstlin
therapi
elig
multipl
myeloma
patient
barlogi
et
al
expect
myeloma
incid
rise
smith
et
al
number
older
patient
consid
asct
increas
significantli
goal
studi
identifi
factor
impact
safeti
efficaci
asct
older
patient
multipl
myeloma
order
better
select
benefit
intervent
method
singl
center
retrospect
studi
examin
outcom
asct
elderli
patient
year
old
multipl
myeloma
compar
younger
patient
year
old
januari
septemb
patient
met
inclus
criteria
includ
studi
patient
sign
inform
consent
ethic
committe
institut
approv
studi
toxic
analyz
accord
age
hematopoiet
cell
transplant
comorbid
index
score
hctci
progressionfreesurviv
pf
overal
surviv
os
analyz
accord
age
time
transplant
hctci
revis
intern
stage
system
riss
diseas
statu
time
transplant
result
patient
includ
studi
includ
younger
group
includ
older
cohort
median
age
transplant
rang
rang
yearsold
respect
distribut
riss
hctci
compar
group
transplant
parenter
aliment
requir
older
patient
group
patient
requir
younger
patient
group
incid
febril
neutropenia
univers
patient
incid
septic
shock
admiss
intens
care
unit
median
engraft
neutrophil
day
day
platelet
median
hospit
stay
durat
significantli
differ
group
day
median
followup
month
rang
older
cohort
better
median
pf
month
compar
month
younger
cohort
median
os
reach
time
evalu
group
estim
year
os
younger
group
compar
older
group
entir
cohort
patient
obtain
partial
respons
pr
better
transplant
significantli
earlier
progress
median
compar
month
p
year
nrm
surprisingli
hctci
correl
toxic
outcom
group
conclus
asct
benefici
treatment
option
wellselect
older
multipl
myeloma
patient
comorbid
must
consid
hctci
guid
clinician
select
elig
patient
data
show
older
patient
toxic
os
compar
younger
patient
obtain
least
pr
power
predictor
greater
surviv
therefor
age
limit
factor
consid
asct
older
patient
multipl
myeloma
conflict
interest
none
author
anyth
disclos
karolinska
institutet
univers
hospit
depart
medicin
hudding
stockholm
sweden
ebmt
statist
unit
data
offic
leiden
leiden
netherland
karolinska
institutet
univers
hospit
stockholm
sweden
ebmt
data
offic
leiden
leid
netherland
germani
huch
comprehens
cancer
center
helsinki
finland
univers
regensburg
regensburg
germani
univers
hospit
essen
germani
ospedal
san
raffael
srl
milano
itali
universitaetsklinikum
dresden
dresden
germani
univers
freiburg
freiburg
germani
leiden
univers
medic
centr
leiden
netherland
klinikum
grosshadern
munich
germani
klinkum
recht
der
isar
munich
germani
univers
hospit
eppendorf
hamburg
germani
jena
jena
germani
klinikum
nuernberg
nuernberg
germani
univers
cologn
colong
germani
ulm
ulm
germani
st
franzisku
hospit
flensburg
germani
klinikum
chemnitz
ggmbh
chemnitz
germani
hallewittenberg
hallo
germani
univers
medic
center
schleswigholstein
germani
hospit
saint
antoin
pari
franc
background
allogen
hematopoiet
stem
cell
transplant
allosct
treatment
multipl
myeloma
mm
controversi
mainli
due
high
nonrelaps
mortal
nrm
myeloabl
condit
howev
allosct
probabl
treatment
may
result
cure
small
fraction
patient
treosulfan
prodrug
bifunct
alkyl
agent
myelotox
immunosuppress
properti
condit
regim
treosulfan
tri
variou
hematolog
neoplasia
aml
md
suggest
result
low
nrm
increas
progress
free
surviv
previou
publish
singl
centr
studi
use
treosulfan
condit
allosct
mm
indic
improv
overal
surviv
os
low
method
conduct
retrospect
analysi
patient
mm
undergo
allosct
report
ebmt
data
registri
patient
analys
three
cohort
receiv
treosulfan
condit
regimen
regardless
upfront
subsequ
line
allo
nontreosulfan
reduc
intens
condit
ric
n
undergo
nontreosulfan
myeloabl
condit
mac
patient
characterist
present
tabl
result
overal
surviv
show
slight
improv
use
treosulfan
regim
compar
ric
mac
respect
signific
differ
progress
free
surviv
cohort
treosulfan
ric
mac
long
term
cumul
incid
ci
relaps
treosulfan
condit
cohort
contrast
ric
mac
p
noteworthi
lower
ci
nr
treosulfan
cohort
compar
ric
mac
conclus
retrospect
studi
treosulfan
reduc
nrm
tend
improv
os
howev
risk
relaps
increas
treosulfan
treat
patient
especi
compar
patient
receiv
mac
addit
mainten
treatment
might
reduc
relaps
rate
allosct
improv
surviv
multipl
myeloma
patient
prospect
studi
treosulfan
condit
warrant
defin
suitabl
dose
mm
allosct
refer
nahi
h
afram
g
liw
j
et
al
treosulfan
plu
fludarabin
encourag
condit
allogen
hematopoiet
stem
cell
transplant
multipl
myeloma
journal
cancer
scienc
clinic
oncolog
conflict
interest
none
author
anyth
disclos
tabl
tabl
patient
characterist
abstract
previous
publish
turku
univers
hospit
dept
medicin
turku
finland
kaikuhealth
helsinki
finland
turku
univers
hospit
turku
finland
background
webbas
symptom
track
shown
improv
overal
surviv
qualiti
life
amongst
metastat
cancer
patient
undergo
howev
similar
approach
pilot
amongst
multipl
myeloma
patient
method
togeth
patientreport
outcom
web
applic
provid
kaiku
health
develop
adapt
symptom
questionnair
cover
common
symptom
treatment
mm
numb
pain
fatigu
etc
turku
univers
hospit
patient
also
possibl
report
symptom
contact
medic
staff
electron
applic
applic
remind
patient
complet
symptom
report
weekli
basi
via
email
remind
sent
patient
applic
highlight
sever
symptom
medic
staff
nurs
follow
symptom
report
applic
opportun
consult
doctor
necessari
result
invit
patient
regist
applic
regist
patient
start
follow
symptom
applic
experi
collect
patient
nurs
doctor
indepth
interview
key
perform
indic
usag
platform
analyz
patient
report
applic
easi
use
would
rather
use
call
clinic
median
time
complet
symptom
report
applic
minut
altogeth
patient
complet
symptom
questionnair
time
expect
complet
report
week
medic
staff
report
caught
patient
symptom
would
miss
tradit
commun
also
clear
decreas
number
phone
call
clinic
complet
symptom
report
patient
simultan
learn
recogn
follow
relev
symptom
reduc
patient
symptomrel
uncertainti
conclus
webbas
symptom
track
suitabl
way
followup
symptom
multipl
myeloma
patient
patient
engag
followup
webbas
track
improv
effect
clinic
appoint
reduc
patient
need
phone
call
larger
studi
assess
impact
followup
recommend
conflict
interest
author
declar
conflict
interest
myelodysplast
syndrom
universidad
feder
hospit
da
fortaleza
brazil
universidad
feder
fortaleza
brazil
universidad
feder
curitiba
brazil
amar
carvalho
brazil
hospit
israelita
albert
einstein
paulo
brazil
hospit
de
infantojuvenil
de
barreto
barreto
brazil
intituto
brasileiro
de
control
paulo
brazil
universidad
estadu
de
campina
campina
brazil
natal
hospit
center
natal
brazil
hospit
da
clinica
de
porto
alegr
porto
alegr
brazil
hospit
de
uruguai
montevideo
uruguay
hospit
de
juiz
de
fora
juiz
de
fora
brazil
pietro
albuquerqu
icdfbmt
paulo
brazil
hospit
paulo
brazil
universidad
feder
da
bahia
salvador
brazil
real
hospit
de
em
pernambuco
recif
brazil
cemoinstituto
nacion
rio
de
janeiro
brazil
universidad
feder
ceara
fortaleza
brazil
background
hematopoiet
stem
cell
transplant
hsct
cur
procedur
myelodysplast
syndrom
md
method
multicent
studi
patient
md
submit
hsct
brazil
uruguay
data
obtain
latin
american
transplant
registri
statist
analys
perform
utilizingth
spss
softwar
version
graphpad
prism
version
signific
level
p
result
predomin
male
caucasian
patient
predomin
age
group
year
accord
ipssr
classif
sampl
classifi
high
risk
high
risk
low
risk
chemotherapi
hypomethyl
agent
use
azacitidin
commonli
use
drug
red
blood
cell
unit
platelet
unit
usedth
myeloabl
condit
perform
reduc
intens
cell
sourc
bone
marrow
bm
peripher
blood
pb
donor
relat
case
posthsct
complic
infect
mucos
acut
gvhd
chronic
gvhd
acut
gvhd
bivari
analysi
show
associ
myeloabl
condit
p
bm
cell
sourc
p
binari
logist
regress
analysi
condit
ci
cell
sourc
ci
signific
predictor
acut
gvhd
chronic
gvhd
associ
myeloabl
condit
observ
bivari
analysi
p
binari
logist
regress
variabl
consid
signific
predictor
ci
chronic
gvhd
develop
overal
patient
surviv
period
observ
patient
submit
reduc
intensitynonmyeloabl
condit
higher
surviv
compar
myeloabl
regimen
p
surviv
higher
case
peripher
blood
cell
sourc
p
chisquar
test
myeloabl
regimen
p
bm
cell
sourc
p
associ
death
hsct
variabl
condit
cell
sourc
donor
type
constitut
predictor
acut
gvhd
posit
result
observ
myeloabl
condit
p
bm
cell
sourc
p
conclus
result
show
reduc
intens
condit
peripher
blood
cell
sourc
associ
longer
surviv
myeloabl
condit
bm
cell
sourc
associ
acut
gvhd
data
open
discuss
ideal
cell
condit
sourc
md
consid
patient
age
prognost
factor
posttransplant
therapi
aim
optim
result
conflict
interest
none
declar
chair
hematolog
unit
blood
diseas
bone
marrow
transplant
asst
spedali
civili
brescia
itali
background
myelodysplast
syndrom
md
heterogen
group
myeloid
malign
character
dysplast
featur
cytopenia
high
variabl
clinic
cours
lead
rapid
transform
acut
leukemia
stabl
diseas
mani
month
even
year
treatment
option
patient
md
still
limit
allogen
hematopoiet
stem
cell
transplant
allosct
cur
treatment
option
advent
less
toxic
condit
regimen
avail
stem
cell
donor
sibl
match
unrel
haploident
great
major
patient
led
increasingli
use
allosct
even
older
md
patient
often
follow
hypometil
agent
hma
aim
reduc
diseas
burden
method
report
seri
patient
submit
allosct
md
januari
june
institut
six
secondari
md
mostli
relat
chemotherapi
hematolog
malign
ten
raeb
raeb
four
md
patient
high
ipss
risk
ipss
risk
fifteen
patient
treat
hma
agent
bridg
transplant
patient
transplant
frontlin
group
hma
patient
achiev
hematolog
respons
transplant
stabl
diseas
median
cours
hma
cycl
rang
median
age
transplant
year
rang
six
patient
receiv
myeloabl
condit
regimen
donor
match
sibl
case
match
unrel
case
haploident
donor
case
median
hematopoiet
cell
transplant
hct
specif
comorbid
index
score
rang
median
time
diagnosi
allosct
month
rang
median
follow
time
allosct
month
rang
result
nine
patient
submit
allosct
md
aliv
last
follow
six
death
consid
transplantrel
mortal
infect
condit
toxic
one
patient
die
recurr
diseas
anoth
one
second
neoplasia
ten
patient
develop
grade
ii
agvhd
allosct
success
treat
standard
steroid
therapi
one
case
two
develop
limit
cgvhd
requir
treatment
conclus
experi
although
limit
suggest
allosct
effect
treatment
option
md
even
older
patient
experi
recurr
md
allosct
low
toxic
condit
especi
secondari
md
group
high
probabl
relat
wors
hct
score
patient
studi
need
evalu
less
toxic
condit
regimen
special
secondari
md
patient
frequent
transplant
activ
although
stabl
diseas
higher
hct
score
conflict
interest
none
author
anyth
disclos
institut
hematolog
blood
transfus
pragu
czech
republ
background
diseas
relaps
repres
major
caus
treatment
failur
allogen
hematopoiet
stemcel
transplant
hsct
myelodysplast
syndrom
md
well
character
variou
combin
somat
mutat
associ
differ
clinic
outcom
md
limit
data
chang
mutat
profil
relaps
autolog
chimer
hsct
method
analyz
bone
marrow
peripher
blood
patient
relaps
md
hsct
character
rise
autolog
chimer
use
illumina
nextgener
sequenc
platform
examin
tumor
sampl
collect
day
start
condit
regimen
time
relaps
hsct
somat
mutat
gene
frequent
mutat
myeloid
malign
result
fifteen
mutat
identifi
patient
name
gene
bcor
mutat
detect
transplant
predominantli
lower
percentag
time
relaps
one
mutat
bcor
show
lower
frequenc
relaps
pretranspl
period
character
loss
homozygos
patient
relaps
reexpans
mutat
clone
exist
prior
hsct
patient
treat
intens
transplant
therefor
detect
mutat
clone
pretranspl
sampl
higher
percentag
three
patient
carri
least
one
new
driver
mutat
hsct
patient
allel
frequenc
mutat
pretranspl
posttranspl
relaps
sampl
shown
figur
conclus
pilot
studi
demonstr
evolut
clonal
structur
relaps
md
patient
hsct
show
consider
heterogen
mutat
profil
data
suggest
posttranspl
relaps
mainli
driven
reexpans
prehsct
persist
mutat
clone
accompani
acquisit
new
mutat
hsct
posttranspl
frequenc
mutat
calcul
accord
autolog
chimer
support
ministri
health
czech
republ
project
conceptu
develop
research
organ
conflict
interest
conflict
interest
report
cathol
univers
korea
hematolog
seoul
korea
republ
background
decis
perform
haploident
stem
cell
transplant
patient
myelodysplast
syndrom
md
made
weigh
potenti
benefit
versu
risk
therefor
import
identifi
patient
may
gain
advantag
procedur
reliabl
transplantspecif
prognost
score
tool
purpos
studi
valid
predict
abil
respect
surviv
md
transplant
prognost
score
system
mtpss
md
patient
receiv
haploident
sct
compar
md
transplant
risk
index
tri
score
system
center
intern
blood
marrow
transplant
research
cibmtr
method
evalu
predict
abil
mtpss
compar
two
transplantspecif
prognost
system
tri
cibmtr
retrospect
analyz
md
patient
receiv
haploident
transplant
result
median
pretranspl
age
rang
year
worst
point
diseas
cours
categor
refractori
anemia
one
refractori
cytopenia
multilineag
dysplasia
refractori
anemia
excess
blast
secondari
acut
myeloid
leukemia
two
patient
ipssr
cytogenet
risk
goodgood
intermedi
poorveri
poor
observ
patient
respect
includ
monosom
karyotyp
addit
patient
pretranspl
treatment
failur
high
hematopoiet
cell
transplant
comorbid
indic
respect
mtpss
year
p
tri
year
p
discrimin
overal
surviv
patient
accord
risk
group
wherea
cibmtr
year
p
cindic
overal
surviv
mtpss
tri
similar
wherea
cibmtr
rel
lower
conclus
result
suggest
potenti
mptss
tri
cibmtr
prognost
tool
haploident
recipi
md
conflict
interest
noth
disclos
chu
grenobl
alp
grenobl
franc
de
dieu
pari
franc
univers
freiburg
freiburg
germani
universitaetsklinikum
dresden
dresden
germani
ebmt
data
offic
leiden
netherland
univers
hospit
essen
germani
hannov
medic
school
hannov
germani
huch
comprehens
cancer
center
helsinki
finland
hospit
universitario
ramon
cajal
madrid
spain
rigshospitalet
copenhagen
denmark
centr
lyon
franc
klinikum
grosshadern
munchen
germani
imperi
colleg
healthcar
nh
trust
london
unit
kingdom
hospit
region
de
malaga
spain
univers
tor
vergata
roma
itali
medic
park
hospit
antalya
turkey
charl
univers
hospit
pilsen
czech
republ
florenc
nightingal
sisli
hospit
istanbul
turkey
radboud
univers
nijmegen
medic
centr
nijmegen
netherland
univers
hospit
eppendorf
hamburg
germani
hopit
st
loui
pari
franc
aphp
pari
franc
background
allogen
stem
cell
transplant
hsct
potenti
cur
treatment
myelodysplast
syndrom
md
md
occur
mainli
elderli
popul
nonrelaps
mortal
nrm
remain
matter
concern
despit
introduct
reducedintens
condit
aim
evalu
predict
role
differ
pretranspl
score
method
md
patient
transplant
center
particip
ebmt
data
qualiti
initi
includ
perform
hctci
hematopoiet
cell
transplantationspecif
comorbid
index
pam
pretranspl
assess
mortal
score
ebmt
score
sorror
blood
jco
parimon
ann
intern
med
gratwohl
bmt
predict
nrm
overal
surviv
os
investig
accord
principl
method
describ
extern
valid
predict
model
royston
bmc
medic
research
methodolog
besid
model
discrimin
assess
concord
c
index
adapt
compet
risk
analys
harrel
jama
wolber
biostatist
index
latter
correspond
mean
absolut
deviat
sampl
individu
log
hazard
ratio
around
sampl
mean
result
median
age
year
four
hundr
patient
md
transform
aml
time
transplant
patient
still
md
statu
time
transplant
good
intermedi
poor
cytogenet
accord
ipss
cytogenet
avail
donor
mostli
match
relat
unrel
use
peripher
blood
stem
cell
predomin
condit
regimen
reduc
transplant
multivari
analysi
adjust
diseas
risk
cytogenet
sex
mismatch
condit
regimen
age
hr
diseas
statu
intermedi
risk
donor
type
unrel
p
karnofski
hr
p
signific
impact
nrm
similar
variabl
test
os
age
hr
diseas
risk
intermedi
hr
donor
type
unrel
hr
sex
mismatch
femal
donor
male
recipi
karnofski
hr
p
cytogenet
poor
hr
p
signific
impact
figur
show
nrm
accord
score
perform
score
accord
cindex
index
cindex
signific
hctcimd
pam
score
hctci
hctciag
ebmt
karnofski
signific
cindex
mean
consid
predict
nrm
best
index
given
karnofski
ebmt
score
hctciag
score
advantag
predict
nrm
low
risk
group
nrm
cohort
predict
origin
hctci
score
regress
analysi
confirm
hctcimd
pam
score
gradual
increas
hazard
ratio
accord
categori
os
predict
score
except
hctcimd
predict
os
includ
pam
score
one
best
conclus
valid
ebmt
cohort
hctci
hctciag
ebmt
score
predict
nrm
pam
predict
os
conflict
interest
conflict
interest
abstract
previous
publish
rmgorbacheva
scientif
research
institut
pediatr
oncolog
hematolog
transplant
pavlov
first
saint
petersburg
state
medic
univers
saint
petersburg
russian
feder
background
aim
studi
assess
impact
hypomethyl
therapi
hmt
allogen
hematopoiet
stem
cell
transplant
allohsct
outcom
myelodysplast
syndrom
md
patient
allosct
method
analyz
patient
pt
md
receiv
allohsct
hmt
pt
characterist
cytogenet
risk
group
moment
diagnosi
goodgood
pt
intermedi
pt
poorveri
poor
pt
allohsct
pt
receiv
pt
decitabin
standard
dose
median
number
cycl
rang
respons
therapi
estim
accord
criteria
intern
work
group
cheson
et
al
allohsct
ric
regimen
use
pt
mac
pt
pt
graft
mrd
mmud
haplodonor
prophylaxi
gvhd
basi
csa
tacro
result
hmt
pt
achiev
complet
respons
cr
pt
partial
respons
pr
pt
stabil
pt
progress
p
allohcst
best
respons
hmt
associ
goodgood
vs
intermediatepoorveri
poor
cytogenet
risk
group
vs
instead
poorveri
poor
vs
intermediategoodveri
good
cytogenet
risk
group
vs
p
worst
respons
hmt
describ
group
complex
cytogenet
abnorm
vs
karyotyp
vs
overal
surviv
os
allohsct
eventfre
surviv
ef
relaps
incid
ri
transplantrel
mortal
trm
pt
achiev
partialcomplet
respons
stabil
hmt
demonstr
significantli
better
ef
allohct
pt
progress
vs
median
os
surviv
day
conclus
hmt
bridg
option
pt
md
allohsct
cytogenet
risk
group
type
respons
hmt
allohsct
influenc
posttranspl
ef
patient
md
conflict
interest
noth
disclos
tabl
characterist
patient
king
faisal
specialist
hospit
research
center
pediatr
hematolog
oncolog
riyadh
saudi
arabia
background
analyz
data
cohort
md
patient
undergo
stem
cell
transplant
review
result
treatment
effort
method
total
patient
transplant
jan
decemb
institut
two
exclud
previous
transplant
hospit
data
demograph
diagnosi
transplantrel
paramet
outcom
abstract
clinic
databas
medic
chart
review
retrospect
cohort
studi
process
analyz
use
ibmspss
studi
preapprov
irb
hospit
result
boy
median
age
transplant
year
median
time
transplant
diagnosi
month
use
bone
marrow
sourc
stem
cell
remain
transplant
cord
blood
got
condit
regimen
follow
buci
bucyatg
receiv
gcsf
donor
hlaident
sibl
transplant
relat
mortal
rate
engraft
primari
secondari
graft
failur
vod
seen
hemorrhag
cystiti
within
first
day
grade
iiiiv
agvhd
observ
median
followup
month
event
mortal
overal
event
free
surviv
cohort
patient
signific
risk
factor
includ
age
diagnosi
time
transplant
diagnosi
pretranspl
diseas
statu
donor
recipi
gender
condit
regimen
sourc
stem
cell
occurr
agvhd
found
uni
multivari
analys
conclus
cohort
patient
result
stem
cell
transplant
term
transplant
relat
toxic
overal
surviv
promis
conflict
interest
none
declar
seoul
st
mari
hospit
colleg
medicin
cathol
univers
korea
hematolog
seoul
korea
republ
colleg
medicin
cathol
univers
korea
microbiolog
seoul
korea
republ
asan
medic
center
univers
ulsan
colleg
medicin
hematolog
seoul
korea
republ
colleg
medicin
cathol
univers
korea
patholog
seoul
korea
republ
background
somat
mutat
involv
pathogenesi
md
becom
relev
md
prognost
investig
prognost
role
somat
mutat
includ
mutat
patient
de
novo
myelodysplast
syndrom
md
underw
allogen
hematopoiet
cell
transplant
hct
method
perform
target
deep
sequenc
analysi
gene
bone
marrow
sampl
obtain
within
week
hct
patient
de
novo
md
two
korean
institut
analyz
associ
somat
mutat
posttranspl
outcom
overal
surviv
os
relapsefre
surviv
rf
eventfre
surviv
ef
nonrelaps
mortal
nrm
result
median
age
patient
femal
male
year
overal
patient
carri
one
somat
mutat
mutat
present
patient
probabl
os
rf
ef
nrm
respect
mutat
independ
risk
factor
shorter
os
vs
hazard
ratio
hr
rf
vs
hr
p
ef
vs
hr
nrm
vs
nra
mutat
independ
risk
factor
shorter
rf
hr
among
clinic
variabl
male
sex
os
ef
nrm
thrombocytopenia
os
old
age
rf
poor
cytogenet
rf
ef
higher
hctcomorbid
index
rf
ef
older
donor
rf
independ
poor
prognost
factor
mutat
frequent
found
patient
poor
ipss
cytogenet
risk
higher
score
ipss
ripss
patient
ipss
higherrisk
score
patient
mutat
patient
mutat
show
significantli
lower
os
vs
p
lower
rf
vs
p
lower
ef
vs
p
similar
nrm
vs
p
mutat
signific
interact
condit
intens
occurr
graftversushost
diseas
regard
posttranspl
outcom
conclus
mutat
significantli
associ
poor
outcom
hct
patient
de
novo
md
mainli
due
higher
incid
diseas
relaps
conflict
interest
none
author
anyth
disclos
asan
medic
center
univers
ulsan
colleg
medicin
depart
hematolog
seoul
korea
republ
background
allogen
hematopoiet
cell
transplant
hct
consid
cur
treatment
option
patient
myelodysplast
syndrom
md
howev
even
hct
substanti
number
patient
experi
diseas
relaps
standard
treatment
relaps
patient
review
clinic
outcom
relaps
md
patient
receiv
allogen
hct
method
thirti
patient
experienc
relaps
progress
allogen
hct
md
juli
may
includ
studi
result
median
age
patient
year
rang
total
patient
diagnos
mdsrefractori
anemia
excess
blast
raeb
refractori
cytopenia
multilineag
dysplasia
rcmd
hct
respect
pretransplant
intern
prognost
score
system
record
low
high
patient
experienc
diseas
relaps
median
month
rang
hct
includ
patient
present
transform
acut
myeloid
leukemia
aml
donor
lymphocyt
infus
dli
deliv
four
patient
one
relaps
rcmd
aliv
complet
remiss
cr
three
show
mix
chimer
dli
eventu
die
diseas
seven
patient
receiv
hypomethyl
agent
hma
one
continu
receiv
cycl
decitabin
time
analysi
stabl
diseas
patient
die
hma
treatment
persist
diseas
pneumonia
patient
progress
aml
cycl
decitabin
underw
salvag
hct
die
diseas
andor
bleed
complic
six
patient
progress
aml
treat
aml
inductionlik
intens
chemotherapi
achiev
cr
patient
underw
second
hct
one
receiv
dli
one
receiv
second
hct
cr
aliv
without
diseas
two
eventu
relaps
die
patient
respond
intens
chemotherapi
die
diseas
four
patient
treat
lowdos
cytarabin
respond
treatment
die
refractori
diseas
one
patient
experienc
cytogenet
relaps
year
hct
receiv
second
transplant
aliv
time
analysi
without
evid
diseas
eight
patient
treat
best
support
care
die
diseas
median
overal
surviv
os
relaps
patient
month
confid
interv
ci
longer
interv
hct
relaps
associ
improv
os
month
vs
month
hazard
ratio
ci
conclus
though
variou
therapeut
approach
attempt
outcom
md
patient
relaps
progress
hct
disappoint
earli
detect
diseas
relaps
applic
therapeut
strategi
prophylact
dli
second
hct
patient
minim
diseas
burden
could
option
induc
longterm
respons
surviv
conflict
interest
author
declar
conflict
interest
new
drug
cellbas
immun
therapi
macopharma
r
biotherapi
mouvaux
franc
background
extracorpor
photopheresi
ecp
autolog
cellular
immunomodulatori
treatment
involv
ex
vivo
collect
mononuclear
cell
mnc
uva
irradi
presenc
photosensit
agent
induc
cell
apoptosi
mainli
tcell
reinfus
treat
cell
patient
although
ecp
benefit
wellknown
clinic
number
tcell
mediat
diseas
studi
ever
report
link
variabl
differ
compon
enter
composit
cell
prepar
treat
vitro
efficaci
ecp
treatment
method
standard
method
approach
mimick
clinic
procedur
defin
follow
compon
present
irradi
contain
plasma
hematocrit
cell
salin
solut
studi
separ
chang
one
compon
ratio
system
set
time
human
lymphoma
tcell
line
model
use
analyz
reproduc
way
vitro
efficaci
ecp
treatment
systemat
analyz
compar
condit
studi
two
differ
cellular
respons
relev
accept
criteria
ecp
techniqu
cell
apoptosi
inhibit
cell
prolifer
consumpt
irradi
also
systemat
determin
treatment
result
vitro
perform
studi
allow
us
highlight
decreas
cellular
respons
follow
increas
hematocrit
plasma
ratio
dosedepend
manner
addit
plasma
ratio
influenc
consumpt
final
studi
also
provid
workaround
counteract
extrem
variat
blood
compon
use
system
set
adjust
notabl
irradi
dose
reach
optim
vitro
ecp
effici
conclus
method
approach
could
especi
use
evalu
leukapheresi
prepar
protocol
better
defin
specif
use
ecp
techniqu
toward
blood
compositiondepend
ecp
procedur
standard
conflict
interest
maco
pharma
provid
support
form
salari
author
ml
sl
dlbr
af
mp
bd
addit
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
maco
pharma
produc
distribut
macogen
irradi
contain
solut
nacl
solut
acda
solut
use
studi
la
fe
valencia
spain
background
relaps
andor
refractori
acut
lymphoblast
leukemia
rraal
children
achiev
remiss
often
fragil
set
urgent
sct
mandatori
sever
option
could
consid
maintain
remiss
transplant
describ
experi
inotuzumab
ozogamicin
ino
bridg
transplant
pediatr
cohort
method
describ
three
pediatr
case
posit
rrall
second
remiss
treat
ino
singl
agent
rescu
treatment
unabl
receiv
chemotherapi
clinic
condit
ino
obtain
per
compassion
use
local
regul
inform
parent
consent
dose
cycl
day
day
cycl
day
dosag
adapt
patient
kg
case
year
old
boy
isol
bone
marrow
relaps
mainten
therapi
start
treatment
spanish
nation
relaps
protocol
admit
picu
week
induct
therapi
e
coli
sepsi
ventil
two
week
inotrop
support
need
present
seizur
picu
admiss
develop
tetraparesi
mri
electromyographi
compat
myopathi
due
prolong
use
muscl
relax
decid
multidisciplinari
meet
avoid
use
neurotox
drug
bone
marrow
complet
remiss
favor
patient
full
recoveri
transplant
appropri
donor
identifi
three
cycl
ino
administ
mud
perform
case
year
old
girl
isol
bone
marrow
relaps
mainten
therapi
refractori
induct
per
spanish
nation
relaps
protocol
combin
clofarabin
base
chemotherapi
administ
grade
toxic
hematolog
neurolog
also
suffer
sever
septic
episod
system
adenoviru
adv
infect
achiev
second
remiss
mrd
mud
identifi
decid
multidisciplinari
meet
previou
toxic
adv
infect
avoid
chemo
infect
resolv
support
second
remiss
haploident
transplant
one
cycl
ino
given
haploident
transplant
perform
case
month
old
girl
refractori
infant
spanish
protocol
administ
flag
myocet
salvag
chemotherapi
grade
hematolog
gastrointestin
toxic
sever
septic
episod
decid
multidisciplinari
meet
previou
toxic
avoid
chemotherapi
mrd
neither
mud
identifi
haploident
transplant
arrang
gave
one
dose
ino
haploident
transplant
perform
result
immedi
toxic
found
relat
ino
administr
nine
ot
eleven
dose
administ
day
bed
unit
three
patient
underw
transplant
complet
remiss
neg
minim
residu
diseas
excel
pre
sct
perform
statu
prophylact
defibrotid
given
everi
patient
case
develop
so
resolv
standard
treatment
conclus
ino
safe
cohort
could
consid
suitabl
option
bridg
transplant
pediatr
rrall
fragil
remiss
bad
toler
chemotherapi
clinic
trial
registri
non
applic
conflict
interest
na
l
hirszfeld
institut
immunolog
experiment
therapi
polish
academi
scienc
wroclaw
poland
lower
silesian
center
cellular
transplant
nation
bone
marrow
donor
registri
wroclaw
poland
background
issu
exhaust
tumour
infiltr
lymphocyt
gain
great
deal
interest
fuell
solid
scientif
data
restor
function
cell
block
receptor
membran
repres
exampl
fight
leukaemia
two
approach
employ
institut
donor
lymphocyt
inject
directli
bone
leukaem
infiltr
marrow
caviti
lower
risk
graftversushost
diseas
gvhd
direct
contact
mononuclear
cell
popul
blast
usual
low
level
ii
multikinas
inhibitor
block
outcom
itd
mutat
boost
independ
immun
function
patient
method
clinic
effect
monitor
highlight
thorough
observ
immun
environ
marrow
altogeth
intrabon
donor
lymphocyt
infus
ibdli
deliv
patient
sorafenib
use
overal
posit
effect
ib
inject
seen
howev
tempor
led
decreas
blast
count
restor
haematopoiesi
result
bodi
observ
follow
situat
gvhd
symptom
appear
exagger
present
patient
ibdlifrom
primari
observ
found
proport
cell
lymphocyt
higher
marrow
compar
blood
vs
p
high
proport
posit
lymphocyt
blood
even
preval
marrow
vs
seen
patient
lack
myeloblast
marrow
suffer
extramedullar
relaps
leukem
skin
lesion
howev
infiltr
cellsan
increas
lymphocyt
marrow
associ
welldocu
retreat
blast
marrow
addit
morpholog
lymphocyt
depict
activ
marrow
biopsi
blastlymphocyt
conjug
could
spottedconsecut
ib
inject
rather
decreas
increas
proport
exhaust
lymphocyt
marrow
vs
sorafenibreceiv
patient
parallel
decreas
proport
lymphocyt
vs
valu
regist
prior
sorafenib
treatment
marrow
infiltr
lymphocyt
coexpress
higher
proport
blood
vs
p
patient
sorafenib
develop
skin
lesion
alloreact
charact
conclus
spite
high
proport
lymphocyt
marrow
appar
preval
contribut
marrow
lymphocyt
antileukem
effect
implement
procedur
document
therefor
posit
cell
necessarili
associ
cell
poor
function
may
repres
presenc
activ
immun
respons
marrow
environ
leukem
blast
conflict
interest
author
declar
conflict
interest
regard
public
abstract
karolinska
institutet
oncolog
patholog
stockholm
sweden
karolinska
univers
hospit
transfus
medicin
clinic
immunolog
stockholm
sweden
background
car
cell
immunotherapi
demonstr
dramat
result
treatment
bcell
malign
chronic
lymphocyt
leukemia
cll
acut
lymphoblast
leukemia
sinc
cell
defect
characterist
patient
cll
compar
cell
patient
cll
healthi
donor
hd
subsequ
car
cell
produc
either
patient
hd
method
packag
cell
clone
produc
retrovir
vector
encod
second
gener
car
costimulatori
domain
use
studi
kindli
provid
prof
steven
rosenberg
nci
product
retrovir
supernat
car
cell
manufactur
perform
accord
publish
method
immunophenotyp
perform
use
monoclon
antibodi
direct
multipl
surfac
antigen
car
cell
detect
use
biotinspconjug
goat
antimous
specif
antibodi
car
transduc
cell
incub
effector
target
ratio
either
ngfr
autolog
b
cell
cll
cell
ebvtransform
b
cell
incub
monoclon
antibodi
direct
use
cell
surfac
stain
fixat
permeabilis
antibodi
tnf
experi
granzym
b
use
intracellular
stain
one
week
transduct
car
cell
stimul
restimul
day
later
addit
cultur
cell
day
car
cell
restimul
hour
cell
determin
express
cytokin
product
ngfr
cell
label
use
celltrac
violet
dye
cell
ad
ratio
car
transduc
cell
hour
cell
analyz
flow
cytometri
result
patient
cll
circul
cell
frequenc
within
lymphocyt
lower
compar
hd
patient
major
cell
significantli
enrich
effector
memori
compart
cell
frequent
termin
differenti
phenotyp
compart
howev
cell
frequenc
express
checkpoint
inhibitor
similar
patient
hd
retrovir
transduct
cell
express
car
construct
either
patient
hd
cell
show
similar
phenotyp
effector
memori
termin
differenti
specif
activ
kill
target
cell
secret
cytokin
ie
tnf
interestingli
frequenc
car
cell
produc
significantli
higher
cell
produc
patient
compar
produc
hd
true
use
either
autolog
b
cell
cell
target
cell
conclus
conclus
patient
cll
express
car
phenotyp
function
measur
express
cytokin
product
compar
hd
howev
increas
product
measur
studi
vitro
may
also
case
vivo
contribut
higher
risk
cytokin
releas
syndrom
patient
conflict
interest
noth
disclos
hospit
clinic
hematolog
barcelona
spain
hospit
clinic
immunolog
barcelona
spain
univers
barcelona
biomed
scienc
barcelona
spain
idibap
hematooncolog
barcelona
spain
josep
carrera
leukemia
research
institut
biomedicin
barcelona
spain
hospit
clinic
patholog
barcelona
spain
hospit
sant
joan
de
deu
hematolog
barcelona
spain
background
shown
car
perform
compet
preclin
studi
effect
compar
construct
current
use
clinic
next
step
set
infrastructur
procedur
take
clinic
stage
repres
big
challeng
rel
small
publicli
fund
institut
present
product
system
success
implement
hospit
clinic
barcelona
cell
product
system
includ
two
separ
process
largescal
lentiviru
product
ex
vivo
transduct
expans
cell
describ
valid
product
method
process
valid
test
method
largescal
lentiviru
cell
master
cell
bank
thaw
day
cell
expand
flask
cell
obtain
day
transfer
cell
factori
later
cell
transfect
use
mg
pei
mg
transfer
vector
mg
pmdlgprre
mg
prsvrev
mg
per
liter
viral
supernat
collect
day
centrifug
filter
mm
pvdf
membran
day
viral
supernat
concentr
ml
use
tangenti
flow
filtrat
hollow
fiber
kda
also
diafilt
use
pb
final
preserv
useex
vivo
transduct
expans
cell
leukoapheres
obtain
healthi
donor
obtain
inform
consent
use
amicu
devic
freseniu
kabi
minimum
cell
requir
cell
introduc
clinimac
prodigi
system
miltenyi
biotec
whole
process
carri
complet
close
steril
system
gmp
condit
cell
underw
magnet
posit
select
cultur
clinimac
prodigi
system
use
texmac
media
supplement
human
ab
serum
cell
immedi
activ
use
transact
gmp
grade
activ
cell
transduc
lentiviru
tcell
expans
continu
day
recommend
perfus
shake
condit
desir
number
cell
reach
result
lentivir
titer
qualiti
control
viral
titer
frozenconcentr
viru
rang
tuml
viral
supernat
lot
neg
bacterialfung
growth
endotoxin
mycoplasma
replicationcompet
lentiviru
rcl
viru
ident
also
confirm
pcr
amplif
princip
viru
product
valid
expans
time
vari
day
mean
total
cell
obtain
percentag
transduct
averag
time
cell
expans
termin
therefor
accept
criteria
reach
three
processesproduct
character
qualiti
control
see
tabl
conclus
develop
novel
cell
product
compos
mab
scfv
plu
signal
domain
although
clinimac
prodigi
disadvantag
compar
technolog
avail
shown
good
process
robust
reproduc
hand
allow
clinic
scale
cell
product
even
mediums
publicli
fund
institut
like
clinic
trial
registri
posit
fulfil
preclin
stage
demonstr
qualiti
reproduc
lentiviru
cell
product
system
product
system
current
use
recent
launch
phase
clinic
trial
eudract
relapsedrefractori
leukemia
lymphoma
hospit
de
barcelona
hospit
sant
joan
de
barcelona
spain
conflict
interest
sourc
fund
project
ari
isciii
univers
children
hospit
tuebingen
tuebingen
germani
univers
tuebingen
depart
immunolog
tuebingen
germani
background
wherea
immunotherapi
highriskrelaps
neuroblastoma
standard
antibodi
format
target
antigen
current
use
autologousallogen
stem
cell
transplant
sct
tcell
rare
address
effector
bispecif
antibodi
bring
tcell
close
proxim
target
activ
region
lack
fcdomain
trigger
adcc
cdc
investig
whether
bispecif
antibodi
ngcu
recogn
util
tcell
might
altern
therapeut
antibodi
mediat
cdc
adcc
nkcell
method
differ
antibodi
concentr
effector
target
ratio
e
evalu
use
xcellig
rtca
system
pbmc
healthi
donor
patient
allogeneicautolog
sct
ls
cell
line
cdc
evalu
use
autolog
serum
result
ngcu
show
enhanc
cytotox
compar
median
specif
lysi
hr
effector
healthi
pbmc
e
vs
ngcu
ngml
take
cdc
account
ad
autolog
serum
cytotox
drastic
increas
adcc
cdc
erad
target
hr
hr
e
howev
use
lower
e
ratio
lysi
remain
static
ngcu
median
lysi
hr
vs
ngcu
hr
target
complet
erad
ngcu
target
treat
still
prolifer
use
patient
pbmc
signific
lysi
construct
detect
depend
percentag
total
number
nkcell
patient
earli
sct
nkcell
repres
major
effector
produc
higher
lysi
wherea
later
associ
increas
tcell
count
ngcu
effect
conclus
ngcu
show
enhanc
cytotox
compar
even
lower
concentr
e
ratio
bispecif
design
repres
altern
classic
base
therapi
depend
differenti
recoveri
effector
cell
posttranspl
either
nkcell
base
tcell
base
antibodi
construct
might
result
optim
anti
tumor
activ
conflict
interest
none
author
anyth
disclos
tehran
univers
medic
scienc
tehran
iran
islam
republ
tarbiat
modarr
univers
biotechnolog
tehran
iran
islam
republ
background
recent
chimer
antigen
receptor
car
cell
therapi
provid
promis
approach
cancer
therapi
heavychain
antibodi
hcab
antibodi
found
camelida
lack
light
chain
antigen
bind
domain
camelid
hcab
consist
one
domain
term
nanobodi
term
inspir
small
size
evalu
perman
express
chimer
antigen
receptor
contain
specif
vhh
surfac
cell
activ
specif
car
cell
method
prsvrev
pmdlgprre
vector
transform
ecoli
purifi
use
mega
prep
kit
mn
antimuci
car
construct
contain
vhh
antimuci
hing
insert
transfer
vector
viru
packag
transfer
vector
contain
car
construct
along
helper
vector
transfect
cell
result
antimuci
construct
obtain
previou
studi
clone
vector
use
digestionlig
method
enzym
digest
sequenc
data
confirm
process
done
success
vector
transfect
cell
success
virus
produc
jurkat
cell
transduc
lentivirus
increas
prolifer
upon
cocultur
whit
muci
posit
cell
conclus
result
demonstr
constantli
express
chimer
antigen
receptor
contain
antimuci
vhh
also
recombin
receptor
abl
target
specif
antigen
muci
cell
surfac
promot
prolifer
engin
jurkat
cell
conflict
interest
author
report
conflict
interest
dmitri
rogachev
nation
medic
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
patient
posttranspl
acut
leukemia
relaps
hardli
curabl
outcom
extrem
poor
effect
standard
chemotherapi
donor
lymphocyt
infus
limit
possibl
altern
standard
chemotherapi
dli
use
inhibitor
may
potenti
allogen
immun
respons
order
har
graftversusleukemia
effect
method
analyz
retrospect
patient
age
year
receiv
therapi
hsct
cohort
includ
patient
acut
myeloid
leukemia
pt
acut
lymphoblast
leukemia
pt
hepatosplen
gammadelta
cell
lymphoma
moment
hsct
patient
advanc
stage
diseas
complet
remiss
posit
minim
residu
diseas
patient
receiv
allohsct
patient
haploident
donor
patient
hlaident
sibl
day
hsct
patient
clinic
molecular
remiss
patient
develop
grade
acut
gvhd
skin
gi
impair
averag
time
relaps
day
bone
marrow
relaps
detect
patient
patient
molecular
relaps
patient
receiv
inject
nivolumab
dose
mgkg
one
patient
aml
receiv
inject
nivolumab
alreadi
remiss
second
hsct
high
risk
relaps
result
advers
event
regist
patient
two
patient
develop
immun
meningoenceph
pt
grade
immunemedi
liver
toxic
pt
grade
skin
gvhd
flare
immun
fever
regist
pt
four
patient
requir
prolong
system
immunosuppress
therapi
control
immunemedi
advers
effect
mortal
relat
checkpointinhibitor
toxic
regist
one
patient
develop
progress
liver
diseas
bone
marrow
aspir
done
evalu
effici
therapi
first
inject
nivolumab
seven
patient
evalu
respons
six
patient
respond
therapi
averag
time
diseas
progress
day
stabl
remiss
achiev
patient
receiv
inject
nivolumab
fullblown
relaps
hsct
one
year
later
patient
remain
clinic
molecular
remiss
although
immunemedi
liver
damag
progress
endstag
liver
diseas
patient
aml
receiv
inject
nivolumab
alreadi
remiss
month
therapi
remain
clinic
molecular
remiss
conclus
limit
experi
suggest
use
inhibitor
allohsct
associ
signific
toxic
prospect
studi
requir
establish
safeti
effici
approach
conflict
interest
author
declar
compet
interest
abstract
previous
publish
hospit
clinic
hematolog
barcelona
spain
hospit
clinic
immunolog
barcelona
spain
univers
barcelona
depart
biomed
scienc
barcelona
spain
idibap
hematooncolog
barcelona
spain
josep
carrera
leukemia
research
institut
barcelona
spain
hospit
clinic
patholog
barcelona
spain
hospit
sant
joan
de
deu
hematolog
barcelona
spain
background
chimer
antigen
receptor
cell
shown
remark
respons
treatment
relapsedrefractori
hematolog
malign
across
sever
clinic
trial
lead
consolid
immunotherapi
one
build
block
modern
cancer
therapi
present
preclin
work
conduct
test
efficaci
specif
cell
name
cell
prepar
lentivir
transduct
construct
compris
scfv
plu
hing
transmembran
region
moieti
method
vitro
cytotox
assay
perform
use
untransduc
ut
cell
cocultur
tumor
target
cell
line
posit
neg
primari
ball
tumor
cell
differ
effector
target
e
ratio
cytotox
determin
number
surviv
target
cell
identifi
neg
flow
cytometri
cocultur
supernat
analyz
cytokin
product
elisa
cell
prolifer
respons
antigen
measur
use
cfse
assay
vivo
assay
perform
use
threemonth
old
nsg
mice
infus
intraven
tumor
cell
x
cellsmic
express
greenfluoresc
protein
gfp
luciferas
mice
randomli
alloc
infus
either
cell
x
ut
cell
x
cellsmic
vehicl
tumor
growth
evalu
weekli
bioluminisc
imag
hamamatsu
detector
intraven
administr
dluciferin
result
detect
express
construct
signific
proport
cell
shown
figur
cell
almost
complet
elimin
cocultur
even
low
e
ratio
effector
cell
everi
target
cell
similar
cytotox
efficaci
demonstr
primari
ball
cell
shown
figur
cell
specif
shown
cocultur
neg
cell
line
kill
appreci
also
signific
efficaci
differ
seen
vitro
cytotox
assay
comparison
cell
current
use
clinic
cytokin
product
measur
effectortarget
cell
cocultur
show
cell
produc
signific
increas
compar
ut
cell
shown
figur
diseas
progress
clearli
observ
period
week
follow
cell
infus
cell
group
ut
cell
group
howev
diseas
detect
mice
belong
group
also
overal
surviv
significantli
improv
treat
mice
compar
vehicl
ut
cell
group
p
valu
respect
conclus
cell
show
robust
specif
cytotox
prolif
effect
posit
cell
cell
exposur
cell
induc
robust
product
proinflammatori
cell
cytotox
compar
cell
current
approv
fda
cell
could
also
elimin
leukemia
cell
xenograph
mous
model
prolong
surviv
conflict
interest
conflict
interest
relat
studi
sourc
fund
project
ari
isciii
seoul
st
mari
hospit
cathol
univers
korea
colleg
medicin
institut
translat
research
molecular
imag
seoul
korea
republ
background
oral
mucos
om
common
complic
cancer
patient
undergo
anticanc
treatment
despit
clinic
econom
consequ
om
drug
avail
fundament
control
show
highmobl
group
box
danger
signal
act
potent
innat
immun
mediat
play
critic
role
pathogenesi
om
method
investig
treatment
om
blockad
use
amin
mice
administ
mgkg
intraperiton
ip
daili
day
day
induc
om
mgkg
intraven
iv
phosphatebuff
salin
pb
administ
daili
day
result
amelior
basallay
epitheli
cell
death
ulcer
size
om
induc
chemotherapi
radiotherapi
protect
effect
mediat
inhibit
releas
downregul
mitochondri
oxid
stress
addit
inhibit
releas
il
well
express
modul
apoptosi
puma
excess
inflammatori
microenviron
includ
nuclear
factor
kb
nfkb
pathway
conclus
find
suggest
play
key
role
pathogenesi
om
therefor
blockad
may
novel
therapeut
strategi
om
conflict
interest
work
support
grant
korea
healthcar
technolog
research
develop
project
ministri
health
welfar
famili
affair
republ
korea
hannov
medic
school
hemalotogi
oncolog
stem
cell
transplant
hannov
germani
hannov
medic
school
institut
cellular
therapeut
gmp
core
facil
hannov
germani
hannov
medic
school
institut
transfus
medicin
hannov
germani
king
colleg
london
cell
gene
therapi
king
london
unit
kingdom
univers
heidelberg
gmpcorefacil
clinic
intern
medicin
heidelberg
germani
background
acut
myeloid
leukemia
aml
patient
morpholog
complet
remiss
cr
posit
measur
residu
diseas
mrd
poor
prognosi
mrd
associ
immun
suppress
process
predispos
high
risk
relaps
therefor
novel
immun
therapi
counteract
immun
suppress
lead
longterm
control
genet
heterogen
leukemia
clone
warrant
broadli
studi
antigen
leukemia
lymphoma
malign
recent
promis
result
obtain
phase
ii
trial
investig
effect
vaccin
ex
vivo
cultiv
dc
electropor
mrna
postremiss
treatment
aml
patient
high
risk
relaps
anguil
et
al
blood
method
propos
novel
dc
modal
advanc
therapeut
medicin
product
atmp
consist
monocyt
manipul
hour
integrasedefect
lentivir
vector
idlv
cryopreserv
upon
cell
thaw
vector
express
gmcsf
ifna
result
vivo
selfdifferenti
monocyt
highli
viabl
activ
induc
dendrit
cell
idc
studi
mice
human
human
stem
cell
obtain
adult
donor
cord
blood
immun
donor
idc
express
hcmv
antigen
show
effect
biodistribut
adjac
distal
lymph
node
promot
acceler
reconstitut
matur
function
b
cell
salguero
et
al
journal
immunolog
upscal
product
idlv
gmpcompliant
condit
valid
sundarasetti
et
al
journal
translat
medicin
safeti
longterm
week
studi
immun
human
mice
show
develop
malign
sundarasetti
et
al
american
journal
patholog
result
tricistron
vector
coexpress
gmcsf
ifna
truncat
lack
zinc
finger
domain
construct
full
vector
sequenc
determin
express
transgen
transduc
cell
confirm
elisa
gmcsf
ifna
flow
cytometri
analys
day
cultur
monocyt
transduc
idlv
selfdifferenti
viabl
idctwt
coexpress
doubl
posit
show
secret
gmcsf
ngml
ifna
ngml
cryopreserv
thaw
high
viabil
vitro
observ
week
conclus
vitro
potenc
assay
ongo
determin
activ
autolog
cell
antileukemia
respons
human
mice
immun
gener
chromatographypurifi
idlv
vector
primeboost
immun
mice
maintain
day
week
evalu
immun
respons
antileukemia
respons
toxic
clinic
trial
explor
autom
system
gmp
valid
cell
manufactur
conflict
interest
intern
patent
pend
induc
dendrit
cell
use
thereof
hospit
de
barcelona
depart
hematolog
barcelona
spain
hospit
de
barcelona
depart
dermatolog
barcelona
spain
hospit
de
barcelona
depart
patholog
barcelona
spain
hospit
de
barcelona
depart
immunolog
barcelona
spain
josep
carrera
leukemia
research
institut
depart
biomedicin
barcelona
spain
ciberonc
barcelona
spain
background
chimer
antigen
receptor
cart
cell
therapi
major
breakthrough
treatment
relapsedrefractori
hematolog
malign
cart
cell
target
hematolog
malign
show
promis
result
across
sever
clinic
trial
worldwid
remain
commonli
use
target
date
even
certain
advers
effect
still
yet
observ
remain
poorli
understood
cart
cell
usual
prepar
autolog
cell
even
gener
allogen
hct
recipi
cart
cell
mediat
gvhd
describ
far
present
case
male
ball
whose
diseas
relaps
month
hlaident
sibl
allohct
receiv
cell
modifi
compos
link
costimulatori
domain
experienc
gener
skin
rash
coincid
prolifer
peak
method
skin
rash
figur
start
day
infus
x
cell
kg
skin
biopsi
perform
histolog
analysi
carri
use
usual
stain
techniqu
addit
immunohistochem
panel
detect
cell
followup
carri
skin
examin
daili
basi
also
daili
analysi
perform
blood
count
biochem
marker
cell
prolifer
leukocyt
count
crp
ferritin
level
also
cell
measur
use
flow
cytometri
hospit
admiss
result
histopatholog
evalu
skin
biopsi
show
discret
chang
spongiot
dermat
evid
interfac
injuri
presenc
dermi
slight
perivascular
lymphocyt
infiltr
detect
lymphocyt
activ
appear
immunohistochemistri
stain
posit
neg
day
onward
clinic
biochem
sign
cytokin
releas
syndrom
cr
also
evid
patient
develop
daili
fever
increas
level
crp
ferritin
cell
also
start
rise
peak
circul
lymphocyt
day
clinic
biochem
manifest
cr
amelior
day
cell
could
longer
detect
flow
cytometri
patient
diarrhea
sign
liver
inflamm
skin
rash
improv
topic
steroid
conclus
particular
case
even
though
cell
technic
allogen
extract
patient
complet
donor
chimer
previou
histori
gvhd
therefor
possibl
cutan
gvhd
unlik
report
cutan
reaction
magnitud
infus
cell
yet
mani
uncertainti
regard
mechan
lead
phenomenon
conclus
sign
gvhd
sampl
examin
may
link
prolifer
tissu
injuri
mechan
classic
gvhd
clinic
trial
registri
patient
particip
recent
launch
clinic
trial
eudract
relapsedrefractori
leukemia
lymphoma
hospit
clinic
hospit
sant
joan
de
deu
barcelona
wwwclinicaltrialsregistereu
conflict
interest
conflict
interest
relat
studi
sourc
fund
project
ari
isciii
children
hospit
soochow
univers
suzhou
china
background
object
refractori
acut
leukemia
al
show
resist
chemotherapi
result
high
minim
residu
diseas
mrd
situat
patient
easili
relaps
hematopoiet
stem
cell
transplant
hsct
recommend
reduc
mrd
optim
condit
regimen
hsct
improv
outcom
hsct
refractori
malign
blood
disord
studi
evalu
safeti
bridg
pretreat
regimen
decitabin
chiatai
tianq
pharmaceut
group
pediatr
hsct
children
refractori
hematolog
malign
efficaci
hsct
pediatr
hematolog
malign
method
retrospect
analyz
clinic
data
case
myelodysplast
syndrom
case
acut
myeloid
leukemia
relaps
case
acut
lymphoblast
leulkemia
case
myeloprolif
disord
children
hospit
soochow
univers
given
decitabin
bridg
pretreat
regimen
hsct
march
januari
safeti
decitabin
evalu
term
engraft
grade
graft
versu
host
diseas
gvhd
side
effect
hematolog
nonhematolog
system
result
eleven
case
children
enrol
studi
succeed
implant
four
case
show
grade
iv
hematolog
toxic
case
grade
iii
hematolog
toxic
case
grade
ii
hematolog
toxic
none
suffer
infect
druginduc
liver
damag
renal
impair
decitabin
administr
case
show
ii
degre
gastrointestin
impair
case
show
iii
degre
gastrointestin
impair
four
case
transplant
haploid
donor
iv
grade
gastrointestin
acut
gvhd
amont
one
case
diagnos
super
agvhd
die
intracrani
hemorrhag
day
hsct
follow
nov
patient
surviv
conclus
decitabin
pretreat
safe
combin
condit
regimen
allogen
hsct
allohsct
effect
treatment
pediatr
refractori
hematolog
malign
conflict
interest
author
declar
conflict
interest
work
declar
commerci
associ
interest
repres
conflict
interest
connect
work
submit
abstract
previous
publish
nonhematopoiet
stem
cell
fondazion
ircc
policlinico
san
matteo
pavia
itali
univers
pavia
pavia
itali
background
immunoglobulin
lightchain
al
amyloidosi
disord
caus
misfold
light
chain
produc
clonal
popul
plasma
cell
bone
marrow
deposit
tissu
caus
organ
dysfunct
recent
report
microenviron
defect
may
either
lead
favor
pathogenesi
differ
hematolog
disord
sinc
mesenchym
stromal
cell
msc
repres
one
key
compon
bm
nich
present
studi
evalu
msc
al
patient
method
msc
bone
marrow
bm
al
patient
bm
healthi
donor
hd
expand
follow
standard
vitro
cultur
procedur
avanzini
et
al
leukemia
msc
character
plastic
adhes
morpholog
clonogen
capac
defin
plate
mnc
immunophenotyp
flowcytometri
adipogen
osteogen
differenti
prolifer
capac
defin
popul
doubl
pd
log
harvest
cellsseed
cell
bm
mononuclear
cell
mnc
al
patient
cultur
almsc
immunomagnet
deplet
result
msc
isol
patient
hd
morpholog
immunophenotyp
osteogen
adipogen
differenti
clonogen
capac
mean
vs
al
hd
respect
prolif
capac
cpd
hdmsc
black
line
almsc
broken
line
grey
line
compar
msc
al
patient
hd
vs
al
hd
respect
among
patient
group
clonogen
capac
significantli
higher
almsc
mean
respect
almsc
arrest
growth
number
harvest
cell
number
plate
cell
significantli
earlier
passag
compar
hdmsc
median
rang
vs
rang
respect
conclus
preliminari
data
suggest
discrep
almsc
hdmsc
whether
featur
involv
pathophysiolog
diseas
caus
diseas
deserv
investig
conflict
interest
noth
disclos
univers
hospit
frankfurt
goeth
univers
depart
children
adolesc
divis
stem
cell
transplant
immunolog
frankfurt
main
germani
institut
patholog
goeth
univers
frankfurt
main
germani
background
hematopoiet
cell
transplant
cure
patient
sever
form
nonmalign
hematopoiet
diseas
nmhd
thalassemia
major
sickl
cell
diseas
congenit
neutropenia
studi
ask
whether
mesenchym
stromal
cell
msc
gener
readili
avail
bone
marrow
backup
patient
nmhd
function
equival
msc
healthi
donor
may
use
autolog
cellbas
therapi
treat
posttranspl
complic
graft
failur
gvhd
osteonecrosi
method
gener
msc
use
bone
marrow
bm
sampl
pediatr
patient
year
old
six
patient
suffer
thalassemia
major
tm
four
sickl
cell
diseas
scd
two
sever
congenit
neutropenia
scn
control
group
serv
msc
gener
pediatr
donor
year
old
assess
frequenc
progenitor
cell
msc
cfuf
per
bmmnc
well
per
ml
bm
msc
phenotyp
prolifer
capac
doubl
timedt
well
differenti
potenti
osteoblast
adipocyt
chondrocyt
allosuppress
effect
evalu
mean
mix
lymphocyt
reaction
mlr
mlr
assess
percentag
treg
level
result
bone
marrow
tm
patient
possess
significantli
higher
number
nucleat
cell
bmmnc
ml
bm
compar
control
vs
p
higher
number
mnc
contribut
mostli
higher
number
bmmnc
ml
bm
whole
group
nmhd
patient
vs
control
p
higher
number
bmmnc
result
higher
number
cfufml
bm
compar
control
diseas
evalu
number
cfuf
per
bmmnc
show
bmmnc
scd
patient
gener
cfuf
tmbmmnc
vs
p
despit
higher
number
cfuf
scd
patient
differ
compar
control
reach
signific
p
patient
msc
show
normal
phenotyp
equal
prolifer
capac
one
pd
per
hour
compar
control
group
hour
differenti
three
lineag
control
group
except
msc
tm
patient
differenti
weakli
adipocyt
mlr
immunosuppress
potenti
nmhd
msc
significantli
differ
control
group
vs
howev
effect
impair
tmmsc
p
vs
control
msc
indomethacin
inhibitor
synthesi
abl
partial
revers
effect
msc
supernat
mlr
patient
msc
amount
significantli
differ
compar
healthi
donor
ngml
vs
ngml
mlr
msc
patient
effici
control
msc
expans
tregulatori
cell
conclus
result
suggest
msc
patient
nmhd
except
msc
patient
tm
may
use
autolog
cellbas
therapi
treat
posttranspl
complic
graft
failur
gvhd
osteonecrosi
conflict
interest
author
noth
disclos
china
medic
univers
hospit
hematolog
oncolog
taichung
taiwan
republ
china
china
medic
univers
hospit
medic
research
taichung
taiwan
republ
china
china
medic
univers
hospit
radiat
oncolog
taichung
taiwan
republ
china
background
total
bodi
irradi
tbi
associ
mani
late
complic
due
radiat
injuri
normal
cell
specif
normal
stem
cell
mesenchym
stromal
stem
cell
msc
cell
respons
adipogenesi
osteogenesi
import
support
hematopoiesi
nevertheless
whole
pictur
tbi
affect
characterist
msc
relev
clinic
implic
remain
unknown
method
bone
marrowderiv
msc
bmmsc
isol
normal
adult
irradi
twice
daili
consecut
three
day
regimen
ident
use
tbicondit
hsct
morpholog
surfac
marker
prolifer
potenti
apoptosi
dna
damag
comet
assay
abil
adipocyt
osteocyt
differenti
hematopoiesissupport
function
cocultur
mobil
peripher
blood
mononuclear
cell
msc
day
evalu
longterm
cultur
initi
cell
ltcic
count
cytogenet
irradi
bmmsc
examin
compar
nonirradi
control
sinc
clonal
cytogenet
abnorm
found
irradi
msc
carcinogen
evalu
vitro
transform
assay
vivo
implant
irradi
msc
onto
balbc
nude
mice
look
tumor
format
parallel
vitro
studi
pair
bmmsc
harvest
transplant
recipi
tbi
also
examin
way
valid
find
vitro
experi
result
irradi
nonirradi
msc
share
similar
morpholog
surfac
marker
howev
irradi
msc
show
much
lower
prolif
abil
figur
higher
percentag
apoptosi
figur
b
cell
comet
tail
much
lower
differenti
potenti
figur
oil
red
stain
adipogen
von
kossa
stain
osteogen
differenti
respect
irradi
also
induc
clonal
cytogenet
abnorm
persist
prolong
ex
vivo
cultur
nevertheless
transform
assay
show
coloni
format
figur
lung
cancer
cell
line
posit
control
patholog
examin
balbc
nude
mice
show
tumor
format
observ
day
hematopoiesissupport
function
similar
irradi
nonirradi
msc
figur
e
rel
fold
chang
ltcic
number
pair
bmmsc
harvest
transplant
recipi
tbi
condit
show
markedli
decreas
prolif
differenti
abil
tbiexpos
msc
cytogenet
test
pairedmsc
done
recipi
sexmismatch
tbicondit
hsct
posttranspl
msc
recipientorigin
clonal
cytogenet
abnorm
could
identifi
case
includ
case
clonal
evolut
conclus
tbi
affect
hematopoiesissupport
function
msc
reflect
fact
engraft
problem
tbibas
condit
howev
tbi
drastic
impair
prolifer
differenti
msc
like
contribut
acquir
lipodystrophi
bone
growth
retard
specif
children
receiv
tbibas
hsct
furthermor
although
incid
second
soft
tissu
malign
tbibas
hsct
low
support
observ
low
carcinogen
irradi
msc
studi
impair
chromosom
integr
irradi
msc
pose
real
risk
increas
incid
second
soft
tissu
malign
patient
compar
gener
popul
clinic
trial
registri
na
conflict
interest
noth
disclos
author
univers
hospit
frankfurt
goeth
univers
depart
children
adolesc
divis
stem
cell
transplant
immunolog
frankfurt
main
germani
german
red
cross
blood
center
frankfurt
institut
transfus
medicin
immunohematolog
frankfurt
main
germani
dr
margaret
fischerboschinstitut
clinic
pharmacolog
stuttgart
germani
background
thu
far
report
genet
signatur
subset
mesenchym
stromal
cell
msc
current
studi
assess
molecular
fingerprint
global
gene
express
mscsubset
deriv
posit
select
bone
marrow
mononuclear
cell
compar
transcriptom
msc
gener
nonselect
bone
marrow
mononuclear
cell
pamsc
method
expand
pamsc
three
donor
passag
msc
type
compar
gene
express
microarray
experi
raw
intens
data
extract
featur
extract
output
file
agil
whole
human
genom
oligo
microarray
agil
technolog
inc
use
rosetta
resolv
softwar
rosetta
inpharmat
llc
set
downregul
gene
pamsc
hierarch
cluster
display
heatmap
imag
use
multipl
experi
viewer
softwar
report
identifi
discriminatori
gene
analysi
annot
inform
gene
ontolog
go
provid
inform
molecular
function
well
variou
pathway
resourc
inform
involv
biolog
signal
pathway
differ
sampl
group
mean
pamsc
assess
student
ttest
twotail
equal
varianc
report
consid
differenti
express
pass
filter
criteria
uncorrect
pvalu
less
fold
chang
differ
least
downregul
mean
sampl
group
compar
pamsc
sampl
group
result
discriminatori
gene
analysi
dga
demonstr
gene
upregul
gene
downregul
compar
pamsc
upregul
gene
primarili
cell
surfac
molecul
particularli
etc
highest
differ
magnitud
lower
express
gene
encod
cell
surfac
molecul
compon
cytoskeleton
includ
among
other
addit
function
group
analysi
reveal
highli
express
gene
significantli
associ
extracellular
matrix
cell
adhes
process
gene
lower
express
pamsc
mainli
associ
differenti
particularli
known
cell
involv
immunoregulatori
process
follow
categori
significantli
enrich
cell
prolifer
differenti
innat
immun
inflamm
tcell
immun
receptor
signal
includ
kinasephosphatas
signal
particularli
sapsign
cascad
angiogenesi
set
downregul
gene
show
signific
member
pathway
consist
find
function
process
signal
pathway
tgfbeta
wnt
affect
may
relat
alter
cytoskeleton
prolifer
addit
cytokinechemokin
signal
pathway
significantli
enrich
confirm
aforement
alter
express
immunoregulatori
molecul
conclus
result
may
therefor
explain
genet
basi
function
differ
pamsc
concern
prolif
differenti
engraftmentpromot
properti
conflict
interest
author
noth
disclos
paediatr
issu
king
faisal
hospit
research
center
pediatr
hematologyoncolog
riyadh
saudi
arabia
alfais
univers
colleg
medicin
riyadh
saudi
arabia
king
faisal
specialist
hospit
research
center
pho
riyadh
saudi
arabia
background
juvenil
myelomonocyt
leukemia
jmml
rare
type
leukemia
affect
infant
earli
childhood
incid
rate
per
million
per
year
character
aggress
clinic
behavior
median
surviv
month
left
untreat
current
hematopoiet
stem
cell
transplant
hsct
cur
treatment
avail
howev
success
limit
engraft
failur
earli
relaps
report
outcom
patient
jmml
underw
hsct
institut
last
year
method
medic
record
children
fulfil
intern
juvenil
myelomonocyt
leukaemia
work
group
criteria
diagnosi
jmml
underw
hsct
institut
januari
decemb
review
result
outcom
children
male
femal
jmml
given
unmanipul
hsct
prepar
regimen
includ
busulfan
cyclophosphamid
patient
addit
etoposid
fifteen
case
one
patient
receiv
busulfan
fludarabin
donor
hlaident
sibl
unrel
cord
blood
mismatch
famili
member
splenectomi
perform
hsct
children
twenti
patient
receiv
chemotherapi
frontlin
treatment
three
patient
activ
diseas
time
transplant
despit
chemotherapi
engraft
document
eighteen
patient
wherea
graft
failur
occur
four
three
receiv
hlamismatch
ucb
six
patient
relaps
includ
three
patient
activ
diseas
hsct
five
patient
one
develop
acut
gvhd
long
term
survivor
five
four
patient
succumb
diseas
recurr
transplantrel
complic
respect
total
patient
surviv
cr
median
followup
year
rang
year
relaps
observ
five
patient
subsequ
succumb
diseas
progress
transplant
relat
mortal
occur
four
patient
overal
surviv
year
probabl
overal
surviv
children
given
hsct
either
familyrel
donor
ucb
respect
p
overal
surviv
poorli
associ
age
year
platelet
count
diagnosi
activ
diseas
hsct
respect
conclus
result
show
two
third
jmml
patient
could
potenti
cure
allogen
hsct
factor
age
platelet
count
diagnosi
diseas
statu
transplant
statist
associ
poorer
outcom
diseas
recurr
remain
major
caus
treatment
failur
novel
strategi
lower
risk
relaps
warrant
conflict
interest
noth
disclos
asan
medic
center
children
hospit
pediatr
seoul
korea
republ
background
allogen
hematopoiet
stem
cell
transplant
hsct
curabl
approach
myelodysplast
syndrom
md
howev
limit
data
avail
focus
children
studi
evalu
outcom
hsct
childhood
md
singl
center
method
thirtysix
patient
md
underw
allogen
hsct
asan
medic
center
children
hospit
amcch
decemb
septemb
patient
diagnos
base
criteria
time
transplant
low
grade
md
refractori
anemia
refractori
cytopenia
multilineag
dysplasia
refractori
cytopenia
childhood
advanc
md
refractori
anemia
excess
patient
blast
pb
bm
time
transplant
exclud
cytogenet
risk
group
stratifi
accord
revis
ipss
good
intermedi
poor
poor
condit
regimen
gvhd
prophylaxi
support
care
accomplish
accord
amcch
protocol
final
followup
visit
endpoint
analysi
conduct
novemb
result
median
age
transplant
patient
male
femal
year
rang
median
time
diagnosi
transplant
month
rang
five
patient
advanc
md
receiv
amltyp
chemotherapi
prior
transplant
ten
transplant
perform
thirti
two
patient
achiev
engraft
median
time
engraft
absolut
neutrophil
count
platelet
day
respect
grade
ii
iii
acut
gvhd
occur
patient
patient
develop
grade
iv
acut
gvhd
extens
chronic
gvhd
occur
patient
median
followup
month
rang
probabl
ef
os
year
patient
respect
four
patient
die
transplantrel
caus
lead
trm
year
year
patient
low
grade
md
repres
significantli
higher
os
compar
advanc
md
vs
ef
trm
differ
two
group
univari
analysi
identifi
diseas
statu
md
year
transplant
variabl
affect
os
multivari
analysi
patient
transplant
associ
lower
os
ci
among
patient
advanc
md
os
improv
accord
time
transplant
vs
nine
patient
underw
haploident
hsct
ric
regimen
low
grade
md
advanc
md
patient
except
one
achiev
sustain
engraft
aliv
remiss
time
analysi
conclus
studi
demonstr
allogen
hsct
feasibl
treatment
option
childhood
md
especi
patient
low
grade
md
outcom
patient
advanc
md
improv
time
furthermor
haploident
hsct
ric
regimen
could
realist
altern
children
md
conflict
interest
jae
yoo
noth
disclos
cansearch
research
laboratori
univers
geneva
faculti
medicin
geneva
switzerland
univers
hospit
genevaunivers
geneva
genev
switzerland
wroclaw
medic
univers
wroclaw
poland
oulu
univers
hospit
oulu
finland
univers
helsinki
children
hospit
helsinki
finland
univers
children
hospit
basel
basel
switzerland
st
anna
children
hospit
vienna
austria
robert
pari
franc
univers
hospit
frankfurt
frankfurt
germani
ospedal
san
gerardo
monza
itali
background
chemotherapyinduc
nausea
vomit
cinv
frequent
concern
oncolog
patient
antineoplast
treatment
lead
reduc
qualiti
life
implement
adequ
prophylaxi
base
evidencebas
guidelin
cinv
could
improv
despit
guidelin
pediatr
oncolog
recommend
lack
hsct
children
present
survey
intend
assess
current
practic
regard
antiemet
prophylaxi
across
european
pediatrichsct
center
part
taskforc
ebmtpdwp
aim
improv
support
care
children
hsct
method
standard
questionnair
sent
ebmt
center
contain
list
wellknown
condit
regimen
use
allogen
autolog
hsct
center
ask
classifi
local
use
regimen
accord
emetogen
potenti
indic
antiemet
drug
employ
prophylaxi
case
accord
local
practic
emetogen
classif
compar
current
recommend
oncolog
drug
dosebas
avail
standard
oper
procedur
sop
antiemet
prophylaxi
hsct
set
also
assess
result
center
repli
declar
use
differ
regimen
median
regimen
per
center
total
regimen
use
least
center
includ
analysi
busulfan
bu
cyclophosphamid
cy
bucymelphalan
mel
frequent
use
across
center
regard
emetogen
potenti
regimen
classifi
moder
emetogen
antimemet
drug
antagonist
use
regimen
classifi
highli
moderatli
emetogen
low
emetogen
potenti
regim
high
emetogen
potenti
second
drug
ad
case
moder
one
highli
emetogen
regimen
lorazepam
dexamethason
prefer
appli
medic
wherea
regimen
moder
potenti
dimenhydrin
prefer
base
current
recommend
overal
rate
discord
classif
emetogen
potenti
center
declar
sop
avail
analysi
across
sop
disagr
notic
dispar
criteria
emetogen
potenti
bu
mel
cy
dose
drugdrug
interact
ddi
dexamethason
contraind
eg
aml
hsct
cn
tumor
conclus
current
guidelin
pediatr
oncolog
recommend
antagonist
everi
patient
receiv
least
lowli
emetogen
regimen
patient
receiv
moder
emetogen
condit
would
benefit
ad
dexamethason
receiv
higli
emotogen
regimen
third
prophylact
medic
associ
otherwis
complianc
practic
seem
low
hsct
set
high
level
disagr
emetogen
classif
might
explain
degre
discord
concern
use
dexamethason
potenti
ddi
may
also
contribut
assess
hurdl
applic
current
recommend
may
allow
adapt
hsct
set
improv
qualiti
life
patient
conflict
interest
author
declar
conflict
interest
schneider
children
medic
center
israel
pediatr
oncolog
petah
tikva
israel
schneider
children
medic
center
israel
oncolog
petah
tikva
israel
background
stem
cell
transplant
sct
frighten
adult
patient
young
children
anticip
unknown
add
stress
mani
children
famili
experi
cusp
admiss
transplant
unit
onlin
interact
tool
develop
mani
center
facilit
age
appropri
prepar
patient
rigor
sct
method
develop
decidedli
lowtech
tool
book
would
permit
children
parent
share
read
experi
transmit
inform
medic
psychosoci
challeng
children
age
year
sibl
experi
sct
period
complex
process
sct
told
cultur
neutral
narr
perspect
teddybear
undergo
sct
experi
side
effect
isol
part
parcel
experi
sct
result
book
bear
get
sick
written
physician
consult
psychologist
social
worker
busi
pediatr
sct
unit
tell
stori
bear
must
leav
home
forest
receiv
treatment
malign
diseas
enter
previous
unknown
world
transplant
book
illustr
soft
warm
imag
discuss
common
question
parent
children
often
rais
stori
follow
process
donor
searchselect
pretranspl
condit
prolong
isol
separ
famili
friend
side
effect
lifestyl
chang
address
forthright
gentl
ageappropri
manner
children
caregiv
use
book
platform
develop
dialogu
facilit
cope
long
often
pain
ordeal
procedur
transplant
explain
use
simpl
metaphor
children
relat
origin
written
hebrew
present
english
translat
book
initi
accept
modal
hand
famili
enthusiast
posit
conclus
enhanc
parentchild
commun
aid
book
design
help
lessen
anxieti
advanc
admiss
stem
cell
unit
copi
book
view
websit
conflict
interest
noth
disclos
hospit
jesu
stem
cell
transplant
unit
madrid
spain
hospit
jesu
blood
bank
madrid
spain
background
hematopoiet
transplant
lymphocyt
inoculum
play
determin
role
promot
hematopoiesi
transfer
immun
pathogen
act
mediat
graftversusleukemia
effect
gvl
howev
also
respons
graftversushost
diseas
gvhd
main
caus
posttranspl
morbid
mortal
deplet
ra
lymphocyt
elimin
naiv
lymphocyt
inoculum
aim
conserv
gvl
without
produc
gvhd
method
sinc
april
patient
boy
girl
median
age
year
undergon
allogen
hematopoiet
transplant
hla
donor
ident
deplet
indic
transplant
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
myelodysplasia
medullari
aplasia
donor
familiar
case
unrel
condit
regimen
fludarabin
busulfan
thiotepa
median
cell
infus
x
kg
day
program
infus
kg
lymphocyt
perform
result
patient
graft
median
leukocyt
l
platelet
l
engraft
time
day
respect
one
patient
develop
acut
gvhd
grade
patient
develop
chronic
gvhd
immun
reconstitut
earli
rapid
cell
subset
see
figur
patient
relaps
far
patient
myelodysplasia
develop
aml
receiv
transplant
die
relaps
case
toxic
mortal
eventfre
surviv
sle
median
followup
month
present
patient
aliv
immunosuppress
treatment
well
conclus
allogen
transplant
lymphocyt
ra
deplet
result
encourag
result
low
incid
acut
chronic
gvhd
preserv
gvl
effect
infus
ra
donor
lymphocyt
conflict
interest
none
author
anyth
disclos
children
medic
center
tehran
univers
medic
scienc
depart
pediatr
stem
cell
transplant
tehran
iran
islam
republ
background
hematopoiet
stem
cell
transplant
hsct
pediatr
patient
start
iran
first
part
joint
program
adult
patient
base
adult
gener
hospit
affili
tehran
univers
medic
scienc
pediatr
team
move
exclus
independ
depart
children
medic
center
cmc
largest
children
hospit
iran
countri
pediatr
center
excel
sinc
septemb
new
depart
serv
countri
hsct
perform
children
follow
transit
diseasescap
patient
transplant
show
chang
compar
roughli
ten
year
earlier
method
studi
yearli
epidemiolog
profil
patient
underw
hsct
cmc
compar
data
august
result
compar
two
time
period
slight
decreas
annual
number
patient
transplant
seen
vs
larg
due
fact
new
depart
need
technic
prepar
complet
first
month
signific
differ
patient
sex
age
distribut
two
time
period
tabl
although
inherit
abnorm
erythrocyt
still
lead
indic
hsct
reduct
rate
patient
occur
establish
new
depart
hand
mark
increas
seen
rate
hscttreat
patient
primari
immunodefici
inborn
error
metabol
start
new
depart
interestingli
commenc
new
depart
rate
unrel
allogen
hsct
increas
conclus
separ
pediatr
program
joint
program
adult
diseasescap
patient
underw
hsct
chang
show
growth
rate
patient
primari
immunodefici
inborn
error
metabol
might
explain
three
underli
reason
public
awar
diseas
cure
hsct
improv
recent
year
increas
visit
hsct
clinic
coupl
children
genet
disord
develop
iranian
hla
registri
program
result
increas
number
unrel
allogen
hsct
owe
nation
thalassemia
prevent
program
annual
incid
rate
diseas
iran
reduc
begin
new
centuri
recent
year
rate
inherit
disord
malign
diseas
remain
rel
unchang
conflict
interest
conflict
interest
report
cincinnati
children
hospit
bone
marrow
transplant
cincinnati
oh
unit
state
cincinnati
children
hospit
cincinnati
oh
unit
state
univers
cincinnati
colleg
medicin
cincinnati
oh
unit
state
background
transplantassoci
thrombot
microangiopathi
tatma
import
caus
morbid
mortal
hematopoiet
cell
transplant
hct
pathogenesi
tatma
poorli
understood
recent
data
show
clinic
respons
termin
complement
blockad
use
eculizumab
howev
recogn
still
patient
refractori
diseas
requir
addit
therapeut
option
moreov
recent
basic
scienc
studi
identifi
import
local
activ
extrahepat
complement
compon
produc
immun
cell
suggest
potenti
direct
role
transplant
stem
cell
patholog
complement
activ
goal
studi
examin
complement
system
tatma
identifi
novel
therapeut
target
method
prospect
collect
serial
weekli
peripher
blood
mononuclear
cell
pbmc
children
receiv
autolog
transplant
neuroblastoma
identifi
four
children
develop
tatma
treat
eculizumab
three
receiv
prepar
regimen
develop
tatma
select
pbmc
collect
prior
start
transplant
time
diagnosi
tatma
equival
time
without
tatma
resolut
tatma
equival
time
without
tatma
perform
rnaseq
identifi
activ
deactiv
pathway
contribut
pathogenesi
tatma
result
transcriptom
analysi
onset
tatma
show
signific
upregul
classic
altern
complement
pathway
activ
tatma
particular
markedli
increas
express
initi
molecul
altern
pathway
rapid
loop
activ
cfd
may
serv
amplifi
complement
activ
lectin
pathway
show
modest
upregul
signific
elev
express
compon
coagul
cascad
analysi
transcriptom
treatment
complement
blockad
use
eculizumab
show
upregul
gene
pathway
return
baselin
express
correl
clinic
resolut
tatma
analysi
global
transcript
regulatori
network
show
notabl
interferon
signatur
associ
tatma
figur
conclus
data
demonstr
broad
increas
express
complement
relat
gene
children
acut
phase
tatma
complement
block
therapi
initi
gene
express
return
essenti
baselin
use
eculizumab
residu
elev
complementrel
pathway
indic
efficaci
therapi
data
also
show
signific
elev
express
interferonrespons
gene
children
tatma
seen
children
without
tatma
find
accord
highli
inflammatori
clinic
phenotyp
children
present
tatma
may
explain
least
part
lack
complet
respons
complement
block
therapi
alon
patient
sever
diseas
interferon
novel
druggabl
target
tatma
could
benefici
sever
eculizumab
refractori
tatma
case
antiinterferon
therapeut
includ
antibodi
target
therapi
clinic
trial
might
offer
altern
strategi
immedi
treatment
critic
ill
children
addit
data
offer
explan
occurr
tatma
interferon
driven
diseas
system
lupu
erythematosu
sle
hemophagocyt
lymphohistiocytosi
hlh
endotheli
injuri
cart
therapi
occurr
tma
therapeut
use
interferon
conflict
interest
sj
smd
us
provision
patent
applic
pend
author
disclosur
report
children
hospit
soochow
univers
suzhou
china
background
wasrel
disord
xlink
thrombocytopenia
xlt
xlink
congenit
neutropenia
xln
recogn
howev
novel
mutat
identifi
next
gener
sequenc
novel
phenotyp
may
accompani
studi
investig
phenotyp
characterist
patient
gene
defect
method
hot
spot
mutat
relat
clinic
phenotyp
patient
gene
defect
retrospect
analyz
includ
inpati
outpati
depart
hematolog
hospit
soochow
univers
januari
august
import
role
wasp
mutat
reevalu
result
total
patient
male
median
onset
age
month
rang
month
median
age
diagnos
month
month
case
classic
case
xlink
thrombocytopenia
xlt
case
intermitt
xlink
thrombocytopenia
ixlt
case
xlink
pancytopenia
case
xlink
thrombocytopenia
granulocytopenia
among
patient
nine
mutant
never
report
among
mutant
detect
patient
includ
mutat
one
patient
mutat
spontan
among
other
inherit
mother
mutat
found
wasp
function
region
region
predominantli
common
mutat
missens
mutat
wasp
mutat
caus
protein
chang
identifi
patient
two
case
whose
complet
blood
count
show
pancytopenia
patient
develop
lymphoblast
leukemia
remain
patient
case
onset
manifest
show
hematochezia
thrombocytopenia
patient
show
thrombocytopenia
repeat
neutropenia
immun
laboratori
examin
show
decreas
patient
decreas
patient
patient
decreas
account
twentyf
patient
surviv
die
among
survivor
patient
treat
hematopoiet
stem
cell
transplant
hsct
prepar
hsct
last
ixlt
patient
stabl
treatment
five
patient
die
two
die
posttranspl
complic
one
die
cerebr
hemorrhag
transplant
two
gave
treatment
econom
reason
conclus
wasp
gene
defect
import
basi
diagnosi
relat
diseas
number
case
increas
gene
function
previous
thought
snp
redefin
hsct
effect
treatment
conflict
interest
potenti
conflict
interest
among
author
abstract
previous
publish
univers
crete
laboratori
blood
diseas
childhood
cancer
biolog
univers
hospit
heraklion
pediatr
hematologyoncolog
heraklion
greec
background
genet
associ
studi
cancer
risk
focus
effect
singl
nucleotid
polymorph
gene
regul
inflamm
tumor
suppress
chemokin
cytochrom
chemokin
induc
motil
endotheli
tumor
cell
bind
chemokin
receptor
select
express
b
lymphocyt
involv
hematopoiesi
thymocyt
traffick
stem
cell
motil
neovascular
tumorigenesi
polymorph
gene
investig
concern
breast
cancer
wilm
tumor
nasopharyng
carcinoma
renal
cell
carcinoma
leukemia
gene
belong
famili
subfamili
cytochrom
protein
phase
xenobiot
metabol
enzym
activ
convers
environment
chemic
carcinogen
gene
contain
two
import
singl
nucleotid
polymorph
investig
concern
breast
cancer
testicular
cancer
lung
cancer
leukemia
aim
studi
investig
role
singl
nucleotid
polymorph
children
adolesc
solid
tumor
includ
central
nervou
system
cn
tumor
neuroblastoma
sarcoma
lymphoma
wilm
tumor
histiocytosi
lch
method
fifti
one
children
solid
tumor
healthi
individu
children
adult
blood
donor
includ
present
studi
genom
dna
isol
peripher
blood
particip
analyz
exist
polymorph
polymeras
chain
reaction
pcr
pcr
product
digest
restrict
enzym
mspi
bsrdi
descript
statist
logist
regress
analysi
use
examin
differ
children
solid
tumor
control
result
shown
tabl
regard
loci
posit
associ
gg
genotyp
solid
tumor
ci
posit
associ
ag
genotyp
normal
phenotyp
ci
statist
signific
differ
polymorph
reveal
children
solid
tumor
control
group
use
logist
regress
analysi
conclus
higher
frequenc
homozygot
allel
g
observ
among
children
solid
tumor
wherea
differ
observ
regard
polymorph
futur
studi
larger
popul
need
order
specifi
role
polymorph
childhood
solid
tumor
conflict
interest
conflict
interest
tabl
tabl
fondazion
ircc
policlinico
san
matteo
pediatr
hematologyoncolog
pavia
itali
fondazion
ircc
policlinico
san
matteo
pediatr
hematologyoncolog
cell
factori
pavia
itali
fondazion
ircc
policlinico
san
matteo
immunohematolog
transfus
servic
pavia
itali
background
haploident
haematopoiet
stem
cell
transplant
haplohsct
neg
deplet
tcell
receptor
tcr
b
lymphocyt
mobil
peripher
stem
cell
graft
therapeut
option
high
risk
relaps
leukaemia
patient
without
hlacompat
sibl
unrel
donor
relaps
opportunist
infect
due
delay
immun
reconstitut
common
posttranspl
complic
posthsct
administr
donor
lymphocyt
infus
dli
prove
abl
enhanc
immun
reconstitut
prevent
complic
advantag
blur
risk
uncontrol
graftversushost
diseas
gvhd
routin
use
unmanipul
dli
therefor
still
discuss
data
paediatr
patient
still
limit
method
report
data
pediatr
recipi
haplohsct
transplant
hematolog
malign
receiv
dli
schedul
start
x
cellskg
dose
proceed
escal
dose
everi
week
x
cellskg
x
cellskg
x
cellskg
x
cellskg
x
cellskg
x
cellskg
x
cellskg
retrospect
compar
patient
patient
underw
haplohsct
receiv
dli
patient
age
year
receiv
hsct
relaps
highrisk
aml
md
result
first
dli
administ
median
time
day
rang
hsct
patient
minimum
follow
month
dli
initi
patient
receiv
median
dli
infus
rang
studi
control
group
patient
develop
grade
iii
acut
gvhd
earli
hsct
dli
dli
patient
develop
agvhd
grade
grade
iv
experienc
chronic
gvhd
resolv
steroid
treatment
extracorpor
photopheresi
three
patient
relaps
dli
group
median
time
day
hsct
patient
relaps
control
group
median
time
day
relaps
mortal
significantli
differ
group
one
patient
die
agvhd
progress
dli
group
gvhdrelat
mortal
observ
control
group
regard
infect
mortal
patient
die
infectionrel
diseas
dli
group
patient
succumb
infecti
complic
control
group
conclus
use
dli
appear
feasibl
therapeut
option
pediatr
haplohsct
highrisk
relaps
malign
main
benefit
cohort
due
infect
control
rather
prevent
diseas
relaps
conflict
interest
none
declar
hospit
de
la
santa
creu
sant
pau
pediatr
unit
hematolog
oncolog
stem
cell
transplant
barcelona
spain
banc
de
sang
teixit
cord
blood
unit
barcelona
spain
banc
de
sang
teixit
transfus
medicin
barcelona
spain
background
mix
donor
chimer
mc
increasingli
common
pediatr
hsct
set
increas
use
reducedintens
condit
regimen
nonmalign
diseas
patient
mc
may
spontan
evolv
complet
donor
chimer
cc
maintain
stabl
mc
onethird
patient
may
graft
failur
preemptiv
usag
dli
manag
patient
unstabl
mc
transplant
limit
nonmalign
diseas
method
januari
decemb
retrospect
studi
chimer
cours
children
nonmalign
diseas
receiv
hsct
afterward
receiv
preemptiv
dli
due
unstabl
mc
five
patient
receiv
reducedintens
condit
regimen
two
receiv
myeloabl
reduc
toxic
regimen
underli
diseas
thalassemia
maior
hurler
syndrom
mucopolysaccharidosi
vii
hyper
igm
syndrom
famili
hemophagocyt
lymphohistiocytosi
pyruv
kinas
defici
chronic
granulomat
diseas
donor
chimer
monitor
pcr
amplif
highli
variabl
short
tandem
repeat
lymphocyt
dli
either
frozen
aliquot
collect
donor
time
origin
harvest
collect
peripher
donor
dli
follow
institut
protocol
consist
progress
increas
dose
start
follow
first
dli
given
median
month
posttranspl
rang
month
median
dli
rang
given
median
interv
infus
day
day
median
donor
chimer
dli
lymphocyt
rang
granulocyt
rang
result
five
seven
patient
show
improv
donor
chimer
dli
three
patient
reach
full
donor
chimer
median
month
first
dli
two
patient
chronic
granulomat
diseas
hurler
syndrom
maintain
mix
donor
chimer
donor
chimer
granulocyt
increas
lymphocyt
chimer
two
patient
continu
mix
donor
chimer
lymphocyt
granulocyt
complet
failur
engraf
one
receiv
success
second
myeloabl
allogen
hsct
month
first
hsct
reach
complet
donor
chimer
two
patient
develop
gvhd
last
dli
one
patient
hepat
gvhd
chronic
characterist
confirm
day
last
dli
liver
biopsi
second
one
initi
acut
gvhd
skin
grade
ii
day
last
dli
patient
show
good
respons
corticoid
develop
gvhd
coincid
improv
mix
chimer
patient
aliv
conclus
experi
dli
show
efficaci
treatment
mix
donor
chimer
nonmalign
diseas
children
receiv
reducedintens
condit
regimen
myeloabl
regimen
mortal
relat
procedur
low
incid
gvhd
would
possibl
strategi
avoid
graft
failur
need
second
transplant
conflict
interest
none
author
anyth
disclos
hospit
sant
joan
de
deu
hsct
unit
esplugu
de
llobregat
barcelona
spain
hospit
sant
joan
de
deu
pediatr
hematolog
esplugu
de
llobregat
barcelona
spain
hospit
sant
joan
de
hematolog
laboratori
esplugu
de
llobregat
barcelona
spain
background
paroxysm
nocturn
hemoglobinuria
pnh
rare
diseas
develop
result
somat
mutat
hematopoiet
stem
cell
character
clonal
complementmedi
intravascular
hemolysi
pnh
character
hemoglobinuria
thrombosi
infect
marrow
failur
hemoglobinuria
thrombosi
major
present
symptom
adult
patient
bone
marrow
failur
bmf
initi
symptom
pediatr
case
eculizumab
human
monoclon
antibodi
function
termin
complement
inhibitor
patient
pnh
reduc
intravascular
hemolysi
need
transfus
risk
thrombosi
improv
qualiti
life
hematopoiet
stem
cell
transplant
hsct
cur
option
patient
pnh
suitabl
match
donor
avail
transplant
consid
method
present
case
girl
pnh
success
underw
unrel
bone
marrow
transplant
ubmt
receiv
treatment
eculizumab
result
previous
healthi
girl
initi
present
histori
asthenia
pallor
ecchymosi
blood
test
show
pancytopenia
hemoglobin
gdl
leukocyt
neutrophil
platelet
bone
marrow
aspir
biopsi
bmabmb
perform
result
compat
bmf
confirm
week
later
new
bma
bmb
studi
bmf
show
flow
cytometri
pnh
clone
neutrophil
monocyt
erythrocyt
remain
studi
result
neg
patient
present
hemoglobinuria
thrombosi
impair
renal
function
present
heavi
menorrhagia
due
thrombocytopenia
requir
multipl
transfus
transfus
week
start
gnrh
analogu
patient
hlamatch
relat
donor
hlamatch
unrel
donor
sought
meanwhil
due
high
transfus
requir
presenc
larg
pnh
clone
avoid
thrombot
renal
complic
start
weekli
treatment
eculizumab
move
everi
two
week
start
eculizumab
patient
becam
transfus
independ
match
unrel
donor
found
dose
eculizumab
patient
underw
ubmt
condit
regimen
use
accord
ewogsaa
guidelin
includ
cyclophosphamid
fludarabin
atg
mgkg
transplant
patient
present
follow
complic
pseudomona
aeuriginosa
septicemia
pneumocysti
jirovecii
pneumonia
grade
ii
agvhd
upper
digest
tract
complic
resolv
platelet
neutrophil
engraft
day
respect
pnh
clone
disappear
current
month
ubmt
patient
present
gvhd
pnh
clone
reappear
total
donor
quimer
persist
conclus
eculizumab
given
hsct
effect
prevent
thrombot
event
nephropathi
compromis
result
hsct
case
pnh
match
donor
avail
hsct
procedur
perform
short
time
hsct
altern
usual
immunosuppress
treatment
conflict
interest
conflict
interest
declar
hospit
universitario
la
paz
pediatr
hematooncolog
stem
cell
transplant
madrid
spain
hospit
la
paz
institut
health
research
idipaz
madrid
spain
wilhelmina
children
hospit
pediatr
blood
marrow
transplant
program
utrecht
netherland
wilhelmina
children
hospit
utrecht
netherland
univers
hospit
santariskiu
kliniko
vilna
lithuania
univers
hospit
lund
sweden
univers
hospit
lund
sweden
lund
sweden
hospit
universitario
la
paz
hepatolog
madrid
spain
la
paz
biomed
research
instituteidipaz
madrid
spain
hospit
universitario
la
paz
clinic
immunolog
madrid
spain
hospit
universitario
la
paz
pediatr
surgeri
madrid
spain
hospit
universitario
la
paz
medic
director
madrid
spain
hospit
universitario
la
paz
madrid
spain
la
paz
biomed
research
instituteidipaz
transplantchild
coordin
madrid
spain
hospit
universitario
la
paz
pediatr
hepatolog
spain
background
paediatr
transplant
pt
hematopoiet
stem
cell
transplant
hcst
solid
organ
sot
greatli
improv
surviv
children
endstag
diseas
becom
main
treatment
option
popul
pt
approach
requir
multidisciplinari
team
support
transplant
procedur
common
process
immunosuppress
immun
reconstitut
reject
toler
risk
infect
psychosoci
wellb
area
common
differ
type
transplant
therefor
holist
procedur
crosscut
approach
improv
expect
longterm
qualiti
life
children
famili
herewith
aim
describ
strateg
approach
transplantchild
improv
life
expect
qualiti
life
eu
paediatr
patient
method
transplantchild
european
refer
network
ern
focus
low
preval
complex
clinic
condit
children
trasplant
includ
sot
hsct
specif
crosscut
approach
transplantchild
aim
ensur
patient
famili
access
network
best
possibl
care
practic
support
procedur
relat
transvers
multidisciplinari
approach
develop
gather
effort
within
network
integr
innov
better
procedur
inform
train
knowledg
expertis
integr
stakehold
transplant
process
make
avail
knowledg
inform
establish
strateg
approach
transplantchild
strateg
area
approv
order
ensur
achiev
mission
vision
network
improv
patient
healthcar
harmonis
clinic
best
practic
harmonis
research
innov
spread
knowledg
educ
train
network
organ
qualiti
safeti
result
transplantchild
integr
healthcar
provid
member
state
proven
experi
pt
address
relat
complic
order
gather
knowledg
experi
avail
throughout
europ
holist
model
ensur
perman
effort
routin
implement
standard
recent
improv
transplant
process
whole
pretranspl
transplant
posttranspl
stage
crosscut
approach
transplantchild
allow
identif
common
topic
transplant
clinic
person
socioeconom
issu
improv
transplant
patient
handl
life
expect
longterm
qualiti
life
children
famili
prevent
practic
anticip
minimis
patient
risk
treatment
standardis
harmonis
clinic
best
practic
improv
chronic
approach
treatment
secondari
diseas
relat
pt
provis
psychosoci
support
differ
phase
patient
life
provis
ground
patient
empower
first
case
recent
upload
network
address
prehsct
question
patient
previous
receiv
deceas
liver
transplant
conclus
pt
care
constitut
yet
medic
challeng
due
lack
robust
data
comparison
adult
transplant
transplantchild
focus
pt
process
approach
instead
diseaseorgan
approach
develop
integr
model
share
within
network
knowledg
expertis
highli
specialis
support
advic
nation
healthcar
provid
transplant
children
conflict
interest
noth
disclos
abstract
previous
publish
tor
vergata
rome
itali
mediterranean
istitut
hematolog
rome
itali
policlinico
tor
vergata
rome
itali
background
allogen
hematopoiet
stem
cell
transplant
potenti
cur
treatment
patient
major
betathalassemia
diseas
gvhd
lead
caus
haematopoiet
stem
cell
transplant
hsct
morbid
mortal
extracorpor
photopheresi
ecp
treatment
steroid
refractori
depend
gvhd
facilit
reduct
immunosuppress
method
sevenyearold
boy
class
thalassemia
major
underw
allogen
bmt
transplant
unrel
donor
major
abo
incompat
june
prophylaxi
therapi
gvhd
cyclosporin
methylprednisolon
short
mtx
day
mix
chimer
donor
cell
identifi
earli
complic
bmt
day
cmv
reactiv
hemorrhag
cystiti
bkvrelat
engraft
syndrom
capillari
leak
pulmonari
distress
sever
acut
gvhd
grade
iv
involv
skin
gut
evolv
progress
skin
rush
skin
involv
itch
fourth
degre
skin
lesion
locat
mainli
head
therefor
thymoglobulin
mycophenol
mofetil
ad
ongo
immunotherapi
csa
methylpdn
mgkgin
septemb
reactiv
intestin
gvhd
grade
iv
sever
gastrointestin
bleed
treat
sandostatin
replac
defibrotid
methylpdn
remiss
symptomatolog
immunotherapi
gvhd
restor
high
dose
methylpdn
increas
mgkgdie
moment
start
extracoerpor
photopheresisphotochemotherapi
administ
time
week
first
month
switch
twice
weekli
present
daydur
procedur
process
one
blood
volum
rate
min
via
central
venou
cathet
whole
cycl
never
advers
event
result
period
decemb
march
gvhd
skin
gastrointestin
visibl
decreas
liver
abnorm
document
abdomin
ultrasound
describ
decemb
mild
hepatosplenomegali
widespread
dishomogen
liver
parenchyma
improv
subsequ
control
march
ecp
interrupt
septemb
worsen
cutan
gvhd
increas
methylpdn
mg
kg
day
episod
patient
restart
photopheresi
week
allow
current
state
reduc
pdn
kg
day
remiss
cutan
gvhd
show
pallor
skin
gastrointestin
evid
seen
egd
show
sign
bleed
stomach
duodenum
import
thick
duoden
mucosa
quickli
normal
conclus
patient
suffer
acut
chronic
gvhd
limit
therapeut
treatment
ecp
treatment
might
improv
clinic
situat
patient
suffer
gvhd
experi
shown
ecp
remain
import
therapeut
option
sinc
ecp
therapi
concurr
immunosuppress
could
reduc
without
appear
increas
opportunist
infect
furthermor
begin
ecp
clear
improv
cutan
symptomatolog
evid
one
month
conflict
interest
none
univers
hospit
center
zagreb
dep
pediatr
zagreb
croatia
univers
hospit
center
zagreb
dep
intern
medicin
zagreb
croatia
univers
hospit
center
zagreb
dep
laboratori
diagnost
zagreb
croatia
background
fanconi
anaemia
fa
rare
inherit
disord
associ
congenit
abnorm
progress
bone
marrow
failur
bmf
predisposit
develop
malign
diseas
bmf
ususali
occur
first
decad
life
characterist
phenotyp
appear
pancytopenia
main
characterist
increas
risk
develop
malign
hematolog
md
aml
nonhematolog
diseas
squamou
cell
carcinoma
head
neck
skull
oesophagu
vulva
anu
cervix
incid
increas
age
age
bmf
neoplasm
mortal
rate
patient
fa
high
median
age
death
year
allogen
hematopoiet
stem
cell
transplant
hsct
cur
option
haematolog
diseas
fa
method
patient
boy
admit
clinic
age
pancytopenia
bone
marrow
aspir
bma
show
moder
decreas
cellular
delet
interphas
chromosom
prolong
pancytopenia
rbc
macrocytosi
microcephali
skin
hyperpigment
rais
suspicion
fa
cultur
without
fragil
stimul
abnorm
chromosom
fragil
found
enhanc
ad
diepoxybutan
confirm
diagnosi
fa
hsct
indic
sinc
relat
donor
initi
androgen
steroid
therapi
benefici
patient
develop
sign
precoci
puberti
match
unrel
donor
hla
found
hsct
perform
engraft
success
without
gvhd
day
post
hsct
bma
normal
without
delet
team
decid
follow
consensu
german
transplant
centr
hematopoiet
stem
cell
transplant
fanconi
anemia
precis
protocol
condit
regimen
nowaday
avoid
total
bodi
irradi
high
dose
alkyl
agent
sinc
associ
increas
risk
later
malign
recent
reduc
intens
condit
regimen
includ
low
dose
fludarabin
cylophosphamid
busulfan
also
use
patient
accord
protocol
vivo
tcell
deplet
agent
use
avoid
gvhd
whether
one
lymphocytedeplet
antibodi
given
prioriti
difficult
say
howev
immunosuppress
alemtuzumab
show
better
surviv
rate
better
overal
surviv
lower
risk
gvhd
compar
atg
gvhd
prophylaxi
alemtuzumab
use
cyclosporin
mycophenol
mofetil
result
case
present
first
fa
patient
treat
hsct
croatia
also
first
paediatr
patient
croatia
alemtuzumab
given
without
complic
side
effect
conclus
patient
month
hsct
good
engraft
without
complic
despit
improv
outcom
patient
fa
posthsct
recent
year
long
term
surviv
still
affect
secondari
malign
solid
tumour
risk
factor
develop
secondari
malign
older
age
peripher
stem
cell
transplant
chronic
gvhd
far
present
patient
long
term
regular
monitor
emphasi
earli
recognit
possibl
secondari
malign
warrant
conflict
interest
none
author
anyth
disclos
abstract
previous
publish
cansearch
research
laboratori
univers
geneva
faculti
medicin
pediatr
oncolog
hematolog
unit
depart
pediatr
geneva
switzerland
charlesbruneau
cancer
center
chu
saintejustin
research
center
hematologyoncolog
divis
montreal
canada
oncohematolog
unit
geneva
univers
hospit
depart
pediatr
geneva
switzerland
faculti
medicin
univers
montreal
depart
pediatr
montreal
canada
divis
hematolog
geneva
univers
hospit
depart
medic
specialti
geneva
switzerland
hospit
sick
children
lesli
dan
faculti
pharmaci
univers
toronto
depart
pharmaci
toronto
canada
hospit
sick
children
blood
marrow
transplant
unit
depart
haematologyoncolog
toronto
canada
univers
medic
center
utrecht
pediatr
blood
marrow
transplant
program
utrecht
netherland
leiden
univers
medic
center
depart
pediatr
center
infecti
diseas
leiden
netherland
robert
hospit
pediatr
immunohematolog
unit
pari
franc
st
anna
children
hospit
depart
pediatr
stem
cell
transplant
unit
vienna
austria
univers
hospit
frankfurt
divis
stem
cell
transplant
immunolog
frankfurt
germani
background
behalf
pediatr
diseas
work
parti
european
societi
blood
marrow
transplant
busulfan
cyclophosphamid
buci
condit
regimen
wide
use
allogen
hematopoiet
stemcel
transplant
hsct
children
bu
conjug
glutathion
glutathion
stransferas
enzym
gst
follow
oxid
cytochrom
cyp
cystathionin
gammalyas
cth
flavincontain
monooxygenas
fmo
cy
bioactiv
cytochrom
enzym
activ
metabolit
elimin
aldehyd
dehydrogenas
gst
aim
studi
evalu
associ
genet
polymorph
main
buci
relat
metabol
enzym
transport
eventfre
surviv
ef
relaps
children
malign
undergo
hsct
order
person
treatment
effici
method
retrospect
studi
associ
common
genet
variant
buci
metabol
enzym
gene
ef
relaps
post
hsct
assess
individu
combin
pediatr
patient
malign
use
univari
multivari
analysi
studi
also
explor
role
determin
cellular
sensit
bu
halfmaxim
inhibitori
concentr
bu
inhibit
cell
viabil
screen
differ
lymphoblastoid
cell
line
lcl
buinduc
activ
cellular
apoptosi
necrosi
screen
lcl
group
basi
genotyp
activ
variou
cellular
pathway
lead
cell
death
assess
relat
genotyp
lcl
result
observ
signific
reduct
ef
increas
incid
relaps
carrier
compar
either
non
null
carrier
vs
p
vs
p
respect
observ
higher
valu
lcl
carri
allel
compar
null
carrier
interestingli
ratio
necrosi
earli
apoptosi
induct
bu
significantli
lower
carrier
combin
p
respect
suggest
slower
progress
rate
carrier
apoptosi
observ
confirm
real
time
experi
measur
apoptosi
trigger
bu
primarili
due
caspas
activ
involv
caspas
activ
rule
total
gst
activ
autophagi
ro
product
mitochondri
membran
potenti
show
signific
differ
stratifi
genotyp
howev
gsh
level
significantli
higher
null
carrier
p
suggest
potenti
compensatori
mechan
conjug
process
bu
lcl
conclus
result
indic
combin
null
carrier
statu
associ
reduc
eventfre
surviv
increas
incid
relaps
children
undergo
allogen
hsct
possibl
influenc
cellular
surviv
clinic
trial
registri
clinicaltrialsgov
identifi
websit
http
conflict
interest
none
author
anyth
disclos
pediatr
hematolog
oncolog
st
anna
children
hospit
depart
pediatr
medic
univers
vienna
vienna
austria
children
cancer
research
institut
ccri
st
anna
kinderkrebsforschung
vienna
austria
background
serotherapi
antithymocyt
globulin
atg
campath
signific
impact
immun
reconstitut
haematopoiet
stem
cell
transplant
hsct
method
retrospect
evalu
impact
gvhd
prophylaxi
serotherapi
versu
posttranspl
cyclophosphamid
children
adolesc
receiv
uniform
reduc
intens
ric
condit
regimen
reconstitut
tcell
tcell
subset
detect
fac
analysi
day
evalu
consecut
children
undergo
hsct
malign
nonmalign
diseas
follow
ric
regimen
consist
fludarabin
thiotepa
melphalan
gvhdprophylaxi
consist
atg
campath
one
patient
group
posttranspl
cyclophosphamid
patient
group
furthermor
group
analys
cytomegaloviru
cmv
adenoviru
adv
viremia
frequenc
acut
gvhd
median
patient
age
year
underli
diseas
leukaemia
solid
tumor
nonmalign
diseas
patient
twentynin
patient
receiv
bone
marrow
peripheralblood
stem
cell
twelv
patient
graft
hlamatch
sibl
match
unrel
donor
nine
patient
receiv
transplant
haploident
donor
clinic
characterist
diagnosi
gender
recipi
age
donor
type
graft
sourc
equal
distribut
within
two
group
result
shown
tabl
detect
median
nk
cell
count
gener
higher
among
patient
receiv
gvhd
prophylaxi
posttranspl
cyclophosphamid
group
reach
statist
signific
nk
cell
day
similarli
found
higher
tcell
number
day
group
recoveri
subset
differ
group
cmv
viremia
detect
among
patient
receiv
serotherapi
group
patient
posttranspl
cyclophosphamid
group
adv
viremia
observ
group
howev
differ
statist
signific
gvhd
rate
compar
group
group
vs
group
acut
gvhd
vs
acut
gvhd
grade
higher
conclus
posttranspl
cyclophosphamidebas
gvhd
prophylaxi
compar
serotherapi
fludarabinbas
ric
condit
children
associ
enhanc
immun
reconstitut
nk
tcell
compart
turn
might
reduc
risk
viru
reactiv
conflict
interest
author
noth
disclos
tabl
tabl
leed
children
hospit
paediatr
haematolog
oncolog
servic
leed
unit
kingdom
background
glanzmann
thrombasthenia
rare
autosom
recess
bleed
disord
platelet
function
caus
qualit
quantit
defect
platelet
membran
glycoprotein
iibiiia
patient
sever
form
condit
haemopoiet
stem
cell
transplant
hsct
cur
option
sinc
allogen
stem
cell
transplant
report
patient
glanzmann
thrombasthenia
report
two
case
patient
sever
glanzmann
thrombasthenia
antiplatelet
antibodi
success
allogen
hsct
centr
method
patient
year
old
boy
underw
hsct
suffer
intracerebr
bleed
patient
year
old
girl
hsct
follow
increas
freqenc
episod
sever
bleed
stem
cell
sourc
patient
receiv
patern
haploident
alphabeta
lymphocyt
deplet
gcsf
mobilis
peripher
blood
stem
cell
patient
receiv
hla
match
sibl
bone
marrow
condit
condit
regim
combin
fludarabin
thiotepa
treosulfan
atg
use
case
patient
atg
day
day
fludarabin
day
day
treosulfan
day
day
thiotepa
bd
day
day
patient
thiotepa
bd
day
day
treosulfan
day
day
fludarabin
day
day
treosulfan
day
day
atg
day
day
gvhd
prophylaxi
patient
ciclosporin
bd
day
onward
methotrex
day
day
day
day
ciclosporin
later
switch
tacrolimu
patient
ciclosporin
bd
day
onward
mycophenol
mofetil
bd
day
ciclosporin
later
switch
tacrolimu
immunosuppress
wean
month
post
hsct
patient
result
engraft
patient
engraft
neutrophil
day
platelet
day
patient
engraft
neutrophil
day
platelet
day
chimer
patient
donor
chimer
cell
fraction
day
subsequ
test
month
post
hsct
transplant
relat
morbid
patient
mild
gut
gvhd
respond
oral
prednisolon
budesonid
switch
immunosuppress
ciclosporin
tacrolimu
also
cmv
reactiv
treat
intraven
ganciclovir
oral
valganciclovir
patient
ciclosporin
induc
gum
hypertrophi
hirsuit
resolv
follow
switch
ciclosporin
tacrolimu
year
month
follow
point
respect
patient
symptom
glanzmann
thrombasthenia
residu
complic
hsct
conclus
case
demonstr
hsct
cur
treatment
option
minim
transplant
relat
complic
rapid
engraft
short
durat
neutropenia
patient
sever
thrombasthenia
conflict
interest
dr
charlott
crone
noth
disclos
grenobl
univers
hospit
depart
pediatr
oncohematolog
grenobl
franc
necker
enfant
malad
univers
hospit
assist
de
pari
pediatr
immunohaematolog
rheumatolog
unit
pari
franc
robert
hospit
aphp
hematolog
depart
pari
franc
univers
hospit
lyon
depart
pediatr
hematolog
oncolog
lyon
franc
timon
hospit
depart
pediatr
hematolog
oncolog
marseil
franc
univers
hospit
strasbourg
depart
pediatr
hematologyoncolog
strasbourg
franc
univers
hospit
strasbourg
depart
pediatr
hematologyoncolog
strasbourg
franc
children
univers
hospit
depart
hematologyoncolog
clermont
ferrand
franc
univers
hospit
pediatr
hematolog
oncolog
depart
montpelli
franc
parisstloui
hospit
parisdiderot
univers
hematolog
depart
pari
franc
bordeauxhospit
bordeaux
univers
pediatr
hematolog
depart
bordeaux
franc
jeann
de
flandr
hospit
lill
nord
de
franc
univers
depart
pediatr
hematolog
lill
franc
saint
antoin
hematolog
depart
pari
franc
saint
antoin
hospit
aphp
hematolog
cellular
therapi
servic
pari
franc
background
aim
studi
perform
review
haplohematopoiet
stem
cell
transplant
pediatr
experi
franc
method
epidemiolog
observ
multicent
descript
retrospect
studi
base
data
french
section
promis
regist
ebmt
result
total
patient
includ
receiv
haplohsct
januari
june
median
age
patient
year
old
main
diagnosi
primari
immun
defici
hemophagocyt
lymphohistiocytosi
bone
marrow
failur
patient
receiv
exvivo
manipul
graft
patient
receiv
posttranspl
highdos
cyclophosphamid
preparatori
regimen
given
patient
includ
myeloabl
median
followup
day
durabl
hematopoiet
reconstitut
seen
patient
neutrophil
platelet
engraft
achiev
median
delay
day
cumul
incid
grade
ii
iv
acut
graftversushost
diseas
day
mainli
skin
agvhd
chronic
gvhd
one
year
respect
infecti
complic
diagnos
patient
includ
viral
infect
incid
relaps
progress
oneyear
overal
surviv
os
rate
one
year
transplant
relat
mortal
conclus
haplohsct
interest
altern
patient
lack
hla
match
donor
prolong
follow
prospect
studi
necessari
assess
role
haplohsct
children
establish
guidelin
manag
conflict
interest
conflict
interest
nation
univers
singapor
paediatr
singapor
singapor
nation
univers
health
system
khoo
teck
puat
nation
univers
children
medic
institut
singapor
singapor
nation
univers
health
system
nation
univers
cancer
institut
singapor
singapor
nation
univers
health
system
laboratori
medicin
singapor
singapor
background
paediatr
haploident
peripher
blood
stem
cell
transplant
pbsct
use
exvivo
cell
deplet
tcd
neg
select
approach
tcrab
deplet
report
acut
chronic
gvhd
rate
rang
respect
addit
tcd
major
patient
receiv
addit
gvhd
prophylaxi
could
includ
pretranspl
atg
posttranspl
mycophenol
motfetil
mmf
calcineurin
inhibitor
disadvantag
posttranspl
immunosuppress
tcd
set
delay
immun
reconstitut
result
infect
relaps
risk
novel
graft
engin
techniqu
deplet
cell
retain
function
pathogenspecif
memori
cell
use
adult
patient
acut
leukaemia
receiv
hla
match
sibl
donor
pbsct
result
excel
outcom
gvhd
prophylaxi
patient
develop
acut
grade
iii
chronic
gvhd
respect
bleakley
use
set
hla
haploident
pbsct
paediatr
patient
leukaemia
addit
gvhd
prophylaxi
includ
sirolimu
mmf
grade
iiiiv
acut
chronic
gvhd
occur
patient
respect
triplett
method
treat
consecut
paediatr
patient
acut
leukaemia
lymphoid
myeloid
mix
use
similar
approach
cell
deplet
haploident
pbsct
without
addit
drug
prophylaxi
gvhd
attempt
improv
qualiti
life
overal
outcom
stem
cell
graft
either
enrich
deplet
result
median
age
rang
year
cr
time
pbsct
prepar
regimen
either
tli
thiotepa
treosulfan
base
gcsf
given
median
tnc
rang
x
rang
x
rang
x
respect
myeloid
platelet
engraft
occur
median
rang
rang
day
respect
secondari
graft
reject
rescu
altern
donor
progress
leukaemia
note
patient
respect
cytomegaloviru
adenoviru
dnaemia
without
diseas
note
patient
respect
ebv
fungal
infect
acut
gvhd
grade
iiiii
occur
grade
iv
acut
gvhd
seen
de
novo
limit
chronic
gvhd
occur
patient
extens
chronic
gvhd
seen
patient
receiv
repeat
dose
dli
gvhd
steroid
respons
evalu
patient
median
durat
posttranspl
immunosuppress
rang
day
median
followup
rang
day
patient
aliv
remiss
conclus
haploident
pbsct
drugfre
gvhd
prophylaxi
paediatr
patient
acut
leukaemia
safe
grade
iv
acut
gvhd
provid
overal
surviv
clinic
trial
registri
na
conflict
interest
none
author
anyth
disclos
fundacion
vall
del
lili
stem
cell
transplant
cali
colombia
fundacion
vall
del
lili
clinic
research
center
cali
colombia
background
haploident
stem
cell
transplant
option
patient
without
relat
unrel
donor
posttransplant
cyclophosphamid
ptci
effect
method
graft
versu
host
diseas
gvhd
prophylaxi
permit
use
replet
graft
set
manipul
avail
method
retrospect
review
pediatr
hematolog
malign
underw
year
patient
receiv
prepar
regimen
fludarabin
busulfan
total
bodi
irradi
melphalan
gvhd
prophylaxi
consist
ptci
mgrkg
day
cyclosporin
csa
plu
mycophenol
mmf
tid
po
mini
dose
methotrex
dose
mtx
day
result
total
children
enrol
median
age
year
iqr
rang
year
male
indic
hsct
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
myelodysplast
md
chronic
myeloid
leukemia
cml
non
hodgkin
lymphoma
nhl
hodgkin
lymphoma
diseas
statu
patient
acut
leukemia
patient
sct
first
complet
remiss
second
remiss
activ
diseas
median
donor
age
year
iqr
rang
year
donor
sourc
bone
marrow
patient
peripher
blood
stem
cell
pbsc
patient
common
donor
father
follow
sibl
mother
donor
abo
compat
minor
abomismatch
major
abomismatch
median
cell
dose
cellskg
bodi
weight
iqr
rang
median
time
engraft
neutrophil
day
rang
median
time
engraft
platelet
day
rang
complic
report
hemorrhag
cystiti
cytomegaloviru
cmv
reactiv
cmv
diseas
one
patient
primari
graft
failur
agvhd
prophylaxi
patient
receiv
ptci
csa
minidos
mtx
patient
receiv
ptci
csa
mmf
patient
surviv
less
day
graft
failur
exclud
gvhd
analysi
cumul
incid
acut
gvhd
iiiv
acut
gvhd
iiiiv
chronic
gvhd
respect
grade
iv
agvhd
occur
patient
receiv
prophylaxi
csa
mfm
receiv
csa
minidos
mtx
transplant
relat
mortal
trm
day
overal
eventfre
surviv
respect
conclus
ptci
avail
safe
feasibl
option
children
hematolog
malign
use
minidos
methotrex
associ
lower
rate
acut
gvhd
howev
result
requir
support
prospect
random
studi
improv
efficaci
prophylaxi
strategi
conflict
interest
conflict
interest
declar
bmtdepart
referencelaboratori
diagnost
oncohematolog
diseas
children
center
pediatr
oncohematolog
bmt
nation
children
special
hospit
okhmatdyt
kyiv
ukrain
background
patient
highrisk
hematolog
malign
poor
prognosi
without
hematopoet
stem
cell
transplant
haploident
sct
potenti
cure
patient
without
hlaident
donor
experi
haplosct
posttranspl
hdcyclophosphamid
pediatr
popul
still
limit
method
april
decemb
total
pt
differ
malign
tabl
underw
haploident
hsct
posttranspl
hdci
patient
moment
aliv
earli
posttranspl
period
day
transplant
report
patient
differ
reduc
toxyc
condit
regimen
use
tabl
patient
receiv
highdos
cy
day
cyclosporin
cya
iv
mgkgd
po
adjust
blood
level
ngml
mycophenol
mofetil
mmf
two
time
daili
per
os
start
day
mmf
discontinu
day
patient
receiv
antimicrobi
prophylaxi
bacteria
fungal
herp
virus
infect
pneumocysti
jiroveci
accord
institut
practic
firstli
chimer
pb
bm
control
day
day
patient
donor
stemcel
harvest
characterist
describ
tabl
patient
underw
transplant
cr
high
risk
aml
ahl
snhl
patient
cr
sct
tabl
patient
donor
harvest
characterist
variabl
age
median
rang
year
gender
n
male
femal
diagnosi
n
iii
cr
aml
aml
ii
cr
nhl
ahl
condit
regimen
n
flu
treo
flu
arac
flame
flu
po
ara
c
donor
n
father
mother
stem
cell
sourc
peripher
blood
bone
result
pt
die
engraft
day
fulmin
ps
aeruginosa
sepsi
pt
die
relaps
day
pt
lfu
day
pt
achiev
full
engraft
pt
neutrophil
platelet
engraft
day
despit
complet
donor
chimer
transplant
addit
donor
day
transplant
pt
achiev
engraft
day
despit
complet
donor
chimer
pt
dec
remain
aliv
median
followup
day
rang
day
pt
grade
agvhd
cgvhd
pt
tall
relaps
day
salvagect
pt
secondari
md
day
transplant
donor
conclus
hlahaploident
hsct
posttranspl
tcell
vivo
deplet
use
highdos
cyclophosphamid
feasibl
children
adolesc
conflict
interest
none
hospit
la
paz
madrid
spain
hospit
carlo
haya
malaga
spain
hospit
jesu
madrid
spain
hospit
vall
hebron
barcelona
spain
hospit
santa
creu
sant
pau
barcelona
spain
hospit
la
fe
valencia
spain
hospit
santiago
de
compostela
santiago
de
compostela
spain
hospit
virgen
de
la
arreixaca
murcia
spain
hospit
virgen
del
rocio
sevilla
spain
hospit
de
salamanca
salamanca
spain
hospiit
gregorio
madrid
spain
hospit
sant
joan
de
barcelona
spain
background
haploident
hematopoiet
stem
cell
transplant
haplohsct
emerg
altern
transplant
strategi
patient
without
hla
match
relat
donor
without
time
wait
hla
match
unrel
donor
howev
graft
failur
graft
versu
host
diseas
gvhd
delay
immun
recoveri
major
concern
method
report
retrospect
analysi
consecut
children
adolesc
highrisk
haematolog
malign
receiv
haplohsct
use
posttransplant
cyclophosphamid
ex
vivo
tcell
deplet
graft
versu
host
diseas
prophylaxi
januari
decemb
center
spain
result
total
children
male
median
age
transplant
year
underli
diseas
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
myelodysplast
syndrom
myelopolif
syndrom
biphenotipyc
leukaemia
donor
mother
father
brother
sister
stem
cell
sourc
peripher
blood
stem
cell
bone
marrow
median
dose
kg
one
hundr
sixtyf
patient
engraft
cumul
incid
rate
sever
acut
gvhd
cumul
incid
total
chronic
gvhd
trasplant
relat
mortal
day
twoyear
estim
relaps
probabl
patient
surviv
throughout
followup
period
day
rang
day
overal
surviv
rate
statist
differ
found
posttransplant
cyclophosphamid
ex
vivo
cell
deplet
univari
analysi
show
lower
overal
surviv
lymphoid
malign
previou
hsct
posit
minim
residu
diseas
p
kir
haplotyp
donor
p
univari
analysi
show
higher
probabl
relaps
lymphoid
malign
patient
posit
minim
residu
diseas
p
kir
haplotyp
donor
p
multivari
analysi
show
higher
overal
surviv
myeloid
diseas
kir
b
haplotyp
donor
lower
overal
surviv
minim
residu
diseas
posit
multivari
analysi
show
lower
relaps
probabl
kir
b
haplotyp
donor
use
conclus
haplohsct
feasibl
therapeut
option
children
adolesc
highrisk
haematolog
malign
suggest
outcom
haplohsct
may
improv
select
kir
b
haplotyp
donor
acut
myeloid
leukaemia
patient
pretransplant
neg
minim
residu
diseas
conflict
interest
noth
disclos
medic
park
pediatr
bone
marrow
transplant
unit
antalya
turkey
medic
park
pediatr
bone
marrow
transplant
unit
istanbul
turkey
background
although
regular
red
cell
transfus
improv
iron
chelat
therapi
altern
prolong
life
allogen
hematopoiet
stem
cell
transplant
hsct
cur
treatment
option
patient
beta
thalassemia
major
howev
presenc
hlamatch
relat
donor
remain
main
barrier
allogen
hsct
promis
studi
report
still
insuffici
data
unrel
transplant
aim
evalu
result
children
beta
thalassemia
major
receiv
allogen
hsct
hlamatch
unrel
donor
method
retrospect
evalu
unrel
hsct
children
beta
thalassemia
major
patient
receiv
myeloabl
regimen
weight
adjust
dose
busulfan
addit
patient
receiv
fludarabin
mg
five
day
cyclophosphamid
mg
kg
three
day
thiotepa
mg
kg
one
day
atg
mg
kg
three
day
cyclosporina
mtx
use
prophylaxi
grafthost
diseas
gvhd
peripher
blood
assess
donor
chimer
day
result
median
age
patient
month
rang
month
two
patient
class
rest
class
ii
median
serum
ferritin
level
ngml
rang
although
donor
match
hla
high
resolut
graft
failur
direct
patient
match
gvhd
direct
bm
use
stem
cell
sourc
thirtyfour
transplant
median
tnc
rang
pbsc
transplant
median
mnc
rang
median
cell
number
rang
median
neutrophil
platelet
engraft
day
day
pbsc
day
bm
group
respect
graft
failur
experienc
one
graft
reject
patient
moder
vod
observ
patient
treat
defibrotid
success
grade
iiv
acut
gvhd
observ
patient
six
experienc
grade
iiiv
howev
chronic
gvhd
observ
patient
aliv
full
donor
chimer
median
month
rang
month
follow
except
one
patient
lost
sepsi
posttranspl
day
probabl
thalassemiafre
tf
overal
surviv
os
found
respect
conclus
data
show
result
hsct
unrel
donor
select
low
risk
thalassemia
patient
class
ii
may
compar
hsct
match
sibl
donor
believ
import
event
provid
success
outcom
unrel
stem
cell
transplant
fulli
match
donor
howev
need
studi
long
term
follow
larger
studi
popul
conflict
interest
noth
disclos
hacettep
univers
faculti
medicin
depart
pediatr
divis
bmt
unit
ankara
turkey
hacettep
univers
faculti
medicin
departmet
pediatr
divis
immunolog
ankara
turkey
hacettep
univers
faculti
medicin
depart
pediatr
divis
hematolog
ankara
turkey
background
wiskottaldrich
syndrom
sever
xlink
disord
character
immunodefici
microthrombocytopenia
eczema
syndrom
caus
homozyg
mutat
gene
encod
protein
wasp
despit
advanc
clinic
care
patient
classic
poor
prognosi
median
life
expect
year
unless
hematolog
immun
reconstitut
achiev
hematopoiet
stem
cell
transplant
hsct
report
result
hsct
children
method
studi
includ
nine
male
patient
underw
hsct
may
march
center
detail
hsct
shown
tabl
median
age
patient
month
rang
month
one
patient
case
underw
second
hsct
due
engraft
failur
patient
receiv
myeloabl
condit
regimen
includ
busulfan
mgkg
mgkg
accord
condit
protocol
bodi
weight
patient
cyclophosphamid
mgkg
fludarabin
mgkg
globulin
mgkg
thymoglobulin
mgkg
atgfreseniu
cyclosporin
amethotrex
use
graft
versu
host
diseas
gvhd
prophylaxi
result
result
transplant
shown
tabl
engraft
achiev
patient
except
case
two
patient
develop
acut
chronic
gvhd
complic
follow
cytomegaloviru
cmv
reactiv
three
patient
cmv
retin
two
patient
engraft
syndrom
one
patient
venooccluss
diseas
one
patient
pulmonari
infect
one
patient
skin
infect
one
patient
one
patient
case
die
due
engraft
failur
pulmonari
infect
six
day
second
transplant
remain
eight
patient
aliv
diseas
free
seven
eight
patient
full
donor
chimer
donor
profil
case
full
donor
chimer
first
two
month
develop
mix
chimer
donor
profil
one
patient
still
activ
chronic
gvhd
median
durat
followup
month
rang
month
tabl
conclus
singl
center
studi
evalu
result
hsct
myeloabl
condit
regimen
three
patient
year
age
bad
prognost
factor
eight
nine
patient
aliv
diseas
free
ratio
full
donor
chimer
found
cmv
reactiv
infect
seen
major
complic
hsct
studi
conflict
interest
conflict
interest
tabl
tabl
characterist
patient
result
ege
univers
faculti
medicin
pediatr
hematolog
oncolog
izmir
turkey
ege
univers
faculti
medicin
radiat
oncolog
izmir
turkey
background
hematopoiet
stem
cell
transplant
hsct
major
indic
acut
lymphoblast
leukemia
children
studi
retrospect
analyz
patient
transplant
year
aim
investig
clinic
outcom
patient
underw
hsct
risk
factor
donor
type
tbi
base
regimen
stem
cell
sourc
may
affect
surviv
patient
method
januari
patient
acut
lymphoblast
leukemia
underw
hsct
ege
univers
hospit
inform
procedur
collect
retrospect
patient
medic
record
data
analys
primarili
conduct
use
spss
softwar
mean
age
transplant
year
year
ratio
male
femal
twentysix
patient
achiev
first
complet
remiss
cr
time
transplant
patient
beyond
cr
four
patient
underw
transplant
activ
refractori
leukemia
result
transplant
allogen
donor
match
sibl
match
relat
match
unrel
mismatch
donor
patient
respect
stem
cell
sourc
bone
marrow
patient
peripher
blood
stem
cell
pbsc
patient
unrel
cord
blood
patient
bone
marrow
cord
blood
sibl
use
two
patient
total
bodi
irradi
use
part
condit
regimen
acut
lymphoblast
leukemia
patient
one
patient
graft
failur
patient
die
engraft
among
other
neutrophil
engraf
result
relaps
relaps
isol
extramedullari
patient
median
time
transplant
relaps
month
rang
month
year
estim
overal
surviv
os
event
free
surviv
ef
patient
respect
ef
donor
mrd
mud
transplant
relat
mortal
conclus
unrel
donor
good
option
match
relat
donor
avail
pediatr
patient
conflict
interest
noth
disclos
bc
children
hospit
research
instituteubc
michael
cuccion
childhood
cancer
research
program
vancouv
canada
bc
cancer
agenc
cancer
control
research
vancouv
canada
background
blood
marrow
transplant
bmt
increasingli
use
treatment
children
adolesc
hematolog
malign
number
nonmalign
indic
children
adolesc
chronic
graftversushost
diseas
cgvhd
remain
primari
late
complic
children
receiv
bmt
moreov
cgvhd
signific
morbid
increas
mortal
poorli
recogn
canadian
healthcar
resourc
alloc
effect
cgvhd
children
qualiti
life
increasingli
studi
littl
known
regard
impact
cgvhd
health
servic
util
due
central
singl
payer
system
british
columbia
abl
evalu
impact
children
adolesc
receiv
allogen
bmt
cancer
diagnosi
method
analysi
restrict
cancer
patient
identifi
provinci
cancer
registri
diagnos
year
age
british
columbia
bc
patient
record
link
clinic
data
includ
bc
children
hospit
bmt
program
dataset
receiv
allogen
bmt
bc
start
program
file
link
provinci
healthcar
administr
dataset
provid
inform
medicallynecessari
hospit
outpati
physician
servic
prescript
drug
result
bmt
oncolog
patient
identifi
receiv
bmt
cgvhd
develop
patient
followup
period
hospit
rate
patient
without
cgvhd
per
case
contrast
rate
physician
servic
util
commun
significantli
higher
cgvhd
patient
versu
per
case
compar
without
cgvhd
p
similarli
prescript
rate
per
case
higher
cgvhd
compar
cgvhd
versu
p
conclus
sinc
cgvhd
primarili
treat
outpati
diseas
surpris
increas
hospit
contrast
ultiz
physician
servic
drug
higher
children
cgvhd
low
rate
cgvhd
versu
believ
due
difficulti
cgvhd
diagnosi
document
probabl
estim
cost
cgvhd
cgvhd
patient
includ
control
group
result
indic
impact
cgvhd
later
health
servic
demand
signific
consid
alloc
resourc
help
highli
vulner
popul
conflict
interest
conflict
interest
declar
author
hospit
carlo
haya
hospit
maternoinfantil
pediatr
hematolog
malaga
spain
hospit
la
paz
pediatr
hematolog
oncolog
madrid
spain
hospit
jesu
sct
unit
madrid
spain
hospit
virgen
de
la
arreixaca
pediatr
hematolog
oncolog
murcia
spain
hospit
la
fe
pediatr
hematolog
oncolog
valencia
spain
hospit
santiago
de
compostela
pediatr
hematolog
oncolog
santiago
de
compostela
spain
hospit
vall
hebron
pediatr
hematolog
onclog
barcelona
spain
hospit
virgen
del
rocio
pediatr
hematolog
sevilla
spain
hospit
santa
creu
sant
pau
pediatr
hematolog
oncolog
barcerlona
spain
hospit
sant
joan
de
deu
pediatr
barcelona
spain
hospit
de
salamanca
pediatr
hematolog
oncolog
salamanca
spain
hospit
gregorio
pediatrica
hematolog
oncolog
madrid
spain
hospit
de
santiago
pediatr
hematolog
oncolog
santiago
de
compostela
spain
hospit
la
paz
pediatr
hematolgi
oncolog
madrid
spain
hospit
vall
pediatr
hematolog
oncolog
barcelona
spain
hospit
jesu
pediatr
sct
unit
madrid
spain
background
allogen
hsct
wide
use
pediatr
patient
malign
nonmalign
diseas
smaller
famili
size
difficult
find
match
sibl
donor
mani
children
option
patient
altern
donor
sourc
hlahaploident
hsct
haplohsct
provid
altern
option
patient
lack
avail
hlaident
sibl
donor
unrel
donor
need
urgent
allograft
method
report
retrospect
analysi
consecut
children
adolesc
malign
nonmalign
diseas
receiv
haplohsct
use
posttranspl
cyclophosphamid
pt
cy
ex
vivo
tcell
deplet
graft
versu
host
diseas
prophylaxi
hospit
center
spain
result
median
age
transplant
year
underli
diseas
malign
diseas
acut
leukaemia
solid
tumour
nonmalign
diseas
immunodefici
aplast
anaemia
osteopetrosi
thalassemia
congenit
neutropenia
stem
cell
sourc
peripher
blood
stem
cell
bone
marrow
one
hundr
eightyf
patient
engraft
cumul
incid
rate
sever
acut
gvhd
cumul
incid
total
chronic
gvhd
trasplant
relat
mortal
day
twoyear
estim
relaps
probabl
patient
surviv
throughout
followup
period
day
rang
day
overal
surviv
rate
statist
differ
found
pt
cy
ex
vivo
cell
deplet
univari
analysi
show
lower
overal
surviv
pt
cy
group
compar
posit
select
group
neg
select
group
tcr
neg
select
group
ra
neg
select
group
previou
hsct
posit
minim
residu
diseas
p
chronic
gvhd
p
kir
haplotyp
donor
p
multivari
analysi
show
lower
overal
surviv
minim
residu
diseas
posit
conclus
haplohsct
effect
therapeut
option
children
malign
nonmalign
diseas
need
hsct
lack
hla
match
donor
result
minim
residu
diseas
pretransplant
affect
global
diseas
free
surviv
prospect
studi
design
need
compar
ex
vivo
vitro
cell
deplet
conflict
interest
none
rigshospitalet
univers
copenhagen
depart
children
adolesc
copenhagen
denmark
rigshospitalet
univers
copenhagen
depart
clinic
immunolog
copenhagen
denmark
univers
copenhagen
depart
public
health
section
biostatist
copenhagen
denmark
background
relaps
remain
primari
treatment
failur
hct
acut
childhood
leukaemia
develop
novel
therapi
accentu
need
earli
detect
relaps
measur
chimer
perform
peripher
blood
enabl
frequent
test
children
strpcr
chimer
recommend
eurochimer
consortium
sensit
rqpcr
base
chimer
fold
sensit
clinic
studi
children
spars
aim
describ
applic
method
three
differ
cutoff
use
relaps
primari
endpoint
method
retrospect
includ
children
year
age
transplant
aml
nation
paediatr
transplant
centr
copenhagen
rqpcr
chimer
perform
use
commerci
kit
kmrtypetrack
gendx
utrecht
netherland
increas
mix
chimer
imc
defin
increas
recipi
dna
cutoff
respect
strpcr
imc
defin
increas
result
rqpcr
strpcr
compar
associ
imc
relaps
analys
use
cox
regress
model
imc
timedepend
variabl
result
fiftyseven
children
acut
leukaemia
receiv
hct
studi
period
total
sampl
whole
peripher
blood
analys
median
rang
sampl
per
child
total
children
relaps
median
month
transplant
year
relaps
incid
ci
median
followup
time
month
transplant
strpcr
sampl
imc
rqpcr
cutoff
cutof
cutoff
strpcr
rqpcr
chimer
result
equal
distribut
p
appli
cutoff
rqpcr
risk
relaps
significantli
higher
children
imc
compar
children
without
imc
cutoff
hazard
ratio
hr
relaps
ci
p
ci
p
ci
imc
recipi
dna
respect
among
children
relaps
imc
observ
median
day
prior
relaps
comparison
strpcr
imc
detect
day
prior
relaps
associ
relaps
hr
ci
cumul
incid
relaps
cir
children
imc
ci
ci
imc
respect
figur
conclus
chang
chimer
rqpcr
associ
subsequ
relaps
three
cutoff
level
month
prior
relaps
although
limit
retrospect
design
result
indic
monitor
chimer
rqpcr
applic
earli
detect
relaps
conflict
interest
studi
support
childhood
cancer
foundat
danish
cancer
societi
dansk
none
author
anyth
disclos
rigshospitalet
univers
copenhagen
depart
paediatr
adolesc
medicin
copenhagen
denmark
rigshospitalet
univers
copenhagen
depart
growth
reproduct
copenhagen
denmark
background
allohsct
challeng
signific
toxic
mainli
relat
infect
inflammatori
complic
induc
due
depress
marrow
function
damag
epitheli
barrier
insulinlik
growth
factor
play
key
role
growth
repair
tissu
includ
epithelium
endothelium
hematopoiet
cell
previou
studi
anim
adult
undergo
hsct
indic
reduct
lead
poorer
outcom
investig
retrospect
level
baselin
year
posthsct
pediatr
cohort
explor
associ
outcom
hematopoiet
reconstitut
method
includ
children
age
rang
undergo
hsct
nation
danish
hsct
center
januari
decemb
diagnos
includ
malign
n
nonmalign
disord
n
donor
either
match
sibl
n
match
unrel
donor
n
graft
includ
marrow
n
peripher
stem
cell
n
due
clinic
routin
institut
schedul
measur
avail
pretranspl
regular
interv
sever
year
posthsct
due
age
sexrel
differ
level
sdscore
appli
analys
base
healthi
danish
children
result
median
prehsct
level
significantli
reduc
median
sdscore
p
remain
reduc
two
year
posthsct
figur
pretranspl
level
relat
sex
age
malignnonmalign
diagnosi
patient
level
sdscore
prehsct
remain
sdscore
first
year
posthsct
tend
normal
figur
group
patient
significantli
slower
hematolog
recoveri
median
time
anc
vs
day
p
thrombocyt
x
vs
day
p
thrombocyt
x
vs
day
p
patient
malign
diagnosi
patient
undergo
highintens
myeloabl
condit
tbi
nontbi
regimen
without
fludarabin
gener
lower
median
level
posttranspl
year
median
vs
sdscore
p
vs
sdscore
p
respect
furthermor
reduct
pronounc
patient
higher
degre
system
inflamm
phase
aplasia
crp
day
posttranspl
rs
p
pre
posttranspl
level
relat
agvhd
relaps
os
conclus
studi
demonstr
children
refer
allogen
hsct
reduc
longstand
reduct
level
impact
hematolog
reconstitut
translat
poorer
surviv
find
explor
valid
prospect
studi
includ
studi
growth
tissu
composit
conflict
interest
none
author
anyth
disclos
nation
univers
health
system
khoo
teck
puatnat
univers
children
medic
institut
singapor
singapor
nation
univers
cancer
institut
singapor
singapor
nation
univers
health
system
laboratori
medicin
singapor
singapor
nation
univers
singapor
singapor
singapor
background
haploident
stem
cell
transplant
haplosct
vari
degre
tcell
manipul
chang
kinet
engraft
higher
incid
cytokin
releas
syndrom
method
retrospect
review
pediatr
haplosct
done
center
result
thirtyeight
pediatr
haplosct
perform
septemb
decemb
patient
receiv
tdeplet
tcd
haplosct
major
tcd
tcr
ab
tcd
patient
treplet
pci
haplosct
graft
failur
tcd
haplosct
show
fast
engraft
also
note
monocyt
engraft
preced
neutrophil
engraft
cohort
tcd
fever
time
neutrophil
engraft
major
cr
grade
one
patient
grade
cr
major
requir
support
care
requir
short
cours
hydrocortison
requir
tocilizumab
patient
cr
develop
agvhd
grade
grade
grade
year
patient
requir
steroid
immunosuppress
discontinu
conclus
tcd
haploident
sct
show
rapid
engraft
accompani
low
grade
cr
rare
need
system
steroid
treatment
despit
high
incid
cr
agvhd
develop
mostli
incid
grade
gvhd
conflict
interest
none
tabl
kinet
engraft
hacettep
univers
faculti
medicin
depart
pediatr
divis
bmt
unit
ankara
turkey
hacettep
univers
faculti
medicin
depart
pediatr
divis
bmt
unit
ankara
turkey
hacettep
univers
faculti
medicin
ankara
turkey
background
skin
commonli
affect
organ
chronic
graftvshost
diseas
gvhd
cutan
manifest
chronic
gvhd
vari
nonsclerot
lichen
planuslik
erupt
poikiloderma
morphealik
deep
sclerot
condit
vitiligo
well
character
chronic
gvhd
set
extens
leucoderma
leucotrichia
rare
report
present
leucoderma
leucotrichia
associ
gvhd
boy
undergon
allogen
bone
marrow
transplant
wiskottaldrich
syndrom
method
clinic
transplant
characterist
patient
record
result
year
old
boy
wiskottaldrich
syndrom
underw
hsct
hla
ident
sister
sourc
stem
cell
peripher
blood
number
cell
condit
regimen
includ
busulfan
mgkgday
cyclophosphamid
mgkgday
day
cyclosporin
csa
methotrex
use
graft
versu
host
diseas
prophylaxi
neutrophil
platelet
engraft
achiev
day
respect
posttransplant
period
patient
develop
skin
infect
neutropen
fever
broad
spectrum
antibacteri
antifung
treatment
given
patient
develop
acut
gvhd
grade
skin
intestin
involv
day
methyl
prednisolon
mgkg
start
month
patient
develop
chronic
gvhd
involv
skin
oral
mucosa
skin
lesion
includ
vitiligo
hand
month
vitiligo
lesion
progress
gener
leucoderma
leucotrichia
follow
period
chronic
gvhd
also
involv
organ
includ
liver
eye
lung
patient
given
methyl
prednisolon
csatacrolimu
mycophenol
mofetil
chronic
gvhd
although
chronic
gvhd
organ
system
respond
partial
complet
agent
leucoderma
leucotrichia
nonrespons
puva
psoralen
ultraviolet
treatment
plan
present
patient
month
full
donor
chimer
conclus
sever
case
report
small
seri
report
vitiligo
follow
hsct
occur
set
gvhd
gvhd
seem
play
part
destruct
melanocyt
skinhom
autoreact
melanocytespecif
cytotox
lymphocyt
prematur
gray
hair
eyelash
vitiligolik
leukoderma
report
associ
chronic
gvhd
case
consequ
sclerodermat
lesion
poikiloderm
aspect
patient
leucoderma
leucotrichia
appear
absenc
sclerodermat
skin
lesion
conflict
interest
conflict
interest
copenhagen
univers
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
copenhagen
univers
hospit
rigshospitalet
institut
inflamm
research
copenhagen
denmark
background
sosvod
lifethreaten
complic
allogen
hsct
new
pediatr
diagnost
criteria
suggest
due
agerel
differ
present
incid
outcom
corbacioglu
et
al
criteria
score
bilirubin
weight
gain
individu
baselin
moreov
transfus
refractori
thrombocytopenia
rt
ad
addit
criterion
time
restrict
retrospect
studi
assess
pediatr
ebmt
criteria
along
baltimor
modifi
seattl
criteria
method
children
age
year
rang
undergo
allohsct
denmark
includ
diagnos
malign
benign
diseas
patient
diagnos
associ
increas
risk
sosvod
donor
msd
mud
haploident
ucb
stem
cell
sourc
bm
pbsc
ucb
graft
condit
regimen
tbibas
busulfanbas
clinic
paramet
regist
first
year
follow
hsct
bilirubin
consid
increas
normal
rang
time
baselin
valu
rt
defin
unexplain
platelet
transfus
daili
day
result
patient
fulfil
ebmt
criteria
patient
fulfil
modifi
seattl
criteria
none
met
baltimor
criteria
patient
fulfil
ebmt
criteria
present
rise
bilirubin
weight
gain
consumpt
rt
hepatomegali
ascit
group
includ
patient
fulfil
seattl
criteria
except
one
evalu
clinic
relev
appli
ebmt
criteria
look
clinic
cours
transplant
patient
fulfil
ebmt
sosvod
criteria
longer
durat
primari
admiss
day
vs
day
furthermor
patient
fulfil
ebmt
sosvod
criteria
receiv
diuret
day
within
month
day
vs
day
p
longer
time
platelet
engraft
day
vs
day
p
found
signific
differ
patient
without
sosvod
regard
develop
acut
chronic
gvhd
time
neutrophil
engraft
admiss
icu
p
two
patient
select
fulfil
embt
criteria
die
treatmentrel
complic
within
one
year
posthsct
pulmonari
sosvod
macrophag
activ
syndrom
clinic
detail
patient
present
conclus
applic
pediatr
ebmt
criteria
defin
broader
group
patient
group
defin
seattl
criteria
still
contain
patient
fulfil
seattl
criteria
patient
meet
ebmt
criteria
gener
longer
durat
primari
admiss
major
cours
transplant
without
sever
complic
importantli
howev
applic
ebmt
criteria
identifi
patient
fatal
inflammatori
complic
identifi
seattl
criteria
find
suggest
applic
pediatr
ebmt
criteria
may
help
identifi
patient
increas
risk
sever
treatmentrel
complic
mortal
although
risk
overdiagnosi
assess
ebmt
criteria
base
prospect
studi
need
conflict
interest
none
author
anyth
disclos
univers
crete
laboratori
blood
diseas
childhood
cancer
biolog
univers
hospit
heraklion
pediatr
hematologyoncolog
heraklion
greec
univers
crete
medic
school
univers
hospit
heraklion
gastrenterologyhepatolog
heraklion
greec
univers
crete
medic
school
clinic
social
famili
medicin
heraklion
greec
background
nonalcohol
fatti
liver
diseas
nafld
repres
common
caus
liver
diseas
children
adolesc
western
world
affect
pediatr
popul
exce
amongst
obes
patient
children
adolesc
treat
acut
lymphoblast
leukemia
lymphoma
risk
develop
metabol
disord
obes
hyperglycemia
insulin
resist
ir
hypertriglyceridemia
hypertens
lead
increas
morbid
mortal
earli
adulthood
aim
studi
preval
nafld
childhood
lymphoma
survivor
assess
diagnost
prognost
marker
method
eighti
six
male
femal
children
adolesc
young
adult
median
age
year
diagnos
hematolog
malign
lymphoma
includ
studi
antineoplast
treatment
ceas
least
one
year
median
posttreat
year
patient
underw
bodi
measur
biochem
assay
liver
ultrasound
studi
small
group
fibroscan
cap
homair
quicki
calcul
fast
plasma
glucos
insulin
valu
histori
impair
glucos
metabol
caus
liver
toxic
exclud
result
us
find
due
nafld
observ
studi
popul
overweight
obes
patient
base
bmi
adjust
age
account
greater
risk
nafld
p
patient
nafld
significantli
higher
bmi
waist
circumfer
waistheight
ratio
whtr
without
nafld
p
correl
analysi
show
nafld
posit
correl
alt
ast
ratio
p
total
cholesterol
ldl
triglycerid
p
homair
significantli
correl
bmi
p
waist
circumfer
p
whtr
p
ldl
hdl
p
triglycerid
p
nafld
fibrosi
score
patient
homair
valu
indic
earli
insulin
resist
consid
variabl
stepwis
analysi
age
bmi
waist
circumfer
whtr
alt
ast
ratio
independ
associ
nafld
p
conclus
ongo
studi
show
childhood
lymphoma
survivor
increas
preval
nafld
ir
viscer
adipos
data
support
need
prevent
viscer
adipos
search
metabol
syndrom
ephas
need
intervent
diet
lifestyl
followup
patient
conflict
interest
conflict
interest
hadassah
hebrew
univers
medic
center
depart
clinic
immunolog
bone
marrow
transplant
jerusalem
israel
hadassahhebrew
univers
medic
center
depart
bone
marrow
transplant
jerusalem
israel
hadassah
hebrew
univers
medic
center
jerusalem
israel
background
relaps
follow
hematopoiet
stem
cell
transplant
hsct
lead
indic
second
transplant
patient
malign
diseas
hsct
shown
superior
chemotherapi
alon
palli
measur
patient
nonmalign
diseas
second
transplant
may
consid
graft
failur
first
transplant
data
regard
outcom
second
hsct
especi
non
malign
diseas
scare
retrospect
analyz
pediatr
patient
underw
one
hsct
hadassah
hospit
surviv
toxic
method
children
age
receiv
hsct
institut
patient
underli
malign
transplant
non
malign
indic
includ
inborn
error
metabol
non
malign
hematolog
diseas
immun
defici
group
non
malign
diseas
patient
receiv
hsct
children
hsct
among
patient
malign
receiv
hsct
children
underw
hsct
result
malign
group
patient
surviv
surviv
patient
transplant
symptom
gvhd
children
die
relaps
malign
diseas
die
differ
complic
hsct
trm
group
non
malign
diseas
patient
surviv
without
evid
diseas
ef
od
rest
die
transplant
relat
toxic
graft
versu
host
diseas
conclus
treatment
relat
mortal
follow
second
hsct
higher
compar
first
transplant
higher
surviv
rate
non
malign
group
suggest
transplant
follow
graft
failur
consid
patient
otherwis
incur
underli
diseas
though
outcom
patient
relaps
malign
diseas
follow
hsct
poor
second
transplant
may
benefit
subset
patient
attempt
achiev
complet
remiss
prior
transplant
made
improv
outcom
due
small
number
patient
cohort
multicent
trial
need
conflict
interest
noth
disclos
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
immunolog
servic
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
imib
univers
murcia
haematolog
servic
stem
cell
transplant
unit
el
palmar
murcia
spain
background
allogen
stem
cell
transplant
wide
use
treatment
varieti
hematolog
diseas
solid
tumor
main
problem
mortal
trm
mostli
due
toxic
rrt
myeloabl
condit
mac
diseas
gvhd
diseas
relaps
usual
higher
nonmyeloabl
regimen
method
retrospect
observ
studi
base
medic
record
patient
age
year
underw
allogen
stem
cell
transplant
tertiari
hospit
januari
decemb
result
overal
allosct
perform
pediatr
patient
male
median
age
year
followup
month
patient
transplant
malign
hemopathi
aml
md
jmml
solid
tumor
ewe
sarcoma
neuroblastoma
osteosarcoma
non
malign
disord
inborn
error
metabol
haemoglobinopathi
scid
inherit
acquir
bone
marrow
failur
syndrom
primari
hemophagocyt
lymphohistiocytosi
sideroblast
anemia
sourc
stem
cell
peripher
blood
procedur
unrel
donor
relat
donor
bone
marrow
procedur
unrel
donor
relat
donor
ident
sibl
umbil
cord
procedur
match
relat
donor
mrd
account
case
mismatch
one
case
haploident
case
side
unrel
donor
match
case
mismatch
case
two
main
type
condit
regimen
use
high
intens
regimen
patient
busulfan
melphalan
base
cyclophosphamid
tbi
base
low
intens
regimen
fludarabin
base
gvhd
prophylaxi
consist
csp
mtx
csp
mmf
other
csp
mmf
cycspmmf
case
venoocclus
diseas
vod
prophylaxi
made
ursodeoxychol
acid
low
molecular
weight
heparin
graft
failur
occur
procedur
frequent
earli
toxic
mucos
patient
grade
grade
acut
gvhd
grade
ii
grade
iiiiv
acut
transient
hepat
toxic
pulmonari
complic
infecti
transfus
relat
acut
lung
injuri
cyclosporin
induc
acut
renal
injuri
neurolog
impair
posterior
revers
encephalopathi
syndrom
frequent
metabol
complic
vod
engraft
syndrom
late
toxic
endocrin
anomali
follow
chronic
gvhd
progressionfre
surviv
day
day
overal
surviv
day
day
mortal
rate
case
relapseprogress
diseas
case
chronic
gvhd
multiorgan
failur
secondari
septic
shock
conclus
allosct
pediatr
patient
safe
effect
treatment
hematolog
non
hematolog
malign
overal
result
pediatr
program
start
similar
obtain
pediatr
seri
conflict
interest
none
king
hussein
cancer
center
pediatr
stem
cell
transplant
amman
jordan
king
hussein
cancer
center
depart
pediatr
amman
jordan
king
hussein
cancer
center
clinic
pharmaci
amman
jordan
king
hussein
cancer
center
bone
marrowstem
cell
lab
amman
jordan
background
haploident
stem
cell
umbil
cord
blood
ucb
match
unrel
donor
mud
transplant
common
altern
donor
strategi
use
match
relat
sibl
donor
mrd
avail
jordan
patient
mrd
altern
donor
pursu
remain
studi
compar
outcom
haploident
stem
cell
umbil
cord
blood
ucb
transplant
program
method
retrospect
analysi
conduct
pediatr
patient
underw
haploident
stem
cell
umbil
cord
blood
ucb
transplant
king
hussein
cancer
center
khcc
obtain
irb
approv
data
collect
includ
transplant
indic
acut
chronic
graftversushost
diseas
agvhd
cgvhd
cytomegaloviru
cmv
reactiv
note
cyclophosphamid
post
unmanipul
stem
cell
infus
use
tcell
deplet
haploident
transplant
result
total
fifti
six
pediatr
patient
transplant
use
either
haploident
stem
cell
umbil
cord
blood
ucb
transplant
transplant
indic
haploident
primari
immun
defici
syndrom
acut
leukemia
sever
aplast
anemia
fanconi
anemia
inborn
error
metabol
relaps
hodgkin
diseas
osteopetrosi
congenit
amegakaryocyt
thrombocytopenia
transplant
indic
ucb
acut
leukemia
chediakhigashi
syndrom
thalassemia
fanconi
anemia
jmml
sever
aplast
anemia
leukocyt
adhes
defici
transplant
condit
intens
posttranspl
complic
depict
tabl
conclus
haploident
stem
cell
umbil
cord
blood
ucb
transplant
viabl
lifesav
altern
donor
program
complic
center
manag
mortal
similar
report
literatur
time
avail
haploident
donor
make
option
plausibl
place
umbil
cord
transplant
feasibl
conflict
interest
conflict
interest
tabl
tabl
transplant
condit
intens
post
mazumdar
shaw
cancer
center
narayana
health
citi
pediatr
hematolog
oncolog
bangalor
india
manip
hospit
jaipur
india
artemi
hospit
gurgaon
india
kokilaben
dhirubhai
ambani
hospit
mumbai
india
medanta
medic
hospit
gurgaon
india
hcg
hospit
bangalor
india
gleneagl
global
health
citi
chennai
india
bg
gleneagl
global
hospit
bangalor
india
mazumdar
shaw
cancer
center
narayana
health
citi
bangalor
india
sir
gangaram
hospit
delhi
india
background
hematopoiet
stem
cell
transplant
hsct
life
save
sometim
treatment
option
manag
mani
children
malign
nonmalign
diseas
india
popul
billion
children
need
robust
hsct
program
children
across
multipl
center
pauciti
data
hsct
pediatr
patient
india
indian
pediatr
hematolog
oncolog
group
iphog
collabor
research
group
report
outcom
hsct
children
variou
center
across
india
method
retrospect
studi
hsct
data
pediatr
transplant
center
across
india
till
dec
collect
standard
format
analysi
data
collect
demograph
profil
indic
transplant
condit
regimen
sourc
stem
cell
graft
versu
host
diseas
gvhd
outcom
result
total
number
hsct
perform
center
time
frame
complet
data
avail
transplant
mean
age
transplant
year
month
year
male
femal
patient
common
indic
hsct
hemoglobinopathi
thalassemia
contribut
major
acut
chronic
leukemia
constitut
bone
marrow
failur
syndrom
autolog
transplant
solid
tumor
primari
immunodefici
disord
variou
condit
major
transplant
done
first
transplant
allogen
autolog
transplant
compris
patient
respect
among
allogen
hsct
fulli
match
siblingfamili
donor
compris
haploident
transplant
match
unrel
donor
mud
cord
blood
compris
transplant
respect
stem
cell
collect
peripher
blood
donor
bone
marrow
sourc
cord
blood
use
case
combin
stem
cell
sourc
use
acut
gvhd
report
patient
chronic
gvhd
patient
acut
gvhd
commonli
seen
patient
haploident
transplant
match
unrel
transplant
among
patient
undergo
hsct
overal
mortal
compris
infect
common
caus
follow
diseas
recurr
gvhd
overal
surviv
autolog
match
siblingfamili
donor
haploident
mud
transplant
respect
trend
year
shown
graph
graph
conclus
report
largest
indian
data
hsct
pediatr
patient
india
thalassemia
commonest
indic
outcom
allogen
hsct
best
match
sibl
donor
categori
howev
outcom
haploident
mud
transplant
encourag
haploident
transplant
rise
conflict
interest
none
instituto
de
oncologia
porto
depart
immunehemotherapi
porto
portug
instituto
de
oncologia
porto
depart
pediatr
porto
portug
instituto
de
oncologia
porto
bone
marrow
transplant
unit
porto
portug
centro
hospitalar
porto
depart
clinic
hematolog
thrombosi
haemostasi
unit
porto
portug
instituto
de
oncologia
porto
depart
cellular
therapi
porto
portug
background
paper
report
first
case
sever
congenit
hemophiliac
child
highrisk
neuroblastoma
propos
highdos
chemotherapi
peripher
blood
stem
cell
pbsc
support
method
child
present
age
left
adren
mass
accompani
retroperiton
lymph
node
renal
bone
marrow
metastasi
stage
iv
inss
neuroblastoma
undifferenti
larg
cell
variant
fishmut
present
diagnosi
rel
loss
rel
gain
mycngen
standard
chemotherapi
start
rapidcojecprotocol
lead
good
partial
respons
tumor
surgic
excis
done
propos
matinprotocol
mibgtopotecan
follow
doubl
autolog
pbsc
transplant
patient
initi
prophylaxi
fviii
concentr
immedi
tumor
diagnosi
ondemand
treatment
use
adapt
fviii
dose
hemorrhag
risk
associ
differ
therapi
invas
procedur
insertionreplac
central
venou
cathet
abdomin
surgeri
pbsc
collectioninfus
result
old
patient
collect
pbsc
apheresi
separ
spectra
version
mnc
program
insert
right
subclavian
vein
hickman
cathet
mobil
number
cell
peripher
blood
oneday
collect
perform
whole
blood
process
hour
extracorpor
circuit
anticoagul
citrat
ratio
graft
present
good
cellular
content
cellskg
function
cfugmkg
steril
neg
bacterialmycolog
cultur
fishneg
subsequ
cryopreserv
liquid
nitrogen
ten
twelv
month
diagnosi
cellskg
thaw
infus
transplant
hematolog
recoveri
occur
respect
despit
hemorrhag
diseas
patient
experi
sever
bleed
event
need
increas
transfusion
use
bone
marrow
trephin
biopsi
mibgscintigraphi
show
absenc
metastat
involv
howev
ctscan
reveal
metastat
renal
lesion
patient
current
propos
local
radiotherapi
conclus
pbsc
collect
demonstr
safe
effect
adult
prove
success
also
pediatr
reli
optim
techniqu
age
group
time
harvest
product
obtain
met
qualiti
requir
necessari
ensur
hematopoiet
graft
multidisciplinari
team
integr
clinic
laboratori
expert
allow
realiz
propos
treatment
name
highdos
chemotherapi
low
weight
child
sever
coagulopathi
metastat
tumor
conflict
interest
author
declar
conflict
interest
accomplish
work
tabl
clinic
set
abstract
previous
publish
wroclaw
medic
univers
dept
pediatr
hematolog
oncolog
bmt
unit
cic
poland
background
haploident
stem
cell
transplant
haplosct
altern
patient
advanc
hematolog
malign
without
match
famili
donor
especi
due
increas
alloreact
hla
kir
mismatch
risk
sever
gvhd
prevent
ex
vivo
tcell
deplet
posttranspl
cyclophosphamid
ptci
method
present
six
pediatr
patient
transplant
haploident
donor
ptci
three
girl
three
boy
age
year
underw
haplosct
august
novemb
result
patient
classic
baltimor
protocol
use
gy
total
bodi
irradi
fludarabin
cyclophosphamid
two
patient
condit
origin
protocol
fcm
fludarabin
cyclophosphamid
mgkg
melphalan
one
patient
treat
treosulfan
fludarabin
one
treosulfan
fludarabin
cyclophosphamid
sourc
cell
bone
marrow
five
case
peripher
blood
apheresi
one
case
cyclosporin
use
recipi
mycophenol
mofetil
four
engraft
complet
donor
chimer
achiev
four
patient
one
patient
reject
one
die
leukocyt
recoveri
engraft
patient
develop
skin
agvhd
maxim
stage
iii
two
gut
agvhd
stage
iii
one
liver
agvhd
stage
ii
recipi
cgvhd
observ
engraft
patient
aliv
two
patient
fcm
condit
live
complet
remiss
month
transplant
one
patient
baltimor
condit
die
due
relaps
diagnos
month
transplant
one
patient
condit
treofluci
condit
aliv
month
transplant
tcell
count
cellsul
reach
day
haplosct
patient
patient
reject
graft
salvag
stem
cell
transplant
ation
unrel
donor
conclus
haplosct
viabl
option
patient
advanc
malign
relaps
transplant
heavili
pretreat
altern
tbifre
protocol
use
condit
ptci
haplosct
agvhd
rate
protocol
need
investig
conflict
interest
none
author
anyth
disclos
tabl
haploident
sct
ptci
pediatr
patient
hospit
universitario
la
paz
madrid
spain
universidad
autonoma
de
madrid
medicin
school
madrid
spain
hospit
universitario
la
paz
pediatr
hematooncolog
stem
cell
transplant
madrid
spain
universidad
autonoma
de
madrid
nation
center
biotechnolog
csic
madrid
spain
background
identif
pretransplant
variabl
risk
mortal
paediatr
haematopoiet
stem
cell
transplant
hsct
might
help
accur
patient
counsel
clinic
decisionmak
score
european
bone
marrow
transplant
ebmt
risk
score
shown
predict
pretranspl
risk
assess
adult
hsct
howev
address
yet
paediatr
hsct
fact
variabl
age
incorpor
origin
one
surviv
tree
model
easytointerpret
altern
statist
approach
identifi
subgroup
offer
cutoff
point
differ
covari
studi
aim
propos
surviv
tree
model
could
help
predict
mortal
paediatr
hsct
cohort
high
risk
leukemia
patient
method
analys
leukaemia
patient
receiv
hsct
center
construct
random
forest
classifi
databas
patient
malign
diseas
transplant
last
year
random
forest
identifi
four
variabl
highli
relat
final
result
death
surviv
patient
transplant
diseas
state
patient
age
time
diagnosi
transplant
ebmt
risk
score
variabl
construct
classif
tree
order
predict
outcom
hsct
result
diseas
surviv
df
wherea
cumul
nonrelaps
mortal
nrm
relaps
incid
valu
ebmt
risk
score
accord
univari
analysi
associ
increas
score
interv
decreas
probabl
os
lf
tree
show
three
group
significantli
differ
gener
popul
neg
side
patient
advanc
diseas
state
nonadvanc
age
month
year
ebmt
risk
score
larger
whose
transplant
occur
year
diagnost
mortal
significantli
larger
gener
popul
posit
side
small
children
age
month
year
transplant
prognost
significantli
better
gener
popul
two
group
point
promis
posit
prognost
nonadvanc
diseas
age
nonadvanc
diseas
age
howev
observ
number
patient
allow
show
statist
signific
differ
conclus
conclus
demonstr
tree
model
accur
attract
tool
predict
pediatr
hsct
outcom
institut
may
aid
evalu
individu
patient
prognosi
therebi
design
measur
improv
hsct
outcom
poor
prognosi
group
conflict
interest
noth
disclos
univers
medic
center
ulm
pediatr
ulm
germani
background
genet
defect
result
sever
combin
immunodefici
scid
absent
cell
nonfunct
b
cell
tb
scid
bcell
function
hematopoiet
stem
cell
transplant
hsct
depend
engraft
donor
bcell
object
studi
identifi
bcell
subpopul
earli
predictor
matur
function
bcell
hsct
addit
detect
iga
igm
method
retrospect
analys
long
term
surviv
patient
b
scid
due
mutat
hsct
institut
patient
independ
wherea
patient
remain
depend
regular
immunoglobulin
substitut
flow
cytometri
analysi
perform
blood
sampl
mnc
frozen
hsct
day
result
total
number
memori
bcell
proport
posit
cell
correl
well
bcell
function
hsct
depend
bcell
chimer
presenc
class
switch
memori
bcell
relat
total
memori
b
cell
though
prove
reliabl
marker
posit
bcell
function
sensit
specif
conclus
patient
bscid
ratio
specif
sensit
marker
day
identifi
need
igsubstitut
hsct
conflict
interest
author
noth
disclos
wroclaw
medic
univers
dept
pediatr
hematolog
oncolog
bmt
unit
cic
poland
background
killer
immunoglobulinlik
kir
receptor
play
role
regul
nklymphocyt
reactiv
affect
immunolog
respons
stem
cell
transplant
sct
recipi
inclus
kirassoci
factor
result
better
donor
select
allogen
sct
method
analys
role
donor
recipientrel
factor
children
allogen
sct
match
sibl
case
match
unrel
donor
case
children
transplant
due
nonmalign
indic
primari
fanconi
anemia
hlh
storag
malign
diseas
donor
sampl
test
kir
genotyp
use
kir
type
kit
miltenyi
de
impact
diagnosi
malign
vs
nonmalign
degre
hlamatch
locu
separ
pretranspl
condit
busulfan
treosulfan
tbicontain
kirgenotyp
result
analys
use
statistica
graphpad
prism
result
patient
hla
match
sibl
donor
msd
pt
match
unrel
donor
mud
pt
partial
match
donor
pmd
mismatch
hla
antigen
present
locu
patient
b
b
pt
c
pt
pt
hla
pt
calcul
bcontent
graftversushost
gvh
kirligand
mismatch
observ
patient
hostversusgraft
hvg
case
probabl
os
analys
group
better
donor
choic
associ
higher
probabl
surviv
msd
vs
mud
vs
pmd
vs
vs
probabl
os
decreas
presenc
gvh
kir
mismatch
vs
analys
factor
affect
os
multivari
analysi
use
cox
regress
model
reveal
gvh
kir
mismatch
hr
ci
relev
factor
os
trm
whole
group
statist
signific
factor
affect
trm
identifi
conclus
case
partial
match
donor
optim
donor
choic
algorithm
elimin
presenc
graftversushost
kir
ligand
mismatch
effect
kir
genotyp
presenc
singl
activ
inhibit
kir
allel
sct
outcom
elus
need
cautiou
consider
donor
select
conflict
interest
none
author
anyth
disclos
carol
davila
univers
medicin
bucharest
pediatr
hematolog
bmt
bucharest
romania
carol
davila
univers
medicin
bucharest
romania
fundeni
clinic
institut
bucharest
romania
background
hodgkin
lymphoma
hl
repres
pediatr
cancer
highli
curabl
rate
standard
chemotherapi
despit
good
prognosi
approxim
patient
relaps
treatment
option
relaps
refractori
hl
highdos
chemotherapi
cht
autolog
sct
studi
evalu
singl
center
experi
year
treatment
pediatr
hodgkin
lymphoma
patient
method
retrospect
evalu
pediatr
patient
refractori
relaps
hl
receiv
autolog
sct
pediatr
hematolog
bone
marrow
transplant
depart
fundeni
clinic
institut
patient
record
demograph
data
clinic
find
diagnosi
treatment
cours
followup
first
line
treatment
includ
sever
chemotherapi
regimen
abvd
coppabv
oepa
beacopp
local
radiotherapi
rt
second
line
treatment
refractori
relaps
hl
consist
salvag
therapi
dhap
igev
regimen
follow
highdos
chemotherapi
autolog
hsct
salvag
therapi
patient
evalu
petct
parent
sign
inform
consent
form
result
analyz
consecut
pediatr
patient
hl
sex
ratio
age
rang
refer
center
base
hystopatholog
result
patient
diagnos
nodular
sclerosi
mix
cellular
lymphocyt
deplet
earli
stage
diagnosi
advanc
stage
salvag
therapi
consist
cycl
dhap
case
cycl
igev
case
pet
evalu
transplant
show
complet
remiss
case
partial
remiss
case
progress
diseas
case
beam
regimen
use
leam
median
time
transplant
month
rang
moth
diseas
free
surviv
accord
pretranspl
statu
show
pet
neg
patient
pet
posit
partial
remiss
pet
posit
progress
diseas
conclus
conclus
patient
maintain
cr
autolog
sct
relaps
relaps
patient
die
autolog
hsct
recommend
patient
relaps
refractori
diseas
chemosensit
diseas
demonstr
petct
patient
progress
diseas
salvag
chemotherapi
therapeut
option
consid
conflict
interest
noth
disclos
wroclaw
medic
univers
depart
pediatr
hematolog
oncolog
bmt
wroclaw
poland
sheffield
children
hospit
depart
paediatr
haematolog
sheffield
unit
kingdom
univers
hospit
collegium
medicum
umk
depart
paediatr
haematolog
oncolog
bydgoszcz
poland
univers
hospit
frankfurt
goeth
univers
depart
children
adolesc
divis
stem
cell
transplant
immunolog
frankfurt
germani
univers
hospit
regensburg
depart
paediatr
oncolog
haematolog
regensburg
germani
univers
hospit
muenster
depart
children
adolesc
pediatr
hematolog
oncolog
muenster
germani
hannov
medic
school
center
pediatr
adolesc
medicin
pediatr
hematolog
oncolog
hannov
germani
medic
univers
lublin
depart
pediatr
hematolog
oncolog
lublin
poland
jagiellonian
univers
medic
collag
univers
children
hospit
cracow
depart
clinic
immunolog
transplantolog
cracow
poland
children
hospit
regina
margherita
clinic
research
unit
turin
itali
univers
hospit
heidelberg
depart
pediatr
hematolog
oncolog
heidelberg
germani
univers
hospit
jena
depart
pediatr
unit
hematolog
oncolog
stem
cell
transplant
jena
germani
univers
hospit
essen
depart
pediatr
iii
essen
germani
ircc
ospedal
pediatrico
bambino
depart
pediatr
hematolog
oncolog
rome
itali
univers
hospit
hamburg
eppendorf
clinic
pediatr
hematolog
oncolog
hamburg
germani
children
hospit
juliu
maximilian
univers
depart
pediatr
hematolog
oncolog
stem
cell
transplant
wuerzburg
germani
medic
school
charl
univers
motol
depart
pediatr
hematolog
oncolog
pragu
czech
republ
univers
hospit
erlangen
depart
pediatr
hematolog
oncolog
erlangen
germani
great
ormond
street
hospit
depart
haematolog
london
unit
kingdom
background
standard
myeloabl
condit
regimen
prior
allogen
haematopoiet
stem
cell
transplant
allohsct
associ
consider
risk
sever
earli
late
advers
event
ae
especi
young
children
clinic
studi
indic
treosulfanbas
condit
myeloabl
immunosuppress
antineoplast
effect
favour
toxic
profil
present
efficaci
safeti
result
multicentr
intern
openlabel
prospect
phase
ii
trial
evalu
treosulfanbas
prepar
regimen
paediatr
patient
undergo
allohsct
method
patient
male
femal
less
year
old
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
haematolog
remiss
myelodysplast
syndrom
juvenil
myelomonocyt
leukaemia
receiv
treosulfan
intraven
accord
bodi
surfac
area
day
fludarabin
fludarabin
thiotepa
administ
addit
investig
discret
total
patient
receiv
bone
marrow
wherea
patient
receiv
peripher
blood
stem
cell
primari
object
studi
freedom
transplant
treatment
relat
mortal
start
condit
treatment
day
allohsct
result
data
present
abstract
describ
day
trial
result
final
followup
avail
confer
median
patient
age
year
total
patient
underw
match
ie
allelematch
unrel
donor
allohsct
remain
given
match
sibl
donor
transplant
freedom
transplant
treatment
relat
mortal
day
allohsct
confid
interv
ci
transplantationrel
death
day
sepsi
stenotrophomona
maltophilia
incid
complet
donortyp
chimer
ci
visit
day
ci
visit
day
day
cumul
incid
grade
iv
acut
graftversushost
diseas
ci
grade
iii
iv
ci
median
durat
ctcae
grade
iv
neutropenia
day
rang
day
primari
secondari
graft
failur
patient
receiv
stem
cell
boost
occur
common
ae
least
ctcae
grade
iii
mucos
infect
nausea
patient
develop
hepat
sinusoid
occlus
syndrom
conclus
treosulfanbas
condit
result
excel
engraft
low
transplant
treatment
relat
mortal
day
allohsct
paediatr
patient
haematolog
malign
addit
regimenrel
toxic
limit
chimer
data
day
highlight
myeloabl
properti
condit
regimen
clinic
trial
registri
eudract
number
clinicaltrialsgov
identifi
conflict
interest
vora
advisori
board
member
jazz
pfizer
novarti
k
kalwak
travel
grant
medac
sanofi
sykora
speaker
fee
jazz
research
travel
grant
medac
travel
grant
neovii
p
bader
research
grant
neovii
medac
b
kremen
dsmc
member
miltenyi
biotec
mueller
k
patrick
travel
grant
medac
remain
author
noth
disclos
first
state
pavlov
medic
univers
saint
petersburg
raisa
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
saint
petersburg
russian
feder
background
eventu
outcom
infant
leukemia
yo
term
relapsefre
surviv
rf
poor
compar
leukemia
older
children
despit
use
maxim
intensifi
standard
therapi
compar
effect
chemotherapi
allogen
hematopoiet
stem
cell
transplant
allohsct
data
contradictori
sever
studi
suggest
allohsct
improv
outcom
infant
acut
leukemia
al
primari
aim
evalu
feasibl
outcom
allohsct
infant
al
secondari
aim
assess
factor
contribut
longterm
surviv
method
may
juli
infant
rang
month
birth
median
month
al
normal
analyz
pt
receiv
chemotherapi
allohsct
prednisolon
good
respond
pgr
prednisolon
poor
respond
ppr
median
time
day
statu
moment
allohsct
receiv
bridg
chemotherapi
allohsct
primari
resist
resist
relaps
achiev
respons
type
allohsct
condit
regimen
mac
bucygiac
macreduc
toxic
treoflu
ric
flumel
pt
receiv
prophylaxi
agvhd
base
addit
atg
receiv
pt
ptci
atg
ptci
median
median
followup
surviv
patient
year
statist
analys
perform
use
spss
result
group
os
pt
transplant
os
better
pt
bridg
chemotherapi
allohsct
vs
respect
statist
signific
os
allohsct
patient
vs
aml
vs
mllr
vs
type
allohsct
haplo
vs
msd
mud
age
moment
allohsct
vs
condit
regimen
mac
vs
macr
vs
ric
cumul
incid
grade
agvhd
grade
moder
cumul
incid
relaps
mortal
vod
bloodstream
relaps
conclus
hsct
without
mrd
allow
achiev
longterm
surviv
infant
al
despit
accept
frequenc
acut
chronic
gvhd
main
caus
death
studi
relaps
allohsct
encourag
overal
surviv
achiev
unfavor
group
bridg
therapi
take
account
frequenc
posttranspl
relaps
group
patient
necessari
carri
prevent
prophylaxi
therapi
earli
posttranspl
period
conflict
interest
autorth
declar
conflict
interest
univers
hospit
muenster
depart
pediatr
hematolog
oncolog
bmt
muenster
germani
universityhospit
padua
depart
child
woman
health
oncolog
hematolog
divis
padua
itali
royal
marsden
hospit
depart
paediatr
oncolog
sutton
unit
kingdom
hospic
civil
de
lyon
institut
pediatr
hematolog
oncolog
lyon
cedex
franc
gustav
roussi
cancer
campu
depart
pediatr
oncolog
villejuif
franc
medic
park
hospit
depart
pediatr
hematolog
oncolog
bmt
unit
istanbul
turkey
sahlgrenska
univers
hospit
depart
pediatr
institut
clinic
scienc
gothenburg
sweden
children
cancer
center
nation
center
child
health
develop
tokyo
japan
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
clinic
research
depart
minsk
belaru
feder
center
pediatr
hematolog
oncolog
immunolog
pediatr
hematolog
oncolog
moscow
russian
feder
univers
hospit
valencia
depart
pediatr
hematolog
oncolog
valencia
spain
univers
hospit
la
depart
pediatr
oncolog
valencia
spain
charl
univers
univers
hospit
motol
depart
paediatr
haematolog
oncolog
pragu
czech
republ
st
anna
children
hospit
medic
univers
vienna
depart
pediatr
hematolog
oncolog
vienna
austria
univers
hong
kong
li
ka
shing
faculti
medicin
queen
mari
hospit
depart
pediatr
adolesc
medicin
hong
kong
china
slovak
health
univers
children
faculti
hospit
clinic
pediatr
oncolog
hematolog
bystrica
slovakia
nation
ukrainian
children
hospit
ochmatdyt
center
pediatr
oncohematolog
bmt
kiev
ukrain
univers
hospit
copenhagen
depart
paediatr
adolesc
medicin
rigshospitalet
copenhagen
denmark
poznan
univers
medic
scienc
depart
pediatr
oncolog
hematolog
transplantolog
poznan
poland
univers
hospit
gasthuisberg
depart
paediatr
haematolog
oncolog
leuven
belgium
erasmu
medic
center
rotterdam
sophia
children
hospit
depart
pediatr
oncolog
hematolog
rotterdam
netherland
oslo
univers
hospit
depart
pediatr
hematolog
oncolog
oslo
norway
univers
hospit
zurich
depart
pediatr
oncolog
zurich
switzerland
univers
chile
faculti
medicin
hospit
dr
lui
calvo
mackenna
depart
pediatr
bone
marrow
transplant
unit
santiago
chile
cambridg
univers
hospit
nh
foundat
trust
depart
paediatr
haematolog
oncolog
palli
care
addenbrook
hospit
cambridg
unit
kingdom
justusliebigunivers
depart
pediatr
hematolog
oncolog
giessen
germani
hannov
medic
school
depart
pediatr
hematolog
oncolog
hannov
germani
clinica
pediatrica
degli
studi
di
milano
bicocca
ospedal
san
gerardo
monza
itali
background
nonhodgkin
lymphoma
nhl
children
adolesc
systemat
treatment
protocol
result
improv
eventfre
surviv
rate
without
transplant
indic
first
cr
howev
far
standard
treatment
approach
could
establish
relaps
refractori
nhl
rr
nhl
aim
current
project
gather
intern
experi
reinduct
strategi
children
adolesc
rr
nhl
identifi
factor
predict
outcom
method
retrospect
analysi
elig
case
collect
common
project
specif
crf
inclus
criteria
nhl
diagnosi
subtyp
except
alcl
b
age
diagnosi
year
c
diagnosi
inaft
jan
refractori
diseas
diseas
progress
relaps
primari
endpoint
studi
overal
surviv
po
secondari
endpoint
treatmentrel
mortal
trm
diseaserel
mortal
dod
result
total
elig
patient
report
follow
nation
group
germani
itali
uk
franc
turkey
sweden
finland
japan
belaru
moscow
spain
czech
republ
austria
hong
kong
slovakia
ukrain
denmark
poland
belgium
netherland
norway
switzerland
chile
median
age
initi
diagnosi
year
patient
male
distribut
histolog
subtyp
burkitt
dlbcl
pmlbl
matur
bnhl
specifi
tlbl
pblbl
ptcl
nhl
subtyp
eightyear
po
total
cohort
highli
signific
differ
accord
nhl
subtyp
po
burkitt
dlbcl
pmlbl
lbl
rare
subtyp
late
relaps
month
diagnosi
po
associ
superior
po
compar
rr
nhl
diagnos
month
po
month
po
month
po
nhl
onset
total
pt
receiv
hsct
plan
one
third
pt
achiev
diseas
progress
remain
two
third
outcom
poor
patient
receiv
highdos
treatment
po
compar
autolog
po
allogen
po
transplant
cumul
incid
trm
dod
patient
without
hsct
autolog
hsct
allo
hsct
among
patient
underw
hsct
remiss
statu
hsct
highli
signific
associ
outcom
po
cr
cru
vgpr
pr
sd
progress
diseas
conclus
intern
cooper
effort
provid
far
largest
seri
rr
nhl
allow
identif
prognost
paramet
rr
nhl
may
support
transplant
strategi
clinic
trial
registri
applic
conflict
interest
burk
consult
janssen
ibrutinib
daratumomab
payment
lectur
london
lymphoma
forum
remain
author
noth
disclos
rigshospitalet
copenhagen
univers
hospit
paediatr
pulmonari
servic
copenhagen
denmark
rigshospitalet
copenhagen
univers
hospit
nation
paediatr
hsct
centr
depart
paediatr
adolesc
medicin
copenhagen
denmark
background
pulmonari
chronic
graftversushost
diseas
cgvhd
complic
follow
allohsct
children
primarili
character
impair
small
airway
assess
lung
clearanc
index
lci
gain
multipl
breath
washouttest
mbw
might
sensit
spirometri
detect
small
airway
impair
feasibl
even
infant
might
therefor
potenti
lead
earlier
detect
pulmonari
complic
aim
studi
evalu
mbw
earli
diagnosi
cgvhdrelat
pulmonari
complic
predictor
pulmonari
outcom
follow
hsct
children
method
perform
prospect
longitudin
studi
children
treat
allohsct
spirometri
sulfur
hexafluorid
mbw
ami
innovis
denmark
total
lung
capac
tlc
diffus
capac
dlco
perform
baselin
day
allohsct
respiratori
symptom
sign
cgvhd
record
visit
accord
common
terminolog
criteria
advers
event
nih
criteria
respect
lci
calcul
use
custom
softwar
testpoint
capit
equip
result
twentyeight
children
includ
median
age
rang
year
median
zscore
valu
lci
increas
dlco
tlc
decreas
first
day
howev
valu
significantli
differ
baselin
measur
tendenc
toward
normal
zscore
paramet
seen
day
onward
eight
patient
fulfil
criteria
cgvhd
median
rang
day
hsct
one
verifi
lung
biopsi
seven
remain
patient
cgvhd
five
experienc
pulmonari
symptom
decreas
predict
andor
gastrap
hrct
day
signific
higher
lci
seen
children
develop
cgvhd
compar
patient
without
cgvhd
hsct
median
lci
zscore
vs
vs
vs
respect
similar
nonsignific
trend
day
howev
also
significantli
lower
children
cgvhd
day
median
zscore
vs
vs
vs
well
significantli
lower
tlc
day
median
tlc
zscore
vs
respect
patient
still
report
respiratori
symptom
day
tend
deterior
wherea
children
without
respiratori
symptom
improv
median
lci
zscore
baselin
day
indic
possibl
role
lci
predictor
persist
late
pulmonari
complic
conclus
found
signific
associ
increas
lci
day
follow
hsct
later
develop
cgvhd
although
signal
also
seen
believ
larger
studi
need
prefer
closer
measur
first
month
follow
hsct
order
evalu
potenti
role
mbw
earli
detect
cgvhd
predictor
pulmonari
outcom
allohsct
conflict
interest
none
author
anyth
disclos
hospit
israelita
albert
einstein
hematolog
hematopoiet
stem
cell
transplant
sao
paulo
brazil
instituto
da
hospit
da
da
universidad
de
paulo
sao
paulo
brazil
background
graft
failur
gf
sever
complic
hematopoiet
stem
cell
transplant
hsct
high
mortal
rate
report
incid
gf
higher
patient
receiv
hsct
nonmalign
diseas
salvag
second
hsct
rescu
patient
gf
optim
condit
regimen
donor
sourc
yet
determin
method
studi
retrospect
analys
experi
paediatr
patient
nonmalign
diseas
treat
tcell
replet
haploident
hsct
posttranspl
cyclophosphamid
graft
failur
first
hsct
result
januari
novemb
patient
nonmalign
diseas
submit
hsct
two
differ
institut
care
paediatr
patient
twelv
patient
develop
earli
graft
failur
underw
salvag
second
transplant
median
age
year
rang
diagnos
primari
immun
defici
diamondblackfan
anemia
leukodystrophi
sourc
stem
cell
donor
first
transplant
haploident
donor
bone
marrow
peripher
blood
stem
cell
unrel
cord
blood
unit
unrel
bone
marrow
four
patient
receiv
myeloabl
condit
regimen
receiv
reduc
toxic
regimen
graft
failur
diagnos
either
failur
recov
neutrophil
count
case
autolog
reconstitut
recipi
chimer
case
median
interv
first
second
transplant
day
rang
day
second
transplant
patient
receiv
tcell
replet
graft
haploident
rel
first
second
degre
cell
sourc
bone
marrow
case
granulocytecoloni
stimul
factor
use
five
donor
harvest
patient
receiv
reduc
toxic
condit
regimen
consist
fludarabin
day
cyclophosphamid
mgkg
day
total
bodi
irradi
gy
day
gvhd
prophylaxi
consist
cyclophosphamid
mgkgd
day
tacrolimu
cyclosporin
mycophenol
mofetil
start
day
patient
engraft
day
second
transplant
complet
donor
chimer
one
patient
die
earli
engraft
day
pulmonari
haemorrhag
three
patient
develop
acut
gvhd
grade
iiiii
nine
patient
viral
infect
part
cmv
five
patient
develop
chronic
gvhd
sever
case
one
patient
die
month
transplant
sever
pulmonari
gvhd
median
followup
month
ten
patient
aliv
complet
donor
chimer
month
second
transplant
seven
immunosuppress
conclus
conclus
tcell
replet
haploident
hsct
posttranspl
cyclophosphamid
rescu
patient
earli
graft
failur
excel
engraft
high
incid
chronic
gvhd
cohort
issu
better
prevent
conflict
interest
noth
disclos
citi
health
scienc
regina
margherita
children
hospit
pediatr
oncohematolog
turin
itali
citi
health
scienc
regina
margherita
children
hospit
pediatr
cardiolog
turin
itali
citi
health
scienc
regina
margherita
children
hospit
pediatr
surgeri
turin
itali
citi
health
scienc
san
giovanni
battista
hospit
radiolog
depart
turin
itali
background
select
splenic
arteri
embol
ssae
follow
splenectomi
show
feasibl
procedur
adult
patient
hypersplen
purpos
articl
describ
two
case
pediatr
patient
scid
jmml
hypersplen
sever
thrombocytopenia
hsct
method
case
month
old
girl
diagnos
scid
tbnk
mutat
underw
haploident
alfabeta
deplet
peripher
blood
hsct
mother
month
age
condit
base
treosulanfludarabin
serotherapi
post
transplant
immunosuppress
given
achiev
full
donor
engraft
month
hsct
develop
atyp
mycobatterium
infect
mycobacterium
avium
despit
intens
treatment
progress
hypersplen
occur
case
three
old
boy
diagnos
jmml
follow
unsuccess
search
unrel
donor
receiv
haploident
bone
marrow
hsct
mother
condit
regimen
base
busulfanthiotepafludarabin
gvhd
prophylaxi
base
post
hsct
cyclophosphamid
togeth
tacrolimu
mofetil
mycofenol
despit
earli
partial
engraft
splenomegali
reduc
hypersplen
dramat
worsen
select
splenic
arteri
embol
splenectomi
patient
splenectomi
indic
high
risk
sever
trombocytopenia
decid
perform
preoper
ssae
ssae
perform
catheter
laboratori
pediatr
intervent
cardiologist
intervent
radiologist
patient
receiv
platelet
plasma
infus
pre
procedur
case
splenic
arteri
incannul
judkin
righi
coronari
cathet
fr
microcathet
distal
branch
splenic
arter
micron
microparticl
slowli
inject
proxim
part
arteri
sever
platinum
coil
implant
total
occlus
splenic
arteri
patient
immedi
procedur
move
oper
room
laparoscop
splenectomi
perform
without
signif
complic
result
postsurgeri
outcom
unev
pt
quickli
return
normal
count
pt
present
earli
improv
transfus
need
three
month
first
haploident
hsct
receiv
second
haploident
hsct
primari
graft
failur
histolog
review
show
massiv
infiltr
atypyc
mycobatterium
diffus
leukem
infiltr
pt
respect
conclus
ssae
feasibl
procedur
pediatr
patient
also
earli
hsct
patient
present
postsurg
cours
without
signific
complic
return
bone
marrow
ward
one
night
icu
clinic
trial
registri
na
conflict
interest
none
author
anyth
disclos
tabl
clinic
data
patient
ssae
wroclaw
univers
econom
depart
manag
financ
comput
studi
wroclaw
poland
wroclaw
medic
univers
depart
pediatr
hematolog
oncolog
bmt
wroclaw
poland
background
rabbit
atg
remain
gold
standard
gvhd
prophylaxi
pediatr
patient
undergo
unrel
donor
transplant
udhsct
clear
data
atg
formul
would
result
better
outcom
aim
studi
compar
influenc
type
atg
grafalon
formerli
atg
freseniu
vs
thymoglobulin
outcom
includ
overal
surviv
eventfre
surviv
well
incid
agvhd
cgvhd
method
retrospect
singlecentr
studi
includ
children
male
femal
malign
nonmalign
diseas
underw
udhsct
pretranspl
rabbit
atg
infus
day
day
match
mismatch
donorrecipi
pair
patient
receiv
atg
freseniu
median
dose
mgkg
thymoglobulin
median
dose
analyz
outcom
overal
surviv
eventfre
surviv
well
cumul
incid
agvhd
cgvhd
multivari
analysi
influenc
variou
risk
factor
includ
type
atg
os
ef
done
use
cox
proport
hazard
model
logrank
test
cumul
incid
agvhd
cgvhd
assess
use
compet
risk
regress
gray
test
death
graft
reject
compet
event
result
studi
includ
patient
underw
udhsct
centr
year
median
followup
whole
cohort
day
iqr
overal
surviv
probabl
entir
studi
popul
wherea
patient
surviv
year
without
relaps
graft
reject
among
patient
develop
grade
iiiv
agvhd
grade
iiiiv
agvhd
sever
cgvhd
compar
influenc
atg
freseniu
vs
thymoglobulin
found
evid
statist
signific
betweengroup
differ
term
analyz
outcom
thymoglobulin
use
mainli
patient
nonmalign
disord
wherea
atg
freseniu
malign
diseas
p
overal
surviv
probabl
among
patient
receiv
atg
freseniu
vs
thymoglobulin
group
hazard
ratio
hr
eventfre
surviv
atg
freseniu
group
thymoglobulin
group
hr
cumul
incid
grade
iiiv
agvhd
group
hr
wherea
grade
iiiiv
agvhd
develop
atg
freseniu
group
thymoglobulin
group
hr
cumul
incid
sever
cgvhd
close
group
hr
conclus
pretranspl
rabbit
atg
remain
gold
standard
pediatr
udhsct
type
rabbit
atg
prove
success
optim
outcom
patient
worth
mention
despit
widespread
use
atg
freseniu
patient
malign
disord
result
includ
os
incid
gvhd
differ
patient
nonmalign
diseas
use
thymoglobulin
predomin
may
interest
see
futur
whether
atg
freseniu
nowaday
could
improv
outcom
children
nonmalign
disord
undergo
udhsct
conflict
interest
k
kalwak
travel
grant
sanofi
remain
author
noth
disclos
hacettep
univers
faculti
medicin
depart
pediatr
pulmonolog
ankara
turkey
hacettep
univers
faculti
medicin
depart
pediatr
hematolog
ankara
turkey
hacettep
univers
faculti
medicin
depart
pediatr
hematolog
bone
marrow
transplant
unit
ankara
turkey
background
pulmonari
alveolar
proteinosi
pap
rare
disord
character
accumul
surfact
like
lipoprotein
materi
within
alveolar
lumen
may
lead
progress
respiratori
failur
primari
pap
hereditari
form
caus
granulocytemacrophag
colonystimul
factor
gmcsf
receptor
defici
lead
function
insuffici
alveolar
macrophag
requir
gmcsf
signal
termin
differenti
effect
degrad
alveolar
protein
phospholipid
therapi
choic
primari
pap
extrem
limit
whole
lung
lavag
treatment
choic
want
describ
primari
pap
patient
success
treat
allogen
hematopoet
stem
cell
transplant
hsct
best
knowledg
first
case
report
success
transplant
literatur
method
clinic
transplant
characterist
patient
record
result
year
old
boy
present
cough
dyspnea
year
old
diagnos
primari
pap
homozyg
mutat
gene
code
treat
bilater
partial
lung
lavag
year
howev
lung
condit
get
wors
gradual
oxygen
depend
progress
disord
may
progress
fatal
respiratori
insuffici
led
emerg
altern
experiment
treatment
hsct
idea
function
macrophag
transplant
age
year
underw
hsct
match
father
donor
mesenchym
stem
cell
also
given
week
day
tranplant
ameolior
success
hsct
nonmyeloabl
condit
regimen
includ
fludarabin
day
melphalan
day
antithymocyt
globulin
atgfreseniu
mgkgd
day
given
patient
cyclosporin
methotrex
use
graft
versu
host
diseas
gvhd
prophylaxi
bone
marrow
use
stem
cell
sourc
number
cell
neutrophil
platelet
engraft
achiev
day
respect
chimer
analysi
show
donor
profil
day
day
respect
transplant
longer
requir
continu
oxygen
therapi
howev
experienc
acut
gvhd
cmv
reactiv
transplant
cytopenia
day
may
relat
cmv
infect
andor
acut
gvhd
period
complaint
hoars
diagnosi
biopsi
proven
vocal
cord
aspergillosi
pulmonari
nodul
receiv
antifung
treatment
month
transplant
evid
clinic
worsen
hypoxia
conclus
effect
treatment
primari
pap
repetit
wholelung
lavag
novel
therapeut
strategi
primari
pap
case
urgent
requir
moreov
hsct
requir
myeloabl
may
aggrav
respiratori
insuffici
may
lead
increas
risk
infect
therefor
case
choos
nonmyeloabl
regimen
think
mix
chiemer
suffici
decreas
progress
pulmonari
symptomp
first
case
repres
success
nonmyeloabl
hsct
primari
pap
new
treatment
option
patient
conflict
interest
none
faculti
medicin
univers
hospit
motol
pragu
czech
republ
center
cardiovascular
surgeri
transplant
brno
czech
republ
institut
hematolog
blood
transfus
pragu
czech
republ
background
defici
xlink
inhibitor
apoptosi
xiap
associ
xlink
lymphoprolif
diseas
hemophagocyt
lymphohistiocytosi
hlh
phenotyp
inflammatori
bowel
diseas
allogen
hematopoiet
stem
cell
transplant
hsct
cur
affect
patient
loss
xiap
apoptot
function
contribut
high
risk
treatmentrel
toxic
use
reduc
intens
condit
ric
regimen
improv
surviv
rate
cost
frequent
mix
chimer
potenti
risk
diseas
recurr
date
littl
publish
concern
outcom
second
hsct
xiap
defici
method
patient
manifest
hlh
age
month
xiap
defici
diagnos
identifi
hemizyg
nonsens
mutat
gene
treat
thymoglobulin
etoposid
dexamethason
intrathec
methotrex
eurohithlh
studi
diseas
reactiv
document
week
therapi
respons
increas
dexamethason
etoposid
dose
transplant
remiss
hlh
age
month
peripher
blood
stem
cell
pbsc
match
unrel
donor
mud
condit
regimen
includ
alemtuzumab
start
day
fludarabin
melfalan
gvhd
prophylaxi
consist
cyclosporin
csa
mycophenol
mofetil
mmf
result
engraft
granulocyt
document
day
gvhd
gr
ii
respons
corticosteroid
manifest
day
chimer
donor
day
rapid
decreas
donor
signal
document
day
day
mmf
stop
day
corticosteroid
day
csa
day
suffer
recurr
automimmun
hemolyt
anemia
aiha
day
treat
corticoseroid
rituximab
hdivig
mmf
sirolimu
recurr
cytopenia
intermit
diarrhea
fever
hepatosplenomegali
elev
ferritin
triglycerid
solubil
document
day
donor
chimer
decreas
nonsepar
peripher
blood
tlymphocyt
less
nk
cell
indic
second
allogen
hsct
low
level
donor
chimer
presenc
clinic
laboratori
sign
incipi
diseas
recurr
boy
underw
retransplant
defrost
pbsc
mud
one
year
first
hsct
second
ric
regimen
includ
alemtuzumab
day
fludarabin
treosulfan
atg
total
dose
ad
day
diseas
acceler
engraft
granulocyt
day
trombocyt
day
seriou
toxic
gvhd
viral
reactiv
document
posttranspl
cours
complic
aiha
manifest
day
good
respons
corticosteroid
hdivig
rituximab
treatment
patient
remain
remiss
hlh
stabl
level
donor
chimer
nonsepar
peripher
blood
tlymfocyt
nk
cell
month
second
hsct
conclus
perform
second
allogen
hsct
use
differ
ric
regimen
patient
xiap
defici
without
seriou
toxic
believ
second
transplant
allow
us
achiev
stabl
level
donor
chimer
protect
diseas
recurr
support
mhcz
conflict
interest
author
noth
disclos
instituto
de
oncologia
de
lisboa
hematologia
lisboa
portug
instituto
de
oncologia
de
lisboa
pediatria
lisboa
portug
background
central
nervou
system
cn
tumor
common
pediatr
solid
tumor
dismal
prognosi
low
cure
rate
univers
accept
treatment
tumor
highdos
chemotherapi
follow
tandem
autolog
hematopoiet
stem
cell
transplant
hdctautohsct
incorpor
differ
protocol
consolid
either
induct
rt
chemotherapi
later
relev
young
children
decreas
toxic
avoid
advers
effect
brain
irradi
studi
present
experi
use
hdctautohsct
protocol
treat
cn
tumor
method
retrospect
review
medic
record
newli
diagnos
children
cn
tumor
treat
institut
decemb
novemb
patient
pt
surgic
resect
follow
treatment
use
two
differ
protocol
accord
age
children
yo
treat
induct
chemotherapi
cisplatin
vincristin
cyclophosphamid
follow
hdctautohsct
use
carboplatin
thiotepa
condit
thorarinsdottir
et
al
relaps
salvag
rt
use
ii
children
yo
treat
riskadapt
rt
subsequ
consolid
hdctautohsct
use
cisplatin
vincristin
cyclophosphamid
condit
chintagumpala
et
al
eventfre
surviv
ef
calcul
diagnosi
date
relaps
progress
death
whichev
occur
first
overal
surviv
os
calcul
diagnosi
date
death
caus
last
followup
kaplanmei
method
use
surviv
analysi
result
studi
includ
total
pt
male
median
age
year
rang
year
newli
diagnos
malign
cn
tumor
histolog
analysi
reveal
medulloblastoma
supratentori
primit
neuroectoderm
tumor
pnet
glioblastoma
pineoblastoma
cn
embryon
tumor
soe
nine
pt
treat
accord
protocol
five
pt
receiv
intend
tandem
transplant
tt
suspend
protocol
tt
hematolog
toxic
tt
due
progress
diseas
relaps
occur
pt
die
rescu
rt
relaps
month
tt
cr
relaps
first
transplant
current
salvag
seven
pt
treat
accord
protocol
ii
five
pt
complet
total
number
tt
pt
suspend
protocol
tt
neurolog
toxic
relaps
occur
one
patient
month
tt
die
month
later
eleven
pt
receiv
rt
treatment
prior
tt
plan
protocol
ii
transplant
relaps
protocol
median
followup
year
pt
aliv
cr
ef
os
estim
ci
ci
respect
treatment
relat
mortal
conclus
although
studi
present
limit
mainli
impos
sampl
size
data
show
rt
remain
import
compon
treatment
brain
tumor
hdctautohsct
must
consid
import
adjuv
tool
avoid
defer
rt
popul
tandem
hdctautohsct
effect
treat
pediatr
aggress
brain
tumor
low
toxic
encourag
os
ef
conflict
interest
none
dmitri
rogachev
nation
medic
research
centr
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
background
outcom
hematopoiet
stem
cell
transplant
hsct
cohort
children
chemorefractori
acut
myeloid
leukemia
poor
addit
attempt
remiss
induct
variou
combin
chemotherapi
unlik
improv
outcom
contribut
toxic
tcr
deplet
technolog
graft
manipul
potenti
increas
gvl
effect
improv
gvhd
control
immun
reconstitut
group
patient
method
total
pt
chemorefractori
aml
induct
failur
refractori
relaps
median
age
year
underw
hsct
may
septemb
median
fu
year
pt
transplant
haploident
donor
activ
diseas
ad
moment
sct
receiv
treosulfanbas
condit
regimen
three
regimen
gvhd
prophylaxi
use
regimen
atgam
mgkg
tacromtx
regimen
thymoglobulin
rituximab
bortezomib
day
regimen
tocilizumab
mgkg
day
posttranspl
bortezomib
pt
receiv
addit
abatacept
mgkg
sct
clinimac
technolog
implement
case
engraft
pt
receiv
addit
posttranspl
therapi
cours
includ
hypomethyl
agent
andor
modifi
donor
lymphocyt
infus
dli
dli
includ
either
part
primari
graft
cell
deplet
mnc
memori
cell
enrich
fraction
dli
result
primari
engraft
achiev
pt
pt
diseas
progress
die
moment
engraft
immunemedi
idiopath
graft
failur
aliv
sct
median
time
anc
platelet
recoveri
day
engraft
pt
achiev
complet
chimer
day
cumul
incid
agvhd
grade
chronic
gvhd
use
serotherapi
atg
affect
incid
gvhd
among
patient
transplantrel
mortal
cumul
incid
relaps
incid
relaps
subgroup
without
atg
less
subgroup
atg
median
followup
year
eventfre
surviv
overal
surviv
nkcell
recoveri
day
significantli
associ
decreas
incid
relaps
ci
relaps
peripher
blood
nk
recoveri
median
vs
nkcell
count
median
improv
eventfre
surviv
ef
nk
high
vs
nk
low
conclus
confirm
deplet
lymphocyt
haploidenticalgraft
ensur
high
engraft
rate
low
transplantrel
mortal
combin
administr
tocilizumab
abatacept
bortezomib
posttcr
graft
without
serotherapi
might
improv
gvl
effect
without
extens
gvhdrelat
morbid
mortal
attempt
improv
earli
nk
cell
recoveri
may
open
possibl
effect
enhanc
antitumor
effect
decreas
relaps
rate
children
chemorefractori
aml
conflict
interest
author
declar
compet
interest
medipol
univers
pediatr
hematologyoncologybmt
istanbul
turkey
medipol
univers
pediatr
intens
care
unit
istanbul
turkey
medipol
univers
depart
pediatr
istanbul
turkey
background
pediatr
earli
warn
score
system
peuss
nurseadminist
clinic
identif
tool
provid
earli
detect
clinic
impair
hospit
patient
earli
diagnosi
critic
patient
effect
condens
monitor
mortal
pediatr
hematooncolog
patient
constitut
highest
risk
group
term
sudden
clinic
deterior
need
intens
care
method
studi
nh
institut
innov
improv
pew
use
score
chart
applic
contain
everi
patient
pewss
evalu
physician
transfer
pediatr
intens
care
unit
januari
juli
hsct
patient
hospit
requir
pediatr
intens
care
picu
evalu
retrospect
demograph
data
age
sex
diagnosi
mortal
rate
evalu
compar
rate
usag
pediatr
earli
warn
system
pew
march
result
pediatr
patient
male
femal
diagnosi
case
thalassemia
case
aplast
anemia
case
neuroblastoma
case
hurler
case
diamondblack
anemia
case
aml
case
lymphoma
case
lymphoma
case
syndrom
case
transplant
etiolog
intens
care
admiss
determin
septic
shock
patient
venoocclus
diseas
patient
gastrointestin
gvhd
patient
pneumonia
patient
hyponatrem
convuls
patient
hypovolem
shock
patient
idiopat
gener
tonic
clonic
seizur
patient
mean
number
day
intens
care
unit
day
day
pediatr
earli
warn
system
day
usag
pew
total
transplant
perform
transplant
unit
patient
die
followup
period
picu
mortal
rate
patient
usag
pew
patient
pew
conclus
studi
show
earli
warn
system
feasibl
effect
applic
decreas
rate
mortal
signific
differ
intens
care
hospit
period
patient
hospit
longer
unexpect
period
need
prospect
multicent
studi
assess
valu
earli
warn
system
conflict
interest
none
author
anyth
report
adana
acibadem
hospit
adana
turkey
adana
acibadem
hospit
bone
marrow
transplant
unit
adana
turkey
cukurova
univers
pediatr
hematololi
adana
turkey
background
bk
polyoma
viru
infect
treatment
modal
evolv
challeng
follow
allogen
pediatr
hematopoiet
stem
cell
transplant
allohsct
sever
risk
factor
report
includ
bucontain
myeloabl
condit
unrel
donor
gvhd
contrast
earli
onset
hc
lateonset
hc
mainli
result
polyomaviru
bk
less
frequent
adenoviru
cytomegaloviru
reactiv
human
polyomaviru
bk
bkv
may
caus
polyomavirusassoci
nephropathi
polyoma
virusassoci
hemorrhag
cystiti
bone
marrowtranspl
patient
present
patient
bk
polyoma
viru
bkv
ascoci
hemorrhag
cystiti
patient
bk
polyoma
viru
associ
hemorrhag
cystiti
nephriti
method
patient
receiv
allogen
bmt
adana
hospit
pediatr
bone
marrow
transplant
unit
thirti
five
patient
occur
bkv
associ
hemorrhag
cystiti
nephriti
check
bkv
pcr
transplant
patient
pretranspl
period
bkv
detect
urin
analysi
blood
pcr
polymeras
chain
reaction
patient
result
present
patient
bkv
infect
age
rang
averag
year
underw
allogen
bmt
due
thalassemia
major
patient
aplast
anemia
patient
acut
leukemia
patient
kostmann
syndrom
one
patient
patient
treat
firstli
hydrat
continu
bladder
irrig
ciprofloxacin
weekli
intraves
hyaluron
acid
instil
four
week
cidofovir
thirti
three
patient
show
complet
resolut
hematuria
one
patient
refractori
therapi
also
receiv
hyperbar
oxygen
recombin
factor
viia
rfviia
novoseven
novo
nordisk
bagsvaerd
denmark
hemodialysi
perform
two
patient
develop
renal
failur
due
nephriti
conclus
bkv
ubiquit
present
gener
popul
reactiv
infect
occur
condit
sever
immunosuppress
particularli
hsct
renal
transplant
caus
lateonset
hc
bkv
manag
bkv
cystiti
nephriti
sometim
may
difficult
could
refractori
treatment
modal
retrospect
studi
present
experi
bkv
infect
manag
treatment
modal
pediatr
transplant
patient
center
conflict
interest
noth
disclos
adana
acibadem
hospit
bone
marrow
transplant
unit
adana
turkey
cukurova
univers
pediatr
hematolog
adana
turkey
background
hepat
venoocclus
diseas
vod
common
seriou
complic
hemotopoiet
stem
cell
transplant
hsct
children
aim
assess
prospect
use
prophylact
defibrotid
pediatr
patient
undergo
hsct
present
treatment
result
method
studi
patient
underw
hsct
given
defibrotid
prophylaxi
mgkg
per
day
four
divid
intraven
infus
start
day
pretransplant
condit
regimen
mean
durat
use
defibrotid
day
prophylaxi
result
studi
patient
recruit
male
patient
femal
patient
averag
year
rang
infant
children
adolesc
patient
thalassemia
major
patient
leukemia
patient
aplast
anemia
one
patient
diamond
blackfan
anemia
two
patient
congenital
dyserythropoet
anemia
one
patient
osteopetrosi
five
patient
famial
hemophagocyt
lymphohistiocytosi
three
patient
sever
immun
defici
threee
patient
sickl
cell
diseas
threee
patient
kostman
syndrom
transplant
allogen
seriou
side
effect
seen
patient
develop
clinic
vod
seattl
criteria
patient
defibrotid
dose
increas
treatment
dose
mgkg
per
day
one
infant
patient
kostman
syndrom
die
due
hepat
pulmonari
vod
month
follow
patient
develop
vod
well
patient
transplant
relat
complic
conclus
hepat
venoocclus
diseas
caus
hepatocyt
sinusoid
vessel
endothelium
damag
ocur
usual
earli
phase
hsct
sever
form
may
lead
liver
failur
hepatoren
syndrom
portal
hypertens
eventu
death
multiorgan
faillur
prospect
studi
demonstr
use
defibrotid
safe
effect
prevent
treat
vod
pediatr
patient
high
risk
group
conflict
interest
noth
disclos
adana
acibadem
hospit
bone
marrow
transplant
unit
adana
turkey
cukurova
univers
pediatr
hematolog
adana
turkey
background
thrombocytopenia
allogen
hematopoet
stem
cell
transplant
common
complic
eltrombopag
oral
thrombopoietin
receptor
agonist
interact
transmembran
domain
receptor
bone
marrow
megakartocyt
upstream
progenitor
stem
cell
report
eltrombopag
treatment
allogen
hematopoet
stem
cell
transplant
report
eltrombopag
experi
pediatr
patient
treat
eltrombopag
sever
thrombocytopenia
allogen
hematopoet
stem
cell
transplant
center
method
total
allogen
hematopoet
stem
cell
transplant
perform
acibadem
adana
hospit
pediatr
bone
marrow
transplant
unit
turkey
seven
case
patient
treat
eltrombopag
persistan
thrombocytopenia
allogen
hematopoet
stem
cell
transplant
bone
marrow
aspir
biyopsi
perform
patient
start
eltrombopag
treatment
medic
record
treatment
modal
evalu
retrospect
result
studi
patient
treat
eltrombopag
age
rang
year
averag
year
patient
thalassemia
major
patient
acut
lymphoblast
leukemia
one
patient
aplast
anemia
one
patient
myelodysplast
syndrom
four
patient
male
three
femal
five
patient
hematopoet
stem
cell
transplant
unrel
donor
two
patient
haploident
transplant
mother
five
patient
bone
marrow
peripher
blood
stem
cell
transplant
eltrombopag
start
patient
prolong
isol
thrombocytopenia
one
patient
secondari
failur
platelet
recoveri
number
megacaryocyt
decreas
patient
within
normal
rang
one
patient
start
eltrombopag
treatment
patient
depend
platelet
transfus
weekli
eltrombopag
start
median
day
hsct
rang
day
patient
pit
eltrombopag
start
dose
mg
daili
median
durat
treatment
day
seriou
side
effect
seen
incid
rate
success
platelet
recoveri
without
transfus
support
patient
conclus
eltrombopag
current
avail
oral
thrombopoietin
receptor
agonist
show
experi
use
eltrombopag
effect
minim
side
effect
persist
thrombocytopenia
allogen
hematopoet
stem
cell
transplant
pediatr
patient
depend
platelet
transfus
conflict
interest
noth
disclos
vilniu
univers
hospit
santaro
kliniko
hematolog
oncolog
transfus
medicin
center
vilniu
lithuania
vilniu
univers
vilniu
lithuania
children
hospit
affili
vilniu
univers
hospit
santaro
kliniko
center
pediatr
oncolog
hematolog
vilniu
lithuania
background
lower
bodi
mass
bodi
mass
index
associ
inferior
outcom
children
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
percutan
endoscop
gastrostomi
peg
safe
effect
way
ensur
enter
nutrit
sinc
peg
placement
prior
allohsct
becom
standard
procedur
institut
current
studi
aim
assess
impact
peg
placement
weight
kinet
overal
surviv
method
retrospect
singlecent
analysi
children
year
old
underw
allohsct
perform
entir
cohort
compris
patient
peg
place
prior
allohsct
transplant
nonpeg
patient
transplant
data
patient
weight
relev
hsct
characterist
primari
diseas
donor
type
condit
graft
sourc
gvhd
retriev
medic
record
weight
data
day
hsct
includ
evalu
weight
chang
allohsct
primari
studi
end
point
defin
overal
surviv
os
day
year
follow
allohsct
result
compar
analysi
weight
kinet
reveal
increas
median
weight
kg
day
kg
day
p
peg
group
wherea
nonpeg
group
median
weight
respect
timepoint
declin
kg
kg
p
os
day
follow
peg
placement
compar
nonpeg
group
p
os
year
allohsct
peg
nonpeg
group
vs
p
median
follow
period
rang
year
rang
year
respect
univari
analysi
peg
placement
associ
better
os
hr
ci
p
remain
signific
factor
os
multivari
analysi
hr
ci
p
transplant
period
diseas
type
malign
vs
inborn
error
prepar
regimen
ric
vs
mac
donor
type
hla
ident
sibl
vs
mud
stem
cell
cours
bm
vs
pbsc
acut
gvhd
iii
vs
iiiiv
peg
placement
peg
vs
nonpeg
includ
model
sever
pegassoci
complic
observ
within
studi
cohort
conclus
peg
placement
children
undergo
allohsct
appear
feasibl
effect
prevent
weight
loss
earli
posttranspl
period
retrospect
analysi
indic
peg
placement
associ
improv
os
howev
larger
prospect
trial
warrant
confirm
result
conflict
interest
author
financi
kind
bia
disclos
univers
chldren
hospit
depart
oncolog
hematolog
krakow
poland
institut
pediatr
jagiellonian
univers
medic
colleg
depart
clinic
biochemistri
krakow
poland
institut
pediatr
jagiellonian
univers
medic
colleg
depart
oncolog
hematolog
krakow
poland
univers
children
hospit
depart
oncolog
hematolog
krakow
poland
institut
pharmacolog
polish
academi
scienc
depart
molecular
neuropharmacolog
krakow
poland
jagiellonian
univers
medic
colleg
krakow
poland
background
igf
pathway
import
regul
prolifer
differenti
apoptosi
normal
tissu
tumor
cell
obes
pathway
hyperstimul
obes
children
recruit
addit
control
goal
studi
determin
chosen
igf
igfbp
concentr
gene
express
profil
children
treat
stem
cell
transplant
method
plasma
total
igfi
ii
concentr
measur
use
elisa
fast
state
children
averag
year
old
boy
girl
refer
allogen
haematopoiet
stem
cell
transplant
hsct
due
neoplast
nonneoplast
diseas
hsct
group
studi
twice
transplant
median
month
transplant
hsct
type
follow
group
recruit
control
healthi
group
hc
consist
patient
averag
year
old
boy
girl
obes
group
ob
includ
children
averag
year
old
boy
girl
addit
studi
protein
gene
express
peripher
blood
leukocyt
use
genechip
human
gene
st
array
affymetrix
santa
clara
usa
assess
hsct
ob
group
result
signific
differ
peptid
concentr
gene
express
valu
present
tabl
figur
tabl
concentr
studi
peptid
conclus
concentr
peptid
except
igfi
increas
hsct
differ
signific
concentr
igfii
posthsct
significantli
higher
ob
concentr
posthsct
significantli
higher
hc
interestingli
gene
express
analysi
show
compar
differ
biochem
analysi
biochem
result
suggest
contribut
igf
pathway
reconstitut
regener
process
children
hsct
conflict
interest
studi
sponsor
nation
grant
number
nn
none
author
anyth
disclos
medic
univers
wroclaw
depart
clinic
paediatr
oncolog
haematolog
bone
marrow
transplant
wroclaw
poland
medic
univers
wroclaw
depart
basic
medic
scienc
wroclaw
poland
background
viral
opportunist
infect
acut
graft
versu
host
diseas
agvhd
lead
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
allohsct
sophist
balanc
infect
agvhd
earli
period
hsct
depend
innat
immun
system
reconstitut
adapt
immun
system
tolllik
receptor
tlr
express
tlymphocyt
nk
cell
form
specif
link
innat
adapt
immun
analyz
possibl
connect
frequenc
viral
infect
agvhd
incid
express
tlr
reconstitut
lymphocyt
method
pediatr
patient
underw
allohsct
februari
februari
monitor
express
level
nklymphocyt
express
list
receptor
measur
flow
cytometri
five
time
point
day
posthsct
tlr
express
analys
connect
viral
infect
ebv
adv
bkv
cmv
agvhd
incid
result
risk
agvhd
associ
high
express
level
lymphocyt
nk
cell
p
lymphocyt
lymphocyt
nk
cell
level
p
p
nk
lymphocyt
p
lymphocyt
posit
correl
occurr
cytomegaloviru
cmv
infect
express
level
p
natur
killer
cell
also
posit
correl
adenovir
adv
infect
otherwis
valu
lymphocyt
correl
neg
bk
polyomaviru
bkv
infect
urin
p
conclus
obtain
result
suggest
connect
express
level
tlr
lymphocyt
nk
cell
viral
infectionagvhd
event
patient
allohsct
contribut
induct
agvhd
activ
signal
pathway
precis
determin
correl
influenc
condit
patient
help
identifi
patient
popul
prone
viral
infect
agvhd
provid
opportun
earli
intervent
conflict
interest
none
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
cincinnati
children
hospit
cincinnati
oh
unit
state
royal
manchest
children
hospit
manchest
unit
kingdom
univers
medic
center
hamburg
eppendorf
hamburg
germani
hospit
universitario
cruce
barakaldo
spain
univers
children
hospit
zurich
switzerland
motol
univers
hospit
pragu
czech
republ
neckerenf
malad
pari
franc
rigshospitalet
copenhagen
denmark
baylor
colleg
medicin
houston
tx
unit
state
kyoto
univers
hospit
kyoto
japan
background
asymptomat
carrier
pathogen
mutat
caus
gene
primari
hlh
highrisk
develop
lifethreaten
condit
requir
allogen
sct
cure
activ
current
data
inform
treatment
pathway
asymptomat
pt
analys
outcom
pair
index
case
ic
asymptomat
famili
member
ac
genet
defect
predispos
primari
hlh
method
collect
data
sct
centr
worldwid
analys
pairstriad
icsac
report
perforin
syntaxin
defici
griscelli
ii
chediak
higashi
syndrom
result
ic
present
median
age
year
underw
sct
aliv
cr
transplant
pt
die
toxic
progress
nontranspl
pt
aliv
cr
die
progress
toxic
lost
followup
median
age
ac
diagnosi
year
pt
activ
hlh
whilst
observ
patient
underw
sct
aliv
cr
die
progress
toxic
ac
remain
asymptomat
receiv
treatment
cr
underw
preemptiv
sct
aliv
cr
median
followup
month
os
nonact
ac
higher
ic
vs
p
os
ac
activ
hlh
observ
vs
conclus
preemptiv
sct
nonact
ac
prove
safe
os
consid
treatment
option
conflict
interest
conflict
interest
declar
pusan
nationak
univers
children
hospit
depart
pediatr
yangsan
korea
republ
yeungnam
univers
colleg
medicin
depart
pediatr
daegu
korea
republ
daegu
fatima
hospit
pediatr
daegu
korea
republ
ulsan
univers
hospit
pediatr
ulsan
korea
republ
gyeongsang
nation
univers
school
medicin
pediatr
jinju
korea
republ
donga
univers
colleg
medicin
pediatr
busan
korea
republ
kosin
univers
colleg
medicin
pediatr
busan
korea
republ
background
prognosi
highrisk
advanc
childhood
acut
lymphoblast
leukemia
still
unsatisfactori
allogen
hematopoiet
stem
cell
transplant
hsct
still
cur
option
report
transplant
outcom
children
relaps
high
risk
initi
present
receiv
hsct
yeungnam
region
korea
method
januari
decemb
children
age
year
receiv
hsct
yeungnam
region
korea
review
retrospect
patient
transplant
first
complet
remiss
highrisk
featur
present
includ
highrisk
chromosom
transloc
white
blood
cell
count
exceed
induct
failur
other
patient
transplant
relaps
second
remiss
hsct
result
median
age
transplant
year
rang
year
patient
receiv
human
leukocyt
antigen
match
relat
donor
transplant
receiv
match
unrel
donor
transplant
receiv
partial
match
unrel
donor
urd
transplant
stem
cell
sourc
includ
peripher
blood
stem
cell
pbsc
bone
marrow
bm
umbil
cord
blood
cb
patient
receiv
condit
regimen
includ
fraction
total
bodi
irradi
tbi
cyclophosphamid
melphalan
patient
receiv
busulfan
base
condit
regimen
median
infus
cell
x
bm
pbsc
transplant
x
cb
transplant
patient
receiv
unrel
cord
blood
transplant
show
success
engraft
median
time
anc
recoveri
day
rang
day
incid
acut
graft
versu
host
diseas
gvhd
includ
grade
iiiiv
acut
gvhd
chronic
gvhd
develop
evalu
patient
patient
transplant
suffer
significantli
higher
incid
grade
iiiiv
acut
gvhd
compar
transplant
estim
eventfre
surviv
ef
overal
surviv
os
respect
ef
os
significantli
higher
patient
patient
howev
signific
differ
outcom
patient
receiv
tbi
without
tbi
addit
ef
os
significantli
differ
cbt
urd
transplant
cumul
incid
relaps
patient
relaps
patient
conclus
hsct
effect
treatment
pediatr
patient
highrisk
featur
alreadi
relaps
addit
outcom
cb
transplant
compar
outcom
urd
transplant
conflict
interest
conflict
interest
disclos
hospit
santa
creu
sant
pauuniversitat
pediatr
hematolog
oncolog
hsct
unit
barcelona
spain
hospit
la
paz
hematolog
madrid
spain
banc
de
sang
teixit
celular
therapi
unit
barcelona
spain
hospit
la
paz
pediatr
hematologyoncolog
madrid
spain
hospit
de
octubr
clinic
research
unit
spanish
nation
cancer
research
centr
madrid
spain
hospit
sant
joan
de
deu
pediatr
hsct
unit
barcelona
spain
hospit
la
pazinstituto
de
molecular
ingemm
madrid
spain
hospit
del
mar
imim
hospit
del
mar
medic
research
institut
immunolog
depart
barcelona
spain
hospit
la
paz
immunolog
madrid
spain
background
haploident
stem
cell
transplant
haplohsct
present
major
clinic
challeng
past
decad
due
mainli
high
incid
gvhd
induc
strong
donor
tcell
alloreact
cell
deplet
method
perform
deplet
cell
prevent
gvhd
preserv
memori
cell
provid
immedi
function
cell
antiinfect
antileukemia
antireject
effect
although
reactiv
human
common
hsct
yet
describ
type
tcell
deplet
method
twentyfour
consecut
highrisk
leukemia
patient
receiv
haploident
transplant
follow
nonmyeloabl
condit
regimen
patient
receiv
two
cell
product
one
creat
posit
select
deplet
neg
fraction
clinimac
devic
enrich
product
provid
median
dose
rang
respect
cell
dose
median
rang
cell
dose
median
rang
median
deplet
cell
rang
result
patient
achiev
neutrophil
engraft
median
day
rang
posttranspl
two
patient
experienc
secondari
graft
reject
immun
recoveri
fast
median
absolut
lymphocyt
count
alc
day
posttranspl
eleven
patient
develop
acut
gvhd
grade
iii
four
patient
develop
acut
gvhd
grade
iiiiv
three
patient
show
chronic
gvhd
overal
surviv
os
diseasefre
surviv
df
respect
month
followup
observ
unexpect
high
rate
limbic
enceph
due
case
prove
demonstr
viral
dna
csf
sampl
infect
appear
earli
engraft
median
onset
day
transplant
characterist
infect
follow
similar
pattern
almost
case
clinic
sign
compat
strong
preengraft
syndrom
fluid
retent
erythemat
rash
fever
preced
start
neurolog
symptom
hand
none
patient
nt
develop
infect
show
preengraft
syndrom
show
mild
sign
like
fever
patient
die
due
enceph
one
patient
experienc
secondari
graft
failur
infect
one
patient
show
neuropsycholog
sequela
hyponatremia
persist
one
half
year
postinfect
median
alc
enceph
start
similarli
high
patient
withouth
infect
conclus
deplet
haplohsct
well
toler
rapid
engraft
low
risk
sever
acut
gvhd
chronic
gvhd
seen
robust
fast
immun
recoveri
allow
rapid
control
viral
reactiv
cmv
unexpectedli
observ
high
rate
enceph
need
studi
find
mechan
relat
conflict
interest
potenti
conflict
interest
disclos
regen
medicin
degli
studi
di
brescia
dipartimento
di
scienz
clinich
e
sperimentali
brescia
itali
degli
studi
di
brescia
dipartimento
di
ingegneria
meccanica
e
industrial
brescia
itali
asst
spedali
civili
servizio
immunotrasfusional
brescia
itali
univers
glasgow
depart
biomed
engin
glasgow
unit
kingdom
degli
studi
di
brescia
dipartimento
di
ingegneria
dellinformazion
brescia
itali
asst
spedali
civili
uo
di
ortopedia
e
traumatologia
brescia
itali
background
regen
medicin
aim
restor
normal
tissu
function
repair
replac
damag
cell
tissu
patient
scaffold
act
temporari
matrix
cell
prolifer
extracellular
matrix
deposit
tissu
total
restor
mesenchym
stromal
cell
msc
promot
tissu
repair
prolif
potenti
abil
migrat
injur
tissu
well
immunomodulatori
trophic
effect
method
differ
natur
hydrogel
scaffold
character
first
seri
obtain
gelatin
hydroxyethylcellulos
hec
peg
polyethylen
glycol
crosslink
second
seri
base
gelatin
differ
concentr
chitosan
ch
peg
scaffold
character
physicochem
thermomechan
morpholog
properti
msc
seed
scaffold
dri
wet
hydrat
state
cellular
densiti
x
cellsscaffold
x
cellsscaffold
context
msc
prolifer
presenc
fetal
bovin
serum
fb
versu
hpl
human
platelet
lysat
test
expans
msc
bone
marrow
bm
adipos
tissu
evalu
aim
find
best
sourc
msc
viabil
msc
determin
use
mtt
cell
prolifer
assay
day
cultur
induc
osteogen
chondrogen
differenti
cellsscaffold
construct
cultur
plate
week
osteogen
differenti
media
consist
highglucos
dmem
supplement
fb
hpl
dex
mgml
lascorb
acid
chondrogen
media
compos
highglucos
dmem
supplement
dex
sodium
pyruv
mm
lascorb
phosphat
prolin
ngml
human
transform
growth
factor
media
renew
everi
day
scaffold
without
cell
use
control
result
hydrogel
scaffold
ch
seem
optim
model
host
msc
compar
scaffold
base
hec
moreov
ch
materi
show
highli
porou
structur
interconnect
pore
tensil
properti
specif
pore
size
wettabl
weight
loss
hydrolyt
degrad
differ
hec
ch
well
ch
concentr
msc
seed
ch
scaffold
cellular
densiti
x
cellsscaffold
abl
occupi
whole
volum
show
good
viabil
prolifer
adhes
furthermor
synergist
effect
hpl
combin
proper
scaffold
use
support
msc
prolifer
better
fb
current
explor
effect
scaffold
modul
msc
osteogen
chondrogen
differenti
well
assess
msc
different
immunofluoresc
characteris
express
osteogen
chondrogen
specif
marker
conclus
hydrogel
scaffold
ch
select
design
potenti
substrat
support
msc
differ
sourc
moreov
use
hpl
cell
expans
offer
possibl
obtain
safer
cellular
product
without
xenogen
contamin
abl
transfer
clinic
applic
human
conflict
interest
federica
noth
disclos
l
hirszfeld
institut
immunolog
experiment
therapi
polish
academi
scienc
wroclaw
poland
lower
silesian
center
cellular
transplant
nation
bone
marrow
donor
registri
wroclaw
poland
background
show
blood
mesenchym
stem
cell
msc
retain
recipi
phenotyp
hsct
spite
presenc
full
haematolog
chimera
observ
led
conclus
marrow
sever
zone
hematopoiet
stemprogenitor
cell
mesenchym
stem
cell
msc
differ
stage
differenti
kept
dormant
state
msc
recogn
master
cell
broad
potenti
differenti
differ
tissu
presenc
differenti
msc
quiescent
stage
marrow
unequivoc
confirm
method
address
issu
evalu
efficaci
marrow
cell
msc
marker
improv
vascular
limb
ischaemia
patient
age
median
rang
year
old
improv
function
wornout
hip
knee
procedur
patient
age
median
rang
year
old
two
group
patient
receiv
marrowderiv
mononuclear
cell
inject
either
ischem
leg
calf
muscl
intraarticular
hip
knee
ischem
leg
patient
receiv
autolog
leukophoret
product
freshli
taken
marrow
caviti
cell
inject
calf
muscl
ml
small
portion
patient
wornout
hip
receiv
joint
marrow
cell
harvest
prepar
od
ml
marrow
auto
stem
cell
kit
pharm
accord
procedur
dose
inject
cell
standard
begin
volum
marrow
process
patient
compos
two
group
subsequ
subdivid
patient
respond
favour
treatment
heal
foot
ulcer
cessat
intermitt
claudic
pain
releas
improv
joint
function
respect
two
group
investig
fail
result
found
patient
improv
joint
function
higher
contribut
cell
marrow
cell
popul
cell
harvest
prepar
auto
stem
cell
kit
suffer
recurr
symptom
report
month
procedur
vs
popul
vs
cell
popul
contrast
patient
critic
limb
ischemia
show
remiss
month
intervent
receiv
less
deterior
vs
conclus
intraarticular
inject
cell
marrow
origin
improv
joint
function
play
posit
role
revascular
process
ischem
leg
latter
effect
rather
due
endotheli
stem
cell
esc
found
inoculum
employ
revascularis
purpos
support
nation
centr
research
develop
grant
number
innov
economi
oper
programm
fund
framework
european
region
develop
fund
conflict
interest
author
declar
conflict
interest
regard
public
abstract
hirszfeld
institut
immunolog
experiment
therapi
pa
wroclaw
poland
institut
human
genet
pa
poznan
poland
background
muscular
dystrophi
repres
group
diseas
may
develop
sever
form
sever
diseas
usual
associ
gene
mutat
therapeut
effect
individu
transplant
msc
bone
marroworigin
bmmsc
stemprogenitor
cell
myogenicorigin
limit
due
complex
muscular
dystrophi
biolog
activ
stemprogenitor
cell
analyz
biolog
properti
bmmsc
myogen
stemprogenitor
cell
potenti
applic
treatment
patient
suffer
duchenn
muscular
dystrophi
dmd
method
bone
marrow
sampl
skelet
muscl
oligobiopsi
collect
three
healthi
donor
approv
local
bioethic
committe
msc
isol
donor
bm
nucleat
cell
concentr
ncc
obtain
use
marrow
stim
mini
instrument
ncc
resuspend
alphamem
medium
supplement
platelet
lysat
antibiot
place
cell
cultur
system
macopharma
myogen
progenitor
cell
isol
skelet
muscl
oligobiopsi
procedur
includ
combin
method
mechan
agit
enzymat
digest
separ
cell
place
tissu
cultur
gelatinco
flask
standard
dmem
medium
supplement
fb
fgf
antibiot
msc
bmorigin
myogen
progenitor
cell
kept
standard
vitro
cultur
condit
humidifi
atmospher
cultur
medium
chang
everi
three
day
adher
cell
reach
confluenc
phenotyp
cultur
cell
bmmsc
myogen
progenitor
cell
character
flow
cytometri
immunocytochemistri
hlaabc
hladr
costimulatori
molecul
cocultur
bmmsc
label
red
myogen
progenitor
cell
label
green
perform
dmem
medium
supplement
fb
antibiot
result
adher
cell
bm
myogenicorigin
exhibit
similar
phenotyp
characterist
msc
adher
cell
myogen
progenitor
cell
bm
cultur
addit
express
adher
cell
observ
suggest
popul
msc
musclespecif
cultur
cell
bm
myogenicorigin
neg
hladr
antigen
hematopoiet
marker
costimulatori
molecul
proangiogen
properti
bmmsc
confirm
express
adher
cell
spontan
fusion
bmmsc
myogen
progenitor
observ
earli
hour
cocultur
start
plateau
seen
hour
conclus
stemprogenitor
cell
gener
bm
skelet
muscl
express
phenotyp
characterist
msc
express
immunogen
phenotyp
abl
gener
spontan
fusion
vitro
condit
thu
develop
cellbas
therapi
muscular
dystrophi
deliveri
two
popul
normal
stemprogenitor
cell
bmmsc
myogen
progenitor
would
promis
tool
treat
muscular
dystrophi
hypothes
popul
cell
fuse
damag
muscl
cell
vivo
facilit
skelet
muscl
recoveri
conflict
interest
studi
support
nation
scienc
center
grant
n
first
pavlov
state
medic
univers
saint
petersburg
r
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
saint
petersburg
russian
feder
background
parent
child
cancer
profoundli
distress
parent
perman
support
take
care
children
treatment
oncolog
clinic
risk
develop
psycholog
trauma
method
prospect
singlecent
studi
collect
data
mother
whose
children
undergo
treatment
raisa
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
sever
method
use
includ
clinic
psycholog
method
aim
assess
person
respons
mother
ill
experiment
psycholog
method
impact
event
scale
revis
iesr
assess
selfactu
poi
questionnair
diagnost
mother
reaction
child
ill
result
studi
level
traumat
stress
iesr
allow
identifi
three
group
mother
low
high
extrem
high
level
psycholog
distress
group
women
extrem
high
level
psycholog
distress
predominantli
includ
mother
rais
child
undergo
relaps
treatment
women
group
came
outsid
citi
analysi
selfactu
assess
poi
show
mother
high
level
psycholog
distress
tend
express
feel
spontan
directli
higher
degre
traumat
stress
higher
express
behaviour
often
manifest
interact
peopl
primarili
doctor
rather
children
mother
high
level
psycholog
distress
like
accept
irrit
anger
aggress
studi
reaction
ill
show
mother
high
level
psycholog
distress
felt
impot
inabl
influenc
outcom
diseas
increas
proport
durat
diseas
especi
case
relaps
gener
exhaust
mother
psycholog
physic
level
reduc
control
behaviour
child
undergo
treatment
led
decreas
respons
could
sign
asthen
parent
mother
tend
seek
extern
support
dramat
mother
perceiv
child
diseas
need
support
husband
famili
conclus
correl
analysi
result
show
parent
abil
cope
psycholog
emot
state
import
success
time
treatment
child
sinc
larg
determin
behaviour
sick
child
hisher
attitud
treatment
doctor
oncolog
malign
children
traumat
experi
mother
women
includ
studi
exhibit
high
extrem
high
level
psycholog
distress
reaction
behaviour
determin
emot
state
must
taken
account
commun
thu
mother
sick
children
need
psycholog
help
conflict
interest
conflict
interest
univers
pavia
pavia
itali
fondazion
ircc
policlinico
san
matteo
pavia
itali
background
liver
dysfunct
major
health
problem
world
restrict
avail
donor
organ
limit
liver
transplant
establish
success
treatment
current
extracellular
matrix
ecm
scaffold
obtain
decellular
discard
organ
consid
good
threedimension
structur
subsequ
recellular
order
creat
function
organ
stem
cell
mesenchym
stromal
cell
msc
capabl
selfrenew
capac
differenti
specif
cell
type
observ
msc
fate
could
influenc
ecm
aim
present
studi
investig
capac
msc
differenti
function
hepatocytelik
cell
interact
liver
ecm
method
porcin
liver
decellular
sd
solut
follow
previous
publish
procedur
peloso
et
al
annal
surgeri
ecmscaffold
stain
haematoxylineosin
test
absenc
nuclei
integr
matrix
evalu
immunofluoresc
msc
isol
expand
porcin
bone
marrow
character
plastic
adhes
morpholog
differenti
capac
immunophenotyp
comit
p
et
al
transplant
proc
cellsscaffold
seed
ecmscaffold
dimens
well
plate
cultur
day
cultur
sampl
goldsputt
high
vacuum
analyz
scan
electron
microscop
sem
zeiss
evo
carl
zeiss
addit
adher
cell
trypsin
analyz
intracellular
albumin
r
system
flow
cytometri
navio
beckman
coulter
result
observ
complet
homogen
coverag
inner
scaffold
surfac
msc
ii
acquisit
polygon
cell
morpholog
typic
hepatocyt
iii
weak
intracellular
albumin
product
main
function
hepatocyt
conclus
preliminari
result
suggest
interact
msc
liver
ecm
promot
differenti
hepatocytelik
cell
show
chang
morpholog
abil
produc
albumin
studi
need
confirm
approach
suitabl
complex
organ
engin
regen
medicin
conflict
interest
noth
disclos
solid
tumour
instituto
de
oncologia
de
lisboa
francisco
gentil
medic
oncolog
depart
lisboa
portug
centro
hospitalar
lisboa
ocident
medic
oncolog
depart
lisboa
portug
instituto
de
oncologia
de
lisboa
francisco
gentil
blood
marrow
transplant
unit
lisboa
portug
background
high
dose
therapi
hdt
autolog
stem
cell
transplant
asct
use
high
risk
relaps
sarcoma
es
although
hdt
evalu
smaller
uncontrol
studi
euroew
trial
first
evalu
approach
randomis
fashion
show
may
effect
treatment
select
patient
localis
highrisk
es
provid
signific
efficaci
benefit
patient
lung
metastas
method
retrospect
cohort
studi
patient
es
diagnosi
treat
hdt
asct
singl
cancer
centr
januari
decemb
indic
asct
treatment
metastat
highvolum
localis
diseas
b
treatment
chemosensit
recurr
clinic
data
obtain
individu
medic
chart
review
time
relaps
surviv
asct
calcul
kaplanmei
method
surviv
analysi
indic
perform
logrank
test
use
softwar
stata
consid
statist
signific
level
result
identifi
patient
median
age
asct
iqr
male
regard
poor
prognosi
factor
age
diagnosi
ii
tumour
locat
axial
report
iii
tumour
volum
localis
diseas
iv
ldh
elev
primari
tumour
bone
diseas
statu
metastat
diagnosi
secondari
diseas
localis
lung
bone
bone
marrow
patient
initi
treat
euroew
protocol
surgic
remov
primari
tumour
chemotherapi
present
residu
viabl
tumour
specimen
receiv
radiat
therapi
indic
asct
distribut
follow
complet
respons
cr
good
partial
respons
vgpr
b
chemosensit
recurr
hdt
perform
busulphan
melphalan
febril
neutropenia
complic
patient
median
length
stay
iqr
day
median
time
progress
month
median
surviv
month
overal
surviv
os
os
median
surviv
indic
group
significantli
differ
reach
cr
month
vgpr
b
month
chemosensit
recurr
conclus
hdt
asct
show
effect
treatment
cohort
patient
mainli
treatment
either
without
cr
patient
cr
better
benefit
treatment
longer
surviv
thu
effort
made
obtain
cr
conflict
interest
noth
disclos
seoul
nation
univers
children
hospit
pediatr
seoul
korea
republ
seoul
nation
univers
colleg
medicin
orthoped
surgeri
seoul
korea
republ
seoul
nation
univers
colleg
medicin
patholog
seoul
korea
republ
background
despit
great
advanc
outcom
osteosarcoma
patient
respond
poorli
neoadjuv
chemotherapi
show
poor
outcom
event
free
surviv
ef
retrospect
analysi
evalu
role
high
dose
chemotherapi
autolog
stem
cell
transplant
hdct
asct
osteosarcoma
patient
poor
respons
neoadjuv
chemotherapi
sole
risk
factor
method
retrospect
medic
chart
review
done
patient
diagnos
osteosarcoma
june
may
seoul
nation
univers
children
hospit
patient
tumor
necrosi
neoadjuv
chemotherapi
sole
risk
factor
identifi
outcom
patient
treat
convent
chemotherapi
group
treat
hdct
asct
group
compar
condit
regimen
hdct
asct
consist
melphalan
day
day
etoposid
carboplatin
day
day
result
review
includ
patient
male
femal
diagnos
median
age
year
old
singl
primari
mass
extrem
none
metastat
lesion
underw
neoadjuv
chemotherapi
subsequ
wide
excis
limb
salvag
oper
ef
patient
group
median
rang
year
diagnosi
wherea
group
median
rang
year
diagnosi
rang
year
asct
patient
group
patient
lung
metastas
median
year
diagnosi
patient
primari
site
relaps
median
year
offtherapi
overal
surviv
patient
group
median
rang
year
diagnosi
wherea
group
median
year
diagnosi
year
asct
three
patient
group
die
diseas
asct
patient
experienc
moderategrad
venoocclus
diseas
resolv
support
care
conclus
hdct
asct
melphalan
etoposid
carboplatin
improv
ef
osteosarcoma
patient
poor
respons
neoadjuv
chemotherapi
sole
risk
factor
conflict
interest
author
relev
financi
relationship
disclos
conflict
interest
solv
nh
greater
glasgow
clyde
bmt
glasgow
unit
kingdom
beatson
west
scotland
cancer
centr
nh
greater
glasgow
clyde
oncolog
glasgow
unit
kingdom
aberdeen
royal
infirmari
aberdeen
unit
kingdom
background
patient
germ
cell
tumour
respond
poorli
relaps
follow
first
line
therapi
poor
prognosi
optim
salvag
treatment
patient
uncertain
convent
dose
salvag
regimen
high
dose
chemotherapi
autolog
stem
cell
transplant
hdct
utilis
method
patient
relapsedrefractori
metastat
germ
cell
tumour
treat
hdct
beatson
west
scotland
cancer
centr
identifi
medic
record
review
baselin
patient
tumour
characterist
prognost
featur
toxic
surviv
outcom
result
eighteen
patient
male
femal
receiv
hdct
salvag
gonad
primari
nonseminomat
mix
patholog
poor
prognost
score
diagnosi
patient
platinumbas
chemotherapi
surgeri
seven
evid
diseas
follow
line
therapi
refractori
ipfsg
prognost
score
calcul
male
patient
high
high
risk
patient
receiv
cycl
induct
chemotherapi
contain
paclitaxel
ifosfamid
cisplatin
twelv
patient
receiv
carboplatin
etoposid
tandem
hdct
accord
einhorn
protocol
patient
receiv
palitaxel
etoposid
carboplatin
cyclpohosphamid
hdct
accord
mcneish
protocol
patient
cycl
hdct
accord
tice
protocol
median
dose
transfus
cell
rang
patient
engraft
median
time
neutrophil
recoveri
day
rang
median
time
platelet
recoveri
day
rang
day
rang
respect
toxic
common
follow
hdct
support
transfus
requir
patient
median
unit
red
cell
rang
platelet
transfus
rang
given
patient
least
infect
episod
requir
broadspectrum
intraven
antibiot
grade
mucos
common
transplant
episod
patient
lost
weight
hdct
patient
requir
nutrit
support
two
patient
requir
critic
care
due
sepsi
multiorgan
failur
common
longterm
toxic
neurotox
patient
ototox
patient
due
cumul
platinum
exposur
time
hdct
cycl
significantli
longer
publish
literatur
mean
week
compar
week
reflect
toxic
procedur
median
length
followup
post
hdct
month
septemb
patient
die
posttranspl
complic
intrapulmonari
haemorrhag
follow
relaps
pf
os
patient
least
year
followup
respect
conclus
deliveri
hdct
asct
salvag
treatment
metastat
germ
cell
cancer
tertiari
cancer
centr
scotland
result
surviv
outcom
compar
publish
literatur
though
toxic
signific
maintain
dose
intens
challeng
hope
recruit
intern
tiger
trial
attempt
clarifi
hdct
superior
conventionaldos
chemotherapi
salvag
set
conflict
interest
conflict
interest
univers
milan
milano
itali
istituto
clinico
studi
milano
itali
asst
vall
olona
busto
arsizio
itali
asst
vall
olona
oncolog
busto
arsizio
itali
background
human
endogen
retrovirus
herv
remnant
ancient
exogen
retrovir
infect
human
repres
human
genom
regul
mainli
base
epigenet
mechan
methyl
provir
long
termin
repeat
ltr
report
shown
exist
relationship
herv
express
colon
cancer
base
mrna
andor
protein
express
profil
normal
cancer
tissu
conclus
evid
still
lack
method
express
env
genom
region
hervh
hervk
hervp
hervr
w
evalu
tumor
adjac
normal
tissu
circul
plasma
microvesicl
colorect
cancer
patient
rna
isol
clinic
specimen
reversetranscrib
subject
rel
quantit
realtim
pcr
env
express
relat
express
housekeep
gapdh
gene
quantif
conduct
use
compar
ct
method
differ
level
env
gene
express
differ
specimen
given
folddiffer
methyl
statu
herv
ltr
evalu
mean
bisulfitepcr
pyrosequenc
result
higher
level
express
hervr
found
tumor
tissu
compar
adjac
normal
tissu
hervh
k
p
w
express
level
compar
decreas
tumor
tissu
compar
normal
tissu
fold
hervh
k
ltr
significantli
p
hypomethyl
tumor
tissu
respect
compar
normal
adjac
tissu
respect
hervw
methyl
chang
tumor
normal
adjac
tissu
hervh
k
r
p
env
sequenc
present
plasma
circul
microvesicl
patient
respect
hervw
env
sequenc
absent
conclus
herv
express
level
significantli
differ
among
tumor
normal
clinic
sampl
demethyl
hervh
k
ltr
might
support
hypothesi
specif
releas
hervh
k
ltr
epigenet
control
colon
cancer
hypothesi
hold
true
specif
viral
sequenc
might
target
antigenspecif
cell
therapi
colon
cancer
known
cancersecret
microvesicl
influenc
tumor
microenviron
support
cancer
growth
metastasi
herv
h
k
sequenc
present
circul
plasma
microvesicl
may
transfer
one
cell
anoth
favour
cellular
transform
mechan
clinic
trial
registri
applic
conflict
interest
none
tianjin
medic
univers
cancer
institut
hospit
nation
clinic
research
center
cancer
key
laboratori
cancer
prevent
therapi
depart
hemotolog
tianjin
china
tianjin
medic
univers
cancer
institut
hospit
nation
clinic
research
center
cancer
key
laboratori
cancer
prevent
therapi
depart
children
oncolog
tianjin
china
background
prognosi
neuroblastoma
highrisk
advanc
stage
still
poor
highdos
chemotherapi
follow
singl
tandem
autolog
peripher
blood
stem
cell
transplant
apbsct
may
improv
prognosi
children
studi
aim
investig
prognosi
children
highrisk
neuroblastoma
receiv
intens
chemotherapi
follow
apbsct
analys
differ
therapeut
effect
singl
tandem
transplant
method
medic
record
highrisk
advanc
neuroblastoma
patient
treat
highdos
chemotherapi
apbsct
hospit
retrospect
review
primari
site
diseas
abdomin
caviti
adren
gland
mediastinum
bone
marrow
multipl
bone
metastasi
distant
lymphnod
metastasi
patient
receiv
high
dose
chemotherapi
surgeri
local
radiat
gy
apbsct
well
mainten
treatment
condit
regimen
consist
busulfan
melphalan
busulfan
melphalan
cem
regimen
carboplatin
etoposid
cyclophosphamid
relaps
patient
treat
salvag
chemotherapi
radiat
therapi
result
median
age
diagnosi
month
rang
month
median
number
rang
induct
patient
got
complet
remiss
cr
patient
fail
got
cr
got
good
partial
remiss
vgpr
got
partial
respons
pr
apbsctin
studi
total
patient
receiv
tandem
transplantational
patient
success
underw
mobil
collect
reinfus
without
treatmentassoci
death
occouredinfecti
fever
gastrointestin
symptom
main
toxic
apbsctbi
end
follow
total
patient
got
relaps
die
mean
time
diagnosi
relaps
month
eventfre
surviv
overal
surviv
allpati
respect
cr
group
patient
receiv
singl
transplat
got
better
outcom
tandem
transplant
mean
vs
month
wherea
noncr
group
show
opposit
outcom
mean
month
vs
month
singl
transplat
tandem
transplant
conclus
find
small
cohort
indic
highdos
chemotherapi
follow
apbsct
feasibl
toler
pediatr
patient
highrisk
neuroblastoma
lower
relaps
rate
better
survivaltandem
transplant
might
benefit
patient
fail
get
crthere
need
longterm
follow
case
investig
respect
advantag
singl
tandem
transplant
conflict
interest
correspond
author
jie
yan
email
yizhuo
zhang
email
lei
mao
bing
xia
contribut
equal
cofirst
author
grant
financi
support
work
support
grant
nation
natur
scienc
foundat
china
stem
cell
donor
hospit
de
santa
maria
centro
hospitalar
de
lisboa
nort
epe
de
hematologia
e
de
medula
lisboa
portug
centro
de
sangu
e
de
lisboa
ipst
ip
lisboa
portug
background
portugues
bone
marrow
donor
registri
also
known
cedac
nation
center
bone
marrow
stem
cell
cord
blood
donor
databas
hematopoiet
stem
cell
donor
creat
avail
find
match
graft
nation
foreign
patient
cedac
steadi
growth
year
constitut
tenth
largest
bone
marrow
donor
registri
world
third
largest
per
capita
method
part
analysi
cedac
registri
queri
databas
regard
selfdeclar
epidemiolog
characterist
popul
name
age
gender
ethnic
countri
origin
resid
crossreferenc
distribut
offici
ine
nation
statist
institut
data
avail
websit
institut
result
august
cedac
registri
compris
donor
total
portugues
popul
type
also
includ
hlacw
includ
type
hla
loci
includ
median
donor
age
year
greater
represent
women
compar
men
vs
respect
even
larger
actual
gender
differ
countri
vs
consid
resid
popul
portug
born
countri
represent
portugues
nation
registri
much
larger
although
nation
present
foreign
donor
come
brazil
portuguesespeak
african
countri
cape
verd
angola
mozambiqu
guineabissau
also
compris
signific
proport
remain
foreign
donor
popul
three
countri
repres
donor
name
franc
ukrain
spain
donor
voluntarili
selfdeclar
ethnicityorigin
identifi
western
african
mix
south
asian
eastern
hindu
seven
nut
nomenclatur
territori
unit
statist
region
portug
center
region
per
capita
donor
follow
metropolitan
area
lisbon
north
alentejo
algarv
lastli
autonom
region
madeira
azor
despit
fact
donor
resid
subregion
lisbon
oporto
repres
registri
respect
nut
subregion
one
per
capita
donor
coimbra
follow
portalegr
aveiro
one
least
azor
follow
madeira
faro
lisbon
oporto
per
capita
donor
respect
conclus
besid
ongo
hla
data
analysi
knowledg
epidemiolog
characterist
cedac
registri
enabl
us
redirect
effort
recruit
donor
underrepres
region
countri
name
autonom
region
also
encourag
us
mobil
donor
recruit
campaign
underrepres
ethnic
minor
conflict
interest
author
noth
disclos
german
red
cross
blood
servic
johannwolfganggoeth
medic
univers
institut
transfusion
medicin
immun
hematolog
frankfurt
germani
univers
washington
school
medicin
divis
hematolog
seattl
wa
unit
state
background
annual
allogen
stem
cell
transplant
hsct
perform
often
remain
cur
treatment
option
hematolog
malign
mobilis
peripher
blood
stem
cell
establish
main
sourc
stem
cell
among
healthi
donor
mobilis
efficaci
applic
granulocyt
coloni
stimul
factor
gcsf
vari
dramat
far
reliabl
factor
establish
predict
satisfactori
stem
cell
collect
yield
healthi
donor
therefor
studi
intend
analyz
genomewid
singl
nucleotid
polymorph
discov
predict
marker
stem
cell
yield
peripher
stem
cell
donor
method
genom
dna
healthi
stem
cell
donor
analyz
singl
nucleotid
polymorph
use
illumina
humanomni
bead
chip
stem
cell
mobilis
gcsf
lenograstim
chugai
administ
dosag
sc
consecut
day
apheresi
perform
day
dosag
split
twice
inject
daili
yield
measur
apheresi
bioinformat
analysi
perform
use
plink
rbioconductor
packag
gwastool
data
compar
public
avail
genom
data
set
result
donor
show
poor
yield
donor
good
mobilis
effici
donor
show
valu
rang
qualiti
control
miss
call
rate
minor
allel
freqenc
maf
variant
pass
filter
criteria
use
quantit
phenotyp
associ
analysi
snp
pvalu
associ
test
use
downstream
analysi
especi
genom
region
chr
chr
chr
show
enrich
signifc
snp
associ
studi
conclus
knowledg
predict
marker
stem
cell
yield
gcsf
mobilis
may
help
optim
mobilis
regimen
select
potenti
donor
genom
wide
associ
studi
snp
may
associ
cell
yield
could
detect
analysi
larger
donor
cohort
need
valid
identifi
snp
conflict
interest
noth
disclos
studi
fund
german
red
cross
blood
servic
soonchunhyang
univers
hospit
hematolog
bucheon
korea
republ
soonchunhyang
univers
hospit
hematolog
seoul
korea
republ
background
immun
reconstitut
follow
allogen
hematopoiet
stem
cell
transplant
hsct
affect
mani
variabl
transplant
process
particular
condit
regimen
donor
type
gvhd
prophylaxi
haploident
hsct
accept
worldwid
altern
treatment
patient
hematolog
malign
complet
hlamatch
sibl
requir
urgent
transplant
assess
clinic
outcom
accord
immun
recoveri
statu
day
haploident
sct
compar
hsct
relat
donor
unrel
donor
method
patient
receiv
allogen
hsct
use
peripher
blood
stem
cell
fludarabinebusulfanantithymocyt
globulin
condit
immunophenotyp
analysi
use
flowcytometri
perform
evalu
percentag
absolut
number
cell
subset
cell
nk
cell
cell
b
cell
cell
serum
immunoglobulin
level
well
clinic
outcom
investig
result
patient
achiev
normal
rang
nk
cell
tcell
subset
recoveri
achiev
refer
rang
patient
bcell
recoveri
achiev
refer
rang
patient
haploident
hsct
seem
associ
delay
immun
reconstitut
cell
subset
b
cell
although
incid
grade
iiiv
acut
gvhd
slightli
increas
incid
chronic
gvhd
lower
haploident
hsct
group
compar
hsct
use
donor
type
event
viral
reactiv
includ
cmv
reactiv
frequent
abnorm
group
cell
subset
addit
incid
relaps
seem
frequent
abnorm
group
cell
subset
conclus
immun
reconstitut
haploident
hsct
tend
delay
especi
cell
subset
delay
immun
reconstitut
might
caus
increas
morbid
viral
reactiv
need
strategi
prevent
infecti
complic
enhanc
immun
reconstitut
accord
immun
recoveri
statu
follow
haploident
sct
clinic
trial
registri
noth
conflict
interest
noth
disclos
nation
univers
hospit
depart
haematolog
oncolog
nation
univers
cancer
institut
singapor
singapor
singapor
gener
hospit
depart
haematolog
singapor
singapor
nation
univers
singapor
saw
swee
hock
school
public
health
singapor
singapor
background
outcom
unmanipul
haploident
haematopoiet
cell
transplant
hct
unrel
cord
blood
transplant
ucbt
encourag
becom
altern
option
treat
patient
highrisk
haematolog
malign
without
human
leukocyt
antigen
hla
match
donor
method
studi
adult
patient
receiv
allogen
hct
variou
haematolog
malign
jan
dec
patient
receiv
hct
use
hlamatch
relat
donor
mrd
hlamatch
unrel
donor
mud
haploident
hla
match
ucb
graft
myeloabl
mac
reduc
intens
condit
ric
regimen
haploident
recipi
receiv
calcineurin
inhibitor
cni
mycophenol
posttranspl
cyclophosphamid
pt
cy
graftversushost
diseas
gvhd
prophylaxi
result
year
overal
surviv
patient
undergo
mrd
mud
ucb
haploident
transplant
diseas
free
surviv
df
respect
significantli
differ
among
donor
group
cumul
incid
ci
nonrelaps
mortal
nrm
relaps
respect
ci
grade
acut
gvhd
month
respect
p
chronic
gvhd
occur
patient
respect
p
despit
higher
nrm
use
haploident
donor
hr
ci
ucb
hr
ci
use
two
altern
donor
result
statist
signific
differ
df
compar
donor
conclus
ucbt
haploident
hct
use
unmanipul
graft
pt
cy
result
equival
outcom
contemporan
hct
perform
use
mrd
mud
provid
addit
altern
patient
lack
hla
match
donor
conflict
interest
noth
disclos
univers
hospit
essen
institut
experiment
cellular
therapi
essen
germani
univers
hospit
essen
institut
transfus
medicin
essen
germani
leiden
univers
medic
center
depart
hematolog
leiden
netherland
univers
hospit
essen
depart
bone
marrow
transplant
west
german
cancer
center
essen
germani
background
donorrecipi
mismatch
frequent
stem
cell
transplant
sct
associ
risk
graftversushostdiseas
relaps
nonrelaps
mortal
high
low
express
level
link
singlenucleotid
polymorph
snp
ga
region
mismatch
involv
highli
express
allel
patient
associ
higher
risk
acut
gvhd
unrel
sct
expressionmodel
hand
snp
ga
linkag
structur
defin
tcell
epitop
tce
group
associ
highrisk
nonpermiss
lowrisk
permiss
mismatch
combin
unrel
sct
tcemodel
comprehens
analysi
hladp
express
immun
cell
lack
relationship
express
tcemodel
sct
remain
unclear
investig
potenti
mechan
basi
differenti
express
relat
invitro
alloreact
predict
structur
differ
tce
group
method
express
tcemodel
compar
appli
donorrecipi
pair
receiv
unrel
sct
univers
hospit
essen
transcript
protein
cell
surfac
express
level
investig
b
celllin
bcl
primari
b
cell
monocyt
exposur
interferong
well
matur
immatur
dendrit
cell
dc
quantit
pcr
flow
cytometri
map
eight
overlap
fragment
analys
transcript
activ
dual
luciferas
assay
bcl
hela
cell
transduc
express
singl
hladp
molecul
viral
promot
absenc
use
target
tcell
alloreact
tcemismatch
tcematch
hladp
strength
respons
quantifi
upregul
assay
result
low
highrisk
mismatch
combin
concordantli
assign
express
tcemodel
signific
differ
transcript
cell
surfac
express
level
found
ga
homozyg
bcl
unstimul
primari
bcell
monocyt
cell
interferong
exposur
dc
common
allel
identifi
least
ga
haplotyp
character
snp
number
short
tandem
repeat
str
intron
tce
classif
map
two
repres
haplotyp
reveal
signific
differ
luciferas
activ
overlap
fragment
includ
encompass
ga
evid
altern
splice
associ
intron
str
independ
tcell
cultur
observ
signific
differ
percentag
respond
tcell
tcematch
compar
tcemismatch
combin
vs
p
despit
similar
hladp
express
level
transduc
target
cell
conclus
mechan
underli
genet
control
express
ga
bcl
remain
unclear
data
challeng
relev
profession
antigenpresentingcel
suggest
structur
tce
variabl
associ
differenti
alloimmunogen
independ
express
level
clinic
risk
associ
sct
mismatch
discordantli
assign
high
low
risk
express
tcemodel
remain
investig
conflict
interest
author
conflict
interest
disclos
work
support
grant
deutsch
carrera
stiftung
djcl
r
chu
de
clermont
ferrand
servic
cliniqu
adult
et
de
cellulair
clermontferrand
franc
chu
de
clermont
ferrand
biostatist
unit
drci
clermontferrand
franc
centr
hospitali
lyon
sud
sfgmtc
franc
centr
hospitali
lyon
sud
hematolog
depart
franc
hopit
saint
loui
aphp
depart
hematolog
pari
franc
chu
de
nice
depart
hematolog
nice
franc
hopit
haut
levequ
chu
de
bordeaux
servic
cliniqu
et
cellulair
pessac
franc
chu
de
nant
depart
hematolog
nant
franc
chu
de
nanci
depart
hematolog
nanci
franc
background
haploident
donor
cordblood
stem
cell
provid
altern
transplant
option
patient
lack
hlamatch
donor
patient
relaps
diseas
graft
failur
second
altern
allogen
hematopoiet
stem
cell
transplant
ahsct
usual
consid
high
risk
transplantrel
mortal
trm
report
outcom
patient
receiv
two
allogen
transplant
altern
donor
method
perform
retrospect
multicent
analysi
patient
underw
two
allogen
transplant
altern
donor
use
promis
databas
analys
progressionfre
surviv
pf
gvh
relapsefre
surviv
grf
trm
overal
surviv
os
result
forti
patient
receiv
two
cordblood
ahsct
patient
receiv
two
haploident
ahsct
patient
receiv
first
haploident
ahsct
cordblood
second
ahsct
patient
cordblood
ahsct
haploident
ahsct
main
diagnosi
de
novo
aml
diagnos
md
mpd
secondari
aml
lymphoprolif
disord
patient
median
age
year
thirtyon
receiv
myeloabl
regimen
atg
respect
median
delay
two
ahsct
month
indic
graft
failur
relaps
diseas
progress
fourtytwo
patient
complet
remiss
time
time
probabl
os
pf
grf
trm
respect
among
evalu
patient
surviv
day
engraft
twentyseven
patient
develop
acut
gvhd
patient
chronic
gvhd
fiftynin
patient
die
includ
trm
median
delay
month
rang
eleven
patient
aliv
median
followup
month
rang
multivari
analysi
agvhd
second
ahsct
complet
remiss
statu
second
hsct
significantli
associ
better
outcom
p
wherea
use
atg
associ
worst
outcom
higher
trm
choic
donor
haploident
cordblood
stem
cell
ahsct
impact
os
trm
pf
grf
conclus
result
suggest
second
haploident
cordblood
stem
cell
transplant
highrisk
procedur
could
consid
patient
achiev
complet
remiss
receiv
second
ahsct
conflict
interest
noth
disclos
uhc
zagreb
hematolog
zagreb
croatia
univers
zagreb
school
medicin
intern
medicin
zagreb
croatia
background
introduct
posttranspl
cyclophosphamid
ptci
haploident
transplant
becam
increasingli
use
coupl
expand
number
indic
result
transplant
done
analyz
length
initi
hospit
stay
number
rehospit
hospit
day
first
year
posttranspl
gvhd
incid
compar
transplant
use
haploident
haplo
match
relat
mrd
unrel
donor
mud
method
time
period
perform
total
allogen
transplant
adult
use
mrd
use
mud
use
haploident
donor
patient
transplant
haploident
donor
receiv
ptci
data
comput
use
r
packag
link
variabl
assess
use
kruskalw
test
probabl
gvhd
calcul
use
cumul
incid
method
subgroup
compar
use
gray
test
result
median
age
entir
group
year
year
haplo
group
haplo
patient
receiv
bone
marrow
bm
peripher
blood
stem
cell
pbsc
mrd
patient
receiv
bm
pbsc
mud
patient
receiv
bm
pbsc
respect
haploident
group
patient
receiv
nma
baltimor
condit
standard
myeloabl
condit
mac
mrd
mud
group
receiv
reduc
intens
condit
receiv
mac
respect
median
follow
day
overal
surviv
ci
signific
differ
group
median
number
day
discharg
posttranspl
significantli
longer
haplo
group
rang
vs
mrd
mud
first
year
post
transplant
patient
averag
rehospit
haplo
mrd
mud
group
respect
median
number
hospit
day
first
year
significantli
shorter
mrd
day
similar
mud
day
haplo
day
transplant
cumul
incid
agvhd
iiiv
ci
entir
group
even
though
highest
mud
ci
particularli
comparison
haplo
ci
statist
signific
reach
cumul
incid
cgvhd
ci
significantli
less
cgvhd
haplo
ci
comparison
mrd
ci
mud
ci
conclus
haploident
transplant
program
center
consider
expand
even
though
number
haplo
transplant
comparison
two
group
still
modest
believ
analysi
reflect
valu
longer
time
discharg
haplo
group
sure
partli
influenc
cautious
earli
day
program
develop
overal
day
spent
hospit
less
rehospit
particularli
incid
cgvhd
haplo
group
speak
overal
better
qualiti
life
qol
posttranspl
haplo
patient
conflict
interest
author
declar
conflict
interest
abstract
previous
publish
king
hussein
cancer
center
adult
medic
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
oncolog
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
pediatr
oncolgi
hematolog
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
amman
jordan
king
hussein
cancer
center
nurs
depart
amman
jordan
king
hussein
cancer
center
clinic
pharmaci
depart
bone
marrpw
transplant
program
amman
jordan
king
hussein
cancer
center
depart
cell
therapi
appli
genom
amman
jordan
king
hussein
cancer
center
pediatr
medic
oncolog
hematolog
bone
marrpw
transplant
program
amman
jordan
king
hussein
cancer
center
bone
marrow
transplnat
program
amman
jordan
background
hematopoiet
cell
transplant
hct
promis
method
treatment
patient
malign
nonmalign
condit
half
patient
abl
find
hlamatch
relat
unrel
donorhaploident
hct
hit
altern
transplant
strategi
patient
without
hlamatch
donor
haploident
donor
readili
avail
patient
need
immedi
hctat
king
hussien
cancer
cent
hit
start
sinc
limit
number
case
adapt
valid
screen
method
antihla
antidsa
laboratori
start
desenset
protocol
adapt
mdacc
regimen
method
medic
record
patient
underw
hit
king
hussein
cancer
center
bone
marrow
transplant
till
retrospect
reveiweddatabas
creat
microsoft
accessdescript
analys
relev
demograph
clinic
laboratori
data
includ
transplant
indic
donor
sourc
condit
regimen
gvhd
prophylaxi
engaft
chimer
dynam
perform
summari
statist
demograph
clinic
paramet
summer
relaps
incid
trm
agvhd
day
post
transplant
calcul
use
kaplanmeir
method
result
total
patient
includedtwo
third
malign
condit
six
patient
hit
second
transplant
fourteen
receiv
myeloabl
mac
reduc
intensit
condit
ric
ric
condit
classic
hopkin
protocol
fludarabinetbi
mac
pici
day
use
regimensal
patient
receiv
pbsc
graft
sourc
reciev
gcsf
prime
bone
marrow
graft
age
donor
variabl
differ
sourc
transplant
sexmismatch
half
femal
male
one
third
blood
group
mismatch
three
cmv
igg
dr
mismatch
engarft
sustain
full
donor
chimerismat
last
encount
patient
aliv
complet
remiss
relaps
four
graft
failur
bone
marrow
failur
syndrom
day
post
hct
relaps
trm
conclus
trend
hit
increas
feasibl
nowaday
jordan
especi
use
post
infusion
cyclophosphamid
need
complex
tcd
procedur
conflict
interest
conflict
interest
tabl
foscal
santand
bucaramanga
colombia
carlo
ardila
lull
hematolog
transplant
bucaramanga
colombia
background
hematopoiet
stem
cell
transplant
sct
altern
cur
treatment
patient
diagnos
differ
hematolog
malign
metabol
immunolog
diseas
context
ideal
donor
would
one
share
hla
ident
howev
probabl
find
hla
ident
brother
nowaday
new
modal
sct
use
haploident
sct
posttranspl
cyclophosphamid
ptci
even
thought
antigen
differ
essenti
erad
minim
residu
diseas
graft
tumor
effect
haploident
sct
associ
greater
graft
vs
host
diseas
graft
reject
slow
immun
reconstitut
less
surviv
despit
consider
advantag
transplant
modal
includ
high
donor
avail
reduc
cost
easi
applic
result
similar
compar
hla
match
sct
regard
progress
free
surviv
overal
surviv
method
review
patient
taken
hhsct
institut
januari
decemb
twenti
patient
receiv
condit
therapi
tiothepa
fludarabin
busulfan
one
patient
receiv
busulfan
fludarabin
one
receiv
melphalan
thiotepa
fludarabin
prepar
regimen
patient
receiv
posttransplant
cyclophosphamid
cycl
os
estim
day
year
follow
result
median
age
rang
year
patient
male
femal
number
patient
sibl
donor
parent
donor
patient
son
donor
condit
therapi
tiothepa
fludarabin
busulfan
posttransplant
cyclophosphamid
util
patient
fludarabin
busulfan
without
tiothepa
posttransplant
cyclophosphamid
util
patient
melphalan
fludarabin
tiothepa
patient
major
patient
acut
lymphocyt
leukemia
follow
myelodysplast
syndrom
two
hodgkin
diseas
one
acut
myeloid
leukemia
associ
one
patient
acut
leukemia
mix
phenotyp
time
transplant
patient
complet
remiss
wherea
patient
remiss
transplant
major
patient
achiev
donor
chimer
day
median
time
neutrophil
x
day
rang
platelet
x
rang
acut
gvhd
seen
eleven
patient
chronic
gvhd
gvhd
beyond
day
mild
sever
observ
five
patient
major
posttranspl
complic
hemorrhag
cystiti
hc
evid
cmv
reactiv
detect
patient
success
preemptiv
erad
one
patient
got
prophylact
valganciclovir
day
evid
ebv
viremiareactiv
found
patient
three
patient
got
rituximab
patient
ebv
viru
load
vanish
without
ill
os
within
median
follow
month
three
year
respect
four
patient
relaps
one
ball
md
aml
hodgkin
diseas
allograft
conclus
experi
regard
hhsct
suggest
treatment
modal
could
caus
long
await
increas
cur
allogen
transplant
patient
transplant
option
conflict
interest
author
declar
conflict
interest
hospit
clinico
univerisario
de
salamanca
hematolog
salamanca
spain
background
allogen
transplant
hct
one
option
high
refractori
hodgkin
lymphoma
hl
especi
indic
chemosensit
relaps
autolog
stem
cell
transplant
last
year
posttranspl
cyclophosphamidebas
haploident
hct
haploptci
greatli
develop
mani
studi
shown
efficaci
safeti
especi
h
method
nowaday
hl
patient
underw
allohct
relat
donor
institut
match
sibl
donor
ihlasib
aim
analyz
clinic
biolog
characterist
haploptci
hl
patient
outcom
compar
result
wellmatch
group
ihlasib
hl
patient
result
patient
allohct
transplant
patient
age
number
treatment
line
percentag
patient
activ
diseas
prior
allohct
similar
group
patient
group
treat
reduc
intens
condit
regimen
peripher
blood
stem
cell
sourc
use
result
haploptci
hematopoiet
recoveri
patient
engraft
median
time
neutrophil
platelet
recoveri
day
day
respect
complic
patient
develop
acut
gvhd
grade
iii
grade
iv
median
day
chronic
gvhd
cgvhd
evidenc
patient
mild
cghvd
moder
cgvhd
observ
tendenc
agvhd
cgvhd
patient
receiv
drug
prior
haploptci
cmv
infect
diagnos
patient
without
evid
cmv
diseas
four
patient
suffer
hemorrhag
cystiti
one
develop
sever
sinusoid
obstruct
syndrom
resolv
defibrotid
data
thrombot
microangiopathi
observ
outcom
median
followup
month
two
patient
die
one
due
sepsi
one
agvhd
patient
reevalu
petct
day
reach
complet
respons
evalu
patient
one
patient
relaps
day
immunosuppress
treatment
discontinu
aliv
patient
median
day
compar
outcom
haploptci
ihlasib
hl
group
patient
overal
surviv
month
haploptci
ihlasib
group
respect
median
followup
ihlasib
month
relaps
free
surviv
rf
month
statist
superior
haploptci
group
compar
ihlasib
patient
respect
incid
agvhd
cgvhd
similar
group
trend
toward
incid
sever
cgvhd
ihlasib
group
conclus
haploptci
interest
approach
highrisk
hl
patient
show
good
result
outcom
similar
standard
procedur
ihlasib
even
superior
paramet
like
rf
without
incid
agvhd
cgvhd
random
studi
longer
followup
necessari
confirm
data
conflict
interest
noth
disclos
medicana
intern
ankara
hospit
ankara
turkey
ankara
univers
school
medicin
ankara
turkey
background
allogen
hematopoiet
stem
cell
transplant
still
cur
treatment
option
certain
malign
non
malign
hematolog
diseas
unfortun
less
patient
lucki
enough
hla
match
sibl
donor
altern
donor
option
cord
blood
hla
match
mismatch
unrel
donor
haploident
famili
donor
parent
children
sibl
method
retrospect
compar
outcom
altern
donor
transplant
perform
center
accord
donor
sourc
donor
unrel
haploident
unrel
donor
hla
mismatch
result
tabpati
characterist
similar
mean
diagnosi
age
patient
donor
recipientdonor
gender
match
percentag
refractori
leukaemia
patient
high
haploident
donor
group
vs
condit
regiment
mostli
reduc
intens
haploident
donor
group
patient
treat
abl
condit
regiment
antithymocyt
globulin
graft
versu
host
diseas
prophylaxi
engraft
kinet
better
advantag
earli
neutrophil
platelet
recoveri
matchmismatch
unrel
donor
group
p
respect
acut
chronic
graft
versu
host
diseas
incid
cytomegaloviru
reactiv
transplant
relat
mortal
relaps
incid
similar
group
compar
diseas
free
df
overal
surviv
os
match
mismatch
unrel
donor
group
better
whole
patient
cohort
well
leukaemia
patient
estim
year
df
patient
vs
accord
haploident
match
mismatch
unrel
donor
os
vs
leukaemia
patient
df
vs
os
vs
conclus
conclus
haploident
donor
transplant
provid
quick
donor
avail
patient
especi
high
risk
relaps
mortal
show
advantag
diseas
overal
surviv
leukaemia
haematolog
diseas
cohort
patient
clinic
trial
registri
conflict
interest
none
san
raffael
scientif
institut
clinic
health
psycholog
unit
milano
itali
ircc
san
raffael
scientif
institut
hematolog
bmt
unit
milan
itali
san
raffael
scientif
institut
immunohematolog
transfusion
medicin
unit
milano
itali
san
raffael
scientif
institut
hematolog
bone
marrow
transplant
unit
milano
itali
background
care
donor
allogen
hematopoiet
stem
cell
transplant
hsct
requir
identifi
factor
predict
poorer
donat
experi
sinc
predon
qualiti
life
qol
score
predict
time
recoveri
donat
billen
factor
potenti
associ
donor
percept
qol
investig
particularli
interest
could
assess
donor
psycholog
condit
psychopatholog
symptom
andor
relationship
patient
caregiv
style
famili
function
could
associ
donor
percept
qol
far
specif
psycholog
intervent
individu
focus
coupl
donorpati
time
address
help
donor
face
donat
method
may
june
san
raffael
hospit
milan
relat
donor
femal
male
mean
age
donor
acut
leukemia
patient
studi
period
donat
selfadminist
questionnair
use
evalu
donor
qol
medic
outcom
studi
ware
e
sherbourn
psychopatholog
symptom
daniel
caregiv
style
caregiv
questionnair
kunc
shaver
famili
function
famili
apgar
smilkstein
associ
qol
variabl
studi
univari
analysi
statist
test
result
result
show
donor
describ
good
physic
qol
psycholog
describ
good
famili
function
tot
apgar
rang
report
psychopatholog
symptom
global
sever
index
show
respons
caregiv
style
degre
proxim
patient
averag
mental
qol
neg
associ
p
control
compuls
caregiv
style
psychopatholog
symptom
physic
qol
posit
associ
p
good
degre
proxim
patient
respons
caregiv
style
percept
adequ
famili
function
conclus
data
suggest
multidisciplinari
approach
donor
develop
order
assess
act
psycholog
variabl
pre
donat
phase
relationship
donor
patient
appear
key
variabl
evalu
sinc
correl
mental
physic
qol
also
influenc
donor
complianc
treatment
could
modifi
donat
side
effect
consid
great
import
donor
role
treatment
hsct
patient
import
notic
donor
would
seem
benefit
treat
multidisciplinari
set
structur
implement
psycholog
assess
conflict
interest
author
noth
disclos
nation
univers
cancer
institut
dept
hematolog
oncolog
singapor
singapor
singapor
gener
hospit
dept
hematolog
singapor
singapor
nation
univers
hospit
dept
paediatr
singapor
singapor
kandang
kerbau
children
women
hospit
singapor
dept
paediatr
singapor
singapor
background
outcom
haploident
haplo
hematopoiet
cell
transplant
hct
encourag
becom
altern
option
patient
without
hlamatch
donor
gvhd
engraft
failur
infecti
complic
continu
main
caus
transplantrel
morbid
trm
hypothes
select
deplet
cell
subset
permit
hematopoiet
engraft
effect
reduc
gvhd
provid
improv
donor
immun
reconstitut
adopt
transfer
donor
matur
nk
cell
memori
cell
herein
present
result
first
patient
poorprognosi
hematolog
malign
receiv
haplohct
deplet
graft
follow
reducedintens
condit
ric
regimen
method
condit
regimen
consist
total
nodal
irradi
gy
equal
fraction
fludarabin
divid
daili
day
thiotepa
mgkg
divid
twice
daili
day
melphalan
day
short
term
gvhd
prophylaxi
day
given
patient
use
mmf
use
tacrolimu
use
sirolimu
result
transplant
adult
median
age
year
rang
children
age
rang
year
high
risk
aml
md
graft
contain
median
x
rang
cellskg
x
rang
cellskg
addit
graft
contain
median
x
rang
cellskg
x
rang
cellskg
fifteen
patient
engraft
anc
median
day
rang
plt
median
day
rang
complet
donor
chimer
seen
time
engraft
patient
primari
engraft
one
patient
experienc
primari
graft
failur
requir
retranspl
use
differ
mismatch
famili
member
secondari
graft
failur
six
patient
develop
acut
gvhd
grade
iiiv
cumul
incid
day
one
patient
experienc
chronic
gvhd
cumul
incid
trm
day
relaps
day
respect
viral
reactiv
includ
cmv
ebv
adenoviru
fatal
viral
infect
occur
within
day
addit
fatal
blood
stream
infect
within
day
kaplanmei
estim
month
month
overal
surviv
median
follow
day
rang
respect
conclus
preliminari
result
suggest
haplohct
deplet
graft
follow
ric
regimen
allow
success
allograft
highrisk
patient
lack
suitabl
donor
trm
due
gvhd
remain
major
obstacl
success
hct
effect
strategi
need
elimin
high
risk
sever
gvhd
preserv
antitumor
antimicrobi
immunocompet
clinic
trial
registri
na
conflict
interest
w
leung
work
miltenyi
biotec
none
author
anyth
disclos
azienda
ospedaliera
universitaria
integrata
transfus
medicin
depart
verona
itali
ent
ospedaliero
ospedai
galliera
italian
bone
marrow
donor
registri
genova
itali
background
stem
cell
transplant
famili
set
relat
donor
recipi
usual
perform
transplant
centr
tc
collect
center
cc
part
transplant
program
hospit
citi
rare
happen
donor
recipi
live
differ
citi
case
donor
normal
move
donor
center
collect
center
closer
transplant
center
describ
experi
manag
famili
donor
live
itali
donat
pbsc
peripher
blood
stem
cell
brother
live
germani
transplant
german
tc
method
end
octob
receiv
formal
request
pbsc
donat
italian
familiy
donor
brother
live
germani
donor
alreadi
declar
difficulti
make
donat
germani
ask
donat
itali
request
sent
german
tc
registri
zkrd
italian
registri
ibmdr
order
ask
nearest
donor
center
avail
contact
donor
evalu
elig
donat
ibmdr
forward
request
cd
closest
home
put
ct
contact
cd
cd
contact
cc
donor
predon
workup
cc
strict
agreement
cd
agre
ct
workup
program
donat
date
donor
clearanc
start
mobil
therapi
ct
respons
transport
pbsc
administr
aspect
fee
appli
ibmdr
ct
declar
accept
also
appli
organiz
aspect
manag
donor
pbsc
unit
oper
protocol
establish
ibmdr
standard
follow
unrel
donor
favor
intern
recipi
ibmdr
updat
real
time
phase
donat
result
donat
took
place
novemb
unit
transport
ct
author
export
issu
italian
compet
author
sec
assign
accord
european
legisl
transplant
success
performd
full
haematolog
recoveri
day
donor
current
follow
cd
postdon
followup
conclus
experi
show
case
famili
donor
donat
pbsc
bm
famili
member
live
differ
countri
oper
protocol
follow
unrel
donor
appli
relat
unrel
donor
manag
also
emphas
import
role
play
registri
ibmdr
zkrd
case
facilit
import
refer
organiz
aspect
stem
cell
donat
differ
countri
involv
conflict
interest
vassanelli
noth
disclos
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
immunolog
servic
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
imib
univers
murcia
haematolog
servic
stem
cell
transplant
unit
el
palmar
murcia
spain
background
recoveri
immun
system
allogen
haematopoiet
stem
cell
transplant
allohsct
highli
dynam
process
often
delay
result
prepar
regimen
use
prior
transplant
predispos
recipi
infect
method
retrospect
observ
studi
patient
age
year
undergo
allohsct
tertiari
hospit
januari
decemb
studi
total
pediatr
patient
underw
allo
hsct
median
followup
month
immunolog
reconstitut
assess
total
lymphocyt
lymphocyt
ratio
b
lymphocyt
natur
killer
nk
day
post
allohsct
normal
lymphocyt
popul
valu
defin
includ
pediatr
aid
clinic
trial
group
studi
perform
group
accord
donor
type
relat
donor
rd
unrel
donor
urd
haploident
haplo
cord
blood
cb
immun
recoveri
data
avail
rdhsct
urdhsct
haplohsct
deplet
cbhsct
result
depict
immun
evolut
post
allohsct
type
lymphocyt
accord
donor
type
signific
differ
group
recoveri
normal
valu
found
urd
group
sinc
day
sinc
day
rd
group
group
show
slow
steadi
increas
achiev
normal
valu
year
transplant
cb
group
recoveri
faster
rd
group
show
normal
valu
day
cb
group
achiev
day
urd
group
posttranspl
lymphocyt
recoveri
significantli
lower
p
day
haplo
group
rd
group
day
also
significantli
lower
p
cb
group
rd
group
rd
urd
group
show
normal
valu
sinc
haplo
group
recov
normal
valu
sinc
day
cb
group
sinc
day
ratio
day
significantli
lower
p
urd
group
rd
haplo
group
haplo
cb
group
show
ratio
greater
sinc
day
rd
urd
group
show
ratio
invers
day
rd
group
day
urd
group
rd
first
group
recov
normal
valu
day
significantli
differ
urd
group
p
follow
cb
day
urd
day
contrast
haplo
group
reach
normal
level
one
year
followup
lymphocyt
show
earli
recoveri
normal
valu
sinc
day
without
signific
differ
group
conclus
immun
reconstitut
variabl
accord
donor
sc
sourc
overal
innat
immun
recov
within
first
week
hct
follow
adapt
immun
system
conflict
interest
none
univers
hospit
basel
divis
hematolog
basel
switzerland
swiss
red
cross
blood
transfus
center
basel
switzerland
zurich
univers
appli
scienc
school
health
profess
winterthur
switzerland
background
hlaantibodi
increasingli
recogn
play
import
role
set
hsct
aim
current
prospect
studi
evalu
occurr
dynam
hlaantibodi
match
relat
hsct
method
patient
match
relat
donor
prospect
includ
irb
approv
studi
hlaantibodi
determin
luminex
techniqu
predefin
time
point
patient
sampl
drawn
baselin
hsct
hsct
weekli
thereaft
week
hsct
donor
elig
assess
donat
use
gener
estim
equat
model
gaussian
neg
binomi
famili
log
link
robust
standard
error
order
assess
tempor
trajectori
patient
averag
mean
fluoresc
intens
mfi
highest
mfi
number
antibodi
mfi
result
among
patient
includ
studi
femal
median
age
transplant
year
major
patient
aml
mm
receiv
myeloabl
condit
gvhd
prophylaxi
consist
mainli
cyclosporin
contain
regimen
baselin
hlaantibodi
detect
patient
mean
number
antibodi
specif
rang
donor
mean
number
antibodi
specif
rang
overal
number
mfi
class
antibodi
higher
compar
class
ii
antibodi
baselin
total
number
class
mean
mfi
class
ii
antibodi
mean
mfi
highest
mean
mfi
class
class
ii
antibodi
respect
surprisingli
consider
increas
number
intens
antibodi
observ
within
day
baselin
day
transplant
hsct
total
number
antibodi
class
mean
highest
mfi
class
ii
antibodi
mean
highest
mfi
respect
thereaft
number
antibodi
well
mfilevel
measur
weekli
remain
stabl
end
observ
find
similar
adjust
gender
age
diagnosi
condit
gvhd
prophylaxi
cmv
statu
abo
incompat
figur
furthermor
patient
develop
new
hla
antibodi
increas
steadili
number
intens
observ
time
period
new
class
ii
antibodi
mean
number
mean
mfi
occur
often
higher
intens
class
antibodi
mean
number
mean
mfi
molecular
specif
antibodi
emerg
patient
found
correspond
donor
conclus
data
show
hla
antibodi
frequent
present
patient
undergo
hsct
measur
day
transplant
addit
patient
develop
new
includ
presum
donorderiv
antibodi
might
impact
regard
transfus
strategi
platelet
transfus
refractori
well
transplant
outcom
sinc
hlamismatch
incl
haploident
hsct
increasingli
perform
worldwid
studi
signific
hlaantibodi
set
warrant
conflict
interest
author
declar
conflict
interest
dokuz
eylul
univers
pediatr
hematolog
izmir
turkey
background
report
donorderiv
autoimmun
diseas
allogen
stem
cell
transplant
case
posttranspl
adopt
autoimmun
autoantibodi
produc
clone
program
donor
lymphocyt
describ
pediatr
acut
lymphoblast
leukemia
patient
transplant
mother
diagnosi
rheumatoid
arthriti
ra
nine
year
transplant
develop
autoantibodi
without
clinic
find
ra
method
male
high
risk
cell
underw
myeloabl
allogen
peripher
blood
stem
cell
transplant
first
complet
remiss
hla
match
mother
juli
donor
diagnos
seroposit
ra
year
old
clinic
diseas
full
control
mgday
methylprednisolon
high
titer
rheumatoid
factor
iuml
anticycl
citrullin
antibodi
anticcp
antibodi
uml
detect
time
peripher
stem
cell
collect
patient
donor
allel
phenotyp
may
involv
suscept
ra
patient
receiv
busulfan
etoposid
cyclophosphamid
condit
graft
versu
host
diseas
gvhd
prophylaxi
consist
cylosporin
shortcours
methotrex
neutrophil
thrombocyt
engraft
day
respect
posttranspl
period
uncompl
except
cultur
neg
febril
neutropenia
mucos
occur
acut
chronic
gvhd
followup
bone
marrow
sampl
demonstr
complet
donor
chimer
fluoresc
situ
hybrid
result
posttranspl
nineyear
followup
period
complaint
physic
examin
find
might
associ
rheumatoid
ra
develop
rheumatoid
factor
neg
novemb
highli
specif
anticcp
antibodi
ra
detect
posit
low
titer
uml
addit
antinuclear
antibodi
posit
nucleolar
granular
pattern
conclus
think
donor
deriv
memori
b
cell
may
contribut
product
autoantibodi
patient
exlud
possibl
de
novo
autoimmun
antibodi
develop
firstdegre
rel
person
ra
slightli
like
develop
condit
patient
allel
appear
autoantibodi
autoimmun
diaseas
often
appear
develop
clinic
diseas
even
low
anticcp
antibodi
level
known
associ
progress
ra
therefor
patient
close
follow
develop
ra
conflict
interest
none
author
anyth
disclos
king
colleg
hospit
guy
st
thoma
nh
foundat
trust
haematolog
london
unit
kingdom
univers
hospit
bristol
haematolog
bristol
unit
kingdom
bart
health
nh
trust
haematolog
london
unit
kingdom
leed
teach
hospit
nh
trust
haematolog
leed
unit
kingdom
sheffield
teach
hospit
nh
foundat
trust
haematolog
sheffield
unit
kingdom
cambridg
univers
hospit
nh
foundat
trust
haematolog
cambridg
unit
kingdom
nh
greater
glasgow
clyde
haematolog
glasgow
unit
kingdom
newcastl
upon
tyne
hospit
nh
foundat
trust
northern
centr
cancer
care
newcastl
unit
kingdom
heart
england
nh
foundat
trust
haematolog
stem
cell
transplant
birmingham
unit
kingdom
royal
liverpool
univers
hospit
haematolog
stem
cell
transplant
liverpool
unit
kingdom
manchest
royal
infirmari
manchest
univers
foundat
trust
manchest
unit
kingdom
cr
uk
ucl
cancer
trial
centr
london
unit
kingdom
univers
hospit
bristol
bristol
unit
kingdom
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
king
colleg
hospit
guy
king
colleg
haematolog
london
unit
kingdom
background
tcell
replet
haploident
haplo
stem
cell
transplant
posttranspl
cyclophosphamid
develop
bone
marrow
graft
peripher
blood
stem
cell
pbsc
commonest
sourc
use
intern
donor
higher
rate
graftversushostdiseas
gvhd
studi
pbsc
ric
haplo
transplant
method
multicentr
singl
arm
prospect
phase
ii
studi
haplo
hsct
patient
without
donor
direct
hla
antibodi
ric
condit
fludarabin
day
cyclophosphamid
day
gy
tbi
posttranspl
cyclophosphamid
gvhd
prophylaxi
tacrolimu
cyclosporin
mycophenol
mofetil
mmf
primari
outcom
overal
surviv
os
year
secondari
outcom
includ
progress
free
surviv
pf
nonrelaps
mortal
nrm
incid
gvhd
engraft
result
fifti
patient
enrol
uk
centr
median
age
patient
characterist
tabl
median
cell
administ
acut
classic
gvhd
grade
occur
grade
ii
grade
iv
acut
persist
recurr
late
onset
gvhd
grade
occur
grade
ii
iii
grade
iv
patient
develop
chronic
classic
gvhd
chronic
overlap
syndrom
occur
cumul
incid
ci
grade
iiiv
agvhd
respect
median
time
gvhd
day
death
attribut
gvhd
median
followup
survivor
month
ci
nrm
year
os
year
respect
pf
year
year
relaps
rate
graft
reject
occur
two
fail
despit
adequ
cell
dose
third
harvest
inadequ
dose
final
earli
withdraw
ist
lead
reject
salvag
cord
blood
transplant
eight
patient
die
postrelaps
diseas
unknown
infect
day
trm
follow
second
sct
post
graft
failur
conclus
preliminari
result
demonstr
pbsc
haplo
ric
transplant
safe
multicentr
set
low
level
sever
gvhd
os
pf
year
compar
bm
haplo
sib
match
unrel
donor
low
nrm
relaps
rate
followup
need
clinic
trial
registri
clinicaltrialsgov
eudract
conflict
interest
conflict
interest
author
trial
fund
research
grant
blood
wise
grant
tabl
patient
characterist
king
abdulaziz
medic
citi
riyadh
saudi
arabia
king
abdullah
intern
medic
research
center
riyadh
saudi
arabia
king
saud
bin
abdulaziz
univers
health
scienc
riyadh
saudi
arabia
background
peripher
hematopoiet
stem
cell
mobil
use
gcsf
wide
use
allogen
hct
patient
sickl
cell
diseas
scd
prone
signific
risk
gcsf
includ
splenic
ruptur
death
part
due
precipit
vasoocclus
crise
voc
voc
also
seen
patient
sickl
cell
trait
sct
condit
sever
stress
although
allogen
hct
cur
scd
donor
avail
major
limit
sibl
donor
often
affect
furthermor
pauciti
literatur
regard
safeti
gcsf
sct
carrier
aim
examin
safeti
efficaci
util
growth
factor
donor
sct
method
due
irb
approv
allogen
donor
sibl
recipi
scd
identifi
medic
record
retrospect
extract
sickl
cell
screen
perform
posit
high
perform
liquid
chromatographi
hplc
complet
donor
interview
post
mobil
survey
complet
inquir
advers
effect
rang
sever
none
mild
moder
sever
gcsf
administ
dose
mcgkg
round
nearest
vial
size
day
follow
high
flow
apheresi
enumer
measur
day
goal
collect
cell
recipi
weight
allow
safe
engraft
categor
continu
variabl
compar
use
chisquar
wilcoxon
kruskalw
respect
result
total
donor
identifi
sct
carrier
cohort
stratifi
base
presenc
sct
correspond
baselin
characterist
similar
regard
age
gender
weight
cmv
statu
gcsf
dosekg
use
trend
toward
multipl
day
collect
control
donor
complet
blood
count
cbc
peripher
count
day
collect
also
similar
donor
report
symptom
post
mobil
survey
shown
tabl
incid
sever
advers
event
similar
cohort
includ
percentag
analgesia
util
durat
symptom
major
donor
report
symptom
requir
analgesia
control
pain
none
donor
develop
infect
thrombosi
seizur
requir
transfus
support
seriou
advers
event
cohort
includ
voc
acut
chest
syndrom
hospit
admiss
due
gcsf
splenic
ruptur
death
conclus
demonstr
gcsf
use
safe
donor
sct
result
similar
advers
event
profil
control
subject
furthermor
sct
donor
abl
mobil
target
yield
stem
cell
one
apheresi
session
result
import
appropri
counsel
prospect
donor
sct
thu
potenti
increas
donor
pool
patient
afflict
scd
conflict
interest
relev
conflict
interest
institut
paolicalmett
centr
de
cellulair
marseil
franc
centr
dinvestig
cliniqu
en
marseil
franc
institut
paolicalmett
de
transplant
et
de
cellulair
marseil
franc
institut
paolicalmett
direct
du
dinform
et
de
lorganis
marseil
franc
background
given
constant
increas
number
allogen
transplant
carri
establish
lack
comput
tool
avail
market
creation
softwar
becom
essenti
order
optim
manag
pretranspl
parallel
step
donor
recipi
allow
multipl
actor
involv
reduc
risk
oversight
error
limit
workload
method
main
object
tool
reduc
delay
preparatori
process
allogen
transplant
creat
work
list
specif
function
updat
real
time
autom
alert
noncompli
deadlin
accomplish
task
facilit
interact
profession
intern
extern
institut
realtim
share
inform
associ
document
avoid
loss
inform
secur
exchang
result
main
benefit
observ
increas
probabl
identifi
donor
time
manner
reduct
frequenc
match
relat
donor
search
last
day
first
year
use
figur
greatli
reduc
risk
patient
disappear
activ
file
realtim
access
inform
reduc
workload
telephon
call
work
disrupt
variou
actor
archiv
sourc
document
hla
type
report
exampl
allow
onlin
access
stakehold
reduct
frequenc
durat
meet
actor
process
automat
calcul
indic
sinc
process
optim
prior
use
softwar
month
reduct
search
time
unrel
donor
efficaci
indic
remain
stabl
sinc
introduct
softwar
conclus
prep
gref
tool
repres
prototyp
complex
care
process
model
adapt
pilot
activ
field
health
autograft
exampl
even
outsid
tool
avail
market
allow
track
flow
patient
dynam
tool
develop
make
possibl
go
beyond
stage
usual
tradit
organ
set
mani
hospit
pilot
complex
care
process
preallograft
process
includ
step
systemat
perform
order
softwar
adapt
real
time
redefin
patient
donor
path
accord
respons
provid
step
possibl
valu
first
year
use
action
identifi
softwar
carri
intern
extern
actor
institut
conflict
interest
none
hanyang
univers
medic
center
depart
pediatr
seoul
korea
republ
chungbuk
nation
univers
colleg
medicin
depart
pediatr
cheongju
korea
republ
background
current
util
rate
cord
blood
cb
low
store
cb
unit
korea
tri
remodel
public
cb
inventori
enhanc
util
cb
clinic
cord
blood
transplant
cbt
well
basic
clinic
research
method
data
collect
public
cb
bank
cb
inform
center
well
publish
paper
regard
cbt
korea
compar
characterist
store
transplant
cb
unit
prelegisl
postlegisl
era
juli
dec
korea
optim
public
cb
inventori
base
current
statu
cbt
research
requir
well
nation
budget
korean
govern
result
compar
prelegisl
period
store
cb
unit
total
nucleat
cell
tnc
increas
public
cb
inventori
proport
transplant
cb
unit
tnc
increas
tnc
storedtranspl
cb
unit
increas
retrospect
data
analysi
sever
research
regard
cbt
korea
median
tnc
cb
use
cbt
respect
accord
patient
categori
age
transplant
cb
among
store
cb
sinc
yr
ago
yr
cb
yr
age
use
yr
yr
request
cb
unit
research
sinc
postlegisl
era
total
unit
unit
annual
requir
could
satisfi
cb
inventori
tnc
andor
yr
age
conclus
base
data
increas
cutoff
level
postprocess
tnc
upcom
storag
public
cb
furthermor
remodel
public
cb
inventori
follow
cb
tnc
yr
store
age
avail
clinic
cbt
cb
tnc
andor
yr
age
basic
clinic
research
conflict
interest
noth
disclos
univers
manitoba
intern
medicin
hematologyoncolog
winnipeg
canada
center
intern
blood
marrow
transplant
research
minneapoli
mn
unit
state
nation
marrow
donor
program
minneapoli
mn
unit
state
fred
hutchinson
cancer
research
center
clinic
research
seattl
wa
unit
state
medic
colleg
wisconsin
center
intern
blood
marrow
transplant
research
milwauke
wi
unit
state
massachusett
gener
hospit
harvard
medic
school
boston
unit
state
children
hospit
lo
angel
lo
angel
ca
unit
state
nation
cancer
institut
nih
bethesda
md
unit
state
univers
pittsburgh
pittsburgh
pa
unit
state
background
hematopoiet
cell
transplant
hct
donor
must
evalu
condit
transmiss
intend
recipi
increas
interest
risk
transfer
potenti
seriou
noninfecti
syndrom
particular
clonal
hematopoiesi
ch
unknown
extent
hct
centr
screen
ch
blood
marrow
relat
donor
rd
found
find
manag
conduct
survey
better
understand
process
hct
center
util
identifi
rd
may
ch
ii
whether
rd
would
exclud
donat
method
sent
confidenti
onlin
survey
medic
director
cibmtrregist
hct
centr
evalu
rd
survey
consist
question
prompt
respond
approach
assess
otherwis
healthi
rd
normal
complet
blood
count
cbc
hct
centr
adult
pediatr
program
separ
respons
adult
pediatr
program
director
request
result
survey
request
sent
receiv
respons
figur
summar
differ
respond
nonrespond
centr
respond
collect
bone
marrow
bm
peripher
blood
pb
hematopoiet
cell
center
collect
cell
adult
adult
children
center
factjaci
accredit
lower
volum
hct
center
hctsyear
constitut
respond
major
hct
center
report
routin
screen
rd
ch
howev
routin
peripher
blood
test
ch
frequent
perform
monoclon
gammopathi
respond
monoclon
bcell
lymphocytosi
mbl
gene
sequenc
somat
mutat
routin
bm
aspir
perform
respond
addit
perform
test
specif
subgroup
rd
especi
older
adult
routin
bm
aspir
frequent
perform
lower
volum
hct
center
vs
larger
center
vs
respond
besid
standard
morpholog
assess
common
routin
test
bm
cytogenet
mbl
somat
mutat
test
respond
recal
detect
least
one
case
follow
abnorm
routin
workup
rd
monoclon
gammopathi
mbl
clonal
cytogenet
abnorm
although
respond
would
defer
donor
find
signific
minor
would
defer
uncertain
whether
defer
donor
deferr
definit
recommend
respond
monoclon
gammopathi
mbl
clonal
cytogenet
somat
mutat
conclus
otherwis
healthi
rd
normal
cbc
small
appreci
number
hct
centr
activ
look
ch
pb
bm
test
routin
bm
aspir
perform
rd
hct
center
especi
older
rd
rd
lower
volum
hct
center
howev
consider
uncertainti
whether
detect
ch
pb
bm
constitut
ground
donor
exclus
recommend
develop
intern
guidelin
standard
specif
evalu
manag
potenti
transmiss
disord
clonal
hematopoiesi
donor
clinic
trial
registri
na
conflict
interest
noth
disclos
universita
cattolica
policlinico
gemelli
istituto
di
ematologia
roma
itali
ircc
auo
ist
san
martino
division
ematologia
genova
itali
background
reject
follow
haploident
transplant
haplo
posttranspl
high
dose
cyclophosphamid
ptci
describ
associ
donor
specif
antibodi
dsa
bmt
aim
studi
assess
incid
reject
patient
hematolog
malign
prepar
myeloabl
condit
regimen
outcom
second
transplant
method
studi
patient
hematolog
malign
receiv
unmanipul
haplo
marrow
graft
median
age
advanc
diseas
patient
receiv
gvhd
prophylaxi
cyclosporin
mycophenol
ptci
condit
regimen
use
one
follow
three
fludarabin
flu
total
bodi
irradi
tbi
gy
thiotepa
thio
busulfan
bu
flu
tbf
thio
bu
flu
result
reject
seen
patient
tbi
tbf
day
busulfan
patient
receiv
tbf
day
busulfan
could
find
correl
reject
donor
age
patient
age
diagnosi
phase
diseas
abo
mismatch
bone
marrow
cell
dose
infus
busulfan
find
trend
reject
rome
bu
given
divid
daili
dose
h
compar
genova
bu
given
singl
daili
dose
reject
full
dose
tbf
day
patient
receiv
bu
vs
bu
given
second
transplant
patient
fail
recov
neutrophil
day
found
recipi
chimer
patient
evalu
sinc
receiv
second
graft
day
ago
second
patient
infus
select
cell
donor
without
condit
regimen
die
without
recoveri
fail
third
transplant
patient
receiv
second
graft
median
interv
day
rang
baltimor
protocol
pb
donor
anoth
famili
member
gvhd
prophylaxi
cya
ptci
trilineag
recoveri
becam
donor
neutrophil
count
reach
day
platelet
count
day
acut
gvhd
occur
patient
grade
patient
grade
ii
moderatesever
chronic
gvhd
develop
patient
one
year
actuari
surviv
patient
receiv
second
graft
conclus
risk
reject
depend
intens
condit
regimen
occur
tbi
low
full
dose
tbf
b
trend
reject
busulfan
given
c
full
engraft
achiev
second
transplant
patient
reject
mortal
due
reject
seri
patient
conflict
interest
author
declar
conflict
interest
american
univers
beirut
medic
center
beirut
lebanon
background
donor
select
consid
key
element
improv
outcom
hematopoiet
stem
cell
transplant
hsct
sexmismatch
hsct
link
increas
graftversushost
diseas
gvhd
transplantrel
mortal
trm
overal
mortal
adult
current
consensu
present
regard
effect
outcom
hsct
children
adolesc
method
retrospect
chart
review
conduct
patient
age
less
year
underw
allogen
hsct
relat
fullymatch
donor
american
univers
beirut
effect
sexmismatch
trm
reject
relaps
acut
gvhd
chronic
gvhd
done
use
coxregress
model
result
donor
recipi
sex
combin
categor
follow
male
donor
male
recipi
mm
male
donor
femal
recipi
mf
femal
donor
femal
recipi
ff
femal
donor
male
recipi
fm
transplant
done
follow
diseas
leukemia
lymphoma
hemoglobinopathi
inherit
immun
system
disord
inherit
metabol
disord
famili
hemophagocyt
lymphohistiocytosi
bone
marrow
failur
diseas
stem
cell
sourc
bone
marrow
patient
mobil
peripher
blood
stem
cell
patient
median
followup
month
rang
month
overal
surviv
rate
ci
use
univari
analysi
sexmismatch
effect
overal
mortal
hr
p
trm
hr
p
relaps
hr
p
reject
hr
p
acut
gvhd
hr
p
chronic
gvhd
hr
p
subgroup
analysi
neither
femaletomal
malefemal
transplant
predictor
wors
surviv
reject
acut
chronic
gvhd
conclus
sexmismatch
effect
major
outcom
allogen
matchedrel
hsct
pediatr
popul
larger
studi
need
confirm
conflict
interest
relev
conflict
interest
stem
cell
mobil
collect
engin
puc
santiago
chile
background
autolog
hematopoiet
stem
cell
transplant
proven
therapi
sever
diseas
perform
adequ
harvest
stem
cell
requir
patient
poor
mobil
collect
stem
cell
challeng
achiev
satisfactori
cell
count
gcsf
chemotherapi
plerixafor
potent
drug
promot
releas
stem
cell
bone
marrow
nich
peripher
blood
allow
satisfactori
harvest
high
cost
method
conduct
retrospect
analysi
harvest
perform
patient
treat
autolog
transplant
institut
result
patient
mainli
myeloma
lymphoma
harvest
failur
use
plerixafor
satisfactori
harvest
obtain
patient
mobil
gcsf
plerixafor
patient
use
plerixafor
necessari
perform
less
apheresi
p
multivari
analysi
factor
predict
need
plerixafor
presenc
less
ul
day
apheresi
conclus
conclud
ration
standard
use
plerixafor
favor
satisfactori
harvest
patient
requir
autolog
transplant
conflict
interest
noth
disclos
institut
paolicalmett
centr
de
cellulair
marseil
franc
inserm
centr
dinvestig
cliniqu
en
de
marseil
marseil
franc
institut
paolicalmett
depart
biostatist
marseil
franc
institut
paolicalmett
depart
hematolog
transplant
program
marseil
franc
aix
marseil
univers
marseil
franc
background
apheresi
techniqu
wide
usag
select
collect
deplet
variou
blood
compon
therapeut
purpos
context
autolog
allogen
hematopoiet
cell
transplant
peripher
blood
stem
cell
pbsc
nowaday
repres
exclus
wide
use
sourc
stem
cell
respect
graft
qualiti
evalu
flow
cytometr
enumer
collect
cell
thereaft
clonogenec
collect
effici
ce
gross
estim
proport
circul
cell
harvest
separ
consid
measur
perform
procedur
goal
studi
identifi
patientrel
procedur
factor
could
influenc
ce
method
total
first
apheresi
procedur
perform
donor
patient
carri
calendar
year
retrospect
studi
factor
investig
includ
patientrel
criteria
age
sex
bodi
mass
index
diseas
statu
collect
type
mobilis
preapheresi
biolog
paramet
preprocedur
cell
concentr
procedur
criteria
oper
continu
discontinu
mononuclear
cell
collect
total
process
blood
volum
number
process
blood
mass
statist
relationship
ce
variou
characterist
determin
multipl
linear
regress
analysi
result
median
valu
ce
individu
donor
patient
respect
stepwis
multipl
regress
analysi
diseas
statu
signific
impact
ce
valu
convers
procedur
criteria
patientrel
criteria
may
explain
variabl
ce
studi
demonstr
ce
valu
stabl
whatev
oper
type
cell
collect
consid
total
process
blood
volum
significantli
correl
ce
beta
allogen
apheres
preapheresi
leucocyt
count
beta
haemoglobin
beta
percentag
cell
beta
independ
predict
factor
affect
ce
autolog
apheres
leucocyt
count
beta
p
neutrophil
count
beta
hematocrit
beta
introduct
plerixafor
beta
significantli
contribut
variabl
ce
valu
conclus
ce
use
criteria
monitor
effici
perform
apheresi
procedur
time
valu
ce
depend
preapheresi
biolog
factor
must
consid
independ
allogen
autolog
procedur
due
clinic
biolog
differ
two
popul
better
inclus
preapheresi
biolog
paramet
consid
order
limit
variabl
pbsc
collect
conflict
interest
conflict
interest
hospit
universitario
de
valdecilla
santand
hematolog
santand
spain
banco
de
sangr
tejido
de
cantrabria
liencr
spain
background
abomismatch
bone
marrow
bm
transplant
red
blood
cell
rbc
remov
essenti
minim
risk
inmunohematolog
complic
maximum
volum
mismatch
rbc
safe
infus
clearli
defin
practic
differ
hospit
although
gener
accept
recipi
bodyweight
toler
without
signific
acut
haemolysi
differ
techniqu
use
reduc
rbc
maxim
stem
cell
recoveri
apheresi
devic
instanc
cobe
separ
util
succes
year
withdraw
market
replac
spectra
evalu
spectra
apheresi
system
determin
effect
aboincompat
bm
process
method
anal
aboincompat
process
bm
transplant
perform
center
sinc
date
optia
devic
implement
practic
sampl
process
use
spectra
optia
direct
manufactur
run
semiautomat
rbc
deplet
protocol
initi
collect
prefer
entir
bm
volum
process
averag
time
minut
typic
flow
veloc
volum
reduct
rbc
deplet
recoveri
total
nucleat
cell
tnc
mononuclear
cell
mnc
calcul
hematopoiet
engraft
asses
data
analyz
ibm
spss
version
result
express
mean
desviat
median
rang
engraft
result
sampl
includ
allogen
fresh
aboincompat
bm
transplant
process
proceed
success
without
technic
incid
seriou
post
infus
advers
effect
mean
volum
collect
ml
reduc
ml
process
inici
residu
mean
rbc
volum
ml
ml
respect
correspond
deplet
residu
rbc
volum
larger
mlkg
mean
mlkg
maximum
thu
case
maxim
recomend
volum
mean
percentag
recoveri
tnc
mnc
cell
cell
recoveri
therefor
optim
line
previou
report
full
data
shown
tabl
median
engraft
neutrophil
platelet
rbc
respect
patient
two
engraft
one
due
toxic
mortal
earli
relaps
conclus
spectra
effici
devic
rbc
volumen
deplet
abo
incompat
bm
transplant
provid
excel
recoveri
clinic
routin
refer
danieljohnson
j
et
al
transfus
kimwann
sz
et
al
journal
translat
medicin
conflict
interest
none
author
disclos
conflict
interest
tabl
tabl
schneider
children
medic
center
israel
pediatr
oncolog
bone
marrow
transplant
unit
petah
tikva
israel
tel
aviv
univers
sackler
faculti
medicin
tel
aviv
israel
schneider
children
medic
center
israel
bone
marrow
transplant
lab
petah
tikva
israel
schneider
children
medic
center
israel
ezer
mizion
petah
tikva
israel
background
adequ
vascular
access
prerequisit
success
peripher
blood
stem
cell
collect
pbscc
adult
difficult
vein
children
central
venou
cathet
use
pbscc
placement
line
fraught
complic
sometim
sever
previous
report
larg
seri
children
underw
pbscc
use
radial
arteri
cannul
report
use
procedur
allogen
donat
adult
difficult
vein
donat
pbscc
method
data
adult
peripher
allogen
stem
cell
collect
perform
januari
decemb
use
radial
arteri
line
collect
line
insert
percutan
use
local
anesthet
physician
train
procedur
result
nineteen
apbscc
procedur
unrel
donor
four
famili
donor
perform
studi
period
use
arteri
line
averag
donor
age
weight
year
kg
respect
averag
total
volum
process
averag
number
blood
volum
process
averag
collect
time
singl
blood
volum
minut
averag
number
cell
collect
per
donat
kg
three
donor
requir
one
collect
meet
request
cell
target
seriou
advers
effect
associ
vascular
access
occur
cohort
although
hematoma
requir
treatment
develop
one
donor
donor
satisfact
procedur
high
collect
return
line
insert
arm
collect
could
proceed
time
fashion
without
undu
alarm
caus
high
pressur
collect
line
conclus
percutan
radial
arteri
cathet
easi
rapid
safe
altern
placement
central
venou
cathet
adult
donat
pbscc
allogen
transplant
conflict
interest
noth
disclos
queen
univers
belfast
unit
kingdom
institut
paoli
calmett
marseil
franc
semmelweiss
univers
budapest
hungari
nottingham
univers
nottingham
unit
kingdom
karolinska
univers
hospit
stockholm
sweden
univers
hospit
dusseldorf
dusseldorf
germani
univers
hospit
brno
czech
republ
hammersmith
hospit
london
unit
kingdom
charl
univers
hospit
pragu
czech
republ
st
jame
hospit
dublin
ireland
medic
univers
warsaw
warsaw
poland
skane
univers
hospit
lund
sweden
radboud
univers
medic
centr
nijmegen
netherland
european
bone
marrow
transplant
societi
leiden
netherland
univers
tor
vergata
rome
itali
sanofi
genzym
cambridg
unit
state
hospit
saint
antoin
pari
franc
univers
hospit
hamburg
germani
background
plerixafor
plu
granulocyt
coloni
stimul
factor
gcsf
enhanc
mobilis
haematopoiet
stem
cell
hsc
collect
subsequ
autolog
haematopoiet
stem
cell
transplant
hsct
patient
multipl
myeloma
mm
poor
mobilis
hsc
method
intern
multicentr
nonintervent
registri
studi
year
followup
evalu
longterm
outcom
mm
patient
receiv
plerixafor
compar
hsc
mobilis
regimen
patient
achiev
first
autolog
hsct
patient
receiv
transplant
includ
analys
mobilis
comparison
gcsf
plu
plerixafor
gcsfp
versu
gcsf
alon
comparison
gcsfp
versu
gcsf
plu
chemotherapi
gcsfc
comparison
gcsfp
plu
chemotherapi
gcsfpc
versu
gcsfc
comparison
primari
outcom
progress
free
surviv
pf
overal
surviv
os
relaps
rate
rr
transplant
patient
fail
previou
mobilis
attempt
defin
proven
poor
mobilis
result
overal
patient
met
elig
criteria
studi
patient
receiv
plerixafor
baselin
characterist
cohort
balanc
use
propens
score
match
propens
analysi
versu
patient
match
gcsfp
versu
gcsf
alon
cohort
versu
gcsfp
versu
gcsfc
cohort
versu
gcsfpc
versu
gcsfc
cohort
propens
score
match
result
loss
statist
power
imbal
comparison
arm
overcom
propens
score
proven
poor
mobilis
plerixafor
cohort
versu
compar
cohort
proven
poor
mobilis
gcsfp
versu
gcsf
alon
gcsfp
versu
gc
gcsfpc
versu
gcsfc
estim
median
pf
gcsfp
cohort
month
ci
month
versu
month
ci
month
gcsf
alon
cohort
pf
gcsfp
cohort
month
ci
month
versu
month
ci
month
gcsfc
cohort
pf
gcsfpc
cohort
month
ci
month
versu
month
ci
month
gcsfc
cohort
kaplanmei
curv
show
trend
toward
lower
pf
os
plerixafor
cohort
versu
gcsf
compar
rr
rate
higher
plerixafor
cohort
proport
patient
advers
event
similar
plerixafor
compar
cohort
conclus
registri
studi
show
mobilis
issu
patient
difficult
mobilis
overcom
plerixafor
treatment
patient
studi
may
receiv
transplant
without
plerixafor
cohort
treat
plerixafor
shorter
pf
os
time
higher
rr
similar
safeti
respect
compar
firm
conclus
made
studi
due
imbal
cohort
proven
poor
mobilis
plerixafor
cohort
possibl
select
patient
wors
outcom
absenc
inform
genet
risk
mainten
treatment
observ
natur
studi
limit
studi
clinic
trial
registri
conflict
interest
studi
fund
sanofi
genzym
n
report
research
grant
ebmt
sanofi
honoraria
sanofi
l
garderet
report
advisori
board
amgen
takeda
c
chabannon
report
grant
ebmt
studi
well
grant
person
fee
nonfinanci
support
sanofi
outsid
submit
work
masszi
report
advisori
board
membership
abbvi
bm
janssencilag
novarti
pfizer
takeda
outsid
submit
work
g
kobb
report
grant
ebmt
studi
p
hayden
report
receiv
sanofi
support
meet
g
basak
report
person
fee
ebmt
studi
well
person
fee
nonfinanci
support
sanofigenzym
outsid
submit
work
q
liu
celanov
sanofi
employe
remain
author
noth
disclos
instituto
de
oncologia
de
lisboa
francisco
gentil
epe
bmt
unit
lisbon
portug
background
adult
bone
marrow
bm
harvest
typic
order
volum
smaller
volum
paediatr
harvest
contain
high
number
red
cell
volum
repres
clinic
risk
patient
term
fluid
lyse
red
cell
load
impract
cryopreserv
reason
bone
marrow
harvest
process
cell
separ
yield
reduc
volum
stem
cell
enrich
buffi
coat
deplet
red
blood
cell
plasma
buffi
coat
prepar
also
indic
fresh
infus
allogen
set
donor
recipi
abo
incompat
mandatori
major
abo
incompat
work
aim
compar
effici
two
cell
separ
cobe
vs
spectra
optia
method
retrospect
studi
bm
process
institut
januari
decemb
divid
two
group
accord
equip
use
effici
process
assess
total
nucleat
cell
tnc
recoveri
cell
recoveri
red
blood
cell
rbc
reduct
total
volum
reduct
bm
analys
pre
post
process
regard
tnc
cell
rbc
volum
result
last
year
bm
requir
process
perform
cobe
spectra
optia
data
analys
spectra
optia
present
mean
tnc
recoveri
lower
cobe
lower
tnc
recoveri
mainli
due
loss
neutrophil
eosinophil
import
transplant
context
regard
cell
recoveri
result
similar
use
cell
separ
spectra
optia
present
higher
rbc
volum
reduct
valu
remain
rate
among
procedur
use
cobe
valu
variabl
depend
oper
decis
collect
less
rbc
reason
mean
total
volum
reduct
also
higher
spectra
optia
util
compar
result
present
tabl
note
valu
accept
consid
cell
count
error
valu
exclud
conclus
compar
cobe
spectra
optia
appear
present
advantag
regard
bone
marrow
process
especi
rbc
volum
reduct
import
allogen
transplant
major
donor
recipi
abo
incompat
spectra
optia
also
less
time
consum
equip
present
good
similar
cell
recoveri
conflict
interest
noth
disclos
tabl
result
bm
process
saitama
medic
center
jichi
medic
univers
divis
hematolog
saitama
japan
background
monocyt
recent
identifi
follow
mobil
granulocytecoloni
stimul
factor
gcsf
suggest
potenti
modul
immun
function
howev
impact
clinic
outcom
allogen
hematopoiet
cell
transplant
allohct
still
remain
unclear
method
among
patient
receiv
allohct
relat
donor
identifi
donor
whose
peripher
blood
cell
gcsf
mobil
avail
flowcytometri
analys
defin
detect
donor
consid
test
posit
result
donor
detect
rang
significantli
detect
male
donor
vs
distribut
donor
age
donor
bodi
weight
differ
furthermor
ratio
total
peripher
blood
significantli
higher
donor
test
posit
vs
p
patient
diseas
acut
leukemia
lymphoma
myelodysplast
syndrom
other
highrisk
diseas
includ
detect
donor
differ
patient
background
includ
age
gender
diseas
diseas
risk
hlamismatch
condit
intens
graftversushost
diseas
gvhd
prophylaxi
whole
cohort
signific
differ
observ
overal
surviv
os
neutrophil
engraft
acut
gvhd
nonrelaps
mortal
nrm
relaps
incid
howev
focus
subgroup
standardrisk
diseas
os
donor
group
significantli
superior
donor
group
without
vs
allohct
addit
nrm
significantli
lower
donor
group
vs
relaps
incid
differ
vs
allohct
incid
cmv
infect
tend
lower
donor
group
vs
hand
differ
observ
incid
acut
gvhd
conclus
detect
donor
gcsf
mobil
differ
observ
incid
acut
gvhd
well
clinic
outcom
whole
cohort
focus
standardrisk
diseas
detect
donor
may
favor
effect
surviv
howev
studi
popul
includ
variou
diseas
total
dose
actual
infus
graft
assess
therefor
investig
still
necessari
conclud
impact
donor
graft
clinic
outcom
follow
allohct
conflict
interest
none
author
anyth
disclos
karolinska
institut
depart
clinic
scienc
intervent
technolog
hudding
sweden
karolinska
institut
depart
oncolog
patholog
stockholm
sweden
karolinska
institut
depart
clinic
scienc
intervent
technolog
clintec
stockholm
sweden
karolinska
univers
hospit
depart
haematolog
hudding
sweden
karolinska
univers
hospit
depart
clinic
immunolog
transfus
medicin
hudding
sweden
background
composit
graft
use
allogen
stem
cell
transplant
hsct
import
treatment
outcom
differ
apheresi
devic
may
yield
signific
differ
peripher
blood
stem
cell
graft
cellular
composit
compar
stem
cell
graft
produc
cobe
spectra
cobe
spectra
optia
optia
evalu
clinic
outcom
paramet
graftversushost
diseas
gvhd
transplant
relat
mortal
trm
relaps
overal
surviv
os
method
three
year
cobe
spectra
spectra
optia
graft
analyz
cell
content
clinic
outcom
paramet
correl
compar
two
patient
group
use
differ
apheresi
devic
result
optia
graft
contain
less
lymphocyt
compar
cobe
p
optia
graft
significantli
lower
incid
acut
gvhd
grade
iiiv
cobe
vs
optia
p
grade
iiiiv
cobe
vs
optia
p
trm
vs
p
higher
chronic
gvhd
vs
p
compar
cobe
graft
differ
relaps
incid
os
observ
final
multivari
analysi
show
signific
correl
differ
apheresi
devic
agvhd
iiiv
sever
cgvhd
multivari
analysi
also
show
signific
correl
cell
dose
incid
sever
agvhd
conclus
optiaobtain
graft
yield
lower
agvhd
grade
iiiv
trm
risk
impact
relaps
os
studi
understand
improv
pbsc
apheresi
techniqu
may
use
futur
person
hsct
eg
finetun
gvhd
incid
conflict
interest
conflict
interest
samsung
medic
center
sungkyunkwan
univers
seoul
korea
republ
soon
chun
hyang
univers
hospit
seoul
korea
republ
background
highdos
chemotherapi
follow
autolog
stem
cell
transplant
asct
one
essenti
treatment
option
patient
lymphoma
myeloma
success
asct
collect
suffici
number
peripher
blood
stem
cell
mandatori
howev
repeat
mobil
attempt
increas
medic
cost
risk
morbid
relat
apheresi
gener
mobil
gcsf
alon
less
effect
chemomobil
consist
chemotherapi
gcsf
administr
thu
develop
effect
less
toxic
chemomobil
regimen
extrem
import
avoid
mobil
failur
well
success
asct
method
analyz
outcom
chemomobil
reduceddos
etoposid
patient
lymphoma
myeloma
etoposid
intraven
administ
lymphoma
patient
day
myeloma
patient
day
gcsf
administ
dose
daili
start
day
continu
last
day
stem
cell
collect
apheresi
initi
white
blood
cell
platelet
count
respect
target
number
cell
count
recipi
bodi
weight
result
total
patient
analyz
lymphoma
n
myeloma
n
lymphoma
patient
underw
asct
upfront
n
salvag
n
set
howev
patient
myeloma
underw
upfront
asct
mean
number
cell
per
kg
bodi
weight
lymphoma
myeloma
patient
patient
perform
averag
two
cycl
apheresi
collect
peripher
blood
stem
cell
patient
myeloma
reach
goal
apheresi
cell
patient
lymphoma
collect
cell
efficaci
stem
cell
collect
differ
upfront
salvag
asct
lymphoma
mean
time
interv
first
date
etoposid
administr
first
date
apheresi
patient
n
collect
cell
first
cycl
apheresi
etoposid
administr
event
grade
febril
neutropenia
observ
sever
advers
event
relat
hematolog
toxic
occur
case
engraft
failur
lymphoma
myeloma
patient
conclus
taken
togeth
chemomobil
reduceddos
etoposid
effect
stem
cell
collect
lymphoma
myeloma
patient
efficaci
toxic
etoposid
administr
compar
highdos
etoposid
especi
one
dose
etoposid
could
effect
asct
myeloma
patient
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
king
hussein
cancer
center
pharmaci
amman
jordan
king
hussein
cancer
center
cell
therapi
appli
genom
amman
jordan
king
hussein
cancer
center
nurs
amman
jordan
king
hussein
cancer
center
pediatr
amman
jordan
king
hussein
cancer
center
bone
marrow
transplant
program
amman
jordan
king
hussein
cancer
center
cancer
registri
amman
jordan
background
introduct
biosimilar
product
common
practic
decreas
cost
therapi
especi
oncolog
similar
efficaci
safeti
profil
filgrastim
biosimilar
product
studi
post
chemotherapi
effect
aim
review
compar
efficaci
biosimilar
product
filgrastim
recombin
human
granulocyt
colonystimul
factor
refer
product
term
peripher
cell
mobil
healthi
donor
subsequ
replac
formulari
list
singl
institut
king
hussein
cancer
center
method
conduct
retrospect
compar
analysi
healthi
relat
donor
receiv
either
peripher
stem
cell
mobil
year
period
septemb
septemb
singl
center
institut
donor
receiv
filgrastim
dose
mcgkgdose
subcutan
everi
hour
day
complet
blood
count
cbc
enumer
done
donor
peripher
blood
sampl
mobil
period
immedi
prior
leukapheresi
day
day
mobil
actual
number
circul
cell
per
microlit
peripher
blood
use
determin
optimum
time
stem
cell
collect
result
total
healthi
subject
receiv
either
product
filgrastim
stem
cell
mobil
period
year
exclud
receiv
product
transit
period
one
product
use
donor
donor
receiv
product
mean
age
donor
harvest
year
fiftyseven
percent
donor
male
averag
circul
cell
per
microlit
group
group
consid
statist
signific
howev
mean
total
number
dose
need
stem
cell
mobil
dose
dose
respect
consid
statist
differ
conclus
biosimilar
show
compar
efficaci
profil
publish
data
refer
product
term
peripher
stem
cell
mobil
healthi
donor
less
number
dose
requir
use
nivestim
may
lead
signific
cost
contain
present
observ
verifi
wider
prospect
research
conflict
interest
conflict
interest
declar
bone
marrow
transplant
unit
hematolog
intern
medicin
verona
itali
cattaneo
centro
ricerch
economich
milan
itali
di
milano
dipartimento
di
scienz
clinich
e
di
statistica
medica
biometria
ed
epidemiologia
milan
itali
background
current
econom
context
led
nation
health
servic
implement
costeffect
criteria
sustain
decisionmak
process
health
technolog
use
lenograstim
leno
filgrastim
fil
biosimilar
granulocytecoloni
stimul
factor
gcsf
use
clinic
transplant
induc
hematopoiet
stem
cell
hsc
mobil
method
azienda
ospedaliera
universitaria
integrata
verona
budget
impact
analysi
increment
costeffect
studi
leno
use
vs
fil
perform
patient
undergo
autolog
hsc
mobil
hsct
evalu
assign
group
accord
gcsf
use
hsc
mobil
hematopoiet
cell
recoveri
transplant
treat
leno
mobil
hematolog
recoveri
lenoleno
initi
treat
leno
biosimilar
fil
lenofil
treat
biosimilar
fil
mobil
posttransplatant
support
filfil
efficaci
posttranspl
recoveri
evalu
consid
number
gcsf
vial
use
requir
day
recov
adequ
level
wbc
plt
hospit
day
percentag
patient
experienc
advers
event
ae
result
analysi
cohort
patient
show
statist
signific
differ
higher
number
harvest
cell
leno
group
vs
fil
group
statist
signific
differ
found
regard
number
gcsf
vial
apheresi
number
cell
peak
posttranspl
hematolog
recoveri
faster
leno
group
compar
fil
group
median
neutrophil
vs
day
median
platelet
vs
day
p
regard
ae
leno
group
observ
lower
pneumonia
fever
incid
higher
sepsi
incid
fil
group
term
budget
impact
leno
use
would
allow
lower
fund
absorpt
amount
lower
cost
relat
fewer
day
hospit
overal
lower
incid
ae
laboratori
test
transfus
plt
recoveri
follow
discharg
balanc
higher
cost
associ
gcsf
leno
use
apheresi
bone
marrow
recoveri
conclus
term
costeffect
leno
use
allow
obtain
better
result
measur
paramet
therefor
leno
domin
fil
term
efficaci
lower
global
cost
transplant
treatment
biosimilar
fil
entail
increas
mean
durat
hospit
daystranspl
consid
transplantsyear
depart
increas
correspond
addit
day
hospit
correspond
total
cost
amount
transplant
lost
per
year
loss
earn
account
tabl
studi
reveal
clinic
superior
lenoleno
group
vs
filfil
group
postul
potenti
costsav
favour
leno
fil
well
signific
econom
impact
term
higher
cost
lower
earn
conflict
interest
noth
disclos
tabl
tabl
croatian
institut
transfus
medicin
zagreb
croatia
clinic
hospit
merkur
depart
hematolog
zagreb
croatia
clinic
hospit
merkur
transfus
medicin
zagreb
croatia
school
medicin
univers
osijek
osijek
croatia
school
medicin
univers
zagreb
zagreb
croatia
background
chemomobil
gener
accept
approach
collect
peripher
blood
stem
cell
autopbsct
use
pegyl
filgrastim
yet
wide
accept
good
altern
due
simplic
use
shorter
hospit
stay
aim
studi
determin
optim
time
cell
collect
chemomobil
protocol
pegfilgrastim
administr
hour
chemotherapi
well
find
group
patient
could
reduc
number
leukapheresi
leukapheresi
day
chang
method
analyz
data
patient
period
januari
octob
minimum
number
cell
requir
one
autopbsct
per
kilogram
patient
bodi
mass
multipl
myeloma
patient
aim
collect
cell
two
transplant
previou
therapi
fludarabin
melphalan
low
platelet
count
protocol
fever
prior
harvest
consid
risk
factor
adequ
mobil
collect
start
number
peripher
blood
result
patient
multipl
myeloma
receiv
cyclophosphamid
suffici
number
stem
cell
collect
one
leukapheresi
patient
two
leukapheresi
patient
patient
three
leukapheresi
harvest
day
day
median
patient
harvest
start
earli
singl
procedur
follow
day
would
enough
collect
adequ
number
cell
lymphoma
patient
receiv
follow
protocol
minibeam
protocol
ice
protocol
dhap
protocol
remain
patient
protocol
suffici
number
stem
cell
collect
one
harvest
patient
patient
two
three
leukapheresi
respect
accord
protocol
day
collect
minibeam
day
median
ice
day
median
dhap
protocol
day
median
harvest
start
earli
patient
risk
poor
mobil
present
patient
patient
mobil
later
other
group
receiv
cyclophosphamid
harvest
day
median
receiv
minibeam
day
median
also
compar
group
patient
receiv
cyclophosphamid
number
collect
cell
significantli
higher
first
leukapheresi
day
patient
without
risk
factor
nt
differ
group
patient
receiv
chemomobil
protocol
conclus
accord
analyz
data
patient
receiv
pegfilgrastim
chemomobil
protocol
conclud
small
number
patient
adequ
number
cell
could
collect
singl
procedur
follow
day
infer
necessari
chang
collect
strategi
group
includ
risk
poor
mobil
conflict
interest
none
author
anyth
disclos
univers
hospit
dubrava
zagreb
croatia
background
last
decad
along
filgrastim
sever
new
drug
becom
avail
stem
cell
mobil
includ
pegfilgrastim
biosimilar
filgrastim
plerixafor
poor
mobil
real
life
set
current
multipl
possibl
differ
avail
cost
due
posit
experi
pegfilgrastim
treatment
nonhodgkin
lymphoma
nhl
daepoch
also
predominantli
use
chemomobil
protocol
nhl
due
chang
avail
filgrastim
prepar
increasingli
use
pegfilgrastim
stem
cell
mobil
compar
pegfilgrastim
filgrastim
base
mobil
respect
mobil
dynam
efficaci
cost
analyz
retrospect
cohort
consecut
patient
mobil
hospit
method
januari
decemb
perform
chemomobil
steadyst
mobil
multipl
multipl
myeloma
mm
nhl
hodgkin
lymphoma
hl
patient
mobil
use
filgrastim
mobilz
use
pegfilgrastim
chemomobil
use
high
dose
cyclophosphamid
hdc
dhap
minibeam
protocol
filgrastim
pegfilgrastim
administ
fromat
leukocyt
l
nadir
fromat
l
apheresi
start
cell
reach
peripher
blood
result
differ
filgrastim
pegfilgrastim
group
regard
sex
mf
vs
age
median
age
vs
diagnosi
mmnhlhl
vs
bmi
vs
signific
differ
chemotherapi
protocol
median
time
chemotherapi
start
filgrastim
pegfilgrastim
start
ie
day
hdc
n
day
daepoch
day
dhap
day
minibeam
differ
filgrastim
pegfilgrastim
subgroup
differ
time
filgrastim
pegfilgrastim
start
apheresi
median
day
whole
group
includ
steadi
state
mobil
howev
significantli
less
variabl
pegfilgrastim
vs
filgrastim
group
sd
vs
p
signific
differ
number
peripher
blood
prior
apheresi
differ
filgrastim
pegfilgrastim
regard
blood
volum
process
per
apheresi
bv
mean
yield
vs
howev
pegfilgrastim
significantli
higher
mean
yield
total
collectedtot
pb
prior
apheresi
per
first
apheresi
vs
p
indic
signific
cell
recruit
form
bone
marrow
lvl
differ
independ
chemomobil
protocol
use
less
pronounc
subsequ
apheres
result
significantli
complet
procedur
singl
apheresi
pegfilgrastim
group
vs
p
although
drug
cost
pegfilgrastim
compar
filgrastim
significantli
higher
signific
differ
total
cost
mobil
seri
probabl
compens
smaller
number
apheresi
conclus
result
show
compar
efficaci
cost
filgrastim
pegfilgrastim
base
mobil
howev
pegfilgrastim
group
show
predict
dynam
mobil
better
intraapheresi
recruit
larg
volum
leukapheresi
lead
less
apheresi
procedur
pegilgrastim
also
conveni
patient
conflict
interest
none
ospedal
vito
fazzi
hematolog
depart
lecc
itali
ospedal
vito
fazzi
servizio
di
medicina
trasfusional
ed
immunoematologia
lecc
itali
background
recent
studi
suggest
addit
exposur
cytoreduct
agent
part
mobilis
regimen
significantli
impact
progressionfre
overal
surviv
autologu
stem
cell
transplant
asct
multpl
myeloma
mm
rather
increas
morbid
associ
sc
mobilis
gl
et
al
bmt
plerixafor
plu
granulocytecoloni
stimul
factor
gcsf
safe
effect
stem
cell
sc
mobil
regimen
myeloma
patient
proven
superior
gcsf
alon
base
phase
iii
studi
dipersio
cowork
plerixafor
use
set
chemofre
mobil
regimen
multipl
myeloma
mm
patient
follow
schedul
gcsf
gkg
per
day
subcutan
morn
even
day
plerixafor
mgkg
subcutan
daili
dipersio
et
al
blood
method
retrospect
evalu
thirteen
consecut
mm
patient
treat
center
underw
chemofre
stem
cell
mobil
januari
octob
focu
studi
evalu
efficaci
earli
plerixafor
admnistr
night
day
name
three
day
gcsf
administr
result
mean
age
women
men
cohort
year
old
rang
stem
cell
mobilis
start
cycl
induct
therapi
twelv
patient
receiv
vtd
velcad
talidomid
desametason
one
patient
underw
veldex
velcad
desametason
induct
nine
patient
obtain
vgpr
induct
therapi
remain
four
cr
one
patient
receiv
prior
radiotherapi
thirteen
patient
except
one
requir
two
apheresi
day
collect
equal
cellskg
median
cellskg
collect
rang
day
median
peripher
blood
cell
count
rang
day
cell
rang
patient
studi
underw
least
one
asct
mean
number
cell
transplant
x
median
rang
patient
underw
tandem
transplant
patient
mean
number
cell
transplant
second
transplant
x
median
rang
transplant
outcom
line
data
publish
literatur
patient
success
neutrophil
platelet
engraf
whose
median
time
respect
day
neutrophil
day
platelet
conclus
consid
limit
retrospect
studi
small
number
patient
includ
could
show
comparison
data
report
dipersio
et
al
earli
administr
plerixafor
third
day
show
advantag
neither
term
collect
number
apheresi
stem
cell
collect
transplant
outcom
confirm
data
multicent
prospect
studi
promot
rete
ematologica
puglies
rep
earli
use
plerixafor
patient
multipl
myeloma
uderway
conflict
interest
author
declar
conflict
interest
hospit
juan
huelva
spain
background
recent
year
biosimilar
gcsf
approv
mobil
agent
vast
major
clinic
trial
support
effect
perform
healthi
donor
use
singl
agent
patient
mostli
use
combin
chemotherapi
well
plerixafor
aim
studi
compar
effect
mobil
agent
without
chemotherapi
andor
plerixafor
real
clinic
context
method
retrospect
evalu
outcom
mobil
attempt
apheresi
session
carri
octob
may
one
singl
center
defin
maximum
number
mobil
peripher
blood
number
first
apheresi
collect
cellskg
rate
patient
plerixafor
need
obtain
adequ
apheresi
product
number
episod
apheresi
perform
insuffici
amount
peripher
blood
patient
alloc
group
depend
date
may
receiv
date
receiv
result
perform
apheresi
session
patient
period
group
patient
lymphoprolif
syndrom
slpc
monoclon
gammapathi
gm
group
perform
mobil
procedur
patient
slpc
patient
gm
group
patient
receiv
chemotherapi
plu
receiv
also
plerixafor
group
receiv
plu
chemotherapi
plerixafor
also
given
reach
maximun
concentr
cell
preapheresi
per
microlit
number
episod
cell
collect
first
apheresi
procedur
rate
mobil
failur
low
concentr
cell
preapheresi
group
plerixafor
necessari
obtain
adequ
amount
cell
trasplant
group
patient
given
approxim
patient
median
cell
kg
rang
cellskg
appropi
mobil
none
observ
differ
group
statist
signific
conclus
experi
find
differ
effect
could
seri
small
major
patient
receiv
neupogen
therefor
continu
evalu
data
futur
obtain
compar
group
conflict
interest
none
asan
medic
center
pediatr
seoul
korea
republ
colleg
nurs
cathol
univers
korea
seoul
korea
republ
background
deplet
cell
prevent
gvhd
essenti
compon
haploident
hematopoiet
cell
transplant
haplohct
moreov
chronic
gvhd
critic
issu
pediatr
patient
undergo
allogen
hct
associ
qualiti
life
recent
deplet
method
target
cell
produc
graft
contain
mani
lymphocyt
implic
develop
gvhd
addit
establish
consist
reproduc
deplet
techniqu
critic
success
haplohct
sinc
celldeplet
method
appli
haplohct
pediatr
patient
center
studi
evalu
efficaci
ex
vivo
celldeplet
techniqu
perform
one
clinic
nurs
specialist
method
may
decemb
deplet
procedur
use
biotinyl
antibodi
perform
children
adolesc
use
system
miltenyibiotec
germani
initi
deplet
procedur
perform
combin
product
collect
sinc
decemb
harvest
strategi
modifi
oneday
collect
suffici
number
cell
obtain
first
collect
apheresi
carri
number
cell
deplet
process
booster
infus
stem
cell
perform
result
patient
hematolog
malign
nonmalign
diseas
solid
tumor
donor
mother
case
father
case
sibl
case
median
log
deplet
cell
rang
cell
median
yield
b
cell
nk
cell
cell
respect
tnc
exceed
cell
preprocessedproduct
associ
lower
deplet
efficaci
cell
log
versu
log
chronolog
analysi
deplet
efficaci
cell
significantli
improv
time
p
addit
total
elaps
time
manipul
significantli
shorter
time
median
minut
p
howev
signific
chang
recoveri
cell
b
cell
nk
cell
case
intend
receiv
collect
case
obtain
suffici
number
cell
collect
hand
donor
underw
collect
cell
collect
first
day
enough
case
requir
collect
associ
higher
weight
percentag
recipi
donor
less
cell
raw
bag
sixteen
case
intend
performoneday
collect
total
transplant
case
necessit
booster
infus
stem
cell
conclus
experi
celldeplet
procedur
perform
one
technic
staff
studi
suggest
deplet
method
skill
personnel
highli
effici
reproduc
remov
cell
haplohct
conflict
interest
noth
disclos
faculti
medicin
mansoura
univers
clinic
patholog
mansoura
egypt
faculti
medicin
mansoura
univers
research
center
cord
stem
cell
mansoura
egypt
faculti
medicin
mansoura
univers
pediatr
hematologyoncolog
unit
mansoura
egypt
faculti
medicin
mansoura
univers
obstetr
gynecolog
mansoura
egypt
background
umbil
cord
blood
ucb
promis
altern
bone
marrow
sourc
stem
cell
qualiti
ucb
lead
factor
determin
success
transplant
therefor
donor
select
becam
worldwid
issu
studi
tri
identifi
effect
mani
matern
neonat
factor
qualiti
ucb
unit
affect
bankabl
unit
factor
may
vari
accord
geograph
distribut
egypt
new
comer
field
public
cord
blood
bank
therefor
great
benefit
studi
factor
area
method
inform
consent
obtain
elig
mother
donat
cord
blood
ucb
unit
collect
utero
mansoura
univers
hospit
cord
blood
volum
measur
qualiti
ucb
unit
evalu
measur
cord
blood
volum
total
nucleat
cell
tnc
count
cell
count
coloni
form
unit
cfu
assay
coloni
form
unit
assay
consid
gold
standard
assay
potenc
ucb
unit
assess
viabil
cell
well
differenti
abil
result
found
factor
associ
high
qualiti
ucb
unit
volum
ml
birth
weight
gm
male
gender
babi
younger
gestat
age
matern
age
year
conclus
umbil
cord
blood
donat
associ
high
qualiti
collect
heavier
babi
birth
younger
gestat
age
larger
cord
blood
volum
older
mother
male
babi
conflict
interest
studi
fund
scienc
technolog
develop
fund
stdf
egypt
frankfurt
main
pediatr
stem
cell
transplant
frankfurtm
germani
german
red
cross
blood
center
frankfurt
institut
transfus
medicin
immunohematolog
frankfurtm
germani
background
autolog
stem
cell
transplant
remain
integr
tool
treatment
certain
childhood
malign
order
facilit
prepar
apheresi
pediatr
patient
typic
central
venou
cathet
necessari
provid
adequ
flow
rate
pediatr
patient
center
howev
preimplant
hickman
cathet
chemotherapi
evalu
feasibl
collect
adequ
number
cell
via
hickman
cathet
instead
place
addit
temporari
central
venou
dialysi
cathet
method
apheres
pediatr
patient
undergo
leukapheresi
autolog
hsct
februari
march
review
preimplant
hickman
cathet
avail
use
apheresi
patient
receiv
temporari
shaldon
cathet
apheresi
perform
use
spectra
optia
mnc
consid
success
dose
pbsckg
bodi
weight
kgbw
achiev
result
patient
hickman
cathet
use
leukapheresi
patient
receiv
temporari
shaldon
cathet
group
apheresi
toler
well
without
appar
advers
reaction
dose
pbsc
apheresi
product
amount
rang
cellskgbw
hickman
rang
cellskgbw
shaldon
group
show
statist
signific
differ
group
primari
endpoint
minim
cell
concentr
cellskgbw
achiev
patient
maximum
two
leukapheresi
session
efficaci
apheresi
confirm
collect
effici
hickman
shaldon
group
conclus
data
indic
reliabl
feasibl
efficaci
mobil
apheresi
via
indwel
central
line
light
routin
insert
dialysi
cathet
purpos
stem
cell
apheresi
reconsid
conflict
interest
none
author
anyth
disclos
medic
center
univers
hospit
tuebingen
hematologyoncolog
tuebingen
germani
medic
center
univers
hospit
wuerzburg
hematologyoncolog
wuerzburg
germani
medic
center
univers
hospit
leipzig
hematologyoncolog
leipzig
germani
univers
hospit
duesseldorf
pediatr
oncolog
duesseldorf
germani
medic
center
univers
hospit
ulm
hematologyoncolog
ulm
germani
dkd
helio
hospit
wiesbaden
bone
marrow
transplant
wiesbaden
germani
medic
center
univers
hospit
utrecht
hematolog
utrecht
netherland
miltenyi
biotec
gmbh
bergisch
gladbach
germani
children
univers
hospit
tuebingen
tuebingen
germani
children
univers
hospit
wuerzburg
wuerzburg
germani
institut
clinic
transfus
medicin
immunogenet
ulm
ulm
germani
medic
center
univers
hospit
utrecht
pharmaci
celltherapi
facil
utrecht
netherland
background
report
first
result
prospect
multicent
singlearm
phase
iii
studi
eudract
haploident
stem
cell
transplant
sct
tcralphabeta
deplet
peripher
blood
stem
cell
graft
method
graft
deplet
perform
use
clinimac
plu
system
miltenyi
biotec
patient
receiv
ric
regimen
consist
mg
atg
neoviigrafalon
gy
total
nodal
irradi
fludarabin
mgkg
thiotepa
melphalan
mmf
mgkgday
use
gvhd
prophylaxi
day
result
adult
patient
median
age
year
rang
femal
male
enrol
center
patient
diagnosi
includ
aml
mdsmp
multipl
myeloma
acut
undifferenti
leukemia
sickl
cell
anemia
malign
diseas
cr
pr
nonremiss
eight
previou
sct
median
followup
day
rang
median
graft
contentkg
recipi
weight
cell
x
rang
tcrab
cell
x
rang
cell
x
rang
nk
cell
x
rang
tcrgd
cell
x
rang
patient
primari
engraft
anc
median
day
rang
plt
median
day
rang
patient
experienc
primari
graft
failur
patient
secondari
graft
failur
patient
success
retranspl
peripher
donor
tcell
chimer
time
engraft
complet
patient
mix
patient
develop
acut
gvhd
grade
iiiiv
patient
grade
ii
grade
gvhd
patient
evalu
immun
reconstitut
figur
median
cell
count
nk
cell
rang
cell
rang
tcrgd
cell
rang
day
day
median
tcrab
cell
increas
follow
infecti
event
occur
viral
reactiv
cmv
adv
stool
viral
diseas
cmv
bkv
posit
hemorrhag
bacteri
median
followup
day
patient
aliv
patient
die
relaps
organ
failur
lung
liver
cn
cardiac
result
kaplanmei
estim
os
df
day
year
respect
day
year
cumul
incid
nrm
relaps
respect
conclus
haploident
sct
use
graft
ric
result
primari
engraft
acut
gvhd
grade
iiiiv
nrm
os
day
estim
os
year
immun
reconstitut
innat
immun
rapid
lethal
viral
fungal
infect
clinic
trial
registri
eudract
conflict
interest
studi
sponsor
miltenyi
biotec
gmbh
w
bethg
honoraria
research
fund
miltenyi
biotech
gmbh
neovii
gmbh
mielk
travel
grant
kiadi
pharma
celgen
msd
gilead
cellex
gmbh
consult
novarti
msd
niederwies
research
fund
novarti
r
meisel
research
fund
miltenyi
biotech
gmbh
neovii
gmbh
j
kubal
research
fund
miltenyi
gmbh
consult
equiti
ownership
gadeta
r
handreting
copat
holder
tcr
alphabeta
deplet
technolog
research
fund
miltenyi
biotech
gmbh
karitzki
holtkamp
c
siewert
pflitsch
employe
miltenyi
gmbh
schumm
eyrich
v
vucin
wiesneth
k
westinga
bunj
brecht
noth
disclos
tor
vergata
univers
rome
stem
cell
transplant
unit
policlinico
universitario
tor
vergata
rome
itali
ifo
regina
elena
nation
cancer
institut
rome
itali
campu
biomedico
univers
hospit
rome
itali
azienda
ospedaliera
santandrea
rome
itali
santeugenio
hospit
rome
itali
azienda
ospedaliera
san
giovanni
addolorata
rome
itali
tor
vergata
univers
hospit
rome
itali
background
variabl
process
autolog
hematopoiet
stem
cell
ahsc
repres
major
qualiti
control
challeng
request
jaci
standard
method
valid
assur
adequ
potenc
graft
essenti
wide
accept
criteria
cell
quantif
viabil
test
guarante
function
activ
ahsc
post
longterm
storag
thaw
moreov
vitro
coloni
assay
standard
remain
barrier
widespread
adopt
studi
effect
longterm
cryopreserv
vivo
compar
neutrophil
platelet
engraft
time
patient
receiv
two
ahsc
transplant
multipl
myeloma
mm
method
inclus
criteria
consist
doubl
transplant
singl
ahsc
mobil
equival
cell
dose
cell
two
transplant
procedur
space
period
least
two
year
januari
june
patient
affect
mm
f
median
age
first
transplant
year
enter
studi
diseas
statu
time
first
second
transplant
respect
cr
vgpr
pr
sd
pd
apheresi
collect
ahsc
product
split
two
equival
fraction
mix
volum
cryoprotect
solut
dmso
human
albumin
cryopreserv
use
control
rate
freezer
minim
freez
damag
accord
patient
age
comorbid
condit
regimen
consist
melphalan
high
dose
patient
first
transplant
patient
second
one
intens
myeloid
engraft
defin
first
consecut
day
neutrophil
anc
wherea
platelet
engraft
defin
day
platelet
plt
absenc
transfus
support
week
result
median
storag
time
first
second
transplant
month
month
respect
median
cell
dose
first
ahsct
second
ahsct
dose
median
time
neutrophil
platelet
engraft
day
transplant
anc
day
plt
day
first
anc
plt
second
one
respect
signific
correl
found
time
engraft
diseas
statu
dose
ahsc
transplant
conclus
qualiti
method
valid
cellular
therapi
product
storag
still
matter
debat
ahsc
transplant
set
data
indic
longterm
storag
ahsc
neg
impact
neutrophil
platelet
engraft
conclus
vivo
qualiti
control
could
use
tool
valid
graft
function
longterm
storag
requir
jaci
standard
conflict
interest
none
yamagata
prefectur
central
hospit
depart
hematolog
yamagata
japan
hiroshima
red
cross
hospit
automicbomb
survivor
hospit
depart
hematolog
hiroshima
japan
kanazawa
univers
hospit
depart
haematolog
kanazawa
japan
tsukuba
memori
hospit
depart
hematolog
tsukuba
japan
hakod
citi
hospit
depart
hematolog
hakod
japan
japanes
red
cross
medic
center
depart
hematolog
tokyo
japan
yamanashi
prefectur
central
hospit
depart
hematolog
medic
oncolog
kofu
japan
japanes
date
center
hematopoiet
cell
transplant
nagoya
japan
aichi
medic
univers
school
medicin
depart
promot
blood
marrow
transplant
nagakut
japan
keio
univers
school
medicin
divis
hematolog
depart
medicin
tokyo
japan
tokai
univers
school
medicin
depart
cell
transplant
regen
medicin
isehara
japan
background
biosimilar
granulocyt
colonystimul
factor
gcsf
approv
mobil
hematopoiet
stem
cell
hsc
healthi
donor
howev
safeti
efficaci
fulli
elucid
clinic
trial
method
donor
committe
japan
societi
hematopoiet
cell
transplant
set
prospect
observ
studi
entitl
shortterm
followup
investig
rel
hematopoiet
stem
cell
donor
receiv
biosimilar
gcsf
mobil
peripher
blood
stem
cell
april
part
relat
donor
followup
initi
total
donor
receiv
biosimilar
gcsf
mobil
regist
transplant
facil
end
march
data
analyz
result
men
women
median
age
year
rang
year
devic
use
apheresi
cobe
spectra
collect
hsc
perform
one
two
threeday
apheresi
donor
respect
first
apheresi
start
day
biosimilar
administr
donor
day
donor
collect
suffici
number
hsc
complet
day
donor
day
donor
forti
six
donor
requir
one
apheresi
collect
suffici
number
hsc
day
day
day
apheresi
cbc
donor
day
biosimilar
gcsf
show
mean
white
blood
cell
wbc
count
red
blood
cell
rbc
count
platelet
count
day
valu
show
wbc
count
rbc
count
platelet
count
mean
count
collect
cell
per
kilogram
recipi
weight
day
day
mean
cell
count
per
liter
process
blood
day
day
donor
start
apheresi
day
mean
cell
count
donor
bodi
weight
process
blood
volum
respect
studi
donor
age
gender
wbc
count
day
gcsf
dose
reduct
type
apheresi
apparatu
blood
collect
speed
treat
blood
volum
signific
impact
hsc
collect
efficaci
regard
safeti
biosimilar
gcsf
advers
event
donor
report
none
seriou
common
advers
event
could
attribut
biosimilar
gscf
includ
low
back
pain
headach
bone
pain
none
seriou
conclus
biosimilar
gcsf
administ
healthi
relat
donor
compar
origin
gcsf
respect
qualiti
efficaci
safeti
least
short
term
observ
conflict
interest
okamoto
honoraria
chugai
mochida
kyowa
kirin
sanofi
grant
support
chugai
kyowa
kirin
mochida
sanofi
author
state
relationship
disclos
korea
univers
colleg
medicin
seoul
korea
republ
sungkyunkwan
univers
school
medicin
seoul
korea
republ
background
peripher
blood
hematopoiet
stem
cell
collect
use
increasingli
thu
mobil
hematopoiet
stem
cell
bone
marrow
peripher
blood
becom
import
issu
sever
mobil
method
one
use
chemotherapi
cyclophosphamid
etoposid
previou
studi
hematopoiet
stem
cell
mobil
use
etoposid
granulocytecoloni
stimul
factor
gcsf
collect
cellkg
use
cyclophosphamid
gcsf
howev
mechan
autolog
stem
cell
mobil
cyclophosphamid
etoposid
unclear
identifi
analyz
mechan
mobil
hematopoiet
stem
cell
examin
express
cytokin
method
mesenchym
stem
cell
msc
obtain
healthi
control
hospit
collect
hematopoiet
stem
cell
bone
marrow
first
cell
viabil
curv
drawn
use
assay
dojindo
determin
concentr
inhibit
growth
mesenchym
stem
cell
subsequ
experi
cyclophosphamid
etoposid
use
concentr
inhibit
mesenchym
stem
cell
growth
second
mesenchym
stem
cell
dispens
per
well
plate
treat
cyclophosphamid
etoposid
one
day
three
day
treatment
supernat
collect
cytokin
analysi
carri
use
human
cytokin
array
c
seri
ray
biotech
third
cell
growth
curv
apoptosi
analysi
cell
cycl
distribut
msc
treat
cyclophosphamid
etoposid
perform
result
msc
treat
etoposid
scf
sdf
tpo
interfer
mobil
hematopoiet
stem
cell
shown
trend
decreas
cytokin
promot
hematopoiet
stem
cell
mobil
shown
statist
signific
increas
msc
treat
cyclophosphamid
secret
cytokin
relat
inflamm
increas
msc
repeatedli
treat
cyclophosphamid
etoposid
interv
three
day
identifi
msc
growth
inhibit
etoposid
apoptosi
analysi
differ
msc
treat
cyclophosphamid
etoposid
cell
cycl
distribut
analysi
msc
treat
etoposid
show
cell
cycl
arrest
phase
conclus
etoposid
could
induc
mobil
hsc
mediat
mechan
mobil
use
etoposid
gcsf
may
show
synergi
effect
compar
cyclophosphamid
gcsf
howev
accumul
etoposid
may
interfer
growth
msc
thought
toxic
msc
cell
cycl
arrest
clinic
trial
registri
na
conflict
interest
noth
disclos
univers
hospit
basel
diagnost
hematolog
basel
switzerland
background
dimethylsulfoxid
dmso
final
concentr
use
cryoprotect
deepfreez
store
autolog
stem
cell
transplant
recoveri
posit
stem
cell
thaw
variat
consider
affect
stem
cell
engraft
low
recoveri
partial
attribut
dmso
explain
strike
interpati
differ
product
treat
dmso
concentr
character
cell
composit
autolog
transplant
collect
order
find
addit
reason
could
explain
low
recoveri
postthaw
test
hypothesi
increas
number
leukocyt
subset
known
cytotox
neutrophil
respons
stem
cell
loss
postthaw
method
flow
cytometri
clinic
data
consecut
autolog
stem
cell
transplant
singl
center
retrospect
analyz
stem
cell
content
thaw
transplant
regist
correl
neutrophil
platelet
engraft
possibl
dmsorel
complic
record
immedi
transplant
immunophenotyp
data
stem
cell
product
retrospect
analyz
elucid
influenc
leukocyt
subset
neutrophil
monocyt
lymphocyt
recoveri
furthermor
correl
time
engraft
count
viabl
cell
prefreez
postthaw
result
viabil
stem
cell
harvest
high
well
leukocyt
subset
correl
leukocyt
subset
viabil
prefreez
recoveri
viabil
postthaw
heterogen
rel
absolut
count
monocyt
lymphocyt
stem
cell
product
influenc
recoveri
contrast
clear
neg
correl
rel
absolut
neutrophil
count
prefreez
recoveri
postthaw
found
r
p
p
respect
stem
cell
engraft
categor
normal
vs
late
use
day
cutoff
late
engraft
significantli
less
viabl
cell
transplant
postthaw
compar
normal
engraft
vs
wherea
differ
prefreez
group
vs
ns
conclus
set
autolog
stem
cell
transplant
high
neutrophil
count
stem
cell
product
correl
poor
recoveri
postthaw
delay
engraft
viabil
neutrophil
low
postthaw
product
postul
releas
cytotox
substanc
apoptot
neutrophil
detriment
influenc
viabil
dose
depend
manner
although
mandatori
current
jaci
standard
viabil
measur
postthaw
valuabl
tool
qualiti
control
stem
cell
product
addit
regular
monitor
neutrophil
count
prefreez
might
help
explain
low
recoveri
obtain
realtim
might
help
achiev
optim
stem
cell
apheresi
condit
conflict
interest
author
declar
conflict
interest
abstract
previous
publish
regina
elena
nation
cancer
institut
hematolog
stem
cell
transplant
unit
rome
itali
camilloforlanini
hospit
leukapheresi
cellular
therapi
unit
rome
itali
regina
elena
nation
cancer
institut
scientif
direct
rome
itali
background
far
mani
studi
compar
efficaci
safeti
biosimilar
filgrastim
origin
data
publish
comparison
lenograstim
previous
publish
studi
suggest
biosimilar
filgrastim
could
less
effect
lenograstim
use
standard
dosag
mcgkg
patient
lymphoma
undergo
peripher
blood
stem
cell
pbsc
mobil
method
octob
septemb
patient
lymphoma
nonhodgkin
hodgkin
randomli
assign
receiv
lenograstim
mcgkg
mcgkg
pbsc
mobil
patient
stratifi
accord
treatment
line
time
pbsc
mobil
firstlin
treatment
salvag
treatment
refractoryrelaps
diseas
target
cell
dose
x
patient
underw
standard
procedur
includ
criteria
plerixafor
administr
primari
endpoint
studi
compar
rate
mobil
failur
patient
unabl
reach
plan
cell
dose
result
octob
plan
first
interimanalysi
studi
two
cohort
patient
well
balanc
baselin
clinic
featur
analyz
primari
endpoint
observ
ident
rate
mobil
failur
cohort
pn
patient
unabl
reach
target
cell
plan
dose
cohort
pn
also
observ
similar
rate
patient
need
plerixafor
administr
due
suboptim
level
peak
gcsf
group
vs
lenograstim
group
pn
moreov
median
day
gcsf
administr
median
leukepheresi
median
number
x
collect
first
leukapheresi
similar
two
cohort
patient
differ
term
drugrel
advers
event
observ
two
group
patient
report
seriou
advers
event
conclus
first
interimanalysi
data
clearli
demonstr
lenograstim
mcgkg
could
consid
substanti
equival
term
efficaci
safeti
compar
dosag
mcgkg
lymphoma
patient
undergo
pbsc
mobil
collect
conflict
interest
none
author
anyth
disclos
ravenna
hospit
ravenna
itali
ospedali
riuniti
ancona
ancona
itali
ospedal
bianchimelacrinomorelli
reggio
calabria
itali
european
institut
oncolog
milano
itali
background
optim
stem
cell
mobil
strategi
patient
pt
multipl
myeloma
mm
still
matter
debateposs
approach
includ
low
intermediatehigh
dose
cyclophosphamid
cy
granulocyt
colonystimul
factor
gcsf
alon
method
retrospect
analyz
mm
patient
undergo
stem
cell
mobil
four
italian
center
ravenna
ancona
milano
reggio
calabria
januari
august
patient
receiv
low
dose
cyclophosphamid
ldci
group
defin
intermediatehigh
dose
cyclophosphamid
hdci
group
defin
receiv
gcsf
alon
gcsf
group
result
total
patient
fulfil
inclus
criteriamedian
age
time
mobil
year
iqr
without
signific
differ
among
groupsal
patient
receiv
previou
treatment
mobil
attempt
mainli
bortezomibbas
lenalidomidebas
protocol
patient
receiv
karfilzomibinclud
regimen
prior
stem
cell
mobil
cy
patient
tend
receiv
mainli
lenalidomid
karfilzomib
base
regimen
p
respect
gcsf
patient
tend
receiv
mainli
bortezomibbas
regimen
p
day
plan
mobil
schedul
median
platelet
count
inferior
ldci
group
compar
hdci
gcsf
group
hemoglobin
wbc
count
differ
median
peak
circul
ldci
hdci
gcsf
group
respect
p
median
amount
stem
cell
collect
respect
ninetysix
percent
gcsf
patient
achiev
stem
cell
collect
least
compar
ldci
hdci
group
statist
differ
observ
number
day
apheresi
necessari
achiev
mimimum
yieldsimilarli
signific
differ
observ
probabl
achiev
collect
least
target
dose
singl
transplant
minimum
dose
doubl
transplant
success
collect
ldci
hdci
gcsf
patient
twentyfour
percent
gcsf
patient
achiev
collect
greater
target
dose
doubl
transplant
compar
ldci
hdci
p
plerixafor
ad
plan
mobil
regimen
ldci
hdci
gcsf
group
respect
p
multivari
analysi
kind
mobil
strategi
significantli
affect
stem
cell
collect
similarli
impact
age
previou
treatment
lenalidomid
bortezomib
karfilzomib
hb
plt
wbc
count
observ
grade
advers
event
mobil
neutropen
fever
pt
cy
group
diarrhea
pt
gcsf
group
median
day
hospit
ldctx
gcsf
compar
hdctx
p
conclus
given
limit
retrospect
analysi
result
suggest
low
dose
cy
intermediatehigh
dose
cy
gcsf
compar
efficaci
stem
cell
mobil
mm
patient
modern
era
novel
agent
conflict
interest
author
noth
declar
medic
univers
warsaw
hematolog
oncolog
intern
diseas
warszawa
poland
background
highdos
chemotherapi
follow
autolog
stem
cell
transplant
asct
remain
standard
care
elig
patient
multipl
myeloma
perfect
mobil
regimen
advantag
known
protocol
predict
time
mobil
blood
gcsf
mobil
lack
seriou
side
effect
gcsf
mobil
high
stem
cell
collect
number
low
number
apheresi
high
dose
arac
mobil
abil
held
outpati
set
gcsf
also
free
major
disadvantag
known
protocol
sever
cytopenia
high
dose
arac
cyclophosphamid
mobil
unpredict
optim
day
apheresi
cyclophosphamid
rel
low
number
collect
cell
gcsf
price
plerixafor
aim
creat
protocol
would
meet
expect
reduc
arac
dose
adjust
dose
gcsf
given
prior
apheresi
method
medic
record
patient
mobil
ambulatori
set
new
protocol
analys
retrospect
mobil
protocol
arac
day
gcsf
dose
day
escal
split
two
dose
day
apheresi
start
day
patient
regardless
count
potenti
side
effect
monitor
result
patient
underw
complet
ambulatori
mobil
low
dose
arac
outpati
set
patient
receiv
arac
day
tailor
gcsf
day
day
best
result
averag
collect
cell
x
per
kg
first
apheresi
target
cell
count
x
cellskg
reach
one
patient
collect
x
cellskg
averag
number
apheresi
need
collect
x
cellskg
apheres
never
perform
one
collect
perform
peripher
venou
access
picc
cvc
use
moreov
patient
proceed
transplant
none
analys
patient
experienc
sever
advers
event
includ
cytopenia
infect
transfus
requir
hospit
stay
mobil
commonli
report
advers
event
connect
gcsf
mild
bone
pain
need
drug
intak
treatabl
otc
drug
includ
paracetamol
econom
analysi
least
euro
save
per
patient
due
lower
cost
medic
care
conclus
low
dose
cytarabin
tailor
gcsf
protocol
becam
prefer
regimen
stem
cell
mobil
patient
multipl
myeloma
centr
accord
advantag
known
mobil
protocol
clinic
trial
registri
applic
conflict
interest
none
declar
heidelberg
univers
depart
medicin
v
heidelberg
germani
heidelberg
univers
institut
patholog
heidelberg
germani
heidelberg
univers
institut
medic
biometri
und
informat
heidelberg
germani
medic
faculti
mannheim
heidelberg
univers
depart
medicin
iii
univers
medic
center
mannheim
umm
mannheim
germani
medic
faculti
mannheim
heidelberg
univers
institut
transfus
medicin
immunolog
mannheim
germani
background
effici
collect
autolog
peripher
blood
stem
cell
pbsc
depend
optim
time
mobil
chemotherapi
applic
granulocytecolonystimul
factor
gcsf
assess
cell
number
peripher
blood
pb
therefor
implement
valid
timet
depend
appli
chemomobil
regimen
essenti
method
eight
commonli
use
chemomobil
regimen
develop
comprehens
time
schedul
pbsc
mobil
retrospect
analysi
mobil
process
repres
select
patient
varieti
diagnos
includ
multipl
myeloma
malign
lymphoma
sarcoma
perform
patient
per
regimen
clinic
pbsc
collect
paramet
analyz
includ
durat
gcsf
applic
time
point
assess
pb
cell
count
number
leukapheresi
session
process
blood
volum
collect
result
tabl
time
mobil
result
patient
success
collect
least
one
transplant
ie
cell
kg
bodi
weight
reach
individu
collect
goal
adher
given
schedul
chemotherapi
applic
gcsf
measur
cell
pb
subsequ
leukapheresi
propos
schedul
provid
earliest
time
point
one
start
monitor
cell
pb
consid
first
lp
session
may
well
start
one
sever
day
later
conclus
studi
analyz
commonli
use
chemomobil
regimen
regard
optim
time
subsequ
gcsf
applic
stem
cell
collect
result
present
valid
blueprint
time
schedul
improv
effici
mobil
attempt
also
contribut
patient
satisfact
increas
transpar
calcul
approach
conflict
interest
first
author
coauthor
confirm
potenti
conflict
interest
disclos
except
follow
schmitt
travel
grant
hexal
ag
p
wuchter
honoraria
membership
advisori
board
sanofiaventi
membership
advisori
board
travel
grant
hexal
ag
ruth
rappaport
children
hospit
pediatr
hematolog
oncolog
bmt
haifa
israel
weizmann
institut
sciens
depart
immunolog
rehovot
israel
rambam
medic
center
hematolog
bmt
haifa
israel
background
hematopoiet
stem
progenitor
cell
hspc
mobil
repeat
granulocyt
coloni
stimul
factor
gcsf
treatment
frequent
use
protocol
allogen
transplant
coagul
system
regul
murin
bone
marrow
bm
hspc
retent
egress
rapid
mobil
herein
aim
assess
function
clinic
import
thrombin
receptor
proteas
activ
receptor
human
gcsf
induc
cell
mobil
method
mononuclear
cell
mnc
healthi
match
sibl
stem
cell
donor
isol
stain
analyz
fac
treatment
gcsf
next
use
preclin
function
mice
model
result
statist
signific
least
repeat
result
reveal
express
level
circul
donor
leukocyt
gcsf
treatment
posit
correl
higher
yield
mobil
leukocyt
stimul
p
addit
percentag
hspc
blood
absolut
number
initi
mobil
posit
correl
peripher
blood
leukocyt
count
p
yield
mobil
hspc
p
gain
insight
role
play
signal
regul
gcsfinduc
hspc
mobil
use
function
preclin
mous
model
observ
signific
regul
express
bm
hspc
follow
gcsf
treatment
elev
critic
sinc
interf
signal
specif
antagonist
inhibit
stem
cell
mobil
gcsf
treatment
dramat
acceler
depend
nitric
oxid
product
bm
leukocyt
includ
hspc
notabl
mice
defici
express
high
level
bm
hspc
baselin
fail
elev
treatment
gcsf
result
mobil
much
lower
extent
compar
wild
type
wt
counterpart
pharmacolog
inhibit
gener
lname
gcsf
mobil
also
abrog
mobil
via
inhibit
bm
hspc
elev
concomit
expans
bm
hspc
endotheli
protein
c
receptor
epcr
stem
cell
high
adhes
repopul
potenti
interestingli
mobil
stem
cell
lack
epcr
express
part
mobil
process
reappear
follow
transplant
bm
repopul
antagon
signal
gcsf
stimuli
expand
bm
epcr
long
term
lt
hspc
support
stromal
progenitor
cell
mspc
confirm
increas
repopul
transplant
mice
importantli
evalu
clinic
influenc
hspc
function
report
block
signal
significantli
block
human
mnc
migrat
toward
gradient
vitro
line
express
human
cell
higher
stimul
gcsf
among
healthi
stem
cell
donor
cell
migrat
better
toward
final
trace
consequ
followup
stem
cell
transplant
found
acceler
neutrophil
platelet
recoveri
patient
transplant
mobil
cell
express
higher
surfac
level
baselin
p
p
conclus
studi
indentifi
signal
gener
essenti
regul
gcsf
induc
hspc
mobil
highlight
express
level
predictor
hspc
mobil
migrat
repopul
conflict
interest
none
author
anyth
disclos
birmingham
women
children
hospit
birmingham
unit
kingdom
univers
hospit
brno
st
anna
univers
hospit
brno
czech
republ
ircc
giannina
gaslini
genova
itali
hospit
infantil
universitario
jesu
fib
hiunj
ciber
madrid
spain
royal
hospit
children
glasgow
unit
kingdom
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
schneider
children
medic
center
israel
tel
aviv
israel
frankfurt
main
frankfurt
germani
medic
center
univers
freiburg
freiburg
germani
univers
padova
padova
itali
hannov
medic
school
hannov
germani
germani
erasmu
mcsophia
children
hospit
rotterdam
netherland
faculti
hospit
motol
praha
czech
republ
unit
st
istvan
st
laszlo
hospit
budapest
hungari
sanofi
genzym
cambridg
unit
state
ircc
bambino
children
hospit
rome
itali
background
plerixafor
promot
releas
cell
peripher
blood
collect
subsequ
autolog
transplant
safeti
efficaci
plerixafor
establish
adult
studi
investig
plerixafor
safeti
efficaci
children
method
stage
investig
dosag
pharmacokinet
pk
pharmacodynam
pd
safeti
plerixafor
addit
standard
mobilis
gcsf
chemotherapi
paediatr
cancer
patient
stage
primari
endpoint
differ
proport
patient
achiev
doubl
cell
count
plerixaforstandard
mobilis
group
versu
standard
mobilis
alon
secondari
stage
endpoint
number
apheres
requir
reach
cellskg
total
perapheresi
cell
yield
percentag
patient
proceed
transplant
sustain
engraft
month
posttransplant
result
stage
patient
treat
across
age
group
age
year
patient
age
group
treat
dose
level
base
pk
pd
data
dose
propos
stage
patient
experienc
treatmentemerg
advers
event
teae
patient
experienc
seriou
teae
death
occur
period
follow
last
plerixafor
dose
death
due
diseas
progress
consid
unrel
studi
drug
stage
patient
randomis
receiv
plerixaforstandard
mobilis
versu
standard
mobilis
alon
demograph
characterist
similar
across
group
patient
age
age
age
year
treat
primari
cancer
histolog
similar
treatment
arm
patient
complet
studi
period
patient
cohort
die
due
diseas
progress
patient
plerixafor
arm
versu
patient
standard
arm
met
primari
endpoint
median
percent
chang
cell
count
overwhelmingli
favour
plerixafor
arm
versu
patient
plerixafor
vs
standard
proceed
transplant
plerixafor
arm
sustain
engraft
rate
similar
treatment
arm
month
patient
experienc
teae
versu
patient
plerixafor
standard
arm
respect
teae
report
patient
plerixafor
arm
versu
patient
standard
arm
teae
relat
studi
treatment
grade
report
patient
plerixafor
arm
seriou
teae
occur
patient
plerixafor
arm
versu
patient
standard
arm
none
relat
studi
treatment
patient
discontinu
treatment
experienc
death
due
seriou
teae
conclus
plerixafor
effect
children
versu
patient
meet
primari
endpoint
plerixafor
standard
mobilis
arm
respect
increas
peripher
blood
cell
count
children
compar
standard
mobilis
treatment
plerixafor
accept
safeti
profil
children
clinic
trial
registri
conflict
interest
studi
fund
sanofi
genzym
j
sevilla
report
payment
sanofi
genzym
institut
receiv
conduct
clinic
trial
report
financi
support
outsid
submit
work
educ
lectur
novarti
advisori
board
member
rocket
pharma
educ
lectur
miltenyi
advisori
board
member
novarti
j
bernard
q
liu
e
doyl
employe
sanofi
genzym
jochen
report
grant
pfizer
person
fee
pierr
fabr
outsid
submit
work
britta
maeckerkolhoff
report
person
fee
nonfinanci
support
jazz
pharmaceut
outsid
submit
work
remain
author
noth
disclos
hospit
gener
universitario
gregorio
maranon
madrid
spain
background
plerixafor
pl
select
antagonist
receptor
block
union
hematopoiet
progenitor
cell
marrow
stromal
pl
mobil
cell
peripher
blood
pb
potenc
gcsf
capac
use
combin
pl
licens
patient
multipl
myeloma
nonhodgkin
lymphoma
achiev
poor
mobil
gcsf
present
five
allogen
healthi
donor
poor
mobil
gcsf
use
pl
label
achiev
adequ
graft
stem
cell
transplant
method
report
five
healthi
donor
june
novemb
use
pl
case
poor
mobil
gcsf
institut
median
followup
month
patient
characterist
describ
tabl
start
mobil
gcsf
dosag
subcutan
four
day
cell
count
blood
determin
flow
cytometri
pl
mgkgday
ad
hour
second
third
leukapheresi
due
poor
mobil
ml
pb
preapheresi
short
time
avail
previou
cyclophosphamid
posttranspl
cypost
one
case
pl
ad
due
need
high
graft
previou
failur
engraft
cell
blood
count
cbc
perform
unicel
dhx
beckman
cell
quantif
flow
cytometri
cytomet
accord
protocol
ishag
result
pl
administr
count
preapheresi
increas
time
media
optim
cellular
reach
five
donor
tabl
term
side
effect
emet
syndrom
describ
durat
hour
two
donor
without
side
effect
attribut
pl
retard
neutrophil
platelet
engraft
time
describ
except
third
case
develop
failur
engraft
presenc
anoth
risk
factor
sever
aplast
anaemia
graft
cellular
similar
literatur
report
acut
gvhd
grade
iiiv
conclus
pl
well
toler
case
ensur
procur
adequ
graft
transplant
result
normal
hematopoiet
engraft
case
report
use
pl
without
sever
side
effect
permit
achiev
enough
cellular
case
poor
mobil
transplant
need
high
dose
time
cypost
although
use
healthi
donor
consid
use
pl
use
safe
combin
gcsf
reach
satisfactori
mobil
conflict
interest
conflict
interest
tabl
tabl
patient
characterist
schneider
children
medic
center
israel
petach
tikva
israel
ezer
mizion
petach
tikva
israel
tel
aviv
univers
sackler
faculti
medicin
tel
aviv
israel
background
durat
peripher
blood
stem
cell
collect
pbscc
function
target
cell
count
cell
count
donor
blood
effici
pheresi
process
project
anticip
pbscc
yield
import
collect
staff
permit
custom
pheresi
durat
formula
predict
yield
pbscc
publish
evalu
two
model
predict
endcollect
endc
cell
yield
predic
either
precollect
prec
donor
blood
sampl
midcollect
midc
sampl
obtain
collect
bag
process
one
blood
volum
method
pbscc
perform
use
spectra
apheresi
system
version
terumo
denver
colorado
usa
use
cmncmnc
procedur
default
collect
volum
center
total
blood
volum
tbv
cell
enumer
flow
cytometri
use
twostag
ishag
protocol
compar
predict
valu
use
prec
midc
sampl
donor
forecast
cellkg
recipi
end
collect
endc
need
extend
collect
arrang
second
day
apheresi
abil
shorten
collect
consecut
perform
month
healthi
donor
analyz
calcul
base
effici
coeffici
valid
center
collect
complet
x
cellskg
recipi
obtain
endc
sampl
result
mean
endc
x
cellskg
mean
recipi
weight
kg
midc
cell
count
correctli
forecast
adequ
collect
accuraci
correctli
predict
collect
would
need
lengthen
midc
count
allow
us
shorten
blood
volum
mean
decreas
initi
predict
collect
durat
prec
determin
would
unnecessarili
prolong
pbscc
case
would
collect
tbv
base
prec
collect
prec
count
fals
predict
target
count
would
achiev
one
procedur
correl
pre
midc
endc
respect
midc
count
obtain
process
one
blood
volum
reflect
adequaci
venou
access
actual
progress
collect
addit
efficaci
gcsfmediat
stem
cell
mobil
conclus
midcollect
cell
count
reliabl
predictor
pbscc
cellkg
yield
compar
sampl
obtain
donor
blood
precollect
conflict
interest
none
kosin
univers
colleg
medicin
depart
intern
medicin
busan
korea
republ
kosin
univers
gospel
hospit
regist
nurs
stem
cell
transplant
clinic
nurs
specialist
busan
korea
republ
kosin
univers
colleg
medicin
depart
biochemistri
cancer
research
institut
busan
korea
republ
donga
univers
colleg
medicin
depart
intern
medicin
busan
korea
republ
pusan
nation
univers
yangsan
hospit
yangsan
korea
republ
ulsan
univers
hospit
univers
ulsan
colleg
medicin
ulsan
korea
republ
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
republ
background
autolog
stem
cell
transplant
asct
import
treatment
option
multipl
myeloma
malign
lymphoma
patient
receiv
asct
due
poor
mobil
therefor
assess
incid
rate
investig
predict
factor
poor
mobil
patient
lymphoma
multipl
myeloma
perform
peripher
blood
stem
cell
collect
pbscc
method
studi
includ
patient
histolog
confirm
malign
lymphoma
multipl
myeloma
confirm
bone
marrow
aspir
receiv
chemotherapi
follow
pbscc
mobil
failur
defin
inabl
procur
cellskg
least
apheresi
session
studi
conduct
casecontrol
studi
construct
sampl
popul
compar
success
mobil
group
mobil
failur
group
result
data
total
patient
four
univers
hospit
south
korea
jan
sep
collect
retrospect
total
patient
patient
fail
suffici
mobil
incid
pbscc
failur
rate
analyz
patient
success
failur
median
age
year
rang
male
patient
receiv
first
line
chemotherapi
ctx
patient
receiv
second
line
ctx
patient
receiv
third
line
treatment
prior
mobil
patient
complet
remiss
first
line
chemotherapi
patient
pbscc
patient
use
gcsf
mobil
patient
use
ctx
plu
gcsf
median
interv
diagnosi
pbscc
month
rang
univari
analysi
show
factor
affect
poor
mobil
age
younger
less
year
vs
vs
risk
diseas
low
vs
intermedi
vs
high
vs
vs
number
ctx
line
first
line
vs
second
line
vs
diseas
statu
pbscc
vs
noncr
vs
p
alc
pbscc
less
vs
vs
interv
diagnosi
pbscc
less
month
vs
month
vs
multivari
analysi
year
old
rr
mobil
rr
interv
diagnosi
pbscc
month
rr
independ
signific
poor
risk
factor
success
pbscc
conclus
studi
incid
rate
poor
mobil
defin
defin
inabl
procur
cellskg
least
apheresi
session
patient
year
old
noncr
prior
mobil
interv
diagnosi
mobil
month
show
signific
high
incid
rate
poor
mobil
conflict
interest
author
conflict
interest
report
hospit
do
capucho
lisboa
portug
hospit
do
capucho
hematologia
lisboa
portug
background
autolog
transplant
hematopoiet
progenitor
cell
pc
need
marrow
engraft
usual
harvest
peripher
blood
mobil
granulocyt
colonystimul
factor
chemotherapi
sourc
mani
advantag
bone
marrow
confort
resourc
utilis
speed
engraft
due
highli
variabl
efficaci
mobil
procedur
becam
necessari
devis
pc
threshold
guid
clinic
decis
relat
number
apheresi
need
safey
proceed
transplant
establish
threshold
cell
howev
assay
may
fail
reflect
quantit
function
loss
subsequ
handl
freez
thaw
process
ultim
measur
success
cell
process
must
prompt
reproduc
engraft
clinic
criteria
transplant
suboptim
number
pc
unusu
heavili
pretreat
poor
mobilis
center
evalu
influenc
factor
qualiti
engraft
analis
hematolog
recoveri
consecut
transplant
perform
center
method
transplant
given
patient
median
age
myeloma
non
hodgkin
hodgkin
lymphoma
acut
leukemia
solid
tumor
second
transplant
tandem
salvag
transplant
relaps
first
mobilis
attempt
success
patient
one
apheresi
suffici
patient
day
necessari
day
pool
multipl
mobilis
use
day
ph
cryopreserv
condit
beambeac
regimen
eight
transplant
result
death
neutrophil
recoveri
patient
censor
regener
analysi
result
median
cell
reinfus
dose
transplant
median
time
recoveri
neutrophil
ul
valu
achiev
transplant
respect
recoveri
plateletsul
occur
median
achiev
e
transplant
e
pn
comparison
case
platelet
nadir
none
receiv
conclus
data
confirm
optimis
cell
process
allow
neutrophil
engraft
within
day
case
within
day
platelet
engraft
within
day
even
suboptim
pc
dose
signific
differ
dose
delay
beyond
limit
indic
exaust
case
review
context
qualiti
control
programm
center
conflict
interest
conflict
kuopio
univers
hospit
kuopio
finland
univers
eastern
finland
kuopio
finland
central
hospit
central
finland
finland
oulu
univers
hospit
oulu
finland
north
karelia
central
hospit
joensuu
finland
central
hospit
savonlinna
savonlinna
finland
finnish
medicin
agenc
kuopio
finland
tamper
univers
hospit
tamper
finland
kuopio
univers
hospit
scienc
servic
center
kuopio
finland
eastern
finland
laboratori
centr
kuopio
finland
kymenlaakso
central
hospit
kotka
finland
background
autolog
stem
cell
transplant
autosct
commonli
employ
nonhodgkin
lymphoma
nhl
patient
relaps
consolid
first
line
therapi
granulocyt
stimul
factor
gcsf
prerequisit
mobil
blood
progenitor
cell
histor
shortact
filgrastim
use
limit
data
avail
effect
novel
longact
cytokin
lipegfilgrastim
well
pegfilgrastim
chemotherapi
mobil
purpos
regard
mobil
effici
graft
cellular
composit
posttranspl
engraft
method
prospect
multicent
studi
includ
part
graft
outcom
autolog
transplant
goa
studi
altogeth
nhl
patient
mobil
chemotherapi
plu
gcsf
end
thirtynin
patient
receiv
filgrastim
fil
group
sixtyfour
pegfilgrastim
peg
group
sixteen
lipegfilgrastim
lipeg
group
cytokin
chemomobil
thu
form
three
studi
group
efficaci
cell
mobil
well
blood
graft
cellular
composit
thaw
cryopreserv
sampl
analyz
flow
cytometri
hematolog
recoveri
total
blood
count
month
posttranspl
well
outcom
analyz
result
patient
lipeg
group
significantli
less
apheresi
session
well
approxim
higher
yield
first
apheresi
day
compar
fil
group
peg
group
graft
cellular
composit
compar
group
except
significantli
higher
count
without
addit
lipeg
group
engraft
kinet
significantli
slower
fil
group
compar
group
hematolog
recoveri
rapid
lipeg
group
term
leukocyt
well
neutrophil
count
day
autosct
conclus
lipeg
ad
chemotherapi
appear
effici
mobil
blood
graft
autosct
compar
peg
especi
fil
lipeg
group
achiev
adequ
graft
proceed
transplant
significantli
less
apheresi
session
neither
pf
os
affect
type
cytokin
mobil
procedur
conflict
interest
partanen
report
honoraria
behring
valtola
report
honoraria
sanofi
jansencilag
dr
siitonen
report
honoraria
amgen
celgen
particip
advisori
board
organ
pfizer
amgen
e
jantunen
report
honoraria
genzym
amgen
sanofi
particip
eu
leadership
meet
organ
genzym
well
medic
advisori
board
meet
organ
genzym
amgen
takeda
v
varmavuo
report
consult
fee
abbvi
roch
celgen
amgen
sanofi
author
declar
conflict
interest
tabl
tabl
abstract
previous
publish
st
bartholomew
hospit
haematooncolog
london
unit
kingdom
hexal
ag
hematologynephrolog
holzkirchen
germani
background
granulocyt
colonystimul
factor
gcsf
filgrastim
biosimilar
wide
use
prevent
treatment
chemotherapyinduc
neutropenia
cin
stem
cell
mobil
scm
biosimilar
filgrastim
avail
europ
sinc
includ
sandoz
biosimilar
filgrastim
filgrastimsndz
hexal
ag
approv
studi
sandoz
biosimilar
filgrastim
perform
prevent
cin
patient
breast
cancer
consid
sensit
indic
confirm
biosimilar
confirm
match
efficaci
safeti
immunogen
sandoz
biosimilar
filgrastim
refer
filgrastim
sensit
patient
popul
allow
extrapol
indic
refer
medicin
includ
scm
base
total
evid
approach
consequ
biosimilar
regulatori
process
requir
compar
studi
safeti
efficaci
biosimilar
versu
refer
biolog
scm
postapprov
longterm
safeti
studi
current
underway
healthi
donor
receiv
sandoz
filgrastim
biosimilar
almost
year
clinic
experi
sandoz
biosimilar
filgrastim
use
healthi
donor
larg
bodi
clinic
evid
support
safeti
profil
method
medlin
literatur
search
perform
identifi
publish
evid
avail
regard
use
sandoz
biosimilar
filgrastim
autolog
allogen
scm
includ
postapprov
safeti
studi
healthi
donor
abstract
poster
relev
congress
also
identifi
result
fifteen
prospect
retrospect
studi
identifi
report
efficaci
safeti
sandoz
biosimilar
filgrastim
use
scm
autolog
set
total
patient
receiv
zarzio
compar
data
avail
studi
consist
report
similar
mobil
yield
advers
event
ae
sandoz
biosimilar
filgrastim
refer
filgrastim
signific
bodi
evid
emerg
allogen
scm
postapprov
safeti
studi
report
healthi
volunt
receiv
sandoz
biosimilar
mean
followup
day
rang
scm
efficaci
ae
sandoz
biosimilar
filgrastim
similar
report
previous
refer
harvest
achiev
yield
cellskg
recipi
weight
achiev
rang
longterm
data
becom
avail
retrospect
analysi
healthi
sibl
donor
demonstr
effect
mobil
without
notabl
ae
year
followup
median
time
neutrophil
platelet
engraft
day
rang
day
rang
conclus
decad
clinic
experi
reassur
term
safeti
efficaci
sandoz
biosimilar
filgrastim
scm
evid
longterm
studi
emerg
allogen
set
includ
ongo
safeti
studi
healthi
donor
review
suggest
date
safeti
efficaci
sandoz
biosimilar
filgrastim
match
refer
biolog
scm
refer
becker
p
et
al
transfus
barosi
g
et
al
haematologica
taylor
et
al
bone
marrow
transplant
uddin
et
al
ther
adv
hematol
clinic
trial
registri
na
conflict
interest
agraw
act
consult
sandoz
n
mathieson
krendyukov
employe
hexal
ag
abstract
previous
publish
zdenka
blanka
zdenka
martina
iuri
marinov
pavla
institut
haematolog
blood
transfus
apheresi
depart
pragu
czech
republ
institut
clinic
experiment
medicin
charl
univers
pragu
czech
republ
gener
faculti
hospit
intern
clinic
hematolog
pragu
czech
republ
institut
haematolog
blood
transfus
laboratori
flow
cytometri
pragu
czech
republ
institut
haematolog
transfus
medicin
depart
statist
analysi
pragu
czech
republ
background
aim
studi
evalu
optim
new
cmnc
protocol
spectra
optia
v
terumo
pbpc
collect
patient
haematooncolog
malign
diseas
method
result
autolog
pbpc
collect
evalu
case
well
mobil
patient
precollect
cd
cell
concentr
blood
higher
b
first
collect
perform
either
use
cmnc
spectra
optia
v
cobe
spectra
v
v
terumo
c
collect
perform
standard
larg
volum
leukapheresi
regimen
lvl
engraft
data
transplant
patient
assess
statist
analysi
perform
mean
mannwhitney
u
test
f
test
result
express
median
rang
result
standard
collect
perform
patient
yield
cd
cell
high
signific
differ
found
number
cd
cell
prepar
spectra
optia
cobe
spectra
kg
b
w
pval
depend
cd
cell
yield
precollect
concentr
cd
cell
blood
consid
linear
high
correl
coeffici
cmnc
spectra
optia
cobe
spectra
lvl
collect
perform
patient
signific
differ
number
cd
cell
prepar
cmnc
spectra
optia
cobe
spectra
kg
bw
pval
relat
precollect
cd
cell
concentr
blood
number
cd
cell
collect
also
consid
linear
correl
coeffici
cmnc
spectra
optia
cobe
spectra
respect
lvl
median
platelet
loss
significantli
lower
cmnc
spectra
optia
cobe
spectra
group
patient
transplant
mean
pbpc
prepar
standard
regimen
median
time
neutrophil
reconstitut
cmnc
spectra
optia
well
cobe
spectra
day
platelet
cmnc
day
cobe
spectra
day
respect
number
patient
obtain
pbpc
lvl
median
time
neutrophil
platelet
reconstitut
cmnc
spectra
optia
well
cobe
spectra
correspond
day
respect
conclus
cmnc
protocol
spectra
optia
modern
effici
safe
system
use
standard
lvl
procedur
well
mobil
patient
suffici
dose
cd
cell
transplant
could
prepar
one
standard
one
lvl
procedur
seriou
advers
reaction
observ
conflict
interest
none
author
anyth
disclos
univers
calgari
calgari
canada
calgari
laboratori
servic
calgari
canada
alberta
children
hospit
calgari
canada
background
use
high
dose
chemotherapi
hdc
autolog
hematopoiet
stem
cell
transplant
hsct
result
improv
surviv
certain
patient
central
nervou
system
cn
tumour
use
radiotherapi
delay
spare
approach
aim
studi
factor
relat
success
stem
cell
collect
scc
correl
stem
cell
dose
infus
hsct
outcom
method
retrospect
chart
review
undertaken
pediatr
patient
cn
tumour
treat
centr
hdc
hsct
decemb
decemb
result
fiftyf
patient
identifi
male
femal
median
age
year
time
scc
rang
patient
diagnos
medulloblastoma
atrt
pnet
major
patient
underw
singl
scc
remain
underw
scc
procedur
peripher
blood
stem
cell
sourc
collect
success
scc
defin
dose
collect
achiev
patient
wherea
ideal
scc
defin
dose
collect
achiev
patient
use
chemotherapi
gcsf
mobil
significantli
associ
achiev
ideal
collect
compar
use
gcsf
alon
ci
gender
age
stem
cell
sourc
preapheresi
peripher
blood
count
found
signific
predictor
ideal
collect
median
time
neutrophil
engraft
day
hsct
cours
day
cours
median
time
platelet
engraft
day
cours
day
cours
higher
dose
per
kg
infus
associ
faster
neutrophil
recoveri
first
cours
chemotherapi
respect
cours
faster
platelet
engraft
first
cours
conclus
patient
cn
tumour
mobil
chemotherapi
gcsf
higher
yield
compar
patient
mobil
gcsf
alon
major
scc
autolog
hsct
success
complet
singl
apheresi
session
higher
dose
infus
associ
faster
neutrophil
recoveri
posthsct
limit
scale
faster
platelet
recoveri
conflict
interest
noth
disclos
stanford
univers
pediatr
stanford
ca
unit
state
stanford
univers
obstetr
gynecolog
stanford
ca
unit
state
background
umbil
cord
blood
ucb
vital
sourc
hematopoiet
stem
progenitor
cell
hspc
sinc
ucb
collect
store
public
cord
blood
bank
primarili
use
sourc
allogen
hematopoiet
stem
cell
transplant
hsct
sinc
semin
ucb
transplant
report
gluckman
et
al
ucb
contribut
advanc
hsct
clinic
trial
howev
ucbderiv
cell
remain
costli
difficult
procur
preclin
research
present
protocol
selfsustain
cord
blood
program
dedic
biomed
research
binn
program
cord
blood
research
pilot
stanford
univers
school
medicin
method
elig
donor
identifi
use
irbapprov
inclus
criteria
ucb
sampl
collect
utero
inform
consent
obstetr
provid
time
deliveri
within
hour
isol
sampl
process
three
fraction
plasma
hematopoiet
stem
progenitor
cell
hspc
immunomagnet
separ
nonhspc
cellular
flowthrough
ucbderiv
fraction
distribut
research
upon
request
result
novemb
novemb
expect
mother
consent
collect
cord
blood
deliveri
ucb
sampl
collect
process
distribut
consent
form
inform
materi
develop
english
spanish
streamlin
protocol
place
median
hspc
yield
per
cord
account
obstetr
paramet
might
affect
sampl
qualiti
notabl
delay
cord
clamp
million
rang
million
figur
tabl
manual
process
ucb
sampl
result
median
puriti
follow
onestep
purif
rang
figur
tabl
octob
protocol
develop
optim
binn
program
begin
provid
ucbderiv
product
six
laboratori
june
number
nearli
tripl
laboratori
program
respond
increas
interest
research
open
laboratori
research
support
binn
program
span
broad
array
topic
includ
normal
abnorm
hematopoiesi
genet
engin
includ
genom
edit
novel
approach
hsct
report
collect
volum
inclus
anticoagul
citrat
phosphat
dextros
therefor
whole
blood
collect
volum
rang
conclus
binn
program
cord
blood
research
repres
feasibl
financi
selfsustain
model
cord
blood
bank
support
advanc
biomed
research
provid
fresh
cryopreserv
ucbderiv
cell
research
commun
fraction
commerci
cost
hope
model
may
use
institut
center
need
support
research
high
tradit
model
public
cord
blood
bank
requir
extens
financi
infrastructur
may
suitabl
option
conflict
interest
none
author
anyth
disclos
tabl
key
paramet
ucb
collect
process
instituto
de
oncologia
porto
porto
portug
background
graft
failur
progress
diseas
frequent
indic
second
allogen
hematopoiet
stem
cell
transplant
bring
need
new
collect
donor
effect
repeat
peripher
blood
stem
cell
pbsc
mobil
graft
qualiti
poorli
studi
still
unknown
method
retrospect
evalu
result
two
cycl
pbsc
mobil
collect
unrel
relat
donor
care
institut
cycl
apheresi
start
fifth
day
mobil
use
cobe
spectra
first
year
spectra
optia
last
five
donor
age
weight
dose
circul
collect
cell
count
record
order
evalu
impact
interv
two
cycl
donor
popul
divid
two
group
day
group
day
group
b
result
among
total
donor
volunt
donor
portugues
donor
registri
familiar
twentyon
donor
remobil
recipi
graft
failur
diseas
progressionrelaps
time
first
collect
median
donor
age
year
rang
median
weight
median
delay
collect
day
although
mean
dose
administ
similar
first
second
mobil
versu
mean
number
circul
lower
second
mobil
versu
concern
number
apheresi
day
per
collect
donor
need
one
day
obtain
request
number
cell
first
cycl
compar
second
mean
total
number
cell
collect
higher
first
mobil
second
versu
respect
five
donor
cell
yield
second
mobil
wherea
fail
first
analysi
graft
cell
content
accord
time
interv
collect
show
group
donor
yield
fewer
cell
second
mobil
first
compar
group
b
conclus
studi
show
second
cycl
pbsc
mobil
collect
donor
associ
reduct
circul
collect
cell
even
use
dose
hematopoiet
growth
factor
moreov
shorter
time
interv
collect
seem
associ
lower
cell
yield
howev
minimum
number
cell
requir
gener
accomplish
cycl
way
opinion
second
pbsc
collect
may
consid
first
prefer
tri
maintain
gcsf
dose
respect
minimum
period
day
state
donor
registri
despit
studi
address
donor
safeti
consid
followup
period
must
extend
order
detect
possibl
longterm
effect
repeat
gcsf
exposur
conflict
interest
author
noth
disclos
univers
health
scienc
ankara
child
health
diseas
hematolog
oncolog
train
research
hospit
depart
pediatr
hematolog
oncolog
ankara
turkey
univers
health
scienc
ankara
train
research
hospit
depart
pediatr
hematolog
oncolog
ankara
turkey
univers
health
scienc
ankara
child
health
diseas
hematolog
oncolog
train
research
hospit
stem
cell
research
laboratori
ankara
turkey
background
disproportion
small
bone
marrow
bm
donor
compar
recipi
weight
mobil
granulocytecoloni
stimul
factor
gcsf
use
studi
concern
upfront
use
gcsf
bm
donor
boost
graft
yield
establish
safeti
well
efficaci
obtain
secur
engraf
howev
optim
dose
schedul
gcsf
prime
stem
cell
harvest
clearli
defin
literatur
order
decreas
exposur
gcsf
compar
effect
two
versu
three
day
gcsf
prime
bm
yield
donor
method
donor
prime
gcsf
daili
group
group
consecut
day
peripher
blood
pb
sampl
analyz
white
blood
cell
wbc
mononuclear
cell
mnc
cell
number
hour
first
day
gcsf
day
harvest
donor
also
bm
sampl
donor
analyz
wbc
mnc
cell
number
result
seventeen
donor
includ
studi
eleven
donor
median
year
median
weight
kg
mf
includ
group
donor
median
age
year
kg
mf
includ
group
match
sibl
donor
hla
compat
except
one
firstdegre
cousin
hla
compat
donor
experienc
major
advers
event
relat
gcsf
administr
differ
myeloid
platelet
engraf
day
two
group
peripher
blood
analysi
reveal
median
cell
number
hour
gcsf
prime
respect
hand
bm
graft
analysi
disclos
median
number
group
group
bone
marrow
harvest
yield
similar
total
nucleat
cell
tnc
mnc
cell
per
kilogram
recipi
weight
patient
tabl
donor
group
accord
age
result
demonstr
younger
donor
year
pb
bm
mnc
bm
cell
number
compar
donor
year
age
conclus
although
number
cell
higher
day
gcsf
prime
achiev
number
cell
per
recipi
weight
day
gcsf
prime
group
addit
number
tnc
harvest
bm
similar
two
three
day
regimen
anoth
interest
find
studi
obtain
adequ
number
peripher
blood
stem
cell
leukapheresi
three
day
gcsf
administr
sinc
engraf
time
also
similar
two
group
conclud
gcsf
prime
result
suffici
mobil
bm
stem
cell
conflict
interest
author
noth
disclos
tabl
bone
marrow
cell
count
accord
gcsf
prime
leiden
univers
medic
center
depart
immunohematolog
blood
transfus
leiden
netherland
background
peripher
blood
stem
cell
pbsc
collect
use
apheresi
devic
collect
effici
ce
mononuclear
cell
mnc
often
calcul
indic
success
procedur
ce
determin
mnc
concentr
blood
influenc
continu
mobil
white
blood
cell
chemotherapi
andor
gcsf
mobil
effect
lack
unstimul
donor
howev
apheresi
procedur
could
stimul
cellular
shift
extra
intravascular
aim
separ
effect
pbsc
mobil
apheresi
procedur
mnc
homeostasi
compar
apheresi
procedur
gcsfmobil
donor
unstimul
donor
bone
marrow
harvest
method
data
apheresi
procedur
perform
januari
june
spectra
optia
collect
donor
leukocyt
x
collect
elutri
chamber
use
otherwis
continu
mnc
collect
bm
bmprocess
program
use
apheresi
donor
bm
harvest
sampl
measur
mnc
number
flow
cytometr
analysi
use
scatter
pattern
stimul
donor
bm
use
sum
monocyt
lymphocyt
measur
routin
unstimul
donor
calcul
accord
mnc
product
preprocedur
mnc
count
process
volum
l
recoveri
defin
mnc
product
mnc
total
blood
volum
use
nadler
formula
unstimul
donor
estim
number
harvest
mnc
calcul
subtract
absolut
intravascular
mnc
count
post
absolut
intravascular
mnc
count
apheresi
result
highest
found
procedur
perform
mobil
allogen
compar
autolog
donor
due
higher
mnc
precount
median
respect
unstimul
mnc
apheresi
much
lower
lowest
bm
recoveri
howev
higher
bm
compar
unstimul
mnc
apheresi
stimul
donor
recoveri
highest
unstimul
donor
real
number
mnc
harvest
higher
estim
number
median
repres
intravascular
replenish
mnc
apheresi
conclus
larg
differ
exist
ce
recoveri
respect
donor
type
sourc
mnc
healthi
stimul
compar
autolog
donor
higher
explain
higher
amount
mnc
preapheresi
high
recoveri
due
releas
mnc
marrow
intravascular
space
procedur
lower
unstimul
mnc
apheresi
explain
lack
ongo
product
situat
entir
steadi
state
shift
occur
extra
intravascular
bm
apheresi
aim
get
recoveri
therefor
mani
cycl
perform
apheresi
machin
lead
higher
process
volum
therefor
low
knowledg
help
interpret
ce
outcom
conflict
interest
j
overdevest
noth
disclos
tabl
result
depart
haematolog
cruce
univers
hospit
biocruc
health
research
institut
barakaldo
spain
background
plerixafor
molecul
use
mobil
hematopoiet
stem
progenitor
cell
hspc
patient
treat
autolog
transplant
use
patient
poor
bad
mobil
reduc
mobil
failur
rate
plerixafor
administ
beetween
hour
plan
apheresi
center
administ
plerixafor
apheresi
seen
plerixafor
mobil
fast
hspc
administr
method
made
mobil
plerixafor
patient
women
differ
patholog
sometim
use
time
remobil
strategi
patient
use
one
dose
need
one
mobil
without
plerixafor
have
use
plerixafor
morn
hour
start
apheresi
patient
night
hour
start
apheresi
patient
fewer
time
use
morn
hour
start
apheresi
result
signif
differ
beetween
group
amount
littl
bit
bigger
group
observ
effici
apheresi
good
result
patient
receiv
drug
apheresi
effici
product
x
volum
collect
day
plerixafor
administr
x
volum
process
wich
could
mean
plerixafor
capabl
mobil
hspc
fast
peripher
blood
tabl
conclus
use
plerixafor
avoid
reduc
fail
mobil
reduc
number
apheresi
session
problem
administr
sometim
need
regist
patient
give
drug
night
anoth
situat
result
collect
till
hour
later
mayb
give
drug
patient
case
use
plerixafor
apheresi
could
good
strategi
seen
plerixafor
enhac
hspc
peripher
blood
fast
avoid
time
strategi
although
use
plerixafor
hour
mayb
littl
better
result
conflict
interest
collabor
sanofi
meet
round
tabl
plerixafor
tabl
tabl
leiden
univers
medic
center
immuno
hematolog
bloodtransfus
leiden
netherland
background
high
risk
system
sclerosi
patient
treat
autolog
stem
cell
transplant
condit
cyclophosphamid
stem
cell
mobil
apheresi
clinimac
select
procedur
perform
erad
autoimmun
cell
allow
subsequ
cryopreserv
purifi
cell
post
thaw
viabil
transplant
import
qualiti
criterion
center
routin
assess
refer
vial
undergo
freez
procedur
product
viabil
product
approv
clinic
use
viabil
sampl
thaw
product
alway
assess
addit
vial
nonselect
product
show
median
post
thaw
viabil
rang
notic
viabil
vial
product
seem
lower
investig
studi
viabil
vial
product
thaw
relat
engraft
method
juli
novemb
cryopreserv
cell
patient
use
clinimac
system
miltenyi
data
collect
viabil
thaw
refer
vial
transplant
infus
engraft
platelet
granulocyt
recipi
viabil
test
perform
use
ishag
gate
strategi
marker
dead
cell
engraft
data
transplant
patient
collect
patient
record
engraft
defin
first
day
granulocyt
first
day
platelet
count
result
vial
cell
product
show
median
viabil
rang
vial
viabil
even
upon
thaw
product
administr
show
viabil
case
median
rang
clear
relat
viabil
vial
stem
cell
product
howev
present
p
wilcoxon
signedrank
test
although
refer
vial
show
lower
viabil
thaw
product
case
two
patient
decid
second
stem
cell
mobil
due
insuffici
amount
viabl
stem
cell
decis
taken
sacrif
part
product
viabil
test
reveal
also
littl
viabl
cell
median
neutrophil
platelet
engraft
transplant
scleroderma
patient
took
rang
rang
day
respect
illustr
respect
engraft
failur
occur
transplant
x
cell
viabil
refer
vial
conclus
product
viabil
occur
half
thaw
refer
vial
might
explain
select
cell
concentr
andor
medium
condit
select
cell
frozen
thaw
make
vulner
unselect
counterpart
altern
unselect
transplant
cell
might
protect
cell
good
overal
engraft
transplant
seem
suggest
present
cut
valu
vial
viabil
could
adjust
product
conflict
interest
none
author
anyth
disclos
stem
cell
sourc
ajou
univers
school
medicin
pediatr
suwon
korea
republ
korea
univers
colleg
medicin
pediatr
seoul
korea
republ
biomed
research
institut
lifeliv
co
ltd
yongin
korea
republ
background
sever
aplast
anemia
saa
rare
potenti
fatal
diseas
character
immunemedi
function
impair
hematopoiet
stem
cell
hsct
peripher
blood
stem
cell
transplant
pbsct
bone
marrow
transplant
bmt
treatment
choic
young
patient
match
relat
donor
mrd
especi
cell
dose
known
influenc
outcom
peripher
stem
cell
andor
tcelldeplet
transplant
previou
studi
show
x
cellskg
may
ideal
minimum
cell
dose
allogen
transplant
although
lower
dose
preclud
success
therapi
method
review
chart
patient
report
result
old
patient
diagnos
aplast
anemia
treat
hematopoiet
cell
transplant
match
sibl
donor
suffici
amount
harvest
cell
gave
total
five
time
transplant
five
day
day
includ
cord
blood
cryopreserv
birth
donor
day
first
transplant
white
blood
cell
engraft
achiev
result
bone
marrow
biopsi
pcr
str
short
tandem
repeat
marker
show
complet
engraft
month
day
first
date
stem
cell
infus
conclus
multipl
infus
hematopoiet
stem
cell
includ
umbil
cord
blood
stem
cell
could
engraft
even
amount
total
count
hematopoiet
stem
cell
insuffici
conflict
interest
conflict
interest
nation
research
center
hematolog
moscow
russian
feder
background
primari
secondari
graft
failur
gf
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
lead
prolong
neutropenia
infect
complic
consequ
lower
overal
surviv
report
feasibl
risk
factor
influenc
gf
acut
leukemia
patient
pt
first
six
month
allohsct
unrel
donor
method
analyz
medic
record
pt
acut
leukemia
underw
allohsct
unrel
donor
nation
research
center
hematolog
aliv
day
allohsct
median
age
patient
year
male
femal
time
transplant
pt
complet
remiss
pt
advanc
diseas
pt
receiv
reduc
intens
condit
regimen
ric
pt
underw
myeloabl
condit
mac
donor
unrel
hlamatch
mismatch
bone
marrow
bm
use
graft
sourc
pt
peripher
blood
stem
cell
pbsc
pt
analysi
gf
defin
neutropenia
host
chimer
bone
marrow
cox
proportionalhazard
model
use
identifi
independ
prognost
factor
age
sex
condit
regimen
donor
type
type
leukemia
graft
sourc
graft
cell
dose
enter
covari
kaplanmei
surviv
analysi
longrank
test
use
compar
two
group
result
result
cox
proportionalhazard
model
shown
figur
accord
data
use
bm
graft
sourc
allohsct
unrel
donor
associ
high
risk
gf
within
six
month
follow
period
allohsct
cl
probabl
gf
six
month
depend
graft
sourc
bm
recipi
compar
patient
receiv
pbsc
conclus
bm
graft
sourc
character
low
risk
graftversushost
diseas
onset
apart
fact
use
bm
increas
probabl
gf
reason
could
consid
bm
graft
sourc
seem
controversi
acut
leukemia
pt
go
undergo
allohsct
unrel
donor
conflict
interest
noth
disclos
blk
hospit
new
delhi
india
background
allogen
stem
cell
transplant
accept
postremiss
therapi
patient
high
intermedi
risk
acut
myeloid
leukemia
patient
without
match
sibl
donor
msd
altern
donor
transplant
indic
scenario
haploident
donor
hid
transplant
make
strong
point
consid
readi
avail
especi
better
applic
indian
set
due
cost
implic
involv
procur
match
unrel
stem
cell
transplant
selffund
data
compar
match
unrel
donor
vs
haploident
donor
suggest
equival
outcom
aml
howev
pauciti
literatur
compar
match
sibl
vs
haploident
donor
transplant
patient
aml
prompt
us
compar
singl
center
experi
patient
aml
first
remiss
undergo
allogen
stem
cell
transplant
either
msd
hid
donor
center
method
retrospect
compar
aml
patient
first
remiss
underw
allogen
transplant
either
msd
donor
tcell
replet
hid
donor
januari
juli
condit
regim
variabl
hid
transplant
use
posttranspl
cyclophosphamid
approach
gvh
prophylaxi
primari
end
point
overal
surviv
os
diseas
free
surviv
df
secondari
end
point
acut
chronic
gvhd
relaps
rate
result
patient
compar
regard
median
age
followup
durat
cmv
serostatu
condit
intens
three
year
overal
surviv
os
compar
group
trend
better
surviv
msd
transplant
vs
three
year
diseas
free
surviv
df
also
compar
trend
better
surviv
favor
msd
donor
vs
acut
gvhd
grade
compar
group
msd
acut
grade
gvhd
compar
hid
grade
acut
gvhd
msd
compar
hid
incid
chronic
gvhd
higher
hid
transplant
msd
compar
hid
transplant
detail
data
analysi
present
later
conclus
present
studi
found
similar
overal
diseas
free
surviv
outcom
patient
undergo
msd
vs
hid
transplant
patient
aml
first
remiss
howev
trend
chronic
gvhd
patient
hid
compar
msd
transplant
also
much
differ
donor
sourc
term
gvhd
relaps
mortal
appear
aml
patient
first
remiss
lack
msd
hid
readili
avail
donor
sourc
compar
efficaci
probabl
due
recent
updat
better
understand
field
haploident
transplant
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
vall
hospit
hematolog
oncolog
hsct
unit
barcelona
spain
banc
de
sang
teixit
barcelona
spain
vall
hospit
barcelona
spain
background
cryopreserv
bone
marrow
stem
cell
bmsc
graft
occasion
need
due
problem
relat
donor
recipi
logist
issu
nevertheless
direct
infus
cryopreserv
bone
marrow
associ
develop
advers
event
ae
ae
known
associ
use
dimethyl
sulfoxid
dmso
red
cell
volum
nonmononuclear
cell
method
data
patient
receiv
cryopreserv
bone
marrow
transplant
retrospect
collect
product
red
cell
deplet
prior
cryopreserv
patient
classifi
two
differ
group
accord
use
non
use
wash
method
post
bone
marrow
thaw
prior
graft
infus
ae
analyz
classifi
follow
ctcae
version
patient
receiv
premed
dexchlorpheniramin
methylprednisolon
infus
graft
result
sixteen
patient
studi
receiv
thaw
nonwash
bmsc
graft
receiv
thaw
wash
bmsc
graft
patient
product
characterist
advers
event
describ
tabl
eight
patient
present
ae
wash
product
group
nonwash
product
group
ae
hypertens
hemoglobinuria
headach
nausea
vomit
bradycardia
allerg
reaction
acut
renal
failur
relat
hemolysi
dmso
three
patient
present
grade
ae
grade
one
grade
six
eight
patient
present
ae
receiv
bone
marrow
graft
ml
red
cell
conclus
ae
frequent
bmsc
thaw
even
absenc
red
cell
incompat
graft
wash
seem
reduc
incid
actual
volum
red
cell
infus
could
import
factor
regard
occurr
ae
cyopreserv
bm
infus
investig
need
ascertain
impact
wash
cryopreserv
bm
graft
occurr
ae
infus
clinic
trial
registri
applic
conflict
interest
conflict
interest
tabl
tabl
characterist
patient
product
instituto
de
oncologia
porto
francisco
gentil
immunohemotherapi
porto
portug
instituto
de
oncologia
porto
francisco
gentil
cellular
therapi
porto
portug
background
autolog
stem
cell
transplant
asct
essenti
consolid
treatment
hematolog
malign
cellular
content
apheresi
product
evalu
cellular
efficaci
cryopreserv
seem
influenc
directli
effici
stabil
bone
marrow
engraft
clinic
methodolog
definit
contribut
patient
overal
long
time
period
diseasefre
surviv
method
evalu
hematolog
recoveri
defin
neutrophil
platelet
recoveri
adult
patient
underw
asct
due
multipl
myeloma
mm
hodgkin
hl
nonhodgkin
lymphoma
nhl
year
descript
retrospect
studi
perform
review
patient
electron
clinic
record
cryopreserv
done
liquid
nitrogen
c
hepat
b
posit
patient
statist
analysi
perform
result
evalu
patient
submit
asct
male
median
age
year
min
max
median
weight
kg
min
max
patient
mm
iss
iss
ii
iss
iii
hl
nhl
stage
ii
iii
iv
median
preasct
followup
time
month
min
max
mobil
peripher
blood
stem
cell
sourc
patient
regard
cryopreserv
time
signific
differ
found
lymphoma
month
mm
month
patient
exclud
due
shorter
preserv
time
motiv
posit
viral
serolog
mm
melphalan
use
condit
chemotherapi
patient
lymphoma
fotemustin
etoposid
cytarabin
melphalan
feam
use
patient
three
group
defin
cellular
thaw
median
cfugm
cellular
viabil
determin
tripan
blue
method
lymphoma
mm
statist
signific
bacteri
evalu
neg
product
sampl
patient
admit
hospit
median
period
day
min
max
cellular
viabil
statist
impact
shorten
period
lymphoma
mm
mm
patient
lymphoma
patient
neutrophil
platelet
recoveri
appropri
time
mm
patient
lymphoma
patient
neutrophil
recoveri
maintain
platelet
transfus
need
almost
patient
aliv
end
studi
postasct
median
followup
time
month
conclus
high
cellular
viabil
thaw
seem
determin
better
hematolog
recoveri
shorter
inpati
period
import
develop
similar
studi
larger
number
patient
establish
definit
conclus
conflict
interest
noth
disclos
instituto
nacion
de
ciencia
medica
nutricion
salvador
zubiran
hematolog
oncolog
tlalpan
mexico
background
current
peripher
blood
pbsc
commonli
use
sourc
allogen
hematopoiet
stem
cell
transplant
allohsct
due
faster
engraft
faster
immunolog
reconstitut
practic
howev
associ
higher
incid
graftversushostdiseas
gvhd
hand
cohort
studi
describ
safeti
efficaci
use
relat
gcsfprime
bone
marrow
gbm
allograft
addit
acceler
engraft
use
gbm
sourc
hsc
associ
decreas
incid
gvhd
nonetheless
date
gbm
main
sourc
hematopoiet
stem
cell
rare
use
worldwid
aim
studi
describ
outcom
patient
undergo
allohsct
use
gbm
tertiaryreferr
center
develop
countri
method
consecut
patient
underw
allohsct
ident
hla
donor
use
gbm
nation
institut
medic
scienc
nutrit
mexico
citi
may
april
retrospect
analyz
dataset
use
studi
deriv
medic
record
collect
hsct
program
electron
institut
medic
record
inform
consent
obtain
patient
donor
undergo
allohsct
hsc
collect
donor
multipl
aspir
iliac
crest
gcsf
administ
day
everi
hour
prior
procedur
volum
harvest
adapt
recipi
bodi
weight
result
total
consecut
patient
includ
overal
patient
characterist
shown
tabl
median
age
year
common
underli
diseas
aplast
anemia
acut
lymphoblast
leukemia
myelodysplast
syndrom
patient
ident
hlaident
sibl
donor
engraft
occur
patient
late
posttranspl
graft
failur
observ
toxic
present
patient
grade
iii
acut
gvhd
develop
patient
grade
iii
patient
chronic
gvhd
limit
thirti
nrm
respect
one
nrm
respect
trm
account
gvhd
last
follow
relaps
free
overal
surviv
respect
conclus
allohsct
becom
establish
therapi
mani
hematolog
diseas
howev
seriou
complic
includ
gvhd
sepsi
infect
still
limit
success
procedur
also
increas
overal
financi
cost
report
use
gbm
associ
platelet
engraft
similar
report
literatur
pbsc
although
day
longer
neutrophil
patient
includ
studi
engraft
frequenc
acut
chronic
gvhd
lower
compar
publish
literatur
use
ssbm
pbsc
conclus
gbm
gener
favor
outcom
includ
low
frequenc
agvhd
produc
measur
clinic
benefit
minim
nrm
reduct
gvhd
reduc
cost
lowmiddl
incom
countri
make
gbm
best
sourc
allohsct
scenario
conflict
interest
none
author
conflict
interest
disclos
european
institut
oncolog
haematooncolog
milano
itali
background
hematopoiet
stem
cell
transplant
hsct
haploident
donor
use
highdos
posttranspl
cyclophosphamid
cy
altern
procedur
patient
advanc
haematolog
malign
lack
hla
ident
donor
prospect
studi
base
use
peripher
blood
stem
cell
pbsc
graft
sourc
launch
european
institut
oncolog
updat
experi
patient
report
method
haploident
hsct
perform
gcsf
mobil
pbsc
condit
regimen
either
nonmyeloabl
patient
cy
mgkgdie
day
fludarabin
day
cgi
total
bodi
irradi
day
myeloabl
treosulfan
day
fludarabin
day
gvhd
prophylaxi
includ
posttranspl
high
dose
cy
day
mycophenol
tacrolimu
among
evalu
patient
receiv
haplohsct
refractoryrelaps
lymphoma
nonhodgkin
hodgkin
lymphoma
remain
patient
includ
highrisk
acut
leukemia
al
multipl
myeloma
mm
myelodysplast
syndrom
md
median
age
diseas
statu
includ
complet
remiss
partial
respons
pr
stabl
diseas
sd
progress
diseas
pd
one
md
patient
receiv
hsct
upfront
median
rang
cellskg
infus
median
rang
cellskg
result
four
toxic
death
due
infect
engraft
remain
patient
median
time
absolut
neutrophil
day
rang
day
rang
platelet
incid
grade
iii
acut
gvhd
grade
iii
mild
chronic
gvhd
observ
evalu
patient
cumul
incid
mix
donor
chimer
achiev
evalu
patient
chimer
day
day
cmv
reactiv
occur
patient
median
day
rang
posthsct
infect
resolv
preemptiv
therapi
patient
fatal
heavili
pretreat
patient
median
followup
day
patient
aliv
whole
seri
cr
cumul
incid
relaps
overal
patient
die
caus
death
pd
patient
infect
noninfect
complic
cumul
transplant
relat
mortal
among
lymphoma
patient
aliv
cr
median
followup
day
prehsct
diseas
statu
includ
patient
pr
pd
pf
os
lymphoma
patient
respect
patient
transplant
crpr
transplant
sdpd
conclus
haploident
tcell
replet
pbsc
transplant
highdos
posttranspl
cy
feasibl
procedur
highrisk
haematolog
malign
overal
toxic
analog
hsct
hlaident
donor
approach
effect
salvag
option
heavili
pretreat
lymphoma
patient
conflict
interest
author
noth
disclos
sahlgrenska
univers
hospit
stem
cell
laboratori
clinic
immunolog
transfus
medicin
gothenburg
sweden
background
hematopoiet
stem
progenitor
cell
hspc
use
hematopoiet
stem
cell
transplant
hsct
harvest
bone
marrow
bm
bm
retriev
posterior
iliac
crest
gener
anesthesia
volum
ml
per
kilogram
donor
weight
donor
collect
relat
factor
affect
concentr
hspc
result
cellular
product
harvest
physician
frequent
request
evalu
qualiti
bm
harvest
procedur
outcom
hsct
weigh
heavili
number
transplant
hspc
aim
calcul
refer
valu
hspc
concentr
bm
harvest
investig
donor
age
affect
hspc
concentr
method
bm
harvest
perform
without
gcsf
mobil
investig
mononuclear
cell
mnc
concentr
manual
count
microscop
concentr
viabl
cell
bd
facscalibur
bd
bioscienc
descript
statist
includ
median
percentil
calcul
donor
year
donor
year
donor
year
mnc
cell
concentr
correl
rho
calcul
mnc
cell
concentr
age
group
comparison
result
age
group
year
year
year
perform
use
kruskallw
test
result
median
mnc
cell
concentr
mncl
donor
year
mncl
donor
year
mncl
donor
year
signific
correl
age
donor
concentr
cell
r
p
bm
harvest
correl
age
mnc
concentr
kruskallw
test
reveal
signific
differ
cell
concentr
across
differ
age
group
p
mnc
concentr
conclus
establish
refer
valu
rel
age
donor
hspc
concentr
bm
harvest
enabl
us
give
feedback
qualiti
bm
harvest
harvest
procedur
younger
donor
significantli
higher
concentr
cell
bm
indic
age
relat
differ
hematopoiesi
mean
smaller
volum
bm
per
kilogram
donor
weight
might
harvest
younger
donor
without
compromis
total
dose
hspc
avail
hsct
recipi
lack
correl
age
mnc
concentr
probabl
due
lesser
precis
manual
count
cell
greater
heterogen
cell
popul
compar
cell
conflict
interest
none
author
anyth
disclos
st
istvan
st
hospit
haematolog
stem
cell
transplant
budapest
hungari
semmelweiss
univers
rd
depart
intern
medicin
budapest
hungari
background
haploident
hematopoiet
stem
cell
transplant
hsct
increasingli
consid
viabl
therapeut
option
patient
lack
hlaident
sibl
hlamatch
unrel
donor
initi
approach
haplohsct
lead
unaccept
high
complic
rate
nowaday
new
vivo
approach
posttransplant
cyclophosphamid
ptci
vitro
graft
manipul
strategi
mark
improv
clinic
outcom
method
retrospect
analyz
data
consecut
patient
underw
haploidenticalhsct
june
novemb
unit
accord
baltimor
group
employ
ptci
patient
nine
patient
acut
leukemia
treat
tcell
deplet
allograft
total
patient
male
femal
median
age
year
baselin
diseas
aml
md
saa
hd
cml
diseas
state
time
haplohsct
follow
patient
responseact
diseas
myeloabl
conditionin
mac
use
patient
reduc
intens
regimen
ric
patient
mac
regimen
consist
thiotepa
busulfan
mgkgbw
fludarabin
tbi
fludarabin
stem
cell
sourc
pbsc
bm
result
median
followup
day
patient
aliv
remiss
seven
patient
die
includ
due
nrm
one
patient
diseas
relaps
os
df
os
higher
compar
activ
diseas
diseas
state
vs
trm
first
day
grade
acut
gvhd
mainli
skin
involv
observ
grade
acut
gvhd
occur
two
patient
chronic
extens
gvhd
two
median
time
absolut
neutrophyl
leukocyt
engraft
day
day
respect
median
time
platelet
engraft
day
patient
success
engraft
chimer
shortli
hsct
median
followup
day
os
ptci
group
tcrab
select
group
followup
period
median
day
rang
short
median
time
neutrophyl
engraft
day
ptci
select
subgroup
median
platelet
engraft
day
ptci
select
subgroup
patient
engraft
tcelldeplet
goup
slightli
lower
ptci
group
incid
sever
gvhd
group
sever
hemorrhag
cystiti
observ
ptci
group
conclus
base
experi
haplohsct
show
better
outcom
earlier
result
match
mud
hsct
ptci
tcelldeplet
haplohsct
safe
feasibl
treatment
option
patient
wait
allograft
emphas
use
vitro
graft
manipul
technic
might
provid
improv
effect
haplohsct
conflict
interest
disclosur
conflict
interest
none
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
spain
hospit
universitario
virgen
de
la
arrixaca
immunolog
servic
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
paediatr
oncolog
haematolog
unit
el
palmar
murcia
spain
hospit
universitario
virgen
de
la
arrixaca
imib
univers
murcia
haematolog
servic
stem
cell
transplant
unit
el
palmar
murcia
spain
background
recoveri
immun
system
allogen
haematopoiet
stem
cell
transplant
allohsct
highli
dynam
process
often
delay
result
prepar
regimen
use
prior
transplant
predispos
recipi
infect
method
retrospect
observ
studi
patient
age
year
undergo
allohsct
tertiari
hospit
januari
decemb
studi
total
pediatr
patient
underw
allo
hsct
median
followup
month
immunolog
reconstitut
assess
total
lymphocyt
lymphocyt
ratio
b
lymphocyt
natur
killer
nk
day
post
allohsct
normal
lymphocyt
popul
valu
defin
includ
pediatr
aid
clinic
trial
group
studi
divid
data
group
accord
stem
cell
sourc
peripher
blood
pb
bone
marrow
bm
result
depict
immun
evolut
post
allohsct
type
lymphocyt
accord
stem
cell
sourc
lymphocyt
present
normal
count
sinc
day
pb
group
sinc
day
bm
group
similarli
lymphocyt
present
normal
count
sinc
day
pb
group
delay
day
bm
group
contrast
lymphocyt
present
normal
count
sinc
day
pb
group
sinc
day
bm
group
consequ
ratio
show
initi
invers
group
normal
sinc
day
pb
group
bm
group
persist
invert
day
lymphocyt
present
normal
count
group
sinc
day
lymphocyt
exhibit
similar
cours
group
normal
count
sinc
day
encount
signific
differ
p
pb
bm
lymphocyt
recoveri
day
day
ratio
day
conclus
result
confirm
kinet
immun
reconstitut
differ
among
bone
marrow
peripher
blood
sc
sourc
overal
innat
immun
recov
within
first
week
hct
follow
adapt
immun
system
invers
ratio
one
earliest
featur
cell
reconstitut
persist
sever
year
hsct
conflict
interest
none
instituto
portugu
oncologia
bmt
lisbon
portug
instituto
portugu
oncologia
lisbon
portug
background
allohsct
potenti
cur
treatment
lifethr
malign
nonmalign
disord
sinc
implement
transplant
program
may
introduc
numer
modif
follow
trend
field
aim
reduc
transplant
associ
morbid
mortal
improv
result
evalu
whether
chang
implement
past
decad
posit
reflect
outcom
method
retrospect
review
consecut
first
allohsct
conduct
data
may
may
analyz
transplant
databas
cutoff
date
analys
may
survivor
data
censor
date
last
followup
compar
cumul
incid
os
pf
nrm
relaps
cohort
studi
decad
os
pf
calcul
use
kaplanmei
method
logrank
test
group
comparison
probabl
relaps
nrm
calcul
use
cumul
incid
procedur
compet
risk
model
gray
test
group
comparison
patient
acut
leukemia
al
cml
first
chronic
phase
aplast
anemia
nonmalign
condit
consid
standard
risk
patient
al
beyond
cml
beyond
lymphoma
malign
partial
remiss
progress
relaps
includ
high
risk
group
tbicyclophosphamid
busulfan
cyclophosphamid
commonli
use
condit
regimen
al
cml
reduc
intens
regimen
introduc
last
decad
gvhd
prophylaxi
calcineurin
inhibitor
methotrex
mycophenol
mofetil
vivo
cell
deplet
atgalg
ad
use
unrel
donor
patient
hlac
mismatch
given
alemtuzumab
infect
prophylaxi
includ
low
dose
acyclovir
oral
quinolon
azol
trimethoprimsulfamethoxazol
result
median
age
patient
transplant
increas
year
first
decad
year
last
decad
p
proport
patient
transplant
aml
increas
past
decad
p
wherea
proport
cml
patient
decreas
significantli
p
regard
diseas
statu
transplant
signific
increas
high
risk
patient
use
peripher
blood
p
number
unrel
donor
p
increas
dramat
studi
period
patient
aliv
date
last
followup
median
fu
year
respect
consecut
decad
os
first
decad
increas
last
decad
pf
remain
rel
stabl
decad
nrm
decreas
significantli
first
decad
last
one
cumul
incid
relapseprogress
stabl
decad
conclus
despit
increas
age
higher
risk
patient
use
unrel
donor
result
last
year
show
continu
significantli
reduc
nrm
togeth
improv
overal
surviv
stabl
pf
relaps
rate
conflict
interest
noth
disclos
azienda
ospedaliera
policlinico
hematolog
bmt
unit
catania
itali
azienda
ospedaliera
bianchi
melacrino
morelli
trapianti
di
midollo
reggio
calabria
itali
centro
riferimento
oncologico
aviano
high
dose
chemotherapi
aviano
itali
azienda
ospedaliera
policlinico
catania
itali
azienda
ospedaliera
policlinico
hematolog
bmt
unit
catania
itali
cnr
ibim
reggio
calabria
itali
background
use
algorithm
administ
plx
increas
success
rate
mobil
treatment
hand
also
increas
dose
gcsf
mcgkg
mcgkg
could
import
end
harvest
optim
amount
cell
known
high
dose
gcsf
demand
plx
show
synergist
effect
combin
use
may
addit
use
method
patient
retrospect
studi
affect
mm
first
mobil
attempt
patient
receiv
ctx
grsqm
patient
enrol
demand
plx
plx
group
plx
group
plx
group
patient
receiv
gcsf
mcgkg
receiv
dose
mcgkg
plx
group
receiv
gcsf
dose
mcgkg
dose
mcgkg
result
plx
group
percentag
patient
fail
harvest
minimum
patient
receiv
mcgkg
versu
patient
receiv
gcsf
mcgkg
patient
receiv
gcsf
dose
mcgkg
reach
harvest
cell
case
outcom
reach
patient
receiv
gcsf
dose
mcgkg
mean
harvest
cell
versu
plx
group
patient
fail
minimum
harvest
two
group
treat
respect
mcgkg
optim
threshold
reach
receiv
gcsf
mcgkg
patient
treat
gcsf
mcgkg
pnot
signific
mean
number
harvest
cell
versu
respect
mcgkg
group
pn
thu
high
dose
gcsf
seem
advantag
plx
demand
use
efficaci
less
evid
plx
demand
program
therefor
wish
studi
exist
interact
two
factor
anova
test
amount
cell
harvest
use
depend
variabl
dose
gcsf
enrol
plx
demand
studi
evalu
interact
two
factor
signific
f
conclus
ctx
base
mobil
dose
gcsf
mcgkg
allow
reach
optim
amount
cell
frequent
respect
dose
mcgkg
howev
hold
true
plx
use
fact
patient
enrol
plx
studi
evid
higher
dose
gcsf
determin
improv
respect
obtain
use
demand
plx
conflict
interest
conflict
interest
abstract
previous
publish
clinic
trial
registri
applic
conflict
interest
none
author
anyth
disclos
univers
bristol
bristol
unit
kingdom
background
transplant
peripher
blood
hematopoiet
stem
cell
pbsc
predomin
graft
sourc
unrel
adult
allogen
hematopoiet
stem
cell
transplant
hsct
howev
paediatr
bone
marrow
bm
remain
first
option
allogen
unrel
hsct
mainli
due
increas
risk
acut
chronic
gvhd
associ
pbsc
graft
method
object
herein
compar
outcom
children
receiv
allo
unrel
bmt
util
bm
vs
pbsc
graft
sourc
larg
dedic
uk
paediatr
hsct
programm
bristol
studi
design
retrospect
analysi
result
children
receiv
allogen
unrel
hsct
malign
cml
hl
nhl
md
jmml
major
receiv
myeloabl
condit
regimen
patient
receiv
campath
surviv
superior
bm
recipi
compar
pbsc
vs
inferior
outcom
pbsc
recipi
due
higher
non
relaps
mortal
nrm
pbsc
vs
bm
recipi
interestingli
malign
diagnosi
aml
relaps
rate
similar
regardless
stem
cell
sourc
relaps
rate
pbsc
bm
respect
aml
relaps
rate
pbsc
bm
respect
conclus
studi
suggest
children
pbsc
sourc
stem
cell
associ
higher
nrm
without
better
graft
versu
leukemia
gvl
effect
lead
inferior
outcom
unlik
adult
bm
sourc
stem
cell
continu
prefer
option
paediatr
hcst
conflict
interest
noth
declar
san
raffael
scientif
institut
hematolog
bone
marrow
transplant
unit
milano
itali
vitasalut
san
raffael
univers
san
raffael
scientif
institut
milano
itali
san
raffael
scientif
institut
immunohematolog
transfus
medicin
unit
milano
itali
background
procur
adequ
amount
hematopoiet
stem
cell
hsc
essenti
engraft
recipi
allogen
stem
cell
transplant
allohct
estim
healthi
donor
undergo
hsc
mobil
reach
minimum
target
dose
cell
plerixafor
pl
chemokin
receptor
cxc
inhibitor
hscmobil
properti
synergist
gcsf
poor
mobil
patient
pt
other
previous
report
use
pl
adjuv
altern
gcsf
healthi
donor
safe
transient
advers
effect
aim
present
studi
evalu
outcom
longtermfollowup
ltfu
pt
receiv
hsc
mobil
pl
gcsf
healthi
famili
donor
method
report
case
hct
perform
hsc
collect
pl
pl
given
label
provis
inform
sign
consent
absenc
altern
option
includ
clinic
trial
data
prospect
collect
institut
databas
written
consent
given
pt
allow
use
medic
record
research
accord
declar
helsinki
result
institut
healthi
famili
donor
underw
hsc
harvest
except
case
pl
use
pl
plgcsf
overal
femal
male
pt
receiv
hct
acut
leukemia
myelodisplasia
nonhodgkinlymphoma
renal
cancer
median
age
transplant
median
time
diagnosi
transplant
day
donor
match
sibl
case
haploident
condit
case
treosulphan
base
gvhd
prophylaxi
rapamycin
base
case
cyclosporin
case
perform
exvivo
tcell
deplet
case
plan
harvest
consist
peripher
hsc
engraft
possibl
case
median
time
neutrophilsplatelet
take
day
pt
engraft
evalu
due
earli
death
overal
pt
experienc
periengraft
syndrom
acut
gvhd
giiiv
diagnos
pt
giiiiv
median
time
day
chronic
gvhd
diagnos
pt
classic
overlap
syndrom
median
time
day
accord
nih
sever
moder
obtain
meaning
respons
evalu
pt
reach
goal
sustain
immunereconstitut
b
cell
figur
evid
second
solidtumor
sever
advers
event
unexpect
advers
event
regist
last
followup
overal
pt
deceas
day
pt
day
caus
death
diseas
relaps
gvhd
infect
far
pt
aliv
median
followup
day
conclus
experi
pl
ensur
adequ
graft
hct
pt
need
provid
normal
hematopoiet
engraft
effect
immun
reconstitut
compoar
rate
transplant
relat
complic
gvhd
outcom
differ
institut
experi
conflict
interest
noth
disclos
univers
southern
california
norri
cancer
center
intern
medicin
lo
angel
ca
unit
state
background
haploident
hematopoiet
stem
cell
transplant
hsct
increasingli
popular
altern
sourc
stem
cell
allogen
hsct
due
widespread
avail
compar
outcom
hlamatch
donor
method
conduct
retrospect
studi
patient
underw
haploident
hsct
norri
comprehens
cancer
center
nccc
privat
hospit
identifi
patient
undergon
haploident
hsct
administr
record
patient
demograph
treatment
relat
factor
outcom
collect
primari
endpoint
surviv
one
year
post
haploident
hsct
descript
statist
use
describ
popul
surviv
analysi
done
chisquar
logrank
test
result
total
patient
median
age
year
hispan
nonhispan
white
nhw
africanamerican
asian
includ
primari
diagnos
includ
acut
lymphocyt
leukemia
philadelphia
chromosom
ph
posit
ph
neg
acut
myeloid
leukemia
myelodysplast
syndrom
sever
aplast
anemia
mix
acut
lymphoid
acut
myeloid
leukemia
nonhodgkin
lymphoma
hodgkin
lymphoma
system
mastocytosi
myelofibrosi
chronic
myeloid
leukemia
patient
stage
prior
transplant
complet
remiss
cr
activ
diseas
patient
experienc
acut
graft
versu
host
diseas
gvhd
commonli
skin
gi
patient
experienc
chronic
gvhd
commonli
skin
liver
overal
surviv
one
year
achiev
patient
patient
aliv
complet
remiss
one
year
median
day
transplant
death
day
caus
death
includ
septic
shock
hemorrhag
stroke
cardiac
arrest
relaps
diseas
diffus
alveolar
hemorrhag
signific
differ
overal
surviv
younger
patient
older
patient
vs
ci
p
prognost
impact
seen
primari
diseas
type
stage
transplant
race
overal
surviv
howev
patient
aml
primari
diseas
process
trend
toward
lower
one
year
surviv
primari
diseas
signific
conclus
haploident
hsct
promis
altern
treatment
option
patient
hematolog
malign
without
hlamatch
donor
regardless
primari
diseas
type
stage
transplant
patient
race
howev
one
year
overal
surviv
significantli
lower
patient
year
older
conflict
interest
author
noth
disclos
agia
sophia
children
hospit
athen
stem
cell
transplant
unit
athen
greec
agia
sophia
children
hospit
athen
immunolog
histocompat
depart
athen
greec
background
transplant
adult
children
pbsc
associ
increas
incid
chronic
graft
versu
host
diseas
cgvhd
number
lymphocyt
pbsc
tenfold
higher
compar
bone
marrow
role
incid
cgvhd
clear
studi
process
pbsc
graft
unrel
donor
order
decreas
lymphocyt
number
compar
bone
marrow
graft
x
aim
mainli
assess
incid
gvhd
also
outcom
transplant
gener
method
thirti
seven
patient
girl
median
age
year
transplant
tailor
pbsc
graft
hlamatch
unrel
donor
twenti
seven
hematolog
malign
ten
nonmalign
diseas
condit
myeloabl
patient
six
patient
tbibas
gvhd
prophylaxi
consist
cyclosporin
methotrex
antithymocyt
globulin
process
graft
done
posit
select
cell
clinimac
addit
certain
number
lymphocyt
x
endpoint
incid
acut
chronic
gvhd
overal
surviv
os
leukemia
free
surviv
lf
relaps
rate
rr
treatment
relat
mortal
trm
result
median
number
graft
x
x
x
x
respect
patient
engraft
median
time
engraft
neutrophil
day
platelet
day
median
followup
two
year
os
ci
ef
ci
incid
agvhd
ci
cgvhd
ci
rr
ci
trm
ci
two
children
manifest
cgvhd
one
limit
extens
conclus
accord
result
studi
transplant
tailor
pbsc
graft
contain
similar
number
lymphocyt
bone
marrow
graft
lead
low
incid
cgvhd
addit
os
lf
compar
surviv
children
transplant
bone
marrow
graft
unrel
donor
clinic
trial
registri
applic
conflict
interest
author
noth
disclos
samsung
medic
center
sungkyunkwan
univers
school
medicin
pediatr
seoul
korea
republ
samsung
medic
center
sungkyunkwan
univers
school
medicin
laboratori
medicin
genet
seoul
korea
republ
background
given
limit
avail
hlamatch
donor
haploident
hematopoiet
stem
cell
transplant
haplohsct
increasingli
use
current
strategi
deplet
tcell
includ
ex
vivo
tcell
deplet
incorpor
antithymocyt
globulin
condit
administr
posttranspl
cyclophosphamid
aim
studi
analyz
outcom
unmanipul
haplohsct
use
antithymocyt
globulin
children
method
retrospect
review
data
patient
receiv
unmanipul
haplohsct
variou
hematolog
diseas
primari
immunodefici
diseas
januari
march
transplant
outcom
relat
prognost
factor
analyz
result
patient
underli
diseas
hematolog
malign
sever
aplast
anemia
primari
immunodefici
diseas
median
age
haplohsct
year
median
followup
month
transplant
twentyon
transplant
perform
patient
patient
retranspl
engraft
failur
haploident
donor
result
success
engraft
incid
acut
graftversushost
diseas
gvhd
grade
iiiv
grade
iiiiv
seven
patient
develop
chronic
gvhd
extens
diseas
patient
develop
cmv
diseas
although
patient
cmv
antigenemia
four
patient
die
primari
diseas
gvhd
sepsi
posttranspl
lymphoprolif
diseas
overal
surviv
rate
develop
score
system
use
paramet
diseas
statu
nonmalign
advanc
number
previou
transplant
donor
gender
patient
group
accord
sum
risk
score
os
rate
low
risk
score
intermedi
risk
score
high
risk
score
group
conclus
unmanipul
haplohsct
seem
reason
treatment
option
children
without
hlamatch
donor
score
system
may
serv
use
refer
unmanipul
haplohsct
consid
conflict
interest
noth
disclos
